观察<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制<|>RELATION_NOE 物1<|>RELATION_NOE (<|>RELATION_NOE TSLCl<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE 计数<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 11.39<|>RELATION_NOE ±<|>RELATION_NOE 1.52<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE FQ-PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 160<|>RELATION_NOE 例<|>RELATION_NOE I<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 等<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_NOE 可能<|>RELATION_NOE 存在<|>RELATION_S 微<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ;<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_NOE 可能<|>RELATION_NOE 存在<|>RELATION_NOE 微转移<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_B 差<|>RELATION_E ;<|>RELATION_NOE
微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 通过<|>RELATION_NOE 调控<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE 抑制<|>RELATION_S 肺腺癌<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE
在<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 中<|>RELATION_NOE 探讨<|>RELATION_NOE 微小<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE miRNA<|>RELATION_NOE )<|>RELATION_NOE -145<|>RELATION_NOE 调控<|>RELATION_S 肺腺癌<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 发生<|>RELATION_NOE 及其<|>RELATION_NOE 分子<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_S A549<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_S ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起<|>RELATION_NOE 始细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起<|>RELATION_NOE 始细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_S 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE
研究<|>RELATION_NOE 雌激素受体<|>RELATION_NOE (<|>RELATION_NOE ER<|>RELATION_NOE )<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE 有<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 147<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 相关<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE 收集<|>RELATION_NOE 有<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 147<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 相关<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 细胞核<|>RELATION_B 阳性<|>RELATION_I 表达<|>RELATION_E ,<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 4.1%<|>RELATION_NOE (<|>RELATION_NOE 6/<|>RELATION_NOE 147<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE ER<|>RELATION_NOE 口表达<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 86.4%<|>RELATION_NOE (<|>RELATION_NOE 127<|>RELATION_NOE /<|>RELATION_NOE 147<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 具有<|>RELATION_NOE 相关<|>RELATION_S 性<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 雌激素受体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 具有<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 雌激素受体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 重要<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
超声<|>RELATION_NOE 介导<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 125I<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 近<|>RELATION_NOE 距离<|>RELATION_NOE 治疗<|>RELATION_S 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 研究<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 通过<|>RELATION_NOE 声像图<|>RELATION_NOE 所<|>RELATION_NOE 提供<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 周围<|>RELATION_NOE 器官<|>RELATION_NOE 的<|>RELATION_NOE 信息<|>RELATION_NOE 得出<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 计划<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 计划<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 将<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 预定<|>RELATION_NOE 部位<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 超声检查<|>RELATION_S 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 部位<|>RELATION_NOE 是否<|>RELATION_NOE 与<|>RELATION_NOE 计划<|>RELATION_NOE 相符<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 确定<|>RELATION_NOE 补充<|>RELATION_NOE 。<|>RELATION_NOE
卵巢癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 睾丸癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 低<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 65.7%<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE 5.1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 11.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 1年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 34.3%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 35<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_S 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 综合<|>RELATION_NOE 运用<|>RELATION_NOE Logistic<|>RELATION_NOE 回归<|>RELATION_NOE 和<|>RELATION_NOE 受试者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE 曲线<|>RELATION_NOE (<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE )<|>RELATION_NOE 分析<|>RELATION_S 四<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21.1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE [<|>RELATION_NOE 4.53<|>RELATION_NOE (<|>RELATION_NOE 2.22-11.53<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 28.97<|>RELATION_NOE (<|>RELATION_NOE 11.39-62.10<|>RELATION_NOE )<|>RELATION_NOE u<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 4.05<|>RELATION_NOE (<|>RELATION_NOE 2.29-8.18<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 14.11<|>RELATION_NOE (<|>RELATION_NOE 11.35-24.12<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE m1<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE [<|>RELATION_NOE 2.08<|>RELATION_NOE (<|>RELATION_NOE 1.45-2.52<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 12.90<|>RELATION_NOE (<|>RELATION_NOE 9.80-19.44<|>RELATION_NOE )<|>RELATION_NOE U<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 1.53<|>RELATION_NOE (<|>RELATION_NOE 1.21-2.17<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 11.38<|>RELATION_NOE (<|>RELATION_NOE 9.07-12.80<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE m1<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
IP<|>RELATION_NOE 方案<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_E 广泛期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_S 导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 导管<|>RELATION_NOE 持续<|>RELATION_NOE 引<|>RELATION_NOE 流<|>RELATION_NOE 后<|>RELATION_NOE 接受<|>RELATION_S 顺铂<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 有效率<|>RELATION_NOE 89.3%<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE /<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 有效率<|>RELATION_NOE 83.9%<|>RELATION_NOE (<|>RELATION_NOE 52<|>RELATION_NOE /<|>RELATION_NOE 62<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE χ^2<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 91<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 的<|>RELATION_NOE 首选<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 1<|>RELATION_NOE 辅助<|>RELATION_B 治疗<|>RELATION_E 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 1<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE A<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 给予<|>RELATION_S 综合治疗<|>RELATION_NOE 加<|>RELATION_NOE 胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE ;<|>RELATION_NOE
磨玻璃<|>RELATION_NOE 样<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_S
所有<|>RELATION_NOE 病例<|>RELATION_NOE 通过<|>RELATION_NOE cT<|>RELATION_B 动态<|>RELATION_I 随<|>RELATION_I 访<|>RELATION_I 观察<|>RELATION_E ,<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 密度<|>RELATION_NOE 略<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 进行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 非黏液型<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 。<|>RELATION_NOE 所有<|>RELATION_NOE 病例<|>RELATION_NOE 通过<|>RELATION_NOE cT<|>RELATION_NOE 动态<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 观察<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 密度<|>RELATION_NOE 略<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 进行<|>RELATION_NOE 肺叶<|>RELATION_B 切除<|>RELATION_I 经<|>RELATION_I 病理<|>RELATION_I 诊断<|>RELATION_E 为<|>RELATION_NOE 非黏液型<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 。<|>RELATION_NOE
磨玻璃<|>RELATION_NOE 样<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 进展<|>RELATION_NOE 缓慢<|>RELATION_NOE ,<|>RELATION_NOE 影像学<|>RELATION_B 动态<|>RELATION_I 观察<|>RELATION_E 有助于<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_S 转移性<|>RELATION_NOE 肾细胞癌<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
评价<|>RELATION_S 细胞<|>RELATION_NOE 因子<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE CIK<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_NOE 转移性<|>RELATION_NOE 肾癌<|>RELATION_NOE (<|>RELATION_NOE MRCC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 入住<|>RELATION_NOE 河南省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE (<|>RELATION_NOE 郑州<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE )<|>RELATION_NOE 生物<|>RELATION_NOE 治疗<|>RELATION_NOE 科经<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE MRCC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 接受<|>RELATION_S 至少<|>RELATION_NOE 4<|>RELATION_NOE 周期<|>RELATION_NOE CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 次要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE TTP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE TTP<|>RELATION_NOE 采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S ,<|>RELATION_NOE 影响<|>RELATION_NOE 1rrP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 采用<|>RELATION_NOE Log-Rank<|>RELATION_NOE 方法<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 次要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE TTP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE TTP<|>RELATION_NOE 采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 影响<|>RELATION_NOE 1rrP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 采用<|>RELATION_NOE Log-Rank<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S 。<|>RELATION_NOE
21<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE (<|>RELATION_NOE PR<|>RELATION_NOE )<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 稳定<|>RELATION_NOE (<|>RELATION_NOE SD<|>RELATION_NOE )<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE (<|>RELATION_NOE PD<|>RELATION_NOE )<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 80.9<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE /<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE TTP<|>RELATION_NOE 为<|>RELATION_NOE 11.68<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ;<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_S 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 采用<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE 满意度<|>RELATION_NOE 及<|>RELATION_NOE 住院时间<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 死亡率<|>RELATION_NOE 显著<|>RELATION_NOE 少于<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 真正<|>RELATION_NOE 的<|>RELATION_NOE 体现<|>RELATION_NOE 以<|>RELATION_NOE 人<|>RELATION_NOE 为<|>RELATION_NOE 本<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 理念<|>RELATION_NOE ,<|>RELATION_NOE 有利于<|>RELATION_S 满足<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心理<|>RELATION_NOE 和<|>RELATION_NOE 生理<|>RELATION_NOE 需求<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 病死率<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 联合<|>RELATION_NOE 诱导培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE 或<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
比较<|>RELATION_S 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE (<|>RELATION_NOE 3DCRT<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 诱导培<|>RELATION_NOE 美曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 或<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
3DCRT<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 提高<|>RELATION_E 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE 3DCRT<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 提高<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_B 轻<|>RELATION_E ,<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE 分泌<|>RELATION_NOE 不<|>RELATION_NOE 当<|>RELATION_NOE 综合征<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_S
分析<|>RELATION_NOE 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE (<|>RELATION_NOE ADH<|>RELATION_NOE )<|>RELATION_NOE 分泌<|>RELATION_NOE 不<|>RELATION_NOE 当<|>RELATION_NOE 综合征<|>RELATION_NOE (<|>RELATION_NOE SIADH<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 机制<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 在<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE
研究<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
局限期<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE 6.81<|>RELATION_NOE ±<|>RELATION_NOE 28.66<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移者<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 8.09<|>RELATION_NOE ±<|>RELATION_NOE 16.67<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 局限期<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 6.09<|>RELATION_NOE ±<|>RELATION_NOE 18.75<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 广泛期<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 5.55<|>RELATION_NOE ±<|>RELATION_NOE 30.93<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Livin<|>RELATION_NOE 影响<|>RELATION_NOE 水疱<|>RELATION_NOE 口炎<|>RELATION_NOE 病毒诱导<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 效应<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_S
探讨<|>RELATION_S Livin<|>RELATION_NOE 表达<|>RELATION_NOE 影响<|>RELATION_NOE 水疱<|>RELATION_NOE 口炎<|>RELATION_NOE 病毒<|>RELATION_NOE (<|>RELATION_NOE VSV<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 促<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE 。<|>RELATION_NOE
利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_S Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_NOE Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE 利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_S VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_NOE Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE 利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_S Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制<|>RELATION_NOE 物1<|>RELATION_NOE (<|>RELATION_NOE TSLCl<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE 计数<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 11.39<|>RELATION_NOE ±<|>RELATION_NOE 1.52<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE FQ-PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 160<|>RELATION_NOE 例<|>RELATION_NOE I<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 等<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_NOE 可能<|>RELATION_NOE 存在<|>RELATION_S 微<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ;<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_NOE 可能<|>RELATION_NOE 存在<|>RELATION_NOE 微转移<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_B 差<|>RELATION_E ;<|>RELATION_NOE
微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 通过<|>RELATION_NOE 调控<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE 抑制<|>RELATION_S 肺腺癌<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE
在<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 中<|>RELATION_NOE 探讨<|>RELATION_NOE 微小<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE miRNA<|>RELATION_NOE )<|>RELATION_NOE -145<|>RELATION_NOE 调控<|>RELATION_S 肺腺癌<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 发生<|>RELATION_NOE 及其<|>RELATION_NOE 分子<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_S A549<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_S ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起<|>RELATION_NOE 始细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起<|>RELATION_NOE 始细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_S 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE
研究<|>RELATION_NOE 雌激素受体<|>RELATION_NOE (<|>RELATION_NOE ER<|>RELATION_NOE )<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE 有<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 147<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 相关<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE 收集<|>RELATION_NOE 有<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 147<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 相关<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 细胞核<|>RELATION_B 阳性<|>RELATION_I 表达<|>RELATION_E ,<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 4.1%<|>RELATION_NOE (<|>RELATION_NOE 6/<|>RELATION_NOE 147<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE ER<|>RELATION_NOE 口表达<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 86.4%<|>RELATION_NOE (<|>RELATION_NOE 127<|>RELATION_NOE /<|>RELATION_NOE 147<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 具有<|>RELATION_NOE 相关<|>RELATION_S 性<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 雌激素受体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 具有<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 雌激素受体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 重要<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
超声<|>RELATION_NOE 介导<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 125I<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 近<|>RELATION_NOE 距离<|>RELATION_NOE 治疗<|>RELATION_S 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 研究<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 通过<|>RELATION_NOE 声像图<|>RELATION_NOE 所<|>RELATION_NOE 提供<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 周围<|>RELATION_NOE 器官<|>RELATION_NOE 的<|>RELATION_NOE 信息<|>RELATION_NOE 得出<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 计划<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 计划<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 将<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 预定<|>RELATION_NOE 部位<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 超声检查<|>RELATION_S 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 部位<|>RELATION_NOE 是否<|>RELATION_NOE 与<|>RELATION_NOE 计划<|>RELATION_NOE 相符<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 确定<|>RELATION_NOE 补充<|>RELATION_NOE 。<|>RELATION_NOE
卵巢癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 睾丸癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 低<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 65.7%<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE 5.1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 11.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 1年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 34.3%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 35<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_S 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 综合<|>RELATION_NOE 运用<|>RELATION_NOE Logistic<|>RELATION_NOE 回归<|>RELATION_NOE 和<|>RELATION_NOE 受试者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE 曲线<|>RELATION_NOE (<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE )<|>RELATION_NOE 分析<|>RELATION_S 四<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21.1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE [<|>RELATION_NOE 4.53<|>RELATION_NOE (<|>RELATION_NOE 2.22-11.53<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 28.97<|>RELATION_NOE (<|>RELATION_NOE 11.39-62.10<|>RELATION_NOE )<|>RELATION_NOE u<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 4.05<|>RELATION_NOE (<|>RELATION_NOE 2.29-8.18<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 14.11<|>RELATION_NOE (<|>RELATION_NOE 11.35-24.12<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE m1<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE [<|>RELATION_NOE 2.08<|>RELATION_NOE (<|>RELATION_NOE 1.45-2.52<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 12.90<|>RELATION_NOE (<|>RELATION_NOE 9.80-19.44<|>RELATION_NOE )<|>RELATION_NOE U<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 1.53<|>RELATION_NOE (<|>RELATION_NOE 1.21-2.17<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 11.38<|>RELATION_NOE (<|>RELATION_NOE 9.07-12.80<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE m1<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
IP<|>RELATION_NOE 方案<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_E 广泛期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_S 导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 导管<|>RELATION_NOE 持续<|>RELATION_NOE 引<|>RELATION_NOE 流<|>RELATION_NOE 后<|>RELATION_NOE 接受<|>RELATION_S 顺铂<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 有效率<|>RELATION_NOE 89.3%<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE /<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 有效率<|>RELATION_NOE 83.9%<|>RELATION_NOE (<|>RELATION_NOE 52<|>RELATION_NOE /<|>RELATION_NOE 62<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE χ^2<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 91<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 的<|>RELATION_NOE 首选<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 1<|>RELATION_NOE 辅助<|>RELATION_B 治疗<|>RELATION_E 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 1<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE A<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 给予<|>RELATION_S 综合治疗<|>RELATION_NOE 加<|>RELATION_NOE 胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE ;<|>RELATION_NOE
磨玻璃<|>RELATION_NOE 样<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_S
所有<|>RELATION_NOE 病例<|>RELATION_NOE 通过<|>RELATION_NOE cT<|>RELATION_B 动态<|>RELATION_I 随<|>RELATION_I 访<|>RELATION_I 观察<|>RELATION_E ,<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 密度<|>RELATION_NOE 略<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 进行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 非黏液型<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 。<|>RELATION_NOE 所有<|>RELATION_NOE 病例<|>RELATION_NOE 通过<|>RELATION_NOE cT<|>RELATION_NOE 动态<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 观察<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 密度<|>RELATION_NOE 略<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 进行<|>RELATION_NOE 肺叶<|>RELATION_B 切除<|>RELATION_I 经<|>RELATION_I 病理<|>RELATION_I 诊断<|>RELATION_E 为<|>RELATION_NOE 非黏液型<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 。<|>RELATION_NOE
磨玻璃<|>RELATION_NOE 样<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 进展<|>RELATION_NOE 缓慢<|>RELATION_NOE ,<|>RELATION_NOE 影像学<|>RELATION_B 动态<|>RELATION_I 观察<|>RELATION_E 有助于<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_S 转移性<|>RELATION_NOE 肾细胞癌<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
评价<|>RELATION_S 细胞<|>RELATION_NOE 因子<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE CIK<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_NOE 转移性<|>RELATION_NOE 肾癌<|>RELATION_NOE (<|>RELATION_NOE MRCC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 入住<|>RELATION_NOE 河南省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE (<|>RELATION_NOE 郑州<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE )<|>RELATION_NOE 生物<|>RELATION_NOE 治疗<|>RELATION_NOE 科经<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE MRCC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 接受<|>RELATION_S 至少<|>RELATION_NOE 4<|>RELATION_NOE 周期<|>RELATION_NOE CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 次要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE TTP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE TTP<|>RELATION_NOE 采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S ,<|>RELATION_NOE 影响<|>RELATION_NOE 1rrP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 采用<|>RELATION_NOE Log-Rank<|>RELATION_NOE 方法<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 次要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE TTP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE TTP<|>RELATION_NOE 采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 影响<|>RELATION_NOE 1rrP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 采用<|>RELATION_NOE Log-Rank<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S 。<|>RELATION_NOE
21<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE (<|>RELATION_NOE PR<|>RELATION_NOE )<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 稳定<|>RELATION_NOE (<|>RELATION_NOE SD<|>RELATION_NOE )<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE (<|>RELATION_NOE PD<|>RELATION_NOE )<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 80.9<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE /<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE TTP<|>RELATION_NOE 为<|>RELATION_NOE 11.68<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ;<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_S 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 采用<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE 满意度<|>RELATION_NOE 及<|>RELATION_NOE 住院时间<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 死亡率<|>RELATION_NOE 显著<|>RELATION_NOE 少于<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 真正<|>RELATION_NOE 的<|>RELATION_NOE 体现<|>RELATION_NOE 以<|>RELATION_NOE 人<|>RELATION_NOE 为<|>RELATION_NOE 本<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 理念<|>RELATION_NOE ,<|>RELATION_NOE 有利于<|>RELATION_S 满足<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心理<|>RELATION_NOE 和<|>RELATION_NOE 生理<|>RELATION_NOE 需求<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 病死率<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 联合<|>RELATION_NOE 诱导培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE 或<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
比较<|>RELATION_S 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE (<|>RELATION_NOE 3DCRT<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 诱导培<|>RELATION_NOE 美曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 或<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
3DCRT<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 提高<|>RELATION_E 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE 3DCRT<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 提高<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_B 轻<|>RELATION_E ,<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE 分泌<|>RELATION_NOE 不<|>RELATION_NOE 当<|>RELATION_NOE 综合征<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_S
分析<|>RELATION_NOE 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE (<|>RELATION_NOE ADH<|>RELATION_NOE )<|>RELATION_NOE 分泌<|>RELATION_NOE 不<|>RELATION_NOE 当<|>RELATION_NOE 综合征<|>RELATION_NOE (<|>RELATION_NOE SIADH<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 机制<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 在<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE
研究<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
局限期<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE 6.81<|>RELATION_NOE ±<|>RELATION_NOE 28.66<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移者<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 8.09<|>RELATION_NOE ±<|>RELATION_NOE 16.67<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 局限期<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 6.09<|>RELATION_NOE ±<|>RELATION_NOE 18.75<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 广泛期<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 5.55<|>RELATION_NOE ±<|>RELATION_NOE 30.93<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Livin<|>RELATION_NOE 影响<|>RELATION_NOE 水疱<|>RELATION_NOE 口炎<|>RELATION_NOE 病毒诱导<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 效应<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_S
探讨<|>RELATION_S Livin<|>RELATION_NOE 表达<|>RELATION_NOE 影响<|>RELATION_NOE 水疱<|>RELATION_NOE 口炎<|>RELATION_NOE 病毒<|>RELATION_NOE (<|>RELATION_NOE VSV<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 促<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE 。<|>RELATION_NOE
利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_S Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_NOE Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE 利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_S VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_NOE Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE 利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_S Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生<|>RELATION_S 因素<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_NOE 研究<|>RELATION_NOE
对<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE 肺靶区<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE (<|>RELATION_NOE 纵隔<|>RELATION_NOE 靶区<|>RELATION_NOE )<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 中<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE RP<|>RELATION_NOE )<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 及<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方图<|>RELATION_NOE (<|>RELATION_NOE DVH<|>RELATION_NOE )<|>RELATION_NOE 参数<|>RELATION_NOE 进行<|>RELATION_NOE 对比<|>RELATION_B 研究<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 接受<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 患者<|>RELATION_NOE 83<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE 检验<|>RELATION_NOE 对<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE RP<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ;<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 接受<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 患者<|>RELATION_NOE 83<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE χ<|>RELATION_B 2<|>RELATION_I 检验<|>RELATION_E 对<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE RP<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ;<|>RELATION_NOE
改良<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 巨块型<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
研究<|>RELATION_NOE 在<|>RELATION_NOE -65<|>RELATION_NOE ℃<|>RELATION_NOE 条件<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 不同<|>RELATION_NOE 冷冻<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE ,<|>RELATION_NOE 确定<|>RELATION_S 最佳<|>RELATION_NOE 冷冻<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 择期<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 患者<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 5组<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 膈神经<|>RELATION_NOE 冷冻<|>RELATION_NOE 30<|>RELATION_NOE 、<|>RELATION_NOE 60<|>RELATION_NOE 、<|>RELATION_NOE 90<|>RELATION_NOE 、<|>RELATION_NOE 120<|>RELATION_NOE s<|>RELATION_NOE 组<|>RELATION_NOE 。<|>RELATION_NOE
记录<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 的<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 、<|>RELATION_NOE 胸腔<|>RELATION_NOE 引<|>RELATION_NOE 流量<|>RELATION_NOE 、<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_B 进行<|>RELATION_E 肩胛区<|>RELATION_NOE 牵涉<|>RELATION_NOE 视觉<|>RELATION_NOE 模拟<|>RELATION_NOE 痛<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE VAS<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
拔除<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 管<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 常规<|>RELATION_NOE 行<|>RELATION_NOE 胸部<|>RELATION_NOE 正侧<|>RELATION_NOE 位<|>RELATION_NOE X<|>RELATION_NOE 线片<|>RELATION_NOE 及<|>RELATION_NOE 胸部<|>RELATION_NOE B<|>RELATION_NOE 型<|>RELATION_NOE 超声检查<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 各<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 残腔<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 90d<|>RELATION_NOE 进行<|>RELATION_NOE 胸部<|>RELATION_NOE 透视<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 患侧<|>RELATION_NOE 膈肌<|>RELATION_NOE 运动<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
各组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 术后<|>RELATION_NOE 残腔<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE (<|>RELATION_NOE ><|>RELATION_NOE 200ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 积液<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE (<|>RELATION_NOE ><|>RELATION_NOE 200ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1例行<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 抽取<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 冷冻<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 残腔<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE (<|>RELATION_NOE <<|>RELATION_NOE 100ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 需<|>RELATION_NOE 处理<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 及<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞二钠<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 15min<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 20mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 至<|>RELATION_NOE 第4<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 3<|>RELATION_NOE 周<|>RELATION_NOE 重复<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 口服<|>RELATION_NOE 地塞米松<|>RELATION_NOE 、<|>RELATION_NOE 叶酸<|>RELATION_NOE 和<|>RELATION_NOE 肌肉<|>RELATION_NOE 注射<|>RELATION_NOE 维生素<|>RELATION_NOE B12<|>RELATION_NOE 预处理<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 至少<|>RELATION_NOE 完成<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
P13K-AKT<|>RELATION_NOE 信号<|>RELATION_NOE 在<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 调节<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
分析<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE H1299<|>RELATION_NOE 体外<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S ,<|>RELATION_NOE 探讨<|>RELATION_NOE 磷脂酰肌醇<|>RELATION_NOE -3<|>RELATION_NOE -<|>RELATION_NOE 激酶.<|>RELATION_NOE
细胞计数<|>RELATION_NOE 方法<|>RELATION_NOE -8<|>RELATION_NOE (<|>RELATION_NOE CCK-8<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 效应<|>RELATION_NOE ;<|>RELATION_NOE
酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S CD40<|>RELATION_NOE 对<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 分泌<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 9<|>RELATION_NOE (<|>RELATION_NOE MMP-9<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
CCK-8<|>RELATION_NOE 法示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 其<|>RELATION_NOE 吸<|>RELATION_NOE 光度<|>RELATION_NOE (<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 提高<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 96h<|>RELATION_NOE 时<|>RELATION_NOE 10.0mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 浓度<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 2.75<|>RELATION_NOE ±<|>RELATION_NOE 0.35<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 1.72<|>RELATION_NOE ±<|>RELATION_NOE 0.18<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
侵袭<|>RELATION_NOE 实验示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 穿过<|>RELATION_NOE 微孔<|>RELATION_NOE 贴<|>RELATION_NOE 于<|>RELATION_NOE 下室<|>RELATION_NOE 的<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 168<|>RELATION_NOE ±<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 105<|>RELATION_NOE ±<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 增多<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5C11<|>RELATION_NOE +<|>RELATION_NOE LY294002<|>RELATION_NOE 组<|>RELATION_NOE 下室<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 118<|>RELATION_NOE ±<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE 侵袭<|>RELATION_NOE 实验示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 穿过<|>RELATION_NOE 微孔<|>RELATION_NOE 贴<|>RELATION_NOE 于<|>RELATION_NOE 下室<|>RELATION_NOE 的<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 168<|>RELATION_NOE ±<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 105<|>RELATION_NOE ±<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_NOE 增多<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5C11<|>RELATION_NOE +<|>RELATION_NOE LY294002<|>RELATION_NOE 组<|>RELATION_NOE 下室<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 118<|>RELATION_NOE ±<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE H1299<|>RELATION_NOE 具有<|>RELATION_NOE 促进<|>RELATION_B 体外<|>RELATION_I 增殖<|>RELATION_I 、<|>RELATION_I 侵袭<|>RELATION_I 能力<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 部分<|>RELATION_NOE 在于<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 激发<|>RELATION_NOE 介导<|>RELATION_NOE 的<|>RELATION_NOE P13K-AKT<|>RELATION_NOE 信号<|>RELATION_NOE 活化<|>RELATION_NOE 。<|>RELATION_NOE
TaqMan-<|>RELATION_NOE 扩增<|>RELATION_NOE 阻滞<|>RELATION_NOE 突变<|>RELATION_NOE 系统法<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE T<|>RELATION_NOE aqMan<|>RELATION_NOE 扩增<|>RELATION_NOE 阻滞<|>RELATION_NOE 突变<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE ARMS<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE ,<|>RELATION_NOE 北京<|>RELATION_NOE 4<|>RELATION_NOE 家<|>RELATION_NOE 三级<|>RELATION_NOE 甲等<|>RELATION_NOE 医院<|>RELATION_NOE 的<|>RELATION_NOE 199<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外科手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 预留<|>RELATION_NOE 石蜡<|>RELATION_NOE 样本<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_S TaqMan<|>RELATION_NOE .<|>RELATION_NOE
ARMS<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S EGFR<|>RELATION_NOE 外显子<|>RELATION_NOE 19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE (<|>RELATION_NOE EGFRl9<|>RELATION_NOE 和<|>RELATION_NOE EGFR21<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE DNA<|>RELATION_NOE 测<|>RELATION_NOE 序法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE EGFRl9<|>RELATION_NOE 和<|>RELATION_NOE EGFR21<|>RELATION_NOE 总<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 19.6%<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 199<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 分<|>RELATION_NOE :<|>RELATION_NOE 腺癌<|>RELATION_NOE 35.9%<|>RELATION_NOE (<|>RELATION_NOE 37<|>RELATION_NOE /<|>RELATION_NOE 103<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 2.2%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 93<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺鳞<|>RELATION_NOE 癌0<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变率<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 高度<|>RELATION_B 一致性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 1.000<|>RELATION_NOE ,<|>RELATION_NOE K<|>RELATION_NOE =<|>RELATION_NOE 0.9<|>RELATION_NOE 84<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 腺癌<|>RELATION_NOE 组织<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_S 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 。<|>RELATION_NOE
TaqMan-ARMS<|>RELATION_NOE 法<|>RELATION_NOE 与<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 在<|>RELATION_NOE 检测<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 上<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_B 好<|>RELATION_I 的<|>RELATION_I 一致性<|>RELATION_E 。<|>RELATION_NOE
观察<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制<|>RELATION_NOE 物1<|>RELATION_NOE (<|>RELATION_NOE TSLCl<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE 计数<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 11.39<|>RELATION_NOE ±<|>RELATION_NOE 1.52<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制<|>RELATION_NOE 物1<|>RELATION_NOE (<|>RELATION_NOE TSLCl<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE 计数<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 11.39<|>RELATION_NOE ±<|>RELATION_NOE 1.52<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE FQ-PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 160<|>RELATION_NOE 例<|>RELATION_NOE I<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 等<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_NOE 可能<|>RELATION_NOE 存在<|>RELATION_S 微<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ;<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_NOE 可能<|>RELATION_NOE 存在<|>RELATION_NOE 微转移<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_B 差<|>RELATION_E ;<|>RELATION_NOE
微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 通过<|>RELATION_NOE 调控<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE 抑制<|>RELATION_S 肺腺癌<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE
在<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 中<|>RELATION_NOE 探讨<|>RELATION_NOE 微小<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE miRNA<|>RELATION_NOE )<|>RELATION_NOE -145<|>RELATION_NOE 调控<|>RELATION_S 肺腺癌<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 发生<|>RELATION_NOE 及其<|>RELATION_NOE 分子<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_S A549<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_S ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起<|>RELATION_NOE 始细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起<|>RELATION_NOE 始细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_S 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE
研究<|>RELATION_NOE 雌激素受体<|>RELATION_NOE (<|>RELATION_NOE ER<|>RELATION_NOE )<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE 有<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 147<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 相关<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE 收集<|>RELATION_NOE 有<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 147<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 相关<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 细胞核<|>RELATION_B 阳性<|>RELATION_I 表达<|>RELATION_E ,<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 4.1%<|>RELATION_NOE (<|>RELATION_NOE 6/<|>RELATION_NOE 147<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE ER<|>RELATION_NOE 口表达<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 86.4%<|>RELATION_NOE (<|>RELATION_NOE 127<|>RELATION_NOE /<|>RELATION_NOE 147<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 具有<|>RELATION_NOE 相关<|>RELATION_S 性<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 雌激素受体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 具有<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 雌激素受体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 重要<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
超声<|>RELATION_NOE 介导<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 125I<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 近<|>RELATION_NOE 距离<|>RELATION_NOE 治疗<|>RELATION_S 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 研究<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 通过<|>RELATION_NOE 声像图<|>RELATION_NOE 所<|>RELATION_NOE 提供<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 周围<|>RELATION_NOE 器官<|>RELATION_NOE 的<|>RELATION_NOE 信息<|>RELATION_NOE 得出<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 计划<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 计划<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 将<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 预定<|>RELATION_NOE 部位<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 超声检查<|>RELATION_S 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 部位<|>RELATION_NOE 是否<|>RELATION_NOE 与<|>RELATION_NOE 计划<|>RELATION_NOE 相符<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 确定<|>RELATION_NOE 补充<|>RELATION_NOE 。<|>RELATION_NOE
卵巢癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 睾丸癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 低<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 65.7%<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE 5.1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 11.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 1年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 34.3%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 35<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_S 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 综合<|>RELATION_NOE 运用<|>RELATION_NOE Logistic<|>RELATION_NOE 回归<|>RELATION_NOE 和<|>RELATION_NOE 受试者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE 曲线<|>RELATION_NOE (<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE )<|>RELATION_NOE 分析<|>RELATION_S 四<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21.1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE [<|>RELATION_NOE 4.53<|>RELATION_NOE (<|>RELATION_NOE 2.22-11.53<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 28.97<|>RELATION_NOE (<|>RELATION_NOE 11.39-62.10<|>RELATION_NOE )<|>RELATION_NOE u<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 4.05<|>RELATION_NOE (<|>RELATION_NOE 2.29-8.18<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 14.11<|>RELATION_NOE (<|>RELATION_NOE 11.35-24.12<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE m1<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE [<|>RELATION_NOE 2.08<|>RELATION_NOE (<|>RELATION_NOE 1.45-2.52<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 12.90<|>RELATION_NOE (<|>RELATION_NOE 9.80-19.44<|>RELATION_NOE )<|>RELATION_NOE U<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 1.53<|>RELATION_NOE (<|>RELATION_NOE 1.21-2.17<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 11.38<|>RELATION_NOE (<|>RELATION_NOE 9.07-12.80<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE m1<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
IP<|>RELATION_NOE 方案<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_E 广泛期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_S 导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 导管<|>RELATION_NOE 持续<|>RELATION_NOE 引<|>RELATION_NOE 流<|>RELATION_NOE 后<|>RELATION_NOE 接受<|>RELATION_S 顺铂<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 有效率<|>RELATION_NOE 89.3%<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE /<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 有效率<|>RELATION_NOE 83.9%<|>RELATION_NOE (<|>RELATION_NOE 52<|>RELATION_NOE /<|>RELATION_NOE 62<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE χ^2<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 91<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 的<|>RELATION_NOE 首选<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 1<|>RELATION_NOE 辅助<|>RELATION_B 治疗<|>RELATION_E 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 1<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE A<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 给予<|>RELATION_S 综合治疗<|>RELATION_NOE 加<|>RELATION_NOE 胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE ;<|>RELATION_NOE
磨玻璃<|>RELATION_NOE 样<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_S
所有<|>RELATION_NOE 病例<|>RELATION_NOE 通过<|>RELATION_NOE cT<|>RELATION_B 动态<|>RELATION_I 随<|>RELATION_I 访<|>RELATION_I 观察<|>RELATION_E ,<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 密度<|>RELATION_NOE 略<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 进行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 非黏液型<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 。<|>RELATION_NOE 所有<|>RELATION_NOE 病例<|>RELATION_NOE 通过<|>RELATION_NOE cT<|>RELATION_NOE 动态<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 观察<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 密度<|>RELATION_NOE 略<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 进行<|>RELATION_NOE 肺叶<|>RELATION_B 切除<|>RELATION_I 经<|>RELATION_I 病理<|>RELATION_I 诊断<|>RELATION_E 为<|>RELATION_NOE 非黏液型<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 。<|>RELATION_NOE
磨玻璃<|>RELATION_NOE 样<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 进展<|>RELATION_NOE 缓慢<|>RELATION_NOE ,<|>RELATION_NOE 影像学<|>RELATION_B 动态<|>RELATION_I 观察<|>RELATION_E 有助于<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_S 转移性<|>RELATION_NOE 肾细胞癌<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
评价<|>RELATION_S 细胞<|>RELATION_NOE 因子<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE CIK<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_NOE 转移性<|>RELATION_NOE 肾癌<|>RELATION_NOE (<|>RELATION_NOE MRCC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 入住<|>RELATION_NOE 河南省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE (<|>RELATION_NOE 郑州<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE )<|>RELATION_NOE 生物<|>RELATION_NOE 治疗<|>RELATION_NOE 科经<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE MRCC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 接受<|>RELATION_S 至少<|>RELATION_NOE 4<|>RELATION_NOE 周期<|>RELATION_NOE CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 次要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE TTP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE TTP<|>RELATION_NOE 采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S ,<|>RELATION_NOE 影响<|>RELATION_NOE 1rrP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 采用<|>RELATION_NOE Log-Rank<|>RELATION_NOE 方法<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 次要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE TTP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE TTP<|>RELATION_NOE 采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 影响<|>RELATION_NOE 1rrP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 采用<|>RELATION_NOE Log-Rank<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S 。<|>RELATION_NOE
21<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE (<|>RELATION_NOE PR<|>RELATION_NOE )<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 稳定<|>RELATION_NOE (<|>RELATION_NOE SD<|>RELATION_NOE )<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE (<|>RELATION_NOE PD<|>RELATION_NOE )<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 80.9<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE /<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE TTP<|>RELATION_NOE 为<|>RELATION_NOE 11.68<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ;<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_S 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 采用<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE 满意度<|>RELATION_NOE 及<|>RELATION_NOE 住院时间<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 死亡率<|>RELATION_NOE 显著<|>RELATION_NOE 少于<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 真正<|>RELATION_NOE 的<|>RELATION_NOE 体现<|>RELATION_NOE 以<|>RELATION_NOE 人<|>RELATION_NOE 为<|>RELATION_NOE 本<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 理念<|>RELATION_NOE ,<|>RELATION_NOE 有利于<|>RELATION_S 满足<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心理<|>RELATION_NOE 和<|>RELATION_NOE 生理<|>RELATION_NOE 需求<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 病死率<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 联合<|>RELATION_NOE 诱导培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE 或<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
比较<|>RELATION_S 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE (<|>RELATION_NOE 3DCRT<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 诱导培<|>RELATION_NOE 美曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 或<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
3DCRT<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 提高<|>RELATION_E 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE 3DCRT<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 提高<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_B 轻<|>RELATION_E ,<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE 分泌<|>RELATION_NOE 不<|>RELATION_NOE 当<|>RELATION_NOE 综合征<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_S
分析<|>RELATION_NOE 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE (<|>RELATION_NOE ADH<|>RELATION_NOE )<|>RELATION_NOE 分泌<|>RELATION_NOE 不<|>RELATION_NOE 当<|>RELATION_NOE 综合征<|>RELATION_NOE (<|>RELATION_NOE SIADH<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 机制<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 在<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE
研究<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
局限期<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE 6.81<|>RELATION_NOE ±<|>RELATION_NOE 28.66<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移者<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 8.09<|>RELATION_NOE ±<|>RELATION_NOE 16.67<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 局限期<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 6.09<|>RELATION_NOE ±<|>RELATION_NOE 18.75<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 广泛期<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 5.55<|>RELATION_NOE ±<|>RELATION_NOE 30.93<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Livin<|>RELATION_NOE 影响<|>RELATION_NOE 水疱<|>RELATION_NOE 口炎<|>RELATION_NOE 病毒诱导<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 效应<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_S
探讨<|>RELATION_S Livin<|>RELATION_NOE 表达<|>RELATION_NOE 影响<|>RELATION_NOE 水疱<|>RELATION_NOE 口炎<|>RELATION_NOE 病毒<|>RELATION_NOE (<|>RELATION_NOE VSV<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 促<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE 。<|>RELATION_NOE
利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_S Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_NOE Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE 利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_S VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_NOE Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE 利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_S Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生<|>RELATION_S 因素<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_NOE 研究<|>RELATION_NOE
对<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE 肺靶区<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE (<|>RELATION_NOE 纵隔<|>RELATION_NOE 靶区<|>RELATION_NOE )<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 中<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE RP<|>RELATION_NOE )<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 及<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方图<|>RELATION_NOE (<|>RELATION_NOE DVH<|>RELATION_NOE )<|>RELATION_NOE 参数<|>RELATION_NOE 进行<|>RELATION_NOE 对比<|>RELATION_B 研究<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 接受<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 患者<|>RELATION_NOE 83<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE 检验<|>RELATION_NOE 对<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE RP<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ;<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 接受<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 患者<|>RELATION_NOE 83<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE χ<|>RELATION_B 2<|>RELATION_I 检验<|>RELATION_E 对<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE RP<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ;<|>RELATION_NOE
改良<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 巨块型<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
研究<|>RELATION_NOE 在<|>RELATION_NOE -65<|>RELATION_NOE ℃<|>RELATION_NOE 条件<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 不同<|>RELATION_NOE 冷冻<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE ,<|>RELATION_NOE 确定<|>RELATION_S 最佳<|>RELATION_NOE 冷冻<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 择期<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 患者<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 5组<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 膈神经<|>RELATION_NOE 冷冻<|>RELATION_NOE 30<|>RELATION_NOE 、<|>RELATION_NOE 60<|>RELATION_NOE 、<|>RELATION_NOE 90<|>RELATION_NOE 、<|>RELATION_NOE 120<|>RELATION_NOE s<|>RELATION_NOE 组<|>RELATION_NOE 。<|>RELATION_NOE
记录<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 的<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 、<|>RELATION_NOE 胸腔<|>RELATION_NOE 引<|>RELATION_NOE 流量<|>RELATION_NOE 、<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_B 进行<|>RELATION_E 肩胛区<|>RELATION_NOE 牵涉<|>RELATION_NOE 视觉<|>RELATION_NOE 模拟<|>RELATION_NOE 痛<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE VAS<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
拔除<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 管<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 常规<|>RELATION_NOE 行<|>RELATION_NOE 胸部<|>RELATION_NOE 正侧<|>RELATION_NOE 位<|>RELATION_NOE X<|>RELATION_NOE 线片<|>RELATION_NOE 及<|>RELATION_NOE 胸部<|>RELATION_NOE B<|>RELATION_NOE 型<|>RELATION_NOE 超声检查<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 各<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 残腔<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 90d<|>RELATION_NOE 进行<|>RELATION_NOE 胸部<|>RELATION_NOE 透视<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 患侧<|>RELATION_NOE 膈肌<|>RELATION_NOE 运动<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
各组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 术后<|>RELATION_NOE 残腔<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE (<|>RELATION_NOE ><|>RELATION_NOE 200ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 积液<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE (<|>RELATION_NOE ><|>RELATION_NOE 200ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1例行<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 抽取<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 冷冻<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 残腔<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE (<|>RELATION_NOE <<|>RELATION_NOE 100ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 需<|>RELATION_NOE 处理<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 及<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞二钠<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 15min<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 20mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 至<|>RELATION_NOE 第4<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 3<|>RELATION_NOE 周<|>RELATION_NOE 重复<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 口服<|>RELATION_NOE 地塞米松<|>RELATION_NOE 、<|>RELATION_NOE 叶酸<|>RELATION_NOE 和<|>RELATION_NOE 肌肉<|>RELATION_NOE 注射<|>RELATION_NOE 维生素<|>RELATION_NOE B12<|>RELATION_NOE 预处理<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 至少<|>RELATION_NOE 完成<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
P13K-AKT<|>RELATION_NOE 信号<|>RELATION_NOE 在<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 调节<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
分析<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE H1299<|>RELATION_NOE 体外<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S ,<|>RELATION_NOE 探讨<|>RELATION_NOE 磷脂酰肌醇<|>RELATION_NOE -3<|>RELATION_NOE -<|>RELATION_NOE 激酶.<|>RELATION_NOE
细胞计数<|>RELATION_NOE 方法<|>RELATION_NOE -8<|>RELATION_NOE (<|>RELATION_NOE CCK-8<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 效应<|>RELATION_NOE ;<|>RELATION_NOE
酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S CD40<|>RELATION_NOE 对<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 分泌<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 9<|>RELATION_NOE (<|>RELATION_NOE MMP-9<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
CCK-8<|>RELATION_NOE 法示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 其<|>RELATION_NOE 吸<|>RELATION_NOE 光度<|>RELATION_NOE (<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 提高<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 96h<|>RELATION_NOE 时<|>RELATION_NOE 10.0mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 浓度<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 2.75<|>RELATION_NOE ±<|>RELATION_NOE 0.35<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 1.72<|>RELATION_NOE ±<|>RELATION_NOE 0.18<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
侵袭<|>RELATION_NOE 实验示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 穿过<|>RELATION_NOE 微孔<|>RELATION_NOE 贴<|>RELATION_NOE 于<|>RELATION_NOE 下室<|>RELATION_NOE 的<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 168<|>RELATION_NOE ±<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 105<|>RELATION_NOE ±<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 增多<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5C11<|>RELATION_NOE +<|>RELATION_NOE LY294002<|>RELATION_NOE 组<|>RELATION_NOE 下室<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 118<|>RELATION_NOE ±<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE 侵袭<|>RELATION_NOE 实验示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 穿过<|>RELATION_NOE 微孔<|>RELATION_NOE 贴<|>RELATION_NOE 于<|>RELATION_NOE 下室<|>RELATION_NOE 的<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 168<|>RELATION_NOE ±<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 105<|>RELATION_NOE ±<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_NOE 增多<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5C11<|>RELATION_NOE +<|>RELATION_NOE LY294002<|>RELATION_NOE 组<|>RELATION_NOE 下室<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 118<|>RELATION_NOE ±<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE H1299<|>RELATION_NOE 具有<|>RELATION_NOE 促进<|>RELATION_B 体外<|>RELATION_I 增殖<|>RELATION_I 、<|>RELATION_I 侵袭<|>RELATION_I 能力<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 部分<|>RELATION_NOE 在于<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 激发<|>RELATION_NOE 介导<|>RELATION_NOE 的<|>RELATION_NOE P13K-AKT<|>RELATION_NOE 信号<|>RELATION_NOE 活化<|>RELATION_NOE 。<|>RELATION_NOE
TaqMan-<|>RELATION_NOE 扩增<|>RELATION_NOE 阻滞<|>RELATION_NOE 突变<|>RELATION_NOE 系统法<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE T<|>RELATION_NOE aqMan<|>RELATION_NOE 扩增<|>RELATION_NOE 阻滞<|>RELATION_NOE 突变<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE ARMS<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE ,<|>RELATION_NOE 北京<|>RELATION_NOE 4<|>RELATION_NOE 家<|>RELATION_NOE 三级<|>RELATION_NOE 甲等<|>RELATION_NOE 医院<|>RELATION_NOE 的<|>RELATION_NOE 199<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外科手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 预留<|>RELATION_NOE 石蜡<|>RELATION_NOE 样本<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_S TaqMan<|>RELATION_NOE .<|>RELATION_NOE
ARMS<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S EGFR<|>RELATION_NOE 外显子<|>RELATION_NOE 19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE (<|>RELATION_NOE EGFRl9<|>RELATION_NOE 和<|>RELATION_NOE EGFR21<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE DNA<|>RELATION_NOE 测<|>RELATION_NOE 序法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE EGFRl9<|>RELATION_NOE 和<|>RELATION_NOE EGFR21<|>RELATION_NOE 总<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 19.6%<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 199<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 分<|>RELATION_NOE :<|>RELATION_NOE 腺癌<|>RELATION_NOE 35.9%<|>RELATION_NOE (<|>RELATION_NOE 37<|>RELATION_NOE /<|>RELATION_NOE 103<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 2.2%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 93<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺鳞<|>RELATION_NOE 癌0<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变率<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 高度<|>RELATION_B 一致性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 1.000<|>RELATION_NOE ,<|>RELATION_NOE K<|>RELATION_NOE =<|>RELATION_NOE 0.9<|>RELATION_NOE 84<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 腺癌<|>RELATION_NOE 组织<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_S 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 。<|>RELATION_NOE
TaqMan-ARMS<|>RELATION_NOE 法<|>RELATION_NOE 与<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 在<|>RELATION_NOE 检测<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 上<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_B 好<|>RELATION_I 的<|>RELATION_I 一致性<|>RELATION_E 。<|>RELATION_NOE
观察<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制<|>RELATION_NOE 物1<|>RELATION_NOE (<|>RELATION_NOE TSLCl<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE 计数<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 11.39<|>RELATION_NOE ±<|>RELATION_NOE 1.52<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE FQ-PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 160<|>RELATION_NOE 例<|>RELATION_NOE I<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 等<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_NOE 可能<|>RELATION_NOE 存在<|>RELATION_S 微<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ;<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_NOE 可能<|>RELATION_NOE 存在<|>RELATION_NOE 微转移<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_B 差<|>RELATION_E ;<|>RELATION_NOE
微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 通过<|>RELATION_NOE 调控<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE 抑制<|>RELATION_S 肺腺癌<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE
在<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 中<|>RELATION_NOE 探讨<|>RELATION_NOE 微小<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE miRNA<|>RELATION_NOE )<|>RELATION_NOE -145<|>RELATION_NOE 调控<|>RELATION_S 肺腺癌<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 发生<|>RELATION_NOE 及其<|>RELATION_NOE 分子<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_S A549<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_S ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起<|>RELATION_NOE 始细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起<|>RELATION_NOE 始细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_S 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE
研究<|>RELATION_NOE 雌激素受体<|>RELATION_NOE (<|>RELATION_NOE ER<|>RELATION_NOE )<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE 有<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 147<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 相关<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE 收集<|>RELATION_NOE 有<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 147<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 相关<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 细胞核<|>RELATION_B 阳性<|>RELATION_I 表达<|>RELATION_E ,<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 4.1%<|>RELATION_NOE (<|>RELATION_NOE 6/<|>RELATION_NOE 147<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE ER<|>RELATION_NOE 口表达<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 86.4%<|>RELATION_NOE (<|>RELATION_NOE 127<|>RELATION_NOE /<|>RELATION_NOE 147<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 具有<|>RELATION_NOE 相关<|>RELATION_S 性<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 雌激素受体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 具有<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 雌激素受体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 重要<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
超声<|>RELATION_NOE 介导<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 125I<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 近<|>RELATION_NOE 距离<|>RELATION_NOE 治疗<|>RELATION_S 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 研究<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 通过<|>RELATION_NOE 声像图<|>RELATION_NOE 所<|>RELATION_NOE 提供<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 周围<|>RELATION_NOE 器官<|>RELATION_NOE 的<|>RELATION_NOE 信息<|>RELATION_NOE 得出<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 计划<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 计划<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 将<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 预定<|>RELATION_NOE 部位<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 超声检查<|>RELATION_S 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 部位<|>RELATION_NOE 是否<|>RELATION_NOE 与<|>RELATION_NOE 计划<|>RELATION_NOE 相符<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 确定<|>RELATION_NOE 补充<|>RELATION_NOE 。<|>RELATION_NOE
卵巢癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 睾丸癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 低<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 65.7%<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE 5.1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 11.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 1年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 34.3%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 35<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_S 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 综合<|>RELATION_NOE 运用<|>RELATION_NOE Logistic<|>RELATION_NOE 回归<|>RELATION_NOE 和<|>RELATION_NOE 受试者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE 曲线<|>RELATION_NOE (<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE )<|>RELATION_NOE 分析<|>RELATION_S 四<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21.1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE [<|>RELATION_NOE 4.53<|>RELATION_NOE (<|>RELATION_NOE 2.22-11.53<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 28.97<|>RELATION_NOE (<|>RELATION_NOE 11.39-62.10<|>RELATION_NOE )<|>RELATION_NOE u<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 4.05<|>RELATION_NOE (<|>RELATION_NOE 2.29-8.18<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 14.11<|>RELATION_NOE (<|>RELATION_NOE 11.35-24.12<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE m1<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE [<|>RELATION_NOE 2.08<|>RELATION_NOE (<|>RELATION_NOE 1.45-2.52<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 12.90<|>RELATION_NOE (<|>RELATION_NOE 9.80-19.44<|>RELATION_NOE )<|>RELATION_NOE U<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 1.53<|>RELATION_NOE (<|>RELATION_NOE 1.21-2.17<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 11.38<|>RELATION_NOE (<|>RELATION_NOE 9.07-12.80<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE m1<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
IP<|>RELATION_NOE 方案<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_E 广泛期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_S 导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 导管<|>RELATION_NOE 持续<|>RELATION_NOE 引<|>RELATION_NOE 流<|>RELATION_NOE 后<|>RELATION_NOE 接受<|>RELATION_S 顺铂<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 有效率<|>RELATION_NOE 89.3%<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE /<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 有效率<|>RELATION_NOE 83.9%<|>RELATION_NOE (<|>RELATION_NOE 52<|>RELATION_NOE /<|>RELATION_NOE 62<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE χ^2<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 91<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 的<|>RELATION_NOE 首选<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 1<|>RELATION_NOE 辅助<|>RELATION_B 治疗<|>RELATION_E 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 1<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE A<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 给予<|>RELATION_S 综合治疗<|>RELATION_NOE 加<|>RELATION_NOE 胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE ;<|>RELATION_NOE
磨玻璃<|>RELATION_NOE 样<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_S
所有<|>RELATION_NOE 病例<|>RELATION_NOE 通过<|>RELATION_NOE cT<|>RELATION_B 动态<|>RELATION_I 随<|>RELATION_I 访<|>RELATION_I 观察<|>RELATION_E ,<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 密度<|>RELATION_NOE 略<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 进行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 非黏液型<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 。<|>RELATION_NOE 所有<|>RELATION_NOE 病例<|>RELATION_NOE 通过<|>RELATION_NOE cT<|>RELATION_NOE 动态<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 观察<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 密度<|>RELATION_NOE 略<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 进行<|>RELATION_NOE 肺叶<|>RELATION_B 切除<|>RELATION_I 经<|>RELATION_I 病理<|>RELATION_I 诊断<|>RELATION_E 为<|>RELATION_NOE 非黏液型<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 。<|>RELATION_NOE
磨玻璃<|>RELATION_NOE 样<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 进展<|>RELATION_NOE 缓慢<|>RELATION_NOE ,<|>RELATION_NOE 影像学<|>RELATION_B 动态<|>RELATION_I 观察<|>RELATION_E 有助于<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_S 转移性<|>RELATION_NOE 肾细胞癌<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
评价<|>RELATION_S 细胞<|>RELATION_NOE 因子<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE CIK<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_NOE 转移性<|>RELATION_NOE 肾癌<|>RELATION_NOE (<|>RELATION_NOE MRCC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 入住<|>RELATION_NOE 河南省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE (<|>RELATION_NOE 郑州<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE )<|>RELATION_NOE 生物<|>RELATION_NOE 治疗<|>RELATION_NOE 科经<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE MRCC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 接受<|>RELATION_S 至少<|>RELATION_NOE 4<|>RELATION_NOE 周期<|>RELATION_NOE CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 次要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE TTP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE TTP<|>RELATION_NOE 采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S ,<|>RELATION_NOE 影响<|>RELATION_NOE 1rrP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 采用<|>RELATION_NOE Log-Rank<|>RELATION_NOE 方法<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 次要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE TTP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE TTP<|>RELATION_NOE 采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 影响<|>RELATION_NOE 1rrP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 采用<|>RELATION_NOE Log-Rank<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S 。<|>RELATION_NOE
21<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE (<|>RELATION_NOE PR<|>RELATION_NOE )<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 稳定<|>RELATION_NOE (<|>RELATION_NOE SD<|>RELATION_NOE )<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE (<|>RELATION_NOE PD<|>RELATION_NOE )<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 80.9<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE /<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE TTP<|>RELATION_NOE 为<|>RELATION_NOE 11.68<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ;<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_S 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 采用<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE 满意度<|>RELATION_NOE 及<|>RELATION_NOE 住院时间<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 死亡率<|>RELATION_NOE 显著<|>RELATION_NOE 少于<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 真正<|>RELATION_NOE 的<|>RELATION_NOE 体现<|>RELATION_NOE 以<|>RELATION_NOE 人<|>RELATION_NOE 为<|>RELATION_NOE 本<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 理念<|>RELATION_NOE ,<|>RELATION_NOE 有利于<|>RELATION_S 满足<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心理<|>RELATION_NOE 和<|>RELATION_NOE 生理<|>RELATION_NOE 需求<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 病死率<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 联合<|>RELATION_NOE 诱导培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE 或<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
比较<|>RELATION_S 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE (<|>RELATION_NOE 3DCRT<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 诱导培<|>RELATION_NOE 美曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 或<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
3DCRT<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 提高<|>RELATION_E 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE 3DCRT<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 提高<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_B 轻<|>RELATION_E ,<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE 分泌<|>RELATION_NOE 不<|>RELATION_NOE 当<|>RELATION_NOE 综合征<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_S
分析<|>RELATION_NOE 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE (<|>RELATION_NOE ADH<|>RELATION_NOE )<|>RELATION_NOE 分泌<|>RELATION_NOE 不<|>RELATION_NOE 当<|>RELATION_NOE 综合征<|>RELATION_NOE (<|>RELATION_NOE SIADH<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 机制<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 在<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE
研究<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
局限期<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE 6.81<|>RELATION_NOE ±<|>RELATION_NOE 28.66<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移者<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 8.09<|>RELATION_NOE ±<|>RELATION_NOE 16.67<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 局限期<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 6.09<|>RELATION_NOE ±<|>RELATION_NOE 18.75<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 广泛期<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 5.55<|>RELATION_NOE ±<|>RELATION_NOE 30.93<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Livin<|>RELATION_NOE 影响<|>RELATION_NOE 水疱<|>RELATION_NOE 口炎<|>RELATION_NOE 病毒诱导<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 效应<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_S
探讨<|>RELATION_S Livin<|>RELATION_NOE 表达<|>RELATION_NOE 影响<|>RELATION_NOE 水疱<|>RELATION_NOE 口炎<|>RELATION_NOE 病毒<|>RELATION_NOE (<|>RELATION_NOE VSV<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 促<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE 。<|>RELATION_NOE
利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_S Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_NOE Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE 利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_S VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_NOE Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE 利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_S Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生<|>RELATION_S 因素<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_NOE 研究<|>RELATION_NOE
对<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE 肺靶区<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE (<|>RELATION_NOE 纵隔<|>RELATION_NOE 靶区<|>RELATION_NOE )<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 中<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE RP<|>RELATION_NOE )<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 及<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方图<|>RELATION_NOE (<|>RELATION_NOE DVH<|>RELATION_NOE )<|>RELATION_NOE 参数<|>RELATION_NOE 进行<|>RELATION_NOE 对比<|>RELATION_B 研究<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 接受<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 患者<|>RELATION_NOE 83<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE 检验<|>RELATION_NOE 对<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE RP<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ;<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 接受<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 患者<|>RELATION_NOE 83<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE χ<|>RELATION_B 2<|>RELATION_I 检验<|>RELATION_E 对<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE RP<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ;<|>RELATION_NOE
改良<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 巨块型<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
研究<|>RELATION_NOE 在<|>RELATION_NOE -65<|>RELATION_NOE ℃<|>RELATION_NOE 条件<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 不同<|>RELATION_NOE 冷冻<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE ,<|>RELATION_NOE 确定<|>RELATION_S 最佳<|>RELATION_NOE 冷冻<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 择期<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 患者<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 5组<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 膈神经<|>RELATION_NOE 冷冻<|>RELATION_NOE 30<|>RELATION_NOE 、<|>RELATION_NOE 60<|>RELATION_NOE 、<|>RELATION_NOE 90<|>RELATION_NOE 、<|>RELATION_NOE 120<|>RELATION_NOE s<|>RELATION_NOE 组<|>RELATION_NOE 。<|>RELATION_NOE
记录<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 的<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 、<|>RELATION_NOE 胸腔<|>RELATION_NOE 引<|>RELATION_NOE 流量<|>RELATION_NOE 、<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_B 进行<|>RELATION_E 肩胛区<|>RELATION_NOE 牵涉<|>RELATION_NOE 视觉<|>RELATION_NOE 模拟<|>RELATION_NOE 痛<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE VAS<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
拔除<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 管<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 常规<|>RELATION_NOE 行<|>RELATION_NOE 胸部<|>RELATION_NOE 正侧<|>RELATION_NOE 位<|>RELATION_NOE X<|>RELATION_NOE 线片<|>RELATION_NOE 及<|>RELATION_NOE 胸部<|>RELATION_NOE B<|>RELATION_NOE 型<|>RELATION_NOE 超声检查<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 各<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 残腔<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 90d<|>RELATION_NOE 进行<|>RELATION_NOE 胸部<|>RELATION_NOE 透视<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 患侧<|>RELATION_NOE 膈肌<|>RELATION_NOE 运动<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
各组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 术后<|>RELATION_NOE 残腔<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE (<|>RELATION_NOE ><|>RELATION_NOE 200ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 积液<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE (<|>RELATION_NOE ><|>RELATION_NOE 200ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1例行<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 抽取<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 冷冻<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 残腔<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE (<|>RELATION_NOE <<|>RELATION_NOE 100ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 需<|>RELATION_NOE 处理<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 及<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞二钠<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 15min<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 20mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 至<|>RELATION_NOE 第4<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 3<|>RELATION_NOE 周<|>RELATION_NOE 重复<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 口服<|>RELATION_NOE 地塞米松<|>RELATION_NOE 、<|>RELATION_NOE 叶酸<|>RELATION_NOE 和<|>RELATION_NOE 肌肉<|>RELATION_NOE 注射<|>RELATION_NOE 维生素<|>RELATION_NOE B12<|>RELATION_NOE 预处理<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 至少<|>RELATION_NOE 完成<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
P13K-AKT<|>RELATION_NOE 信号<|>RELATION_NOE 在<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 调节<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
分析<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE H1299<|>RELATION_NOE 体外<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S ,<|>RELATION_NOE 探讨<|>RELATION_NOE 磷脂酰肌醇<|>RELATION_NOE -3<|>RELATION_NOE -<|>RELATION_NOE 激酶.<|>RELATION_NOE
细胞计数<|>RELATION_NOE 方法<|>RELATION_NOE -8<|>RELATION_NOE (<|>RELATION_NOE CCK-8<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 效应<|>RELATION_NOE ;<|>RELATION_NOE
酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S CD40<|>RELATION_NOE 对<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 分泌<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 9<|>RELATION_NOE (<|>RELATION_NOE MMP-9<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
CCK-8<|>RELATION_NOE 法示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 其<|>RELATION_NOE 吸<|>RELATION_NOE 光度<|>RELATION_NOE (<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 提高<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 96h<|>RELATION_NOE 时<|>RELATION_NOE 10.0mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 浓度<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 2.75<|>RELATION_NOE ±<|>RELATION_NOE 0.35<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 1.72<|>RELATION_NOE ±<|>RELATION_NOE 0.18<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
侵袭<|>RELATION_NOE 实验示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 穿过<|>RELATION_NOE 微孔<|>RELATION_NOE 贴<|>RELATION_NOE 于<|>RELATION_NOE 下室<|>RELATION_NOE 的<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 168<|>RELATION_NOE ±<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 105<|>RELATION_NOE ±<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 增多<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5C11<|>RELATION_NOE +<|>RELATION_NOE LY294002<|>RELATION_NOE 组<|>RELATION_NOE 下室<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 118<|>RELATION_NOE ±<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE 侵袭<|>RELATION_NOE 实验示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 穿过<|>RELATION_NOE 微孔<|>RELATION_NOE 贴<|>RELATION_NOE 于<|>RELATION_NOE 下室<|>RELATION_NOE 的<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 168<|>RELATION_NOE ±<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 105<|>RELATION_NOE ±<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_NOE 增多<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5C11<|>RELATION_NOE +<|>RELATION_NOE LY294002<|>RELATION_NOE 组<|>RELATION_NOE 下室<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 118<|>RELATION_NOE ±<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE H1299<|>RELATION_NOE 具有<|>RELATION_NOE 促进<|>RELATION_B 体外<|>RELATION_I 增殖<|>RELATION_I 、<|>RELATION_I 侵袭<|>RELATION_I 能力<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 部分<|>RELATION_NOE 在于<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 激发<|>RELATION_NOE 介导<|>RELATION_NOE 的<|>RELATION_NOE P13K-AKT<|>RELATION_NOE 信号<|>RELATION_NOE 活化<|>RELATION_NOE 。<|>RELATION_NOE
TaqMan-<|>RELATION_NOE 扩增<|>RELATION_NOE 阻滞<|>RELATION_NOE 突变<|>RELATION_NOE 系统法<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE T<|>RELATION_NOE aqMan<|>RELATION_NOE 扩增<|>RELATION_NOE 阻滞<|>RELATION_NOE 突变<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE ARMS<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE ,<|>RELATION_NOE 北京<|>RELATION_NOE 4<|>RELATION_NOE 家<|>RELATION_NOE 三级<|>RELATION_NOE 甲等<|>RELATION_NOE 医院<|>RELATION_NOE 的<|>RELATION_NOE 199<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外科手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 预留<|>RELATION_NOE 石蜡<|>RELATION_NOE 样本<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_S TaqMan<|>RELATION_NOE .<|>RELATION_NOE
ARMS<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S EGFR<|>RELATION_NOE 外显子<|>RELATION_NOE 19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE (<|>RELATION_NOE EGFRl9<|>RELATION_NOE 和<|>RELATION_NOE EGFR21<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE DNA<|>RELATION_NOE 测<|>RELATION_NOE 序法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE EGFRl9<|>RELATION_NOE 和<|>RELATION_NOE EGFR21<|>RELATION_NOE 总<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 19.6%<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 199<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 分<|>RELATION_NOE :<|>RELATION_NOE 腺癌<|>RELATION_NOE 35.9%<|>RELATION_NOE (<|>RELATION_NOE 37<|>RELATION_NOE /<|>RELATION_NOE 103<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 2.2%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 93<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺鳞<|>RELATION_NOE 癌0<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变率<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 高度<|>RELATION_B 一致性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 1.000<|>RELATION_NOE ,<|>RELATION_NOE K<|>RELATION_NOE =<|>RELATION_NOE 0.9<|>RELATION_NOE 84<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 腺癌<|>RELATION_NOE 组织<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_S 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 。<|>RELATION_NOE
TaqMan-ARMS<|>RELATION_NOE 法<|>RELATION_NOE 与<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 在<|>RELATION_NOE 检测<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 上<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_B 好<|>RELATION_I 的<|>RELATION_I 一致性<|>RELATION_E 。<|>RELATION_NOE
观察<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制<|>RELATION_NOE 物1<|>RELATION_NOE (<|>RELATION_NOE TSLCl<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE 计数<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE TSLCl<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 42.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 91.11<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 45<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 在<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 38.25<|>RELATION_NOE ±<|>RELATION_NOE 4.37<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 11.39<|>RELATION_NOE ±<|>RELATION_NOE 1.52<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE TSLCl<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CDl05<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE MVD<|>RELATION_NOE 表达<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 食管癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE FQ-PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 160<|>RELATION_NOE 例<|>RELATION_NOE I<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 等<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_NOE 可能<|>RELATION_NOE 存在<|>RELATION_S 微<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ;<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 中<|>RELATION_NOE LUNXmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_NOE 可能<|>RELATION_NOE 存在<|>RELATION_NOE 微转移<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_B 差<|>RELATION_E ;<|>RELATION_NOE
微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 通过<|>RELATION_NOE 调控<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE 抑制<|>RELATION_S 肺腺癌<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE
在<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE 中<|>RELATION_NOE 探讨<|>RELATION_NOE 微小<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE miRNA<|>RELATION_NOE )<|>RELATION_NOE -145<|>RELATION_NOE 调控<|>RELATION_S 肺腺癌<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 发生<|>RELATION_NOE 及其<|>RELATION_NOE 分子<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_S A549<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起始<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_S ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起<|>RELATION_NOE 始细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 采用<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE 方法<|>RELATION_NOE 富集<|>RELATION_NOE A549<|>RELATION_NOE 起<|>RELATION_NOE 始细胞<|>RELATION_NOE 微球<|>RELATION_NOE ,<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE miR-145<|>RELATION_NOE 阻遏物<|>RELATION_NOE 及<|>RELATION_NOE 模拟物<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 细胞<|>RELATION_NOE 微球<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE CD133<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_S 上皮细胞<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE Slug<|>RELATION_NOE 、<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 标志<|>RELATION_NOE E<|>RELATION_NOE 一<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角蛋白18<|>RELATION_NOE (<|>RELATION_NOE Cytokeratin18<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 间充质<|>RELATION_NOE 细胞<|>RELATION_NOE 标志<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE .<|>RELATION_NOE
研究<|>RELATION_NOE 雌激素受体<|>RELATION_NOE (<|>RELATION_NOE ER<|>RELATION_NOE )<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE 有<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 147<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 相关<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE 收集<|>RELATION_NOE 有<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 147<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 相关<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 细胞核<|>RELATION_B 阳性<|>RELATION_I 表达<|>RELATION_E ,<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 4.1%<|>RELATION_NOE (<|>RELATION_NOE 6/<|>RELATION_NOE 147<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE ER<|>RELATION_NOE 口表达<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 86.4%<|>RELATION_NOE (<|>RELATION_NOE 127<|>RELATION_NOE /<|>RELATION_NOE 147<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 具有<|>RELATION_NOE 相关<|>RELATION_S 性<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 雌激素受体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 具有<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 雌激素受体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 重要<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
超声<|>RELATION_NOE 介导<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 125I<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 近<|>RELATION_NOE 距离<|>RELATION_NOE 治疗<|>RELATION_S 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 研究<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 通过<|>RELATION_NOE 声像图<|>RELATION_NOE 所<|>RELATION_NOE 提供<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 周围<|>RELATION_NOE 器官<|>RELATION_NOE 的<|>RELATION_NOE 信息<|>RELATION_NOE 得出<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 计划<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 计划<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 将<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 预定<|>RELATION_NOE 部位<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 超声检查<|>RELATION_S 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 部位<|>RELATION_NOE 是否<|>RELATION_NOE 与<|>RELATION_NOE 计划<|>RELATION_NOE 相符<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 确定<|>RELATION_NOE 补充<|>RELATION_NOE 。<|>RELATION_NOE
卵巢癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 睾丸癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 低<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 65.7%<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE 5.1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 11.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 1年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 34.3%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 35<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_S 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 综合<|>RELATION_NOE 运用<|>RELATION_NOE Logistic<|>RELATION_NOE 回归<|>RELATION_NOE 和<|>RELATION_NOE 受试者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE 曲线<|>RELATION_NOE (<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE )<|>RELATION_NOE 分析<|>RELATION_S 四<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21.1<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE [<|>RELATION_NOE 4.53<|>RELATION_NOE (<|>RELATION_NOE 2.22-11.53<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 28.97<|>RELATION_NOE (<|>RELATION_NOE 11.39-62.10<|>RELATION_NOE )<|>RELATION_NOE u<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 4.05<|>RELATION_NOE (<|>RELATION_NOE 2.29-8.18<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 14.11<|>RELATION_NOE (<|>RELATION_NOE 11.35-24.12<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE m1<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE [<|>RELATION_NOE 2.08<|>RELATION_NOE (<|>RELATION_NOE 1.45-2.52<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 12.90<|>RELATION_NOE (<|>RELATION_NOE 9.80-19.44<|>RELATION_NOE )<|>RELATION_NOE U<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 1.53<|>RELATION_NOE (<|>RELATION_NOE 1.21-2.17<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 11.38<|>RELATION_NOE (<|>RELATION_NOE 9.07-12.80<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE m1<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
IP<|>RELATION_NOE 方案<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_E 广泛期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_S 导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 导管<|>RELATION_NOE 持续<|>RELATION_NOE 引<|>RELATION_NOE 流<|>RELATION_NOE 后<|>RELATION_NOE 接受<|>RELATION_S 顺铂<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 有效率<|>RELATION_NOE 89.3%<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE /<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 有效率<|>RELATION_NOE 83.9%<|>RELATION_NOE (<|>RELATION_NOE 52<|>RELATION_NOE /<|>RELATION_NOE 62<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE χ^2<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 91<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
导管<|>RELATION_NOE 持续<|>RELATION_NOE 引流<|>RELATION_NOE 心包积液<|>RELATION_NOE 联合<|>RELATION_NOE 香菇多糖<|>RELATION_NOE 心包<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S 肺癌<|>RELATION_NOE 导致<|>RELATION_NOE 恶性<|>RELATION_NOE 心包积液<|>RELATION_NOE 的<|>RELATION_NOE 首选<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 1<|>RELATION_NOE 辅助<|>RELATION_B 治疗<|>RELATION_E 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_S 胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 1<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE A<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 给予<|>RELATION_S 综合治疗<|>RELATION_NOE 加<|>RELATION_NOE 胸腺<|>RELATION_NOE 肽<|>RELATION_NOE α<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE ;<|>RELATION_NOE
磨玻璃<|>RELATION_NOE 样<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_S
所有<|>RELATION_NOE 病例<|>RELATION_NOE 通过<|>RELATION_NOE cT<|>RELATION_B 动态<|>RELATION_I 随<|>RELATION_I 访<|>RELATION_I 观察<|>RELATION_E ,<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 密度<|>RELATION_NOE 略<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 进行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 非黏液型<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 。<|>RELATION_NOE 所有<|>RELATION_NOE 病例<|>RELATION_NOE 通过<|>RELATION_NOE cT<|>RELATION_NOE 动态<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 观察<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 密度<|>RELATION_NOE 略<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 进行<|>RELATION_NOE 肺叶<|>RELATION_B 切除<|>RELATION_I 经<|>RELATION_I 病理<|>RELATION_I 诊断<|>RELATION_E 为<|>RELATION_NOE 非黏液型<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 。<|>RELATION_NOE
磨玻璃<|>RELATION_NOE 样<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 进展<|>RELATION_NOE 缓慢<|>RELATION_NOE ,<|>RELATION_NOE 影像学<|>RELATION_B 动态<|>RELATION_I 观察<|>RELATION_E 有助于<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_S 转移性<|>RELATION_NOE 肾细胞癌<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
评价<|>RELATION_S 细胞<|>RELATION_NOE 因子<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE CIK<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_NOE 转移性<|>RELATION_NOE 肾癌<|>RELATION_NOE (<|>RELATION_NOE MRCC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 入住<|>RELATION_NOE 河南省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE (<|>RELATION_NOE 郑州<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE )<|>RELATION_NOE 生物<|>RELATION_NOE 治疗<|>RELATION_NOE 科经<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE MRCC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 接受<|>RELATION_S 至少<|>RELATION_NOE 4<|>RELATION_NOE 周期<|>RELATION_NOE CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 次要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE TTP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE TTP<|>RELATION_NOE 采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S ,<|>RELATION_NOE 影响<|>RELATION_NOE 1rrP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 采用<|>RELATION_NOE Log-Rank<|>RELATION_NOE 方法<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 次要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE TTP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE TTP<|>RELATION_NOE 采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 影响<|>RELATION_NOE 1rrP<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 采用<|>RELATION_NOE Log-Rank<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S 。<|>RELATION_NOE
21<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE (<|>RELATION_NOE PR<|>RELATION_NOE )<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 稳定<|>RELATION_NOE (<|>RELATION_NOE SD<|>RELATION_NOE )<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE (<|>RELATION_NOE PD<|>RELATION_NOE )<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 80.9<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE /<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE TTP<|>RELATION_NOE 为<|>RELATION_NOE 11.68<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ;<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_S 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 采用<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE 满意度<|>RELATION_NOE 及<|>RELATION_NOE 住院时间<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 死亡率<|>RELATION_NOE 显著<|>RELATION_NOE 少于<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 真正<|>RELATION_NOE 的<|>RELATION_NOE 体现<|>RELATION_NOE 以<|>RELATION_NOE 人<|>RELATION_NOE 为<|>RELATION_NOE 本<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 理念<|>RELATION_NOE ,<|>RELATION_NOE 有利于<|>RELATION_S 满足<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心理<|>RELATION_NOE 和<|>RELATION_NOE 生理<|>RELATION_NOE 需求<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 病死率<|>RELATION_NOE 。<|>RELATION_NOE
三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 联合<|>RELATION_NOE 诱导培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE 或<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
比较<|>RELATION_S 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE (<|>RELATION_NOE 3DCRT<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 诱导培<|>RELATION_NOE 美曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 或<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
3DCRT<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 提高<|>RELATION_E 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE 3DCRT<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 提高<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_B 轻<|>RELATION_E ,<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE 分泌<|>RELATION_NOE 不<|>RELATION_NOE 当<|>RELATION_NOE 综合征<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_S
分析<|>RELATION_NOE 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE (<|>RELATION_NOE ADH<|>RELATION_NOE )<|>RELATION_NOE 分泌<|>RELATION_NOE 不<|>RELATION_NOE 当<|>RELATION_NOE 综合征<|>RELATION_NOE (<|>RELATION_NOE SIADH<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 机制<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 在<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE
研究<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
局限期<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE 6.81<|>RELATION_NOE ±<|>RELATION_NOE 28.66<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移者<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 8.09<|>RELATION_NOE ±<|>RELATION_NOE 16.67<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 局限期<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 6.09<|>RELATION_NOE ±<|>RELATION_NOE 18.75<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 广泛期<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 5.55<|>RELATION_NOE ±<|>RELATION_NOE 30.93<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Livin<|>RELATION_NOE 影响<|>RELATION_NOE 水疱<|>RELATION_NOE 口炎<|>RELATION_NOE 病毒诱导<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 效应<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_S
探讨<|>RELATION_S Livin<|>RELATION_NOE 表达<|>RELATION_NOE 影响<|>RELATION_NOE 水疱<|>RELATION_NOE 口炎<|>RELATION_NOE 病毒<|>RELATION_NOE (<|>RELATION_NOE VSV<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 促<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE 。<|>RELATION_NOE
利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_S Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_NOE Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE 利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_S VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_NOE Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE 利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE Livin<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Tunel<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE VSV<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 效应<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量法<|>RELATION_NOE 检测<|>RELATION_S Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生<|>RELATION_S 因素<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_NOE 研究<|>RELATION_NOE
对<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE 肺靶区<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE (<|>RELATION_NOE 纵隔<|>RELATION_NOE 靶区<|>RELATION_NOE )<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 中<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE RP<|>RELATION_NOE )<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 及<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方图<|>RELATION_NOE (<|>RELATION_NOE DVH<|>RELATION_NOE )<|>RELATION_NOE 参数<|>RELATION_NOE 进行<|>RELATION_NOE 对比<|>RELATION_B 研究<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_B 分析<|>RELATION_E 接受<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 患者<|>RELATION_NOE 83<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE 检验<|>RELATION_NOE 对<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE RP<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ;<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 接受<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 纵隔肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 食管癌<|>RELATION_NOE 患者<|>RELATION_NOE 83<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE χ<|>RELATION_B 2<|>RELATION_I 检验<|>RELATION_E 对<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE RP<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ;<|>RELATION_NOE
改良<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 巨块型<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
研究<|>RELATION_NOE 在<|>RELATION_NOE -65<|>RELATION_NOE ℃<|>RELATION_NOE 条件<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 不同<|>RELATION_NOE 冷冻<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE ,<|>RELATION_NOE 确定<|>RELATION_S 最佳<|>RELATION_NOE 冷冻<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 择期<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 患者<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 5组<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 膈神经<|>RELATION_NOE 冷冻<|>RELATION_NOE 30<|>RELATION_NOE 、<|>RELATION_NOE 60<|>RELATION_NOE 、<|>RELATION_NOE 90<|>RELATION_NOE 、<|>RELATION_NOE 120<|>RELATION_NOE s<|>RELATION_NOE 组<|>RELATION_NOE 。<|>RELATION_NOE
记录<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 的<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 、<|>RELATION_NOE 胸腔<|>RELATION_NOE 引<|>RELATION_NOE 流量<|>RELATION_NOE 、<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_B 进行<|>RELATION_E 肩胛区<|>RELATION_NOE 牵涉<|>RELATION_NOE 视觉<|>RELATION_NOE 模拟<|>RELATION_NOE 痛<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE VAS<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
拔除<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 管<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 常规<|>RELATION_NOE 行<|>RELATION_NOE 胸部<|>RELATION_NOE 正侧<|>RELATION_NOE 位<|>RELATION_NOE X<|>RELATION_NOE 线片<|>RELATION_NOE 及<|>RELATION_NOE 胸部<|>RELATION_NOE B<|>RELATION_NOE 型<|>RELATION_NOE 超声检查<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 各<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 残腔<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 90d<|>RELATION_NOE 进行<|>RELATION_NOE 胸部<|>RELATION_NOE 透视<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 患侧<|>RELATION_NOE 膈肌<|>RELATION_NOE 运动<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
各组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 术后<|>RELATION_NOE 残腔<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE (<|>RELATION_NOE ><|>RELATION_NOE 200ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 积液<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE (<|>RELATION_NOE ><|>RELATION_NOE 200ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1例行<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 抽取<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 冷冻<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 残腔<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE (<|>RELATION_NOE <<|>RELATION_NOE 100ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 需<|>RELATION_NOE 处理<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 及<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞二钠<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 15min<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 20mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 至<|>RELATION_NOE 第4<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 3<|>RELATION_NOE 周<|>RELATION_NOE 重复<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 口服<|>RELATION_NOE 地塞米松<|>RELATION_NOE 、<|>RELATION_NOE 叶酸<|>RELATION_NOE 和<|>RELATION_NOE 肌肉<|>RELATION_NOE 注射<|>RELATION_NOE 维生素<|>RELATION_NOE B12<|>RELATION_NOE 预处理<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 至少<|>RELATION_NOE 完成<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
P13K-AKT<|>RELATION_NOE 信号<|>RELATION_NOE 在<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 调节<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
分析<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE H1299<|>RELATION_NOE 体外<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S ,<|>RELATION_NOE 探讨<|>RELATION_NOE 磷脂酰肌醇<|>RELATION_NOE -3<|>RELATION_NOE -<|>RELATION_NOE 激酶.<|>RELATION_NOE
细胞计数<|>RELATION_NOE 方法<|>RELATION_NOE -8<|>RELATION_NOE (<|>RELATION_NOE CCK-8<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 效应<|>RELATION_NOE ;<|>RELATION_NOE
酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S CD40<|>RELATION_NOE 对<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 分泌<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 9<|>RELATION_NOE (<|>RELATION_NOE MMP-9<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
CCK-8<|>RELATION_NOE 法示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 其<|>RELATION_NOE 吸<|>RELATION_NOE 光度<|>RELATION_NOE (<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 提高<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 96h<|>RELATION_NOE 时<|>RELATION_NOE 10.0mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 浓度<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 2.75<|>RELATION_NOE ±<|>RELATION_NOE 0.35<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 1.72<|>RELATION_NOE ±<|>RELATION_NOE 0.18<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
侵袭<|>RELATION_NOE 实验示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 穿过<|>RELATION_NOE 微孔<|>RELATION_NOE 贴<|>RELATION_NOE 于<|>RELATION_NOE 下室<|>RELATION_NOE 的<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 168<|>RELATION_NOE ±<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 105<|>RELATION_NOE ±<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 增多<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5C11<|>RELATION_NOE +<|>RELATION_NOE LY294002<|>RELATION_NOE 组<|>RELATION_NOE 下室<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 118<|>RELATION_NOE ±<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE 侵袭<|>RELATION_NOE 实验示<|>RELATION_NOE 5C11<|>RELATION_NOE 组<|>RELATION_NOE 穿过<|>RELATION_NOE 微孔<|>RELATION_NOE 贴<|>RELATION_NOE 于<|>RELATION_NOE 下室<|>RELATION_NOE 的<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 168<|>RELATION_NOE ±<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 105<|>RELATION_NOE ±<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_NOE 增多<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5C11<|>RELATION_NOE +<|>RELATION_NOE LY294002<|>RELATION_NOE 组<|>RELATION_NOE 下室<|>RELATION_NOE 细胞数<|>RELATION_NOE (<|>RELATION_NOE 118<|>RELATION_NOE ±<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
CD40<|>RELATION_NOE 分子<|>RELATION_NOE 活化<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE H1299<|>RELATION_NOE 具有<|>RELATION_NOE 促进<|>RELATION_B 体外<|>RELATION_I 增殖<|>RELATION_I 、<|>RELATION_I 侵袭<|>RELATION_I 能力<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 部分<|>RELATION_NOE 在于<|>RELATION_NOE CD40<|>RELATION_NOE 分子<|>RELATION_NOE 激发<|>RELATION_NOE 介导<|>RELATION_NOE 的<|>RELATION_NOE P13K-AKT<|>RELATION_NOE 信号<|>RELATION_NOE 活化<|>RELATION_NOE 。<|>RELATION_NOE
TaqMan-<|>RELATION_NOE 扩增<|>RELATION_NOE 阻滞<|>RELATION_NOE 突变<|>RELATION_NOE 系统法<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE T<|>RELATION_NOE aqMan<|>RELATION_NOE 扩增<|>RELATION_NOE 阻滞<|>RELATION_NOE 突变<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE ARMS<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE ,<|>RELATION_NOE 北京<|>RELATION_NOE 4<|>RELATION_NOE 家<|>RELATION_NOE 三级<|>RELATION_NOE 甲等<|>RELATION_NOE 医院<|>RELATION_NOE 的<|>RELATION_NOE 199<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外科手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 预留<|>RELATION_NOE 石蜡<|>RELATION_NOE 样本<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_S TaqMan<|>RELATION_NOE .<|>RELATION_NOE
ARMS<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 检测<|>RELATION_S EGFR<|>RELATION_NOE 外显子<|>RELATION_NOE 19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE (<|>RELATION_NOE EGFRl9<|>RELATION_NOE 和<|>RELATION_NOE EGFR21<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE DNA<|>RELATION_NOE 测<|>RELATION_NOE 序法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE EGFRl9<|>RELATION_NOE 和<|>RELATION_NOE EGFR21<|>RELATION_NOE 总<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 19.6%<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 199<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 分<|>RELATION_NOE :<|>RELATION_NOE 腺癌<|>RELATION_NOE 35.9%<|>RELATION_NOE (<|>RELATION_NOE 37<|>RELATION_NOE /<|>RELATION_NOE 103<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 2.2%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 93<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺鳞<|>RELATION_NOE 癌0<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变率<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 高度<|>RELATION_B 一致性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 1.000<|>RELATION_NOE ,<|>RELATION_NOE K<|>RELATION_NOE =<|>RELATION_NOE 0.9<|>RELATION_NOE 84<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 腺癌<|>RELATION_NOE 组织<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_S 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 。<|>RELATION_NOE
TaqMan-ARMS<|>RELATION_NOE 法<|>RELATION_NOE 与<|>RELATION_NOE DNA<|>RELATION_NOE 测序法<|>RELATION_NOE 在<|>RELATION_NOE 检测<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 上<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_B 好<|>RELATION_I 的<|>RELATION_I 一致性<|>RELATION_E 。<|>RELATION_NOE
肺移植<|>RELATION_NOE 治疗<|>RELATION_S 肺部<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 4例<|>RELATION_NOE
1例<|>RELATION_NOE 为<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 为<|>RELATION_NOE 支气管<|>RELATION_NOE 源性<|>RELATION_NOE 肺癌<|>RELATION_NOE 伴终<|>RELATION_NOE 末期<|>RELATION_NOE 肺疾病<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 为<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 。<|>RELATION_NOE
4例<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 行序贯式<|>RELATION_NOE 双<|>RELATION_NOE 肺移植<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 行单<|>RELATION_NOE 肺移植<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 1例单<|>RELATION_NOE 肺移植<|>RELATION_NOE 在<|>RELATION_NOE 体外<|>RELATION_NOE 膜肺<|>RELATION_NOE 氧合<|>RELATION_NOE 辅助<|>RELATION_NOE 下<|>RELATION_NOE 完成<|>RELATION_NOE 。<|>RELATION_NOE
1例<|>RELATION_NOE 于<|>RELATION_NOE 术后<|>RELATION_NOE 25<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 3例<|>RELATION_NOE 至<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 截止<|>RELATION_NOE 已<|>RELATION_NOE 分别<|>RELATION_NOE 存活<|>RELATION_NOE 11<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 、<|>RELATION_NOE 1年<|>RELATION_NOE 和<|>RELATION_NOE 8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 肺功能<|>RELATION_NOE 良好<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 出现<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 表现<|>RELATION_NOE 。<|>RELATION_NOE
温石棉<|>RELATION_NOE 暴露<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 剂量<|>RELATION_B 反应<|>RELATION_I 关系<|>RELATION_E 的<|>RELATION_NOE 队列研究<|>RELATION_NOE
究<|>RELATION_NOE 温石棉<|>RELATION_NOE 矿工<|>RELATION_NOE 接触<|>RELATION_NOE 石棉<|>RELATION_NOE 粉尘量<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_B 反应<|>RELATION_I 关系<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE 不同<|>RELATION_NOE 石棉<|>RELATION_NOE 暴露<|>RELATION_NOE 剂量<|>RELATION_NOE 下<|>RELATION_NOE 的<|>RELATION_NOE 究<|>RELATION_NOE 温石棉<|>RELATION_NOE 矿工<|>RELATION_NOE 接触<|>RELATION_NOE 石棉<|>RELATION_NOE 粉尘量<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 反应<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_S 不同<|>RELATION_NOE 石棉<|>RELATION_NOE 暴露<|>RELATION_NOE 剂量<|>RELATION_NOE 下<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 规律<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 从<|>RELATION_NOE 2009年<|>RELATION_NOE 7月<|>RELATION_NOE 开始<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 回顾性<|>RELATION_NOE 队列研究<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 人选<|>RELATION_NOE 条件<|>RELATION_NOE 为<|>RELATION_NOE 1981年<|>RELATION_NOE 1月<|>RELATION_NOE 1日<|>RELATION_NOE 至<|>RELATION_NOE 1988年<|>RELATION_NOE 12月<|>RELATION_NOE 31日<|>RELATION_NOE 登记在册<|>RELATION_NOE ,<|>RELATION_NOE 工龄<|>RELATION_NOE 满<|>RELATION_NOE 1<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 没有<|>RELATION_NOE 明显<|>RELATION_NOE 心<|>RELATION_NOE 肺疾病<|>RELATION_NOE 者<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 符合<|>RELATION_NOE 标准<|>RELATION_NOE 的<|>RELATION_NOE 1932<|>RELATION_NOE 例<|>RELATION_NOE 石棉<|>RELATION_NOE 矿工<|>RELATION_NOE 纳入<|>RELATION_NOE 队列<|>RELATION_NOE ,<|>RELATION_NOE 追踪<|>RELATION_NOE 29<|>RELATION_NOE 年<|>RELATION_NOE (<|>RELATION_NOE 1981<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 接尘<|>RELATION_NOE 矿工<|>RELATION_NOE 的<|>RELATION_NOE 个人<|>RELATION_NOE 信息<|>RELATION_NOE 、<|>RELATION_NOE 职业史<|>RELATION_NOE 、<|>RELATION_NOE 疾病史<|>RELATION_NOE 、<|>RELATION_NOE 健康<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 收集<|>RELATION_NOE 该矿<|>RELATION_NOE 历年<|>RELATION_NOE 粉尘<|>RELATION_NOE 浓度<|>RELATION_NOE 监测<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 寿命<|>RELATION_NOE 表法<|>RELATION_NOE 建立<|>RELATION_S 石棉<|>RELATION_NOE 尘<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 反应<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 拟合<|>RELATION_NOE 剂量<|>RELATION_NOE 患病<|>RELATION_NOE 概率<|>RELATION_NOE 回归<|>RELATION_NOE 方程<|>RELATION_NOE ,<|>RELATION_NOE 估算<|>RELATION_NOE 不同<|>RELATION_NOE 工作<|>RELATION_NOE 年限<|>RELATION_NOE 不同<|>RELATION_NOE 粉尘<|>RELATION_NOE 浓度<|>RELATION_NOE 下<|>RELATION_NOE 肺癌<|>RELATION_NOE 超额<|>RELATION_NOE 发病率<|>RELATION_NOE 。<|>RELATION_NOE 应用<|>RELATION_NOE 寿命表<|>RELATION_NOE 法<|>RELATION_NOE 建立<|>RELATION_NOE 石棉<|>RELATION_NOE 尘<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 反应<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 拟合<|>RELATION_S 剂量<|>RELATION_NOE 患病<|>RELATION_NOE 概率<|>RELATION_NOE 回归<|>RELATION_NOE 方程<|>RELATION_NOE ,<|>RELATION_NOE 估算<|>RELATION_NOE 不同<|>RELATION_NOE 工作<|>RELATION_NOE 年限<|>RELATION_NOE 不同<|>RELATION_NOE 粉尘<|>RELATION_NOE 浓度<|>RELATION_NOE 下<|>RELATION_NOE 肺癌<|>RELATION_NOE 超额<|>RELATION_NOE 发病率<|>RELATION_NOE 。<|>RELATION_NOE 应用<|>RELATION_NOE 寿命表<|>RELATION_NOE 法<|>RELATION_NOE 建立<|>RELATION_NOE 石棉<|>RELATION_NOE 尘<|>RELATION_NOE 质量<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 反应<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 拟合<|>RELATION_NOE 剂量<|>RELATION_NOE 患病<|>RELATION_NOE 概率<|>RELATION_NOE 回归<|>RELATION_NOE 方程<|>RELATION_NOE ,<|>RELATION_NOE 估算<|>RELATION_S 不同<|>RELATION_NOE 工作<|>RELATION_NOE 年限<|>RELATION_NOE 不同<|>RELATION_NOE 粉尘<|>RELATION_NOE 浓度<|>RELATION_NOE 下<|>RELATION_NOE 肺癌<|>RELATION_NOE 超额<|>RELATION_NOE 发病率<|>RELATION_NOE 。<|>RELATION_NOE
工人<|>RELATION_NOE 累积<|>RELATION_NOE 接尘量<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 累积<|>RELATION_NOE 发病<|>RELATION_NOE 概率<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_B 的<|>RELATION_I 剂量<|>RELATION_I 反应<|>RELATION_I 关系<|>RELATION_E ,<|>RELATION_NOE 且<|>RELATION_NOE 吸烟组<|>RELATION_NOE 的<|>RELATION_NOE 工人<|>RELATION_NOE 累积<|>RELATION_NOE 接尘量<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 累积<|>RELATION_NOE 发病<|>RELATION_NOE 概率<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 反应<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 吸烟组<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 累积<|>RELATION_NOE 发病<|>RELATION_NOE 概率<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 非<|>RELATION_NOE 吸烟组<|>RELATION_NOE 。<|>RELATION_NOE
开展<|>RELATION_NOE 本次<|>RELATION_NOE 研究<|>RELATION_NOE 的<|>RELATION_NOE 石棉<|>RELATION_NOE 矿<|>RELATION_NOE 生产<|>RELATION_NOE 车间<|>RELATION_NOE 2009<|>RELATION_NOE 年<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 粉尘<|>RELATION_NOE 浓度<|>RELATION_NOE 超标<|>RELATION_NOE 85<|>RELATION_NOE 倍<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 方程<|>RELATION_NOE 推测<|>RELATION_S 在<|>RELATION_NOE 此<|>RELATION_NOE 暴露<|>RELATION_NOE 环境<|>RELATION_NOE 下<|>RELATION_NOE 工作<|>RELATION_NOE 40<|>RELATION_NOE 年<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 超额<|>RELATION_NOE 发病率<|>RELATION_NOE 将<|>RELATION_NOE 达到<|>RELATION_NOE 11<|>RELATION_NOE 2.5<|>RELATION_NOE 98<|>RELATION_NOE ,<|>RELATION_NOE 万<|>RELATION_NOE 。<|>RELATION_NOE
石棉<|>RELATION_NOE 矿工<|>RELATION_NOE 石棉<|>RELATION_NOE 累积<|>RELATION_NOE 接尘量<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 间<|>RELATION_NOE 存在<|>RELATION_NOE 明显<|>RELATION_B 的<|>RELATION_I 剂量<|>RELATION_I 反应<|>RELATION_I 关系<|>RELATION_E ,<|>RELATION_NOE 石棉<|>RELATION_NOE 矿工<|>RELATION_NOE 石棉<|>RELATION_NOE 累积<|>RELATION_NOE 接尘量<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 间<|>RELATION_NOE 存在<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 反应<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 风险<|>RELATION_NOE 随<|>RELATION_NOE 暴露量<|>RELATION_NOE 的<|>RELATION_NOE 增加<|>RELATION_NOE 呈现<|>RELATION_NOE 上升<|>RELATION_B 趋势<|>RELATION_E 。<|>RELATION_NOE
Caveolin-1<|>RELATION_NOE 在<|>RELATION_NOE 超微细<|>RELATION_NOE 炭黑<|>RELATION_NOE 颗粒<|>RELATION_NOE 人胞<|>RELATION_NOE 途径<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
A549<|>RELATION_NOE 细胞<|>RELATION_NOE 接受0<|>RELATION_NOE 、<|>RELATION_NOE 25<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE 、<|>RELATION_NOE 100<|>RELATION_NOE 、<|>RELATION_NOE 200<|>RELATION_NOE 、<|>RELATION_NOE 400<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE mlCBNPs<|>RELATION_NOE 染毒<|>RELATION_S 24h<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 台<|>RELATION_NOE 盼<|>RELATION_NOE 蓝<|>RELATION_NOE 染色法<|>RELATION_NOE 检测<|>RELATION_NOE CBNPs<|>RELATION_NOE 对<|>RELATION_NOE 细胞<|>RELATION_NOE 活性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 接受0<|>RELATION_NOE 、<|>RELATION_NOE 25<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE 、<|>RELATION_NOE 100<|>RELATION_NOE 、<|>RELATION_NOE 200<|>RELATION_NOE 、<|>RELATION_NOE 400<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE mlCBNPs<|>RELATION_NOE 染毒<|>RELATION_NOE 24h<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 台<|>RELATION_NOE 盼<|>RELATION_NOE 蓝<|>RELATION_NOE 染色法<|>RELATION_NOE 检测<|>RELATION_S CBNPs<|>RELATION_NOE 对<|>RELATION_NOE 细胞<|>RELATION_NOE 活性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
0<|>RELATION_NOE 、<|>RELATION_NOE 25<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE 、<|>RELATION_NOE 100<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE mlCBNPs<|>RELATION_NOE 染毒<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 24h<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 细胞<|>RELATION_B 检测<|>RELATION_E 侧<|>RELATION_NOE 向<|>RELATION_NOE 角散<|>RELATION_NOE 射<|>RELATION_NOE 参数<|>RELATION_NOE (<|>RELATION_NOE sidescatter<|>RELATION_NOE ,<|>RELATION_NOE SSC<|>RELATION_NOE )<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 透射<|>RELATION_NOE 电镜<|>RELATION_NOE 观察<|>RELATION_NOE 细胞<|>RELATION_NOE 形态学<|>RELATION_NOE 变化<|>RELATION_NOE ;<|>RELATION_NOE 0<|>RELATION_NOE 、<|>RELATION_NOE 25<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE 、<|>RELATION_NOE 100<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE mlCBNPs<|>RELATION_NOE 染毒<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 24h<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 细胞<|>RELATION_NOE 检测<|>RELATION_NOE 侧<|>RELATION_NOE 向<|>RELATION_NOE 角散<|>RELATION_NOE 射<|>RELATION_NOE 参数<|>RELATION_NOE (<|>RELATION_NOE sidescatter<|>RELATION_NOE ,<|>RELATION_NOE SSC<|>RELATION_NOE )<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 透射<|>RELATION_NOE 电镜<|>RELATION_NOE 观察<|>RELATION_S 细胞<|>RELATION_NOE 形态学<|>RELATION_NOE 变化<|>RELATION_NOE ;<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 标记<|>RELATION_NOE 检测<|>RELATION_S 肺腺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE E746-A750<|>RELATION_NOE 缺失<|>RELATION_NOE 和<|>RELATION_NOE L858R<|>RELATION_NOE 点突变<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE
研究<|>RELATION_NOE 2种<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 突变<|>RELATION_NOE 特异性<|>RELATION_NOE 抗体<|>RELATION_NOE 外显子<|>RELATION_NOE 19<|>RELATION_NOE 中<|>RELATION_NOE E746-A750<|>RELATION_NOE 缺失<|>RELATION_NOE 和<|>RELATION_NOE 外显子<|>RELATION_NOE 21<|>RELATION_NOE 中<|>RELATION_NOE L858R<|>RELATION_NOE 点突变<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 标记<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_B EGFR<|>RELATION_I 突变<|>RELATION_I 检测<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 2种<|>RELATION_NOE 抗<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 特异性<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE E746-A750<|>RELATION_NOE 缺失<|>RELATION_NOE 和<|>RELATION_NOE L858R<|>RELATION_NOE 点突变<|>RELATION_NOE 对<|>RELATION_NOE 175<|>RELATION_NOE 例<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 进行<|>RELATION_NOE 免疫<|>RELATION_B 组织<|>RELATION_I 化学<|>RELATION_I 检测<|>RELATION_E ,<|>RELATION_NOE 这些<|>RELATION_NOE 病例<|>RELATION_NOE 以往<|>RELATION_NOE 均<|>RELATION_NOE 曾<|>RELATION_NOE 通过<|>RELATION_NOE 直接<|>RELATION_NOE DNA<|>RELATION_NOE 测序<|>RELATION_NOE 进行<|>RELATION_NOE 过<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 和<|>RELATION_NOE 直接<|>RELATION_NOE 基因<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 2种<|>RELATION_NOE 方法<|>RELATION_NOE 在<|>RELATION_NOE 检测<|>RELATION_NOE delE746-A750<|>RELATION_NOE 和<|>RELATION_NOE L858R<|>RELATION_NOE 总体<|>RELATION_NOE 突变率<|>RELATION_NOE 方面<|>RELATION_NOE 并<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 差异<|>RELATION_E [<|>RELATION_NOE 33.7%<|>RELATION_NOE (<|>RELATION_NOE 59<|>RELATION_NOE /<|>RELATION_NOE 175<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 30.9%<|>RELATION_NOE (<|>RELATION_NOE 54<|>RELATION_NOE /<|>RELATION_NOE 175<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 基因<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 结果<|>RELATION_NOE 为<|>RELATION_NOE 金标准<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 、<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 和<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 83.1%<|>RELATION_NOE 、<|>RELATION_NOE 95.7%<|>RELATION_NOE 、<|>RELATION_NOE 90.7%<|>RELATION_NOE 和<|>RELATION_NOE 90.9%<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 特异性<|>RELATION_NOE 抗体<|>RELATION_NOE E746-A750<|>RELATION_NOE 缺失<|>RELATION_NOE 和<|>RELATION_NOE L858R<|>RELATION_NOE 点突变<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 标记<|>RELATION_NOE 在<|>RELATION_NOE 检测<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 方面<|>RELATION_NOE 具<|>RELATION_NOE 有<|>RELATION_B 较<|>RELATION_I 高<|>RELATION_I 的<|>RELATION_I 敏感性<|>RELATION_I 和<|>RELATION_I 特异性<|>RELATION_E ,<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 经济<|>RELATION_NOE 、<|>RELATION_NOE 快捷<|>RELATION_NOE 和<|>RELATION_NOE 高效<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 筛选<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 特异性<|>RELATION_NOE 抗体<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
验证<|>RELATION_NOE 针对<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 经典<|>RELATION_NOE 突变<|>RELATION_NOE —<|>RELATION_NOE -19de1E746.A750<|>RELATION_NOE /<|>RELATION_NOE 211858R<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 抗体<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 探讨<|>RELATION_S 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 检测<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE (<|>RELATION_NOE EnVision<|>RELATION_NOE 二<|>RELATION_NOE 步<|>RELATION_NOE 法<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Q<|>RELATION_NOE 评分<|>RELATION_NOE 体系<|>RELATION_NOE 及<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 检测<|>RELATION_S 309<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 标准<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE -DNA<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE (<|>RELATION_NOE EnVision<|>RELATION_NOE 二<|>RELATION_NOE 步<|>RELATION_NOE 法<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Q<|>RELATION_NOE 评分<|>RELATION_NOE 体系<|>RELATION_NOE 及<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 检测<|>RELATION_NOE 309<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 标准<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE -DNA<|>RELATION_NOE 测<|>RELATION_B 序<|>RELATION_E
结果<|>RELATION_NOE :<|>RELATION_NOE 经过<|>RELATION_NOE PCR-DNA<|>RELATION_NOE 直接<|>RELATION_NOE 测序<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 92<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 外显子<|>RELATION_NOE 19de1E746-A750<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 110<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 外显子<|>RELATION_NOE 21L858R<|>RELATION_NOE 点突变<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE delEGFR<|>RELATION_NOE 抗体<|>RELATION_NOE 检测<|>RELATION_NOE 外显子<|>RELATION_NOE 19de1E746-A750<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 为<|>RELATION_NOE 84.8%<|>RELATION_NOE (<|>RELATION_NOE 78<|>RELATION_NOE /<|>RELATION_NOE 92<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 特异度<|>RELATION_NOE 为<|>RELATION_NOE 77.6%<|>RELATION_NOE (<|>RELATION_NOE 83<|>RELATION_NOE /<|>RELATION_NOE 107<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE ROC<|>RELATION_NOE 曲线下面积<|>RELATION_NOE 为<|>RELATION_NOE 0.8<|>RELATION_NOE 85<|>RELATION_NOE ,<|>RELATION_NOE 最佳<|>RELATION_NOE 分界值<|>RELATION_NOE 为<|>RELATION_NOE 85.00<|>RELATION_NOE ;<|>RELATION_NOE
用<|>RELATION_NOE L858R<|>RELATION_NOE 抗体<|>RELATION_NOE 检测<|>RELATION_NOE 外显子<|>RELATION_NOE 21L858R<|>RELATION_NOE 点突变<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 为<|>RELATION_NOE 94.5%<|>RELATION_NOE (<|>RELATION_NOE 104<|>RELATION_NOE /<|>RELATION_NOE 110<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 特异度<|>RELATION_NOE 为<|>RELATION_NOE 62.5%<|>RELATION_NOE (<|>RELATION_NOE 55<|>RELATION_NOE /<|>RELATION_NOE 88<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE ROC<|>RELATION_NOE 曲线下面积<|>RELATION_NOE 为<|>RELATION_NOE 0.9<|>RELATION_NOE 24<|>RELATION_NOE ,<|>RELATION_NOE 最佳<|>RELATION_NOE 分界值<|>RELATION_NOE 为<|>RELATION_NOE 97.50<|>RELATION_NOE 。<|>RELATION_NOE
delEGFR<|>RELATION_NOE 和<|>RELATION_NOE L858R<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 特异性<|>RELATION_NOE 抗体<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 检测<|>RELATION_S EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 结果<|>RELATION_NOE 判读<|>RELATION_NOE 使用<|>RELATION_NOE Q<|>RELATION_NOE 评分<|>RELATION_NOE 及<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 评价<|>RELATION_NOE delEGFR<|>RELATION_NOE 和<|>RELATION_NOE L858R<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 特异性<|>RELATION_NOE 抗体<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 检测<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 结果<|>RELATION_NOE 判读<|>RELATION_NOE 使用<|>RELATION_NOE Q<|>RELATION_NOE 评分<|>RELATION_NOE 及<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 评价<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_B 好<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 分子<|>RELATION_NOE 肝素<|>RELATION_NOE 治疗<|>RELATION_S 对<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 效果<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
低<|>RELATION_NOE 分子<|>RELATION_NOE 肝素<|>RELATION_NOE 治疗<|>RELATION_NOE 可以<|>RELATION_NOE 延长<|>RELATION_S 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_NOE 血液<|>RELATION_NOE 高凝<|>RELATION_NOE 状态<|>RELATION_NOE 。<|>RELATION_NOE
超<|>RELATION_NOE 细支气管镜<|>RELATION_NOE 在<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 32<|>RELATION_NOE 例行<|>RELATION_NOE 超<|>RELATION_NOE 细支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 的<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 常规<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 未<|>RELATION_NOE 发现<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 再次<|>RELATION_NOE 行超<|>RELATION_NOE 细支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 。<|>RELATION_NOE
确诊<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 分类癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 50.0%<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
超<|>RELATION_NOE 细支气管镜<|>RELATION_NOE 对<|>RELATION_NOE 肺不同<|>RELATION_NOE 部位<|>RELATION_NOE 的<|>RELATION_NOE 肿块<|>RELATION_NOE 诊断<|>RELATION_B 阳性<|>RELATION_I 率<|>RELATION_I 差异<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 17<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 肺内<|>RELATION_NOE 带<|>RELATION_NOE 肿块<|>RELATION_NOE 诊断<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 较<|>RELATION_NOE 肺外<|>RELATION_NOE 带<|>RELATION_NOE 及<|>RELATION_NOE 胸膜<|>RELATION_NOE 高<|>RELATION_NOE 。<|>RELATION_NOE
超<|>RELATION_NOE 细支气管镜<|>RELATION_NOE 总<|>RELATION_NOE 检查<|>RELATION_NOE 时间<|>RELATION_NOE 25<|>RELATION_NOE －<|>RELATION_NOE 65min<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 38.9min<|>RELATION_NOE ,<|>RELATION_NOE 超<|>RELATION_NOE 细支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 时间<|>RELATION_NOE 较<|>RELATION_NOE 常规<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE 检查<|>RELATION_NOE 时间<|>RELATION_NOE 长<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 13<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 顺利<|>RELATION_NOE 完成<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 发生<|>RELATION_NOE 气胸<|>RELATION_NOE 和<|>RELATION_NOE 致命性<|>RELATION_NOE 大<|>RELATION_NOE 出血<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 咳嗽<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 普通<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 明显<|>RELATION_NOE 小<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF-B<|>RELATION_NOE 和<|>RELATION_NOE PIGF<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 样本<|>RELATION_NOE 中<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE -B<|>RELATION_NOE (<|>RELATION_NOE VEGF-B<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 胎盘<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE PIGF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE ,<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE 效果<|>RELATION_NOE 等<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
通过<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 和<|>RELATION_NOE 健康<|>RELATION_NOE 对照者<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 样本<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE VEGF-B<|>RELATION_NOE 、<|>RELATION_NOE PIGF<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 统计学<|>RELATION_NOE 处理<|>RELATION_NOE 。<|>RELATION_NOE
VEGF-B<|>RELATION_NOE 和<|>RELATION_NOE PIGF<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 健康<|>RELATION_NOE 人群<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE VEGF-B<|>RELATION_NOE 和<|>RELATION_NOE PIGF<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 健康<|>RELATION_NOE 人群<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
经<|>RELATION_NOE EP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE VEGF-B<|>RELATION_NOE 和<|>RELATION_NOE PIGF<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 与<|>RELATION_NOE 治疗<|>RELATION_NOE 效果<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
急性<|>RELATION_NOE 时<|>RELATION_NOE 相反<|>RELATION_NOE 应<|>RELATION_NOE 蛋白<|>RELATION_NOE 与<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_B 分析<|>RELATION_E 研究<|>RELATION_NOE
C<|>RELATION_NOE 反应<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE CRP<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 急性<|>RELATION_NOE 时<|>RELATION_NOE 相反<|>RELATION_NOE 应<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 除了<|>RELATION_NOE 在<|>RELATION_NOE 机体<|>RELATION_NOE 急性<|>RELATION_NOE 损伤<|>RELATION_NOE 感染<|>RELATION_NOE 时<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 得到<|>RELATION_NOE 公认<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 升高<|>RELATION_NOE 的<|>RELATION_NOE 急性<|>RELATION_NOE 时<|>RELATION_NOE 相反<|>RELATION_NOE 应<|>RELATION_NOE 蛋白<|>RELATION_NOE 与<|>RELATION_NOE 多种<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌差<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_S 。<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 旨在<|>RELATION_NOE 调查<|>RELATION_NOE 治疗<|>RELATION_NOE 前血<|>RELATION_NOE CRP<|>RELATION_NOE 对<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
治疗<|>RELATION_NOE 前<|>RELATION_NOE 血清<|>RELATION_NOE CRP<|>RELATION_NOE 值<|>RELATION_NOE 的<|>RELATION_NOE 升高<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE ECOGPS<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 37<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 直径<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 34<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤分期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 血清白蛋白<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE :<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 血清<|>RELATION_NOE CRP<|>RELATION_NOE 值<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 47<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE ECOGPS<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 17<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 前白蛋白<|>RELATION_NOE 值<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE 数<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 34<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_S 。<|>RELATION_NOE
应用<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 上述<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 结果<|>RELATION_NOE 发现<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 血清<|>RELATION_NOE CRP<|>RELATION_NOE 值<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE =<|>RELATION_NOE 1.5<|>RELATION_NOE 25<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 37<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE ECOGPS<|>RELATION_NOE 评分<|>RELATION_NOE 高<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE =<|>RELATION_NOE 1.904<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 分期晚<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE =<|>RELATION_NOE 1.7<|>RELATION_NOE 98<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 前白蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 低下<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE =<|>RELATION_NOE 1.5<|>RELATION_NOE 42<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 导致<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 差<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 因子<|>RELATION_E 。<|>RELATION_NOE
对于<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE CRP<|>RELATION_NOE 的<|>RELATION_NOE 存在<|>RELATION_NOE 及<|>RELATION_NOE 强度<|>RELATION_NOE 是<|>RELATION_NOE 独立<|>RELATION_B 的<|>RELATION_I 预后<|>RELATION_I 因素<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 功能<|>RELATION_NOE 状态<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 低蛋白血症<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE 对于<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE CRP<|>RELATION_NOE 的<|>RELATION_NOE 存在<|>RELATION_NOE 及<|>RELATION_NOE 强度<|>RELATION_NOE 是<|>RELATION_NOE 独立<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 功能<|>RELATION_NOE 状态<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 低蛋白血症<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
高体<|>RELATION_NOE 积分<|>RELATION_NOE 数氧<|>RELATION_NOE 暴露<|>RELATION_NOE 下<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中小窝<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 与<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE -<|>RELATION_NOE β<|>RELATION_NOE 1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 相互<|>RELATION_I 关系<|>RELATION_E
观察<|>RELATION_NOE 高体<|>RELATION_NOE 积分<|>RELATION_NOE 数氧<|>RELATION_NOE (<|>RELATION_NOE 高氧<|>RELATION_NOE )<|>RELATION_NOE 暴露<|>RELATION_NOE 后<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中小窝<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE CAV-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE TGF<|>RELATION_NOE )<|>RELATION_NOE -<|>RELATION_NOE β1<|>RELATION_NOE 的<|>RELATION_NOE 动态<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE CAV-1<|>RELATION_NOE 和<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE 在<|>RELATION_NOE 高氧<|>RELATION_NOE 肺损伤<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE 观察<|>RELATION_NOE 高体<|>RELATION_NOE 积分<|>RELATION_NOE 数氧<|>RELATION_NOE (<|>RELATION_NOE 高氧<|>RELATION_NOE )<|>RELATION_NOE 暴露<|>RELATION_NOE 后<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中小窝<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE CAV-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE TGF<|>RELATION_NOE )<|>RELATION_NOE -<|>RELATION_NOE β1<|>RELATION_NOE 的<|>RELATION_NOE 动态<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE CAV-1<|>RELATION_NOE 和<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE 在<|>RELATION_NOE 高氧<|>RELATION_NOE 肺损伤<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S 。<|>RELATION_NOE
复苏液<|>RELATION_NOE 氮罐<|>RELATION_NOE 中<|>RELATION_NOE 冻存<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞系<|>RELATION_NOE ,<|>RELATION_NOE 体外<|>RELATION_NOE 传代<|>RELATION_NOE 培养<|>RELATION_NOE ,<|>RELATION_NOE 待<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 37<|>RELATION_NOE ℃<|>RELATION_NOE 、<|>RELATION_NOE 50mL<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 二氧化碳<|>RELATION_NOE (<|>RELATION_NOE CO<|>RELATION_NOE :<|>RELATION_NOE )<|>RELATION_NOE 饱和<|>RELATION_NOE 湿度<|>RELATION_NOE 培养<|>RELATION_NOE 箱<|>RELATION_NOE 中<|>RELATION_NOE 生长<|>RELATION_NOE 至<|>RELATION_NOE 接近<|>RELATION_NOE 融合<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 高氧组<|>RELATION_NOE 。<|>RELATION_NOE
肺内<|>RELATION_NOE 大<|>RELATION_NOE 肿块<|>RELATION_NOE 呼吸<|>RELATION_NOE 动度<|>RELATION_NOE 的<|>RELATION_NOE 测量<|>RELATION_B 与<|>RELATION_I 分析<|>RELATION_E
分析<|>RELATION_NOE 肺内<|>RELATION_NOE 肿瘤<|>RELATION_NOE 因<|>RELATION_NOE 呼吸<|>RELATION_NOE 导致<|>RELATION_NOE 运动<|>RELATION_B 的<|>RELATION_I 影响<|>RELATION_I 因素<|>RELATION_E ,<|>RELATION_NOE 寻找<|>RELATION_NOE 运动度<|>RELATION_NOE 大<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 特征<|>RELATION_NOE 。<|>RELATION_NOE
分别<|>RELATION_NOE 在<|>RELATION_NOE 平静<|>RELATION_NOE 吸气<|>RELATION_NOE 后<|>RELATION_NOE 屏气<|>RELATION_NOE 、<|>RELATION_NOE 平静<|>RELATION_NOE 呼气<|>RELATION_NOE 后<|>RELATION_NOE 屏气<|>RELATION_NOE 状态<|>RELATION_NOE 下<|>RELATION_NOE 接受<|>RELATION_NOE CT<|>RELATION_NOE 扫捕<|>RELATION_NOE 的<|>RELATION_NOE 目市<|>RELATION_NOE 内<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺内<|>RELATION_NOE 可<|>RELATION_NOE 测量<|>RELATION_NOE 病灶<|>RELATION_NOE 30<|>RELATION_NOE 个<|>RELATION_NOE 。<|>RELATION_NOE
南同一<|>RELATION_NOE 位<|>RELATION_NOE 医生<|>RELATION_NOE 在<|>RELATION_NOE 两<|>RELATION_NOE 个<|>RELATION_NOE 时相<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 数据<|>RELATION_NOE 上<|>RELATION_NOE 勾画<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE (<|>RELATION_NOE GTV<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 测量<|>RELATION_S GTV<|>RELATION_NOE 中心层<|>RELATION_NOE 而<|>RELATION_NOE 前后<|>RELATION_NOE 内外界<|>RELATION_NOE 在<|>RELATION_NOE 呼吸<|>RELATION_NOE 周期<|>RELATION_NOE 中<|>RELATION_NOE 左右<|>RELATION_NOE 、<|>RELATION_NOE 前后<|>RELATION_NOE 方向<|>RELATION_NOE 的<|>RELATION_NOE 运动<|>RELATION_NOE 幅度<|>RELATION_NOE ;<|>RELATION_NOE
肺内<|>RELATION_NOE 大<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位置<|>RELATION_NOE 相对<|>RELATION_NOE 同<|>RELATION_NOE 定<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 中心层<|>RELATION_NOE 而<|>RELATION_NOE 各<|>RELATION_NOE 方向<|>RELATION_NOE 动度<|>RELATION_NOE 多数<|>RELATION_NOE 在<|>RELATION_NOE 3－<|>RELATION_NOE 5mm<|>RELATION_NOE ,<|>RELATION_NOE 只<|>RELATION_NOE 有<|>RELATION_NOE 2例<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 各个<|>RELATION_NOE 方向<|>RELATION_NOE 运动<|>RELATION_NOE 幅度<|>RELATION_NOE ><|>RELATION_NOE 5Hmm<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 位于<|>RELATION_NOE 胸腔<|>RELATION_NOE 中<|>RELATION_NOE 下部<|>RELATION_NOE 及<|>RELATION_NOE 中后部<|>RELATION_NOE ,<|>RELATION_NOE 粘连系数<|>RELATION_NOE 较<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 体积<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 上下<|>RELATION_NOE 方向<|>RELATION_NOE 运动<|>RELATION_NOE 。<|>RELATION_NOE
呼吸<|>RELATION_NOE 导致<|>RELATION_NOE 的<|>RELATION_NOE 肺内<|>RELATION_NOE 肿瘤<|>RELATION_NOE 运动度<|>RELATION_NOE 受<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE 体积<|>RELATION_NOE 及<|>RELATION_NOE 粘连<|>RELATION_NOE 程度<|>RELATION_NOE 等<|>RELATION_NOE 因素<|>RELATION_NOE 影响<|>RELATION_S ,<|>RELATION_NOE 但<|>RELATION_NOE 运动<|>RELATION_NOE 幅度<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 下<|>RELATION_NOE 后<|>RELATION_NOE 带<|>RELATION_NOE 运动度<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 发生<|>RELATION_NOE 在<|>RELATION_NOE 上下<|>RELATION_NOE 方向<|>RELATION_NOE 。<|>RELATION_NOE 呼吸<|>RELATION_NOE 导致<|>RELATION_NOE 的<|>RELATION_NOE 肺内<|>RELATION_NOE 肿瘤<|>RELATION_NOE 运动度<|>RELATION_NOE 受<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE 体积<|>RELATION_NOE 及<|>RELATION_NOE 粘连<|>RELATION_NOE 程度<|>RELATION_NOE 等<|>RELATION_NOE 因素<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 运动<|>RELATION_NOE 幅度<|>RELATION_NOE 较<|>RELATION_B 小<|>RELATION_E ,<|>RELATION_NOE 下<|>RELATION_NOE 后<|>RELATION_NOE 带<|>RELATION_NOE 运动度<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 发生<|>RELATION_NOE 在<|>RELATION_NOE 上下<|>RELATION_NOE 方向<|>RELATION_NOE 。<|>RELATION_NOE 呼吸<|>RELATION_NOE 导致<|>RELATION_NOE 的<|>RELATION_NOE 肺内<|>RELATION_NOE 肿瘤<|>RELATION_NOE 运动<|>RELATION_NOE 度<|>RELATION_NOE 受<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE 体积<|>RELATION_NOE 及<|>RELATION_NOE 粘连<|>RELATION_NOE 程度<|>RELATION_NOE 等<|>RELATION_NOE 因素<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 运动<|>RELATION_NOE 幅度<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 下<|>RELATION_NOE 后<|>RELATION_NOE 带<|>RELATION_NOE 运动度<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 发生<|>RELATION_S 在<|>RELATION_NOE 上下<|>RELATION_NOE 方向<|>RELATION_NOE 。<|>RELATION_NOE
新型<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片段<|>RELATION_NOE 2G2<|>RELATION_NOE 诊断<|>RELATION_S 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 新型<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片段<|>RELATION_NOE 2G2<|>RELATION_NOE (<|>RELATION_NOE CK19-2G2<|>RELATION_NOE )<|>RELATION_NOE 血清<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 并<|>RELATION_NOE 比较<|>RELATION_NOE 了<|>RELATION_NOE 150<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 肺炎<|>RELATION_NOE 和<|>RELATION_NOE 150<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 空腹<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CK19-2G2<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 对比<|>RELATION_NOE 血清<|>RELATION_NOE CK19-2G2<|>RELATION_NOE 与<|>RELATION_NOE CYFRA21.1<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效能<|>RELATION_NOE 。<|>RELATION_NOE 采用<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 并<|>RELATION_NOE 比较<|>RELATION_NOE 了<|>RELATION_NOE 150<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 肺炎<|>RELATION_NOE 和<|>RELATION_NOE 150<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 空腹<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CK19-2G2<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 对比<|>RELATION_NOE 血清<|>RELATION_NOE CK19-2G2<|>RELATION_NOE 与<|>RELATION_NOE CYFRA21.1<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 效能<|>RELATION_E 。<|>RELATION_NOE
CK19-2G2<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 准确度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 55<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 83<|>RELATION_NOE /<|>RELATION_NOE 150<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 80.3%<|>RELATION_NOE (<|>RELATION_NOE 28<|>RELATION_NOE 1/3<|>RELATION_NOE 50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 准确度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 28.0%<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE /<|>RELATION_NOE 150<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 67.4%<|>RELATION_NOE (<|>RELATION_NOE 236<|>RELATION_NOE /<|>RELATION_NOE 350<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
新型<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CK19-2G2<|>RELATION_NOE 血清<|>RELATION_NOE 水平<|>RELATION_NOE 能够<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_B 辅助<|>RELATION_I 诊断<|>RELATION_E 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
17<|>RELATION_NOE 例<|>RELATION_NOE 胃<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 分析<|>RELATION_S
方法<|>RELATION_NOE :<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 1999年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 3月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 胃<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 国内外<|>RELATION_NOE 报道<|>RELATION_NOE 的<|>RELATION_NOE 胃<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 位于<|>RELATION_NOE 贲门<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 胃底<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 胃体<|>RELATION_NOE 1例<|>RELATION_NOE ;<|>RELATION_NOE
无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 42<|>RELATION_NOE 和<|>RELATION_NOE 13<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 。<|>RELATION_NOE
胃<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 发病率<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 常<|>RELATION_NOE 不易<|>RELATION_NOE 确诊<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_S 主要<|>RELATION_NOE 依赖<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 需<|>RELATION_NOE 根据<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 决定<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 采用<|>RELATION_NOE 针对<|>RELATION_NOE 肺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 可能<|>RELATION_NOE 有助于<|>RELATION_NOE 延长<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE 胃<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 发病率<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 常<|>RELATION_NOE 不易<|>RELATION_NOE 确诊<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 主要<|>RELATION_NOE 依赖<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 需<|>RELATION_NOE 根据<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 决定<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 采用<|>RELATION_NOE 针对<|>RELATION_NOE 肺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 可能<|>RELATION_NOE 有助于<|>RELATION_NOE 延长<|>RELATION_S 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
可<|>RELATION_NOE 完全<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ERCC1<|>RELATION_NOE 和<|>RELATION_NOE RRM1<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 完全<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
ERCC1<|>RELATION_NOE 和<|>RELATION_NOE RRM1<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
可<|>RELATION_NOE 完全<|>RELATION_NOE 切除<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE RRM1<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 相关<|>RELATION_S 。<|>RELATION_NOE
单<|>RELATION_NOE 发<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移<|>RELATION_NOE 瘤<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 是否<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_B 比较<|>RELATION_E
比较<|>RELATION_S 单<|>RELATION_NOE 发<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移<|>RELATION_NOE 瘤<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 及<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
2001年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 问<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 单<|>RELATION_NOE 发<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 共计<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 了<|>RELATION_NOE 肾上腺<|>RELATION_NOE 切除<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 接受<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE 包括<|>RELATION_NOE :<|>RELATION_NOE 体能<|>RELATION_NOE 情况<|>RELATION_NOE 差<|>RELATION_NOE 、<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 融合<|>RELATION_NOE 、<|>RELATION_NOE 违背<|>RELATION_NOE 患者<|>RELATION_NOE 意愿<|>RELATION_NOE 等等<|>RELATION_NOE 。<|>RELATION_NOE
手术<|>RELATION_NOE 切除<|>RELATION_NOE 肺癌<|>RELATION_NOE 单<|>RELATION_NOE 发<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移<|>RELATION_NOE 瘤<|>RELATION_NOE 疗效<|>RELATION_NOE 优于<|>RELATION_S 非手术者<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 侧<|>RELATION_NOE 。<|>RELATION_NOE
肾上腺<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 是<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 不利<|>RELATION_B 因素<|>RELATION_E ,<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移瘤<|>RELATION_NOE 的<|>RELATION_NOE 发现<|>RELATION_NOE 时间<|>RELATION_NOE 对<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 是<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 不利<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移瘤<|>RELATION_NOE 的<|>RELATION_NOE 发现<|>RELATION_NOE 时间<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 影响<|>RELATION_E 。<|>RELATION_NOE
Bcl-2<|>RELATION_NOE 基因沉默<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 杀伤<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 抑制<|>RELATION_NOE Bcl-2<|>RELATION_NOE 基因表达<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 杀伤<|>RELATION_NOE 敏感性<|>RELATION_NOE 及其<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
构建<|>RELATION_NOE 靶向<|>RELATION_NOE 人<|>RELATION_NOE Bcl-2<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 微小<|>RELATION_NOE RNA<|>RELATION_NOE 重组<|>RELATION_NOE 质粒<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 转染<|>RELATION_NOE 至<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 设<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE 实验组<|>RELATION_NOE 、<|>RELATION_NOE 阴性<|>RELATION_NOE 对照<|>RELATION_NOE 质粒组<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 运用<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 琼脂糖<|>RELATION_NOE 凝胶<|>RELATION_NOE 电泳<|>RELATION_NOE 、<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 和<|>RELATION_NOE 蛋白质<|>RELATION_NOE 免疫印迹法<|>RELATION_NOE (<|>RELATION_NOE Westernblot<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 转染<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE Bcl-2mRNA<|>RELATION_NOE 转录<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 分析<|>RELATION_NOE 转染<|>RELATION_NOE 后<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 和<|>RELATION_NOE 周期<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
MTT<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 干扰<|>RELATION_NOE 后<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 、<|>RELATION_NOE 5-<|>RELATION_NOE 氟尿嘧啶<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 、<|>RELATION_NOE 阿霉素<|>RELATION_NOE 、<|>RELATION_NOE 长春新碱<|>RELATION_NOE 、<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 及<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 等<|>RELATION_NOE 7<|>RELATION_NOE 种<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 及<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 方法<|>RELATION_NOE 进行<|>RELATION_NOE 核苷酸<|>RELATION_NOE 切除<|>RELATION_NOE 修复<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE ERCC1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 胸腺嘧啶<|>RELATION_NOE 合成<|>RELATION_NOE 酶<|>RELATION_NOE (<|>RELATION_NOE TYMS<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ型<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 微管蛋白<|>RELATION_NOE (<|>RELATION_NOE Class<|>RELATION_NOE Ⅲ<|>RELATION_NOE β<|>RELATION_NOE -tubulin<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 拓扑<|>RELATION_NOE 异构<|>RELATION_NOE 酶<|>RELATION_NOE 2<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE TOP2<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 等<|>RELATION_NOE 化疗<|>RELATION_NOE 敏感性<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_S 。<|>RELATION_NOE
成功<|>RELATION_NOE 构建<|>RELATION_NOE 微小<|>RELATION_NOE RNA<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE Bcl-2mRNA<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 相对<|>RELATION_NOE 表达量<|>RELATION_NOE 为<|>RELATION_NOE 0.002<|>RELATION_NOE ±<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 阴性<|>RELATION_NOE 对照<|>RELATION_NOE 质粒<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 相对<|>RELATION_NOE 表达量<|>RELATION_NOE 为<|>RELATION_NOE 0.104<|>RELATION_NOE ±<|>RELATION_NOE 0.003<|>RELATION_NOE )<|>RELATION_NOE 相比<|>RELATION_B 下降<|>RELATION_I 98.1%<|>RELATION_I ,<|>RELATION_I 蛋白<|>RELATION_I 表达<|>RELATION_I 水平<|>RELATION_I 下调<|>RELATION_I 57.6%<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 98.70<|>RELATION_NOE 和<|>RELATION_NOE 7.66<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
流式细胞术<|>RELATION_NOE 测定<|>RELATION_S 实验组<|>RELATION_NOE 细胞周期<|>RELATION_NOE 阻滞<|>RELATION_NOE 在<|>RELATION_NOE G1<|>RELATION_NOE 期<|>RELATION_NOE ,<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 示<|>RELATION_NOE 实验组<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 受到<|>RELATION_NOE 明显<|>RELATION_NOE 抑制<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 、<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 、<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 等<|>RELATION_NOE 4<|>RELATION_NOE 种<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 明显<|>RELATION_NOE 增加<|>RELATION_NOE [<|>RELATION_NOE 实验组<|>RELATION_NOE IC50<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE 7.3<|>RELATION_NOE ±<|>RELATION_NOE 0.1<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 7.7<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 11.5<|>RELATION_NOE ±<|>RELATION_NOE 1.9<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 10.8<|>RELATION_NOE ±<|>RELATION_NOE 1.6<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 阴性<|>RELATION_NOE 对照<|>RELATION_NOE 质粒组<|>RELATION_NOE IC50<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 5.8<|>RELATION_NOE ±<|>RELATION_NOE 0.1<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 60.7<|>RELATION_NOE ±<|>RELATION_NOE 1.4<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 80.6<|>RELATION_NOE ±<|>RELATION_NOE 1.7<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 20.6<|>RELATION_NOE ±<|>RELATION_NOE 1.7<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 65<|>RELATION_NOE 5.33<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 8.04<|>RELATION_NOE ,<|>RELATION_NOE 82.16<|>RELATION_NOE 和<|>RELATION_NOE 12.48<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 测定<|>RELATION_NOE 实验组<|>RELATION_NOE 细胞周期<|>RELATION_NOE 阻滞<|>RELATION_NOE 在<|>RELATION_NOE G1<|>RELATION_NOE 期<|>RELATION_NOE ,<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 示<|>RELATION_NOE 实验组<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 受到<|>RELATION_NOE 明显<|>RELATION_NOE 抑制<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 、<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 、<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 等<|>RELATION_NOE 4<|>RELATION_NOE 种<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 明显<|>RELATION_NOE 增加<|>RELATION_NOE [<|>RELATION_NOE 实验组<|>RELATION_NOE IC50<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE 7.3<|>RELATION_NOE ±<|>RELATION_NOE 0.1<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 7.7<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 11.5<|>RELATION_NOE ±<|>RELATION_NOE 1.9<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 10.8<|>RELATION_NOE ±<|>RELATION_NOE 1.6<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 阴性<|>RELATION_NOE 对照<|>RELATION_NOE 质粒组<|>RELATION_NOE IC50<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 5.8<|>RELATION_NOE ±<|>RELATION_NOE 0.1<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 60.7<|>RELATION_NOE ±<|>RELATION_NOE 1.4<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 80.6<|>RELATION_NOE ±<|>RELATION_NOE 1.7<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 20.6<|>RELATION_NOE ±<|>RELATION_NOE 1.7<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 65<|>RELATION_NOE 5.33<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 8.04<|>RELATION_NOE ,<|>RELATION_NOE 82.16<|>RELATION_NOE 和<|>RELATION_NOE 12.48<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
靶<|>RELATION_NOE 向性<|>RELATION_NOE 抑制<|>RELATION_NOE 抗<|>RELATION_NOE 凋亡<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE Bcl-2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 、<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 、<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 等<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE ,<|>RELATION_NOE 下调<|>RELATION_NOE ERCCl<|>RELATION_NOE 、<|>RELATION_NOE TYMS<|>RELATION_NOE 、<|>RELATION_NOE TOP2<|>RELATION_NOE 仪<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE 靶<|>RELATION_NOE 向性<|>RELATION_NOE 抑制<|>RELATION_NOE 抗<|>RELATION_NOE 凋亡<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE Bcl-2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 、<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 、<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 等<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE ,<|>RELATION_NOE 下调<|>RELATION_S ERCCl<|>RELATION_NOE 、<|>RELATION_NOE TYMS<|>RELATION_NOE 、<|>RELATION_NOE TOP2<|>RELATION_NOE 仪<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
显像<|>RELATION_NOE 完成<|>RELATION_NOE 后<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 处<|>RELATION_NOE 死2<|>RELATION_NOE 只<|>RELATION_NOE 荷<|>RELATION_NOE 瘤兔<|>RELATION_NOE ,<|>RELATION_NOE 取出<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE HE<|>RELATION_NOE 染色<|>RELATION_NOE 观察<|>RELATION_NOE 病理<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
最后<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE (<|>RELATION_NOE 5例<|>RELATION_NOE )<|>RELATION_NOE 证实<|>RELATION_NOE 有<|>RELATION_NOE 神经胶质瘤<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 胚胎<|>RELATION_NOE 发育<|>RELATION_NOE 不<|>RELATION_NOE 良性<|>RELATION_NOE 神经上皮瘤<|>RELATION_NOE (<|>RELATION_NOE DNT<|>RELATION_NOE )<|>RELATION_NOE 1例<|>RELATION_NOE 和<|>RELATION_NOE 非肿瘤<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 6例<|>RELATION_NOE (<|>RELATION_NOE 3例<|>RELATION_NOE 放射性<|>RELATION_NOE 坏死<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 脑炎<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 脑缺血<|>RELATION_NOE 病变<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
12<|>RELATION_NOE 例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 7例<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE ^<|>RELATION_NOE 13N-NH3<|>RELATION_NOE 摄取<|>RELATION_NOE 增高<|>RELATION_NOE (<|>RELATION_NOE 星形细胞瘤<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 胶质<|>RELATION_NOE 母细胞<|>RELATION_NOE 瘤2<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 灵敏度<|>RELATION_NOE 为<|>RELATION_NOE 58%<|>RELATION_NOE (<|>RELATION_NOE 7/12<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_B 、<|>RELATION_I 病理<|>RELATION_I 分型<|>RELATION_I 和<|>RELATION_I 临床<|>RELATION_I 分期<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
研究<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相关<|>RELATION_NOE 抗原<|>RELATION_NOE 125<|>RELATION_NOE (<|>RELATION_NOE CA125<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 199<|>RELATION_NOE (<|>RELATION_NOE CA199<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_B 、<|>RELATION_I 病理<|>RELATION_I 分型<|>RELATION_I 和<|>RELATION_I 临床<|>RELATION_I 分期<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 郑州<|>RELATION_NOE 大学<|>RELATION_NOE 第一<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 9月<|>RELATION_NOE 入院<|>RELATION_NOE 患者<|>RELATION_NOE 309<|>RELATION_NOE 例<|>RELATION_NOE 血清<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 电化学<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 发光法<|>RELATION_NOE 检测<|>RELATION_S 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 5<|>RELATION_NOE 种<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_B 高于<|>RELATION_E 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变组<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 检测<|>RELATION_NOE 人<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE H446<|>RELATION_NOE 及其<|>RELATION_NOE 获得<|>RELATION_NOE 性多药<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE (<|>RELATION_NOE MDR<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE H446<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 受<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE DDP<|>RELATION_NOE )<|>RELATION_NOE 冲击<|>RELATION_NOE 后<|>RELATION_NOE 乳酸<|>RELATION_NOE 代谢<|>RELATION_NOE 与<|>RELATION_NOE 活性氧<|>RELATION_NOE (<|>RELATION_NOE ROS<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 了解<|>RELATION_NOE SCLC<|>RELATION_NOE 获得性<|>RELATION_NOE MDR<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 分子生物学<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 逆转<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 提供<|>RELATION_B 理论<|>RELATION_I 和<|>RELATION_I 实验<|>RELATION_I 依据<|>RELATION_E 。<|>RELATION_NOE
体外<|>RELATION_NOE 常规<|>RELATION_NOE 培养<|>RELATION_NOE SCLC<|>RELATION_NOE 细胞<|>RELATION_NOE H446<|>RELATION_NOE 及<|>RELATION_NOE H446<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 相同<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE 0.5<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 点<|>RELATION_NOE 的<|>RELATION_NOE 顺铂<|>RELATION_NOE 刺激<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 应用<|>RELATION_NOE 干<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 和<|>RELATION_NOE 激光<|>RELATION_NOE 共<|>RELATION_NOE 聚焦<|>RELATION_NOE 显微镜法<|>RELATION_NOE 检测<|>RELATION_S 乳酸<|>RELATION_NOE 浓度<|>RELATION_NOE 和<|>RELATION_NOE ROS<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
此外<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 刺激<|>RELATION_NOE 40min<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE H446<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE ROS<|>RELATION_NOE 产量<|>RELATION_NOE 呈<|>RELATION_NOE 衰减<|>RELATION_NOE 趋势<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE H446<|>RELATION_NOE 细胞<|>RELATION_NOE ROS<|>RELATION_NOE 产量<|>RELATION_NOE 随着<|>RELATION_B 时间<|>RELATION_I 的<|>RELATION_I 延长<|>RELATION_I 而<|>RELATION_I 增加<|>RELATION_E ,<|>RELATION_NOE 15min<|>RELATION_NOE 时<|>RELATION_NOE 达到<|>RELATION_NOE 峰值<|>RELATION_NOE ,<|>RELATION_NOE 随后<|>RELATION_NOE 逐渐<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 伴随<|>RELATION_NOE 细胞<|>RELATION_NOE 皱缩<|>RELATION_NOE 这<|>RELATION_NOE 一<|>RELATION_NOE 现象<|>RELATION_NOE 。<|>RELATION_NOE
较<|>RELATION_NOE 强<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 氧化<|>RELATION_NOE 损伤<|>RELATION_NOE 能力<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE SCLC<|>RELATION_NOE 获得性<|>RELATION_NOE MDR<|>RELATION_NOE 抵御<|>RELATION_NOE 顺铂<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 因素<|>RELATION_E 。<|>RELATION_NOE
经<|>RELATION_NOE 人工<|>RELATION_NOE 气道<|>RELATION_NOE 冷冻<|>RELATION_NOE 联合<|>RELATION_NOE 氩等<|>RELATION_NOE 离子<|>RELATION_NOE 电凝<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 经<|>RELATION_NOE 人工<|>RELATION_NOE 气道<|>RELATION_NOE 支气管镜<|>RELATION_NOE 下<|>RELATION_NOE 冷冻<|>RELATION_NOE 联合<|>RELATION_NOE 氩等<|>RELATION_NOE 离子<|>RELATION_NOE 电凝<|>RELATION_NOE (<|>RELATION_NOE APC<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_B 、<|>RELATION_I 安全性<|>RELATION_E 。<|>RELATION_NOE
回顾<|>RELATION_NOE 分析<|>RELATION_NOE 我院<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 2月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 12<|>RELATION_NOE 月经<|>RELATION_NOE 人工<|>RELATION_NOE 气道<|>RELATION_NOE 在<|>RELATION_NOE 支气管镜<|>RELATION_NOE 下<|>RELATION_NOE 对<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE 冷冻<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 联合<|>RELATION_NOE APC<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 一<|>RELATION_NOE 周<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
评价<|>RELATION_NOE 指标<|>RELATION_NOE 包括<|>RELATION_S 术<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 咯血<|>RELATION_NOE 、<|>RELATION_NOE 发热<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 指数<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 检查<|>RELATION_NOE 、<|>RELATION_NOE 支气管镜<|>RELATION_NOE 复查<|>RELATION_NOE 气道<|>RELATION_NOE 狭窄<|>RELATION_NOE 情况<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 咳嗽<|>RELATION_NOE 减轻<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 31.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 咯血<|>RELATION_NOE 缓解<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 34.1%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 发热<|>RELATION_NOE 缓解<|>RELATION_NOE 9例<|>RELATION_NOE (<|>RELATION_NOE 22.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 指数<|>RELATION_NOE 3.5<|>RELATION_NOE ±<|>RELATION_NOE 0.42<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 1.8<|>RELATION_NOE ±<|>RELATION_NOE 0.33<|>RELATION_NOE ;<|>RELATION_NOE
影像学<|>RELATION_NOE 提示<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺炎<|>RELATION_NOE 、<|>RELATION_NOE 肺不张<|>RELATION_NOE 消退<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 29.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 好转<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 65.9%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 变化者<|>RELATION_NOE 2例<|>RELATION_NOE ;<|>RELATION_NOE
将<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分成<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 给予<|>RELATION_NOE 单用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 相同<|>RELATION_NOE 用法<|>RELATION_NOE 用量<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 选用<|>RELATION_NOE 国产<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE ,<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 选用<|>RELATION_NOE 进口培<|>RELATION_NOE 美曲塞<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 血清<|>RELATION_NOE MMP-2<|>RELATION_NOE 和<|>RELATION_NOE TIMP-2<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE MMP-2<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE TIMP-2<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
选取<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_S 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 放射<|>RELATION_NOE 免疫<|>RELATION_NOE 分析<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE TIMP-2<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE 选取<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 放射<|>RELATION_NOE 免疫<|>RELATION_NOE 分析法<|>RELATION_NOE 检测<|>RELATION_S 所有<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE TIMP-2<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 血清<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE TIMP-2<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变组<|>RELATION_NOE 及<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 其<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 下降<|>RELATION_NOE 或<|>RELATION_NOE 接近<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变组<|>RELATION_NOE 。<|>RELATION_NOE
曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE TIMP-2<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 抑制<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_NOE 降低<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE TIMP-2<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 抑制<|>RELATION_S 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 针吸<|>RELATION_NOE 活<|>RELATION_NOE 检术<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 伴<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 研究<|>RELATION_E
探讨<|>RELATION_NOE 经<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 针吸<|>RELATION_NOE 活<|>RELATION_NOE 检术<|>RELATION_NOE (<|>RELATION_NOE TBNA<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 伴<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_I 和<|>RELATION_I 安全性<|>RELATION_E 。<|>RELATION_NOE
对<|>RELATION_NOE 新乡市<|>RELATION_NOE 第一<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 经<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 怀疑<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 伴<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 活检<|>RELATION_NOE 、<|>RELATION_NOE 刷<|>RELATION_NOE 检<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肿大<|>RELATION_NOE 的<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 或<|>RELATION_NOE 管腔<|>RELATION_NOE 外<|>RELATION_NOE 肿块<|>RELATION_NOE 采用<|>RELATION_NOE 经<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 针吸<|>RELATION_NOE 活<|>RELATION_NOE 检术<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 所<|>RELATION_B 获<|>RELATION_I 标本<|>RELATION_I 直接<|>RELATION_I 涂片<|>RELATION_I 进行<|>RELATION_I 病理<|>RELATION_I 细胞学<|>RELATION_I 检查<|>RELATION_E 。<|>RELATION_NOE
50<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 经<|>RELATION_NOE 活检<|>RELATION_NOE 、<|>RELATION_NOE 刷<|>RELATION_NOE 检<|>RELATION_NOE 与<|>RELATION_NOE TBNA<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 结核<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 总阳<|>RELATION_NOE 性率<|>RELATION_NOE 为<|>RELATION_NOE 88%<|>RELATION_NOE 。<|>RELATION_NOE
通补<|>RELATION_NOE 消积<|>RELATION_NOE 饮<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
瘦素<|>RELATION_NOE 激活<|>RELATION_NOE MAPK<|>RELATION_NOE 和<|>RELATION_NOE P13K<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 上调<|>RELATION_NOE Bcl-2<|>RELATION_NOE 调控<|>RELATION_S 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE
瘦素<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE Westernblotting<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 内<|>RELATION_NOE Bcl-2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
MAPK<|>RELATION_NOE 及<|>RELATION_NOE P13K<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 阻滞剂<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE Westernblotting<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 下游<|>RELATION_NOE 复合物<|>RELATION_NOE ERK1<|>RELATION_NOE /<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE P-ERK1<|>RELATION_NOE /<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE Akt<|>RELATION_NOE 、<|>RELATION_NOE P-Akt<|>RELATION_NOE 等<|>RELATION_NOE 蛋白<|>RELATION_NOE 及<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE Bcl-2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
瘦素<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE MAPK<|>RELATION_NOE 和<|>RELATION_NOE P13K<|>RELATION_NOE 通路<|>RELATION_NOE ,<|>RELATION_NOE 介导<|>RELATION_NOE 抗<|>RELATION_NOE 凋亡<|>RELATION_NOE 蛋白<|>RELATION_NOE Bcl-2<|>RELATION_NOE 的<|>RELATION_NOE 过度<|>RELATION_NOE 表达<|>RELATION_NOE 而<|>RELATION_NOE 使<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 呈<|>RELATION_NOE 持续<|>RELATION_B 增殖<|>RELATION_E ,<|>RELATION_NOE 从而<|>RELATION_NOE 为<|>RELATION_NOE 开发<|>RELATION_NOE 抗肿瘤<|>RELATION_NOE 药物<|>RELATION_NOE 提供<|>RELATION_NOE 新<|>RELATION_NOE 思路<|>RELATION_NOE 。<|>RELATION_NOE
转化<|>RELATION_NOE 生长因子<|>RELATION_NOE β1<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 晚期<|>RELATION_NOE 糖基化<|>RELATION_NOE 终<|>RELATION_NOE 产物<|>RELATION_NOE 受体<|>RELATION_NOE 与<|>RELATION_NOE 细胞外基质<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
研究<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE Bl<|>RELATION_NOE (<|>RELATION_NOE transforminggrowthfactorbeta1<|>RELATION_NOE ,<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 糖基化<|>RELATION_NOE 终<|>RELATION_NOE 产物<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE receptorforadvancedglycationend-products<|>RELATION_NOE ,<|>RELATION_NOE RAGE<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 胶原<|>RELATION_NOE -I<|>RELATION_NOE 、<|>RELATION_NOE a-<|>RELATION_NOE 平滑肌<|>RELATION_NOE 肌动<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE a-smoothmuscleactin<|>RELATION_NOE ,<|>RELATION_NOE d-SMA<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S 。<|>RELATION_NOE
体外<|>RELATION_NOE 培养<|>RELATION_NOE 人<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 不<|>RELATION_NOE 加<|>RELATION_NOE TGF-<|>RELATION_NOE [<|>RELATION_NOE 31<|>RELATION_NOE 刺激<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 不同<|>RELATION_NOE 终浓度<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE (<|>RELATION_NOE 2μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE ,<|>RELATION_NOE ag<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE /<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 为<|>RELATION_NOE 实验组<|>RELATION_NOE ,<|>RELATION_NOE RT-PCR<|>RELATION_NOE 和<|>RELATION_NOE Westernblotting<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S TGF-<|>RELATION_NOE β1<|>RELATION_NOE 刺激<|>RELATION_NOE 12h<|>RELATION_NOE 、<|>RELATION_NOE 24h<|>RELATION_NOE 、<|>RELATION_NOE 36h<|>RELATION_NOE 后<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 实验组<|>RELATION_NOE RAGEmRNA<|>RELATION_NOE 和<|>RELATION_NOE RAGE<|>RELATION_NOE 、<|>RELATION_NOE 胶原<|>RELATION_NOE -I<|>RELATION_NOE 及<|>RELATION_NOE a-SMA<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
下调<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE RAGE<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 胶原<|>RELATION_NOE -I<|>RELATION_NOE 及<|>RELATION_NOE a-SMA<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 上调<|>RELATION_NOE 呈<|>RELATION_NOE 负<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 提示<|>RELATION_NOE RAGE<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 和<|>RELATION_NOE 发展<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE
2例<|>RELATION_NOE 肝癌<|>RELATION_NOE 患者<|>RELATION_NOE 单发脑<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 脑卒中<|>RELATION_NOE 。<|>RELATION_NOE
干涉<|>RELATION_S Gankyrin<|>RELATION_NOE 基因表达<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
建立<|>RELATION_NOE 稳定<|>RELATION_NOE 干涉<|>RELATION_NOE 癌基因<|>RELATION_NOE Gankyrin<|>RELATION_NOE 的<|>RELATION_NOE 4T1-luc<|>RELATION_NOE 细胞株<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE Gankyrin<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 慢病毒感染<|>RELATION_NOE 和<|>RELATION_NOE 抗性<|>RELATION_NOE 筛选<|>RELATION_NOE 方法<|>RELATION_NOE 获得<|>RELATION_NOE 稳定<|>RELATION_NOE 干涉<|>RELATION_NOE Gankyrin<|>RELATION_NOE 的<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE 4T1-luc<|>RELATION_NOE /<|>RELATION_NOE shGankyrin<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 蛋白质<|>RELATION_NOE 印迹<|>RELATION_NOE 和<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 方法<|>RELATION_NOE 分别<|>RELATION_NOE 在<|>RELATION_NOE 蛋白质<|>RELATION_B 和<|>RELATION_I mRNA<|>RELATION_I 水平<|>RELATION_I 检测<|>RELATION_E Gankyrin<|>RELATION_NOE 的<|>RELATION_NOE 干涉<|>RELATION_NOE 效果<|>RELATION_NOE ;<|>RELATION_NOE
选用<|>RELATION_NOE BALB<|>RELATION_NOE /<|>RELATION_NOE c<|>RELATION_NOE 小鼠<|>RELATION_NOE 进行<|>RELATION_NOE 4T1<|>RELATION_NOE 细胞<|>RELATION_NOE 原位<|>RELATION_NOE 种植<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 活体<|>RELATION_NOE 成像<|>RELATION_NOE 技术<|>RELATION_NOE 实时<|>RELATION_NOE 观测<|>RELATION_NOE 小鼠<|>RELATION_NOE 体内<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤转移<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 小鼠肺<|>RELATION_NOE 转移瘤<|>RELATION_NOE 进行<|>RELATION_NOE 病理学<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 印迹<|>RELATION_NOE 和<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 稳定<|>RELATION_NOE 敲<|>RELATION_NOE 低<|>RELATION_NOE Gankyrin4T1<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 蛋白质<|>RELATION_NOE 水平<|>RELATION_NOE 和<|>RELATION_NOE mRNA<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE
利用<|>RELATION_NOE 活体<|>RELATION_NOE 成像<|>RELATION_NOE 进行<|>RELATION_NOE 细胞数<|>RELATION_NOE 与<|>RELATION_NOE 细胞<|>RELATION_NOE 发光<|>RELATION_NOE 强度<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 选择<|>RELATION_NOE 细胞数<|>RELATION_NOE 与<|>RELATION_NOE 发光<|>RELATION_NOE 强度<|>RELATION_NOE 基本<|>RELATION_NOE 一致<|>RELATION_NOE 的<|>RELATION_NOE #<|>RELATION_NOE 2细胞株<|>RELATION_NOE 进行<|>RELATION_NOE 小鼠<|>RELATION_NOE 原位<|>RELATION_NOE 种植<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 产生<|>RELATION_NOE 的<|>RELATION_NOE 转移瘤<|>RELATION_NOE 进行<|>RELATION_NOE 实时<|>RELATION_NOE 观测<|>RELATION_NOE ,<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE 敲<|>RELATION_NOE 低<|>RELATION_NOE Gankyrin<|>RELATION_NOE 的<|>RELATION_NOE 4T1<|>RELATION_NOE 细胞<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 肺转移<|>RELATION_NOE 瘤<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 3.02<|>RELATION_NOE ×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 6<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 对照<|>RELATION_NOE 细胞<|>RELATION_NOE 为<|>RELATION_NOE 10.9<|>RELATION_NOE ×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 6<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 病理学<|>RELATION_NOE 证实<|>RELATION_NOE 了<|>RELATION_NOE 对照<|>RELATION_NOE 细胞<|>RELATION_NOE 产生<|>RELATION_NOE 的<|>RELATION_NOE 肺转移<|>RELATION_NOE 瘤<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE Gankyrin<|>RELATION_NOE 染色<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 敲<|>RELATION_NOE 低<|>RELATION_NOE Gankyrin<|>RELATION_NOE 的<|>RELATION_NOE 4T1<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 肺转移<|>RELATION_NOE 瘤<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE Gankyrin<|>RELATION_NOE 染色<|>RELATION_NOE 阴性<|>RELATION_NOE 。<|>RELATION_NOE
责任制<|>RELATION_NOE 整体<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
将<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分成<|>RELATION_NOE 观察组<|>RELATION_NOE (<|>RELATION_NOE 责任制<|>RELATION_NOE 整体<|>RELATION_NOE 护理<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 各<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 疼痛<|>RELATION_NOE 程度<|>RELATION_NOE 分级<|>RELATION_NOE 法<|>RELATION_NOE 、<|>RELATION_NOE 焦虑<|>RELATION_NOE 自<|>RELATION_NOE 评量表<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 自<|>RELATION_NOE 评量表<|>RELATION_NOE 、<|>RELATION_NOE 自制<|>RELATION_NOE 满意度<|>RELATION_NOE 调查表<|>RELATION_NOE 及<|>RELATION_NOE 自制<|>RELATION_NOE 求助<|>RELATION_NOE 次数<|>RELATION_NOE 统计表<|>RELATION_NOE 对<|>RELATION_NOE 观察组<|>RELATION_NOE 及<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 人院<|>RELATION_NOE 后<|>RELATION_NOE 和<|>RELATION_NOE 护理<|>RELATION_NOE 两<|>RELATION_NOE 周<|>RELATION_NOE 后<|>RELATION_NOE 进行<|>RELATION_NOE 测试<|>RELATION_NOE 和<|>RELATION_NOE 调查<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE 和<|>RELATION_NOE x<|>RELATION_NOE ^<|>RELATION_NOE 2检验<|>RELATION_NOE 进行<|>RELATION_NOE 统计<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
责任制<|>RELATION_NOE 整体<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 实施<|>RELATION_NOE 明显<|>RELATION_S 提高<|>RELATION_NOE 了<|>RELATION_NOE 专科<|>RELATION_NOE 护理<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 有效<|>RELATION_NOE 缓解<|>RELATION_NOE 了<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 躯体<|>RELATION_NOE 痛苦<|>RELATION_NOE 和<|>RELATION_NOE 精神<|>RELATION_NOE 压力<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 了<|>RELATION_NOE 家属<|>RELATION_NOE 的<|>RELATION_NOE 陪护<|>RELATION_NOE 任务<|>RELATION_NOE 。<|>RELATION_NOE
microRNA-646<|>RELATION_NOE 在<|>RELATION_NOE 脂多糖<|>RELATION_B 处理<|>RELATION_E 后<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 功能<|>RELATION_NOE 分析<|>RELATION_NOE
实验<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 及<|>RELATION_NOE 实验组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 以<|>RELATION_NOE RPMI-1640<|>RELATION_NOE 培养液<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 24h<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 分别<|>RELATION_NOE 以<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 15mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 的<|>RELATION_NOE 脂多糖<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 24h<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞化学<|>RELATION_NOE 染色<|>RELATION_NOE 、<|>RELATION_NOE Westernblot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 肺<|>RELATION_NOE 表面<|>RELATION_NOE 活性<|>RELATION_NOE 蛋白<|>RELATION_NOE A<|>RELATION_NOE (<|>RELATION_NOE SP-A<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺表面<|>RELATION_NOE 活性<|>RELATION_NOE 蛋白<|>RELATION_NOE C<|>RELATION_NOE (<|>RELATION_NOE SP-C<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 。<|>RELATION_NOE
实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE miR<|>RELATION_NOE .<|>RELATION_NOE
实验组<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 脂多糖<|>RELATION_NOE 处理<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE SP-A<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 均<|>RELATION_NOE 下降<|>RELATION_S ,<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE SP-A<|>RELATION_NOE 的<|>RELATION_NOE 实验组<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 脂多糖<|>RELATION_NOE 处理<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE SP-A<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 均<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE SP-A<|>RELATION_NOE 的<|>RELATION_NOE 下降<|>RELATION_S 呈<|>RELATION_NOE 药物<|>RELATION_NOE 浓度<|>RELATION_NOE 依赖性<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 病理学<|>RELATION_NOE 样本<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分类<|>RELATION_NOE 及<|>RELATION_NOE 分子<|>RELATION_NOE 病理学<|>RELATION_NOE 检测<|>RELATION_S
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 在<|>RELATION_NOE 细胞<|>RELATION_NOE 病理学<|>RELATION_NOE 样本<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分类<|>RELATION_NOE 及<|>RELATION_NOE 分子<|>RELATION_NOE 学<|>RELATION_NOE 检测<|>RELATION_NOE 解决<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞学<|>RELATION_NOE 样本<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 涂片<|>RELATION_NOE 做出<|>RELATION_NOE 定性<|>RELATION_NOE 诊断<|>RELATION_NOE 并<|>RELATION_NOE 部分子<|>RELATION_NOE 以<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分类<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 细胞<|>RELATION_NOE 蜡块<|>RELATION_NOE 切片<|>RELATION_NOE 进行<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE TTF-1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE p63<|>RELATION_NOE 、<|>RELATION_NOE E-<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cad<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE (<|>RELATION_NOE CK5<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 上皮膜抗原<|>RELATION_NOE (<|>RELATION_NOE EMA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 突触素<|>RELATION_NOE (<|>RELATION_NOE Syn<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经细胞黏附<|>RELATION_NOE 分子<|>RELATION_NOE (<|>RELATION_NOE GD56<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 嗜<|>RELATION_NOE 铬素<|>RELATION_NOE A<|>RELATION_NOE (<|>RELATION_NOE CgA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 视网膜<|>RELATION_NOE 钙<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE CR<|>RELATION_NOE )<|>RELATION_NOE 等<|>RELATION_NOE 8<|>RELATION_NOE 项<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 后<|>RELATION_NOE 再<|>RELATION_NOE 分类<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 两者<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE ;<|>RELATION_NOE
部分<|>RELATION_NOE 腺癌<|>RELATION_NOE 病例<|>RELATION_NOE 进行<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 。<|>RELATION_NOE
常规<|>RELATION_NOE 涂片<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 总体<|>RELATION_NOE 分型率<|>RELATION_NOE 及<|>RELATION_NOE 非<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 分型率<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 细胞<|>RELATION_NOE 蜡块<|>RELATION_NOE 并<|>RELATION_NOE 结合<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE 分型率<|>RELATION_NOE (<|>RELATION_NOE 39.2%<|>RELATION_NOE 比<|>RELATION_NOE 88.3%<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 细胞学<|>RELATION_NOE 样本<|>RELATION_NOE 应<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 涂片<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 蜡块<|>RELATION_NOE 切片<|>RELATION_NOE 并<|>RELATION_NOE 结合<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 再<|>RELATION_NOE 进行<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分类<|>RELATION_NOE ;<|>RELATION_NOE
磷脂酰肌醇<|>RELATION_NOE 蛋白<|>RELATION_NOE 聚糖<|>RELATION_NOE -5<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 验证<|>RELATION_S GPC-5<|>RELATION_NOE 在<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 组织<|>RELATION_NOE 芯片<|>RELATION_NOE (<|>RELATION_NOE 包含<|>RELATION_NOE 75<|>RELATION_NOE 例<|>RELATION_NOE 鱗癌<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE 较<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE GPC-5mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E (<|>RELATION_NOE 29.00<|>RELATION_NOE 74<|>RELATION_NOE ±<|>RELATION_NOE 6.40<|>RELATION_NOE 13<|>RELATION_NOE 比<|>RELATION_NOE 11.4<|>RELATION_NOE 849<|>RELATION_NOE ±<|>RELATION_NOE 2.<|>RELATION_NOE 50<|>RELATION_NOE 66<|>RELATION_NOE ,<|>RELATION_NOE p<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
GPC-5<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 1种<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 抑癌<|>RELATION_NOE 基因<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E 。<|>RELATION_NOE
CC<|>RELATION_NOE 趋化<|>RELATION_NOE 因子<|>RELATION_NOE 受体7<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE -C<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_B 潜能<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_E
临床<|>RELATION_NOE 收集<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 完全<|>RELATION_NOE 切除<|>RELATION_NOE 加<|>RELATION_NOE 系统<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 的<|>RELATION_NOE 55<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 标本<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE X2<|>RELATION_NOE 检验<|>RELATION_NOE 比较<|>RELATION_NOE CCR7<|>RELATION_NOE 及<|>RELATION_NOE VEGF-C<|>RELATION_NOE 表达<|>RELATION_NOE 差异<|>RELATION_S ,<|>RELATION_NOE 并<|>RELATION_NOE 应用<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 判定<|>RELATION_NOE 肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE 应用<|>RELATION_NOE X2<|>RELATION_NOE 检验<|>RELATION_NOE 比较<|>RELATION_NOE CCR7<|>RELATION_NOE 及<|>RELATION_NOE VEGF-C<|>RELATION_NOE 表达<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 应用<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 判定<|>RELATION_NOE 肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 相关<|>RELATION_I 因素<|>RELATION_E 。<|>RELATION_NOE
CCR7<|>RELATION_NOE 及<|>RELATION_NOE VEGF-C<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ;<|>RELATION_NOE
32<|>RELATION_NOE 例<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移<|>RELATION_NOE 性肿瘤<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_B 因素<|>RELATION_I 分析<|>RELATION_E
探讨<|>RELATION_S 胰腺<|>RELATION_NOE 转移<|>RELATION_NOE 性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 9例<|>RELATION_NOE 、<|>RELATION_NOE 肾癌<|>RELATION_NOE 6例<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 5例<|>RELATION_NOE 、<|>RELATION_NOE 其他<|>RELATION_NOE 肿瘤<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE :<|>RELATION_NOE 转移<|>RELATION_NOE 性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 与<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 种类<|>RELATION_NOE 、<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 方式<|>RELATION_NOE 、<|>RELATION_NOE 出现<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 时间<|>RELATION_NOE 间隔<|>RELATION_NOE 、<|>RELATION_NOE 是否<|>RELATION_NOE 为<|>RELATION_NOE 局限性<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 胰腺<|>RELATION_NOE 局部<|>RELATION_NOE 治疗<|>RELATION_NOE 方式<|>RELATION_NOE 相关<|>RELATION_S 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE AAA<|>RELATION_NOE 算法<|>RELATION_NOE 与<|>RELATION_NOE PBC<|>RELATION_NOE 算法<|>RELATION_NOE 比较<|>RELATION_B 研究<|>RELATION_E
比较<|>RELATION_NOE Eclipse<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE 系统<|>RELATION_NOE 笔形<|>RELATION_NOE 束<|>RELATION_NOE 卷积<|>RELATION_NOE 算法<|>RELATION_NOE (<|>RELATION_NOE PBC<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 各向异性<|>RELATION_NOE 分析<|>RELATION_NOE 算法<|>RELATION_NOE (<|>RELATION_NOE AAA<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 的<|>RELATION_NOE 剂量学<|>RELATION_B 差异<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 算法<|>RELATION_NOE 进行<|>RELATION_NOE 胸部<|>RELATION_NOE 模体<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 测量<|>RELATION_NOE 验证<|>RELATION_NOE 。<|>RELATION_NOE 比较<|>RELATION_NOE Eclipse<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE 系统<|>RELATION_NOE 笔形<|>RELATION_NOE 束<|>RELATION_NOE 卷积<|>RELATION_NOE 算法<|>RELATION_NOE (<|>RELATION_NOE PBC<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 各向异性<|>RELATION_NOE 分析<|>RELATION_NOE 算法<|>RELATION_NOE (<|>RELATION_NOE AAA<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 的<|>RELATION_NOE 剂量学<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 算法<|>RELATION_NOE 进行<|>RELATION_NOE 胸部<|>RELATION_NOE 模体<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 测量<|>RELATION_B 验证<|>RELATION_E 。<|>RELATION_NOE
选取<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 使用<|>RELATION_NOE PBC<|>RELATION_NOE 算法<|>RELATION_NOE 与<|>RELATION_NOE AAA<|>RELATION_NOE 算法<|>RELATION_NOE 进行<|>RELATION_NOE 剂量<|>RELATION_B 计算<|>RELATION_E ,<|>RELATION_NOE 比较<|>RELATION_NOE 计划<|>RELATION_NOE 靶体<|>RELATION_NOE 积<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE 及<|>RELATION_NOE 肺和<|>RELATION_NOE 脊髓<|>RELATION_NOE 受量<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE 选取<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 使用<|>RELATION_NOE PBC<|>RELATION_NOE 算法<|>RELATION_NOE 与<|>RELATION_NOE AAA<|>RELATION_NOE 算法<|>RELATION_NOE 进行<|>RELATION_NOE 剂量<|>RELATION_NOE 计算<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_S 计划<|>RELATION_NOE 靶体<|>RELATION_NOE 积<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE 及<|>RELATION_NOE 肺和<|>RELATION_NOE 脊髓<|>RELATION_NOE 受量<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
AAA<|>RELATION_NOE 算法<|>RELATION_NOE 的<|>RELATION_NOE 肺<|>RELATION_NOE Dmean<|>RELATION_NOE 、<|>RELATION_NOE V20<|>RELATION_NOE 和<|>RELATION_NOE 脊髓<|>RELATION_NOE Dmax<|>RELATION_NOE 高于<|>RELATION_S PBC<|>RELATION_NOE 算法<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE -3.99<|>RELATION_NOE 、<|>RELATION_NOE -2.79<|>RELATION_NOE 、<|>RELATION_NOE -5.46<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 38<|>RELATION_NOE 、<|>RELATION_NOE 0.003<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
验证<|>RELATION_NOE 测量<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE AAA<|>RELATION_NOE 算法<|>RELATION_NOE 计算值<|>RELATION_NOE 与<|>RELATION_NOE 测量<|>RELATION_NOE 值<|>RELATION_NOE 平均<|>RELATION_NOE 偏差<|>RELATION_NOE <<|>RELATION_NOE 2%<|>RELATION_NOE ,<|>RELATION_NOE 等<|>RELATION_NOE 中心<|>RELATION_NOE 点处<|>RELATION_NOE 优于<|>RELATION_S PBC<|>RELATION_NOE 算法<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE -3.82<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE PBC<|>RELATION_NOE 算法<|>RELATION_NOE 高估<|>RELATION_S 了<|>RELATION_NOE 靶区<|>RELATION_NOE 剂量<|>RELATION_NOE 、<|>RELATION_NOE 低估<|>RELATION_NOE 了<|>RELATION_NOE 肺<|>RELATION_NOE 和<|>RELATION_NOE 脊髓<|>RELATION_NOE 剂量<|>RELATION_NOE ,<|>RELATION_NOE 因此<|>RELATION_NOE 推荐<|>RELATION_NOE 使用<|>RELATION_NOE 对<|>RELATION_NOE 组织<|>RELATION_NOE 不<|>RELATION_NOE 均匀<|>RELATION_NOE 处理<|>RELATION_NOE 能力<|>RELATION_NOE 更<|>RELATION_NOE 强<|>RELATION_NOE 的<|>RELATION_NOE AAA<|>RELATION_NOE 算法<|>RELATION_NOE 。<|>RELATION_NOE 肺癌<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE PBC<|>RELATION_NOE 算法<|>RELATION_NOE 高估<|>RELATION_NOE 了<|>RELATION_NOE 靶区<|>RELATION_NOE 剂量<|>RELATION_NOE 、<|>RELATION_NOE 低估<|>RELATION_S 了<|>RELATION_NOE 肺和<|>RELATION_NOE 脊髓<|>RELATION_NOE 剂量<|>RELATION_NOE ,<|>RELATION_NOE 因此<|>RELATION_NOE 推荐<|>RELATION_NOE 使用<|>RELATION_NOE 对<|>RELATION_NOE 组织<|>RELATION_NOE 不<|>RELATION_NOE 均匀<|>RELATION_NOE 处理<|>RELATION_NOE 能力<|>RELATION_NOE 更<|>RELATION_NOE 强<|>RELATION_NOE 的<|>RELATION_NOE AAA<|>RELATION_NOE 算法<|>RELATION_NOE 。<|>RELATION_NOE 肺癌<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE PBC<|>RELATION_NOE 算法<|>RELATION_NOE 高估<|>RELATION_NOE 了<|>RELATION_NOE 靶区<|>RELATION_NOE 剂量<|>RELATION_NOE 、<|>RELATION_NOE 低估<|>RELATION_NOE 了<|>RELATION_NOE 肺<|>RELATION_NOE 和<|>RELATION_NOE 脊髓<|>RELATION_NOE 剂量<|>RELATION_NOE ,<|>RELATION_NOE 因此<|>RELATION_NOE 推荐<|>RELATION_B 使用<|>RELATION_E 对<|>RELATION_NOE 组织<|>RELATION_NOE 不<|>RELATION_NOE 均匀<|>RELATION_NOE 处理<|>RELATION_NOE 能力<|>RELATION_NOE 更<|>RELATION_NOE 强<|>RELATION_NOE 的<|>RELATION_NOE AAA<|>RELATION_NOE 算法<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 剂量<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 模拟<|>RELATION_B 定位<|>RELATION_E 应用<|>RELATION_NOE 价值<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 有<|>RELATION_NOE 症状<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 治疗<|>RELATION_B 及<|>RELATION_I 转<|>RELATION_I 归<|>RELATION_I 分析<|>RELATION_E
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 检测<|>RELATION_S 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE
采用<|>RELATION_NOE 特异引物<|>RELATION_NOE 即时<|>RELATION_NOE 荧光<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 对<|>RELATION_NOE 268<|>RELATION_NOE 例<|>RELATION_NOE 收集<|>RELATION_NOE 于<|>RELATION_NOE 2007年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 4月<|>RELATION_NOE 间<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 标本<|>RELATION_NOE 进行<|>RELATION_NOE EML4-ALK<|>RELATION_B 融合<|>RELATION_I 基因检测<|>RELATION_E ,<|>RELATION_NOE 应用<|>RELATION_NOE Sanger<|>RELATION_NOE 测序法<|>RELATION_NOE 对<|>RELATION_NOE 其中<|>RELATION_NOE 164<|>RELATION_NOE 例<|>RELATION_NOE 进行<|>RELATION_NOE 验证<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 资料<|>RELATION_NOE 分析<|>RELATION_NOE EML4<|>RELATION_NOE 一<|>RELATION_NOE ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 存在<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
EML4-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 较为<|>RELATION_B 多<|>RELATION_I 见<|>RELATION_E ,<|>RELATION_NOE 代表<|>RELATION_NOE 了<|>RELATION_NOE 一<|>RELATION_NOE 类<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 亚型<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 66<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 选择<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE .<|>RELATION_NOE
Treg<|>RELATION_NOE 比例<|>RELATION_NOE 的<|>RELATION_NOE 异常<|>RELATION_NOE 升高<|>RELATION_NOE 可能<|>RELATION_B 参与<|>RELATION_E 了<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE ,<|>RELATION_NOE Treg<|>RELATION_NOE 比例<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 分级<|>RELATION_NOE 以及<|>RELATION_NOE 预后<|>RELATION_NOE 评估.<|>RELATION_NOE Treg<|>RELATION_NOE 比例<|>RELATION_NOE 的<|>RELATION_NOE 异常<|>RELATION_NOE 升高<|>RELATION_NOE 可能<|>RELATION_NOE 参与<|>RELATION_NOE 了<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE ,<|>RELATION_NOE Treg<|>RELATION_NOE 比例<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 分级<|>RELATION_B 以及<|>RELATION_I 预后<|>RELATION_I 评估<|>RELATION_E .<|>RELATION_NOE
左主<|>RELATION_NOE 支气管<|>RELATION_NOE 根部<|>RELATION_NOE 延长术<|>RELATION_NOE 和<|>RELATION_NOE Kergin<|>RELATION_NOE 右<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 治疗<|>RELATION_S 累及<|>RELATION_NOE 气管<|>RELATION_NOE 下<|>RELATION_NOE 段<|>RELATION_NOE 的<|>RELATION_NOE T4<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE
选择<|>RELATION_NOE 累<|>RELATION_NOE 及<|>RELATION_NOE 气管<|>RELATION_NOE 下<|>RELATION_NOE 段<|>RELATION_NOE 的<|>RELATION_NOE T4<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 10<|>RELATION_NOE 例行<|>RELATION_NOE 左主<|>RELATION_NOE 支气管<|>RELATION_NOE 根部<|>RELATION_NOE 延长术<|>RELATION_NOE ,<|>RELATION_NOE 3例行<|>RELATION_NOE Kergin<|>RELATION_NOE 右<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 。<|>RELATION_NOE
13<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 顺利<|>RELATION_NOE 完成<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 同期<|>RELATION_NOE 行<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 置换术<|>RELATION_NOE ,<|>RELATION_NOE 2例行<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 侧壁<|>RELATION_NOE 切除术<|>RELATION_NOE ,<|>RELATION_NOE 1例行<|>RELATION_NOE 食管<|>RELATION_NOE 肌层<|>RELATION_NOE 部分<|>RELATION_NOE 切除术<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 心房颤动<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 声音<|>RELATION_NOE 嘶哑<|>RELATION_NOE 合并<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 吻合口瘘<|>RELATION_NOE 及<|>RELATION_NOE 狭窄<|>RELATION_NOE 等<|>RELATION_NOE 严重<|>RELATION_NOE 气道<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
左主<|>RELATION_NOE 支气管<|>RELATION_NOE 根部<|>RELATION_NOE 延长术<|>RELATION_NOE 和<|>RELATION_NOE Kergin<|>RELATION_NOE 右<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 气管<|>RELATION_NOE 支气管<|>RELATION_NOE 成<|>RELATION_NOE 形术<|>RELATION_NOE 用于<|>RELATION_NOE 治疗<|>RELATION_NOE 累及<|>RELATION_NOE 气管<|>RELATION_NOE 下<|>RELATION_NOE 段<|>RELATION_NOE 的<|>RELATION_NOE T4<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 围手术期<|>RELATION_B 并发症<|>RELATION_I 较<|>RELATION_I 少<|>RELATION_I 、<|>RELATION_I 病死率<|>RELATION_I 较<|>RELATION_I 低<|>RELATION_E 。<|>RELATION_NOE
益气<|>RELATION_NOE 散<|>RELATION_NOE 结<|>RELATION_NOE 汤<|>RELATION_NOE 联合<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
观察<|>RELATION_NOE 益气<|>RELATION_NOE 散<|>RELATION_NOE 结<|>RELATION_NOE 汤<|>RELATION_NOE 联合<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE NP<|>RELATION_NOE )<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
厄洛替尼<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 合并<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE
观察<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 及<|>RELATION_I 对<|>RELATION_I 其<|>RELATION_I 通气<|>RELATION_I 功能<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_E 。<|>RELATION_NOE
选择<|>RELATION_NOE 既<|>RELATION_NOE 往<|>RELATION_NOE 未<|>RELATION_NOE 接受<|>RELATION_NOE 过<|>RELATION_NOE 手术<|>RELATION_NOE 、<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 79<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_S 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_B 临床<|>RELATION_I 治疗<|>RELATION_I 提供<|>RELATION_I 依据<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 早期<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 选择<|>RELATION_NOE 临床<|>RELATION_NOE 同期<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 手术<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 手术<|>RELATION_NOE 进行<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两者<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
85<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE (<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 单纯<|>RELATION_NOE 腋下<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE (<|>RELATION_NOE 腋下<|>RELATION_NOE 小<|>RELATION_NOE 切<|>RELATION_NOE 口组<|>RELATION_NOE )<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 组<|>RELATION_NOE 手术时间<|>RELATION_NOE 和<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 腋下<|>RELATION_NOE 小<|>RELATION_NOE 切<|>RELATION_NOE 口组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 6.5<|>RELATION_NOE 14<|>RELATION_NOE 、<|>RELATION_NOE 2.4<|>RELATION_NOE 13<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 术后<|>RELATION_NOE 胸腔<|>RELATION_NOE 引<|>RELATION_NOE 流管<|>RELATION_NOE 留置<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 以及<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 0.4<|>RELATION_NOE 90<|>RELATION_NOE 、<|>RELATION_NOE 0.3<|>RELATION_NOE 38<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
螺旋<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 对<|>RELATION_NOE 周围型<|>RELATION_NOE 小<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
螺旋<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 及<|>RELATION_NOE 薄层<|>RELATION_NOE 重建<|>RELATION_NOE 对<|>RELATION_NOE 周围型<|>RELATION_NOE 小<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 及<|>RELATION_I 鉴别诊断<|>RELATION_I 有<|>RELATION_I 较<|>RELATION_I 高<|>RELATION_I 的<|>RELATION_I 临床<|>RELATION_I 应用<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
原发性<|>RELATION_NOE 支气管<|>RELATION_NOE 黏液<|>RELATION_NOE 表皮样癌<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 诊治<|>RELATION_NOE 分析<|>RELATION_S
探讨<|>RELATION_S 原发性<|>RELATION_NOE 支气管<|>RELATION_NOE 黏液<|>RELATION_NOE 表皮样癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 治疗<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 支气管<|>RELATION_NOE 黏液<|>RELATION_NOE 表皮样癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 支气管<|>RELATION_NOE 黏液<|>RELATION_NOE 表皮样癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 同期<|>RELATION_NOE 31<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 0.5<|>RELATION_NOE 8%<|>RELATION_NOE 。<|>RELATION_NOE
根治性<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_S 支气管<|>RELATION_NOE 黏液<|>RELATION_NOE 表皮样癌<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 方法<|>RELATION_NOE ;<|>RELATION_NOE
血浆<|>RELATION_NOE 白细胞介素<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 紧张素<|>RELATION_NOE 转换<|>RELATION_NOE 酶<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 放射<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方<|>RELATION_NOE 图<|>RELATION_NOE 参数<|>RELATION_NOE 对<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 预测<|>RELATION_S 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE
研究<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE 白细胞介素<|>RELATION_NOE 6<|>RELATION_NOE (<|>RELATION_NOE IL-6<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 紧张素<|>RELATION_NOE 转换<|>RELATION_NOE 酶<|>RELATION_NOE (<|>RELATION_NOE ACE<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方图<|>RELATION_NOE (<|>RELATION_NOE DVH<|>RELATION_NOE )<|>RELATION_NOE 参数<|>RELATION_NOE 与<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S ,<|>RELATION_NOE 并<|>RELATION_NOE 评价<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 预测<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
分别<|>RELATION_NOE 在<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 放疗<|>RELATION_NOE 中<|>RELATION_NOE (<|>RELATION_NOE 放疗<|>RELATION_NOE 第1<|>RELATION_NOE 周<|>RELATION_NOE 至<|>RELATION_NOE 第6<|>RELATION_NOE 周<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE (<|>RELATION_NOE 放疗<|>RELATION_NOE 第8<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 周<|>RELATION_NOE )<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 血浆<|>RELATION_NOE 中<|>RELATION_NOE IL-6<|>RELATION_NOE 及<|>RELATION_NOE ACE<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE 。<|>RELATION_NOE
依照<|>RELATION_NOE 美国<|>RELATION_NOE 放射肿<|>RELATION_NOE 瘤学<|>RELATION_NOE 协作组<|>RELATION_NOE (<|>RELATION_NOE RTOG<|>RELATION_NOE )<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 标准<|>RELATION_NOE 进行<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 诊断<|>RELATION_B 及<|>RELATION_I 分级<|>RELATION_E ,<|>RELATION_NOE 以<|>RELATION_NOE 出现<|>RELATION_NOE
血浆<|>RELATION_NOE 中<|>RELATION_NOE IL-6<|>RELATION_NOE 、<|>RELATION_NOE ACE<|>RELATION_NOE 水平<|>RELATION_NOE 、<|>RELATION_NOE V20<|>RELATION_NOE 、<|>RELATION_NOE V30<|>RELATION_NOE 、<|>RELATION_NOE MLD<|>RELATION_NOE 及<|>RELATION_NOE NTCP<|>RELATION_NOE 指标<|>RELATION_NOE 均<|>RELATION_NOE 与<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
后程<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 大<|>RELATION_NOE 分割<|>RELATION_NOE 放疗<|>RELATION_NOE 加<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 探讨<|>RELATION_NOE
放疗<|>RELATION_NOE 中<|>RELATION_NOE 第1<|>RELATION_NOE 周<|>RELATION_NOE 和<|>RELATION_NOE 第5<|>RELATION_NOE 周<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE (<|>RELATION_NOE NVB<|>RELATION_NOE )<|>RELATION_NOE 25mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 推注<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE DDP<|>RELATION_NOE )<|>RELATION_NOE 30nag<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 至<|>RELATION_NOE 第3<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 。<|>RELATION_NOE
放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 46.6%<|>RELATION_NOE (<|>RELATION_NOE 34<|>RELATION_NOE /<|>RELATION_NOE 73<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE V20<|>RELATION_NOE ≤<|>RELATION_NOE 25%<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 仅<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 17.2%<|>RELATION_NOE )<|>RELATION_NOE 发生<|>RELATION_NOE 了<|>RELATION_NOE 1级<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 44<|>RELATION_NOE 例<|>RELATION_NOE V20<|>RELATION_NOE ><|>RELATION_NOE 25%<|>RELATION_NOE 且<|>RELATION_NOE ≤<|>RELATION_NOE 30%<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 65.9%<|>RELATION_NOE )<|>RELATION_NOE 发生<|>RELATION_NOE 了<|>RELATION_NOE 1-3<|>RELATION_NOE 级<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE =<|>RELATION_NOE 16.63<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 发热<|>RELATION_NOE 、<|>RELATION_NOE 血红<|>RELATION_NOE 蛋白<|>RELATION_NOE 减少<|>RELATION_NOE 和<|>RELATION_NOE 血小板减少<|>RELATION_NOE 等<|>RELATION_NOE 多<|>RELATION_NOE 为<|>RELATION_NOE 1.2<|>RELATION_NOE 级<|>RELATION_NOE 急性<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 对<|>RELATION_NOE 症<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 全部<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 能<|>RELATION_NOE 耐受<|>RELATION_NOE 计划<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
后期<|>RELATION_NOE 放射性<|>RELATION_NOE 损伤<|>RELATION_NOE 以<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 34.3%<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE /<|>RELATION_NOE 73<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 调强<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_B 因素<|>RELATION_E 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 调强<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE (<|>RELATION_NOE IMRT<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE RP<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 寻找<|>RELATION_NOE 合理<|>RELATION_NOE 的<|>RELATION_NOE 预测性<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE c<|>RELATION_NOE 的<|>RELATION_NOE 制定<|>RELATION_NOE 提供<|>RELATION_NOE 参考<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 163<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE IMRT<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 及<|>RELATION_NOE 剂量<|>RELATION_NOE -<|>RELATION_NOE 体积<|>RELATION_NOE 直方图<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 参数<|>RELATION_NOE 进行<|>RELATION_NOE 量化<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 放疗<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 时间<|>RELATION_NOE ><|>RELATION_NOE 16<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 统计学<|>RELATION_NOE 方法<|>RELATION_NOE 研究<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE RP<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 发现<|>RELATION_NOE 下叶<|>RELATION_NOE 肿瘤<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 合并<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE (<|>RELATION_NOE COPD<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 联合化疗<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 未<|>RELATION_NOE 预防性<|>RELATION_NOE 使用<|>RELATION_NOE 糖皮<|>RELATION_NOE 质激素<|>RELATION_NOE 及<|>RELATION_NOE 抗生素<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 25<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE RP<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
体部<|>RELATION_NOE 伽玛刀<|>RELATION_NOE 治疗<|>RELATION_S 头<|>RELATION_NOE 颈部<|>RELATION_NOE 腺样囊性癌<|>RELATION_NOE 多发肺<|>RELATION_NOE 转移瘤<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
nm23-H1<|>RELATION_NOE 及<|>RELATION_NOE 热休克<|>RELATION_NOE 蛋白<|>RELATION_NOE 27<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
分析<|>RELATION_NOE nm23.H1<|>RELATION_NOE 和<|>RELATION_NOE 热休克<|>RELATION_NOE 蛋白<|>RELATION_NOE 27<|>RELATION_NOE (<|>RELATION_NOE HSP27<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 及<|>RELATION_NOE 转移<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 7<|>RELATION_NOE 5例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 良性<|>RELATION_NOE 肺病<|>RELATION_NOE 变<|>RELATION_NOE 中<|>RELATION_NOE nm23-H1<|>RELATION_NOE 和<|>RELATION_NOE HSP27<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 将<|>RELATION_NOE
nm23-H1<|>RELATION_NOE 、<|>RELATION_NOE HSP27<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 二者<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 判断<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE nm23-H1<|>RELATION_NOE 、<|>RELATION_NOE HSP27<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 联合<|>RELATION_B 检测<|>RELATION_E 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 判断<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
异源<|>RELATION_NOE 基因<|>RELATION_NOE α1<|>RELATION_NOE ,<|>RELATION_NOE 3<|>RELATION_NOE 半乳糖<|>RELATION_NOE 转移酶<|>RELATION_NOE 与<|>RELATION_NOE 增强型<|>RELATION_NOE 绿色<|>RELATION_NOE 荧光<|>RELATION_NOE 蛋白<|>RELATION_NOE 融合<|>RELATION_NOE 对<|>RELATION_NOE 荧光<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
研究<|>RELATION_NOE 异源<|>RELATION_NOE (<|>RELATION_NOE 猪<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE α1<|>RELATION_NOE ,<|>RELATION_NOE 3<|>RELATION_NOE 半乳糖<|>RELATION_NOE 转移酶<|>RELATION_NOE (<|>RELATION_NOE 3GT<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 增强型<|>RELATION_NOE 绿色<|>RELATION_NOE 荧光<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE EGFP<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 形成<|>RELATION_NOE 的<|>RELATION_NOE 融合<|>RELATION_NOE 蛋白<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 荧光<|>RELATION_NOE 表达量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 该<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE 转染<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE A549<|>RELATION_NOE 、<|>RELATION_NOE 人<|>RELATION_NOE 胚<|>RELATION_NOE 肾细胞<|>RELATION_NOE 293FT<|>RELATION_NOE ,<|>RELATION_NOE EGFP<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 用<|>RELATION_NOE 荧光<|>RELATION_NOE 显微镜<|>RELATION_NOE 观察<|>RELATION_NOE 和<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 进行<|>RELATION_NOE 荧光<|>RELATION_B 定量分析<|>RELATION_E 。<|>RELATION_NOE
pEGFP<|>RELATION_NOE /<|>RELATION_NOE α1<|>RELATION_NOE ,<|>RELATION_NOE 3GT<|>RELATION_NOE 载体<|>RELATION_NOE 转染<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE 293FT<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE 48h<|>RELATION_NOE 的<|>RELATION_NOE 转染<|>RELATION_NOE 效率<|>RELATION_NOE 则<|>RELATION_NOE 为<|>RELATION_NOE 75.8%<|>RELATION_NOE 和<|>RELATION_NOE 81.2%<|>RELATION_NOE 。<|>RELATION_NOE
A549<|>RELATION_NOE 细胞<|>RELATION_NOE 空白<|>RELATION_NOE 对照<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_NOE pEGFP-N1<|>RELATION_NOE 和<|>RELATION_NOE pEGFP<|>RELATION_NOE /<|>RELATION_NOE α1<|>RELATION_NOE ,<|>RELATION_NOE 3GT<|>RELATION_NOE 载体<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 平均<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.21<|>RELATION_NOE 、<|>RELATION_NOE 0.9<|>RELATION_NOE 56<|>RELATION_NOE ;<|>RELATION_NOE
293FT<|>RELATION_NOE 细胞<|>RELATION_NOE 空白<|>RELATION_NOE 对照<|>RELATION_NOE ,<|>RELATION_NOE pEGFP-N1<|>RELATION_NOE 和<|>RELATION_NOE pEGFP<|>RELATION_NOE /<|>RELATION_NOE α1<|>RELATION_NOE ,<|>RELATION_NOE 3GT<|>RELATION_NOE 载体<|>RELATION_NOE 的<|>RELATION_NOE 293FT<|>RELATION_NOE 细胞<|>RELATION_NOE 平均<|>RELATION_NOE 荧光<|>RELATION_NOE 表达量<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 7.66<|>RELATION_NOE 、<|>RELATION_NOE 1.00<|>RELATION_NOE 。<|>RELATION_NOE
结直肠癌<|>RELATION_NOE 根治<|>RELATION_NOE 术后<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_B 分析<|>RELATION_E
了解<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 根治<|>RELATION_NOE 术后<|>RELATION_NOE 单纯肺<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 提高<|>RELATION_NOE 高危<|>RELATION_NOE 患者<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 的<|>RELATION_NOE 针对性<|>RELATION_NOE 和<|>RELATION_NOE 早诊率<|>RELATION_NOE 。<|>RELATION_NOE
16<|>RELATION_NOE 例<|>RELATION_NOE 术后<|>RELATION_NOE 单纯肺<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 单侧肺<|>RELATION_NOE 转移<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 双侧肺<|>RELATION_NOE 转移<|>RELATION_NOE 6例<|>RELATION_NOE ;<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.003<|>RELATION_NOE ,<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 5.<|>RELATION_NOE 503<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 1.794-16.884<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 术前<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 19<|>RELATION_NOE ,<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 4.3<|>RELATION_NOE 19<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 1.269-14.692<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 根治术<|>RELATION_NOE 后<|>RELATION_NOE 肺<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 危险因素<|>RELATION_E 。<|>RELATION_NOE
直肠癌<|>RELATION_NOE 和<|>RELATION_NOE 术前<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 异常<|>RELATION_NOE 增高<|>RELATION_NOE 是<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 根治术<|>RELATION_NOE 后<|>RELATION_NOE 肺<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 高危<|>RELATION_B 因素<|>RELATION_E ,<|>RELATION_NOE 对<|>RELATION_NOE 这<|>RELATION_NOE 部分<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 要<|>RELATION_NOE 加强<|>RELATION_NOE 随访<|>RELATION_NOE ,<|>RELATION_NOE 常规<|>RELATION_NOE 行<|>RELATION_NOE 胸部<|>RELATION_NOE 增强<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 。<|>RELATION_NOE
肺结节病<|>RELATION_NOE 并<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 诊治<|>RELATION_B 分析<|>RELATION_E
8例<|>RELATION_NOE 曾<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 结核性<|>RELATION_NOE 胸膜炎<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 曾<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 。<|>RELATION_NOE
肺结节病<|>RELATION_NOE 出现<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 不明<|>RELATION_S ,<|>RELATION_NOE 有<|>RELATION_NOE 症状<|>RELATION_NOE 的<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 结节病<|>RELATION_NOE 患者<|>RELATION_NOE 需要<|>RELATION_NOE 行激素<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE 肺结节病<|>RELATION_NOE 出现<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 不明<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 症状<|>RELATION_NOE 的<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 结节病<|>RELATION_NOE 患者<|>RELATION_NOE 需要<|>RELATION_NOE 行<|>RELATION_NOE 激素<|>RELATION_NOE 治疗<|>RELATION_S 。<|>RELATION_NOE
结节病<|>RELATION_NOE 并<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 确诊<|>RELATION_NOE 依赖<|>RELATION_S 胸膜<|>RELATION_NOE 、<|>RELATION_NOE 肺<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 活检<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 、<|>RELATION_NOE 影像<|>RELATION_NOE 及<|>RELATION_NOE 实验室<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 降低<|>RELATION_NOE 误诊率<|>RELATION_NOE 。<|>RELATION_NOE
人<|>RELATION_NOE 肺癌<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白1<|>RELATION_NOE 重组<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 载体<|>RELATION_NOE 的<|>RELATION_NOE 构建<|>RELATION_B 和<|>RELATION_I 病毒<|>RELATION_I 包装<|>RELATION_I 及其<|>RELATION_I 鉴定<|>RELATION_E
构建<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白1<|>RELATION_NOE (<|>RELATION_NOE LCMR1<|>RELATION_NOE )<|>RELATION_NOE 重组<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 包装<|>RELATION_NOE 慢<|>RELATION_NOE 病毒颗粒<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 进一步<|>RELATION_NOE 研究<|>RELATION_NOE 该<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 功能<|>RELATION_NOE 提供<|>RELATION_NOE 实验<|>RELATION_NOE 基础<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE LCMR1<|>RELATION_NOE 扩增<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 酶<|>RELATION_NOE 切<|>RELATION_NOE 连接<|>RELATION_NOE 构建<|>RELATION_NOE 人<|>RELATION_NOE pLVX-IRES-Neo<|>RELATION_NOE 病毒<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 转化<|>RELATION_NOE DH5a<|>RELATION_NOE 大肠杆菌<|>RELATION_NOE ,<|>RELATION_NOE 挑取<|>RELATION_NOE 阳性<|>RELATION_NOE 克隆<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 鉴定<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 重组<|>RELATION_NOE 质粒<|>RELATION_NOE 与<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 系统<|>RELATION_NOE 一起<|>RELATION_NOE 转染<|>RELATION_NOE Lenti-X293T<|>RELATION_NOE 病毒<|>RELATION_NOE 包装<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 将<|>RELATION_NOE 收集<|>RELATION_NOE 的<|>RELATION_NOE 病毒<|>RELATION_NOE 感染<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 95C<|>RELATION_NOE ,<|>RELATION_NOE 即时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE q-PCR<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 蛋白质<|>RELATION_NOE 印迹法<|>RELATION_NOE 验证<|>RELATION_S 其<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
包装<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 病毒颗粒<|>RELATION_NOE 感染<|>RELATION_NOE 95C<|>RELATION_NOE 细胞系<|>RELATION_NOE ,<|>RELATION_NOE LCMR1<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 水平<|>RELATION_NOE 提高<|>RELATION_B 9.98<|>RELATION_I 倍<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 也<|>RELATION_NOE 明显<|>RELATION_NOE 增强<|>RELATION_NOE 。<|>RELATION_NOE 包装<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 病毒颗粒<|>RELATION_NOE 感染<|>RELATION_NOE 95C<|>RELATION_NOE 细胞系<|>RELATION_NOE ,<|>RELATION_NOE LCMR1<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 水平<|>RELATION_NOE 提高<|>RELATION_NOE 9.98<|>RELATION_NOE 倍<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 也<|>RELATION_NOE 明显<|>RELATION_B 增强<|>RELATION_E 。<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 成功<|>RELATION_NOE 构建<|>RELATION_NOE 了<|>RELATION_NOE pLVX-IRES-LCMR1-Neo<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 获得<|>RELATION_NOE 的<|>RELATION_NOE 慢<|>RELATION_NOE 病毒颗粒<|>RELATION_NOE 有效<|>RELATION_NOE 感染<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 95C<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 该<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 功能<|>RELATION_NOE 建立<|>RELATION_NOE 了<|>RELATION_NOE 模型<|>RELATION_NOE 。<|>RELATION_NOE
阿托伐<|>RELATION_NOE 他<|>RELATION_NOE 汀<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 化疗<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 阿托伐<|>RELATION_NOE 他<|>RELATION_NOE 汀<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 化疗<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 预先<|>RELATION_NOE 暴露<|>RELATION_NOE 于<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE 0<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 40nmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 阿托伐<|>RELATION_NOE 他<|>RELATION_NOE 汀<|>RELATION_NOE 的<|>RELATION_NOE 培养<|>RELATION_NOE 液中<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 20nmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 40nmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 实验<|>RELATION_NOE 重复<|>RELATION_NOE 3<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 磺酰罗丹明<|>RELATION_NOE B<|>RELATION_NOE (<|>RELATION_NOE SRB<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 研究<|>RELATION_NOE 常用<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 、<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨和<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
阿托伐<|>RELATION_NOE 他<|>RELATION_NOE 汀<|>RELATION_NOE 体外<|>RELATION_NOE 能<|>RELATION_NOE 增加<|>RELATION_S 人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE ,<|>RELATION_NOE 合用<|>RELATION_NOE 有助于<|>RELATION_NOE 降低<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
家族性<|>RELATION_NOE 胃癌<|>RELATION_NOE 发病<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 调查<|>RELATION_B 分析<|>RELATION_E
横<|>RELATION_NOE 断面<|>RELATION_NOE 调查<|>RELATION_NOE 和<|>RELATION_NOE 采集<|>RELATION_NOE 广东<|>RELATION_NOE 地区<|>RELATION_NOE 5<|>RELATION_NOE 家<|>RELATION_NOE 医院<|>RELATION_NOE 2000<|>RELATION_NOE －<|>RELATION_NOE 2007年<|>RELATION_NOE 住院<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 36<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 胃癌<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 和<|>RELATION_NOE 家系<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE Amsterdam<|>RELATION_NOE 标准<|>RELATION_NOE 筛选<|>RELATION_NOE FGC<|>RELATION_NOE 家系<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE FGC<|>RELATION_NOE 家<|>RELATION_NOE 系<|>RELATION_NOE 结构<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE FGC<|>RELATION_NOE 与<|>RELATION_NOE 散发性<|>RELATION_NOE 胃癌<|>RELATION_NOE (<|>RELATION_NOE SGC<|>RELATION_NOE )<|>RELATION_NOE 肿瘤<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
FGC<|>RELATION_NOE 家<|>RELATION_NOE 系<|>RELATION_NOE 一<|>RELATION_NOE 、<|>RELATION_NOE 二级<|>RELATION_NOE 亲属<|>RELATION_NOE 中共<|>RELATION_NOE 有<|>RELATION_NOE 肿瘤<|>RELATION_NOE 182<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 胃癌<|>RELATION_NOE 最<|>RELATION_NOE 常见<|>RELATION_NOE (<|>RELATION_NOE 154<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 84.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其次<|>RELATION_NOE 是<|>RELATION_NOE 食管癌<|>RELATION_NOE (<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 4.4%<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 3.3%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
FGC<|>RELATION_NOE 较<|>RELATION_NOE SGC<|>RELATION_NOE 发病<|>RELATION_NOE 年龄<|>RELATION_NOE 早<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 无<|>RELATION_NOE 显著<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 家<|>RELATION_NOE 系<|>RELATION_NOE 调查<|>RELATION_NOE 和<|>RELATION_NOE 遗传性<|>RELATION_NOE 检测<|>RELATION_NOE 才<|>RELATION_NOE 能<|>RELATION_NOE 诊断<|>RELATION_S FGC<|>RELATION_NOE 。<|>RELATION_NOE
阿司匹林<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE PICC<|>RELATION_NOE 置<|>RELATION_NOE 管<|>RELATION_NOE 后<|>RELATION_NOE 血栓<|>RELATION_NOE 发生率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S :<|>RELATION_NOE 99<|>RELATION_NOE 7例<|>RELATION_NOE 回顾性研究<|>RELATION_NOE
观察<|>RELATION_NOE 阿司匹林<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE PICC<|>RELATION_NOE 置<|>RELATION_NOE 管<|>RELATION_NOE 后<|>RELATION_NOE 血栓<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 2007年<|>RELATION_NOE 12月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 6月<|>RELATION_NOE 在<|>RELATION_NOE 上海市<|>RELATION_NOE 胸科<|>RELATION_NOE 医院<|>RELATION_NOE PICC<|>RELATION_NOE 置管<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 997<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 入院<|>RELATION_NOE 时间<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 2007年<|>RELATION_NOE 12月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 10月<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 562<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 6月<|>RELATION_NOE 为<|>RELATION_NOE 研究组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 435<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 在<|>RELATION_NOE 置管<|>RELATION_NOE 后<|>RELATION_NOE 1<|>RELATION_NOE 周<|>RELATION_NOE 内<|>RELATION_NOE 发生<|>RELATION_NOE 血栓<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 在<|>RELATION_NOE 1周<|>RELATION_NOE 至<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 间<|>RELATION_NOE 发生<|>RELATION_NOE 血栓<|>RELATION_NOE ,<|>RELATION_NOE 3例1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 后<|>RELATION_NOE 发生<|>RELATION_NOE 血栓<|>RELATION_NOE ;<|>RELATION_NOE
对照组<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 血栓<|>RELATION_NOE 发生<|>RELATION_NOE 在<|>RELATION_NOE 外<|>RELATION_NOE 周浅<|>RELATION_NOE 静脉<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE 在<|>RELATION_NOE 锁骨<|>RELATION_NOE 上<|>RELATION_NOE 静脉<|>RELATION_NOE 及<|>RELATION_NOE 颈内<|>RELATION_NOE 静脉<|>RELATION_NOE ;<|>RELATION_NOE
研究组<|>RELATION_NOE 5例<|>RELATION_NOE 在<|>RELATION_NOE 外<|>RELATION_NOE 周浅<|>RELATION_NOE 静脉<|>RELATION_NOE ,<|>RELATION_NOE 8例<|>RELATION_NOE 在<|>RELATION_NOE 锁骨<|>RELATION_NOE 上<|>RELATION_NOE 静脉<|>RELATION_NOE 及<|>RELATION_NOE 颈内<|>RELATION_NOE 静脉<|>RELATION_NOE ,<|>RELATION_NOE 血栓<|>RELATION_NOE 部位<|>RELATION_NOE 的<|>RELATION_NOE 组<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 也<|>RELATION_NOE 有<|>RELATION_B 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE Z<|>RELATION_NOE =<|>RELATION_NOE -2.066<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 39<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
预防性<|>RELATION_NOE 口服<|>RELATION_NOE 拜<|>RELATION_NOE 阿司匹林<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_B 控制<|>RELATION_E 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE PICC<|>RELATION_NOE 置<|>RELATION_NOE 管<|>RELATION_NOE 后<|>RELATION_NOE 血栓<|>RELATION_NOE 发生<|>RELATION_NOE 。<|>RELATION_NOE
针对性<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
应用<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 核心<|>RELATION_NOE 量表<|>RELATION_NOE EORTC<|>RELATION_NOE QI<|>RELATION_NOE ,<|>RELATION_NOE Q-C30<|>RELATION_NOE 对<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 针对性<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 前后<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
心理<|>RELATION_NOE 支持<|>RELATION_NOE 、<|>RELATION_NOE 护<|>RELATION_NOE 患<|>RELATION_NOE 沟通<|>RELATION_NOE 、<|>RELATION_NOE 饮食<|>RELATION_NOE 指导<|>RELATION_NOE 、<|>RELATION_NOE 对症<|>RELATION_NOE 护理<|>RELATION_NOE 及<|>RELATION_NOE 社会<|>RELATION_NOE 心理<|>RELATION_NOE 支持<|>RELATION_NOE 等<|>RELATION_NOE 护理<|>RELATION_NOE 活动<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_B 提高<|>RELATION_E 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
368<|>RELATION_NOE 例<|>RELATION_NOE 吸烟<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_B 特点<|>RELATION_I 与<|>RELATION_I 生存<|>RELATION_I 分析<|>RELATION_E
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 368<|>RELATION_NOE 例<|>RELATION_NOE 吸烟<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 构成<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 比例<|>RELATION_NOE 、<|>RELATION_NOE 组织学分型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 及<|>RELATION_NOE 中医<|>RELATION_NOE 分型<|>RELATION_NOE 等<|>RELATION_NOE 临床<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 各<|>RELATION_NOE 指标<|>RELATION_NOE 对<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
性别<|>RELATION_NOE 、<|>RELATION_NOE 组织学分型<|>RELATION_NOE 、<|>RELATION_NOE 中医<|>RELATION_NOE 分型<|>RELATION_NOE 对<|>RELATION_NOE 生存<|>RELATION_NOE 预后<|>RELATION_NOE 影响<|>RELATION_B 不<|>RELATION_I 明显<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 10.3<|>RELATION_NOE 56<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 11.2<|>RELATION_NOE 89<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.6<|>RELATION_NOE 24<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.021<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 3.6<|>RELATION_NOE 81<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.021<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 组织学分型<|>RELATION_NOE 、<|>RELATION_NOE 中医<|>RELATION_NOE 分型<|>RELATION_NOE 对<|>RELATION_NOE 生存<|>RELATION_NOE 预后<|>RELATION_NOE 影响<|>RELATION_NOE 不<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 10.3<|>RELATION_NOE 56<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 11.2<|>RELATION_NOE 89<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.6<|>RELATION_NOE 24<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.021<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 3.6<|>RELATION_NOE 81<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 生存<|>RELATION_NOE 预后<|>RELATION_NOE 有<|>RELATION_B 影响<|>RELATION_E 。<|>RELATION_NOE
368<|>RELATION_NOE 例<|>RELATION_NOE 吸烟<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 发病<|>RELATION_NOE 多<|>RELATION_NOE 集中<|>RELATION_NOE 在<|>RELATION_NOE 50<|>RELATION_NOE －<|>RELATION_NOE 69<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 为<|>RELATION_NOE 多<|>RELATION_NOE ,<|>RELATION_NOE 就诊<|>RELATION_NOE 时<|>RELATION_NOE 多<|>RELATION_NOE 为<|>RELATION_NOE 中晚期<|>RELATION_NOE ,<|>RELATION_NOE 非手术<|>RELATION_NOE 治疗<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 与<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE 可<|>RELATION_NOE 影响<|>RELATION_S 患者<|>RELATION_NOE 生存<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
伊立<|>RELATION_NOE 替康<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 沙利度胺<|>RELATION_NOE 治疗<|>RELATION_S 复发性<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 研究<|>RELATION_NOE
选取<|>RELATION_NOE 同时期<|>RELATION_NOE 的<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 复发性<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 不<|>RELATION_NOE 平衡<|>RELATION_NOE 指数<|>RELATION_NOE 最<|>RELATION_NOE 小<|>RELATION_NOE 的<|>RELATION_NOE 分配<|>RELATION_NOE 原则<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 采用<|>RELATION_NOE 伊立<|>RELATION_NOE 替康<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 沙利度<|>RELATION_NOE 胺化疗<|>RELATION_NOE ;<|>RELATION_NOE
肺原发性<|>RELATION_NOE 霍奇金<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 分析<|>RELATION_S
探讨<|>RELATION_NOE 肺原发性<|>RELATION_NOE 霍奇金<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 与<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 。<|>RELATION_NOE
3例<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 男性<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 咳嗽<|>RELATION_NOE 症状<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 直径<|>RELATION_NOE 为<|>RELATION_NOE 5cm<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 肺门<|>RELATION_NOE 及<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE ,<|>RELATION_NOE 镜<|>RELATION_NOE 下<|>RELATION_NOE 均<|>RELATION_NOE 可见<|>RELATION_NOE 典型<|>RELATION_NOE 的<|>RELATION_NOE R-S<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 背景<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 明显<|>RELATION_NOE 嗜酸<|>RELATION_NOE 粒细胞<|>RELATION_NOE 浸润<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 见<|>RELATION_NOE 干尸<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE CD15<|>RELATION_NOE 和<|>RELATION_NOE CD30<|>RELATION_NOE 阳性<|>RELATION_NOE 。<|>RELATION_NOE
肺原发性<|>RELATION_NOE 霍奇金<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 病理学<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 表型<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 恰当<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 预后<|>RELATION_NOE 良好<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛单<|>RELATION_NOE 药<|>RELATION_NOE 与<|>RELATION_NOE 联合<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_E 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
将<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 期<|>RELATION_NOE 或<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期<|>RELATION_NOE 的<|>RELATION_NOE 一线<|>RELATION_NOE 治疗失败<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 分成<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 奥沙利<|>RELATION_NOE 铂组<|>RELATION_NOE (<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE 多<|>RELATION_NOE 西他赛<|>RELATION_NOE 60mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE +<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 100mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第2<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛单<|>RELATION_NOE 药组<|>RELATION_NOE (<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE 多<|>RELATION_NOE 西他赛<|>RELATION_NOE 75mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 3周<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 2－<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
SDF-1<|>RELATION_NOE 、<|>RELATION_NOE CXCR4<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 与<|>RELATION_I 凋亡<|>RELATION_I 抑制蛋白<|>RELATION_I 基因<|>RELATION_I livin<|>RELATION_I 的<|>RELATION_I 相关性<|>RELATION_E 初步<|>RELATION_NOE 探讨<|>RELATION_NOE
分析<|>RELATION_NOE 基质<|>RELATION_NOE 细胞<|>RELATION_NOE 衍生<|>RELATION_NOE 因子<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE SDF-1<|>RELATION_NOE )<|>RELATION_NOE 及其<|>RELATION_NOE 受体<|>RELATION_NOE CXCR4<|>RELATION_NOE 、<|>RELATION_NOE 凋亡<|>RELATION_NOE 抑制蛋白<|>RELATION_NOE 基因<|>RELATION_NOE livin<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 各<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 多<|>RELATION_NOE 聚<|>RELATION_NOE 酶<|>RELATION_NOE 链式<|>RELATION_NOE 反应<|>RELATION_NOE 检测<|>RELATION_S 52<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 及<|>RELATION_NOE 3例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE SDF-1<|>RELATION_NOE 、<|>RELATION_NOE CXCR4<|>RELATION_NOE 及<|>RELATION_NOE livinmRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
SDF-1<|>RELATION_NOE 、<|>RELATION_NOE CXCR4<|>RELATION_NOE 及<|>RELATION_NOE livina<|>RELATION_NOE 、<|>RELATION_NOE livin<|>RELATION_NOE β<|>RELATION_NOE mRNA<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 是否<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 及<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 化疗<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关<|>RELATION_I 关系<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CXCR4<|>RELATION_NOE 与<|>RELATION_NOE livina<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 是否<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE CXCR4<|>RELATION_NOE 与<|>RELATION_NOE livina<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 是否<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关<|>RELATION_I 关系<|>RELATION_E 。<|>RELATION_NOE
慢性<|>RELATION_NOE 支气管<|>RELATION_NOE 异物<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 特征<|>RELATION_I 和<|>RELATION_I 诊疗<|>RELATION_I 分析<|>RELATION_E
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 9例<|>RELATION_NOE 慢性<|>RELATION_NOE 支气管<|>RELATION_NOE 异物<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 首<|>RELATION_NOE 诊<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 支气管镜<|>RELATION_NOE 下<|>RELATION_NOE 表现<|>RELATION_NOE 以及<|>RELATION_NOE 经镜<|>RELATION_NOE 取出<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
首<|>RELATION_NOE 诊<|>RELATION_NOE 症状<|>RELATION_NOE :<|>RELATION_NOE 慢性<|>RELATION_NOE 咳嗽<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 伴随<|>RELATION_NOE 咯血<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 反复<|>RELATION_NOE 肺炎<|>RELATION_NOE 4例<|>RELATION_NOE 。<|>RELATION_NOE
初步<|>RELATION_NOE 诊断<|>RELATION_NOE :<|>RELATION_NOE 肺炎<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 团块影<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 可能<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 肺不张<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺门<|>RELATION_NOE 钙化<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
影像学<|>RELATION_NOE 特征<|>RELATION_NOE :<|>RELATION_NOE 渗出<|>RELATION_NOE 表现<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺炎<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 伴<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 肺不张<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 外周团<|>RELATION_NOE 块影<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺门<|>RELATION_NOE 增大<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
异物<|>RELATION_NOE 部位<|>RELATION_NOE :<|>RELATION_NOE 右肺<|>RELATION_NOE 中<|>RELATION_NOE 下<|>RELATION_NOE 叶<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 左肺<|>RELATION_NOE 上<|>RELATION_NOE 叶<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 可见<|>RELATION_NOE 管口<|>RELATION_NOE 狭窄<|>RELATION_NOE 或<|>RELATION_NOE 完全<|>RELATION_NOE 堵塞<|>RELATION_NOE ,<|>RELATION_NOE 肉芽<|>RELATION_NOE 形成<|>RELATION_NOE ,<|>RELATION_NOE 黏膜<|>RELATION_NOE 充血<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 可见<|>RELATION_NOE 到<|>RELATION_NOE 异物<|>RELATION_NOE 边缘<|>RELATION_NOE 或者<|>RELATION_NOE 上端<|>RELATION_NOE 。<|>RELATION_NOE
慢性<|>RELATION_NOE 支气管<|>RELATION_NOE 异物<|>RELATION_NOE 缺乏<|>RELATION_NOE 典型<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 针对<|>RELATION_NOE 不明<|>RELATION_NOE 原因<|>RELATION_NOE 的<|>RELATION_NOE 慢性<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 肺不张<|>RELATION_NOE 、<|>RELATION_NOE 疑似<|>RELATION_NOE 肺恶性肿瘤者<|>RELATION_NOE 的<|>RELATION_NOE 鉴别诊断<|>RELATION_S 要<|>RELATION_NOE 考虑<|>RELATION_NOE 慢性<|>RELATION_NOE 支气管<|>RELATION_NOE 异物<|>RELATION_NOE 的<|>RELATION_NOE 可能<|>RELATION_NOE 。<|>RELATION_NOE
艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 评价<|>RELATION_NOE
探讨<|>RELATION_NOE 艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
80<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 给予<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE (<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨和<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE 进行<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 联合<|>RELATION_NOE 使用<|>RELATION_NOE 艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 进行<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
槐耳<|>RELATION_NOE 清膏<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 增殖<|>RELATION_B 和<|>RELATION_I 自噬<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
以<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE CCK-8<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 槐耳<|>RELATION_NOE 清膏<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制率<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE Westernblot<|>RELATION_NOE 方法<|>RELATION_NOE 以<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE CCK-8<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 槐<|>RELATION_NOE 耳清膏<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制率<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE Westernblot<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 自噬<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE P62<|>RELATION_NOE 、<|>RELATION_NOE LC3B<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 和<|>RELATION_NOE mTOR<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 分子<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
疾病<|>RELATION_NOE 分期<|>RELATION_NOE 在<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE 特发性<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 价值<|>RELATION_E
了解<|>RELATION_NOE GAP<|>RELATION_NOE 评分<|>RELATION_NOE 和<|>RELATION_NOE 分期<|>RELATION_NOE 系统<|>RELATION_NOE 对<|>RELATION_NOE 特发性<|>RELATION_NOE 肺纤维化<|>RELATION_NOE (<|>RELATION_NOE IPF<|>RELATION_NOE )<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE 北京市<|>RELATION_NOE 第六<|>RELATION_NOE 医院<|>RELATION_NOE 住院<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE IPF<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE 完善<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡<|>RELATION_NOE 灌洗<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 全部<|>RELATION_NOE 病例<|>RELATION_NOE 进行<|>RELATION_NOE GAP<|>RELATION_NOE 指数<|>RELATION_NOE 评估<|>RELATION_NOE 及<|>RELATION_NOE 分期<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 各期<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE 及<|>RELATION_NOE 氧分压<|>RELATION_NOE (<|>RELATION_NOE POz<|>RELATION_NOE )<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 了解<|>RELATION_NOE 各期<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进一步<|>RELATION_NOE 评价<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 肺泡灌洗液<|>RELATION_NOE (<|>RELATION_NOE BALF<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE 比例<|>RELATION_NOE 和<|>RELATION_NOE 嗜酸<|>RELATION_NOE 粒细胞<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 9.9<|>RELATION_NOE ±<|>RELATION_NOE 3.O<|>RELATION_NOE )%<|>RELATION_NOE 及<|>RELATION_NOE (<|>RELATION_NOE 6.3<|>RELATION_NOE ±<|>RELATION_NOE 2.3<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE 或<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Ⅱ<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE IPF<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 异常<|>RELATION_NOE 及<|>RELATION_NOE 合并<|>RELATION_NOE 肺动脉高压<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 增多<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE 或<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE IPF<|>RELATION_NOE 患者<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 发生率<|>RELATION_NOE 高于<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE Ⅱ<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE IPF<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 异常<|>RELATION_NOE 及<|>RELATION_NOE 合并<|>RELATION_NOE 肺动脉高压<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 增多<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE 或<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE IPF<|>RELATION_NOE 患者<|>RELATION_NOE 急性<|>RELATION_B 发作<|>RELATION_I 发生率<|>RELATION_E 高于<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血沉<|>RELATION_NOE 、<|>RELATION_NOE 职业<|>RELATION_NOE 暴露<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 及<|>RELATION_NOE 合并<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 反流性<|>RELATION_NOE 食管炎<|>RELATION_NOE 在<|>RELATION_NOE 各期<|>RELATION_NOE 分布<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE IPF<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE POz<|>RELATION_NOE 低下<|>RELATION_NOE ,<|>RELATION_NOE C<|>RELATION_NOE 反应<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE BALF<|>RELATION_NOE 中<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE 比例<|>RELATION_NOE 和<|>RELATION_NOE 嗜酸<|>RELATION_NOE 粒细胞<|>RELATION_NOE 比例<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 异常<|>RELATION_NOE 比例<|>RELATION_NOE 、<|>RELATION_NOE 并发<|>RELATION_NOE 肺动脉高压<|>RELATION_NOE 及<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 发生率<|>RELATION_NOE 增多<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 773<|>RELATION_NOE 例<|>RELATION_NOE 压疮<|>RELATION_NOE 高危<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 406<|>RELATION_NOE 例<|>RELATION_NOE 实施<|>RELATION_NOE 压疮<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 36<|>RELATION_NOE 7例<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE ,<|>RELATION_NOE 实施<|>RELATION_NOE 以<|>RELATION_NOE 患者<|>RELATION_NOE 需求<|>RELATION_NOE 为<|>RELATION_NOE 导向<|>RELATION_NOE 的<|>RELATION_NOE 人文<|>RELATION_NOE 护理<|>RELATION_NOE 。<|>RELATION_NOE
股骨<|>RELATION_NOE 上<|>RELATION_NOE 段<|>RELATION_NOE 转移癌<|>RELATION_NOE 的<|>RELATION_NOE 外科<|>RELATION_NOE 分型<|>RELATION_NOE 与<|>RELATION_NOE 治疗<|>RELATION_B 策略<|>RELATION_E
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2003年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 12月<|>RELATION_NOE 接受<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 99<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 102<|>RELATION_NOE 侧<|>RELATION_NOE )<|>RELATION_NOE 股骨<|>RELATION_NOE 上<|>RELATION_NOE 段<|>RELATION_NOE 转移癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男性<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 年龄<|>RELATION_NOE 56<|>RELATION_NOE 岁<|>RELATION_NOE (<|>RELATION_NOE 15<|>RELATION_NOE －<|>RELATION_NOE 87<|>RELATION_NOE 岁<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 来源<|>RELATION_NOE 以<|>RELATION_NOE 肺癌<|>RELATION_NOE 最为<|>RELATION_NOE 常见<|>RELATION_NOE (<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其次<|>RELATION_NOE 为<|>RELATION_NOE 乳腺癌<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
根据<|>RELATION_NOE 解剖<|>RELATION_NOE 部位<|>RELATION_NOE 及<|>RELATION_NOE 生物力学<|>RELATION_NOE 特点<|>RELATION_NOE 将<|>RELATION_NOE 股骨<|>RELATION_NOE 上<|>RELATION_NOE 段<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 分为<|>RELATION_NOE 4型<|>RELATION_NOE (<|>RELATION_NOE Ⅰ<|>RELATION_NOE －Ⅳ型<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 各型<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 重建<|>RELATION_NOE 方式<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
重建<|>RELATION_NOE 方式<|>RELATION_NOE 包括<|>RELATION_NOE :<|>RELATION_NOE 双动<|>RELATION_NOE 半<|>RELATION_NOE 髋关节<|>RELATION_NOE 置换<|>RELATION_NOE 3侧<|>RELATION_NOE 、<|>RELATION_NOE 全<|>RELATION_NOE 髋关节<|>RELATION_NOE 置换<|>RELATION_NOE lO<|>RELATION_NOE 侧<|>RELATION_NOE 、<|>RELATION_NOE 股骨<|>RELATION_NOE 上端肿<|>RELATION_NOE 瘤型<|>RELATION_NOE 双<|>RELATION_NOE 动<|>RELATION_NOE 半<|>RELATION_NOE 髋关节<|>RELATION_NOE 置换<|>RELATION_NOE 48<|>RELATION_NOE 侧<|>RELATION_NOE 、<|>RELATION_NOE 股骨<|>RELATION_NOE 上端肿<|>RELATION_NOE 瘤型<|>RELATION_NOE 全<|>RELATION_NOE 髋关节<|>RELATION_NOE 置换<|>RELATION_NOE 8侧<|>RELATION_NOE ,<|>RELATION_NOE 髓内针<|>RELATION_NOE 固定<|>RELATION_NOE 21<|>RELATION_NOE 侧<|>RELATION_NOE 、<|>RELATION_NOE 螺钉<|>RELATION_NOE 钢板<|>RELATION_NOE 固定<|>RELATION_NOE 12<|>RELATION_NOE 侧<|>RELATION_NOE 。<|>RELATION_NOE
海水<|>RELATION_NOE 处理<|>RELATION_S 对<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞低氧<|>RELATION_NOE 诱导<|>RELATION_NOE 因子1<|>RELATION_NOE α<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
探讨<|>RELATION_NOE 不同<|>RELATION_NOE 海水<|>RELATION_NOE 处理<|>RELATION_NOE 时间<|>RELATION_NOE 对<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 及<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞低氧<|>RELATION_NOE 诱导<|>RELATION_NOE 因子<|>RELATION_NOE 1d<|>RELATION_NOE (<|>RELATION_NOE HIF-1<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞系<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 海水<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE S<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 海水<|>RELATION_NOE 处理<|>RELATION_NOE 时间<|>RELATION_NOE 不同<|>RELATION_NOE ,<|>RELATION_NOE s<|>RELATION_NOE 组<|>RELATION_NOE 再<|>RELATION_NOE 分为<|>RELATION_NOE S1-S6<|>RELATION_NOE 组<|>RELATION_NOE 。<|>RELATION_NOE
吉姆萨<|>RELATION_NOE 染色<|>RELATION_NOE 后<|>RELATION_NOE 细胞<|>RELATION_NOE 形态<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE MTr<|>RELATION_NOE 检测<|>RELATION_S 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 蛋白<|>RELATION_NOE 免疫<|>RELATION_NOE 印记法<|>RELATION_NOE 吉姆萨<|>RELATION_NOE 染色<|>RELATION_NOE 后<|>RELATION_NOE 细胞<|>RELATION_NOE 形态<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE MTr<|>RELATION_NOE 检测<|>RELATION_NOE 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 蛋白<|>RELATION_NOE 免疫<|>RELATION_NOE 印记法<|>RELATION_NOE 检测<|>RELATION_S 细胞低氧<|>RELATION_NOE 诱导<|>RELATION_NOE 因子<|>RELATION_NOE 1d<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 海水<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE 发生<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 海水<|>RELATION_NOE 处理<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 8h<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 抑制率<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE HIF-1d<|>RELATION_NOE 在<|>RELATION_NOE 海水<|>RELATION_NOE 处理<|>RELATION_NOE 1h<|>RELATION_NOE 后<|>RELATION_NOE 开始<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 4h<|>RELATION_NOE 达<|>RELATION_NOE 最高峰<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 此后<|>RELATION_NOE 略<|>RELATION_NOE 有<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 仍<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
海水<|>RELATION_NOE 长<|>RELATION_NOE 时间<|>RELATION_NOE 处理<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_S 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 海水<|>RELATION_NOE 处理<|>RELATION_NOE 可<|>RELATION_NOE 诱导<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE HIF-1d<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE HIF-1d<|>RELATION_NOE 在<|>RELATION_NOE 海水<|>RELATION_NOE 致<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 损伤<|>RELATION_NOE 中<|>RELATION_NOE 可能<|>RELATION_NOE 起<|>RELATION_NOE 着<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE 海水<|>RELATION_NOE 长<|>RELATION_NOE 时间<|>RELATION_NOE 处理<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 海水<|>RELATION_NOE 处理<|>RELATION_NOE 可<|>RELATION_NOE 诱导<|>RELATION_S 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE HIF-1d<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE HIF-1d<|>RELATION_NOE 在<|>RELATION_NOE 海水<|>RELATION_NOE 致<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 损伤<|>RELATION_NOE 中<|>RELATION_NOE 可能<|>RELATION_NOE 起<|>RELATION_NOE 着<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
舟山<|>RELATION_NOE 地区<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE Ⅲ<|>RELATION_NOE 型<|>RELATION_NOE β<|>RELATION_NOE 微管蛋白<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
研究<|>RELATION_NOE 舟山<|>RELATION_NOE 地区<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE non-small<|>RELATION_NOE cell<|>RELATION_NOE lungcancer<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 与<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE Ⅲ<|>RELATION_NOE 型<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 微管蛋白<|>RELATION_NOE (<|>RELATION_NOE class<|>RELATION_NOE Ⅲ<|>RELATION_NOE β<|>RELATION_NOE -tubulin<|>RELATION_NOE ,<|>RELATION_NOE TUBB3<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 差异<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 86<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 相应<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE ,<|>RELATION_NOE 一<|>RELATION_NOE 步<|>RELATION_NOE 法<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE (<|>RELATION_NOE qRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE TUBB3mRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
TUBB3mRNA<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 0.50<|>RELATION_NOE ±<|>RELATION_NOE 1.94<|>RELATION_NOE )<|>RELATION_NOE 高于<|>RELATION_S 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 0.18<|>RELATION_NOE ±<|>RELATION_NOE 0.57<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 43<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_NOE 关系<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 35<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 是<|>RELATION_NOE 致<|>RELATION_NOE TUBB3mRNA<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 42<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE TUBB3mRNA<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 0.50<|>RELATION_NOE ±<|>RELATION_NOE 1.94<|>RELATION_NOE )<|>RELATION_NOE 高于<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 0.18<|>RELATION_NOE ±<|>RELATION_NOE 0.57<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 43<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 有<|>RELATION_B 明显<|>RELATION_I 关系<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 35<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 是<|>RELATION_NOE 致<|>RELATION_NOE TUBB3mRNA<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 42<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
舟山<|>RELATION_NOE 地区<|>RELATION_NOE TUBB3mRNA<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_NOE 高<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 增高<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 无关<|>RELATION_NOE 。<|>RELATION_NOE
局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 同步<|>RELATION_NOE 加量<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_S
主要<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 为<|>RELATION_NOE 总<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE (<|>RELATION_NOE ORR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 局部<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE LCR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 总<|>RELATION_NOE 生存率<|>RELATION_NOE (<|>RELATION_NOE OS<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 生存率<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 3级<|>RELATION_NOE 及<|>RELATION_NOE 以上<|>RELATION_NOE 食管<|>RELATION_NOE 和<|>RELATION_NOE 肺损伤<|>RELATION_NOE 。<|>RELATION_NOE
67<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 85.9%<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 以<|>RELATION_NOE 顺铂<|>RELATION_NOE 或<|>RELATION_NOE 卡铂<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 的<|>RELATION_NOE 第三<|>RELATION_NOE 代<|>RELATION_NOE 细胞<|>RELATION_NOE 毒<|>RELATION_NOE 药物<|>RELATION_NOE 两<|>RELATION_NOE 药<|>RELATION_NOE 联合<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 21.8%<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 64.1%<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 序贯<|>RELATION_NOE 放化<|>RELATION_NOE 疗.<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 共<|>RELATION_NOE 发生<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 食管<|>RELATION_NOE 损伤<|>RELATION_NOE 59<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 75.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 相关性<|>RELATION_NOE 肺损伤<|>RELATION_NOE (<|>RELATION_NOE TRP<|>RELATION_NOE )<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 26.9%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 3<|>RELATION_NOE 级<|>RELATION_NOE 及<|>RELATION_NOE 以上<|>RELATION_NOE 放射性<|>RELATION_NOE 食管<|>RELATION_NOE 损伤<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 24.4%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 3级<|>RELATION_NOE 及<|>RELATION_NOE 以上<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 9例<|>RELATION_NOE (<|>RELATION_NOE 11.5%<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
基于<|>RELATION_NOE 主动<|>RELATION_NOE 呼吸<|>RELATION_NOE 控制<|>RELATION_NOE 辅助<|>RELATION_NOE 3DCT<|>RELATION_NOE 与<|>RELATION_NOE 4DCT<|>RELATION_NOE 扫描<|>RELATION_NOE 确定<|>RELATION_S 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 内<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 比<|>RELATION_NOE 对<|>RELATION_NOE 研究<|>RELATION_NOE
比较<|>RELATION_NOE 基于<|>RELATION_NOE 主动<|>RELATION_NOE 呼吸<|>RELATION_NOE 控制<|>RELATION_NOE (<|>RELATION_NOE ABC<|>RELATION_NOE )<|>RELATION_NOE 辅助<|>RELATION_NOE 三维<|>RELATION_NOE CT<|>RELATION_NOE (<|>RELATION_NOE 3DCT<|>RELATION_NOE )<|>RELATION_NOE 扫描<|>RELATION_NOE 与<|>RELATION_NOE 基于<|>RELATION_NOE 自由<|>RELATION_NOE 呼吸<|>RELATION_NOE 3DCT<|>RELATION_NOE 及<|>RELATION_NOE 四维<|>RELATION_NOE CT<|>RELATION_NOE (<|>RELATION_NOE 4DCT<|>RELATION_NOE )<|>RELATION_NOE 扫描<|>RELATION_NOE 所<|>RELATION_NOE 构建<|>RELATION_NOE 周围<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 内<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE (<|>RELATION_NOE IGTV<|>RELATION_NOE )<|>RELATION_NOE 中心点<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE 体积<|>RELATION_NOE 大小<|>RELATION_NOE 及<|>RELATION_NOE 匹配<|>RELATION_NOE 指数<|>RELATION_NOE (<|>RELATION_NOE MI<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
18<|>RELATION_NOE 例<|>RELATION_NOE 周围<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 序贯<|>RELATION_NOE 完成<|>RELATION_NOE 自由<|>RELATION_NOE 呼吸<|>RELATION_NOE 胸部<|>RELATION_NOE 3DCT<|>RELATION_NOE 和<|>RELATION_NOE 4DCT<|>RELATION_NOE 扫描<|>RELATION_NOE 及<|>RELATION_NOE ABC<|>RELATION_NOE 辅助<|>RELATION_NOE 平静<|>RELATION_NOE 吸气<|>RELATION_NOE 末<|>RELATION_NOE 和<|>RELATION_NOE 平静<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 3DCT<|>RELATION_NOE 扫描.<|>RELATION_NOE
4DCT<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 时相<|>RELATION_NOE GTV<|>RELATION_NOE 融合<|>RELATION_NOE 得到<|>RELATION_NOE IGTV10<|>RELATION_NOE ,0%<|>RELATION_NOE 和<|>RELATION_NOE 50%<|>RELATION_NOE 时相<|>RELATION_NOE 的<|>RELATION_NOE GTV<|>RELATION_NOE 融合<|>RELATION_NOE 得到<|>RELATION_NOE IGTV2<|>RELATION_NOE ,<|>RELATION_NOE 基于<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 密度<|>RELATION_NOE 投影<|>RELATION_NOE (<|>RELATION_NOE MIP<|>RELATION_NOE )<|>RELATION_NOE 图像<|>RELATION_NOE 构建<|>RELATION_NOE IGTVMIP<|>RELATION_NOE ,<|>RELATION_NOE 自由<|>RELATION_NOE 呼吸<|>RELATION_NOE 3DCT<|>RELATION_NOE 图像<|>RELATION_NOE GTV<|>RELATION_NOE 外<|>RELATION_NOE 扩<|>RELATION_NOE 基于<|>RELATION_NOE 4DCT<|>RELATION_NOE 测得<|>RELATION_NOE 的<|>RELATION_NOE 运动<|>RELATION_NOE 范围<|>RELATION_NOE 得到<|>RELATION_NOE IGTV3D<|>RELATION_NOE ,<|>RELATION_NOE 平静<|>RELATION_NOE 吸气<|>RELATION_NOE 末<|>RELATION_NOE 和<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 屏气<|>RELATION_NOE 3DCT<|>RELATION_NOE 图像<|>RELATION_NOE GTV<|>RELATION_NOE 融合<|>RELATION_NOE 得到<|>RELATION_NOE IGTVABC<|>RELATION_NOE 。<|>RELATION_NOE
GDC-0941<|>RELATION_NOE 联合<|>RELATION_NOE AZD6244<|>RELATION_NOE 对<|>RELATION_NOE KRAS<|>RELATION_NOE 突变<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_B 抑制<|>RELATION_I 作用<|>RELATION_E
常规<|>RELATION_NOE 培养<|>RELATION_NOE NCI-H157<|>RELATION_NOE 细胞<|>RELATION_NOE 并<|>RELATION_NOE 分别<|>RELATION_NOE 用<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE P13K<|>RELATION_NOE 抑制剂<|>RELATION_NOE GDC-0941<|>RELATION_NOE 和<|>RELATION_NOE MEK<|>RELATION_NOE 抑制剂<|>RELATION_NOE AZD6244<|>RELATION_NOE 单独<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑盐<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 初步<|>RELATION_NOE 观察<|>RELATION_NOE 对<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
P13K<|>RELATION_NOE 抑制<|>RELATION_NOE (<|>RELATION_NOE AZD6244<|>RELATION_NOE )<|>RELATION_NOE 可<|>RELATION_NOE 协同<|>RELATION_NOE MEK<|>RELATION_NOE 抑制<|>RELATION_NOE (<|>RELATION_NOE GDC-0941<|>RELATION_NOE )<|>RELATION_NOE 诱导<|>RELATION_S NCI-H157<|>RELATION_NOE 细胞<|>RELATION_NOE 发生<|>RELATION_NOE 生长<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 联合<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 效果<|>RELATION_NOE 受到<|>RELATION_NOE 药物<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE P13K<|>RELATION_NOE 抑制<|>RELATION_NOE (<|>RELATION_NOE AZD6244<|>RELATION_NOE )<|>RELATION_NOE 可<|>RELATION_NOE 协同<|>RELATION_NOE MEK<|>RELATION_NOE 抑制<|>RELATION_NOE (<|>RELATION_NOE GDC-0941<|>RELATION_NOE )<|>RELATION_NOE 诱导<|>RELATION_NOE NCI-H157<|>RELATION_NOE 细胞<|>RELATION_NOE 发生<|>RELATION_NOE 生长<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 联合<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 效果<|>RELATION_NOE 受到<|>RELATION_NOE 药物<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
微管<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE -2<|>RELATION_NOE 在<|>RELATION_NOE 240<|>RELATION_NOE 例<|>RELATION_NOE 活检<|>RELATION_NOE 肺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_S 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 微管<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE MAP-2<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 240<|>RELATION_NOE 例<|>RELATION_NOE 2008<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11<|>RELATION_NOE 年<|>RELATION_NOE 间<|>RELATION_NOE 收集<|>RELATION_NOE 的<|>RELATION_NOE 肺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 中<|>RELATION_NOE 突触素<|>RELATION_NOE 、<|>RELATION_NOE 嗜<|>RELATION_NOE 铬粒素<|>RELATION_NOE A<|>RELATION_NOE (<|>RELATION_NOE CgA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE CD56<|>RELATION_NOE 、<|>RELATION_NOE MAP-2<|>RELATION_NOE 及<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE TTF-1<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
MAP-2<|>RELATION_NOE 是<|>RELATION_NOE 敏感性<|>RELATION_B 及<|>RELATION_I 准确性<|>RELATION_I 高<|>RELATION_E 的<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 标志<|>RELATION_NOE 抗体<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 在<|>RELATION_NOE 肺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 肺结核<|>RELATION_NOE 临床<|>RELATION_NOE 影像学<|>RELATION_NOE 分析<|>RELATION_S
并发症<|>RELATION_NOE :<|>RELATION_NOE 肺气肿<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 气胸<|>RELATION_NOE 5<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张症<|>RELATION_NOE 6例<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE Real-timePCR<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 134<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小<|>RELATION_NOE 细胞<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 对应<|>RELATION_NOE 的<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE GPC5<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
GPC5<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小<|>RELATION_NOE 细胞<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 评估<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_NOE 标志物<|>RELATION_NOE 。<|>RELATION_NOE
马斯洛<|>RELATION_NOE 需要<|>RELATION_NOE 层次<|>RELATION_NOE 理论<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
选择<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 4月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 干预组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 给予<|>RELATION_NOE 临床<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 干预组<|>RELATION_NOE 采取<|>RELATION_NOE 马斯洛<|>RELATION_NOE 需要<|>RELATION_NOE 层次<|>RELATION_NOE 理论<|>RELATION_NOE 进行<|>RELATION_NOE 干预<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 匹兹堡<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量量表<|>RELATION_NOE (<|>RELATION_NOE PSQI<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 抑郁<|>RELATION_NOE 自<|>RELATION_NOE 评量表<|>RELATION_NOE (<|>RELATION_NOE SDS<|>RELATION_NOE )<|>RELATION_NOE 评估<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 和<|>RELATION_NOE 患者<|>RELATION_NOE 抑郁<|>RELATION_NOE 状态<|>RELATION_NOE 。<|>RELATION_NOE
Toll<|>RELATION_NOE 样受体<|>RELATION_NOE -3<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE Toll<|>RELATION_NOE 样<|>RELATION_NOE 受体<|>RELATION_NOE -3<|>RELATION_NOE (<|>RELATION_NOE TLR3<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE (<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 人<|>RELATION_NOE 支气管<|>RELATION_NOE 上皮细胞<|>RELATION_NOE (<|>RELATION_NOE HBE<|>RELATION_NOE 细胞<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
体外<|>RELATION_NOE 培养<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE HBE<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S TLR3<|>RELATION_NOE 在<|>RELATION_NOE 2种<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE Real-timePCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S TLR3mRNA<|>RELATION_NOE 在<|>RELATION_NOE 2种<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
细胞免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 显示<|>RELATION_NOE TLR3<|>RELATION_NOE 主要<|>RELATION_NOE 表达<|>RELATION_NOE 于<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 胞膜<|>RELATION_NOE 和<|>RELATION_NOE 胞质<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 呈棕<|>RELATION_NOE 黄色<|>RELATION_NOE 颗粒状<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE TLR3mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 相对值<|>RELATION_NOE 为<|>RELATION_NOE 1.01<|>RELATION_NOE 680<|>RELATION_NOE ±<|>RELATION_NOE 0.02<|>RELATION_NOE 376<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S HBE<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 后者<|>RELATION_NOE 为<|>RELATION_NOE 0.04<|>RELATION_NOE 780<|>RELATION_NOE ±<|>RELATION_NOE 0.01<|>RELATION_NOE 792<|>RELATION_NOE ,<|>RELATION_NOE TLR3<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 相对值<|>RELATION_NOE 为<|>RELATION_NOE 0.3<|>RELATION_NOE 19<|>RELATION_NOE 30<|>RELATION_NOE ±<|>RELATION_NOE 0.01<|>RELATION_NOE 116<|>RELATION_NOE ,<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 显示<|>RELATION_NOE TLR3<|>RELATION_NOE 主要<|>RELATION_NOE 表达<|>RELATION_NOE 于<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 胞膜<|>RELATION_NOE 和<|>RELATION_NOE 胞质<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 呈棕<|>RELATION_NOE 黄色<|>RELATION_NOE 颗粒状<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE TLR3mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 相对值<|>RELATION_NOE 为<|>RELATION_NOE 1.01<|>RELATION_NOE 680<|>RELATION_NOE ±<|>RELATION_NOE 0.02<|>RELATION_NOE 376<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_NOE HBE<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 后者<|>RELATION_NOE 为<|>RELATION_NOE 0.04<|>RELATION_NOE 780<|>RELATION_NOE ±<|>RELATION_NOE 0.01<|>RELATION_NOE 792<|>RELATION_NOE ,<|>RELATION_NOE TLR3<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 相对值<|>RELATION_NOE 为<|>RELATION_NOE 0.3<|>RELATION_NOE 19<|>RELATION_NOE 30<|>RELATION_NOE ±<|>RELATION_NOE 0.01<|>RELATION_NOE 116<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S HBE<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 后者<|>RELATION_NOE 为<|>RELATION_NOE 0.1<|>RELATION_NOE 6070<|>RELATION_NOE ±<|>RELATION_NOE 0.00<|>RELATION_NOE 303<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
TLR3<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 高于<|>RELATION_S HBE<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE TLR3<|>RELATION_NOE 可能<|>RELATION_NOE 参与<|>RELATION_NOE 促进<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 进展<|>RELATION_NOE 过程<|>RELATION_NOE 。<|>RELATION_NOE TLR3<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 高于<|>RELATION_NOE HBE<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE TLR3<|>RELATION_NOE 可能<|>RELATION_B 参与<|>RELATION_I 促进<|>RELATION_E 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 进展<|>RELATION_NOE 过程<|>RELATION_NOE 。<|>RELATION_NOE
从<|>RELATION_NOE 淋巴道<|>RELATION_NOE 转移<|>RELATION_NOE 潜能<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞<|>RELATION_NOE 株<|>RELATION_NOE 中<|>RELATION_NOE 分离<|>RELATION_NOE 出<|>RELATION_NOE 高<|>RELATION_NOE 转移<|>RELATION_NOE 潜能<|>RELATION_NOE 的<|>RELATION_NOE 单<|>RELATION_NOE 克隆细胞<|>RELATION_NOE 株<|>RELATION_NOE 并<|>RELATION_NOE 建立<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植<|>RELATION_NOE 模型<|>RELATION_NOE 。<|>RELATION_NOE
取<|>RELATION_NOE 能<|>RELATION_NOE 在<|>RELATION_NOE 体外<|>RELATION_NOE 连续<|>RELATION_NOE 增殖<|>RELATION_NOE 的<|>RELATION_NOE 9<|>RELATION_NOE 个<|>RELATION_NOE 细胞株<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 4周龄<|>RELATION_NOE 裸鼠<|>RELATION_NOE 爪垫<|>RELATION_NOE 进行<|>RELATION_NOE 第1<|>RELATION_NOE 轮<|>RELATION_NOE 筛选<|>RELATION_NOE ,<|>RELATION_NOE 再<|>RELATION_NOE 取<|>RELATION_NOE 其中<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE 的<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 细胞株<|>RELATION_NOE 进行<|>RELATION_NOE 肝脏<|>RELATION_NOE 原位<|>RELATION_NOE 移植<|>RELATION_NOE ,<|>RELATION_NOE 5周<|>RELATION_NOE 后<|>RELATION_NOE 解剖<|>RELATION_NOE 观察<|>RELATION_NOE 体内<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 情况<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 病理学<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 筛选<|>RELATION_NOE 出<|>RELATION_NOE 不同<|>RELATION_NOE 转移<|>RELATION_NOE 潜能<|>RELATION_NOE 的<|>RELATION_NOE 细胞株<|>RELATION_NOE 。<|>RELATION_NOE
筛选<|>RELATION_NOE 出<|>RELATION_NOE 高<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 、<|>RELATION_NOE 低肺<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肝癌<|>RELATION_NOE 单<|>RELATION_NOE 克隆细胞<|>RELATION_NOE 株<|>RELATION_NOE ,<|>RELATION_NOE 命名<|>RELATION_NOE 为<|>RELATION_NOE HCCLYM-H2<|>RELATION_NOE ,<|>RELATION_NOE 该<|>RELATION_NOE 细胞株<|>RELATION_NOE 的<|>RELATION_NOE 肺转移率<|>RELATION_NOE 为<|>RELATION_NOE 20%<|>RELATION_NOE ,<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE 。<|>RELATION_NOE
成功<|>RELATION_NOE 建立<|>RELATION_NOE 人<|>RELATION_NOE 肝癌<|>RELATION_NOE 高<|>RELATION_NOE 淋巴道<|>RELATION_NOE 转移<|>RELATION_NOE 细胞株<|>RELATION_NOE 和<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 证实<|>RELATION_NOE 了<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 异质性<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
探讨<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 经验<|>RELATION_NOE 。<|>RELATION_NOE
42<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 施行<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE +<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE 。<|>RELATION_NOE
术前<|>RELATION_NOE eTNM<|>RELATION_NOE 分期Ⅰ<|>RELATION_NOE －Ⅱ期<|>RELATION_NOE (<|>RELATION_NOE T1N0M0-T2N1M0<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 5cm<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 肺门<|>RELATION_NOE 及<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 或<|>RELATION_NOE 胸膜<|>RELATION_NOE 肥厚<|>RELATION_NOE 。<|>RELATION_NOE
手术时间<|>RELATION_NOE 100<|>RELATION_NOE －<|>RELATION_NOE 400<|>RELATION_NOE (<|>RELATION_NOE 220<|>RELATION_NOE ±<|>RELATION_NOE 37<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 失血量<|>RELATION_NOE 120<|>RELATION_NOE －<|>RELATION_NOE 700<|>RELATION_NOE (<|>RELATION_NOE 150<|>RELATION_NOE ±<|>RELATION_NOE 63<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 后<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 3－<|>RELATION_NOE 12<|>RELATION_NOE (<|>RELATION_NOE 4.5<|>RELATION_NOE ±<|>RELATION_NOE 2.1<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 9-31<|>RELATION_NOE (<|>RELATION_NOE 12.2<|>RELATION_NOE ±<|>RELATION_NOE 5.0<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 在<|>RELATION_NOE 技术<|>RELATION_B 上<|>RELATION_I 是<|>RELATION_I 安全<|>RELATION_I 、<|>RELATION_I 可行<|>RELATION_E 的<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 要<|>RELATION_NOE 把握<|>RELATION_NOE 好<|>RELATION_NOE 手术<|>RELATION_NOE 适应证<|>RELATION_NOE 。<|>RELATION_NOE
细支气管<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_B 表现<|>RELATION_I 及<|>RELATION_I 诊断<|>RELATION_E
探讨<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 征象<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 该病<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
合并<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 或<|>RELATION_NOE 单侧<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 者<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 心包积液者<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 纵隔<|>RELATION_NOE 内<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大者<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 骨盆骨<|>RELATION_NOE 转移者<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
细支气管<|>RELATION_NOE 肺泡<|>RELATION_NOE 细胞癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 复杂<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE ,<|>RELATION_NOE 熟悉<|>RELATION_NOE 其<|>RELATION_NOE 各型<|>RELATION_NOE 表现<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 便<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_NOE 诊断<|>RELATION_NOE 正确率<|>RELATION_NOE 。<|>RELATION_NOE
吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
60<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 各<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 采用<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 、<|>RELATION_NOE 阿霉素<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 弥散性<|>RELATION_NOE 血管<|>RELATION_NOE 内<|>RELATION_NOE 凝血<|>RELATION_NOE (<|>RELATION_NOE DIC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE
其中<|>RELATION_NOE 急性<|>RELATION_NOE 白血病<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 消化系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 73<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肾癌<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
同时<|>RELATION_NOE 死亡组<|>RELATION_NOE 和<|>RELATION_NOE 未<|>RELATION_NOE 死亡组<|>RELATION_NOE 的<|>RELATION_NOE 纤维蛋白原<|>RELATION_NOE 浓度<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 死亡<|>RELATION_NOE 组<|>RELATION_NOE 全身<|>RELATION_NOE 炎症<|>RELATION_NOE 反应<|>RELATION_NOE 综合征<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 未<|>RELATION_NOE 死亡组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 同时<|>RELATION_NOE 死亡组<|>RELATION_NOE 和<|>RELATION_NOE 未<|>RELATION_NOE 死亡组<|>RELATION_NOE 的<|>RELATION_NOE 纤维蛋白原<|>RELATION_NOE 浓度<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 死亡组<|>RELATION_NOE 全身<|>RELATION_NOE 炎症<|>RELATION_NOE 反应<|>RELATION_NOE 综合征<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 未<|>RELATION_NOE 死亡组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
恶性肿瘤<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE DIC<|>RELATION_NOE 的<|>RELATION_NOE 病因<|>RELATION_NOE 主要<|>RELATION_NOE 以<|>RELATION_NOE 血液<|>RELATION_NOE 系统<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 消化道<|>RELATION_NOE 肿瘤<|>RELATION_NOE 较<|>RELATION_B 多<|>RELATION_I 见<|>RELATION_E ,<|>RELATION_NOE 及时<|>RELATION_NOE 使用<|>RELATION_NOE 抗凝<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 积极<|>RELATION_NOE 治疗<|>RELATION_NOE 原发<|>RELATION_NOE 疾病<|>RELATION_NOE 是<|>RELATION_NOE 提高<|>RELATION_NOE 生存率<|>RELATION_NOE 的<|>RELATION_NOE 关键<|>RELATION_NOE 。<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE DIC<|>RELATION_NOE 的<|>RELATION_NOE 病因<|>RELATION_NOE 主要<|>RELATION_NOE 以<|>RELATION_NOE 血液<|>RELATION_NOE 系统<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 及<|>RELATION_NOE 消化道<|>RELATION_NOE 肿瘤<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE 见<|>RELATION_NOE ,<|>RELATION_NOE 及时<|>RELATION_NOE 使用<|>RELATION_NOE 抗凝<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 积极<|>RELATION_NOE 治疗<|>RELATION_NOE 原发<|>RELATION_NOE 疾病<|>RELATION_NOE 是<|>RELATION_NOE 提高<|>RELATION_S 生存率<|>RELATION_NOE 的<|>RELATION_NOE 关键<|>RELATION_NOE 。<|>RELATION_NOE
星状神经节<|>RELATION_NOE 阻滞<|>RELATION_NOE 联合<|>RELATION_NOE 吗啡<|>RELATION_NOE 缓释片<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 星状神经节<|>RELATION_NOE 阻滞<|>RELATION_NOE 联合<|>RELATION_NOE 吗啡<|>RELATION_NOE 缓释片<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 给予<|>RELATION_NOE 吗啡<|>RELATION_NOE 缓释片<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 此<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 联合<|>RELATION_NOE 星状神经节<|>RELATION_NOE 阻滞<|>RELATION_NOE 镇痛<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 吗啡<|>RELATION_NOE 用量<|>RELATION_NOE 明显<|>RELATION_B 少于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 9.<|>RELATION_NOE 11<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 镇痛<|>RELATION_NOE 持续<|>RELATION_NOE 时间<|>RELATION_NOE 明显<|>RELATION_NOE 长于<|>RELATION_NOE
星状神经节<|>RELATION_NOE 阻滞<|>RELATION_NOE 联合<|>RELATION_NOE 吗啡<|>RELATION_NOE 缓释片<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疼痛<|>RELATION_NOE 能够<|>RELATION_NOE 显著<|>RELATION_B 提高<|>RELATION_E 镇痛<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 吗啡<|>RELATION_NOE 用量<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE 星状神经节<|>RELATION_NOE 阻滞<|>RELATION_NOE 联合<|>RELATION_NOE 吗啡<|>RELATION_NOE 缓释片<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 疼痛<|>RELATION_NOE 能够<|>RELATION_NOE 显著<|>RELATION_NOE 提高<|>RELATION_NOE 镇痛<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_S 吗啡<|>RELATION_NOE 用量<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 抑制剂<|>RELATION_NOE 对<|>RELATION_NOE 肾移植<|>RELATION_NOE 受者<|>RELATION_NOE 术后<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 肾移植术<|>RELATION_NOE 后<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 情况<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 抑制剂<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 1996年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2006年<|>RELATION_NOE 12月<|>RELATION_NOE 在<|>RELATION_NOE 济南<|>RELATION_NOE 军区<|>RELATION_NOE 总医院<|>RELATION_NOE 进行<|>RELATION_NOE 同<|>RELATION_NOE 种<|>RELATION_NOE 异体<|>RELATION_NOE 肾移植<|>RELATION_NOE 的<|>RELATION_NOE 85<|>RELATION_NOE 2例受者<|>RELATION_NOE 中<|>RELATION_NOE 39<|>RELATION_NOE 例<|>RELATION_NOE 发生<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 分为<|>RELATION_NOE 硫唑嘌呤<|>RELATION_NOE (<|>RELATION_NOE AZA<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 吗替<|>RELATION_NOE 麦考<|>RELATION_NOE 酚酯<|>RELATION_NOE (<|>RELATION_NOE MMF<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 法<|>RELATION_NOE 估计<|>RELATION_NOE 并<|>RELATION_NOE 绘制<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 生存<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE log-rank<|>RELATION_NOE 法<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 生存率<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 免疫<|>RELATION_NOE 抑制剂<|>RELATION_NOE 对<|>RELATION_NOE 并发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
852<|>RELATION_NOE 例<|>RELATION_NOE 肾移植<|>RELATION_NOE 受者<|>RELATION_NOE 术后<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 总<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 4.6%<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 852<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 泌尿<|>RELATION_NOE 系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 占<|>RELATION_NOE 74.4%<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE /<|>RELATION_NOE 39<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 消化系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 占<|>RELATION_NOE 15.4%<|>RELATION_NOE (<|>RELATION_NOE 6/<|>RELATION_NOE 39<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 占<|>RELATION_NOE 7.7%<|>RELATION_NOE (<|>RELATION_NOE 3/39<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 皮肤癌<|>RELATION_NOE 占<|>RELATION_NOE 2.5%<|>RELATION_NOE (<|>RELATION_NOE 1/39<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
使用<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 不同<|>RELATION_NOE 免疫<|>RELATION_NOE 抑制剂<|>RELATION_NOE 的<|>RELATION_NOE 肾移植术<|>RELATION_NOE 后<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病死率<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 0.0<|>RELATION_NOE 75<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
AZA<|>RELATION_NOE 与<|>RELATION_NOE MMF<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 免疫<|>RELATION_NOE 抑制剂<|>RELATION_NOE 对<|>RELATION_NOE 肾移植术<|>RELATION_NOE 后<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_B 没有<|>RELATION_I 明显<|>RELATION_I 区别<|>RELATION_E 。<|>RELATION_NOE
周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 与<|>RELATION_NOE 血清<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE 周围<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 与<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 8月<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE 本院<|>RELATION_NOE 经<|>RELATION_NOE 手术<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 与<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE NSE<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE 病理<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 与<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE NSE<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 胸膜<|>RELATION_NOE 凹陷征<|>RELATION_NOE 、<|>RELATION_NOE 毛刺征<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 气相<|>RELATION_NOE ,<|>RELATION_NOE 增强<|>RELATION_NOE 值>/<|>RELATION_NOE 20Hu<|>RELATION_NOE 与<|>RELATION_NOE <<|>RELATION_NOE 20Hu<|>RELATION_NOE 、<|>RELATION_NOE 钙化<|>RELATION_NOE 或<|>RELATION_NOE 肺门<|>RELATION_NOE 、<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 肿<|>RELATION_NOE 大<|>RELATION_NOE 问<|>RELATION_NOE 血清<|>RELATION_NOE NSE<|>RELATION_NOE 浓度<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE Kj<|>RELATION_NOE －<|>RELATION_NOE 67<|>RELATION_NOE 抗原<|>RELATION_NOE 阳性<|>RELATION_NOE 百分率<|>RELATION_NOE 与<|>RELATION_NOE 血清<|>RELATION_NOE NSE<|>RELATION_NOE 浓度<|>RELATION_NOE 无<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 28<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.8<|>RELATION_NOE 48<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE Ki-67<|>RELATION_NOE 抗原<|>RELATION_NOE 及<|>RELATION_NOE p53<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 血清<|>RELATION_NOE NSE<|>RELATION_NOE 浓度<|>RELATION_NOE 之间<|>RELATION_NOE 无<|>RELATION_B 相关<|>RELATION_E 。<|>RELATION_NOE
CT<|>RELATION_NOE 能谱<|>RELATION_NOE 成像<|>RELATION_NOE 对<|>RELATION_NOE 肺内良<|>RELATION_NOE 恶性肿块<|>RELATION_NOE 诊断<|>RELATION_S 的<|>RELATION_NOE 初步<|>RELATION_NOE 研究<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_S 临床<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 254<|>RELATION_NOE 例<|>RELATION_NOE
遵循<|>RELATION_NOE 科学<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 学习曲线<|>RELATION_NOE ,<|>RELATION_NOE 完全<|>RELATION_NOE 可<|>RELATION_NOE 在<|>RELATION_NOE 市<|>RELATION_NOE 区级<|>RELATION_NOE 医院<|>RELATION_NOE 开展<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 置管<|>RELATION_NOE 并发症<|>RELATION_NOE 180<|>RELATION_NOE 例<|>RELATION_NOE 分析<|>RELATION_B 及<|>RELATION_I 护理<|>RELATION_E
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 置管<|>RELATION_NOE (<|>RELATION_NOE PICC<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 并发症<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 180<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE PICC<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 使用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 方式<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 运用<|>RELATION_NOE 循证<|>RELATION_NOE 护理<|>RELATION_NOE 理论<|>RELATION_NOE ,<|>RELATION_NOE 仔细<|>RELATION_NOE 分析<|>RELATION_NOE 并发症<|>RELATION_NOE 出现<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE ,<|>RELATION_NOE 采取<|>RELATION_NOE 具体<|>RELATION_NOE 护理<|>RELATION_NOE 步骤<|>RELATION_NOE 实施<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 穿<|>RELATION_NOE 刺点<|>RELATION_NOE 感染<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 静脉炎9<|>RELATION_NOE ,<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 导管<|>RELATION_NOE 堵塞<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 导管<|>RELATION_NOE 脱出<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 发生率<|>RELATION_NOE 8.9%<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 穿<|>RELATION_NOE 刺点<|>RELATION_NOE 感染<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 静脉炎<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 导管<|>RELATION_NOE 堵塞<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 导管<|>RELATION_NOE 脱出<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 发生率<|>RELATION_NOE 33.3%<|>RELATION_NOE 。<|>RELATION_NOE
循证<|>RELATION_NOE 护理<|>RELATION_NOE 改变<|>RELATION_S 了<|>RELATION_NOE 临床<|>RELATION_NOE 护士<|>RELATION_NOE 传统<|>RELATION_NOE 经验<|>RELATION_NOE 以及<|>RELATION_NOE 感觉<|>RELATION_NOE 为主<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 习惯<|>RELATION_NOE ,<|>RELATION_NOE PICC<|>RELATION_NOE 并发症<|>RELATION_NOE 护理<|>RELATION_NOE 能<|>RELATION_NOE 显著性<|>RELATION_NOE 降低<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE 循证<|>RELATION_NOE 护理<|>RELATION_NOE 改变<|>RELATION_NOE 了<|>RELATION_NOE 临床<|>RELATION_NOE 护士<|>RELATION_NOE 传统<|>RELATION_NOE 经验<|>RELATION_NOE 以及<|>RELATION_NOE 感觉<|>RELATION_NOE 为主<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 习惯<|>RELATION_NOE ,<|>RELATION_NOE PICC<|>RELATION_NOE 并发症<|>RELATION_NOE 护理<|>RELATION_NOE 能<|>RELATION_NOE 显著性<|>RELATION_B 降低<|>RELATION_E 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE
研究<|>RELATION_NOE 携带<|>RELATION_NOE BRCA1<|>RELATION_NOE /<|>RELATION_NOE 2<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 中国<|>RELATION_NOE 汉族<|>RELATION_NOE 家族性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 家系<|>RELATION_NOE 中<|>RELATION_NOE 非<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 卵巢癌<|>RELATION_NOE 的<|>RELATION_NOE 其他<|>RELATION_NOE 肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 风险<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 一直<|>RELATION_NOE 接测<|>RELATION_NOE 序法<|>RELATION_NOE 检测<|>RELATION_NOE 465<|>RELATION_NOE 个<|>RELATION_NOE 汉族<|>RELATION_NOE 家族性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 家系<|>RELATION_NOE 中<|>RELATION_NOE 先证者<|>RELATION_NOE 的<|>RELATION_NOE BRCA1<|>RELATION_NOE /<|>RELATION_NOE 2基因<|>RELATION_NOE 胚系<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 突变<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 突变<|>RELATION_NOE 组<|>RELATION_NOE 有<|>RELATION_NOE 非<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 卵巢癌<|>RELATION_NOE 的<|>RELATION_NOE 其他<|>RELATION_NOE 肿瘤<|>RELATION_NOE 家族史<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 突变<|>RELATION_NOE 组<|>RELATION_NOE 家族<|>RELATION_NOE 中<|>RELATION_NOE 最<|>RELATION_NOE 常见<|>RELATION_NOE 的<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 和<|>RELATION_NOE 食管癌<|>RELATION_NOE 。<|>RELATION_NOE
进一步<|>RELATION_NOE 分析<|>RELATION_NOE 发现<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 胰腺癌<|>RELATION_NOE 和<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 3种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 家族史<|>RELATION_NOE 总<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 在<|>RELATION_NOE 突变<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 非<|>RELATION_NOE 突变<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 突变<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE
突变<|>RELATION_NOE 组<|>RELATION_NOE 家族<|>RELATION_NOE 中<|>RELATION_NOE 发生<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 胰腺癌<|>RELATION_NOE 和<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 的<|>RELATION_NOE 风险<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_NOE 突变<|>RELATION_NOE 组<|>RELATION_NOE 家族<|>RELATION_NOE 的<|>RELATION_NOE 2.47<|>RELATION_B 倍<|>RELATION_E (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 1.07<|>RELATION_NOE －5.74<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 肺组织<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -9<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_B 与<|>RELATION_I 表达<|>RELATION_E
观察<|>RELATION_NOE 吸烟<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE (<|>RELATION_NOE COPD<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肺组织<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -9<|>RELATION_NOE (<|>RELATION_NOE MMP-9<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺内<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 和<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 气流<|>RELATION_NOE 受限<|>RELATION_NOE 、<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE COPD<|>RELATION_NOE 的<|>RELATION_NOE 可能<|>RELATION_NOE 发病<|>RELATION_NOE 机制<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 临床<|>RELATION_NOE 提供<|>RELATION_NOE 防治<|>RELATION_NOE 新<|>RELATION_NOE 思路<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 10月<|>RELATION_NOE 天津<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 总医院胸<|>RELATION_NOE 、<|>RELATION_NOE 肺外科手术<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 边缘<|>RELATION_NOE 肺组织<|>RELATION_NOE (<|>RELATION_NOE 距<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE ><|>RELATION_NOE 5cm<|>RELATION_NOE )<|>RELATION_NOE 标本<|>RELATION_NOE 63<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
根据<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 体征<|>RELATION_NOE 、<|>RELATION_NOE 肺功能<|>RELATION_NOE 等<|>RELATION_NOE 将<|>RELATION_NOE 标本<|>RELATION_NOE 来源<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 5组<|>RELATION_NOE ,<|>RELATION_NOE 不<|>RELATION_NOE 吸<|>RELATION_NOE 烟非<|>RELATION_NOE COPD<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 非<|>RELATION_NOE COPD<|>RELATION_NOE (<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 轻度<|>RELATION_NOE COPD<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 中度<|>RELATION_NOE COPD<|>RELATION_NOE (<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 重度<|>RELATION_NOE COPD<|>RELATION_NOE (<|>RELATION_NOE E<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 肺功能<|>RELATION_NOE 、<|>RELATION_NOE 血气分析<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 程度<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE HE<|>RELATION_NOE 染色法<|>RELATION_NOE 观察<|>RELATION_NOE 各组<|>RELATION_NOE 肺组织<|>RELATION_NOE 形态学<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE MMP-9<|>RELATION_NOE 在<|>RELATION_NOE 肺组织<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 与<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 相关性<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
②<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 重度<|>RELATION_NOE COPD<|>RELATION_NOE 组<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_NOE 肺泡<|>RELATION_NOE 结构<|>RELATION_NOE 破坏<|>RELATION_NOE ,<|>RELATION_NOE 支气管<|>RELATION_NOE 壁<|>RELATION_NOE 、<|>RELATION_NOE 肺泡<|>RELATION_NOE 腔<|>RELATION_NOE 可见<|>RELATION_NOE 更<|>RELATION_NOE 多<|>RELATION_NOE 炎性<|>RELATION_NOE 细胞<|>RELATION_NOE 浸润<|>RELATION_NOE ,<|>RELATION_NOE 细胞外基质<|>RELATION_NOE 降解<|>RELATION_NOE 明显<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 纤支镜<|>RELATION_NOE 和<|>RELATION_NOE 经皮<|>RELATION_NOE 联合<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 气管<|>RELATION_NOE 狭窄<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
评价<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 气管<|>RELATION_NOE 狭窄<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
18<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE l<|>RELATION_NOE 周气<|>RELATION_NOE 急症状<|>RELATION_NOE 均<|>RELATION_NOE 减轻<|>RELATION_NOE ,<|>RELATION_NOE 30d<|>RELATION_NOE 后<|>RELATION_NOE 有<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 显示<|>RELATION_NOE 支气管<|>RELATION_NOE 管腔<|>RELATION_NOE 扩大<|>RELATION_NOE ,<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺炎<|>RELATION_NOE 症状<|>RELATION_NOE 消失<|>RELATION_NOE 。<|>RELATION_NOE
塞来昔布<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 辐射<|>RELATION_B 增敏<|>RELATION_E 实验<|>RELATION_NOE 研究<|>RELATION_NOE
建立<|>RELATION_NOE 裸鼠<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE 动物模型<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 环氧化酶2<|>RELATION_NOE 选择性<|>RELATION_NOE 抑制剂<|>RELATION_NOE 塞来昔布<|>RELATION_NOE 对<|>RELATION_NOE H460<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 增敏<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 作用<|>RELATION_NOE 机理<|>RELATION_NOE 进行<|>RELATION_NOE 初步<|>RELATION_NOE 探讨<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_S 毛细血管<|>RELATION_NOE 扩张性<|>RELATION_NOE 共济失调<|>RELATION_NOE 症<|>RELATION_NOE 突变<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE ATM<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
B<|>RELATION_NOE 细胞<|>RELATION_NOE 易位<|>RELATION_NOE 基因<|>RELATION_NOE 2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
研究<|>RELATION_NOE B<|>RELATION_NOE 细胞<|>RELATION_NOE 易位<|>RELATION_NOE 基因<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE BTG2<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE pcDNA3.BTG2<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 提高<|>RELATION_S 细胞<|>RELATION_NOE 的<|>RELATION_NOE BTG2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE 和<|>RELATION_NOE 细胞<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Westernblot<|>RELATION_NOE 方法<|>RELATION_NOE 研究<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE 通过<|>RELATION_NOE pcDNA3.BTG2<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 提高<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE BTG2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE 和<|>RELATION_NOE 细胞<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_S 实验<|>RELATION_NOE 研究<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Westernblot<|>RELATION_NOE 方法<|>RELATION_NOE 研究<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE 通过<|>RELATION_NOE pcDNA3.BTG2<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 提高<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE BTG2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE 和<|>RELATION_NOE 细胞<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Westernblot<|>RELATION_NOE 方法<|>RELATION_NOE 研究<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_S 。<|>RELATION_NOE
高<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE BRCAl<|>RELATION_NOE 明显<|>RELATION_B 地<|>RELATION_I 抑制<|>RELATION_E 了<|>RELATION_NOE BTG2<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 调节<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 降低<|>RELATION_NOE BRCA1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 则<|>RELATION_NOE 提高<|>RELATION_NOE 了<|>RELATION_NOE BTG2<|>RELATION_NOE 对<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 调节<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE BRCAl<|>RELATION_NOE 明显<|>RELATION_NOE 地<|>RELATION_NOE 抑制<|>RELATION_NOE 了<|>RELATION_NOE BTG2<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 调节<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 降低<|>RELATION_NOE BRCA1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 则<|>RELATION_NOE 提高<|>RELATION_S 了<|>RELATION_NOE BTG2<|>RELATION_NOE 对<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 调节<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
另外<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 与<|>RELATION_NOE 其<|>RELATION_NOE 所<|>RELATION_NOE 含<|>RELATION_NOE 的<|>RELATION_NOE BRCAl<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 成<|>RELATION_NOE 反比<|>RELATION_S ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE BTG2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 成<|>RELATION_NOE 正比<|>RELATION_NOE 。<|>RELATION_NOE 另外<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 与<|>RELATION_NOE 其<|>RELATION_NOE 所<|>RELATION_NOE 含<|>RELATION_NOE 的<|>RELATION_NOE BRCAl<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 成<|>RELATION_NOE 反比<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE BTG2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 成<|>RELATION_NOE 正比<|>RELATION_S 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 突变<|>RELATION_NOE 阴性<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_B 疗效<|>RELATION_E 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 基因<|>RELATION_NOE 编码区<|>RELATION_NOE 第19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 阴性<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
40<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE 和<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 采用<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 或<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 加<|>RELATION_NOE 顺铂<|>RELATION_NOE 或<|>RELATION_NOE 卡铂<|>RELATION_NOE 化疗<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 阴性<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE (<|>RELATION_NOE PR<|>RELATION_NOE )<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 稳定<|>RELATION_NOE (<|>RELATION_NOE SD<|>RELATION_NOE )<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE (<|>RELATION_NOE PD<|>RELATION_NOE )<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 82.2%<|>RELATION_NOE ;<|>RELATION_NOE
EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE 和<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 3.8<|>RELATION_NOE －4.6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 4.0<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 3.6<|>RELATION_NOE －<|>RELATION_NOE 4.4<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.021<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE 和<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 总<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE OS<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 9.2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 8.4<|>RELATION_NOE －1<|>RELATION_NOE 0.0<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 7.8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE C1<|>RELATION_NOE 为<|>RELATION_NOE 6.9<|>RELATION_NOE －<|>RELATION_NOE 8.7<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 28<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
小细胞肺癌<|>RELATION_NOE 外周<|>RELATION_NOE 血肿<|>RELATION_NOE 瘤细胞<|>RELATION_NOE 定量<|>RELATION_B 研究<|>RELATION_E 方法<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_NOE
建立<|>RELATION_NOE 定量<|>RELATION_NOE 检测<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 循环肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE CTC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 设计<|>RELATION_NOE 前胃<|>RELATION_NOE 泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽原<|>RELATION_NOE (<|>RELATION_NOE preproGRP<|>RELATION_NOE )<|>RELATION_NOE 特异性<|>RELATION_NOE 引物<|>RELATION_NOE 和<|>RELATION_NOE 探针<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 检测<|>RELATION_NOE preproGRPmRNA<|>RELATION_NOE 的<|>RELATION_NOE 定量<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 癌细胞<|>RELATION_NOE 掺入法<|>RELATION_NOE 评价<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 。<|>RELATION_NOE
铝工业<|>RELATION_NOE 接氟<|>RELATION_NOE 工人<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 流行病学<|>RELATION_B 调查<|>RELATION_E
以<|>RELATION_NOE 铝电解<|>RELATION_NOE 废气<|>RELATION_NOE 净化<|>RELATION_NOE 车间<|>RELATION_NOE 为<|>RELATION_NOE 中心<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 半径<|>RELATION_NOE 距离<|>RELATION_NOE 的<|>RELATION_NOE 工作<|>RELATION_NOE 位点<|>RELATION_NOE 设<|>RELATION_NOE 采样点<|>RELATION_NOE 检测<|>RELATION_NOE 空气<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 氟<|>RELATION_NOE 、<|>RELATION_NOE 铝和<|>RELATION_NOE 苯并<|>RELATION_NOE [<|>RELATION_NOE a<|>RELATION_NOE ]<|>RELATION_NOE 芘<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 氟离子<|>RELATION_NOE 选择<|>RELATION_NOE 电极<|>RELATION_NOE 法测<|>RELATION_NOE 定氟<|>RELATION_NOE ,<|>RELATION_NOE 原子<|>RELATION_NOE 吸收<|>RELATION_NOE 分光光度法<|>RELATION_NOE 测定<|>RELATION_NOE 铝<|>RELATION_NOE ,<|>RELATION_NOE 高效<|>RELATION_NOE 液相色谱法<|>RELATION_NOE 测定<|>RELATION_NOE 苯并<|>RELATION_NOE [<|>RELATION_NOE a<|>RELATION_NOE ]<|>RELATION_NOE 芘<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 年龄<|>RELATION_NOE 高峰<|>RELATION_NOE 为<|>RELATION_NOE 40<|>RELATION_NOE －<|>RELATION_NOE 49<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 前<|>RELATION_NOE 2位<|>RELATION_NOE 肿瘤<|>RELATION_NOE 男性<|>RELATION_NOE 为<|>RELATION_NOE 肝癌<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 为<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 企业<|>RELATION_NOE 所在市<|>RELATION_NOE 非暴露<|>RELATION_NOE 人群<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 工人<|>RELATION_NOE 的<|>RELATION_NOE 氟暴露<|>RELATION_NOE 使<|>RELATION_NOE 女性肿瘤<|>RELATION_NOE 发病率<|>RELATION_NOE 升高<|>RELATION_S ,<|>RELATION_NOE 为<|>RELATION_NOE 该市<|>RELATION_NOE 的<|>RELATION_NOE 2.14<|>RELATION_NOE 倍<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 年龄<|>RELATION_NOE 提前<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 构成<|>RELATION_NOE 基本<|>RELATION_NOE 相同<|>RELATION_NOE 。<|>RELATION_NOE
盐酸<|>RELATION_NOE 氮革<|>RELATION_NOE 司汀<|>RELATION_NOE 与<|>RELATION_NOE 丙酸氟<|>RELATION_NOE 替卡松<|>RELATION_NOE 治疗<|>RELATION_S 青少年<|>RELATION_NOE 季节<|>RELATION_NOE 性变应性<|>RELATION_NOE 鼻炎<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE
研究<|>RELATION_NOE 盐酸<|>RELATION_NOE 氮革<|>RELATION_NOE 司汀<|>RELATION_NOE 与<|>RELATION_NOE 丙酸氟<|>RELATION_NOE 替卡松<|>RELATION_NOE 治疗<|>RELATION_NOE 青少年<|>RELATION_NOE 季节<|>RELATION_NOE 性变应性<|>RELATION_NOE 鼻炎<|>RELATION_NOE (<|>RELATION_NOE SAR<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
盐酸<|>RELATION_NOE 氮革<|>RELATION_NOE 司汀组<|>RELATION_NOE 有<|>RELATION_NOE 2例<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 嗜睡<|>RELATION_NOE ,<|>RELATION_NOE 丙酸氟<|>RELATION_NOE 替卡<|>RELATION_NOE 松组<|>RELATION_NOE 1例<|>RELATION_NOE 鼻出血<|>RELATION_NOE 。<|>RELATION_NOE
痰热清<|>RELATION_NOE 预防<|>RELATION_S 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE
将<|>RELATION_NOE 116<|>RELATION_NOE 例<|>RELATION_NOE 需要<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 在<|>RELATION_NOE 放疗<|>RELATION_NOE 同时<|>RELATION_NOE 给予<|>RELATION_NOE 痰<|>RELATION_NOE 热清<|>RELATION_NOE 注射液<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ;<|>RELATION_NOE
治疗组<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 总<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 25.8<|>RELATION_NOE 1%<|>RELATION_NOE ,<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE 为<|>RELATION_NOE 35.1<|>RELATION_NOE 6%<|>RELATION_NOE ;<|>RELATION_NOE
治疗组<|>RELATION_NOE 严重性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 6.4<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE 的<|>RELATION_NOE 25.9<|>RELATION_NOE 3%<|>RELATION_NOE ;<|>RELATION_NOE
治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 严重性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 平均<|>RELATION_NOE 发病<|>RELATION_NOE 剂量<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 60<|>RELATION_NOE ±<|>RELATION_NOE 11<|>RELATION_NOE )<|>RELATION_NOE GY<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 51<|>RELATION_NOE ±<|>RELATION_NOE 11<|>RELATION_NOE )<|>RELATION_NOE GY<|>RELATION_NOE ;<|>RELATION_NOE
治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 平均<|>RELATION_NOE 发病<|>RELATION_NOE 时间<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE ±<|>RELATION_NOE 8<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 34<|>RELATION_NOE ±<|>RELATION_NOE 7<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 人<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
2006年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 1月<|>RELATION_NOE 同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 2<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 给予<|>RELATION_NOE 多<|>RELATION_NOE 西他赛<|>RELATION_NOE 60mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2+<|>RELATION_NOE 顺铂<|>RELATION_NOE 75mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE DP<|>RELATION_NOE 方案<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 行<|>RELATION_NOE ^<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE +<|>RELATION_NOE DP<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
局部<|>RELATION_NOE 病变<|>RELATION_NOE 控制<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE 分析<|>RELATION_NOE 采用<|>RELATION_NOE log-rank<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE Fisher<|>RELATION_NOE 确切<|>RELATION_NOE 概率<|>RELATION_NOE 法<|>RELATION_NOE 比较<|>RELATION_NOE 2组<|>RELATION_NOE 肿瘤<|>RELATION_NOE CR<|>RELATION_NOE 率<|>RELATION_NOE 和<|>RELATION_NOE 近期<|>RELATION_NOE 有效率<|>RELATION_NOE 。<|>RELATION_NOE
11<|>RELATION_NOE 例<|>RELATION_NOE 转移<|>RELATION_NOE 性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE HCC<|>RELATION_NOE (<|>RELATION_NOE 8例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE 2例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 食管癌<|>RELATION_NOE (<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 18F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 和<|>RELATION_NOE 同机<|>RELATION_NOE CT<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE 对<|>RELATION_NOE 肺硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
参照<|>RELATION_NOE CT<|>RELATION_NOE 图像<|>RELATION_NOE 勾画<|>RELATION_NOE ROI<|>RELATION_NOE ,<|>RELATION_NOE 获得<|>RELATION_NOE 病灶<|>RELATION_NOE PET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 图像<|>RELATION_NOE 的<|>RELATION_NOE 13<|>RELATION_NOE 项<|>RELATION_NOE 纹理<|>RELATION_NOE 特征<|>RELATION_NOE 参数值<|>RELATION_NOE [<|>RELATION_NOE 包括<|>RELATION_NOE 均值<|>RELATION_NOE 、<|>RELATION_NOE 标准<|>RELATION_NOE 差<|>RELATION_NOE 、<|>RELATION_NOE 偏度<|>RELATION_NOE 、<|>RELATION_NOE 峰度<|>RELATION_NOE 、<|>RELATION_NOE 角二阶矩<|>RELATION_NOE (<|>RELATION_NOE ASM<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 熵<|>RELATION_NOE 、<|>RELATION_NOE 对比性<|>RELATION_NOE 、<|>RELATION_NOE 相关性<|>RELATION_NOE 、<|>RELATION_NOE 粗糙度<|>RELATION_NOE 、<|>RELATION_NOE 对比<|>RELATION_NOE 度<|>RELATION_NOE 、<|>RELATION_NOE 频度<|>RELATION_NOE 、<|>RELATION_NOE 复杂度<|>RELATION_NOE 、<|>RELATION_NOE 强度<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE SUVmax<|>RELATION_NOE 采用<|>RELATION_NOE logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 进行<|>RELATION_NOE 统计<|>RELATION_NOE ,<|>RELATION_NOE 提取<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 纹理<|>RELATION_NOE 参数<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 回归<|>RELATION_NOE 方程<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 通过<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 评估<|>RELATION_NOE 其<|>RELATION_NOE 判断<|>RELATION_NOE 肺结节良<|>RELATION_NOE 恶性<|>RELATION_NOE 的<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 示<|>RELATION_NOE SUVmax<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 为<|>RELATION_NOE 0.7<|>RELATION_NOE 57<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE C10.711<|>RELATION_NOE －0.802<|>RELATION_NOE ;<|>RELATION_NOE
肺鳞癌<|>RELATION_NOE 中<|>RELATION_NOE 高迁移<|>RELATION_NOE 率族<|>RELATION_NOE 蛋白<|>RELATION_NOE A1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
支气管<|>RELATION_NOE 针吸<|>RELATION_NOE 活组织检查<|>RELATION_NOE 在<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_S 与<|>RELATION_NOE 分期<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 支气管<|>RELATION_NOE 针吸<|>RELATION_NOE 活组织检查<|>RELATION_NOE (<|>RELATION_NOE TBNA<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 分期<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 采用<|>RELATION_NOE TBNA<|>RELATION_NOE 对<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 纵隔<|>RELATION_NOE 气管<|>RELATION_NOE 周围<|>RELATION_NOE 淋巴结病<|>RELATION_NOE 变<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 分期<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 相关<|>RELATION_NOE 文献<|>RELATION_NOE 进行<|>RELATION_NOE 复习<|>RELATION_NOE 。<|>RELATION_NOE
32<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE TBNA<|>RELATION_NOE 确诊<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 并<|>RELATION_NOE 协助<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 诊断<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 87.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 阴性<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 操作<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 未<|>RELATION_NOE 出现<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 与<|>RELATION_NOE 青年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 对比<|>RELATION_S
对<|>RELATION_NOE 经<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 153<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 老年<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE 青年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 青年组<|>RELATION_NOE )<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 资料<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位置<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 与<|>RELATION_NOE 青年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 相比<|>RELATION_NOE 周边型<|>RELATION_NOE 、<|>RELATION_NOE 吸烟者<|>RELATION_NOE 及<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 青年组<|>RELATION_NOE 以<|>RELATION_NOE 胸痛<|>RELATION_NOE 为<|>RELATION_NOE 首发<|>RELATION_NOE 症状<|>RELATION_NOE 者<|>RELATION_NOE 比例<|>RELATION_NOE 高于<|>RELATION_S 老年<|>RELATION_NOE 组<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 相关<|>RELATION_B 因素<|>RELATION_I 分析<|>RELATION_E
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发病<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 寻找<|>RELATION_NOE 合理<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
处方<|>RELATION_NOE 剂量<|>RELATION_NOE 60<|>RELATION_NOE －<|>RELATION_NOE 68<|>RELATION_NOE Gy<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 胸部<|>RELATION_NOE X<|>RELATION_NOE 线片<|>RELATION_NOE 、<|>RELATION_NOE 薄层<|>RELATION_NOE CT<|>RELATION_NOE 了解<|>RELATION_NOE 患者<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE 等<|>RELATION_NOE 指标<|>RELATION_NOE 进行<|>RELATION_NOE 单因素<|>RELATION_NOE 及<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE 合并<|>RELATION_NOE 有<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺病<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE 、<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 靶区<|>RELATION_NOE (<|>RELATION_NOE GTV<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE V20<|>RELATION_NOE 、<|>RELATION_NOE V25<|>RELATION_NOE 、<|>RELATION_NOE V30<|>RELATION_NOE 与<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE x<|>RELATION_NOE 2<|>RELATION_NOE =<|>RELATION_NOE 12<|>RELATION_NOE 253<|>RELATION_NOE ,<|>RELATION_NOE x<|>RELATION_NOE 2<|>RELATION_NOE =<|>RELATION_NOE 8.<|>RELATION_NOE 802<|>RELATION_NOE ,<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.7<|>RELATION_NOE 58<|>RELATION_NOE ,<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.4<|>RELATION_NOE 32<|>RELATION_NOE ,<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.2<|>RELATION_NOE 10<|>RELATION_NOE ,<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.1<|>RELATION_NOE 90<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肺<|>RELATION_NOE V20<|>RELATION_NOE 、<|>RELATION_NOE V30<|>RELATION_NOE 、<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 肺部<|>RELATION_NOE 慢性疾病<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 是<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 影响<|>RELATION_I 因素<|>RELATION_E .<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 一线<|>RELATION_B 治疗<|>RELATION_E 70<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
81<|>RELATION_NOE 例<|>RELATION_NOE 初<|>RELATION_NOE 治<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 适于<|>RELATION_NOE 全身<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 接受<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 或<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 不可<|>RELATION_NOE 耐受<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 体力<|>RELATION_NOE 状态<|>RELATION_NOE 改善<|>RELATION_NOE 情况<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
间隙<|>RELATION_NOE 连接<|>RELATION_NOE 蛋白<|>RELATION_NOE Cx43<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
观察<|>RELATION_NOE 间隙<|>RELATION_NOE 连接<|>RELATION_NOE 蛋白<|>RELATION_NOE Cx43<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 人类<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 以及<|>RELATION_NOE 原位杂交<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 148<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE Cx43<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 及<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 癌浸润<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 以及<|>RELATION_NOE 原位杂交<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 148<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE Cx43<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 及<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 癌浸润<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
Cx43<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 人类<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_S .<|>RELATION_NOE
Cx43<|>RELATION_NOE 可能<|>RELATION_B 参与<|>RELATION_E 人类<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 的<|>RELATION_NOE 过程<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE 之一<|>RELATION_NOE .<|>RELATION_NOE Cx43<|>RELATION_NOE 可能<|>RELATION_NOE 参与<|>RELATION_NOE 人类<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 的<|>RELATION_NOE 过程<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可能<|>RELATION_B 是<|>RELATION_E 肺腺癌<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE 之一<|>RELATION_NOE .<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 袖式<|>RELATION_NOE 支气管<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_B 治疗<|>RELATION_E 中心型<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 支气管<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_NOE 早期<|>RELATION_NOE 中心型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE ,<|>RELATION_NOE 适应证<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 2例<|>RELATION_NOE 左肺<|>RELATION_NOE 上<|>RELATION_NOE 叶切除<|>RELATION_NOE 同时<|>RELATION_NOE 行<|>RELATION_NOE 支气管<|>RELATION_NOE 及<|>RELATION_NOE 肺动脉<|>RELATION_NOE 成形<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
未有术<|>RELATION_NOE 后<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘<|>RELATION_NOE 、<|>RELATION_NOE 脓胸<|>RELATION_NOE 、<|>RELATION_NOE 肺不张<|>RELATION_NOE 等<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 袖式<|>RELATION_NOE 支气管<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 项<|>RELATION_NOE 安全<|>RELATION_B 、<|>RELATION_I 有效<|>RELATION_E 的<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE ,<|>RELATION_NOE 使<|>RELATION_NOE 更<|>RELATION_NOE 多<|>RELATION_NOE 的<|>RELATION_NOE 中心型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 受益<|>RELATION_NOE 。<|>RELATION_NOE
局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 锁骨<|>RELATION_NOE 上区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 规律<|>RELATION_B 及<|>RELATION_I 靶区<|>RELATION_I 勾画<|>RELATION_E
分析<|>RELATION_NOE 局限期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE LS-SCLC<|>RELATION_NOE )<|>RELATION_NOE 锁骨<|>RELATION_NOE 上区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 规律<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE LS-SCLC<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 锁骨<|>RELATION_NOE 上<|>RELATION_NOE 区<|>RELATION_NOE 的<|>RELATION_NOE 合理<|>RELATION_NOE 照射<|>RELATION_NOE 范围<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 锁骨<|>RELATION_NOE 上<|>RELATION_NOE 区<|>RELATION_NOE 细分<|>RELATION_NOE 为<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 区域<|>RELATION_NOE :<|>RELATION_NOE 喉返神经<|>RELATION_NOE 旁区<|>RELATION_NOE (<|>RELATION_NOE Ⅰ<|>RELATION_NOE 区<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 区<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 颈内<|>RELATION_NOE 静脉<|>RELATION_NOE 旁区<|>RELATION_NOE (<|>RELATION_NOE Ⅲ<|>RELATION_NOE 区<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 锁骨<|>RELATION_NOE 上区<|>RELATION_NOE (<|>RELATION_NOE Ⅳ<|>RELATION_NOE 区<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 其他<|>RELATION_NOE 区<|>RELATION_NOE (<|>RELATION_NOE V<|>RELATION_NOE 区<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 各区<|>RELATION_NOE 转移<|>RELATION_NOE 规律<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 纵隔<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 是<|>RELATION_NOE 锁骨<|>RELATION_NOE 上区<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 高危<|>RELATION_B 因素<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.006<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
锁骨<|>RELATION_NOE 上区<|>RELATION_NOE 转移<|>RELATION_NOE 主要<|>RELATION_B 集中<|>RELATION_E 在<|>RELATION_NOE 靠<|>RELATION_NOE 体中线<|>RELATION_NOE 的<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ<|>RELATION_NOE 区<|>RELATION_NOE 。<|>RELATION_NOE
95.0%<|>RELATION_NOE 的<|>RELATION_NOE 锁骨<|>RELATION_NOE 上<|>RELATION_NOE 转移<|>RELATION_NOE 累及<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ<|>RELATION_NOE 区<|>RELATION_NOE ,<|>RELATION_NOE 该<|>RELATION_NOE 两<|>RELATION_NOE 区<|>RELATION_NOE 阴性<|>RELATION_NOE 而<|>RELATION_NOE 其他<|>RELATION_NOE 区域<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 病例<|>RELATION_NOE 只<|>RELATION_NOE 有<|>RELATION_NOE 3例<|>RELATION_NOE (<|>RELATION_NOE 5.O<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
纵隔<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 阳性<|>RELATION_NOE 的<|>RELATION_NOE LS-SCLC<|>RELATION_NOE 建议<|>RELATION_B 给予<|>RELATION_E 锁骨<|>RELATION_NOE 上<|>RELATION_NOE 预防<|>RELATION_NOE 照射<|>RELATION_NOE 。<|>RELATION_NOE
副<|>RELATION_NOE 肿瘤性<|>RELATION_NOE 视网膜<|>RELATION_NOE 视神经病变<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 初步<|>RELATION_NOE 分析<|>RELATION_S
2006年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 3月<|>RELATION_NOE 解放军<|>RELATION_NOE 总医院<|>RELATION_NOE 眼科<|>RELATION_NOE 连续<|>RELATION_NOE 诊治<|>RELATION_NOE 副<|>RELATION_NOE 肿瘤性<|>RELATION_NOE 视网膜<|>RELATION_NOE 视神经病变<|>RELATION_NOE 患者<|>RELATION_NOE 8例<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE 只<|>RELATION_NOE 眼<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE 眼部<|>RELATION_NOE 照相<|>RELATION_NOE 、<|>RELATION_NOE 视觉<|>RELATION_NOE 电<|>RELATION_NOE 生理<|>RELATION_NOE 、<|>RELATION_NOE 荧光素<|>RELATION_NOE 眼底<|>RELATION_NOE 血管<|>RELATION_NOE 造影<|>RELATION_NOE 、<|>RELATION_NOE 相干<|>RELATION_NOE 光断<|>RELATION_NOE 层<|>RELATION_NOE 扫描<|>RELATION_NOE 、<|>RELATION_NOE 眼底<|>RELATION_NOE 自发<|>RELATION_NOE 荧光<|>RELATION_NOE 、<|>RELATION_NOE 视野<|>RELATION_NOE 、<|>RELATION_NOE 超声<|>RELATION_NOE 、<|>RELATION_NOE MRI<|>RELATION_NOE 检查<|>RELATION_NOE 及<|>RELATION_NOE 腰<|>RELATION_NOE 穿<|>RELATION_NOE 脑脊<|>RELATION_NOE 液化验<|>RELATION_NOE 、<|>RELATION_NOE 副<|>RELATION_NOE 肿瘤<|>RELATION_NOE 综合征<|>RELATION_NOE 抗体<|>RELATION_NOE 检测<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 经<|>RELATION_NOE 门诊<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE 电话<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病情<|>RELATION_NOE 变化<|>RELATION_NOE 和<|>RELATION_NOE 结局<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 病变<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 治疗<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 8例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 癌症<|>RELATION_NOE 相关性<|>RELATION_NOE 视网膜<|>RELATION_NOE 病变<|>RELATION_NOE 3例<|>RELATION_NOE 、<|>RELATION_NOE 双眼<|>RELATION_NOE 弥漫性<|>RELATION_NOE 葡萄膜<|>RELATION_NOE 黑色素细胞增生<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 副<|>RELATION_NOE 肿瘤性<|>RELATION_NOE 视神经病变<|>RELATION_NOE 3例<|>RELATION_NOE 。<|>RELATION_NOE
5例<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 副<|>RELATION_NOE 肿瘤<|>RELATION_NOE 综合征<|>RELATION_NOE 的<|>RELATION_NOE 抗体<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 结果<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 结果<|>RELATION_NOE 阴性<|>RELATION_NOE 。<|>RELATION_NOE
8例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 源自<|>RELATION_NOE 肺癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 源自<|>RELATION_NOE 侵袭性<|>RELATION_NOE 胸腺瘤<|>RELATION_NOE 、<|>RELATION_NOE 肾癌<|>RELATION_NOE 、<|>RELATION_NOE 急性<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 白血病<|>RELATION_NOE 、<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 8例<|>RELATION_NOE 16<|>RELATION_NOE 只<|>RELATION_NOE 眼中<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 结束<|>RELATION_NOE 时<|>RELATION_NOE 无<|>RELATION_NOE 光感<|>RELATION_NOE 的<|>RELATION_NOE 6只眼<|>RELATION_NOE ,<|>RELATION_NOE 光感<|>RELATION_NOE 至<|>RELATION_NOE 0.05<|>RELATION_NOE 的<|>RELATION_NOE 5<|>RELATION_NOE 只<|>RELATION_NOE 眼<|>RELATION_NOE ,<|>RELATION_NOE 视力<|>RELATION_NOE ≥<|>RELATION_NOE 0.4<|>RELATION_NOE 的<|>RELATION_NOE 5<|>RELATION_NOE 只<|>RELATION_NOE 眼<|>RELATION_NOE 。<|>RELATION_NOE
各型<|>RELATION_NOE 副<|>RELATION_NOE 肿瘤性<|>RELATION_NOE 视网膜<|>RELATION_NOE 视神经病变<|>RELATION_NOE 有<|>RELATION_NOE 其<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 副<|>RELATION_NOE 肿瘤<|>RELATION_NOE 综合征<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 双<|>RELATION_NOE 眼<|>RELATION_NOE 弥漫性<|>RELATION_NOE 葡萄膜<|>RELATION_NOE 黑色素细胞增生<|>RELATION_NOE 可能<|>RELATION_B 是<|>RELATION_E 一<|>RELATION_NOE 种<|>RELATION_NOE 转移<|>RELATION_NOE 前<|>RELATION_NOE 病变<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 发<|>RELATION_NOE 转移性<|>RELATION_NOE 肾癌<|>RELATION_NOE 舒尼<|>RELATION_NOE 替尼<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_B 治疗<|>RELATION_E 后<|>RELATION_NOE 减瘤<|>RELATION_NOE 手术<|>RELATION_NOE 1例<|>RELATION_NOE 报告<|>RELATION_NOE 并<|>RELATION_NOE 文献<|>RELATION_NOE 复习<|>RELATION_NOE
CT<|>RELATION_NOE 检查<|>RELATION_NOE 示<|>RELATION_NOE 左<|>RELATION_NOE 肾下<|>RELATION_NOE 极<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 6.6cm<|>RELATION_NOE ×<|>RELATION_NOE 6.3cm<|>RELATION_NOE ,<|>RELATION_NOE 左<|>RELATION_NOE 肾静脉<|>RELATION_NOE 瘤栓<|>RELATION_NOE 形成<|>RELATION_NOE ,<|>RELATION_NOE 肾门<|>RELATION_NOE 可见<|>RELATION_NOE 肿大<|>RELATION_NOE 淋巴结<|>RELATION_NOE ,<|>RELATION_NOE 局部<|>RELATION_NOE 浸润<|>RELATION_NOE ,<|>RELATION_NOE 伴肺<|>RELATION_NOE 和<|>RELATION_NOE 右侧<|>RELATION_NOE 胫骨<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE T3bN1M1<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
新<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE CT<|>RELATION_NOE 复查<|>RELATION_NOE 示<|>RELATION_NOE 左<|>RELATION_NOE 肾肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 5.1cm<|>RELATION_NOE ×<|>RELATION_NOE 4.4cm<|>RELATION_NOE (<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径线<|>RELATION_NOE 缩小<|>RELATION_NOE 23%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肾静脉<|>RELATION_NOE 瘤栓<|>RELATION_NOE 体积<|>RELATION_NOE 缩小<|>RELATION_NOE ,<|>RELATION_NOE 局部<|>RELATION_NOE 浸润<|>RELATION_NOE 情况<|>RELATION_NOE 好转<|>RELATION_NOE ,<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 基本<|>RELATION_NOE 消失<|>RELATION_NOE ,<|>RELATION_NOE 右<|>RELATION_NOE 胫骨<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 。<|>RELATION_NOE
按照<|>RELATION_NOE RECIST<|>RELATION_NOE 标准<|>RELATION_NOE 判断<|>RELATION_S 为<|>RELATION_NOE 疾病<|>RELATION_NOE 稳定<|>RELATION_NOE 。<|>RELATION_NOE
病理<|>RELATION_NOE 报告<|>RELATION_NOE 肾透明<|>RELATION_NOE 细胞<|>RELATION_NOE 癌Ⅱ级<|>RELATION_NOE ,<|>RELATION_NOE 瘤内<|>RELATION_NOE 有<|>RELATION_NOE 大片<|>RELATION_NOE 坏死<|>RELATION_NOE ,<|>RELATION_NOE 瘤栓<|>RELATION_NOE 局限<|>RELATION_NOE 于<|>RELATION_NOE 肾静脉<|>RELATION_NOE 内<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 复查<|>RELATION_NOE ,<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 处<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 完全<|>RELATION_NOE 消失<|>RELATION_NOE ,<|>RELATION_NOE 右<|>RELATION_NOE 胫骨<|>RELATION_NOE 转移<|>RELATION_NOE 灶尢<|>RELATION_NOE 进展<|>RELATION_NOE 。<|>RELATION_NOE
随<|>RELATION_NOE 访<|>RELATION_NOE 至<|>RELATION_NOE 今<|>RELATION_NOE 20<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 及<|>RELATION_NOE 其他<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 控制<|>RELATION_NOE 效果<|>RELATION_NOE 为<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE 。<|>RELATION_NOE
全覆<|>RELATION_NOE 膜自<|>RELATION_NOE 膨胀<|>RELATION_NOE 金属<|>RELATION_NOE 支架<|>RELATION_NOE 在<|>RELATION_NOE 气管<|>RELATION_NOE 瘘<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_E
评价<|>RELATION_NOE 全<|>RELATION_NOE 覆<|>RELATION_NOE 膜自<|>RELATION_NOE 膨胀<|>RELATION_NOE 气管<|>RELATION_NOE 一<|>RELATION_NOE 支气管<|>RELATION_NOE 支架<|>RELATION_NOE 治疗<|>RELATION_NOE 气管<|>RELATION_NOE 瘘<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2005年<|>RELATION_NOE 8月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 山东<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 千佛山<|>RELATION_NOE 医院<|>RELATION_NOE 胸外科<|>RELATION_NOE 应用<|>RELATION_NOE 全<|>RELATION_NOE 覆膜<|>RELATION_NOE 气管<|>RELATION_NOE 一<|>RELATION_NOE 支气管<|>RELATION_NOE 支架<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 9例<|>RELATION_NOE 气管<|>RELATION_NOE 瘘患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 28<|>RELATION_NOE －<|>RELATION_NOE 65<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 46<|>RELATION_NOE 岁<|>RELATION_NOE 。<|>RELATION_NOE
9例<|>RELATION_NOE 中<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘7<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘1<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 左主<|>RELATION_NOE 支气管<|>RELATION_NOE 一<|>RELATION_NOE 食管瘘<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 8例<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 脓胸<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 局部<|>RELATION_NOE 麻醉<|>RELATION_NOE 和<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 透视<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE 放置<|>RELATION_NOE L<|>RELATION_NOE 型<|>RELATION_NOE 支架<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 放置<|>RELATION_NOE I<|>RELATION_NOE 型<|>RELATION_NOE 支架<|>RELATION_NOE ,<|>RELATION_NOE 伴脓<|>RELATION_NOE 胸者<|>RELATION_NOE 于<|>RELATION_NOE 支架<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 后<|>RELATION_NOE 给予<|>RELATION_NOE 胸腔<|>RELATION_NOE 冲洗<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 成功<|>RELATION_NOE 置人<|>RELATION_NOE 支架<|>RELATION_NOE ,<|>RELATION_NOE 从<|>RELATION_NOE 插入<|>RELATION_NOE 导丝<|>RELATION_NOE 至<|>RELATION_NOE 支架<|>RELATION_NOE 成功<|>RELATION_NOE 释放<|>RELATION_NOE 所<|>RELATION_NOE 需<|>RELATION_NOE 时间<|>RELATION_NOE 5-16min<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE ±<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 发生<|>RELATION_NOE 与<|>RELATION_NOE 操作<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
1例<|>RELATION_NOE 在<|>RELATION_NOE 支架<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 后<|>RELATION_NOE 第5<|>RELATION_NOE 天<|>RELATION_NOE 由于<|>RELATION_NOE 剧烈<|>RELATION_NOE 咳嗽<|>RELATION_NOE 将<|>RELATION_NOE 支架<|>RELATION_NOE 咳<|>RELATION_NOE 出<|>RELATION_NOE ,<|>RELATION_NOE 重新<|>RELATION_NOE 置人<|>RELATION_NOE 新<|>RELATION_NOE 支架<|>RELATION_NOE 后<|>RELATION_NOE 未<|>RELATION_NOE 再<|>RELATION_NOE 发生<|>RELATION_NOE 移位<|>RELATION_NOE 。<|>RELATION_NOE
8例<|>RELATION_NOE 脓胸<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 1例行<|>RELATION_NOE 支架<|>RELATION_NOE 置<|>RELATION_NOE 人<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 8d<|>RELATION_NOE 因<|>RELATION_NOE 脓胸<|>RELATION_NOE 合并<|>RELATION_NOE 败血症<|>RELATION_NOE 去世<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 1例6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 后<|>RELATION_NOE 脓胸<|>RELATION_NOE 未<|>RELATION_NOE 治愈<|>RELATION_NOE ,<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 6例<|>RELATION_NOE 在<|>RELATION_NOE 支架<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 术后<|>RELATION_NOE 2－<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 平均<|>RELATION_NOE 3.7<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 治愈<|>RELATION_NOE 。<|>RELATION_NOE
7例<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 3－<|>RELATION_NOE 36<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 13.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 中<|>RELATION_NOE 1例<|>RELATION_NOE 于<|>RELATION_NOE 支架<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 术后<|>RELATION_NOE 8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 取出<|>RELATION_NOE 支架<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 发现<|>RELATION_NOE 脓胸<|>RELATION_NOE 复发<|>RELATION_NOE ;<|>RELATION_NOE
其他<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 支架<|>RELATION_NOE 耐受<|>RELATION_NOE 良好<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 移位<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 脓胸<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 饮食<|>RELATION_NOE 良好<|>RELATION_NOE 。<|>RELATION_NOE
使用<|>RELATION_NOE 全覆<|>RELATION_NOE 膜自<|>RELATION_NOE 膨胀<|>RELATION_NOE 金属<|>RELATION_NOE 支架<|>RELATION_NOE 治疗<|>RELATION_NOE 气管<|>RELATION_NOE 瘘<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_B 、<|>RELATION_I 有效<|>RELATION_I 、<|>RELATION_I 快速<|>RELATION_I 的<|>RELATION_I 微创<|>RELATION_I 治疗<|>RELATION_I 方法<|>RELATION_E ,<|>RELATION_NOE 尤其<|>RELATION_NOE 适合<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 耐受<|>RELATION_NOE 手术<|>RELATION_NOE 或<|>RELATION_NOE 其他<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 失败<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -9<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 治疗<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE
探讨<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -9<|>RELATION_NOE (<|>RELATION_NOE MMP-9<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 白细胞<|>RELATION_NOE MMP-9<|>RELATION_NOE 启动子<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S 血浆<|>RELATION_NOE MMP-9<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE 及<|>RELATION_NOE RT-PCR<|>RELATION_NOE 检测<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 白细胞<|>RELATION_NOE 中<|>RELATION_NOE MMP-9mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE 用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_NOE 血浆<|>RELATION_NOE MMP-9<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE 及<|>RELATION_NOE RT-PCR<|>RELATION_NOE 检测<|>RELATION_S 外<|>RELATION_NOE 周血<|>RELATION_NOE 白细胞<|>RELATION_NOE 中<|>RELATION_NOE MMP-9mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 组<|>RELATION_NOE MMP-9<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 平均<|>RELATION_NOE 甲基化<|>RELATION_NOE 密度<|>RELATION_NOE 显著<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_B 有<|>RELATION_I 显著性<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE 23.5<|>RELATION_NOE ±<|>RELATION_NOE 4.7<|>RELATION_NOE vs<|>RELATION_NOE 40.6<|>RELATION_NOE ±<|>RELATION_NOE 3.8<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
MMP-9<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE MMP-9<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 处于<|>RELATION_NOE 低<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 通过<|>RELATION_NOE 增强<|>RELATION_NOE MMP-9mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 促进<|>RELATION_NOE MMP-9<|>RELATION_NOE 蛋白<|>RELATION_NOE 分泌<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 发挥<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
肺<|>RELATION_NOE 错构瘤<|>RELATION_NOE 的<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 体层<|>RELATION_NOE 摄影<|>RELATION_NOE -CT<|>RELATION_NOE 表现<|>RELATION_S
分析<|>RELATION_NOE 肺<|>RELATION_NOE 错构瘤<|>RELATION_NOE 的<|>RELATION_NOE 脱氧<|>RELATION_NOE 氟代<|>RELATION_NOE 葡萄糖<|>RELATION_NOE (<|>RELATION_NOE 18F-FDG<|>RELATION_NOE )<|>RELATION_NOE PET-CT<|>RELATION_NOE 表现<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
18F-FDGPET-CT<|>RELATION_NOE 与<|>RELATION_NOE MSCT<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 肺<|>RELATION_NOE 错构瘤<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 11<|>RELATION_NOE 和<|>RELATION_NOE 8例<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
1例<|>RELATION_NOE 有<|>RELATION_NOE 分叶<|>RELATION_NOE 和<|>RELATION_NOE 胸膜<|>RELATION_NOE 牵拉<|>RELATION_NOE 的<|>RELATION_NOE 病变<|>RELATION_NOE ,<|>RELATION_NOE MSCT<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE PET-CT<|>RELATION_NOE 可疑<|>RELATION_NOE 恶性<|>RELATION_NOE ;<|>RELATION_NOE
肺<|>RELATION_NOE 放线菌病<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_B 及<|>RELATION_I 误诊<|>RELATION_E 分析<|>RELATION_NOE
分析<|>RELATION_NOE 肺<|>RELATION_NOE 放线菌病<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 误诊<|>RELATION_NOE 原因<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 提高<|>RELATION_NOE 临床<|>RELATION_NOE 诊断率<|>RELATION_NOE 。<|>RELATION_NOE
肺<|>RELATION_NOE 放线菌病<|>RELATION_NOE 的<|>RELATION_NOE 团块样<|>RELATION_NOE 表现<|>RELATION_NOE 易<|>RELATION_B 被<|>RELATION_I 误诊<|>RELATION_E 为<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 或<|>RELATION_NOE 其他<|>RELATION_NOE 病变<|>RELATION_NOE ,<|>RELATION_NOE CT<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE 病灶<|>RELATION_NOE 呈<|>RELATION_NOE 外周<|>RELATION_NOE 延迟<|>RELATION_NOE 强化<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 特征性<|>RELATION_NOE 。<|>RELATION_NOE 肺<|>RELATION_NOE 放线菌病<|>RELATION_NOE 的<|>RELATION_NOE 团块样<|>RELATION_NOE 表现<|>RELATION_NOE 易<|>RELATION_NOE 被<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 或<|>RELATION_NOE 其他<|>RELATION_NOE 病变<|>RELATION_NOE ,<|>RELATION_NOE CT<|>RELATION_NOE 增强<|>RELATION_B 扫描<|>RELATION_E 病灶<|>RELATION_NOE 呈<|>RELATION_NOE 外周<|>RELATION_NOE 延迟<|>RELATION_NOE 强化<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 特征性<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 及<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 相关<|>RELATION_NOE 因子<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 鉴别<|>RELATION_S 结核病<|>RELATION_NOE 与<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 检测<|>RELATION_NOE 血清<|>RELATION_NOE 与<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 瘦素<|>RELATION_NOE (<|>RELATION_NOE LEP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 反应<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE CRP<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE IL-6<|>RELATION_NOE 在<|>RELATION_NOE 鉴别<|>RELATION_NOE 诊断<|>RELATION_NOE 结核病<|>RELATION_NOE 与<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
抽取<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 41<|>RELATION_NOE 例<|>RELATION_NOE 结核<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 与<|>RELATION_NOE 血清<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE ELISA<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 比浊法<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 和<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE LEP<|>RELATION_NOE 、<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CRP<|>RELATION_NOE 和<|>RELATION_NOE IL-6<|>RELATION_NOE 含<|>RELATION_NOE 趋<|>RELATION_NOE ,<|>RELATION_NOE 正态分布<|>RELATION_NOE 数据<|>RELATION_NOE 采用<|>RELATION_NOE ￡<|>RELATION_NOE 检验<|>RELATION_NOE ,<|>RELATION_NOE 非正态分布<|>RELATION_NOE 数据<|>RELATION_NOE 采用<|>RELATION_NOE 秩和检验<|>RELATION_NOE 。<|>RELATION_NOE
结核<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE LEP<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 0.42<|>RELATION_NOE ±<|>RELATION_NOE 0.47<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.80<|>RELATION_NOE ±<|>RELATION_NOE 0.91<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE mL<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 9.6<|>RELATION_NOE 66<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0001<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
结核<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE LEP<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 0.69<|>RELATION_NOE ±<|>RELATION_NOE 0.65<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 4.33<|>RELATION_NOE ±<|>RELATION_NOE 2.16<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE mL<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 11.7<|>RELATION_NOE 11<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0001<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 与<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE LEP<|>RELATION_NOE 、<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_S 结核病<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE IL-6<|>RELATION_NOE 水平<|>RELATION_NOE 则<|>RELATION_NOE 相反<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 这些<|>RELATION_NOE 指标<|>RELATION_NOE 有助于<|>RELATION_NOE 结核病<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 与<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 铂类<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
胸部<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 与<|>RELATION_NOE 多<|>RELATION_NOE 层<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_S 周围型<|>RELATION_NOE 小<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 对照<|>RELATION_NOE 分析<|>RELATION_NOE
比较<|>RELATION_NOE 胸部<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 与<|>RELATION_NOE 多<|>RELATION_NOE 层<|>RELATION_NOE 螺旗<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_NOE 对<|>RELATION_NOE 周围型<|>RELATION_NOE 小<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 诊断<|>RELATION_NOE 与<|>RELATION_NOE 胸部<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE CT<|>RELATION_NOE 在<|>RELATION_NOE 空洞<|>RELATION_NOE 、<|>RELATION_NOE 毛刺征<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 凹陷征<|>RELATION_NOE 、<|>RELATION_NOE 空泡<|>RELATION_NOE 征<|>RELATION_NOE 及<|>RELATION_NOE 血管<|>RELATION_NOE 集束<|>RELATION_NOE 等<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 诊出率<|>RELATION_NOE 均<|>RELATION_NOE 优于<|>RELATION_S X<|>RELATION_NOE 线<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
强化<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗期<|>RELATION_NOE 继发<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
将<|>RELATION_NOE 168<|>RELATION_NOE 例<|>RELATION_NOE 化疗期<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE ≤<|>RELATION_NOE 1.0×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 9/<|>RELATION_NOE L<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 强化<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 各<|>RELATION_NOE 84<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 化疗<|>RELATION_NOE 后行<|>RELATION_NOE 常规<|>RELATION_NOE 预防<|>RELATION_NOE 感染<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 强化<|>RELATION_NOE 组<|>RELATION_NOE 在<|>RELATION_NOE 此<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 加强<|>RELATION_NOE 对<|>RELATION_NOE 预防<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 。<|>RELATION_NOE
强化<|>RELATION_NOE 组化<|>RELATION_NOE 疗期<|>RELATION_NOE 继发<|>RELATION_NOE 感染<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 在<|>RELATION_NOE 发热<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 治疗<|>RELATION_NOE 时间<|>RELATION_NOE 上<|>RELATION_NOE 强化<|>RELATION_NOE 组<|>RELATION_NOE 短于<|>RELATION_NOE 强化<|>RELATION_NOE 组化<|>RELATION_NOE 疗期<|>RELATION_NOE 继发<|>RELATION_NOE 感染<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 在<|>RELATION_NOE 发热<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 治疗<|>RELATION_NOE 时间<|>RELATION_NOE 上<|>RELATION_NOE 强化<|>RELATION_NOE 组<|>RELATION_NOE 短<|>RELATION_B 于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 安全<|>RELATION_NOE 度过<|>RELATION_NOE 感染期<|>RELATION_NOE 。<|>RELATION_NOE
RRM1<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 含吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨化疗<|>RELATION_NOE 方案<|>RELATION_NOE 疗效<|>RELATION_S 的<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE RRM1<|>RELATION_NOE 基因表达<|>RELATION_NOE 与<|>RELATION_NOE 晚期<|>RELATION_NOE tN<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 肺癌<|>RELATION_NOE 含吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨化疗<|>RELATION_NOE 方案<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
有<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 含吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 人<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 分支<|>RELATION_NOE DNA-<|>RELATION_NOE 液相<|>RELATION_NOE 芯片<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_NOE RRM1mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 预测<|>RELATION_NOE 吉西<|>RELATION_NOE 他滨<|>RELATION_NOE 在<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
RRM1<|>RELATION_NOE 低<|>RELATION_NOE 表达者<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE f57.5<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 高<|>RELATION_NOE 表达者<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 42.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 78.2%<|>RELATION_NOE 、<|>RELATION_NOE 12.4<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 和<|>RELATION_NOE 35.2%<|>RELATION_NOE 、<|>RELATION_NOE 8.2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
RRM1<|>RELATION_NOE 基因表达<|>RELATION_NOE 水平<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 预测<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 对<|>RELATION_NOE 含吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨化疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE 之一<|>RELATION_NOE 。<|>RELATION_NOE
11<|>RELATION_NOE β<|>RELATION_NOE -HSD2<|>RELATION_NOE 重组<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE 构建<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE IL-6<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
本文<|>RELATION_NOE 旨在<|>RELATION_NOE 构建<|>RELATION_NOE 11<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 羟基<|>RELATION_NOE 类固<|>RELATION_NOE 醇脱氢酶<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE β<|>RELATION_NOE -HSD2<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 重组<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 检测<|>RELATION_NOE 其<|>RELATION_NOE 转染<|>RELATION_NOE 人<|>RELATION_NOE 哺乳动物<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE 对<|>RELATION_NOE 白介素6<|>RELATION_NOE (<|>RELATION_NOE interleukin-6<|>RELATION_NOE ,<|>RELATION_NOE IL-6<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE PCR<|>RELATION_NOE 方法<|>RELATION_NOE 扩增<|>RELATION_NOE 11<|>RELATION_NOE β<|>RELATION_NOE -HSD2<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 全长<|>RELATION_NOE cDNA<|>RELATION_NOE ,<|>RELATION_NOE 先<|>RELATION_NOE 亚<|>RELATION_NOE 克隆<|>RELATION_NOE 至<|>RELATION_NOE pGMT<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 正确<|>RELATION_NOE 后<|>RELATION_NOE 再<|>RELATION_NOE 亚<|>RELATION_NOE 克隆<|>RELATION_NOE 至<|>RELATION_NOE pcDNA3.1myc-hisC<|>RELATION_NOE 以<|>RELATION_NOE 构建<|>RELATION_NOE 其<|>RELATION_NOE 重组<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 重组<|>RELATION_NOE 的<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE 瞬时<|>RELATION_NOE 转染<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞系<|>RELATION_NOE A549<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 方法<|>RELATION_NOE 鉴定<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE ELISA<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE IL-6<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
下调<|>RELATION_NOE Wnt<|>RELATION_NOE 通路<|>RELATION_NOE 活性<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 株吉非替尼<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
不同<|>RELATION_NOE 浓度<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 处理<|>RELATION_NOE PC9<|>RELATION_NOE 细胞株<|>RELATION_NOE (<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 敏感<|>RELATION_NOE 株<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE PC9<|>RELATION_NOE /<|>RELATION_NOE AB2<|>RELATION_NOE 细胞株<|>RELATION_NOE (<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 耐药<|>RELATION_NOE 株<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 细胞计数<|>RELATION_NOE 检测<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE (<|>RELATION_NOE CCK8<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 细胞株<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE β<|>RELATION_NOE -catenin<|>RELATION_NOE 序列特异<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE 抑制<|>RELATION_NOE PC9<|>RELATION_NOE /<|>RELATION_NOE AB2<|>RELATION_NOE 中<|>RELATION_NOE Wnt<|>RELATION_NOE 通路<|>RELATION_NOE 的<|>RELATION_NOE 转录<|>RELATION_NOE 活性<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE CCK8<|>RELATION_NOE 检测<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 在<|>RELATION_NOE 肺部<|>RELATION_NOE 肿块<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
术后<|>RELATION_NOE 不同<|>RELATION_NOE 镇痛<|>RELATION_NOE 方式<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 不同<|>RELATION_NOE 术后<|>RELATION_NOE 镇痛<|>RELATION_NOE 方式<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
50<|>RELATION_NOE 例<|>RELATION_NOE 择期<|>RELATION_NOE 全身麻醉<|>RELATION_NOE 下行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 根据<|>RELATION_NOE 术后<|>RELATION_NOE 镇痛<|>RELATION_NOE 方式<|>RELATION_NOE 不同<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 单纯<|>RELATION_NOE 吗啡<|>RELATION_NOE 硬膜<|>RELATION_NOE 外自控<|>RELATION_NOE 镇痛<|>RELATION_NOE (<|>RELATION_NOE PCEA<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
于<|>RELATION_NOE 麻醉<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 2h<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 24h<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 48h4<|>RELATION_NOE 个<|>RELATION_NOE 时间点<|>RELATION_NOE 采用<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE (<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 、<|>RELATION_NOE CD8<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 自然<|>RELATION_NOE 杀伤<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 麻醉<|>RELATION_NOE 前<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 、<|>RELATION_NOE CD8<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 及<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 水平<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
与<|>RELATION_NOE 麻醉<|>RELATION_NOE 前<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 术后<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48h<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_NOE 下降<|>RELATION_NOE (<|>RELATION_NOE 0.1<|>RELATION_NOE 12<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 0.1<|>RELATION_NOE 13<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 16<|>RELATION_NOE 比<|>RELATION_NOE 0.1<|>RELATION_NOE 26<|>RELATION_NOE ±<|>RELATION_NOE 0.01<|>RELATION_NOE 9,0.1<|>RELATION_NOE 17<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 16<|>RELATION_NOE 、<|>RELATION_NOE 0.1<|>RELATION_NOE 20<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 18<|>RELATION_NOE 比<|>RELATION_NOE 0.1<|>RELATION_NOE 27<|>RELATION_NOE ±<|>RELATION_NOE 0.021<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 术后<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48h<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E A<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
帕瑞<|>RELATION_NOE 考昔<|>RELATION_NOE 复合<|>RELATION_NOE 吗啡<|>RELATION_NOE PCEA<|>RELATION_NOE 可以<|>RELATION_NOE 通过<|>RELATION_NOE 降低<|>RELATION_S CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 以及<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 数量<|>RELATION_NOE 的<|>RELATION_NOE 下降<|>RELATION_NOE 幅度<|>RELATION_NOE ,<|>RELATION_NOE 减轻<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 抑制<|>RELATION_NOE .<|>RELATION_NOE
外周型<|>RELATION_NOE 孤立性<|>RELATION_NOE 肺结节<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 外科<|>RELATION_NOE 治疗<|>RELATION_NOE 探讨<|>RELATION_S
洛铂<|>RELATION_NOE 或<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 洛铂<|>RELATION_NOE 或<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
洛铂<|>RELATION_NOE 或<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 都<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 疗效<|>RELATION_NOE 相似<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 洛铂<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_NOE 顺铂<|>RELATION_NOE 。<|>RELATION_NOE 洛铂<|>RELATION_NOE 或<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 都<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 疗效<|>RELATION_NOE 相似<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 洛铂<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_S 顺铂<|>RELATION_NOE 。<|>RELATION_NOE
心理<|>RELATION_NOE 干预<|>RELATION_NOE 和<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 心理<|>RELATION_NOE 状态<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
结果<|>RELATION_NOE :<|>RELATION_NOE 观察组<|>RELATION_NOE 躯体<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 角色<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 情绪<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 认知<|>RELATION_NOE 功能<|>RELATION_NOE 和<|>RELATION_NOE 社会<|>RELATION_NOE 功能<|>RELATION_NOE 评分<|>RELATION_NOE 及<|>RELATION_NOE 总体<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 干预<|>RELATION_NOE 前<|>RELATION_NOE 显著<|>RELATION_NOE 提高<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 7.12<|>RELATION_NOE 、<|>RELATION_NOE 6.31<|>RELATION_NOE 、<|>RELATION_NOE 7.90<|>RELATION_NOE 、<|>RELATION_NOE 5.51<|>RELATION_NOE 、<|>RELATION_NOE 3.98<|>RELATION_NOE 、<|>RELATION_NOE 5.21<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 4.63<|>RELATION_NOE 、<|>RELATION_NOE 4.10<|>RELATION_NOE 、<|>RELATION_NOE 4.33<|>RELATION_NOE 、<|>RELATION_NOE 4.08<|>RELATION_NOE 、<|>RELATION_NOE 3.91<|>RELATION_NOE 、<|>RELATION_NOE 4.12<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 躯体化<|>RELATION_NOE 、<|>RELATION_NOE 焦虑<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 因<|>RELATION_NOE 子评分<|>RELATION_NOE 较<|>RELATION_NOE 干预<|>RELATION_NOE 前<|>RELATION_NOE 显著<|>RELATION_NOE 改善<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 7.67<|>RELATION_NOE 、<|>RELATION_NOE 8.30<|>RELATION_NOE 、<|>RELATION_NOE 6.32<|>RELATION_NOE 、<|>RELATION_NOE 4.12<|>RELATION_NOE 、<|>RELATION_NOE 4.81<|>RELATION_NOE 、<|>RELATION_NOE 4.43<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 改善<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_B 优于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 4.11<|>RELATION_NOE 、<|>RELATION_NOE 4.22<|>RELATION_NOE 、<|>RELATION_NOE 4.31<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
纵隔<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE 及<|>RELATION_NOE MRI<|>RELATION_NOE 的<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 诊断<|>RELATION_NOE 灵敏度<|>RELATION_NOE 比较<|>RELATION_S
探讨<|>RELATION_NOE 纵隔<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE x<|>RELATION_NOE 线<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE 及<|>RELATION_NOE MRI<|>RELATION_NOE 的<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 诊断<|>RELATION_NOE 灵敏度<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 经<|>RELATION_NOE 手术<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 纵隔<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 胸部<|>RELATION_NOE 正侧<|>RELATION_NOE 位<|>RELATION_NOE x<|>RELATION_NOE 线<|>RELATION_NOE 和<|>RELATION_NOE CT<|>RELATION_NOE 平扫<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 7例行<|>RELATION_NOE 增强<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE ,<|>RELATION_NOE 21<|>RELATION_NOE 例行<|>RELATION_NOE MRI<|>RELATION_NOE 平扫<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 3例<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE 。<|>RELATION_NOE
纵隔<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸部<|>RELATION_NOE x<|>RELATION_NOE 片<|>RELATION_NOE 的<|>RELATION_NOE 共同<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 纵隔<|>RELATION_NOE 明显<|>RELATION_NOE 增<|>RELATION_NOE 宽<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 受<|>RELATION_NOE 压<|>RELATION_NOE 移位<|>RELATION_NOE 变形<|>RELATION_NOE ;<|>RELATION_NOE
CT<|>RELATION_NOE 显示<|>RELATION_NOE 肿块<|>RELATION_NOE 边缘<|>RELATION_NOE 不<|>RELATION_NOE 规则<|>RELATION_NOE ,<|>RELATION_NOE 外缘<|>RELATION_NOE 呈<|>RELATION_NOE 分叶<|>RELATION_NOE 、<|>RELATION_NOE 毛刺状<|>RELATION_NOE ,<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺炎<|>RELATION_NOE 和<|>RELATION_NOE 肺不张<|>RELATION_NOE ;<|>RELATION_NOE
MRI<|>RELATION_NOE 的<|>RELATION_NOE 影像学<|>RELATION_NOE 特征<|>RELATION_NOE 除了<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 外<|>RELATION_NOE 则<|>RELATION_NOE 可<|>RELATION_NOE 较<|>RELATION_NOE 准确<|>RELATION_NOE 显示<|>RELATION_NOE 肿块<|>RELATION_NOE 侵及<|>RELATION_NOE 胸膜<|>RELATION_NOE 、<|>RELATION_NOE 胸壁<|>RELATION_NOE 和<|>RELATION_NOE 胸椎<|>RELATION_NOE 。<|>RELATION_NOE
纵隔<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 极<|>RELATION_B 易<|>RELATION_I 出现<|>RELATION_E 误诊<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 与<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 结合<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE 纵隔<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 极<|>RELATION_NOE 易<|>RELATION_NOE 出现<|>RELATION_NOE 误诊<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 与<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 结合<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_S 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE
诱导<|>RELATION_NOE 化疗<|>RELATION_NOE 并<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 加重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 治疗<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
观察<|>RELATION_NOE 诱导<|>RELATION_NOE 化疗<|>RELATION_NOE 并<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 加重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 治疗<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 毒副反应<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE :<|>RELATION_NOE 采用<|>RELATION_NOE 诱导<|>RELATION_NOE 化疗<|>RELATION_NOE +<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE +<|>RELATION_NOE 放疗<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 第8<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 25mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第2<|>RELATION_NOE －<|>RELATION_NOE 4<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 30mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ;<|>RELATION_NOE
第<|>RELATION_NOE 1-14<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 注射液<|>RELATION_NOE 7.5mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 间隙<|>RELATION_NOE 7d<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 重复<|>RELATION_NOE 使用<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 2-4<|>RELATION_NOE 个<|>RELATION_NOE 疗程<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 主要<|>RELATION_NOE 毒副反应<|>RELATION_NOE 为<|>RELATION_NOE 血液<|>RELATION_NOE 毒性<|>RELATION_NOE 、<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 、<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 和<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 联合<|>RELATION_NOE 诱导<|>RELATION_NOE 放化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 在<|>RELATION_NOE 客观<|>RELATION_NOE 缓解率<|>RELATION_NOE 和<|>RELATION_NOE 总<|>RELATION_NOE 生存率<|>RELATION_NOE 方面<|>RELATION_NOE 均<|>RELATION_NOE 有所<|>RELATION_B 提高<|>RELATION_E ,<|>RELATION_NOE 毒副反应<|>RELATION_NOE 可以<|>RELATION_NOE 耐受<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 结果<|>RELATION_NOE 有待<|>RELATION_NOE 进一步<|>RELATION_NOE 的<|>RELATION_NOE 随机<|>RELATION_NOE 多<|>RELATION_NOE 中心<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE 。<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 联合<|>RELATION_NOE 诱导<|>RELATION_NOE 放化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 在<|>RELATION_NOE 客观<|>RELATION_NOE 缓解率<|>RELATION_NOE 和<|>RELATION_NOE 总<|>RELATION_NOE 生存率<|>RELATION_NOE 方面<|>RELATION_NOE 均<|>RELATION_NOE 有所<|>RELATION_NOE 提高<|>RELATION_NOE ,<|>RELATION_NOE 毒副反应<|>RELATION_NOE 可以<|>RELATION_NOE 耐受<|>RELATION_S ,<|>RELATION_NOE 但<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 结果<|>RELATION_NOE 有待<|>RELATION_NOE 进一步<|>RELATION_NOE 的<|>RELATION_NOE 随机<|>RELATION_NOE 多<|>RELATION_NOE 中心<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 营养不良<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_B 及<|>RELATION_I 护理<|>RELATION_I 对策<|>RELATION_E
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 营养不良<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 对策<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 我院<|>RELATION_NOE 在<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 1月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 总结<|>RELATION_NOE 其<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 在<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 1－<|>RELATION_NOE 3d<|>RELATION_NOE 和<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE 1－<|>RELATION_NOE 3d<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 体格<|>RELATION_NOE 、<|>RELATION_NOE 实验室<|>RELATION_NOE 检查<|>RELATION_NOE 和<|>RELATION_NOE 状况<|>RELATION_NOE 询问<|>RELATION_NOE ,<|>RELATION_NOE 采取<|>RELATION_NOE SGA<|>RELATION_NOE 营养<|>RELATION_NOE 评估<|>RELATION_NOE 对<|>RELATION_NOE 每<|>RELATION_NOE 一<|>RELATION_NOE 位<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 综合<|>RELATION_NOE 营养状况<|>RELATION_NOE 评估<|>RELATION_NOE 。<|>RELATION_NOE
2009年<|>RELATION_NOE 河南省<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 与<|>RELATION_NOE 死亡<|>RELATION_NOE 情况<|>RELATION_NOE 分析<|>RELATION_S
分析<|>RELATION_NOE 河南省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 地区<|>RELATION_NOE 2009年<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发病<|>RELATION_NOE 与<|>RELATION_NOE 死亡<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
按照<|>RELATION_NOE 全国<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 中心<|>RELATION_NOE 制定<|>RELATION_NOE 的<|>RELATION_NOE 审核<|>RELATION_NOE 方法<|>RELATION_NOE 和<|>RELATION_NOE 评价<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 河南省<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记处<|>RELATION_NOE 上报<|>RELATION_NOE 的<|>RELATION_NOE 2009年<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 数据<|>RELATION_NOE 进行<|>RELATION_NOE 评估<|>RELATION_NOE ,<|>RELATION_NOE 登记<|>RELATION_NOE 地区<|>RELATION_NOE 覆盖<|>RELATION_NOE 人口<|>RELATION_NOE 606<|>RELATION_NOE 15<|>RELATION_NOE 64<|>RELATION_NOE 名<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 2009年<|>RELATION_NOE 河南省<|>RELATION_NOE 人口<|>RELATION_NOE 总数<|>RELATION_NOE 的<|>RELATION_NOE 6.4<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男性<|>RELATION_NOE 310<|>RELATION_NOE 49<|>RELATION_NOE 91<|>RELATION_NOE 名<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 29<|>RELATION_NOE 565<|>RELATION_NOE 73<|>RELATION_NOE 名<|>RELATION_NOE 。<|>RELATION_NOE
计算<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病率<|>RELATION_NOE 、<|>RELATION_NOE 死亡率<|>RELATION_NOE ,<|>RELATION_NOE 前<|>RELATION_NOE 10<|>RELATION_NOE 位<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 顺位<|>RELATION_NOE 、<|>RELATION_NOE 发病<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 累积率<|>RELATION_NOE (<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 74<|>RELATION_NOE 岁<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE 19<|>RELATION_NOE 82年<|>RELATION_NOE 中国<|>RELATION_NOE 标准<|>RELATION_NOE 人口<|>RELATION_NOE 构成<|>RELATION_NOE 和<|>RELATION_NOE Segi's<|>RELATION_NOE 世界<|>RELATION_NOE 人口<|>RELATION_NOE 构成<|>RELATION_NOE 分别<|>RELATION_NOE 计算<|>RELATION_NOE 中国<|>RELATION_NOE 和<|>RELATION_NOE 世界<|>RELATION_NOE 人口<|>RELATION_NOE 年龄<|>RELATION_NOE 标化<|>RELATION_NOE 发病率<|>RELATION_NOE 和<|>RELATION_NOE 死亡率<|>RELATION_NOE (<|>RELATION_NOE 以下<|>RELATION_NOE 简称<|>RELATION_NOE 中标<|>RELATION_NOE 发病率<|>RELATION_NOE 、<|>RELATION_NOE 中标<|>RELATION_NOE 死亡率<|>RELATION_NOE 和<|>RELATION_NOE 世标<|>RELATION_NOE 发病率<|>RELATION_NOE 、<|>RELATION_NOE 世标<|>RELATION_NOE 死亡率<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
2009年<|>RELATION_NOE 河南省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 地区<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 新<|>RELATION_NOE 发<|>RELATION_NOE 病例<|>RELATION_NOE 120<|>RELATION_NOE 91<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE 80<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
病理<|>RELATION_NOE 诊断<|>RELATION_NOE 比例<|>RELATION_NOE 为<|>RELATION_NOE 68.2%<|>RELATION_NOE (<|>RELATION_NOE 82<|>RELATION_NOE 46<|>RELATION_NOE /<|>RELATION_NOE 12091<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 只有<|>RELATION_NOE 死亡<|>RELATION_NOE 证明书<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 为<|>RELATION_NOE 1.7<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 21<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 12091<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 死亡<|>RELATION_NOE 发病<|>RELATION_NOE 比<|>RELATION_NOE 为<|>RELATION_NOE 0.66<|>RELATION_NOE (<|>RELATION_NOE 8040<|>RELATION_NOE /<|>RELATION_NOE 12091<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
恶性肿瘤<|>RELATION_NOE 发病率<|>RELATION_NOE 为<|>RELATION_NOE 199.47<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE (<|>RELATION_NOE 12091<|>RELATION_NOE /<|>RELATION_NOE 606<|>RELATION_NOE 1564<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 为<|>RELATION_NOE 21<|>RELATION_NOE 6.36<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE (<|>RELATION_NOE 67<|>RELATION_NOE 18<|>RELATION_NOE /<|>RELATION_NOE 310<|>RELATION_NOE 4991<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 为<|>RELATION_NOE 18<|>RELATION_NOE 1.73<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE (<|>RELATION_NOE 5373<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE 565<|>RELATION_NOE 73<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 中标<|>RELATION_NOE 发病率<|>RELATION_NOE 为<|>RELATION_NOE 12<|>RELATION_NOE 6.50<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 世标<|>RELATION_NOE 发病率<|>RELATION_NOE 为<|>RELATION_NOE 166.08<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 累积率<|>RELATION_NOE 为<|>RELATION_NOE 19.9<|>RELATION_NOE 5%<|>RELATION_NOE 。<|>RELATION_NOE
登记<|>RELATION_NOE 地区<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 13<|>RELATION_NOE 2.64<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE (<|>RELATION_NOE 8040<|>RELATION_NOE /<|>RELATION_NOE 606<|>RELATION_NOE 1564<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 为<|>RELATION_NOE 16<|>RELATION_NOE 0.58<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE (<|>RELATION_NOE 498<|>RELATION_NOE 6/3<|>RELATION_NOE 10<|>RELATION_NOE 4991<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 为<|>RELATION_NOE 10<|>RELATION_NOE 3.30<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE (<|>RELATION_NOE 3054<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE 565<|>RELATION_NOE 73<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 中标<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 78.41<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 世标<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 10<|>RELATION_NOE 7.49<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 累积率<|>RELATION_NOE 为<|>RELATION_NOE 12.1<|>RELATION_NOE 8%<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 脑神经系统<|>RELATION_NOE 癌症<|>RELATION_NOE 、<|>RELATION_NOE 结肠癌<|>RELATION_NOE 、<|>RELATION_NOE 子宫颈癌<|>RELATION_NOE 和<|>RELATION_NOE 子宫<|>RELATION_NOE 体癌<|>RELATION_NOE 是<|>RELATION_NOE 前<|>RELATION_NOE 十<|>RELATION_NOE 位<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 种类<|>RELATION_NOE ,<|>RELATION_NOE 约<|>RELATION_NOE 占<|>RELATION_NOE 全部<|>RELATION_NOE 新<|>RELATION_NOE 发病例<|>RELATION_NOE 的<|>RELATION_NOE 82.2<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 99<|>RELATION_NOE 43<|>RELATION_NOE /<|>RELATION_NOE 12091<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 脑神经系统<|>RELATION_NOE 癌症<|>RELATION_NOE 、<|>RELATION_NOE 胰腺癌<|>RELATION_NOE 、<|>RELATION_NOE 结肠癌<|>RELATION_NOE 和<|>RELATION_NOE 胆囊癌<|>RELATION_NOE 是<|>RELATION_NOE 主要<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死因<|>RELATION_NOE ,<|>RELATION_NOE 约<|>RELATION_NOE 占<|>RELATION_NOE 全部<|>RELATION_NOE 肿瘤<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 86.2<|>RELATION_NOE 9%<|>RELATION_NOE (<|>RELATION_NOE 69<|>RELATION_NOE 38<|>RELATION_NOE /<|>RELATION_NOE 8040<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
2009年<|>RELATION_NOE 浙江省<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 与<|>RELATION_NOE 死亡<|>RELATION_NOE 情况<|>RELATION_NOE 分析<|>RELATION_S
分析<|>RELATION_NOE 2009年<|>RELATION_NOE 浙江省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 地区<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 与<|>RELATION_NOE 死亡<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 2009年<|>RELATION_NOE 浙汀<|>RELATION_NOE 省6<|>RELATION_NOE 个<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 地区<|>RELATION_NOE 上报<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 与<|>RELATION_NOE 死亡<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 报告<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 新<|>RELATION_NOE 发<|>RELATION_NOE 病例<|>RELATION_NOE 306<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE 169<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
2009年<|>RELATION_NOE 浙江省<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 地区<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 粗<|>RELATION_NOE 发病率<|>RELATION_NOE 为<|>RELATION_NOE 32<|>RELATION_NOE 0.20<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 中标率<|>RELATION_NOE 为<|>RELATION_NOE 16<|>RELATION_NOE 1.99<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 世标率<|>RELATION_NOE 为<|>RELATION_NOE 20<|>RELATION_NOE 7.92<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 累积<|>RELATION_NOE 发病率<|>RELATION_NOE 为<|>RELATION_NOE 23.8<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 截缩率<|>RELATION_NOE 为<|>RELATION_NOE 34<|>RELATION_NOE 6.87<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ;<|>RELATION_NOE
恶性肿瘤<|>RELATION_NOE 粗<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 17<|>RELATION_NOE 6.97<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 中标率<|>RELATION_NOE 为<|>RELATION_NOE 79.17<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 世标率<|>RELATION_NOE 为<|>RELATION_NOE 10<|>RELATION_NOE 7.02<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 累积<|>RELATION_NOE 死亡<|>RELATION_NOE 膏墨<|>RELATION_NOE 为<|>RELATION_NOE 23.8<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 截缩<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 13<|>RELATION_NOE 9.75<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE 。<|>RELATION_NOE
发病<|>RELATION_NOE 前<|>RELATION_NOE 10<|>RELATION_NOE 位<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 依次<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 、<|>RELATION_NOE 胰腺癌<|>RELATION_NOE 、<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE 和<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 全部<|>RELATION_NOE 发病<|>RELATION_NOE 的<|>RELATION_NOE 74.3<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE 763<|>RELATION_NOE /<|>RELATION_NOE 306<|>RELATION_NOE 13<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
死亡<|>RELATION_NOE 前<|>RELATION_NOE 10<|>RELATION_NOE 位<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 依次<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 、<|>RELATION_NOE 胰腺癌<|>RELATION_NOE 、<|>RELATION_NOE 白血病<|>RELATION_NOE 、<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 、<|>RELATION_NOE 脑肿瘤<|>RELATION_NOE 和<|>RELATION_NOE 乳腺癌<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 全部<|>RELATION_NOE 死亡<|>RELATION_NOE 的<|>RELATION_NOE 87.7<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 848<|>RELATION_NOE /<|>RELATION_NOE 169<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
2009年<|>RELATION_NOE 浙江省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 地区<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病率<|>RELATION_NOE 和<|>RELATION_NOE 死亡率<|>RELATION_NOE 均<|>RELATION_NOE 有所<|>RELATION_NOE 上升<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 、<|>RELATION_NOE 消化系统<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 和<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 仍然<|>RELATION_NOE 是<|>RELATION_NOE 浙江省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 防治<|>RELATION_NOE 工作<|>RELATION_NOE 的<|>RELATION_NOE 重点<|>RELATION_S ,<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 发病率<|>RELATION_NOE 的<|>RELATION_NOE 升高<|>RELATION_NOE 不容忽视<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 纵隔镜<|>RELATION_NOE 在<|>RELATION_NOE 可<|>RELATION_NOE 切除非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 术前<|>RELATION_NOE 系统性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结切除<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
探讨<|>RELATION_NOE 应用电视<|>RELATION_NOE 纵隔镜<|>RELATION_NOE 对<|>RELATION_NOE 可<|>RELATION_NOE 切除非<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 行术<|>RELATION_NOE 前<|>RELATION_NOE 系统性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结切除<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 56<|>RELATION_NOE 例术<|>RELATION_NOE 前<|>RELATION_NOE 检查<|>RELATION_NOE 发现<|>RELATION_NOE 有<|>RELATION_NOE 影像学<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 电视<|>RELATION_NOE 纵隔镜<|>RELATION_NOE 下行<|>RELATION_NOE 系统性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结切除<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 记录<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 每<|>RELATION_NOE 例<|>RELATION_NOE 切除<|>RELATION_NOE 各组<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 数目<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 阴性<|>RELATION_NOE 和<|>RELATION_NOE 单站<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 术后<|>RELATION_NOE 2周<|>RELATION_NOE 行根治性<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 2站<|>RELATION_NOE 及<|>RELATION_NOE 以上<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 行术<|>RELATION_NOE 前<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗2<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 行根治性<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE
手术<|>RELATION_NOE 中<|>RELATION_NOE 对<|>RELATION_NOE 已<|>RELATION_NOE 行<|>RELATION_NOE 纵隔镜<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结切除<|>RELATION_NOE 的<|>RELATION_NOE 区域<|>RELATION_NOE 再次<|>RELATION_NOE 探查<|>RELATION_NOE ,<|>RELATION_NOE 了解<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 残留<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE 电视<|>RELATION_NOE 纵隔镜<|>RELATION_NOE 行术<|>RELATION_NOE 前<|>RELATION_NOE 系统性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结切除<|>RELATION_NOE ,<|>RELATION_NOE 耗时<|>RELATION_NOE 26-86min<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE ±<|>RELATION_NOE 13.5<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ;<|>RELATION_NOE
术中<|>RELATION_NOE 平均<|>RELATION_NOE 出血<|>RELATION_NOE 少于<|>RELATION_NOE 40m1<|>RELATION_NOE ,<|>RELATION_NOE 全<|>RELATION_NOE 组<|>RELATION_NOE 无<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 住院<|>RELATION_NOE 3<|>RELATION_NOE 天<|>RELATION_NOE 。<|>RELATION_NOE
纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 阴性<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 单站<|>RELATION_NOE 转移<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 术后<|>RELATION_NOE 2周<|>RELATION_NOE 接受<|>RELATION_NOE 根治性<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 2站<|>RELATION_NOE (<|>RELATION_NOE 包括<|>RELATION_NOE 2<|>RELATION_NOE 站<|>RELATION_NOE )<|>RELATION_NOE 以上<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 先<|>RELATION_NOE 进行<|>RELATION_NOE 2周期<|>RELATION_NOE 的<|>RELATION_NOE 术前<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 再<|>RELATION_NOE 进行<|>RELATION_NOE 根治性<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 术中<|>RELATION_NOE 对<|>RELATION_NOE 纵隔镜<|>RELATION_NOE 淋巴结切除<|>RELATION_NOE 区域<|>RELATION_NOE 再次<|>RELATION_NOE 探查<|>RELATION_NOE 发现<|>RELATION_NOE 有<|>RELATION_NOE 5例<|>RELATION_NOE 共<|>RELATION_NOE 16<|>RELATION_NOE 枚<|>RELATION_NOE 淋巴结<|>RELATION_NOE 残留<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 分布<|>RELATION_NOE 于<|>RELATION_NOE 第2<|>RELATION_NOE 、<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 7组<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 残留<|>RELATION_NOE 淋巴结切除<|>RELATION_NOE 送<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 结果<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 阴性<|>RELATION_NOE 。<|>RELATION_NOE
因此<|>RELATION_NOE ,<|>RELATION_NOE 纵隔镜<|>RELATION_NOE 系统<|>RELATION_NOE 淋巴结切除<|>RELATION_NOE 的<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 诊断率<|>RELATION_NOE 可<|>RELATION_B 达<|>RELATION_I 100%<|>RELATION_E ,<|>RELATION_NOE 90.9%<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE /<|>RELATION_NOE 55<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 达到<|>RELATION_NOE 完全<|>RELATION_NOE 切除<|>RELATION_NOE 。<|>RELATION_NOE
七<|>RELATION_NOE 氟醚<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE γ射线<|>RELATION_NOE 抑制<|>RELATION_S 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 作用<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
探讨<|>RELATION_NOE 七<|>RELATION_NOE 氟醚<|>RELATION_NOE 对<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE γ射线<|>RELATION_NOE 抑制<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 作用<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 培养<|>RELATION_NOE 板<|>RELATION_NOE ,<|>RELATION_NOE 培养<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 分为<|>RELATION_NOE 6组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 6<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 七氟<|>RELATION_NOE 醚组<|>RELATION_NOE (<|>RELATION_NOE s<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 顺铂组<|>RELATION_NOE (<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE +<|>RELATION_NOE 七氟<|>RELATION_NOE 醚组<|>RELATION_NOE (<|>RELATION_NOE DS<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE γ射线<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE R<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE γ射线<|>RELATION_NOE +<|>RELATION_NOE 七氟<|>RELATION_NOE 醚组<|>RELATION_NOE (<|>RELATION_NOE Rs<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
七<|>RELATION_NOE 氟醚<|>RELATION_NOE 可<|>RELATION_NOE 增强<|>RELATION_S 顺铂<|>RELATION_NOE 和<|>RELATION_NOE γ射线<|>RELATION_NOE 抑制<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 下调<|>RELATION_NOE XIAP<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 上调<|>RELATION_NOE caspase-3<|>RELATION_NOE 表达<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE
2005<|>RELATION_NOE －<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE 中国<|>RELATION_NOE 城市<|>RELATION_NOE 居民<|>RELATION_NOE 期望<|>RELATION_NOE 寿命<|>RELATION_NOE 性别<|>RELATION_B 差异<|>RELATION_E 的<|>RELATION_NOE 分析<|>RELATION_NOE
利用<|>RELATION_NOE 2005<|>RELATION_NOE －<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 《<|>RELATION_NOE 中国<|>RELATION_NOE 卫生<|>RELATION_NOE 统计<|>RELATION_NOE 年鉴<|>RELATION_NOE 》<|>RELATION_NOE 中<|>RELATION_NOE 城市<|>RELATION_NOE 居民<|>RELATION_NOE 年龄<|>RELATION_NOE 别<|>RELATION_NOE 死亡率<|>RELATION_NOE 及<|>RELATION_NOE 死因<|>RELATION_NOE 等<|>RELATION_NOE 死亡<|>RELATION_NOE 数据<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 绘制<|>RELATION_NOE 寿命表法<|>RELATION_NOE 、<|>RELATION_NOE 期望<|>RELATION_NOE 寿命<|>RELATION_NOE 性别<|>RELATION_NOE 差异<|>RELATION_NOE 及其<|>RELATION_NOE 年龄<|>RELATION_NOE 分解<|>RELATION_NOE 和<|>RELATION_NOE 死因<|>RELATION_NOE 分解<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 城市<|>RELATION_NOE 居民<|>RELATION_NOE 期望<|>RELATION_NOE 寿命<|>RELATION_NOE 性别<|>RELATION_NOE 差异<|>RELATION_NOE 的<|>RELATION_NOE 分析<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 、<|>RELATION_NOE 循环系统<|>RELATION_NOE 疾病<|>RELATION_NOE 和<|>RELATION_NOE 呼吸系统<|>RELATION_NOE 疾病<|>RELATION_NOE 是<|>RELATION_NOE 导致<|>RELATION_S 中国<|>RELATION_NOE 城市<|>RELATION_NOE 人群<|>RELATION_NOE 期望<|>RELATION_NOE 寿命<|>RELATION_NOE 性别<|>RELATION_NOE 差异<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 疾病<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 不可<|>RELATION_NOE 忽视<|>RELATION_NOE 外<|>RELATION_NOE 伤<|>RELATION_NOE 、<|>RELATION_NOE 自杀<|>RELATION_NOE 等<|>RELATION_NOE 对<|>RELATION_NOE 期望<|>RELATION_NOE 寿命<|>RELATION_NOE 差异<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
调强<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 多<|>RELATION_NOE 目标<|>RELATION_NOE 优化<|>RELATION_NOE 算法<|>RELATION_NOE 比较<|>RELATION_S 研究<|>RELATION_NOE
随机<|>RELATION_NOE 抽取<|>RELATION_NOE 已<|>RELATION_NOE 接受<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 和<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 调强<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE ,<|>RELATION_NOE 这些<|>RELATION_NOE 计划<|>RELATION_NOE 都<|>RELATION_NOE 是<|>RELATION_NOE 基于<|>RELATION_NOE 直接<|>RELATION_NOE 子野<|>RELATION_NOE 优化<|>RELATION_NOE 算法<|>RELATION_NOE 进行<|>RELATION_NOE 优化<|>RELATION_NOE 的<|>RELATION_NOE 。<|>RELATION_NOE
比较<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 优化<|>RELATION_NOE 算法<|>RELATION_NOE 得到<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方<|>RELATION_NOE 图<|>RELATION_NOE 参数<|>RELATION_NOE 、<|>RELATION_NOE 计划<|>RELATION_NOE 优化<|>RELATION_NOE 时间<|>RELATION_NOE 和<|>RELATION_NOE 机器<|>RELATION_NOE 跳数<|>RELATION_NOE ,<|>RELATION_NOE 并行<|>RELATION_NOE 配对<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE DMPO<|>RELATION_NOE 算法<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 靶区<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE 无<|>RELATION_NOE 差别<|>RELATION_NOE 下<|>RELATION_NOE MCO<|>RELATION_NOE 算法<|>RELATION_NOE 使得<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 计划<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 直肠<|>RELATION_NOE 、<|>RELATION_NOE 膀胱<|>RELATION_NOE 及<|>RELATION_NOE 小肠<|>RELATION_NOE 受量<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 不同<|>RELATION_B 程度<|>RELATION_I 降低<|>RELATION_E ,<|>RELATION_NOE 计划<|>RELATION_NOE 优化<|>RELATION_NOE 时间<|>RELATION_NOE 减少<|>RELATION_NOE 58%<|>RELATION_NOE ,<|>RELATION_NOE 机器<|>RELATION_NOE 跳数<|>RELATION_NOE 平均<|>RELATION_NOE 增加<|>RELATION_NOE 32%<|>RELATION_NOE ;<|>RELATION_NOE 与<|>RELATION_NOE DMPO<|>RELATION_NOE 算法<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 靶区<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE 无<|>RELATION_NOE 差别<|>RELATION_NOE 下<|>RELATION_NOE MCO<|>RELATION_NOE 算法<|>RELATION_NOE 使得<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 计划<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 直肠<|>RELATION_NOE 、<|>RELATION_NOE 膀胱<|>RELATION_NOE 及<|>RELATION_NOE 小肠<|>RELATION_NOE 受量<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 计划<|>RELATION_NOE 优化<|>RELATION_NOE 时间<|>RELATION_NOE 减少<|>RELATION_B 58%<|>RELATION_E ,<|>RELATION_NOE 机器<|>RELATION_NOE 跳数<|>RELATION_NOE 平均<|>RELATION_NOE 增加<|>RELATION_NOE 32%<|>RELATION_NOE ;<|>RELATION_NOE 与<|>RELATION_NOE DMPO<|>RELATION_NOE 算法<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 靶区<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE 无<|>RELATION_NOE 差别<|>RELATION_NOE 下<|>RELATION_NOE MCO<|>RELATION_NOE 算法<|>RELATION_NOE 使得<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 计划<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 直肠<|>RELATION_NOE 、<|>RELATION_NOE 膀胱<|>RELATION_NOE 及<|>RELATION_NOE 小肠<|>RELATION_NOE 受量<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 计划<|>RELATION_NOE 优化<|>RELATION_NOE 时间<|>RELATION_NOE 减少<|>RELATION_NOE 58%<|>RELATION_NOE ,<|>RELATION_NOE 机器<|>RELATION_NOE 跳数<|>RELATION_NOE 平均<|>RELATION_B 增加<|>RELATION_I 32%<|>RELATION_E ;<|>RELATION_NOE
在<|>RELATION_NOE 肺癌<|>RELATION_NOE 计划<|>RELATION_NOE 中<|>RELATION_NOE 肺<|>RELATION_NOE 、<|>RELATION_NOE 心脏<|>RELATION_NOE 和<|>RELATION_NOE 脊髓<|>RELATION_NOE 受量<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 计划<|>RELATION_NOE 优化<|>RELATION_NOE 时间<|>RELATION_NOE 减少<|>RELATION_NOE 59%<|>RELATION_NOE ,<|>RELATION_NOE 机器<|>RELATION_NOE 跳数<|>RELATION_NOE 平均<|>RELATION_NOE 增加<|>RELATION_NOE 11%<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE DMPO<|>RELATION_NOE 算法<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE MCO<|>RELATION_NOE 算法<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_S 降低<|>RELATION_NOE 危及器官<|>RELATION_NOE 受照<|>RELATION_NOE 剂量<|>RELATION_NOE 、<|>RELATION_NOE 缩短<|>RELATION_NOE 计划<|>RELATION_NOE 优化<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
基于<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE CT<|>RELATION_NOE 图像<|>RELATION_NOE 勾画<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 靶体<|>RELATION_NOE 积<|>RELATION_NOE 比较<|>RELATION_S 研究<|>RELATION_NOE
在<|>RELATION_NOE 3DCT<|>RELATION_NOE 、<|>RELATION_NOE 4DCT<|>RELATION_NOE 的<|>RELATION_NOE 50%<|>RELATION_NOE 时相<|>RELATION_NOE 、<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 密度<|>RELATION_NOE 投影<|>RELATION_NOE (<|>RELATION_NOE MIP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE CBCT<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 勾画<|>RELATION_NOE 得到<|>RELATION_NOE GTV3D<|>RELATION_NOE 、<|>RELATION_NOE GTV4D50<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE IGTVMIP<|>RELATION_NOE 和<|>RELATION_NOE IGTVCBCT<|>RELATION_NOE 对<|>RELATION_NOE 组间<|>RELATION_NOE 位移<|>RELATION_NOE 比较<|>RELATION_NOE 行<|>RELATION_NOE Wilcoxon<|>RELATION_NOE 秩和检验<|>RELATION_NOE ,<|>RELATION_NOE 靶区<|>RELATION_NOE 位置<|>RELATION_NOE 及<|>RELATION_NOE 包含<|>RELATION_NOE 度<|>RELATION_NOE 比较<|>RELATION_NOE 行<|>RELATION_NOE 配对<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 三维<|>RELATION_NOE 运动<|>RELATION_NOE 相关<|>RELATION_NOE 性行<|>RELATION_NOE Pearson<|>RELATION_NOE 法<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
局限期<|>RELATION_NOE 食管<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 规律<|>RELATION_B 及<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E 初探<|>RELATION_NOE
探讨<|>RELATION_NOE 局限期<|>RELATION_NOE 原发<|>RELATION_NOE 食管<|>RELATION_NOE 小细胞癌<|>RELATION_NOE (<|>RELATION_NOE PESC<|>RELATION_NOE )<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 规律<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 指导<|>RELATION_NOE 放疗<|>RELATION_NOE 临床<|>RELATION_NOE 靶体<|>RELATION_NOE 积勾画<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
平均<|>RELATION_NOE 清扫<|>RELATION_NOE 淋巴结<|>RELATION_NOE 27.9<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 弥散性<|>RELATION_NOE 分布<|>RELATION_NOE 8例<|>RELATION_NOE 、<|>RELATION_NOE 聚集性<|>RELATION_NOE 分布<|>RELATION_NOE 7例<|>RELATION_NOE 。<|>RELATION_NOE
Logistic<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE T<|>RELATION_NOE 分期晚<|>RELATION_NOE 、<|>RELATION_NOE 食管<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 较<|>RELATION_NOE 长<|>RELATION_NOE 是<|>RELATION_NOE 发生<|>RELATION_S 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE T<|>RELATION_NOE 分期晚<|>RELATION_NOE 、<|>RELATION_NOE 脉管<|>RELATION_NOE 侵犯<|>RELATION_NOE 是<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 分布<|>RELATION_NOE 弥散性<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.007<|>RELATION_NOE 、<|>RELATION_NOE 0.005<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE Logistic<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE T<|>RELATION_NOE 分期晚<|>RELATION_NOE 、<|>RELATION_NOE 食管<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 较<|>RELATION_NOE 长<|>RELATION_NOE 是<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE T<|>RELATION_NOE 分期晚<|>RELATION_NOE 、<|>RELATION_NOE 脉管<|>RELATION_NOE 侵犯<|>RELATION_NOE 是<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 分布<|>RELATION_NOE 弥散性<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.007<|>RELATION_NOE 、<|>RELATION_NOE 0.005<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 弥散性<|>RELATION_NOE 分布<|>RELATION_NOE 占<|>RELATION_NOE 38%<|>RELATION_NOE ,<|>RELATION_NOE 依据<|>RELATION_NOE T<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 脉管<|>RELATION_NOE 侵犯<|>RELATION_NOE 甄别<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 分布<|>RELATION_NOE 状况<|>RELATION_NOE 探讨<|>RELATION_S PESC<|>RELATION_NOE 淋巴<|>RELATION_NOE 引流<|>RELATION_NOE 区域<|>RELATION_NOE 预防性<|>RELATION_NOE 照射<|>RELATION_NOE 价值<|>RELATION_NOE 值得<|>RELATION_NOE 研究<|>RELATION_NOE 。<|>RELATION_NOE
全身<|>RELATION_NOE MR<|>RELATION_NOE 扩散<|>RELATION_NOE 加权<|>RELATION_NOE 成像<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 诊断<|>RELATION_B 与<|>RELATION_I 鉴别诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
比较<|>RELATION_NOE 全身<|>RELATION_NOE MR-DWI<|>RELATION_NOE (<|>RELATION_NOE WB-DWI<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 常规<|>RELATION_NOE MRI<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE CT<|>RELATION_NOE (<|>RELATION_NOE MRI-CT<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 二者<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE (<|>RELATION_NOE WB-DWI<|>RELATION_NOE +<|>RELATION_NOE MRI-CT<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE WB-DWI<|>RELATION_NOE 、<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 于<|>RELATION_NOE 扫描<|>RELATION_NOE 后<|>RELATION_NOE 1周<|>RELATION_NOE 内<|>RELATION_NOE 对<|>RELATION_NOE 可疑<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 部位<|>RELATION_NOE 行<|>RELATION_NOE 常规<|>RELATION_NOE MR<|>RELATION_NOE 扫描<|>RELATION_NOE ,<|>RELATION_NOE 必要<|>RELATION_NOE 时<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 比较<|>RELATION_S WB-DWI<|>RELATION_NOE 、<|>RELATION_NOE MRI-CT<|>RELATION_NOE 及<|>RELATION_NOE 二者<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
DWI<|>RELATION_NOE 、<|>RELATION_NOE MRI-CT<|>RELATION_NOE 及<|>RELATION_NOE 二者<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 对<|>RELATION_NOE 不同<|>RELATION_NOE 大小<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 方差分析<|>RELATION_NOE 比较<|>RELATION_S ADC<|>RELATION_NOE 值<|>RELATION_NOE 在<|>RELATION_NOE 良恶性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 鉴别<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE WB-DWI<|>RELATION_NOE 、<|>RELATION_NOE MRI-CT<|>RELATION_NOE 及<|>RELATION_NOE 二者<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 3种<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE 长径<|>RELATION_NOE <<|>RELATION_NOE 2cm<|>RELATION_NOE 淋巴结<|>RELATION_NOE (<|>RELATION_NOE 共<|>RELATION_NOE 123<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 三者<|>RELATION_NOE 分别<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 109<|>RELATION_NOE 、<|>RELATION_NOE 98<|>RELATION_NOE 、<|>RELATION_NOE 117<|>RELATION_NOE 枚<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 检出率<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 13.8<|>RELATION_NOE 19<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 优于<|>RELATION_S 单独<|>RELATION_NOE 应用<|>RELATION_NOE MRI-CT<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 13.3<|>RELATION_NOE 24<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 对<|>RELATION_NOE 其余<|>RELATION_NOE 2组<|>RELATION_NOE (<|>RELATION_NOE 长径<|>RELATION_NOE 2－<|>RELATION_NOE 3cm<|>RELATION_NOE 淋巴结<|>RELATION_NOE 共<|>RELATION_NOE 46<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 三者<|>RELATION_NOE 分别<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 43<|>RELATION_NOE 、<|>RELATION_NOE 40<|>RELATION_NOE 、<|>RELATION_NOE 45<|>RELATION_NOE 枚<|>RELATION_NOE ;<|>RELATION_NOE
DWI<|>RELATION_NOE ,<|>RELATION_NOE WB-DWI<|>RELATION_NOE +<|>RELATION_NOE MRI-CT<|>RELATION_NOE 诊断<|>RELATION_NOE NSCLC<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE ROC<|>RELATION_NOE 曲线下面积<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 0.9<|>RELATION_NOE 78<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 敏感度<|>RELATION_NOE 、<|>RELATION_NOE 特异度<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE (<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 97.4%<|>RELATION_NOE 、<|>RELATION_NOE 88.9%<|>RELATION_NOE 、<|>RELATION_NOE 86.3%<|>RELATION_NOE )<|>RELATION_NOE 均<|>RELATION_B 高于<|>RELATION_E MRI-CT<|>RELATION_NOE 或<|>RELATION_NOE WB-DWI<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE NSCLC<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE ADC<|>RELATION_NOE 值<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 良性<|>RELATION_NOE 淋巴结组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 0.79<|>RELATION_NOE ±<|>RELATION_NOE 0.15<|>RELATION_NOE )<|>RELATION_NOE ×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE -3<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 1.59<|>RELATION_NOE ±<|>RELATION_NOE 0.15<|>RELATION_NOE )<|>RELATION_NOE ×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE -3mm2<|>RELATION_NOE /<|>RELATION_NOE s<|>RELATION_NOE ,<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 33<|>RELATION_NOE 2.8<|>RELATION_NOE 13<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
WB-DWI<|>RELATION_NOE 是<|>RELATION_NOE 常规<|>RELATION_NOE MRI-CT<|>RELATION_NOE 的<|>RELATION_NOE 有益<|>RELATION_B 补充<|>RELATION_E ,<|>RELATION_NOE 可以<|>RELATION_NOE 用于<|>RELATION_NOE 疑似<|>RELATION_NOE NSCLC<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 筛查<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE WB-DWI<|>RELATION_NOE 是<|>RELATION_NOE 常规<|>RELATION_NOE MRI-CT<|>RELATION_NOE 的<|>RELATION_NOE 有益<|>RELATION_NOE 补充<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 用于<|>RELATION_NOE 疑似<|>RELATION_NOE NSCLC<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_B 筛查<|>RELATION_E ,<|>RELATION_NOE 结合<|>RELATION_NOE 常规<|>RELATION_NOE MRI-CT<|>RELATION_NOE 图像<|>RELATION_NOE 及<|>RELATION_NOE ADC<|>RELATION_NOE 值<|>RELATION_NOE 测定<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 诊断<|>RELATION_NOE 与<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 方面<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 前<|>RELATION_NOE 肺功能<|>RELATION_NOE 的<|>RELATION_NOE 综合<|>RELATION_B 评判<|>RELATION_E 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
肺功能<|>RELATION_NOE 重度<|>RELATION_NOE 异常<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 并发症<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 肺炎<|>RELATION_NOE 合并<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 而<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
研究<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE MALAT-1<|>RELATION_NOE lncRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 对应<|>RELATION_NOE 的<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 的<|>RELATION_NOE MALAT-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 进行<|>RELATION_NOE 检测<|>RELATION_S 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE MALAT-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 细胞分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 以及<|>RELATION_NOE 术后<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Cox<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_NOE 细胞<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE ,<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 和<|>RELATION_NOE MALAT-1<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 本组<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 因素<|>RELATION_E 。<|>RELATION_NOE
MALAT-1<|>RELATION_NOE 将来<|>RELATION_NOE 可能<|>RELATION_NOE 作为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_NOE 判断<|>RELATION_S 的<|>RELATION_NOE 分子<|>RELATION_NOE 标志物<|>RELATION_NOE 。<|>RELATION_NOE
培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞化疗<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 肺腺<|>RELATION_NOE 癌脑<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
选择<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 并且<|>RELATION_NOE 出现<|>RELATION_NOE 脑转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 诊断<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 分层<|>RELATION_NOE 区组<|>RELATION_NOE 随机化<|>RELATION_NOE 方法<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 采用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞化疗<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 单纯<|>RELATION_NOE 放疗<|>RELATION_NOE ,<|>RELATION_NOE 对比<|>RELATION_NOE 观察<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 颅内<|>RELATION_NOE 转移瘤<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 和<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存期<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 应用<|>RELATION_NOE 于<|>RELATION_NOE 肺腺<|>RELATION_B 癌脑<|>RELATION_I 转移<|>RELATION_I 的<|>RELATION_I 治疗<|>RELATION_E 中<|>RELATION_NOE ,<|>RELATION_NOE 有效<|>RELATION_NOE 改善<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 轻微<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 与<|>RELATION_NOE 开<|>RELATION_NOE 胸肺<|>RELATION_NOE 叶切<|>RELATION_NOE 除术<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE
比较<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 与<|>RELATION_NOE 开<|>RELATION_NOE 胸肺<|>RELATION_NOE 叶切<|>RELATION_NOE 除术<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
80<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 根据<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 不同<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 104<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 接受<|>RELATION_NOE 全<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 接受<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE (<|>RELATION_NOE OT<|>RELATION_NOE )<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 。<|>RELATION_NOE
比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 胸液<|>RELATION_NOE 引<|>RELATION_NOE 流量<|>RELATION_NOE 、<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 数量<|>RELATION_NOE 及<|>RELATION_NOE 围手术期<|>RELATION_NOE 并发症<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 手术时间<|>RELATION_NOE 缩短<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 及<|>RELATION_NOE 胸液<|>RELATION_NOE 引<|>RELATION_NOE 流量<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 围手术期<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 更<|>RELATION_NOE 符合<|>RELATION_B 微创<|>RELATION_I 外科<|>RELATION_I 的<|>RELATION_I 要求<|>RELATION_E 。<|>RELATION_NOE
新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 手术<|>RELATION_NOE 与<|>RELATION_NOE 直接<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE
观察<|>RELATION_NOE 可<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 以<|>RELATION_NOE 手术<|>RELATION_NOE 为主<|>RELATION_NOE 的<|>RELATION_NOE 综合疗法<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
据<|>RELATION_NOE 多<|>RELATION_NOE 学科<|>RELATION_NOE 综合治疗<|>RELATION_NOE 中<|>RELATION_NOE 手术<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 先后<|>RELATION_NOE 次序<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 82<|>RELATION_NOE 例<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE (<|>RELATION_NOE NAC<|>RELATION_NOE )<|>RELATION_NOE 后<|>RELATION_NOE 手术<|>RELATION_NOE 切除组<|>RELATION_NOE (<|>RELATION_NOE NAC<|>RELATION_NOE +<|>RELATION_NOE 手术组<|>RELATION_NOE )<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE 以及<|>RELATION_NOE 直接<|>RELATION_NOE 手术<|>RELATION_NOE 组<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
NAC<|>RELATION_NOE +<|>RELATION_NOE 手术<|>RELATION_NOE 组术<|>RELATION_NOE 前<|>RELATION_NOE 给予<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE NP<|>RELATION_NOE (<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE 或<|>RELATION_NOE EP<|>RELATION_NOE (<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 结束<|>RELATION_NOE 3<|>RELATION_NOE 周<|>RELATION_NOE 后<|>RELATION_NOE 进行<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE
微波<|>RELATION_NOE 消融<|>RELATION_NOE 联合<|>RELATION_NOE ^<|>RELATION_NOE 131I<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞核<|>RELATION_NOE 人<|>RELATION_NOE 鼠嵌<|>RELATION_NOE 合<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE 注射液<|>RELATION_NOE 治疗<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 微波<|>RELATION_NOE 消融<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE ^<|>RELATION_NOE 131I<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞核<|>RELATION_NOE 人<|>RELATION_NOE 鼠嵌<|>RELATION_NOE 合<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE 注射<|>RELATION_NOE 液^<|>RELATION_NOE (<|>RELATION_NOE 131I-chTNT<|>RELATION_NOE )<|>RELATION_NOE 放射<|>RELATION_NOE 免疫<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 二者<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_B 及其<|>RELATION_I 抗<|>RELATION_I 肿瘤<|>RELATION_I 机制<|>RELATION_E 。<|>RELATION_NOE
将<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE i<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE 单纯<|>RELATION_NOE 微波<|>RELATION_NOE 消融<|>RELATION_NOE 治疗<|>RELATION_NOE 组<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE ^<|>RELATION_NOE 131I-chTNT<|>RELATION_NOE 放射<|>RELATION_NOE 免疫<|>RELATION_NOE 治疗组<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 微波<|>RELATION_NOE 消融<|>RELATION_NOE 联合<|>RELATION_NOE ^<|>RELATION_NOE 131I-chTNT<|>RELATION_NOE 放射<|>RELATION_NOE 免疫<|>RELATION_NOE 治疗<|>RELATION_NOE 组<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 、<|>RELATION_NOE NK<|>RELATION_NOE 细胞<|>RELATION_NOE 活性<|>RELATION_NOE 和<|>RELATION_NOE 白细胞介素<|>RELATION_NOE (<|>RELATION_NOE IL<|>RELATION_NOE )<|>RELATION_NOE -2<|>RELATION_NOE 、<|>RELATION_NOE IL-10<|>RELATION_NOE 、<|>RELATION_NOE IL-12<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE 干扰<|>RELATION_NOE 素1<|>RELATION_NOE (<|>RELATION_NOE IFN-1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
四维<|>RELATION_NOE CT<|>RELATION_NOE 与<|>RELATION_NOE 自主<|>RELATION_NOE 呼吸<|>RELATION_NOE 控制<|>RELATION_NOE 辅助<|>RELATION_NOE 三维<|>RELATION_NOE CT<|>RELATION_NOE 确定<|>RELATION_S 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 位移<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_NOE
比较<|>RELATION_NOE 四维<|>RELATION_NOE CT<|>RELATION_NOE (<|>RELATION_NOE 4DCT<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 自主<|>RELATION_NOE 呼吸<|>RELATION_NOE 控制<|>RELATION_NOE (<|>RELATION_NOE ABC<|>RELATION_NOE )<|>RELATION_NOE 辅助<|>RELATION_NOE 三维<|>RELATION_NOE CT<|>RELATION_NOE (<|>RELATION_NOE 3DCT<|>RELATION_NOE )<|>RELATION_NOE 确定<|>RELATION_S 的<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE (<|>RELATION_NOE GTV<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE 位移<|>RELATION_NOE 及<|>RELATION_NOE 相互<|>RELATION_NOE 包含<|>RELATION_NOE 度<|>RELATION_NOE 和<|>RELATION_NOE 匹配<|>RELATION_NOE 指数<|>RELATION_NOE 。<|>RELATION_NOE
8例<|>RELATION_NOE 周围<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 依次<|>RELATION_NOE 完成<|>RELATION_NOE 胸部<|>RELATION_NOE 4DCT<|>RELATION_NOE 扫描<|>RELATION_NOE 及<|>RELATION_NOE ABC<|>RELATION_NOE 辅助<|>RELATION_NOE 平静<|>RELATION_NOE 吸气<|>RELATION_NOE 末<|>RELATION_NOE 屏气<|>RELATION_NOE (<|>RELATION_NOE EIH<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 屏气<|>RELATION_NOE (<|>RELATION_NOE EEH<|>RELATION_NOE )<|>RELATION_NOE 3DCT<|>RELATION_NOE 扫描<|>RELATION_NOE 。<|>RELATION_NOE
每个<|>RELATION_NOE 呼吸<|>RELATION_NOE 周期<|>RELATION_NOE 的<|>RELATION_NOE 4DCT<|>RELATION_NOE 图像<|>RELATION_NOE 平均<|>RELATION_NOE 分为<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 呼吸<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE ,<|>RELATION_NOE 0时<|>RELATION_NOE 相<|>RELATION_NOE 为<|>RELATION_NOE 吸气<|>RELATION_NOE 末<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE (<|>RELATION_NOE CTo<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 50时<|>RELATION_NOE 相<|>RELATION_NOE 为<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE (<|>RELATION_NOE ck<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 在<|>RELATION_NOE CT0<|>RELATION_NOE 、<|>RELATION_NOE CT50<|>RELATION_NOE 、<|>RELATION_NOE CTEIH<|>RELATION_NOE 和<|>RELATION_NOE CTEEH<|>RELATION_NOE 上<|>RELATION_NOE 勾画<|>RELATION_NOE GTV<|>RELATION_NOE ,<|>RELATION_NOE 得到<|>RELATION_NOE GTV0<|>RELATION_NOE 、<|>RELATION_NOE GTV50<|>RELATION_NOE 、<|>RELATION_NOE GTVEIH<|>RELATION_NOE 和<|>RELATION_NOE GTVEEH<|>RELATION_NOE 。<|>RELATION_NOE
基于<|>RELATION_NOE ABC<|>RELATION_NOE 辅助<|>RELATION_NOE 3DCT<|>RELATION_NOE 扫描<|>RELATION_NOE 测<|>RELATION_NOE 得<|>RELATION_NOE 的<|>RELATION_NOE 平静<|>RELATION_NOE 吸气<|>RELATION_NOE 末<|>RELATION_NOE 屏气<|>RELATION_NOE 和<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 屏气<|>RELATION_NOE 间<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 位移<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 代替<|>RELATION_S 4DCT<|>RELATION_NOE 极限<|>RELATION_NOE 时<|>RELATION_NOE 相测<|>RELATION_NOE 得<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位<|>RELATION_NOE 移<|>RELATION_NOE 用于<|>RELATION_NOE 内<|>RELATION_NOE 靶区<|>RELATION_NOE 的<|>RELATION_NOE 构建<|>RELATION_NOE 。<|>RELATION_NOE
但<|>RELATION_NOE ABC<|>RELATION_NOE 辅助<|>RELATION_NOE 3DCT<|>RELATION_NOE 扫描<|>RELATION_NOE 平静<|>RELATION_NOE 吸气<|>RELATION_NOE 末<|>RELATION_NOE 和<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 图像<|>RELATION_NOE 获取<|>RELATION_NOE 的<|>RELATION_NOE GTV<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 4DCT<|>RELATION_NOE 扫描<|>RELATION_NOE 得到<|>RELATION_NOE 的<|>RELATION_NOE 极限<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE 图像<|>RELATION_NOE 获取<|>RELATION_NOE 的<|>RELATION_NOE GTV<|>RELATION_NOE 存在<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 空间<|>RELATION_NOE 错位<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 体积<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE 且<|>RELATION_NOE 运动<|>RELATION_NOE 幅度<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 。<|>RELATION_NOE
siRNA<|>RELATION_NOE 沉默<|>RELATION_NOE TRPCI<|>RELATION_NOE 基因<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 增殖<|>RELATION_B 和<|>RELATION_I 侵袭<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
应用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 抑制<|>RELATION_S 瞬时<|>RELATION_NOE 受体<|>RELATION_NOE 电位<|>RELATION_NOE 通道<|>RELATION_NOE (<|>RELATION_NOE TRPCI<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE TRPCI<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 经<|>RELATION_NOE 化学<|>RELATION_NOE 修饰<|>RELATION_NOE 的<|>RELATION_NOE TRPCI<|>RELATION_NOE 特异性<|>RELATION_NOE 小<|>RELATION_NOE 干扰性<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 转染<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 和<|>RELATION_NOE 蛋白质<|>RELATION_NOE 印迹法<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE TRPCImRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE MTr<|>RELATION_NOE 、<|>RELATION_NOE 细胞周期<|>RELATION_NOE 检测<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 实验<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 恶性生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
靶向<|>RELATION_NOE TRPCI<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE 明显<|>RELATION_B 抑制<|>RELATION_E 了<|>RELATION_NOE 目的<|>RELATION_NOE :<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
体外<|>RELATION_NOE 实验<|>RELATION_NOE 表明<|>RELATION_NOE ,<|>RELATION_NOE 靶向<|>RELATION_NOE TRPCI<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE 转染<|>RELATION_NOE A459<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 抑制率<|>RELATION_NOE 达<|>RELATION_NOE 34.7%<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 非<|>RELATION_NOE 特异性<|>RELATION_NOE siRNA<|>RELATION_NOE 未能<|>RELATION_NOE 影响<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 。<|>RELATION_NOE
同时<|>RELATION_NOE ,<|>RELATION_NOE 当<|>RELATION_NOE TRPCI<|>RELATION_NOE 基因表达<|>RELATION_NOE 被<|>RELATION_NOE 抑制<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE A459<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 明显<|>RELATION_B 下降<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
抑制<|>RELATION_NOE TRPCI<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_B 抑制<|>RELATION_E 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 达芬奇<|>RELATION_NOE 机器人<|>RELATION_NOE 诊治<|>RELATION_S 肺周围<|>RELATION_NOE 小<|>RELATION_NOE 结节病<|>RELATION_NOE 变<|>RELATION_NOE
术后<|>RELATION_NOE 病理<|>RELATION_NOE 为<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 结核<|>RELATION_NOE 或<|>RELATION_NOE 肉芽肿<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 错构瘤<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 恶性病<|>RELATION_NOE 变<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 腺癌<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 黏液<|>RELATION_NOE 表皮样癌<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 包括<|>RELATION_NOE 楔形<|>RELATION_NOE 切除<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 右肺<|>RELATION_NOE 上<|>RELATION_NOE 叶<|>RELATION_NOE 切除<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 右肺<|>RELATION_NOE 下<|>RELATION_NOE 叶<|>RELATION_NOE 切除<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 右肺<|>RELATION_NOE 中叶<|>RELATION_NOE 切除<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 左肺<|>RELATION_NOE 下<|>RELATION_NOE 叶<|>RELATION_NOE 切除<|>RELATION_NOE 6例<|>RELATION_NOE 。<|>RELATION_NOE
29<|>RELATION_NOE 例<|>RELATION_NOE 均<|>RELATION_NOE 顺利<|>RELATION_NOE 完成<|>RELATION_NOE 机器人手术<|>RELATION_NOE ,<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 平均<|>RELATION_NOE 术中<|>RELATION_NOE 出血<|>RELATION_NOE 15<|>RELATION_NOE －<|>RELATION_NOE 200ml<|>RELATION_NOE (<|>RELATION_NOE 中位数<|>RELATION_NOE 50ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 输血<|>RELATION_NOE 。<|>RELATION_NOE
随<|>RELATION_NOE 访<|>RELATION_NOE 时间<|>RELATION_NOE 2-14<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 5.9<|>RELATION_NOE ±<|>RELATION_NOE 2.7<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 复发<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 达芬奇<|>RELATION_NOE 机器人手术<|>RELATION_NOE 系统<|>RELATION_NOE 治疗<|>RELATION_B 肺小<|>RELATION_I 结节病<|>RELATION_I 变<|>RELATION_E 安全<|>RELATION_NOE 、<|>RELATION_NOE 可行<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 手术<|>RELATION_NOE 中<|>RELATION_NOE 具有<|>RELATION_NOE 优势<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 推荐<|>RELATION_NOE 用于<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
转化<|>RELATION_NOE 生长因子<|>RELATION_NOE -<|>RELATION_NOE β<|>RELATION_NOE 1核<|>RELATION_NOE 转录因子<|>RELATION_NOE -<|>RELATION_NOE κ<|>RELATION_NOE B<|>RELATION_NOE 在<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
观察<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE -<|>RELATION_NOE β1<|>RELATION_NOE (<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 核<|>RELATION_NOE 转录因子<|>RELATION_NOE κ<|>RELATION_NOE B<|>RELATION_NOE (<|>RELATION_NOE NF-<|>RELATION_NOE κ<|>RELATION_NOE B<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE (<|>RELATION_NOE COPD<|>RELATION_NOE )<|>RELATION_NOE 肺组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 肺功能<|>RELATION_NOE 指标<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE COPD<|>RELATION_NOE 的<|>RELATION_NOE 发病<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 因<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 患者<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 未<|>RELATION_NOE 达到<|>RELATION_NOE COPD<|>RELATION_NOE 诊断<|>RELATION_NOE 标准<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE 61.7<|>RELATION_NOE ±<|>RELATION_NOE 8.8<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 符合<|>RELATION_NOE COPD<|>RELATION_NOE 诊断<|>RELATION_NOE 标准<|>RELATION_NOE 患者<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE COPD<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE 60.5<|>RELATION_NOE ±<|>RELATION_NOE 9.4<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 取<|>RELATION_NOE 其<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE 的<|>RELATION_NOE 远离<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 外周<|>RELATION_NOE 肺组织<|>RELATION_NOE 。<|>RELATION_NOE
反转录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 所<|>RELATION_NOE 取<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE TGFB-<|>RELATION_NOE β1<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 半定量<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
高迁移<|>RELATION_NOE 率族<|>RELATION_NOE 蛋白<|>RELATION_NOE B1<|>RELATION_NOE 在<|>RELATION_NOE 肺结核<|>RELATION_NOE 患者<|>RELATION_NOE 肺组织<|>RELATION_NOE 和<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S
探讨<|>RELATION_NOE 高<|>RELATION_NOE 迁移<|>RELATION_NOE 率族<|>RELATION_NOE 蛋白<|>RELATION_NOE B1<|>RELATION_NOE (<|>RELATION_NOE HMGBl<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺结核<|>RELATION_NOE 患者<|>RELATION_NOE 肺组织<|>RELATION_NOE 和<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE -<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE IL-1<|>RELATION_NOE β<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE 10年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 12月<|>RELATION_NOE 遵义<|>RELATION_NOE 医学院<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 胸外科手术<|>RELATION_NOE 切除<|>RELATION_NOE 肺结核<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 检查<|>RELATION_NOE 证实<|>RELATION_NOE 。<|>RELATION_NOE
40<|>RELATION_NOE 例<|>RELATION_NOE 因<|>RELATION_NOE 外伤<|>RELATION_NOE 致<|>RELATION_NOE 肺切除<|>RELATION_NOE 组织<|>RELATION_NOE 或<|>RELATION_NOE 肺癌<|>RELATION_NOE 切除<|>RELATION_NOE 组织<|>RELATION_NOE 距<|>RELATION_NOE 肿瘤<|>RELATION_NOE 5Onl<|>RELATION_NOE 以上<|>RELATION_NOE 的<|>RELATION_NOE 大致<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 作为<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 实时<|>RELATION_NOE 逆转录<|>RELATION_NOE -PCR<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色法<|>RELATION_NOE 检测<|>RELATION_S 肺组织<|>RELATION_NOE 中<|>RELATION_NOE HMGBl<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 检测<|>RELATION_S 89<|>RELATION_NOE 例<|>RELATION_NOE 未经<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 活动性<|>RELATION_NOE 肺结核<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 肺结核组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 血清<|>RELATION_NOE HMGBl<|>RELATION_NOE 、<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE IL-1<|>RELATION_NOE β<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 89<|>RELATION_NOE 例<|>RELATION_NOE 活动性<|>RELATION_NOE 肺结核<|>RELATION_NOE 分为<|>RELATION_NOE 血行<|>RELATION_NOE 播散型<|>RELATION_NOE 肺结核<|>RELATION_NOE (<|>RELATION_NOE Ⅱ型<|>RELATION_NOE )<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 继发型<|>RELATION_NOE 肺结核<|>RELATION_NOE (<|>RELATION_NOE Ⅲ型<|>RELATION_NOE )<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE Ⅲ<|>RELATION_NOE 型<|>RELATION_NOE 肺结核<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 无<|>RELATION_NOE 空洞组<|>RELATION_NOE (<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 有空<|>RELATION_NOE 洞组<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE <2<|>RELATION_NOE 个<|>RELATION_NOE 肺野组<|>RELATION_NOE (<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE ≥<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 肺野组<|>RELATION_NOE (<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺结核<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HMGBl<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 吸<|>RELATION_NOE 光度值<|>RELATION_NOE (<|>RELATION_NOE 694-29<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 224-12<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE HMGBl<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 相对<|>RELATION_NOE 转录<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE 7864-86<|>RELATION_NOE )<|>RELATION_NOE 肺结核<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HMGBl<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 吸<|>RELATION_NOE 光度值<|>RELATION_NOE (<|>RELATION_NOE 694-29<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 224-12<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE HMGBl<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 相对<|>RELATION_NOE 转录<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE 7864-86<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 2024-60<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2.3<|>RELATION_NOE 89<|>RELATION_NOE 和<|>RELATION_NOE 3.8<|>RELATION_NOE 72<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE 和<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
1I<|>RELATION_NOE 型<|>RELATION_NOE 肺结核<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE HMGBl<|>RELATION_NOE 和<|>RELATION_NOE TNF-d<|>RELATION_NOE 水平<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 6.4-<|>RELATION_NOE }<|>RELATION_NOE -3.3<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 147<|>RELATION_NOE ±<|>RELATION_NOE 89<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ]<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E Ⅲ<|>RELATION_NOE 型<|>RELATION_NOE 肺结核<|>RELATION_NOE 患者<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 4.1<|>RELATION_NOE ±<|>RELATION_NOE 2.7<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 854-37<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 3.6<|>RELATION_NOE 43<|>RELATION_NOE 和<|>RELATION_NOE 3.1<|>RELATION_NOE 11<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
HMGBl<|>RELATION_NOE 在<|>RELATION_NOE 肺结核<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_B 增高<|>RELATION_E ,<|>RELATION_NOE 提示<|>RELATION_NOE HMGBl<|>RELATION_NOE 可能<|>RELATION_NOE 参与<|>RELATION_NOE 结核性<|>RELATION_NOE 炎症<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 降钙素<|>RELATION_NOE 原<|>RELATION_NOE 、<|>RELATION_NOE 肾上腺髓质<|>RELATION_NOE 素浓度<|>RELATION_NOE 变化<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 肺炎<|>RELATION_NOE 患者<|>RELATION_NOE 诊断<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 血清<|>RELATION_NOE 降钙素<|>RELATION_NOE 原<|>RELATION_NOE (<|>RELATION_NOE PCT<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肾上腺髓质<|>RELATION_NOE 素<|>RELATION_NOE (<|>RELATION_NOE ADM<|>RELATION_NOE )<|>RELATION_NOE 浓度<|>RELATION_NOE 变化<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 肺炎<|>RELATION_NOE 患者<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
另<|>RELATION_NOE 选择<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 同期<|>RELATION_NOE 住院<|>RELATION_NOE 的<|>RELATION_NOE 呼吸科<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 感染性<|>RELATION_NOE 肺间<|>RELATION_NOE 质性<|>RELATION_NOE 疾病<|>RELATION_NOE 、<|>RELATION_NOE 肺水肿<|>RELATION_NOE 等<|>RELATION_NOE 呼吸道<|>RELATION_NOE 症状<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 肺炎<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 设<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 肺炎<|>RELATION_NOE 轻<|>RELATION_NOE 、<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 重度<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 亚组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE PCT<|>RELATION_NOE 、<|>RELATION_NOE ADM<|>RELATION_NOE 浓度<|>RELATION_NOE 经过<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 均<|>RELATION_NOE 有所<|>RELATION_NOE 下降<|>RELATION_S ,<|>RELATION_NOE 与<|>RELATION_NOE 轻<|>RELATION_NOE 、<|>RELATION_NOE 中度<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 重度<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 时间点<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE PCT<|>RELATION_NOE [<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 2.19<|>RELATION_NOE ±<|>RELATION_NOE 0.36<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.80<|>RELATION_NOE ±<|>RELATION_NOE 0.28<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.83<|>RELATION_NOE ±<|>RELATION_NOE 0.22<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 第3<|>RELATION_NOE 天<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 2.08<|>RELATION_NOE ±<|>RELATION_NOE 0.34<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.73<|>RELATION_NOE ±<|>RELATION_NOE 0.35<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.75<|>RELATION_NOE ±<|>RELATION_NOE 0.24<|>RELATION_NOE )<|>RELATION_NOE rig<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ;<|>RELATION_NOE
血清<|>RELATION_NOE PCT<|>RELATION_NOE 、<|>RELATION_NOE ADM<|>RELATION_NOE 浓度<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 老年<|>RELATION_NOE 肺炎<|>RELATION_NOE 患者<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 病情<|>RELATION_NOE 严重<|>RELATION_NOE 程度<|>RELATION_NOE 估计<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 判断<|>RELATION_NOE 的<|>RELATION_NOE 参考<|>RELATION_B 指标<|>RELATION_E 。<|>RELATION_NOE
ERCC1<|>RELATION_NOE 与<|>RELATION_NOE TS<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 与<|>RELATION_I 铂类<|>RELATION_I 化疗<|>RELATION_I 敏感性<|>RELATION_I 的<|>RELATION_I 关系<|>RELATION_E
通过<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 与<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 切除<|>RELATION_NOE 修复<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE ERCC1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 胸苷酸<|>RELATION_NOE 合成<|>RELATION_NOE 酶<|>RELATION_NOE (<|>RELATION_NOE Ts<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE NSCLC<|>RELATION_NOE 个体化<|>RELATION_NOE 治疗<|>RELATION_NOE 提供<|>RELATION_NOE 实验<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 50<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 术后癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE TS<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE TS<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 总<|>RELATION_NOE 生存期<|>RELATION_NOE (<|>RELATION_NOE OS<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE OS<|>RELATION_NOE 、<|>RELATION_NOE 中位<|>RELATION_NOE TTP<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
音乐<|>RELATION_NOE 治疗<|>RELATION_NOE 联合<|>RELATION_NOE 舒芬太尼<|>RELATION_NOE 术后<|>RELATION_NOE 静脉<|>RELATION_NOE 镇痛<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 血流动力学<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
术后<|>RELATION_NOE M<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 接<|>RELATION_NOE 舒芬太尼<|>RELATION_NOE 静脉<|>RELATION_NOE 自控<|>RELATION_NOE 镇痛<|>RELATION_NOE 泵<|>RELATION_NOE 镇痛<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_NOE 并<|>RELATION_NOE 记录<|>RELATION_NOE 术后<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 16<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 和<|>RELATION_NOE 24h<|>RELATION_NOE 患者<|>RELATION_NOE 收缩<|>RELATION_NOE 压<|>RELATION_NOE (<|>RELATION_NOE SBP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 舒张压<|>RELATION_NOE (<|>RELATION_NOE DBP<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 心率<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE )<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 记录<|>RELATION_NOE 术后<|>RELATION_NOE 舒芬太尼<|>RELATION_NOE 用量<|>RELATION_NOE 和<|>RELATION_NOE 视觉<|>RELATION_NOE 模拟<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE visual<|>RELATION_NOE analogue<|>RELATION_NOE score<|>RELATION_NOE ,<|>RELATION_NOE VAS<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 数值<|>RELATION_NOE 。<|>RELATION_NOE
音乐<|>RELATION_NOE 治疗<|>RELATION_NOE 联合<|>RELATION_NOE 舒芬太尼<|>RELATION_NOE 静脉<|>RELATION_NOE 自控<|>RELATION_NOE 镇痛<|>RELATION_NOE 用于<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 能够<|>RELATION_NOE 产生<|>RELATION_S 更<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 镇痛<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 能<|>RELATION_NOE 减少<|>RELATION_NOE 舒芬太尼<|>RELATION_NOE 的<|>RELATION_NOE 用量<|>RELATION_NOE 和<|>RELATION_NOE 更<|>RELATION_NOE 有效<|>RELATION_NOE 降低<|>RELATION_NOE 患者<|>RELATION_NOE 血压<|>RELATION_NOE 和<|>RELATION_NOE 心率<|>RELATION_NOE ,<|>RELATION_NOE 缓解<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE 。<|>RELATION_NOE 音乐<|>RELATION_NOE 治疗<|>RELATION_NOE 联合<|>RELATION_NOE 舒芬太尼<|>RELATION_NOE 静脉<|>RELATION_NOE 自控<|>RELATION_NOE 镇痛<|>RELATION_NOE 用于<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 能够<|>RELATION_NOE 产生<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 镇痛<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 能<|>RELATION_NOE 减少<|>RELATION_S 舒芬太尼<|>RELATION_NOE 的<|>RELATION_NOE 用量<|>RELATION_NOE 和<|>RELATION_NOE 更<|>RELATION_NOE 有效<|>RELATION_NOE 降低<|>RELATION_NOE 患者<|>RELATION_NOE 血压<|>RELATION_NOE 和<|>RELATION_NOE 心率<|>RELATION_NOE ,<|>RELATION_NOE 缓解<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE 。<|>RELATION_NOE 音乐<|>RELATION_NOE 治疗<|>RELATION_NOE 联合<|>RELATION_NOE 舒芬太尼<|>RELATION_NOE 静脉<|>RELATION_NOE 自控<|>RELATION_NOE 镇痛<|>RELATION_NOE 用于<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 能够<|>RELATION_NOE 产生<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 镇痛<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 能<|>RELATION_NOE 减少<|>RELATION_NOE 舒芬太尼<|>RELATION_NOE 的<|>RELATION_NOE 用量<|>RELATION_NOE 和<|>RELATION_NOE 更<|>RELATION_NOE 有效<|>RELATION_S 降低<|>RELATION_NOE 患者<|>RELATION_NOE 血压<|>RELATION_NOE 和<|>RELATION_NOE 心率<|>RELATION_NOE ,<|>RELATION_NOE 缓解<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE 。<|>RELATION_NOE
细胞<|>RELATION_NOE 因子<|>RELATION_NOE 激活<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 及<|>RELATION_NOE 自然<|>RELATION_NOE 杀伤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 细胞<|>RELATION_NOE 因子<|>RELATION_NOE 激活<|>RELATION_NOE 的<|>RELATION_NOE 杀伤<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE CIK<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 及<|>RELATION_NOE 自然<|>RELATION_NOE 杀伤<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE NK<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 61<|>RELATION_NOE 例<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 应用<|>RELATION_NOE 抽签<|>RELATION_NOE 法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 先<|>RELATION_NOE 给予<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 同步<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 给予<|>RELATION_NOE CIK<|>RELATION_NOE 回<|>RELATION_NOE 输<|>RELATION_NOE 治疗<|>RELATION_NOE ;<|>RELATION_NOE
CIK<|>RELATION_NOE 治疗<|>RELATION_NOE 可以<|>RELATION_NOE 改善<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 机体<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 卡铂<|>RELATION_NOE 对比<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 和<|>RELATION_NOE 卡铂<|>RELATION_NOE 同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 卡铂<|>RELATION_NOE 对比<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 和<|>RELATION_NOE 卡铂<|>RELATION_NOE 方案<|>RELATION_NOE 联合<|>RELATION_NOE 同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 毒副反应<|>RELATION_NOE 。<|>RELATION_NOE
60<|>RELATION_NOE 例<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE Ⅲ<|>RELATION_NOE A<|>RELATION_NOE 期<|>RELATION_NOE 39<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 期<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 一<|>RELATION_NOE 组<|>RELATION_NOE 接受<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE ㎡<|>RELATION_NOE ,<|>RELATION_NOE d1<|>RELATION_NOE ,<|>RELATION_NOE 卡铂<|>RELATION_NOE AUC5<|>RELATION_NOE ,<|>RELATION_NOE d1<|>RELATION_NOE ,<|>RELATION_NOE 21<|>RELATION_NOE 天<|>RELATION_NOE 重复<|>RELATION_NOE ;<|>RELATION_NOE
培美<|>RELATION_NOE 曲赛<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 期间<|>RELATION_NOE 的<|>RELATION_NOE 优选<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 毒性<|>RELATION_NOE 可<|>RELATION_NOE 耐受<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 及<|>RELATION_NOE 生存率<|>RELATION_NOE 较<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 方案<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_NOE 。<|>RELATION_NOE
期<|>RELATION_NOE 周围型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE (<|>RELATION_NOE 1.35<|>RELATION_NOE ±<|>RELATION_NOE 0.48<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE ,<|>RELATION_NOE N<|>RELATION_NOE ,<|>RELATION_NOE N<|>RELATION_NOE :<|>RELATION_NOE 淋巴<|>RELATION_NOE
一次性<|>RELATION_NOE 多<|>RELATION_NOE 瓶塞<|>RELATION_NOE 穿刺<|>RELATION_NOE 器式<|>RELATION_NOE 输液器<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 药物性<|>RELATION_NOE 静脉炎<|>RELATION_NOE 的<|>RELATION_NOE 预防<|>RELATION_B 效果<|>RELATION_E
方法<|>RELATION_NOE :<|>RELATION_NOE 将<|>RELATION_NOE 75<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 37<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE Ⅰ级<|>RELATION_NOE 静脉炎<|>RELATION_NOE 护理<|>RELATION_NOE 疗效率<|>RELATION_NOE 为<|>RELATION_NOE 69.2%<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE Ⅰ级<|>RELATION_NOE 静脉炎<|>RELATION_NOE 护理<|>RELATION_NOE 疗效率<|>RELATION_NOE 为<|>RELATION_NOE 85.7%<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE z<|>RELATION_NOE =<|>RELATION_NOE -2.681<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
使用<|>RELATION_NOE 一次性<|>RELATION_NOE 多<|>RELATION_NOE 瓶塞<|>RELATION_NOE 穿刺<|>RELATION_NOE 器式<|>RELATION_NOE 输液器<|>RELATION_NOE 、<|>RELATION_NOE 恒速<|>RELATION_NOE 恒压<|>RELATION_NOE 滴注法<|>RELATION_NOE 的<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 了<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 药物性<|>RELATION_NOE 静脉炎<|>RELATION_NOE 的<|>RELATION_NOE 预防<|>RELATION_NOE 与<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 更<|>RELATION_NOE 经济<|>RELATION_NOE 、<|>RELATION_NOE 更<|>RELATION_NOE 简便<|>RELATION_NOE 的<|>RELATION_NOE 给药<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
手术<|>RELATION_NOE 联合<|>RELATION_NOE 辅助<|>RELATION_NOE 性化疗<|>RELATION_NOE 治疗<|>RELATION_S 孤立性<|>RELATION_NOE 肺癌<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移瘤<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
传统<|>RELATION_NOE 研究<|>RELATION_NOE 认为<|>RELATION_NOE 其<|>RELATION_NOE 不可<|>RELATION_NOE 治愈<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 有<|>RELATION_NOE 研究<|>RELATION_NOE 报道<|>RELATION_NOE 表明<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 孤立<|>RELATION_NOE 的<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移瘤<|>RELATION_NOE 能够<|>RELATION_NOE 延长<|>RELATION_S 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 旨在<|>RELATION_NOE 探讨<|>RELATION_NOE 手术<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 孤立性<|>RELATION_NOE 肺癌<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 解放军<|>RELATION_NOE 第169<|>RELATION_NOE 医院<|>RELATION_NOE 和<|>RELATION_NOE 南华<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 第一<|>RELATION_NOE 医院<|>RELATION_NOE 2005年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 9月<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE 于<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 完整<|>RELATION_NOE 切除<|>RELATION_NOE 后<|>RELATION_NOE 发现<|>RELATION_NOE 并<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 孤立性<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移<|>RELATION_NOE 瘤患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 给予<|>RELATION_NOE 辅助<|>RELATION_NOE 性化疗<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男性<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 3例<|>RELATION_NOE 。<|>RELATION_NOE
诊断<|>RELATION_NOE 为<|>RELATION_NOE 肾上腺<|>RELATION_NOE 同时<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 异时<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
22<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 9例<|>RELATION_NOE 接受<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 肾上腺<|>RELATION_NOE 切除术<|>RELATION_NOE ,<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 了<|>RELATION_NOE 开放<|>RELATION_NOE 的<|>RELATION_NOE 肾上腺<|>RELATION_NOE 切除术<|>RELATION_NOE 。<|>RELATION_NOE
对比<|>RELATION_NOE 开放<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移<|>RELATION_NOE 瘤切<|>RELATION_NOE 除<|>RELATION_NOE 并<|>RELATION_NOE 不<|>RELATION_B 会<|>RELATION_I 增加<|>RELATION_E 患者<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 、<|>RELATION_NOE 切缘<|>RELATION_NOE 阳性<|>RELATION_NOE 的<|>RELATION_NOE 风险<|>RELATION_NOE 。<|>RELATION_NOE
手术<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移<|>RELATION_NOE 疗效<|>RELATION_NOE 肯定<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 对于<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 以后<|>RELATION_NOE 再<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 疗效<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 。<|>RELATION_NOE
小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预防性<|>RELATION_B 全脑<|>RELATION_I 放射<|>RELATION_I 治疗<|>RELATION_E 疗效<|>RELATION_NOE 及<|>RELATION_NOE 健康<|>RELATION_NOE 相关<|>RELATION_NOE 生命<|>RELATION_NOE 质量<|>RELATION_NOE 分析<|>RELATION_NOE
晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_B 前后<|>RELATION_E 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 变化<|>RELATION_NOE 与<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
回顾性研究<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFAR21-1<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 放疗<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
常规<|>RELATION_NOE 检查<|>RELATION_NOE 205<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 后<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFAR21-1<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 等<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE 应用<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 评估<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
此<|>RELATION_NOE 113<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFAR21-1<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 水平均<|>RELATION_NOE 较<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE 发生<|>RELATION_NOE 了<|>RELATION_NOE 明显<|>RELATION_NOE 下降<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.2<|>RELATION_NOE 24<|>RELATION_NOE ,<|>RELATION_NOE 2.8<|>RELATION_NOE 96<|>RELATION_NOE ,<|>RELATION_NOE 3.1<|>RELATION_NOE 37<|>RELATION_NOE ,<|>RELATION_NOE 3.2<|>RELATION_NOE 19<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 及<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFAR21-1<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 放<|>RELATION_NOE 疗<|>RELATION_NOE 后<|>RELATION_NOE 与<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE Ⅲ期<|>RELATION_NOE :<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.4<|>RELATION_NOE 84<|>RELATION_NOE ,<|>RELATION_NOE 2.4<|>RELATION_NOE 45<|>RELATION_NOE ,<|>RELATION_NOE 2.1<|>RELATION_NOE 48<|>RELATION_NOE ,<|>RELATION_NOE 2.<|>RELATION_NOE 109<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ;<|>RELATION_NOE
血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFAR21-1<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 水平<|>RELATION_NOE 或<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 评估<|>RELATION_S 。<|>RELATION_NOE
甘氨<|>RELATION_NOE 双唑钠<|>RELATION_NOE 修饰<|>RELATION_NOE 纳米金<|>RELATION_NOE 对<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE 放射<|>RELATION_B 增敏<|>RELATION_E 研究<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_B 规律<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
分析<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_B 规律<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE NSCLC<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 靶区<|>RELATION_NOE 的<|>RELATION_NOE 勾画<|>RELATION_NOE 范围<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 291<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 前行<|>RELATION_NOE 纵隔<|>RELATION_NOE CT<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 纵隔<|>RELATION_NOE 各<|>RELATION_NOE 分区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 探索<|>RELATION_NOE NSCLC<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 规律<|>RELATION_NOE 。<|>RELATION_NOE
左右<|>RELATION_NOE 肺叶<|>RELATION_NOE NSCLC<|>RELATION_NOE 具有<|>RELATION_B 不同<|>RELATION_E 高危<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 区域<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 这些<|>RELATION_NOE 高危<|>RELATION_NOE 区域<|>RELATION_NOE 进行<|>RELATION_NOE 选择性<|>RELATION_NOE 预防<|>RELATION_NOE 照射<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_NOE 降低<|>RELATION_NOE 复发率<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 局部<|>RELATION_NOE 控制率<|>RELATION_NOE 。<|>RELATION_NOE 左右<|>RELATION_NOE 肺叶<|>RELATION_NOE NSCLC<|>RELATION_NOE 具有<|>RELATION_NOE 不同<|>RELATION_NOE 高危<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 区域<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 这些<|>RELATION_NOE 高危<|>RELATION_NOE 区域<|>RELATION_NOE 进行<|>RELATION_NOE 选择性<|>RELATION_B 预防<|>RELATION_I 照射<|>RELATION_E ,<|>RELATION_NOE 有助于<|>RELATION_NOE 降低<|>RELATION_NOE 复发率<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 局部<|>RELATION_NOE 控制率<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组外<|>RELATION_NOE 周血<|>RELATION_NOE 中<|>RELATION_NOE Th17<|>RELATION_NOE 细胞<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 1.7<|>RELATION_NOE 95<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE 23<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE Tc17<|>RELATION_NOE 细胞<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 0.8<|>RELATION_NOE 65<|>RELATION_NOE ±<|>RELATION_NOE 0.3<|>RELATION_NOE 57<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 1.405<|>RELATION_NOE ±<|>RELATION_NOE 0.2<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.6<|>RELATION_NOE 40<|>RELATION_NOE ±<|>RELATION_NOE 0.204<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 28.9<|>RELATION_NOE 44<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE ;<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 内<|>RELATION_NOE Th17<|>RELATION_NOE 细胞<|>RELATION_NOE 与<|>RELATION_NOE Tc17<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 70<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 体内<|>RELATION_NOE Th17<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE Tc17<|>RELATION_NOE 细胞<|>RELATION_NOE 表达<|>RELATION_NOE 升高<|>RELATION_S ,<|>RELATION_NOE 二者<|>RELATION_NOE 可能<|>RELATION_NOE 参与<|>RELATION_NOE 了<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE ;<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 体内<|>RELATION_NOE Th17<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE Tc17<|>RELATION_NOE 细胞<|>RELATION_NOE 表达<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 可能<|>RELATION_B 参与<|>RELATION_E 了<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE ;<|>RELATION_NOE
Th17<|>RELATION_NOE 与<|>RELATION_NOE Tc17<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 评价<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 状态<|>RELATION_NOE 的<|>RELATION_NOE 新<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 为<|>RELATION_NOE 病情<|>RELATION_NOE 监测<|>RELATION_NOE 提供<|>RELATION_NOE 参考<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 氨基酸<|>RELATION_NOE 稳定<|>RELATION_NOE 同位素标记<|>RELATION_NOE -<|>RELATION_NOE 质谱<|>RELATION_NOE 技术<|>RELATION_NOE 构建<|>RELATION_S 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 14-3-3sigma<|>RELATION_NOE 相互作用<|>RELATION_NOE 的<|>RELATION_NOE 分子<|>RELATION_NOE 网络<|>RELATION_NOE
构建<|>RELATION_NOE 稳定<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 14-3-3sigma<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE (<|>RELATION_NOE PG<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 大<|>RELATION_NOE 细胞<|>RELATION_NOE 肺癌<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S PG<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 速度<|>RELATION_NOE 。<|>RELATION_NOE
转染<|>RELATION_NOE 14-3-3sigma<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE PG<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 速度<|>RELATION_NOE 明显<|>RELATION_B 减慢<|>RELATION_E 。<|>RELATION_NOE
构建<|>RELATION_NOE 的<|>RELATION_NOE 分子<|>RELATION_NOE 网络<|>RELATION_NOE 中<|>RELATION_NOE 含有<|>RELATION_NOE 26<|>RELATION_NOE 个<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 参与<|>RELATION_NOE 了<|>RELATION_NOE 多<|>RELATION_NOE 个<|>RELATION_NOE 细胞<|>RELATION_NOE 活动<|>RELATION_NOE (<|>RELATION_NOE 细胞周期<|>RELATION_NOE 调控<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 分化<|>RELATION_NOE 、<|>RELATION_NOE 凋亡<|>RELATION_NOE 等<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_NOE 激酶<|>RELATION_NOE ——<|>RELATION_NOE 酪蛋白激酶<|>RELATION_NOE Ⅱ<|>RELATION_NOE 0t<|>RELATION_NOE 亚基<|>RELATION_NOE (<|>RELATION_NOE casein<|>RELATION_NOE kinase<|>RELATION_NOE II<|>RELATION_NOE subunit<|>RELATION_NOE alpha<|>RELATION_NOE ,<|>RELATION_NOE CSNK2A1<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 表达<|>RELATION_NOE 升高<|>RELATION_NOE 最<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 蛋白质<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 调节<|>RELATION_NOE 机制<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 转录<|>RELATION_NOE 调节<|>RELATION_NOE 因子<|>RELATION_NOE MENl<|>RELATION_NOE (<|>RELATION_NOE Menin<|>RELATION_NOE )<|>RELATION_NOE 则<|>RELATION_NOE 是<|>RELATION_NOE 表达<|>RELATION_NOE 降低<|>RELATION_B 幅度<|>RELATION_I 最<|>RELATION_I 大<|>RELATION_E 的<|>RELATION_NOE 蛋白质<|>RELATION_NOE 。<|>RELATION_NOE
14.3-3sigma<|>RELATION_NOE 可以<|>RELATION_NOE 抑制<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE PG<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 速度<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 细胞周期<|>RELATION_NOE 、<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 修复<|>RELATION_NOE 等<|>RELATION_NOE 机制<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 蛋白质<|>RELATION_NOE 发生<|>RELATION_NOE 了<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 构成<|>RELATION_NOE 了<|>RELATION_NOE 相互作用<|>RELATION_NOE 的<|>RELATION_NOE 分子<|>RELATION_NOE 网络<|>RELATION_NOE 。<|>RELATION_NOE
芦荟胶<|>RELATION_NOE 治疗<|>RELATION_S 小<|>RELATION_NOE 分子<|>RELATION_NOE 靶向<|>RELATION_NOE 药物<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 药疹<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_NOE 芦荟<|>RELATION_NOE 胶外<|>RELATION_NOE 涂<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 口服<|>RELATION_NOE 小<|>RELATION_NOE 分子<|>RELATION_NOE 靶向<|>RELATION_NOE 药物<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 药疹<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 小分子<|>RELATION_NOE 靶向<|>RELATION_NOE 药物治疗<|>RELATION_NOE 致<|>RELATION_NOE 药疹<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 随机<|>RELATION_NOE 分组<|>RELATION_NOE 作<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 应用<|>RELATION_NOE 芦荟<|>RELATION_NOE 胶涂抹<|>RELATION_NOE 皮疹<|>RELATION_NOE 处<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 应用<|>RELATION_NOE 莫匹罗星<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 药疹<|>RELATION_NOE 治疗效果<|>RELATION_NOE 明显<|>RELATION_B 优于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
芦荟胶<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_B 治疗<|>RELATION_E 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 小分子<|>RELATION_NOE 靶向<|>RELATION_NOE 药物<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 药疹<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 导向<|>RELATION_NOE 下<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 治疗<|>RELATION_S 肺恶性肿瘤<|>RELATION_NOE 近期<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
18<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 肺转移瘤<|>RELATION_NOE (<|>RELATION_NOE 原<|>RELATION_NOE 发癌<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 肝癌<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 为<|>RELATION_NOE 肠癌<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 为<|>RELATION_NOE 乳腺癌<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 内膜<|>RELATION_NOE 结核<|>RELATION_NOE 漏诊<|>RELATION_NOE 误诊<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 分析<|>RELATION_S
56<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 慢性<|>RELATION_NOE 支气管炎<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 支气管哮喘<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 漏诊<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 后<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 联合<|>RELATION_B 检测<|>RELATION_E 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE
探讨<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 选出<|>RELATION_NOE 敏感性<|>RELATION_NOE 最高<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 组合<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 检测<|>RELATION_S 62<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NES<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 糖链<|>RELATION_NOE 抗原<|>RELATION_NOE 125<|>RELATION_NOE (<|>RELATION_NOE CA125<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 及<|>RELATION_NOE NES<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
4<|>RELATION_NOE 种<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 对于<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21.1<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 联合<|>RELATION_B 检测<|>RELATION_I 肺癌<|>RELATION_E 的<|>RELATION_NOE 首选<|>RELATION_NOE 标志物<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非鳞非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE 比较<|>RELATION_NOE
比较<|>RELATION_NOE 2组<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE
治疗<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞组<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛组<|>RELATION_NOE [<|>RELATION_NOE 32.1%<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE /<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 17.8%<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 90<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 46<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞组<|>RELATION_NOE 与<|>RELATION_NOE 治疗<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞组<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛组<|>RELATION_NOE [<|>RELATION_NOE 32.1%<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE /<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 17.8%<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 90<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 46<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞组<|>RELATION_NOE 与<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛组<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E [<|>RELATION_NOE 73.2%<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 77.8%<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 90<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.5<|>RELATION_NOE 30<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
2组<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 血小板减少<|>RELATION_NOE 、<|>RELATION_NOE 贫血<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 周围神经<|>RELATION_NOE 毒性<|>RELATION_NOE 、<|>RELATION_NOE 脱发<|>RELATION_NOE 等<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞组<|>RELATION_NOE Ⅲ<|>RELATION_NOE －<|>RELATION_NOE Ⅳ<|>RELATION_NOE 级<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 脱发<|>RELATION_NOE 和<|>RELATION_NOE Ⅰ<|>RELATION_NOE －<|>RELATION_NOE Ⅱ<|>RELATION_NOE 级<|>RELATION_NOE 周围神经<|>RELATION_NOE 毒性<|>RELATION_NOE 发生率<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛组<|>RELATION_NOE [<|>RELATION_NOE 7.1%<|>RELATION_NOE (<|>RELATION_NOE 4/56<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 27.8%<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE /<|>RELATION_NOE 90<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE ;<|>RELATION_NOE
观察<|>RELATION_NOE 肺康<|>RELATION_NOE 饮<|>RELATION_NOE 结合<|>RELATION_NOE 化疗<|>RELATION_NOE 改善<|>RELATION_S 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 机体<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 84<|>RELATION_NOE 例<|>RELATION_NOE 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
肺康<|>RELATION_NOE 饮<|>RELATION_NOE 结合<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_B 中晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E ,<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 机体<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 疗效<|>RELATION_NOE 肯定<|>RELATION_NOE 、<|>RELATION_NOE 安全性<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 综合治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 合并症<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
研究<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE (<|>RELATION_NOE COPD<|>RELATION_NOE )<|>RELATION_NOE 合并症<|>RELATION_NOE 的<|>RELATION_NOE 患病<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
依据<|>RELATION_NOE 20<|>RELATION_NOE 11<|>RELATION_NOE 版<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 处理<|>RELATION_NOE 和<|>RELATION_NOE 预防<|>RELATION_NOE 全球<|>RELATION_NOE 策略<|>RELATION_NOE 提出<|>RELATION_NOE 对<|>RELATION_NOE COPD<|>RELATION_NOE 合并症<|>RELATION_NOE 进行<|>RELATION_NOE 综合<|>RELATION_NOE 评估<|>RELATION_NOE 的<|>RELATION_NOE 指导<|>RELATION_NOE 思想<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 5月<|>RELATION_NOE 间<|>RELATION_NOE 在<|>RELATION_NOE 北京<|>RELATION_NOE 协和<|>RELATION_NOE 医院<|>RELATION_NOE 急诊<|>RELATION_NOE /<|>RELATION_NOE 住院<|>RELATION_NOE 的<|>RELATION_NOE COPD<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病案<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
49<|>RELATION_NOE 2例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 86.0%<|>RELATION_NOE 合并<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 或<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 以上<|>RELATION_NOE 的<|>RELATION_NOE 合并症<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 高血压<|>RELATION_NOE 、<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE 患病率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 49.4%<|>RELATION_NOE 、<|>RELATION_NOE 41.3%<|>RELATION_NOE ;<|>RELATION_NOE
心功能<|>RELATION_NOE 不<|>RELATION_NOE 全<|>RELATION_NOE 、<|>RELATION_NOE 冠状动脉<|>RELATION_NOE 粥样<|>RELATION_NOE 硬化性<|>RELATION_NOE 心脏病<|>RELATION_NOE 和<|>RELATION_NOE 糖尿病<|>RELATION_NOE 的<|>RELATION_NOE 患病率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 25.6%<|>RELATION_NOE 、<|>RELATION_NOE 24.2%<|>RELATION_NOE 和<|>RELATION_NOE 23.2%<|>RELATION_NOE ;<|>RELATION_NOE
房颤<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE COPD<|>RELATION_NOE 合并<|>RELATION_NOE 哮喘<|>RELATION_NOE 的<|>RELATION_NOE 患病率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 13.4%<|>RELATION_NOE 、<|>RELATION_NOE 10.0%<|>RELATION_NOE 和<|>RELATION_NOE 7.1%<|>RELATION_NOE ;<|>RELATION_NOE
代谢<|>RELATION_NOE 综合征<|>RELATION_NOE 、<|>RELATION_NOE 骨质疏松<|>RELATION_NOE 、<|>RELATION_NOE 焦虑<|>RELATION_NOE 抑郁<|>RELATION_NOE 存在<|>RELATION_NOE 明显<|>RELATION_S 的<|>RELATION_NOE 低<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
研究<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 体重<|>RELATION_NOE 、<|>RELATION_NOE 血糖<|>RELATION_NOE 浓度<|>RELATION_NOE 和<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 对^<|>RELATION_NOE 18F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 病灶<|>RELATION_NOE SUV<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
50<|>RELATION_NOE 例<|>RELATION_NOE 无<|>RELATION_NOE 糖尿病<|>RELATION_NOE 病史<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 有<|>RELATION_NOE 纵隔<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 。<|>RELATION_NOE
所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 常规^<|>RELATION_NOE 18F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE AdvantageWorkstation<|>RELATION_NOE 图像<|>RELATION_NOE 处理<|>RELATION_NOE 工作站<|>RELATION_NOE 自动<|>RELATION_NOE 提取<|>RELATION_NOE 肺癌<|>RELATION_NOE 病灶<|>RELATION_NOE SUV<|>RELATION_NOE 以及<|>RELATION_NOE 经过<|>RELATION_NOE 体重<|>RELATION_NOE 和<|>RELATION_NOE 体型<|>RELATION_NOE 校正<|>RELATION_NOE 的<|>RELATION_NOE SUV<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 原发灶<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 诊断<|>RELATION_NOE 参考标准<|>RELATION_NOE 按照<|>RELATION_S 肝脏<|>RELATION_NOE 参考<|>RELATION_NOE 本底<|>RELATION_NOE SUV<|>RELATION_NOE 或<|>RELATION_NOE 体型<|>RELATION_NOE 校正<|>RELATION_NOE SUVx1.5<|>RELATION_NOE +<|>RELATION_NOE 2×<|>RELATION_NOE 标准差<|>RELATION_NOE 。<|>RELATION_NOE
50<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血糖<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE 肝脏<|>RELATION_NOE 参考<|>RELATION_NOE 本底<|>RELATION_NOE SUV<|>RELATION_NOE 之间<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 原发灶<|>RELATION_NOE SUV<|>RELATION_NOE 呈<|>RELATION_NOE 负<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 但是<|>RELATION_NOE 与<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE SUV<|>RELATION_NOE 之间<|>RELATION_NOE 却<|>RELATION_NOE 呈<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血糖<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE 肝脏<|>RELATION_NOE 参考<|>RELATION_NOE 本底<|>RELATION_NOE SUV<|>RELATION_NOE 之间<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 原发灶<|>RELATION_NOE SUV<|>RELATION_NOE 呈<|>RELATION_NOE 负<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 但是<|>RELATION_NOE 与<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE SUV<|>RELATION_NOE 之间<|>RELATION_NOE 却<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血糖<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE 肝脏<|>RELATION_NOE 参考<|>RELATION_NOE 本底<|>RELATION_NOE SUV<|>RELATION_NOE 之间<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 原发灶<|>RELATION_NOE SUV<|>RELATION_NOE 呈<|>RELATION_NOE 负<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 但是<|>RELATION_NOE 与<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE SUV<|>RELATION_NOE 之间<|>RELATION_NOE 却<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_B 相关<|>RELATION_E 。<|>RELATION_NOE
按照<|>RELATION_NOE 参考<|>RELATION_NOE 诊断<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 50<|>RELATION_NOE 个<|>RELATION_NOE 肺癌<|>RELATION_NOE 原发灶<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 个<|>RELATION_NOE 肺癌<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 经过<|>RELATION_NOE 血糖<|>RELATION_NOE 浓度<|>RELATION_NOE 、<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 进行<|>RELATION_NOE 校正<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 校正<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 90.00%<|>RELATION_NOE 、<|>RELATION_NOE 71.4<|>RELATION_NOE 3%<|>RELATION_NOE 和<|>RELATION_NOE 100%<|>RELATION_NOE 、<|>RELATION_NOE 95.2<|>RELATION_NOE 4%<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 体重<|>RELATION_NOE 、<|>RELATION_NOE 血糖<|>RELATION_NOE 浓度<|>RELATION_NOE 和<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 准确率<|>RELATION_NOE 具有<|>RELATION_NOE 显著<|>RELATION_B 影响<|>RELATION_E 。<|>RELATION_NOE
经过<|>RELATION_NOE 血糖<|>RELATION_NOE 浓度<|>RELATION_NOE 、<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 校正<|>RELATION_NOE 后<|>RELATION_NOE 临床<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确率<|>RELATION_NOE 明显<|>RELATION_B 提高<|>RELATION_E 。<|>RELATION_NOE
影像<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE ^<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
p53<|>RELATION_NOE 和<|>RELATION_NOE p27<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 27.5%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 66.0%<|>RELATION_NOE (<|>RELATION_NOE 66<|>RELATION_NOE /<|>RELATION_NOE 100<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE p27<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 87.5%<|>RELATION_NOE (<|>RELATION_NOE 35<|>RELATION_NOE /<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE p53<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 27.5%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 66.0%<|>RELATION_NOE (<|>RELATION_NOE 66<|>RELATION_NOE /<|>RELATION_NOE 100<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE p27<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 87.5%<|>RELATION_NOE (<|>RELATION_NOE 35<|>RELATION_NOE /<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 41.0%<|>RELATION_NOE (<|>RELATION_NOE 411<|>RELATION_NOE 100<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE p53<|>RELATION_NOE 和<|>RELATION_NOE p27<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 无<|>RELATION_B 显著<|>RELATION_I 相关性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 存在<|>RELATION_NOE 显著<|>RELATION_NOE 相关性<|>RELATION_NOE (<|>RELATION_NOE .<|>RELATION_NOE
p53<|>RELATION_NOE 和<|>RELATION_NOE p27<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 异常<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_B 参与<|>RELATION_E 了<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 的<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 有<|>RELATION_NOE 可能<|>RELATION_NOE 成为<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 以及<|>RELATION_NOE 预后<|>RELATION_NOE 评估<|>RELATION_NOE 的<|>RELATION_NOE 新<|>RELATION_NOE 分子<|>RELATION_NOE 标记物<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 联合<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 在<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 预后<|>RELATION_B 评价<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 联合<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 在<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 预后<|>RELATION_B 评价<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
抽取<|>RELATION_NOE 外周<|>RELATION_NOE 静脉<|>RELATION_NOE 血<|>RELATION_NOE 检查<|>RELATION_NOE 血清<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 糖<|>RELATION_NOE 蛋白<|>RELATION_NOE 125<|>RELATION_NOE (<|>RELATION_NOE CA125<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 角质素<|>RELATION_NOE 19<|>RELATION_NOE (<|>RELATION_NOE CY211<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE 糖<|>RELATION_NOE 蛋白<|>RELATION_NOE 199<|>RELATION_NOE (<|>RELATION_NOE CA199<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE .<|>RELATION_NOE
观察<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 血清标记物<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 边缘<|>RELATION_NOE 增强<|>RELATION_NOE 密度<|>RELATION_NOE 以及<|>RELATION_NOE 两者<|>RELATION_NOE 联合<|>RELATION_NOE 检查<|>RELATION_NOE 对<|>RELATION_NOE 周围<|>RELATION_NOE 型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 年<|>RELATION_NOE 肿瘤转移率<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE CY211<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 年<|>RELATION_NOE 肿瘤转移率<|>RELATION_NOE 显著<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 63<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
血清<|>RELATION_NOE CY211<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 边缘<|>RELATION_NOE 增强<|>RELATION_NOE 密度<|>RELATION_NOE 联合<|>RELATION_NOE 检查<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_B 提高<|>RELATION_E 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 年<|>RELATION_NOE 肿瘤转移<|>RELATION_NOE 的<|>RELATION_NOE 检出率<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 平扫<|>RELATION_NOE 及<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE 联合<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE CY211<|>RELATION_NOE 有助于<|>RELATION_NOE 提高<|>RELATION_S 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤转移<|>RELATION_NOE 的<|>RELATION_NOE 检出率<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 具有<|>RELATION_NOE 预测<|>RELATION_NOE 价值<|>RELATION_NOE .<|>RELATION_NOE CT<|>RELATION_NOE 平扫<|>RELATION_NOE 及<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE 联合<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE CY211<|>RELATION_NOE 有助于<|>RELATION_NOE 提高<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤转移<|>RELATION_NOE 的<|>RELATION_NOE 检出率<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 具有<|>RELATION_NOE 预测<|>RELATION_B 价值<|>RELATION_E .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 生物<|>RELATION_NOE 标记物<|>RELATION_NOE 角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 克隆<|>RELATION_B 、<|>RELATION_I 表达<|>RELATION_I 及<|>RELATION_I 纯化<|>RELATION_E
方法<|>RELATION_NOE :<|>RELATION_NOE 从<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE HeLa<|>RELATION_NOE 细胞株<|>RELATION_NOE 中<|>RELATION_NOE 提取<|>RELATION_NOE 总<|>RELATION_NOE RNA<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE RT-PCR<|>RELATION_NOE 合成<|>RELATION_NOE eDNA<|>RELATION_NOE ,<|>RELATION_NOE 设计<|>RELATION_NOE 特异性<|>RELATION_NOE 的<|>RELATION_NOE 引物<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE PCR<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 扩增<|>RELATION_NOE 目的<|>RELATION_NOE :<|>RELATION_NOE 片段<|>RELATION_NOE ,<|>RELATION_NOE 构建<|>RELATION_NOE pET<|>RELATION_NOE .<|>RELATION_NOE
成功<|>RELATION_NOE 克隆<|>RELATION_NOE CK19<|>RELATION_NOE 基因<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 获得<|>RELATION_NOE 高<|>RELATION_NOE 纯度<|>RELATION_NOE 的<|>RELATION_NOE CK19<|>RELATION_NOE 融合<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 进一步<|>RELATION_NOE 制备<|>RELATION_NOE 体外<|>RELATION_NOE 诊断<|>RELATION_NOE 试剂<|>RELATION_NOE 打下<|>RELATION_NOE 基础<|>RELATION_NOE 。<|>RELATION_NOE
建立<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 后<|>RELATION_NOE 早期<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘<|>RELATION_NOE 临床<|>RELATION_B 风险<|>RELATION_I 模型<|>RELATION_E
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 后<|>RELATION_NOE 早期<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘发生<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 一个<|>RELATION_NOE 可以<|>RELATION_NOE 评估<|>RELATION_NOE 其<|>RELATION_NOE 风险<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 早期<|>RELATION_NOE 干预<|>RELATION_NOE 提供<|>RELATION_NOE 可能<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 429<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE 和<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 发现<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 后<|>RELATION_NOE 早期<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘发生<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 综合<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 建立<|>RELATION_NOE 临床<|>RELATION_NOE 模型<|>RELATION_NOE 。<|>RELATION_NOE
早期<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘发生率<|>RELATION_NOE 为<|>RELATION_NOE 6.5%<|>RELATION_NOE (<|>RELATION_NOE 28<|>RELATION_NOE /<|>RELATION_NOE 429<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 相关<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE :<|>RELATION_NOE 2.406<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 围术期<|>RELATION_NOE 失<|>RELATION_NOE 血量<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE :<|>RELATION_NOE 2.1<|>RELATION_NOE 71<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 合并<|>RELATION_NOE 糖尿病<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE :<|>RELATION_NOE 1.1<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
根据<|>RELATION_NOE 相对<|>RELATION_NOE 危险比<|>RELATION_NOE 建立<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 评分<|>RELATION_NOE 系统<|>RELATION_NOE ,<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE 和<|>RELATION_NOE 围术期<|>RELATION_NOE 失<|>RELATION_NOE 血量<|>RELATION_NOE ≥<|>RELATION_NOE 1000ml<|>RELATION_NOE 定义<|>RELATION_NOE 为<|>RELATION_NOE 2分<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 合并<|>RELATION_NOE 糖尿病<|>RELATION_NOE 定义<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 分<|>RELATION_NOE 。<|>RELATION_NOE
这个<|>RELATION_NOE 临床<|>RELATION_NOE 模型<|>RELATION_NOE 建立<|>RELATION_NOE 在<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_NOE 预测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 后<|>RELATION_NOE 发生<|>RELATION_NOE 早期<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘<|>RELATION_NOE 的<|>RELATION_NOE 工具<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 提早<|>RELATION_NOE 干预<|>RELATION_NOE 提供<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
急性<|>RELATION_NOE 低氧<|>RELATION_NOE 对<|>RELATION_NOE 中度<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 离体<|>RELATION_NOE 肺细<|>RELATION_NOE 小动脉<|>RELATION_NOE 收缩<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
评价<|>RELATION_NOE 急性<|>RELATION_NOE 低氧<|>RELATION_NOE 对<|>RELATION_NOE 中度<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE (<|>RELATION_NOE COPD<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 离体<|>RELATION_NOE 肺细<|>RELATION_NOE 小动脉<|>RELATION_NOE 收缩<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
择期<|>RELATION_NOE 拟行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 性别<|>RELATION_NOE 不<|>RELATION_NOE 限<|>RELATION_NOE ,<|>RELATION_NOE 心脏<|>RELATION_NOE B<|>RELATION_NOE 超<|>RELATION_NOE 提示<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 肺动脉高压<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 肺功能<|>RELATION_NOE 检查<|>RELATION_NOE 正常<|>RELATION_NOE 患者<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 中度<|>RELATION_NOE COPD<|>RELATION_NOE 患者<|>RELATION_NOE 6例<|>RELATION_NOE 。<|>RELATION_NOE
术<|>RELATION_NOE 中<|>RELATION_NOE 取<|>RELATION_NOE 距<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 5cm<|>RELATION_NOE 以外<|>RELATION_NOE 的<|>RELATION_NOE 肺组织<|>RELATION_NOE ,<|>RELATION_NOE 分离<|>RELATION_NOE 肺细<|>RELATION_NOE 小动脉<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 7<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 实验组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 6<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 急性<|>RELATION_NOE 低氧<|>RELATION_NOE 状态<|>RELATION_NOE 下<|>RELATION_NOE 采用<|>RELATION_NOE 微血管<|>RELATION_NOE 张力<|>RELATION_NOE 测定仪<|>RELATION_NOE 测定<|>RELATION_NOE 肺细<|>RELATION_NOE 小动脉<|>RELATION_NOE 的<|>RELATION_NOE 收缩<|>RELATION_NOE 幅度<|>RELATION_NOE 。<|>RELATION_NOE
实验组<|>RELATION_NOE 离体<|>RELATION_NOE 肺细<|>RELATION_NOE 小动脉<|>RELATION_NOE 的<|>RELATION_NOE 收缩<|>RELATION_NOE 幅度<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
急性<|>RELATION_NOE 低氧<|>RELATION_NOE 可<|>RELATION_NOE 进一步<|>RELATION_NOE 降低<|>RELATION_S 中度<|>RELATION_NOE COPD<|>RELATION_NOE 患者<|>RELATION_NOE 离体<|>RELATION_NOE 肺细<|>RELATION_NOE 小动脉<|>RELATION_NOE 的<|>RELATION_NOE 收缩<|>RELATION_NOE 功能<|>RELATION_NOE 。<|>RELATION_NOE
46<|>RELATION_NOE 例<|>RELATION_NOE 从事<|>RELATION_NOE 装修<|>RELATION_NOE 工作<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 电子<|>RELATION_B 支气管镜<|>RELATION_I 检查<|>RELATION_E
对<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 职业<|>RELATION_NOE 为<|>RELATION_NOE 装修工<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 装修<|>RELATION_NOE 职业<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 电子<|>RELATION_NOE 支气管镜<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 细胞<|>RELATION_NOE 学检<|>RELATION_NOE 出<|>RELATION_NOE
病理<|>RELATION_NOE 分型<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE 鳞癌<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 52.17%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 39.1<|>RELATION_NOE 3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 3例<|>RELATION_NOE (<|>RELATION_NOE 6.5<|>RELATION_NOE 2%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 装修<|>RELATION_NOE 工组<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 39.1<|>RELATION_NOE 3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 非<|>RELATION_NOE 装修工<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
46<|>RELATION_NOE 例<|>RELATION_NOE 装修工<|>RELATION_NOE 所<|>RELATION_NOE 患<|>RELATION_NOE 肺癌<|>RELATION_NOE 病变<|>RELATION_NOE 好<|>RELATION_NOE 发<|>RELATION_NOE 于<|>RELATION_NOE 双<|>RELATION_NOE 肺上叶<|>RELATION_NOE ,<|>RELATION_NOE 支气管镜<|>RELATION_NOE 下<|>RELATION_NOE 改变<|>RELATION_NOE 以<|>RELATION_NOE 管内<|>RELATION_NOE 增生型<|>RELATION_NOE 和<|>RELATION_NOE 管壁<|>RELATION_NOE 浸润型<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 是<|>RELATION_NOE 其<|>RELATION_NOE 主要<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 。<|>RELATION_NOE
国产<|>RELATION_NOE AccStar<|>RELATION_NOE 医用<|>RELATION_NOE 直线<|>RELATION_NOE 加速器<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 验证<|>RELATION_E
选取<|>RELATION_NOE 鼻咽癌<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 自愿<|>RELATION_NOE 受试<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE AccStar<|>RELATION_NOE 医用<|>RELATION_NOE 直线<|>RELATION_NOE 加速器<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 适形<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 国家<|>RELATION_NOE 临床<|>RELATION_NOE 试验<|>RELATION_NOE 标准<|>RELATION_NOE 实施<|>RELATION_S 多<|>RELATION_NOE 项目<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 依据<|>RELATION_NOE RECIST<|>RELATION_NOE 标准<|>RELATION_NOE 和<|>RELATION_NOE RTOG<|>RELATION_NOE 标准<|>RELATION_NOE 分别<|>RELATION_NOE 进行<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 急性<|>RELATION_NOE 放射<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 评价<|>RELATION_NOE ,<|>RELATION_NOE 按照<|>RELATION_NOE IEC<|>RELATION_NOE /<|>RELATION_NOE TR60977<|>RELATION_NOE 国际<|>RELATION_NOE 标准<|>RELATION_NOE 以及<|>RELATION_NOE GB<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE 19046<|>RELATION_NOE 和<|>RELATION_NOE GBZ126-2002<|>RELATION_NOE 等<|>RELATION_NOE 国家标准<|>RELATION_NOE 规定<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 该<|>RELATION_NOE 加速器<|>RELATION_NOE 的<|>RELATION_NOE 机械<|>RELATION_NOE 、<|>RELATION_NOE 电气<|>RELATION_NOE 、<|>RELATION_NOE 辐射<|>RELATION_NOE 和<|>RELATION_NOE 几何<|>RELATION_NOE 性能<|>RELATION_NOE 参数<|>RELATION_NOE 进行<|>RELATION_NOE 质量<|>RELATION_NOE 检测<|>RELATION_NOE 与<|>RELATION_NOE 校正<|>RELATION_NOE 。<|>RELATION_NOE 选取<|>RELATION_NOE 鼻咽癌<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 自愿<|>RELATION_NOE 受试<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE AccStar<|>RELATION_NOE 医用<|>RELATION_NOE 直线<|>RELATION_NOE 加速器<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 适形<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 国家<|>RELATION_NOE 临床<|>RELATION_NOE 试验<|>RELATION_NOE 标准<|>RELATION_NOE 实施<|>RELATION_NOE 多<|>RELATION_NOE 项目<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 依据<|>RELATION_NOE RECIST<|>RELATION_NOE 标准<|>RELATION_NOE 和<|>RELATION_NOE RTOG<|>RELATION_NOE 标准<|>RELATION_NOE 分别<|>RELATION_NOE 进行<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 急性<|>RELATION_NOE 放射<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 评价<|>RELATION_S ,<|>RELATION_NOE 按照<|>RELATION_NOE IEC<|>RELATION_NOE /<|>RELATION_NOE TR60977<|>RELATION_NOE 国际<|>RELATION_NOE 标准<|>RELATION_NOE 以及<|>RELATION_NOE GB<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE 19046<|>RELATION_NOE 和<|>RELATION_NOE GBZ126-2002<|>RELATION_NOE 等<|>RELATION_NOE 国家标准<|>RELATION_NOE 规定<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 该<|>RELATION_NOE 加速器<|>RELATION_NOE 的<|>RELATION_NOE 机械<|>RELATION_NOE 、<|>RELATION_NOE 电气<|>RELATION_NOE 、<|>RELATION_NOE 辐射<|>RELATION_NOE 和<|>RELATION_NOE 几何<|>RELATION_NOE 性能<|>RELATION_NOE 参数<|>RELATION_NOE 进行<|>RELATION_NOE 质量<|>RELATION_NOE 检测<|>RELATION_NOE 与<|>RELATION_NOE 校正<|>RELATION_NOE 。<|>RELATION_NOE
共<|>RELATION_NOE 入<|>RELATION_NOE 组<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 鼻咽癌<|>RELATION_NOE 患者<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 全部<|>RELATION_NOE 完成<|>RELATION_NOE 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 和<|>RELATION_NOE 辅助<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 总体<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 达到<|>RELATION_NOE 100%<|>RELATION_NOE ,<|>RELATION_NOE 放射<|>RELATION_NOE 反应<|>RELATION_NOE 均<|>RELATION_NOE 能<|>RELATION_NOE 耐受<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 为<|>RELATION_NOE 皮肤<|>RELATION_NOE 反应<|>RELATION_NOE 和<|>RELATION_NOE 口腔黏膜<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 对<|>RELATION_NOE 症<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE 改善<|>RELATION_NOE ;<|>RELATION_NOE
肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 株<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 突变<|>RELATION_NOE 对<|>RELATION_NOE 射线<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE DNA<|>RELATION_NOE 修复<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 株<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 区域<|>RELATION_NOE 突变<|>RELATION_NOE 对<|>RELATION_NOE 放射线<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE DNA<|>RELATION_NOE 双链<|>RELATION_NOE 断裂<|>RELATION_NOE 后<|>RELATION_NOE 修复<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
H1975<|>RELATION_NOE 细胞株<|>RELATION_NOE (<|>RELATION_NOE mutEGFR<|>RELATION_NOE )<|>RELATION_NOE 经<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE DNA<|>RELATION_NOE 双链<|>RELATION_NOE 断裂<|>RELATION_NOE 修复<|>RELATION_NOE 延缓<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 不<|>RELATION_NOE 进行<|>RELATION_NOE 核转运<|>RELATION_NOE ,<|>RELATION_NOE 细胞核<|>RELATION_NOE 中<|>RELATION_NOE 无<|>RELATION_NOE EGFR-DNA-PKcs<|>RELATION_NOE 复合物<|>RELATION_NOE 形成<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 不<|>RELATION_NOE 影响<|>RELATION_NOE 细胞核<|>RELATION_NOE RAD51<|>RELATION_NOE 的<|>RELATION_NOE 表达.<|>RELATION_NOE
肺结节<|>RELATION_NOE 加强<|>RELATION_NOE 观察<|>RELATION_NOE 功能<|>RELATION_NOE 对<|>RELATION_NOE 双源<|>RELATION_NOE CT<|>RELATION_NOE 低<|>RELATION_NOE 剂量<|>RELATION_NOE 扫描<|>RELATION_NOE 图像<|>RELATION_NOE 肺结节<|>RELATION_NOE 检<|>RELATION_B 出<|>RELATION_I 效能<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
CT<|>RELATION_NOE 图像<|>RELATION_NOE 由<|>RELATION_NOE 2<|>RELATION_NOE 名<|>RELATION_NOE 具有<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE 以上<|>RELATION_NOE 胸部<|>RELATION_NOE 影像<|>RELATION_NOE 诊断<|>RELATION_NOE 经验<|>RELATION_NOE 的<|>RELATION_NOE 医师<|>RELATION_NOE ,<|>RELATION_NOE 共同<|>RELATION_NOE 阅片<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 肺结节<|>RELATION_NOE 为<|>RELATION_NOE 诊断<|>RELATION_NOE 标准<|>RELATION_NOE 。<|>RELATION_NOE
由<|>RELATION_NOE 住院<|>RELATION_NOE 医师<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 采用<|>RELATION_NOE 辅助<|>RELATION_NOE NEV<|>RELATION_NOE 分析<|>RELATION_NOE 软件<|>RELATION_NOE 阅读<|>RELATION_NOE 同一组<|>RELATION_NOE CT<|>RELATION_NOE 图像<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 单独<|>RELATION_NOE NEV<|>RELATION_NOE 软件<|>RELATION_NOE 、<|>RELATION_NOE 住院<|>RELATION_NOE 医师<|>RELATION_NOE 采用<|>RELATION_NOE 辅助<|>RELATION_NOE NEV<|>RELATION_NOE 分析<|>RELATION_NOE 软件<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 采用<|>RELATION_NOE 辅助<|>RELATION_NOE 情况<|>RELATION_NOE 下<|>RELATION_NOE 发现<|>RELATION_NOE 的<|>RELATION_NOE 肺结节<|>RELATION_NOE 数量<|>RELATION_NOE 和<|>RELATION_NOE 阅读<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
同时<|>RELATION_NOE 以<|>RELATION_NOE 具有<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE 以上<|>RELATION_NOE 胸部<|>RELATION_NOE 影像<|>RELATION_NOE 诊断<|>RELATION_NOE 经验<|>RELATION_NOE 的<|>RELATION_NOE 医师<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_NOE 为<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 计算<|>RELATION_NOE 3种<|>RELATION_NOE 情况<|>RELATION_NOE 下<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 准确度<|>RELATION_NOE 。<|>RELATION_NOE
住院<|>RELATION_NOE 医师<|>RELATION_NOE 、<|>RELATION_NOE NEV<|>RELATION_NOE 、<|>RELATION_NOE 住院<|>RELATION_NOE 医师<|>RELATION_NOE 借助<|>RELATION_NOE NEV<|>RELATION_NOE 的<|>RELATION_NOE 阅读<|>RELATION_NOE 时间<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 120－<|>RELATION_NOE 444s<|>RELATION_NOE /<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 85－<|>RELATION_NOE 262s<|>RELATION_NOE /<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 13<|>RELATION_NOE 1－<|>RELATION_NOE 1512s<|>RELATION_NOE /<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 间变性<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 激酶<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 荧光<|>RELATION_NOE 原位杂交<|>RELATION_NOE 检测<|>RELATION_NOE 规范化<|>RELATION_B 流程<|>RELATION_E 探讨<|>RELATION_NOE
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 荧光<|>RELATION_NOE 原位杂交<|>RELATION_NOE (<|>RELATION_NOE FISH<|>RELATION_NOE )<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 收集<|>RELATION_NOE 中国<|>RELATION_NOE 医学<|>RELATION_NOE 科学<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 病理科<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 7月<|>RELATION_NOE 共<|>RELATION_NOE 146<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE Vysis<|>RELATION_NOE 公司<|>RELATION_NOE 的<|>RELATION_NOE ALK<|>RELATION_NOE 基因<|>RELATION_NOE 断裂<|>RELATION_NOE 探针<|>RELATION_NOE 、<|>RELATION_NOE 采用<|>RELATION_NOE FISH<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 进行<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 显微镜<|>RELATION_NOE 下<|>RELATION_NOE 根据<|>RELATION_NOE 荧光<|>RELATION_NOE 信号<|>RELATION_NOE 进行<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 146<|>RELATION_NOE 例<|>RELATION_NOE 合格<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 标本<|>RELATION_NOE 110<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 75.4%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺活检<|>RELATION_NOE 标本<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 7.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 标本<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 13.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 6例<|>RELATION_NOE (<|>RELATION_NOE 4.1%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 标准化<|>RELATION_NOE 的<|>RELATION_NOE 流程<|>RELATION_NOE 进行<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 切片<|>RELATION_NOE 、<|>RELATION_NOE 切片<|>RELATION_NOE 预处理<|>RELATION_NOE 、<|>RELATION_NOE FISH<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 是<|>RELATION_NOE 可行<|>RELATION_NOE 的<|>RELATION_NOE 。<|>RELATION_NOE
该<|>RELATION_NOE 流程<|>RELATION_NOE 适用<|>RELATION_B 于<|>RELATION_E 检测<|>RELATION_NOE 包括<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 和<|>RELATION_NOE 支气管镜<|>RELATION_NOE 活检<|>RELATION_NOE 标本<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 及<|>RELATION_NOE 其他<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 标本<|>RELATION_NOE 在内<|>RELATION_NOE 的<|>RELATION_NOE 常见<|>RELATION_NOE 标本<|>RELATION_NOE ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 。<|>RELATION_NOE
姑息性<|>RELATION_NOE 放疗<|>RELATION_NOE 对<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_S 的<|>RELATION_NOE 影响<|>RELATION_NOE
研究组<|>RELATION_NOE 患者<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 2<|>RELATION_NOE 年<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 生存<|>RELATION_NOE ,<|>RELATION_NOE 110<|>RELATION_NOE 例<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 失访<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 29.4<|>RELATION_NOE 6%<|>RELATION_NOE (<|>RELATION_NOE 38<|>RELATION_NOE /<|>RELATION_NOE 129<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 12.40%<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 129<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 7例<|>RELATION_NOE 生存<|>RELATION_NOE ,<|>RELATION_NOE 106<|>RELATION_NOE 例<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 失访<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 11.<|>RELATION_NOE 30%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 115<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 6.09<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 7/<|>RELATION_NOE 115<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 生存率<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 8.4<|>RELATION_NOE 51<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 14<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 误诊<|>RELATION_NOE 分析<|>RELATION_S
17<|>RELATION_NOE 例<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 孤立<|>RELATION_NOE 结节<|>RELATION_NOE /<|>RELATION_NOE 肿块型<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 内<|>RELATION_NOE 出现<|>RELATION_NOE 空泡<|>RELATION_NOE 征<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 出现<|>RELATION_NOE 毛刺征<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 出现<|>RELATION_NOE 充气<|>RELATION_NOE 支气管<|>RELATION_NOE 征<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 边缘<|>RELATION_NOE 出现<|>RELATION_NOE 环晕征6<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
17<|>RELATION_NOE 例<|>RELATION_NOE 肺细<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 误诊<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 误诊率<|>RELATION_NOE 为<|>RELATION_NOE 5/17<|>RELATION_NOE (<|>RELATION_NOE 29.4%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 大叶性<|>RELATION_NOE 肺炎<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 粟粒型<|>RELATION_NOE 肺结核<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺脓肿<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 多种多样<|>RELATION_NOE ,<|>RELATION_NOE 也<|>RELATION_NOE 存在<|>RELATION_NOE 一定<|>RELATION_NOE 相对<|>RELATION_NOE 特征性<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 病史<|>RELATION_NOE ,<|>RELATION_NOE 做出<|>RELATION_NOE 全面<|>RELATION_NOE 分析<|>RELATION_NOE 和<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 减少<|>RELATION_NOE 该病<|>RELATION_NOE 误诊率<|>RELATION_NOE 。<|>RELATION_NOE
单硝酸<|>RELATION_NOE 异山梨酯<|>RELATION_NOE 联合<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 单硝酸<|>RELATION_NOE 异山梨酯<|>RELATION_NOE 对<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE －<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期<|>RELATION_NOE 初<|>RELATION_B 治<|>RELATION_E 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE 增敏<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
10<|>RELATION_NOE 例<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE －<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期初<|>RELATION_NOE 治<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字表<|>RELATION_NOE 方法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 试验组<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE +<|>RELATION_NOE 单<|>RELATION_NOE 硝酸<|>RELATION_NOE 异山梨酯<|>RELATION_NOE 缓释片<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 2周期<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 实体瘤<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 标准<|>RELATION_NOE (<|>RELATION_NOE RECIST<|>RELATION_NOE )<|>RELATION_NOE 1.1<|>RELATION_NOE 评价<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 美国<|>RELATION_NOE 国立<|>RELATION_NOE 癌症<|>RELATION_NOE 研究所<|>RELATION_NOE 抗癌<|>RELATION_NOE 药物<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 评定<|>RELATION_NOE 标准<|>RELATION_NOE (<|>RELATION_NOE NCI-CTC<|>RELATION_NOE )<|>RELATION_NOE 3.0<|>RELATION_NOE 评价<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 。<|>RELATION_NOE
A<|>RELATION_NOE 组<|>RELATION_NOE 头痛<|>RELATION_NOE 发生率<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E B<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 毒性<|>RELATION_NOE 及<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 头痛<|>RELATION_NOE 发生率<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 毒性<|>RELATION_NOE 及<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 综合征<|>RELATION_NOE 的<|>RELATION_NOE 介入<|>RELATION_B 治疗<|>RELATION_E
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 综合征<|>RELATION_NOE 实行<|>RELATION_NOE 介入<|>RELATION_B 治疗<|>RELATION_E 的<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 52<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 综合征<|>RELATION_NOE (<|>RELATION_NOE SVCS<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 血管<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 成形<|>RELATION_NOE 及<|>RELATION_NOE 支架<|>RELATION_NOE 置人术<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 测量<|>RELATION_NOE 血管<|>RELATION_NOE 梗阻<|>RELATION_NOE 远端<|>RELATION_NOE 静脉<|>RELATION_NOE 压力<|>RELATION_NOE 。<|>RELATION_NOE
血管<|>RELATION_NOE 梗阻<|>RELATION_NOE 远端<|>RELATION_NOE 静脉<|>RELATION_NOE 压力<|>RELATION_NOE 检测<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 术前<|>RELATION_NOE 血管<|>RELATION_NOE 梗阻<|>RELATION_NOE 远端<|>RELATION_NOE 静脉<|>RELATION_NOE 压力<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 28.2<|>RELATION_NOE ±<|>RELATION_NOE 1.9<|>RELATION_NOE )<|>RELATION_NOE cmH2O<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 血管<|>RELATION_NOE 梗阻<|>RELATION_NOE 远端<|>RELATION_NOE 静脉<|>RELATION_NOE 压力<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 8.7<|>RELATION_NOE ±<|>RELATION_NOE 0.5<|>RELATION_NOE )<|>RELATION_NOE cmH2O<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.00<|>RELATION_NOE 85<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血管<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 成形<|>RELATION_NOE 及<|>RELATION_NOE 支架<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 术后<|>RELATION_NOE ,<|>RELATION_NOE 完全<|>RELATION_NOE 改善<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 改善<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 无效<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 总<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 92.3%<|>RELATION_NOE 。<|>RELATION_NOE
血管<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 成形<|>RELATION_NOE 及<|>RELATION_NOE 支架<|>RELATION_NOE 置<|>RELATION_NOE 入<|>RELATION_NOE 术后<|>RELATION_NOE 出现<|>RELATION_NOE 胸痛<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 23.1%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 穿刺<|>RELATION_NOE 部位<|>RELATION_NOE 血肿<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 9.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 发热<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 3.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 大<|>RELATION_NOE 出血<|>RELATION_NOE 、<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 和<|>RELATION_NOE 支架<|>RELATION_NOE 移位<|>RELATION_NOE 进入<|>RELATION_NOE 心房<|>RELATION_NOE 等<|>RELATION_NOE 严重<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 和<|>RELATION_NOE 1年<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 74.1%<|>RELATION_NOE 和<|>RELATION_NOE 21.0%<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 和<|>RELATION_NOE 1年<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 21.7%<|>RELATION_NOE 和<|>RELATION_NOE 35.0%<|>RELATION_NOE 。<|>RELATION_NOE
血管<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 成形<|>RELATION_NOE 及<|>RELATION_NOE 支架<|>RELATION_NOE 置人术<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE SVCS<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 首选<|>RELATION_B 治疗<|>RELATION_E 。<|>RELATION_NOE
但<|>RELATION_NOE 血管<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 成形<|>RELATION_NOE 及<|>RELATION_NOE 支架<|>RELATION_NOE 置人术<|>RELATION_NOE 仅仅<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 姑息性<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_B 手段<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 支架<|>RELATION_NOE 置<|>RELATION_NOE 人<|>RELATION_NOE 后<|>RELATION_NOE 继续<|>RELATION_NOE 针对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 十分<|>RELATION_NOE 必要<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 治疗<|>RELATION_S 初<|>RELATION_NOE 治<|>RELATION_NOE 后<|>RELATION_NOE 进展<|>RELATION_NOE 或<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE 不可<|>RELATION_NOE 耐受<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE
评价<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 治疗<|>RELATION_S 初<|>RELATION_NOE 治<|>RELATION_NOE 后<|>RELATION_NOE 进展<|>RELATION_NOE 或<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE 不可<|>RELATION_NOE 耐受<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 随机<|>RELATION_NOE 、<|>RELATION_NOE 双盲<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 中心<|>RELATION_NOE 前瞻性<|>RELATION_NOE 临床<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑素<|>RELATION_NOE (<|>RELATION_NOE 联合组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 单药<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE (<|>RELATION_NOE 化疗组<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 一线<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 继续<|>RELATION_NOE 治疗<|>RELATION_NOE 嗍<|>RELATION_NOE NSCLC<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 客观<|>RELATION_NOE 缓解率<|>RELATION_NOE (<|>RELATION_NOE ORR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 受益率<|>RELATION_NOE (<|>RELATION_NOE CBR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞学<|>RELATION_NOE 标本<|>RELATION_NOE 检测<|>RELATION_S 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 和<|>RELATION_NOE K-ras<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE
探讨<|>RELATION_NOE 采用<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 细胞学<|>RELATION_NOE 标本<|>RELATION_NOE 检测<|>RELATION_S 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE K-ras<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE (<|>RELATION_NOE FOB<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细针<|>RELATION_NOE 穿刺<|>RELATION_NOE (<|>RELATION_NOE FNA<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 胸水<|>RELATION_NOE (<|>RELATION_NOE PLE<|>RELATION_NOE )<|>RELATION_NOE 细胞学<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE PCR<|>RELATION_NOE 技术<|>RELATION_NOE 扩增<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第18<|>RELATION_NOE －<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 和<|>RELATION_NOE K-ras<|>RELATION_NOE 基因<|>RELATION_NOE 第12<|>RELATION_NOE 、<|>RELATION_NOE 13<|>RELATION_NOE 号<|>RELATION_NOE 密码子<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 扩增<|>RELATION_NOE 片段<|>RELATION_NOE 进行<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 和<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
50<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 细胞学<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE DNA<|>RELATION_NOE 提取<|>RELATION_NOE 满意率<|>RELATION_NOE 为<|>RELATION_NOE 86.0%<|>RELATION_NOE (<|>RELATION_NOE 43<|>RELATION_NOE /<|>RELATION_NOE 50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 有<|>RELATION_NOE 特异性<|>RELATION_NOE PCR<|>RELATION_NOE 扩<|>RELATION_NOE 增产物<|>RELATION_NOE 可以<|>RELATION_NOE 进行<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 。<|>RELATION_NOE
42<|>RELATION_NOE 例<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 33.3%<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE /<|>RELATION_NOE 42<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第19<|>RELATION_NOE 外显子<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 16.7%<|>RELATION_NOE (<|>RELATION_NOE 7/42<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 第<|>RELATION_NOE 20<|>RELATION_NOE 外显子<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 4.8%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 42<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 第21<|>RELATION_NOE 外显子<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 11.9%<|>RELATION_NOE (<|>RELATION_NOE 5/42<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 第18<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 第19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 占<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 85.7%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 14<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
42<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 细胞学<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE K-ras<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 突变率<|>RELATION_NOE 为<|>RELATION_NOE 4.8%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 42<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 发现<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE K-ras<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 存在<|>RELATION_NOE 于<|>RELATION_NOE 同一<|>RELATION_NOE 病例<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 可行<|>RELATION_NOE ,<|>RELATION_NOE 结果<|>RELATION_NOE 可靠<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 无法<|>RELATION_NOE 获得<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 可以<|>RELATION_NOE 尝试<|>RELATION_NOE 采用<|>RELATION_NOE 细胞学<|>RELATION_NOE 标本<|>RELATION_NOE 进行<|>RELATION_NOE 检测<|>RELATION_S 。<|>RELATION_NOE
表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE AG1478<|>RELATION_NOE 通过<|>RELATION_NOE 叉头<|>RELATION_NOE 转录因子<|>RELATION_NOE O3a<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 中<|>RELATION_NOE 叉头<|>RELATION_NOE 转录因子<|>RELATION_NOE M1<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE AG1478<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 中<|>RELATION_NOE 又<|>RELATION_NOE 头<|>RELATION_NOE 转录因子<|>RELATION_NOE M1<|>RELATION_NOE (<|>RELATION_NOE FOXM1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 叉头<|>RELATION_NOE 转录因子<|>RELATION_NOE O3a<|>RELATION_NOE (<|>RELATION_NOE FOX03a<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 调控<|>RELATION_E ,<|>RELATION_NOE 以及<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE FOXM1<|>RELATION_NOE 、<|>RELATION_NOE FOX03a<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 后<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 及其<|>RELATION_NOE 对<|>RELATION_NOE AG1478<|>RELATION_NOE 药物<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE 探讨<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE AG1478<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 中<|>RELATION_NOE 又<|>RELATION_NOE 头<|>RELATION_NOE 转录因子<|>RELATION_NOE M1<|>RELATION_NOE (<|>RELATION_NOE FOXM1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 叉头<|>RELATION_NOE 转录因子<|>RELATION_NOE O3a<|>RELATION_NOE (<|>RELATION_NOE FOX03a<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 调控<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 技术<|>RELATION_NOE 下调<|>RELATION_NOE FOXM1<|>RELATION_NOE 、<|>RELATION_NOE FOX03a<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 后<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 及其<|>RELATION_NOE 对<|>RELATION_NOE AG1478<|>RELATION_NOE 药物<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
瞬时<|>RELATION_NOE 转染<|>RELATION_NOE FOXM1<|>RELATION_NOE 和<|>RELATION_NOE FOX03a<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE RT-PCR<|>RELATION_NOE 和<|>RELATION_NOE Westernblot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 转染<|>RELATION_NOE 效率<|>RELATION_NOE 和<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE CCK-8<|>RELATION_NOE 法<|>RELATION_NOE 、<|>RELATION_NOE 集落<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 和<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 分别<|>RELATION_B 检测<|>RELATION_E 细胞增殖<|>RELATION_NOE 、<|>RELATION_NOE 集落<|>RELATION_NOE 形成<|>RELATION_NOE 能力<|>RELATION_NOE 及<|>RELATION_NOE 细胞周期<|>RELATION_NOE 分布<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
转染<|>RELATION_NOE FOXM1siRNA<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE FOXM1mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 及其<|>RELATION_NOE 细胞周期<|>RELATION_NOE 蛋白<|>RELATION_NOE B1<|>RELATION_NOE (<|>RELATION_NOE eyelinB1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE c-Myc<|>RELATION_NOE 、<|>RELATION_NOE Bcl-2<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_B 下降<|>RELATION_E ,<|>RELATION_NOE p21<|>RELATION_NOE 和<|>RELATION_NOE 剪切<|>RELATION_NOE 后<|>RELATION_NOE 多<|>RELATION_NOE 腺苷二磷酸<|>RELATION_NOE 核糖<|>RELATION_NOE 聚合<|>RELATION_NOE 酶<|>RELATION_NOE (<|>RELATION_NOE cleaved-PARP<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 则<|>RELATION_NOE 明显<|>RELATION_NOE 上调<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 转染<|>RELATION_NOE FOXM1siRNA<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE FOXM1mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 及其<|>RELATION_NOE 细胞周期<|>RELATION_NOE 蛋白<|>RELATION_NOE B1<|>RELATION_NOE (<|>RELATION_NOE eyelinB1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE c-Myc<|>RELATION_NOE 、<|>RELATION_NOE Bcl-2<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE p21<|>RELATION_NOE 和<|>RELATION_NOE 剪切<|>RELATION_NOE 后<|>RELATION_NOE 多<|>RELATION_NOE 腺苷二磷酸<|>RELATION_NOE 核糖<|>RELATION_NOE 聚合<|>RELATION_NOE 酶<|>RELATION_NOE (<|>RELATION_NOE cleaved-PARP<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 则<|>RELATION_NOE 明显<|>RELATION_B 上调<|>RELATION_E (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
转染<|>RELATION_NOE FOXM1siRNA<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_B 增加<|>RELATION_E A549<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE AG1478<|>RELATION_NOE 的<|>RELATION_NOE 药物<|>RELATION_NOE 敏感性<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 癌症<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 相关<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 预期<|>RELATION_S 的<|>RELATION_NOE 调查<|>RELATION_NOE 研究<|>RELATION_NOE
以<|>RELATION_NOE 102<|>RELATION_NOE 例<|>RELATION_NOE 住院<|>RELATION_NOE 的<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 胃肠道<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 调查<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE 自制<|>RELATION_NOE 调查<|>RELATION_NOE 问卷<|>RELATION_NOE 进行<|>RELATION_NOE 调查<|>RELATION_NOE 。<|>RELATION_NOE
排<|>RELATION_NOE 在<|>RELATION_NOE 前<|>RELATION_NOE 5<|>RELATION_NOE 位<|>RELATION_NOE 的<|>RELATION_NOE 症状<|>RELATION_NOE 分别<|>RELATION_NOE 是<|>RELATION_NOE 疼痛<|>RELATION_NOE (<|>RELATION_NOE 3.58<|>RELATION_NOE ±<|>RELATION_NOE 1.76<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE (<|>RELATION_NOE 3.17<|>RELATION_NOE ±<|>RELATION_NOE 0.97<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 消瘦<|>RELATION_NOE (<|>RELATION_NOE 3.15<|>RELATION_NOE ±<|>RELATION_NOE 0.96<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 疲劳<|>RELATION_NOE (<|>RELATION_NOE 3.13<|>RELATION_NOE ±<|>RELATION_NOE 1.11<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 睡眠<|>RELATION_NOE 问题<|>RELATION_NOE (<|>RELATION_NOE 3.08<|>RELATION_NOE ±<|>RELATION_NOE 1.00<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
不同<|>RELATION_NOE 性别<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 脱发<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 的<|>RELATION_NOE 预期<|>RELATION_NOE 强度<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5.9<|>RELATION_NOE 15<|>RELATION_NOE ,<|>RELATION_NOE 8.1<|>RELATION_NOE 87<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
脱发<|>RELATION_NOE 、<|>RELATION_NOE 皮肤<|>RELATION_NOE 问题<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 、<|>RELATION_NOE 呼吸<|>RELATION_NOE 短促<|>RELATION_NOE 及<|>RELATION_NOE 注意力<|>RELATION_NOE 难以<|>RELATION_NOE 集中<|>RELATION_NOE 等<|>RELATION_NOE 不同<|>RELATION_NOE 疾病<|>RELATION_NOE 组间<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 预期<|>RELATION_NOE 强度<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 6.1<|>RELATION_NOE 96<|>RELATION_NOE ,<|>RELATION_NOE 8.3<|>RELATION_NOE 86<|>RELATION_NOE ,<|>RELATION_NOE 3.6<|>RELATION_NOE 87<|>RELATION_NOE ,<|>RELATION_NOE 7.3<|>RELATION_NOE 74<|>RELATION_NOE ,<|>RELATION_NOE 3.4<|>RELATION_NOE 10<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 抑癌<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 细胞株<|>RELATION_NOE MG63<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 肺癌<|>RELATION_NOE 抑癌<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE TSLC1l<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 细胞株<|>RELATION_NOE MG63<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
将<|>RELATION_NOE 稳定<|>RELATION_NOE 表达<|>RELATION_NOE TSLC1<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE MG63<|>RELATION_NOE 细胞株<|>RELATION_NOE M8T<|>RELATION_NOE 设<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_NOE 空<|>RELATION_NOE 载体<|>RELATION_NOE 的<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE MG63<|>RELATION_NOE 细胞株<|>RELATION_NOE M8P<|>RELATION_NOE 设<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 人<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 细胞株<|>RELATION_NOE MG63<|>RELATION_NOE 设<|>RELATION_NOE 为<|>RELATION_NOE 空白组<|>RELATION_NOE 。<|>RELATION_NOE
稳定<|>RELATION_NOE 转染<|>RELATION_NOE TSLC1<|>RELATION_NOE 的<|>RELATION_NOE 实验组<|>RELATION_NOE M8T<|>RELATION_NOE 细胞株<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 及<|>RELATION_NOE 空白<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 能力<|>RELATION_NOE 下降<|>RELATION_S ,<|>RELATION_NOE 生长<|>RELATION_NOE 速度<|>RELATION_NOE 明显<|>RELATION_NOE 受到<|>RELATION_NOE 抑制<|>RELATION_NOE ;<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE TSLC1<|>RELATION_NOE 的<|>RELATION_NOE 实验组<|>RELATION_NOE M8T<|>RELATION_NOE 细胞株<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 及<|>RELATION_NOE 空白<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 能力<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 生长<|>RELATION_NOE 速度<|>RELATION_NOE 明显<|>RELATION_B 受到<|>RELATION_I 抑制<|>RELATION_E ;<|>RELATION_NOE
M8T<|>RELATION_NOE 细胞<|>RELATION_NOE G0<|>RELATION_NOE －<|>RELATION_NOE G1<|>RELATION_NOE 期细胞数<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 63.76<|>RELATION_NOE ±<|>RELATION_NOE 2.78<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 生长<|>RELATION_NOE 周期<|>RELATION_NOE 出现<|>RELATION_NOE 了<|>RELATION_NOE G0-G0<|>RELATION_NOE 期<|>RELATION_NOE 阻滞<|>RELATION_NOE ,<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 总数<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 28.45<|>RELATION_NOE ±<|>RELATION_NOE 0.65<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 显著<|>RELATION_NOE 增加<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.1<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
TSLC1<|>RELATION_NOE 能<|>RELATION_NOE 明显<|>RELATION_B 抑制<|>RELATION_E 骨肉瘤<|>RELATION_NOE MG63<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 增殖<|>RELATION_NOE 。<|>RELATION_NOE
小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE 沉默<|>RELATION_NOE Y<|>RELATION_NOE 盒<|>RELATION_NOE 结合<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 基因<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 株<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 表达<|>RELATION_S 的<|>RELATION_NOE 影响<|>RELATION_NOE
观察<|>RELATION_NOE Y<|>RELATION_NOE 盒<|>RELATION_NOE 结合<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE YB-1<|>RELATION_NOE )<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 株<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
针对<|>RELATION_NOE YB-1mRNA<|>RELATION_NOE 设计<|>RELATION_NOE 特异性<|>RELATION_NOE siRNA<|>RELATION_NOE 及<|>RELATION_NOE ControlsiRNA<|>RELATION_NOE 序列<|>RELATION_NOE 转染<|>RELATION_NOE 至<|>RELATION_NOE A549<|>RELATION_NOE 细胞株<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 逆转录<|>RELATION_NOE -<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 空白<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE Lipofectamine2000<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE ControlsiRNA<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE YB-1siRNA<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE YB-1<|>RELATION_NOE 和<|>RELATION_NOE EGFR<|>RELATION_NOE 在<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
MTT<|>RELATION_NOE 检测<|>RELATION_NOE 转染<|>RELATION_NOE 72h<|>RELATION_NOE 后<|>RELATION_NOE YB-1<|>RELATION_NOE siRNA<|>RELATION_NOE 组<|>RELATION_NOE 吸<|>RELATION_NOE 光度值<|>RELATION_NOE 为<|>RELATION_NOE 1.34<|>RELATION_NOE ±<|>RELATION_NOE 0.11<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 转染<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE YB-1siRNA<|>RELATION_NOE 组<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
盐霉素<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 株生物学<|>RELATION_NOE 特性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
无<|>RELATION_NOE 血清<|>RELATION_NOE 培养<|>RELATION_NOE A549<|>RELATION_NOE 干细胞<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 划痕<|>RELATION_NOE 、<|>RELATION_NOE Transwell<|>RELATION_NOE 和<|>RELATION_NOE 细胞计数<|>RELATION_NOE 实验<|>RELATION_NOE ,<|>RELATION_NOE 运用<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE 侧群<|>RELATION_NOE 比例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_S 盐<|>RELATION_NOE 霉素<|>RELATION_NOE 对<|>RELATION_NOE 转录因子<|>RELATION_NOE Oct4<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织分型<|>RELATION_NOE 与<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE -<|>RELATION_NOE β<|>RELATION_NOE Ⅱ型<|>RELATION_NOE 受体<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相关性<|>RELATION_NOE 巨噬细胞计数<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
检测<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 和<|>RELATION_NOE 肺鳞状细胞癌<|>RELATION_NOE 中<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE -<|>RELATION_NOE β<|>RELATION_NOE Ⅱ型<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE TGF-<|>RELATION_NOE β<|>RELATION_NOE R<|>RELATION_NOE Ⅱ<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相关性<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE (<|>RELATION_NOE TAMs<|>RELATION_NOE )<|>RELATION_NOE 计数<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 两者<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 和<|>RELATION_NOE 肺鳞状细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S TGF-<|>RELATION_NOE β<|>RELATION_NOE R<|>RELATION_NOE Ⅱ<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE TAMs<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 和<|>RELATION_NOE 肺鳞状细胞癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE TGF-<|>RELATION_NOE β<|>RELATION_NOE R<|>RELATION_NOE Ⅱ<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE TGF-<|>RELATION_NOE β<|>RELATION_NOE R<|>RELATION_NOE Ⅱ<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE TAMs<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 间<|>RELATION_NOE 质<|>RELATION_NOE 内<|>RELATION_NOE 浸润<|>RELATION_NOE 数量<|>RELATION_NOE 明显<|>RELATION_B 增多<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
TGF-<|>RELATION_NOE β<|>RELATION_NOE R<|>RELATION_NOE Ⅱ<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 降低<|>RELATION_NOE 可<|>RELATION_NOE 促进<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 浸润<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 发生<|>RELATION_NOE 或<|>RELATION_NOE 进展<|>RELATION_NOE 影响<|>RELATION_NOE 很<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 下调<|>RELATION_NOE TGF-<|>RELATION_NOE β<|>RELATION_NOE R<|>RELATION_NOE Ⅱ<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE 诱导<|>RELATION_NOE TAMs<|>RELATION_NOE 至<|>RELATION_NOE 肿瘤<|>RELATION_NOE 间<|>RELATION_NOE 质<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 促进<|>RELATION_S 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 这种<|>RELATION_NOE 作用<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 普遍<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE 相关<|>RELATION_NOE 凋亡<|>RELATION_NOE 诱导<|>RELATION_NOE 配体<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 及<|>RELATION_NOE 单倍型<|>RELATION_NOE 研究<|>RELATION_S
探讨<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE 相关<|>RELATION_NOE 凋亡<|>RELATION_NOE 诱导<|>RELATION_NOE 配体<|>RELATION_NOE (<|>RELATION_NOE TRAIL<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 及<|>RELATION_NOE 单倍型<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 592<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 健康<|>RELATION_NOE 对照者<|>RELATION_NOE 636<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 扩增<|>RELATION_NOE TRAIL<|>RELATION_NOE 目的<|>RELATION_NOE :<|>RELATION_NOE 基因<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 直接<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 检测<|>RELATION_NOE TRAIL<|>RELATION_NOE 基因<|>RELATION_NOE 3'<|>RELATION_NOE 非编码区<|>RELATION_NOE (<|>RELATION_NOE G1525A<|>RELATION_NOE /<|>RELATION_NOE G1588A<|>RELATION_NOE /<|>RELATION_NOE C1595T<|>RELATION_NOE )<|>RELATION_NOE 3种单<|>RELATION_NOE 核苷酸多态性<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 做<|>RELATION_NOE TRAIL<|>RELATION_NOE 单倍型<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE TRAILG1525A<|>RELATION_NOE 突变<|>RELATION_NOE 等位基因<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 基因型<|>RELATION_NOE (<|>RELATION_NOE GA<|>RELATION_NOE +<|>RELATION_NOE AA<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 频率<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
NSCLC<|>RELATION_NOE 组<|>RELATION_NOE TRAILG1588A<|>RELATION_NOE 和<|>RELATION_NOE C1595T<|>RELATION_NOE 两<|>RELATION_NOE 位<|>RELATION_NOE 点突变<|>RELATION_NOE 等位基因<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE T<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 频率<|>RELATION_NOE 亦<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
进一步<|>RELATION_NOE 分层<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE Ⅰ期<|>RELATION_NOE +<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE TRAILC1595T<|>RELATION_NOE 突变<|>RELATION_NOE 等位基因<|>RELATION_NOE (<|>RELATION_NOE T<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE CT<|>RELATION_NOE +<|>RELATION_NOE TT<|>RELATION_NOE )<|>RELATION_NOE 基因型<|>RELATION_NOE 频率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 47.8<|>RELATION_NOE 9%<|>RELATION_NOE 和<|>RELATION_NOE 62.01%<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE +<|>RELATION_NOE Ⅳ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 58.80%<|>RELATION_NOE 和<|>RELATION_NOE 74.6<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E [<|>RELATION_NOE 优势<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE )<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE =<|>RELATION_NOE 1.5<|>RELATION_NOE 53<|>RELATION_NOE 和<|>RELATION_NOE 1.804<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE 可信<|>RELATION_NOE 区间<|>RELATION_NOE (<|>RELATION_NOE CI<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE 1.2<|>RELATION_NOE 34<|>RELATION_NOE －1.9<|>RELATION_NOE 55<|>RELATION_NOE 和<|>RELATION_NOE 1.2<|>RELATION_NOE 68.<|>RELATION_NOE 2.5<|>RELATION_NOE 67<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
单倍型<|>RELATION_NOE 分析<|>RELATION_NOE TRAIL<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE G1525A<|>RELATION_NOE /<|>RELATION_NOE G1588A<|>RELATION_NOE /<|>RELATION_NOE c1595T<|>RELATION_NOE )<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 位<|>RELATION_NOE 点<|>RELATION_NOE 紧密<|>RELATION_NOE 连锁<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE AAT<|>RELATION_NOE 单倍型<|>RELATION_NOE 频率<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 42.4<|>RELATION_NOE 5%<|>RELATION_NOE 比<|>RELATION_NOE 58.2<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 1.525-2.824<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 细胞周期<|>RELATION_NOE 调节<|>RELATION_NOE 蛋白<|>RELATION_NOE A1<|>RELATION_NOE 及<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 易感<|>RELATION_NOE 基因<|>RELATION_NOE 1基因<|>RELATION_NOE 甲基化<|>RELATION_NOE 研究<|>RELATION_S
探讨<|>RELATION_NOE 细胞周期<|>RELATION_NOE 调节<|>RELATION_NOE 蛋白<|>RELATION_NOE A1<|>RELATION_NOE (<|>RELATION_NOE 细胞周期<|>RELATION_NOE 素<|>RELATION_NOE A1<|>RELATION_NOE ,<|>RELATION_NOE CCNA1<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 易感<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE BRCA1<|>RELATION_NOE )<|>RELATION_NOE 甲基化<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_B 频率<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE MSP<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 50<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 实验组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 良性<|>RELATION_NOE 肺部疾病<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE CCNA1<|>RELATION_NOE 及<|>RELATION_NOE BRCA1<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 建立<|>RELATION_NOE 广西非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 谱式<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 中<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 良性<|>RELATION_NOE 肺部疾病<|>RELATION_NOE 患者<|>RELATION_NOE 这<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 基因<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 。<|>RELATION_NOE
检测<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE CCNA1<|>RELATION_NOE 及<|>RELATION_NOE BRCA1<|>RELATION_NOE 基因<|>RELATION_NOE DNA<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE 有助于<|>RELATION_NOE 诊断<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 。<|>RELATION_NOE
氧化苦<|>RELATION_NOE 参碱<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_B 及其<|>RELATION_I 机制<|>RELATION_E
Westernblot<|>RELATION_NOE 方法<|>RELATION_NOE 测定<|>RELATION_S OXY<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 外<|>RELATION_NOE 信号<|>RELATION_NOE 调节<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE ERK<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE c-Jun<|>RELATION_NOE 氨基端<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE JNK<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE p38<|>RELATION_NOE 丝<|>RELATION_NOE 裂原<|>RELATION_NOE 活化激酶<|>RELATION_NOE (<|>RELATION_NOE p38MAPK<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 磷酸化<|>RELATION_NOE ERK<|>RELATION_NOE (<|>RELATION_NOE p-ERK<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE p-JNK<|>RELATION_NOE 、<|>RELATION_NOE p-p38MAPK<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
利用<|>RELATION_NOE 新型<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠<|>RELATION_NOE 富集<|>RELATION_NOE 原理<|>RELATION_NOE 检测<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE
检测<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 中<|>RELATION_NOE 循环<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE CTCs<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 经<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 组织<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 初<|>RELATION_NOE 治<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE I<|>RELATION_NOE 期<|>RELATION_NOE 7例<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 9例<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 健康<|>RELATION_NOE 志愿者<|>RELATION_NOE 20<|>RELATION_NOE 名<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 不同<|>RELATION_NOE 数量<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE 、<|>RELATION_NOE 100<|>RELATION_NOE 、<|>RELATION_NOE 200<|>RELATION_NOE 、<|>RELATION_NOE 500<|>RELATION_NOE 、<|>RELATION_NOE 1000<|>RELATION_NOE 个<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE (<|>RELATION_NOE A549<|>RELATION_NOE )<|>RELATION_NOE 混入<|>RELATION_NOE 2ml<|>RELATION_NOE 健康<|>RELATION_NOE 成人<|>RELATION_NOE 血<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 以<|>RELATION_NOE 模拟<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 血样<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 该<|>RELATION_NOE 血样<|>RELATION_NOE 进行<|>RELATION_NOE 红细胞<|>RELATION_NOE 裂解<|>RELATION_NOE 和<|>RELATION_NOE 离心<|>RELATION_NOE ,<|>RELATION_NOE 沉淀<|>RELATION_NOE 所<|>RELATION_NOE 得<|>RELATION_NOE 细胞<|>RELATION_NOE 与<|>RELATION_NOE 经过<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 上皮细胞黏附<|>RELATION_NOE 分子<|>RELATION_NOE (<|>RELATION_NOE EpCAM<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 抗体<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 经<|>RELATION_NOE 一<|>RELATION_NOE 套<|>RELATION_NOE 自制<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 装置<|>RELATION_NOE 对<|>RELATION_NOE 细胞<|>RELATION_NOE 进行<|>RELATION_NOE 富集<|>RELATION_NOE 和<|>RELATION_NOE 分离<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 磁标记<|>RELATION_NOE 的<|>RELATION_NOE EpCAM<|>RELATION_NOE 抗体<|>RELATION_NOE 反应<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 因为<|>RELATION_NOE 磁力<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 被<|>RELATION_NOE 集中<|>RELATION_NOE 在<|>RELATION_NOE 一<|>RELATION_NOE 张<|>RELATION_NOE 玻片<|>RELATION_NOE 上<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 用<|>RELATION_NOE 经典<|>RELATION_NOE 的<|>RELATION_NOE HE<|>RELATION_NOE 染色<|>RELATION_NOE 鉴定<|>RELATION_NOE 循环<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 并<|>RELATION_NOE 计数<|>RELATION_NOE 。<|>RELATION_NOE
计算<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 回收率<|>RELATION_NOE 验证<|>RELATION_NOE 该<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 检测<|>RELATION_NOE 20<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 志愿者<|>RELATION_NOE 血标本<|>RELATION_NOE 验证<|>RELATION_NOE 该<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 。<|>RELATION_NOE
据<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 进行<|>RELATION_NOE 分组<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 卡方检验<|>RELATION_NOE 分析<|>RELATION_NOE CTCs<|>RELATION_NOE 的<|>RELATION_NOE 检出率<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 等<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 以<|>RELATION_NOE 直线<|>RELATION_NOE 相关法<|>RELATION_NOE 研究<|>RELATION_NOE 掺<|>RELATION_NOE 入<|>RELATION_NOE 细胞数<|>RELATION_NOE 与<|>RELATION_NOE 回收<|>RELATION_NOE 细胞数<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 掺人<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 回收<|>RELATION_NOE 试验<|>RELATION_NOE 的<|>RELATION_NOE 回收率<|>RELATION_NOE 在<|>RELATION_NOE 68%<|>RELATION_NOE －8<|>RELATION_NOE 2%<|>RELATION_NOE 之间<|>RELATION_NOE ,<|>RELATION_NOE 掺<|>RELATION_NOE 入<|>RELATION_NOE 细胞<|>RELATION_NOE 间<|>RELATION_NOE 回归<|>RELATION_NOE 方程<|>RELATION_NOE 为<|>RELATION_NOE Y<|>RELATION_NOE =<|>RELATION_NOE 0.6419X<|>RELATION_NOE +<|>RELATION_NOE 8.88<|>RELATION_NOE 75<|>RELATION_NOE ,<|>RELATION_NOE 回收<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 与<|>RELATION_NOE 添加<|>RELATION_NOE 细胞<|>RELATION_NOE 间<|>RELATION_NOE 数量<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_B 的<|>RELATION_I 相关性<|>RELATION_E (<|>RELATION_NOE 相关<|>RELATION_NOE 系数<|>RELATION_NOE 尺<|>RELATION_NOE 。<|>RELATION_NOE
新型<|>RELATION_NOE 免疫<|>RELATION_NOE 磁珠<|>RELATION_NOE 富集<|>RELATION_NOE 技术<|>RELATION_NOE 可以<|>RELATION_NOE 有效<|>RELATION_B 分离<|>RELATION_I 和<|>RELATION_I 鉴定<|>RELATION_E 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 循环<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE ;<|>RELATION_NOE
随着<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 分期<|>RELATION_NOE 增高<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 增大<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 发生<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 逐渐<|>RELATION_NOE 增多<|>RELATION_NOE ,<|>RELATION_NOE CTCs<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 亦<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE 早期<|>RELATION_NOE 发现<|>RELATION_NOE 肺癌<|>RELATION_NOE 隐形微<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 重新<|>RELATION_NOE 确定<|>RELATION_NOE 肺癌<|>RELATION_NOE 分期<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 仍<|>RELATION_NOE 需<|>RELATION_NOE 进一步<|>RELATION_NOE 多<|>RELATION_NOE 中心<|>RELATION_NOE 、<|>RELATION_NOE 大<|>RELATION_NOE 样本<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE 加以<|>RELATION_NOE 证实<|>RELATION_NOE 。<|>RELATION_NOE
ProGRP<|>RELATION_NOE 对<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 与<|>RELATION_I 预后<|>RELATION_I 评价<|>RELATION_E 的<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 血清<|>RELATION_NOE 胃泌素<|>RELATION_NOE 前体<|>RELATION_NOE 释放<|>RELATION_NOE 肽<|>RELATION_NOE (<|>RELATION_NOE ProGRP<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 疗效<|>RELATION_B 监测<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 评估<|>RELATION_NOE ProCRP<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE SCLC<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE 探讨<|>RELATION_NOE 血清<|>RELATION_NOE 胃泌素<|>RELATION_NOE 前体<|>RELATION_NOE 释放<|>RELATION_NOE 肽<|>RELATION_NOE (<|>RELATION_NOE ProGRP<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 疗效<|>RELATION_NOE 监测<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 评估<|>RELATION_NOE ProCRP<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE SCLC<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
用<|>RELATION_NOE ELISA<|>RELATION_NOE 检测<|>RELATION_NOE 2005年<|>RELATION_NOE 12月<|>RELATION_NOE 至<|>RELATION_NOE 2008年<|>RELATION_NOE 10月<|>RELATION_NOE 期间<|>RELATION_NOE 山西省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 呼吸<|>RELATION_NOE 与<|>RELATION_NOE 放疗科<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 完整<|>RELATION_NOE 资料<|>RELATION_NOE 的<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 413<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 418<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE 及<|>RELATION_NOE 200<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 人<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE ProGRP<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
119<|>RELATION_NOE 例<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE ProGRP<|>RELATION_NOE <<|>RELATION_NOE 1000<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 的<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 死亡<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 16<|>RELATION_NOE (<|>RELATION_NOE 4－23<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 249<|>RELATION_NOE 例<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE ProGRP<|>RELATION_NOE ><|>RELATION_NOE 1000<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 死亡<|>RELATION_NOE 159<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 12<|>RELATION_NOE (<|>RELATION_NOE 2－<|>RELATION_NOE 18<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 2组<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 矿<|>RELATION_NOE =<|>RELATION_NOE 11.04<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE :<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
液态<|>RELATION_NOE 芯片<|>RELATION_NOE 与<|>RELATION_NOE PCR-LDR<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE K-ras<|>RELATION_NOE 基因<|>RELATION_NOE 分型<|>RELATION_NOE 初探<|>RELATION_S
方法<|>RELATION_NOE :<|>RELATION_NOE 实验<|>RELATION_NOE 诊断<|>RELATION_NOE 技术<|>RELATION_NOE 研究<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 2月<|>RELATION_NOE 上海市<|>RELATION_NOE 胸科<|>RELATION_NOE 医院<|>RELATION_NOE 的<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 新鲜<|>RELATION_NOE 组织<|>RELATION_NOE 样本<|>RELATION_NOE ,<|>RELATION_NOE 提取<|>RELATION_NOE 基因组<|>RELATION_NOE DNA<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 采用<|>RELATION_NOE PCR-<|>RELATION_NOE 连接<|>RELATION_NOE 酶<|>RELATION_NOE 检测<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE LDR<|>RELATION_NOE )<|>RELATION_NOE 结合<|>RELATION_NOE 液态<|>RELATION_NOE 芯片<|>RELATION_NOE 技术<|>RELATION_NOE ,<|>RELATION_NOE 对待<|>RELATION_NOE 测样品<|>RELATION_NOE K-ras<|>RELATION_NOE 基因<|>RELATION_NOE 2号<|>RELATION_NOE 外显子<|>RELATION_NOE 上<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 13<|>RELATION_NOE 密码子<|>RELATION_NOE 上8<|>RELATION_NOE 个<|>RELATION_NOE 突变<|>RELATION_NOE 位<|>RELATION_NOE 点<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 通过<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 验证<|>RELATION_NOE
从<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 组织<|>RELATION_NOE 样本<|>RELATION_NOE 中共<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 5例<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE Gly12Val<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 为<|>RELATION_NOE Gly12Asp<|>RELATION_NOE 突变<|>RELATION_NOE 。<|>RELATION_NOE
基<|>RELATION_NOE 于<|>RELATION_NOE 液态<|>RELATION_NOE 芯片<|>RELATION_NOE 与<|>RELATION_NOE PCR-LDR<|>RELATION_NOE 技术<|>RELATION_NOE 的<|>RELATION_NOE K-ras<|>RELATION_NOE 基因<|>RELATION_NOE 分型<|>RELATION_NOE 检测<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 通量<|>RELATION_NOE 高<|>RELATION_NOE 、<|>RELATION_NOE 灵敏度<|>RELATION_NOE 高<|>RELATION_NOE 、<|>RELATION_NOE 重复性<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 个体化<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 判断<|>RELATION_NOE 的<|>RELATION_NOE K-ras<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 分析<|>RELATION_NOE 的<|>RELATION_NOE 合理<|>RELATION_B 方法<|>RELATION_E 。<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 及<|>RELATION_NOE 止吐药<|>RELATION_NOE 使用<|>RELATION_S 调查<|>RELATION_NOE 与<|>RELATION_NOE 评析<|>RELATION_NOE
对<|>RELATION_NOE 我院<|>RELATION_NOE 住院<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 及<|>RELATION_NOE 止吐<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 使用<|>RELATION_NOE 情况<|>RELATION_NOE 进行<|>RELATION_NOE 调查<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 该类<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 药物治疗<|>RELATION_NOE 监控<|>RELATION_NOE 与<|>RELATION_NOE 评析<|>RELATION_NOE 提供<|>RELATION_B 依据<|>RELATION_E 。<|>RELATION_NOE
收集<|>RELATION_NOE 住院<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 病例<|>RELATION_NOE 86<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 共<|>RELATION_NOE 203<|>RELATION_NOE 个<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 提取<|>RELATION_NOE 医嘱<|>RELATION_NOE 中<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 和<|>RELATION_NOE 止吐<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 名称<|>RELATION_NOE 、<|>RELATION_NOE 用<|>RELATION_NOE 法<|>RELATION_NOE 用<|>RELATION_NOE 量<|>RELATION_NOE 、<|>RELATION_NOE 起止<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 溶媒<|>RELATION_NOE 选择<|>RELATION_NOE ,<|>RELATION_NOE 对照<|>RELATION_NOE 指南<|>RELATION_NOE 和<|>RELATION_NOE 药品<|>RELATION_NOE 说明书<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 、<|>RELATION_NOE 止吐<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 合理性<|>RELATION_NOE 进行<|>RELATION_NOE 评价<|>RELATION_NOE 。<|>RELATION_NOE
铂类<|>RELATION_NOE 与<|>RELATION_NOE 三<|>RELATION_NOE 代<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 两<|>RELATION_NOE 药<|>RELATION_NOE 联用<|>RELATION_NOE 方案<|>RELATION_NOE 占<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 82.8%<|>RELATION_NOE (<|>RELATION_NOE 168<|>RELATION_NOE /<|>RELATION_NOE 203<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 6.4%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 203<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 使用<|>RELATION_NOE 三<|>RELATION_NOE 代<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 两<|>RELATION_NOE 药<|>RELATION_NOE 联用<|>RELATION_NOE ,<|>RELATION_NOE 10.3%<|>RELATION_NOE (<|>RELATION_NOE 21<|>RELATION_NOE /<|>RELATION_NOE 203<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 使用<|>RELATION_NOE 三<|>RELATION_NOE 代<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 单药<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
91.1%<|>RELATION_NOE (<|>RELATION_NOE 185<|>RELATION_NOE /<|>RELATION_NOE 203<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE 使用<|>RELATION_NOE 地塞米松<|>RELATION_NOE ,<|>RELATION_NOE 时间<|>RELATION_NOE 1－<|>RELATION_NOE 14d<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE (<|>RELATION_NOE 3.8<|>RELATION_NOE ±<|>RELATION_NOE 2.3<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ;<|>RELATION_NOE
84.7%<|>RELATION_NOE (<|>RELATION_NOE 172<|>RELATION_NOE /<|>RELATION_NOE 203<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE 使用<|>RELATION_NOE 质子泵<|>RELATION_NOE 抑制剂<|>RELATION_NOE 或<|>RELATION_NOE H<|>RELATION_NOE ,<|>RELATION_NOE 受体<|>RELATION_NOE 拮抗剂<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 单<|>RELATION_NOE 用<|>RELATION_NOE 质子泵<|>RELATION_NOE 抑制剂<|>RELATION_NOE 的<|>RELATION_NOE 有<|>RELATION_NOE 100<|>RELATION_NOE 个<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 单<|>RELATION_NOE 用<|>RELATION_NOE H<|>RELATION_NOE :<|>RELATION_NOE 受体<|>RELATION_NOE 拮抗剂<|>RELATION_NOE 有<|>RELATION_NOE 8<|>RELATION_NOE 个<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 使用<|>RELATION_NOE 质子泵<|>RELATION_NOE 抑制剂<|>RELATION_NOE 和<|>RELATION_NOE H<|>RELATION_NOE :<|>RELATION_NOE 受体<|>RELATION_NOE 拮抗剂<|>RELATION_NOE 的<|>RELATION_NOE 有<|>RELATION_NOE 64<|>RELATION_NOE 个<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 护理<|>RELATION_NOE 工作<|>RELATION_NOE 需求<|>RELATION_S 的<|>RELATION_NOE 调查<|>RELATION_NOE
了解<|>RELATION_NOE 肺癌<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 住院<|>RELATION_NOE 期间<|>RELATION_NOE 对<|>RELATION_NOE 护理<|>RELATION_NOE 工作<|>RELATION_NOE 的<|>RELATION_NOE 需求<|>RELATION_S 。<|>RELATION_NOE
选取<|>RELATION_NOE 216<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 问卷调查<|>RELATION_NOE 方式<|>RELATION_NOE 进行<|>RELATION_NOE 调查<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 护理<|>RELATION_NOE 需求<|>RELATION_NOE 呈现<|>RELATION_NOE 多样化<|>RELATION_NOE 趋势<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 对<|>RELATION_NOE 护士<|>RELATION_NOE 的<|>RELATION_NOE 技术<|>RELATION_NOE 操作<|>RELATION_NOE 需求<|>RELATION_NOE 为<|>RELATION_NOE 91.7%<|>RELATION_NOE 、<|>RELATION_NOE 对<|>RELATION_NOE 护士<|>RELATION_NOE 态度<|>RELATION_NOE 和<|>RELATION_NOE 责任心<|>RELATION_NOE 需求<|>RELATION_NOE 为<|>RELATION_NOE 96.7%<|>RELATION_NOE 、<|>RELATION_NOE 对<|>RELATION_NOE 出院<|>RELATION_NOE 指导<|>RELATION_NOE 需求<|>RELATION_NOE 为<|>RELATION_NOE 93.5%<|>RELATION_NOE 、<|>RELATION_NOE 病房<|>RELATION_NOE 环境<|>RELATION_NOE 的<|>RELATION_NOE 需求<|>RELATION_NOE 为<|>RELATION_NOE 89.3%<|>RELATION_NOE 、<|>RELATION_NOE 希望<|>RELATION_NOE 了解<|>RELATION_NOE 病情<|>RELATION_NOE 知识<|>RELATION_NOE 的<|>RELATION_NOE 为<|>RELATION_NOE 91.2%<|>RELATION_NOE 。<|>RELATION_NOE
右美托咪啶<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 患者<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 全身麻醉<|>RELATION_NOE 围<|>RELATION_NOE 术期<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_E
选择<|>RELATION_NOE 老年<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE (<|>RELATION_NOE 肺癌<|>RELATION_NOE 或<|>RELATION_NOE 食管癌<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 盐酸<|>RELATION_NOE 右美托咪啶组<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 诱导<|>RELATION_NOE 开始<|>RELATION_NOE 后<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 分别<|>RELATION_NOE 静脉<|>RELATION_NOE 泵注<|>RELATION_NOE 盐酸<|>RELATION_NOE 右美托咪啶<|>RELATION_NOE 0.8<|>RELATION_NOE ug<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 和<|>RELATION_NOE 等<|>RELATION_NOE 容量<|>RELATION_NOE 的<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 麻醉<|>RELATION_NOE 诱导<|>RELATION_NOE 与<|>RELATION_NOE 维持<|>RELATION_NOE 方法<|>RELATION_NOE 均<|>RELATION_NOE 相同<|>RELATION_NOE 。<|>RELATION_NOE
术中<|>RELATION_NOE 监测<|>RELATION_NOE BIS<|>RELATION_NOE (<|>RELATION_NOE 脑电<|>RELATION_NOE 双频<|>RELATION_NOE 指数<|>RELATION_NOE )<|>RELATION_NOE 以<|>RELATION_NOE 了解<|>RELATION_NOE 麻醉<|>RELATION_NOE 深度<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 并<|>RELATION_NOE 记录<|>RELATION_NOE 入室<|>RELATION_NOE 后<|>RELATION_NOE (<|>RELATION_NOE T0<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 插管<|>RELATION_NOE 即刻<|>RELATION_NOE (<|>RELATION_NOE T1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 开始<|>RELATION_NOE (<|>RELATION_NOE T2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 结束<|>RELATION_NOE (<|>RELATION_NOE T3<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 拔管<|>RELATION_NOE 即刻<|>RELATION_NOE (<|>RELATION_NOE T4<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 进入<|>RELATION_NOE 复苏室<|>RELATION_NOE (<|>RELATION_NOE T5<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 离开<|>RELATION_NOE 复苏室<|>RELATION_NOE (<|>RELATION_NOE T6<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 动脉<|>RELATION_NOE 血<|>RELATION_NOE (<|>RELATION_NOE MAP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 心率<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 脉搏<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE (<|>RELATION_NOE SpO2<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 进行<|>RELATION_NOE 苏醒期<|>RELATION_NOE 躁动<|>RELATION_NOE 评分<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 拔管<|>RELATION_NOE 后<|>RELATION_NOE 相关<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
GP<|>RELATION_NOE 和<|>RELATION_NOE TP<|>RELATION_NOE 方案<|>RELATION_NOE 一线<|>RELATION_B 治疗<|>RELATION_E 晚期<|>RELATION_NOE 肺鳞状细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 以<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 、<|>RELATION_NOE 脱发<|>RELATION_NOE 和<|>RELATION_NOE 消化道<|>RELATION_NOE 反应<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_B 可<|>RELATION_I 耐受<|>RELATION_E 。<|>RELATION_NOE
204<|>RELATION_NOE 例经病<|>RELATION_NOE 理学<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 铂类<|>RELATION_NOE 药物<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE ,<|>RELATION_NOE 抽取<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE ,<|>RELATION_NOE 提取<|>RELATION_NOE DNA<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 基质<|>RELATION_NOE 辅助<|>RELATION_NOE 激光<|>RELATION_NOE 解析<|>RELATION_NOE 电离<|>RELATION_NOE 飞行<|>RELATION_NOE 时间<|>RELATION_NOE 质谱<|>RELATION_NOE (<|>RELATION_NOE MALDI-TOF-MS<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE ERCC1<|>RELATION_NOE 第1<|>RELATION_NOE 18<|>RELATION_NOE 位<|>RELATION_NOE 密码子<|>RELATION_NOE [<|>RELATION_NOE ERCC1<|>RELATION_NOE (<|>RELATION_NOE 118<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 的<|>RELATION_NOE 基因型<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 随机<|>RELATION_NOE 抽取<|>RELATION_NOE 5%<|>RELATION_NOE 的<|>RELATION_NOE 样本<|>RELATION_NOE 进行<|>RELATION_NOE 基因<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 来<|>RELATION_NOE 验证<|>RELATION_NOE 该<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE
ERCC1<|>RELATION_NOE (<|>RELATION_NOE 118<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 铂类<|>RELATION_NOE 药物<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 生存期<|>RELATION_NOE 有<|>RELATION_B 相关性<|>RELATION_E ,<|>RELATION_NOE 有<|>RELATION_NOE 可能<|>RELATION_NOE 成为<|>RELATION_NOE 铂类<|>RELATION_NOE 药物<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 生存期<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE ERCC1<|>RELATION_NOE (<|>RELATION_NOE 118<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 铂类<|>RELATION_NOE 药物<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 生存期<|>RELATION_NOE 有<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 可能<|>RELATION_NOE 成为<|>RELATION_NOE 铂类<|>RELATION_NOE 药物<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 生存期<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_B 指标<|>RELATION_E 。<|>RELATION_NOE
2000<|>RELATION_NOE －<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE 肥城市<|>RELATION_NOE 农村<|>RELATION_NOE 居民<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡<|>RELATION_NOE 及<|>RELATION_NOE 减寿<|>RELATION_NOE 分析<|>RELATION_S
利用<|>RELATION_NOE 肥城市<|>RELATION_NOE 农村<|>RELATION_NOE 居民<|>RELATION_NOE 2000-2010<|>RELATION_NOE 年<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 登记<|>RELATION_NOE 报告<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 标化<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 潜在<|>RELATION_NOE 减寿<|>RELATION_NOE 年数<|>RELATION_NOE 、<|>RELATION_NOE 标化<|>RELATION_NOE 潜在<|>RELATION_NOE 减寿<|>RELATION_NOE 年数<|>RELATION_NOE 、<|>RELATION_NOE 潜在<|>RELATION_NOE 减寿率<|>RELATION_NOE 、<|>RELATION_NOE 平均<|>RELATION_NOE 潜在<|>RELATION_NOE 减寿率<|>RELATION_NOE 、<|>RELATION_NOE 平均<|>RELATION_NOE 减寿<|>RELATION_NOE 年数<|>RELATION_NOE 等<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 运用<|>RELATION_NOE Prais-Winsten<|>RELATION_NOE 一<|>RELATION_NOE 阶<|>RELATION_NOE 自<|>RELATION_NOE 回归<|>RELATION_NOE 模型<|>RELATION_NOE 对<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 死亡率<|>RELATION_NOE 的<|>RELATION_NOE 自然<|>RELATION_NOE 对数<|>RELATION_NOE 转换值<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
2000-2010<|>RELATION_NOE 年<|>RELATION_NOE 肥城市<|>RELATION_NOE 农村<|>RELATION_NOE 居民<|>RELATION_NOE 男性<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 男性<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 女性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 标化<|>RELATION_NOE 死亡率<|>RELATION_NOE 均<|>RELATION_NOE 呈<|>RELATION_B 上升<|>RELATION_I 趋势<|>RELATION_E (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 食管癌<|>RELATION_NOE
男性<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 男性<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 女性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 标化<|>RELATION_NOE 死亡率<|>RELATION_NOE 呈<|>RELATION_B 上升<|>RELATION_I 趋势<|>RELATION_E ,<|>RELATION_NOE 女性<|>RELATION_NOE 食管癌<|>RELATION_NOE 男性<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 男性<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 女性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 标化<|>RELATION_NOE 死亡率<|>RELATION_NOE 呈<|>RELATION_NOE 上升<|>RELATION_NOE 趋势<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 食管癌<|>RELATION_NOE 标化<|>RELATION_NOE 死亡率<|>RELATION_NOE 呈<|>RELATION_B 下降<|>RELATION_I 趋势<|>RELATION_E 。<|>RELATION_NOE
消化系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE 女性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 是<|>RELATION_NOE 肥城市<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 监测<|>RELATION_B 和<|>RELATION_I 控制<|>RELATION_I 的<|>RELATION_I 重点<|>RELATION_E 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 雌激素受体<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE 雌激素受体<|>RELATION_NOE β<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
将<|>RELATION_NOE 698<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 石蜡<|>RELATION_NOE 标本<|>RELATION_NOE 构建<|>RELATION_NOE 组织<|>RELATION_NOE 芯片<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 651<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 包括<|>RELATION_NOE 腺癌<|>RELATION_NOE 309<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 342<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_S ERa<|>RELATION_NOE 和<|>RELATION_NOE ER<|>RELATION_NOE β<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE ER<|>RELATION_NOE β<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
ER<|>RELATION_NOE α<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 和<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 和<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
ER<|>RELATION_NOE β<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 和<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE ER<|>RELATION_NOE β<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 和<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE ER<|>RELATION_NOE β<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 均<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 且<|>RELATION_NOE 女性<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ER<|>RELATION_NOE β<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 高于<|>RELATION_NOE 男性<|>RELATION_NOE 。<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE ER<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE ER<|>RELATION_NOE β<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 均<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 女性<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ER<|>RELATION_NOE β<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 高于<|>RELATION_S 男性<|>RELATION_NOE 。<|>RELATION_NOE
乳腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 可疑<|>RELATION_NOE 复发<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 再<|>RELATION_B 活检<|>RELATION_I 的<|>RELATION_I 价值<|>RELATION_E
2009年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 7月<|>RELATION_NOE 上海<|>RELATION_NOE 交通<|>RELATION_NOE 大学<|>RELATION_NOE 医学院<|>RELATION_NOE 附属<|>RELATION_NOE 瑞金<|>RELATION_NOE 医院<|>RELATION_NOE 乳腺疾病<|>RELATION_NOE 诊治<|>RELATION_NOE 中心<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 临床<|>RELATION_NOE 可疑<|>RELATION_NOE 复发<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 我<|>RELATION_NOE 中心<|>RELATION_NOE 多<|>RELATION_NOE 学科<|>RELATION_NOE 讨论<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 接受<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 再次<|>RELATION_NOE 活检<|>RELATION_NOE ,<|>RELATION_NOE 明确<|>RELATION_NOE 其<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE ER<|>RELATION_NOE 、<|>RELATION_NOE PR<|>RELATION_NOE 、<|>RELATION_NOE HER-2<|>RELATION_NOE 状态<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE ,<|>RELATION_NOE 明确<|>RELATION_NOE 为<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 复发<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 与<|>RELATION_NOE 原发灶<|>RELATION_NOE 的<|>RELATION_NOE ER<|>RELATION_NOE 、<|>RELATION_NOE PR<|>RELATION_NOE 、<|>RELATION_NOE HER-2<|>RELATION_NOE 不<|>RELATION_NOE 一致率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 22.6%<|>RELATION_NOE 、<|>RELATION_NOE 25.8%<|>RELATION_NOE 和<|>RELATION_NOE 9.7%<|>RELATION_NOE ;<|>RELATION_NOE
明确<|>RELATION_NOE 非<|>RELATION_NOE 乳腺<|>RELATION_NOE 第2<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 5例<|>RELATION_NOE 和<|>RELATION_NOE 原发性<|>RELATION_NOE 胰腺癌<|>RELATION_NOE 2例<|>RELATION_NOE ;<|>RELATION_NOE
Fascin<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 诊断<|>RELATION_NOE 意义<|>RELATION_NOE
初步<|>RELATION_NOE 评价<|>RELATION_NOE Fascin<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_S 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 双<|>RELATION_NOE 抗体<|>RELATION_NOE 夹心<|>RELATION_NOE ELISA<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 内蒙古<|>RELATION_NOE 医学院<|>RELATION_NOE 第一<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 胸外科<|>RELATION_NOE 及<|>RELATION_NOE 北京<|>RELATION_NOE 胸科<|>RELATION_NOE 医院<|>RELATION_NOE 胸外科<|>RELATION_NOE 2009年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 5月<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 110<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE Fascin<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 鳞状<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 癌抗原<|>RELATION_NOE (<|>RELATION_NOE SCC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 21-1<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE (<|>RELATION_NOE pro-GRP<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE 。<|>RELATION_NOE
Fascin<|>RELATION_NOE 可能<|>RELATION_NOE 作为<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_B 筛查<|>RELATION_I 及<|>RELATION_I 预后<|>RELATION_E 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE .<|>RELATION_NOE
探讨<|>RELATION_NOE 直径<|>RELATION_NOE 2cm<|>RELATION_NOE 以下<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 的<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 收集<|>RELATION_NOE 2004年<|>RELATION_NOE 4月<|>RELATION_NOE 至<|>RELATION_NOE 2007年<|>RELATION_NOE 3月<|>RELATION_NOE 郑州<|>RELATION_NOE 大学<|>RELATION_NOE 第一<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 192<|>RELATION_NOE 例经<|>RELATION_NOE 高<|>RELATION_NOE 分辨<|>RELATION_NOE CT<|>RELATION_NOE 确定<|>RELATION_NOE 瘤体<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 直径<|>RELATION_NOE 在<|>RELATION_NOE 2cm<|>RELATION_NOE 以下<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌术<|>RELATION_NOE 前<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 、<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 所<|>RELATION_NOE 见<|>RELATION_NOE 和<|>RELATION_NOE 快速<|>RELATION_NOE 病理<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 选择<|>RELATION_NOE 合理<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 和<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 范围<|>RELATION_NOE 。<|>RELATION_NOE
瘤体<|>RELATION_NOE 直径<|>RELATION_NOE 在<|>RELATION_NOE 1cm<|>RELATION_NOE 以下<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 无<|>RELATION_NOE 胸膜<|>RELATION_NOE 受侵<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 生存率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
肿瘤<|>RELATION_NOE 位于<|>RELATION_NOE 肺上叶<|>RELATION_NOE ,<|>RELATION_NOE 51.7%<|>RELATION_NOE (<|>RELATION_NOE 61<|>RELATION_NOE /<|>RELATION_NOE 118<|>RELATION_NOE )<|>RELATION_NOE 发生<|>RELATION_NOE 同<|>RELATION_NOE 侧<|>RELATION_NOE 肺门<|>RELATION_NOE 和<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 28.8%<|>RELATION_NOE (<|>RELATION_NOE 38<|>RELATION_NOE /<|>RELATION_NOE 192<|>RELATION_NOE )<|>RELATION_NOE 发生<|>RELATION_NOE 隆凸<|>RELATION_NOE 下<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ;<|>RELATION_NOE
腺癌<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 32.2%<|>RELATION_NOE 和<|>RELATION_NOE 15.4%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.00<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 发生<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 风险<|>RELATION_NOE 是<|>RELATION_NOE 鳞癌<|>RELATION_NOE 的<|>RELATION_NOE 1.97<|>RELATION_B 倍<|>RELATION_E (<|>RELATION_NOE OR<|>RELATION_NOE 值<|>RELATION_NOE 为<|>RELATION_NOE 1.97<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
直径<|>RELATION_NOE 2cm<|>RELATION_NOE 以下<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 时<|>RELATION_NOE 无论<|>RELATION_NOE 瘤体<|>RELATION_NOE 大小<|>RELATION_NOE ,<|>RELATION_NOE 只要<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心<|>RELATION_NOE 肺功能<|>RELATION_NOE 等<|>RELATION_NOE 许可<|>RELATION_NOE ,<|>RELATION_NOE 应行<|>RELATION_NOE 包括<|>RELATION_NOE 隆突<|>RELATION_NOE 下<|>RELATION_NOE 淋巴结<|>RELATION_NOE 在内<|>RELATION_NOE 的<|>RELATION_NOE 区域<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE ,<|>RELATION_NOE 精准<|>RELATION_NOE 合理<|>RELATION_NOE 的<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_B 提高<|>RELATION_E 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE .<|>RELATION_NOE
椎间<|>RELATION_NOE 孔镜<|>RELATION_NOE 下<|>RELATION_NOE 射频<|>RELATION_NOE 消融<|>RELATION_NOE 治疗<|>RELATION_S 椎旁骨<|>RELATION_NOE 转移瘤<|>RELATION_NOE 患者<|>RELATION_NOE 顽固性<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
乳腺癌<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 消化道<|>RELATION_NOE 肿瘤<|>RELATION_NOE 4<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 4例<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE PICC<|>RELATION_NOE 置管<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_S
血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 在<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
观察<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE vascular<|>RELATION_NOE endothelial<|>RELATION_NOE growth<|>RELATION_NOE factor<|>RELATION_NOE ,<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE (<|>RELATION_NOE differentiated<|>RELATION_NOE thyroid<|>RELATION_NOE carcinoma<|>RELATION_NOE ,<|>RELATION_NOE DTC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 前后<|>RELATION_NOE 及<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 血清<|>RELATION_NOE 甲状腺<|>RELATION_NOE 球<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE thyroglobulin<|>RELATION_NOE ,<|>RELATION_NOE Tg<|>RELATION_NOE )<|>RELATION_NOE 浓度<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE (<|>RELATION_NOE enzymelinked<|>RELATION_NOE immunosorbentassay<|>RELATION_NOE ,<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE OTC<|>RELATION_NOE (<|>RELATION_NOE 术后肺<|>RELATION_NOE 转移<|>RELATION_NOE 7例<|>RELATION_NOE 、<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 及<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE (<|>RELATION_NOE serumVEGF<|>RELATION_NOE ,<|>RELATION_NOE sVEGF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 血清<|>RELATION_NOE Tg<|>RELATION_NOE 及<|>RELATION_NOE TgA<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
肺转移<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE 局部<|>RELATION_NOE 复发组<|>RELATION_NOE 在<|>RELATION_NOE 复发<|>RELATION_NOE 前后<|>RELATION_NOE sVEGF<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 7.3<|>RELATION_NOE 87<|>RELATION_NOE 、<|>RELATION_NOE 12.1<|>RELATION_NOE 60<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 复发<|>RELATION_NOE 后<|>RELATION_NOE 肺转移<|>RELATION_NOE 组<|>RELATION_NOE sVEGF<|>RELATION_NOE 较<|>RELATION_NOE 局部<|>RELATION_NOE 复发<|>RELATION_NOE 组<|>RELATION_NOE 明显<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 亦<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 4.1<|>RELATION_NOE 67<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 肺转移<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE 局部<|>RELATION_NOE 复发组<|>RELATION_NOE 在<|>RELATION_NOE 复发<|>RELATION_NOE 前后<|>RELATION_NOE sVEGF<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 7.3<|>RELATION_NOE 87<|>RELATION_NOE 、<|>RELATION_NOE 12.1<|>RELATION_NOE 60<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 复发<|>RELATION_NOE 后<|>RELATION_NOE 肺转移组<|>RELATION_NOE sVEGF<|>RELATION_NOE 较<|>RELATION_NOE 局部<|>RELATION_NOE 复发组<|>RELATION_NOE 明显<|>RELATION_B 增高<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 亦<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 4.1<|>RELATION_NOE 67<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
sVEGF<|>RELATION_NOE 在<|>RELATION_NOE DTC<|>RELATION_NOE 术前<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 高<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 评估<|>RELATION_NOE DTC<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 项<|>RELATION_NOE 重要<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE sVEGF<|>RELATION_NOE 在<|>RELATION_NOE DTC<|>RELATION_NOE 术前<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 评估<|>RELATION_S DTC<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 项<|>RELATION_NOE 重要<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
某<|>RELATION_NOE 煤矿<|>RELATION_NOE 矿工<|>RELATION_NOE 健康<|>RELATION_B 检查<|>RELATION_I 结果<|>RELATION_E
血清<|>RELATION_NOE 丙氨酸<|>RELATION_NOE 转<|>RELATION_NOE 氨酶<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE 24.06%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 甘油<|>RELATION_NOE 三酯<|>RELATION_NOE 偏<|>RELATION_NOE 高<|>RELATION_NOE (<|>RELATION_NOE 20.7<|>RELATION_NOE 3%<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 高血压<|>RELATION_NOE 检出率<|>RELATION_NOE (<|>RELATION_NOE 18.8<|>RELATION_NOE 1%<|>RELATION_NOE )<|>RELATION_NOE 列<|>RELATION_NOE 前<|>RELATION_NOE 3位.<|>RELATION_NOE
新<|>RELATION_NOE 诊断<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 尘肺<|>RELATION_NOE 15<|>RELATION_NOE 人<|>RELATION_NOE ,<|>RELATION_NOE 晋期<|>RELATION_NOE 2<|>RELATION_NOE 人<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 对象<|>RELATION_NOE 12<|>RELATION_NOE 人<|>RELATION_NOE 。<|>RELATION_NOE
千伏级<|>RELATION_NOE 锥形束<|>RELATION_NOE CT<|>RELATION_NOE 勾画<|>RELATION_S 心脏<|>RELATION_NOE 可行性研究<|>RELATION_NOE
在<|>RELATION_NOE 每次<|>RELATION_NOE CBCT<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 按照<|>RELATION_NOE 统一<|>RELATION_NOE 标准<|>RELATION_NOE 进行<|>RELATION_NOE 心脏<|>RELATION_NOE 勾画<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 基于<|>RELATION_NOE 计划<|>RELATION_NOE cT<|>RELATION_NOE 和<|>RELATION_NOE CBCT<|>RELATION_NOE 心脏<|>RELATION_NOE 勾画<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 以及<|>RELATION_NOE 不同<|>RELATION_NOE 扫描<|>RELATION_NOE 时机<|>RELATION_NOE CBCT<|>RELATION_NOE 勾画<|>RELATION_NOE 心脏<|>RELATION_NOE 的<|>RELATION_NOE 重复性<|>RELATION_NOE ,<|>RELATION_NOE 测量<|>RELATION_NOE 基于<|>RELATION_NOE 计划<|>RELATION_NOE CT<|>RELATION_NOE 获得<|>RELATION_NOE 心脏<|>RELATION_NOE 各个<|>RELATION_NOE 轴<|>RELATION_NOE 向<|>RELATION_NOE 外<|>RELATION_NOE 放<|>RELATION_NOE 距离<|>RELATION_NOE 。<|>RELATION_NOE
15<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 计划<|>RELATION_NOE CT<|>RELATION_NOE 获得<|>RELATION_NOE 的<|>RELATION_NOE 心脏体<|>RELATION_NOE 积<|>RELATION_NOE 均<|>RELATION_NOE 小于<|>RELATION_S CBCT<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 平均值<|>RELATION_NOE 为<|>RELATION_NOE 588<|>RELATION_NOE 、<|>RELATION_NOE 717cm<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 不同<|>RELATION_NOE 次数<|>RELATION_NOE
伴骨<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 同期<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE 预后<|>RELATION_B 分析<|>RELATION_E
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 胸部<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE 在<|>RELATION_NOE 综合治疗<|>RELATION_B 中<|>RELATION_I 的<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
选取<|>RELATION_NOE 2003-2010<|>RELATION_NOE 年间<|>RELATION_NOE 伴骨<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 95<|>RELATION_NOE 例Ⅳ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 化疗<|>RELATION_NOE ≥<|>RELATION_NOE 2周期<|>RELATION_NOE 且<|>RELATION_NOE 同期<|>RELATION_NOE 胸部<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 前瞻性研究<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE 单纯骨<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE 合并<|>RELATION_NOE 其他<|>RELATION_NOE 脏器<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 胸部<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE 技术<|>RELATION_NOE 及<|>RELATION_NOE 剂量<|>RELATION_NOE 在<|>RELATION_NOE 综合治疗<|>RELATION_NOE 中<|>RELATION_NOE 对<|>RELATION_NOE 改善<|>RELATION_B 生存<|>RELATION_E 具有<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
混合型<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_B 特点<|>RELATION_I 及<|>RELATION_I 放疗<|>RELATION_I 价值<|>RELATION_E
广泛期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 脑预防<|>RELATION_NOE 照射<|>RELATION_NOE 及<|>RELATION_NOE 颅外<|>RELATION_NOE 病变<|>RELATION_NOE 放<|>RELATION_NOE 疗<|>RELATION_NOE 的<|>RELATION_NOE Ⅱ<|>RELATION_B 期<|>RELATION_I 临床<|>RELATION_I 研究<|>RELATION_E
急性<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 中<|>RELATION_NOE ≥<|>RELATION_NOE 2级<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 改变<|>RELATION_NOE 、<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 分别<|>RELATION_NOE 占<|>RELATION_NOE 33%<|>RELATION_NOE 、<|>RELATION_NOE 13%<|>RELATION_NOE 。<|>RELATION_NOE
甲状腺癌<|>RELATION_NOE 上<|>RELATION_NOE 纵隔<|>RELATION_NOE 和<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S
探讨<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 上<|>RELATION_NOE 纵隔<|>RELATION_NOE 和<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 特点<|>RELATION_I 及<|>RELATION_I 手术<|>RELATION_I 疗效<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2006年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 5月<|>RELATION_NOE 6例<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 伴<|>RELATION_NOE 上<|>RELATION_NOE 纵隔<|>RELATION_NOE 及<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊治<|>RELATION_NOE 经过<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 甲状腺<|>RELATION_NOE 乳头状癌<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 滤泡<|>RELATION_NOE 状癌<|>RELATION_NOE 1例<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE 甲状腺<|>RELATION_NOE 全切<|>RELATION_NOE 或<|>RELATION_NOE 残体<|>RELATION_NOE 切除术<|>RELATION_NOE +<|>RELATION_NOE 颈部<|>RELATION_NOE 、<|>RELATION_NOE 上<|>RELATION_NOE 纵隔<|>RELATION_NOE 及<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴<|>RELATION_NOE 清扫术<|>RELATION_NOE +<|>RELATION_NOE 131I<|>RELATION_NOE 治疗<|>RELATION_NOE +<|>RELATION_NOE 左旋<|>RELATION_NOE 甲状腺素<|>RELATION_NOE 抑制<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
上<|>RELATION_NOE 纵隔<|>RELATION_NOE 转移<|>RELATION_NOE 淋巴结<|>RELATION_NOE 数目<|>RELATION_NOE 2－<|>RELATION_NOE 6<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 4.3<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 伴咽<|>RELATION_NOE 后<|>RELATION_NOE 间隙<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 1/1<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 暂时性<|>RELATION_NOE 低钙血症<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 乳糜<|>RELATION_NOE 漏1<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 霍纳综合征<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 新<|>RELATION_NOE 发<|>RELATION_NOE 喉返神经<|>RELATION_NOE 麻痹<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 锁骨<|>RELATION_NOE 下动<|>RELATION_NOE 静脉<|>RELATION_NOE 或<|>RELATION_NOE 腋动<|>RELATION_NOE 静脉<|>RELATION_NOE 损伤<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 上肢<|>RELATION_NOE 水肿<|>RELATION_NOE 、<|>RELATION_NOE 感觉<|>RELATION_NOE 或<|>RELATION_NOE 运动障碍<|>RELATION_NOE 者<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 肺气肿<|>RELATION_NOE 或<|>RELATION_NOE 纵隔气肿者<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 分别<|>RELATION_NOE 随诊<|>RELATION_NOE 23<|>RELATION_NOE 、<|>RELATION_NOE 37<|>RELATION_NOE 、<|>RELATION_NOE 43<|>RELATION_NOE 、<|>RELATION_NOE 49<|>RELATION_NOE 、<|>RELATION_NOE 54<|>RELATION_NOE 及<|>RELATION_NOE 77<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 颈部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 复发<|>RELATION_NOE (<|>RELATION_NOE 同侧<|>RELATION_NOE V<|>RELATION_NOE 区<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 新<|>RELATION_NOE 发肺<|>RELATION_NOE 转移<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 肺转移者<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 较<|>RELATION_NOE 前<|>RELATION_NOE 无增大<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE 肺叶切<|>RELATION_NOE 除术<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 组术<|>RELATION_NOE 中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 吗啡<|>RELATION_NOE 用量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 显著<|>RELATION_B 小于<|>RELATION_E 传统<|>RELATION_NOE 开<|>RELATION_NOE 胸组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE 0.3<|>RELATION_NOE ±<|>RELATION_NOE 54.0<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE 7.7<|>RELATION_NOE ±<|>RELATION_NOE 62.9<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 9.3<|>RELATION_NOE ±<|>RELATION_NOE 6.9<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 18.2<|>RELATION_NOE ±<|>RELATION_NOE 8.5<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 7.3<|>RELATION_NOE ±<|>RELATION_NOE 2.4<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 10.4<|>RELATION_NOE ±<|>RELATION_NOE 3.3<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 引流<|>RELATION_NOE 总量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 胸管<|>RELATION_NOE 留置<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 数目<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨化疗<|>RELATION_NOE 疗效<|>RELATION_B 及<|>RELATION_I 毒性<|>RELATION_I 相关<|>RELATION_I 基因<|>RELATION_I 多态性<|>RELATION_E 的<|>RELATION_NOE 研究<|>RELATION_NOE
对<|>RELATION_NOE 切除<|>RELATION_NOE 修复<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 组1<|>RELATION_NOE (<|>RELATION_NOE ERCCl<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨化<|>RELATION_NOE 疗<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 毒性<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 进行<|>RELATION_NOE 研究<|>RELATION_NOE 。<|>RELATION_NOE
选<|>RELATION_NOE 取经<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 抽取<|>RELATION_NOE 静脉<|>RELATION_NOE 血<|>RELATION_NOE 5m1<|>RELATION_NOE ,<|>RELATION_NOE 提取<|>RELATION_NOE 白细胞<|>RELATION_NOE DNA<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE PCR-RFLP<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE ERCCl118<|>RELATION_NOE 基因型<|>RELATION_NOE 进行<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE ERCCl118<|>RELATION_NOE 基因型<|>RELATION_NOE 与<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨化<|>RELATION_NOE 疗<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 毒性<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 进行<|>RELATION_NOE 探讨<|>RELATION_NOE 。<|>RELATION_NOE
健康<|>RELATION_NOE 体检<|>RELATION_NOE 中<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 检<|>RELATION_B 出<|>RELATION_I 情况<|>RELATION_E 分析<|>RELATION_NOE
肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发病率<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 33.6%<|>RELATION_NOE ,<|>RELATION_NOE 其次<|>RELATION_NOE 为<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 14.2%<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 问卷调查<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 社会<|>RELATION_NOE 支持<|>RELATION_NOE 量表<|>RELATION_NOE 及<|>RELATION_NOE 世界<|>RELATION_NOE 卫生<|>RELATION_NOE 组织生存<|>RELATION_NOE 质量量表<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 社会<|>RELATION_NOE 支持<|>RELATION_NOE 水平<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 现状<|>RELATION_NOE 进行<|>RELATION_NOE 调查<|>RELATION_NOE 。<|>RELATION_NOE
重症监护室<|>RELATION_NOE 成人<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 呼吸机<|>RELATION_NOE 支持<|>RELATION_B 治疗<|>RELATION_E 的<|>RELATION_NOE 护理<|>RELATION_NOE 研究<|>RELATION_NOE
通过<|>RELATION_NOE 危险因素<|>RELATION_NOE 调查<|>RELATION_NOE 探讨<|>RELATION_NOE 重症监护室<|>RELATION_NOE 成人<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 呼吸机<|>RELATION_NOE 支持<|>RELATION_B 治疗<|>RELATION_E 的<|>RELATION_NOE 护理<|>RELATION_NOE 研究<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 1月<|>RELATION_NOE 我院<|>RELATION_NOE 重症监护室<|>RELATION_NOE 收<|>RELATION_NOE 住<|>RELATION_NOE 的<|>RELATION_NOE 成人<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 临床<|>RELATION_NOE 病例<|>RELATION_NOE 资料<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 情况<|>RELATION_NOE 进行<|>RELATION_NOE 调查<|>RELATION_NOE 与<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 研究<|>RELATION_NOE 表明<|>RELATION_NOE 机械通气<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 内<|>RELATION_NOE 吸引<|>RELATION_NOE 、<|>RELATION_NOE 再<|>RELATION_NOE 插管<|>RELATION_NOE 、<|>RELATION_NOE 并发<|>RELATION_NOE 疾病<|>RELATION_NOE 与<|>RELATION_NOE 呼吸机<|>RELATION_NOE 相关性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE 机械通气<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 内<|>RELATION_NOE 吸引<|>RELATION_NOE 与<|>RELATION_NOE 并发症<|>RELATION_NOE 疾病<|>RELATION_NOE 是<|>RELATION_NOE 呼吸机<|>RELATION_NOE 相关性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 危险因素<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
发生<|>RELATION_NOE 呼吸机<|>RELATION_NOE 相关性<|>RELATION_NOE 肺炎<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE ICU<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 用机<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE APACHEII<|>RELATION_NOE 评分<|>RELATION_NOE 和<|>RELATION_NOE 死亡率<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
重症监护室<|>RELATION_NOE 成人<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 呼吸机<|>RELATION_NOE 支持<|>RELATION_NOE 治疗<|>RELATION_NOE 可<|>RELATION_NOE 导致<|>RELATION_S 呼吸机<|>RELATION_NOE 相关性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 与<|>RELATION_NOE 机械通气<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 内<|>RELATION_NOE 吸引<|>RELATION_NOE 和<|>RELATION_NOE 并发<|>RELATION_NOE 疾病<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 预后<|>RELATION_NOE 比较<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 要<|>RELATION_NOE 根据<|>RELATION_NOE 危险因素<|>RELATION_NOE 加强<|>RELATION_NOE 护理<|>RELATION_NOE 配合<|>RELATION_NOE 。<|>RELATION_NOE 重症监护室<|>RELATION_NOE 成人<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 呼吸机<|>RELATION_NOE 支持<|>RELATION_NOE 治疗<|>RELATION_NOE 可<|>RELATION_NOE 导致<|>RELATION_NOE 呼吸机<|>RELATION_NOE 相关性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 与<|>RELATION_NOE 机械通气<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 内<|>RELATION_NOE 吸引<|>RELATION_NOE 和<|>RELATION_NOE 并发<|>RELATION_NOE 疾病<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 预后<|>RELATION_NOE 比较<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 要<|>RELATION_NOE 根据<|>RELATION_NOE 危险因素<|>RELATION_NOE 加强<|>RELATION_NOE 护理<|>RELATION_NOE 配合<|>RELATION_NOE 。<|>RELATION_NOE
铬酸盐<|>RELATION_NOE 职业<|>RELATION_NOE 接触者<|>RELATION_NOE 健康<|>RELATION_NOE 监护<|>RELATION_NOE 指标<|>RELATION_NOE 的<|>RELATION_NOE 循证<|>RELATION_B 研究<|>RELATION_E
外<|>RELATION_NOE 周血<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 双核<|>RELATION_NOE 细胞<|>RELATION_NOE 微核率<|>RELATION_NOE 可<|>RELATION_NOE 反映<|>RELATION_S 铬酸盐<|>RELATION_NOE 接触<|>RELATION_NOE 的<|>RELATION_NOE 遗传<|>RELATION_NOE 损伤<|>RELATION_NOE .<|>RELATION_NOE
建议<|>RELATION_NOE 将<|>RELATION_NOE 检测<|>RELATION_NOE 血清<|>RELATION_NOE 谷丙<|>RELATION_NOE 转<|>RELATION_NOE 氨酶<|>RELATION_NOE 改<|>RELATION_B 为<|>RELATION_E 检测<|>RELATION_NOE 肝功能<|>RELATION_NOE 全<|>RELATION_NOE 项<|>RELATION_NOE ,<|>RELATION_NOE 尿铬<|>RELATION_NOE 由<|>RELATION_NOE 选检<|>RELATION_NOE 项目<|>RELATION_NOE 提升<|>RELATION_NOE 为<|>RELATION_NOE 必<|>RELATION_NOE 检<|>RELATION_NOE 项目<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 增加<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 双核<|>RELATION_NOE 细胞<|>RELATION_NOE 微核率<|>RELATION_NOE 作为<|>RELATION_NOE 选检<|>RELATION_NOE 项目<|>RELATION_NOE .<|>RELATION_NOE 建议<|>RELATION_NOE 将<|>RELATION_NOE 检测<|>RELATION_NOE 血清<|>RELATION_NOE 谷丙<|>RELATION_NOE 转<|>RELATION_NOE 氨酶<|>RELATION_NOE 改<|>RELATION_NOE 为<|>RELATION_NOE 检测<|>RELATION_NOE 肝功能<|>RELATION_NOE 全<|>RELATION_NOE 项<|>RELATION_NOE ,<|>RELATION_NOE 尿铬<|>RELATION_NOE 由<|>RELATION_NOE 选检<|>RELATION_NOE 项目<|>RELATION_NOE 提升<|>RELATION_S 为<|>RELATION_NOE 必<|>RELATION_NOE 检<|>RELATION_NOE 项目<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 增加<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 双核<|>RELATION_NOE 细胞<|>RELATION_NOE 微核率<|>RELATION_NOE 作为<|>RELATION_NOE 选检<|>RELATION_NOE 项目<|>RELATION_NOE .<|>RELATION_NOE 建议<|>RELATION_NOE 将<|>RELATION_NOE 检测<|>RELATION_NOE 血清<|>RELATION_NOE 谷丙<|>RELATION_NOE 转<|>RELATION_NOE 氨酶<|>RELATION_NOE 改<|>RELATION_NOE 为<|>RELATION_NOE 检测<|>RELATION_NOE 肝功能<|>RELATION_NOE 全<|>RELATION_NOE 项<|>RELATION_NOE ,<|>RELATION_NOE 尿铬<|>RELATION_NOE 由<|>RELATION_NOE 选检<|>RELATION_NOE 项目<|>RELATION_NOE 提升<|>RELATION_NOE 为<|>RELATION_NOE 必<|>RELATION_NOE 检<|>RELATION_NOE 项目<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 增加<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 双核<|>RELATION_NOE 细胞<|>RELATION_NOE 微核率<|>RELATION_NOE 作为<|>RELATION_S 选<|>RELATION_NOE 检<|>RELATION_NOE 项目<|>RELATION_NOE .<|>RELATION_NOE
eIF5A-2<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 上皮<|>RELATION_NOE 间<|>RELATION_NOE 质化<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_B 机制<|>RELATION_E
探讨<|>RELATION_NOE 真核细胞<|>RELATION_NOE 翻译<|>RELATION_NOE 起始<|>RELATION_NOE 因子<|>RELATION_NOE 5A-2<|>RELATION_NOE (<|>RELATION_NOE eIF5A-2<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 上皮<|>RELATION_NOE 间质化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_B 及其<|>RELATION_I 机制<|>RELATION_E 。<|>RELATION_NOE
通过<|>RELATION_NOE Westrn-blotting<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 表型<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE siRNA<|>RELATION_NOE 转染<|>RELATION_NOE 下调<|>RELATION_NOE eIF5A-2<|>RELATION_NOE 表达<|>RELATION_NOE 后<|>RELATION_NOE 再<|>RELATION_NOE 以<|>RELATION_NOE Western-blotting<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE
NCI-H358<|>RELATION_NOE 和<|>RELATION_NOE HCC827<|>RELATION_NOE 细胞系<|>RELATION_NOE 低<|>RELATION_B 表达<|>RELATION_E eIF5A-2<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 上皮<|>RELATION_NOE 表型<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE NCI-H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE NCI-H358<|>RELATION_NOE 和<|>RELATION_NOE HCC827<|>RELATION_NOE 细胞系<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE eIF5A-2<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 上皮<|>RELATION_NOE 表型<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE NCI-H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 高<|>RELATION_B 表达<|>RELATION_E eIF5A-2<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 问质<|>RELATION_NOE 表型<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 不同<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 间质<|>RELATION_NOE 表型<|>RELATION_NOE 细胞<|>RELATION_NOE 较<|>RELATION_NOE 上皮<|>RELATION_NOE 表型<|>RELATION_NOE 者<|>RELATION_NOE 高<|>RELATION_B 表达<|>RELATION_I eIF5A-2<|>RELATION_E 。<|>RELATION_NOE
TGF-<|>RELATION_NOE β1<|>RELATION_NOE 可<|>RELATION_NOE 诱导<|>RELATION_S 上皮<|>RELATION_NOE 表型<|>RELATION_NOE 细胞<|>RELATION_NOE 发生<|>RELATION_NOE EMT<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 干扰<|>RELATION_NOE eIF5A-2<|>RELATION_NOE 则<|>RELATION_NOE 可<|>RELATION_NOE 阻止<|>RELATION_NOE EMT<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 。<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE 可<|>RELATION_NOE 诱导<|>RELATION_NOE 上皮<|>RELATION_NOE 表型<|>RELATION_NOE 细胞<|>RELATION_NOE 发生<|>RELATION_NOE EMT<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 干扰<|>RELATION_NOE eIF5A-2<|>RELATION_NOE 则<|>RELATION_NOE 可<|>RELATION_NOE 阻止<|>RELATION_S EMT<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 。<|>RELATION_NOE
小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 致<|>RELATION_NOE 急性<|>RELATION_NOE 肿瘤<|>RELATION_NOE 溶解<|>RELATION_NOE 综合征<|>RELATION_NOE 的<|>RELATION_NOE 观察<|>RELATION_B 与<|>RELATION_I 护理<|>RELATION_E
探讨<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 致<|>RELATION_NOE 急性<|>RELATION_NOE 肿瘤<|>RELATION_NOE 溶解<|>RELATION_NOE 综合征<|>RELATION_NOE (<|>RELATION_NOE ATLS<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_B 观察<|>RELATION_I 和<|>RELATION_I 护理<|>RELATION_E 的<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 通过<|>RELATION_NOE 制定<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 预防<|>RELATION_NOE ATLS<|>RELATION_NOE 的<|>RELATION_NOE 观察表<|>RELATION_NOE ,<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 58<|>RELATION_NOE 例<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 行<|>RELATION_NOE 348<|>RELATION_NOE 次<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 于<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 后<|>RELATION_NOE 进行<|>RELATION_NOE 密切<|>RELATION_NOE 的<|>RELATION_NOE 病情<|>RELATION_NOE 观察<|>RELATION_NOE 和<|>RELATION_NOE 护理.<|>RELATION_NOE
小细胞肺<|>RELATION_NOE 癌化<|>RELATION_NOE 疗致<|>RELATION_NOE ATLS<|>RELATION_NOE 早期<|>RELATION_NOE 观察<|>RELATION_NOE 和<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 预防<|>RELATION_B 和<|>RELATION_I 治疗<|>RELATION_E 急性<|>RELATION_NOE 肿瘤<|>RELATION_NOE 溶解<|>RELATION_NOE 综合征<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_NOE 极其<|>RELATION_NOE 重要<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE .<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 治疗<|>RELATION_S 70<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 及<|>RELATION_NOE 危险因素<|>RELATION_NOE 研究<|>RELATION_NOE
调查<|>RELATION_NOE 研究<|>RELATION_NOE 70<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 后<|>RELATION_NOE 并发症<|>RELATION_B 发生<|>RELATION_I 及其<|>RELATION_I 影响<|>RELATION_I 因素<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 预测<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 指导<|>RELATION_NOE 围术期<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 手术<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
分析<|>RELATION_NOE 2009年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 3月<|>RELATION_NOE 接受<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 70<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 380<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 进行<|>RELATION_NOE 单因素<|>RELATION_NOE 及<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 发现<|>RELATION_NOE :<|>RELATION_NOE 年龄<|>RELATION_NOE ><|>RELATION_NOE 75<|>RELATION_NOE 岁<|>RELATION_NOE 是<|>RELATION_NOE 70<|>RELATION_NOE 岁<|>RELATION_NOE 以上<|>RELATION_NOE 肺癌<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 危险因素<|>RELATION_E [<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE ,<|>RELATION_NOE 比值比<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE )<|>RELATION_NOE =<|>RELATION_NOE 2.5<|>RELATION_NOE 25<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
机器人<|>RELATION_NOE 辅助<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 复杂<|>RELATION_NOE 肾上腺肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 达芬奇<|>RELATION_NOE 机器人<|>RELATION_NOE 辅助<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肾上腺<|>RELATION_NOE 切除术<|>RELATION_NOE (<|>RELATION_NOE RALA<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_S 不<|>RELATION_NOE 适合<|>RELATION_NOE 传统<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 复杂<|>RELATION_NOE 肾上腺肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 、<|>RELATION_NOE 安全性<|>RELATION_NOE 及<|>RELATION_NOE 疗效<|>RELATION_NOE .<|>RELATION_NOE
因<|>RELATION_NOE 病情<|>RELATION_NOE 或<|>RELATION_NOE 患者<|>RELATION_NOE 要求<|>RELATION_NOE 需<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 程度<|>RELATION_NOE 保留<|>RELATION_NOE 肿瘤<|>RELATION_NOE 旁<|>RELATION_NOE 肾上腺<|>RELATION_NOE 组织<|>RELATION_NOE 4例<|>RELATION_NOE ;<|>RELATION_NOE
肿瘤<|>RELATION_NOE 压迫<|>RELATION_NOE 腔静脉<|>RELATION_NOE 、<|>RELATION_NOE 主动脉<|>RELATION_NOE 等<|>RELATION_NOE 大<|>RELATION_NOE 血管<|>RELATION_NOE 或<|>RELATION_NOE 毗邻<|>RELATION_NOE 肝脏<|>RELATION_NOE 、<|>RELATION_NOE 肾门<|>RELATION_NOE 等<|>RELATION_NOE 脏器<|>RELATION_NOE 3例<|>RELATION_NOE ;<|>RELATION_NOE
手术<|>RELATION_NOE 均<|>RELATION_NOE 在<|>RELATION_NOE 全麻<|>RELATION_NOE 下<|>RELATION_NOE 进行<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 健侧<|>RELATION_NOE 卧位<|>RELATION_NOE 经<|>RELATION_NOE 腹腔<|>RELATION_NOE 途径<|>RELATION_NOE 结肠<|>RELATION_NOE 旁<|>RELATION_NOE 沟<|>RELATION_NOE 入<|>RELATION_NOE 路<|>RELATION_NOE ,<|>RELATION_NOE 左侧<|>RELATION_NOE 肿瘤<|>RELATION_NOE 使用<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 套管<|>RELATION_NOE (<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 达芬奇<|>RELATION_NOE 机器人<|>RELATION_NOE 专用<|>RELATION_NOE 套管<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 辅助<|>RELATION_NOE 孔<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 右侧<|>RELATION_NOE 肿瘤<|>RELATION_NOE 使用<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 套管<|>RELATION_NOE (<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 达芬奇<|>RELATION_NOE 机器人<|>RELATION_NOE 专用<|>RELATION_NOE 套管<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 辅助<|>RELATION_NOE 孔<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
术后<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 嗜铬细胞瘤<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 含<|>RELATION_NOE 1例<|>RELATION_NOE 副神经节瘤<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 大结节性<|>RELATION_NOE 增生<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 结节<|>RELATION_NOE 增生<|>RELATION_NOE 伴<|>RELATION_NOE 皮质<|>RELATION_NOE 腺瘤<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 单纯<|>RELATION_NOE 皮质<|>RELATION_NOE 腺瘤<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 髓样<|>RELATION_NOE 脂肪瘤<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 肾上腺<|>RELATION_NOE 转移<|>RELATION_NOE 肿瘤<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 复杂性<|>RELATION_NOE 肾上腺<|>RELATION_NOE 囊肿<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 支气管<|>RELATION_NOE 源性<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 钙化<|>RELATION_NOE 囊肿<|>RELATION_NOE 1例.<|>RELATION_NOE
对于<|>RELATION_NOE 传统<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 困难<|>RELATION_NOE 的<|>RELATION_NOE 复杂<|>RELATION_NOE 肾上腺肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 考虑<|>RELATION_B 选择<|>RELATION_E 机器人<|>RELATION_NOE 辅助<|>RELATION_NOE 腹腔镜<|>RELATION_NOE 手术<|>RELATION_NOE .<|>RELATION_NOE
血液<|>RELATION_NOE 中<|>RELATION_NOE 游离<|>RELATION_NOE DNA<|>RELATION_NOE 浓度<|>RELATION_NOE 和<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 相关性<|>RELATION_S 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 血液<|>RELATION_NOE 中<|>RELATION_NOE 游离<|>RELATION_NOE DNA<|>RELATION_NOE 浓度<|>RELATION_NOE 和<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_NOE 等<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 实验组<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 初诊<|>RELATION_NOE 时<|>RELATION_NOE 抽取<|>RELATION_NOE 患者<|>RELATION_NOE 10ml<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 针对<|>RELATION_NOE 人<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 球<|>RELATION_NOE 蛋白<|>RELATION_NOE 基因<|>RELATION_NOE 来<|>RELATION_NOE 计算<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE DNA<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 为期<|>RELATION_NOE 6<|>RELATION_NOE 年<|>RELATION_NOE 的<|>RELATION_NOE 生存期<|>RELATION_NOE 跟踪<|>RELATION_NOE 调查<|>RELATION_NOE ;<|>RELATION_NOE
实验组<|>RELATION_NOE 死亡<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 87%<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 中位<|>RELATION_NOE DNA<|>RELATION_NOE 浓度<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 仍然<|>RELATION_NOE 存活<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE DNA<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE 59mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 与<|>RELATION_NOE 25mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.02<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
病理分型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 和<|>RELATION_NOE 肺部炎症<|>RELATION_NOE 情况<|>RELATION_NOE 与<|>RELATION_NOE 血液<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE DNA<|>RELATION_NOE 浓度<|>RELATION_NOE 无<|>RELATION_B 相关性<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
非小细胞性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 初始<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 血液<|>RELATION_NOE 中<|>RELATION_NOE DNA<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 和<|>RELATION_NOE 肺部炎症<|>RELATION_NOE 情况<|>RELATION_NOE 等<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 无关<|>RELATION_NOE 。<|>RELATION_NOE 非小细胞性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 初始<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 血液<|>RELATION_NOE 中<|>RELATION_NOE DNA<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 和<|>RELATION_NOE 肺部炎症<|>RELATION_NOE 情况<|>RELATION_NOE 等<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 无关<|>RELATION_S 。<|>RELATION_NOE
芪胶<|>RELATION_NOE 升白<|>RELATION_NOE 胶囊<|>RELATION_NOE 治疗<|>RELATION_S 肺恶性肿瘤<|>RELATION_NOE 化疗<|>RELATION_NOE 引起<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 症<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 芪胶<|>RELATION_NOE 升白<|>RELATION_NOE 胶囊<|>RELATION_NOE 治疗<|>RELATION_S 肺恶性肿瘤<|>RELATION_NOE 化疗<|>RELATION_NOE 引起<|>RELATION_NOE 的<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 症<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
当<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 至<|>RELATION_NOE 2.0×<|>RELATION_NOE 109/<|>RELATION_NOE L<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 联合<|>RELATION_NOE 使用<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 粒细胞<|>RELATION_NOE 集落<|>RELATION_NOE 刺激<|>RELATION_NOE 因子<|>RELATION_NOE 。<|>RELATION_NOE
转移性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 出现<|>RELATION_S 脑转移<|>RELATION_NOE 相关<|>RELATION_NOE 危险因素<|>RELATION_NOE 分析<|>RELATION_NOE
采用<|>RELATION_NOE x<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE 检验<|>RELATION_NOE 分析<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 雌激素受体<|>RELATION_NOE (<|>RELATION_NOE ER<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 孕激素<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE PR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 人<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE CerbB-2<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 与<|>RELATION_NOE 脑转移<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE COX<|>RELATION_NOE 比例<|>RELATION_NOE 风险<|>RELATION_NOE 模型<|>RELATION_NOE 进行<|>RELATION_NOE 单因素<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 得出<|>RELATION_NOE 影响<|>RELATION_NOE 脑转移<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
复发<|>RELATION_NOE 转移<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 再<|>RELATION_NOE 出现<|>RELATION_NOE 脑转移者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE ≤<|>RELATION_NOE 35<|>RELATION_NOE 岁<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 激素<|>RELATION_NOE 受体<|>RELATION_NOE 阴性<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE CerbB-2<|>RELATION_NOE (<|>RELATION_NOE 2+<|>RELATION_NOE )<|>RELATION_NOE /<|>RELATION_NOE (<|>RELATION_NOE 3+<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 更<|>RELATION_NOE 易<|>RELATION_B 出现<|>RELATION_E 脑转移<|>RELATION_NOE (<|>RELATION_NOE x<|>RELATION_NOE ^2<|>RELATION_NOE =<|>RELATION_NOE 24.92<|>RELATION_NOE ,<|>RELATION_NOE 8.28<|>RELATION_NOE ,<|>RELATION_NOE 4.02<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE 或<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
开<|>RELATION_NOE 胸术<|>RELATION_NOE 后<|>RELATION_NOE 肋间神经<|>RELATION_NOE 冷冻<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 自<|>RELATION_NOE 控<|>RELATION_NOE 静脉<|>RELATION_NOE 镇痛<|>RELATION_NOE 效果<|>RELATION_B 的<|>RELATION_I 临床<|>RELATION_I 比较<|>RELATION_E
观察<|>RELATION_NOE 肋间神经<|>RELATION_NOE 冷冻<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 自<|>RELATION_NOE 控<|>RELATION_NOE 静脉<|>RELATION_NOE 镇痛<|>RELATION_NOE (<|>RELATION_NOE PCIA<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 开<|>RELATION_B 胸术<|>RELATION_I 后<|>RELATION_I 的<|>RELATION_I 镇痛<|>RELATION_I 效果<|>RELATION_E 及其<|>RELATION_NOE 对<|>RELATION_NOE 血浆<|>RELATION_NOE 白细胞介素<|>RELATION_NOE (<|>RELATION_NOE IL<|>RELATION_NOE )<|>RELATION_NOE -6<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 反应<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE CRP<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE 观察<|>RELATION_NOE 肋间神经<|>RELATION_NOE 冷冻<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 自<|>RELATION_NOE 控<|>RELATION_NOE 静脉<|>RELATION_NOE 镇痛<|>RELATION_NOE (<|>RELATION_NOE PCIA<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 开<|>RELATION_NOE 胸术<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 镇痛<|>RELATION_NOE 效果<|>RELATION_NOE 及其<|>RELATION_NOE 对<|>RELATION_NOE 血浆<|>RELATION_NOE 白细胞介素<|>RELATION_NOE (<|>RELATION_NOE IL<|>RELATION_NOE )<|>RELATION_NOE -6<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 反应<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE CRP<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
选择<|>RELATION_NOE 行<|>RELATION_NOE 常规<|>RELATION_NOE 开胸<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 三<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE 肋间神经<|>RELATION_NOE 冷冻<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE PCIA<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE 临时<|>RELATION_NOE 肌肉<|>RELATION_NOE 注射<|>RELATION_NOE 哌替啶<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 40<|>RELATION_NOE 例.<|>RELATION_NOE
视觉<|>RELATION_NOE 模拟<|>RELATION_NOE 疼痛<|>RELATION_NOE 量表<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE VAS<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 评价<|>RELATION_NOE 疼痛<|>RELATION_NOE 程度<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 各<|>RELATION_NOE 组术<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 相应<|>RELATION_NOE 时间点<|>RELATION_NOE IL-6<|>RELATION_NOE 及<|>RELATION_NOE CRP<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 观察<|>RELATION_NOE 比较<|>RELATION_NOE 各<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE
临时<|>RELATION_NOE 肌肉<|>RELATION_NOE 注射<|>RELATION_NOE 哌替啶<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 肋间神经<|>RELATION_NOE 冷冻组<|>RELATION_NOE 和<|>RELATION_NOE PCIA<|>RELATION_NOE 组<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 22.5%<|>RELATION_NOE (<|>RELATION_NOE 9/40<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 5.0%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 12.5%<|>RELATION_NOE (<|>RELATION_NOE 5/40<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 三<|>RELATION_NOE 组<|>RELATION_NOE 间<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
组织<|>RELATION_NOE 间<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 联合化疗<|>RELATION_NOE 与<|>RELATION_NOE 外<|>RELATION_NOE 照射<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 对比<|>RELATION_NOE 研究<|>RELATION_NOE
比较<|>RELATION_NOE ^<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 组织<|>RELATION_NOE 间<|>RELATION_NOE 植入<|>RELATION_NOE 和<|>RELATION_NOE 外放疗<|>RELATION_NOE 分别<|>RELATION_NOE 联合<|>RELATION_NOE PC<|>RELATION_NOE 方案<|>RELATION_NOE (<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 非小胞<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 87<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 44<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE ^<|>RELATION_NOE 125I<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 后<|>RELATION_NOE 联合<|>RELATION_NOE 同步<|>RELATION_NOE PC<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 外<|>RELATION_NOE 放疗<|>RELATION_NOE 同步<|>RELATION_NOE PC<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE :<|>RELATION_NOE 研究组<|>RELATION_NOE 为<|>RELATION_NOE 气胸<|>RELATION_NOE (<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 1例<|>RELATION_NOE 为<|>RELATION_NOE 大量<|>RELATION_NOE 气胸<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血胸<|>RELATION_NOE (<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 发现<|>RELATION_NOE 有<|>RELATION_NOE 针道<|>RELATION_NOE 种植<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 主要<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 为<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺间质<|>RELATION_NOE 纤维化<|>RELATION_NOE (<|>RELATION_NOE 5例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE (<|>RELATION_NOE 2例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 放射性<|>RELATION_NOE 心脏损伤<|>RELATION_NOE (<|>RELATION_NOE 2例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 组织<|>RELATION_NOE HMGB-1<|>RELATION_NOE 和<|>RELATION_NOE Tiaml<|>RELATION_NOE 表达<|>RELATION_B 的<|>RELATION_I 意义<|>RELATION_E
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 组织<|>RELATION_NOE 高迁移<|>RELATION_NOE 率族<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE HMGB-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE T<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 侵袭<|>RELATION_NOE 转移<|>RELATION_NOE 诱导<|>RELATION_NOE 因子1<|>RELATION_NOE (<|>RELATION_NOE Tiaml<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_B 的<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
选择<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 癌组织<|>RELATION_NOE 作为<|>RELATION_NOE 观察组<|>RELATION_NOE ,<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 染色<|>RELATION_NOE 测定<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HMGB-1<|>RELATION_NOE 和<|>RELATION_NOE Tiaml<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
Tiaml<|>RELATION_NOE 阳性<|>RELATION_NOE 染色<|>RELATION_NOE 位于<|>RELATION_NOE 细胞质<|>RELATION_NOE 和<|>RELATION_NOE 细胞膜<|>RELATION_NOE ,<|>RELATION_NOE 呈<|>RELATION_NOE 黄色<|>RELATION_NOE 、<|>RELATION_NOE 棕黄色<|>RELATION_NOE 或<|>RELATION_NOE 棕褐色<|>RELATION_NOE ,<|>RELATION_NOE Tiaml<|>RELATION_NOE 在<|>RELATION_NOE 观察组<|>RELATION_NOE 中<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 为<|>RELATION_NOE 66.7%<|>RELATION_NOE (<|>RELATION_NOE 34<|>RELATION_NOE /<|>RELATION_NOE 51<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE 中<|>RELATION_NOE 为<|>RELATION_NOE 5.9%<|>RELATION_NOE (<|>RELATION_NOE 3/51<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE X<|>RELATION_NOE ^2<|>RELATION_NOE =<|>RELATION_NOE 10.36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HMGB-1<|>RELATION_NOE 和<|>RELATION_NOE Tiaml<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 均<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 是否<|>RELATION_NOE 复发<|>RELATION_NOE 有<|>RELATION_NOE 密切<|>RELATION_NOE 关系<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HMGB-1<|>RELATION_NOE 和<|>RELATION_NOE Tiaml<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 均<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 是否<|>RELATION_NOE 复发<|>RELATION_NOE 有<|>RELATION_NOE 密切<|>RELATION_B 关系<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HMGB-1<|>RELATION_NOE 和<|>RELATION_NOE Tiaml<|>RELATION_NOE 高<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 并且<|>RELATION_NOE 可以<|>RELATION_NOE 预测<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HMGB-1<|>RELATION_NOE 和<|>RELATION_NOE Tiaml<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 可以<|>RELATION_NOE 预测<|>RELATION_B 患者<|>RELATION_I 预后<|>RELATION_E 。<|>RELATION_NOE
快速<|>RELATION_NOE 康复<|>RELATION_NOE 外科<|>RELATION_NOE 在<|>RELATION_NOE 支气管<|>RELATION_NOE 袖状<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
探讨<|>RELATION_NOE 快速<|>RELATION_NOE 康复<|>RELATION_NOE 外科<|>RELATION_NOE 理念<|>RELATION_NOE 在<|>RELATION_NOE 支气管<|>RELATION_NOE 袖状<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S 。<|>RELATION_NOE
选择<|>RELATION_NOE 在<|>RELATION_NOE 郑州<|>RELATION_NOE 大学<|>RELATION_NOE 第一<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 接受<|>RELATION_NOE 支气管<|>RELATION_NOE 袖状<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 快速<|>RELATION_NOE 康复<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE 围术期<|>RELATION_NOE 采用<|>RELATION_NOE 快速<|>RELATION_NOE 康复<|>RELATION_NOE 外科<|>RELATION_NOE 理念<|>RELATION_NOE 进行<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE 围术期<|>RELATION_NOE 按<|>RELATION_NOE 传统<|>RELATION_NOE 方法<|>RELATION_NOE 处理<|>RELATION_NOE 。<|>RELATION_NOE
快速<|>RELATION_NOE 康复<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE 术后<|>RELATION_NOE 排气<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 拔除<|>RELATION_NOE 胸腔<|>RELATION_NOE 引<|>RELATION_NOE 流管<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 住院<|>RELATION_NOE 总<|>RELATION_NOE 费用<|>RELATION_NOE 均<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
完全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 淋巴结<|>RELATION_B 清扫<|>RELATION_I 范围<|>RELATION_E 的<|>RELATION_NOE 探讨<|>RELATION_NOE
探讨<|>RELATION_NOE 完全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_B 清扫<|>RELATION_I 范围<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 1月<|>RELATION_NOE 341<|>RELATION_NOE 例<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 及<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 总结<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位置<|>RELATION_NOE 与<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位于<|>RELATION_NOE 上肺<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 上<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴<|>RELATION_NOE 结癌<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 为<|>RELATION_NOE 13.8%<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE /<|>RELATION_NOE 210<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 这个<|>RELATION_NOE 比例<|>RELATION_NOE 在<|>RELATION_NOE 下<|>RELATION_NOE 纵隔<|>RELATION_NOE (<|>RELATION_NOE 除外<|>RELATION_NOE 第7<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 仅<|>RELATION_NOE 为<|>RELATION_NOE 1.9%<|>RELATION_NOE (<|>RELATION_NOE 4/2<|>RELATION_NOE 10<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 下<|>RELATION_NOE 肺叶<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 6.9%<|>RELATION_NOE (<|>RELATION_NOE 9/<|>RELATION_NOE 131<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 5.3%<|>RELATION_NOE (<|>RELATION_NOE 7/<|>RELATION_NOE 131<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
早期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 适宜<|>RELATION_B 进行<|>RELATION_E 肺叶<|>RELATION_NOE 特异性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE 。<|>RELATION_NOE
12<|>RELATION_NOE 8<|>RELATION_NOE 层<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 三维<|>RELATION_NOE 多<|>RELATION_NOE 平面<|>RELATION_NOE 重建<|>RELATION_NOE 在<|>RELATION_NOE 肺类癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_S 价值<|>RELATION_NOE
主要<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 痰<|>RELATION_NOE 中<|>RELATION_NOE 带<|>RELATION_NOE 血丝<|>RELATION_NOE 或<|>RELATION_NOE 咯血<|>RELATION_NOE 、<|>RELATION_NOE 胸闷<|>RELATION_NOE 、<|>RELATION_NOE 胸痛<|>RELATION_NOE 、<|>RELATION_NOE 发热<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
中央型<|>RELATION_NOE 尚<|>RELATION_NOE 可见<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺炎<|>RELATION_NOE 、<|>RELATION_NOE 肺气肿<|>RELATION_NOE 或<|>RELATION_NOE 肺不张<|>RELATION_NOE 。<|>RELATION_NOE
肺类<|>RELATION_NOE 癌影像学<|>RELATION_NOE 缺乏<|>RELATION_NOE 特征性<|>RELATION_NOE ,<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 三维<|>RELATION_NOE 重建<|>RELATION_NOE 技术<|>RELATION_NOE 有助于<|>RELATION_NOE 肺类癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 和<|>RELATION_I 鉴别诊断<|>RELATION_E .<|>RELATION_NOE
支气管动脉<|>RELATION_NOE 介入<|>RELATION_NOE 治疗<|>RELATION_S 中晚期<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
39<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 采取<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 加<|>RELATION_NOE 栓塞<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 单纯<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 化疗<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
每<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 有效<|>RELATION_NOE 例数<|>RELATION_NOE 及<|>RELATION_NOE 有效率<|>RELATION_NOE (<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE +<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 加<|>RELATION_NOE 栓塞<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 84.00%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 单纯<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 化疗<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 50.00%<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 加<|>RELATION_NOE 栓塞<|>RELATION_NOE 疗效<|>RELATION_NOE 明显<|>RELATION_B 优于<|>RELATION_E 单纯<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 灌注<|>RELATION_NOE 化疗<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
观察<|>RELATION_NOE 全反式<|>RELATION_NOE 维甲酸<|>RELATION_NOE (<|>RELATION_NOE ATRA<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S ,<|>RELATION_NOE 探索<|>RELATION_NOE ATRA<|>RELATION_NOE 应用<|>RELATION_NOE 的<|>RELATION_NOE 最<|>RELATION_NOE 适<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_NOE 各组<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE PDCD5<|>RELATION_NOE 、<|>RELATION_NOE TP53<|>RELATION_NOE 基因表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE 观察<|>RELATION_NOE 全反式<|>RELATION_NOE 维甲酸<|>RELATION_NOE (<|>RELATION_NOE ATRA<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 探索<|>RELATION_NOE ATRA<|>RELATION_NOE 应用<|>RELATION_S 的<|>RELATION_NOE 最<|>RELATION_NOE 适<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_NOE 各组<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE PDCD5<|>RELATION_NOE 、<|>RELATION_NOE TP53<|>RELATION_NOE 基因表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE 观察<|>RELATION_NOE 全反式<|>RELATION_NOE 维甲酸<|>RELATION_NOE (<|>RELATION_NOE ATRA<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 探索<|>RELATION_NOE ATRA<|>RELATION_NOE 应用<|>RELATION_NOE 的<|>RELATION_NOE 最<|>RELATION_NOE 适<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_NOE 各组<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE PDCD5<|>RELATION_NOE 、<|>RELATION_NOE TP53<|>RELATION_NOE 基因<|>RELATION_NOE 表达<|>RELATION_B 情况<|>RELATION_E 。<|>RELATION_NOE
以<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE ATRA<|>RELATION_NOE (<|>RELATION_NOE 10-5mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE 10-6mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE 10-7mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE 10-2<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 作用<|>RELATION_NOE 于<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 细胞增殖<|>RELATION_NOE 情况<|>RELATION_NOE .<|>RELATION_NOE
利用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 检测<|>RELATION_S ATRA<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 作用<|>RELATION_NOE 于<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 凋亡<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE PDCD5<|>RELATION_NOE 、<|>RELATION_NOE TP53mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
ATRA<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 具有<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E ,<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE 和<|>RELATION_NOE 时间<|>RELATION_NOE 依赖性<|>RELATION_NOE ;<|>RELATION_NOE ATRA<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 具有<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_S 的<|>RELATION_NOE 浓度<|>RELATION_NOE 和<|>RELATION_NOE 时间<|>RELATION_NOE 依赖性<|>RELATION_NOE ;<|>RELATION_NOE
单药培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE 一线<|>RELATION_B 治疗<|>RELATION_E 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非鳞非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
microRNA-1Ob<|>RELATION_NOE 促进<|>RELATION_S 人<|>RELATION_NOE 低<|>RELATION_NOE 转移<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE 95-C<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 及<|>RELATION_NOE 侵袭<|>RELATION_NOE
探讨<|>RELATION_NOE microRNA-10b<|>RELATION_NOE (<|>RELATION_NOE miRNA-10b<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 低<|>RELATION_NOE 转移<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 95-C<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 细胞周期<|>RELATION_NOE 、<|>RELATION_NOE 凋亡<|>RELATION_NOE 以及<|>RELATION_NOE 侵袭<|>RELATION_NOE 及<|>RELATION_NOE 迁移<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
用<|>RELATION_NOE 脂质体法<|>RELATION_NOE 将<|>RELATION_NOE miRNA-10b<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 质粒<|>RELATION_NOE 瞬时<|>RELATION_NOE 转染<|>RELATION_NOE 入<|>RELATION_NOE 95-C<|>RELATION_NOE ,<|>RELATION_NOE 实验<|>RELATION_NOE 设置<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 空<|>RELATION_NOE 载体<|>RELATION_NOE 转染组<|>RELATION_NOE 和<|>RELATION_NOE miRNA-10b<|>RELATION_NOE 质粒<|>RELATION_NOE 转染组<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_NOE 后<|>RELATION_NOE 荧光<|>RELATION_NOE 显微镜<|>RELATION_NOE 下<|>RELATION_NOE 观察<|>RELATION_NOE 转染<|>RELATION_NOE 效率<|>RELATION_NOE ,<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE RT-PCR<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE 细胞<|>RELATION_NOE miRNA-10b<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE 细胞周期<|>RELATION_NOE 及<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE ,<|>RELATION_NOE Transwell<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 划痕<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE 细胞迁移<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 肝癌<|>RELATION_NOE 衍生<|>RELATION_NOE 生长因子<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 肝癌<|>RELATION_NOE 衍生<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE HDGF<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_B 水平<|>RELATION_I 及其<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
HDGF<|>RELATION_NOE 与<|>RELATION_NOE VEGF<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 组织学分型<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
microRNAlet-7e<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_S 的<|>RELATION_NOE 研究<|>RELATION_NOE
应用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 反<|>RELATION_NOE 转录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE TaqmanMGB<|>RELATION_NOE 探<|>RELATION_NOE 针法<|>RELATION_NOE 检测<|>RELATION_S 35<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 癌组织<|>RELATION_NOE 及<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE microRNAlet<|>RELATION_NOE .<|>RELATION_NOE
7e<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 看家<|>RELATION_NOE 基因<|>RELATION_NOE U6snRNA<|>RELATION_NOE 为<|>RELATION_NOE 内参<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 统计<|>RELATION_NOE 分析<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
7e<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE 10.301<|>RELATION_NOE ±<|>RELATION_NOE 5.2<|>RELATION_NOE 28<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE (<|>RELATION_NOE 9.6<|>RELATION_NOE 35<|>RELATION_NOE ±<|>RELATION_NOE 8.<|>RELATION_NOE 300<|>RELATION_NOE )<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 不同<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸娴史<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 分型<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
7e<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 应用<|>RELATION_NOE 于<|>RELATION_NOE NSCLC<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 与<|>RELATION_NOE 腺癌<|>RELATION_NOE 的<|>RELATION_NOE 分子生物学<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 可能<|>RELATION_NOE 发挥<|>RELATION_NOE 癌基因<|>RELATION_NOE 样<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE 7e<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 应用<|>RELATION_NOE 于<|>RELATION_NOE NSCLC<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 与<|>RELATION_NOE 腺癌<|>RELATION_NOE 的<|>RELATION_NOE 分子生物学<|>RELATION_B 鉴别诊断<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 可能<|>RELATION_NOE 发挥<|>RELATION_NOE 癌基因<|>RELATION_NOE 样<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_NOE 中<|>RELATION_NOE 减轻<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 和<|>RELATION_NOE 改善<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S 。<|>RELATION_NOE
中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE Nanog<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 效果<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE 中晚期<|>RELATION_NOE (<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 和<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期<|>RELATION_NOE )<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE Nanog<|>RELATION_NOE 基因<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 关系<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 对<|>RELATION_NOE 生存期<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 使用<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 使用<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE qRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 均<|>RELATION_NOE 检测<|>RELATION_NOE 出<|>RELATION_NOE Nanog<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 进行<|>RELATION_NOE 对比<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 生存期<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 进行<|>RELATION_NOE 统计<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
Nanog<|>RELATION_NOE 表达<|>RELATION_NOE 增强<|>RELATION_NOE 可能<|>RELATION_B 导致<|>RELATION_E NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 不<|>RELATION_NOE 敏感<|>RELATION_NOE 并<|>RELATION_NOE 导致<|>RELATION_NOE 5年<|>RELATION_NOE 生存期<|>RELATION_NOE 缩短<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE Nanog<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 为<|>RELATION_NOE 临床<|>RELATION_NOE 制定<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 个体化<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 提供<|>RELATION_NOE 依据<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 预测<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 提供<|>RELATION_NOE 参考<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 与<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_S
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2008年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 1月<|>RELATION_NOE 首都<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 宣武<|>RELATION_NOE 医院<|>RELATION_NOE 胸外科行<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 分为<|>RELATION_NOE 完全<|>RELATION_NOE 胸腔镜组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 47<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 直<|>RELATION_NOE 视<|>RELATION_NOE 下<|>RELATION_NOE 手术组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 43<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 数<|>RELATION_NOE 、<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 放置<|>RELATION_NOE 引流<|>RELATION_NOE 管<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 并发症率<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 评分<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 放置<|>RELATION_NOE 引流<|>RELATION_NOE 管<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 住院<|>RELATION_NOE 天数<|>RELATION_NOE 明显<|>RELATION_B 少于<|>RELATION_E 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小切<|>RELATION_NOE 口组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 评分<|>RELATION_NOE 及<|>RELATION_NOE 镇痛<|>RELATION_NOE 药物<|>RELATION_NOE 使用量<|>RELATION_NOE 亦<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小切<|>RELATION_NOE 口组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Tla<|>RELATION_NOE 期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 影像学<|>RELATION_NOE 特征<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相关性<|>RELATION_B 分析<|>RELATION_E
记录<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 受侵<|>RELATION_NOE 、<|>RELATION_NOE 空气<|>RELATION_NOE 支气管<|>RELATION_NOE 征<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 患者<|>RELATION_NOE 曾行<|>RELATION_NOE PET-CT<|>RELATION_NOE 者<|>RELATION_NOE 则<|>RELATION_NOE 记录<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 标准<|>RELATION_NOE 摄取值<|>RELATION_NOE (<|>RELATION_NOE SUVmax<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
表现<|>RELATION_NOE 为<|>RELATION_NOE 纯磨<|>RELATION_NOE 玻璃影<|>RELATION_NOE 的<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 腺瘤<|>RELATION_NOE 样<|>RELATION_NOE 增生<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 原位腺癌<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 1例<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ;<|>RELATION_NOE
表现<|>RELATION_NOE 为<|>RELATION_NOE 混合型<|>RELATION_NOE 磨玻璃影<|>RELATION_NOE 的<|>RELATION_NOE 89<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 84<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 94.4%<|>RELATION_NOE )<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 只<|>RELATION_NOE 有<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 6.0%<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ;<|>RELATION_NOE
高<|>RELATION_NOE 分辨<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 纯毛<|>RELATION_NOE 玻璃影<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 一般<|>RELATION_B 没有<|>RELATION_E 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE ><|>RELATION_NOE 1cm<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 混合<|>RELATION_NOE 性结节<|>RELATION_NOE 或<|>RELATION_NOE 实性<|>RELATION_NOE 结节<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE ><|>RELATION_NOE 5μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE SUVmax<|>RELATION_NOE ><|>RELATION_NOE 5<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 更<|>RELATION_NOE 易<|>RELATION_NOE 发生<|>RELATION_NOE
肺癌<|>RELATION_NOE 相关<|>RELATION_NOE 副<|>RELATION_NOE 肿瘤性<|>RELATION_NOE 边缘叶脑炎<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_S
分析<|>RELATION_S 肺癌<|>RELATION_NOE 相关<|>RELATION_NOE 副<|>RELATION_NOE 肿瘤性<|>RELATION_NOE 边缘叶脑炎<|>RELATION_NOE (<|>RELATION_NOE PLE<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 诊治<|>RELATION_NOE 要点<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 总结<|>RELATION_NOE 2000年<|>RELATION_NOE 1月<|>RELATION_NOE 到<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 89<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 2004年<|>RELATION_NOE 神经系统<|>RELATION_NOE 副<|>RELATION_NOE 肿瘤<|>RELATION_NOE 综合征<|>RELATION_NOE 欧洲<|>RELATION_NOE 工作网<|>RELATION_NOE 制定<|>RELATION_NOE 的<|>RELATION_NOE PLE<|>RELATION_NOE 诊断<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 从中<|>RELATION_NOE 筛选<|>RELATION_NOE 出<|>RELATION_NOE PLE<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 男性<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 41<|>RELATION_NOE －<|>RELATION_NOE 54<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 48<|>RELATION_NOE 岁<|>RELATION_NOE ;<|>RELATION_NOE
症状<|>RELATION_NOE 方面<|>RELATION_NOE ,<|>RELATION_NOE 7例<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 短期<|>RELATION_NOE 记忆力<|>RELATION_NOE 丧失<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE 有<|>RELATION_NOE 癫痫发作<|>RELATION_NOE ,<|>RELATION_NOE 4例<|>RELATION_NOE 有<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 精神<|>RELATION_NOE 异常<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 合并<|>RELATION_NOE 抗<|>RELATION_NOE 利尿<|>RELATION_NOE 激素<|>RELATION_NOE 分泌<|>RELATION_NOE 不<|>RELATION_NOE 当<|>RELATION_NOE 综合征<|>RELATION_NOE .<|>RELATION_NOE
PLE<|>RELATION_NOE 为<|>RELATION_NOE 罕见<|>RELATION_NOE 疾病<|>RELATION_NOE ,<|>RELATION_NOE 熟悉<|>RELATION_NOE 疾病<|>RELATION_NOE 特点<|>RELATION_NOE 有助于<|>RELATION_NOE 早期<|>RELATION_B 诊断<|>RELATION_E ,<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 治疗<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 改善<|>RELATION_NOE 神经系统<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 神经系统<|>RELATION_NOE 症状<|>RELATION_NOE 缓解<|>RELATION_NOE 不<|>RELATION_NOE 完全<|>RELATION_NOE 以及<|>RELATION_NOE 肺癌<|>RELATION_NOE 分期<|>RELATION_NOE 偏<|>RELATION_NOE 晚<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 相关.<|>RELATION_NOE PLE<|>RELATION_NOE 为<|>RELATION_NOE 罕见<|>RELATION_NOE 疾病<|>RELATION_NOE ,<|>RELATION_NOE 熟悉<|>RELATION_NOE 疾病<|>RELATION_NOE 特点<|>RELATION_NOE 有助于<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 治疗<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 改善<|>RELATION_E 神经系统<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE PLE<|>RELATION_NOE 为<|>RELATION_NOE 罕见<|>RELATION_NOE 疾病<|>RELATION_NOE ,<|>RELATION_NOE 熟悉<|>RELATION_NOE 疾病<|>RELATION_NOE 特点<|>RELATION_NOE 有助于<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 治疗<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_NOE 改善<|>RELATION_NOE 神经系统<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 神经系统<|>RELATION_NOE 症状<|>RELATION_NOE 缓解<|>RELATION_NOE 不<|>RELATION_NOE 完全<|>RELATION_NOE 以及<|>RELATION_NOE 肺癌<|>RELATION_NOE 分期<|>RELATION_NOE 偏<|>RELATION_NOE 晚<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_S .<|>RELATION_NOE
经皮<|>RELATION_NOE 全面<|>RELATION_NOE 冷冻<|>RELATION_NOE 治疗<|>RELATION_S Ⅳ<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE
对<|>RELATION_NOE 2004年<|>RELATION_NOE 8月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 广州<|>RELATION_NOE 复大<|>RELATION_NOE 医院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 全面<|>RELATION_NOE 冷冻<|>RELATION_NOE 组<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 同时<|>RELATION_NOE 冷冻<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 及<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 不<|>RELATION_NOE 冷冻<|>RELATION_NOE 或<|>RELATION_NOE 只<|>RELATION_NOE 冷冻<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 术后<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 进行<|>RELATION_NOE 观察<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 。<|>RELATION_NOE
VEGF<|>RELATION_NOE 对<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE MMP-2<|>RELATION_NOE 及<|>RELATION_NOE MMP-9<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
建立<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE 三维<|>RELATION_NOE 立体<|>RELATION_NOE 培养<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE MMP-2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -9<|>RELATION_NOE (<|>RELATION_NOE MMP-9<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE H460<|>RELATION_NOE 细胞系<|>RELATION_NOE 建立<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 三维<|>RELATION_NOE 立体<|>RELATION_NOE 培养<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分成<|>RELATION_NOE 三<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE VEGF<|>RELATION_NOE ,<|>RELATION_NOE 明胶<|>RELATION_NOE 酶<|>RELATION_NOE 谱<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_NOE 三<|>RELATION_NOE 组<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ;<|>RELATION_NOE
各<|>RELATION_NOE 实验组<|>RELATION_NOE 的<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE 的<|>RELATION_NOE MMP-2<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 均<|>RELATION_B 有<|>RELATION_I 差异<|>RELATION_E .<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 对于<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 一线<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 预测<|>RELATION_E 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 对于<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 一线<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 预测<|>RELATION_E 意义<|>RELATION_NOE 。<|>RELATION_NOE
随<|>RELATION_NOE 访<|>RELATION_NOE 郑州<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 2008年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 3月<|>RELATION_NOE 接受<|>RELATION_NOE 标准<|>RELATION_NOE 一线<|>RELATION_NOE 含<|>RELATION_NOE 铂双<|>RELATION_NOE 联<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE Ⅳ期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 确诊<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 突变型<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 野生型<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
癌胚抗原<|>RELATION_NOE 、<|>RELATION_NOE 糖类<|>RELATION_NOE 抗原<|>RELATION_NOE 125<|>RELATION_NOE 、<|>RELATION_NOE 神经<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 早期<|>RELATION_B 诊断<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 糖类<|>RELATION_NOE 抗原<|>RELATION_NOE 125<|>RELATION_NOE (<|>RELATION_NOE CA125<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 早期<|>RELATION_B 诊断<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_S 原发性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 分析<|>RELATION_NOE
分析<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_S 原发性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 我<|>RELATION_NOE 院<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 2月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 开<|>RELATION_NOE 胸肺<|>RELATION_NOE 叶切<|>RELATION_NOE 除术<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 分析<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 引流量<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 和<|>RELATION_NOE 并发症率<|>RELATION_NOE 都<|>RELATION_NOE 显著<|>RELATION_B 小于<|>RELATION_E 对照组<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但是<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 数目<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 引流量<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 和<|>RELATION_NOE 并发症率<|>RELATION_NOE 都<|>RELATION_NOE 显著<|>RELATION_NOE 小于<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但是<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 数目<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 具有<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 创伤<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE 等<|>RELATION_NOE 优势<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 与<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 对<|>RELATION_NOE 机体<|>RELATION_NOE 创伤<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_NOE
比较<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 机体<|>RELATION_NOE 创伤<|>RELATION_NOE 及<|>RELATION_NOE 围手术期<|>RELATION_NOE 恢复<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
通过<|>RELATION_NOE 随机表法<|>RELATION_NOE 将<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE OT<|>RELATION_NOE 组<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE VATS<|>RELATION_NOE 组<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 1d<|>RELATION_NOE 晨问<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 晨间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 第2<|>RELATION_NOE 天<|>RELATION_NOE 晨间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 第3<|>RELATION_NOE 天<|>RELATION_NOE 晨间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 第7<|>RELATION_NOE 天<|>RELATION_NOE 晨间<|>RELATION_NOE 静脉<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 皮质醇<|>RELATION_NOE (<|>RELATION_NOE Cor<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 生长激素<|>RELATION_NOE (<|>RELATION_NOE GH<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 三<|>RELATION_NOE 碘<|>RELATION_NOE 甲状腺<|>RELATION_NOE 原<|>RELATION_NOE 氨酸<|>RELATION_NOE (<|>RELATION_NOE T3<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 四<|>RELATION_NOE 碘<|>RELATION_NOE 甲状腺<|>RELATION_NOE 原<|>RELATION_NOE 氨酸<|>RELATION_NOE (<|>RELATION_NOE T4<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE C-<|>RELATION_NOE 反应<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE CRP<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 入<|>RELATION_NOE 路<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 机体<|>RELATION_NOE 创伤<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE .<|>RELATION_NOE
并且<|>RELATION_NOE 通过<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清<|>RELATION_NOE 扫数<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 胸腔<|>RELATION_NOE 闭式<|>RELATION_NOE 引流管<|>RELATION_NOE 放置<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 在<|>RELATION_NOE 治疗效果<|>RELATION_NOE 、<|>RELATION_NOE 围手术期<|>RELATION_NOE 恢复<|>RELATION_NOE 情况<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 手术时间<|>RELATION_NOE (<|>RELATION_NOE OT<|>RELATION_NOE 组<|>RELATION_NOE vs<|>RELATION_NOE VATS<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE 3.08<|>RELATION_NOE vs<|>RELATION_NOE 3.90<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE (<|>RELATION_NOE OT<|>RELATION_NOE 组<|>RELATION_NOE vs<|>RELATION_NOE VATS<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE 7.49vs<|>RELATION_NOE 6.26<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
蛋白<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 磷酸酶<|>RELATION_NOE 1B<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 与<|>RELATION_I 预后<|>RELATION_I 的<|>RELATION_I 关系<|>RELATION_E
探讨<|>RELATION_NOE 蛋白<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 磷酸酶<|>RELATION_NOE 1B<|>RELATION_NOE (<|>RELATION_NOE 胛<|>RELATION_NOE P1B<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 对<|>RELATION_I 预后<|>RELATION_I 的<|>RELATION_I 预测<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
运用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 2000年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 2006年<|>RELATION_NOE 10月<|>RELATION_NOE 南京<|>RELATION_NOE 军区<|>RELATION_NOE 南京<|>RELATION_NOE 总医院<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 经常规<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 63<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 9例<|>RELATION_NOE 肺炎<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 门<|>RELATION_NOE P1B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 统计学<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
胛<|>RELATION_NOE P1B<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 化疗<|>RELATION_NOE 与否<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE pTNM<|>RELATION_NOE 分期<|>RELATION_NOE 显著<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE =<|>RELATION_NOE 6.4<|>RELATION_NOE 26<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 胛<|>RELATION_NOE P1B<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 化疗<|>RELATION_NOE 与否<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE pTNM<|>RELATION_NOE 分期<|>RELATION_NOE 显著<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE χ2<|>RELATION_NOE =<|>RELATION_NOE 6.4<|>RELATION_NOE 26<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE Cox<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_NOE 门<|>RELATION_NOE P1B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_S N<|>RELATION_NOE SCLC<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE =<|>RELATION_NOE 2.0<|>RELATION_NOE 50<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE pTNM<|>RELATION_NOE 分期<|>RELATION_NOE 也<|>RELATION_NOE 是<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 对<|>RELATION_NOE 肺部<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_S 价值<|>RELATION_NOE
分析<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 患者<|>RELATION_NOE 体位<|>RELATION_NOE 、<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 进<|>RELATION_NOE 针<|>RELATION_NOE 深度<|>RELATION_NOE 、<|>RELATION_NOE 是否<|>RELATION_NOE 合并<|>RELATION_NOE COPD<|>RELATION_NOE 、<|>RELATION_NOE 穿刺<|>RELATION_NOE 针数<|>RELATION_NOE 以及<|>RELATION_NOE 操作者<|>RELATION_NOE 经验<|>RELATION_NOE 是否<|>RELATION_NOE 丰富<|>RELATION_NOE 等<|>RELATION_NOE 因素<|>RELATION_NOE 对<|>RELATION_NOE 气胸<|>RELATION_NOE 和<|>RELATION_NOE 咯血<|>RELATION_NOE 发生率<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
病理<|>RELATION_NOE 分布<|>RELATION_NOE 为<|>RELATION_NOE 腺癌<|>RELATION_NOE 38<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 62.1%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 166<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 26.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 4.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 分型癌<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 2.9%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肉瘤<|>RELATION_NOE 样癌<|>RELATION_NOE 6例<|>RELATION_NOE (<|>RELATION_NOE 0.9%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 平滑肌肉瘤<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 0.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 及<|>RELATION_NOE 神经<|>RELATION_NOE 内分泌癌<|>RELATION_NOE 各<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 0.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 低<|>RELATION_NOE 分化<|>RELATION_NOE 类癌<|>RELATION_NOE 、<|>RELATION_NOE 筛状癌<|>RELATION_NOE 、<|>RELATION_NOE 转移性<|>RELATION_NOE 肾细胞癌<|>RELATION_NOE 、<|>RELATION_NOE 恶性淋巴瘤<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 0.2%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
5例<|>RELATION_NOE (<|>RELATION_NOE 0.8%<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肺穿刺<|>RELATION_NOE 病理<|>RELATION_NOE 为<|>RELATION_NOE 慢性<|>RELATION_NOE 炎症<|>RELATION_NOE ,<|>RELATION_NOE 后<|>RELATION_NOE 经<|>RELATION_NOE 手术<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 3例<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 及<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
并<|>RELATION_NOE 发<|>RELATION_NOE 气胸<|>RELATION_NOE 73<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 11.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 65<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 10.4%<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 少量<|>RELATION_NOE 气胸<|>RELATION_NOE (<|>RELATION_NOE 肺压缩<|>RELATION_NOE <<|>RELATION_NOE 20%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 吸氧<|>RELATION_NOE 、<|>RELATION_NOE 休息<|>RELATION_NOE 等<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 气胸<|>RELATION_NOE 吸收<|>RELATION_NOE ;<|>RELATION_NOE
并<|>RELATION_NOE 发<|>RELATION_NOE 咯血<|>RELATION_NOE 84<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 13.5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 大部分<|>RELATION_NOE 为<|>RELATION_NOE 痰血<|>RELATION_NOE 或<|>RELATION_NOE 少量<|>RELATION_NOE 咯血<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 自限性<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 口服<|>RELATION_NOE 止血药<|>RELATION_NOE 等<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE 咯血<|>RELATION_NOE 消失<|>RELATION_NOE ;<|>RELATION_NOE
中等量<|>RELATION_NOE 咯血<|>RELATION_NOE (<|>RELATION_NOE 24h<|>RELATION_NOE 咯血量<|>RELATION_NOE 100-500m1<|>RELATION_NOE )<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 0.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE 止血药<|>RELATION_NOE 、<|>RELATION_NOE 休息<|>RELATION_NOE 等<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE 咯血<|>RELATION_NOE 消失<|>RELATION_NOE 。<|>RELATION_NOE
气胸<|>RELATION_NOE 发生率<|>RELATION_NOE 与<|>RELATION_NOE 病灶<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 2am<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.006<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 进<|>RELATION_NOE 针<|>RELATION_NOE 深度<|>RELATION_NOE ><|>RELATION_NOE 3cm<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 穿刺<|>RELATION_NOE 针数<|>RELATION_NOE ≥<|>RELATION_NOE 3针<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 25<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 操作者<|>RELATION_NOE 经验<|>RELATION_NOE 欠<|>RELATION_NOE 丰富<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.003<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 合并<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE (<|>RELATION_NOE COPD<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE 等<|>RELATION_NOE 因素<|>RELATION_NOE 相关<|>RELATION_S ;<|>RELATION_NOE
咯血<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 也<|>RELATION_NOE 与<|>RELATION_NOE 病灶<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 2em<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 进<|>RELATION_NOE 针<|>RELATION_NOE 深度<|>RELATION_NOE ><|>RELATION_NOE 3cm<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 18<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 穿刺<|>RELATION_NOE 针数<|>RELATION_NOE ≥<|>RELATION_NOE 3针<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 操作者<|>RELATION_NOE 经验<|>RELATION_NOE 欠<|>RELATION_NOE 丰富<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 14<|>RELATION_NOE )<|>RELATION_NOE 等<|>RELATION_NOE 因素<|>RELATION_NOE 相关<|>RELATION_S ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 是否<|>RELATION_NOE 合并<|>RELATION_NOE COPD<|>RELATION_NOE 无关<|>RELATION_NOE 。<|>RELATION_NOE 咯血<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 也<|>RELATION_NOE 与<|>RELATION_NOE 病灶<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 2em<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 进<|>RELATION_NOE 针<|>RELATION_NOE 深度<|>RELATION_NOE ><|>RELATION_NOE 3cm<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 18<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 穿刺<|>RELATION_NOE 针数<|>RELATION_NOE ≥<|>RELATION_NOE 3针<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 操作者<|>RELATION_NOE 经验<|>RELATION_NOE 欠<|>RELATION_NOE 丰富<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 14<|>RELATION_NOE )<|>RELATION_NOE 等<|>RELATION_NOE 因素<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 是否<|>RELATION_NOE 合并<|>RELATION_NOE COPD<|>RELATION_NOE 无关<|>RELATION_S 。<|>RELATION_NOE
而<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 体位<|>RELATION_NOE 、<|>RELATION_NOE 穿刺<|>RELATION_NOE 部位<|>RELATION_NOE 等<|>RELATION_NOE 因素<|>RELATION_NOE 与<|>RELATION_NOE 气胸<|>RELATION_NOE 及<|>RELATION_NOE 咯血<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 无<|>RELATION_B 显著<|>RELATION_I 相关<|>RELATION_E 。<|>RELATION_NOE
18<|>RELATION_NOE 氟<|>RELATION_NOE -<|>RELATION_NOE 氟代<|>RELATION_NOE 脱氧葡萄糖<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 断层<|>RELATION_NOE 扫描<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 早期<|>RELATION_B 诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE
对<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 10月<|>RELATION_NOE 复旦<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 中山<|>RELATION_NOE 医院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 347<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 占<|>RELATION_NOE 位<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性研究<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE PET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效度<|>RELATION_NOE 以及<|>RELATION_NOE 病变<|>RELATION_NOE 形态<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 诊断<|>RELATION_NOE 效度<|>RELATION_NOE 与<|>RELATION_NOE 病灶<|>RELATION_NOE FDG<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 标准<|>RELATION_NOE 摄取值<|>RELATION_NOE (<|>RELATION_NOE SUVmax<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE PET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 联合<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 肺部<|>RELATION_NOE 占位<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
18F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 对<|>RELATION_NOE 肺结节<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 也<|>RELATION_NOE 有<|>RELATION_NOE -<|>RELATION_NOE 定<|>RELATION_NOE 的<|>RELATION_NOE 提示<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 联合<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S 肺癌<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 特异度<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 剂量<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 筛查<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE
前瞻性<|>RELATION_NOE 人<|>RELATION_NOE 组<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 12月<|>RELATION_NOE 于<|>RELATION_NOE 复旦<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 中山<|>RELATION_NOE 医院<|>RELATION_NOE 体检<|>RELATION_NOE 中心<|>RELATION_NOE 行<|>RELATION_NOE 胸部<|>RELATION_NOE LDCT<|>RELATION_NOE 检查<|>RELATION_NOE 的<|>RELATION_NOE 无<|>RELATION_NOE 症状<|>RELATION_NOE 人群<|>RELATION_NOE ,<|>RELATION_NOE 总结<|>RELATION_NOE 肺结节<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 检出率<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 吸烟<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 高<|>RELATION_NOE 、<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 低危<|>RELATION_NOE 人群组<|>RELATION_NOE 中<|>RELATION_NOE LDCT<|>RELATION_NOE 筛查<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角质<|>RELATION_NOE 蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE Cyfra211<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 鳞<|>RELATION_NOE 癌细胞<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE SCC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 单独<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 未能<|>RELATION_B 预测<|>RELATION_E 肺结节<|>RELATION_NOE 检出率<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
探讨<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 多位点<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 及<|>RELATION_NOE 异质性<|>RELATION_NOE 存在<|>RELATION_B 状态<|>RELATION_I 及<|>RELATION_I 对<|>RELATION_I 患者<|>RELATION_I 整体<|>RELATION_I 预后<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_E 作用<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2006年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2007年<|>RELATION_NOE 1月<|>RELATION_NOE 间<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE Ⅲ<|>RELATION_NOE a<|>RELATION_NOE 期<|>RELATION_NOE N2<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 获取<|>RELATION_NOE 肺部<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 配对<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 扩增<|>RELATION_NOE 阻滞<|>RELATION_NOE 突变<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE amplification<|>RELATION_NOE refractory<|>RELATION_NOE mutation<|>RELATION_NOE system<|>RELATION_NOE ,<|>RELATION_NOE ARMS<|>RELATION_NOE )<|>RELATION_NOE 针对<|>RELATION_NOE 腺癌<|>RELATION_NOE 原发灶<|>RELATION_NOE 和<|>RELATION_NOE 配对<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 灶<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 单因素<|>RELATION_NOE 分析<|>RELATION_NOE 和<|>RELATION_NOE Cox<|>RELATION_NOE 比例<|>RELATION_NOE 风险<|>RELATION_NOE 模型<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 及其<|>RELATION_NOE 异质性<|>RELATION_NOE 作为<|>RELATION_NOE 影响<|>RELATION_NOE 因子<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 52.6<|>RELATION_NOE 3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 9例<|>RELATION_NOE (<|>RELATION_NOE 22.5%<|>RELATION_NOE )<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 肺部<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 与<|>RELATION_NOE 配对<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶间<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 异质性<|>RELATION_NOE 。<|>RELATION_NOE
基因<|>RELATION_NOE 异质性<|>RELATION_NOE 因素<|>RELATION_NOE 对<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 总<|>RELATION_NOE 生存期<|>RELATION_NOE 和<|>RELATION_NOE 无<|>RELATION_NOE 疾病<|>RELATION_NOE 进展期<|>RELATION_NOE 不<|>RELATION_B 构成<|>RELATION_I 影响<|>RELATION_E (<|>RELATION_NOE 矿=<|>RELATION_NOE 1.7<|>RELATION_NOE 74<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.183<|>RELATION_NOE ;<|>RELATION_NOE
以往<|>RELATION_NOE 使用<|>RELATION_NOE 单一<|>RELATION_NOE 位<|>RELATION_NOE 点<|>RELATION_NOE 标本<|>RELATION_NOE 评估<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 不<|>RELATION_B 能够<|>RELATION_I 反应<|>RELATION_E 患者<|>RELATION_NOE 整体<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 造成<|>RELATION_NOE 靶向<|>RELATION_NOE 药物<|>RELATION_NOE 预测<|>RELATION_NOE 效果<|>RELATION_NOE 和<|>RELATION_NOE 实际<|>RELATION_NOE 使用<|>RELATION_NOE 效果<|>RELATION_NOE 间<|>RELATION_NOE 的<|>RELATION_NOE 偏差<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 预测<|>RELATION_NOE 预后<|>RELATION_NOE 方面<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 状态<|>RELATION_NOE 作为<|>RELATION_NOE 独立<|>RELATION_NOE 影响<|>RELATION_NOE 因子<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 预测<|>RELATION_B 作用<|>RELATION_I 有限<|>RELATION_E 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 中转<|>RELATION_NOE 开胸<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_B 影响<|>RELATION_E
淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 干扰<|>RELATION_NOE 是<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 手术<|>RELATION_NOE 中<|>RELATION_NOE 转<|>RELATION_NOE 开胸<|>RELATION_NOE 最<|>RELATION_B 主要<|>RELATION_I 的<|>RELATION_I 原因<|>RELATION_E ,<|>RELATION_NOE 导致<|>RELATION_NOE 手术时间<|>RELATION_NOE 延长<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 出血<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 恢复<|>RELATION_NOE 延迟<|>RELATION_NOE 。<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 干扰<|>RELATION_NOE 是<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 手术<|>RELATION_NOE 中转<|>RELATION_NOE 开胸<|>RELATION_NOE 最<|>RELATION_NOE 主要<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE ,<|>RELATION_NOE 导致<|>RELATION_S 手术时间<|>RELATION_NOE 延长<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 出血<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 恢复<|>RELATION_NOE 延迟<|>RELATION_NOE 。<|>RELATION_NOE
天龙<|>RELATION_NOE 咳喘灵<|>RELATION_NOE 提取物<|>RELATION_NOE 抑制<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间质<|>RELATION_NOE 转化<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 微<|>RELATION_NOE RNA<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE
探讨<|>RELATION_NOE 天龙<|>RELATION_NOE 咳喘灵<|>RELATION_NOE 提取物<|>RELATION_NOE 抑制<|>RELATION_S 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE B1<|>RELATION_NOE (<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE )<|>RELATION_NOE 诱导<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间质<|>RELATION_NOE 转化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 微<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE miRNA<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
体外<|>RELATION_NOE 培养<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE 刺激<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 60min<|>RELATION_NOE 后<|>RELATION_NOE 加入<|>RELATION_NOE 天龙<|>RELATION_NOE 咳喘灵<|>RELATION_NOE 提取物<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 相差<|>RELATION_NOE 显微镜<|>RELATION_NOE 观察<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 形态学<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
反转录<|>RELATION_NOE -PCR<|>RELATION_NOE 、<|>RELATION_NOE 免疫印迹法<|>RELATION_NOE 检测<|>RELATION_S a-<|>RELATION_NOE 平滑肌<|>RELATION_NOE 肌动<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE a-SMA<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
miRNA<|>RELATION_NOE 芯片<|>RELATION_NOE 检测<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE EMT<|>RELATION_NOE 前后<|>RELATION_NOE miRNA<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
miRNA<|>RELATION_NOE 芯片<|>RELATION_NOE 检测<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 未<|>RELATION_NOE 处理<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE EMT<|>RELATION_NOE 后<|>RELATION_NOE 有<|>RELATION_NOE 41<|>RELATION_B 种<|>RELATION_I miRNA<|>RELATION_I 表达<|>RELATION_I 出现<|>RELATION_I 显著<|>RELATION_I 改变<|>RELATION_E ,<|>RELATION_NOE 其中<|>RELATION_NOE 26<|>RELATION_NOE 种<|>RELATION_NOE 表达<|>RELATION_NOE 上调<|>RELATION_NOE 2<|>RELATION_NOE 倍<|>RELATION_NOE 以上<|>RELATION_NOE ,<|>RELATION_NOE 15<|>RELATION_NOE 种<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 2<|>RELATION_NOE 倍<|>RELATION_NOE 以上<|>RELATION_NOE ;<|>RELATION_NOE
肺原发性<|>RELATION_NOE 平滑肌瘤<|>RELATION_NOE CT<|>RELATION_NOE 征象<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 对照<|>RELATION_B 分析<|>RELATION_E
6例<|>RELATION_NOE 病理<|>RELATION_NOE 结果<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 良性<|>RELATION_NOE ,<|>RELATION_NOE 镜<|>RELATION_NOE 下示<|>RELATION_NOE 平滑肌<|>RELATION_NOE 瘤细胞<|>RELATION_NOE 呈<|>RELATION_NOE 梭形<|>RELATION_NOE 或<|>RELATION_NOE 束状<|>RELATION_NOE ,<|>RELATION_NOE 可见<|>RELATION_NOE 假<|>RELATION_NOE 包膜<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 平滑肌<|>RELATION_NOE 瘤细胞<|>RELATION_NOE 发生<|>RELATION_NOE 玻璃样<|>RELATION_NOE 变性<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 检验示<|>RELATION_NOE 平滑肌<|>RELATION_NOE 肌动<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE SMA<|>RELATION_NOE )<|>RELATION_NOE 均<|>RELATION_NOE 标记<|>RELATION_NOE 阳性<|>RELATION_NOE 。<|>RELATION_NOE
维生素<|>RELATION_NOE D<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE 多<|>RELATION_NOE 态<|>RELATION_NOE 性位点<|>RELATION_NOE rs7975232<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 风险<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
维生素<|>RELATION_NOE D<|>RELATION_NOE 受体<|>RELATION_NOE 基因<|>RELATION_NOE rs7975232<|>RELATION_NOE 位点<|>RELATION_NOE 等位基因<|>RELATION_NOE A<|>RELATION_NOE 携带者<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 风险<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 等位基因<|>RELATION_NOE C<|>RELATION_NOE 携带者<|>RELATION_NOE [<|>RELATION_NOE 比值比<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE )<|>RELATION_NOE =<|>RELATION_NOE 0.<|>RELATION_NOE 501<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE 置信区间<|>RELATION_NOE (<|>RELATION_NOE CI<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 0.2<|>RELATION_NOE 73<|>RELATION_NOE －0.9<|>RELATION_NOE 20<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 26<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 临床<|>RELATION_B 效果<|>RELATION_E 观察<|>RELATION_NOE
比较<|>RELATION_NOE 电视<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 常规<|>RELATION_NOE 开<|>RELATION_NOE 胸肺<|>RELATION_NOE 叶切<|>RELATION_NOE 除术<|>RELATION_NOE 治疗<|>RELATION_B 早期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_I (<|>RELATION_I NSCLC<|>RELATION_I )<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 引流管<|>RELATION_NOE 放置<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE 7.05<|>RELATION_NOE ±<|>RELATION_NOE 0.19<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 引流量<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE 96.7<|>RELATION_NOE ±<|>RELATION_NOE 51<|>RELATION_NOE 7.5<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE (<|>RELATION_NOE 6.73<|>RELATION_NOE ±<|>RELATION_NOE 0.16<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 方面<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 8.94<|>RELATION_NOE ±<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 233<|>RELATION_NOE 1.9<|>RELATION_NOE ±<|>RELATION_NOE 43<|>RELATION_NOE 1.5<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 11.7<|>RELATION_NOE ±<|>RELATION_NOE 0.67<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ]<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.9<|>RELATION_NOE 58<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 25<|>RELATION_NOE ;<|>RELATION_NOE
人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE 1<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_NOE 转录因子<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE MALATl<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 发生<|>RELATION_B 、<|>RELATION_I 发展<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 新鲜<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 及其<|>RELATION_NOE 对应<|>RELATION_NOE 的<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 各<|>RELATION_NOE 86<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE 1iT<|>RELATION_NOE .<|>RELATION_NOE
MALATl<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE [<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 52.3<|>RELATION_NOE 8%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ期<|>RELATION_NOE 76.00%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 25<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 97.50%<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 11.8<|>RELATION_NOE 39<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 42<|>RELATION_NOE ]<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE [<|>RELATION_NOE 高<|>RELATION_NOE 分化<|>RELATION_NOE 39.1<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 9/<|>RELATION_NOE 23<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 中<|>RELATION_NOE 分化<|>RELATION_NOE 74.4<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE 35<|>RELATION_NOE /<|>RELATION_NOE 47<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 低<|>RELATION_NOE 分化<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 16<|>RELATION_NOE /<|>RELATION_NOE 16<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 15.3<|>RELATION_NOE 83<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 32<|>RELATION_NOE ]<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE [<|>RELATION_NOE 有<|>RELATION_NOE 97.2<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 35<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 46.00%<|>RELATION_NOE (<|>RELATION_NOE 23<|>RELATION_NOE /<|>RELATION_NOE 50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 23.9<|>RELATION_NOE 47<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 30<|>RELATION_NOE ]<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
老年性<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 单肺通气<|>RELATION_B 的<|>RELATION_I 麻醉<|>RELATION_I 护理<|>RELATION_E 心得<|>RELATION_NOE
本文<|>RELATION_NOE 主要<|>RELATION_NOE 分析<|>RELATION_NOE 老年性<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 使用<|>RELATION_S 单肺通气<|>RELATION_NOE 的<|>RELATION_NOE 麻醉<|>RELATION_NOE 护理<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 选择<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 4月<|>RELATION_NOE 我院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE 计算机<|>RELATION_NOE 随机<|>RELATION_NOE 方法<|>RELATION_NOE 将<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 与<|>RELATION_NOE 实验组<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 31<|>RELATION_NOE 例.<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 给予<|>RELATION_NOE 针对<|>RELATION_NOE 性循证<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 对比<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
实验组<|>RELATION_NOE 患者<|>RELATION_NOE 单肺通气<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 麻醉<|>RELATION_NOE 苏醒<|>RELATION_NOE 时间<|>RELATION_NOE 与<|>RELATION_NOE 伤口<|>RELATION_NOE 疼痛<|>RELATION_NOE 程度<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 优于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 在<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 研究<|>RELATION_E
主要<|>RELATION_NOE 毒副反应<|>RELATION_NOE 是<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 、<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 和<|>RELATION_NOE 轻度<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 对<|>RELATION_B 症<|>RELATION_I 支持<|>RELATION_I 治疗<|>RELATION_E 患者<|>RELATION_NOE 均<|>RELATION_NOE 能<|>RELATION_NOE 耐受<|>RELATION_NOE 。<|>RELATION_NOE
晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE -<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_I 获得<|>RELATION_I 性耐<|>RELATION_I 药<|>RELATION_E 后<|>RELATION_NOE 培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞化疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
收集<|>RELATION_NOE 山西省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 呼吸科<|>RELATION_NOE 2009年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 10月<|>RELATION_NOE 可<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE (<|>RELATION_NOE 非<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 75<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 二线<|>RELATION_NOE 使用<|>RELATION_NOE EGFR-TKI<|>RELATION_NOE 达到<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 以上<|>RELATION_NOE 出现<|>RELATION_NOE 病情<|>RELATION_NOE 进展<|>RELATION_NOE 者<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ;<|>RELATION_NOE
顺铂<|>RELATION_NOE 每<|>RELATION_NOE 次<|>RELATION_NOE 20－<|>RELATION_NOE 30mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 至<|>RELATION_NOE 第4<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 2－<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 1<|>RELATION_NOE 年<|>RELATION_NOE 。<|>RELATION_NOE
75<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 可<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 接受<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 及<|>RELATION_NOE 以上<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 总<|>RELATION_NOE 有效率<|>RELATION_NOE 16.0%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 75<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 52.0%<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE /<|>RELATION_NOE 75<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 3.4<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 为<|>RELATION_NOE 8.8<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE .<|>RELATION_NOE
不良<|>RELATION_NOE 反应<|>RELATION_NOE 主要<|>RELATION_NOE 为<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE ,<|>RELATION_NOE Ⅲ<|>RELATION_NOE －<|>RELATION_NOE Ⅳ<|>RELATION_NOE 度<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 16%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 75<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 还有<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 乏力<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 发生率<|>RELATION_B 均<|>RELATION_I 较<|>RELATION_I 低<|>RELATION_E 。<|>RELATION_NOE
18F-<|>RELATION_NOE 脱氧葡萄糖<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 断层<|>RELATION_NOE 扫描<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 标准化<|>RELATION_NOE 摄取值<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 540<|>RELATION_NOE 例行<|>RELATION_NOE 18<|>RELATION_NOE F-FDG<|>RELATION_NOE PET-CT<|>RELATION_NOE 检查<|>RELATION_NOE 后<|>RELATION_NOE 接受<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 初治<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 患者<|>RELATION_NOE 不同<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 参数<|>RELATION_NOE 进行<|>RELATION_NOE 分组<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE 或<|>RELATION_NOE 单因素<|>RELATION_NOE 方差分析<|>RELATION_NOE 比较<|>RELATION_NOE 不同<|>RELATION_NOE 组别<|>RELATION_NOE 间<|>RELATION_NOE SUVmax<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Pearson<|>RELATION_NOE 相关<|>RELATION_NOE 或<|>RELATION_NOE Spearman<|>RELATION_NOE 秩<|>RELATION_NOE 相关<|>RELATION_NOE 分析<|>RELATION_NOE SUVmax<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 基线<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_B 的<|>RELATION_I 关系<|>RELATION_E
基线<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 升高<|>RELATION_NOE 提示<|>RELATION_S NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 分期晚<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 大<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 侵犯<|>RELATION_NOE 以及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 血管<|>RELATION_NOE 生成<|>RELATION_NOE 丰富<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 地<|>RELATION_NOE 预测<|>RELATION_NOE 不<|>RELATION_NOE 同<|>RELATION_NOE 分期<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE .<|>RELATION_NOE
波形蛋白<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE
观察<|>RELATION_NOE 波形蛋白<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤转移<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
使用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 164<|>RELATION_NOE 例<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 、<|>RELATION_NOE 108<|>RELATION_NOE 例<|>RELATION_NOE 腺癌<|>RELATION_NOE 以及<|>RELATION_NOE 其他<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE 其他<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 波形蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
波形蛋白<|>RELATION_NOE 在<|>RELATION_NOE 上述<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 总<|>RELATION_NOE 检出率<|>RELATION_NOE 为<|>RELATION_NOE 49.2%<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE /<|>RELATION_NOE 间<|>RELATION_NOE 质<|>RELATION_NOE 表面<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 状态<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E .<|>RELATION_NOE
随<|>RELATION_NOE 访<|>RELATION_NOE 患者<|>RELATION_NOE 表明<|>RELATION_NOE ,<|>RELATION_NOE ><|>RELATION_NOE 50%<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 表达<|>RELATION_NOE 波形蛋白<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 出现<|>RELATION_S 肿瘤转移<|>RELATION_NOE 。<|>RELATION_NOE
塞来昔布<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 手术<|>RELATION_NOE 应激<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE
3组<|>RELATION_NOE 小鼠<|>RELATION_NOE 均尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 1×<|>RELATION_NOE 106<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 4<|>RELATION_NOE 周<|>RELATION_NOE 后<|>RELATION_NOE 处死<|>RELATION_NOE 所有<|>RELATION_NOE 小鼠<|>RELATION_NOE ,<|>RELATION_NOE 5%<|>RELATION_NOE 苦味<|>RELATION_NOE 酸染色<|>RELATION_NOE 比较<|>RELATION_NOE 各组<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺<|>RELATION_NOE 表面结节数<|>RELATION_NOE ;<|>RELATION_NOE
苏木素<|>RELATION_NOE -<|>RELATION_NOE 伊红<|>RELATION_NOE (<|>RELATION_NOE HE<|>RELATION_NOE )<|>RELATION_NOE 染色<|>RELATION_NOE 明确<|>RELATION_S 各组<|>RELATION_NOE 肺结节病<|>RELATION_NOE 理<|>RELATION_NOE 性质<|>RELATION_NOE ,<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE 检测<|>RELATION_NOE 不<|>RELATION_NOE 同时<|>RELATION_NOE 间点<|>RELATION_NOE 小鼠<|>RELATION_NOE 血清<|>RELATION_NOE 前列腺素<|>RELATION_NOE E2<|>RELATION_NOE (<|>RELATION_NOE PGE2<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE .<|>RELATION_NOE 苏木素<|>RELATION_NOE -<|>RELATION_NOE 伊红<|>RELATION_NOE (<|>RELATION_NOE HE<|>RELATION_NOE )<|>RELATION_NOE 染色<|>RELATION_NOE 明确<|>RELATION_NOE 各组<|>RELATION_NOE 肺结节病<|>RELATION_NOE 理<|>RELATION_NOE 性质<|>RELATION_NOE ,<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE 检测<|>RELATION_S 不同<|>RELATION_NOE 时间<|>RELATION_NOE 点<|>RELATION_NOE 小鼠<|>RELATION_NOE 血清<|>RELATION_NOE 前列腺素<|>RELATION_NOE E2<|>RELATION_NOE (<|>RELATION_NOE PGE2<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE .<|>RELATION_NOE
利用<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 进行<|>RELATION_NOE 划痕<|>RELATION_NOE 实验<|>RELATION_NOE 、<|>RELATION_NOE Transwell<|>RELATION_NOE 小室<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_S 体外<|>RELATION_NOE PGE2<|>RELATION_NOE 和<|>RELATION_NOE Celecoxib<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 迁移<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE Real-time<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE
HE<|>RELATION_NOE 染色<|>RELATION_NOE 确定<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺<|>RELATION_NOE 表面结节系<|>RELATION_NOE A549<|>RELATION_NOE 细胞肺<|>RELATION_NOE 转移<|>RELATION_NOE 灶.<|>RELATION_NOE
与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 组<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺<|>RELATION_NOE 表面<|>RELATION_NOE 肺结节数<|>RELATION_NOE 明显<|>RELATION_B 增多<|>RELATION_E [<|>RELATION_NOE (<|>RELATION_NOE 30.2<|>RELATION_NOE ±<|>RELATION_NOE 8.8<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 17.2<|>RELATION_NOE ±<|>RELATION_NOE 5.2<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 第3<|>RELATION_NOE 天<|>RELATION_NOE 血清<|>RELATION_NOE 平均<|>RELATION_NOE PGE2<|>RELATION_NOE 水平<|>RELATION_NOE 较<|>RELATION_NOE 术前<|>RELATION_NOE 明显<|>RELATION_NOE 升高<|>RELATION_NOE 达到<|>RELATION_NOE (<|>RELATION_NOE 21<|>RELATION_NOE 2.8<|>RELATION_NOE ±<|>RELATION_NOE 52.9<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 手术组<|>RELATION_NOE 给予<|>RELATION_NOE Celecoxib<|>RELATION_NOE 则<|>RELATION_NOE 能<|>RELATION_NOE 明显<|>RELATION_NOE 抑制<|>RELATION_NOE 肺结节数<|>RELATION_NOE 增多<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 9.1<|>RELATION_NOE ±<|>RELATION_NOE 4.2<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE 血清<|>RELATION_NOE PGE2<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE 2.7<|>RELATION_NOE ±<|>RELATION_NOE 11.2<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 手术组<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺<|>RELATION_NOE 表面<|>RELATION_NOE 肺结节<|>RELATION_NOE 数<|>RELATION_NOE 明显<|>RELATION_NOE 增多<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 30.2<|>RELATION_NOE ±<|>RELATION_NOE 8.8<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 17.2<|>RELATION_NOE ±<|>RELATION_NOE 5.2<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 第3<|>RELATION_NOE 天<|>RELATION_NOE 血清<|>RELATION_NOE 平均<|>RELATION_NOE PGE2<|>RELATION_NOE 水平<|>RELATION_NOE 较术<|>RELATION_NOE 前<|>RELATION_NOE 明显<|>RELATION_B 升高<|>RELATION_E 达到<|>RELATION_NOE (<|>RELATION_NOE 21<|>RELATION_NOE 2.8<|>RELATION_NOE ±<|>RELATION_NOE 52.9<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 手术组<|>RELATION_NOE 给予<|>RELATION_NOE Celecoxib<|>RELATION_NOE 则<|>RELATION_NOE 能<|>RELATION_NOE 明显<|>RELATION_NOE 抑制<|>RELATION_NOE 肺结节数<|>RELATION_NOE 增多<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 9.1<|>RELATION_NOE ±<|>RELATION_NOE 4.2<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE 血清<|>RELATION_NOE PGE2<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE 2.7<|>RELATION_NOE ±<|>RELATION_NOE 11.2<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
过<|>RELATION_NOE 表达<|>RELATION_NOE 磷脂酰肌醇<|>RELATION_NOE 蛋白<|>RELATION_NOE 聚糖<|>RELATION_NOE -5<|>RELATION_NOE 对<|>RELATION_NOE 肺鳞<|>RELATION_NOE 癌细胞株<|>RELATION_NOE SK-MES-1<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 迁移<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 磷脂酰肌醇<|>RELATION_NOE 蛋白<|>RELATION_NOE 聚糖<|>RELATION_NOE -5<|>RELATION_NOE (<|>RELATION_NOE GPC5<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺鳞<|>RELATION_NOE 癌细胞株<|>RELATION_NOE SK-MES-1<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 迁移<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
通过<|>RELATION_NOE 细胞<|>RELATION_NOE 划痕<|>RELATION_NOE 和<|>RELATION_NOE Transwell<|>RELATION_NOE 小室<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE GPC5<|>RELATION_NOE 对<|>RELATION_NOE 肺鳞<|>RELATION_NOE 癌细胞株<|>RELATION_NOE SK-MES-1<|>RELATION_NOE 迁移<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE .<|>RELATION_NOE
细胞计数<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE (<|>RELATION_NOE CCK-8<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 过<|>RELATION_NOE 表达<|>RELATION_NOE GPC5<|>RELATION_NOE 对<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 细胞计数<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE (<|>RELATION_NOE CCK-8<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE GPC5<|>RELATION_NOE 对<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 其<|>RELATION_NOE 细胞周期<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 阴性<|>RELATION_NOE 对照组<|>RELATION_NOE NC-SK-MES-1<|>RELATION_NOE 细胞<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE GPC5<|>RELATION_NOE 的<|>RELATION_NOE 肺鳞<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE GPC5<|>RELATION_NOE 基因表达<|>RELATION_NOE 量<|>RELATION_NOE (<|>RELATION_NOE 79.1<|>RELATION_NOE 13<|>RELATION_NOE ±<|>RELATION_NOE 9.2<|>RELATION_NOE 46<|>RELATION_NOE )<|>RELATION_NOE 增加<|>RELATION_B 了<|>RELATION_I 86<|>RELATION_I 倍<|>RELATION_E .<|>RELATION_NOE
细胞周期<|>RELATION_NOE 检测<|>RELATION_NOE 显示<|>RELATION_NOE S<|>RELATION_NOE 期<|>RELATION_NOE 细胞数<|>RELATION_NOE 比率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 50.32<|>RELATION_NOE ±<|>RELATION_NOE 0.97<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 32.59<|>RELATION_NOE ±<|>RELATION_NOE 1.54<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 显著<|>RELATION_B 增加<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
18F-<|>RELATION_NOE 氟代<|>RELATION_NOE 脱氧葡萄糖<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 断层<|>RELATION_NOE 显像<|>RELATION_NOE 对<|>RELATION_NOE 诊断<|>RELATION_S 肺癌<|>RELATION_NOE 脊柱<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE
应用<|>RELATION_NOE 18F-<|>RELATION_NOE 氟代<|>RELATION_NOE 脱氧葡萄糖<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 断层<|>RELATION_NOE 显像<|>RELATION_NOE (<|>RELATION_NOE FDG-PET-CT<|>RELATION_NOE )<|>RELATION_NOE 检查<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 脊柱骨<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 影像学<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 2005年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 9月<|>RELATION_NOE 在<|>RELATION_NOE 本院<|>RELATION_NOE 行<|>RELATION_NOE 18F-FDG-PET-CT<|>RELATION_NOE 的<|>RELATION_NOE 89<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 脊柱<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 18F-FDG-PET-CT<|>RELATION_NOE 检查<|>RELATION_NOE 发现<|>RELATION_NOE 的<|>RELATION_NOE 422<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 分别<|>RELATION_NOE 在<|>RELATION_NOE PET<|>RELATION_NOE 、<|>RELATION_NOE 同机<|>RELATION_NOE CT<|>RELATION_NOE 及<|>RELATION_NOE PET-CT<|>RELATION_NOE 融合<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE 表现<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 图像<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 位置<|>RELATION_NOE ,<|>RELATION_NOE CT<|>RELATION_NOE 图像<|>RELATION_NOE 骨质<|>RELATION_NOE 破坏<|>RELATION_NOE 以及<|>RELATION_NOE 骨<|>RELATION_NOE 破坏<|>RELATION_NOE 周围<|>RELATION_NOE 软组织<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE PET<|>RELATION_NOE 对<|>RELATION_NOE 骨质<|>RELATION_NOE 破坏<|>RELATION_NOE 检出<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE ,<|>RELATION_NOE 对比<|>RELATION_NOE PET<|>RELATION_NOE 、<|>RELATION_NOE 同机<|>RELATION_NOE CT<|>RELATION_NOE 对<|>RELATION_NOE 脊柱<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 检出率<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE 。<|>RELATION_NOE
18F-FDG-PET-CT<|>RELATION_NOE 共<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 的<|>RELATION_NOE 422<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 中<|>RELATION_NOE 确诊<|>RELATION_NOE 脊柱<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 351<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 胸椎<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 119<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 腰椎<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 104<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 骶椎<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 83<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 颈椎<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 45<|>RELATION_NOE 个<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 脊柱<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 270<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 溶骨<|>RELATION_NOE 性骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 162<|>RELATION_NOE 个<|>RELATION_NOE (<|>RELATION_NOE 60%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 成骨性<|>RELATION_NOE 骨质<|>RELATION_NOE 破坏<|>RELATION_NOE 病灶<|>RELATION_NOE 35<|>RELATION_NOE 个<|>RELATION_NOE (<|>RELATION_NOE 13%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 混合性<|>RELATION_NOE 骨质<|>RELATION_NOE 破坏<|>RELATION_NOE 73<|>RELATION_NOE 个<|>RELATION_NOE (<|>RELATION_NOE 27%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
351<|>RELATION_NOE 个<|>RELATION_NOE 脊柱<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 病灶<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 66<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE (<|>RELATION_NOE 18-8<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE 有<|>RELATION_NOE 椎体<|>RELATION_NOE 周围<|>RELATION_NOE 软组织<|>RELATION_NOE 肿块<|>RELATION_NOE 形成<|>RELATION_NOE 或<|>RELATION_NOE 软组织<|>RELATION_NOE 异常<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 有<|>RELATION_NOE 9<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 侵犯<|>RELATION_NOE 硬膜<|>RELATION_NOE 外<|>RELATION_NOE 间隙<|>RELATION_NOE ,<|>RELATION_NOE 9<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 侵犯<|>RELATION_NOE 椎间孔<|>RELATION_NOE ,<|>RELATION_NOE 11<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 两者<|>RELATION_NOE 同时<|>RELATION_NOE 侵犯<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 操作孔<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 单<|>RELATION_NOE 操作孔<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术加<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
回顾<|>RELATION_NOE 分析<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 3月<|>RELATION_NOE 采用<|>RELATION_NOE 单操作孔<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 并且<|>RELATION_NOE 系统性<|>RELATION_NOE 清扫<|>RELATION_NOE 淋巴结<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术加<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 手术时间<|>RELATION_NOE 90<|>RELATION_NOE －<|>RELATION_NOE 200min<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 出血量<|>RELATION_NOE 50<|>RELATION_NOE －<|>RELATION_NOE 400ml<|>RELATION_NOE ,<|>RELATION_NOE 清扫<|>RELATION_NOE 淋巴结<|>RELATION_NOE 数量<|>RELATION_NOE 9－<|>RELATION_NOE 16<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 5-8d<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 住院<|>RELATION_NOE 6－<|>RELATION_NOE 10d<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 操作孔<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术加<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 传统<|>RELATION_NOE 的<|>RELATION_NOE 三<|>RELATION_NOE 孔<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 基础<|>RELATION_NOE 上进<|>RELATION_NOE －步<|>RELATION_NOE 减少<|>RELATION_NOE 了<|>RELATION_NOE 手术<|>RELATION_NOE 创伤<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 优势<|>RELATION_NOE ,<|>RELATION_NOE 只要<|>RELATION_NOE 病例<|>RELATION_NOE 选择<|>RELATION_NOE 合适<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_S 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 更<|>RELATION_NOE 微创化<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 并存<|>RELATION_NOE 疾病<|>RELATION_NOE 和<|>RELATION_NOE 年龄<|>RELATION_NOE 对<|>RELATION_NOE 一线<|>RELATION_NOE 单<|>RELATION_NOE 药<|>RELATION_NOE 化疗<|>RELATION_NOE 耐受性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 并存<|>RELATION_NOE 疾病<|>RELATION_NOE 及<|>RELATION_NOE 年龄<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 一线<|>RELATION_NOE 单<|>RELATION_NOE 药<|>RELATION_NOE 化疗<|>RELATION_NOE 耐受性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 61<|>RELATION_NOE 例本院<|>RELATION_NOE 肿瘤<|>RELATION_NOE 内科<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 70<|>RELATION_NOE 岁<|>RELATION_NOE 及<|>RELATION_NOE 以上<|>RELATION_NOE 一线<|>RELATION_NOE 行<|>RELATION_NOE 单药<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
疗前<|>RELATION_NOE 并存<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 评价<|>RELATION_NOE 有助于<|>RELATION_B 判断<|>RELATION_E 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 单<|>RELATION_NOE 药<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 耐受性<|>RELATION_NOE 。<|>RELATION_NOE
沐<|>RELATION_NOE 舒坦<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植入术<|>RELATION_NOE 中<|>RELATION_NOE 肺<|>RELATION_B 的<|>RELATION_I 保护<|>RELATION_I 作用<|>RELATION_E
选取<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 3月<|>RELATION_NOE 在<|>RELATION_NOE 天津<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 第二<|>RELATION_NOE 医院<|>RELATION_NOE 胸外科行<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 肺癌<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 93<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分成<|>RELATION_NOE 大<|>RELATION_NOE 剂量组<|>RELATION_NOE 、<|>RELATION_NOE 小<|>RELATION_NOE 剂量组<|>RELATION_NOE 以及<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 三<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 术后行<|>RELATION_NOE 常规<|>RELATION_NOE 免疫<|>RELATION_NOE 以及<|>RELATION_NOE 营养支持<|>RELATION_NOE 等<|>RELATION_NOE 综合治疗<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 大<|>RELATION_NOE 剂量组<|>RELATION_NOE 给予<|>RELATION_NOE 沐<|>RELATION_NOE 舒坦<|>RELATION_NOE 990mg<|>RELATION_NOE /<|>RELATION_NOE d<|>RELATION_NOE 持续<|>RELATION_NOE 静脉<|>RELATION_NOE 泵入<|>RELATION_NOE ,<|>RELATION_NOE 小<|>RELATION_NOE 剂量组<|>RELATION_NOE 给予<|>RELATION_NOE 300mg<|>RELATION_NOE /<|>RELATION_NOE d<|>RELATION_NOE 持续<|>RELATION_NOE 静脉<|>RELATION_NOE 泵入<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 给<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 三<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 气胸<|>RELATION_NOE 发生率<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 第<|>RELATION_NOE l<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 天<|>RELATION_NOE 的<|>RELATION_NOE C<|>RELATION_NOE 反应<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE CRP<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE a<|>RELATION_NOE (<|>RELATION_NOE TNF-a<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE 绝对值<|>RELATION_NOE (<|>RELATION_NOE ANC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
三<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE CRP<|>RELATION_NOE 、<|>RELATION_NOE TNF-a<|>RELATION_NOE 以及<|>RELATION_NOE ANC<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 术后<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 天<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 大<|>RELATION_NOE 剂量组<|>RELATION_NOE 患者<|>RELATION_NOE CRP<|>RELATION_NOE 、<|>RELATION_NOE TNF-a<|>RELATION_NOE 以及<|>RELATION_NOE ANC<|>RELATION_NOE 在<|>RELATION_NOE 术后<|>RELATION_NOE 第5<|>RELATION_NOE 天<|>RELATION_NOE 均<|>RELATION_NOE 低于<|>RELATION_NOE 小<|>RELATION_NOE 剂量组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 3.5<|>RELATION_NOE 96<|>RELATION_NOE 、<|>RELATION_NOE 3.5<|>RELATION_NOE 55<|>RELATION_NOE 、<|>RELATION_NOE 3.406<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 31<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 33<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 37<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE 组<|>RELATION_NOE 气胸<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 4.31<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 三<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE CRP<|>RELATION_NOE 、<|>RELATION_NOE TNF-a<|>RELATION_NOE 以及<|>RELATION_NOE ANC<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 术后<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 3天<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 大<|>RELATION_NOE 剂量组<|>RELATION_NOE 患者<|>RELATION_NOE CRP<|>RELATION_NOE 、<|>RELATION_NOE TNF-a<|>RELATION_NOE 以及<|>RELATION_NOE ANC<|>RELATION_NOE 在<|>RELATION_NOE 术后<|>RELATION_NOE 第5<|>RELATION_NOE 天<|>RELATION_NOE 均<|>RELATION_NOE 低于<|>RELATION_S 小<|>RELATION_NOE 剂量组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 3.5<|>RELATION_NOE 96<|>RELATION_NOE 、<|>RELATION_NOE 3.5<|>RELATION_NOE 55<|>RELATION_NOE 、<|>RELATION_NOE 3.406<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 31<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 33<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 37<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE 组<|>RELATION_NOE 气胸<|>RELATION_NOE 发生率<|>RELATION_NOE 三<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE CRP<|>RELATION_NOE 、<|>RELATION_NOE TNF-a<|>RELATION_NOE 以及<|>RELATION_NOE ANC<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 术后<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 3天<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 大<|>RELATION_NOE 剂量组<|>RELATION_NOE 患者<|>RELATION_NOE CRP<|>RELATION_NOE 、<|>RELATION_NOE TNF-a<|>RELATION_NOE 以及<|>RELATION_NOE ANC<|>RELATION_NOE 在<|>RELATION_NOE 术后<|>RELATION_NOE 第5<|>RELATION_NOE 天<|>RELATION_NOE 均<|>RELATION_NOE 低于<|>RELATION_NOE 小<|>RELATION_NOE 剂量组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 3.5<|>RELATION_NOE 96<|>RELATION_NOE 、<|>RELATION_NOE 3.5<|>RELATION_NOE 55<|>RELATION_NOE 、<|>RELATION_NOE 3.406<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 31<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 33<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 37<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE 组<|>RELATION_NOE 气胸<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 4.31<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 术围<|>RELATION_NOE 术期<|>RELATION_NOE 应用<|>RELATION_NOE 大<|>RELATION_B 剂量<|>RELATION_I 沐<|>RELATION_I 舒坦<|>RELATION_I 治疗<|>RELATION_E 有助于<|>RELATION_NOE 较<|>RELATION_NOE 快<|>RELATION_NOE 减轻<|>RELATION_NOE 肺部<|>RELATION_NOE 的<|>RELATION_NOE 炎性<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 气胸<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE
厄洛替尼<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射<|>RELATION_B 增敏<|>RELATION_I 作用<|>RELATION_E
采用<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S 厄洛替尼<|>RELATION_NOE 对<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 半数<|>RELATION_NOE 抑制<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE IC50<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
厄洛替尼<|>RELATION_NOE 作用<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 受到<|>RELATION_B 抑制<|>RELATION_E ,<|>RELATION_NOE 且<|>RELATION_NOE 细胞<|>RELATION_NOE 抑制率<|>RELATION_NOE 随<|>RELATION_NOE 药物<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 升高<|>RELATION_NOE 而<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE IC50<|>RELATION_NOE 为<|>RELATION_NOE 19.26<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 。<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 作用<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 受到<|>RELATION_NOE 抑制<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 细胞<|>RELATION_NOE 抑制率<|>RELATION_NOE 随<|>RELATION_NOE 药物<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 升高<|>RELATION_NOE 而<|>RELATION_NOE 增加<|>RELATION_S ,<|>RELATION_NOE IC50<|>RELATION_NOE 为<|>RELATION_NOE 19.26<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 。<|>RELATION_NOE
厄洛替尼<|>RELATION_NOE 与<|>RELATION_NOE 不同<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 照射<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 单纯<|>RELATION_NOE 照射组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 厄洛替尼<|>RELATION_B 照射组<|>RELATION_I 的<|>RELATION_I 细胞存活<|>RELATION_I 分数<|>RELATION_I (<|>RELATION_I SF<|>RELATION_I )<|>RELATION_I 下降<|>RELATION_E ,<|>RELATION_NOE 而且<|>RELATION_NOE 随着<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 作用<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 延长<|>RELATION_NOE 和<|>RELATION_NOE 照射<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE SF<|>RELATION_NOE 明显<|>RELATION_NOE 下降<|>RELATION_NOE 。<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 与<|>RELATION_NOE 不同<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 照射<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 单纯<|>RELATION_NOE 照射组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 照射组<|>RELATION_NOE 的<|>RELATION_NOE 细胞存活<|>RELATION_NOE 分数<|>RELATION_NOE (<|>RELATION_NOE SF<|>RELATION_NOE )<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 随着<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 作用<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 延长<|>RELATION_NOE 和<|>RELATION_NOE 照射<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE SF<|>RELATION_NOE 明显<|>RELATION_B 下降<|>RELATION_E 。<|>RELATION_NOE
中药<|>RELATION_NOE 松友<|>RELATION_NOE 饮<|>RELATION_NOE 对<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体内<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 残余<|>RELATION_NOE 肝癌<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
探讨<|>RELATION_NOE 中药<|>RELATION_NOE 松友<|>RELATION_NOE 饮<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 残余<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 转移<|>RELATION_NOE 潜能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及<|>RELATION_NOE 相关<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 人<|>RELATION_NOE 肝癌<|>RELATION_NOE MHCC97L<|>RELATION_NOE 细胞<|>RELATION_NOE 构建<|>RELATION_NOE 奥沙利<|>RELATION_NOE 铂化疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 残余<|>RELATION_NOE 肝癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 原位<|>RELATION_NOE 移植<|>RELATION_NOE 模型<|>RELATION_NOE 。<|>RELATION_NOE
成瘤<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 以<|>RELATION_NOE 2.1g<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 、<|>RELATION_NOE 4.2g<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 和<|>RELATION_NOE 8.4g<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 的<|>RELATION_NOE 松友<|>RELATION_NOE 饮<|>RELATION_NOE 灌胃<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 灌服<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 松友<|>RELATION_NOE 饮<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 残余<|>RELATION_NOE 肝癌<|>RELATION_NOE 生长<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 裸鼠<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
松友<|>RELATION_NOE 饮<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_B 降低<|>RELATION_E 化疗<|>RELATION_NOE 后<|>RELATION_NOE 残余<|>RELATION_NOE 肝癌<|>RELATION_NOE 的<|>RELATION_NOE 肺转移<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 2.1g<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE
松友<|>RELATION_NOE 饮<|>RELATION_NOE 可<|>RELATION_NOE 延长<|>RELATION_S 残余<|>RELATION_NOE 肝癌<|>RELATION_NOE 再<|>RELATION_NOE 接种<|>RELATION_NOE 裸鼠<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 2.1g<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE
甲状腺结节<|>RELATION_NOE 纵横<|>RELATION_NOE 比<|>RELATION_NOE 在<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
收集<|>RELATION_NOE 20<|>RELATION_NOE 11<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 在<|>RELATION_NOE 天津<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 甲状腺结节<|>RELATION_NOE 患者<|>RELATION_NOE 491<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 683<|>RELATION_NOE 个<|>RELATION_NOE 结节<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 超声<|>RELATION_NOE 测量<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 横切面<|>RELATION_NOE 纵横径<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE A<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE ≥<|>RELATION_NOE 1<|>RELATION_NOE 诊断<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 。<|>RELATION_NOE
根据<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径将<|>RELATION_NOE 结节<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 第一<|>RELATION_NOE 组<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE ,<|>RELATION_NOE 1cm<|>RELATION_NOE ,<|>RELATION_NOE 第二<|>RELATION_NOE 组<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE ≤<|>RELATION_NOE 1cm<|>RELATION_NOE 即<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE A<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE ≥<|>RELATION_NOE 1<|>RELATION_NOE 在<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 分布<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 通过<|>RELATION_NOE SPSS17.0<|>RELATION_NOE 软件<|>RELATION_NOE 进行<|>RELATION_NOE 统计<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
184<|>RELATION_NOE 个<|>RELATION_NOE 甲状腺<|>RELATION_NOE 良性<|>RELATION_NOE 结节<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 29<|>RELATION_NOE 个<|>RELATION_NOE (<|>RELATION_NOE 15.8%<|>RELATION_NOE )<|>RELATION_NOE A<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE ≥<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 155<|>RELATION_NOE 个<|>RELATION_NOE (<|>RELATION_NOE 84.2%<|>RELATION_NOE )<|>RELATION_NOE A<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE <<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.00<|>RELATION_NOE 0.4<|>RELATION_NOE 99<|>RELATION_NOE 个<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 233<|>RELATION_NOE 个<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 结节<|>RELATION_NOE ><|>RELATION_NOE 1em<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 132<|>RELATION_NOE 个<|>RELATION_NOE (<|>RELATION_NOE 56.7%<|>RELATION_NOE )<|>RELATION_NOE A<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE ≥<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 101<|>RELATION_NOE 个<|>RELATION_NOE (<|>RELATION_NOE 43.3%<|>RELATION_NOE )<|>RELATION_NOE A<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE <<|>RELATION_NOE 1<|>RELATION_NOE ;<|>RELATION_NOE
持续<|>RELATION_NOE 质量<|>RELATION_NOE 改进<|>RELATION_NOE 管理<|>RELATION_NOE 方法<|>RELATION_NOE 在<|>RELATION_NOE 抗肿瘤<|>RELATION_NOE 药物<|>RELATION_NOE 临床<|>RELATION_NOE 试验<|>RELATION_NOE 血<|>RELATION_NOE 标本<|>RELATION_NOE 采集<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
右<|>RELATION_NOE 美托<|>RELATION_NOE 咪定<|>RELATION_NOE 对<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 围术<|>RELATION_NOE 期末<|>RELATION_NOE 梢灌注<|>RELATION_NOE 指数<|>RELATION_NOE 和<|>RELATION_NOE 心率<|>RELATION_NOE 变异性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
择期<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE ASA<|>RELATION_NOE 分级<|>RELATION_NOE Ⅰ级<|>RELATION_NOE 或<|>RELATION_NOE Ⅱ<|>RELATION_NOE 级<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 40<|>RELATION_NOE －<|>RELATION_NOE 70<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 体重<|>RELATION_NOE 38<|>RELATION_NOE －<|>RELATION_NOE 80<|>RELATION_NOE kg<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 分为<|>RELATION_NOE 2组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 右<|>RELATION_NOE 美托<|>RELATION_NOE 咪定组<|>RELATION_NOE (<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
C<|>RELATION_NOE 组<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 20ml<|>RELATION_NOE ,<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 右<|>RELATION_NOE 美托咪<|>RELATION_NOE 定<|>RELATION_NOE 1μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE (<|>RELATION_NOE 20ml<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
麻醉<|>RELATION_NOE 诱导<|>RELATION_NOE :<|>RELATION_NOE TCI<|>RELATION_NOE 异丙酚<|>RELATION_NOE ,<|>RELATION_NOE 血浆<|>RELATION_NOE 靶<|>RELATION_NOE 浓度<|>RELATION_NOE 4μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 芬太尼<|>RELATION_NOE 5μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 或<|>RELATION_NOE 3μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE (<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 罗库<|>RELATION_NOE 溴铵<|>RELATION_NOE 0.9mg<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE .<|>RELATION_NOE
麻醉<|>RELATION_NOE 维持<|>RELATION_NOE :<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE TCI<|>RELATION_NOE 异丙酚<|>RELATION_NOE ,<|>RELATION_NOE 血浆<|>RELATION_NOE 靶<|>RELATION_NOE 浓度<|>RELATION_NOE 4μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE 右<|>RELATION_NOE 美托<|>RELATION_NOE 咪定<|>RELATION_NOE 0.5<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE ·<|>RELATION_NOE kg-1<|>RELATION_NOE ·<|>RELATION_NOE h-1<|>RELATION_NOE ,<|>RELATION_NOE 必要<|>RELATION_NOE 时<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 芬太尼<|>RELATION_NOE 0.1mg<|>RELATION_NOE ;<|>RELATION_NOE
C<|>RELATION_NOE 组<|>RELATION_NOE TCI<|>RELATION_NOE 异丙酚<|>RELATION_NOE ,<|>RELATION_NOE 血浆<|>RELATION_NOE 靶<|>RELATION_NOE 浓度<|>RELATION_NOE 4μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 间断<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 芬太尼<|>RELATION_NOE 0.1mg<|>RELATION_NOE .<|>RELATION_NOE
分别<|>RELATION_NOE 于<|>RELATION_NOE 麻醉<|>RELATION_NOE 诱导<|>RELATION_NOE 前<|>RELATION_NOE (<|>RELATION_NOE T0<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 插管<|>RELATION_NOE 前<|>RELATION_NOE 即刻<|>RELATION_NOE (<|>RELATION_NOE T1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 插<|>RELATION_NOE 管<|>RELATION_NOE 后<|>RELATION_NOE 即刻<|>RELATION_NOE (<|>RELATION_NOE T2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 切皮<|>RELATION_NOE 即刻<|>RELATION_NOE (<|>RELATION_NOE T3<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 胸骨<|>RELATION_NOE 撑<|>RELATION_NOE 开<|>RELATION_NOE 即刻<|>RELATION_NOE (<|>RELATION_NOE T4<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 开<|>RELATION_NOE 胸后<|>RELATION_NOE 30min<|>RELATION_NOE (<|>RELATION_NOE T5<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 1h<|>RELATION_NOE (<|>RELATION_NOE T6<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 术毕<|>RELATION_NOE (<|>RELATION_NOE T7<|>RELATION_NOE )<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE TPI<|>RELATION_NOE 、<|>RELATION_NOE 低频<|>RELATION_NOE 功率<|>RELATION_NOE (<|>RELATION_NOE LF<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 高频<|>RELATION_NOE 功率<|>RELATION_NOE (<|>RELATION_NOE HF<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE LF<|>RELATION_NOE 与<|>RELATION_NOE HF<|>RELATION_NOE 的<|>RELATION_NOE 比值<|>RELATION_NOE (<|>RELATION_NOE LF<|>RELATION_NOE /<|>RELATION_NOE HF<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
NJ001<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 113<|>RELATION_NOE 份<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE NJ001<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 84.07%<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 肿瘤组<|>RELATION_NOE 的<|>RELATION_NOE 8.<|>RELATION_NOE 70%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE x<|>RELATION_NOE ^2<|>RELATION_NOE =<|>RELATION_NOE 79.0<|>RELATION_NOE 50<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
同时<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE NJ001<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 91.5<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移者<|>RELATION_NOE 的<|>RELATION_NOE 75.5<|>RELATION_NOE 1%<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE x<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 5.1<|>RELATION_NOE 77<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
Cox<|>RELATION_NOE 比例<|>RELATION_NOE 风险<|>RELATION_NOE 模型<|>RELATION_NOE 分析<|>RELATION_NOE 提示<|>RELATION_NOE ,<|>RELATION_NOE NJ001<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_B 肺腺癌<|>RELATION_I 患者<|>RELATION_I 术后<|>RELATION_I 总体<|>RELATION_I 生存<|>RELATION_I 时间<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE NJ001<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 有望<|>RELATION_NOE 成为<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 新<|>RELATION_NOE 指标<|>RELATION_NOE .<|>RELATION_NOE
嗜酸<|>RELATION_NOE 粒细胞<|>RELATION_NOE 增高<|>RELATION_NOE 在<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 预后<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 嗜酸<|>RELATION_NOE 粒细胞<|>RELATION_NOE 增高<|>RELATION_NOE 在<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 预后<|>RELATION_B 评估<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 在<|>RELATION_NOE 宝鸡<|>RELATION_NOE 市中心<|>RELATION_NOE 医院<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 756<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 患者<|>RELATION_NOE 嗜酸<|>RELATION_NOE 粒细胞<|>RELATION_NOE 正常<|>RELATION_NOE 与否<|>RELATION_NOE 分为<|>RELATION_NOE 嗜酸<|>RELATION_NOE 粒细胞<|>RELATION_NOE 增高<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 增高组<|>RELATION_NOE )<|>RELATION_NOE 121<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 嗜酸<|>RELATION_NOE 粒细胞<|>RELATION_NOE 正常<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 正常组<|>RELATION_NOE )<|>RELATION_NOE 635<|>RELATION_NOE 例.<|>RELATION_NOE
嗜酸<|>RELATION_NOE 粒细胞<|>RELATION_NOE 增高<|>RELATION_NOE 可能<|>RELATION_NOE 为<|>RELATION_NOE 预测<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 预后<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE 标志<|>RELATION_NOE .<|>RELATION_NOE
自制<|>RELATION_NOE 体部<|>RELATION_NOE 固定<|>RELATION_NOE 装置<|>RELATION_NOE 在<|>RELATION_NOE SBRT<|>RELATION_NOE 放疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S 分析<|>RELATION_NOE
CTVision<|>RELATION_NOE 图像<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 立体<|>RELATION_B 定向<|>RELATION_I 放疗<|>RELATION_E 的<|>RELATION_NOE 精确性<|>RELATION_NOE 分析<|>RELATION_NOE
容积<|>RELATION_NOE 调<|>RELATION_NOE 强<|>RELATION_NOE 弧形<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE 的<|>RELATION_NOE 多<|>RELATION_NOE 中心<|>RELATION_NOE 比较<|>RELATION_S
鼻咽癌<|>RELATION_NOE 病例<|>RELATION_NOE 没有<|>RELATION_NOE 计划<|>RELATION_NOE 可以<|>RELATION_NOE 严格<|>RELATION_NOE 满足<|>RELATION_NOE 所有<|>RELATION_NOE 剂量<|>RELATION_NOE 目标<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 计划<|>RELATION_NOE 虽然<|>RELATION_NOE 无法<|>RELATION_NOE 满足<|>RELATION_NOE 所有<|>RELATION_NOE 目标<|>RELATION_NOE 但<|>RELATION_NOE 可<|>RELATION_NOE 达到<|>RELATION_NOE 临床<|>RELATION_NOE 接受<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE 计划<|>RELATION_NOE 无法<|>RELATION_NOE 接受<|>RELATION_NOE .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 同期<|>RELATION_NOE 放化<|>RELATION_NOE 疗<|>RELATION_NOE 后<|>RELATION_NOE 重度<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_B 模型<|>RELATION_E 研究<|>RELATION_NOE
利用<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方图<|>RELATION_NOE (<|>RELATION_NOE DVH<|>RELATION_NOE )<|>RELATION_NOE 参数<|>RELATION_NOE 建立<|>RELATION_NOE Logistic<|>RELATION_NOE 剂量<|>RELATION_NOE 反应<|>RELATION_NOE 及<|>RELATION_NOE Lyman-Kutcher-Burman<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 并发症<|>RELATION_NOE 概率<|>RELATION_NOE (<|>RELATION_NOE LKB-NTCP<|>RELATION_NOE )<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 评估<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 重度<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE (<|>RELATION_NOE SARP<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
对<|>RELATION_NOE 铀矿工<|>RELATION_NOE 肺癌<|>RELATION_NOE 辐射<|>RELATION_NOE 病因<|>RELATION_NOE 判断值<|>RELATION_S 的<|>RELATION_NOE 探讨<|>RELATION_NOE
利用<|>RELATION_NOE 既往<|>RELATION_NOE 流行病学<|>RELATION_NOE 调查<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE 铀矿工<|>RELATION_NOE 肺癌<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 按照<|>RELATION_NOE 新<|>RELATION_NOE 、<|>RELATION_NOE 旧<|>RELATION_NOE 标准<|>RELATION_NOE GBZ<|>RELATION_NOE 97-2002<|>RELATION_NOE 和<|>RELATION_NOE GBZ97-2009<|>RELATION_NOE 进行<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 辐射<|>RELATION_NOE 病因<|>RELATION_NOE 计算<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE 铀矿工<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 病因<|>RELATION_NOE 概率<|>RELATION_NOE (<|>RELATION_NOE PC<|>RELATION_NOE )<|>RELATION_NOE 计算<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 旧<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 7例<|>RELATION_NOE 判断<|>RELATION_NOE 为<|>RELATION_NOE 放射性<|>RELATION_NOE 肿瘤<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE 新<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 则<|>RELATION_NOE 可能<|>RELATION_NOE 有<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 被<|>RELATION_NOE 判断<|>RELATION_NOE 为<|>RELATION_NOE 放射性<|>RELATION_NOE 肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 增加<|>RELATION_NOE 了<|>RELATION_NOE 1.1<|>RELATION_NOE 倍.<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 恶性肿瘤<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
小细胞肺癌<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 全脑<|>RELATION_NOE 预防性<|>RELATION_NOE 照射<|>RELATION_NOE 计划<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_B 学<|>RELATION_I 比较<|>RELATION_E
IMRT<|>RELATION_NOE 、<|>RELATION_NOE RapidArc<|>RELATION_NOE 较<|>RELATION_NOE 3D-CRT<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E 左右<|>RELATION_NOE 视神经<|>RELATION_NOE Dmax<|>RELATION_NOE 、<|>RELATION_NOE 左右<|>RELATION_NOE 腮腺<|>RELATION_NOE Dmean<|>RELATION_NOE 及<|>RELATION_NOE 脑干<|>RELATION_NOE Dmax<|>RELATION_NOE 的<|>RELATION_NOE 受量<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
基于<|>RELATION_NOE 千伏级<|>RELATION_NOE 锥形束<|>RELATION_NOE CT<|>RELATION_NOE 进行<|>RELATION_NOE 心脏<|>RELATION_NOE 受量<|>RELATION_NOE 评估<|>RELATION_S 的<|>RELATION_NOE 研究<|>RELATION_NOE
研究<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 立体<|>RELATION_NOE 定向<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE (<|>RELATION_NOE SBRT<|>RELATION_NOE )<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 基于<|>RELATION_NOE 千伏级<|>RELATION_NOE 锥形束<|>RELATION_NOE CT<|>RELATION_NOE (<|>RELATION_NOE kV-CBCT<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 定位<|>RELATION_NOE CT<|>RELATION_NOE 制定<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 的<|>RELATION_NOE 心脏<|>RELATION_NOE 受量<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_S 。<|>RELATION_NOE
根据<|>RELATION_NOE kV-CBCT<|>RELATION_NOE 的<|>RELATION_NOE 特性<|>RELATION_NOE 及其<|>RELATION_NOE 心脏<|>RELATION_NOE 受量<|>RELATION_NOE 统计<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE kV-CBCT<|>RELATION_NOE 进行<|>RELATION_NOE 心脏<|>RELATION_B 受量<|>RELATION_I 评价<|>RELATION_E 可<|>RELATION_NOE 弥补<|>RELATION_NOE 心跳<|>RELATION_NOE 和<|>RELATION_NOE 呼吸<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 得到<|>RELATION_NOE 更<|>RELATION_NOE 真实<|>RELATION_NOE 、<|>RELATION_NOE 客观<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE -<|>RELATION_NOE 体积<|>RELATION_NOE 参数<|>RELATION_NOE .<|>RELATION_NOE
电离辐射<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE STAT3<|>RELATION_NOE 靶<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 1射线<|>RELATION_NOE 照射<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 促<|>RELATION_NOE 血管<|>RELATION_NOE 生成<|>RELATION_NOE 基因<|>RELATION_NOE VEGF<|>RELATION_NOE 以及<|>RELATION_NOE 抗<|>RELATION_NOE 凋亡<|>RELATION_NOE 基因<|>RELATION_NOE bcl-2<|>RELATION_NOE 和<|>RELATION_NOE 存活素<|>RELATION_NOE (<|>RELATION_NOE survivin<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 与<|>RELATION_NOE 转录因子<|>RELATION_NOE STAT3<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
y<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 可<|>RELATION_NOE 通过<|>RELATION_NOE 激活<|>RELATION_NOE STAT3<|>RELATION_NOE 上调<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE Survivin<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Survivin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 上调<|>RELATION_NOE 在<|>RELATION_NOE 一定<|>RELATION_B 程度<|>RELATION_I 上<|>RELATION_I 抑制<|>RELATION_E 了<|>RELATION_NOE 辐射<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 升高<|>RELATION_NOE 则<|>RELATION_NOE 有助于<|>RELATION_NOE 肿瘤<|>RELATION_NOE 血管<|>RELATION_NOE 生成<|>RELATION_NOE 。<|>RELATION_NOE y<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 可<|>RELATION_NOE 通过<|>RELATION_NOE 激活<|>RELATION_NOE STAT3<|>RELATION_NOE 上调<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE Survivin<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Survivin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 上调<|>RELATION_NOE 在<|>RELATION_NOE 一定<|>RELATION_NOE 程度<|>RELATION_NOE 上<|>RELATION_NOE 抑制<|>RELATION_NOE 了<|>RELATION_NOE 辐射<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 升高<|>RELATION_NOE 则<|>RELATION_NOE 有助于<|>RELATION_S 肿瘤<|>RELATION_NOE 血管<|>RELATION_NOE 生成<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 总<|>RELATION_NOE 碱性磷酸酶<|>RELATION_NOE 和<|>RELATION_NOE 骨<|>RELATION_NOE 特异性<|>RELATION_NOE 碱性磷酸酶<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌骨<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
分析<|>RELATION_NOE 湖北省<|>RELATION_NOE 新华<|>RELATION_NOE 医院<|>RELATION_NOE 2009年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 9月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 无骨<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光法<|>RELATION_NOE 和<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 血清<|>RELATION_NOE tALP<|>RELATION_NOE 和<|>RELATION_NOE bALP<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE 血清<|>RELATION_NOE tALP<|>RELATION_NOE 和<|>RELATION_NOE bALP<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_S 无骨<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 158<|>RELATION_NOE ±<|>RELATION_NOE 13<|>RELATION_NOE )<|>RELATION_NOE U<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 69<|>RELATION_NOE ±<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE U<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 34<|>RELATION_NOE ±<|>RELATION_NOE 7<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE ±<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE bALP<|>RELATION_NOE 升高<|>RELATION_NOE 判断<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 灵敏度<|>RELATION_NOE 为<|>RELATION_NOE 86.7%<|>RELATION_NOE ,<|>RELATION_NOE 特<|>RELATION_NOE 异度<|>RELATION_NOE 为<|>RELATION_NOE 83.3%<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE tALP<|>RELATION_NOE 和<|>RELATION_NOE bALP<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 具有<|>RELATION_I 重要<|>RELATION_I 的<|>RELATION_I 参考<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 和<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 分别<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 联用<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 化疗<|>RELATION_NOE 期间<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 药物<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 作为<|>RELATION_NOE 三<|>RELATION_NOE 线<|>RELATION_NOE 药物<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_S
探讨<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 作为<|>RELATION_NOE 三<|>RELATION_NOE 线<|>RELATION_NOE 药物<|>RELATION_NOE 对于<|>RELATION_NOE 一线<|>RELATION_NOE 和<|>RELATION_NOE 二线<|>RELATION_NOE 治疗失败<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_S 。<|>RELATION_NOE
对<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 一线<|>RELATION_NOE 含<|>RELATION_NOE 铂化疗<|>RELATION_NOE 及<|>RELATION_NOE 二<|>RELATION_NOE 线<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE (<|>RELATION_NOE TKIs<|>RELATION_NOE )<|>RELATION_NOE 治疗无效<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 给予<|>RELATION_NOE 单药培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE (<|>RELATION_NOE 600mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2第1<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 疗程<|>RELATION_NOE )<|>RELATION_NOE 作为<|>RELATION_NOE 三<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 每<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 周期<|>RELATION_NOE 中<|>RELATION_NOE 位数<|>RELATION_NOE 为<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 疗程<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_NOE 疗效<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 身体<|>RELATION_NOE 状态<|>RELATION_NOE 、<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 周期<|>RELATION_NOE 数<|>RELATION_NOE 、<|>RELATION_NOE EGFR<|>RELATION_NOE 基因型<|>RELATION_NOE 等<|>RELATION_NOE 对<|>RELATION_NOE 培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 对<|>RELATION_NOE 一般<|>RELATION_NOE 状态<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 一线<|>RELATION_B 含<|>RELATION_I 铂化疗<|>RELATION_I 及<|>RELATION_I 二<|>RELATION_I 线<|>RELATION_I TKIs<|>RELATION_I 靶向<|>RELATION_I 治疗无效<|>RELATION_I 时<|>RELATION_I 可<|>RELATION_I 作为<|>RELATION_I 三<|>RELATION_I 线<|>RELATION_I 药物<|>RELATION_E ,<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE KTIs<|>RELATION_NOE 没有<|>RELATION_NOE 交叉<|>RELATION_NOE 耐药<|>RELATION_NOE 。<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 对<|>RELATION_NOE 一般<|>RELATION_NOE 状态<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 一线<|>RELATION_NOE 含<|>RELATION_NOE 铂化疗<|>RELATION_NOE 及<|>RELATION_NOE 二<|>RELATION_NOE 线<|>RELATION_NOE TKIs<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗无效<|>RELATION_NOE 时<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 三<|>RELATION_NOE 线<|>RELATION_NOE 药物<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 和<|>RELATION_NOE KTIs<|>RELATION_NOE 没有<|>RELATION_B 交叉<|>RELATION_I 耐<|>RELATION_I 药<|>RELATION_E 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE Foxp3<|>RELATION_NOE 检测<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
检测<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE Foxp3<|>RELATION_NOE 以及<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE
利用<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 96<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 对照者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE Foxp3<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 的<|>RELATION_NOE 动态<|>RELATION_NOE 观察<|>RELATION_NOE 。<|>RELATION_NOE
CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE CD25<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE Foxp3<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 调节性<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 的<|>RELATION_NOE 增多<|>RELATION_NOE 与<|>RELATION_NOE 机体<|>RELATION_NOE 的<|>RELATION_NOE 免疫力<|>RELATION_NOE 下降<|>RELATION_NOE 以及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 有<|>RELATION_B 一定<|>RELATION_I 关系<|>RELATION_E ,<|>RELATION_NOE 化学<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 恢复<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE Foxp3<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 发病<|>RELATION_NOE 机制<|>RELATION_NOE 的<|>RELATION_NOE 探讨<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 观察<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肺功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
86<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 第1<|>RELATION_NOE 秒<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 呼气量<|>RELATION_NOE (<|>RELATION_NOE FEV1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 用力肺活量<|>RELATION_NOE (<|>RELATION_NOE FVC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 呼气<|>RELATION_NOE 流速<|>RELATION_NOE 峰值<|>RELATION_NOE (<|>RELATION_NOE PEF<|>RELATION_NOE )<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
胱抑素<|>RELATION_NOE C<|>RELATION_NOE 、<|>RELATION_NOE 同型<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 诊断<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE
将<|>RELATION_NOE 210<|>RELATION_NOE 例<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 根据<|>RELATION_NOE 发病<|>RELATION_NOE 部位<|>RELATION_NOE 分为<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 胃癌组<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 以<|>RELATION_NOE 127<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 免疫<|>RELATION_NOE 比浊法<|>RELATION_NOE 检测<|>RELATION_S 其<|>RELATION_NOE 血清<|>RELATION_NOE Cys-C<|>RELATION_NOE 、<|>RELATION_NOE 用<|>RELATION_NOE 酶<|>RELATION_NOE 法<|>RELATION_NOE 将<|>RELATION_NOE 210<|>RELATION_NOE 例<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 根据<|>RELATION_NOE 发病<|>RELATION_NOE 部位<|>RELATION_NOE 分为<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 胃癌组<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 以<|>RELATION_NOE 127<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 免疫<|>RELATION_NOE 比浊法<|>RELATION_NOE 检测<|>RELATION_NOE 其<|>RELATION_NOE 血清<|>RELATION_NOE Cys-C<|>RELATION_NOE 、<|>RELATION_NOE 用<|>RELATION_NOE 酶法<|>RELATION_NOE 检测<|>RELATION_S HCY<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 微粒子<|>RELATION_NOE 发光<|>RELATION_NOE 免疫法<|>RELATION_NOE 将<|>RELATION_NOE 210<|>RELATION_NOE 例<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 根据<|>RELATION_NOE 发病<|>RELATION_NOE 部位<|>RELATION_NOE 分为<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 胃癌组<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 以<|>RELATION_NOE 127<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 免疫<|>RELATION_NOE 比浊法<|>RELATION_NOE 检测<|>RELATION_NOE 其<|>RELATION_NOE 血清<|>RELATION_NOE Cys-C<|>RELATION_NOE 、<|>RELATION_NOE 用<|>RELATION_NOE 酶<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE HCY<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 微粒子<|>RELATION_NOE 发光<|>RELATION_NOE 免疫法<|>RELATION_NOE 检测<|>RELATION_S CEA<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 比较<|>RELATION_NOE 三者<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 11月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 4月<|>RELATION_NOE 在<|>RELATION_NOE 天津<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 接受<|>RELATION_NOE 门诊<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 214<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 调查<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 完成<|>RELATION_NOE 量表<|>RELATION_NOE EORTC<|>RELATION_NOE QLQ-LC43<|>RELATION_NOE 和<|>RELATION_NOE SF-36<|>RELATION_NOE 的<|>RELATION_NOE 测评<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE KPS<|>RELATION_NOE 评分<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE
EORTC<|>RELATION_NOE QLQ-LC43<|>RELATION_NOE 与<|>RELATION_NOE SF-36<|>RELATION_NOE 中<|>RELATION_NOE 相同<|>RELATION_NOE 或<|>RELATION_NOE 相似<|>RELATION_NOE 的<|>RELATION_NOE 维度<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 性量表<|>RELATION_NOE C30<|>RELATION_NOE 中<|>RELATION_NOE 与<|>RELATION_NOE 功能<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 维度<|>RELATION_NOE 除<|>RELATION_NOE 情绪<|>RELATION_NOE 功能<|>RELATION_NOE (<|>RELATION_NOE EF<|>RELATION_NOE )<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 维度<|>RELATION_NOE 与<|>RELATION_NOE KPS<|>RELATION_NOE 得分<|>RELATION_NOE 相关性<|>RELATION_B 均<|>RELATION_I 较<|>RELATION_I 好<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 症状<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 维度<|>RELATION_NOE 相关性<|>RELATION_NOE 则<|>RELATION_NOE 较<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 症状<|>RELATION_NOE 子量表<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 呼吸困难<|>RELATION_NOE (<|>RELATION_NOE LC-DY<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE KPS<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 条目<|>RELATION_NOE 均<|>RELATION_NOE 相关性<|>RELATION_NOE 一般<|>RELATION_NOE ;<|>RELATION_NOE EORTC<|>RELATION_NOE QLQ-LC43<|>RELATION_NOE 与<|>RELATION_NOE SF-36<|>RELATION_NOE 中<|>RELATION_NOE 相同<|>RELATION_NOE 或<|>RELATION_NOE 相似<|>RELATION_NOE 的<|>RELATION_NOE 维度<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 性量表<|>RELATION_NOE C30<|>RELATION_NOE 中<|>RELATION_NOE 与<|>RELATION_NOE 功能<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 维度<|>RELATION_NOE 除<|>RELATION_NOE 情绪<|>RELATION_NOE 功能<|>RELATION_NOE (<|>RELATION_NOE EF<|>RELATION_NOE )<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 维度<|>RELATION_NOE 与<|>RELATION_NOE KPS<|>RELATION_NOE 得分<|>RELATION_NOE 相关性<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 症状<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 维度<|>RELATION_NOE 相关性<|>RELATION_NOE 则<|>RELATION_NOE 较<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 症状<|>RELATION_NOE 子量表<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 呼吸困难<|>RELATION_NOE (<|>RELATION_NOE LC-DY<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE KPS<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_B 较<|>RELATION_I 好<|>RELATION_E ,<|>RELATION_NOE 其余<|>RELATION_NOE 条目<|>RELATION_NOE 均<|>RELATION_NOE 相关性<|>RELATION_NOE 一般<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_B 发生<|>RELATION_I 支气管<|>RELATION_I 胸膜<|>RELATION_I 瘘<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 危险因素<|>RELATION_NOE
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_B 发生<|>RELATION_I 支气管<|>RELATION_I 胸膜<|>RELATION_I 瘘<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 597<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘发生<|>RELATION_NOE 情况<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 单因素<|>RELATION_NOE 分析<|>RELATION_NOE 及<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE Logistics<|>RELATION_NOE 回归分析<|>RELATION_NOE 明确<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 针对<|>RELATION_NOE 危险因素<|>RELATION_NOE 明确<|>RELATION_NOE 护理<|>RELATION_NOE 对策<|>RELATION_NOE 。<|>RELATION_NOE
本组<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 发生率<|>RELATION_NOE 3.18%<|>RELATION_NOE ;<|>RELATION_NOE
支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘发生<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_S 包括<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE 、<|>RELATION_NOE 术前<|>RELATION_NOE FVC<|>RELATION_NOE 、<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 、<|>RELATION_NOE 存在<|>RELATION_NOE 残端<|>RELATION_NOE 存留<|>RELATION_NOE 和<|>RELATION_NOE 术前<|>RELATION_NOE 放疗<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 针对<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘高危<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE 术前<|>RELATION_NOE 准备<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 继发性<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE 预防<|>RELATION_NOE 以及<|>RELATION_NOE 合理<|>RELATION_NOE 进行<|>RELATION_NOE 胸腔<|>RELATION_NOE 冲洗<|>RELATION_NOE 等<|>RELATION_NOE 对于<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜瘘<|>RELATION_NOE 的<|>RELATION_NOE 预防<|>RELATION_NOE 与<|>RELATION_NOE 治疗<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 意义<|>RELATION_NOE .<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘发生<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE 包括<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE 、<|>RELATION_NOE 术前<|>RELATION_NOE FVC<|>RELATION_NOE 、<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 、<|>RELATION_NOE 存在<|>RELATION_NOE 残端<|>RELATION_NOE 存留<|>RELATION_NOE 和<|>RELATION_NOE 术前<|>RELATION_NOE 放疗<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 针对<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘高危<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE 术前<|>RELATION_NOE 准备<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 继发性<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE 预防<|>RELATION_NOE 以及<|>RELATION_NOE 合理<|>RELATION_NOE 进行<|>RELATION_NOE 胸腔<|>RELATION_NOE 冲洗<|>RELATION_NOE 等<|>RELATION_NOE 对于<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘<|>RELATION_NOE 的<|>RELATION_NOE 预防<|>RELATION_B 与<|>RELATION_I 治疗<|>RELATION_E 具有<|>RELATION_NOE 重要<|>RELATION_NOE 意义<|>RELATION_NOE .<|>RELATION_NOE
舒缓<|>RELATION_NOE 护理<|>RELATION_NOE 在<|>RELATION_NOE 癌症<|>RELATION_NOE 患者<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 症状<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 及<|>RELATION_I 效果<|>RELATION_E
选取<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 症状<|>RELATION_NOE 患者<|>RELATION_NOE 200<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 舒缓<|>RELATION_NOE 护理<|>RELATION_NOE 前<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 症状<|>RELATION_NOE 患者<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE 设<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 舒缓<|>RELATION_NOE 护理<|>RELATION_NOE 后<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 症状<|>RELATION_NOE 患者<|>RELATION_NOE 100<|>RELATION_NOE 例设<|>RELATION_NOE 为<|>RELATION_NOE 观察<|>RELATION_NOE 组.<|>RELATION_NOE
对照组<|>RELATION_NOE 接受<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 模式<|>RELATION_NOE 指导<|>RELATION_NOE 下<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 健康<|>RELATION_NOE 宣教<|>RELATION_NOE 、<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 饮食<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 指导<|>RELATION_NOE 等<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ;<|>RELATION_NOE
比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 情况<|>RELATION_NOE 和<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 护理<|>RELATION_NOE 人员<|>RELATION_NOE 提供<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 方式<|>RELATION_NOE 和<|>RELATION_NOE 态度<|>RELATION_NOE 的<|>RELATION_NOE 满意度<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 少于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 护理<|>RELATION_NOE 人员<|>RELATION_NOE 提供<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 方式<|>RELATION_NOE 和<|>RELATION_NOE 态度<|>RELATION_NOE 的<|>RELATION_NOE 满意度<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 少于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 护理<|>RELATION_NOE 人员<|>RELATION_NOE 提供<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 方式<|>RELATION_NOE 和<|>RELATION_NOE 态度<|>RELATION_NOE 的<|>RELATION_NOE 满意度<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
院<|>RELATION_NOE 外<|>RELATION_NOE 延伸<|>RELATION_NOE 护理<|>RELATION_NOE 模式<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
将<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 10月<|>RELATION_NOE 我<|>RELATION_NOE 院胸<|>RELATION_NOE 外科<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 74<|>RELATION_NOE 例行<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE 各<|>RELATION_NOE 37<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 出院<|>RELATION_NOE 后<|>RELATION_NOE 不<|>RELATION_NOE 给予<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 出院<|>RELATION_NOE 后<|>RELATION_NOE 实施<|>RELATION_NOE 院<|>RELATION_NOE 外<|>RELATION_NOE 延伸<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 于<|>RELATION_NOE 出院<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 出院<|>RELATION_NOE 后<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 采用<|>RELATION_NOE EORTC<|>RELATION_NOE QLQ-C30<|>RELATION_NOE 量表<|>RELATION_NOE 评估<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE 疲乏<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 、<|>RELATION_NOE 失眠<|>RELATION_NOE 和气<|>RELATION_NOE 促<|>RELATION_NOE 症状<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
自<|>RELATION_NOE 荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 气管<|>RELATION_NOE 支气管<|>RELATION_NOE 受侵<|>RELATION_NOE T<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
比较<|>RELATION_NOE WLB<|>RELATION_NOE 与<|>RELATION_NOE AFB<|>RELATION_NOE 检查<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 气管<|>RELATION_NOE 支气管<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 肿瘤<|>RELATION_NOE 边缘<|>RELATION_NOE 的<|>RELATION_NOE 判定<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 肿瘤<|>RELATION_NOE 边界<|>RELATION_NOE 黏膜<|>RELATION_NOE 活检<|>RELATION_NOE
确定<|>RELATION_NOE 气管<|>RELATION_NOE 支气管<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 肿瘤<|>RELATION_NOE 受侵<|>RELATION_NOE T<|>RELATION_NOE 分期<|>RELATION_NOE 。<|>RELATION_NOE
香豆素<|>RELATION_NOE 缩<|>RELATION_NOE 氨基酸型<|>RELATION_NOE 曼尼西碱<|>RELATION_NOE 香豆素类<|>RELATION_NOE 铜药物<|>RELATION_NOE 体<|>RELATION_B 内外<|>RELATION_I 抗<|>RELATION_E 肺癌<|>RELATION_NOE 增殖<|>RELATION_NOE 及其<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE
研究<|>RELATION_NOE 香豆素<|>RELATION_NOE 缩<|>RELATION_NOE 氨基酸型<|>RELATION_NOE 曼尼西<|>RELATION_NOE 碱金属<|>RELATION_NOE 香豆素类<|>RELATION_NOE 铜<|>RELATION_NOE 药物<|>RELATION_NOE (<|>RELATION_NOE 简称<|>RELATION_NOE 香豆素类<|>RELATION_NOE 铜药物<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 体<|>RELATION_B 内外<|>RELATION_I 抗<|>RELATION_E 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 活性<|>RELATION_NOE 。<|>RELATION_NOE
建立<|>RELATION_NOE A549<|>RELATION_NOE 荷瘤<|>RELATION_NOE 裸鼠<|>RELATION_NOE 模型<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 经过<|>RELATION_NOE 香豆素类<|>RELATION_NOE 铜药物<|>RELATION_NOE 的<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 绘制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE 并<|>RELATION_NOE 计算<|>RELATION_NOE 肿瘤<|>RELATION_NOE 干预<|>RELATION_NOE 的<|>RELATION_NOE 抑瘤率<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE TUNEL<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 体内<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 。<|>RELATION_NOE
香豆素类<|>RELATION_NOE 铜<|>RELATION_NOE 药物<|>RELATION_NOE 以<|>RELATION_NOE 浓度<|>RELATION_NOE 时间<|>RELATION_NOE 依赖性<|>RELATION_NOE 方式<|>RELATION_NOE 有效<|>RELATION_B 地<|>RELATION_I 抑制<|>RELATION_E A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 活力<|>RELATION_NOE 的<|>RELATION_NOE IC50<|>RELATION_NOE 为<|>RELATION_NOE 2.0μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ;<|>RELATION_NOE
香豆素类<|>RELATION_NOE 铜<|>RELATION_NOE 药物<|>RELATION_NOE 体内<|>RELATION_NOE 以<|>RELATION_NOE 浓度<|>RELATION_NOE 依赖性<|>RELATION_NOE 方式<|>RELATION_NOE 抑制<|>RELATION_S 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 凋亡<|>RELATION_NOE 明显<|>RELATION_NOE 增多<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
靶向<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31-<|>RELATION_NOE 脂质体<|>RELATION_NOE 复合物<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺微<|>RELATION_NOE 血管<|>RELATION_NOE 内皮细胞<|>RELATION_NOE PECAM-1<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
研究<|>RELATION_NOE 以<|>RELATION_NOE 血管<|>RELATION_NOE 内皮细胞<|>RELATION_NOE 为<|>RELATION_NOE 靶向<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE '<|>RELATION_NOE 对<|>RELATION_NOE 血小板<|>RELATION_NOE 内皮<|>RELATION_NOE 黏附<|>RELATION_NOE 分子<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE PECAM-1<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
实验<|>RELATION_NOE 分为<|>RELATION_NOE 裸<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31FAM<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 稳定<|>RELATION_NOE 阴性<|>RELATION_NOE 对照<|>RELATION_NOE (<|>RELATION_NOE SNC<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
实验<|>RELATION_NOE 以<|>RELATION_NOE 阳离子<|>RELATION_NOE 脂质体<|>RELATION_NOE (<|>RELATION_NOE RNAi-mate<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 2<|>RELATION_NOE '<|>RELATION_NOE -O<|>RELATION_NOE -<|>RELATION_NOE 甲基<|>RELATION_NOE 修饰<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 转染<|>RELATION_NOE 体外<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肺微<|>RELATION_NOE 血管<|>RELATION_NOE 内皮细胞<|>RELATION_NOE (<|>RELATION_NOE HPMVEC<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 对<|>RELATION_NOE HPMVEC<|>RELATION_NOE 增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE RT-PCR<|>RELATION_NOE 、<|>RELATION_NOE Westernblot<|>RELATION_NOE 实验<|>RELATION_NOE 以<|>RELATION_NOE 阳离子<|>RELATION_NOE 脂质体<|>RELATION_NOE (<|>RELATION_NOE RNAi-mate<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 2<|>RELATION_NOE '<|>RELATION_NOE -O<|>RELATION_NOE -<|>RELATION_NOE 甲基<|>RELATION_NOE 修饰<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 转染<|>RELATION_NOE 体外<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肺微<|>RELATION_NOE 血管<|>RELATION_NOE 内皮细胞<|>RELATION_NOE (<|>RELATION_NOE HPMVEC<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 对<|>RELATION_NOE HPMVEC<|>RELATION_NOE 增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE RT-PCR<|>RELATION_NOE 、<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_S PECAM1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
裸<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 和<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31FAM<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE HPMVEC<|>RELATION_NOE 的<|>RELATION_NOE PECAM-1mRNA<|>RELATION_NOE 、<|>RELATION_NOE PECAM-1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 、<|>RELATION_NOE HPMVEC<|>RELATION_NOE 的<|>RELATION_NOE 增殖率<|>RELATION_NOE 均<|>RELATION_NOE 低于<|>RELATION_S SNC<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 裸<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 和<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31-FAM<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE HPMVEC<|>RELATION_NOE 的<|>RELATION_NOE PECAM1mRNA<|>RELATION_NOE 、<|>RELATION_NOE PECAM-1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 、<|>RELATION_NOE HPMVEC<|>RELATION_NOE 的<|>RELATION_NOE 增殖率<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 裸<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 和<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31FAM<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE HPMVEC<|>RELATION_NOE 的<|>RELATION_NOE PECAM-1mRNA<|>RELATION_NOE 、<|>RELATION_NOE PECAM-1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 、<|>RELATION_NOE HPMVEC<|>RELATION_NOE 的<|>RELATION_NOE 增殖率<|>RELATION_NOE 均<|>RELATION_NOE 低于<|>RELATION_NOE SNC<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 裸<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 和<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31-FAM<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE HPMVEC<|>RELATION_NOE 的<|>RELATION_NOE PECAM1mRNA<|>RELATION_NOE 、<|>RELATION_NOE PECAM-1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 、<|>RELATION_NOE HPMVEC<|>RELATION_NOE 的<|>RELATION_NOE 增殖率<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
靶向<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 可<|>RELATION_NOE 下调<|>RELATION_NOE HPMVEC<|>RELATION_NOE 的<|>RELATION_NOE PECAM-1mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_NOE HPMVEC<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE '<|>RELATION_NOE O<|>RELATION_NOE 甲基<|>RELATION_NOE 修饰<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 可<|>RELATION_B 作为<|>RELATION_E 沉默<|>RELATION_NOE 靶<|>RELATION_NOE 基因<|>RELATION_NOE PECAM-1<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 技术<|>RELATION_NOE 手段<|>RELATION_NOE ,<|>RELATION_NOE RNAimate<|>RELATION_NOE 靶向<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 可<|>RELATION_NOE 下调<|>RELATION_NOE HPMVEC<|>RELATION_NOE 的<|>RELATION_NOE PECAM-1mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_NOE HPMVEC<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE '<|>RELATION_NOE O<|>RELATION_NOE 甲基<|>RELATION_NOE 修饰<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 沉默<|>RELATION_NOE 靶<|>RELATION_NOE 基因<|>RELATION_NOE PECAM-1<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 技术<|>RELATION_NOE 手段<|>RELATION_NOE ,<|>RELATION_NOE RNAimate<|>RELATION_NOE 可<|>RELATION_B 作为<|>RELATION_E siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 的<|>RELATION_NOE 转染<|>RELATION_NOE 靶<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE PECAM1<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 干预<|>RELATION_NOE 肺癌<|>RELATION_NOE 癌细胞微环境<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 微血管<|>RELATION_NOE 内皮细胞<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 潜在<|>RELATION_NOE 靶标<|>RELATION_NOE 。<|>RELATION_NOE 靶向<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 可<|>RELATION_NOE 下调<|>RELATION_NOE HPMVEC<|>RELATION_NOE 的<|>RELATION_NOE PECAM-1mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_NOE HPMVEC<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE '<|>RELATION_NOE O<|>RELATION_NOE 甲基<|>RELATION_NOE 修饰<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 沉默<|>RELATION_NOE 靶<|>RELATION_NOE 基因<|>RELATION_NOE PECAM-1<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 技术<|>RELATION_NOE 手段<|>RELATION_NOE ,<|>RELATION_NOE RNAimate<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE siRNA<|>RELATION_NOE ^<|>RELATION_NOE CD31<|>RELATION_NOE 的<|>RELATION_NOE 转染<|>RELATION_NOE 靶<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE PECAM1<|>RELATION_NOE 可能<|>RELATION_B 是<|>RELATION_E 干预<|>RELATION_NOE 肺癌<|>RELATION_NOE 癌细胞微环境<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 微血管<|>RELATION_NOE 内皮细胞<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 潜在<|>RELATION_NOE 靶标<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HPV<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE E6<|>RELATION_NOE 和<|>RELATION_NOE E7<|>RELATION_NOE 与<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE 和<|>RELATION_NOE CD8<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 相关性<|>RELATION_S 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 人<|>RELATION_NOE 乳头<|>RELATION_NOE 瘤病毒<|>RELATION_NOE (<|>RELATION_NOE HPV<|>RELATION_NOE )<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE E6<|>RELATION_NOE 和<|>RELATION_NOE E7<|>RELATION_NOE 及<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE 和<|>RELATION_NOE CD8<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 二者<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 107<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HPV<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE E6<|>RELATION_NOE 和<|>RELATION_NOE E7<|>RELATION_NOE 及<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE 和<|>RELATION_NOE CD8<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
107<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HPV<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 57.9<|>RELATION_NOE 4%<|>RELATION_NOE (<|>RELATION_NOE 62<|>RELATION_NOE /<|>RELATION_NOE 107<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE HPV<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 吸烟史<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE x<|>RELATION_NOE ^<|>RELATION_NOE 2值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 9.4<|>RELATION_NOE 83<|>RELATION_NOE 和<|>RELATION_NOE 6.6<|>RELATION_NOE 83<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
HPV<|>RELATION_NOE 感染<|>RELATION_NOE 可<|>RELATION_NOE 引起<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 机体<|>RELATION_NOE 特异性<|>RELATION_NOE 炎症<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 免疫<|>RELATION_NOE 治疗<|>RELATION_NOE 提供<|>RELATION_NOE 理论<|>RELATION_NOE 基础<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 心理<|>RELATION_NOE 弹性<|>RELATION_NOE 与<|>RELATION_NOE 情绪<|>RELATION_NOE 调节<|>RELATION_NOE 方式<|>RELATION_NOE 和<|>RELATION_NOE 人格<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 研究<|>RELATION_NOE
研究<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 心理<|>RELATION_NOE 弹性<|>RELATION_NOE 与<|>RELATION_NOE 情绪<|>RELATION_NOE 调节<|>RELATION_NOE 方式<|>RELATION_NOE 和<|>RELATION_NOE 人格<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 中文<|>RELATION_NOE 简化<|>RELATION_NOE 版<|>RELATION_NOE Connor-Davidson<|>RELATION_NOE 心理<|>RELATION_NOE 弹性<|>RELATION_NOE 问卷<|>RELATION_NOE (<|>RELATION_NOE CD-RISC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 艾森克人格<|>RELATION_NOE 问卷<|>RELATION_NOE (<|>RELATION_NOE EPQ<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE 情绪<|>RELATION_NOE 调节<|>RELATION_NOE 方式<|>RELATION_NOE 问卷<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 问卷调查<|>RELATION_NOE .<|>RELATION_NOE
采用<|>RELATION_NOE Pearson<|>RELATION_NOE 相关<|>RELATION_NOE 分析法<|>RELATION_NOE 分析<|>RELATION_NOE 患者<|>RELATION_NOE 心理<|>RELATION_NOE 弹性<|>RELATION_NOE 与<|>RELATION_NOE 情绪<|>RELATION_NOE 调节<|>RELATION_NOE 方式<|>RELATION_NOE 和<|>RELATION_NOE 人格<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
情绪<|>RELATION_NOE 调节<|>RELATION_NOE 方式<|>RELATION_NOE 和<|>RELATION_NOE 人格<|>RELATION_NOE 特征<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 心理<|>RELATION_NOE 弹性<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_NOE 因素.<|>RELATION_NOE
肿瘤<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 黏附<|>RELATION_NOE 因子<|>RELATION_NOE CD44<|>RELATION_NOE 、<|>RELATION_NOE C-erbB-2<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE HER-2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE (<|>RELATION_NOE MMP<|>RELATION_NOE )<|>RELATION_NOE 9<|>RELATION_NOE 、<|>RELATION_NOE 抑癌<|>RELATION_NOE 基因<|>RELATION_NOE P53<|>RELATION_NOE 、<|>RELATION_NOE ras<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE P21<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 、<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
选取术<|>RELATION_NOE 后<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE Envision<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE x2<|>RELATION_NOE 检验<|>RELATION_NOE 分析<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE 相关<|>RELATION_NOE 基因表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
Meier<|>RELATION_NOE 生存<|>RELATION_NOE 曲线<|>RELATION_NOE 分析<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.82<|>RELATION_NOE 、<|>RELATION_NOE 3.36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE MMP-9<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE X2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 3.75<|>RELATION_NOE 、<|>RELATION_NOE 3.60<|>RELATION_NOE 、<|>RELATION_NOE 4.44<|>RELATION_NOE 、<|>RELATION_NOE 3.96<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P53<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.82<|>RELATION_NOE 、<|>RELATION_NOE 3.36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE MMP-9<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 3.75<|>RELATION_NOE 、<|>RELATION_NOE 3.60<|>RELATION_NOE 、<|>RELATION_NOE 4.44<|>RELATION_NOE 、<|>RELATION_NOE 3.96<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P53<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE x2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 10.99<|>RELATION_NOE 、<|>RELATION_NOE 12.38<|>RELATION_NOE 、<|>RELATION_NOE 14.40<|>RELATION_NOE 、<|>RELATION_NOE 4.44<|>RELATION_NOE 、<|>RELATION_NOE 3.96<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P21<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.82<|>RELATION_NOE 、<|>RELATION_NOE 3.36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE MMP-9<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 3.75<|>RELATION_NOE 、<|>RELATION_NOE 3.60<|>RELATION_NOE 、<|>RELATION_NOE 4.44<|>RELATION_NOE 、<|>RELATION_NOE 3.96<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P53<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 10.99<|>RELATION_NOE 、<|>RELATION_NOE 12.38<|>RELATION_NOE 、<|>RELATION_NOE 14.40<|>RELATION_NOE 、<|>RELATION_NOE 4.44<|>RELATION_NOE 、<|>RELATION_NOE 3.96<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P21<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 3.89<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.82<|>RELATION_NOE 、<|>RELATION_NOE 3.36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE MMP-9<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 3.75<|>RELATION_NOE 、<|>RELATION_NOE 3.60<|>RELATION_NOE 、<|>RELATION_NOE 4.44<|>RELATION_NOE 、<|>RELATION_NOE 3.96<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P53<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 10.99<|>RELATION_NOE 、<|>RELATION_NOE 12.38<|>RELATION_NOE 、<|>RELATION_NOE 14.40<|>RELATION_NOE 、<|>RELATION_NOE 4.44<|>RELATION_NOE 、<|>RELATION_NOE 3.96<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P21<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 3.89<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 7.62<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE VEGF<|>RELATION_NOE 与<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.82<|>RELATION_NOE 、<|>RELATION_NOE 3.36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE MMP-9<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 3.75<|>RELATION_NOE 、<|>RELATION_NOE 3.60<|>RELATION_NOE 、<|>RELATION_NOE 4.44<|>RELATION_NOE 、<|>RELATION_NOE 3.96<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P53<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 10.99<|>RELATION_NOE 、<|>RELATION_NOE 12.38<|>RELATION_NOE 、<|>RELATION_NOE 14.40<|>RELATION_NOE 、<|>RELATION_NOE 4.44<|>RELATION_NOE 、<|>RELATION_NOE 3.96<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P21<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 3.89<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 7.62<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE VEGF<|>RELATION_NOE 与<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE x2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5.50<|>RELATION_NOE 、<|>RELATION_NOE 3.36<|>RELATION_NOE 、<|>RELATION_NOE 5.43<|>RELATION_NOE 、<|>RELATION_NOE 3.30<|>RELATION_NOE 、<|>RELATION_NOE 6.08<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Kaplan-Meier<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 提示<|>RELATION_NOE CD44<|>RELATION_NOE 、<|>RELATION_NOE HER-2<|>RELATION_NOE 、<|>RELATION_NOE P53<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 基因<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_B 差<|>RELATION_E (<|>RELATION_NOE x2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 7.56<|>RELATION_NOE 、<|>RELATION_NOE 5.56<|>RELATION_NOE 、<|>RELATION_NOE 17.14<|>RELATION_NOE 、<|>RELATION_NOE 6.24<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CD44<|>RELATION_NOE 、<|>RELATION_NOE HER-2<|>RELATION_NOE 、<|>RELATION_NOE P53<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 阳性<|>RELATION_NOE 表达者<|>RELATION_NOE 预后<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 判断<|>RELATION_S NSCLC<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 参考<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 治疗<|>RELATION_S 肺腺癌<|>RELATION_NOE
观察<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 抑制素<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE (<|>RELATION_NOE 恩度<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_S 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 及<|>RELATION_NOE 细胞学<|>RELATION_NOE 诊断<|>RELATION_NOE 明确<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 初治<|>RELATION_NOE 患者<|>RELATION_NOE 52<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 住院号<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 给予<|>RELATION_NOE 培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 恩度<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 仅<|>RELATION_NOE 给予<|>RELATION_NOE 培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE 7.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 长于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 5.71<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 在<|>RELATION_NOE 治疗<|>RELATION_NOE 期间<|>RELATION_NOE 均<|>RELATION_NOE 出现<|>RELATION_NOE 相似<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_B 反应<|>RELATION_E ,<|>RELATION_NOE 主要<|>RELATION_NOE 为<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 血红<|>RELATION_NOE 蛋白<|>RELATION_NOE 减少<|>RELATION_NOE 、<|>RELATION_NOE 血小板减少<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 便秘<|>RELATION_NOE 、<|>RELATION_NOE 心律失常<|>RELATION_NOE 、<|>RELATION_NOE 出血<|>RELATION_NOE 、<|>RELATION_NOE 乏力<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 在<|>RELATION_NOE
肺黏膜<|>RELATION_NOE 相关<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 与<|>RELATION_I 鉴别诊断<|>RELATION_E
探讨<|>RELATION_NOE 肺黏膜<|>RELATION_NOE 相关<|>RELATION_NOE 淋巴组织<|>RELATION_NOE 边缘区<|>RELATION_NOE B<|>RELATION_NOE 细胞<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE (<|>RELATION_NOE MALToma<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 、<|>RELATION_NOE 影像<|>RELATION_NOE 、<|>RELATION_NOE 病理学<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 可靠<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 依据<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 形态<|>RELATION_NOE 非常<|>RELATION_NOE 相似<|>RELATION_NOE 的<|>RELATION_NOE 3<|>RELATION_NOE 种<|>RELATION_NOE 肺良性<|>RELATION_NOE 淋巴组织<|>RELATION_NOE 增生<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE 相<|>RELATION_NOE 鉴别<|>RELATION_S 。<|>RELATION_NOE
分析<|>RELATION_NOE 3例肺<|>RELATION_NOE MALToma<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病史<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 组织学<|>RELATION_NOE 等<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 淋巴细胞性<|>RELATION_NOE 间质性肺炎<|>RELATION_NOE 、<|>RELATION_NOE 淋巴细胞性<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 、<|>RELATION_NOE 滤泡性<|>RELATION_NOE 支气管炎<|>RELATION_NOE 鉴别<|>RELATION_NOE 。<|>RELATION_NOE
肺<|>RELATION_NOE MALToma<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 和<|>RELATION_NOE 影像学<|>RELATION_NOE 缺乏<|>RELATION_B 特异性<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 不易<|>RELATION_NOE 鉴别.<|>RELATION_NOE 肺<|>RELATION_NOE MALToma<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 和<|>RELATION_NOE 影像学<|>RELATION_NOE 缺乏<|>RELATION_NOE 特异性<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 不易<|>RELATION_B 鉴别<|>RELATION_E .<|>RELATION_NOE
病理<|>RELATION_NOE 示<|>RELATION_NOE 边缘区<|>RELATION_NOE 淋巴细胞增生<|>RELATION_NOE 、<|>RELATION_NOE 围绕<|>RELATION_NOE 生发中心<|>RELATION_NOE 并<|>RELATION_NOE 相互<|>RELATION_NOE 融合<|>RELATION_NOE ,<|>RELATION_NOE 侵入<|>RELATION_NOE 支气管<|>RELATION_NOE 上皮<|>RELATION_NOE 形成<|>RELATION_NOE “<|>RELATION_NOE 淋巴<|>RELATION_NOE 上皮<|>RELATION_NOE 病变<|>RELATION_NOE ”<|>RELATION_NOE ,<|>RELATION_NOE 侵入<|>RELATION_NOE 滤泡<|>RELATION_NOE 生发中心<|>RELATION_NOE 形成<|>RELATION_NOE “<|>RELATION_NOE 滤泡<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE ”<|>RELATION_NOE 。<|>RELATION_NOE
肺<|>RELATION_NOE MALToma<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 少见<|>RELATION_NOE 的<|>RELATION_NOE 低度<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 和<|>RELATION_NOE 影像<|>RELATION_NOE 学<|>RELATION_NOE 无<|>RELATION_NOE 特异性<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_S 需<|>RELATION_NOE 依据<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 自我<|>RELATION_NOE 管理<|>RELATION_NOE 效能感<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 调查<|>RELATION_S
用<|>RELATION_NOE 描述<|>RELATION_NOE 相关性<|>RELATION_NOE 研究设计<|>RELATION_NOE ,<|>RELATION_NOE 采取<|>RELATION_NOE 便利<|>RELATION_NOE 抽样<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 调查<|>RELATION_NOE 了<|>RELATION_NOE 北京市<|>RELATION_NOE 4<|>RELATION_NOE 所<|>RELATION_NOE 三级<|>RELATION_NOE 甲等<|>RELATION_NOE 医院<|>RELATION_NOE 共<|>RELATION_NOE 72<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
医护<|>RELATION_NOE 人员<|>RELATION_NOE 在<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 患者<|>RELATION_I 的<|>RELATION_I 管理<|>RELATION_E 中<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 结合<|>RELATION_NOE 实际<|>RELATION_NOE 情况<|>RELATION_NOE 向<|>RELATION_NOE 不同<|>RELATION_NOE 层次<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 提供<|>RELATION_NOE 有<|>RELATION_NOE 针对性<|>RELATION_NOE 的<|>RELATION_NOE 信息<|>RELATION_NOE ,<|>RELATION_NOE 重点<|>RELATION_NOE 关注<|>RELATION_NOE 文化<|>RELATION_NOE 程度<|>RELATION_NOE 低<|>RELATION_NOE 、<|>RELATION_NOE 社会<|>RELATION_NOE 支持<|>RELATION_NOE 水平<|>RELATION_NOE 低<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 不同<|>RELATION_NOE 民族<|>RELATION_NOE 及<|>RELATION_NOE 患病<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 提供<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 疾病<|>RELATION_NOE 信息<|>RELATION_NOE 指导<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 有效<|>RELATION_NOE 提高<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 自我<|>RELATION_NOE 管理<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_NOE 健康<|>RELATION_NOE 状况<|>RELATION_NOE 。<|>RELATION_NOE
血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 及<|>RELATION_NOE 受体<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE -C<|>RELATION_NOE (<|>RELATION_NOE VEGF-C<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE -D<|>RELATION_NOE (<|>RELATION_NOE VEGF-D<|>RELATION_NOE )<|>RELATION_NOE 及其<|>RELATION_NOE 受体<|>RELATION_NOE -3<|>RELATION_NOE (<|>RELATION_NOE VEGFR-3<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 逆转录<|>RELATION_NOE -<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE 96<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_B 组织<|>RELATION_I 中<|>RELATION_I VEGF-C<|>RELATION_I 、<|>RELATION_I VEGF-D<|>RELATION_I 和<|>RELATION_I VEGFR-3<|>RELATION_I 的<|>RELATION_I 表达量<|>RELATION_E 进行<|>RELATION_NOE 定量分析<|>RELATION_NOE 。<|>RELATION_NOE
VEGF-C<|>RELATION_NOE 、<|>RELATION_NOE VEGF-D<|>RELATION_NOE 和<|>RELATION_NOE VEGFR-3mRNA<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 正常<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
选择<|>RELATION_NOE 本院<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 6月<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 取<|>RELATION_NOE 切除<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 为<|>RELATION_NOE 观察组<|>RELATION_NOE ,<|>RELATION_NOE 取<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 39<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 非<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 组织<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE .<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 观察<|>RELATION_S Shh<|>RELATION_NOE 和<|>RELATION_NOE Gli2<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
Shh<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 激活<|>RELATION_NOE Shh<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE Gli<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 促进<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 异常<|>RELATION_NOE 增殖<|>RELATION_NOE 及<|>RELATION_NOE 细胞<|>RELATION_NOE 癌变<|>RELATION_NOE .<|>RELATION_NOE
Notch1<|>RELATION_NOE 和<|>RELATION_NOE Notch3<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE
对<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_NOE Notch1<|>RELATION_NOE 和<|>RELATION_NOE Notch3<|>RELATION_NOE 在<|>RELATION_NOE 其<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
Notch1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
负载<|>RELATION_NOE k-ras<|>RELATION_NOE 抗原<|>RELATION_NOE 的<|>RELATION_NOE 树突<|>RELATION_NOE 状<|>RELATION_NOE 细胞<|>RELATION_NOE 诱导细胞<|>RELATION_NOE 毒性<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 体内<|>RELATION_B 杀伤<|>RELATION_I 作用<|>RELATION_E
观察<|>RELATION_NOE k-ras<|>RELATION_NOE 突变<|>RELATION_NOE 多肽<|>RELATION_NOE 致敏<|>RELATION_NOE 的<|>RELATION_NOE 树突<|>RELATION_NOE 状<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE DC<|>RELATION_NOE )<|>RELATION_NOE 诱导<|>RELATION_NOE 活化<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 毒性<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE (<|>RELATION_NOE CTL<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 体内<|>RELATION_B 杀伤<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
联合<|>RELATION_NOE 应用<|>RELATION_NOE 粒细胞<|>RELATION_NOE -<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 集落<|>RELATION_NOE 刺激<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE GM-CSF<|>RELATION_NOE )<|>RELATION_NOE 1000mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE 白细胞介素<|>RELATION_NOE 4<|>RELATION_NOE (<|>RELATION_NOE IL-4<|>RELATION_NOE )<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 诱导<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE DC<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 使用<|>RELATION_NOE 表达<|>RELATION_NOE k-ras<|>RELATION_NOE 突变体<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 抗原<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE k-ras<|>RELATION_NOE 突变<|>RELATION_NOE 体<|>RELATION_NOE 抗原<|>RELATION_NOE 表位<|>RELATION_NOE 肽<|>RELATION_NOE 和<|>RELATION_NOE k-ras<|>RELATION_NOE 突变<|>RELATION_NOE 体<|>RELATION_NOE 抗原<|>RELATION_NOE 表位<|>RELATION_NOE 肽<|>RELATION_NOE 阳离子<|>RELATION_NOE 纳米<|>RELATION_NOE 颗粒<|>RELATION_NOE 致敏<|>RELATION_NOE DC<|>RELATION_NOE ,<|>RELATION_NOE 进而<|>RELATION_NOE 通过<|>RELATION_NOE 诱导<|>RELATION_NOE 刺激<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 得到<|>RELATION_NOE 特异性<|>RELATION_NOE 的<|>RELATION_NOE CTL<|>RELATION_NOE .<|>RELATION_NOE
负载<|>RELATION_NOE 全瘤<|>RELATION_NOE 抗原<|>RELATION_NOE 的<|>RELATION_NOE DC<|>RELATION_NOE 诱导<|>RELATION_NOE 产生<|>RELATION_NOE 的<|>RELATION_NOE CTL<|>RELATION_NOE 对<|>RELATION_NOE 表达<|>RELATION_NOE k-ras<|>RELATION_NOE 阳性<|>RELATION_NOE (<|>RELATION_NOE A549<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_B 好<|>RELATION_I 的<|>RELATION_I 抑制<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 对<|>RELATION_NOE k-ras<|>RELATION_NOE 表达<|>RELATION_NOE 阴性<|>RELATION_NOE (<|>RELATION_NOE NCH-446<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肾移植<|>RELATION_NOE 术后<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_B 分析<|>RELATION_E
18<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE 肾移植<|>RELATION_NOE 受者<|>RELATION_NOE 中<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE 并发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤发生率<|>RELATION_NOE 为<|>RELATION_NOE 1.60%<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE /<|>RELATION_NOE 18<|>RELATION_NOE 14<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 发生<|>RELATION_NOE 肿瘤<|>RELATION_NOE 时<|>RELATION_NOE 受者<|>RELATION_NOE 年龄<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 52.7<|>RELATION_NOE ±<|>RELATION_NOE 9.5<|>RELATION_NOE 岁<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE 30-69<|>RELATION_NOE 岁<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 发生<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 肾移植<|>RELATION_NOE 后<|>RELATION_NOE (<|>RELATION_NOE 54.5<|>RELATION_NOE ±<|>RELATION_NOE 28.2<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 14<|>RELATION_NOE －1<|>RELATION_NOE 20<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
29<|>RELATION_NOE 例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 类型<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 尿路<|>RELATION_NOE 上<|>RELATION_NOE 皮癌<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 72.4%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 3例<|>RELATION_NOE (<|>RELATION_NOE 10.3%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 6.9%<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 皮肤癌<|>RELATION_NOE 和<|>RELATION_NOE 鼻咽癌<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 3.4%<|>RELATION_NOE 0<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
共有<|>RELATION_NOE 6例受者<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 尿路<|>RELATION_NOE 上皮<|>RELATION_NOE 癌受者<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 肝癌<|>RELATION_NOE 受者<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 受者<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 受者<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 死亡率<|>RELATION_NOE 为<|>RELATION_NOE 20.7%<|>RELATION_NOE 0<|>RELATION_NOE (<|>RELATION_NOE 6/<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 发生<|>RELATION_NOE 肿瘤<|>RELATION_NOE 后<|>RELATION_NOE 受者<|>RELATION_NOE 存活<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 12.0<|>RELATION_NOE ±<|>RELATION_NOE 8.9<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 3-28<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 诱导<|>RELATION_NOE 治疗<|>RELATION_NOE 是<|>RELATION_NOE 导致<|>RELATION_NOE 恶性肿瘤发生<|>RELATION_NOE 的<|>RELATION_NOE 免疫性<|>RELATION_B 危险因素<|>RELATION_E (<|>RELATION_NOE 相对危险度<|>RELATION_NOE =<|>RELATION_NOE 1.05<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 46<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肾移植<|>RELATION_NOE 受者<|>RELATION_NOE 术后<|>RELATION_NOE 恶性肿瘤发生率<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 普通<|>RELATION_NOE 人群<|>RELATION_NOE ,<|>RELATION_NOE 移植<|>RELATION_NOE 时<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 原<|>RELATION_NOE 发病<|>RELATION_NOE 及<|>RELATION_NOE 抗体<|>RELATION_NOE 免疫<|>RELATION_NOE 诱导<|>RELATION_NOE 治疗<|>RELATION_NOE 是<|>RELATION_NOE 导致<|>RELATION_NOE 肿瘤发生<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE ;<|>RELATION_NOE 肾移植<|>RELATION_NOE 受者<|>RELATION_NOE 术后<|>RELATION_NOE 恶性肿瘤发生率<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 普通<|>RELATION_NOE 人群<|>RELATION_NOE ,<|>RELATION_NOE 移植<|>RELATION_NOE 时<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 原<|>RELATION_NOE 发病<|>RELATION_NOE 及<|>RELATION_NOE 抗体<|>RELATION_NOE 免疫<|>RELATION_NOE 诱导<|>RELATION_NOE 治疗<|>RELATION_NOE 是<|>RELATION_NOE 导致<|>RELATION_NOE 肿瘤发生<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_S ;<|>RELATION_NOE
尿路<|>RELATION_NOE 上皮<|>RELATION_NOE 恶性肿瘤发生率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 与<|>RELATION_NOE 长期<|>RELATION_NOE 服用<|>RELATION_NOE 药物<|>RELATION_NOE 史<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 应<|>RELATION_NOE 积极<|>RELATION_NOE 采取<|>RELATION_NOE 根治性<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
结<|>RELATION_NOE 直肠<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 分析<|>RELATION_S
探讨<|>RELATION_NOE 结<|>RELATION_NOE 直肠<|>RELATION_NOE 小细胞癌<|>RELATION_NOE (<|>RELATION_NOE small<|>RELATION_NOE cell<|>RELATION_NOE carcinoma<|>RELATION_NOE ,<|>RELATION_NOE SCC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 影响<|>RELATION_NOE 其<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
原发<|>RELATION_NOE 病变<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 位于<|>RELATION_NOE 直肠<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 位于<|>RELATION_NOE 结肠<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 降结肠<|>RELATION_NOE 、<|>RELATION_NOE 横结肠<|>RELATION_NOE 及<|>RELATION_NOE 乙状结肠<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE ;<|>RELATION_NOE
14<|>RELATION_NOE 例<|>RELATION_NOE 以<|>RELATION_NOE 手术<|>RELATION_NOE 为<|>RELATION_NOE 初始<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 6例行根治<|>RELATION_NOE 性肿瘤<|>RELATION_NOE 切除术<|>RELATION_NOE ,<|>RELATION_NOE 7例<|>RELATION_NOE 因<|>RELATION_NOE 肿瘤<|>RELATION_NOE 侵及<|>RELATION_NOE 范围<|>RELATION_NOE 较<|>RELATION_NOE 广<|>RELATION_NOE 经术<|>RELATION_NOE 中<|>RELATION_NOE 探查<|>RELATION_NOE 后<|>RELATION_NOE 行姑息性肿瘤<|>RELATION_NOE 切除术<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 在<|>RELATION_NOE 外院<|>RELATION_NOE 先行<|>RELATION_NOE 乙状结肠<|>RELATION_NOE 双腔造<|>RELATION_NOE 瘘术<|>RELATION_NOE 后<|>RELATION_NOE 又<|>RELATION_NOE 于<|>RELATION_NOE 医科院<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 继续<|>RELATION_NOE 行放<|>RELATION_NOE 化疗<|>RELATION_NOE ;<|>RELATION_NOE
结<|>RELATION_NOE 直肠<|>RELATION_NOE SCC<|>RELATION_NOE 是<|>RELATION_NOE 结<|>RELATION_NOE 直肠<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 罕见<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE ,<|>RELATION_NOE 初期<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE ,<|>RELATION_NOE 病情<|>RELATION_NOE 进展<|>RELATION_NOE 迅速<|>RELATION_NOE 且<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 根治性<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 肿瘤<|>RELATION_NOE 加<|>RELATION_NOE 术后<|>RELATION_NOE 辅助<|>RELATION_NOE 性放<|>RELATION_NOE 化疗<|>RELATION_NOE 可以<|>RELATION_NOE 延长<|>RELATION_S 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存期<|>RELATION_NOE 。<|>RELATION_NOE
从<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 1月<|>RELATION_NOE 对<|>RELATION_NOE 下肢<|>RELATION_NOE 深静脉血栓<|>RELATION_NOE 形成<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 肿瘤<|>RELATION_NOE 筛查<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 肿瘤<|>RELATION_NOE 筛查<|>RELATION_NOE 阳性<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE ,<|>RELATION_NOE 性别<|>RELATION_NOE ,<|>RELATION_NOE 血栓<|>RELATION_NOE 形成<|>RELATION_NOE 部位<|>RELATION_NOE ,<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 癌症<|>RELATION_NOE 标志物<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 特点<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 筛查阴性<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
本组<|>RELATION_NOE 入选<|>RELATION_NOE 接受<|>RELATION_NOE 肿瘤<|>RELATION_NOE 筛查<|>RELATION_NOE 84<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE 危险因素<|>RELATION_NOE 的<|>RELATION_NOE 下肢<|>RELATION_NOE 深静脉血栓<|>RELATION_NOE 形成<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 肺癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 胰头癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 软组织肉瘤<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 卵巢癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 结肠癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 子宫颈癌<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 筛查<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志<|>RELATION_NOE 物阳<|>RELATION_NOE 性率<|>RELATION_NOE 为<|>RELATION_NOE 62.5%<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S 筛查<|>RELATION_NOE 阴性<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 10.5<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 14.95<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 下肢<|>RELATION_NOE 深静脉血栓<|>RELATION_NOE 形成<|>RELATION_NOE 为<|>RELATION_NOE 最初<|>RELATION_NOE 临床<|>RELATION_NOE 主要<|>RELATION_NOE 表现<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 特点<|>RELATION_S 为<|>RELATION_NOE 大多<|>RELATION_NOE 为<|>RELATION_NOE 近<|>RELATION_NOE 心端<|>RELATION_NOE 深静脉血栓<|>RELATION_NOE ,<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 比例<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 多<|>RELATION_NOE 见<|>RELATION_NOE 。<|>RELATION_NOE
中等<|>RELATION_NOE 浓度<|>RELATION_NOE 氧气<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 及其<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE -<|>RELATION_NOE β<|>RELATION_NOE 1mRNA<|>RELATION_NOE 和<|>RELATION_NOE 结缔组织<|>RELATION_NOE 生长因子<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
培养<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 以<|>RELATION_NOE 1×<|>RELATION_NOE 1O5<|>RELATION_NOE 个<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 的<|>RELATION_NOE 密度<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 6孔<|>RELATION_NOE 培养<|>RELATION_NOE 板<|>RELATION_NOE 或<|>RELATION_NOE 培养<|>RELATION_NOE 皿<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 分为<|>RELATION_NOE 3组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE 空气<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 40%<|>RELATION_NOE 氧浓度<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 40%<|>RELATION_NOE O2<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 95%<|>RELATION_NOE 氧浓度<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE O2<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
趋化<|>RELATION_NOE 因子<|>RELATION_NOE 受体<|>RELATION_NOE CXCR7<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S
免疫<|>RELATION_NOE 细胞化学<|>RELATION_NOE 分析<|>RELATION_NOE cxcR7<|>RELATION_NOE /<|>RELATION_NOE CxCR4<|>RELATION_NOE /<|>RELATION_NOE CxcLl2<|>RELATION_NOE 在<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE A549<|>RELATION_NOE 、<|>RELATION_NOE 95D<|>RELATION_NOE 和<|>RELATION_NOE H292<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE 例<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 表达<|>RELATION_NOE CXCR7<|>RELATION_NOE ,<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 表达<|>RELATION_NOE CXCR4<|>RELATION_NOE ,<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE 表达<|>RELATION_NOE CXCLl2<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 胞浆<|>RELATION_NOE 和<|>RELATION_NOE 胞膜<|>RELATION_NOE 均<|>RELATION_NOE 可<|>RELATION_NOE 观察<|>RELATION_NOE 到<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 染色<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE AKAP95<|>RELATION_NOE 与<|>RELATION_NOE 细胞周期<|>RELATION_NOE 蛋白<|>RELATION_NOE D1<|>RELATION_NOE 和<|>RELATION_NOE E1<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 病理学<|>RELATION_NOE 指标<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE PKA<|>RELATION_NOE 的<|>RELATION_NOE 锚定<|>RELATION_NOE 蛋白<|>RELATION_NOE A-kinaseanchorprotein95<|>RELATION_NOE (<|>RELATION_NOE AKAP95<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞周期<|>RELATION_NOE 蛋白<|>RELATION_NOE CyclinEl<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE CyclinDl<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_B 的<|>RELATION_I 关联性<|>RELATION_E 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 51<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE AKAP95<|>RELATION_NOE 、<|>RELATION_NOE CyclinEl<|>RELATION_NOE 和<|>RELATION_NOE CyclinDl<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 学分型<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 是否<|>RELATION_NOE 发生<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 均<|>RELATION_NOE 无关<|>RELATION_S ,<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
2.<|>RELATION_NOE CyclinDl<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 69.3<|>RELATION_NOE 9%<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 14.2<|>RELATION_NOE 9%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 学分型<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 3.AKAP95<|>RELATION_NOE 和<|>RELATION_NOE CyclinEl<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE AKAP95<|>RELATION_NOE 和<|>RELATION_NOE CyclinDl<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 呈<|>RELATION_NOE 关联性<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 2.CyclinDl<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 69.3<|>RELATION_NOE 9%<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 14.2<|>RELATION_NOE 9%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 学分型<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 3.<|>RELATION_NOE AKAP95<|>RELATION_NOE 和<|>RELATION_NOE CyclinEl<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE AKAP95<|>RELATION_NOE 和<|>RELATION_NOE CyclinDl<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 呈<|>RELATION_NOE 关联性<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
1.<|>RELATION_NOE CyclinEl<|>RELATION_NOE 和<|>RELATION_NOE CyclinDl<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 发挥<|>RELATION_B 作用<|>RELATION_E ;<|>RELATION_NOE
2.<|>RELATION_NOE CyclinEl<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 组织学分型<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 均<|>RELATION_NOE 无关<|>RELATION_S ;<|>RELATION_NOE
血清<|>RELATION_NOE Pentraxin-3<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_B 及<|>RELATION_I 疗效<|>RELATION_I 评估<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 研究<|>RELATION_NOE
分析<|>RELATION_NOE 血清<|>RELATION_NOE Pentraxin-3<|>RELATION_NOE (<|>RELATION_NOE PTX-3<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_B 及<|>RELATION_I 疗效<|>RELATION_I 评估<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
ELISA<|>RELATION_NOE 或<|>RELATION_NOE 电化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 血清<|>RELATION_NOE PTX-3<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 片段<|>RELATION_NOE 19<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 神经<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE .<|>RELATION_NOE
ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 确定<|>RELATION_NOE PTX-3<|>RELATION_NOE 最佳<|>RELATION_NOE cut-off<|>RELATION_NOE 值<|>RELATION_NOE ,<|>RELATION_NOE 评估<|>RELATION_NOE 血清标记物<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE .<|>RELATION_NOE
对<|>RELATION_NOE 61<|>RELATION_NOE 例行<|>RELATION_NOE 肺癌<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 术后<|>RELATION_NOE 3d<|>RELATION_NOE 、<|>RELATION_NOE 7d<|>RELATION_NOE 、<|>RELATION_NOE 14d<|>RELATION_NOE 血清<|>RELATION_NOE PTX-3<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 随访研究<|>RELATION_NOE 。<|>RELATION_NOE
ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE PTX-3<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 最佳<|>RELATION_NOE cut-off<|>RELATION_NOE 值<|>RELATION_NOE 为<|>RELATION_NOE 8.03g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 和<|>RELATION_NOE 验证组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE PTX-3<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 76.1%<|>RELATION_NOE 、<|>RELATION_NOE 75.2%<|>RELATION_NOE 和<|>RELATION_NOE 71.3%<|>RELATION_NOE 、<|>RELATION_NOE 89.2%<|>RELATION_NOE ;<|>RELATION_NOE
PTX-3<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE ROC<|>RELATION_NOE 曲线下面积<|>RELATION_NOE (<|>RELATION_NOE AUC<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.8<|>RELATION_NOE 36<|>RELATION_NOE 、<|>RELATION_NOE 0.8<|>RELATION_NOE 24<|>RELATION_NOE ;<|>RELATION_NOE
实验组<|>RELATION_NOE 和<|>RELATION_NOE 验证组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE PTX-3<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E CEA<|>RELATION_NOE 和<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE .<|>RELATION_NOE 在<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE PTX-3<|>RELATION_NOE 在<|>RELATION_NOE 实验组<|>RELATION_NOE 和<|>RELATION_NOE 验证组<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 79.1%<|>RELATION_NOE 、<|>RELATION_NOE 62.2%<|>RELATION_NOE 和<|>RELATION_NOE 71.3%<|>RELATION_NOE 、<|>RELATION_NOE 69.6%<|>RELATION_NOE ,<|>RELATION_NOE AUC<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.7<|>RELATION_NOE 64<|>RELATION_NOE 、<|>RELATION_NOE 0.74<|>RELATION_NOE 4.<|>RELATION_NOE PTX-3<|>RELATION_NOE 诊断<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 高于<|>RELATION_NOE 实验组<|>RELATION_NOE 和<|>RELATION_NOE 验证组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE PTX-3<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE CEA<|>RELATION_NOE 和<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE .<|>RELATION_NOE 在<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE PTX-3<|>RELATION_NOE 在<|>RELATION_NOE 实验组<|>RELATION_NOE 和<|>RELATION_NOE 验证组<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 79.1%<|>RELATION_NOE 、<|>RELATION_NOE 62.2%<|>RELATION_NOE 和<|>RELATION_NOE 71.3%<|>RELATION_NOE 、<|>RELATION_NOE 69.6%<|>RELATION_NOE ,<|>RELATION_NOE AUC<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.7<|>RELATION_NOE 64<|>RELATION_NOE 、<|>RELATION_NOE 0.74<|>RELATION_NOE 4.<|>RELATION_NOE PTX-3<|>RELATION_NOE 诊断<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 高于<|>RELATION_S CEA<|>RELATION_NOE 和<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE .PTX-3<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 诊断<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE PTX-3<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 实验组<|>RELATION_NOE 和<|>RELATION_NOE 验证组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE PTX-3<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE CEA<|>RELATION_NOE 和<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE .<|>RELATION_NOE 在<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE PTX-3<|>RELATION_NOE 在<|>RELATION_NOE 实验组<|>RELATION_NOE 和<|>RELATION_NOE 验证组<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 79.1%<|>RELATION_NOE 、<|>RELATION_NOE 62.2%<|>RELATION_NOE 和<|>RELATION_NOE 71.3%<|>RELATION_NOE 、<|>RELATION_NOE 69.6%<|>RELATION_NOE ,<|>RELATION_NOE AUC<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.7<|>RELATION_NOE 64<|>RELATION_NOE 、<|>RELATION_NOE 0.74<|>RELATION_NOE 4.<|>RELATION_NOE PTX-3<|>RELATION_NOE 诊断<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 高于<|>RELATION_NOE CEA<|>RELATION_NOE 和<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE .<|>RELATION_NOE PTX-3<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 诊断<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E ,<|>RELATION_NOE PTX-3<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 高于<|>RELATION_NOE NSE<|>RELATION_NOE .<|>RELATION_NOE 实验组<|>RELATION_NOE 和<|>RELATION_NOE 验证组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE PTX-3<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE CEA<|>RELATION_NOE 和<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE .<|>RELATION_NOE 在<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE PTX-3<|>RELATION_NOE 在<|>RELATION_NOE 实验组<|>RELATION_NOE 和<|>RELATION_NOE 验证组<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 79.1%<|>RELATION_NOE 、<|>RELATION_NOE 62.2%<|>RELATION_NOE 和<|>RELATION_NOE 71.3%<|>RELATION_NOE 、<|>RELATION_NOE 69.6%<|>RELATION_NOE ,<|>RELATION_NOE AUC<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.7<|>RELATION_NOE 64<|>RELATION_NOE 、<|>RELATION_NOE 0.74<|>RELATION_NOE 4.<|>RELATION_NOE PTX-3<|>RELATION_NOE 诊断<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 高于<|>RELATION_NOE CEA<|>RELATION_NOE 和<|>RELATION_NOE CYFRA21-1.PTX-3<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 诊断<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE PTX-3<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 高于<|>RELATION_S NSE<|>RELATION_NOE .<|>RELATION_NOE
血清<|>RELATION_NOE PTX-3<|>RELATION_NOE 和<|>RELATION_NOE CRP<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病组<|>RELATION_NOE 及<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 相关性<|>RELATION_S (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 64<|>RELATION_NOE 、<|>RELATION_NOE 0.5<|>RELATION_NOE 92<|>RELATION_NOE 、<|>RELATION_NOE 0.5<|>RELATION_NOE 12<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE PTX-3<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 及<|>RELATION_I 早期<|>RELATION_I 肺癌<|>RELATION_I 诊断<|>RELATION_E 中<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE PTX-3<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE ,<|>RELATION_NOE 辅助<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 判断<|>RELATION_NOE .<|>RELATION_NOE
胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE 和<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE 对<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 诊断<|>RELATION_S 的<|>RELATION_NOE 差异<|>RELATION_NOE 及<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 特异性<|>RELATION_NOE 循环<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 特异性<|>RELATION_NOE 循环<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE SCLCC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 特异性<|>RELATION_NOE 识别<|>RELATION_NOE SPC-A1<|>RELATION_NOE 的<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE NJ001<|>RELATION_NOE 进行<|>RELATION_NOE 荧光<|>RELATION_NOE 标记<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE SCLCC<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE .<|>RELATION_NOE
采用<|>RELATION_NOE 病例<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 收集<|>RELATION_NOE 到<|>RELATION_NOE 的<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 3<|>RELATION_NOE 至<|>RELATION_NOE 7月<|>RELATION_NOE 南京<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 第一<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 、<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 35<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 对照者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 进行<|>RELATION_NOE SCLCC<|>RELATION_NOE 水平<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 秩和检验<|>RELATION_NOE 分析<|>RELATION_NOE 各组<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 绘制<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 分析<|>RELATION_NOE .<|>RELATION_NOE
同时<|>RELATION_NOE 将<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE SCLCC<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 角质<|>RELATION_NOE 蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 采用<|>RELATION_NOE x2<|>RELATION_NOE 检验<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
线粒体<|>RELATION_NOE DNA<|>RELATION_NOE 在<|>RELATION_NOE 百草枯<|>RELATION_NOE 中毒<|>RELATION_B 机制<|>RELATION_I 中<|>RELATION_I 的<|>RELATION_I 作用<|>RELATION_E
利用<|>RELATION_NOE 体外<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE 线粒体<|>RELATION_NOE DNA<|>RELATION_NOE (<|>RELATION_NOE mtDNA<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 百草枯<|>RELATION_NOE (<|>RELATION_NOE PQ<|>RELATION_NOE )<|>RELATION_NOE 致病<|>RELATION_B 机理<|>RELATION_I 中<|>RELATION_I 的<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
首先<|>RELATION_NOE 用<|>RELATION_NOE PQ<|>RELATION_NOE 处理人<|>RELATION_NOE Ⅱ型<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE (<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE CCK-8<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 细胞生存率<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 利用<|>RELATION_NOE 绝对<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 培养<|>RELATION_NOE 上<|>RELATION_NOE 清液<|>RELATION_NOE 中<|>RELATION_NOE mtDNA<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 激光<|>RELATION_NOE 共<|>RELATION_NOE 聚焦<|>RELATION_NOE 成像法<|>RELATION_NOE 检测<|>RELATION_NOE 线粒体<|>RELATION_NOE 膜电位<|>RELATION_NOE 来<|>RELATION_NOE 验证<|>RELATION_NOE PQ<|>RELATION_NOE 对<|>RELATION_NOE 线粒体<|>RELATION_NOE 的<|>RELATION_NOE 损伤<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
接着<|>RELATION_NOE 通过<|>RELATION_NOE Transwell<|>RELATION_NOE 趋化<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_S mtDNA<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 单个<|>RELATION_NOE 核细胞<|>RELATION_NOE (<|>RELATION_NOE PBMC<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE (<|>RELATION_NOE PMN<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 趋化<|>RELATION_NOE 活性<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 确定<|>RELATION_NOE 趋化<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 亚型<|>RELATION_NOE 。<|>RELATION_NOE 接着<|>RELATION_NOE 通过<|>RELATION_NOE Transwell<|>RELATION_NOE 趋化<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_NOE mtDNA<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 单个<|>RELATION_NOE 核细胞<|>RELATION_NOE (<|>RELATION_NOE PBMC<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE (<|>RELATION_NOE PMN<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 趋化<|>RELATION_NOE 活性<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 确定<|>RELATION_S 趋化<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 亚型<|>RELATION_NOE 。<|>RELATION_NOE
同时<|>RELATION_NOE 应用<|>RELATION_NOE Xcelligence<|>RELATION_NOE 系统<|>RELATION_NOE 和<|>RELATION_NOE 体外<|>RELATION_NOE 血管通透性<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE 检测<|>RELATION_S 了<|>RELATION_NOE mtDNA<|>RELATION_NOE 对<|>RELATION_NOE 血管通透性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
PQ<|>RELATION_NOE 致<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 半数<|>RELATION_NOE 致死<|>RELATION_NOE 浓度<|>RELATION_NOE 为<|>RELATION_NOE 600<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生存率<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 线粒体<|>RELATION_NOE 的<|>RELATION_NOE 损伤<|>RELATION_NOE 存在<|>RELATION_B 浓度<|>RELATION_I 和<|>RELATION_I 时间<|>RELATION_I 依赖<|>RELATION_I 关系<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
PQ<|>RELATION_NOE 损伤<|>RELATION_NOE 细胞<|>RELATION_NOE 释放<|>RELATION_NOE 的<|>RELATION_NOE mtDNA<|>RELATION_NOE 在<|>RELATION_NOE PQ<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE 炎症<|>RELATION_NOE 及<|>RELATION_NOE 增殖<|>RELATION_NOE 反应<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 着<|>RELATION_NOE 重要<|>RELATION_B 的<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 体层<|>RELATION_NOE 成像<|>RELATION_NOE -CT<|>RELATION_NOE 评估<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 治疗效果<|>RELATION_NOE 的<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE
回顾性<|>RELATION_NOE 收集<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE 至少<|>RELATION_NOE 行2<|>RELATION_NOE 次<|>RELATION_NOE PET-CT<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 靶病<|>RELATION_NOE 灶<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 的<|>RELATION_NOE 直径<|>RELATION_NOE 、<|>RELATION_NOE 标准<|>RELATION_NOE 摄取值<|>RELATION_NOE 变化<|>RELATION_NOE 百分比<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 配对<|>RELATION_NOE 资料<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE 比较<|>RELATION_NOE 其<|>RELATION_NOE 均数<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 差异<|>RELATION_NOE ;<|>RELATION_NOE
PERCIST<|>RELATION_NOE 标准<|>RELATION_NOE 评价<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 治疗效果<|>RELATION_NOE 与<|>RELATION_NOE RECIST<|>RELATION_NOE 标准<|>RELATION_NOE 比较<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 敏感度<|>RELATION_B 更<|>RELATION_I 高<|>RELATION_E ,<|>RELATION_NOE 但<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 有待<|>RELATION_NOE 确认<|>RELATION_NOE .<|>RELATION_NOE
骨巨细胞瘤<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 和<|>RELATION_I 影像<|>RELATION_I 特征<|>RELATION_E
5例<|>RELATION_NOE 患者<|>RELATION_NOE 原发<|>RELATION_NOE 灶术式<|>RELATION_NOE 都<|>RELATION_NOE 为<|>RELATION_NOE 瘤段<|>RELATION_NOE 刮<|>RELATION_NOE 除<|>RELATION_NOE 并<|>RELATION_NOE 经历<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 肺转移瘤<|>RELATION_NOE 被<|>RELATION_NOE 发现<|>RELATION_NOE 在<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 诊断<|>RELATION_NOE 后<|>RELATION_NOE 5－<|>RELATION_NOE 26<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE .<|>RELATION_NOE
骨巨细胞瘤<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 动态<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 观察<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 特征性<|>RELATION_NOE ,<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 诊断<|>RELATION_NOE 后<|>RELATION_NOE 2<|>RELATION_NOE 年<|>RELATION_NOE 内<|>RELATION_NOE 规律<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_S 及时<|>RELATION_NOE 发现<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 并<|>RELATION_NOE 帮助<|>RELATION_NOE 临床<|>RELATION_NOE 判断<|>RELATION_NOE 预后<|>RELATION_NOE .<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE MMP-9<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
将<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 按照<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE 采用<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE 采用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 42d<|>RELATION_NOE 后<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 测定<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE MMP-9<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 治疗<|>RELATION_S 复发性<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
对<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 复发性<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 给予<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 75mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 分<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 130mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 第2<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 21<|>RELATION_NOE 天<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
心理<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 及<|>RELATION_NOE 健康<|>RELATION_NOE 宣教<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 癌性<|>RELATION_NOE 疼痛<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 及<|>RELATION_NOE 健康<|>RELATION_NOE 宣教<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 癌性<|>RELATION_NOE 疼痛<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
选取<|>RELATION_NOE 本院<|>RELATION_NOE 74<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 进行<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 及<|>RELATION_NOE 健康<|>RELATION_NOE 宣教<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 干预<|>RELATION_NOE 前后<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE 进行<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
留置<|>RELATION_NOE 针留置<|>RELATION_NOE 时间<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 静脉<|>RELATION_NOE 血管<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 不同<|>RELATION_NOE 静脉<|>RELATION_NOE 留置<|>RELATION_NOE 针留置<|>RELATION_NOE 时间<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 中<|>RELATION_NOE 静脉炎<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
A<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 紫杉<|>RELATION_NOE 醇类<|>RELATION_NOE 化疗<|>RELATION_NOE 完成<|>RELATION_NOE 后<|>RELATION_NOE 拔除<|>RELATION_NOE 留置针<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 铂类<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 时<|>RELATION_NOE 患者<|>RELATION_NOE 呵<|>RELATION_NOE 选择<|>RELATION_NOE 是否<|>RELATION_NOE 留置<|>RELATION_NOE 静脉<|>RELATION_NOE 留置针<|>RELATION_NOE ,<|>RELATION_NOE 选择<|>RELATION_NOE 24G<|>RELATION_NOE (<|>RELATION_NOE 小号<|>RELATION_NOE )<|>RELATION_NOE 留置针<|>RELATION_NOE 。<|>RELATION_NOE
紫杉<|>RELATION_NOE 醇类<|>RELATION_NOE 化疗<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE 应<|>RELATION_NOE 立即<|>RELATION_NOE 拔除<|>RELATION_NOE 静脉<|>RELATION_NOE 留置针<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 保护<|>RELATION_NOE 静脉<|>RELATION_NOE 血管<|>RELATION_NOE 。<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 心理<|>RELATION_NOE 状态<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 影响<|>RELATION_S
选取<|>RELATION_NOE 我院<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 8月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 8月<|>RELATION_NOE 收治<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE 为<|>RELATION_NOE 分界点<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 围术期<|>RELATION_NOE 采用<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 重度<|>RELATION_NOE 焦虑<|>RELATION_NOE ,<|>RELATION_NOE 抑郁<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 显著<|>RELATION_B 少于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 术后<|>RELATION_NOE 12h<|>RELATION_NOE 、<|>RELATION_NOE 24h<|>RELATION_NOE 、<|>RELATION_NOE 48h<|>RELATION_NOE 的<|>RELATION_NOE 疼痛<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 有利于<|>RELATION_S 满足<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 围术期<|>RELATION_NOE 的<|>RELATION_NOE 身心<|>RELATION_NOE 需求<|>RELATION_NOE ,<|>RELATION_NOE 缓解<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 情绪<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 。<|>RELATION_NOE
DNA<|>RELATION_NOE 甲基<|>RELATION_NOE 转移酶<|>RELATION_NOE 在<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
观察<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE DNA<|>RELATION_NOE 甲基<|>RELATION_NOE 转移酶<|>RELATION_NOE (<|>RELATION_NOE DNMT<|>RELATION_NOE )<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 3a<|>RELATION_NOE 、<|>RELATION_NOE 3b<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_S ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 对<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 9月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 6月<|>RELATION_NOE 郑州<|>RELATION_NOE 大学<|>RELATION_NOE 第一<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 呼吸<|>RELATION_NOE 内科<|>RELATION_NOE 136<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 同期<|>RELATION_NOE 郑州市<|>RELATION_NOE 第六<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 进行<|>RELATION_NOE 健康<|>RELATION_NOE 体检<|>RELATION_NOE 的<|>RELATION_NOE 147<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 人群<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE DNMT1<|>RELATION_NOE 、<|>RELATION_NOE 3a<|>RELATION_NOE 、<|>RELATION_NOE 3b<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 进行<|>RELATION_NOE 测定<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 危险<|>RELATION_NOE 性关系<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 条件<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 提示<|>RELATION_NOE DNMTl<|>RELATION_NOE 、<|>RELATION_NOE 3a<|>RELATION_NOE 、<|>RELATION_NOE 3b<|>RELATION_NOE 蛋白<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 均<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_S 患<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 危险性<|>RELATION_NOE (<|>RELATION_NOE X2<|>RELATION_NOE =<|>RELATION_NOE 14.8<|>RELATION_NOE 11<|>RELATION_NOE 、<|>RELATION_NOE 26.7<|>RELATION_NOE 68<|>RELATION_NOE 、<|>RELATION_NOE 12.0<|>RELATION_NOE 57<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE 、<|>RELATION_NOE 0.000<|>RELATION_NOE 、<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE DNMTl<|>RELATION_NOE 显著<|>RELATION_NOE
血清<|>RELATION_NOE 中<|>RELATION_NOE DNMTl<|>RELATION_NOE 、<|>RELATION_NOE 5a<|>RELATION_NOE 、<|>RELATION_NOE 3b<|>RELATION_NOE 蛋白<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_S 患<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 危险性<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 发展<|>RELATION_NOE 早期<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_NOE 生物学<|>RELATION_NOE 标志<|>RELATION_NOE 。<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE DNMTl<|>RELATION_NOE 、<|>RELATION_NOE 5a<|>RELATION_NOE 、<|>RELATION_NOE 3b<|>RELATION_NOE 蛋白<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_NOE 患<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 危险性<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 发展<|>RELATION_NOE 早期<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 生物学<|>RELATION_I 标志<|>RELATION_E 。<|>RELATION_NOE
应用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE 应用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 与<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 一线<|>RELATION_NOE 治疗组<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 突变<|>RELATION_NOE 及<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE 不详<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE PFS<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5.2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 2.8<|>RELATION_NOE －<|>RELATION_NOE 7.7<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 4.0<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 10.8<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 4.6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 3.4<|>RELATION_NOE －5.8<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.6<|>RELATION_NOE 61<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 维持<|>RELATION_NOE 治疗组<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 突变<|>RELATION_NOE 及<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE 不详<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE PFS<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 8.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 4.0<|>RELATION_NOE －1<|>RELATION_NOE 3.1<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 12.6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 11.6<|>RELATION_NOE －1<|>RELATION_NOE 3.7<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 8.0<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 5.8<|>RELATION_NOE －1<|>RELATION_NOE 0.3<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.4<|>RELATION_NOE 68<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE CT<|>RELATION_NOE 征象<|>RELATION_NOE 与<|>RELATION_NOE 病理<|>RELATION_NOE 及<|>RELATION_NOE 血清<|>RELATION_NOE 可溶性<|>RELATION_NOE B7<|>RELATION_NOE －<|>RELATION_NOE H4<|>RELATION_NOE 检测<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 血清<|>RELATION_NOE B7-H4<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 征象<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 血清<|>RELATION_NOE B7<|>RELATION_NOE =<|>RELATION_NOE H4<|>RELATION_NOE 水平<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 46.61<|>RELATION_NOE ±<|>RELATION_NOE 4.48<|>RELATION_NOE )<|>RELATION_NOE uj<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 44.76<|>RELATION_NOE ±<|>RELATION_NOE 3.78<|>RELATION_NOE )<|>RELATION_NOE ug<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE B7-H4<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE 29.52<|>RELATION_NOE ±<|>RELATION_NOE 4.85<|>RELATION_NOE )<|>RELATION_NOE ug<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 15.5<|>RELATION_NOE 805<|>RELATION_NOE 、<|>RELATION_NOE 12.7<|>RELATION_NOE 966<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
按<|>RELATION_NOE 鳞癌<|>RELATION_NOE 联系<|>RELATION_NOE 强度<|>RELATION_NOE 依次<|>RELATION_NOE 为<|>RELATION_NOE 毛刺征<|>RELATION_NOE 、<|>RELATION_NOE 分叶征<|>RELATION_NOE 、<|>RELATION_NOE 空泡<|>RELATION_NOE 征<|>RELATION_NOE 、<|>RELATION_NOE 细支气管<|>RELATION_NOE 充气征<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 凹陷征<|>RELATION_NOE ;<|>RELATION_NOE
按<|>RELATION_NOE 腺癌<|>RELATION_NOE 联系<|>RELATION_NOE 强度<|>RELATION_NOE 依次<|>RELATION_NOE 为<|>RELATION_NOE 毛刺征<|>RELATION_NOE 、<|>RELATION_NOE 分叶征<|>RELATION_NOE 、<|>RELATION_NOE 细支气管<|>RELATION_NOE 充气征<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 凹陷征<|>RELATION_NOE 、<|>RELATION_NOE 空泡<|>RELATION_NOE 征<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 血清<|>RELATION_NOE B7<|>RELATION_NOE 一<|>RELATION_NOE H4<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 进一步<|>RELATION_NOE 提高<|>RELATION_S 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确率<|>RELATION_NOE 及<|>RELATION_NOE 检出率<|>RELATION_NOE 。<|>RELATION_NOE
身心灵<|>RELATION_NOE 全人<|>RELATION_NOE 健康<|>RELATION_NOE 模式<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
将<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分成<|>RELATION_NOE 辅导组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 给予<|>RELATION_NOE 常规<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE 指导<|>RELATION_NOE ,<|>RELATION_NOE 辅导组<|>RELATION_NOE 开设<|>RELATION_NOE 身心灵<|>RELATION_NOE 全人<|>RELATION_NOE 健康<|>RELATION_NOE 模式<|>RELATION_NOE 的<|>RELATION_NOE 团体<|>RELATION_NOE 辅导<|>RELATION_NOE 课程<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 于<|>RELATION_NOE 干预<|>RELATION_NOE 前后<|>RELATION_NOE 使用<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE (<|>RELATION_NOE QOL<|>RELATION_NOE )<|>RELATION_NOE 量表<|>RELATION_NOE 进行<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 评定<|>RELATION_NOE 。<|>RELATION_NOE
辅导组<|>RELATION_NOE 在<|>RELATION_NOE 食欲<|>RELATION_NOE (<|>RELATION_NOE 2.03<|>RELATION_NOE ±<|>RELATION_NOE 0.85<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 睡眠<|>RELATION_NOE (<|>RELATION_NOE 3.27<|>RELATION_NOE ±<|>RELATION_NOE 1.0<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 精神<|>RELATION_NOE 及<|>RELATION_NOE 体力<|>RELATION_NOE (<|>RELATION_NOE 2.57<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE 79<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE (<|>RELATION_NOE 4.00<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE 43<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 家庭<|>RELATION_NOE 理解<|>RELATION_NOE 与<|>RELATION_NOE 照顾<|>RELATION_NOE (<|>RELATION_NOE 4.30<|>RELATION_NOE ±<|>RELATION_NOE 0.4<|>RELATION_NOE 66<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 自身<|>RELATION_NOE 对<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 认识<|>RELATION_NOE (<|>RELATION_NOE 4.03<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 对<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 态度<|>RELATION_NOE (<|>RELATION_NOE 4.20<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE 10<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 面部表情<|>RELATION_NOE (<|>RELATION_NOE 3.17<|>RELATION_NOE ±<|>RELATION_NOE 0.5<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 等<|>RELATION_NOE 方面<|>RELATION_NOE 得分<|>RELATION_NOE 均<|>RELATION_B 高于<|>RELATION_E 辅导<|>RELATION_NOE 前<|>RELATION_NOE (<|>RELATION_NOE 1.80<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE 61<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 2.60<|>RELATION_NOE ±<|>RELATION_NOE 0.8<|>RELATION_NOE 55<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 2.27<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 2.40<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 4.03<|>RELATION_NOE ±<|>RELATION_NOE 0.4<|>RELATION_NOE 90<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 3.07<|>RELATION_NOE ±<|>RELATION_NOE 0.8<|>RELATION_NOE 68<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 3.73<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 2.73<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 辅导<|>RELATION_NOE 前后<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE -2.249<|>RELATION_NOE ,<|>RELATION_NOE -4.325<|>RELATION_NOE ,<|>RELATION_NOE -3.071<|>RELATION_NOE ,<|>RELATION_NOE -9.798<|>RELATION_NOE ,<|>RELATION_NOE -3.247<|>RELATION_NOE ,<|>RELATION_NOE -6.547<|>RELATION_NOE ,<|>RELATION_NOE -3.294<|>RELATION_NOE ,<|>RELATION_NOE -3.067<|>RELATION_NOE ;<|>RELATION_NOE
对照组<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE 睡眠<|>RELATION_NOE 维度<|>RELATION_NOE 得分<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 2.90<|>RELATION_NOE ±<|>RELATION_NOE 0.8<|>RELATION_NOE 85<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 疼痛<|>RELATION_NOE 维度<|>RELATION_NOE 得分<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 3.90<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE 62<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 干预<|>RELATION_NOE 前<|>RELATION_NOE (<|>RELATION_NOE 2.43<|>RELATION_NOE ±<|>RELATION_NOE 0.9<|>RELATION_NOE 71<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 2.30<|>RELATION_NOE ±<|>RELATION_NOE 0.8<|>RELATION_NOE 77<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 干预<|>RELATION_NOE 前后<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE -2.454<|>RELATION_NOE ,<|>RELATION_NOE -7.954<|>RELATION_NOE ;<|>RELATION_NOE
辅导<|>RELATION_NOE 后<|>RELATION_NOE 辅导组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 家庭<|>RELATION_NOE 理解<|>RELATION_NOE 与<|>RELATION_NOE 照顾<|>RELATION_NOE (<|>RELATION_NOE 4.30<|>RELATION_NOE ±<|>RELATION_NOE 0.4<|>RELATION_NOE 66<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 自身<|>RELATION_NOE 对<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 认识<|>RELATION_NOE (<|>RELATION_NOE 4.03<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 对<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 态度<|>RELATION_NOE (<|>RELATION_NOE 4.20<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE 10<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 面部<|>RELATION_NOE 表情<|>RELATION_NOE (<|>RELATION_NOE 3.17<|>RELATION_NOE ±<|>RELATION_NOE 0.5<|>RELATION_NOE 31<|>RELATION_NOE )<|>RELATION_NOE 项目<|>RELATION_NOE 得分<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 3.87<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 2.83<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE 47<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 3.83<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE 99<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 2.73<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE 40<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2.7<|>RELATION_NOE 83<|>RELATION_NOE ,<|>RELATION_NOE 6.7<|>RELATION_NOE 95<|>RELATION_NOE ,<|>RELATION_NOE 2.1<|>RELATION_NOE 64<|>RELATION_NOE ,<|>RELATION_NOE 2.<|>RELATION_NOE 607<|>RELATION_NOE ;<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE CD44<|>RELATION_NOE 、<|>RELATION_NOE HER-2<|>RELATION_NOE 、<|>RELATION_NOE P53<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_B 病理<|>RELATION_I 特征<|>RELATION_I 的<|>RELATION_I 关系<|>RELATION_E
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE Envision<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE 检验<|>RELATION_NOE 分析<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 及<|>RELATION_NOE 良性<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 及<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE 相关<|>RELATION_NOE 基因表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 生存<|>RELATION_NOE 曲线<|>RELATION_NOE 分析<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
Kaplan-Meier<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 提示<|>RELATION_NOE CD44<|>RELATION_NOE 、<|>RELATION_NOE HER-2<|>RELATION_NOE 、<|>RELATION_NOE MtP53<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 基因<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_B 差<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CD44<|>RELATION_NOE 、<|>RELATION_NOE HER-2<|>RELATION_NOE 、<|>RELATION_NOE MtP53<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 阳性<|>RELATION_NOE 表达者<|>RELATION_NOE 预后<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 判断<|>RELATION_S NSCLC<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 参考<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
运用<|>RELATION_NOE 全<|>RELATION_NOE 基因组<|>RELATION_NOE 表达<|>RELATION_NOE 谱<|>RELATION_NOE 分析<|>RELATION_B 筛选<|>RELATION_E 肺腺癌<|>RELATION_NOE 不同<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 相关<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
应用<|>RELATION_NOE 商品化<|>RELATION_NOE 的<|>RELATION_NOE 博奥晶芯<|>RELATION_NOE @<|>RELATION_NOE 35KOligo<|>RELATION_NOE 基因<|>RELATION_NOE 芯片<|>RELATION_NOE 比较<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 不同<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 基因表达谱<|>RELATION_NOE ,<|>RELATION_NOE 筛选<|>RELATION_S 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 基因<|>RELATION_NOE 。<|>RELATION_NOE
从<|>RELATION_NOE 中<|>RELATION_NOE 挑选<|>RELATION_NOE Zimp7<|>RELATION_NOE 、<|>RELATION_NOE GINS2<|>RELATION_NOE 及<|>RELATION_NOE NAG-1<|>RELATION_NOE 共<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 基因<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE RT-PCR<|>RELATION_NOE 方法<|>RELATION_NOE 进一步<|>RELATION_NOE 验证<|>RELATION_NOE 它们<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 这<|>RELATION_NOE 592<|>RELATION_NOE 个<|>RELATION_NOE 基因<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 进一步<|>RELATION_NOE 筛选<|>RELATION_NOE 不同<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ<|>RELATION_NOE A<|>RELATION_NOE 期<|>RELATION_NOE )<|>RELATION_NOE 样本<|>RELATION_NOE 间<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 基因<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 获得<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 显著<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 基因<|>RELATION_NOE 。<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 共<|>RELATION_NOE 筛选<|>RELATION_NOE 到<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 中国<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 相关<|>RELATION_NOE 作用<|>RELATION_NOE 基因<|>RELATION_NOE ,<|>RELATION_NOE 预期<|>RELATION_NOE 将<|>RELATION_NOE 为<|>RELATION_NOE 揭示<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 的<|>RELATION_NOE 内在<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE ,<|>RELATION_NOE 寻找<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 预后<|>RELATION_NOE 判断<|>RELATION_NOE 的<|>RELATION_NOE 新<|>RELATION_NOE 靶点<|>RELATION_NOE 提供<|>RELATION_NOE 思路<|>RELATION_NOE ,<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 变化<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
探讨<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 角质<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE SCC<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 神经<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 变化<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
分别<|>RELATION_NOE 采集<|>RELATION_NOE 2006年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 6月<|>RELATION_NOE 确诊<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE Ⅲ<|>RELATION_NOE b-<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期<|>RELATION_NOE )<|>RELATION_NOE 116<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 及<|>RELATION_NOE 四<|>RELATION_NOE 疗<|>RELATION_NOE 程化疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 每份<|>RELATION_NOE 标本<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 四<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 它们<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 差值<|>RELATION_NOE 差异<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 效果<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 比较<|>RELATION_NOE 不同<|>RELATION_NOE 生存<|>RELATION_NOE 时间组<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 差值<|>RELATION_NOE 差异<|>RELATION_NOE 发现<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 越<|>RELATION_NOE 长<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 下降<|>RELATION_B 幅度<|>RELATION_I 越<|>RELATION_I 大<|>RELATION_E ;<|>RELATION_NOE
微波<|>RELATION_NOE 消融<|>RELATION_NOE 序贯<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 免疫学<|>RELATION_NOE 效应<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_NOE 冷循环<|>RELATION_NOE 微波<|>RELATION_NOE 消融<|>RELATION_NOE 序贯<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 免疫学<|>RELATION_NOE 效应<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 58<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 行<|>RELATION_NOE 微波<|>RELATION_NOE 凝固<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 1周<|>RELATION_NOE 后<|>RELATION_NOE 序贯化疗<|>RELATION_NOE (<|>RELATION_NOE 方案<|>RELATION_NOE 为<|>RELATION_NOE 多<|>RELATION_NOE 烯<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 75mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 30mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 1－<|>RELATION_NOE 3d<|>RELATION_NOE ,<|>RELATION_NOE 21<|>RELATION_NOE 天<|>RELATION_NOE 为<|>RELATION_NOE 一<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 4周期<|>RELATION_NOE 为<|>RELATION_NOE 一疗程<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 采<|>RELATION_NOE 血<|>RELATION_NOE 检测<|>RELATION_NOE 免疫<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 胸部<|>RELATION_NOE 增强<|>RELATION_NOE CT<|>RELATION_NOE 动态<|>RELATION_NOE 观察<|>RELATION_NOE 前后<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
58<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 微波<|>RELATION_NOE 凝固<|>RELATION_NOE 治疗<|>RELATION_NOE 7d<|>RELATION_NOE 后<|>RELATION_NOE 细胞<|>RELATION_NOE 毒性<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE (<|>RELATION_NOE CTL<|>RELATION_NOE )<|>RELATION_NOE 活性<|>RELATION_NOE 升高<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 升高率<|>RELATION_NOE 51.7%<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 冷循环<|>RELATION_NOE 微波<|>RELATION_NOE 消融<|>RELATION_NOE 系统<|>RELATION_NOE 治疗<|>RELATION_B 肺癌<|>RELATION_E 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 局部<|>RELATION_NOE 治疗<|>RELATION_NOE 手段<|>RELATION_NOE 。<|>RELATION_NOE
靶向<|>RELATION_NOE 沉默<|>RELATION_NOE ATM<|>RELATION_NOE 基因<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 质粒<|>RELATION_NOE 介导<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 抑制<|>RELATION_NOE ATM<|>RELATION_NOE 基因表达<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
构建<|>RELATION_NOE ATM<|>RELATION_NOE 基因<|>RELATION_NOE 小<|>RELATION_NOE 分子<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 真核<|>RELATION_NOE 表达<|>RELATION_NOE 质粒<|>RELATION_NOE pSilencer2.1-ATM<|>RELATION_NOE 并<|>RELATION_NOE 转染<|>RELATION_NOE A<|>RELATION_NOE 。<|>RELATION_NOE
细胞<|>RELATION_NOE (<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_NOE pSilencer2.1-nonspecific<|>RELATION_NOE 质粒<|>RELATION_NOE 为<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 转染<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
RT-PCR<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 印迹法<|>RELATION_NOE 分别<|>RELATION_B 检测<|>RELATION_E ATM<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_NOE 细胞周期<|>RELATION_NOE 和<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 。<|>RELATION_NOE RT-PCR<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 印迹法<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_NOE ATM<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 细胞周期<|>RELATION_NOE 和<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 。<|>RELATION_NOE
成功<|>RELATION_NOE 构建<|>RELATION_NOE 了<|>RELATION_NOE ATM<|>RELATION_NOE 基因<|>RELATION_NOE siRNA<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 质粒<|>RELATION_NOE 。<|>RELATION_NOE
RT-PCR<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 印迹法<|>RELATION_NOE 证实<|>RELATION_S 阳性<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE ATM<|>RELATION_NOE 基因表达<|>RELATION_NOE 下调<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE 的<|>RELATION_NOE 放射<|>RELATION_NOE 增敏<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE D0<|>RELATION_NOE 值<|>RELATION_NOE 比<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.50<|>RELATION_NOE 、<|>RELATION_NOE 1.01<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_NOE 显示<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE G1<|>RELATION_NOE 、<|>RELATION_NOE G2<|>RELATION_NOE +<|>RELATION_NOE M<|>RELATION_NOE 期<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE 减少<|>RELATION_NOE [<|>RELATION_NOE 51.27%<|>RELATION_NOE :<|>RELATION_NOE 61.8<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 6.34%<|>RELATION_NOE :<|>RELATION_NOE 10.9<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.008<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 则<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 阴性<|>RELATION_NOE 组<|>RELATION_NOE [<|>RELATION_NOE 49.31%<|>RELATION_NOE :<|>RELATION_NOE 13.5<|>RELATION_NOE 8%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 49.31%<|>RELATION_NOE :<|>RELATION_NOE 13.1<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE RT-PCR<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 印迹法<|>RELATION_NOE 证实<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE ATM<|>RELATION_NOE 基因表达<|>RELATION_NOE 下调<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE 的<|>RELATION_NOE 放射<|>RELATION_NOE 增敏<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE D0<|>RELATION_NOE 值<|>RELATION_NOE 比<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.50<|>RELATION_NOE 、<|>RELATION_NOE 1.01<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_NOE 显示<|>RELATION_S 阳性<|>RELATION_NOE 组<|>RELATION_NOE G1<|>RELATION_NOE 、<|>RELATION_NOE G2<|>RELATION_NOE +<|>RELATION_NOE M<|>RELATION_NOE 期<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE 减少<|>RELATION_NOE [<|>RELATION_NOE 51.27%<|>RELATION_NOE :<|>RELATION_NOE 61.8<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 6.34%<|>RELATION_NOE :<|>RELATION_NOE 10.9<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.008<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 则<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 阴性<|>RELATION_NOE 组<|>RELATION_NOE [<|>RELATION_NOE 49.31%<|>RELATION_NOE :<|>RELATION_NOE 13.5<|>RELATION_NOE 8%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 49.31%<|>RELATION_NOE :<|>RELATION_NOE 13.1<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE RT-PCR<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 印迹法<|>RELATION_NOE 证实<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE ATM<|>RELATION_NOE 基因表达<|>RELATION_NOE 下调<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE 的<|>RELATION_NOE 放射<|>RELATION_NOE 增敏<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE D0<|>RELATION_NOE 值<|>RELATION_NOE 比<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.50<|>RELATION_NOE 、<|>RELATION_NOE 1.01<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_NOE 显示<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE G1<|>RELATION_NOE 、<|>RELATION_NOE G2<|>RELATION_NOE +<|>RELATION_NOE M<|>RELATION_NOE 期<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE 减少<|>RELATION_NOE [<|>RELATION_NOE 51.27%<|>RELATION_NOE :<|>RELATION_NOE 61.8<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 6.34%<|>RELATION_NOE :<|>RELATION_NOE 10.9<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.008<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 则<|>RELATION_NOE 高于<|>RELATION_S 对照组<|>RELATION_NOE 、<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE [<|>RELATION_NOE 49.31%<|>RELATION_NOE :<|>RELATION_NOE 13.5<|>RELATION_NOE 8%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 49.31%<|>RELATION_NOE :<|>RELATION_NOE 13.1<|>RELATION_NOE 7%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
ATM<|>RELATION_NOE 基因沉默<|>RELATION_NOE 可<|>RELATION_NOE 增加<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射敏感性<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 细胞周期<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 凋亡<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE
CBCT<|>RELATION_NOE 配准<|>RELATION_NOE 前后<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 比较<|>RELATION_S 研究<|>RELATION_NOE
肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE 立体<|>RELATION_NOE 定向<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE MRI<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 近期<|>RELATION_B 疗效<|>RELATION_I 评价<|>RELATION_I 影响<|>RELATION_E
蛋白<|>RELATION_NOE 酶体<|>RELATION_NOE 抑制剂<|>RELATION_NOE MG132<|>RELATION_NOE 联合<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 生长<|>RELATION_NOE 迁移<|>RELATION_NOE 和<|>RELATION_NOE 周期<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE
MGl32<|>RELATION_NOE 明显<|>RELATION_B 抑制<|>RELATION_E 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 呈现<|>RELATION_NOE 剂量<|>RELATION_NOE 一<|>RELATION_NOE 效应<|>RELATION_NOE 和<|>RELATION_NOE 时间<|>RELATION_NOE 一<|>RELATION_NOE 效应<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE MGl32<|>RELATION_NOE 明显<|>RELATION_NOE 抑制<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 呈现<|>RELATION_B 剂量<|>RELATION_I 一<|>RELATION_I 效应<|>RELATION_I 和<|>RELATION_I 时间<|>RELATION_I 一<|>RELATION_I 效应<|>RELATION_I 关系<|>RELATION_E 。<|>RELATION_NOE
MGl32<|>RELATION_NOE 联合<|>RELATION_NOE x<|>RELATION_NOE 射线<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 克隆<|>RELATION_NOE 存活<|>RELATION_NOE 能力<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_B 抑制<|>RELATION_I 作用<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 55<|>RELATION_NOE 4.78<|>RELATION_NOE 、<|>RELATION_NOE 95<|>RELATION_NOE 4.64<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 加<|>RELATION_NOE MGl32<|>RELATION_NOE 组<|>RELATION_NOE 克隆<|>RELATION_NOE 存活率<|>RELATION_NOE 均<|>RELATION_NOE 低于<|>RELATION_NOE 照射组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 4.44<|>RELATION_NOE 、<|>RELATION_NOE 12.41<|>RELATION_NOE 、<|>RELATION_NOE 3.52<|>RELATION_NOE 、<|>RELATION_NOE 6.72<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE MGl32<|>RELATION_NOE 联合<|>RELATION_NOE x<|>RELATION_NOE 射线<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 克隆<|>RELATION_NOE 存活<|>RELATION_NOE 能力<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 55<|>RELATION_NOE 4.78<|>RELATION_NOE 、<|>RELATION_NOE 95<|>RELATION_NOE 4.64<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 加<|>RELATION_NOE MGl32<|>RELATION_NOE 组<|>RELATION_NOE 克隆<|>RELATION_NOE 存活率<|>RELATION_NOE 均<|>RELATION_B 低于<|>RELATION_E 照射组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 4.44<|>RELATION_NOE 、<|>RELATION_NOE 12.41<|>RELATION_NOE 、<|>RELATION_NOE 3.52<|>RELATION_NOE 、<|>RELATION_NOE 6.72<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
MGl32<|>RELATION_NOE 可以<|>RELATION_NOE 显著<|>RELATION_B 抑制<|>RELATION_E 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 在<|>RELATION_NOE 无毒性<|>RELATION_NOE 剂量<|>RELATION_NOE 下<|>RELATION_NOE 联合<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 可以<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE 其<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 显著<|>RELATION_NOE 增加<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE G1<|>RELATION_NOE 期<|>RELATION_NOE 阻滞<|>RELATION_NOE 。<|>RELATION_NOE
复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE NP<|>RELATION_NOE 方案<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 2006年<|>RELATION_NOE 12月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 12月<|>RELATION_NOE 于<|>RELATION_NOE 河南<|>RELATION_NOE 大学<|>RELATION_NOE 淮河<|>RELATION_NOE 医院<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 132<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 患者<|>RELATION_NOE 就诊<|>RELATION_NOE 顺序<|>RELATION_NOE 进行<|>RELATION_NOE 编号<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 66<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE (<|>RELATION_NOE 66<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 采取<|>RELATION_NOE 常规<|>RELATION_NOE NP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE :<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 25mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2+<|>RELATION_NOE 0.9%<|>RELATION_NOE 氯化钠<|>RELATION_NOE 注射液<|>RELATION_NOE 100ml<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE (<|>RELATION_NOE 10min<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE ;<|>RELATION_NOE
顺铂<|>RELATION_NOE 30mg<|>RELATION_NOE /<|>RELATION_NOE (<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2·<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE +<|>RELATION_NOE 0.9%<|>RELATION_NOE 氯化钠<|>RELATION_NOE 注射液<|>RELATION_NOE 100ml<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 治疗<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 治疗<|>RELATION_NOE 周期<|>RELATION_NOE ;<|>RELATION_NOE
观察组<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE NP<|>RELATION_NOE 方案<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 加<|>RELATION_NOE 用<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 30ml<|>RELATION_NOE +<|>RELATION_NOE 5%<|>RELATION_NOE 葡萄糖<|>RELATION_NOE 溶液<|>RELATION_NOE 500ml<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 1次/<|>RELATION_NOE d<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 21d<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 治疗<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 治疗<|>RELATION_NOE 周期<|>RELATION_NOE ;<|>RELATION_NOE
复方<|>RELATION_NOE 苦参<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE NP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 效果<|>RELATION_NOE 优于<|>RELATION_S 单纯<|>RELATION_NOE NP<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
自体<|>RELATION_NOE 荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE 在<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 评估<|>RELATION_NOE 价值<|>RELATION_NOE
对<|>RELATION_NOE 161<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 怀疑<|>RELATION_NOE 为<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 使用<|>RELATION_NOE AFB<|>RELATION_NOE 联合<|>RELATION_NOE 白光<|>RELATION_NOE 支气管镜<|>RELATION_NOE (<|>RELATION_NOE WLB<|>RELATION_NOE )<|>RELATION_NOE 检查<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE
重度<|>RELATION_NOE 以上<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 增生<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 定义<|>RELATION_NOE 为<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 正常<|>RELATION_NOE 支气管<|>RELATION_NOE 黏膜<|>RELATION_NOE 、<|>RELATION_NOE 黏膜<|>RELATION_NOE 增生<|>RELATION_NOE 、<|>RELATION_NOE 肥厚<|>RELATION_NOE 、<|>RELATION_NOE 慢性<|>RELATION_NOE 炎症<|>RELATION_NOE 定义<|>RELATION_NOE 为<|>RELATION_NOE 阴性<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE AFB<|>RELATION_NOE 与<|>RELATION_NOE WLB<|>RELATION_NOE 镜<|>RELATION_NOE 下<|>RELATION_NOE 异常<|>RELATION_NOE 表现<|>RELATION_NOE 与<|>RELATION_NOE 病理<|>RELATION_NOE 结果<|>RELATION_NOE 。<|>RELATION_NOE
比较<|>RELATION_NOE WLB<|>RELATION_NOE 、<|>RELATION_NOE AFB<|>RELATION_NOE 及<|>RELATION_NOE WLB<|>RELATION_NOE +<|>RELATION_NOE AFB<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
AFB<|>RELATION_NOE 比<|>RELATION_NOE WLB<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 方面<|>RELATION_NOE 具有<|>RELATION_NOE 更<|>RELATION_B 好<|>RELATION_I 的<|>RELATION_I 敏感性<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 联合<|>RELATION_NOE 使用<|>RELATION_NOE WLB<|>RELATION_NOE +<|>RELATION_NOE AFB<|>RELATION_NOE 则<|>RELATION_NOE 能<|>RELATION_NOE 改善<|>RELATION_NOE 单用<|>RELATION_NOE AFB<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 缺陷<|>RELATION_NOE 。<|>RELATION_NOE AFB<|>RELATION_NOE 比<|>RELATION_NOE WLB<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 方面<|>RELATION_NOE 具有<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 联合<|>RELATION_NOE 使用<|>RELATION_NOE WLB<|>RELATION_NOE +<|>RELATION_NOE AFB<|>RELATION_NOE 则<|>RELATION_NOE 能<|>RELATION_NOE 改善<|>RELATION_S 单<|>RELATION_NOE 用<|>RELATION_NOE AFB<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 缺陷<|>RELATION_NOE 。<|>RELATION_NOE
CYP2C19<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 影响<|>RELATION_E
探讨<|>RELATION_NOE CYP2C19<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
EM<|>RELATION_NOE 组<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 肌肉<|>RELATION_NOE 或<|>RELATION_NOE 关节<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_S PM<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
CYP2C19<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 影响<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_B 发现<|>RELATION_E 对<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
热化疗<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 对<|>RELATION_NOE IL-2<|>RELATION_NOE 、<|>RELATION_NOE IL-6<|>RELATION_NOE 、<|>RELATION_NOE IL-8<|>RELATION_NOE 、<|>RELATION_NOE IL-10<|>RELATION_NOE 及<|>RELATION_NOE TNF<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 热化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 对<|>RELATION_NOE IL-2<|>RELATION_NOE 、<|>RELATION_NOE IL-6<|>RELATION_NOE 、<|>RELATION_NOE IL-8<|>RELATION_NOE 、<|>RELATION_NOE IL-10<|>RELATION_NOE 及<|>RELATION_NOE TNF<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 热化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 白细胞介素<|>RELATION_NOE .<|>RELATION_NOE
2<|>RELATION_NOE (<|>RELATION_NOE IL-2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 白细胞介素<|>RELATION_NOE -6<|>RELATION_NOE (<|>RELATION_NOE IL-6<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 白细胞介素<|>RELATION_NOE -8<|>RELATION_NOE (<|>RELATION_NOE IL-8<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 白细胞介素<|>RELATION_NOE -10<|>RELATION_NOE (<|>RELATION_NOE IL-10<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE TNF<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 大同<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 2004年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 1月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 134<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 热疗<|>RELATION_NOE 联合<|>RELATION_NOE NP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE (<|>RELATION_NOE NVB<|>RELATION_NOE +<|>RELATION_NOE DDP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分别<|>RELATION_NOE 在<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE IL-2<|>RELATION_NOE 、<|>RELATION_NOE IL-6<|>RELATION_NOE 、<|>RELATION_NOE IL-8<|>RELATION_NOE 、<|>RELATION_NOE IL-10<|>RELATION_NOE 及<|>RELATION_NOE TNF<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 进行<|>RELATION_NOE 监测<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE 获得<|>RELATION_B 性耐药<|>RELATION_I 的<|>RELATION_I 逆转<|>RELATION_E
以<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 靶点<|>RELATION_NOE 治疗<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 是<|>RELATION_NOE 治疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 前沿<|>RELATION_NOE 手段<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 产生<|>RELATION_NOE 的<|>RELATION_NOE 获得<|>RELATION_NOE 性耐药<|>RELATION_NOE 限制<|>RELATION_NOE 了<|>RELATION_NOE 靶向<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 发展<|>RELATION_NOE 。<|>RELATION_NOE
目前<|>RELATION_NOE 已<|>RELATION_NOE 有<|>RELATION_NOE 大量<|>RELATION_NOE 的<|>RELATION_NOE 有关<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 的<|>RELATION_NOE 数据<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 这些<|>RELATION_NOE 数据<|>RELATION_NOE ,<|>RELATION_NOE 人们<|>RELATION_NOE 正在<|>RELATION_NOE 探讨<|>RELATION_NOE 克服<|>RELATION_NOE EGFR<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 耐药<|>RELATION_NOE 的<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 基本<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 强化<|>RELATION_NOE EGFR<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 、<|>RELATION_NOE EGFR<|>RELATION_NOE 抑制剂<|>RELATION_NOE 与<|>RELATION_NOE 其他<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 相<|>RELATION_NOE 结合<|>RELATION_NOE 以及<|>RELATION_NOE 通过<|>RELATION_NOE 替代<|>RELATION_NOE 途径<|>RELATION_NOE 改变<|>RELATION_S 抗癌<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
心理<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 改善<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 不良<|>RELATION_NOE 心理<|>RELATION_NOE 状态<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
探讨<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 在<|>RELATION_NOE 改善<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 不良<|>RELATION_NOE 心理<|>RELATION_NOE 状态<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 于<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 8月<|>RELATION_NOE －<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 2月<|>RELATION_NOE 将<|>RELATION_NOE 接受<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按照<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 干预组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 对照组<|>RELATION_NOE 给予<|>RELATION_NOE 传统<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 与<|>RELATION_NOE 指导<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 干预组<|>RELATION_NOE 在<|>RELATION_NOE 此<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 采取<|>RELATION_NOE 有<|>RELATION_NOE 针对性<|>RELATION_NOE 的<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 干预<|>RELATION_NOE 前后<|>RELATION_NOE 的<|>RELATION_NOE 负性<|>RELATION_NOE 心理<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
干预组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 前<|>RELATION_NOE 的<|>RELATION_NOE SAS<|>RELATION_NOE 和<|>RELATION_NOE SDS<|>RELATION_NOE 评分<|>RELATION_NOE 比较<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 0.24<|>RELATION_NOE 、<|>RELATION_NOE 0.58<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但是<|>RELATION_NOE 在于<|>RELATION_NOE 预后<|>RELATION_NOE 干预组<|>RELATION_NOE 的<|>RELATION_NOE SAS<|>RELATION_NOE 和<|>RELATION_NOE SDS<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 4.25<|>RELATION_NOE 、<|>RELATION_NOE 4.01<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 干预组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 前<|>RELATION_NOE 的<|>RELATION_NOE SAS<|>RELATION_NOE 和<|>RELATION_NOE SDS<|>RELATION_NOE 评分<|>RELATION_NOE 比较<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 差异<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 0.24<|>RELATION_NOE 、<|>RELATION_NOE 0.58<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但是<|>RELATION_NOE 在于<|>RELATION_NOE 预后<|>RELATION_NOE 干预组<|>RELATION_NOE 的<|>RELATION_NOE SAS<|>RELATION_NOE 和<|>RELATION_NOE SDS<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 4.25<|>RELATION_NOE 、<|>RELATION_NOE 4.01<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
风险<|>RELATION_NOE 管理<|>RELATION_NOE 在<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
有效<|>RELATION_NOE 地<|>RELATION_NOE 规避<|>RELATION_NOE 和<|>RELATION_NOE 化解<|>RELATION_NOE 护理<|>RELATION_NOE 风险<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 病人<|>RELATION_NOE 提供<|>RELATION_S 安全<|>RELATION_NOE 、<|>RELATION_NOE 优质<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 风险<|>RELATION_NOE 管理<|>RELATION_NOE 知识<|>RELATION_NOE 为<|>RELATION_NOE 指导<|>RELATION_NOE ,<|>RELATION_NOE 识别<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 病人<|>RELATION_NOE 护理<|>RELATION_NOE 安全<|>RELATION_NOE 工作<|>RELATION_NOE 中<|>RELATION_NOE 存在<|>RELATION_NOE 或<|>RELATION_NOE 潜在<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 风险<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 风险<|>RELATION_NOE 衡量<|>RELATION_NOE 与<|>RELATION_NOE 评价<|>RELATION_NOE ,<|>RELATION_NOE 制订<|>RELATION_NOE 风险<|>RELATION_NOE 管理<|>RELATION_NOE 策略<|>RELATION_NOE ,<|>RELATION_NOE 指导<|>RELATION_NOE 临床<|>RELATION_NOE 规避<|>RELATION_NOE 和<|>RELATION_NOE 化解<|>RELATION_NOE 护理<|>RELATION_NOE 风险<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 风险<|>RELATION_NOE 管理<|>RELATION_NOE 实施<|>RELATION_NOE 前后<|>RELATION_NOE 患者<|>RELATION_NOE 满意度<|>RELATION_NOE 和<|>RELATION_NOE 护士<|>RELATION_NOE 静脉<|>RELATION_NOE 穿刺<|>RELATION_NOE 成功率<|>RELATION_NOE 。<|>RELATION_NOE
间质性<|>RELATION_NOE 肺病<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 分析<|>RELATION_E
5例<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 3例<|>RELATION_NOE 患者<|>RELATION_NOE 无法<|>RELATION_NOE 耐受术<|>RELATION_NOE 后<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 给予<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 1例行<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 出现<|>RELATION_NOE 重度<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 及<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 颅脑<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
腺癌<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 服药<|>RELATION_NOE 前<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<<|>RELATION_NOE 5cm<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE DCR<|>RELATION_NOE 高于<|>RELATION_S 非腺癌<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 服药<|>RELATION_NOE 前<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小≥<|>RELATION_NOE 5cm<|>RELATION_NOE 者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
生存<|>RELATION_NOE 分析<|>RELATION_NOE 示<|>RELATION_NOE 服药<|>RELATION_NOE 前<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<<|>RELATION_NOE 5cm<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 控制者<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE PFS<|>RELATION_NOE 优于<|>RELATION_S 服药<|>RELATION_NOE 前<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE ≥<|>RELATION_NOE 5cm<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 进展者<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
常规肺<|>RELATION_NOE 功能<|>RELATION_NOE 检测<|>RELATION_NOE 联合<|>RELATION_NOE 登<|>RELATION_NOE 楼梯<|>RELATION_NOE 试验<|>RELATION_NOE 在<|>RELATION_NOE 预测<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 心<|>RELATION_NOE 肺并发症<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE
Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE EOD<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 满足<|>RELATION_NOE 肺功能<|>RELATION_NOE 术式<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 术后<|>RELATION_NOE 心<|>RELATION_NOE 肺并发症<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 危险因素<|>RELATION_E 。<|>RELATION_NOE
^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE mN-NOET<|>RELATION_NOE 双时<|>RELATION_NOE 相单<|>RELATION_NOE 光子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 断层<|>RELATION_NOE 成像术<|>RELATION_NOE 鉴别诊断<|>RELATION_S 肺部良<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE
探讨<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE mN-NOET<|>RELATION_NOE 双时<|>RELATION_NOE 相单<|>RELATION_NOE 光子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 断层<|>RELATION_NOE 成像术<|>RELATION_NOE (<|>RELATION_NOE SPECT<|>RELATION_NOE )<|>RELATION_NOE 鉴别诊断<|>RELATION_S 肺部良<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE mN-NOET<|>RELATION_NOE 双时相<|>RELATION_NOE SPECT<|>RELATION_NOE 可以<|>RELATION_NOE 鉴别诊断<|>RELATION_S 肺部良<|>RELATION_NOE 、<|>RELATION_NOE 恶性肿物<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 效能<|>RELATION_NOE 与<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 无<|>RELATION_NOE 显著<|>RELATION_NOE 差别<|>RELATION_NOE 。<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE mN-NOET<|>RELATION_NOE 双时相<|>RELATION_NOE SPECT<|>RELATION_NOE 可以<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 肺部良<|>RELATION_NOE 、<|>RELATION_NOE 恶性肿物<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_NOE 效能<|>RELATION_NOE 与<|>RELATION_B CT<|>RELATION_I 检查<|>RELATION_I 无<|>RELATION_I 显著<|>RELATION_I 差别<|>RELATION_E 。<|>RELATION_NOE
^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE mN-NOET<|>RELATION_NOE 显像<|>RELATION_NOE 的<|>RELATION_NOE 半定量<|>RELATION_NOE 指标<|>RELATION_NOE (<|>RELATION_NOE ER<|>RELATION_NOE 、<|>RELATION_NOE DR<|>RELATION_NOE 和<|>RELATION_NOE nI<|>RELATION_NOE )<|>RELATION_NOE 也<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 鉴别诊断<|>RELATION_S 肺部良<|>RELATION_NOE 、<|>RELATION_NOE 恶性肿物<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 不<|>RELATION_NOE 受<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 、<|>RELATION_NOE 肺部<|>RELATION_NOE 肿块<|>RELATION_NOE 空洞<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 和<|>RELATION_NOE 性别<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 对<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 治疗<|>RELATION_NOE 中国<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 二线<|>RELATION_NOE 及<|>RELATION_NOE 一线<|>RELATION_NOE 后<|>RELATION_NOE 维持<|>RELATION_NOE 治疗<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 综合<|>RELATION_B 分析<|>RELATION_E
分析<|>RELATION_NOE 二<|>RELATION_NOE 线<|>RELATION_NOE 治疗<|>RELATION_NOE (<|>RELATION_NOE JMID<|>RELATION_NOE 研究<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 一线<|>RELATION_NOE 治疗<|>RELATION_NOE 后换药<|>RELATION_NOE 维持<|>RELATION_NOE 治疗<|>RELATION_NOE (<|>RELATION_NOE JMEN<|>RELATION_NOE 研究<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 中国<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 对<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 疗效<|>RELATION_B 的<|>RELATION_I 影响<|>RELATION_E 。<|>RELATION_NOE
JMEN<|>RELATION_NOE 全球<|>RELATION_NOE 研究<|>RELATION_NOE (<|>RELATION_NOE 维持<|>RELATION_NOE 治疗<|>RELATION_NOE )<|>RELATION_NOE 研究<|>RELATION_NOE 人群<|>RELATION_NOE 为<|>RELATION_NOE 初始<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 期<|>RELATION_NOE 或<|>RELATION_NOE Ⅳ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 己<|>RELATION_NOE 接受<|>RELATION_NOE 过<|>RELATION_NOE 至少<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 的<|>RELATION_NOE 一线<|>RELATION_NOE 含<|>RELATION_NOE 铂化疗<|>RELATION_NOE 后<|>RELATION_NOE 至少<|>RELATION_NOE 达到<|>RELATION_NOE 病情<|>RELATION_NOE 稳定<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 主要<|>RELATION_NOE 终点<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 相对<|>RELATION_NOE 于<|>RELATION_NOE 安慰剂<|>RELATION_NOE 的<|>RELATION_NOE 优效性<|>RELATION_NOE 。<|>RELATION_NOE
靶向<|>RELATION_NOE 敲<|>RELATION_NOE 降<|>RELATION_NOE Sox4<|>RELATION_NOE 基因<|>RELATION_NOE 抑制<|>RELATION_S 宣威<|>RELATION_NOE 地区<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE XWLC-05<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE
探讨<|>RELATION_NOE 抑制<|>RELATION_NOE 宣威<|>RELATION_NOE 地区<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE XWLC-05<|>RELATION_NOE 中<|>RELATION_NOE 转录因子<|>RELATION_NOE Sox4<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 裸鼠皮<|>RELATION_NOE 下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
构建<|>RELATION_NOE 靶向<|>RELATION_NOE 抑制<|>RELATION_NOE Sox4<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE shRNA<|>RELATION_NOE 干扰<|>RELATION_NOE 质粒<|>RELATION_NOE pGFP-V-RS-Sox4<|>RELATION_NOE shRNA<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 转染<|>RELATION_NOE XWLC-05<|>RELATION_NOE 细胞<|>RELATION_NOE ;<|>RELATION_NOE
将<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE 重组<|>RELATION_NOE 质粒<|>RELATION_NOE 的<|>RELATION_NOE XWLC-05<|>RELATION_NOE 细胞<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 裸小鼠皮<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 移植瘤<|>RELATION_NOE 模型<|>RELATION_NOE ;<|>RELATION_NOE
观测<|>RELATION_NOE 裸小鼠<|>RELATION_NOE 一般<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 成瘤<|>RELATION_NOE 情况<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制率<|>RELATION_NOE ;<|>RELATION_NOE
对<|>RELATION_NOE 小鼠<|>RELATION_NOE 行<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 以<|>RELATION_NOE 观察<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE ;<|>RELATION_NOE
成功<|>RELATION_NOE 构建<|>RELATION_NOE 了<|>RELATION_NOE 高效<|>RELATION_NOE 抑制<|>RELATION_NOE Sox4<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE pGFP-V-RS-Sox4<|>RELATION_NOE shRNA<|>RELATION_NOE 重组<|>RELATION_NOE 干扰<|>RELATION_NOE 质粒<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 筛选<|>RELATION_NOE 出<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE 的<|>RELATION_NOE XWLC-05<|>RELATION_NOE 细胞<|>RELATION_NOE 。<|>RELATION_NOE
除<|>RELATION_NOE 接种<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE 组外<|>RELATION_NOE ,<|>RELATION_NOE 接种<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE 干扰<|>RELATION_NOE 质粒<|>RELATION_NOE pGFP-V-RS-Sox4<|>RELATION_NOE shRNA<|>RELATION_NOE 的<|>RELATION_NOE XWLC-05<|>RELATION_NOE 细胞组<|>RELATION_NOE 、<|>RELATION_NOE 接种<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE pGFP-V-RS-seraln<|>RELATION_NOE shRNA<|>RELATION_NOE 的<|>RELATION_NOE XWLC-05<|>RELATION_NOE 细胞组<|>RELATION_NOE 和<|>RELATION_NOE 接种<|>RELATION_NOE 亲本<|>RELATION_NOE XWLC-05<|>RELATION_NOE 细胞组<|>RELATION_NOE 小鼠<|>RELATION_NOE 的<|>RELATION_NOE 成<|>RELATION_NOE 瘤率<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 阴性<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_NOE Sox4<|>RELATION_NOE 基因表达<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 实验组<|>RELATION_NOE 小鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 增长<|>RELATION_NOE 趋势<|>RELATION_NOE 明显<|>RELATION_B 受到<|>RELATION_I 抑制<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
实验组<|>RELATION_NOE 离体<|>RELATION_NOE 移植<|>RELATION_NOE 瘤重量<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 0.8<|>RELATION_NOE 64<|>RELATION_NOE ±<|>RELATION_NOE 0.14<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE ,<|>RELATION_NOE 低于<|>RELATION_S 阴性<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 1.8<|>RELATION_NOE 44<|>RELATION_NOE ±<|>RELATION_NOE 0.27<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 1.8<|>RELATION_NOE 64<|>RELATION_NOE ±<|>RELATION_NOE 0.22<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Sox4<|>RELATION_NOE 和<|>RELATION_NOE ki-67<|>RELATION_NOE 蛋自<|>RELATION_NOE 主要<|>RELATION_B 表达<|>RELATION_I 于<|>RELATION_E 细胞核<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 移植<|>RELATION_NOE 瘤细胞<|>RELATION_NOE 中<|>RELATION_NOE Sox4<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 低于<|>RELATION_NOE 阴性<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE Sox4<|>RELATION_NOE 和<|>RELATION_NOE ki-67<|>RELATION_NOE 蛋自<|>RELATION_NOE 主要<|>RELATION_NOE 表达<|>RELATION_NOE 于<|>RELATION_NOE 细胞核<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 移植<|>RELATION_NOE 瘤细胞<|>RELATION_NOE 中<|>RELATION_NOE Sox4<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 低于<|>RELATION_S 阴性<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
影像学<|>RELATION_NOE 和<|>RELATION_NOE 病理学<|>RELATION_NOE 检查<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 实验期<|>RELATION_NOE 内<|>RELATION_NOE 成瘤<|>RELATION_NOE 小鼠<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 发生<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
成功<|>RELATION_NOE 建立<|>RELATION_NOE 了<|>RELATION_NOE 宣威<|>RELATION_NOE 女性<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE XWLC-05<|>RELATION_NOE 的<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 干扰<|>RELATION_NOE Sox4<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_S 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 。<|>RELATION_NOE
沉默<|>RELATION_NOE 表达<|>RELATION_NOE miR-26a<|>RELATION_NOE A549<|>RELATION_NOE 细胞株<|>RELATION_NOE 的<|>RELATION_NOE 构建<|>RELATION_S
down<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 载体<|>RELATION_NOE 与<|>RELATION_NOE 病毒<|>RELATION_NOE 包装<|>RELATION_NOE 质粒<|>RELATION_NOE pGC-LV<|>RELATION_NOE 载体<|>RELATION_NOE 、<|>RELATION_NOE pHelper1.0<|>RELATION_NOE 载体<|>RELATION_NOE 和<|>RELATION_NOE pHelper2.0<|>RELATION_NOE 载体<|>RELATION_NOE 共<|>RELATION_NOE 转染<|>RELATION_NOE 293T<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 包装<|>RELATION_NOE 产生<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 。<|>RELATION_NOE
依据<|>RELATION_NOE 293T<|>RELATION_NOE 细胞<|>RELATION_NOE 绿色<|>RELATION_NOE 荧光<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE 确定<|>RELATION_NOE 病毒滴度<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 沉默<|>RELATION_NOE 表达<|>RELATION_NOE miR-26a<|>RELATION_NOE 的<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 转染<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 嘌呤霉素<|>RELATION_NOE 筛选<|>RELATION_NOE 后<|>RELATION_NOE 获得<|>RELATION_NOE 稳定<|>RELATION_NOE 细胞株<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 293T<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 将<|>RELATION_NOE 该<|>RELATION_NOE 载体<|>RELATION_NOE 包装<|>RELATION_NOE 成<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE ,<|>RELATION_NOE 测定<|>RELATION_NOE 病毒滴度<|>RELATION_NOE 为<|>RELATION_NOE 2×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 12TU<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 。<|>RELATION_NOE
重组<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 转染<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 效率<|>RELATION_NOE 高<|>RELATION_NOE 达<|>RELATION_NOE 95%<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 2.5mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 嘌呤霉素<|>RELATION_NOE 筛选<|>RELATION_NOE 2周<|>RELATION_NOE 后<|>RELATION_NOE 几乎<|>RELATION_NOE 100%<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 表达<|>RELATION_NOE GFP<|>RELATION_NOE 。<|>RELATION_NOE
A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE 胞质<|>RELATION_NOE 中<|>RELATION_NOE p-GSK-3<|>RELATION_NOE β<|>RELATION_NOE ser9<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 的<|>RELATION_NOE 处理<|>RELATION_NOE 增加<|>RELATION_NOE 了<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE p-GSK-3<|>RELATION_NOE β<|>RELATION_NOE ser9<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 相反<|>RELATION_NOE 却<|>RELATION_NOE 减少<|>RELATION_S 了<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE p-GSK-3<|>RELATION_NOE β<|>RELATION_NOE ser9<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞质<|>RELATION_NOE 中<|>RELATION_NOE p-GSK-3<|>RELATION_NOE β<|>RELATION_NOE tyr6<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 的<|>RELATION_NOE 处理<|>RELATION_NOE 减少<|>RELATION_NOE 了<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE DDP<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE p-GSK-3<|>RELATION_NOE β<|>RELATION_NOE tyr6<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 却<|>RELATION_NOE 增加<|>RELATION_S 了<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE p-GSK-3<|>RELATION_NOE β<|>RELATION_NOE tyr6<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
细胞质<|>RELATION_NOE 中<|>RELATION_NOE GSK-3<|>RELATION_NOE β<|>RELATION_NOE 活性<|>RELATION_NOE 受抑<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 顺铂<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_S 。<|>RELATION_NOE
磁性<|>RELATION_NOE 分选<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 始动<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 异常<|>RELATION_NOE miRNAs<|>RELATION_NOE 验证<|>RELATION_S
将<|>RELATION_NOE 对<|>RELATION_NOE 数<|>RELATION_NOE 生长期<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 离心<|>RELATION_NOE 收集<|>RELATION_NOE ,<|>RELATION_NOE 重<|>RELATION_NOE 悬<|>RELATION_NOE 于<|>RELATION_NOE 无<|>RELATION_NOE 血清<|>RELATION_NOE 培养基<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 培养<|>RELATION_NOE 至<|>RELATION_NOE 第二<|>RELATION_NOE 代<|>RELATION_NOE 后<|>RELATION_NOE 利用<|>RELATION_NOE CD133<|>RELATION_NOE 磁珠<|>RELATION_NOE 标记<|>RELATION_NOE 后<|>RELATION_NOE 分选<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 验证<|>RELATION_NOE 分选<|>RELATION_NOE 后<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE CD133<|>RELATION_NOE /<|>RELATION_NOE CD326<|>RELATION_NOE 双阳<|>RELATION_NOE 性率<|>RELATION_NOE ;<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 利用<|>RELATION_NOE CD133<|>RELATION_NOE 磁珠<|>RELATION_NOE 分选<|>RELATION_NOE 得到<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE CD133<|>RELATION_NOE /<|>RELATION_NOE CD326<|>RELATION_NOE 分子<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 前期<|>RELATION_NOE miRNA<|>RELATION_NOE 芯片<|>RELATION_NOE 结果<|>RELATION_NOE ,<|>RELATION_NOE 选出<|>RELATION_NOE 在<|>RELATION_NOE CD133<|>RELATION_NOE +<|>RELATION_NOE /<|>RELATION_NOE CD326<|>RELATION_NOE +<|>RELATION_NOE 细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 上调<|>RELATION_NOE 的<|>RELATION_NOE miR-663<|>RELATION_NOE ,<|>RELATION_NOE miR-183<|>RELATION_NOE ,<|>RELATION_NOE miR-125a-5p<|>RELATION_NOE ,<|>RELATION_NOE miR-127<|>RELATION_NOE ,<|>RELATION_NOE miR-520h<|>RELATION_NOE 及<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 的<|>RELATION_NOE miR-18b<|>RELATION_NOE ,<|>RELATION_NOE miR-29ab<|>RELATION_NOE ,<|>RELATION_NOE miR-17<|>RELATION_NOE 和<|>RELATION_NOE miR-155<|>RELATION_NOE 行定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_NOE 证实<|>RELATION_NOE miR-29ab<|>RELATION_NOE ,<|>RELATION_NOE miR-155<|>RELATION_NOE ,<|>RELATION_NOE miR-183<|>RELATION_NOE ,<|>RELATION_NOE miR-127-3p<|>RELATION_NOE 及<|>RELATION_NOE miR-17<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 趋势<|>RELATION_NOE 与<|>RELATION_NOE 芯片<|>RELATION_NOE 结果<|>RELATION_NOE 相符<|>RELATION_NOE 。<|>RELATION_NOE
利用<|>RELATION_NOE 磁珠<|>RELATION_NOE 分选<|>RELATION_NOE 方式<|>RELATION_NOE 能<|>RELATION_NOE 获得<|>RELATION_NOE CD133<|>RELATION_NOE +<|>RELATION_NOE /<|>RELATION_NOE CD326<|>RELATION_NOE +<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 始动<|>RELATION_NOE 细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 且<|>RELATION_NOE 包括<|>RELATION_NOE miR-183<|>RELATION_NOE 等<|>RELATION_NOE 在内<|>RELATION_NOE 的<|>RELATION_NOE 6条<|>RELATION_NOE 分子<|>RELATION_NOE 与<|>RELATION_NOE 芯片<|>RELATION_NOE 结果<|>RELATION_NOE 一致<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 始动<|>RELATION_NOE 细胞<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 调控<|>RELATION_S 中<|>RELATION_NOE 发挥<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE -<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE NF-kB<|>RELATION_NOE 在<|>RELATION_NOE 单<|>RELATION_NOE 核<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 促<|>RELATION_NOE 煤焦<|>RELATION_NOE 沥青<|>RELATION_NOE 烟气<|>RELATION_NOE 提取物<|>RELATION_NOE 诱导<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE 恶性<|>RELATION_NOE 转化<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
KB<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 单<|>RELATION_NOE 核<|>RELATION_NOE 巨噬细胞系<|>RELATION_NOE (<|>RELATION_NOE THP-1<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 促<|>RELATION_NOE 煤焦<|>RELATION_NOE 沥青<|>RELATION_NOE 烟气<|>RELATION_NOE 提取物<|>RELATION_NOE (<|>RELATION_NOE CTPE<|>RELATION_NOE )<|>RELATION_NOE 诱导人<|>RELATION_NOE 支气管<|>RELATION_NOE 上皮细胞系<|>RELATION_NOE (<|>RELATION_NOE BEAS-2B<|>RELATION_NOE )<|>RELATION_NOE 细胞<|>RELATION_NOE 恶性<|>RELATION_NOE 转化<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S 。<|>RELATION_NOE
在<|>RELATION_NOE 第10<|>RELATION_NOE 代<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 和<|>RELATION_NOE THP-1<|>RELATION_NOE 细胞<|>RELATION_NOE 共<|>RELATION_NOE 培养<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE 分别<|>RELATION_NOE 加入<|>RELATION_NOE NF-KB<|>RELATION_NOE 的<|>RELATION_NOE 抑制剂<|>RELATION_NOE 一<|>RELATION_NOE 吡<|>RELATION_NOE 咯烷<|>RELATION_NOE 二<|>RELATION_NOE 硫代<|>RELATION_NOE 氨基甲酸<|>RELATION_NOE (<|>RELATION_NOE PDTC<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 中和抗体<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 细胞周期<|>RELATION_NOE 检测<|>RELATION_NOE 、<|>RELATION_NOE 染色体<|>RELATION_NOE 核型分析<|>RELATION_NOE 和<|>RELATION_NOE 软<|>RELATION_NOE 琼脂<|>RELATION_NOE 集落<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_NOE 第<|>RELATION_NOE 20<|>RELATION_NOE 代<|>RELATION_NOE PDTC<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 中和抗体<|>RELATION_NOE 组<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 恶性<|>RELATION_NOE 转化<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 第10<|>RELATION_NOE 代<|>RELATION_NOE 、<|>RELATION_NOE 第20<|>RELATION_NOE 代<|>RELATION_NOE 共<|>RELATION_NOE 培养<|>RELATION_NOE 组<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE ;<|>RELATION_NOE
2B<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE TNFR<|>RELATION_NOE 相关<|>RELATION_NOE 因子2<|>RELATION_NOE (<|>RELATION_NOE TRAF2<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 细胞周期<|>RELATION_NOE 蛋白<|>RELATION_NOE D1<|>RELATION_NOE (<|>RELATION_NOE CyclinDl<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 及其<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
第<|>RELATION_NOE 20<|>RELATION_NOE 代<|>RELATION_NOE PDTC<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 中和抗体<|>RELATION_NOE 组<|>RELATION_NOE 100<|>RELATION_NOE 个<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 出现<|>RELATION_NOE 异常<|>RELATION_NOE 染色体<|>RELATION_NOE 核型<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 数量<|>RELATION_NOE 为<|>RELATION_NOE 40<|>RELATION_NOE 个<|>RELATION_NOE 和<|>RELATION_NOE 37<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 第<|>RELATION_NOE 20<|>RELATION_NOE 代<|>RELATION_NOE 共<|>RELATION_NOE 培养<|>RELATION_NOE 组<|>RELATION_NOE 为<|>RELATION_NOE 75<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
仅<|>RELATION_NOE 和<|>RELATION_NOE NF-KB<|>RELATION_NOE 在<|>RELATION_NOE THP-1<|>RELATION_NOE 细胞<|>RELATION_NOE 促进<|>RELATION_NOE 煤焦<|>RELATION_NOE 沥青<|>RELATION_NOE 烟气<|>RELATION_NOE 提取物<|>RELATION_NOE 诱导<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE 恶性<|>RELATION_NOE 转化<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 阶段<|>RELATION_NOE 发挥<|>RELATION_B 重要<|>RELATION_I 的<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 影响<|>RELATION_NOE TRAF2<|>RELATION_NOE 和<|>RELATION_NOE CyelinD1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 促使<|>RELATION_NOE 细胞<|>RELATION_NOE 恶性<|>RELATION_NOE 变<|>RELATION_NOE 发生<|>RELATION_NOE 。<|>RELATION_NOE 仅<|>RELATION_NOE 和<|>RELATION_NOE NF-KB<|>RELATION_NOE 在<|>RELATION_NOE THP-1<|>RELATION_NOE 细胞<|>RELATION_NOE 促进<|>RELATION_NOE 煤焦<|>RELATION_NOE 沥青<|>RELATION_NOE 烟气<|>RELATION_NOE 提取物<|>RELATION_NOE 诱导<|>RELATION_NOE BEAS-2B<|>RELATION_NOE 细胞<|>RELATION_NOE 恶性<|>RELATION_NOE 转化<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 阶段<|>RELATION_NOE 发挥<|>RELATION_NOE 重要<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 影响<|>RELATION_NOE TRAF2<|>RELATION_NOE 和<|>RELATION_NOE CyelinD1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 促使<|>RELATION_S 细胞<|>RELATION_NOE 恶性<|>RELATION_NOE 变<|>RELATION_NOE 发生<|>RELATION_NOE 。<|>RELATION_NOE
转铁蛋白<|>RELATION_NOE 受体<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S
探讨<|>RELATION_NOE 转铁蛋白<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE transferrin<|>RELATION_NOE receptor<|>RELATION_NOE ,<|>RELATION_NOE TfR<|>RELATION_NOE /<|>RELATION_NOE CD71<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 与<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
51<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE TfR<|>RELATION_NOE /<|>RELATION_NOE CD71<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE [<|>RELATION_NOE 50.9<|>RELATION_NOE 8%<|>RELATION_NOE (<|>RELATION_NOE 26<|>RELATION_NOE /<|>RELATION_NOE 51<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 腺癌<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE [<|>RELATION_NOE 69.2<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE /<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 8例<|>RELATION_NOE [<|>RELATION_NOE 53.3<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 8/15<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ;<|>RELATION_NOE
TfR<|>RELATION_NOE /<|>RELATION_NOE CD71<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 呈正<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.4<|>RELATION_NOE 97<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 其他<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
TfR<|>RELATION_NOE /<|>RELATION_NOE CD71<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 其他<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 。<|>RELATION_NOE
特罗凯<|>RELATION_NOE 和<|>RELATION_NOE 易瑞沙<|>RELATION_NOE 连<|>RELATION_NOE 用<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE
凯<|>RELATION_NOE 美纳<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 肺腺<|>RELATION_NOE 癌脑<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE
鸦<|>RELATION_NOE 胆子<|>RELATION_NOE 油乳<|>RELATION_NOE 配合<|>RELATION_NOE 全<|>RELATION_NOE 脑放疗<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌脑<|>RELATION_NOE 转移<|>RELATION_NOE 效果<|>RELATION_S 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 一线<|>RELATION_B 治疗<|>RELATION_E 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 、<|>RELATION_NOE 生存期<|>RELATION_NOE 和<|>RELATION_NOE 患者<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
34<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 150mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 奈达铂<|>RELATION_NOE 80mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE .<|>RELATION_NOE
34<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 可<|>RELATION_NOE 评价<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 接受<|>RELATION_NOE 174<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE 为<|>RELATION_NOE 5.3<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 脂质体<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 的<|>RELATION_NOE 客观<|>RELATION_NOE 反应率<|>RELATION_NOE 为<|>RELATION_NOE 32.3%<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 为<|>RELATION_NOE 67.6%<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 总<|>RELATION_NOE 生存期<|>RELATION_NOE 为<|>RELATION_NOE 9.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI6.2<|>RELATION_NOE －<|>RELATION_NOE 10.7<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 1年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 40.6%<|>RELATION_NOE .<|>RELATION_NOE
埃兹<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制<|>RELATION_NOE 物1<|>RELATION_NOE 在<|>RELATION_NOE 肝癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE
探讨<|>RELATION_NOE 埃兹<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE Ezrin<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制<|>RELATION_NOE 物1<|>RELATION_NOE (<|>RELATION_NOE TSLC1<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 原发性<|>RELATION_NOE 肝癌<|>RELATION_NOE (<|>RELATION_NOE PLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 两者<|>RELATION_NOE 与<|>RELATION_NOE PLC<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 66<|>RELATION_NOE 例<|>RELATION_NOE PLC<|>RELATION_NOE 、<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 肝硬化<|>RELATION_NOE 和<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 肝组织<|>RELATION_NOE 中<|>RELATION_NOE Ezrin<|>RELATION_NOE 和<|>RELATION_NOE TSLC1<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
Ezrin<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE PLC<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 浸润<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE TSLC1<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE PLC<|>RELATION_NOE 血管<|>RELATION_NOE 浸润<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE Ezrin<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE PLC<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 浸润<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分<|>RELATION_NOE 期<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE TSLC1<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE PLC<|>RELATION_NOE 血管<|>RELATION_NOE 浸润<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
转染<|>RELATION_B 微小<|>RELATION_I RNA-126<|>RELATION_E 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
观察<|>RELATION_NOE 体外<|>RELATION_B 转染<|>RELATION_I 微小<|>RELATION_I RNA-126<|>RELATION_I (<|>RELATION_I miR-126<|>RELATION_I )<|>RELATION_E 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
实时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE Real-time<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE miR-126<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 检测<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_S A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 。<|>RELATION_NOE
蛋白<|>RELATION_B 酶体<|>RELATION_I 抑制剂<|>RELATION_I MG132<|>RELATION_I 与<|>RELATION_I 顺铂<|>RELATION_I 联合<|>RELATION_I 应用<|>RELATION_E 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
调节<|>RELATION_B 自噬<|>RELATION_E 对<|>RELATION_NOE 贝伐<|>RELATION_NOE 单抗<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
观察<|>RELATION_NOE 白噬<|>RELATION_NOE 在<|>RELATION_NOE 血管<|>RELATION_NOE 抑制<|>RELATION_NOE 药物<|>RELATION_NOE 贝伐<|>RELATION_NOE 单抗<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE 各<|>RELATION_NOE 实验组<|>RELATION_NOE 细胞组<|>RELATION_NOE ,<|>RELATION_NOE 膜联<|>RELATION_NOE 蛋白<|>RELATION_NOE Ⅴ<|>RELATION_NOE -<|>RELATION_NOE 异<|>RELATION_NOE 硫氰酸<|>RELATION_NOE 荧光素<|>RELATION_NOE (<|>RELATION_NOE Annexin<|>RELATION_NOE Ⅴ<|>RELATION_NOE -FITC<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 单丹磺<|>RELATION_NOE 酰戊二胺<|>RELATION_NOE (<|>RELATION_NOE MDC<|>RELATION_NOE )<|>RELATION_NOE 染色<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 显微镜<|>RELATION_NOE 下<|>RELATION_NOE 定性<|>RELATION_NOE 观察<|>RELATION_NOE 荧光<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
流式细胞术<|>RELATION_NOE 定量<|>RELATION_B 检测<|>RELATION_E 细胞凋亡<|>RELATION_NOE 、<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 自噬<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE Beclin<|>RELATION_NOE 1<|>RELATION_NOE 和<|>RELATION_NOE 微管<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE 1轻链3<|>RELATION_NOE (<|>RELATION_NOE LC3<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 作用<|>RELATION_NOE 48h<|>RELATION_NOE ,<|>RELATION_NOE 贝伐<|>RELATION_NOE 单抗<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 半数<|>RELATION_NOE 抑制<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE IC50<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 16<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 3-MA<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 抑制率<|>RELATION_NOE 10%<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE IR10<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 8μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ;<|>RELATION_NOE
N-<|>RELATION_NOE 乙酰<|>RELATION_NOE 半乳糖胺<|>RELATION_NOE 转移酶<|>RELATION_NOE -3<|>RELATION_NOE 预测<|>RELATION_S 周围型<|>RELATION_NOE 小<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 预后<|>RELATION_NOE
探讨<|>RELATION_NOE 周围型<|>RELATION_NOE 小<|>RELATION_NOE 肺腺癌<|>RELATION_NOE (<|>RELATION_NOE 癌瘤<|>RELATION_NOE 直径<|>RELATION_NOE <<|>RELATION_NOE 2cm<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE N-<|>RELATION_NOE 乙酰<|>RELATION_NOE 半乳糖胺<|>RELATION_NOE 转移酶<|>RELATION_NOE -3<|>RELATION_NOE (<|>RELATION_NOE GalNAc-T3<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 预后<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE 探讨<|>RELATION_NOE 周围型<|>RELATION_NOE 小<|>RELATION_NOE 肺腺癌<|>RELATION_NOE (<|>RELATION_NOE 癌瘤<|>RELATION_NOE 直径<|>RELATION_NOE <<|>RELATION_NOE 2cm<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE N-<|>RELATION_NOE 乙酰<|>RELATION_NOE 半乳糖胺<|>RELATION_NOE 转移酶<|>RELATION_NOE -3<|>RELATION_NOE (<|>RELATION_NOE GalNAc-T3<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 预后<|>RELATION_NOE 影响<|>RELATION_B 因素<|>RELATION_E 。<|>RELATION_NOE
术后<|>RELATION_NOE 对<|>RELATION_NOE 病灶<|>RELATION_NOE 组织<|>RELATION_NOE 切片<|>RELATION_NOE 采用<|>RELATION_NOE 针对<|>RELATION_NOE GalNAc-T3<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE (<|>RELATION_NOE IHC<|>RELATION_NOE )<|>RELATION_NOE 染色<|>RELATION_NOE 评估<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE GalNAc-T3<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 及其<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 周围型<|>RELATION_NOE 小<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 中低<|>RELATION_NOE 表达<|>RELATION_NOE GalNAc-T3<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 侵犯<|>RELATION_NOE 、<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 、<|>RELATION_NOE 血行<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE Noguchi<|>RELATION_NOE 病理<|>RELATION_NOE 组织分型<|>RELATION_NOE 相关<|>RELATION_S ,<|>RELATION_NOE 并<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_NOE 指标<|>RELATION_NOE .<|>RELATION_NOE 在<|>RELATION_NOE 周围型<|>RELATION_NOE 小<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 中低<|>RELATION_NOE 表达<|>RELATION_NOE GalNAc-T3<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 侵犯<|>RELATION_NOE 、<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 、<|>RELATION_NOE 血行<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE Noguchi<|>RELATION_NOE 病理<|>RELATION_NOE 组织分型<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S 影响<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_NOE 指标<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 与<|>RELATION_NOE 3-<|>RELATION_NOE 磷酸<|>RELATION_NOE 甘油<|>RELATION_NOE 醛脱氢酶<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE 3-<|>RELATION_NOE 磷酸<|>RELATION_NOE 甘油<|>RELATION_NOE 醛脱氢酶<|>RELATION_NOE (<|>RELATION_NOE GAPDH<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学链<|>RELATION_NOE 霉菌<|>RELATION_NOE 抗<|>RELATION_NOE 生物素<|>RELATION_NOE 蛋白<|>RELATION_NOE -<|>RELATION_NOE 过氧化物酶<|>RELATION_NOE (<|>RELATION_NOE SP<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 201<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE GAPDH<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
GAPDH<|>RELATION_NOE 在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 、<|>RELATION_NOE 大细胞癌<|>RELATION_NOE 及<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 81.3%<|>RELATION_NOE 、<|>RELATION_NOE 44.4%<|>RELATION_NOE 、<|>RELATION_NOE 64.7%<|>RELATION_NOE 、<|>RELATION_NOE 71.4%<|>RELATION_NOE ,<|>RELATION_NOE 组内<|>RELATION_B 比较<|>RELATION_I 差异<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
Kaplan-Meier<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 表明<|>RELATION_NOE GAPDH<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
Cox<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 表明<|>RELATION_NOE GAPDH<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_B 患者<|>RELATION_I 预后<|>RELATION_I 评估<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE 微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
分析<|>RELATION_NOE 江苏省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 2005年<|>RELATION_NOE 11月<|>RELATION_NOE 至<|>RELATION_NOE 2007年<|>RELATION_NOE 1月<|>RELATION_NOE 行<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 104<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE .<|>RELATION_NOE
采用<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-qPCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 上述<|>RELATION_NOE 病例<|>RELATION_NOE 肺癌<|>RELATION_NOE 标本<|>RELATION_NOE 的<|>RELATION_NOE 微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 水平<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 方法<|>RELATION_NOE 分析<|>RELATION_NOE 微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生存期<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ;<|>RELATION_NOE
Cox<|>RELATION_NOE 风险<|>RELATION_NOE 比例<|>RELATION_NOE 模型<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE 微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 的<|>RELATION_NOE 标志<|>RELATION_NOE 。<|>RELATION_NOE
微小<|>RELATION_NOE RNA-145<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE .<|>RELATION_NOE
肾盂<|>RELATION_NOE 淋巴<|>RELATION_NOE 上皮瘤<|>RELATION_NOE 样癌<|>RELATION_NOE 伴肺<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE 报告<|>RELATION_S 并<|>RELATION_NOE 文献<|>RELATION_NOE 复习<|>RELATION_NOE
探讨<|>RELATION_NOE 肾盂<|>RELATION_NOE 淋巴<|>RELATION_NOE 上皮瘤<|>RELATION_NOE 样癌<|>RELATION_NOE (<|>RELATION_NOE LELC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE .<|>RELATION_NOE
患者<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 前<|>RELATION_NOE 因<|>RELATION_NOE “<|>RELATION_NOE 左<|>RELATION_NOE 肾铸型<|>RELATION_NOE 结石<|>RELATION_NOE ”<|>RELATION_NOE 于<|>RELATION_NOE 我<|>RELATION_NOE 科行<|>RELATION_NOE 经皮<|>RELATION_NOE 肾镜取<|>RELATION_NOE 石术<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 见<|>RELATION_NOE 尿路<|>RELATION_NOE 上皮<|>RELATION_NOE 黏膜<|>RELATION_NOE 颜色<|>RELATION_NOE 质地<|>RELATION_NOE 正常.<|>RELATION_NOE
泌尿<|>RELATION_NOE 系统<|>RELATION_NOE 增强<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 提示<|>RELATION_NOE 左<|>RELATION_NOE 肾盂<|>RELATION_NOE 癌侵<|>RELATION_NOE 及<|>RELATION_NOE 左<|>RELATION_NOE 输尿管<|>RELATION_NOE 上<|>RELATION_NOE 段<|>RELATION_NOE ,<|>RELATION_NOE 左<|>RELATION_NOE 肾盂扩张<|>RELATION_NOE 积水<|>RELATION_NOE ,<|>RELATION_NOE 左侧<|>RELATION_NOE 肾门<|>RELATION_NOE 及<|>RELATION_NOE 腹膜<|>RELATION_NOE 后<|>RELATION_NOE 多发<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ;<|>RELATION_NOE
泌<|>RELATION_NOE 尿系<|>RELATION_NOE 超声检查<|>RELATION_NOE 提示<|>RELATION_NOE 左<|>RELATION_NOE 肾重度<|>RELATION_NOE 积水<|>RELATION_NOE ,<|>RELATION_NOE 左肾<|>RELATION_NOE 集合<|>RELATION_NOE 系统<|>RELATION_NOE 重度<|>RELATION_NOE 分离<|>RELATION_NOE ,<|>RELATION_NOE 宽<|>RELATION_NOE 35mm<|>RELATION_NOE ,<|>RELATION_NOE 左<|>RELATION_NOE 肾盂<|>RELATION_NOE 输尿管<|>RELATION_NOE 移<|>RELATION_NOE 行<|>RELATION_NOE 处<|>RELATION_NOE 实性<|>RELATION_NOE 占位<|>RELATION_NOE ,<|>RELATION_NOE 大小<|>RELATION_NOE 53mm<|>RELATION_NOE ×<|>RELATION_NOE 38mm<|>RELATION_NOE ,<|>RELATION_NOE 内<|>RELATION_NOE 回声<|>RELATION_NOE 不<|>RELATION_NOE 均<|>RELATION_NOE ,<|>RELATION_NOE 可见<|>RELATION_NOE 点状<|>RELATION_NOE 血运<|>RELATION_NOE ;<|>RELATION_NOE
胸部<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 提示<|>RELATION_NOE 双<|>RELATION_NOE 肺散<|>RELATION_NOE 在<|>RELATION_NOE 结节影<|>RELATION_NOE ,<|>RELATION_NOE 大者<|>RELATION_NOE 横径<|>RELATION_NOE 约<|>RELATION_NOE 1.1cm<|>RELATION_NOE ,<|>RELATION_NOE 考虑<|>RELATION_NOE 肺部<|>RELATION_NOE 多发<|>RELATION_NOE 转移癌<|>RELATION_NOE ,<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE ,<|>RELATION_NOE 大者<|>RELATION_NOE 横径约<|>RELATION_NOE 0.7cm<|>RELATION_NOE .<|>RELATION_NOE
病理<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 左<|>RELATION_NOE 肾盂<|>RELATION_NOE LELC<|>RELATION_NOE ,<|>RELATION_NOE 肉<|>RELATION_NOE 眼见<|>RELATION_NOE 肾盂处<|>RELATION_NOE 肿物<|>RELATION_NOE ,<|>RELATION_NOE 大小<|>RELATION_NOE 为<|>RELATION_NOE 4.5cm<|>RELATION_NOE ×<|>RELATION_NOE 4.0cm<|>RELATION_NOE ×<|>RELATION_NOE 3.5cm<|>RELATION_NOE ,<|>RELATION_NOE 灰白质<|>RELATION_NOE 地<|>RELATION_NOE ,<|>RELATION_NOE 局部<|>RELATION_NOE 见<|>RELATION_NOE 坏死<|>RELATION_NOE ,<|>RELATION_NOE 累<|>RELATION_NOE 及<|>RELATION_NOE 肾实质<|>RELATION_NOE 及<|>RELATION_NOE 肾被膜<|>RELATION_NOE ;<|>RELATION_NOE
光镜<|>RELATION_NOE 下<|>RELATION_NOE 见<|>RELATION_NOE 左<|>RELATION_NOE 肾盂<|>RELATION_NOE 正常<|>RELATION_NOE 尿路<|>RELATION_NOE 上皮<|>RELATION_NOE 黏膜<|>RELATION_NOE 消失<|>RELATION_NOE ,<|>RELATION_NOE 代<|>RELATION_NOE 之<|>RELATION_NOE 以<|>RELATION_NOE 浸润<|>RELATION_NOE 性生长<|>RELATION_NOE ,<|>RELATION_NOE 条索状<|>RELATION_NOE 、<|>RELATION_NOE 实<|>RELATION_NOE 性巢状<|>RELATION_NOE 分布<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 异形性<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 胞质<|>RELATION_NOE 比例<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 泡状<|>RELATION_NOE 核<|>RELATION_NOE ,<|>RELATION_NOE 可见<|>RELATION_NOE 大嗜<|>RELATION_NOE 酸性<|>RELATION_NOE 核仁.<|>RELATION_NOE
单向式<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 分析<|>RELATION_E
对<|>RELATION_NOE 2009年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 3月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 96<|>RELATION_NOE 例非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 施行<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE +<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
术中<|>RELATION_NOE 失血量<|>RELATION_NOE (<|>RELATION_NOE 160<|>RELATION_NOE ±<|>RELATION_NOE 56<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 清扫<|>RELATION_NOE 淋巴结<|>RELATION_NOE 数量<|>RELATION_NOE (<|>RELATION_NOE 10.3<|>RELATION_NOE ±<|>RELATION_NOE 4.1<|>RELATION_NOE )<|>RELATION_NOE 枚<|>RELATION_NOE ,<|>RELATION_NOE 手术时间<|>RELATION_NOE (<|>RELATION_NOE 253<|>RELATION_NOE ±<|>RELATION_NOE 42<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 后<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE 4.3<|>RELATION_NOE ±<|>RELATION_NOE 2.1<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE (<|>RELATION_NOE 13.5<|>RELATION_NOE ±<|>RELATION_NOE 5.3<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 。<|>RELATION_NOE
2004<|>RELATION_NOE －<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 我院<|>RELATION_NOE 首<|>RELATION_NOE 次<|>RELATION_NOE 住院<|>RELATION_NOE 病人<|>RELATION_NOE 前<|>RELATION_NOE 10<|>RELATION_NOE 位<|>RELATION_NOE 疾病<|>RELATION_NOE 构成<|>RELATION_NOE 分析<|>RELATION_S
前<|>RELATION_NOE 十<|>RELATION_NOE 位<|>RELATION_NOE 疾病<|>RELATION_NOE 分别<|>RELATION_NOE 是<|>RELATION_NOE :<|>RELATION_NOE 食管癌<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 鼻咽癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE 、<|>RELATION_NOE 子宫<|>RELATION_NOE 平滑肌瘤<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 毒性<|>RELATION_NOE 甲状腺肿<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 、<|>RELATION_NOE 直肠癌<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 首<|>RELATION_NOE 次<|>RELATION_NOE 住院<|>RELATION_NOE 病人<|>RELATION_NOE 的<|>RELATION_NOE 60.00%<|>RELATION_NOE 以上<|>RELATION_NOE .<|>RELATION_NOE
食管癌<|>RELATION_NOE 高<|>RELATION_NOE 居<|>RELATION_NOE 第1<|>RELATION_NOE 位<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 8<|>RELATION_NOE 年<|>RELATION_NOE 连续<|>RELATION_NOE 保持<|>RELATION_NOE 不<|>RELATION_NOE 变<|>RELATION_NOE ,<|>RELATION_NOE 增长<|>RELATION_NOE 较<|>RELATION_NOE 快<|>RELATION_NOE 的<|>RELATION_NOE 有<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 。<|>RELATION_NOE
食管癌<|>RELATION_NOE 仍<|>RELATION_NOE 为<|>RELATION_NOE 本<|>RELATION_NOE 地区<|>RELATION_NOE 常见<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 增长<|>RELATION_NOE 迅速<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 加强<|>RELATION_NOE 肿瘤<|>RELATION_NOE 宣教<|>RELATION_NOE 和<|>RELATION_NOE 积极<|>RELATION_NOE 防治<|>RELATION_NOE .<|>RELATION_NOE
EGFR<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 及<|>RELATION_NOE Ki-67<|>RELATION_NOE 在<|>RELATION_NOE 肺浸润<|>RELATION_NOE 性腺癌<|>RELATION_NOE 和<|>RELATION_NOE 微浸润<|>RELATION_NOE 性腺癌<|>RELATION_NOE 及<|>RELATION_NOE 浸润<|>RELATION_NOE 前<|>RELATION_NOE 病变<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
按照<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE IASLC<|>RELATION_NOE /<|>RELATION_NOE ATS<|>RELATION_NOE /<|>RELATION_NOE ERS<|>RELATION_NOE 多<|>RELATION_NOE 学科<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 新<|>RELATION_NOE 分类<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 2004年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 间<|>RELATION_NOE 日照市<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 常规<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE 和<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 腺瘤<|>RELATION_NOE 样<|>RELATION_NOE 增生<|>RELATION_NOE 的<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE 和<|>RELATION_NOE 整合<|>RELATION_NOE 病理<|>RELATION_NOE 组织学<|>RELATION_NOE 、<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE TTF-1<|>RELATION_NOE 和<|>RELATION_NOE P63<|>RELATION_NOE [<|>RELATION_NOE 或<|>RELATION_NOE (<|>RELATION_NOE 和<|>RELATION_NOE )<|>RELATION_NOE CK5<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE ]<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 多<|>RELATION_NOE 学科<|>RELATION_NOE 知识<|>RELATION_NOE ,<|>RELATION_NOE 重新<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 分类<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE S-P<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 128<|>RELATION_NOE 例<|>RELATION_NOE 浸润性<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 28<|>RELATION_NOE 例微<|>RELATION_NOE 浸润<|>RELATION_NOE 性腺癌<|>RELATION_NOE 、<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 浸润<|>RELATION_NOE 前<|>RELATION_NOE 病变<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE 原位腺癌<|>RELATION_NOE AIS<|>RELATION_NOE 、<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 腺瘤<|>RELATION_NOE 样<|>RELATION_NOE 增生<|>RELATION_NOE )<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE EGFR<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 及<|>RELATION_NOE Ki-67<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 肺脏<|>RELATION_NOE 组织<|>RELATION_NOE 作<|>RELATION_NOE 对照<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 进行<|>RELATION_NOE 相关性<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE EGFR<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 及<|>RELATION_NOE Ki-67<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 浸润<|>RELATION_NOE 性腺癌<|>RELATION_NOE 、<|>RELATION_NOE 微浸润<|>RELATION_NOE 性腺癌<|>RELATION_NOE 及<|>RELATION_NOE 浸润<|>RELATION_NOE 前<|>RELATION_NOE 病变<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 不同<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 正常<|>RELATION_NOE 黏膜组织<|>RELATION_NOE 差异<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 三者<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 浸润<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 等<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ;<|>RELATION_NOE
EGFR<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 低<|>RELATION_NOE 分化<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 高<|>RELATION_NOE 分<|>RELATION_NOE 期<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
VEGF<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 高<|>RELATION_NOE 分<|>RELATION_NOE 期<|>RELATION_NOE 均<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
Ki-67<|>RELATION_NOE 只<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 高<|>RELATION_NOE 分期<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE Ki-67<|>RELATION_NOE 只<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分级<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 高<|>RELATION_NOE 分<|>RELATION_NOE 期<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 及<|>RELATION_NOE Ki-67<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 浸润<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 早期<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 能<|>RELATION_NOE 辅助<|>RELATION_NOE 预测<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 、<|>RELATION_NOE 评估<|>RELATION_NOE 预后<|>RELATION_NOE 和<|>RELATION_NOE 指导<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE EGFR<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 及<|>RELATION_NOE Ki-67<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 浸润<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 早期<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 能<|>RELATION_NOE 辅助<|>RELATION_B 预测<|>RELATION_E 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 、<|>RELATION_NOE 评估<|>RELATION_NOE 预后<|>RELATION_NOE 和<|>RELATION_NOE 指导<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
ERAP1<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 遗传易感性<|>RELATION_NOE 的<|>RELATION_NOE 关联<|>RELATION_S 研究<|>RELATION_NOE
采用<|>RELATION_NOE Taq<|>RELATION_NOE Man<|>RELATION_NOE 探针<|>RELATION_NOE 基因<|>RELATION_NOE 分型<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE ERAP1<|>RELATION_NOE 基因<|>RELATION_NOE SNP<|>RELATION_NOE rs26653<|>RELATION_NOE 和<|>RELATION_NOE rs26618<|>RELATION_NOE 两<|>RELATION_NOE 个<|>RELATION_NOE 位点<|>RELATION_NOE 进行<|>RELATION_NOE 基因<|>RELATION_NOE 分型<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 构建<|>RELATION_NOE 单倍型<|>RELATION_NOE ,<|>RELATION_NOE 评估<|>RELATION_NOE 上述<|>RELATION_NOE 两<|>RELATION_NOE 个<|>RELATION_NOE SNPs<|>RELATION_NOE 及<|>RELATION_NOE 单倍型<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
病例组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ERAP1<|>RELATION_NOE 基因<|>RELATION_NOE rs26618<|>RELATION_NOE 和<|>RELATION_NOE rs26653<|>RELATION_NOE 基因型<|>RELATION_NOE 和<|>RELATION_NOE 等位基因频率<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
ERAP1<|>RELATION_NOE 基因<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE rs26618<|>RELATION_NOE /<|>RELATION_NOE rs26653-CG<|>RELATION_NOE 单倍型<|>RELATION_NOE 可能<|>RELATION_NOE 增加<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 患病<|>RELATION_NOE 风险<|>RELATION_NOE ,<|>RELATION_NOE rs26618<|>RELATION_NOE /<|>RELATION_NOE rs26653-TC<|>RELATION_NOE 单倍型<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 可能<|>RELATION_NOE 具有<|>RELATION_NOE 保护性<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
浆膜<|>RELATION_NOE 腔<|>RELATION_NOE 积液<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE 对<|>RELATION_NOE 提高<|>RELATION_B 细胞学<|>RELATION_I 诊断<|>RELATION_I 及<|>RELATION_I 开展<|>RELATION_I 基因检测<|>RELATION_E 的<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 低温<|>RELATION_NOE 冷藏<|>RELATION_NOE (<|>RELATION_NOE 4<|>RELATION_NOE ℃<|>RELATION_NOE )<|>RELATION_NOE 过夜<|>RELATION_NOE 离心法<|>RELATION_NOE 制作<|>RELATION_S 浆膜<|>RELATION_NOE 腔<|>RELATION_NOE 积液<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 评估<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 对<|>RELATION_NOE 提高<|>RELATION_NOE 浆膜<|>RELATION_NOE 腔<|>RELATION_NOE 积液<|>RELATION_NOE 细胞学<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 及其<|>RELATION_NOE 作为<|>RELATION_NOE 基因检测<|>RELATION_NOE 新<|>RELATION_NOE 标本<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE 探讨<|>RELATION_NOE 低温<|>RELATION_NOE 冷藏<|>RELATION_NOE (<|>RELATION_NOE 4<|>RELATION_NOE ℃<|>RELATION_NOE )<|>RELATION_NOE 过夜<|>RELATION_NOE 离心法<|>RELATION_NOE 制作<|>RELATION_NOE 浆膜<|>RELATION_NOE 腔<|>RELATION_NOE 积液<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 评估<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 对<|>RELATION_NOE 提高<|>RELATION_B 浆膜<|>RELATION_I 腔<|>RELATION_I 积液<|>RELATION_I 细胞学<|>RELATION_I 诊断<|>RELATION_E 的<|>RELATION_NOE 价值<|>RELATION_NOE 及其<|>RELATION_NOE 作为<|>RELATION_NOE 基因检测<|>RELATION_NOE 新<|>RELATION_NOE 标本<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 20<|>RELATION_NOE 11<|>RELATION_NOE 年<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13<|>RELATION_NOE 年<|>RELATION_NOE 间<|>RELATION_NOE 有<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 积液<|>RELATION_NOE 152<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 采用<|>RELATION_NOE 直接<|>RELATION_NOE 离心<|>RELATION_NOE 和<|>RELATION_NOE 低温<|>RELATION_NOE 冷藏<|>RELATION_NOE 过夜<|>RELATION_NOE 离心<|>RELATION_NOE 制作<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 传统<|>RELATION_NOE 涂片<|>RELATION_NOE 、<|>RELATION_NOE 细胞块<|>RELATION_NOE HE<|>RELATION_NOE 染色<|>RELATION_NOE 、<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 及<|>RELATION_NOE 检测<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 积液<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
低温<|>RELATION_NOE 冷藏<|>RELATION_NOE 过夜<|>RELATION_NOE 离心法<|>RELATION_NOE 制作<|>RELATION_NOE 细胞块<|>RELATION_NOE 的<|>RELATION_NOE 成功率<|>RELATION_NOE (<|>RELATION_NOE 100.0%<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 直接<|>RELATION_NOE 离心法<|>RELATION_NOE (<|>RELATION_NOE 75.0%<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE χ2<|>RELATION_NOE =<|>RELATION_NOE 43.43<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
细胞<|>RELATION_NOE 块<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 准确率<|>RELATION_NOE (<|>RELATION_NOE 92.1%<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 传统<|>RELATION_NOE 涂片<|>RELATION_NOE (<|>RELATION_NOE 67.1%<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 细胞块<|>RELATION_NOE HE<|>RELATION_NOE 染色<|>RELATION_NOE (<|>RELATION_NOE 72.4%<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE χ2<|>RELATION_NOE =<|>RELATION_NOE 29.99<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
EMA<|>RELATION_NOE 对<|>RELATION_NOE 癌性<|>RELATION_B 积液<|>RELATION_I 中<|>RELATION_I 的<|>RELATION_I 癌细胞<|>RELATION_I 诊断<|>RELATION_E 具有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE ,<|>RELATION_NOE TTF-1<|>RELATION_NOE 、<|>RELATION_NOE CDX-2<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE GCDFP-15<|>RELATION_NOE 、<|>RELATION_NOE P63<|>RELATION_NOE 和<|>RELATION_NOE CgA<|>RELATION_NOE 分别<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 胃肠<|>RELATION_NOE 腺癌<|>RELATION_NOE 、<|>RELATION_NOE 卵巢癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE ;<|>RELATION_NOE EMA<|>RELATION_NOE 对<|>RELATION_NOE 癌性<|>RELATION_NOE 积液<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 癌细胞<|>RELATION_NOE 诊断<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE ,<|>RELATION_NOE TTF-1<|>RELATION_NOE 、<|>RELATION_NOE CDX-2<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE GCDFP-15<|>RELATION_NOE 、<|>RELATION_NOE P63<|>RELATION_NOE 和<|>RELATION_NOE CgA<|>RELATION_NOE 分别<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 胃肠<|>RELATION_NOE 腺癌<|>RELATION_NOE 、<|>RELATION_NOE 卵巢癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 具有<|>RELATION_S 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE ;<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 积液<|>RELATION_NOE 细胞<|>RELATION_NOE 块<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 检出率<|>RELATION_NOE 为<|>RELATION_NOE 44.0%<|>RELATION_NOE 。<|>RELATION_NOE
低温<|>RELATION_NOE 冷藏<|>RELATION_NOE 过夜<|>RELATION_NOE 离心法<|>RELATION_NOE 制作<|>RELATION_B 细胞<|>RELATION_I 块<|>RELATION_E 成功率<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 操作<|>RELATION_NOE 简单<|>RELATION_NOE ,<|>RELATION_NOE 易于<|>RELATION_NOE 推广<|>RELATION_NOE ;<|>RELATION_NOE
微波<|>RELATION_NOE 消融<|>RELATION_NOE 联合<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 周围型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 微波<|>RELATION_NOE 消融<|>RELATION_NOE 联合化疗<|>RELATION_NOE 对于<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 周围型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 和<|>RELATION_I 并发症<|>RELATION_I 发生<|>RELATION_I 情况<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE 随机<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 2009年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 12月<|>RELATION_NOE 我<|>RELATION_NOE 科<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 102<|>RELATION_NOE 例<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 周围型<|>RELATION_NOE NSCLC<|>RELATION_NOE (<|>RELATION_NOE T1<|>RELATION_NOE －<|>RELATION_NOE 4N0<|>RELATION_NOE －<|>RELATION_NOE 3M0<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 采取<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 对照组<|>RELATION_NOE :<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 或<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 及<|>RELATION_NOE 常规<|>RELATION_NOE 放疗<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 微波<|>RELATION_NOE 消融<|>RELATION_NOE 联合<|>RELATION_NOE 放化<|>RELATION_NOE 疗组<|>RELATION_NOE (<|>RELATION_NOE 联合组<|>RELATION_NOE )<|>RELATION_NOE 55<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 于<|>RELATION_NOE 微波<|>RELATION_NOE 消融术<|>RELATION_NOE 后<|>RELATION_NOE 1周<|>RELATION_NOE 给予<|>RELATION_NOE 同<|>RELATION_NOE 对照组<|>RELATION_NOE 相同<|>RELATION_NOE 的<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 。<|>RELATION_NOE
联合组<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 并发症<|>RELATION_NOE 为<|>RELATION_NOE 气胸<|>RELATION_NOE 、<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 、<|>RELATION_NOE 咯血<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 发生<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 和<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 并发症<|>RELATION_NOE 为<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 、<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
微波<|>RELATION_NOE 消融<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_B Ⅲ<|>RELATION_I 期<|>RELATION_I 周围型<|>RELATION_I NSCLC<|>RELATION_E 具有<|>RELATION_NOE 协同<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 和<|>RELATION_NOE 延长<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存期<|>RELATION_NOE 方面<|>RELATION_NOE 优于<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 为<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 提供<|>RELATION_NOE 了<|>RELATION_NOE 一<|>RELATION_NOE 条<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
NP<|>RELATION_NOE 方案<|>RELATION_NOE 加<|>RELATION_NOE 同期<|>RELATION_NOE 照射<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 存活<|>RELATION_B 的<|>RELATION_I 影响<|>RELATION_E
MTT<|>RELATION_NOE 方法<|>RELATION_NOE 用于<|>RELATION_NOE 检测<|>RELATION_S 酒石<|>RELATION_NOE 酸<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE +<|>RELATION_NOE 同期<|>RELATION_NOE 照射<|>RELATION_NOE 对<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE FACS<|>RELATION_NOE 用于<|>RELATION_NOE MTT<|>RELATION_NOE 方法<|>RELATION_NOE 用于<|>RELATION_NOE 检测<|>RELATION_NOE 酒石<|>RELATION_NOE 酸<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE +<|>RELATION_NOE 同期<|>RELATION_NOE 照射<|>RELATION_NOE 对<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE FACS<|>RELATION_NOE 用于<|>RELATION_NOE 检测<|>RELATION_S 酒石<|>RELATION_NOE 酸<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE +<|>RELATION_NOE 同期<|>RELATION_NOE 照射<|>RELATION_NOE 对<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 和<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE P-gp<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
B-0<|>RELATION_NOE 组<|>RELATION_NOE P-gp<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E A-0<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE B-4<|>RELATION_NOE 组<|>RELATION_NOE P-gp<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE B-0<|>RELATION_NOE 组<|>RELATION_NOE P-gp<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE A-0<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE B-4<|>RELATION_NOE 组<|>RELATION_NOE P-gp<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E A-4<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE B-8<|>RELATION_NOE 组<|>RELATION_NOE P-gp<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE B-0<|>RELATION_NOE 组<|>RELATION_NOE P-gp<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE A-0<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE B-4<|>RELATION_NOE 组<|>RELATION_NOE P-gp<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE A-4<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE B-8<|>RELATION_NOE 组<|>RELATION_NOE P-gp<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E A-8<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE -3.45<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 41<|>RELATION_NOE ;<|>RELATION_NOE
研究<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 其他<|>RELATION_NOE 癌等<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 以及<|>RELATION_NOE 对<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 等<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE 研究<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 其他<|>RELATION_NOE 癌等<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 以及<|>RELATION_NOE 对<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 等<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
分别<|>RELATION_NOE 采集<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 良性肿<|>RELATION_NOE 瘤组<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 以及<|>RELATION_NOE 其他<|>RELATION_NOE 癌组<|>RELATION_NOE 入院<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 样本<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 荧光<|>RELATION_NOE 逆转<|>RELATION_NOE 录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 含量<|>RELATION_NOE 。<|>RELATION_NOE
良性<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性率<|>RELATION_NOE (<|>RELATION_NOE 10%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 组外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 50%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 良性<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性率<|>RELATION_NOE (<|>RELATION_NOE 10%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 组外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 50%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE 以<|>RELATION_NOE 浸润性<|>RELATION_NOE 导管癌<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 各种<|>RELATION_NOE 类型<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 60%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 良性<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性率<|>RELATION_NOE (<|>RELATION_NOE 10%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 组外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 50%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺<|>RELATION_NOE 癌组<|>RELATION_NOE 中<|>RELATION_NOE 以<|>RELATION_NOE 浸润性<|>RELATION_NOE 导管癌<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 各种<|>RELATION_NOE 类型<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 60%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 癌组<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 20%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 良性<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性率<|>RELATION_NOE (<|>RELATION_NOE 10%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 组外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 50%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE 以<|>RELATION_NOE 浸润性<|>RELATION_NOE 导管癌<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 各种<|>RELATION_NOE 类型<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 60%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 癌组<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 20%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 良性<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性率<|>RELATION_NOE (<|>RELATION_NOE 10%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 组外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 50%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE 以<|>RELATION_NOE 浸润性<|>RELATION_NOE 导管癌<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 各种<|>RELATION_NOE 类型<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 60%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 癌组<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE MUClmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 20%<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
MUCImRNA<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_S 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 标志物<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 对<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 分型<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 没有<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE MUCImRNA<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 标志物<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 对<|>RELATION_NOE 乳腺癌<|>RELATION_B 分型<|>RELATION_I 的<|>RELATION_I 诊断<|>RELATION_E 没有<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
艾迪<|>RELATION_NOE 联合<|>RELATION_NOE NP<|>RELATION_NOE 方案<|>RELATION_NOE 在<|>RELATION_NOE 老年人<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 治疗<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
观察<|>RELATION_NOE 并<|>RELATION_NOE 比较<|>RELATION_NOE 治疗<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 近期<|>RELATION_NOE 治疗效果<|>RELATION_NOE 、<|>RELATION_NOE 毒副作用<|>RELATION_NOE 、<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 变化<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 血细胞<|>RELATION_NOE 减少<|>RELATION_NOE 患者<|>RELATION_NOE 血片<|>RELATION_NOE 和<|>RELATION_NOE 骨髓象<|>RELATION_NOE 检查<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 涂片<|>RELATION_NOE 和<|>RELATION_NOE 骨髓象<|>RELATION_NOE 检查<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE 180<|>RELATION_NOE 例<|>RELATION_NOE 全<|>RELATION_NOE 血细胞<|>RELATION_NOE 减少<|>RELATION_NOE 患者<|>RELATION_NOE 病因<|>RELATION_B 诊断<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 180<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 由<|>RELATION_NOE 非<|>RELATION_NOE 造血系统<|>RELATION_NOE 疾病<|>RELATION_NOE 引起<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 慢性<|>RELATION_NOE 肝炎<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肝硬化<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 心内膜炎<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 结缔组织<|>RELATION_NOE 类<|>RELATION_NOE 疾病<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 系统性<|>RELATION_NOE 红斑<|>RELATION_NOE 狼疮<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 脾功能亢进<|>RELATION_NOE 1例<|>RELATION_NOE ;<|>RELATION_NOE
造血系统<|>RELATION_NOE 疾病<|>RELATION_NOE 引起<|>RELATION_NOE 130<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 急性<|>RELATION_NOE 白血病<|>RELATION_NOE 74<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 骨髓<|>RELATION_NOE 增生<|>RELATION_NOE 异常<|>RELATION_NOE 综合征<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 再生<|>RELATION_NOE 障碍性<|>RELATION_NOE 贫血<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 巨幼红细胞性<|>RELATION_NOE 贫血<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
外<|>RELATION_NOE 周<|>RELATION_NOE 涂<|>RELATION_NOE 血片<|>RELATION_NOE 和<|>RELATION_NOE 骨髓象<|>RELATION_NOE 检查<|>RELATION_NOE 有利于<|>RELATION_S 诊断<|>RELATION_NOE 全<|>RELATION_NOE 血细胞<|>RELATION_NOE 减少<|>RELATION_NOE 的<|>RELATION_NOE 病因<|>RELATION_NOE ,<|>RELATION_NOE 骨髓象<|>RELATION_NOE 检查<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_NOE 诊断<|>RELATION_NOE 全<|>RELATION_NOE 血细胞<|>RELATION_NOE 减少<|>RELATION_NOE 病因<|>RELATION_NOE 的<|>RELATION_NOE 准确率<|>RELATION_NOE .<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 涂<|>RELATION_NOE 血片<|>RELATION_NOE 和<|>RELATION_NOE 骨髓象<|>RELATION_NOE 检查<|>RELATION_NOE 有利于<|>RELATION_NOE 诊断<|>RELATION_NOE 全<|>RELATION_NOE 血细胞<|>RELATION_NOE 减少<|>RELATION_NOE 的<|>RELATION_NOE 病因<|>RELATION_NOE ,<|>RELATION_NOE 骨髓象<|>RELATION_NOE 检查<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_S 诊断<|>RELATION_NOE 全<|>RELATION_NOE 血细胞<|>RELATION_NOE 减少<|>RELATION_NOE 病因<|>RELATION_NOE 的<|>RELATION_NOE 准确率<|>RELATION_NOE .<|>RELATION_NOE
妊娠<|>RELATION_NOE 期<|>RELATION_NOE 肝内<|>RELATION_NOE 胆汁淤积<|>RELATION_NOE 症<|>RELATION_NOE 孕妇<|>RELATION_NOE 所<|>RELATION_NOE 产<|>RELATION_NOE 新生儿<|>RELATION_NOE 脐动脉<|>RELATION_NOE 血清<|>RELATION_NOE 诱导<|>RELATION_S A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 研究<|>RELATION_NOE
分析<|>RELATION_NOE 妊娠<|>RELATION_NOE 期<|>RELATION_NOE 肝内<|>RELATION_NOE 胆汁淤积<|>RELATION_NOE 症<|>RELATION_NOE (<|>RELATION_NOE ICP<|>RELATION_NOE )<|>RELATION_NOE 孕妇<|>RELATION_NOE 产<|>RELATION_NOE 新生儿<|>RELATION_NOE 脐动脉<|>RELATION_NOE 血清<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 蛋白酶<|>RELATION_NOE -3<|>RELATION_NOE (<|>RELATION_NOE Caspase-3<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 凋亡<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE 胆汁<|>RELATION_NOE 酸<|>RELATION_NOE 引起<|>RELATION_NOE 新生儿<|>RELATION_NOE 肺损伤<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE 分析<|>RELATION_NOE 妊娠<|>RELATION_NOE 期<|>RELATION_NOE 肝内<|>RELATION_NOE 胆汁淤积<|>RELATION_NOE 症<|>RELATION_NOE (<|>RELATION_NOE ICP<|>RELATION_NOE )<|>RELATION_NOE 孕妇<|>RELATION_NOE 产<|>RELATION_NOE 新生儿<|>RELATION_NOE 脐动脉<|>RELATION_NOE 血清<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 蛋白酶<|>RELATION_NOE -3<|>RELATION_NOE (<|>RELATION_NOE Caspase-3<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 凋亡<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 胆汁<|>RELATION_NOE 酸<|>RELATION_NOE 引起<|>RELATION_S 新生儿<|>RELATION_NOE 肺损伤<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 细胞<|>RELATION_NOE 随机<|>RELATION_NOE 分成<|>RELATION_NOE 正常<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE ICP<|>RELATION_NOE 组.<|>RELATION_NOE
正常<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 正常<|>RELATION_NOE 培养基<|>RELATION_NOE 进行<|>RELATION_NOE 培养<|>RELATION_NOE ,<|>RELATION_NOE ICP<|>RELATION_NOE 组<|>RELATION_NOE 从<|>RELATION_NOE ICP<|>RELATION_NOE 孕妇<|>RELATION_NOE 胎儿<|>RELATION_NOE 娩<|>RELATION_NOE 出<|>RELATION_NOE 后<|>RELATION_NOE 在<|>RELATION_NOE 胎盘<|>RELATION_NOE 端<|>RELATION_NOE 收集<|>RELATION_NOE 脐动脉<|>RELATION_NOE 血<|>RELATION_NOE 并<|>RELATION_NOE 分离<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 体积<|>RELATION_NOE 比<|>RELATION_NOE 1<|>RELATION_NOE :<|>RELATION_NOE 10<|>RELATION_NOE 配<|>RELATION_NOE 成<|>RELATION_NOE ICP<|>RELATION_NOE 血清<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 进行<|>RELATION_NOE 干预<|>RELATION_NOE .<|>RELATION_NOE
光镜<|>RELATION_NOE 下<|>RELATION_NOE 观察<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE Caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞<|>RELATION_NOE 呈<|>RELATION_NOE 黄褐色<|>RELATION_NOE 表达<|>RELATION_B 于<|>RELATION_E 胞质<|>RELATION_NOE 中.<|>RELATION_NOE
ICP<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 乳酸脱氢酶<|>RELATION_NOE 漏出率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 34.68<|>RELATION_NOE ±<|>RELATION_NOE 0.77<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 、<|>RELATION_NOE Caspase-3<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 光密度<|>RELATION_NOE 值<|>RELATION_NOE (<|>RELATION_NOE 98<|>RELATION_NOE 1.77<|>RELATION_NOE ±<|>RELATION_NOE 55.21<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 27.86<|>RELATION_NOE ±<|>RELATION_NOE 0.53<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 较<|>RELATION_NOE 正常<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 17.39<|>RELATION_NOE ±<|>RELATION_NOE 0.66<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 54<|>RELATION_NOE 0.63<|>RELATION_NOE ±<|>RELATION_NOE 38.41<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 6.99<|>RELATION_NOE ±<|>RELATION_NOE 0.11<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 增加<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE -45.70<|>RELATION_NOE 、<|>RELATION_NOE -15.96<|>RELATION_NOE 、<|>RELATION_NOE -134.41<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 均<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血浆<|>RELATION_NOE Th17<|>RELATION_NOE 细胞<|>RELATION_NOE 相关<|>RELATION_NOE 因子<|>RELATION_NOE 与<|>RELATION_NOE 25-<|>RELATION_NOE 羟基<|>RELATION_NOE 维生素<|>RELATION_NOE D<|>RELATION_NOE 检测<|>RELATION_S 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE
收集<|>RELATION_NOE 本院<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 1月<|>RELATION_NOE 新<|>RELATION_NOE 入院<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 78<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 腺癌<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 选取<|>RELATION_NOE 年龄<|>RELATION_NOE 和<|>RELATION_NOE 性别<|>RELATION_NOE 与<|>RELATION_NOE 其<|>RELATION_NOE 相<|>RELATION_NOE 匹配<|>RELATION_NOE 的<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE .<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 25-<|>RELATION_NOE 羟基<|>RELATION_NOE 维生素<|>RELATION_NOE D<|>RELATION_NOE 、<|>RELATION_NOE IL-17<|>RELATION_NOE 、<|>RELATION_NOE IL-6<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE 肺鳞状细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE IL-6<|>RELATION_NOE 、<|>RELATION_NOE IL-17<|>RELATION_NOE 与<|>RELATION_NOE 25-<|>RELATION_NOE 羟基<|>RELATION_NOE 维生素<|>RELATION_NOE D<|>RELATION_NOE 存在<|>RELATION_NOE 相关性<|>RELATION_NOE (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 69<|>RELATION_NOE ,<|>RELATION_NOE 0.402<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 25-<|>RELATION_NOE 羟基<|>RELATION_NOE 维生素<|>RELATION_NOE D<|>RELATION_NOE 、<|>RELATION_NOE IL-17<|>RELATION_NOE 、<|>RELATION_NOE IL-6<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE 肺鳞状细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE IL-6<|>RELATION_NOE 、<|>RELATION_NOE IL-17<|>RELATION_NOE 与<|>RELATION_NOE 25-<|>RELATION_NOE 羟基<|>RELATION_NOE 维生素<|>RELATION_NOE D<|>RELATION_NOE 存在<|>RELATION_B 相关性<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 69<|>RELATION_NOE ,<|>RELATION_NOE 0.402<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 25-<|>RELATION_NOE 羟基<|>RELATION_NOE 维生素<|>RELATION_NOE D<|>RELATION_NOE 、<|>RELATION_NOE IL-17<|>RELATION_NOE 、<|>RELATION_NOE IL-6<|>RELATION_NOE 浓度<|>RELATION_NOE 异常<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE 25-<|>RELATION_NOE 羟基<|>RELATION_NOE 维生素<|>RELATION_NOE D<|>RELATION_NOE 与<|>RELATION_NOE Th17<|>RELATION_NOE 细胞<|>RELATION_NOE 相关<|>RELATION_NOE 因子<|>RELATION_NOE 浓度<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 治疗<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 监测<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 临床<|>RELATION_B 价值<|>RELATION_E .<|>RELATION_NOE
调强<|>RELATION_NOE 放疗<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 治疗<|>RELATION_S 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 近期<|>RELATION_NOE 效果<|>RELATION_NOE 分析<|>RELATION_NOE
观察<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 在<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_B 疗效<|>RELATION_E 。<|>RELATION_NOE
予<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨加<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 诱导<|>RELATION_NOE 化疗2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE 调<|>RELATION_NOE 强<|>RELATION_NOE 放疗<|>RELATION_NOE 序贯吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨加<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗组<|>RELATION_NOE 和<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨加<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE 。<|>RELATION_NOE
周剂量<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 单药<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_E 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 效果<|>RELATION_NOE 比较<|>RELATION_NOE
比较<|>RELATION_NOE 周剂量<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE (<|>RELATION_NOE DOC<|>RELATION_NOE )<|>RELATION_NOE 单药<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE (<|>RELATION_NOE NDP<|>RELATION_NOE )<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_I 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_I (<|>RELATION_I NSCLC<|>RELATION_I )<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 放疗<|>RELATION_NOE 前后<|>RELATION_NOE 肺功能<|>RELATION_NOE 变化<|>RELATION_NOE 与<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 研究<|>RELATION_NOE
观察<|>RELATION_NOE 接受<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肺功能<|>RELATION_NOE 变化<|>RELATION_NOE 与<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 放疗<|>RELATION_NOE 前<|>RELATION_NOE 1周<|>RELATION_NOE 、<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 和<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 的<|>RELATION_NOE 肺功能<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 发生<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 的<|>RELATION_NOE 联合化疗<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 老年人<|>RELATION_NOE 晚期<|>RELATION_NOE 非鳞非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 经<|>RELATION_NOE 病理学<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非鳞<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 或<|>RELATION_NOE 卡铂<|>RELATION_NOE 方案<|>RELATION_NOE 全身<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂组<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂组<|>RELATION_NOE (<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 实体瘤<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 标准<|>RELATION_NOE (<|>RELATION_NOE RECIST<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 美国<|>RELATION_NOE 国家<|>RELATION_NOE 癌症<|>RELATION_NOE 研究所<|>RELATION_NOE 化疗<|>RELATION_NOE 毒性<|>RELATION_NOE 分级<|>RELATION_NOE 标准<|>RELATION_NOE (<|>RELATION_NOE NCI-CTC<|>RELATION_NOE AE<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 进行<|>RELATION_NOE 评估<|>RELATION_NOE 。<|>RELATION_NOE
注射<|>RELATION_NOE 用<|>RELATION_NOE 丹参<|>RELATION_NOE 多<|>RELATION_NOE 酚酸盐<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 及<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 老年人<|>RELATION_NOE 晚期<|>RELATION_NOE 非鳞非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 注射<|>RELATION_NOE 用<|>RELATION_NOE 丹参<|>RELATION_NOE 多<|>RELATION_NOE 酚酸盐<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 及<|>RELATION_NOE 卡铂<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_B 老年人<|>RELATION_I 晚期<|>RELATION_I 非鳞非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 效果<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 证实<|>RELATION_NOE 初<|>RELATION_NOE 治<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非鳞非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 58<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 区组<|>RELATION_NOE 随机化法<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE 各<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 给予<|>RELATION_NOE 培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE +<|>RELATION_NOE 卡铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE 治疗<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 给予<|>RELATION_NOE 注射<|>RELATION_NOE 用<|>RELATION_NOE 丹参<|>RELATION_NOE 多<|>RELATION_NOE 酚酸盐<|>RELATION_NOE 200mg<|>RELATION_NOE /<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 1次/<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 连<|>RELATION_NOE 用<|>RELATION_NOE 14d<|>RELATION_NOE 。<|>RELATION_NOE
21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生<|>RELATION_NOE 及<|>RELATION_NOE 凝血<|>RELATION_NOE 指标<|>RELATION_NOE 改善<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 总<|>RELATION_NOE 有效率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 44.8%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 37.9%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 86.2%<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 75.8%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 总<|>RELATION_NOE 改善<|>RELATION_NOE 率<|>RELATION_NOE 优于<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE 82.7%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 65.5%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 毒性<|>RELATION_NOE 和<|>RELATION_NOE 消化道<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 血液<|>RELATION_NOE 高凝<|>RELATION_NOE 状态<|>RELATION_NOE 改善<|>RELATION_NOE 情况<|>RELATION_NOE 优于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 总<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 44.8%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 37.9%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 86.2%<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 75.8%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 总<|>RELATION_NOE 改善率<|>RELATION_NOE 优于<|>RELATION_S 对照组<|>RELATION_NOE [<|>RELATION_NOE 82.7%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 65.5%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 毒性<|>RELATION_NOE 和<|>RELATION_NOE 消化道<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 总<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 44.8%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 37.9%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 86.2%<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 75.8%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 总<|>RELATION_NOE 改善<|>RELATION_NOE 率<|>RELATION_NOE 优于<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE 82.7%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 65.5%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 毒性<|>RELATION_NOE 和<|>RELATION_NOE 消化道<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 血液<|>RELATION_NOE 高凝<|>RELATION_NOE 状态<|>RELATION_NOE 改善<|>RELATION_NOE 情况<|>RELATION_NOE 优于<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 总<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 44.8%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 37.9%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 86.2%<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 75.8%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 总<|>RELATION_NOE 改善<|>RELATION_NOE 率<|>RELATION_NOE 优于<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE 82.7%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 65.5%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 29<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 毒性<|>RELATION_NOE 和<|>RELATION_NOE 消化道<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 血液<|>RELATION_NOE 高凝<|>RELATION_NOE 状态<|>RELATION_NOE 改善<|>RELATION_NOE 情况<|>RELATION_NOE 优于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 心包<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 心包积液<|>RELATION_NOE 样本<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 肿瘤<|>RELATION_NOE 心包<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 心包积液<|>RELATION_NOE 样本<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 其中<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 胰腺癌<|>RELATION_NOE 3例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 非肿瘤性<|>RELATION_NOE 心包积液<|>RELATION_NOE 样本<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_S 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE
31<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 过程<|>RELATION_NOE 顺利<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 发生<|>RELATION_NOE 心律失常<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 早搏<|>RELATION_NOE 和<|>RELATION_NOE 房颤<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘发生<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 胸腔<|>RELATION_NOE 感染<|>RELATION_NOE 。<|>RELATION_NOE
2-<|>RELATION_NOE 脱氧<|>RELATION_NOE -D<|>RELATION_NOE -<|>RELATION_NOE 葡萄糖<|>RELATION_NOE 标记<|>RELATION_NOE 的<|>RELATION_NOE 氧化铁<|>RELATION_NOE 纳米粒子<|>RELATION_NOE 对<|>RELATION_NOE 裸鼠<|>RELATION_NOE A549<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 靶向<|>RELATION_B 对比<|>RELATION_I 增强<|>RELATION_I 作用<|>RELATION_E
制备<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 荷瘤<|>RELATION_NOE 裸鼠<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 经尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE γ<|>RELATION_NOE -Fe2O3<|>RELATION_NOE @<|>RELATION_NOE DMSA-DG<|>RELATION_NOE NPs<|>RELATION_NOE 或<|>RELATION_NOE γ<|>RELATION_NOE -Fe2O3<|>RELATION_NOE @<|>RELATION_NOE DMSA<|>RELATION_NOE NPs<|>RELATION_NOE 冻干粉<|>RELATION_NOE 的<|>RELATION_NOE 无菌水<|>RELATION_NOE 悬液<|>RELATION_NOE ,<|>RELATION_NOE 注射<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 注射<|>RELATION_NOE 后<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48h<|>RELATION_NOE 进行<|>RELATION_NOE MRI<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 测量<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 脑组织<|>RELATION_NOE 、<|>RELATION_NOE 肝组织<|>RELATION_NOE 及<|>RELATION_NOE 大<|>RELATION_NOE 腿部骨骼肌<|>RELATION_NOE 的<|>RELATION_NOE T2<|>RELATION_NOE 信号<|>RELATION_NOE 强度<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE T2<|>RELATION_NOE 值<|>RELATION_NOE 。<|>RELATION_NOE
体内<|>RELATION_NOE 实验<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 荷瘤<|>RELATION_NOE 裸鼠<|>RELATION_NOE 在<|>RELATION_NOE -Fe2O3<|>RELATION_NOE @<|>RELATION_NOE DMSA-DG<|>RELATION_NOE NPs<|>RELATION_NOE 注射<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 注射<|>RELATION_NOE 后<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48h<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE T2<|>RELATION_NOE 信号<|>RELATION_NOE 强度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 32<|>RELATION_NOE 6.00<|>RELATION_NOE ±<|>RELATION_NOE 16.26<|>RELATION_NOE )<|>RELATION_NOE s<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 27<|>RELATION_NOE 6.40<|>RELATION_NOE ±<|>RELATION_NOE 5.13<|>RELATION_NOE )<|>RELATION_NOE s<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 26<|>RELATION_NOE 8.40<|>RELATION_NOE ±<|>RELATION_NOE 30.58<|>RELATION_NOE )<|>RELATION_NOE s<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE 0.40<|>RELATION_NOE ±<|>RELATION_NOE 25.93<|>RELATION_NOE )<|>RELATION_NOE s<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 26<|>RELATION_NOE 2.20<|>RELATION_NOE ±<|>RELATION_NOE 30.04<|>RELATION_NOE )<|>RELATION_NOE s<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE T2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 73<|>RELATION_NOE 5.80<|>RELATION_NOE ±<|>RELATION_NOE 20.93<|>RELATION_NOE )<|>RELATION_NOE ms<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 64<|>RELATION_NOE 5.80<|>RELATION_NOE ±<|>RELATION_NOE 69.58<|>RELATION_NOE )<|>RELATION_NOE ms<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 61<|>RELATION_NOE 5.00<|>RELATION_NOE ±<|>RELATION_NOE 12<|>RELATION_NOE 4.61<|>RELATION_NOE )<|>RELATION_NOE ms<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 570.60<|>RELATION_NOE ±<|>RELATION_NOE 67.78<|>RELATION_NOE )<|>RELATION_NOE ms<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 53<|>RELATION_NOE 7.80<|>RELATION_NOE ±<|>RELATION_NOE 10<|>RELATION_NOE 5.29<|>RELATION_NOE )<|>RELATION_NOE ms<|>RELATION_NOE ;<|>RELATION_NOE
而<|>RELATION_NOE 对照组<|>RELATION_NOE 荷瘤<|>RELATION_NOE 裸鼠<|>RELATION_NOE 在<|>RELATION_NOE γ<|>RELATION_NOE -Fe2<|>RELATION_NOE O3<|>RELATION_NOE @<|>RELATION_NOE DMSA<|>RELATION_NOE NPs<|>RELATION_NOE 注射<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 注射<|>RELATION_NOE 后<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48h<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE T2<|>RELATION_NOE 信号<|>RELATION_NOE 强度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 33<|>RELATION_NOE 5.60<|>RELATION_NOE ±<|>RELATION_NOE 4.93<|>RELATION_NOE )<|>RELATION_NOE s<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE 0.80<|>RELATION_NOE ±<|>RELATION_NOE 5.93<|>RELATION_NOE )<|>RELATION_NOE s<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 27<|>RELATION_NOE 3.40<|>RELATION_NOE ±<|>RELATION_NOE 15.08<|>RELATION_NOE )<|>RELATION_NOE s<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 32<|>RELATION_NOE 7.40<|>RELATION_NOE ±<|>RELATION_NOE 16.65<|>RELATION_NOE )<|>RELATION_NOE s<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 31<|>RELATION_NOE 3.20<|>RELATION_NOE ±<|>RELATION_NOE 20.45<|>RELATION_NOE )<|>RELATION_NOE s<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE T2<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 68<|>RELATION_NOE 6.00<|>RELATION_NOE ±<|>RELATION_NOE 21.44<|>RELATION_NOE )<|>RELATION_NOE ms<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 61<|>RELATION_NOE 7.80<|>RELATION_NOE ±<|>RELATION_NOE 69.93<|>RELATION_NOE )<|>RELATION_NOE ms<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 64<|>RELATION_NOE 5.20<|>RELATION_NOE ±<|>RELATION_NOE 85.89<|>RELATION_NOE )<|>RELATION_NOE ms<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 66<|>RELATION_NOE 9.40<|>RELATION_NOE ±<|>RELATION_NOE 13.72<|>RELATION_NOE )<|>RELATION_NOE ms<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 608.80<|>RELATION_NOE ±<|>RELATION_NOE 61.90<|>RELATION_NOE )<|>RELATION_NOE ms<|>RELATION_NOE .<|>RELATION_NOE
γ<|>RELATION_NOE -Fe2O3<|>RELATION_NOE @<|>RELATION_NOE DMSA-DG<|>RELATION_NOE NPs<|>RELATION_NOE 有<|>RELATION_NOE 靶向<|>RELATION_NOE 肿瘤<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 葡萄糖<|>RELATION_NOE 受体<|>RELATION_NOE 的<|>RELATION_NOE 功能<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 靶向<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE MRI<|>RELATION_NOE 对比<|>RELATION_NOE 剂.<|>RELATION_NOE
哺乳动物<|>RELATION_NOE 雷帕霉素<|>RELATION_NOE 靶<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
mTOR<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE 提示<|>RELATION_S NSCLC<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 早期<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
哺乳动物<|>RELATION_NOE 雷帕霉素<|>RELATION_NOE 靶<|>RELATION_NOE 蛋白<|>RELATION_NOE 通路<|>RELATION_B 激活<|>RELATION_E 在<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 哺乳动物<|>RELATION_NOE 雷帕霉素<|>RELATION_NOE 靶<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE mTOR<|>RELATION_NOE )<|>RELATION_NOE 磷酸化<|>RELATION_NOE 代表<|>RELATION_NOE 的<|>RELATION_NOE mTOR<|>RELATION_NOE 通路<|>RELATION_NOE 激活<|>RELATION_NOE 在<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 中<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 指标<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
应用<|>RELATION_NOE 组织<|>RELATION_NOE 微阵列<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 222<|>RELATION_NOE 例<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 中<|>RELATION_NOE 磷酸化<|>RELATION_NOE mTOR<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 指标<|>RELATION_NOE 和<|>RELATION_NOE 生存率<|>RELATION_NOE 进行<|>RELATION_NOE 统计学<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
大肠<|>RELATION_NOE 腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 抑制<|>RELATION_NOE 因子<|>RELATION_NOE -1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 预后<|>RELATION_NOE 及其<|>RELATION_NOE 基因<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE Envision<|>RELATION_NOE 二<|>RELATION_NOE 步法<|>RELATION_NOE 检测<|>RELATION_S 大肠癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE TSLC-1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 参数<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE MSP<|>RELATION_NOE )<|>RELATION_NOE 用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE Envision<|>RELATION_NOE 二<|>RELATION_NOE 步<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 大肠癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE TSLC-1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 参数<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE MSP<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S TSLC-1<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE 。<|>RELATION_NOE
癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 肠黏膜<|>RELATION_NOE 与<|>RELATION_NOE 大肠<|>RELATION_NOE 腺癌<|>RELATION_NOE 的<|>RELATION_NOE TSCL-1<|>RELATION_NOE 表达<|>RELATION_NOE 阳性率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE /<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 41.5<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 53<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
TSLC-1<|>RELATION_NOE 在<|>RELATION_NOE 大肠<|>RELATION_NOE 腺癌<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 判断<|>RELATION_NOE 具有<|>RELATION_B 重要<|>RELATION_I 的<|>RELATION_I 参考<|>RELATION_I 价值<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 大肠<|>RELATION_NOE 腺癌<|>RELATION_NOE TSLC-1<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_NOE 机制<|>RELATION_NOE .<|>RELATION_NOE TSLC-1<|>RELATION_NOE 在<|>RELATION_NOE 大肠<|>RELATION_NOE 腺癌<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 判断<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 的<|>RELATION_NOE 参考<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 大肠<|>RELATION_B 腺癌<|>RELATION_I TSLC-1<|>RELATION_I 表达<|>RELATION_I 下调<|>RELATION_E 的<|>RELATION_NOE 重要<|>RELATION_NOE 机制<|>RELATION_NOE .<|>RELATION_NOE
常氧<|>RELATION_NOE 条件<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE Gy<|>RELATION_NOE 照射<|>RELATION_NOE 和<|>RELATION_NOE 转染<|>RELATION_NOE 质粒<|>RELATION_NOE 后<|>RELATION_NOE 进行<|>RELATION_NOE 2<|>RELATION_NOE Gy<|>RELATION_NOE 照射<|>RELATION_NOE 能<|>RELATION_NOE 显著<|>RELATION_B 增加<|>RELATION_E A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE Smac<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 乏<|>RELATION_NOE 氧能<|>RELATION_NOE
乏氧<|>RELATION_NOE 和<|>RELATION_NOE 辐射<|>RELATION_NOE 均<|>RELATION_NOE 能<|>RELATION_NOE 诱导<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE Smac<|>RELATION_NOE 表达<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 联合2<|>RELATION_NOE Gy<|>RELATION_NOE 照射<|>RELATION_NOE 能<|>RELATION_NOE 显著<|>RELATION_NOE 抑制<|>RELATION_NOE 乏氧<|>RELATION_NOE 条件<|>RELATION_NOE 下<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE .<|>RELATION_NOE
ErbB2<|>RELATION_NOE 转录因子<|>RELATION_NOE 1<|>RELATION_NOE 增加<|>RELATION_S 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE
通过<|>RELATION_NOE 脂质体<|>RELATION_NOE 介导<|>RELATION_NOE 的<|>RELATION_NOE 重组<|>RELATION_NOE 质粒<|>RELATION_NOE 转染<|>RELATION_NOE 及<|>RELATION_NOE G418<|>RELATION_NOE 筛选<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE TOB1<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE 株<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE 单细胞<|>RELATION_NOE 凝胶<|>RELATION_NOE 电泳<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_S TOB1<|>RELATION_NOE 对<|>RELATION_NOE 电离辐射<|>RELATION_NOE 引起<|>RELATION_NOE 的<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 修复<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
通过<|>RELATION_NOE 重组<|>RELATION_NOE 质粒<|>RELATION_NOE 转染<|>RELATION_NOE 及<|>RELATION_NOE G418<|>RELATION_NOE 筛选<|>RELATION_NOE ,<|>RELATION_NOE 成功<|>RELATION_NOE 建立<|>RELATION_NOE TOB1<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE 株<|>RELATION_NOE ;<|>RELATION_NOE
克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 证实<|>RELATION_NOE 外源性<|>RELATION_NOE TOB1<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_B 增加<|>RELATION_E 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射敏感性<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 单击<|>RELATION_NOE 多<|>RELATION_NOE 靶<|>RELATION_NOE 模型<|>RELATION_NOE 拟合<|>RELATION_NOE 细胞存活<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射<|>RELATION_NOE 增敏<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE SER<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 1.63<|>RELATION_NOE ;<|>RELATION_NOE
TOB1<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 增加<|>RELATION_S 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射敏感性<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE TOB1<|>RELATION_NOE 抑制<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 修复<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 抑制<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 修复<|>RELATION_NOE 有关<|>RELATION_NOE .<|>RELATION_NOE TOB1<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 增加<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射敏感性<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE TOB1<|>RELATION_NOE 抑制<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 修复<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 抑制<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 修复<|>RELATION_NOE 有关<|>RELATION_S .<|>RELATION_NOE
偶联<|>RELATION_NOE 西<|>RELATION_NOE 妥昔<|>RELATION_NOE 单抗<|>RELATION_NOE 的<|>RELATION_NOE 金纳米<|>RELATION_NOE 颗粒<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
应用<|>RELATION_NOE 浓度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 100<|>RELATION_NOE 、<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 的<|>RELATION_NOE C225<|>RELATION_NOE 、<|>RELATION_NOE 偶联<|>RELATION_NOE IgG<|>RELATION_NOE 的<|>RELATION_NOE 金纳米<|>RELATION_NOE 颗粒<|>RELATION_NOE (<|>RELATION_NOE IgG-AuNPs<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 偶联<|>RELATION_NOE C225<|>RELATION_NOE 的<|>RELATION_NOE 金纳米<|>RELATION_NOE 颗粒<|>RELATION_NOE (<|>RELATION_NOE C225-AuNPs<|>RELATION_NOE )<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 药物<|>RELATION_NOE 作用<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE 通过<|>RELATION_NOE 细胞计数<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE (<|>RELATION_NOE CCK-8<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 抑制率<|>RELATION_NOE ;<|>RELATION_NOE
通过<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 细胞凋亡<|>RELATION_NOE 和<|>RELATION_NOE 周期<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Transwell<|>RELATION_NOE 小<|>RELATION_NOE 室法<|>RELATION_NOE 通过<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 和<|>RELATION_NOE 周期<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE Transwell<|>RELATION_NOE 小<|>RELATION_NOE 室法<|>RELATION_NOE 检测<|>RELATION_S 细胞迁移<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE
RNA<|>RELATION_B 干扰<|>RELATION_I 抑制<|>RELATION_I 微管<|>RELATION_I 不<|>RELATION_I 稳定<|>RELATION_I 蛋白<|>RELATION_I 基因表达<|>RELATION_E 对<|>RELATION_NOE 胃癌<|>RELATION_NOE BGC803<|>RELATION_NOE 细胞<|>RELATION_NOE 恶性<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
同时<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 迁移<|>RELATION_NOE 能力<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 细胞<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
12<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 经<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 1例<|>RELATION_NOE 经<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 、<|>RELATION_NOE 肺泡灌洗液<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 痰均<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 两<|>RELATION_NOE 年<|>RELATION_NOE 以上<|>RELATION_NOE 证实<|>RELATION_NOE ;<|>RELATION_NOE
13<|>RELATION_NOE 例<|>RELATION_NOE 尘肺<|>RELATION_NOE 患者<|>RELATION_NOE PET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 显像<|>RELATION_NOE 共<|>RELATION_NOE 发现<|>RELATION_NOE 17<|>RELATION_NOE 个<|>RELATION_NOE 高<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 摄取<|>RELATION_NOE 的<|>RELATION_NOE 肺内团<|>RELATION_NOE 块<|>RELATION_NOE 或<|>RELATION_NOE 结节<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE 其中<|>RELATION_NOE 鳞癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 为<|>RELATION_NOE 鳞<|>RELATION_NOE 癌术<|>RELATION_NOE 后<|>RELATION_NOE 复发<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 病理<|>RELATION_NOE 提示<|>RELATION_NOE 为<|>RELATION_NOE 慢性<|>RELATION_NOE 炎性<|>RELATION_NOE 增生<|>RELATION_NOE ;<|>RELATION_NOE
1例<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 后<|>RELATION_NOE 随访<|>RELATION_NOE 2.5<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
18F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_NOE 为<|>RELATION_NOE 62.5%<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 准确性<|>RELATION_NOE 为<|>RELATION_NOE 67.6%<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE /<|>RELATION_NOE 37<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 假阳<|>RELATION_NOE 性率<|>RELATION_NOE 为<|>RELATION_NOE 37.5%<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 阴性<|>RELATION_NOE 结果<|>RELATION_NOE 预测值<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE /<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
二氧化硅<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 中<|>RELATION_NOE miR-149<|>RELATION_NOE 对<|>RELATION_NOE 白细胞介素<|>RELATION_NOE -6<|>RELATION_NOE 的<|>RELATION_NOE 调节<|>RELATION_S
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 建立<|>RELATION_NOE SiO2<|>RELATION_NOE 粉尘<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链式<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE quantitativereal-timepolymerasechainreaction<|>RELATION_NOE ,<|>RELATION_NOE qRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 小鼠<|>RELATION_NOE 肺组织<|>RELATION_NOE miR-149<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 蛋白<|>RELATION_NOE 免疫印迹法<|>RELATION_NOE (<|>RELATION_NOE Westernblot<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 观察<|>RELATION_NOE 白细胞介素<|>RELATION_NOE .<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 建立<|>RELATION_NOE SiO2<|>RELATION_NOE 粉尘<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链式<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE quantitativereal-timepolymerasechainreaction<|>RELATION_NOE ,<|>RELATION_NOE qRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺组织<|>RELATION_NOE miR-149<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 蛋白<|>RELATION_NOE 免疫印迹法<|>RELATION_NOE (<|>RELATION_NOE Westernblot<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 观察<|>RELATION_S 白细胞介素<|>RELATION_NOE .<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 应用<|>RELATION_NOE 具有<|>RELATION_NOE 肺泡<|>RELATION_NOE Ⅱ型<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 特性<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE A549<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 支气管<|>RELATION_NOE 上皮细胞<|>RELATION_NOE (<|>RELATION_NOE HBE<|>RELATION_NOE )<|>RELATION_NOE 构建<|>RELATION_NOE SiO2<|>RELATION_NOE 粉尘<|>RELATION_NOE 刺激<|>RELATION_NOE 的<|>RELATION_NOE 呼吸系统<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE qRT-PCR<|>RELATION_NOE 检测<|>RELATION_S miR<|>RELATION_NOE .<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 通过<|>RELATION_NOE 体外<|>RELATION_NOE 转染<|>RELATION_NOE miR-149<|>RELATION_NOE 相似剂<|>RELATION_NOE (<|>RELATION_NOE mimics<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 抑制剂<|>RELATION_NOE (<|>RELATION_NOE inhibitors<|>RELATION_NOE )<|>RELATION_NOE 至<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 表达<|>RELATION_NOE 炎症<|>RELATION_NOE 因子<|>RELATION_NOE IL-6<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 双<|>RELATION_NOE 抗<|>RELATION_NOE 夹心<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 煤工尘肺<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE IL<|>RELATION_NOE .<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE SiO2<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 模型<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE SiO2<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 时间点<|>RELATION_NOE ,<|>RELATION_NOE 小鼠<|>RELATION_NOE 肺组织<|>RELATION_NOE miR-149<|>RELATION_NOE 表达<|>RELATION_NOE 明显<|>RELATION_B 下调<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE IL<|>RELATION_NOE .<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 粉尘<|>RELATION_NOE 刺激<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 模型<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 及<|>RELATION_NOE HBE<|>RELATION_NOE 细胞<|>RELATION_NOE 经<|>RELATION_NOE SiO2<|>RELATION_B 刺激<|>RELATION_E 后<|>RELATION_NOE ,<|>RELATION_NOE IL-6<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 上调<|>RELATION_NOE ,<|>RELATION_NOE miR-149<|>RELATION_NOE 表达量<|>RELATION_NOE 明显<|>RELATION_NOE 下调<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 、<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 煤工尘肺<|>RELATION_NOE 组<|>RELATION_NOE 血清<|>RELATION_NOE IL<|>RELATION_NOE .<|>RELATION_NOE
窄带成像<|>RELATION_NOE 联合<|>RELATION_NOE 自<|>RELATION_NOE 荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE 对<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
评估<|>RELATION_NOE 窄带成像<|>RELATION_NOE 技术<|>RELATION_NOE (<|>RELATION_NOE NBI<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
对<|>RELATION_NOE 153<|>RELATION_NOE 例<|>RELATION_NOE 高度<|>RELATION_NOE 怀疑<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 病例<|>RELATION_NOE 先<|>RELATION_NOE 进行<|>RELATION_NOE 白光<|>RELATION_NOE 支气管镜<|>RELATION_NOE (<|>RELATION_NOE WLB<|>RELATION_NOE )<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 再<|>RELATION_NOE 使用<|>RELATION_NOE NBI<|>RELATION_NOE 、<|>RELATION_NOE 自<|>RELATION_NOE 荧光<|>RELATION_NOE 支气管镜<|>RELATION_NOE (<|>RELATION_NOE AFB<|>RELATION_NOE )<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 每<|>RELATION_NOE 例<|>RELATION_NOE 镜<|>RELATION_NOE 下<|>RELATION_NOE 观察<|>RELATION_NOE 到<|>RELATION_NOE 的<|>RELATION_NOE 异常<|>RELATION_NOE 黏膜<|>RELATION_NOE 部位<|>RELATION_NOE 取<|>RELATION_NOE 3<|>RELATION_NOE 块<|>RELATION_NOE 或<|>RELATION_NOE 以上<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 送检<|>RELATION_NOE 。<|>RELATION_NOE
酶法<|>RELATION_NOE 检测<|>RELATION_S 唾液酸<|>RELATION_NOE 的<|>RELATION_NOE 性能<|>RELATION_NOE 验证<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 评估<|>RELATION_NOE
对<|>RELATION_NOE 240<|>RELATION_NOE 例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 分组<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 各<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组<|>RELATION_NOE 血清<|>RELATION_NOE SA<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 是否<|>RELATION_NOE 存在<|>RELATION_NOE 差异<|>RELATION_NOE ;<|>RELATION_NOE
对于<|>RELATION_NOE 存在<|>RELATION_NOE 差异<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 进一步<|>RELATION_NOE 收取<|>RELATION_NOE 疾病<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 绘制<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE SA<|>RELATION_NOE 与<|>RELATION_NOE 其他<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 性能<|>RELATION_NOE .<|>RELATION_NOE
胃癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 对应<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE SA<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 757<|>RELATION_NOE ±<|>RELATION_NOE 177<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 514<|>RELATION_NOE ±<|>RELATION_NOE 86<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 597<|>RELATION_NOE ±<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 55.2<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
结直肠癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 对应<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE SA<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 659<|>RELATION_NOE ±<|>RELATION_NOE 127<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 545<|>RELATION_NOE ±<|>RELATION_NOE 66<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 42.8<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 对应<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE SA<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 738<|>RELATION_NOE ±<|>RELATION_NOE 157<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 672<|>RELATION_NOE ±<|>RELATION_NOE 161<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 26.3<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
在<|>RELATION_NOE CEA<|>RELATION_NOE 未<|>RELATION_NOE 增高<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE SA<|>RELATION_NOE 在<|>RELATION_NOE 胃癌组<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE AUC<|>RELATION_NOE 为<|>RELATION_NOE 0.7<|>RELATION_NOE 91<|>RELATION_NOE ,<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 组<|>RELATION_NOE 为<|>RELATION_NOE 0.6<|>RELATION_NOE 87<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 胃癌<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE SA<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 性能<|>RELATION_NOE 优于<|>RELATION_S 传统<|>RELATION_NOE 标志物<|>RELATION_NOE CA72-4<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 辅助<|>RELATION_NOE CEA<|>RELATION_NOE 对<|>RELATION_NOE 部分<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 筛选<|>RELATION_NOE 和<|>RELATION_NOE 诊断<|>RELATION_NOE .<|>RELATION_NOE 在<|>RELATION_NOE 胃癌<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE SA<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 性能<|>RELATION_NOE 优于<|>RELATION_NOE 传统<|>RELATION_NOE 标志物<|>RELATION_NOE CA72-4<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 辅助<|>RELATION_B CEA<|>RELATION_E 对<|>RELATION_NOE 部分<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 筛选<|>RELATION_NOE 和<|>RELATION_NOE 诊断<|>RELATION_NOE .<|>RELATION_NOE
18<|>RELATION_NOE 7例<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 颈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_B 因素<|>RELATION_E 分析<|>RELATION_NOE
通过<|>RELATION_NOE 分析<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小<|>RELATION_NOE 癌颈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 颈<|>RELATION_NOE 淋巴节<|>RELATION_NOE 转移<|>RELATION_NOE 规律<|>RELATION_NOE 及<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 为颈<|>RELATION_B 淋巴结<|>RELATION_I 清扫<|>RELATION_I 指征<|>RELATION_I 及<|>RELATION_I 范围<|>RELATION_I 提供<|>RELATION_I 临床<|>RELATION_I 依据<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 收集<|>RELATION_NOE 2007年<|>RELATION_NOE 1月<|>RELATION_NOE -2011<|>RELATION_NOE 年<|>RELATION_NOE 12月<|>RELATION_NOE 大连<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 第一<|>RELATION_NOE 医院<|>RELATION_NOE 普外科<|>RELATION_NOE 初次<|>RELATION_NOE 收治<|>RELATION_NOE 并<|>RELATION_NOE 经<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 的<|>RELATION_NOE 187<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 颈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 各区<|>RELATION_NOE 转移率<|>RELATION_NOE 、<|>RELATION_NOE 影响<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 直径<|>RELATION_NOE ≥<|>RELATION_NOE 5mm<|>RELATION_NOE 、<|>RELATION_NOE 多发<|>RELATION_NOE 癌灶<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺<|>RELATION_NOE 被膜<|>RELATION_NOE 侵犯<|>RELATION_NOE 与<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 颈部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
甲状腺<|>RELATION_NOE 微小<|>RELATION_NOE 癌颈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 常见于<|>RELATION_S 中央区<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 直径<|>RELATION_NOE ≥<|>RELATION_NOE 5mm<|>RELATION_NOE 、<|>RELATION_NOE 多发<|>RELATION_NOE 癌灶<|>RELATION_NOE 以及<|>RELATION_NOE 甲状腺<|>RELATION_NOE 被膜<|>RELATION_NOE 侵犯<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 更<|>RELATION_NOE 易<|>RELATION_NOE 发生<|>RELATION_NOE 颈<|>RELATION_NOE 淋巴节<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 常规<|>RELATION_NOE 行<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小<|>RELATION_NOE 癌颈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 常见<|>RELATION_NOE 于<|>RELATION_NOE 中央区<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 直径<|>RELATION_NOE ≥<|>RELATION_NOE 5mm<|>RELATION_NOE 、<|>RELATION_NOE 多发<|>RELATION_NOE 癌灶<|>RELATION_NOE 以及<|>RELATION_NOE 甲状腺<|>RELATION_NOE 被膜<|>RELATION_NOE 侵犯<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 更<|>RELATION_NOE 易<|>RELATION_B 发生<|>RELATION_E 颈<|>RELATION_NOE 淋巴节<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 常规<|>RELATION_NOE 行<|>RELATION_NOE 中央区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 术.<|>RELATION_NOE
不同<|>RELATION_NOE 含<|>RELATION_NOE 铂双药<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 及<|>RELATION_I 不良<|>RELATION_I 反应<|>RELATION_E
不良<|>RELATION_NOE 反应<|>RELATION_NOE 主要<|>RELATION_B 为<|>RELATION_E 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 、<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 、<|>RELATION_NOE 脱发<|>RELATION_NOE 和<|>RELATION_NOE 神经毒性<|>RELATION_NOE 等<|>RELATION_NOE .<|>RELATION_NOE
系统性<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 癌因性<|>RELATION_B 疲乏<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_E
对照组<|>RELATION_NOE 根据<|>RELATION_NOE 医嘱行<|>RELATION_NOE 肿瘤<|>RELATION_NOE 内科<|>RELATION_NOE 患者<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 干预组<|>RELATION_NOE 在<|>RELATION_NOE 此<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 进行<|>RELATION_NOE 系统<|>RELATION_NOE 的<|>RELATION_NOE 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 予以<|>RELATION_B 系统性<|>RELATION_I 护理<|>RELATION_I 干预<|>RELATION_E ,<|>RELATION_NOE 可<|>RELATION_NOE 缓解<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 疲乏<|>RELATION_NOE 程度<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 围手术期<|>RELATION_NOE 护理<|>RELATION_B 服务<|>RELATION_I 项目<|>RELATION_I 界定<|>RELATION_E 的<|>RELATION_NOE 研究<|>RELATION_NOE
确定<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 围手术期<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 项目<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 患者<|>RELATION_NOE 围手术期间<|>RELATION_NOE 接受<|>RELATION_NOE 系统<|>RELATION_NOE 、<|>RELATION_NOE 规范<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 提供<|>RELATION_B 准确<|>RELATION_I 路径<|>RELATION_E 。<|>RELATION_NOE
通过<|>RELATION_NOE 临床<|>RELATION_NOE 调研法<|>RELATION_NOE 、<|>RELATION_NOE 专家<|>RELATION_NOE 讨论法<|>RELATION_NOE 、<|>RELATION_NOE 专家<|>RELATION_NOE 咨询法<|>RELATION_NOE 等<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 获取<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 围手术期<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 项目<|>RELATION_NOE 的<|>RELATION_NOE :<|>RELATION_NOE 相关<|>RELATION_NOE 信息<|>RELATION_NOE 。<|>RELATION_NOE
最终<|>RELATION_NOE 确立<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 围手术期<|>RELATION_NOE 所<|>RELATION_NOE 涉及<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 项目<|>RELATION_NOE 共<|>RELATION_NOE 64<|>RELATION_NOE 项<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 术前<|>RELATION_NOE 护理<|>RELATION_NOE 13<|>RELATION_NOE 项<|>RELATION_NOE ,<|>RELATION_NOE 手术室<|>RELATION_NOE 护理<|>RELATION_NOE 16<|>RELATION_NOE 项<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 护理<|>RELATION_NOE 20<|>RELATION_NOE 项<|>RELATION_NOE ,<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 15<|>RELATION_NOE 项<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 临床<|>RELATION_NOE 调研<|>RELATION_NOE 、<|>RELATION_NOE 专家<|>RELATION_NOE 咨询<|>RELATION_NOE 等<|>RELATION_NOE 方法<|>RELATION_NOE 制定<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 项目<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 围手术期<|>RELATION_NOE 非<|>RELATION_NOE 小<|>RELATION_NOE 细胞<|>RELATION_NOE 患者<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE 地<|>RELATION_NOE 接受<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 提供<|>RELATION_NOE 了<|>RELATION_NOE 有力<|>RELATION_NOE 保障<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进一步<|>RELATION_NOE 促进<|>RELATION_NOE 了<|>RELATION_NOE 优质<|>RELATION_NOE 护理<|>RELATION_NOE 服务<|>RELATION_NOE 的<|>RELATION_NOE 开展<|>RELATION_NOE 和<|>RELATION_NOE 深化<|>RELATION_NOE 。<|>RELATION_NOE
内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE 及其<|>RELATION_NOE 获益<|>RELATION_NOE 人群<|>RELATION_NOE 筛选<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表<|>RELATION_NOE 分层<|>RELATION_NOE 随机<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 脑转移瘤<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 联合组<|>RELATION_NOE 和<|>RELATION_NOE 单放组<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 、<|>RELATION_NOE 总<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 脑水肿<|>RELATION_NOE 指数<|>RELATION_NOE 变化<|>RELATION_NOE 、<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ;<|>RELATION_NOE
内皮<|>RELATION_NOE 抑素<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 同步<|>RELATION_B 治疗<|>RELATION_I 肺癌<|>RELATION_I 脑转移瘤<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE VEGFR2<|>RELATION_NOE 蛋白<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 疗效<|>RELATION_NOE 显著<|>RELATION_NOE ,<|>RELATION_NOE 能够<|>RELATION_NOE 明显<|>RELATION_NOE 改善<|>RELATION_NOE 脑水肿<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 近期<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 并发症<|>RELATION_NOE 和<|>RELATION_NOE 毒副反应<|>RELATION_NOE .<|>RELATION_NOE
胸痛<|>RELATION_NOE 三<|>RELATION_NOE 联<|>RELATION_NOE 一站式<|>RELATION_NOE 动态<|>RELATION_NOE 容积<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 价值<|>RELATION_E 及<|>RELATION_NOE 意义<|>RELATION_NOE
全部<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 完成<|>RELATION_NOE 同侧<|>RELATION_NOE 余<|>RELATION_NOE 肺切除<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 为<|>RELATION_NOE 余<|>RELATION_NOE 肺结核<|>RELATION_NOE (<|>RELATION_NOE 31%<|>RELATION_NOE ,<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 余<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE 31%<|>RELATION_NOE ,<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 余肺<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张症<|>RELATION_NOE (<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 3/36<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 多发性<|>RELATION_NOE 肺囊肿<|>RELATION_NOE (<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 3/36<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 余肺<|>RELATION_NOE 感染<|>RELATION_NOE 、<|>RELATION_NOE 脓肿<|>RELATION_NOE 、<|>RELATION_NOE 坏死<|>RELATION_NOE 等<|>RELATION_NOE (<|>RELATION_NOE 22%<|>RELATION_NOE ,<|>RELATION_NOE 8<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
余<|>RELATION_NOE 肺切除<|>RELATION_NOE 后<|>RELATION_NOE 主要<|>RELATION_NOE 并发症<|>RELATION_NOE 有<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE 胸腔<|>RELATION_NOE 感染<|>RELATION_NOE (<|>RELATION_NOE 22%<|>RELATION_NOE ,<|>RELATION_NOE 8<|>RELATION_NOE /<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜瘘<|>RELATION_NOE (<|>RELATION_NOE 14%<|>RELATION_NOE ,<|>RELATION_NOE 5/36<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 严重<|>RELATION_NOE 心血管<|>RELATION_NOE 并发症<|>RELATION_NOE 并<|>RELATION_NOE 导致<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡<|>RELATION_NOE (<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 3/36<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 急性<|>RELATION_NOE 心肌梗死<|>RELATION_NOE 、<|>RELATION_NOE 肺动脉栓塞<|>RELATION_NOE 、<|>RELATION_NOE 恶性<|>RELATION_NOE 心律失常<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
同<|>RELATION_NOE 侧余<|>RELATION_NOE 肺切除<|>RELATION_NOE 完成<|>RELATION_NOE 不<|>RELATION_NOE 同期<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 手术<|>RELATION_NOE 适应证<|>RELATION_NOE 是<|>RELATION_NOE :<|>RELATION_NOE ①<|>RELATION_NOE 肺结核<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 复发<|>RELATION_NOE ;<|>RELATION_NOE
手术<|>RELATION_NOE 中<|>RELATION_NOE 出血<|>RELATION_NOE 较<|>RELATION_NOE 一般<|>RELATION_NOE 全<|>RELATION_NOE 肺切<|>RELATION_NOE 除<|>RELATION_NOE 多<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 主要<|>RELATION_NOE 并发症<|>RELATION_NOE 是<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 感染<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘及<|>RELATION_NOE 循环系统<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
严格<|>RELATION_NOE 手术<|>RELATION_NOE 指征<|>RELATION_NOE 、<|>RELATION_NOE 了解<|>RELATION_NOE 第一<|>RELATION_NOE 次<|>RELATION_NOE 肺手术<|>RELATION_NOE 的<|>RELATION_NOE 全<|>RELATION_NOE 过程<|>RELATION_NOE 、<|>RELATION_NOE 提高<|>RELATION_NOE 手术<|>RELATION_NOE 技巧<|>RELATION_NOE 减少<|>RELATION_NOE 手术<|>RELATION_NOE 中<|>RELATION_NOE 出血<|>RELATION_NOE 、<|>RELATION_NOE 严谨<|>RELATION_NOE 的<|>RELATION_NOE 围手术期<|>RELATION_NOE 处理<|>RELATION_NOE 是<|>RELATION_NOE 余<|>RELATION_B 肺切除术<|>RELATION_I 取得<|>RELATION_I 成功<|>RELATION_E 的<|>RELATION_NOE 关键<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE 同侧<|>RELATION_NOE 余<|>RELATION_NOE 肺切除<|>RELATION_NOE 完成<|>RELATION_NOE 不<|>RELATION_NOE 同期<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 如果<|>RELATION_NOE 手术<|>RELATION_NOE 适应<|>RELATION_NOE 证<|>RELATION_NOE 正确<|>RELATION_NOE ,<|>RELATION_NOE 围手术期<|>RELATION_NOE 处理<|>RELATION_NOE 得当<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 结果<|>RELATION_NOE 是<|>RELATION_NOE 令人满意<|>RELATION_NOE 的<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 单个<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 标志物<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE P63<|>RELATION_NOE 对于<|>RELATION_NOE 诊断<|>RELATION_B 肺鳞癌<|>RELATION_I 和<|>RELATION_I 肺腺癌<|>RELATION_E 有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 灵敏性<|>RELATION_NOE 和<|>RELATION_NOE 准确度<|>RELATION_NOE ,<|>RELATION_NOE TTF-1<|>RELATION_NOE 诊断<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 为<|>RELATION_NOE 86.3%<|>RELATION_NOE ,<|>RELATION_NOE 特<|>RELATION_NOE 异度<|>RELATION_NOE 为<|>RELATION_NOE 87.7%<|>RELATION_NOE ,<|>RELATION_NOE 准确度<|>RELATION_NOE 为<|>RELATION_NOE 86.8%<|>RELATION_NOE ;<|>RELATION_NOE
奈达铂<|>RELATION_NOE 联合<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_E 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
选择<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE 一线<|>RELATION_NOE 治疗失败<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 试验<|>RELATION_NOE 和<|>RELATION_NOE 对照<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 试验组<|>RELATION_NOE 接受<|>RELATION_NOE 奈达<|>RELATION_NOE 铂+<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 接受<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛单<|>RELATION_NOE 药<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 总<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE OS<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
试验组<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 包括<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 血小板减少<|>RELATION_NOE 及<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE ,<|>RELATION_NOE 发生率<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE 。<|>RELATION_NOE
超声<|>RELATION_NOE 造影<|>RELATION_NOE 在<|>RELATION_NOE 经<|>RELATION_B 皮肺<|>RELATION_I 穿刺活检<|>RELATION_E 肺周<|>RELATION_NOE 围型<|>RELATION_NOE 病变<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 相关性<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE 分析<|>RELATION_S
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 发生<|>RELATION_B 化疗<|>RELATION_I 相关性<|>RELATION_I 白细胞减少<|>RELATION_I (<|>RELATION_I CIL<|>RELATION_I )<|>RELATION_E 的<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 回顾<|>RELATION_NOE 性病<|>RELATION_NOE 例<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 192<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 发生<|>RELATION_NOE CIL<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE CIL<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE 无<|>RELATION_NOE CIL<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 指标<|>RELATION_NOE 进行<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE 和<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
CIL<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 体质量<|>RELATION_NOE 下降率<|>RELATION_NOE 、<|>RELATION_NOE PS<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 白细胞计数<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 血小板计数<|>RELATION_NOE 、<|>RELATION_NOE 曾<|>RELATION_NOE 接受<|>RELATION_NOE 化疗<|>RELATION_NOE 次数<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 白细胞<|>RELATION_NOE 减低<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 11.8<|>RELATION_NOE 52<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 体质量<|>RELATION_NOE 下降率<|>RELATION_NOE ≥<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 曾<|>RELATION_NOE 接受<|>RELATION_NOE 化疗<|>RELATION_NOE 次数<|>RELATION_NOE ≥<|>RELATION_NOE 3<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 2.<|>RELATION_NOE 709<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_B 化疗<|>RELATION_I 后<|>RELATION_I 发生<|>RELATION_I CIL<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
治疗<|>RELATION_NOE 前<|>RELATION_NOE 白细胞<|>RELATION_NOE 减<|>RELATION_NOE 低<|>RELATION_NOE 、<|>RELATION_NOE 体质量<|>RELATION_NOE 下降率<|>RELATION_NOE ≥<|>RELATION_NOE 5%<|>RELATION_NOE 、<|>RELATION_NOE 曾<|>RELATION_NOE 接受<|>RELATION_NOE 化疗<|>RELATION_NOE 次数<|>RELATION_NOE ≥<|>RELATION_NOE 3<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_B 化疗<|>RELATION_I 后<|>RELATION_I 发生<|>RELATION_I CIL<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE H114<|>RELATION_NOE 的<|>RELATION_NOE 建立<|>RELATION_S
伊红<|>RELATION_NOE (<|>RELATION_NOE HE<|>RELATION_NOE )<|>RELATION_NOE 染色<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE 、<|>RELATION_NOE 异体<|>RELATION_NOE 移植<|>RELATION_NOE 实验<|>RELATION_NOE 及<|>RELATION_NOE 组织<|>RELATION_NOE HE<|>RELATION_NOE 染色<|>RELATION_NOE 等<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 鉴定<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 细胞系<|>RELATION_NOE 。<|>RELATION_NOE
细胞<|>RELATION_NOE 经液<|>RELATION_NOE 氮罐<|>RELATION_NOE 或<|>RELATION_NOE -80<|>RELATION_NOE ℃<|>RELATION_NOE 低温<|>RELATION_NOE 冰箱<|>RELATION_NOE 反复<|>RELATION_NOE 冻存<|>RELATION_NOE 复苏<|>RELATION_NOE 后<|>RELATION_NOE 仍<|>RELATION_NOE 保持<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 活性<|>RELATION_NOE ,<|>RELATION_NOE 复苏<|>RELATION_NOE 细胞<|>RELATION_NOE 经<|>RELATION_NOE 0.4%<|>RELATION_NOE 胎盘<|>RELATION_NOE 蓝染色<|>RELATION_NOE ,<|>RELATION_NOE 活<|>RELATION_NOE 细胞<|>RELATION_NOE 比率<|>RELATION_NOE 均<|>RELATION_NOE 保持<|>RELATION_NOE 在<|>RELATION_NOE 85%<|>RELATION_NOE 以上<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 整个<|>RELATION_NOE 168h<|>RELATION_NOE 的<|>RELATION_NOE 观察<|>RELATION_NOE 时间<|>RELATION_NOE 里<|>RELATION_NOE ,<|>RELATION_NOE 肺腺癌<|>RELATION_NOE H114<|>RELATION_NOE 细胞<|>RELATION_NOE 始终<|>RELATION_NOE 处于<|>RELATION_NOE 持续<|>RELATION_NOE 增殖<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 可见<|>RELATION_NOE 潜伏期<|>RELATION_NOE 和<|>RELATION_NOE 指数<|>RELATION_NOE 生长期<|>RELATION_NOE ,<|>RELATION_NOE 由于<|>RELATION_NOE 本<|>RELATION_NOE 细胞系<|>RELATION_NOE 传代<|>RELATION_NOE 次数<|>RELATION_NOE 较<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 生长<|>RELATION_NOE 活跃<|>RELATION_NOE ,<|>RELATION_NOE 7d<|>RELATION_NOE 还<|>RELATION_NOE 没<|>RELATION_NOE 出现<|>RELATION_NOE 平顶期<|>RELATION_NOE 和<|>RELATION_NOE 退化<|>RELATION_NOE 衰亡期<|>RELATION_NOE ;<|>RELATION_NOE
体外<|>RELATION_NOE 培养<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 稳定<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 形态学<|>RELATION_NOE 及<|>RELATION_NOE 浸润性<|>RELATION_NOE 生长<|>RELATION_NOE 结果<|>RELATION_NOE 表明<|>RELATION_NOE 该<|>RELATION_NOE 细胞系<|>RELATION_NOE 符合<|>RELATION_NOE 恶性<|>RELATION_NOE 细胞<|>RELATION_NOE 特性<|>RELATION_NOE ,<|>RELATION_NOE 裸鼠<|>RELATION_NOE 接种<|>RELATION_NOE 成功<|>RELATION_NOE 致瘤<|>RELATION_NOE ,<|>RELATION_NOE 瘤细胞<|>RELATION_NOE 形态<|>RELATION_NOE 与<|>RELATION_NOE 原<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 切片<|>RELATION_NOE 相似<|>RELATION_NOE ,<|>RELATION_NOE 命名<|>RELATION_NOE 为<|>RELATION_NOE H114<|>RELATION_NOE 细胞系<|>RELATION_NOE 。<|>RELATION_NOE
原代<|>RELATION_NOE 培养<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 相关<|>RELATION_NOE 成纤维细胞<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 影响<|>RELATION_S 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 在<|>RELATION_NOE 体外<|>RELATION_NOE 直接<|>RELATION_NOE 接触<|>RELATION_NOE 共<|>RELATION_NOE 培养<|>RELATION_NOE 条件<|>RELATION_NOE 下<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 相关<|>RELATION_NOE 成纤维细胞<|>RELATION_NOE (<|>RELATION_NOE CAF<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 进行<|>RELATION_NOE 原代<|>RELATION_NOE 培养<|>RELATION_NOE 后<|>RELATION_NOE 获取<|>RELATION_NOE 人<|>RELATION_NOE 肺<|>RELATION_NOE CAF<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 技术<|>RELATION_NOE 鉴定.<|>RELATION_NOE
CAF<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE A549<|>RELATION_NOE 、<|>RELATION_NOE H1299<|>RELATION_NOE 进行<|>RELATION_NOE 直接<|>RELATION_NOE 接触<|>RELATION_NOE 共<|>RELATION_NOE 培养<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 细胞<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
新鲜人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 经<|>RELATION_NOE 组织<|>RELATION_NOE 块<|>RELATION_NOE 贴<|>RELATION_NOE 壁法<|>RELATION_NOE 原代<|>RELATION_NOE 培养<|>RELATION_NOE 出<|>RELATION_NOE 可<|>RELATION_NOE 稳定<|>RELATION_NOE 传代<|>RELATION_NOE 的<|>RELATION_NOE CAF<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 特异<|>RELATION_NOE 表达<|>RELATION_NOE α<|>RELATION_NOE -<|>RELATION_NOE 平滑肌<|>RELATION_NOE 肌动<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE 波行<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE 成纤维细胞<|>RELATION_NOE 活化<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 无<|>RELATION_NOE 细胞<|>RELATION_NOE 角质<|>RELATION_NOE 蛋白<|>RELATION_NOE -18<|>RELATION_NOE 表达.<|>RELATION_NOE
人<|>RELATION_NOE 肺<|>RELATION_NOE CAF<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 直接<|>RELATION_B 接触<|>RELATION_I 共<|>RELATION_I 培养<|>RELATION_E 后<|>RELATION_NOE 使<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 原因<|>RELATION_NOE 可能<|>RELATION_NOE 为<|>RELATION_NOE CAF<|>RELATION_NOE 促进<|>RELATION_NOE 了<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞增殖<|>RELATION_NOE .<|>RELATION_NOE
应用<|>RELATION_NOE 根治性<|>RELATION_NOE IMRT<|>RELATION_NOE 结合<|>RELATION_NOE 降低<|>RELATION_NOE 预防<|>RELATION_NOE 照射<|>RELATION_NOE 区<|>RELATION_NOE 剂量<|>RELATION_NOE 治疗<|>RELATION_S Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE SCLC<|>RELATION_NOE 研究<|>RELATION_NOE
电离辐射<|>RELATION_NOE 对<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE 线粒体<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
0<|>RELATION_NOE 、<|>RELATION_NOE 0.5<|>RELATION_NOE 、<|>RELATION_NOE 3<|>RELATION_NOE 和<|>RELATION_NOE 8<|>RELATION_NOE Gy60Co<|>RELATION_NOE γ射线<|>RELATION_NOE 照射<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE JC-1<|>RELATION_NOE 探针<|>RELATION_NOE 检测<|>RELATION_S 照射<|>RELATION_NOE 后<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE 线粒体<|>RELATION_NOE 膜电位<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ;<|>RELATION_NOE
使用<|>RELATION_NOE ATP<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE 检测<|>RELATION_NOE 辐射<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ATP<|>RELATION_NOE 生成<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
利用<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 线粒体<|>RELATION_NOE 拷贝数<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 24h<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 剂量组<|>RELATION_NOE A549<|>RELATION_NOE 细胞膜<|>RELATION_NOE 电位<|>RELATION_NOE 出现<|>RELATION_B 明显<|>RELATION_I 改变<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 24<|>RELATION_NOE 3.44<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 0<|>RELATION_NOE Gy<|>RELATION_NOE 照射组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 0.5<|>RELATION_NOE 和<|>RELATION_NOE 3<|>RELATION_NOE Gy<|>RELATION_NOE 照射<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 线粒体膜<|>RELATION_NOE 电位<|>RELATION_NOE 显著<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE -10.12<|>RELATION_NOE 、<|>RELATION_NOE -5.59<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 8<|>RELATION_NOE Gy<|>RELATION_NOE 照射<|>RELATION_NOE 的<|>RELATION_NOE 线粒体膜<|>RELATION_NOE 电位<|>RELATION_NOE 显著<|>RELATION_NOE 降低<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 15.22<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 照后<|>RELATION_NOE 48h<|>RELATION_NOE 各<|>RELATION_NOE 照射<|>RELATION_NOE 组<|>RELATION_NOE 线粒体膜<|>RELATION_NOE 电位<|>RELATION_NOE 基本<|>RELATION_NOE 恢复<|>RELATION_NOE 正常<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 10.36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE 在<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 24h<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 剂量组<|>RELATION_NOE A549<|>RELATION_NOE 细胞膜<|>RELATION_NOE 电位<|>RELATION_NOE 出现<|>RELATION_NOE 明显<|>RELATION_NOE 改变<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 24<|>RELATION_NOE 3.44<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 0<|>RELATION_NOE Gy<|>RELATION_NOE 照射组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 0.5<|>RELATION_NOE 和<|>RELATION_NOE 3<|>RELATION_NOE Gy<|>RELATION_NOE 照射<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 线粒体膜<|>RELATION_NOE 电位<|>RELATION_NOE 显著<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE -10.12<|>RELATION_NOE 、<|>RELATION_NOE -5.59<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 8<|>RELATION_NOE Gy<|>RELATION_NOE 照射<|>RELATION_NOE 的<|>RELATION_NOE 线粒体膜<|>RELATION_NOE 电位<|>RELATION_NOE 显著<|>RELATION_NOE 降低<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 15.22<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 照后<|>RELATION_NOE 48h<|>RELATION_NOE 各<|>RELATION_NOE 照射<|>RELATION_NOE 组<|>RELATION_NOE 线粒体<|>RELATION_NOE 膜电位<|>RELATION_NOE 基本<|>RELATION_B 恢复<|>RELATION_I 正常<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 10.36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
照射<|>RELATION_NOE 后<|>RELATION_NOE 24h<|>RELATION_NOE 线粒体<|>RELATION_NOE 拷贝数<|>RELATION_NOE 显著<|>RELATION_B 增加<|>RELATION_E ,<|>RELATION_NOE 其中<|>RELATION_NOE 0.5<|>RELATION_NOE Gy<|>RELATION_NOE mtDNA<|>RELATION_NOE 拷贝数<|>RELATION_NOE 增加<|>RELATION_NOE 至<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 12<|>RELATION_NOE 倍<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 0.02<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 3<|>RELATION_NOE 和<|>RELATION_NOE 8<|>RELATION_NOE Gy<|>RELATION_NOE 组<|>RELATION_NOE mtDNA<|>RELATION_NOE 拷贝数<|>RELATION_NOE 分别<|>RELATION_NOE 增加<|>RELATION_NOE 至<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 7<|>RELATION_NOE 和<|>RELATION_NOE 10<|>RELATION_NOE 倍<|>RELATION_NOE (<|>RELATION_NOE =<|>RELATION_NOE 9.68<|>RELATION_NOE 、<|>RELATION_NOE 15.10<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
大<|>RELATION_NOE 剂量<|>RELATION_NOE 电离辐射<|>RELATION_NOE 会<|>RELATION_NOE 导致<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 线粒体膜<|>RELATION_NOE 电位<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 影响<|>RELATION_NOE ATP<|>RELATION_NOE 的<|>RELATION_NOE 生成<|>RELATION_NOE ,<|>RELATION_NOE 中等<|>RELATION_NOE 剂量<|>RELATION_NOE 以下<|>RELATION_NOE 的<|>RELATION_NOE 照射<|>RELATION_NOE 会<|>RELATION_NOE 大<|>RELATION_NOE 剂量<|>RELATION_NOE 电离辐射<|>RELATION_NOE 会<|>RELATION_NOE 导致<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 线粒体膜<|>RELATION_NOE 电位<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 影响<|>RELATION_NOE ATP<|>RELATION_NOE 的<|>RELATION_NOE 生成<|>RELATION_NOE ,<|>RELATION_NOE 中等<|>RELATION_NOE 剂量<|>RELATION_NOE 以下<|>RELATION_NOE 的<|>RELATION_NOE 照射<|>RELATION_NOE 会<|>RELATION_NOE 导致<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 线粒体<|>RELATION_NOE 膜电位<|>RELATION_NOE 代偿性<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 从而<|>RELATION_NOE 使<|>RELATION_NOE ATP<|>RELATION_NOE 的<|>RELATION_NOE 生成<|>RELATION_NOE 增多<|>RELATION_NOE ,<|>RELATION_NOE 8<|>RELATION_NOE Gy<|>RELATION_NOE 以内<|>RELATION_NOE 的<|>RELATION_NOE 电离辐射<|>RELATION_NOE 可<|>RELATION_NOE 使<|>RELATION_NOE mtDNA<|>RELATION_NOE 拷贝数<|>RELATION_NOE 代<|>RELATION_NOE 偿性<|>RELATION_NOE 升高.<|>RELATION_NOE
基于<|>RELATION_NOE 3D-CT<|>RELATION_NOE 、<|>RELATION_NOE 4D-CT<|>RELATION_NOE 和<|>RELATION_NOE 锥形束<|>RELATION_NOE CT<|>RELATION_NOE 定义<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 内靶区<|>RELATION_NOE 比较<|>RELATION_S
全自动<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中间<|>RELATION_NOE 变性<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 激酶<|>RELATION_NOE 融合<|>RELATION_NOE 基因表达<|>RELATION_NOE 情况<|>RELATION_NOE
了解<|>RELATION_NOE 全自动<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 间变性<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE ALK<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 和<|>RELATION_NOE 特异度<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 染色<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 收集<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 2月<|>RELATION_NOE 至<|>RELATION_NOE 12月<|>RELATION_NOE 共计<|>RELATION_NOE 404<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 手术<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 选<|>RELATION_NOE 肿瘤<|>RELATION_NOE 蜡<|>RELATION_NOE 块<|>RELATION_NOE 制备<|>RELATION_NOE 成<|>RELATION_NOE 组织<|>RELATION_NOE 芯片<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 全自动<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学染<|>RELATION_NOE 色仪<|>RELATION_NOE 上<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Ventana<|>RELATION_NOE 抗<|>RELATION_NOE ALK<|>RELATION_NOE 兔<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE (<|>RELATION_NOE D5F3<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 超敏<|>RELATION_NOE 检测<|>RELATION_NOE 系统<|>RELATION_NOE 进行<|>RELATION_NOE 染色<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE ALK<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 进行<|>RELATION_NOE 荧光<|>RELATION_NOE 原位杂交<|>RELATION_NOE (<|>RELATION_NOE FISH<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 确认<|>RELATION_NOE ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 。<|>RELATION_NOE
全自动<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_B ALK<|>RELATION_I 蛋白<|>RELATION_E 可以<|>RELATION_NOE 作为<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 抗<|>RELATION_NOE ALK<|>RELATION_NOE 靶向<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 一个<|>RELATION_NOE 经济<|>RELATION_NOE 、<|>RELATION_NOE 简单<|>RELATION_NOE 实用<|>RELATION_NOE 的<|>RELATION_NOE 筛选<|>RELATION_NOE 诊断<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 尚<|>RELATION_NOE 需<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 进一步<|>RELATION_NOE 验证<|>RELATION_NOE .<|>RELATION_NOE
博来霉素<|>RELATION_NOE 胸腔<|>RELATION_NOE 灌注<|>RELATION_NOE 联合培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 全身<|>RELATION_NOE 化学<|>RELATION_NOE 治疗<|>RELATION_S 肺腺癌<|>RELATION_NOE 晚期<|>RELATION_NOE 合并<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 分析<|>RELATION_NOE
评价<|>RELATION_NOE 博来霉素<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 联合培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 全身<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 合并<|>RELATION_NOE 胸膜腔<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 合并<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 首<|>RELATION_NOE 次<|>RELATION_NOE 采用<|>RELATION_NOE 博来霉素<|>RELATION_NOE 45mg<|>RELATION_NOE 胸腔<|>RELATION_NOE 保留<|>RELATION_NOE 灌注<|>RELATION_NOE ,<|>RELATION_NOE 同期<|>RELATION_NOE 应用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 75mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 之后<|>RELATION_NOE 每<|>RELATION_NOE 3<|>RELATION_NOE 周<|>RELATION_NOE 重复<|>RELATION_NOE 培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 序贯<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 第4<|>RELATION_NOE 周期<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 毒副作用<|>RELATION_NOE 。<|>RELATION_NOE
博来霉素<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 灌注<|>RELATION_NOE 联合培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 全身<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 肺腺癌<|>RELATION_I 恶性<|>RELATION_I 胸腔积液<|>RELATION_E 疗效<|>RELATION_NOE 显著<|>RELATION_NOE ,<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE .<|>RELATION_NOE
经<|>RELATION_NOE 支气管<|>RELATION_NOE 针吸活检<|>RELATION_NOE 与<|>RELATION_NOE 经<|>RELATION_NOE 支气管<|>RELATION_NOE 活检<|>RELATION_NOE 对<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
整合素<|>RELATION_NOE 连接<|>RELATION_NOE 激酶<|>RELATION_NOE 通过<|>RELATION_NOE 核因子<|>RELATION_NOE κ<|>RELATION_NOE B<|>RELATION_NOE 途径<|>RELATION_NOE 介导<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 9上调<|>RELATION_NOE 促进<|>RELATION_B 肺癌<|>RELATION_I 细胞<|>RELATION_E 迁移<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE
通过<|>RELATION_NOE 细胞<|>RELATION_NOE 转染<|>RELATION_NOE 、<|>RELATION_NOE siRNA<|>RELATION_NOE 干扰<|>RELATION_NOE 、<|>RELATION_NOE 细胞<|>RELATION_NOE 划痕<|>RELATION_NOE 实验<|>RELATION_NOE 、<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 、<|>RELATION_NOE Western<|>RELATION_NOE Blot<|>RELATION_NOE 方法<|>RELATION_NOE 探讨<|>RELATION_NOE ILK<|>RELATION_NOE 和<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 9<|>RELATION_NOE (<|>RELATION_NOE MMP-9<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 相互<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
加入<|>RELATION_NOE MMP-9<|>RELATION_NOE 抑制剂<|>RELATION_NOE 多西环素<|>RELATION_NOE 显著<|>RELATION_B 影响<|>RELATION_E 了<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 划痕<|>RELATION_NOE 愈合<|>RELATION_NOE 能力<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 加入<|>RELATION_NOE 抗<|>RELATION_NOE -MMP-9<|>RELATION_NOE 中和抗体<|>RELATION_NOE 则<|>RELATION_NOE 严重<|>RELATION_NOE 阻碍<|>RELATION_NOE 了<|>RELATION_NOE 细胞迁移<|>RELATION_NOE 能力<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 体外<|>RELATION_NOE 基底膜<|>RELATION_NOE 侵袭<|>RELATION_NOE 实验<|>RELATION_NOE 亦<|>RELATION_NOE 得到<|>RELATION_NOE 了<|>RELATION_NOE 相同<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE 加入<|>RELATION_NOE MMP-9<|>RELATION_NOE 抑制剂<|>RELATION_NOE 多西环素<|>RELATION_NOE 显著<|>RELATION_NOE 影响<|>RELATION_NOE 了<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 划痕<|>RELATION_NOE 愈合<|>RELATION_NOE 能力<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 加入<|>RELATION_NOE 抗<|>RELATION_NOE -MMP-9<|>RELATION_NOE 中和抗体<|>RELATION_NOE 则<|>RELATION_NOE 严重<|>RELATION_B 阻碍<|>RELATION_E 了<|>RELATION_NOE 细胞迁移<|>RELATION_NOE 能力<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 体外<|>RELATION_NOE 基底膜<|>RELATION_NOE 侵袭<|>RELATION_NOE 实验<|>RELATION_NOE 亦<|>RELATION_NOE 得到<|>RELATION_NOE 了<|>RELATION_NOE 相同<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
芪胶<|>RELATION_NOE 升白<|>RELATION_NOE 胶囊<|>RELATION_NOE 治疗<|>RELATION_B 肺癌<|>RELATION_I 放疗<|>RELATION_I 期间<|>RELATION_E 白细胞<|>RELATION_NOE 抑制<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
评价<|>RELATION_NOE 芪胶<|>RELATION_NOE 升白<|>RELATION_NOE 胶囊<|>RELATION_NOE 治疗<|>RELATION_B 肺癌<|>RELATION_I 放疗<|>RELATION_I 期间<|>RELATION_E 白细胞<|>RELATION_NOE 抑制<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 10月<|>RELATION_NOE 在<|>RELATION_NOE 浙江省<|>RELATION_NOE 台州<|>RELATION_NOE 医院<|>RELATION_NOE 放射<|>RELATION_NOE 治疗科<|>RELATION_NOE 接受<|>RELATION_NOE 序贯<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 或<|>RELATION_NOE 放化<|>RELATION_NOE 同步<|>RELATION_NOE 治疗<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 是否<|>RELATION_NOE 口服<|>RELATION_NOE 芪胶<|>RELATION_NOE 升白<|>RELATION_NOE 胶囊<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE (<|>RELATION_NOE 放疗<|>RELATION_NOE 期间<|>RELATION_NOE 口服<|>RELATION_NOE 芪胶<|>RELATION_NOE 升白<|>RELATION_NOE 胶囊<|>RELATION_NOE ,<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 服用<|>RELATION_NOE 安慰剂<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对比<|>RELATION_NOE 2组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 白细胞<|>RELATION_NOE 下降率<|>RELATION_NOE 和<|>RELATION_NOE 白细胞<|>RELATION_NOE 下降<|>RELATION_NOE 最<|>RELATION_NOE 严重<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
白细胞数<|>RELATION_NOE 下降<|>RELATION_NOE 最<|>RELATION_NOE 严重<|>RELATION_NOE 时间<|>RELATION_NOE 明显<|>RELATION_B 长<|>RELATION_I 未<|>RELATION_E 对照组<|>RELATION_NOE [<|>RELATION_NOE 序贯<|>RELATION_NOE 放化<|>RELATION_NOE 疗<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 23.3<|>RELATION_NOE ±<|>RELATION_NOE 4.3<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 20.2<|>RELATION_NOE ±<|>RELATION_NOE 4.4<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 期间<|>RELATION_NOE 应用<|>RELATION_B 芪胶<|>RELATION_I 升白<|>RELATION_I 胶囊<|>RELATION_E 对<|>RELATION_NOE 白细胞<|>RELATION_NOE 抑制<|>RELATION_NOE 有<|>RELATION_NOE 确切<|>RELATION_NOE 的<|>RELATION_NOE 改善<|>RELATION_NOE 作用<|>RELATION_NOE .<|>RELATION_NOE
胸部<|>RELATION_NOE 放疗<|>RELATION_NOE 及<|>RELATION_NOE 放疗<|>RELATION_NOE 序贯<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
收集<|>RELATION_NOE 2009年<|>RELATION_NOE 7月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 10月<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病历<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 不同<|>RELATION_NOE 分为<|>RELATION_NOE 放化<|>RELATION_NOE 疗组<|>RELATION_NOE (<|>RELATION_NOE 37<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 放疗组<|>RELATION_NOE (<|>RELATION_NOE 39<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
适形<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 序贯<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_B 老年<|>RELATION_I 局部<|>RELATION_I 晚期<|>RELATION_I 肺癌<|>RELATION_E 可<|>RELATION_NOE 延长<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 总<|>RELATION_NOE 生存<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 明显<|>RELATION_NOE 改善<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 易于<|>RELATION_NOE 耐受<|>RELATION_NOE .<|>RELATION_NOE
超<|>RELATION_NOE 选择<|>RELATION_NOE 碘化油<|>RELATION_NOE 动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 栓塞<|>RELATION_NOE 治疗<|>RELATION_S 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE
探讨<|>RELATION_NOE 超<|>RELATION_NOE 选择<|>RELATION_NOE 碘化油<|>RELATION_NOE 动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 栓塞<|>RELATION_NOE 治疗<|>RELATION_S 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
搜集<|>RELATION_NOE 2002年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 12月<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 中晚期<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 确认<|>RELATION_NOE 肿瘤<|>RELATION_NOE 供<|>RELATION_NOE 血<|>RELATION_NOE 动脉<|>RELATION_NOE 后<|>RELATION_NOE 行超<|>RELATION_NOE 选择<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 栓塞<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 记录<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 改变<|>RELATION_NOE 情况<|>RELATION_NOE 及<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
本组<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 右侧<|>RELATION_NOE 支<|>RELATION_NOE -<|>RELATION_NOE 肋<|>RELATION_NOE 共<|>RELATION_NOE 干<|>RELATION_NOE 占<|>RELATION_NOE 14.0%<|>RELATION_NOE (<|>RELATION_NOE 8/57<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 供血<|>RELATION_NOE 占<|>RELATION_NOE 5.3%<|>RELATION_NOE (<|>RELATION_NOE 3/57<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 左<|>RELATION_NOE 、<|>RELATION_NOE 右<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 共<|>RELATION_NOE 干<|>RELATION_NOE 占<|>RELATION_NOE 5.3%<|>RELATION_NOE (<|>RELATION_NOE 3/57<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肋间<|>RELATION_NOE 动脉<|>RELATION_NOE 参与<|>RELATION_NOE 供<|>RELATION_NOE 血<|>RELATION_NOE 占<|>RELATION_NOE 7.0%<|>RELATION_NOE (<|>RELATION_NOE 4/57<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 胸廓<|>RELATION_NOE 内<|>RELATION_NOE 动脉<|>RELATION_NOE 参与<|>RELATION_NOE 供<|>RELATION_NOE 血<|>RELATION_NOE 占<|>RELATION_NOE 1.8%<|>RELATION_NOE (<|>RELATION_NOE 1/57<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
57<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 成功<|>RELATION_NOE 实施<|>RELATION_NOE 了<|>RELATION_NOE 碘化油<|>RELATION_NOE 动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 栓塞<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 减轻<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 消失<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 供<|>RELATION_NOE 血<|>RELATION_NOE 动脉<|>RELATION_NOE 阻断<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤发生<|>RELATION_NOE 缺血<|>RELATION_NOE 坏死<|>RELATION_NOE ,<|>RELATION_NOE 瘤体<|>RELATION_NOE 缩小<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 操作孔<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 与<|>RELATION_NOE 开胸<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 对<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_B 及<|>RELATION_I 疗效<|>RELATION_E 的<|>RELATION_NOE 对比<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 单<|>RELATION_NOE 操作孔<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 中<|>RELATION_NOE 区域<|>RELATION_B 淋巴结<|>RELATION_I 清扫<|>RELATION_E 的<|>RELATION_NOE 可行性<|>RELATION_NOE 、<|>RELATION_NOE 安全性<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
比较<|>RELATION_NOE 2组<|>RELATION_NOE 术中<|>RELATION_NOE 清扫<|>RELATION_NOE 淋巴结<|>RELATION_NOE 数<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 数<|>RELATION_NOE 、<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 带<|>RELATION_NOE 胸引<|>RELATION_NOE 管<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 等<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 操作孔<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 与<|>RELATION_NOE 常规<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_B 早期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 相比<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 可靠<|>RELATION_NOE 、<|>RELATION_NOE 创伤<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE 等<|>RELATION_NOE 优势<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 其<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 范围<|>RELATION_NOE 及<|>RELATION_NOE 效果<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 开放<|>RELATION_NOE 手术<|>RELATION_NOE 相似<|>RELATION_NOE 。<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE B<|>RELATION_NOE 细胞<|>RELATION_NOE 特异性<|>RELATION_NOE 莫洛氏<|>RELATION_NOE 鼠<|>RELATION_NOE 白血病<|>RELATION_NOE 病毒<|>RELATION_NOE 插入<|>RELATION_NOE 位点<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 指标<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
检测<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE B<|>RELATION_NOE 细胞<|>RELATION_NOE 特异性<|>RELATION_NOE 莫洛氏<|>RELATION_NOE 鼠<|>RELATION_NOE 白血病<|>RELATION_NOE 病毒<|>RELATION_NOE 插入<|>RELATION_NOE 位点<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE Bmil<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE Bmil<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
126<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 72<|>RELATION_NOE 例<|>RELATION_NOE 可<|>RELATION_NOE 观察<|>RELATION_NOE 到<|>RELATION_NOE Bmil<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 57.1%<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE Bmil<|>RELATION_NOE 表达<|>RELATION_NOE 以及<|>RELATION_NOE 转移<|>RELATION_NOE 后<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 均<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_B 生存<|>RELATION_I 时间<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 因素<|>RELATION_NOE [<|>RELATION_NOE β<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE -6.212<|>RELATION_NOE 、<|>RELATION_NOE 1.0<|>RELATION_NOE 15<|>RELATION_NOE 、<|>RELATION_NOE 0.8<|>RELATION_NOE 67<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE 置信区间<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.000<|>RELATION_NOE －0.0<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 1.7<|>RELATION_NOE 27<|>RELATION_NOE －<|>RELATION_NOE 4.405<|>RELATION_NOE 、<|>RELATION_NOE 1.6<|>RELATION_NOE 80<|>RELATION_NOE －<|>RELATION_NOE 3.3<|>RELATION_NOE 72<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.000<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
Bmil<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 化疗<|>RELATION_NOE 耐药<|>RELATION_NOE 相关<|>RELATION_S ,<|>RELATION_NOE 提示<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 。<|>RELATION_NOE Bmil<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 化疗<|>RELATION_NOE 耐药<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_S 预后<|>RELATION_NOE 不良<|>RELATION_NOE 。<|>RELATION_NOE
甘露<|>RELATION_NOE 聚糖肽<|>RELATION_NOE 联合<|>RELATION_NOE 静脉<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 甘露<|>RELATION_NOE 聚糖肽<|>RELATION_NOE 联合<|>RELATION_NOE 静脉<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_I 恶性<|>RELATION_I 胸腔积液<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 57<|>RELATION_NOE 例<|>RELATION_NOE 分成<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 给予<|>RELATION_NOE 胸腔<|>RELATION_NOE 灌注<|>RELATION_NOE 联合<|>RELATION_NOE 静脉<|>RELATION_NOE 化疗<|>RELATION_NOE (<|>RELATION_NOE DP<|>RELATION_NOE 方案<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 给予<|>RELATION_NOE 胸腔<|>RELATION_NOE 灌注<|>RELATION_NOE 甘<|>RELATION_NOE 露聚<|>RELATION_NOE 糖肽<|>RELATION_NOE ,<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE 给予<|>RELATION_NOE 胸腔<|>RELATION_NOE 灌注<|>RELATION_NOE 白细胞介素<|>RELATION_NOE -2<|>RELATION_NOE 。<|>RELATION_NOE
甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 手术<|>RELATION_NOE 方式<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S 探讨<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2009年<|>RELATION_NOE 2月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 2月<|>RELATION_NOE 西山<|>RELATION_NOE 煤电<|>RELATION_NOE 集团<|>RELATION_NOE 职工<|>RELATION_NOE 总医院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 89<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 且<|>RELATION_NOE 术后<|>RELATION_NOE 常规<|>RELATION_NOE 终身<|>RELATION_NOE 服用<|>RELATION_NOE 甲状腺素<|>RELATION_NOE 以<|>RELATION_NOE 抑制<|>RELATION_NOE 促<|>RELATION_NOE 甲状腺<|>RELATION_NOE 激素<|>RELATION_NOE (<|>RELATION_NOE TSH<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 定期<|>RELATION_NOE 复查<|>RELATION_NOE 甲状腺<|>RELATION_NOE 激素<|>RELATION_NOE 游离<|>RELATION_NOE 三<|>RELATION_NOE 碘<|>RELATION_NOE 甲状腺<|>RELATION_NOE 原<|>RELATION_NOE 氨酸<|>RELATION_NOE (<|>RELATION_NOE FT3<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 游离<|>RELATION_NOE 甲状腺<|>RELATION_NOE 激素<|>RELATION_NOE (<|>RELATION_NOE FT4<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE TSH<|>RELATION_NOE 值<|>RELATION_NOE 来<|>RELATION_NOE 调节<|>RELATION_NOE 用药量<|>RELATION_NOE ,<|>RELATION_NOE 使<|>RELATION_NOE FT3<|>RELATION_NOE 、<|>RELATION_NOE FT4<|>RELATION_NOE 稍<|>RELATION_NOE 高于<|>RELATION_NOE 正常<|>RELATION_NOE ,<|>RELATION_NOE TSH<|>RELATION_NOE 稍<|>RELATION_NOE 低于<|>RELATION_NOE 正常<|>RELATION_NOE 。<|>RELATION_NOE
双叶<|>RELATION_NOE 甲状腺<|>RELATION_NOE 次<|>RELATION_NOE 全切<|>RELATION_NOE 与<|>RELATION_NOE 双叶<|>RELATION_NOE 甲状腺<|>RELATION_NOE 全<|>RELATION_NOE 切除<|>RELATION_NOE 复发<|>RELATION_NOE 转移率<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 无颈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE TMC<|>RELATION_NOE 患者<|>RELATION_NOE 不行<|>RELATION_S 预防性<|>RELATION_NOE 颈部<|>RELATION_NOE 淋巴<|>RELATION_NOE 清扫<|>RELATION_NOE 。<|>RELATION_NOE
但<|>RELATION_NOE 对<|>RELATION_NOE 有<|>RELATION_NOE 局部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE TMC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 加行<|>RELATION_S 功能性<|>RELATION_NOE 颈部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE 。<|>RELATION_NOE
切除<|>RELATION_NOE 修复<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 酶<|>RELATION_NOE 基因<|>RELATION_NOE 、<|>RELATION_NOE 核糖<|>RELATION_NOE 核苷酸<|>RELATION_NOE 还原<|>RELATION_NOE 酶<|>RELATION_NOE M1<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 易感<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE 在<|>RELATION_NOE 进展期<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 预测<|>RELATION_I 意义<|>RELATION_E
选取<|>RELATION_NOE 有<|>RELATION_NOE 完整<|>RELATION_NOE 病理<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 资料<|>RELATION_NOE 的<|>RELATION_NOE 88<|>RELATION_NOE 例<|>RELATION_NOE 进展期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 癌肿<|>RELATION_NOE 组织<|>RELATION_NOE 分别<|>RELATION_NOE 进行<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 及<|>RELATION_NOE BRCA1<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE 效果<|>RELATION_NOE 、<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 指标<|>RELATION_NOE 间<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 评价<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
ERCC1<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 、<|>RELATION_NOE BRCA1<|>RELATION_NOE 在<|>RELATION_NOE 进展期<|>RELATION_NOE 肺癌<|>RELATION_NOE 中高<|>RELATION_NOE 表达<|>RELATION_NOE 往往<|>RELATION_NOE 提示<|>RELATION_S 对<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 耐药性<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 不<|>RELATION_NOE 佳<|>RELATION_NOE ,<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 、<|>RELATION_NOE BRCA1<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE NSCLC<|>RELATION_NOE 个体化<|>RELATION_NOE 的<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 靶标<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 制定<|>RELATION_NOE 、<|>RELATION_NOE 用药<|>RELATION_NOE 监测<|>RELATION_NOE 、<|>RELATION_NOE 敏感性<|>RELATION_NOE 评估<|>RELATION_NOE 、<|>RELATION_NOE 预后<|>RELATION_NOE 评价<|>RELATION_NOE 等<|>RELATION_NOE 均<|>RELATION_NOE 可能<|>RELATION_NOE 提供<|>RELATION_NOE 比较<|>RELATION_NOE 重要<|>RELATION_NOE 的<|>RELATION_NOE 参考<|>RELATION_NOE 价值<|>RELATION_NOE .<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 、<|>RELATION_NOE BRCA1<|>RELATION_NOE 在<|>RELATION_NOE 进展期<|>RELATION_NOE 肺癌<|>RELATION_NOE 中高<|>RELATION_NOE 表达<|>RELATION_NOE 往往<|>RELATION_NOE 提示<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 耐药性<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 不<|>RELATION_NOE 佳<|>RELATION_NOE ,<|>RELATION_NOE ERCC1<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 、<|>RELATION_NOE BRCA1<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE NSCLC<|>RELATION_NOE 个体化<|>RELATION_NOE 的<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 靶标<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 制定<|>RELATION_NOE 、<|>RELATION_NOE 用药<|>RELATION_NOE 监测<|>RELATION_NOE 、<|>RELATION_NOE 敏感性<|>RELATION_NOE 评估<|>RELATION_NOE 、<|>RELATION_NOE 预后<|>RELATION_NOE 评价<|>RELATION_NOE 等<|>RELATION_NOE 均<|>RELATION_NOE 可能<|>RELATION_B 提供<|>RELATION_I 比较<|>RELATION_I 重要<|>RELATION_I 的<|>RELATION_I 参考<|>RELATION_I 价值<|>RELATION_E .<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
将<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 30<|>RELATION_NOE 例.<|>RELATION_NOE
观察组<|>RELATION_NOE 采用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_NOE .<|>RELATION_NOE
观察组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 一<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 5.9<|>RELATION_NOE ±<|>RELATION_NOE 1.6<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 、<|>RELATION_NOE 50.0%<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 5.7<|>RELATION_NOE ±<|>RELATION_NOE 1.1<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 、<|>RELATION_NOE 53.3%<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 0.39<|>RELATION_NOE ,<|>RELATION_NOE χ<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 1.20<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
观察组<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 毒性<|>RELATION_NOE 、<|>RELATION_NOE 消化道<|>RELATION_NOE 毒性<|>RELATION_NOE 发生率<|>RELATION_NOE 、<|>RELATION_NOE 其他<|>RELATION_NOE 并发症<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 20.0%<|>RELATION_NOE 、<|>RELATION_NOE 20.0%<|>RELATION_NOE 、<|>RELATION_NOE 13.3%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE 的<|>RELATION_NOE 46.7%<|>RELATION_NOE 、<|>RELATION_NOE 66.7%<|>RELATION_NOE 、<|>RELATION_NOE 40.0%<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 4.28<|>RELATION_NOE 、<|>RELATION_NOE 5.41<|>RELATION_NOE 、<|>RELATION_NOE 5.32<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中高迁移<|>RELATION_NOE 率族<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 和<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -9<|>RELATION_NOE 与<|>RELATION_NOE 微血管<|>RELATION_NOE 生成<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中高迁移<|>RELATION_NOE 率族<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE HMGB-1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE MMP-9<|>RELATION_NOE 与<|>RELATION_NOE 微血管<|>RELATION_NOE 生成<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
选择<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 标本<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 癌组织<|>RELATION_NOE 作为<|>RELATION_NOE 观察组<|>RELATION_NOE ,<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 染色<|>RELATION_NOE 测定<|>RELATION_S 组织<|>RELATION_NOE 中<|>RELATION_NOE HMGB-1<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 、<|>RELATION_NOE MMP-9<|>RELATION_NOE 和<|>RELATION_NOE MVD<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE HMGB-1<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE MMP-9<|>RELATION_NOE 与<|>RELATION_NOE 微血管<|>RELATION_NOE 生成<|>RELATION_NOE 有<|>RELATION_NOE 密切<|>RELATION_B 关系<|>RELATION_E .<|>RELATION_NOE
核苷酸<|>RELATION_NOE 切除<|>RELATION_NOE 修复<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 核苷酸<|>RELATION_NOE 还原<|>RELATION_NOE 酶<|>RELATION_NOE M1<|>RELATION_NOE 亚基<|>RELATION_NOE 及<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 微管蛋白<|>RELATION_NOE Ⅲ<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 含<|>RELATION_NOE 铂类<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 内<|>RELATION_NOE 核苷酸<|>RELATION_NOE 切除<|>RELATION_NOE 修复<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE ERCC1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 核苷酸<|>RELATION_NOE 还原<|>RELATION_NOE 酶<|>RELATION_NOE M1<|>RELATION_NOE 亚基<|>RELATION_NOE (<|>RELATION_NOE RRM1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 微管蛋白<|>RELATION_NOE Ⅲ<|>RELATION_NOE (<|>RELATION_NOE β<|>RELATION_NOE -tubulin<|>RELATION_NOE Ⅲ<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 铂类<|>RELATION_NOE 标准化<|>RELATION_NOE 疗<|>RELATION_NOE 方案<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 96<|>RELATION_NOE 例晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应法<|>RELATION_NOE 检测<|>RELATION_S ERCC1<|>RELATION_NOE 、<|>RELATION_NOE RRM1<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE -tubulin<|>RELATION_NOE Ⅲ<|>RELATION_NOE 的<|>RELATION_NOE 表达量<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 基因表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
活化<|>RELATION_NOE 白细胞黏附<|>RELATION_NOE 分子<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 铂类<|>RELATION_NOE 化疗<|>RELATION_NOE 效果<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 研究<|>RELATION_NOE
观察<|>RELATION_NOE 活化<|>RELATION_NOE 白细胞黏附<|>RELATION_NOE 分子<|>RELATION_NOE (<|>RELATION_NOE CD166<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 、<|>RELATION_NOE 铂类<|>RELATION_NOE 化疗<|>RELATION_NOE 效果<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
64<|>RELATION_NOE 例<|>RELATION_NOE Ⅲ<|>RELATION_NOE 、<|>RELATION_NOE Ⅳ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 经<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 或<|>RELATION_NOE 肺<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 获取<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S CD166<|>RELATION_NOE 表达<|>RELATION_NOE .<|>RELATION_NOE
患者<|>RELATION_NOE 给予<|>RELATION_NOE 2－<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 以<|>RELATION_NOE 铂类<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 的<|>RELATION_NOE 联合化疗<|>RELATION_NOE 方案<|>RELATION_NOE (<|>RELATION_NOE NP<|>RELATION_NOE /<|>RELATION_NOE TC<|>RELATION_NOE /<|>RELATION_NOE GP<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE RECIST<|>RELATION_NOE 标准<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
埃克替尼<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 埃克替尼<|>RELATION_NOE 治疗<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 持续<|>RELATION_NOE 服<|>RELATION_NOE 药物<|>RELATION_NOE 24<|>RELATION_NOE 周<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 2<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 、<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存期<|>RELATION_NOE 以及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
埃克替尼<|>RELATION_NOE 治疗<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 有<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 药理作用<|>RELATION_NOE 与<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 相似<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 轻<|>RELATION_NOE .<|>RELATION_NOE
硫链丝菌肽<|>RELATION_NOE 下调<|>RELATION_NOE FOXM1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 及<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
TST<|>RELATION_NOE 增加<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 靶向<|>RELATION_NOE 药物<|>RELATION_NOE AG1478<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE IC50<|>RELATION_NOE 值<|>RELATION_NOE 由<|>RELATION_NOE (<|>RELATION_NOE 4.35<|>RELATION_NOE ±<|>RELATION_NOE 0.45<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 降<|>RELATION_NOE 至<|>RELATION_NOE (<|>RELATION_NOE 0.73<|>RELATION_NOE ±<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 11.02<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
肾移植<|>RELATION_NOE 术后<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发生率<|>RELATION_S 分析<|>RELATION_NOE
其中<|>RELATION_NOE 泌尿<|>RELATION_NOE 系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 包括<|>RELATION_NOE 移植<|>RELATION_NOE 肾<|>RELATION_NOE 肾癌<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 直肠癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 肝细胞癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 宫颈<|>RELATION_NOE 癌3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 胰腺癌<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
肾移植<|>RELATION_NOE 术后<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病率<|>RELATION_NOE 明显<|>RELATION_B 升高<|>RELATION_E ,<|>RELATION_NOE 其中<|>RELATION_NOE 泌尿<|>RELATION_NOE 系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 居多<|>RELATION_NOE ;<|>RELATION_NOE
由<|>RELATION_NOE 慢性<|>RELATION_NOE 间质性肾炎<|>RELATION_NOE 导致<|>RELATION_NOE 肾功能衰竭<|>RELATION_NOE 的<|>RELATION_NOE 肾移植<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 尿路<|>RELATION_NOE 上皮<|>RELATION_NOE 肿瘤<|>RELATION_NOE 好<|>RELATION_B 发<|>RELATION_E ;<|>RELATION_NOE
对<|>RELATION_NOE 移植<|>RELATION_NOE 后<|>RELATION_NOE 出现<|>RELATION_NOE 肿瘤<|>RELATION_NOE 类型<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 可<|>RELATION_NOE 采用<|>RELATION_S 不同<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE ;<|>RELATION_NOE
化疗<|>RELATION_NOE 联合<|>RELATION_NOE 唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 姑息<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE 联合<|>RELATION_NOE 姑息<|>RELATION_NOE 放疗<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 治疗<|>RELATION_I 效果<|>RELATION_E 。<|>RELATION_NOE
将<|>RELATION_NOE 我<|>RELATION_NOE 院<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 12月<|>RELATION_NOE 间<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 58<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE TP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 配合<|>RELATION_NOE 钙<|>RELATION_NOE 、<|>RELATION_NOE 维生素<|>RELATION_NOE D<|>RELATION_NOE +<|>RELATION_NOE 姑息性<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE 治疗<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 联合<|>RELATION_NOE 唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
研究组<|>RELATION_NOE 镇痛<|>RELATION_NOE 有效率<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE .<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 中<|>RELATION_NOE 血管<|>RELATION_NOE 损伤<|>RELATION_NOE 致<|>RELATION_NOE 出血<|>RELATION_NOE 的<|>RELATION_NOE 应对<|>RELATION_B 措施<|>RELATION_E
125<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 肺静脉<|>RELATION_NOE 损伤<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 在<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 修补<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 中<|>RELATION_NOE 转<|>RELATION_NOE 开<|>RELATION_NOE 胸后<|>RELATION_NOE 止血<|>RELATION_NOE ;<|>RELATION_NOE
肺动脉<|>RELATION_NOE 损伤<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 在<|>RELATION_NOE 镜下<|>RELATION_NOE 阻断<|>RELATION_NOE 近端<|>RELATION_NOE 后<|>RELATION_NOE 缝合<|>RELATION_NOE 止血<|>RELATION_NOE ,<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE 转<|>RELATION_NOE 开<|>RELATION_NOE 胸后<|>RELATION_NOE 止血<|>RELATION_NOE .<|>RELATION_NOE
血管<|>RELATION_NOE 损伤<|>RELATION_NOE 导致<|>RELATION_NOE 出血<|>RELATION_NOE 是<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 中<|>RELATION_NOE 较<|>RELATION_B 常见<|>RELATION_I 和<|>RELATION_I 棘手<|>RELATION_I 的<|>RELATION_I 情况<|>RELATION_E ,<|>RELATION_NOE 也<|>RELATION_NOE 是<|>RELATION_NOE 导致<|>RELATION_NOE 中转<|>RELATION_NOE 开胸<|>RELATION_NOE 的<|>RELATION_NOE 常见<|>RELATION_NOE 原因<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 根据<|>RELATION_NOE 血管<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 损伤<|>RELATION_NOE 情况<|>RELATION_NOE 和<|>RELATION_NOE 手术<|>RELATION_NOE 经验<|>RELATION_NOE 分别<|>RELATION_NOE 处理<|>RELATION_NOE .<|>RELATION_NOE 血管<|>RELATION_NOE 损伤<|>RELATION_NOE 导致<|>RELATION_NOE 出血<|>RELATION_NOE 是<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术中<|>RELATION_NOE 较<|>RELATION_NOE 常见<|>RELATION_NOE 和<|>RELATION_NOE 棘手<|>RELATION_NOE 的<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 也<|>RELATION_NOE 是<|>RELATION_NOE 导致<|>RELATION_B 中转<|>RELATION_I 开胸<|>RELATION_E 的<|>RELATION_NOE 常见<|>RELATION_NOE 原因<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 根据<|>RELATION_NOE 血管<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 损伤<|>RELATION_NOE 情况<|>RELATION_NOE 和<|>RELATION_NOE 手术<|>RELATION_NOE 经验<|>RELATION_NOE 分别<|>RELATION_NOE 处理<|>RELATION_NOE .<|>RELATION_NOE
Ⅲ<|>RELATION_NOE a-pN2<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 与<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗<|>RELATION_NOE 随机<|>RELATION_B 对照<|>RELATION_I 研究<|>RELATION_E
POCRT<|>RELATION_NOE 组<|>RELATION_NOE 1例<|>RELATION_NOE 患者<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 脓毒血症<|>RELATION_NOE ,<|>RELATION_NOE POCRT<|>RELATION_NOE 组<|>RELATION_NOE 发生<|>RELATION_NOE 3<|>RELATION_NOE ,<|>RELATION_NOE 4级<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 高于<|>RELATION_S POCT<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 8.0<|>RELATION_NOE 10<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 毒性<|>RELATION_NOE 相似<|>RELATION_NOE 且<|>RELATION_NOE 可<|>RELATION_NOE 耐受<|>RELATION_NOE 。<|>RELATION_NOE POCRT<|>RELATION_NOE 组<|>RELATION_NOE 1例<|>RELATION_NOE 患者<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 脓毒血症<|>RELATION_NOE ,<|>RELATION_NOE POCRT<|>RELATION_NOE 组<|>RELATION_NOE 发生<|>RELATION_NOE 3<|>RELATION_NOE ,<|>RELATION_NOE 4级<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 高于<|>RELATION_NOE POCT<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 8.0<|>RELATION_NOE 10<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 毒性<|>RELATION_NOE 相似<|>RELATION_B 且<|>RELATION_I 可<|>RELATION_I 耐受<|>RELATION_E 。<|>RELATION_NOE
顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 或<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_B 疗效<|>RELATION_I 和<|>RELATION_I 不良<|>RELATION_I 反应<|>RELATION_E 的<|>RELATION_NOE 观察<|>RELATION_NOE
比较<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 或<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
GP<|>RELATION_NOE 组<|>RELATION_NOE 白细胞<|>RELATION_NOE 下降<|>RELATION_NOE 、<|>RELATION_NOE 肌肉酸痛<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E DP<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE [<|>RELATION_NOE 白细胞<|>RELATION_NOE 下降<|>RELATION_NOE :<|>RELATION_NOE 63.3%<|>RELATION_NOE (<|>RELATION_NOE 38<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 81.7%<|>RELATION_NOE (<|>RELATION_NOE 49<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肌肉酸痛<|>RELATION_NOE :<|>RELATION_NOE 0<|>RELATION_NOE 比<|>RELATION_NOE 31.7%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ]<|>RELATION_NOE ;<|>RELATION_NOE
血小板减少<|>RELATION_NOE 、<|>RELATION_NOE 皮疹<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E DP<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE [<|>RELATION_NOE 血小板减少<|>RELATION_NOE :<|>RELATION_NOE 73.3%<|>RELATION_NOE (<|>RELATION_NOE 44<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 33.3%<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 皮疹<|>RELATION_NOE :<|>RELATION_NOE 36.7%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 60<|>RELATION_NOE )<|>RELATION_NOE 比0<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
间歇式<|>RELATION_NOE 充气<|>RELATION_NOE 压力<|>RELATION_NOE 治疗仪<|>RELATION_NOE 预防<|>RELATION_S 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 下肢<|>RELATION_NOE 深静脉血栓<|>RELATION_NOE 形成<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 间歇式<|>RELATION_NOE 充气<|>RELATION_NOE 压力<|>RELATION_NOE 治疗仪<|>RELATION_NOE 预防<|>RELATION_S 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 下肢<|>RELATION_NOE 深静脉血栓<|>RELATION_NOE 形成<|>RELATION_NOE (<|>RELATION_NOE DVT<|>RELATION_NOE )<|>RELATION_NOE 形成<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 给予<|>RELATION_NOE 传统<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE ;<|>RELATION_NOE
试验组<|>RELATION_NOE 给予<|>RELATION_NOE 传统<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE +<|>RELATION_NOE 间歇式<|>RELATION_NOE 充气<|>RELATION_NOE 压力<|>RELATION_NOE 治疗<|>RELATION_NOE 法.<|>RELATION_NOE
于术<|>RELATION_NOE 后<|>RELATION_NOE 第7<|>RELATION_NOE 天<|>RELATION_NOE 观察<|>RELATION_NOE DVT<|>RELATION_NOE 特征性<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 7d<|>RELATION_NOE 观察<|>RELATION_NOE DVT<|>RELATION_NOE 发生率<|>RELATION_NOE 、<|>RELATION_NOE 血流动力学<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 第4<|>RELATION_NOE 、<|>RELATION_NOE 7<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 试验组<|>RELATION_NOE 的<|>RELATION_NOE 股静脉<|>RELATION_NOE 血流速度<|>RELATION_NOE (<|>RELATION_NOE 平均<|>RELATION_NOE 流速<|>RELATION_NOE 和<|>RELATION_NOE 峰值<|>RELATION_NOE 流速<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 好<|>RELATION_I 于<|>RELATION_E 对照组<|>RELATION_NOE [<|>RELATION_NOE 术<|>RELATION_NOE 后<|>RELATION_NOE 第4<|>RELATION_NOE 天<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 15.2<|>RELATION_NOE ±<|>RELATION_NOE 2.9<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE /<|>RELATION_NOE s<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 14.3<|>RELATION_NOE ±<|>RELATION_NOE 3.1<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE /<|>RELATION_NOE s<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 20.5<|>RELATION_NOE ±<|>RELATION_NOE 4.0)<|>RELATION_NOE cm<|>RELATION_NOE /<|>RELATION_NOE s<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 19.5<|>RELATION_NOE ±<|>RELATION_NOE 4.2<|>RELATION_NOE )<|>RELATION_NOE cm<|>RELATION_NOE /<|>RELATION_NOE s<|>RELATION_NOE ;<|>RELATION_NOE
纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 引导<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺癌<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 研究<|>RELATION_E
探讨<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 引导<|>RELATION_NOE 在<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺癌<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S 。<|>RELATION_NOE
选择<|>RELATION_NOE 2009年<|>RELATION_NOE 2月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 9月<|>RELATION_NOE 行<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 美国<|>RELATION_NOE 麻醉<|>RELATION_NOE 医师<|>RELATION_NOE 协会<|>RELATION_NOE 分级<|>RELATION_NOE Ⅰ<|>RELATION_NOE －<|>RELATION_NOE Ⅱ<|>RELATION_NOE 级<|>RELATION_NOE ,<|>RELATION_NOE 心功能<|>RELATION_NOE 分级<|>RELATION_NOE Ⅰ<|>RELATION_NOE －Ⅱ级.<|>RELATION_NOE
完全<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 研究组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 采用<|>RELATION_NOE 静吸<|>RELATION_NOE 复合<|>RELATION_NOE 全身麻醉<|>RELATION_NOE 行<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术.<|>RELATION_NOE
2组<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 采用<|>RELATION_NOE 双腔<|>RELATION_NOE 支气管<|>RELATION_NOE 插<|>RELATION_NOE 管<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 应用<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 进行<|>RELATION_NOE 双腔<|>RELATION_NOE 支气管<|>RELATION_NOE 插管<|>RELATION_NOE 调整<|>RELATION_NOE 定位<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 以往<|>RELATION_NOE 临床<|>RELATION_NOE 最<|>RELATION_NOE 常用<|>RELATION_NOE 的<|>RELATION_NOE 双<|>RELATION_NOE 肺<|>RELATION_NOE 听诊<|>RELATION_NOE 法<|>RELATION_NOE 、<|>RELATION_NOE 气道<|>RELATION_NOE 压力<|>RELATION_NOE 变化法<|>RELATION_NOE 以及<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 二氧化碳<|>RELATION_NOE 分压<|>RELATION_NOE 波形法<|>RELATION_NOE 调整<|>RELATION_NOE 双腔<|>RELATION_NOE 支气管<|>RELATION_NOE 插管<|>RELATION_NOE 位置<|>RELATION_NOE .<|>RELATION_NOE
术中行<|>RELATION_NOE 单肺通气<|>RELATION_NOE ,<|>RELATION_NOE 监测<|>RELATION_NOE 项目<|>RELATION_NOE 包括<|>RELATION_NOE 有<|>RELATION_NOE 创<|>RELATION_NOE 血压<|>RELATION_NOE 、<|>RELATION_NOE 中心静脉压<|>RELATION_NOE 、<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 5导联<|>RELATION_NOE 心电图<|>RELATION_NOE 、<|>RELATION_NOE 脉搏<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 二氧化碳<|>RELATION_NOE 分压<|>RELATION_NOE 以及<|>RELATION_NOE 动脉<|>RELATION_NOE 血气分析<|>RELATION_NOE .<|>RELATION_NOE
研究<|>RELATION_NOE 组术<|>RELATION_NOE 中<|>RELATION_NOE 失<|>RELATION_NOE 血量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 引流量<|>RELATION_NOE 、<|>RELATION_NOE 尿量<|>RELATION_NOE 、<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 单肺通气<|>RELATION_NOE 时间<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 95<|>RELATION_NOE ±<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 130<|>RELATION_NOE ±<|>RELATION_NOE 66<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 566<|>RELATION_NOE ±<|>RELATION_NOE 81<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 132<|>RELATION_NOE ±<|>RELATION_NOE 47<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 95<|>RELATION_NOE ±<|>RELATION_NOE 34<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ;<|>RELATION_NOE
对照组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 220<|>RELATION_NOE ±<|>RELATION_NOE 35<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 260<|>RELATION_NOE ±<|>RELATION_NOE 67<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 580<|>RELATION_NOE ±<|>RELATION_NOE 75<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 130<|>RELATION_NOE ±<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 113<|>RELATION_NOE ±<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_NOE 组术<|>RELATION_NOE 中<|>RELATION_NOE 失<|>RELATION_NOE 血量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 引流量<|>RELATION_NOE 及<|>RELATION_NOE 单肺通气<|>RELATION_NOE 时间<|>RELATION_NOE 均<|>RELATION_B 小于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 单肺通气<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 5例<|>RELATION_NOE 出现<|>RELATION_NOE 低氧血症<|>RELATION_NOE .<|>RELATION_NOE
研究组<|>RELATION_NOE 单肺通气<|>RELATION_NOE 5min<|>RELATION_NOE 平均<|>RELATION_NOE 动脉压<|>RELATION_NOE 、<|>RELATION_NOE 动脉<|>RELATION_NOE 血氧<|>RELATION_NOE 分压<|>RELATION_NOE 、<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 二氧化碳<|>RELATION_NOE 分压<|>RELATION_NOE 、<|>RELATION_NOE 脉搏<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 78<|>RELATION_NOE ±<|>RELATION_NOE 7<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE (<|>RELATION_NOE 1mmHg<|>RELATION_NOE =<|>RELATION_NOE 0.1<|>RELATION_NOE 33<|>RELATION_NOE kPa<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 134<|>RELATION_NOE ±<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 34.7<|>RELATION_NOE ±<|>RELATION_NOE 2.4<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 97.5<|>RELATION_NOE ±<|>RELATION_NOE 1.4<|>RELATION_NOE )%<|>RELATION_NOE ;<|>RELATION_NOE
对照组<|>RELATION_NOE 单肺通气<|>RELATION_NOE 5min<|>RELATION_NOE 平均<|>RELATION_NOE 动脉压<|>RELATION_NOE 、<|>RELATION_NOE 动脉<|>RELATION_NOE 血氧<|>RELATION_NOE 分压<|>RELATION_NOE 、<|>RELATION_NOE 呼气<|>RELATION_NOE 末<|>RELATION_NOE 二氧化碳<|>RELATION_NOE 分压<|>RELATION_NOE 、<|>RELATION_NOE 脉搏<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 77<|>RELATION_NOE ±<|>RELATION_NOE 7<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 113<|>RELATION_NOE ±<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 35.7<|>RELATION_NOE ±<|>RELATION_NOE 2.2<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 93.6<|>RELATION_NOE ±<|>RELATION_NOE 3.6<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 单肺通气<|>RELATION_NOE 15min<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 76<|>RELATION_NOE ±<|>RELATION_NOE 7<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 106<|>RELATION_NOE ±<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 36.6<|>RELATION_NOE ±<|>RELATION_NOE 2.2<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 90.5<|>RELATION_NOE ±<|>RELATION_NOE 6.3<|>RELATION_NOE )<|>RELATION_NOE %.<|>RELATION_NOE
对照组<|>RELATION_NOE 单肺通气<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 15min<|>RELATION_NOE 动脉<|>RELATION_NOE 血氧<|>RELATION_NOE 分压<|>RELATION_NOE 与<|>RELATION_NOE 脉搏<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 均<|>RELATION_B 明显<|>RELATION_I 低于<|>RELATION_E 研究组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
心理<|>RELATION_NOE 护理<|>RELATION_NOE 与<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_B 质量<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_E
将<|>RELATION_NOE 130<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 65<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 常规组<|>RELATION_NOE 给予<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 护理<|>RELATION_NOE 组<|>RELATION_NOE 给予<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 及<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
不同<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 肺部<|>RELATION_NOE 磨<|>RELATION_NOE 玻璃<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_B 诊断<|>RELATION_E
探讨<|>RELATION_NOE cT<|>RELATION_B 影像学<|>RELATION_I 表现<|>RELATION_I 为<|>RELATION_I 肺部<|>RELATION_I 磨<|>RELATION_I 玻璃<|>RELATION_I 结节<|>RELATION_E 中<|>RELATION_NOE 浸润<|>RELATION_NOE 前<|>RELATION_NOE 病变<|>RELATION_NOE [<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE 腺瘤<|>RELATION_NOE 样<|>RELATION_NOE 增生<|>RELATION_NOE (<|>RELATION_NOE AAH<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 原位腺癌<|>RELATION_NOE (<|>RELATION_NOE AIS<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 、<|>RELATION_NOE 微浸润<|>RELATION_NOE 腺癌<|>RELATION_NOE (<|>RELATION_NOE MIA<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 浸润<|>RELATION_NOE 性腺癌<|>RELATION_NOE (<|>RELATION_NOE IAC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE cT<|>RELATION_NOE 表现<|>RELATION_NOE 特征<|>RELATION_NOE 。<|>RELATION_NOE
磨<|>RELATION_NOE 玻璃<|>RELATION_NOE 结节<|>RELATION_NOE 中<|>RELATION_NOE 实性<|>RELATION_NOE 成分<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 术前<|>RELATION_B CT<|>RELATION_I 诊断<|>RELATION_I 的<|>RELATION_I 价值<|>RELATION_E
通过<|>RELATION_NOE 绘制<|>RELATION_NOE ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 得<|>RELATION_NOE 浸润<|>RELATION_NOE 前组<|>RELATION_NOE 与<|>RELATION_NOE MIA<|>RELATION_NOE 间<|>RELATION_NOE 各<|>RELATION_NOE 诊断<|>RELATION_NOE 指标<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 中等<|>RELATION_NOE (<|>RELATION_NOE AUC<|>RELATION_NOE 在<|>RELATION_NOE 0.70<|>RELATION_NOE －0.90<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
MIA<|>RELATION_NOE 与<|>RELATION_NOE IAC<|>RELATION_NOE 间<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 和<|>RELATION_NOE 实性<|>RELATION_NOE 成分<|>RELATION_NOE 最<|>RELATION_NOE 长径<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 中等<|>RELATION_S (<|>RELATION_NOE AUC<|>RELATION_NOE 在<|>RELATION_NOE 0.70<|>RELATION_NOE －0.90<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 实性<|>RELATION_NOE 成分<|>RELATION_NOE 长径<|>RELATION_NOE 、<|>RELATION_NOE 大小<|>RELATION_NOE 及<|>RELATION_NOE 磨玻璃<|>RELATION_NOE 成分<|>RELATION_NOE 所<|>RELATION_NOE 占<|>RELATION_NOE 比例<|>RELATION_NOE MIA<|>RELATION_NOE 与<|>RELATION_NOE IAC<|>RELATION_NOE 间<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 和<|>RELATION_NOE 实性<|>RELATION_NOE 成分<|>RELATION_NOE 最<|>RELATION_NOE 长径<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 中等<|>RELATION_NOE (<|>RELATION_NOE AUC<|>RELATION_NOE 在<|>RELATION_NOE 0.70<|>RELATION_NOE －0.90<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 实性<|>RELATION_NOE 成分<|>RELATION_NOE 长径<|>RELATION_NOE 、<|>RELATION_NOE 大小<|>RELATION_NOE 及<|>RELATION_NOE 磨玻璃<|>RELATION_NOE 成分<|>RELATION_NOE 所<|>RELATION_NOE 占<|>RELATION_NOE 比例<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 较<|>RELATION_B 高<|>RELATION_E (<|>RELATION_NOE AUC<|>RELATION_NOE ><|>RELATION_NOE 0.90<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
将<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 所得<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 界值<|>RELATION_NOE 用于<|>RELATION_NOE 评估<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 检验<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_NOE 结果<|>RELATION_NOE 与<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE 标准<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
经<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 多<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 肺癌<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 疗效<|>RELATION_B 分析<|>RELATION_E
术后<|>RELATION_NOE 被<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 检查<|>RELATION_NOE 证实<|>RELATION_NOE 本组<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE MPLC<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ;<|>RELATION_NOE
多发病灶<|>RELATION_NOE 之间<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 不同者<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 腺癌<|>RELATION_NOE 与<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 与<|>RELATION_NOE 原位癌<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 多发病灶<|>RELATION_NOE 之间<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 相同者<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 腺癌<|>RELATION_NOE ,<|>RELATION_NOE 2例鳞癌<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
有待<|>RELATION_NOE 建立<|>RELATION_NOE 辅助<|>RELATION_NOE 术前<|>RELATION_NOE 诊断<|>RELATION_NOE MPLC<|>RELATION_NOE 的<|>RELATION_NOE 影像学<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 研发<|>RELATION_NOE 辅助<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_NOE 或<|>RELATION_NOE 鉴别<|>RELATION_NOE MPLC<|>RELATION_NOE 的<|>RELATION_NOE 分子<|>RELATION_NOE 标志.<|>RELATION_NOE
谷胱甘肽<|>RELATION_NOE S-<|>RELATION_NOE 转移酶<|>RELATION_NOE π<|>RELATION_NOE 对<|>RELATION_NOE 维吾尔族<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_B 耐药性<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_E
探讨<|>RELATION_NOE 维吾尔族<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 谷胱甘肽<|>RELATION_NOE S-<|>RELATION_NOE 转移酶<|>RELATION_NOE π<|>RELATION_NOE (<|>RELATION_NOE GST-<|>RELATION_NOE π<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 铂类<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 的<|>RELATION_NOE 标准化<|>RELATION_NOE 疗<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_B 耐药性<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_E 。<|>RELATION_NOE
收集<|>RELATION_NOE 2009年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 6月<|>RELATION_NOE 新疆<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 就诊<|>RELATION_NOE 的<|>RELATION_NOE 维吾尔族<|>RELATION_NOE Ⅲ<|>RELATION_NOE 、<|>RELATION_NOE Ⅳ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 94<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 检测<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE GST-<|>RELATION_NOE π<|>RELATION_NOE 的<|>RELATION_NOE 表达.<|>RELATION_NOE
患者<|>RELATION_NOE 给予<|>RELATION_NOE 2－<|>RELATION_NOE 4<|>RELATION_NOE 周期<|>RELATION_NOE 铂类<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 的<|>RELATION_NOE 标准<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 反应率<|>RELATION_NOE (<|>RELATION_NOE RR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 总<|>RELATION_NOE 生存期<|>RELATION_NOE (<|>RELATION_NOE OS<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE 进行<|>RELATION_NOE 评价<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组化<|>RELATION_NOE 显示<|>RELATION_NOE 维吾尔族<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE GST-<|>RELATION_NOE π<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 为<|>RELATION_NOE 57.4%<|>RELATION_NOE (<|>RELATION_NOE 54<|>RELATION_NOE /<|>RELATION_NOE 94<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
STAT3<|>RELATION_NOE 反义寡核苷酸<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_B 辐射<|>RELATION_I 增敏<|>RELATION_E 的<|>RELATION_NOE 研究<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 建立<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体内<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 动物模型<|>RELATION_NOE ,<|>RELATION_NOE 待<|>RELATION_NOE 瘤体<|>RELATION_NOE 直径<|>RELATION_NOE ><|>RELATION_NOE 0.5cm<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 瘤内<|>RELATION_NOE 多<|>RELATION_NOE 点<|>RELATION_NOE 注射<|>RELATION_NOE STAT3<|>RELATION_NOE ASODN<|>RELATION_NOE ,<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 剂量<|>RELATION_NOE :<|>RELATION_NOE 15mg<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE ,<|>RELATION_NOE 1次/<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 2<|>RELATION_NOE 周<|>RELATION_NOE ,<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 2h<|>RELATION_NOE 联合<|>RELATION_NOE γ射线<|>RELATION_NOE 局部<|>RELATION_NOE 照射<|>RELATION_NOE 总<|>RELATION_NOE 剂量<|>RELATION_NOE 20<|>RELATION_NOE Gy<|>RELATION_NOE ,<|>RELATION_NOE 每次<|>RELATION_NOE 2<|>RELATION_NOE Gy<|>RELATION_NOE ,<|>RELATION_NOE 每周<|>RELATION_NOE 5<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 2<|>RELATION_NOE 周<|>RELATION_NOE ,<|>RELATION_NOE 照射剂<|>RELATION_NOE 量率<|>RELATION_NOE 0.75<|>RELATION_NOE Gy<|>RELATION_NOE /<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 定期<|>RELATION_NOE 测量<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE ,<|>RELATION_NOE 绘制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE ;<|>RELATION_NOE
免疫<|>RELATION_NOE 组化<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 组织细胞<|>RELATION_NOE 内<|>RELATION_NOE STAT3<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE 情况<|>RELATION_NOE ;<|>RELATION_NOE
VEGF<|>RELATION_NOE 、<|>RELATION_NOE VEGFR-1<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
研究<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE VEGFR-1<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 情况<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE VEGFR-1<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 发生<|>RELATION_NOE 与<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE 及<|>RELATION_NOE 两者<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE 研究<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE VEGFR-1<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE VEGFR-1<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 发生<|>RELATION_NOE 与<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_B 及<|>RELATION_I 两者<|>RELATION_I 之间<|>RELATION_I 的<|>RELATION_I 关系<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S 40<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 部分<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 5例<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE VEGFR-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
VEGF<|>RELATION_NOE 和<|>RELATION_NOE VEGFR-1<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴转移<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_B 显著<|>RELATION_I 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
病理<|>RELATION_NOE 类型<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_B 独立<|>RELATION_I 危险因素<|>RELATION_E 影响<|>RELATION_NOE NSCLC<|>RELATION_NOE 术后<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE VEGF<|>RELATION_NOE 、<|>RELATION_NOE VEGFR-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 等<|>RELATION_NOE 其他<|>RELATION_NOE 特征<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 影响<|>RELATION_NOE NSCLC<|>RELATION_NOE 术后<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE VEGF<|>RELATION_NOE 、<|>RELATION_NOE VEGFR-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 等<|>RELATION_NOE 其他<|>RELATION_NOE 特征<|>RELATION_NOE 作为<|>RELATION_B 独立<|>RELATION_I 危险因素<|>RELATION_E 影响<|>RELATION_NOE NSCLC<|>RELATION_NOE 术后<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 尚<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 差异<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
VEGF<|>RELATION_NOE 和<|>RELATION_NOE VEGFR-1<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织生物学<|>RELATION_NOE 性质<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关<|>RELATION_E 。<|>RELATION_NOE
吲哚菁<|>RELATION_NOE 绿<|>RELATION_NOE 近<|>RELATION_NOE 红外<|>RELATION_NOE 光成<|>RELATION_NOE 像<|>RELATION_NOE 系统<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌术<|>RELATION_NOE 中<|>RELATION_NOE 探寻<|>RELATION_B 前哨<|>RELATION_I 淋巴结<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 研究<|>RELATION_NOE
研究<|>RELATION_NOE 应用<|>RELATION_NOE 吲哚菁<|>RELATION_NOE 绿<|>RELATION_NOE (<|>RELATION_NOE ICG<|>RELATION_NOE )<|>RELATION_NOE 近<|>RELATION_NOE 红外<|>RELATION_NOE 光成<|>RELATION_NOE 像<|>RELATION_NOE 系统术<|>RELATION_NOE 中<|>RELATION_NOE 探寻<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_I (<|>RELATION_I NSCLC<|>RELATION_I )<|>RELATION_I 前哨<|>RELATION_I 淋巴结<|>RELATION_I (<|>RELATION_I SLN<|>RELATION_I )<|>RELATION_E 的<|>RELATION_NOE 可行性<|>RELATION_NOE 及其<|>RELATION_NOE 判断<|>RELATION_NOE 区域<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE
7例<|>RELATION_NOE c<|>RELATION_NOE Ⅰ<|>RELATION_NOE a<|>RELATION_NOE －<|>RELATION_NOE c<|>RELATION_NOE Ⅱ<|>RELATION_NOE a<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中癌<|>RELATION_NOE 周围<|>RELATION_NOE 注射<|>RELATION_NOE ICG<|>RELATION_NOE 15min<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE SLN<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 近<|>RELATION_NOE 红外<|>RELATION_NOE 光成<|>RELATION_NOE 像<|>RELATION_NOE 系统<|>RELATION_NOE 作用<|>RELATION_NOE 下<|>RELATION_NOE 发光<|>RELATION_NOE 淋巴结<|>RELATION_NOE 定义<|>RELATION_NOE 为<|>RELATION_NOE SLN<|>RELATION_NOE ,<|>RELATION_NOE 并行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 及<|>RELATION_NOE 标准<|>RELATION_NOE 的<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 淋巴结<|>RELATION_NOE 送<|>RELATION_NOE 病理学<|>RELATION_NOE 检查<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 吲哚菁<|>RELATION_NOE 绿<|>RELATION_NOE 近<|>RELATION_NOE 红外<|>RELATION_NOE 光成<|>RELATION_NOE 像<|>RELATION_NOE 系统术<|>RELATION_NOE 中<|>RELATION_NOE 探寻<|>RELATION_B 早期<|>RELATION_I NSCLC<|>RELATION_I 前哨<|>RELATION_I 淋巴结<|>RELATION_E 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 可行<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 判断<|>RELATION_NOE 区域<|>RELATION_NOE 淋巴结<|>RELATION_NOE 状态<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 危险因素<|>RELATION_E 吗<|>RELATION_NOE
背景<|>RELATION_NOE 和<|>RELATION_NOE 目的<|>RELATION_NOE :<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE (<|>RELATION_NOE 简称<|>RELATION_NOE 慢阻肺<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 吸烟<|>RELATION_NOE 相关性<|>RELATION_NOE 疾病<|>RELATION_NOE ,<|>RELATION_NOE 有人<|>RELATION_NOE 认为<|>RELATION_NOE 慢阻肺<|>RELATION_NOE 本身<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 独立<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 也<|>RELATION_NOE 有人<|>RELATION_NOE 认为<|>RELATION_NOE 二者<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 源于<|>RELATION_NOE 共同<|>RELATION_NOE 的<|>RELATION_NOE 烟草<|>RELATION_NOE 暴露<|>RELATION_NOE 。<|>RELATION_NOE
紫杉<|>RELATION_NOE 醇化<|>RELATION_NOE 疗<|>RELATION_NOE 联合<|>RELATION_NOE ezrin-siRNA<|>RELATION_NOE 治疗<|>RELATION_S 转移性<|>RELATION_NOE 肝癌<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 治疗<|>RELATION_NOE 肝癌<|>RELATION_NOE 复发<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 新<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 采用<|>RELATION_NOE 体外<|>RELATION_NOE 和<|>RELATION_NOE 体内<|>RELATION_NOE 实验<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 以<|>RELATION_NOE 人<|>RELATION_NOE 高<|>RELATION_NOE 转移<|>RELATION_NOE 性肝<|>RELATION_NOE 癌细胞<|>RELATION_NOE MHCC97-H<|>RELATION_NOE 和<|>RELATION_NOE 经裸鼠尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 形成<|>RELATION_NOE 的<|>RELATION_NOE 肝癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 模型<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE .<|>RELATION_NOE
采用<|>RELATION_NOE 流式<|>RELATION_NOE 细胞<|>RELATION_NOE 仅<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 、<|>RELATION_NOE 划痕<|>RELATION_NOE 愈合<|>RELATION_NOE 实验<|>RELATION_NOE 采用<|>RELATION_NOE 流式<|>RELATION_NOE 细胞<|>RELATION_NOE 仅<|>RELATION_NOE 检测<|>RELATION_NOE 各<|>RELATION_NOE 组<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 、<|>RELATION_NOE 划痕<|>RELATION_NOE 愈合<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 愈合<|>RELATION_NOE 能力<|>RELATION_NOE 、<|>RELATION_NOE Transwell<|>RELATION_NOE 实验<|>RELATION_NOE 采用<|>RELATION_NOE 流式<|>RELATION_NOE 细胞<|>RELATION_NOE 仅<|>RELATION_NOE 检测<|>RELATION_NOE 各<|>RELATION_NOE 组<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 、<|>RELATION_NOE 划<|>RELATION_NOE 痕<|>RELATION_NOE 愈合<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 愈合<|>RELATION_NOE 能力<|>RELATION_NOE 、<|>RELATION_NOE Transwell<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 运动<|>RELATION_NOE 能力<|>RELATION_NOE 以及<|>RELATION_NOE 各组<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞<|>RELATION_NOE 形成<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 的<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
正常<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞<|>RELATION_NOE 自然<|>RELATION_NOE 凋亡率<|>RELATION_NOE 为<|>RELATION_NOE 2.5<|>RELATION_NOE 2%<|>RELATION_NOE ,<|>RELATION_NOE 划痕<|>RELATION_NOE 愈合<|>RELATION_NOE 能力<|>RELATION_NOE 强<|>RELATION_NOE ,<|>RELATION_NOE 穿过<|>RELATION_NOE 人工<|>RELATION_NOE 基底膜<|>RELATION_NOE 的<|>RELATION_NOE 细胞数<|>RELATION_NOE 为<|>RELATION_NOE 52.5<|>RELATION_NOE ±<|>RELATION_NOE 3.9<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 裸鼠尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE 后<|>RELATION_NOE 形成<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 的<|>RELATION_NOE 数目<|>RELATION_NOE 为<|>RELATION_NOE 12.5<|>RELATION_NOE ±<|>RELATION_NOE 2.4.<|>RELATION_NOE 单纯<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 作用<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 为<|>RELATION_NOE 11.6<|>RELATION_NOE 6%<|>RELATION_NOE ,<|>RELATION_NOE 划痕<|>RELATION_NOE 愈合<|>RELATION_NOE 能力<|>RELATION_NOE 稍<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 跨膜<|>RELATION_NOE 细胞数<|>RELATION_NOE 为<|>RELATION_NOE 32.2<|>RELATION_NOE ±<|>RELATION_NOE 3.2<|>RELATION_NOE ,<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 数目<|>RELATION_NOE 为<|>RELATION_NOE 8.2<|>RELATION_NOE ±<|>RELATION_NOE 1.5.<|>RELATION_NOE 单纯<|>RELATION_NOE ezrin-siRNA<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE 凋亡率<|>RELATION_NOE 为<|>RELATION_NOE 2.3<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 划痕<|>RELATION_NOE 愈合<|>RELATION_NOE 能力<|>RELATION_NOE 更<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 跨膜<|>RELATION_NOE 细胞数<|>RELATION_NOE 为<|>RELATION_NOE 26.6<|>RELATION_NOE ±<|>RELATION_NOE 2.4<|>RELATION_NOE ,<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 数目<|>RELATION_NOE 为<|>RELATION_NOE 7.0<|>RELATION_NOE ±<|>RELATION_NOE 1.<|>RELATION_NOE 3.<|>RELATION_NOE 联合<|>RELATION_NOE 治疗<|>RELATION_NOE 组<|>RELATION_NOE 凋亡率<|>RELATION_NOE 为<|>RELATION_NOE 7.3<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 划痕<|>RELATION_NOE 愈合<|>RELATION_NOE 能力<|>RELATION_NOE 最<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 跨膜<|>RELATION_NOE 细胞数<|>RELATION_NOE 为<|>RELATION_NOE 19.4<|>RELATION_NOE ±<|>RELATION_NOE 1.1<|>RELATION_NOE ,<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 数目<|>RELATION_NOE 为<|>RELATION_NOE 3.8<|>RELATION_NOE ±<|>RELATION_NOE 0.3<|>RELATION_NOE 。<|>RELATION_NOE
紫杉<|>RELATION_NOE 醇化<|>RELATION_NOE 疗<|>RELATION_NOE 联合<|>RELATION_NOE ezrin-siRNA<|>RELATION_NOE 治疗<|>RELATION_NOE 在<|>RELATION_B 体内<|>RELATION_I 及<|>RELATION_I 体外<|>RELATION_I 均<|>RELATION_I 表现<|>RELATION_E 出<|>RELATION_NOE 对<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 、<|>RELATION_NOE 运动<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE 有<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 优于<|>RELATION_NOE 单独<|>RELATION_NOE 化疗<|>RELATION_NOE 和<|>RELATION_NOE 单独<|>RELATION_NOE 基因治疗<|>RELATION_NOE .<|>RELATION_NOE 紫杉<|>RELATION_NOE 醇化<|>RELATION_NOE 疗<|>RELATION_NOE 联合<|>RELATION_NOE ezrin-siRNA<|>RELATION_NOE 治疗<|>RELATION_NOE 在<|>RELATION_NOE 体内<|>RELATION_NOE 及<|>RELATION_NOE 体外<|>RELATION_NOE 均<|>RELATION_NOE 表现<|>RELATION_NOE 出<|>RELATION_NOE 对<|>RELATION_NOE 肝癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 、<|>RELATION_NOE 运动<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE 有<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 优于<|>RELATION_S 单独<|>RELATION_NOE 化疗<|>RELATION_NOE 和<|>RELATION_NOE 单独<|>RELATION_NOE 基因治疗<|>RELATION_NOE .<|>RELATION_NOE
窖<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 185<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 中窖<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE TTF<|>RELATION_NOE .<|>RELATION_NOE
窖<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 男性<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.006<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径><|>RELATION_NOE 3.5cnl<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 48<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 实体<|>RELATION_NOE 为<|>RELATION_NOE 主型<|>RELATION_NOE 腺癌<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 25<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 高<|>RELATION_NOE 危险度<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 脉管<|>RELATION_NOE 侵犯<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 复发<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.021<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 高<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 窖<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 与<|>RELATION_NOE TTF-1<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 组织学<|>RELATION_NOE 亚型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 危险度<|>RELATION_NOE 分级<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.009<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 脉管<|>RELATION_NOE 侵犯<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 18<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 复发<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 生存期<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_B 因素<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE COX<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE 窖<|>RELATION_NOE 蛋白.<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE 生存<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 窖<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 与<|>RELATION_NOE TTF-1<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 组织学<|>RELATION_NOE 亚型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 危险度<|>RELATION_NOE 分级<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.009<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 脉管<|>RELATION_NOE 侵犯<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 18<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 复发<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 是<|>RELATION_NOE 患者术<|>RELATION_NOE 后<|>RELATION_NOE 生存期<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE COX<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_S 窖<|>RELATION_NOE 蛋白<|>RELATION_NOE .<|>RELATION_NOE
窖<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 亚型<|>RELATION_NOE 及<|>RELATION_NOE 侵袭<|>RELATION_NOE 转移<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 判断<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 起源<|>RELATION_NOE 和<|>RELATION_NOE 评估<|>RELATION_NOE 预后<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 窖<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 阳性<|>RELATION_NOE 提示<|>RELATION_S 预后<|>RELATION_NOE 不良<|>RELATION_NOE 。<|>RELATION_NOE
转移<|>RELATION_NOE 至<|>RELATION_NOE 乳腺<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_B 病理学<|>RELATION_I 观察<|>RELATION_E
探讨<|>RELATION_NOE 转移<|>RELATION_NOE 至<|>RELATION_NOE 乳腺<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 2004<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12<|>RELATION_NOE 年<|>RELATION_NOE 间<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 转移<|>RELATION_NOE 至<|>RELATION_NOE 乳腺<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 完善<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 临床<|>RELATION_NOE 病理学<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE 进行<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 检测<|>RELATION_NOE 。<|>RELATION_NOE
原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 至<|>RELATION_NOE 出现<|>RELATION_NOE 乳腺<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 间隔<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 228<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 32<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 。<|>RELATION_NOE
28<|>RELATION_NOE 例<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 8例<|>RELATION_NOE (<|>RELATION_NOE 28.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 卵巢<|>RELATION_NOE 高级别<|>RELATION_NOE 浆<|>RELATION_NOE 液性<|>RELATION_NOE 腺癌<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 17.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 胃腺癌<|>RELATION_NOE 3例<|>RELATION_NOE (<|>RELATION_NOE 10.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 直肠腺癌<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 7.1%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 胰腺<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 和<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 各<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 3.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 恶性<|>RELATION_NOE 黑色素瘤<|>RELATION_NOE 和<|>RELATION_NOE 间<|>RELATION_NOE 叶源性<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 各<|>RELATION_NOE 4例<|>RELATION_NOE (<|>RELATION_NOE 14.3%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 间<|>RELATION_NOE 叶源性<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 中<|>RELATION_NOE 胚胎性<|>RELATION_NOE 横纹肌肉瘤<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 上皮样<|>RELATION_NOE 恶性<|>RELATION_NOE 周围神经鞘<|>RELATION_NOE 膜瘤<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 表型<|>RELATION_NOE 与<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 一致<|>RELATION_S ,<|>RELATION_NOE 而<|>RELATION_NOE 乳腺<|>RELATION_NOE 来源<|>RELATION_NOE 标志物<|>RELATION_NOE 囊泡<|>RELATION_NOE 病<|>RELATION_NOE 液体<|>RELATION_NOE 蛋白<|>RELATION_NOE 15<|>RELATION_NOE 和<|>RELATION_NOE 乳腺<|>RELATION_NOE 珠蛋白<|>RELATION_NOE 均<|>RELATION_NOE 阴性<|>RELATION_NOE 。<|>RELATION_NOE 免疫<|>RELATION_NOE 表型<|>RELATION_NOE 与<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 一致<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 乳腺<|>RELATION_NOE 来源<|>RELATION_NOE 标志物<|>RELATION_NOE 囊泡<|>RELATION_NOE 病<|>RELATION_NOE 液体<|>RELATION_NOE 蛋白<|>RELATION_NOE 15<|>RELATION_NOE 和<|>RELATION_NOE 乳腺<|>RELATION_NOE 珠蛋白<|>RELATION_NOE 均<|>RELATION_B 阴性<|>RELATION_E 。<|>RELATION_NOE
1<|>RELATION_NOE 均<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 卵巢<|>RELATION_NOE 高级别<|>RELATION_NOE 浆<|>RELATION_NOE 液性<|>RELATION_NOE 腺癌<|>RELATION_NOE PAX8<|>RELATION_NOE (<|>RELATION_NOE 5/5<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE WT1<|>RELATION_NOE (<|>RELATION_NOE 4/5<|>RELATION_NOE )<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE CDX2<|>RELATION_NOE (<|>RELATION_NOE 3/3<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 绒毛<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE 1/3<|>RELATION_NOE )<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 直肠癌<|>RELATION_NOE CDX2<|>RELATION_NOE 均<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 胰腺<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 突触素<|>RELATION_NOE 和<|>RELATION_NOE 嗜<|>RELATION_NOE 铬粒素<|>RELATION_NOE A<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 雄激素受体<|>RELATION_NOE 、<|>RELATION_NOE 前列腺<|>RELATION_NOE 特<|>RELATION_NOE 异抗原<|>RELATION_NOE 、<|>RELATION_NOE P504S<|>RELATION_NOE 均<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 恶性<|>RELATION_NOE 黑色素瘤<|>RELATION_NOE HMtM5<|>RELATION_NOE (<|>RELATION_NOE 2/3<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE S-100<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE 3/3<|>RELATION_NOE )<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 横纹肌肉瘤<|>RELATION_NOE 波形蛋白<|>RELATION_NOE 、<|>RELATION_NOE 结蛋白<|>RELATION_NOE 、<|>RELATION_NOE myoDl<|>RELATION_NOE 均<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 上皮<|>RELATION_NOE 样<|>RELATION_NOE 恶性<|>RELATION_NOE 周围神经鞘<|>RELATION_NOE 膜瘤<|>RELATION_NOE S-100<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 。<|>RELATION_NOE
转移<|>RELATION_NOE 至<|>RELATION_NOE 乳腺<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 罕见<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 表现<|>RELATION_S 原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 形态学<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 有时<|>RELATION_NOE 易<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 原发<|>RELATION_NOE 乳腺癌<|>RELATION_NOE ,<|>RELATION_NOE 需<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 病史<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 形态学<|>RELATION_NOE 特点<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 表型<|>RELATION_NOE 等<|>RELATION_NOE 进行<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 。<|>RELATION_NOE 转移<|>RELATION_NOE 至<|>RELATION_NOE 乳腺<|>RELATION_NOE 的<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 罕见<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 表现<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 形态学<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 有时<|>RELATION_NOE 易<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 原发<|>RELATION_NOE 乳腺癌<|>RELATION_NOE ,<|>RELATION_NOE 需<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 病史<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 形态学<|>RELATION_NOE 特点<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 表型<|>RELATION_NOE 等<|>RELATION_NOE 进行<|>RELATION_NOE 诊断<|>RELATION_B 和<|>RELATION_I 鉴别诊断<|>RELATION_E 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 脑转移瘤<|>RELATION_NOE CT<|>RELATION_B 表现<|>RELATION_E
肺癌<|>RELATION_NOE 脑转移瘤<|>RELATION_NOE 发病率<|>RELATION_S 在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 中<|>RELATION_NOE 较<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 在<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 中<|>RELATION_NOE 转移<|>RELATION_NOE 脑部<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE 见<|>RELATION_NOE ,<|>RELATION_NOE 其次<|>RELATION_NOE 则<|>RELATION_NOE 是<|>RELATION_NOE 腺癌<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 治疗<|>RELATION_B 肺腺癌<|>RELATION_I 所<|>RELATION_I 致<|>RELATION_I 恶性<|>RELATION_I 胸腔积液<|>RELATION_E 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
38<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 并<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 使用<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛单<|>RELATION_NOE 药<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE WHO<|>RELATION_NOE 恶性<|>RELATION_NOE 胸水<|>RELATION_NOE 疗效<|>RELATION_NOE 评定<|>RELATION_NOE 标准<|>RELATION_NOE 观察<|>RELATION_NOE 两<|>RELATION_NOE 药<|>RELATION_NOE 化疗<|>RELATION_NOE 有效率<|>RELATION_NOE ,<|>RELATION_NOE WHO<|>RELATION_NOE 抗癌<|>RELATION_NOE 药物<|>RELATION_NOE 毒<|>RELATION_NOE 副<|>RELATION_NOE 反应<|>RELATION_NOE 标准<|>RELATION_NOE 评定<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 毒副不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞组<|>RELATION_NOE 化疗<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 骨髓移植<|>RELATION_NOE 、<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 、<|>RELATION_NOE 皮疹<|>RELATION_NOE 等<|>RELATION_NOE 化疗<|>RELATION_NOE 副作用<|>RELATION_NOE 较<|>RELATION_B 轻<|>RELATION_I 、<|>RELATION_I 较<|>RELATION_I 少<|>RELATION_E (<|>RELATION_NOE U<|>RELATION_NOE =<|>RELATION_NOE 94.5<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 11<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_B 肺癌<|>RELATION_E 对<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE CK19mRNA<|>RELATION_NOE 和<|>RELATION_NOE LunxmRNA<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_B 肺癌<|>RELATION_E 对<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE CK19mRNA<|>RELATION_NOE 和<|>RELATION_NOE LunxmRNA<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
90<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 45<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 45<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 采用<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 测定<|>RELATION_S 患者<|>RELATION_NOE 手术<|>RELATION_NOE 前后<|>RELATION_NOE 血<|>RELATION_NOE CK19mRNA<|>RELATION_NOE 和<|>RELATION_NOE LunxmRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 围术期<|>RELATION_NOE 护理<|>RELATION_B 方法<|>RELATION_I 及<|>RELATION_I 效果<|>RELATION_I 分析<|>RELATION_E
方法<|>RELATION_NOE :<|>RELATION_NOE 选取<|>RELATION_NOE 我院<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 12月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 按照<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 采用<|>RELATION_NOE 舒适<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 的<|>RELATION_NOE 遵医<|>RELATION_NOE 行为<|>RELATION_NOE 显著<|>RELATION_B 好<|>RELATION_I 于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 评分<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE 观察组<|>RELATION_NOE 的<|>RELATION_NOE 遵医<|>RELATION_NOE 行为<|>RELATION_NOE 显著<|>RELATION_NOE 好<|>RELATION_NOE 于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 评分<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 观察组<|>RELATION_NOE 的<|>RELATION_NOE 遵医<|>RELATION_NOE 行为<|>RELATION_NOE 显著<|>RELATION_NOE 好<|>RELATION_NOE 于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 评分<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
呼吸<|>RELATION_NOE 训练<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_B 适应<|>RELATION_I 情况<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_E
探讨<|>RELATION_NOE 呼吸<|>RELATION_NOE 训练<|>RELATION_NOE 护理<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 效果<|>RELATION_E 。<|>RELATION_NOE
将<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 各<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 采用<|>RELATION_NOE 综合<|>RELATION_NOE 呼吸<|>RELATION_NOE 训练<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 术后<|>RELATION_NOE 呼吸功能<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 以及<|>RELATION_NOE 恢复<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 术后<|>RELATION_NOE 2周<|>RELATION_NOE 的<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 肺活量<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE 观察组<|>RELATION_NOE 术后<|>RELATION_NOE 2周<|>RELATION_NOE 的<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 肺活量<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
观察组<|>RELATION_NOE 术后<|>RELATION_NOE 的<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 开始<|>RELATION_NOE 步行<|>RELATION_NOE 显著<|>RELATION_B 少于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_S 与<|>RELATION_NOE 病理<|>RELATION_NOE 对照<|>RELATION_NOE 分析<|>RELATION_NOE
2例<|>RELATION_NOE 可见<|>RELATION_NOE 突入<|>RELATION_NOE 支气管<|>RELATION_NOE 内<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 气体<|>RELATION_NOE 新月<|>RELATION_NOE 征3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 表现<|>RELATION_NOE 磨<|>RELATION_NOE 玻璃<|>RELATION_NOE 密度<|>RELATION_NOE 结节<|>RELATION_NOE 。<|>RELATION_NOE
大部分<|>RELATION_NOE 肺内<|>RELATION_NOE 硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 具有<|>RELATION_NOE 特征性<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_S 术前<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_NOE 仍<|>RELATION_NOE 依靠<|>RELATION_NOE 手术<|>RELATION_NOE 病理<|>RELATION_NOE 。<|>RELATION_NOE 大部分<|>RELATION_NOE 肺内<|>RELATION_NOE 硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 具有<|>RELATION_NOE 特征性<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_NOE 术前<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_NOE 仍<|>RELATION_NOE 依靠<|>RELATION_S 手术<|>RELATION_NOE 病理<|>RELATION_NOE 。<|>RELATION_NOE
吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨单<|>RELATION_NOE 药<|>RELATION_NOE 与<|>RELATION_NOE 联合<|>RELATION_NOE 奥沙利铂<|>RELATION_NOE 治疗<|>RELATION_NOE 初<|>RELATION_B 治<|>RELATION_E 老年人<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE
奥沙利<|>RELATION_NOE 铂化<|>RELATION_NOE 疗<|>RELATION_NOE 剂量<|>RELATION_NOE 按<|>RELATION_NOE 曲线下面积<|>RELATION_NOE =<|>RELATION_NOE 5<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 水平<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE ,<|>RELATION_NOE 第2<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 症状<|>RELATION_NOE 量表<|>RELATION_NOE 观察者<|>RELATION_NOE 表评分<|>RELATION_NOE 显示<|>RELATION_NOE 单药组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 食欲<|>RELATION_NOE 缺乏<|>RELATION_NOE 、<|>RELATION_NOE 乏力<|>RELATION_NOE 及<|>RELATION_NOE 疼痛<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_B 较<|>RELATION_I 治疗<|>RELATION_I 前<|>RELATION_I 明显<|>RELATION_I 改善<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.6<|>RELATION_NOE 87<|>RELATION_NOE 、<|>RELATION_NOE 2.7<|>RELATION_NOE 89<|>RELATION_NOE 、<|>RELATION_NOE 2.603<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 联合<|>RELATION_NOE 组<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 改善<|>RELATION_NOE ;<|>RELATION_NOE
乙酰<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 对<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 的<|>RELATION_NOE 干预<|>RELATION_B 作用<|>RELATION_E 及<|>RELATION_NOE 对<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE β1<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 乙酰<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 对<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 的<|>RELATION_NOE 干预<|>RELATION_NOE 作用<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE β1<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 乙酰<|>RELATION_NOE 半胱氨酸<|>RELATION_NOE 对<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 的<|>RELATION_NOE 干预<|>RELATION_B 作用<|>RELATION_E 及<|>RELATION_NOE 对<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE β1<|>RELATION_NOE (<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 后<|>RELATION_NOE 测定<|>RELATION_NOE 血浆<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 放射性<|>RELATION_NOE 肺损伤<|>RELATION_NOE 发生<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 35.4<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S 治疗组<|>RELATION_NOE 的<|>RELATION_NOE 28.1<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 5.16<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
20<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 肺穿<|>RELATION_NOE 刺<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 间<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 影像学<|>RELATION_NOE 手段<|>RELATION_NOE 观察<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 观察<|>RELATION_NOE 临床<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_B 小细胞肺癌<|>RELATION_I 组织<|>RELATION_I DNA<|>RELATION_I 切除<|>RELATION_I 修复<|>RELATION_I 交叉<|>RELATION_I 互补<|>RELATION_I 基因<|>RELATION_I 1mRNA<|>RELATION_I 表达<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 旨在<|>RELATION_NOE 观察<|>RELATION_NOE DNA<|>RELATION_NOE 切除<|>RELATION_NOE 修复<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE ERCCl<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE
血液<|>RELATION_NOE 中<|>RELATION_NOE 游离<|>RELATION_NOE DNA<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
基因<|>RELATION_NOE 和<|>RELATION_NOE 表观<|>RELATION_NOE 遗传学<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 改变<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE 越来越<|>RELATION_NOE 多<|>RELATION_NOE 地<|>RELATION_NOE 被<|>RELATION_NOE 重视<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 健康<|>RELATION_NOE 人群<|>RELATION_NOE 或<|>RELATION_NOE 与<|>RELATION_NOE 患<|>RELATION_NOE 有<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血液<|>RELATION_NOE 中<|>RELATION_NOE 存在<|>RELATION_B 高浓度<|>RELATION_I 的<|>RELATION_I 游离<|>RELATION_I DNA<|>RELATION_I ^<|>RELATION_E [<|>RELATION_NOE 1<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 旨在<|>RELATION_NOE 探讨<|>RELATION_NOE 血液<|>RELATION_NOE 中<|>RELATION_NOE 游离<|>RELATION_NOE DNA<|>RELATION_NOE 浓度<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
一般<|>RELATION_NOE 资料<|>RELATION_NOE :<|>RELATION_NOE 2004年<|>RELATION_NOE 12月<|>RELATION_NOE 至<|>RELATION_NOE 2005年<|>RELATION_NOE 10月<|>RELATION_NOE ,<|>RELATION_NOE 我们<|>RELATION_NOE 随机<|>RELATION_NOE 选取<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 实验组<|>RELATION_NOE 人群<|>RELATION_NOE ,<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 占位<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE 人群<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 人群<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 明确<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 为期<|>RELATION_NOE 6<|>RELATION_NOE 年<|>RELATION_NOE 的<|>RELATION_NOE 生存期<|>RELATION_NOE 调查<|>RELATION_NOE 。<|>RELATION_NOE
抑制<|>RELATION_NOE Pokemon<|>RELATION_B 蛋白<|>RELATION_I 表达<|>RELATION_E 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE NCI-H520<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE
利用<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE (<|>RELATION_NOE RNAi<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 将<|>RELATION_NOE 针对性<|>RELATION_NOE 构建<|>RELATION_NOE 的<|>RELATION_NOE 重组<|>RELATION_NOE 质粒<|>RELATION_NOE 转染<|>RELATION_NOE 人人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE NCI-H520<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 下调<|>RELATION_NOE Pokemon<|>RELATION_NOE 基因<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
利用<|>RELATION_NOE Ambion<|>RELATION_NOE 公司<|>RELATION_NOE 设计<|>RELATION_NOE 软件<|>RELATION_NOE 设计<|>RELATION_NOE 针对<|>RELATION_NOE Pokemon<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 2条<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 序列<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 合成2<|>RELATION_NOE 对<|>RELATION_NOE 互补<|>RELATION_NOE 的<|>RELATION_NOE siRNA<|>RELATION_NOE 编码<|>RELATION_NOE DNA<|>RELATION_NOE 片段<|>RELATION_NOE ,<|>RELATION_NOE 定向<|>RELATION_NOE 克隆<|>RELATION_NOE 至<|>RELATION_NOE RNAi-ReadypSIREN-RetroQ<|>RELATION_NOE 载体<|>RELATION_NOE 的<|>RELATION_NOE BamHI<|>RELATION_NOE 和<|>RELATION_NOE EcoRI<|>RELATION_NOE 位点<|>RELATION_NOE ,<|>RELATION_NOE 构建<|>RELATION_NOE 重组<|>RELATION_NOE 体质粒<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 命名<|>RELATION_NOE 为<|>RELATION_NOE pSIREN-Pokemon-1<|>RELATION_NOE 和<|>RELATION_NOE pSIREN-Pokemon-2<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 设立<|>RELATION_NOE 转染<|>RELATION_NOE 空<|>RELATION_NOE 载体<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
Westernblot<|>RELATION_NOE 检测<|>RELATION_S 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE Pokemon<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE M1vr<|>RELATION_NOE )<|>RELATION_NOE 比色<|>RELATION_NOE 实验<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE Pokemon<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE M1vr<|>RELATION_NOE )<|>RELATION_NOE 比色<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_S 转染<|>RELATION_NOE 后<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制<|>RELATION_NOE
流式<|>RELATION_NOE 细胞<|>RELATION_NOE 分析<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S 转染<|>RELATION_NOE 后<|>RELATION_NOE 细胞周期<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 。<|>RELATION_NOE
Westernblot<|>RELATION_NOE 检测<|>RELATION_NOE 发现<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE NCI-H520<|>RELATION_NOE 中<|>RELATION_NOE Pokemon<|>RELATION_NOE 蛋白<|>RELATION_NOE 高<|>RELATION_NOE 水平<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_B 后<|>RELATION_E 其<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 下降<|>RELATION_NOE 。<|>RELATION_NOE
流式<|>RELATION_NOE 细胞<|>RELATION_NOE 分析<|>RELATION_NOE 检测<|>RELATION_NOE 发现<|>RELATION_NOE 转染<|>RELATION_NOE siRNA<|>RELATION_NOE 细胞<|>RELATION_NOE 与<|>RELATION_NOE 转染<|>RELATION_NOE 空<|>RELATION_NOE 载体<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 细胞周期<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
使用<|>RELATION_NOE pSIREN<|>RELATION_NOE 载体<|>RELATION_NOE 成功<|>RELATION_NOE 构建<|>RELATION_NOE 的<|>RELATION_NOE 重组<|>RELATION_NOE 质粒<|>RELATION_NOE 转染<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_B 抑制<|>RELATION_E 原癌基因<|>RELATION_NOE Pokemon<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
转染<|>RELATION_NOE 后<|>RELATION_NOE 细胞增殖<|>RELATION_S 受到<|>RELATION_NOE 抑制<|>RELATION_NOE ,<|>RELATION_NOE 生长<|>RELATION_NOE 速度<|>RELATION_NOE 减慢<|>RELATION_NOE 。<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 联合<|>RELATION_NOE 加速<|>RELATION_NOE 康复<|>RELATION_NOE 外科<|>RELATION_NOE 流程<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 中<|>RELATION_NOE 应用<|>RELATION_S 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
评价<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 联合<|>RELATION_NOE 加速<|>RELATION_NOE 康复<|>RELATION_NOE 外科<|>RELATION_NOE (<|>RELATION_NOE FTS<|>RELATION_NOE )<|>RELATION_NOE 流程<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 中<|>RELATION_NOE 应用<|>RELATION_S 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
2006年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 12月<|>RELATION_NOE 对<|>RELATION_NOE 249<|>RELATION_NOE 例行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 应用<|>RELATION_NOE 后<|>RELATION_NOE 外侧<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 开<|>RELATION_NOE 胸肺<|>RELATION_NOE 切除<|>RELATION_NOE (<|>RELATION_NOE Ⅰ<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 开<|>RELATION_NOE 胸(Ⅱ组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE FTS<|>RELATION_NOE 联合<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 开<|>RELATION_NOE 胸(Ⅲ组<|>RELATION_NOE )<|>RELATION_NOE 3种<|>RELATION_NOE 治疗<|>RELATION_NOE 模式<|>RELATION_NOE ,<|>RELATION_NOE 快速<|>RELATION_NOE 康复<|>RELATION_NOE 流程<|>RELATION_NOE 包括<|>RELATION_NOE :<|>RELATION_NOE 有效<|>RELATION_NOE 宣教<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 镇痛<|>RELATION_NOE 、<|>RELATION_NOE 早期<|>RELATION_NOE 下<|>RELATION_NOE 床<|>RELATION_NOE 、<|>RELATION_NOE 早期<|>RELATION_NOE 拔管<|>RELATION_NOE ,<|>RELATION_NOE 对比<|>RELATION_NOE 3组<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
Ⅲ<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 下<|>RELATION_NOE 床<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院<|>RELATION_NOE 天数<|>RELATION_NOE 、<|>RELATION_NOE 胸管<|>RELATION_NOE 拔除<|>RELATION_NOE 时间<|>RELATION_NOE 明显<|>RELATION_B 缩短<|>RELATION_E ,<|>RELATION_NOE 术后<|>RELATION_NOE 曲马<|>RELATION_NOE 多<|>RELATION_NOE 针用量<|>RELATION_NOE 明显<|>RELATION_NOE 减少<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE Ⅲ<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 下<|>RELATION_NOE 床<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院<|>RELATION_NOE 天数<|>RELATION_NOE 、<|>RELATION_NOE 胸管<|>RELATION_NOE 拔除<|>RELATION_NOE 时间<|>RELATION_NOE 明显<|>RELATION_NOE 缩短<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 曲马<|>RELATION_NOE 多<|>RELATION_NOE 针用量<|>RELATION_NOE 明显<|>RELATION_B 减少<|>RELATION_E ,<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE Ⅲ<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 下<|>RELATION_NOE 床<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院<|>RELATION_NOE 天数<|>RELATION_NOE 、<|>RELATION_NOE 胸管<|>RELATION_NOE 拔除<|>RELATION_NOE 时间<|>RELATION_NOE 明显<|>RELATION_NOE 缩短<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 曲马<|>RELATION_NOE 多<|>RELATION_NOE 针用量<|>RELATION_NOE 明显<|>RELATION_NOE 减少<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 基于<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 分型<|>RELATION_NOE 、<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 进行<|>RELATION_NOE 分组<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 各组<|>RELATION_NOE 间<|>RELATION_NOE 18F-FDG<|>RELATION_NOE PET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 的<|>RELATION_NOE SUVmax<|>RELATION_NOE 、<|>RELATION_NOE SUVave<|>RELATION_NOE 值<|>RELATION_NOE 间<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 差异.<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 数目<|>RELATION_NOE 与<|>RELATION_NOE 18F-FDG<|>RELATION_NOE PET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 的<|>RELATION_NOE SUVmax<|>RELATION_NOE 、<|>RELATION_NOE SUVave<|>RELATION_NOE 值<|>RELATION_NOE 进行<|>RELATION_NOE Pearson<|>RELATION_NOE 相关<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进一步<|>RELATION_NOE 对<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 进行<|>RELATION_NOE 回归分析<|>RELATION_NOE 。<|>RELATION_NOE
淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE SUVave<|>RELATION_NOE 值<|>RELATION_NOE 高于<|>RELATION_S 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE CEA<|>RELATION_NOE 升高组<|>RELATION_NOE SUVave<|>RELATION_NOE 值<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE SUVave<|>RELATION_NOE 值<|>RELATION_NOE 高于<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE CEA<|>RELATION_NOE 升高组<|>RELATION_NOE SUVave<|>RELATION_NOE 值<|>RELATION_NOE 高于<|>RELATION_S CEA<|>RELATION_NOE 正常组<|>RELATION_NOE ,<|>RELATION_NOE NSE<|>RELATION_NOE 升高组<|>RELATION_NOE SUVmax<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE SUVave<|>RELATION_NOE 值<|>RELATION_NOE 高于<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移组<|>RELATION_NOE ,<|>RELATION_NOE CEA<|>RELATION_NOE 升高组<|>RELATION_NOE SUVave<|>RELATION_NOE 值<|>RELATION_NOE 高于<|>RELATION_NOE CEA<|>RELATION_NOE 正常组<|>RELATION_NOE ,<|>RELATION_NOE NSE<|>RELATION_NOE 升高组<|>RELATION_NOE SUVmax<|>RELATION_NOE 高于<|>RELATION_S NSE<|>RELATION_NOE 正常组<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 差异<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
男性<|>RELATION_NOE 与<|>RELATION_NOE 女性<|>RELATION_NOE 组间<|>RELATION_NOE 、<|>RELATION_NOE <<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 与<|>RELATION_NOE ≥<|>RELATION_NOE 60<|>RELATION_NOE 岁<|>RELATION_NOE 组间<|>RELATION_NOE 、<|>RELATION_NOE 左肺<|>RELATION_NOE 与<|>RELATION_NOE 右<|>RELATION_NOE 肺组<|>RELATION_NOE 间<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 与<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 组间<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 与<|>RELATION_NOE 无远处<|>RELATION_NOE 转移<|>RELATION_NOE 组间<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 正常<|>RELATION_NOE 与<|>RELATION_NOE 升高组<|>RELATION_NOE 间<|>RELATION_NOE 的<|>RELATION_NOE SUVmax<|>RELATION_NOE 和<|>RELATION_NOE SUVave<|>RELATION_NOE 值<|>RELATION_NOE 均<|>RELATION_NOE 无<|>RELATION_B 统计学<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 与<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组间<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 正常<|>RELATION_NOE 与<|>RELATION_NOE CEA<|>RELATION_NOE 升高组<|>RELATION_NOE 间<|>RELATION_NOE 的<|>RELATION_NOE SUVmax<|>RELATION_NOE 值<|>RELATION_NOE 无<|>RELATION_B 统计学<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 分型<|>RELATION_NOE 、<|>RELATION_NOE 病灶<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 均<|>RELATION_NOE 影响<|>RELATION_S 肺癌<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE SUV<|>RELATION_NOE 值<|>RELATION_NOE .<|>RELATION_NOE
含<|>RELATION_NOE 奈达铂<|>RELATION_NOE 与<|>RELATION_NOE 含<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 比较<|>RELATION_S 的<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE
在<|>RELATION_NOE Medline<|>RELATION_NOE 、<|>RELATION_NOE Embase<|>RELATION_NOE 、<|>RELATION_NOE Cochrane<|>RELATION_NOE 图书馆<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 试验<|>RELATION_NOE 注册库<|>RELATION_NOE 、<|>RELATION_NOE 中国<|>RELATION_NOE 医院<|>RELATION_NOE 数字化<|>RELATION_NOE 图书馆<|>RELATION_NOE 、<|>RELATION_NOE 万方<|>RELATION_NOE 、<|>RELATION_NOE 维普<|>RELATION_NOE 数据库<|>RELATION_NOE 和<|>RELATION_NOE 美国<|>RELATION_NOE 及<|>RELATION_NOE 欧洲<|>RELATION_NOE 临床<|>RELATION_NOE 肿瘤<|>RELATION_NOE 学历年<|>RELATION_NOE 会议<|>RELATION_NOE 中<|>RELATION_NOE 检索<|>RELATION_NOE 有关<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 使用<|>RELATION_NOE 奈达铂<|>RELATION_NOE 或<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 对比<|>RELATION_NOE 的<|>RELATION_NOE 随机<|>RELATION_NOE 临床<|>RELATION_NOE 试验<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE 软件<|>RELATION_NOE (<|>RELATION_NOE RevMan<|>RELATION_NOE 5.1<|>RELATION_NOE )<|>RELATION_NOE 要求<|>RELATION_NOE 处理<|>RELATION_NOE 有关<|>RELATION_NOE 数据<|>RELATION_NOE 。<|>RELATION_NOE
含<|>RELATION_NOE 奈达铂<|>RELATION_NOE 与<|>RELATION_NOE 含<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 无<|>RELATION_B 统计学<|>RELATION_I 差异<|>RELATION_E [<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.03<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE (<|>RELATION_NOE 0.75<|>RELATION_NOE ,<|>RELATION_NOE 1.41<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.84<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE Ⅲ<|>RELATION_NOE －<|>RELATION_NOE Ⅳ<|>RELATION_NOE 级<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE [<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.22<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE (<|>RELATION_NOE 0.14<|>RELATION_NOE ,<|>RELATION_NOE 0.3<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.00001<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 肾脏<|>RELATION_NOE 毒性<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE [<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.41<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE (<|>RELATION_NOE 0.22<|>RELATION_NOE ,<|>RELATION_NOE 0.75<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE ]<|>RELATION_NOE .<|>RELATION_NOE 含<|>RELATION_NOE 奈达铂<|>RELATION_NOE 与<|>RELATION_NOE 含<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 差异<|>RELATION_NOE [<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.03<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE (<|>RELATION_NOE 0.75<|>RELATION_NOE ,<|>RELATION_NOE 1.41<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.84<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE Ⅲ<|>RELATION_NOE －<|>RELATION_NOE Ⅳ<|>RELATION_NOE 级<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E [<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.22<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE (<|>RELATION_NOE 0.14<|>RELATION_NOE ,<|>RELATION_NOE 0.3<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.00001<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 肾脏<|>RELATION_NOE 毒性<|>RELATION_NOE 发生率<|>RELATION_NOE
奈达铂<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 相比<|>RELATION_NOE 在<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 方面<|>RELATION_NOE 无<|>RELATION_B 统计学<|>RELATION_I 差异<|>RELATION_E ,<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 肾脏<|>RELATION_NOE 毒性<|>RELATION_NOE 的<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 顺铂<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 血液性<|>RELATION_NOE 毒性<|>RELATION_NOE 较<|>RELATION_NOE 顺铂<|>RELATION_NOE 组<|>RELATION_NOE 高.<|>RELATION_NOE 奈达铂<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 相比<|>RELATION_NOE 在<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 方面<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 肾脏<|>RELATION_NOE 毒性<|>RELATION_NOE 的<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 顺铂<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 血液性<|>RELATION_NOE 毒性<|>RELATION_NOE 奈达铂<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 相比<|>RELATION_NOE 在<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 方面<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 肾脏<|>RELATION_NOE 毒性<|>RELATION_NOE 的<|>RELATION_NOE 反应<|>RELATION_NOE 较<|>RELATION_NOE 顺铂<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 血液性<|>RELATION_NOE 毒性<|>RELATION_NOE 较<|>RELATION_NOE 顺铂<|>RELATION_NOE 组<|>RELATION_NOE 高<|>RELATION_S .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 促<|>RELATION_NOE 血管<|>RELATION_NOE 生成素<|>RELATION_NOE -2<|>RELATION_NOE 及<|>RELATION_NOE 缺氧<|>RELATION_NOE 诱导<|>RELATION_NOE 因子<|>RELATION_NOE -2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 促<|>RELATION_NOE 血管<|>RELATION_NOE 生成素<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE Ang-2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 缺氧<|>RELATION_NOE 诱导<|>RELATION_NOE 因子<|>RELATION_NOE -2<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 测定<|>RELATION_S 59<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 和<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 病理<|>RELATION_NOE 切片<|>RELATION_NOE 中<|>RELATION_NOE Ang-2<|>RELATION_NOE 、<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 并<|>RELATION_NOE 计数<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE 等<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 参数<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
NCCLS<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 、<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 52.5%<|>RELATION_NOE 、<|>RELATION_NOE 71.2%<|>RELATION_NOE 和<|>RELATION_NOE 76.3%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 三者<|>RELATION_NOE 两<|>RELATION_NOE 两<|>RELATION_NOE 之间<|>RELATION_NOE 在<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.01<|>RELATION_NOE 水平<|>RELATION_NOE 上<|>RELATION_NOE 呈<|>RELATION_NOE 明显<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 与<|>RELATION_NOE VEGF<|>RELATION_NOE 阳性<|>RELATION_NOE 表达组<|>RELATION_NOE MVD<|>RELATION_NOE NCCLS<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 、<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 52.5%<|>RELATION_NOE 、<|>RELATION_NOE 71.2%<|>RELATION_NOE 和<|>RELATION_NOE 76.3%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 三者<|>RELATION_NOE 两<|>RELATION_NOE 两<|>RELATION_NOE 之间<|>RELATION_NOE 在<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.01<|>RELATION_NOE 水平<|>RELATION_NOE 上<|>RELATION_NOE 呈<|>RELATION_NOE 明显<|>RELATION_B 正<|>RELATION_I 相关<|>RELATION_E ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 与<|>RELATION_NOE VEGF<|>RELATION_NOE 阳性<|>RELATION_NOE 表达组<|>RELATION_NOE MVD<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 阴性<|>RELATION_NOE 表达组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 28<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 在<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 高于<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 和<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 较<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE 高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE NCCLS<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 、<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 52.5%<|>RELATION_NOE 、<|>RELATION_NOE 71.2%<|>RELATION_NOE 和<|>RELATION_NOE 76.3%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 三者<|>RELATION_NOE 两<|>RELATION_NOE 两<|>RELATION_NOE 之间<|>RELATION_NOE 在<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.01<|>RELATION_NOE 水平<|>RELATION_NOE 上<|>RELATION_NOE 呈<|>RELATION_NOE 明显<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 与<|>RELATION_NOE VEGF<|>RELATION_NOE 阳性<|>RELATION_NOE 表达组<|>RELATION_NOE MVD<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 阴性<|>RELATION_NOE 表达组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 28<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 在<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 高于<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 和<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 较<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE 高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE NCCLS<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 、<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 52.5%<|>RELATION_NOE 、<|>RELATION_NOE 71.2%<|>RELATION_NOE 和<|>RELATION_NOE 76.3%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 三者<|>RELATION_NOE 两<|>RELATION_NOE 两<|>RELATION_NOE 之间<|>RELATION_NOE 在<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.01<|>RELATION_NOE 水平<|>RELATION_NOE 上<|>RELATION_NOE 呈<|>RELATION_NOE 明显<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 与<|>RELATION_NOE VEGF<|>RELATION_NOE 阳性<|>RELATION_NOE 表达组<|>RELATION_NOE MVD<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 阴性<|>RELATION_NOE 表达组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 28<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 在<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 高于<|>RELATION_S Ⅰ期<|>RELATION_NOE 和<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 较<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE 高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE NCCLS<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 、<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 表达率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 52.5%<|>RELATION_NOE 、<|>RELATION_NOE 71.2%<|>RELATION_NOE 和<|>RELATION_NOE 76.3%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 三者<|>RELATION_NOE 两<|>RELATION_NOE 两<|>RELATION_NOE 之间<|>RELATION_NOE 在<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.01<|>RELATION_NOE 水平<|>RELATION_NOE 上<|>RELATION_NOE 呈<|>RELATION_NOE 明显<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 与<|>RELATION_NOE VEGF<|>RELATION_NOE 阳性<|>RELATION_NOE 表达组<|>RELATION_NOE MVD<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 阴性<|>RELATION_NOE 表达组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 28<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 在<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE Ang-2<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 高于<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 和<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.0<|>RELATION_NOE 5<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达率<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 较<|>RELATION_NOE 阴<|>RELATION_NOE 性组<|>RELATION_NOE 高<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Ang-2<|>RELATION_NOE 、<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_B 有<|>RELATION_I 高<|>RELATION_I 表达<|>RELATION_E 且<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 新生<|>RELATION_NOE 血管<|>RELATION_NOE 形成<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可能<|>RELATION_NOE 影响<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE .<|>RELATION_NOE Ang-2<|>RELATION_NOE 、<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 新生<|>RELATION_NOE 血管<|>RELATION_NOE 形成<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 并<|>RELATION_NOE 可能<|>RELATION_NOE 影响<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE .<|>RELATION_NOE Ang-2<|>RELATION_NOE 、<|>RELATION_NOE HIF-2<|>RELATION_NOE α<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 且<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 新生<|>RELATION_NOE 血管<|>RELATION_NOE 形成<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可能<|>RELATION_B 影响<|>RELATION_E NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE .<|>RELATION_NOE
顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 贝伐<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 表达<|>RELATION_B 的<|>RELATION_I 影响<|>RELATION_I 及<|>RELATION_I 疗效<|>RELATION_I 观察<|>RELATION_E
观察<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 注射<|>RELATION_NOE 贝伐<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 恶性<|>RELATION_NOE 胸水<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 监测<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 贝伐<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 观察<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 注射<|>RELATION_NOE 贝伐<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 恶性<|>RELATION_NOE 胸水<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 监测<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 贝伐<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 治疗<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 疗法<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E 。<|>RELATION_NOE
70<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 贝伐<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂组<|>RELATION_NOE (<|>RELATION_NOE 贝伐组<|>RELATION_NOE ,<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 腔内<|>RELATION_NOE 单纯<|>RELATION_NOE 顺铂组<|>RELATION_NOE (<|>RELATION_NOE 顺铂组<|>RELATION_NOE ,<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 34<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
同时<|>RELATION_NOE ,<|>RELATION_NOE 各组<|>RELATION_NOE 应用<|>RELATION_NOE ELISA<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 胸腔积液<|>RELATION_NOE VEGF<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE VEGF<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 良性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 。<|>RELATION_NOE
胸腔<|>RELATION_NOE 内<|>RELATION_NOE 贝伐<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_B 恶性<|>RELATION_I 胸腔积液<|>RELATION_E 有效<|>RELATION_NOE 且<|>RELATION_NOE 安全<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE ,<|>RELATION_NOE 胸腔积液<|>RELATION_NOE VEGF<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 监测<|>RELATION_NOE 贝伐<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 胸腔<|>RELATION_NOE 内<|>RELATION_NOE 贝伐<|>RELATION_NOE 珠单<|>RELATION_NOE 抗<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 有效<|>RELATION_NOE 且<|>RELATION_NOE 安全<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE ,<|>RELATION_NOE 胸腔积液<|>RELATION_NOE VEGF<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 监测<|>RELATION_B 贝伐<|>RELATION_I 珠单<|>RELATION_I 抗<|>RELATION_I 治疗<|>RELATION_I 恶性<|>RELATION_I 胸腔积液<|>RELATION_I 的<|>RELATION_I 疗效<|>RELATION_E 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 指导<|>RELATION_NOE 意义<|>RELATION_NOE .<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 和<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 检测<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 及<|>RELATION_NOE 配对<|>RELATION_NOE 的<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE MMP-2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 检测<|>RELATION_S 46<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 配对<|>RELATION_NOE 的<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE let-7<|>RELATION_NOE 和<|>RELATION_NOE MMP-2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Spearman<|>RELATION_NOE 等级<|>RELATION_NOE 相关<|>RELATION_NOE 分析<|>RELATION_NOE
免疫<|>RELATION_NOE 组化<|>RELATION_NOE 结果<|>RELATION_NOE 示<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE MMP-2<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 65.2%<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
MMP-2<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 类型<|>RELATION_NOE 无关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE MMP-2<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 类型<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE MMP-2<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 类型<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
实时<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 示<|>RELATION_NOE let-7<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 与<|>RELATION_NOE 配对<|>RELATION_NOE 的<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 比较<|>RELATION_NOE 表达<|>RELATION_NOE 降低<|>RELATION_NOE 的<|>RELATION_NOE 为<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 63.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE MMP-2<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 为<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 67.4%<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
Survivin<|>RELATION_NOE 和<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 痰液<|>RELATION_B 中<|>RELATION_I 的<|>RELATION_I 表达<|>RELATION_E 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
观察<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 痰液<|>RELATION_NOE 中<|>RELATION_NOE Survivin<|>RELATION_NOE 和<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 情况<|>RELATION_I 以及<|>RELATION_I 两者<|>RELATION_I 之间<|>RELATION_I 的<|>RELATION_I 关系<|>RELATION_E ,<|>RELATION_NOE 以<|>RELATION_NOE 探讨<|>RELATION_NOE 痰液<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞化学<|>RELATION_NOE 染色<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE 观察<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 痰液<|>RELATION_NOE 中<|>RELATION_NOE Survivin<|>RELATION_NOE 和<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 以及<|>RELATION_NOE 两者<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 探讨<|>RELATION_NOE 痰液<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞化学<|>RELATION_NOE 染色<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 辅助<|>RELATION_I 诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 改良<|>RELATION_NOE Saccomanno<|>RELATION_NOE 法<|>RELATION_NOE 收集<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 活检<|>RELATION_NOE 或<|>RELATION_NOE 手术<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 痰液<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 肺纤维化<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 正常人<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 痰液<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞化学<|>RELATION_NOE 染色法<|>RELATION_NOE 检测<|>RELATION_S 痰液<|>RELATION_NOE 中<|>RELATION_NOE Survivin<|>RELATION_NOE 和<|>RELATION_NOE Livin<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 这<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 痰液<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 和<|>RELATION_NOE 年龄<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 以及<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 痰液<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞化学<|>RELATION_NOE 染色<|>RELATION_NOE 检测<|>RELATION_NOE 这<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 蛋白<|>RELATION_NOE 可能<|>RELATION_B 为<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_I 的<|>RELATION_I 诊断<|>RELATION_E 提供<|>RELATION_NOE 一个<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 、<|>RELATION_NOE 安全<|>RELATION_NOE 无创<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_NOE 检查<|>RELATION_NOE 方法<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 新型<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CK18-3A9<|>RELATION_NOE 检测<|>RELATION_S 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
评价<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 新型<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CK18-3A9<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 辅助<|>RELATION_I 诊断<|>RELATION_I 和<|>RELATION_I 疗效<|>RELATION_I 评估<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 100<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 100<|>RELATION_NOE 名<|>RELATION_NOE 正常人<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CK18-3A9<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 以及<|>RELATION_NOE 165<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CK18-3A9<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
新型<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CK18-3A9<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 对于<|>RELATION_NOE 肺癌<|>RELATION_B 的<|>RELATION_I 辅助<|>RELATION_I 诊断<|>RELATION_I 和<|>RELATION_I 鉴别诊断<|>RELATION_E 有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE CK18-3A9<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 参考<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 推广<|>RELATION_NOE 使用<|>RELATION_NOE .<|>RELATION_NOE 新型<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CK18-3A9<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 对于<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 鉴别<|>RELATION_NOE 诊断<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE CK18-3A9<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_S 一<|>RELATION_NOE 种<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 参考<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 推广<|>RELATION_NOE 使用<|>RELATION_NOE .<|>RELATION_NOE
18F-FDG<|>RELATION_NOE 显像<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 测定<|>RELATION_NOE 等<|>RELATION_NOE 检查<|>RELATION_NOE 在<|>RELATION_NOE 确诊<|>RELATION_B 肺癌<|>RELATION_I 单发<|>RELATION_I 骨显像<|>RELATION_I 转移<|>RELATION_I 病灶<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 显像<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 测定<|>RELATION_NOE 等<|>RELATION_NOE 检查<|>RELATION_NOE 在<|>RELATION_NOE 确诊<|>RELATION_B 肺癌<|>RELATION_I 单发<|>RELATION_I 骨显像<|>RELATION_I 转移<|>RELATION_I 病灶<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
回顾性研究<|>RELATION_NOE 188<|>RELATION_NOE 例<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 99mTc-MDP<|>RELATION_NOE 全身<|>RELATION_NOE 骨<|>RELATION_NOE 显像<|>RELATION_NOE 示单<|>RELATION_NOE 发<|>RELATION_NOE 异常<|>RELATION_NOE 放射性<|>RELATION_NOE 浓聚灶<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 行<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 显像<|>RELATION_NOE (<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE (<|>RELATION_NOE 106<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 的<|>RELATION_NOE 测定<|>RELATION_NOE (<|>RELATION_NOE 168<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 各种<|>RELATION_NOE 检查<|>RELATION_NOE 间隔<|>RELATION_NOE 时间<|>RELATION_NOE 不<|>RELATION_NOE 超过<|>RELATION_NOE 2周<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 、<|>RELATION_NOE MRI<|>RELATION_NOE 等<|>RELATION_NOE 检查<|>RELATION_NOE 以及<|>RELATION_NOE 临床<|>RELATION_NOE 随访<|>RELATION_NOE
其中<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 利用<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 方法<|>RELATION_NOE 相<|>RELATION_NOE 结合<|>RELATION_NOE 综合<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 为<|>RELATION_NOE 96.8<|>RELATION_NOE 8%<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE 为<|>RELATION_NOE 98.11%<|>RELATION_NOE 、<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 为<|>RELATION_NOE 95.4<|>RELATION_NOE 5%<|>RELATION_NOE 和<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE .<|>RELATION_NOE
18F-FDG<|>RELATION_NOE 显像<|>RELATION_NOE 在<|>RELATION_NOE 对<|>RELATION_B 全身<|>RELATION_I 骨<|>RELATION_I 显像单<|>RELATION_I 发<|>RELATION_I 异常<|>RELATION_I 浓<|>RELATION_I 聚<|>RELATION_I 灶<|>RELATION_I 的<|>RELATION_I 诊断<|>RELATION_E 中<|>RELATION_NOE 较<|>RELATION_NOE 其他<|>RELATION_NOE 方法<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 多种<|>RELATION_NOE 检查<|>RELATION_NOE 方法<|>RELATION_NOE 相<|>RELATION_NOE 结合<|>RELATION_NOE 能够<|>RELATION_NOE 提高<|>RELATION_NOE 诊断<|>RELATION_NOE 率.<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 显像<|>RELATION_NOE 在<|>RELATION_NOE 对<|>RELATION_NOE 全身<|>RELATION_NOE 骨<|>RELATION_NOE 显像单<|>RELATION_NOE 发<|>RELATION_NOE 异常<|>RELATION_NOE 浓<|>RELATION_NOE 聚<|>RELATION_NOE 灶<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 较<|>RELATION_NOE 其他<|>RELATION_NOE 方法<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 多种<|>RELATION_NOE 检查<|>RELATION_NOE 方法<|>RELATION_NOE 相<|>RELATION_NOE 结合<|>RELATION_NOE 能够<|>RELATION_NOE 提高<|>RELATION_S 诊断率<|>RELATION_NOE .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 黑色素瘤<|>RELATION_NOE 抗原<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 模式<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
探讨<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 黑色素瘤<|>RELATION_NOE 抗原<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 状态<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 诊断<|>RELATION_I 和<|>RELATION_I 预后<|>RELATION_I 评估<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE PCR<|>RELATION_NOE (<|>RELATION_NOE MSP<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 49<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE MAGE-A1<|>RELATION_NOE 、<|>RELATION_NOE MAGE-A3<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 参数<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 的<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 。<|>RELATION_NOE
49<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 分别<|>RELATION_NOE 有<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 53.1%<|>RELATION_NOE )<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE MAGE-A1<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 启动子<|>RELATION_NOE 呈<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 49%<|>RELATION_NOE )<|>RELATION_NOE MAGE-A3<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 呈<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 状态<|>RELATION_NOE ;<|>RELATION_NOE
22<|>RELATION_NOE 例<|>RELATION_NOE 肺结核<|>RELATION_NOE 、<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 肺脓肿<|>RELATION_NOE 、<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE 肺炎<|>RELATION_NOE 和<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 标本<|>RELATION_NOE 均<|>RELATION_NOE 呈现<|>RELATION_NOE 甲基化<|>RELATION_NOE (<|>RELATION_NOE 100%<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
MAGE-A1<|>RELATION_NOE 、<|>RELATION_NOE MAGE-A3<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 启动子<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 模式<|>RELATION_NOE 均<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 是否<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 相关<|>RELATION_S ,<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 学分型<|>RELATION_NOE 无关.<|>RELATION_NOE MAGE-A1<|>RELATION_NOE 、<|>RELATION_NOE MAGE-A3<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 启动子<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 模式<|>RELATION_NOE 均<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 是否<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 学分型<|>RELATION_NOE 无关<|>RELATION_S .<|>RELATION_NOE
24<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 的<|>RELATION_NOE 随访<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE MAGE-A1<|>RELATION_NOE 、<|>RELATION_NOE MAGE-A3<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 启动子<|>RELATION_NOE 呈<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 模式<|>RELATION_NOE 患者<|>RELATION_NOE 较<|>RELATION_NOE 呈<|>RELATION_NOE 甲基化<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_B 不良<|>RELATION_E 。<|>RELATION_NOE
MAGE<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 状态<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 检测<|>RELATION_B 肺癌<|>RELATION_I 患者<|>RELATION_I 外<|>RELATION_I 周<|>RELATION_I 癌细胞<|>RELATION_E 的<|>RELATION_NOE 标记物<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 有助于<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 进行<|>RELATION_NOE 判断<|>RELATION_NOE .<|>RELATION_NOE MAGE<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE CpG<|>RELATION_NOE 岛<|>RELATION_NOE 去<|>RELATION_NOE 甲基化<|>RELATION_NOE 的<|>RELATION_NOE 状态<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 检测<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 标记物<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 有助于<|>RELATION_S 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 进行<|>RELATION_NOE 判断<|>RELATION_NOE .<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 开<|>RELATION_NOE 胸下<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 对比<|>RELATION_NOE 的<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE
对<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE (<|>RELATION_NOE OPEN<|>RELATION_NOE )<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 术式<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE 综合<|>RELATION_NOE 分期Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE )<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 综合<|>RELATION_NOE 临床<|>RELATION_NOE 效益<|>RELATION_NOE 进行<|>RELATION_NOE 系统<|>RELATION_B 评价<|>RELATION_E 。<|>RELATION_NOE
按照<|>RELATION_NOE Cochrane<|>RELATION_NOE 系统<|>RELATION_NOE 评价<|>RELATION_NOE 制作<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 计算机<|>RELATION_NOE 检索<|>RELATION_NOE PubMed<|>RELATION_NOE 、<|>RELATION_NOE EMBASE<|>RELATION_NOE 、<|>RELATION_NOE Medline<|>RELATION_NOE 、<|>RELATION_NOE 同方<|>RELATION_NOE 数据库<|>RELATION_NOE 相关<|>RELATION_NOE 文献<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 手工<|>RELATION_NOE 检索<|>RELATION_NOE 收集<|>RELATION_NOE 相关<|>RELATION_NOE 文献<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Cochrane<|>RELATION_NOE 协作网<|>RELATION_NOE 提供<|>RELATION_NOE 的<|>RELATION_NOE RevMan<|>RELATION_NOE 5.0<|>RELATION_NOE 软件<|>RELATION_NOE 对<|>RELATION_NOE 相关<|>RELATION_NOE 研究<|>RELATION_NOE 数据<|>RELATION_NOE 进行<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 获得<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE 综合<|>RELATION_NOE 分期Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE VATS<|>RELATION_NOE 下行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 与<|>RELATION_NOE OPEN<|>RELATION_NOE 下<|>RELATION_NOE 相比<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 优势<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 证据<|>RELATION_NOE 。<|>RELATION_NOE
针对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE 综合<|>RELATION_NOE 分期Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE OPEN<|>RELATION_NOE 术<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE VATS<|>RELATION_NOE 能<|>RELATION_NOE 明显<|>RELATION_B 减少<|>RELATION_I 术后<|>RELATION_I 全身<|>RELATION_I 尤其<|>RELATION_I 是<|>RELATION_I 肺部<|>RELATION_I 并发症<|>RELATION_I 的<|>RELATION_I 发生率<|>RELATION_I 、<|>RELATION_I 减少<|>RELATION_I 五<|>RELATION_I 年<|>RELATION_I 死亡率<|>RELATION_I 、<|>RELATION_I 总<|>RELATION_I 死亡率<|>RELATION_I 和<|>RELATION_I 肿瘤<|>RELATION_I 复发率<|>RELATION_E .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE -2G2<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_S
评价<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 新型<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE (<|>RELATION_NOE CK<|>RELATION_NOE )<|>RELATION_NOE -2G2<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE 效果<|>RELATION_NOE 评估<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
应用<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 124<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 和<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CK-2G2<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 含量<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 125I<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 肺癌<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 4R<|>RELATION_NOE 组<|>RELATION_NOE 转移<|>RELATION_NOE 进<|>RELATION_NOE 针路径<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经<|>RELATION_NOE 皮穿<|>RELATION_NOE 刺<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 4R<|>RELATION_NOE 组<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 进行<|>RELATION_NOE 125I<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 路径<|>RELATION_B 选择<|>RELATION_E 。<|>RELATION_NOE
选取<|>RELATION_NOE 2004年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 4月<|>RELATION_NOE 在<|>RELATION_NOE 我院<|>RELATION_NOE 接受<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 经病<|>RELATION_NOE 理学<|>RELATION_NOE 明确<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 4R<|>RELATION_NOE 组<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 综合征<|>RELATION_NOE .<|>RELATION_NOE
对<|>RELATION_NOE 该组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶行<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿刺<|>RELATION_NOE 125I<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 采取<|>RELATION_NOE 自<|>RELATION_NOE 右<|>RELATION_NOE 前<|>RELATION_NOE 胸壁<|>RELATION_NOE 、<|>RELATION_NOE 右侧<|>RELATION_NOE 胸壁<|>RELATION_NOE 及<|>RELATION_NOE 右<|>RELATION_NOE 后<|>RELATION_NOE 胸壁<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 进<|>RELATION_NOE 针路径<|>RELATION_NOE 进行<|>RELATION_NOE 粒子<|>RELATION_NOE 植入.<|>RELATION_NOE
术中<|>RELATION_NOE 9例<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 气胸<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 6例行<|>RELATION_NOE 胸腔<|>RELATION_NOE 闭式<|>RELATION_NOE 引流术<|>RELATION_NOE ,<|>RELATION_NOE 3例行<|>RELATION_NOE 胸腔<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 抽气<|>RELATION_NOE ;<|>RELATION_NOE
6例<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 肺内<|>RELATION_NOE 出血<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 2例<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 咳血<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 进行性<|>RELATION_NOE 血胸<|>RELATION_NOE ,<|>RELATION_NOE 止血<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE 症状<|>RELATION_NOE 消失<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 后<|>RELATION_NOE 复查<|>RELATION_NOE 出血<|>RELATION_NOE 吸收<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 4R<|>RELATION_NOE 组<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移癌<|>RELATION_NOE 进行<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 125I<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_B 选择<|>RELATION_I 恰当<|>RELATION_I 的<|>RELATION_I 进<|>RELATION_I 针路径<|>RELATION_I 进行<|>RELATION_I 放射性<|>RELATION_I 粒子<|>RELATION_I 植入<|>RELATION_E ,<|>RELATION_NOE 使<|>RELATION_NOE 放射<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE 合理<|>RELATION_NOE 提高<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 可<|>RELATION_NOE 减少<|>RELATION_NOE 穿刺<|>RELATION_NOE 损伤<|>RELATION_NOE 等<|>RELATION_NOE 并发症<|>RELATION_NOE .<|>RELATION_NOE
唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌骨<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 思路<|>RELATION_NOE 总结<|>RELATION_NOE
选取<|>RELATION_NOE 我院<|>RELATION_NOE 于<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 7月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 7月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌骨<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 按照<|>RELATION_NOE 随机<|>RELATION_NOE 分组<|>RELATION_NOE 方式<|>RELATION_NOE 将<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 给予<|>RELATION_NOE 常规<|>RELATION_NOE 化疗<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 化疗<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 给予<|>RELATION_NOE 唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE NRS<|>RELATION_NOE 、<|>RELATION_NOE KPS<|>RELATION_NOE 水平<|>RELATION_NOE 进行<|>RELATION_NOE 测评<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 治疗<|>RELATION_NOE 方式<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_NOE 组骨<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 稳定<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 恶化<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 综合<|>RELATION_NOE 有效率<|>RELATION_NOE (<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE +<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 76.<|>RELATION_NOE 19%<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 完全<|>RELATION_NOE 缓解<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 缓解<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 稳定<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 恶化<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 综合<|>RELATION_NOE 有效率<|>RELATION_NOE 为<|>RELATION_NOE 33.3<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 综合<|>RELATION_NOE 有效率<|>RELATION_NOE 对比<|>RELATION_NOE 具有<|>RELATION_B 显著<|>RELATION_I 的<|>RELATION_I 统计学<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺<|>RELATION_I 癌骨<|>RELATION_I 转移<|>RELATION_E 疗效<|>RELATION_NOE 显著<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_NOE 缓解<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 、<|>RELATION_NOE 改善<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE .<|>RELATION_NOE
单向式<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_B 肺癌<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 对比<|>RELATION_NOE
将<|>RELATION_NOE 2007年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 2月<|>RELATION_NOE 来<|>RELATION_NOE 我院<|>RELATION_NOE 就诊<|>RELATION_NOE 的<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 各<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 采用<|>RELATION_NOE 单向式<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 开<|>RELATION_NOE 胸切<|>RELATION_NOE 除<|>RELATION_NOE 治疗.<|>RELATION_NOE
心理<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 作用<|>RELATION_NOE 研究<|>RELATION_NOE
选择<|>RELATION_NOE 我院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 了<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 对照组<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
护理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE SAS<|>RELATION_NOE 、<|>RELATION_NOE SDS<|>RELATION_NOE 以及<|>RELATION_NOE KPS<|>RELATION_NOE 等<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_B 了<|>RELATION_I 明显<|>RELATION_I 改善<|>RELATION_E ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量量表<|>RELATION_NOE 评分<|>RELATION_NOE 等<|>RELATION_NOE 也<|>RELATION_NOE 护理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE SAS<|>RELATION_NOE 、<|>RELATION_NOE SDS<|>RELATION_NOE 以及<|>RELATION_NOE KPS<|>RELATION_NOE 等<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 了<|>RELATION_NOE 明显<|>RELATION_NOE 改善<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量量表<|>RELATION_NOE 评<|>RELATION_NOE 分<|>RELATION_NOE 等<|>RELATION_NOE 也<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_B 了<|>RELATION_I 明显<|>RELATION_I 改善<|>RELATION_E ,<|>RELATION_NOE 且<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 具有<|>RELATION_NOE 明显<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
外<|>RELATION_NOE 周血<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE 与<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 比值<|>RELATION_NOE 预测<|>RELATION_S 术后<|>RELATION_NOE 复发<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE
分析<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE 与<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 比值<|>RELATION_NOE (<|>RELATION_NOE NLR<|>RELATION_NOE )<|>RELATION_NOE 预测<|>RELATION_S 术后<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 235<|>RELATION_NOE 例<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 建立<|>RELATION_NOE 受试者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE 确定<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE NLR<|>RELATION_NOE 预测<|>RELATION_NOE 复发<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 最佳<|>RELATION_NOE 截点<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 评估<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE NLR<|>RELATION_NOE 对<|>RELATION_NOE 复发<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE ≥<|>RELATION_NOE 65<|>RELATION_NOE 岁<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 为<|>RELATION_NOE 大细胞癌<|>RELATION_NOE 或<|>RELATION_NOE 肉瘤<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 为<|>RELATION_NOE Ⅲ期<|>RELATION_NOE 和<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE NLR<|>RELATION_NOE ><|>RELATION_NOE 2.97<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_B 术后<|>RELATION_I 复发<|>RELATION_I NSCLC<|>RELATION_I 患者<|>RELATION_I 生存<|>RELATION_I 情况<|>RELATION_E 的<|>RELATION_NOE 危险因素<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
复发<|>RELATION_NOE 低<|>RELATION_NOE NLR<|>RELATION_NOE 组<|>RELATION_NOE 复发<|>RELATION_NOE 后<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 74.7%<|>RELATION_NOE 和<|>RELATION_NOE 43.1%<|>RELATION_NOE ,<|>RELATION_NOE 复发<|>RELATION_NOE 高<|>RELATION_NOE NLR<|>RELATION_NOE 组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 35.4%<|>RELATION_NOE 和<|>RELATION_NOE 17.2%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Cox<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE ≥<|>RELATION_NOE 65<|>RELATION_NOE 岁<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 为<|>RELATION_NOE Ⅲ期<|>RELATION_NOE 和<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE NLR<|>RELATION_NOE ><|>RELATION_NOE 2.97<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_B 复发<|>RELATION_I 患者<|>RELATION_I 预后<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 因素<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
复发<|>RELATION_NOE 时<|>RELATION_NOE NLR<|>RELATION_NOE 升高<|>RELATION_NOE 提示<|>RELATION_S NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE 复发<|>RELATION_NOE 时<|>RELATION_NOE NLR<|>RELATION_NOE 升高<|>RELATION_NOE 提示<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_B 术后<|>RELATION_I 复发<|>RELATION_I NSCLC<|>RELATION_I 患者<|>RELATION_I 生存<|>RELATION_I 情况<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
伴微<|>RELATION_B 乳头<|>RELATION_I 结构<|>RELATION_E 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 影像学<|>RELATION_NOE 特点<|>RELATION_NOE
有<|>RELATION_NOE 胸膜<|>RELATION_NOE 侵犯<|>RELATION_NOE 、<|>RELATION_NOE 脉管<|>RELATION_NOE 侵犯<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 壁<|>RELATION_NOE 累及<|>RELATION_NOE 、<|>RELATION_NOE 大<|>RELATION_NOE 血管<|>RELATION_NOE 累及<|>RELATION_NOE 、<|>RELATION_NOE 神经<|>RELATION_NOE 侵犯<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 其中<|>RELATION_NOE 之一者<|>RELATION_NOE 63<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 78.8%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组化<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺<|>RELATION_NOE 转录因子<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE TTF<|>RELATION_NOE －1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 细胞角蛋白7<|>RELATION_NOE (<|>RELATION_NOE CK7<|>RELATION_NOE )<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE ,<|>RELATION_NOE 表面活性剂<|>RELATION_NOE 载脂<|>RELATION_NOE 蛋白<|>RELATION_NOE A<|>RELATION_NOE (<|>RELATION_NOE SPA<|>RELATION_NOE )<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE 84.0%<|>RELATION_NOE 。<|>RELATION_NOE
影像学<|>RELATION_NOE 检查<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 肺门<|>RELATION_NOE 或<|>RELATION_NOE 纵膈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 占<|>RELATION_NOE 18.8%<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 肺门<|>RELATION_NOE 或<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移者<|>RELATION_NOE 占<|>RELATION_NOE 45.0%<|>RELATION_NOE 。<|>RELATION_NOE
伴<|>RELATION_NOE MPP<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 早期<|>RELATION_B 就<|>RELATION_I 出现<|>RELATION_E 胸膜<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 、<|>RELATION_NOE 淋巴管<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 浸润<|>RELATION_NOE 。<|>RELATION_NOE
影像学<|>RELATION_NOE 表现<|>RELATION_S 为<|>RELATION_NOE 周围型<|>RELATION_NOE 和<|>RELATION_NOE 实性<|>RELATION_NOE 病灶<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 多<|>RELATION_NOE 伴<|>RELATION_NOE 分叶征<|>RELATION_NOE 、<|>RELATION_NOE 毛刺征<|>RELATION_NOE 、<|>RELATION_NOE 胸膜<|>RELATION_NOE 凹陷征<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 集束征<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE GGO<|>RELATION_NOE 和<|>RELATION_NOE 空泡<|>RELATION_NOE 征<|>RELATION_NOE 较<|>RELATION_NOE 少<|>RELATION_NOE 。<|>RELATION_NOE
p53<|>RELATION_NOE 凋亡<|>RELATION_NOE 刺激<|>RELATION_NOE 蛋白<|>RELATION_NOE 家族<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S ASPP1<|>RELATION_NOE 、<|>RELATION_NOE ASPP2<|>RELATION_NOE 、<|>RELATION_NOE iASPP<|>RELATION_NOE 和<|>RELATION_NOE p53<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE ASPP<|>RELATION_NOE 家族<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 12<|>RELATION_NOE 只<|>RELATION_NOE C57BL<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE 小鼠<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE 瘤苗<|>RELATION_NOE 免疫组<|>RELATION_NOE (<|>RELATION_NOE 给予<|>RELATION_NOE B16F10-ESAT-6-gpi<|>RELATION_NOE /<|>RELATION_NOE IL-21<|>RELATION_NOE 瘤苗<|>RELATION_NOE 免疫<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 未<|>RELATION_NOE 给予<|>RELATION_NOE 瘤苗<|>RELATION_NOE 免疫<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
B16F10-ESAT-6-gpi<|>RELATION_NOE /<|>RELATION_NOE IL-21<|>RELATION_NOE 瘤苗<|>RELATION_NOE 免疫<|>RELATION_NOE 小鼠<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 经尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE B16F10<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 观察肺<|>RELATION_NOE 转移<|>RELATION_NOE 情况<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE 细胞<|>RELATION_NOE 毒<|>RELATION_NOE 实验<|>RELATION_NOE 分析<|>RELATION_S 瘤苗<|>RELATION_NOE 免疫<|>RELATION_NOE 小鼠<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 毒性<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 活性<|>RELATION_NOE ;<|>RELATION_NOE
酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE 检测<|>RELATION_S 免疫<|>RELATION_NOE 小鼠<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE γ<|>RELATION_NOE -<|>RELATION_NOE 干扰素<|>RELATION_NOE (<|>RELATION_NOE IFN-<|>RELATION_NOE γ<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE ;<|>RELATION_NOE
逆转<|>RELATION_NOE 录<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 瘤组织<|>RELATION_NOE 中<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE β2<|>RELATION_NOE (<|>RELATION_NOE TGF-<|>RELATION_NOE β2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 锌指<|>RELATION_NOE 增强<|>RELATION_NOE 子结合<|>RELATION_NOE 蛋白1<|>RELATION_NOE (<|>RELATION_NOE ZEB1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 丝裂<|>RELATION_NOE 原<|>RELATION_NOE 活化<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶4<|>RELATION_NOE 和<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 肌动<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 检测<|>RELATION_S 瘤组织<|>RELATION_NOE 中<|>RELATION_NOE E-<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE N-<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
瘤苗<|>RELATION_NOE 免疫<|>RELATION_NOE 鼠<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 结节数<|>RELATION_NOE 明显<|>RELATION_B 少于<|>RELATION_E 对照组<|>RELATION_NOE 。<|>RELATION_NOE
瘤苗<|>RELATION_NOE 免疫组<|>RELATION_NOE 小鼠<|>RELATION_NOE CD8<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 对<|>RELATION_NOE 靶细胞<|>RELATION_NOE 的<|>RELATION_NOE 杀伤率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 42.62<|>RELATION_NOE ±<|>RELATION_NOE 3.4<|>RELATION_NOE 65<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 22.29<|>RELATION_NOE ±<|>RELATION_NOE 1.804<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.00<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
瘤苗<|>RELATION_NOE 免疫组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 小鼠<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE IFN-<|>RELATION_NOE γ<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 55<|>RELATION_NOE 。<|>RELATION_NOE
31<|>RELATION_NOE 例<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移癌<|>RELATION_NOE 的<|>RELATION_NOE 原发灶<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 及<|>RELATION_NOE 结肠癌<|>RELATION_NOE 各<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 上颌窦癌<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 、<|>RELATION_NOE 黑色素瘤<|>RELATION_NOE 、<|>RELATION_NOE 胆囊癌<|>RELATION_NOE 及<|>RELATION_NOE 肾癌<|>RELATION_NOE 各<|>RELATION_NOE 1例.<|>RELATION_NOE
胰腺<|>RELATION_NOE 转移<|>RELATION_NOE 癌<|>RELATION_NOE 与<|>RELATION_NOE 原<|>RELATION_NOE 发癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 部位<|>RELATION_NOE 差异<|>RELATION_B 具有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 6.<|>RELATION_NOE 10<|>RELATION_NOE 2<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 14<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE N2<|>RELATION_B 淋巴结<|>RELATION_I 转移<|>RELATION_E 的<|>RELATION_NOE 危险因素<|>RELATION_NOE 分析<|>RELATION_NOE
FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 和<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 分为<|>RELATION_NOE 无<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE 非<|>RELATION_NOE N2<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 有<|>RELATION_NOE N<|>RELATION_NOE :<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE N2<|>RELATION_NOE +<|>RELATION_NOE )<|>RELATION_NOE 2组<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE x2<|>RELATION_NOE 检验<|>RELATION_NOE 或<|>RELATION_NOE 两<|>RELATION_NOE 样本<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE 比较<|>RELATION_NOE 2组<|>RELATION_NOE 问<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE SUVmax<|>RELATION_NOE 、<|>RELATION_NOE 病理学<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 等<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 将<|>RELATION_NOE 组间<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 及<|>RELATION_NOE 分组<|>RELATION_NOE 进行<|>RELATION_NOE 量化<|>RELATION_NOE 赋值<|>RELATION_NOE ,<|>RELATION_NOE 先后<|>RELATION_NOE 用<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE 回归<|>RELATION_NOE 和<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 确定<|>RELATION_NOE 对<|>RELATION_NOE N<|>RELATION_NOE :<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有<|>RELATION_NOE 意义<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE sUVmax<|>RELATION_NOE 及<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 与<|>RELATION_NOE N2<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.201<|>RELATION_NOE 、<|>RELATION_NOE 0.2<|>RELATION_NOE 45<|>RELATION_NOE 和<|>RELATION_NOE 0.1<|>RELATION_NOE 85<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
NSCLCN<|>RELATION_NOE :<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 概率<|>RELATION_NOE 随着<|>RELATION_NOE 原发病灶<|>RELATION_NOE SUVmax<|>RELATION_NOE 的<|>RELATION_NOE 增加<|>RELATION_NOE 而<|>RELATION_NOE 增加<|>RELATION_S ;<|>RELATION_NOE
当<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE SUVmax<|>RELATION_NOE ≤<|>RELATION_NOE 2.5时<|>RELATION_NOE ,<|>RELATION_NOE 发生<|>RELATION_NOE N<|>RELATION_NOE :<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 概率<|>RELATION_NOE 为<|>RELATION_NOE 0<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE SUVmax<|>RELATION_NOE ><|>RELATION_NOE 7.5时<|>RELATION_NOE 概率<|>RELATION_NOE 为<|>RELATION_NOE O<|>RELATION_NOE .<|>RELATION_NOE
SUVmax<|>RELATION_NOE 是<|>RELATION_NOE NSCLC<|>RELATION_B 发生<|>RELATION_I N2<|>RELATION_I 淋巴结<|>RELATION_I 转移<|>RELATION_E 的<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 经病<|>RELATION_NOE 理学<|>RELATION_NOE 确诊<|>RELATION_NOE 或<|>RELATION_NOE 经<|>RELATION_NOE 多<|>RELATION_NOE 种<|>RELATION_NOE 影像学<|>RELATION_NOE 综合<|>RELATION_NOE 诊断<|>RELATION_NOE 并<|>RELATION_NOE 经<|>RELATION_NOE 临床<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 证实<|>RELATION_NOE 。<|>RELATION_NOE
85<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 复发<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
18F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 复发<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 灵敏度<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 97.7%<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE /<|>RELATION_NOE 43<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 95.2%<|>RELATION_NOE (<|>RELATION_NOE 40<|>RELATION_NOE /<|>RELATION_NOE 42<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 96.5%<|>RELATION_NOE (<|>RELATION_NOE 82<|>RELATION_NOE /<|>RELATION_NOE 85<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
术前<|>RELATION_NOE 肿瘤分期<|>RELATION_NOE 、<|>RELATION_NOE 原发灶<|>RELATION_NOE 大小<|>RELATION_NOE 和<|>RELATION_NOE 原发灶<|>RELATION_NOE SUVmax<|>RELATION_NOE 是<|>RELATION_NOE 2<|>RELATION_B 年<|>RELATION_I 内<|>RELATION_I 肿瘤<|>RELATION_I 复发<|>RELATION_I 和<|>RELATION_I 转移<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 似<|>RELATION_NOE 。<|>RELATION_NOE
为<|>RELATION_NOE 2<|>RELATION_NOE 年<|>RELATION_NOE 内<|>RELATION_NOE 发生<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
新型<|>RELATION_NOE 肺癌<|>RELATION_NOE 分子探针<|>RELATION_NOE ^<|>RELATION_NOE 18F-<|>RELATION_NOE 氟丙酰<|>RELATION_NOE -Lladtthhrpwt<|>RELATION_NOE 的<|>RELATION_NOE 合成<|>RELATION_B 及其<|>RELATION_I 小动物<|>RELATION_I PET<|>RELATION_I 显像<|>RELATION_E
Micr0PET<|>RELATION_NOE 显示<|>RELATION_NOE 18F-FP-ZS-6<|>RELATION_NOE 在<|>RELATION_NOE 荷瘤<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肿瘤<|>RELATION_NOE 与<|>RELATION_NOE 腹部<|>RELATION_NOE 呈<|>RELATION_NOE 高<|>RELATION_NOE 摄取<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 注射<|>RELATION_NOE 后<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE 15<|>RELATION_NOE 、<|>RELATION_NOE 25<|>RELATION_NOE 、<|>RELATION_NOE 35<|>RELATION_NOE 、<|>RELATION_NOE 45<|>RELATION_NOE 、<|>RELATION_NOE 55<|>RELATION_NOE 、<|>RELATION_NOE 65<|>RELATION_NOE 、<|>RELATION_NOE 75<|>RELATION_NOE 和<|>RELATION_NOE 85min<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 摄取值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.3<|>RELATION_NOE 29<|>RELATION_NOE 、<|>RELATION_NOE 0.3<|>RELATION_NOE 50<|>RELATION_NOE 、<|>RELATION_NOE 0.405<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 33<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 20<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 15<|>RELATION_NOE 、<|>RELATION_NOE 0.402<|>RELATION_NOE 、<|>RELATION_NOE 0.403<|>RELATION_NOE 、<|>RELATION_NOE 0.3<|>RELATION_NOE 90%<|>RELATION_NOE ID<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE ;<|>RELATION_NOE
重离子<|>RELATION_NOE 与<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_B 肺癌<|>RELATION_I 细胞<|>RELATION_I A549<|>RELATION_E 的<|>RELATION_NOE 生物学<|>RELATION_NOE 效应<|>RELATION_NOE 比较<|>RELATION_NOE
比较<|>RELATION_B 碳<|>RELATION_I 重离子<|>RELATION_I 与<|>RELATION_I x<|>RELATION_I 射线<|>RELATION_E 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 效应<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 照射<|>RELATION_NOE 后<|>RELATION_NOE 48h<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE DNA<|>RELATION_NOE 依赖性<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE 催化亚单位<|>RELATION_NOE (<|>RELATION_NOE DNA-PKcs<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE H2AX<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
碳<|>RELATION_NOE 重离子<|>RELATION_NOE 与<|>RELATION_NOE x<|>RELATION_NOE 射线<|>RELATION_NOE 辐<|>RELATION_NOE 照后<|>RELATION_NOE DNA<|>RELATION_NOE .<|>RELATION_NOE
碳<|>RELATION_NOE 重离子<|>RELATION_NOE 照射<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 造成<|>RELATION_NOE 生物学<|>RELATION_NOE 效应<|>RELATION_NOE 远<|>RELATION_B 高于<|>RELATION_E x<|>RELATION_NOE 射线<|>RELATION_NOE 。<|>RELATION_NOE
A549<|>RELATION_NOE 细胞<|>RELATION_NOE 线粒体<|>RELATION_NOE DNA<|>RELATION_NOE 缺失<|>RELATION_NOE 模型<|>RELATION_NOE 建立<|>RELATION_B 及其<|>RELATION_I 放射敏感性<|>RELATION_I 变化<|>RELATION_E
用<|>RELATION_NOE 含<|>RELATION_NOE 微量<|>RELATION_NOE 溴化<|>RELATION_NOE 乙锭<|>RELATION_NOE (<|>RELATION_NOE EB<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 特殊<|>RELATION_NOE 培养液<|>RELATION_NOE 持续<|>RELATION_NOE 培养<|>RELATION_NOE 正常<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE p<|>RELATION_NOE °<|>RELATION_NOE 细胞<|>RELATION_NOE )<|>RELATION_NOE 以<|>RELATION_NOE 获得<|>RELATION_NOE mtDNA<|>RELATION_NOE 完全<|>RELATION_NOE 缺失<|>RELATION_NOE 的<|>RELATION_NOE p<|>RELATION_NOE °<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 生长<|>RELATION_NOE 缺陷<|>RELATION_NOE 及<|>RELATION_NOE PCR<|>RELATION_NOE 鉴定<|>RELATION_NOE 该<|>RELATION_NOE 细胞<|>RELATION_NOE 模型<|>RELATION_NOE 。<|>RELATION_NOE
利用<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射敏感性<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE 碘化丙啶<|>RELATION_NOE (<|>RELATION_NOE PI<|>RELATION_NOE )<|>RELATION_NOE 染色法<|>RELATION_NOE 及<|>RELATION_NOE 二氯<|>RELATION_NOE 荧光素<|>RELATION_NOE 双<|>RELATION_NOE 醋酸盐<|>RELATION_NOE (<|>RELATION_NOE DCFH<|>RELATION_NOE .<|>RELATION_NOE
DA<|>RELATION_NOE )<|>RELATION_NOE 染色法<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 6MVX<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 细胞周期<|>RELATION_NOE 及<|>RELATION_NOE 活性<|>RELATION_NOE 氧簇<|>RELATION_NOE (<|>RELATION_NOE ROS<|>RELATION_NOE )<|>RELATION_NOE 变化<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
p<|>RELATION_NOE °<|>RELATION_NOE 细胞<|>RELATION_NOE 较<|>RELATION_NOE p<|>RELATION_NOE °<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 降低<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 12.57<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
放射<|>RELATION_NOE 照射<|>RELATION_NOE 8Gy<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE p<|>RELATION_B °<|>RELATION_I 细胞<|>RELATION_I 较<|>RELATION_I p<|>RELATION_I °<|>RELATION_I 细胞<|>RELATION_E G<|>RELATION_NOE :<|>RELATION_NOE 期<|>RELATION_NOE 阻滞<|>RELATION_NOE 时间<|>RELATION_NOE 延长<|>RELATION_NOE ,<|>RELATION_NOE G<|>RELATION_NOE :<|>RELATION_NOE 期<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE 降低<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 6.82<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE p<|>RELATION_NOE °<|>RELATION_NOE 细胞<|>RELATION_NOE ROS<|>RELATION_NOE 升高<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE p<|>RELATION_NOE °细胞<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 14.51<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 放射<|>RELATION_NOE 照射<|>RELATION_NOE 8Gy<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE p<|>RELATION_NOE °<|>RELATION_NOE 细胞<|>RELATION_NOE 较<|>RELATION_NOE p<|>RELATION_NOE °<|>RELATION_NOE 细胞<|>RELATION_NOE G<|>RELATION_NOE :<|>RELATION_NOE 期<|>RELATION_NOE 阻滞<|>RELATION_NOE 时间<|>RELATION_NOE 延长<|>RELATION_NOE ,<|>RELATION_NOE G<|>RELATION_NOE :<|>RELATION_NOE 期<|>RELATION_NOE 细胞<|>RELATION_NOE 比例<|>RELATION_NOE 降低<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 6.82<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE p<|>RELATION_NOE °<|>RELATION_NOE 细胞<|>RELATION_NOE ROS<|>RELATION_NOE 升高<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E p<|>RELATION_NOE °<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 14.51<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
p<|>RELATION_NOE °<|>RELATION_NOE 细胞<|>RELATION_NOE 较<|>RELATION_NOE p<|>RELATION_NOE ‘<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_B 降低<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 放射<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE ROS<|>RELATION_NOE 产量<|>RELATION_NOE 降低<|>RELATION_NOE 及<|>RELATION_NOE G2<|>RELATION_NOE 期<|>RELATION_NOE 阻滞<|>RELATION_NOE 延长<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE p<|>RELATION_NOE °<|>RELATION_NOE 细胞<|>RELATION_NOE 较<|>RELATION_NOE p<|>RELATION_NOE ‘<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 放射<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE ROS<|>RELATION_NOE 产量<|>RELATION_NOE 降低<|>RELATION_NOE 及<|>RELATION_NOE G2<|>RELATION_NOE 期<|>RELATION_NOE 阻滞<|>RELATION_NOE 延长<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE 2009年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 10月<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 经<|>RELATION_NOE 支气管镜<|>RELATION_NOE 插入<|>RELATION_NOE 病变<|>RELATION_NOE 气道<|>RELATION_NOE ,<|>RELATION_NOE 远端<|>RELATION_NOE 穿刺<|>RELATION_NOE 进行<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 每例<|>RELATION_NOE 患者<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 粒子<|>RELATION_NOE 数<|>RELATION_NOE 为<|>RELATION_NOE 3－9<|>RELATION_NOE 粒<|>RELATION_NOE 。<|>RELATION_NOE
18<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 1周<|>RELATION_NOE 症状<|>RELATION_NOE 均<|>RELATION_NOE 减轻<|>RELATION_NOE ,<|>RELATION_NOE 30d<|>RELATION_NOE 后<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 显示<|>RELATION_NOE 支气管<|>RELATION_NOE 管腔<|>RELATION_NOE 扩大<|>RELATION_NOE ,<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 肺不张<|>RELATION_NOE 或<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺炎<|>RELATION_NOE 症状<|>RELATION_NOE 消失<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 未<|>RELATION_NOE 出现<|>RELATION_NOE 严重<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
125I<|>RELATION_NOE 放射性<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 肺癌<|>RELATION_I 中<|>RELATION_I 气管<|>RELATION_I 狭窄<|>RELATION_E 效果<|>RELATION_NOE 良好<|>RELATION_NOE ,<|>RELATION_NOE 操作<|>RELATION_NOE 安全<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 气管<|>RELATION_NOE 狭窄<|>RELATION_NOE 推广<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
加巴<|>RELATION_NOE 喷丁<|>RELATION_NOE 预防<|>RELATION_B 病人<|>RELATION_I 开<|>RELATION_I 胸术<|>RELATION_I 后<|>RELATION_I 疼痛<|>RELATION_I 综合征<|>RELATION_E 的<|>RELATION_NOE 效果<|>RELATION_NOE
择期<|>RELATION_NOE 在<|>RELATION_NOE 全身麻醉<|>RELATION_NOE 联合<|>RELATION_NOE 硬膜<|>RELATION_NOE 外<|>RELATION_NOE 阻滞<|>RELATION_NOE 下行<|>RELATION_NOE 肺癌<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 病人<|>RELATION_NOE 69<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 46<|>RELATION_NOE －<|>RELATION_NOE 69<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 性别<|>RELATION_NOE 不<|>RELATION_NOE 限<|>RELATION_NOE ,<|>RELATION_NOE 体重<|>RELATION_NOE 47<|>RELATION_NOE －<|>RELATION_NOE 78<|>RELATION_NOE kg<|>RELATION_NOE ,<|>RELATION_NOE ASA<|>RELATION_NOE 分级<|>RELATION_NOE Ⅰ<|>RELATION_NOE 或<|>RELATION_NOE Ⅱ<|>RELATION_NOE 级<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 分为<|>RELATION_NOE 2组<|>RELATION_NOE :<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
与<|>RELATION_B B<|>RELATION_I 组<|>RELATION_I 比较<|>RELATION_E ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 术后<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 内<|>RELATION_NOE 疼痛<|>RELATION_NOE 发生率<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 持续<|>RELATION_NOE 时间<|>RELATION_NOE 缩短<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 丙泊酚<|>RELATION_NOE 、<|>RELATION_NOE 瑞<|>RELATION_NOE 芬太尼<|>RELATION_NOE 用量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE PCEA<|>RELATION_NOE 按<|>RELATION_NOE 压<|>RELATION_NOE 次数<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
趋化<|>RELATION_NOE 因子<|>RELATION_NOE MCP-1<|>RELATION_NOE 、<|>RELATION_NOE MSP<|>RELATION_NOE 联合<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺结核<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 鉴别诊断<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 肺结核<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 和<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 中<|>RELATION_NOE 趋化<|>RELATION_NOE 因子<|>RELATION_NOE 单核细胞<|>RELATION_NOE 趋化<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE MCP-1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 刺激<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE MSP<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
选取<|>RELATION_NOE 2009年<|>RELATION_NOE 12月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 12月<|>RELATION_NOE 在<|>RELATION_NOE 浙江省<|>RELATION_NOE 衢州市<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 住院<|>RELATION_NOE 的<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE 肺结核<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 45<|>RELATION_NOE 例<|>RELATION_NOE 经病<|>RELATION_NOE 理学<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 另选<|>RELATION_NOE 30<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 献血<|>RELATION_NOE 成年人<|>RELATION_NOE 作为<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 和<|>RELATION_NOE 胸水<|>RELATION_NOE MCP-1<|>RELATION_NOE 和<|>RELATION_NOE MSP<|>RELATION_NOE 检测<|>RELATION_NOE 采用<|>RELATION_S 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CEA<|>RELATION_NOE 检测<|>RELATION_NOE 血清<|>RELATION_NOE 和<|>RELATION_NOE 胸水<|>RELATION_NOE MCP-1<|>RELATION_NOE 和<|>RELATION_NOE MSP<|>RELATION_NOE 检测<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CEA<|>RELATION_NOE 检测<|>RELATION_NOE 采用<|>RELATION_S 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE 受试者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE 曲线<|>RELATION_NOE 确定<|>RELATION_NOE MCP-1<|>RELATION_NOE 、<|>RELATION_NOE MSP<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE 诊断<|>RELATION_NOE 肺结核<|>RELATION_NOE 或<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临界值<|>RELATION_NOE 。<|>RELATION_NOE
肺结核组<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE MCP-1<|>RELATION_NOE 、<|>RELATION_NOE MSP<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_B 不同<|>RELATION_I 程度<|>RELATION_I 高于<|>RELATION_E 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 样本<|>RELATION_NOE 检测<|>RELATION_NOE 发现<|>RELATION_NOE ,<|>RELATION_NOE 肺结核组<|>RELATION_NOE 患者<|>RELATION_NOE MCP-1<|>RELATION_NOE 水平<|>RELATION_NOE 高于<|>RELATION_S 肺癌<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.69<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 低于<|>RELATION_NOE 血清<|>RELATION_NOE 样本<|>RELATION_NOE 检测<|>RELATION_NOE 发现<|>RELATION_NOE ,<|>RELATION_NOE 肺结核组<|>RELATION_NOE 患者<|>RELATION_NOE MCP-1<|>RELATION_NOE 水平<|>RELATION_NOE 高于<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.69<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 低于<|>RELATION_S 肺癌<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 0.89<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE MSP<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 血清<|>RELATION_NOE 样本<|>RELATION_NOE 检测<|>RELATION_NOE 发现<|>RELATION_NOE ,<|>RELATION_NOE 肺结核组<|>RELATION_NOE 患者<|>RELATION_NOE MCP-1<|>RELATION_NOE 水平<|>RELATION_NOE 高于<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.69<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 低于<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 0.89<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE MSP<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.89<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
胸腔积液<|>RELATION_NOE 样本<|>RELATION_NOE 检测<|>RELATION_NOE 发现<|>RELATION_NOE ,<|>RELATION_NOE 肺结核组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE MCP-1<|>RELATION_NOE 水平<|>RELATION_NOE 高于<|>RELATION_S 肺癌<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE =<|>RELATION_NOE 3.<|>RELATION_NOE 54<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE MSP<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 则<|>RELATION_NOE 低于<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 样本<|>RELATION_NOE 检测<|>RELATION_NOE 发现<|>RELATION_NOE ,<|>RELATION_NOE 肺结核组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE MCP-1<|>RELATION_NOE 水平<|>RELATION_NOE 高于<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE =<|>RELATION_NOE 3.<|>RELATION_NOE 54<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE MSP<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE 水平<|>RELATION_NOE 则<|>RELATION_NOE 低于<|>RELATION_S 肺癌<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE =<|>RELATION_NOE 3.47<|>RELATION_NOE 和<|>RELATION_NOE 3.48<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 和<|>RELATION_NOE 胸水<|>RELATION_NOE 中<|>RELATION_NOE MCP-1<|>RELATION_NOE 、<|>RELATION_NOE MSP<|>RELATION_NOE 以及<|>RELATION_NOE CEA<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_B 鉴别<|>RELATION_E 肺癌<|>RELATION_NOE 与<|>RELATION_NOE 肺结核<|>RELATION_NOE 。<|>RELATION_NOE
OLC1<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_B 及其<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE OLC1<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_B 及其<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
取<|>RELATION_NOE 5－<|>RELATION_NOE 6<|>RELATION_NOE 周龄<|>RELATION_NOE BalB<|>RELATION_NOE /<|>RELATION_NOE c<|>RELATION_NOE 小鼠<|>RELATION_NOE ,<|>RELATION_NOE OLC1<|>RELATION_NOE 全长<|>RELATION_NOE 蛋白<|>RELATION_NOE 作为<|>RELATION_NOE 抗原<|>RELATION_NOE 免疫<|>RELATION_NOE 制备<|>RELATION_NOE OLC1<|>RELATION_NOE 抗体<|>RELATION_NOE 。<|>RELATION_NOE
每<|>RELATION_NOE 只<|>RELATION_NOE 小鼠<|>RELATION_NOE 免疫<|>RELATION_NOE 4次<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 间<|>RELATION_NOE 隔<|>RELATION_NOE 2<|>RELATION_NOE 周<|>RELATION_NOE 免疫<|>RELATION_NOE 1次<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 次<|>RELATION_NOE 15<|>RELATION_NOE －<|>RELATION_NOE 30<|>RELATION_NOE 峙<|>RELATION_NOE 抗原<|>RELATION_NOE 蛋白<|>RELATION_NOE 。<|>RELATION_NOE
通过<|>RELATION_NOE Westernblot<|>RELATION_NOE 方法<|>RELATION_NOE 筛选<|>RELATION_NOE 抗体<|>RELATION_NOE ,<|>RELATION_NOE 制备<|>RELATION_NOE 检测<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE OLC1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 双<|>RELATION_NOE 抗体<|>RELATION_NOE 夹心法<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 试验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 检测<|>RELATION_NOE 28<|>RELATION_NOE 1例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 92<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 对照者<|>RELATION_NOE (<|>RELATION_NOE 性别<|>RELATION_NOE 年龄<|>RELATION_NOE 匹配<|>RELATION_NOE )<|>RELATION_NOE 血浆<|>RELATION_NOE 中<|>RELATION_NOE OLC1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
共<|>RELATION_NOE 制备<|>RELATION_NOE 了<|>RELATION_NOE 11<|>RELATION_NOE 株<|>RELATION_NOE 特异性<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE OLC1<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 成功<|>RELATION_NOE 建立<|>RELATION_NOE 了<|>RELATION_NOE 检测<|>RELATION_NOE 血浆<|>RELATION_NOE OLC1<|>RELATION_NOE 的<|>RELATION_NOE ELISA<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 范围<|>RELATION_NOE 为<|>RELATION_NOE 1.9<|>RELATION_NOE 5－<|>RELATION_NOE 62.50ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 。<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 靶向<|>RELATION_B 基因<|>RELATION_I 放射<|>RELATION_I 治疗<|>RELATION_E 的<|>RELATION_NOE 体内<|>RELATION_NOE 研究<|>RELATION_NOE 及<|>RELATION_NOE 小<|>RELATION_NOE 动物<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 体层<|>RELATION_NOE 摄影<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 靶向<|>RELATION_NOE 基因<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 体内<|>RELATION_NOE 研究<|>RELATION_NOE 及<|>RELATION_NOE 小<|>RELATION_NOE 动物<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 体层<|>RELATION_NOE 摄影<|>RELATION_NOE 评价<|>RELATION_B 疗效<|>RELATION_E 的<|>RELATION_NOE 可行性<|>RELATION_NOE
探讨<|>RELATION_NOE 靶向<|>RELATION_NOE 基因<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_S 在<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 模型<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 联合<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 应用<|>RELATION_NOE 小<|>RELATION_NOE 动物<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 体层<|>RELATION_NOE 摄影<|>RELATION_NOE (<|>RELATION_NOE Micro-PET-CT<|>RELATION_NOE )<|>RELATION_NOE 动态<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE 探讨<|>RELATION_NOE 靶向<|>RELATION_NOE 基因<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 在<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 模型<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 联合<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 应用<|>RELATION_NOE 小<|>RELATION_NOE 动物<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 体层<|>RELATION_NOE 摄影<|>RELATION_NOE (<|>RELATION_NOE Micro-PET-CT<|>RELATION_NOE )<|>RELATION_NOE 动态<|>RELATION_NOE 评价<|>RELATION_B 疗效<|>RELATION_E 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
建立<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 裸鼠<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分为<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒<|>RELATION_NOE 联合<|>RELATION_NOE 放疗组<|>RELATION_NOE (<|>RELATION_NOE 即<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒<|>RELATION_NOE 瘤内<|>RELATION_NOE 注射<|>RELATION_NOE +<|>RELATION_NOE 放疗组<|>RELATION_NOE 、<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒尾<|>RELATION_NOE 静脉内注射<|>RELATION_NOE +<|>RELATION_NOE 放疗组<|>RELATION_NOE 、<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒<|>RELATION_NOE 肌内<|>RELATION_NOE 注射<|>RELATION_NOE +<|>RELATION_NOE 放疗组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE 放疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 其<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 抑制率<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 延缓<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE Micro-PET-CT<|>RELATION_NOE 动态<|>RELATION_B 评价<|>RELATION_E ^<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 代谢<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE CD31<|>RELATION_NOE 和<|>RELATION_NOE Ki-67<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE 采用<|>RELATION_NOE Micro-PET-CT<|>RELATION_NOE 动态<|>RELATION_NOE 评价<|>RELATION_NOE ^<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 代谢<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 血管<|>RELATION_NOE 内皮<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE CD31<|>RELATION_NOE 和<|>RELATION_NOE Ki-67<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组化<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒<|>RELATION_NOE 联合<|>RELATION_NOE 放疗组<|>RELATION_NOE 的<|>RELATION_NOE VEGF<|>RELATION_NOE 、<|>RELATION_NOE CD31<|>RELATION_NOE 和<|>RELATION_NOE Ki-67<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 单纯<|>RELATION_NOE 放疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Micro-PET-CT<|>RELATION_NOE 显像<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒<|>RELATION_NOE 联合<|>RELATION_NOE 放疗组<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 标准<|>RELATION_NOE 摄取值<|>RELATION_NOE (<|>RELATION_NOE SUVmax<|>RELATION_NOE )<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 单纯<|>RELATION_NOE 放疗组<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒<|>RELATION_NOE 瘤内<|>RELATION_NOE 注射<|>RELATION_NOE +<|>RELATION_NOE 放疗组<|>RELATION_NOE 、<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒尾<|>RELATION_NOE 静脉内注射<|>RELATION_NOE +<|>RELATION_NOE 放疗组<|>RELATION_NOE 、<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒<|>RELATION_NOE 肌内<|>RELATION_NOE 注射<|>RELATION_NOE +<|>RELATION_NOE 放疗组<|>RELATION_NOE 和<|>RELATION_NOE 单纯<|>RELATION_NOE 放<|>RELATION_NOE 疗组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 与<|>RELATION_NOE SUVmax<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE r<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.9<|>RELATION_NOE 76<|>RELATION_NOE 、<|>RELATION_NOE 0.9<|>RELATION_NOE 54<|>RELATION_NOE 、<|>RELATION_NOE 0.9<|>RELATION_NOE 29<|>RELATION_NOE 和<|>RELATION_NOE 0.8<|>RELATION_NOE 71<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE Micro-PET-CT<|>RELATION_NOE 显像<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒<|>RELATION_NOE 联合<|>RELATION_NOE 放疗组<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 标准<|>RELATION_NOE 摄取值<|>RELATION_NOE (<|>RELATION_NOE SUVmax<|>RELATION_NOE )<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 单纯<|>RELATION_NOE 放疗组<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒<|>RELATION_NOE 瘤内<|>RELATION_NOE 注射<|>RELATION_NOE +<|>RELATION_NOE 放疗组<|>RELATION_NOE 、<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒尾<|>RELATION_NOE 静脉内注射<|>RELATION_NOE +<|>RELATION_NOE 放疗组<|>RELATION_NOE 、<|>RELATION_NOE 重组<|>RELATION_NOE 杆状<|>RELATION_NOE 病毒<|>RELATION_NOE 肌内<|>RELATION_NOE 注射<|>RELATION_NOE +<|>RELATION_NOE 放疗组<|>RELATION_NOE 和<|>RELATION_NOE 单纯<|>RELATION_NOE 放<|>RELATION_NOE 疗组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 与<|>RELATION_NOE SUVmax<|>RELATION_NOE 正<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.9<|>RELATION_NOE 76<|>RELATION_NOE 、<|>RELATION_NOE 0.9<|>RELATION_NOE 54<|>RELATION_NOE 、<|>RELATION_NOE 0.9<|>RELATION_NOE 29<|>RELATION_NOE 和<|>RELATION_NOE 0.8<|>RELATION_NOE 71<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
AS1411<|>RELATION_NOE 对<|>RELATION_NOE 紫杉<|>RELATION_NOE 醇耐<|>RELATION_NOE 药<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
采用0<|>RELATION_NOE －<|>RELATION_NOE 20.0μ<|>RELATION_NOE moL<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE AS1411<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 甲基<|>RELATION_NOE 甲苯基<|>RELATION_NOE 硫细胞<|>RELATION_NOE 检测<|>RELATION_S (<|>RELATION_NOE MTS<|>RELATION_NOE )<|>RELATION_NOE 实验<|>RELATION_NOE 、<|>RELATION_NOE 平板<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 采用0<|>RELATION_NOE －<|>RELATION_NOE 20.0μ<|>RELATION_NOE moL<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE AS1411<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 甲基<|>RELATION_NOE 甲苯基<|>RELATION_NOE 硫细胞<|>RELATION_NOE 检测<|>RELATION_NOE (<|>RELATION_NOE MTS<|>RELATION_NOE )<|>RELATION_NOE 实验<|>RELATION_NOE 、<|>RELATION_NOE 平板<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 活性<|>RELATION_NOE [<|>RELATION_NOE 吸<|>RELATION_NOE 光度值<|>RELATION_NOE (<|>RELATION_NOE A490nm<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 及<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 采用0<|>RELATION_NOE －<|>RELATION_NOE 20.0μ<|>RELATION_NOE moL<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE AS1411<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 甲基<|>RELATION_NOE 甲苯基<|>RELATION_NOE 硫细胞<|>RELATION_NOE 检测<|>RELATION_NOE (<|>RELATION_NOE MTS<|>RELATION_NOE )<|>RELATION_NOE 实验<|>RELATION_NOE 、<|>RELATION_NOE 平板<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE 活性<|>RELATION_NOE [<|>RELATION_NOE 吸<|>RELATION_NOE 光度值<|>RELATION_NOE (<|>RELATION_NOE A490nm<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 及<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_S 对<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 应用<|>RELATION_NOE 蛋白<|>RELATION_NOE 免疫印迹法<|>RELATION_NOE 采用0<|>RELATION_NOE －<|>RELATION_NOE 20.0μ<|>RELATION_NOE moL<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE AS1411<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 甲基<|>RELATION_NOE 甲苯基<|>RELATION_NOE 硫细胞<|>RELATION_NOE 检测<|>RELATION_NOE (<|>RELATION_NOE MTS<|>RELATION_NOE )<|>RELATION_NOE 实验<|>RELATION_NOE 、<|>RELATION_NOE 平板<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE 活性<|>RELATION_NOE [<|>RELATION_NOE 吸<|>RELATION_NOE 光度值<|>RELATION_NOE (<|>RELATION_NOE A490nm<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE 及<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 应用<|>RELATION_NOE 蛋白<|>RELATION_NOE 免疫印迹法<|>RELATION_NOE 检测<|>RELATION_S 凋亡<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
Ligasure<|>RELATION_NOE 血管<|>RELATION_NOE 闭合<|>RELATION_NOE 技术<|>RELATION_NOE 在<|>RELATION_NOE 全<|>RELATION_B 胸腔镜<|>RELATION_I 肺叶<|>RELATION_I 切除<|>RELATION_I 肺血管<|>RELATION_I 处理<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 共<|>RELATION_NOE 使用<|>RELATION_NOE LVSS<|>RELATION_NOE 处理<|>RELATION_NOE 肺血管<|>RELATION_NOE 124<|>RELATION_NOE 例<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺动脉<|>RELATION_NOE 分支<|>RELATION_NOE 93<|>RELATION_NOE 支<|>RELATION_NOE ,<|>RELATION_NOE 肺静脉<|>RELATION_NOE 分支<|>RELATION_NOE 8支<|>RELATION_NOE ,<|>RELATION_NOE 支气管动脉<|>RELATION_NOE 23<|>RELATION_NOE 支.<|>RELATION_NOE
2例术<|>RELATION_NOE 中<|>RELATION_NOE 出血<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 系<|>RELATION_NOE 操作<|>RELATION_NOE 不当<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE ,<|>RELATION_NOE 1例术<|>RELATION_NOE 后<|>RELATION_NOE 早期<|>RELATION_NOE 出血<|>RELATION_NOE ,<|>RELATION_NOE 系<|>RELATION_NOE 血管<|>RELATION_NOE 较<|>RELATION_NOE 粗<|>RELATION_NOE ,<|>RELATION_NOE 闭合<|>RELATION_NOE 后<|>RELATION_NOE 血管<|>RELATION_NOE 残端<|>RELATION_NOE 在<|>RELATION_NOE 后续<|>RELATION_NOE 操作<|>RELATION_NOE 中<|>RELATION_NOE 被<|>RELATION_NOE 揉搓<|>RELATION_NOE 所<|>RELATION_NOE 致<|>RELATION_NOE ,<|>RELATION_NOE 余者<|>RELATION_NOE 均<|>RELATION_NOE 安全<|>RELATION_NOE 可靠<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 围术期<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
综合<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
20<|>RELATION_NOE 10年<|>RELATION_NOE 2月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 2月<|>RELATION_NOE ,<|>RELATION_NOE 选取<|>RELATION_NOE 在<|>RELATION_NOE 我院<|>RELATION_NOE 住院<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 按照<|>RELATION_NOE 随机<|>RELATION_NOE 数字法<|>RELATION_NOE 分为<|>RELATION_NOE 干预组<|>RELATION_NOE 及<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 化疗<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 仅<|>RELATION_NOE 给予<|>RELATION_NOE 常规<|>RELATION_NOE 抗癌<|>RELATION_NOE 药物治疗<|>RELATION_NOE 及<|>RELATION_NOE 常规<|>RELATION_NOE 基础<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 干预组<|>RELATION_NOE 在<|>RELATION_NOE 常规化疗<|>RELATION_NOE 及<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE ,<|>RELATION_NOE 实施<|>RELATION_NOE 综合<|>RELATION_NOE 护理<|>RELATION_NOE 干预.<|>RELATION_NOE
对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_B 健康<|>RELATION_I 教育<|>RELATION_I 及<|>RELATION_I 综合<|>RELATION_I 护理<|>RELATION_I 干预<|>RELATION_E 可<|>RELATION_NOE 减少<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 焦虑<|>RELATION_NOE 及<|>RELATION_NOE 抑郁症状<|>RELATION_NOE ,<|>RELATION_NOE 全面<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE .<|>RELATION_NOE
浙江省<|>RELATION_NOE 绍兴市<|>RELATION_NOE 20<|>RELATION_NOE 12<|>RELATION_NOE 年<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患病<|>RELATION_NOE 现状<|>RELATION_NOE 分析<|>RELATION_S
男性<|>RELATION_NOE 患病率<|>RELATION_NOE 为<|>RELATION_NOE 33<|>RELATION_NOE 0.46<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 中标率<|>RELATION_NOE 为<|>RELATION_NOE 14<|>RELATION_NOE 9.28<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 患病率<|>RELATION_NOE 为<|>RELATION_NOE 25<|>RELATION_NOE 1.93<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 中标率<|>RELATION_NOE 为<|>RELATION_NOE 12<|>RELATION_NOE 4.79<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE .<|>RELATION_NOE
城市<|>RELATION_NOE 患病率<|>RELATION_NOE 为<|>RELATION_NOE 36<|>RELATION_NOE 4.85<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 中标率<|>RELATION_NOE 为<|>RELATION_NOE 17<|>RELATION_NOE 1.77<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 农村<|>RELATION_NOE 患病率<|>RELATION_NOE 为<|>RELATION_NOE 27<|>RELATION_NOE 7.86<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 中标率<|>RELATION_NOE 为<|>RELATION_NOE 13<|>RELATION_NOE 0.93<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE .<|>RELATION_NOE
20<|>RELATION_NOE 12<|>RELATION_NOE 年<|>RELATION_NOE 绍兴市<|>RELATION_NOE 前<|>RELATION_NOE 十<|>RELATION_NOE 位<|>RELATION_NOE 主要<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 依次<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 、<|>RELATION_NOE 胰腺癌<|>RELATION_NOE 、<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE 、<|>RELATION_NOE 白血病<|>RELATION_NOE ,<|>RELATION_NOE 占<|>RELATION_NOE 全部<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患病<|>RELATION_NOE 的<|>RELATION_NOE 76.7<|>RELATION_NOE 7%<|>RELATION_NOE .<|>RELATION_NOE
小<|>RELATION_NOE 细胞性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 循环<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
选取<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 4月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 4月<|>RELATION_NOE 在<|>RELATION_NOE 上海<|>RELATION_NOE 长海<|>RELATION_NOE 医院<|>RELATION_NOE 住院<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 局限期<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 广泛期<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 非<|>RELATION_NOE 结核<|>RELATION_NOE 肺良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
采集<|>RELATION_NOE 静脉<|>RELATION_NOE 血<|>RELATION_NOE 7.5ml<|>RELATION_NOE 放<|>RELATION_NOE 人<|>RELATION_NOE CellSave<|>RELATION_NOE 管<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 样品<|>RELATION_NOE 经过<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE 经<|>RELATION_NOE CellTracksAutoPrep<|>RELATION_NOE 系统<|>RELATION_NOE 荧光<|>RELATION_NOE 扫描<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 系统<|>RELATION_NOE 根据<|>RELATION_NOE 荧光<|>RELATION_NOE
同时<|>RELATION_NOE ,<|>RELATION_NOE 采集<|>RELATION_NOE 2ml<|>RELATION_NOE 静脉<|>RELATION_NOE 血<|>RELATION_NOE ,<|>RELATION_NOE 离心<|>RELATION_NOE 后<|>RELATION_NOE 取<|>RELATION_NOE 上<|>RELATION_NOE 清液<|>RELATION_NOE 进行<|>RELATION_NOE NSE<|>RELATION_NOE (<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 皮<|>RELATION_NOE 联合<|>RELATION_NOE 支气管<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 冷冻<|>RELATION_NOE 消融<|>RELATION_NOE 治疗<|>RELATION_S 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 联合<|>RELATION_NOE 经皮<|>RELATION_NOE 及<|>RELATION_NOE 经<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE 引导<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 冷冻<|>RELATION_NOE 消融<|>RELATION_NOE 治疗<|>RELATION_S 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
47<|>RELATION_NOE 例<|>RELATION_NOE 不可<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE 个<|>RELATION_NOE 气管<|>RELATION_NOE 内型<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 26<|>RELATION_NOE 个<|>RELATION_NOE 气管<|>RELATION_NOE 壁型<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 21<|>RELATION_NOE 个<|>RELATION_NOE 气管<|>RELATION_NOE 外型<|>RELATION_NOE 病灶<|>RELATION_NOE )<|>RELATION_NOE 共行<|>RELATION_NOE 69<|>RELATION_NOE 次<|>RELATION_NOE 经皮<|>RELATION_NOE 、<|>RELATION_NOE 经<|>RELATION_NOE 气管<|>RELATION_NOE 镜<|>RELATION_NOE 引导<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 冷冻<|>RELATION_NOE 消融<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 统计<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存期<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 冷冻<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE PFS<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 部位<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE PFS<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE ±<|>RELATION_NOE 5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 长于<|>RELATION_E 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE 4<|>RELATION_NOE ±<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.0001<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
重庆<|>RELATION_NOE 地区<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_S 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 分析<|>RELATION_NOE 重庆<|>RELATION_NOE 地区<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 分析<|>RELATION_S
探讨<|>RELATION_NOE 重庆市<|>RELATION_NOE 地区<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE 55<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 癌组织<|>RELATION_NOE 或<|>RELATION_NOE 胸水<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 扩增<|>RELATION_NOE 阻滞<|>RELATION_NOE 突变<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE ARMS<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE EGFR<|>RELATION_NOE 外显子<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 。<|>RELATION_NOE
吸烟<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 患者<|>RELATION_NOE 突变率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 11.11%<|>RELATION_NOE 、<|>RELATION_NOE 39.2<|>RELATION_NOE 9%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 17<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
外显子<|>RELATION_NOE 19<|>RELATION_NOE 突变<|>RELATION_NOE 8例<|>RELATION_NOE (<|>RELATION_NOE 57.1<|>RELATION_NOE 4%<|>RELATION_NOE ,<|>RELATION_NOE 8/14<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 外显子<|>RELATION_NOE 21<|>RELATION_NOE 突变<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 35.7<|>RELATION_NOE 1%<|>RELATION_NOE ,<|>RELATION_NOE 5/14<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 外显子<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 同时<|>RELATION_NOE 突变<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 7.1<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 1/14<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 重庆市<|>RELATION_NOE 地区<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 非吸烟者<|>RELATION_NOE EGFR<|>RELATION_NOE 突变率<|>RELATION_NOE 较<|>RELATION_B 高<|>RELATION_E ,<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 以<|>RELATION_NOE 外显子<|>RELATION_NOE 19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 为主<|>RELATION_NOE 。<|>RELATION_NOE
外<|>RELATION_NOE 周血<|>RELATION_NOE 单核细胞<|>RELATION_NOE 数量<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 近<|>RELATION_NOE 、<|>RELATION_NOE 远期<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 分析<|>RELATION_NOE
基于<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 单核细胞<|>RELATION_NOE (<|>RELATION_NOE pbMXD<|>RELATION_NOE )<|>RELATION_NOE 迁徙<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 放<|>RELATION_NOE 疗<|>RELATION_NOE 后<|>RELATION_NOE 复发<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE pbMXD<|>RELATION_NOE 在<|>RELATION_NOE 监测<|>RELATION_NOE 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 近<|>RELATION_NOE 、<|>RELATION_NOE 远期<|>RELATION_NOE 疗效<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 与<|>RELATION_NOE TYMSmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE nonsmall-celllungcancer<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 棘皮<|>RELATION_NOE 动物<|>RELATION_NOE 微管<|>RELATION_NOE 样<|>RELATION_NOE 蛋白<|>RELATION_NOE 4-<|>RELATION_NOE 间变<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE echinodcriBmicrotubuleassociatedproteinlike4-anaplasticLymphomakinase<|>RELATION_NOE .<|>RELATION_NOE
ALK<|>RELATION_NOE )<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 与<|>RELATION_NOE 胸苷酸<|>RELATION_NOE 合成<|>RELATION_NOE 酶<|>RELATION_NOE (<|>RELATION_NOE Thymidylatesynthase<|>RELATION_NOE ,<|>RELATION_NOE TYMS<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
应用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 257<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE EML4-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 、<|>RELATION_NOE TYMSmRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 占<|>RELATION_NOE 4.2<|>RELATION_NOE 8%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 257<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 较<|>RELATION_B 高<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
与<|>RELATION_NOE 未<|>RELATION_NOE 检测<|>RELATION_NOE 到<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 阳性<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 阳性<|>RELATION_NOE 与<|>RELATION_NOE TYMSmRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 阳性<|>RELATION_NOE 患者<|>RELATION_NOE TYMS<|>RELATION_B 倾向<|>RELATION_I 低<|>RELATION_I 表达<|>RELATION_E ,<|>RELATION_NOE 可能<|>RELATION_NOE 从<|>RELATION_NOE -<|>RELATION_NOE 线化<|>RELATION_NOE 疗药<|>RELATION_NOE 的<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 中<|>RELATION_NOE 受益<|>RELATION_NOE 。<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 阳性<|>RELATION_NOE 患者<|>RELATION_NOE TYMS<|>RELATION_NOE 倾向<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 从<|>RELATION_NOE -<|>RELATION_NOE 线<|>RELATION_NOE 化疗<|>RELATION_NOE 药<|>RELATION_NOE 的<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 中<|>RELATION_NOE 受益<|>RELATION_S 。<|>RELATION_NOE
单<|>RELATION_NOE 操作孔<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 学习曲线<|>RELATION_B 研究<|>RELATION_E
回顾性研究<|>RELATION_NOE 解放军<|>RELATION_NOE 总医院<|>RELATION_NOE 胸外科<|>RELATION_NOE 自<|>RELATION_NOE 2009年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 5月<|>RELATION_NOE 采用<|>RELATION_NOE 单操<|>RELATION_NOE 作孔<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 200<|>RELATION_NOE 例<|>RELATION_NOE 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病历<|>RELATION_NOE 资料.<|>RELATION_NOE
按<|>RELATION_NOE 手术时间<|>RELATION_NOE 顺序<|>RELATION_NOE 将<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 5组<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 、<|>RELATION_NOE D<|>RELATION_NOE 、<|>RELATION_NOE E<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 各组<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 数目<|>RELATION_NOE 及<|>RELATION_NOE 引流管<|>RELATION_NOE 拔<|>RELATION_NOE 出<|>RELATION_NOE 时间<|>RELATION_NOE 。<|>RELATION_NOE
新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 预后<|>RELATION_NOE 影响<|>RELATION_S 的<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE
讨<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 系统<|>RELATION_NOE 检索<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 中文<|>RELATION_NOE 数据库<|>RELATION_NOE (<|>RELATION_NOE 万方<|>RELATION_NOE 、<|>RELATION_NOE 维普<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 英文<|>RELATION_NOE 数据库<|>RELATION_NOE (<|>RELATION_NOE PubMed<|>RELATION_NOE 、<|>RELATION_NOE Cochrane<|>RELATION_NOE Library<|>RELATION_NOE )<|>RELATION_NOE 截止<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 6月<|>RELATION_NOE 发表<|>RELATION_NOE 的<|>RELATION_NOE 有关<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 随机<|>RELATION_NOE 临床<|>RELATION_NOE 对照<|>RELATION_NOE 试验<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 对<|>RELATION_NOE 入选<|>RELATION_NOE 文献<|>RELATION_NOE 进行<|>RELATION_NOE 评价<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 提取<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 直接<|>RELATION_NOE 手术<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 能<|>RELATION_NOE 提高<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_I 患者<|>RELATION_I 的<|>RELATION_I 术后<|>RELATION_I 长期<|>RELATION_I 生存率<|>RELATION_E ,<|>RELATION_NOE 但<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 断定<|>RELATION_NOE
分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 临床<|>RELATION_B 分析<|>RELATION_E
Line-1<|>RELATION_NOE 甲基化<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
了解<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE Line-1<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 吸烟<|>RELATION_NOE 等<|>RELATION_NOE 生活<|>RELATION_NOE 习惯<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE 了解<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE Line-1<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_NOE 吸烟<|>RELATION_NOE 等<|>RELATION_NOE 生活<|>RELATION_NOE 习惯<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
应用<|>RELATION_NOE 焦磷<|>RELATION_NOE 酸测<|>RELATION_NOE 序法<|>RELATION_NOE 检测<|>RELATION_S 197<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 与<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE Line-1<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 非<|>RELATION_NOE 条件<|>RELATION_NOE Logistic<|>RELATION_NOE 回归<|>RELATION_NOE 模型<|>RELATION_NOE 分析<|>RELATION_NOE Line1<|>RELATION_NOE 甲基化<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 吸烟<|>RELATION_NOE 等<|>RELATION_NOE 生活<|>RELATION_NOE 习惯<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
结合<|>RELATION_NOE 流行病学<|>RELATION_NOE 资料<|>RELATION_NOE 构建<|>RELATION_NOE 非条<|>RELATION_NOE Logistic<|>RELATION_NOE 模型<|>RELATION_NOE 表明<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 其他<|>RELATION_NOE 类型<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 比<|>RELATION_NOE 腺癌<|>RELATION_NOE 组织<|>RELATION_NOE Line-1<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 低<|>RELATION_S ,<|>RELATION_NOE OR<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 6.9<|>RELATION_NOE 89<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 1.8<|>RELATION_NOE 18<|>RELATION_NOE －2<|>RELATION_NOE 6.8<|>RELATION_NOE 65<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 17.1<|>RELATION_NOE 89<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 2.3<|>RELATION_NOE 45<|>RELATION_NOE －1<|>RELATION_NOE 26.008<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 比<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE Line-1<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 低<|>RELATION_S ,<|>RELATION_NOE OR-7.477<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 2.002<|>RELATION_NOE －2<|>RELATION_NOE 7.9<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
进一步<|>RELATION_NOE 分析<|>RELATION_NOE 癌<|>RELATION_NOE 组织<|>RELATION_NOE 与<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE Line-1<|>RELATION_NOE 甲基化<|>RELATION_NOE 改变<|>RELATION_NOE 与<|>RELATION_NOE 流行病学<|>RELATION_NOE 资料<|>RELATION_NOE 表明<|>RELATION_NOE ,<|>RELATION_NOE 该<|>RELATION_NOE 低<|>RELATION_NOE 甲基化<|>RELATION_NOE 改变<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE Line-1<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 吸烟<|>RELATION_NOE 情况<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 癌组织<|>RELATION_NOE 及<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 间<|>RELATION_NOE 的<|>RELATION_NOE Line-1<|>RELATION_NOE 低<|>RELATION_NOE 甲基化<|>RELATION_NOE 改变<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE Line-1<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 吸烟<|>RELATION_NOE 情况<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺癌<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 癌组织<|>RELATION_NOE 及<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 间<|>RELATION_NOE 的<|>RELATION_NOE Line-1<|>RELATION_NOE 低<|>RELATION_NOE 甲基化<|>RELATION_NOE 改变<|>RELATION_NOE 相关<|>RELATION_S 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 配对<|>RELATION_NOE 后<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 术前<|>RELATION_NOE 并发症<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE 直径<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 和<|>RELATION_NOE 分期<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 临床<|>RELATION_NOE Ⅰ<|>RELATION_NOE /<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 与<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 具有<|>RELATION_S 同样<|>RELATION_NOE 的<|>RELATION_NOE 安全性<|>RELATION_NOE 和<|>RELATION_NOE 彻底性<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 术<|>RELATION_NOE 后<|>RELATION_NOE 生存<|>RELATION_NOE 和<|>RELATION_NOE 复发<|>RELATION_NOE 情况<|>RELATION_NOE 相仿<|>RELATION_NOE ,<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE Ⅰ<|>RELATION_NOE /<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 与<|>RELATION_NOE 开胸<|>RELATION_NOE 手术<|>RELATION_NOE 具有<|>RELATION_NOE 同样<|>RELATION_NOE 的<|>RELATION_NOE 安全性<|>RELATION_NOE 和<|>RELATION_NOE 彻底性<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 术<|>RELATION_NOE 后<|>RELATION_NOE 生存<|>RELATION_NOE 和<|>RELATION_NOE 复发<|>RELATION_NOE 情况<|>RELATION_NOE 相仿<|>RELATION_NOE ,<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 具有<|>RELATION_S 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 住院时间<|>RELATION_NOE 短<|>RELATION_NOE 的<|>RELATION_NOE 优势<|>RELATION_NOE 。<|>RELATION_NOE
恩度<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_B 组织<|>RELATION_I 血流<|>RELATION_I 灌注<|>RELATION_I 和<|>RELATION_I 血管<|>RELATION_I 生成<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
观察<|>RELATION_NOE 恩度<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 对<|>RELATION_NOE Lewis<|>RELATION_B 肺癌<|>RELATION_I 小鼠<|>RELATION_I 肿瘤<|>RELATION_I 组织<|>RELATION_I 血流<|>RELATION_I 灌注<|>RELATION_I 和<|>RELATION_I 血管<|>RELATION_I 生成<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
从<|>RELATION_NOE 治疗<|>RELATION_NOE 当天<|>RELATION_NOE 开始<|>RELATION_NOE ,<|>RELATION_NOE 隔日<|>RELATION_NOE 测量<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE ,<|>RELATION_NOE 绘制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 采用<|>RELATION_NOE 局部<|>RELATION_NOE 瘤体<|>RELATION_NOE 直接<|>RELATION_NOE 团注声诺维<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 行<|>RELATION_NOE 超声<|>RELATION_NOE 造影<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE SonoLiver1.0<|>RELATION_NOE 软件<|>RELATION_NOE 分析<|>RELATION_NOE 造影<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 获取<|>RELATION_NOE 的<|>RELATION_NOE 时间<|>RELATION_NOE 一<|>RELATION_NOE 强度<|>RELATION_NOE 曲线<|>RELATION_NOE (<|>RELATION_NOE TIC<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 动态<|>RELATION_NOE 血管<|>RELATION_NOE 模式<|>RELATION_NOE 曲线<|>RELATION_NOE (<|>RELATION_NOE DVP<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE TIC<|>RELATION_NOE 各项<|>RELATION_NOE 参数<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
荷瘤<|>RELATION_NOE 小鼠<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 随<|>RELATION_NOE 时间<|>RELATION_NOE 不断<|>RELATION_NOE 增长<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 恩度<|>RELATION_NOE 联合<|>RELATION_NOE 放疗组<|>RELATION_NOE 与<|>RELATION_NOE 其余<|>RELATION_NOE 3组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_B 第6<|>RELATION_I 天<|>RELATION_I 后<|>RELATION_I 生长<|>RELATION_I 速度<|>RELATION_I 明显<|>RELATION_I 变<|>RELATION_I 慢<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
峰值<|>RELATION_NOE 强度<|>RELATION_NOE (<|>RELATION_NOE IMAX<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 曲线下面积<|>RELATION_NOE (<|>RELATION_NOE AUC<|>RELATION_NOE )<|>RELATION_NOE 随着<|>RELATION_B 肿瘤<|>RELATION_I 生长<|>RELATION_I 时间<|>RELATION_E 呈<|>RELATION_NOE 上升<|>RELATION_NOE 趋势<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 在<|>RELATION_NOE 后期<|>RELATION_NOE 由于<|>RELATION_NOE 肿瘤<|>RELATION_NOE 内<|>RELATION_NOE 出现<|>RELATION_NOE 明显<|>RELATION_NOE 坏死<|>RELATION_NOE ,<|>RELATION_NOE 出现<|>RELATION_NOE 下降<|>RELATION_NOE 。<|>RELATION_NOE
siRNA<|>RELATION_NOE 敲除<|>RELATION_NOE PPAR<|>RELATION_NOE β<|>RELATION_NOE /<|>RELATION_NOE δ<|>RELATION_NOE 影响<|>RELATION_NOE 细胞<|>RELATION_NOE 稳定性<|>RELATION_NOE ,<|>RELATION_NOE 促进<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 细胞<|>RELATION_NOE 活力<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 下降<|>RELATION_NOE 到<|>RELATION_NOE 90%<|>RELATION_NOE ;<|>RELATION_NOE
羧胺<|>RELATION_NOE 三<|>RELATION_NOE 唑<|>RELATION_NOE 联合<|>RELATION_NOE 小剂量<|>RELATION_NOE 地塞米松<|>RELATION_NOE 抗<|>RELATION_B 肿瘤<|>RELATION_E 作用<|>RELATION_NOE 研究<|>RELATION_NOE
研究<|>RELATION_NOE 羧胺<|>RELATION_NOE 三<|>RELATION_NOE 唑<|>RELATION_NOE (<|>RELATION_NOE CAI<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_B Lewis<|>RELATION_I 肺癌<|>RELATION_I 移植<|>RELATION_I 瘤<|>RELATION_I 生长<|>RELATION_E 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE 及其<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE .<|>RELATION_NOE
建立<|>RELATION_NOE C57BL<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 评估<|>RELATION_NOE CAI<|>RELATION_NOE 、<|>RELATION_NOE DEX<|>RELATION_NOE 及其<|>RELATION_NOE 合用组<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 疗效<|>RELATION_NOE .<|>RELATION_NOE
ELISA<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 匀浆<|>RELATION_NOE 中<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE -<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE .<|>RELATION_NOE
免疫<|>RELATION_NOE 荧光法<|>RELATION_NOE 对<|>RELATION_NOE 提取<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 内<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 进行<|>RELATION_NOE 鉴定<|>RELATION_S .<|>RELATION_NOE
RT-PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 肿瘤<|>RELATION_NOE 内<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 中<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
CAI<|>RELATION_NOE 能够<|>RELATION_NOE 抑制<|>RELATION_S 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE
前列腺癌<|>RELATION_NOE 肺或<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_S 10<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 肺或<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_S 临床<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
回顾<|>RELATION_NOE 分析<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 11月<|>RELATION_NOE 105<|>RELATION_NOE 例经<|>RELATION_NOE 活检<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 通过<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 肺<|>RELATION_NOE 或<|>RELATION_NOE 胸膜<|>RELATION_NOE 穿刺<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 肺或<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE .<|>RELATION_NOE
复习<|>RELATION_NOE 文献<|>RELATION_NOE 分析<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 肺或<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 肺或<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 主要<|>RELATION_B 见于<|>RELATION_E 老年<|>RELATION_NOE 男性<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 呼吸系统<|>RELATION_NOE 症状<|>RELATION_NOE 为<|>RELATION_NOE 首发<|>RELATION_NOE 症状<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 泌尿<|>RELATION_NOE 系统<|>RELATION_NOE 症状<|>RELATION_NOE 为<|>RELATION_NOE 首发<|>RELATION_NOE 症状<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 均<|>RELATION_NOE 通过<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 肺<|>RELATION_NOE 或<|>RELATION_NOE 胸膜<|>RELATION_NOE 穿刺<|>RELATION_NOE 确诊<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 胸膜<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 病理学<|>RELATION_NOE Gleason<|>RELATION_NOE 评分5<|>RELATION_NOE 分<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 6分<|>RELATION_NOE 2例<|>RELATION_NOE 、<|>RELATION_NOE 7分<|>RELATION_NOE 7例<|>RELATION_NOE 。<|>RELATION_NOE
对于<|>RELATION_NOE 以<|>RELATION_NOE 呼吸系统<|>RELATION_NOE 症状<|>RELATION_NOE 为<|>RELATION_NOE 首发<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 前列腺<|>RELATION_NOE 特异性<|>RELATION_NOE 抗原<|>RELATION_NOE 升高<|>RELATION_NOE 、<|>RELATION_NOE 直肠<|>RELATION_NOE 指诊<|>RELATION_NOE 异常<|>RELATION_NOE 的<|>RELATION_NOE 男性<|>RELATION_NOE 患者<|>RELATION_NOE 应<|>RELATION_NOE 加强<|>RELATION_B 前列腺癌<|>RELATION_I 筛查<|>RELATION_E ,<|>RELATION_NOE 以免<|>RELATION_NOE 延<|>RELATION_NOE 误诊<|>RELATION_NOE 治<|>RELATION_NOE .<|>RELATION_NOE
30<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 疗程<|>RELATION_NOE DC<|>RELATION_NOE /<|>RELATION_NOE CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 输注<|>RELATION_NOE 。<|>RELATION_NOE
输注<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 完成<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 疗程<|>RELATION_NOE 细胞<|>RELATION_NOE 输注<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 测定<|>RELATION_S P-<|>RELATION_NOE 糖<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE P-gp<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 多<|>RELATION_NOE 药耐<|>RELATION_NOE 药<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE MRP<|>RELATION_NOE )<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞<|>RELATION_NOE 百分率<|>RELATION_NOE 以及<|>RELATION_NOE 平均<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 。<|>RELATION_NOE
30<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 全部<|>RELATION_B 检测<|>RELATION_I 出<|>RELATION_E P-gp<|>RELATION_NOE 和<|>RELATION_NOE MRP<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞<|>RELATION_NOE 。<|>RELATION_NOE
DC<|>RELATION_NOE /<|>RELATION_NOE CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 输注<|>RELATION_NOE 前<|>RELATION_NOE ,<|>RELATION_NOE P-gp<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞<|>RELATION_NOE 百分率<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 38.67<|>RELATION_NOE ±<|>RELATION_NOE 8.76<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 2.18<|>RELATION_NOE ±<|>RELATION_NOE 0.34<|>RELATION_NOE ;<|>RELATION_NOE
DC<|>RELATION_NOE /<|>RELATION_NOE CIK<|>RELATION_NOE 细胞<|>RELATION_NOE 输注<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE P-gp<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞<|>RELATION_NOE 百分率<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 34.96<|>RELATION_NOE ±<|>RELATION_NOE 6.9<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 2.07<|>RELATION_NOE ±<|>RELATION_NOE 0.42<|>RELATION_NOE ;<|>RELATION_NOE
射波刀<|>RELATION_NOE 联合<|>RELATION_NOE 热化疗<|>RELATION_NOE 对<|>RELATION_NOE 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 分析<|>RELATION_E
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 11月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 8月<|>RELATION_NOE 于<|>RELATION_NOE 解放军<|>RELATION_NOE 第107<|>RELATION_NOE 医院<|>RELATION_NOE 全军<|>RELATION_NOE 肿瘤<|>RELATION_NOE 无<|>RELATION_NOE 创<|>RELATION_NOE 诊疗<|>RELATION_NOE 中心<|>RELATION_NOE 经<|>RELATION_NOE 射波刀<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 病历<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 纳入<|>RELATION_NOE 标准<|>RELATION_NOE 的<|>RELATION_NOE 119<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 采取<|>RELATION_NOE 了<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 不同<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE :<|>RELATION_NOE 单独<|>RELATION_NOE 射波刀<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 射波刀<|>RELATION_NOE 联合化疗<|>RELATION_NOE 及<|>RELATION_NOE 射波刀<|>RELATION_NOE 联合<|>RELATION_NOE 热化疗<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 局部<|>RELATION_NOE 控制<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE KPS<|>RELATION_NOE 评分<|>RELATION_NOE 和<|>RELATION_NOE 毒性<|>RELATION_NOE 分析<|>RELATION_NOE 进行<|>RELATION_NOE 综合<|>RELATION_NOE 评价<|>RELATION_NOE ,<|>RELATION_NOE 依照<|>RELATION_NOE WHO<|>RELATION_NOE 肿瘤<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 标准<|>RELATION_NOE 判定<|>RELATION_NOE 肿瘤<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE (<|>RELATION_NOE 有效率<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
磷酸肌酸<|>RELATION_NOE 钠<|>RELATION_NOE 对<|>RELATION_NOE 含<|>RELATION_NOE 紫杉烷类<|>RELATION_NOE 药物<|>RELATION_NOE 化疗非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 心脏<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 磷酸肌酸<|>RELATION_NOE 钠<|>RELATION_NOE (<|>RELATION_NOE PHO<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 含<|>RELATION_NOE 紫杉烷类<|>RELATION_NOE 药物<|>RELATION_NOE 化疗<|>RELATION_NOE 时<|>RELATION_NOE 心脏<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
选取<|>RELATION_NOE 150<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 试验组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 75<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 仅<|>RELATION_NOE 采用<|>RELATION_NOE 含<|>RELATION_NOE 紫杉烷类<|>RELATION_NOE 药物<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
所有<|>RELATION_NOE 患者<|>RELATION_NOE 化疗4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 监测<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心脏<|>RELATION_NOE 功能<|>RELATION_NOE 状态<|>RELATION_NOE 变化<|>RELATION_NOE 和<|>RELATION_NOE 非<|>RELATION_NOE 心脏毒性<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 心肌<|>RELATION_NOE 肌钙蛋白<|>RELATION_NOE I<|>RELATION_NOE (<|>RELATION_NOE cTnI<|>RELATION_NOE )<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_B 统计学<|>RELATION_I 意义<|>RELATION_E [<|>RELATION_NOE (<|>RELATION_NOE 12.55<|>RELATION_NOE ±<|>RELATION_NOE 3.63<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE vs<|>RELATION_NOE .<|>RELATION_NOE
PHO<|>RELATION_NOE 在<|>RELATION_NOE 不<|>RELATION_NOE 增加<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 非<|>RELATION_NOE 心脏毒性<|>RELATION_NOE 的<|>RELATION_NOE 前提<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E 紫杉<|>RELATION_NOE 醇类<|>RELATION_NOE 药物<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心脏毒性<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 11<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 首程<|>RELATION_B 诊治<|>RELATION_E 临床<|>RELATION_NOE 分析<|>RELATION_NOE
研究<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 首<|>RELATION_B 次<|>RELATION_I 诊治<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 症状<|>RELATION_NOE 、<|>RELATION_NOE 就诊<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 症状<|>RELATION_NOE :<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 咳痰<|>RELATION_NOE 、<|>RELATION_NOE 痰中<|>RELATION_NOE 带<|>RELATION_NOE 血<|>RELATION_NOE 、<|>RELATION_NOE 胸痛<|>RELATION_NOE 、<|>RELATION_NOE 胸闷<|>RELATION_NOE 、<|>RELATION_NOE 憋喘<|>RELATION_NOE 、<|>RELATION_NOE 发热<|>RELATION_NOE 及<|>RELATION_NOE 肺外<|>RELATION_NOE 症状<|>RELATION_NOE 。<|>RELATION_NOE
就诊<|>RELATION_NOE 时间<|>RELATION_NOE :<|>RELATION_NOE 最<|>RELATION_NOE 短<|>RELATION_NOE 3d<|>RELATION_NOE ,<|>RELATION_NOE 最<|>RELATION_NOE 长<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 时间<|>RELATION_NOE 2.29<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 中位<|>RELATION_NOE 时间<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 。<|>RELATION_NOE
病理<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 类型<|>RELATION_NOE :<|>RELATION_NOE 腺癌<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 及<|>RELATION_NOE 其他<|>RELATION_NOE 类型<|>RELATION_NOE 癌<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 621<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 53.2%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 337<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 28.8%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 143<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 12.2%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 1.5%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 4.2%<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 表明<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE T<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE N<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 及<|>RELATION_NOE 治疗<|>RELATION_NOE 方式<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_B 生存<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 症状<|>RELATION_NOE 不<|>RELATION_NOE 典型<|>RELATION_NOE ,<|>RELATION_NOE 就诊<|>RELATION_NOE 时间<|>RELATION_NOE 较<|>RELATION_NOE 晚<|>RELATION_NOE ,<|>RELATION_NOE 就诊<|>RELATION_NOE 时<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 较<|>RELATION_NOE 晚<|>RELATION_NOE ,<|>RELATION_NOE 预后<|>RELATION_NOE 较<|>RELATION_NOE 差<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE T<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE N<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 及<|>RELATION_NOE 治疗<|>RELATION_NOE 方式<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_B 生存<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 联合<|>RELATION_NOE 动态<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 诊断<|>RELATION_I 和<|>RELATION_I 监控<|>RELATION_I 治疗<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
探讨<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 鳞状<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 癌抗原<|>RELATION_NOE (<|>RELATION_NOE SCC-Ag<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE (<|>RELATION_NOE NSE<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 诊断<|>RELATION_I 和<|>RELATION_I 监控<|>RELATION_I 治疗<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 116<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 观察组<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE (<|>RELATION_NOE 手术<|>RELATION_NOE 或<|>RELATION_NOE 放化疗<|>RELATION_NOE )<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 血清<|>RELATION_NOE SCC-Ag<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 作<|>RELATION_NOE 对照<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE SCC-Ag<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学分型<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 监控<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 其<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 水平<|>RELATION_NOE 较<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 明显<|>RELATION_B 下降<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 肺癌<|>RELATION_NOE 中晚<|>RELATION_NOE 期组<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 复发组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE SCC-Ag<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 较<|>RELATION_NOE 早期<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 转移<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 复发组<|>RELATION_NOE 明显<|>RELATION_B 增高<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
三<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 高<|>RELATION_NOE 达<|>RELATION_NOE 96.5<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 各<|>RELATION_NOE 单项<|>RELATION_NOE 检测<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 敏感性<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE SCC-Ag<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_S ,<|>RELATION_NOE 联合<|>RELATION_NOE 动态<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_NOE 手段<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 有效性<|>RELATION_NOE 及<|>RELATION_NOE 疾病<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 监控<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 有利于<|>RELATION_NOE 临床<|>RELATION_NOE 早期<|>RELATION_NOE 发现<|>RELATION_NOE 、<|>RELATION_NOE 早期<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE 血清<|>RELATION_NOE 肿瘤标记物<|>RELATION_NOE SCC-Ag<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 和<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 联合<|>RELATION_NOE 动态<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_B 肺癌<|>RELATION_I 早期<|>RELATION_I 诊断<|>RELATION_I 的<|>RELATION_I 辅助<|>RELATION_I 手段<|>RELATION_I 和<|>RELATION_I 治疗<|>RELATION_I 有效性<|>RELATION_I 及<|>RELATION_I 疾病<|>RELATION_I 复发<|>RELATION_I 的<|>RELATION_I 监控<|>RELATION_I 指标<|>RELATION_E ,<|>RELATION_NOE 有利于<|>RELATION_NOE 临床<|>RELATION_NOE 早期<|>RELATION_NOE 发现<|>RELATION_NOE 、<|>RELATION_NOE 早期<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE ING4<|>RELATION_NOE 和<|>RELATION_NOE XIAP<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
研究<|>RELATION_NOE ING4<|>RELATION_NOE 和<|>RELATION_NOE XIAP<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 对应<|>RELATION_NOE 的<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_B 的<|>RELATION_I 表达<|>RELATION_I 情况<|>RELATION_I 及其<|>RELATION_I 相关<|>RELATION_I 联系<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 实验<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S ING4<|>RELATION_NOE 和<|>RELATION_NOE XIAP<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 在<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 对应<|>RELATION_NOE 的<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
RT-PCR<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE ING4mRNA<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及其<|>RELATION_NOE 对应<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 有<|>RELATION_B 统计学<|>RELATION_I 意义<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE ING4mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 情况<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 病理分型<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 分组<|>RELATION_NOE 都<|>RELATION_NOE 无关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE (<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE ING4mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 分化<|>RELATION_NOE 情况<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 病理分型<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 分组<|>RELATION_NOE 都<|>RELATION_B 无关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 联合<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_S 老年<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
将<|>RELATION_NOE 63<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 的<|>RELATION_NOE 白细胞<|>RELATION_NOE 下降<|>RELATION_NOE 、<|>RELATION_NOE 贫血<|>RELATION_NOE 及<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 皮疹<|>RELATION_NOE 、<|>RELATION_NOE 腹泻<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 差异<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 治疗组<|>RELATION_NOE 的<|>RELATION_NOE 白细胞<|>RELATION_NOE 下降<|>RELATION_NOE 、<|>RELATION_NOE 贫血<|>RELATION_NOE 及<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 皮疹<|>RELATION_NOE 、<|>RELATION_NOE 腹泻<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 无<|>RELATION_B 统计学<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 联合<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_B 老年<|>RELATION_I 局部<|>RELATION_I 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 可<|>RELATION_NOE 提高<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 局部<|>RELATION_NOE 控制率<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 老年<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
基于<|>RELATION_NOE 131I<|>RELATION_NOE 摄取<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 乳头<|>RELATION_NOE 状<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_B 差异<|>RELATION_I miRNA<|>RELATION_I 的<|>RELATION_I 筛选<|>RELATION_I 及<|>RELATION_I 生物<|>RELATION_I 信息学<|>RELATION_I 分析<|>RELATION_E
筛选<|>RELATION_S 与<|>RELATION_NOE 乳头<|>RELATION_NOE 状<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE (<|>RELATION_NOE PTC<|>RELATION_NOE )<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 131I<|>RELATION_NOE 摄取<|>RELATION_NOE 功能<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE miRNAs<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 伴肺<|>RELATION_NOE 转移<|>RELATION_NOE PTC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE A<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 具有<|>RELATION_NOE 摄取<|>RELATION_NOE 131I<|>RELATION_NOE 功能者<|>RELATION_NOE ,<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 无<|>RELATION_NOE 131I<|>RELATION_NOE 摄取<|>RELATION_NOE 功能<|>RELATION_NOE 者.<|>RELATION_NOE
采用<|>RELATION_NOE miRNA<|>RELATION_NOE 芯片<|>RELATION_NOE 检测<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 间<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 血清<|>RELATION_NOE miRNAs<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 经<|>RELATION_NOE 生物<|>RELATION_NOE 信息学<|>RELATION_NOE 分析<|>RELATION_NOE 筛选<|>RELATION_NOE 相关<|>RELATION_NOE 核心<|>RELATION_NOE miRNA<|>RELATION_NOE 。<|>RELATION_NOE
生物<|>RELATION_NOE 信息学<|>RELATION_NOE 分析<|>RELATION_NOE 发现<|>RELATION_NOE 血清<|>RELATION_NOE miR-106a<|>RELATION_NOE 为<|>RELATION_NOE 核心<|>RELATION_NOE miRNA<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 参与<|>RELATION_NOE 调节<|>RELATION_NOE 193<|>RELATION_NOE 个<|>RELATION_NOE 靶基因<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 包括<|>RELATION_NOE MAPK1<|>RELATION_NOE 、<|>RELATION_NOE MAP3K8<|>RELATION_NOE 、<|>RELATION_NOE MAP3K3<|>RELATION_NOE 、<|>RELATION_NOE MAP3K12<|>RELATION_NOE 、<|>RELATION_NOE MAP3K5<|>RELATION_NOE 、<|>RELATION_NOE MAP3K14<|>RELATION_NOE 、<|>RELATION_NOE MAP3K2<|>RELATION_NOE 、<|>RELATION_NOE MAPK11<|>RELATION_NOE 等<|>RELATION_NOE 基因<|>RELATION_NOE 。<|>RELATION_NOE
PTC<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 具有<|>RELATION_NOE 131I<|>RELATION_NOE 摄取<|>RELATION_NOE 功能组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 与<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 无<|>RELATION_NOE 131I<|>RELATION_NOE 摄取<|>RELATION_NOE 功能组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE miRNAs<|>RELATION_NOE 存在<|>RELATION_B 显著<|>RELATION_I 差异<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 无<|>RELATION_NOE 131I<|>RELATION_NOE 摄取<|>RELATION_NOE 功能组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 显著<|>RELATION_NOE 上调<|>RELATION_NOE 的<|>RELATION_NOE miR-106a<|>RELATION_NOE 为<|>RELATION_NOE 核心<|>RELATION_NOE miRNA<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 丧失<|>RELATION_NOE 131I<|>RELATION_NOE 摄取<|>RELATION_NOE 功能<|>RELATION_NOE 有关<|>RELATION_NOE .<|>RELATION_NOE PTC<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 具有<|>RELATION_NOE 131I<|>RELATION_NOE 摄取<|>RELATION_NOE 功能组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 与<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 无<|>RELATION_NOE 131I<|>RELATION_NOE 摄取<|>RELATION_NOE 功能组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE miRNAs<|>RELATION_NOE 存在<|>RELATION_NOE 显著<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 无<|>RELATION_NOE 131I<|>RELATION_NOE 摄取<|>RELATION_NOE 功能组<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 显著<|>RELATION_NOE 上调<|>RELATION_NOE 的<|>RELATION_NOE miR-106a<|>RELATION_NOE 为<|>RELATION_NOE 核心<|>RELATION_NOE miRNA<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 丧失<|>RELATION_NOE 131I<|>RELATION_NOE 摄取<|>RELATION_NOE 功能<|>RELATION_NOE 有关<|>RELATION_S .<|>RELATION_NOE
免疫<|>RELATION_NOE 组化<|>RELATION_NOE 在<|>RELATION_NOE 肺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 和<|>RELATION_NOE 肺非<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 活检<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 鉴别诊断<|>RELATION_S 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 在<|>RELATION_NOE 肺<|>RELATION_NOE 小细胞癌<|>RELATION_NOE (<|>RELATION_NOE SCLC<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 肺非<|>RELATION_NOE 小细胞癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 鉴别诊断<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 选择<|>RELATION_NOE 肺穿刺<|>RELATION_NOE 及<|>RELATION_NOE 支气管镜<|>RELATION_NOE 活检<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 形态<|>RELATION_NOE 疑似<|>RELATION_NOE SCLC<|>RELATION_NOE 共<|>RELATION_NOE 72<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE CD56<|>RELATION_NOE 、<|>RELATION_NOE Syn<|>RELATION_NOE 、<|>RELATION_NOE TTF1<|>RELATION_NOE 、<|>RELATION_NOE CK5<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE 、<|>RELATION_NOE CK14<|>RELATION_NOE 、<|>RELATION_NOE P63<|>RELATION_NOE 、<|>RELATION_NOE CK7<|>RELATION_NOE 及<|>RELATION_NOE NapsinA<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE SCLC<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 形态<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 表型<|>RELATION_NOE 特点<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 鉴别<|>RELATION_NOE 。<|>RELATION_NOE
72<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE SCLC<|>RELATION_NOE 共<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 低<|>RELATION_NOE 分化<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE (<|>RELATION_NOE SCC<|>RELATION_NOE )<|>RELATION_NOE 共<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 低<|>RELATION_NOE 分化<|>RELATION_NOE 腺癌<|>RELATION_NOE (<|>RELATION_NOE ADC<|>RELATION_NOE )<|>RELATION_NOE 共<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
SCLC<|>RELATION_NOE 和<|>RELATION_NOE NSCLC<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 上<|>RELATION_NOE 方法<|>RELATION_NOE 不同<|>RELATION_NOE ,<|>RELATION_NOE 充分<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 可以<|>RELATION_NOE 进行<|>RELATION_B 诊断<|>RELATION_I 和<|>RELATION_I 鉴别诊断<|>RELATION_E ,<|>RELATION_NOE 从而<|>RELATION_NOE 可以<|>RELATION_NOE 减少<|>RELATION_NOE 误诊<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 给<|>RELATION_NOE 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 选择<|>RELATION_NOE 提供<|>RELATION_NOE 重要<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
SMAD7<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 研究<|>RELATION_NOE
探讨<|>RELATION_NOE SMAD7<|>RELATION_NOE 基因<|>RELATION_NOE rs12953717<|>RELATION_NOE 位点<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE rs12953717<|>RELATION_NOE 位点<|>RELATION_NOE 基因型<|>RELATION_NOE 在<|>RELATION_NOE 病例组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_B 具有<|>RELATION_I 显著<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE χ^2<|>RELATION_NOE =<|>RELATION_NOE 13<|>RELATION_NOE 5.44<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 杂合<|>RELATION_NOE 基因型<|>RELATION_NOE (<|>RELATION_NOE CT<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 纯合<|>RELATION_NOE 基因型<|>RELATION_NOE (<|>RELATION_NOE CC<|>RELATION_NOE /<|>RELATION_NOE TT<|>RELATION_NOE )<|>RELATION_NOE 相<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE OR<|>RELATION_NOE 值<|>RELATION_NOE 为<|>RELATION_NOE 4.107<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 3.20<|>RELATION_NOE 6－<|>RELATION_NOE 5.2<|>RELATION_NOE 60<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0001<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
SMAD7<|>RELATION_NOE 基因<|>RELATION_NOE rs12953717<|>RELATION_NOE 位点<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 发病<|>RELATION_NOE 相关<|>RELATION_S ,<|>RELATION_NOE 杂合型<|>RELATION_NOE CT<|>RELATION_NOE 为<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 易感<|>RELATION_NOE 基因型<|>RELATION_NOE ,<|>RELATION_NOE 吸烟<|>RELATION_NOE 是<|>RELATION_NOE SMAD7<|>RELATION_NOE 基因<|>RELATION_NOE rs12953717<|>RELATION_NOE 位点<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 发病<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 杂合型<|>RELATION_NOE CT<|>RELATION_NOE 为<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 易感<|>RELATION_B 基因型<|>RELATION_E ,<|>RELATION_NOE 吸烟<|>RELATION_NOE 是<|>RELATION_NOE SMAD7<|>RELATION_NOE 基因<|>RELATION_NOE rs12953717<|>RELATION_NOE 位点<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 发病<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 杂合型<|>RELATION_NOE CT<|>RELATION_NOE 为<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 易感<|>RELATION_NOE 基因型<|>RELATION_NOE ,<|>RELATION_NOE 吸烟<|>RELATION_NOE 是<|>RELATION_NOE NSCLC<|>RELATION_B 发病<|>RELATION_E 的<|>RELATION_NOE 易感<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 在<|>RELATION_NOE 发病<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 方面<|>RELATION_NOE 具有<|>RELATION_NOE 协同<|>RELATION_NOE 性.<|>RELATION_NOE
中药<|>RELATION_NOE 组方<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_NOE 中药<|>RELATION_NOE 组方<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 患者<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 11月<|>RELATION_NOE 住院<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 及<|>RELATION_NOE 治疗组<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 45<|>RELATION_NOE 例<|>RELATION_NOE 在<|>RELATION_NOE 化疗<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 加<|>RELATION_NOE 用<|>RELATION_NOE 参芪<|>RELATION_NOE 蛇枝<|>RELATION_NOE 汤<|>RELATION_NOE 中药<|>RELATION_NOE 口服<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 生存率<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
治疗组<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 白细胞<|>RELATION_NOE 降低<|>RELATION_NOE 、<|>RELATION_NOE 肝肾<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 均<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
参芪<|>RELATION_NOE 扶<|>RELATION_NOE 正<|>RELATION_NOE 中药<|>RELATION_NOE 组方<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_B 中晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 临床<|>RELATION_NOE 效果<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 生存率<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE
宝石<|>RELATION_NOE 能谱<|>RELATION_NOE CT<|>RELATION_NOE 在<|>RELATION_NOE 孤立性<|>RELATION_B 肺结节<|>RELATION_I 鉴别诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
肺鳞状细胞癌<|>RELATION_NOE 、<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 错构瘤<|>RELATION_NOE 、<|>RELATION_NOE 硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 、<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 碘<|>RELATION_NOE 含量<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 11.66<|>RELATION_NOE ±<|>RELATION_NOE 2.72<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 12.36<|>RELATION_NOE ±<|>RELATION_NOE 2.97<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 10.20<|>RELATION_NOE ±<|>RELATION_NOE 3.11<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 16.58<|>RELATION_NOE ±<|>RELATION_NOE 3.58<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 21.67<|>RELATION_NOE ±<|>RELATION_NOE 3.76<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 及<|>RELATION_NOE 肺鳞状细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 碘<|>RELATION_NOE 含量<|>RELATION_NOE 之间<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 不同<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 肺鳞状细胞癌<|>RELATION_NOE 、<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 错构瘤<|>RELATION_NOE 、<|>RELATION_NOE 硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 、<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 碘<|>RELATION_NOE 含量<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 11.66<|>RELATION_NOE ±<|>RELATION_NOE 2.72<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 12.36<|>RELATION_NOE ±<|>RELATION_NOE 2.97<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 10.20<|>RELATION_NOE ±<|>RELATION_NOE 3.11<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 16.58<|>RELATION_NOE ±<|>RELATION_NOE 3.58<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 21.67<|>RELATION_NOE ±<|>RELATION_NOE 3.76<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 及<|>RELATION_NOE 肺鳞状细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 碘含量<|>RELATION_NOE 之间<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 不同<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 碘<|>RELATION_NOE 含量<|>RELATION_NOE 之间<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺鳞状细胞癌<|>RELATION_NOE 、<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 错构瘤<|>RELATION_NOE 、<|>RELATION_NOE 硬化性<|>RELATION_NOE 血管瘤<|>RELATION_NOE 、<|>RELATION_NOE 炎性假瘤<|>RELATION_NOE 的<|>RELATION_NOE 水<|>RELATION_NOE 含量<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 102<|>RELATION_NOE 1.31<|>RELATION_NOE ±<|>RELATION_NOE 13.83<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 102<|>RELATION_NOE 7.98<|>RELATION_NOE ±<|>RELATION_NOE 12.53<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 100<|>RELATION_NOE 3.42<|>RELATION_NOE ±<|>RELATION_NOE 13.67<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 102<|>RELATION_NOE 9.61<|>RELATION_NOE ±<|>RELATION_NOE 12.06<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 105<|>RELATION_NOE 1.61<|>RELATION_NOE ±<|>RELATION_NOE 13.81<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 各类<|>RELATION_NOE 不同<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 水含量<|>RELATION_NOE 之间<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
宝石<|>RELATION_NOE 能谱<|>RELATION_NOE CT<|>RELATION_NOE 成像<|>RELATION_NOE 通过<|>RELATION_B 应用<|>RELATION_I 碘<|>RELATION_I 含量<|>RELATION_I 测定<|>RELATION_E ,<|>RELATION_NOE 对<|>RELATION_NOE 鉴别<|>RELATION_NOE 不同<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE SPN<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_NOE SPN<|>RELATION_NOE 良恶性<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 及<|>RELATION_NOE 特异性<|>RELATION_NOE 。<|>RELATION_NOE
易瑞沙<|>RELATION_NOE 联合<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_B 肺癌<|>RELATION_I 脑转移<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
将<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 放疗<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE 治疗<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 口服<|>RELATION_NOE 易<|>RELATION_NOE 瑞沙<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 剂量<|>RELATION_NOE 为<|>RELATION_NOE 每天<|>RELATION_NOE 250mg<|>RELATION_NOE ,<|>RELATION_NOE 服用<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 从<|>RELATION_NOE 入<|>RELATION_NOE 组<|>RELATION_NOE 至<|>RELATION_NOE 开始<|>RELATION_NOE 至<|>RELATION_NOE 病情<|>RELATION_NOE 出现<|>RELATION_NOE 进展<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 生存期<|>RELATION_NOE 。<|>RELATION_NOE
不良<|>RELATION_NOE 反应<|>RELATION_NOE :<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 出现<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 脱发<|>RELATION_NOE 、<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 白细胞<|>RELATION_NOE 及<|>RELATION_NOE 血小板减少<|>RELATION_NOE 状况<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 服药<|>RELATION_NOE 3<|>RELATION_NOE 周<|>RELATION_NOE 内<|>RELATION_NOE 出现<|>RELATION_NOE 皮疹<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE Ⅰ度<|>RELATION_NOE 皮疹<|>RELATION_NOE 7例<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 度<|>RELATION_NOE 皮疹<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 服药<|>RELATION_NOE 2<|>RELATION_NOE 周<|>RELATION_NOE 内<|>RELATION_NOE 出现<|>RELATION_NOE 轻度<|>RELATION_NOE 腹泻<|>RELATION_NOE 9例<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 检测<|>RELATION_NOE 联合<|>RELATION_B CT<|>RELATION_I 扫描<|>RELATION_E 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 意义<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 含量<|>RELATION_NOE 显著<|>RELATION_B 升高<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE 正常<|>RELATION_NOE 人群<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 32.03<|>RELATION_NOE 78<|>RELATION_NOE ,<|>RELATION_NOE 34<|>RELATION_NOE .<|>RELATION_NOE 14<|>RELATION_NOE 56<|>RELATION_NOE ;<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 含量<|>RELATION_NOE 显著<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 正常<|>RELATION_NOE 人群<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 32.03<|>RELATION_NOE 78<|>RELATION_NOE ,<|>RELATION_NOE 34<|>RELATION_NOE .<|>RELATION_NOE 14<|>RELATION_NOE 56<|>RELATION_NOE ;<|>RELATION_NOE
不同<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 含量<|>RELATION_NOE 最高<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 含量<|>RELATION_NOE 最高<|>RELATION_NOE ;<|>RELATION_NOE
CT<|>RELATION_NOE 扫描<|>RELATION_NOE 能<|>RELATION_NOE 较为<|>RELATION_B 准确<|>RELATION_I 的<|>RELATION_I 诊断<|>RELATION_E NSCLC<|>RELATION_NOE ,<|>RELATION_NOE 联合<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 含量<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 准确<|>RELATION_NOE 判断<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病理分型<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 能<|>RELATION_NOE 较为<|>RELATION_NOE 准确<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE NSCLC<|>RELATION_NOE ,<|>RELATION_NOE 联合<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE CEA<|>RELATION_NOE 含量<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 准确<|>RELATION_B 判断<|>RELATION_E 患者<|>RELATION_NOE 的<|>RELATION_NOE 病理分型<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
康复<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 效果<|>RELATION_E
老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术后<|>RELATION_NOE 呼吸道<|>RELATION_B 护理<|>RELATION_E
探讨<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_B 老年<|>RELATION_I 肺癌<|>RELATION_E 围术期<|>RELATION_NOE 护理<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 首都<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 北京<|>RELATION_NOE 胸科<|>RELATION_NOE 医院<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 共<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 左肺<|>RELATION_NOE 上<|>RELATION_NOE 叶<|>RELATION_NOE 切除<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 左肺<|>RELATION_NOE 下<|>RELATION_NOE 叶<|>RELATION_NOE 切除<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 右肺<|>RELATION_NOE 上<|>RELATION_NOE 叶<|>RELATION_NOE 切除<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 其中<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下右肺<|>RELATION_NOE 上<|>RELATION_NOE 叶袖式<|>RELATION_NOE 切除<|>RELATION_NOE 2例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 右肺<|>RELATION_NOE 下<|>RELATION_NOE 叶<|>RELATION_NOE 切除<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 右肺<|>RELATION_NOE 中叶<|>RELATION_NOE 切除<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 右肺<|>RELATION_NOE 中<|>RELATION_NOE 下<|>RELATION_NOE 叶<|>RELATION_NOE 切除<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 采取<|>RELATION_NOE 呼吸道<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 观察<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE 在<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 完成<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 无<|>RELATION_NOE 围术期<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 出现<|>RELATION_NOE 术后<|>RELATION_NOE 支气管<|>RELATION_NOE 胸膜<|>RELATION_NOE 瘘<|>RELATION_NOE 、<|>RELATION_NOE 脓胸<|>RELATION_NOE 、<|>RELATION_NOE 肺不张<|>RELATION_NOE 等<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 技术<|>RELATION_NOE 能<|>RELATION_NOE 让<|>RELATION_NOE 更<|>RELATION_NOE 多<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 外科<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 针对性<|>RELATION_NOE 护理<|>RELATION_NOE 有利于<|>RELATION_S 术后<|>RELATION_NOE 恢复<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE 。<|>RELATION_NOE
乳腺<|>RELATION_NOE 外<|>RELATION_NOE 实体瘤<|>RELATION_NOE 乳腺<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 病理<|>RELATION_I 特征<|>RELATION_I 和<|>RELATION_I 预后<|>RELATION_E
探讨<|>RELATION_NOE 乳腺<|>RELATION_NOE 外<|>RELATION_NOE 实体瘤<|>RELATION_NOE 乳腺<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 病理<|>RELATION_I 特征<|>RELATION_I 和<|>RELATION_I 预后<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2001年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 12月<|>RELATION_NOE 间<|>RELATION_NOE 中国<|>RELATION_NOE 医学<|>RELATION_NOE 科学院<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 诊治<|>RELATION_NOE 的<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE 乳腺<|>RELATION_NOE 外<|>RELATION_NOE 实体<|>RELATION_NOE 瘤<|>RELATION_NOE 乳腺<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 乳腺<|>RELATION_NOE 外<|>RELATION_NOE 原发<|>RELATION_NOE 实体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 和<|>RELATION_NOE 乳腺病<|>RELATION_NOE 灶<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 细胞学<|>RELATION_NOE 证实<|>RELATION_NOE 。<|>RELATION_NOE
原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 鼻腔<|>RELATION_NOE 横纹肌肉瘤<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 嗅神经<|>RELATION_NOE 母细胞<|>RELATION_NOE 瘤3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 卵巢癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 恶性<|>RELATION_NOE 黑色素瘤<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
乳腺<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 多<|>RELATION_NOE 为<|>RELATION_NOE 增长<|>RELATION_NOE 较<|>RELATION_NOE 快<|>RELATION_NOE 的<|>RELATION_NOE 单<|>RELATION_NOE 发<|>RELATION_NOE 结节<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 腋窝<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE ,<|>RELATION_NOE 少见<|>RELATION_NOE 微小<|>RELATION_NOE 钙化<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 细胞学<|>RELATION_NOE 检查<|>RELATION_NOE 可以<|>RELATION_NOE 区分<|>RELATION_S 乳腺<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 乳腺癌<|>RELATION_NOE ,<|>RELATION_NOE 83.3%<|>RELATION_NOE (<|>RELATION_NOE 20<|>RELATION_NOE /<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 同时<|>RELATION_NOE 存在<|>RELATION_NOE 其他<|>RELATION_NOE 器官<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
乳腺<|>RELATION_NOE 外<|>RELATION_NOE 实体<|>RELATION_NOE 瘤<|>RELATION_NOE 乳腺<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_S 差<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 仅<|>RELATION_NOE 为<|>RELATION_NOE 9.2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 。<|>RELATION_NOE
CD4<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE 共<|>RELATION_NOE 抑制<|>RELATION_NOE 分子<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
检测<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE 细胞<|>RELATION_NOE 毒性<|>RELATION_NOE T<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 相关<|>RELATION_NOE 抗原4<|>RELATION_NOE (<|>RELATION_NOE CTLA-4<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 活化<|>RELATION_NOE 基因<|>RELATION_NOE 3<|>RELATION_NOE (<|>RELATION_NOE LAG-3<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 程序性<|>RELATION_NOE 死亡<|>RELATION_NOE 分子1<|>RELATION_NOE (<|>RELATION_NOE PD-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE CD39<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 与<|>RELATION_B NSCLC<|>RELATION_I 疾病<|>RELATION_I 进展<|>RELATION_I 的<|>RELATION_I 关系<|>RELATION_E 。<|>RELATION_NOE
选取<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 对照<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 健康<|>RELATION_NOE 对照<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 88<|>RELATION_NOE 个<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 取<|>RELATION_NOE 新鲜<|>RELATION_NOE 抗<|>RELATION_NOE 凝血<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 体外<|>RELATION_NOE 分离<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 浸润<|>RELATION_NOE 的<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE CTLA-4<|>RELATION_NOE 、<|>RELATION_NOE LAG-3<|>RELATION_NOE 、<|>RELATION_NOE PD-1<|>RELATION_NOE 和<|>RELATION_NOE CD39<|>RELATION_NOE 共<|>RELATION_NOE 抑制<|>RELATION_NOE 分子<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血中<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE CTLA-4<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE LAG-3<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE PD-1<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE CD39<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 2.49<|>RELATION_NOE ±<|>RELATION_NOE 2.43<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 2.47<|>RELATION_NOE ±<|>RELATION_NOE 3.50<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 12.94<|>RELATION_NOE ±<|>RELATION_NOE 5.96<|>RELATION_NOE )%<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 6.78<|>RELATION_NOE ±<|>RELATION_NOE 5.21<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血中<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE CTLA-4<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 正常<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 疾病<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE PD-1<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 也<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血中<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE CTLA-4<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE LAG-3<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE PD-1<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE CD39<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 2.49<|>RELATION_NOE ±<|>RELATION_NOE 2.43<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 2.47<|>RELATION_NOE ±<|>RELATION_NOE 3.50<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 12.94<|>RELATION_NOE ±<|>RELATION_NOE 5.96<|>RELATION_NOE )%<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 6.78<|>RELATION_NOE ±<|>RELATION_NOE 5.21<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血中<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE CTLA-4<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 正常<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 疾病<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE PD-1<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 也<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 正常<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE CTLA-4<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE LAG-3<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE PD-1<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 5.07<|>RELATION_NOE ±<|>RELATION_NOE 2.11<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 7.86<|>RELATION_NOE ±<|>RELATION_NOE 3.24<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 40.20<|>RELATION_NOE ±<|>RELATION_NOE 18.84<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 外<|>RELATION_NOE 周血<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 3.13<|>RELATION_NOE ±<|>RELATION_NOE 1.01<|>RELATION_NOE )%<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 2.65<|>RELATION_NOE ±<|>RELATION_NOE 1.48<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 15.79<|>RELATION_NOE ±<|>RELATION_NOE 5.69<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ]<|>RELATION_NOE ;<|>RELATION_NOE
其中<|>RELATION_NOE NSCLC<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE CTLA-4<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE PD-1<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 还<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 相应<|>RELATION_NOE 的<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE 共<|>RELATION_NOE 抑制<|>RELATION_NOE 分子<|>RELATION_NOE CTLA-4<|>RELATION_NOE 、<|>RELATION_NOE LAG-3<|>RELATION_NOE 和<|>RELATION_NOE PD-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 增高<|>RELATION_E ,<|>RELATION_NOE 这<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 参与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 逃逸<|>RELATION_NOE 、<|>RELATION_NOE 促进<|>RELATION_NOE NSCLC<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE 之一<|>RELATION_NOE 。<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE CD4<|>RELATION_NOE +<|>RELATION_NOE T<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE 共<|>RELATION_NOE 抑制<|>RELATION_NOE 分子<|>RELATION_NOE CTLA-4<|>RELATION_NOE 、<|>RELATION_NOE LAG-3<|>RELATION_NOE 和<|>RELATION_NOE PD-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 可能<|>RELATION_B 是<|>RELATION_I 参与<|>RELATION_I 肿瘤<|>RELATION_I 细胞免疫<|>RELATION_I 逃逸<|>RELATION_I 、<|>RELATION_I 促进<|>RELATION_I NSCLC<|>RELATION_I 疾病<|>RELATION_I 进展<|>RELATION_I 和<|>RELATION_I 预后<|>RELATION_I 不良<|>RELATION_E 的<|>RELATION_NOE 机制<|>RELATION_NOE 之一<|>RELATION_NOE 。<|>RELATION_NOE
miR-610<|>RELATION_NOE 通过<|>RELATION_NOE 调控<|>RELATION_NOE 缝隙<|>RELATION_NOE 连接<|>RELATION_NOE α<|>RELATION_NOE 3<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 抑制<|>RELATION_S 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE
探讨<|>RELATION_NOE miR-610<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_B 及其<|>RELATION_I 机制<|>RELATION_E 。<|>RELATION_NOE
分别<|>RELATION_NOE 将<|>RELATION_NOE miR-610<|>RELATION_NOE 模拟物<|>RELATION_NOE 和<|>RELATION_NOE 抑制<|>RELATION_NOE 物<|>RELATION_NOE 转染<|>RELATION_NOE 入<|>RELATION_NOE 95D<|>RELATION_NOE 和<|>RELATION_NOE 95C<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 细胞计数<|>RELATION_NOE 盒8<|>RELATION_NOE (<|>RELATION_NOE CCK-8<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE 5-<|>RELATION_NOE 溴<|>RELATION_NOE -2<|>RELATION_NOE '<|>RELATION_NOE -<|>RELATION_NOE 脱氧尿苷<|>RELATION_NOE (<|>RELATION_NOE BrdU<|>RELATION_NOE )<|>RELATION_NOE 掺<|>RELATION_NOE 入<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_NOE miR-610<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
miR-610<|>RELATION_NOE 在<|>RELATION_B 低<|>RELATION_I 转移<|>RELATION_I 肺癌<|>RELATION_I 细胞<|>RELATION_I 95C<|>RELATION_I 中<|>RELATION_I 的<|>RELATION_I 表达<|>RELATION_I 水平<|>RELATION_I 是<|>RELATION_I 其<|>RELATION_I 在<|>RELATION_I 高<|>RELATION_I 转移<|>RELATION_I 肺癌<|>RELATION_I 细胞<|>RELATION_I 95D<|>RELATION_I 中<|>RELATION_I 的<|>RELATION_I 表达<|>RELATION_I 水平<|>RELATION_E 的<|>RELATION_NOE (<|>RELATION_NOE 8.75<|>RELATION_NOE ±<|>RELATION_NOE 0.21<|>RELATION_NOE )<|>RELATION_NOE 倍<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
610<|>RELATION_NOE 抑制<|>RELATION_NOE 物组<|>RELATION_NOE 95C<|>RELATION_NOE 细胞<|>RELATION_NOE 划痕<|>RELATION_NOE 的<|>RELATION_NOE 宽度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 初始划痕<|>RELATION_NOE 宽度<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 58.74<|>RELATION_NOE ±<|>RELATION_NOE 4.62<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 34.63<|>RELATION_NOE ±<|>RELATION_NOE 2.73<|>RELATION_NOE )%<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 转染<|>RELATION_NOE miR-610<|>RELATION_NOE 抑制<|>RELATION_NOE 物<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
转染<|>RELATION_NOE miR-610<|>RELATION_NOE 模拟物组<|>RELATION_NOE 95D<|>RELATION_NOE 细胞<|>RELATION_NOE 划痕<|>RELATION_NOE 的<|>RELATION_NOE 宽度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 初始划痕<|>RELATION_NOE 宽度<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 88.59<|>RELATION_NOE ±<|>RELATION_NOE 6.92<|>RELATION_NOE )%<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 72.24<|>RELATION_NOE ±<|>RELATION_NOE 5.46<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 转染<|>RELATION_NOE miR-610<|>RELATION_NOE 模拟物<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
兔肺<|>RELATION_NOE 内<|>RELATION_NOE 肿瘤<|>RELATION_NOE 射频<|>RELATION_NOE 消融<|>RELATION_NOE 后<|>RELATION_NOE 残存<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 新生<|>RELATION_NOE 血管<|>RELATION_NOE 变化<|>RELATION_S
采用<|>RELATION_NOE 组织<|>RELATION_NOE 块<|>RELATION_NOE 悬液<|>RELATION_NOE 注射<|>RELATION_NOE 法<|>RELATION_NOE 建立<|>RELATION_NOE 兔<|>RELATION_NOE VX2<|>RELATION_NOE 肿瘤<|>RELATION_NOE 肺内<|>RELATION_NOE 种植<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 64<|>RELATION_NOE 只<|>RELATION_NOE 新西兰<|>RELATION_NOE 白兔<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 10<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE RFA<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 54<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 控制<|>RELATION_NOE 电极<|>RELATION_NOE 展开<|>RELATION_NOE 范围<|>RELATION_NOE 、<|>RELATION_NOE 输出<|>RELATION_NOE 功率<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 造成<|>RELATION_NOE RFA<|>RELATION_NOE 后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 残存<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 计算<|>RELATION_S 不同<|>RELATION_NOE 时间<|>RELATION_NOE 点<|>RELATION_NOE 残存<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE Ki-67<|>RELATION_NOE 标记<|>RELATION_NOE 指数<|>RELATION_NOE (<|>RELATION_NOE Ki-67LI<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
RFA<|>RELATION_NOE 后<|>RELATION_NOE 肺内<|>RELATION_NOE 残存<|>RELATION_NOE 肿瘤<|>RELATION_NOE 出现<|>RELATION_S 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 新生<|>RELATION_NOE 血管<|>RELATION_NOE 一<|>RELATION_NOE 过<|>RELATION_NOE 性升高<|>RELATION_NOE 现象<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 期间<|>RELATION_NOE 疲劳<|>RELATION_NOE 状况<|>RELATION_NOE 与<|>RELATION_NOE 体力<|>RELATION_NOE 活动<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 期间<|>RELATION_NOE 疲劳<|>RELATION_NOE 状况<|>RELATION_NOE 及<|>RELATION_NOE 体力<|>RELATION_NOE 活动<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 采取<|>RELATION_NOE 有效<|>RELATION_NOE 干预<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 采用<|>RELATION_NOE 问卷调查<|>RELATION_NOE 的<|>RELATION_NOE 方式<|>RELATION_NOE 了解<|>RELATION_NOE 某院<|>RELATION_NOE 191<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 及<|>RELATION_NOE 化疗<|>RELATION_NOE 期间<|>RELATION_NOE 的<|>RELATION_NOE 疲劳<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 体力<|>RELATION_NOE 活动<|>RELATION_NOE 水平<|>RELATION_NOE ;<|>RELATION_NOE
按照<|>RELATION_NOE 美国<|>RELATION_NOE 癌症<|>RELATION_NOE 学会<|>RELATION_NOE 的<|>RELATION_NOE 体力<|>RELATION_NOE 活动<|>RELATION_NOE 指南<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 评价<|>RELATION_S 患者<|>RELATION_NOE 体力<|>RELATION_NOE 活动<|>RELATION_NOE 水平<|>RELATION_NOE 是否<|>RELATION_NOE 达标<|>RELATION_NOE ;<|>RELATION_NOE
应用<|>RELATION_NOE 液相<|>RELATION_NOE 色谱<|>RELATION_NOE -<|>RELATION_NOE 飞行<|>RELATION_NOE 时间<|>RELATION_NOE 质谱<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 代谢组<|>RELATION_NOE 学<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
应用<|>RELATION_NOE 代谢组<|>RELATION_NOE 学<|>RELATION_NOE 技术<|>RELATION_NOE 分析<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 正常<|>RELATION_NOE 人群<|>RELATION_NOE 血清<|>RELATION_NOE 的<|>RELATION_NOE 代谢<|>RELATION_NOE 物质<|>RELATION_NOE 。<|>RELATION_NOE
多变量<|>RELATION_NOE 统计<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 正常<|>RELATION_NOE 对照<|>RELATION_NOE 人群<|>RELATION_NOE 的<|>RELATION_NOE 代谢<|>RELATION_NOE 谱<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_B 差异<|>RELATION_E ,<|>RELATION_NOE 根据<|>RELATION_NOE t<|>RELATION_NOE 检验<|>RELATION_NOE 结果<|>RELATION_NOE 寻找<|>RELATION_NOE 到<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 代谢物<|>RELATION_NOE 36<|>RELATION_NOE 种<|>RELATION_NOE 。<|>RELATION_NOE
三<|>RELATION_NOE 氧化二砷<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE NCI-H520<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 不同<|>RELATION_NOE 作用<|>RELATION_NOE 浓度<|>RELATION_NOE 和<|>RELATION_NOE 作用<|>RELATION_NOE 时间<|>RELATION_NOE 条件<|>RELATION_NOE 下<|>RELATION_NOE 三<|>RELATION_NOE 氧化二砷<|>RELATION_NOE (<|>RELATION_NOE As2O3<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE NCI-H520<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_B 抑制<|>RELATION_I 作用<|>RELATION_I 和<|>RELATION_I 促<|>RELATION_I 凋亡<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
体外<|>RELATION_NOE 培养<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE NCI-520<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 预<|>RELATION_NOE 实验<|>RELATION_NOE 后<|>RELATION_NOE 设立<|>RELATION_NOE 1.0<|>RELATION_NOE 、<|>RELATION_NOE 2.0<|>RELATION_NOE 、<|>RELATION_NOE 3.0<|>RELATION_NOE 、<|>RELATION_NOE 6.0<|>RELATION_NOE 、<|>RELATION_NOE 10.0μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L5<|>RELATION_NOE 个<|>RELATION_NOE 实验<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 以上<|>RELATION_NOE 浓度<|>RELATION_NOE 分别<|>RELATION_NOE 连续<|>RELATION_NOE 培养<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48<|>RELATION_NOE 、<|>RELATION_NOE 72h<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 同期<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE 未经<|>RELATION_NOE 药物<|>RELATION_NOE 处理<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 作为<|>RELATION_NOE 阴性<|>RELATION_NOE 对照<|>RELATION_NOE 。<|>RELATION_NOE
噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 检测<|>RELATION_S 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 和<|>RELATION_NOE 作用<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE As2O3<|>RELATION_NOE 处理<|>RELATION_NOE 前后<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
流式<|>RELATION_NOE 细胞<|>RELATION_NOE 分析<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 药物<|>RELATION_NOE 作用<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 后<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 。<|>RELATION_NOE
p38MAPK<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE ATM<|>RELATION_NOE 、<|>RELATION_NOE ATR<|>RELATION_NOE 和<|>RELATION_NOE p53<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
盐酸埃克替尼<|>RELATION_NOE 诱导<|>RELATION_S 肺癌<|>RELATION_NOE HCC827<|>RELATION_NOE 细胞周期<|>RELATION_NOE 阻滞<|>RELATION_NOE 及其<|>RELATION_NOE 机制<|>RELATION_NOE 研究<|>RELATION_NOE
实验<|>RELATION_NOE 分为<|>RELATION_NOE 空白<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE Icotinib<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 四甲基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 盐法<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE Icotinib<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE HCC827<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
Icotinib<|>RELATION_NOE 以<|>RELATION_NOE 时间<|>RELATION_NOE -<|>RELATION_NOE 剂量<|>RELATION_NOE 依赖<|>RELATION_NOE 的<|>RELATION_NOE 方式<|>RELATION_NOE 抑制<|>RELATION_S HCC827<|>RELATION_NOE 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 48h<|>RELATION_NOE 的<|>RELATION_NOE IC50<|>RELATION_NOE 为<|>RELATION_NOE 0.60<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 72h<|>RELATION_NOE 的<|>RELATION_NOE IC50<|>RELATION_NOE 为<|>RELATION_NOE 0.06<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ;<|>RELATION_NOE
帕瑞昔布<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_B 小细胞肺<|>RELATION_I 癌细胞株<|>RELATION_I A549<|>RELATION_I 增殖<|>RELATION_I 和<|>RELATION_I 迁移<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
C<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 常规<|>RELATION_NOE 培养<|>RELATION_NOE ,<|>RELATION_NOE P1<|>RELATION_NOE 、<|>RELATION_NOE P2<|>RELATION_NOE 和<|>RELATION_NOE P3<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 分别<|>RELATION_NOE 用<|>RELATION_NOE 终浓度<|>RELATION_NOE 为<|>RELATION_NOE 10<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE 40<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE 160<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 的<|>RELATION_NOE 帕瑞昔布<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 24h<|>RELATION_NOE .<|>RELATION_NOE
MTT<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 划痕<|>RELATION_NOE 试验<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 划痕<|>RELATION_NOE 试验<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 迁移<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE
18F-FDG<|>RELATION_NOE 符合<|>RELATION_NOE 线路<|>RELATION_NOE 显像<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 术后<|>RELATION_I 复发<|>RELATION_E 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 符合<|>RELATION_NOE 线路<|>RELATION_NOE 显像<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 术后<|>RELATION_I 复发<|>RELATION_I 诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 81<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治<|>RELATION_NOE 性术<|>RELATION_NOE 后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 期间<|>RELATION_NOE 临床<|>RELATION_NOE 可疑<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 资料<|>RELATION_NOE 、<|>RELATION_NOE 可疑<|>RELATION_NOE 复发<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 符合<|>RELATION_NOE 线路<|>RELATION_NOE 显像<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 符合<|>RELATION_NOE 线路<|>RELATION_NOE 显像<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 59<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 结果<|>RELATION_NOE 证实<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 1例炎性<|>RELATION_NOE 肉芽组织<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 肺内<|>RELATION_NOE 纤维<|>RELATION_NOE 组织<|>RELATION_NOE 增生<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 慢性<|>RELATION_NOE 炎症<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 肺脓肿<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 放射性<|>RELATION_NOE 肺炎<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 肺部<|>RELATION_NOE 真菌<|>RELATION_NOE 感染<|>RELATION_NOE 。<|>RELATION_NOE
FDG<|>RELATION_NOE 显像<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 明显<|>RELATION_NOE 复发<|>RELATION_NOE 转移<|>RELATION_NOE 征象<|>RELATION_NOE 的<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 肺内<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 左侧<|>RELATION_NOE 锁骨<|>RELATION_NOE 上<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 黏液腺癌<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 黏液型<|>RELATION_NOE 细支气管<|>RELATION_NOE 肺泡癌<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 期间<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 明显<|>RELATION_NOE 异常<|>RELATION_NOE 。<|>RELATION_NOE
18F-FDG<|>RELATION_NOE 符合<|>RELATION_NOE 线路<|>RELATION_NOE 显像<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 术后<|>RELATION_I 复发<|>RELATION_I 诊断<|>RELATION_E 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
ROS1<|>RELATION_NOE 基因<|>RELATION_NOE 非<|>RELATION_NOE 重复<|>RELATION_NOE 序列<|>RELATION_NOE 双色<|>RELATION_NOE 荧光<|>RELATION_NOE 原位杂交<|>RELATION_NOE 探针<|>RELATION_NOE 建立<|>RELATION_NOE 及<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_B 小细胞肺癌<|>RELATION_I 组织<|>RELATION_I 检测<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
建立<|>RELATION_NOE ROS1<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 重复<|>RELATION_NOE 序列<|>RELATION_NOE 荧光<|>RELATION_NOE 原位杂交<|>RELATION_NOE (<|>RELATION_NOE FISH<|>RELATION_NOE )<|>RELATION_NOE 探针<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_B 其<|>RELATION_I 与<|>RELATION_I 商品化<|>RELATION_I 普通<|>RELATION_I 探针<|>RELATION_E 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 检测<|>RELATION_NOE 方面<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
探针<|>RELATION_NOE 制备<|>RELATION_NOE 的<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 加入<|>RELATION_NOE Human<|>RELATION_NOE Cot-1<|>RELATION_NOE DNA<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 基因组<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 重复<|>RELATION_NOE 序列复性<|>RELATION_NOE 结合<|>RELATION_NOE 成<|>RELATION_NOE 双链<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 双链<|>RELATION_NOE 特异性<|>RELATION_NOE 酶<|>RELATION_NOE 特异性<|>RELATION_NOE 的<|>RELATION_NOE 切除<|>RELATION_NOE 重复<|>RELATION_NOE 序列.<|>RELATION_NOE
用<|>RELATION_NOE 红色<|>RELATION_NOE 和<|>RELATION_NOE 绿色<|>RELATION_NOE 荧光素<|>RELATION_NOE 分别<|>RELATION_NOE 标记<|>RELATION_NOE BAC<|>RELATION_NOE 克隆<|>RELATION_NOE 片段化<|>RELATION_NOE 的<|>RELATION_NOE PCR<|>RELATION_NOE 产物<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 混合<|>RELATION_NOE 得到<|>RELATION_NOE ROS1<|>RELATION_NOE 基因<|>RELATION_NOE 不<|>RELATION_NOE 含<|>RELATION_NOE 重复<|>RELATION_NOE 序列<|>RELATION_NOE 的<|>RELATION_NOE 双<|>RELATION_NOE 色探<|>RELATION_NOE 针.<|>RELATION_NOE
将<|>RELATION_NOE 制备<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 重复<|>RELATION_NOE 序列<|>RELATION_NOE FISH<|>RELATION_NOE 探针<|>RELATION_NOE 用于<|>RELATION_NOE 2009<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13<|>RELATION_NOE 年<|>RELATION_NOE 收集<|>RELATION_NOE 的<|>RELATION_NOE 经<|>RELATION_NOE 基因<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 检测<|>RELATION_NOE 确定<|>RELATION_NOE 的<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE ROS1<|>RELATION_NOE 基因重排<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 探针<|>RELATION_NOE 测定<|>RELATION_NOE
经<|>RELATION_NOE 比较<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 重复<|>RELATION_NOE 序列<|>RELATION_NOE 的<|>RELATION_NOE ROS1<|>RELATION_NOE 双色<|>RELATION_NOE FISH<|>RELATION_NOE 探针<|>RELATION_NOE 在<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_B 小细胞肺癌<|>RELATION_I 样本<|>RELATION_I 检测<|>RELATION_E 中<|>RELATION_NOE 明显<|>RELATION_NOE 改善<|>RELATION_NOE 探针<|>RELATION_NOE 的<|>RELATION_NOE 杂交<|>RELATION_NOE 效率<|>RELATION_NOE 和<|>RELATION_NOE 信噪比<|>RELATION_NOE ,<|>RELATION_NOE 有利于<|>RELATION_NOE 提高<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE 准确度<|>RELATION_NOE .<|>RELATION_NOE
Snail<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间质<|>RELATION_NOE 转化<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 及<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
研究<|>RELATION_NOE 转录因子<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间质<|>RELATION_NOE 转化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 标记<|>RELATION_NOE 分子<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 与<|>RELATION_I 肺癌<|>RELATION_I 发生<|>RELATION_I 、<|>RELATION_I 侵袭<|>RELATION_I 、<|>RELATION_I 转移<|>RELATION_I 的<|>RELATION_I 相关性<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE 它<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 64<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE Snail<|>RELATION_NOE 、<|>RELATION_NOE 上皮源性<|>RELATION_NOE 标记物<|>RELATION_NOE E-cadherin<|>RELATION_NOE 、<|>RELATION_NOE 间<|>RELATION_NOE 质源性<|>RELATION_NOE 标记物<|>RELATION_NOE Fibronectin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 资料<|>RELATION_NOE 作<|>RELATION_NOE 对照<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 观察<|>RELATION_NOE 到<|>RELATION_NOE E-cadherin<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 缺失<|>RELATION_NOE (<|>RELATION_NOE 46.8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE 观察<|>RELATION_NOE 到<|>RELATION_NOE 胞浆<|>RELATION_NOE 内<|>RELATION_NOE Fibronectin<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE .<|>RELATION_NOE
Snail<|>RELATION_NOE 、<|>RELATION_NOE E-cadherin<|>RELATION_NOE 、<|>RELATION_NOE Fibronectin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 远处<|>RELATION_NOE 转移<|>RELATION_NOE 外侵<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
Snail<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 阳性<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE EMT<|>RELATION_NOE 的<|>RELATION_NOE 标记<|>RELATION_NOE 蛋白<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 调控<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间质<|>RELATION_NOE 转化<|>RELATION_NOE 而<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 发挥<|>RELATION_NOE 作用<|>RELATION_NOE .<|>RELATION_NOE Snail<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE EMT<|>RELATION_NOE 的<|>RELATION_NOE 标记<|>RELATION_NOE 蛋白<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 调控<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间质<|>RELATION_NOE 转化<|>RELATION_NOE 而<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 发挥<|>RELATION_NOE 作用<|>RELATION_NOE .<|>RELATION_NOE
肺动脉<|>RELATION_NOE 肉瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 和<|>RELATION_I 外科<|>RELATION_I 治疗<|>RELATION_E
比较<|>RELATION_B 分析<|>RELATION_E 肺动脉<|>RELATION_NOE 肉瘤<|>RELATION_NOE (<|>RELATION_NOE PAS<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 影像学<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 外科<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
二氢<|>RELATION_NOE 杨梅素<|>RELATION_NOE 对<|>RELATION_NOE 4T1<|>RELATION_NOE 小鼠<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E
为了<|>RELATION_NOE 探讨<|>RELATION_NOE 二氢<|>RELATION_NOE 杨梅素<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 转移<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE Balb<|>RELATION_NOE /<|>RELATION_NOE c<|>RELATION_NOE 雌性<|>RELATION_NOE 小鼠<|>RELATION_NOE 右<|>RELATION_NOE 后<|>RELATION_NOE 腿皮<|>RELATION_NOE 下<|>RELATION_NOE 建立<|>RELATION_NOE 了<|>RELATION_NOE 4T1<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 移植<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 给予<|>RELATION_NOE 二氢<|>RELATION_NOE 杨梅<|>RELATION_NOE 素灌<|>RELATION_NOE 胃给药<|>RELATION_NOE 。<|>RELATION_NOE
MTT<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 二氢<|>RELATION_NOE 杨梅素<|>RELATION_NOE 对<|>RELATION_NOE 4T1<|>RELATION_NOE 小鼠<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 增殖<|>RELATION_NOE 作用<|>RELATION_NOE ;<|>RELATION_NOE
Transwell<|>RELATION_NOE 侵袭<|>RELATION_NOE 小室法<|>RELATION_NOE 检测<|>RELATION_S 二氢<|>RELATION_NOE 杨梅素<|>RELATION_NOE 对<|>RELATION_NOE 4T1<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 转移<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
检测<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 体积<|>RELATION_NOE 、<|>RELATION_NOE 远端肺<|>RELATION_NOE 转移<|>RELATION_NOE 灶数<|>RELATION_NOE 、<|>RELATION_NOE 荷<|>RELATION_NOE 瘤鼠<|>RELATION_NOE 血清<|>RELATION_NOE 及<|>RELATION_NOE 条件<|>RELATION_NOE 培养基<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE MMP-9<|>RELATION_NOE 和<|>RELATION_NOE MMP-2<|>RELATION_NOE 。<|>RELATION_NOE
二氢<|>RELATION_NOE 杨梅素<|>RELATION_NOE 处理<|>RELATION_NOE 4T1<|>RELATION_NOE 细胞<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 半数<|>RELATION_NOE 抑制<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE IC50<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 10<|>RELATION_NOE 2.1μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 。<|>RELATION_NOE
二氢<|>RELATION_NOE 杨梅素<|>RELATION_NOE 能<|>RELATION_NOE 不<|>RELATION_B 依赖<|>RELATION_I 细胞<|>RELATION_I 毒<|>RELATION_I 作用<|>RELATION_I 减少<|>RELATION_E 细胞培养<|>RELATION_NOE 液中<|>RELATION_NOE MMP-2<|>RELATION_NOE 和<|>RELATION_NOE MMP-9<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 抑制<|>RELATION_NOE 4T1<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 。<|>RELATION_NOE 二氢<|>RELATION_NOE 杨梅素<|>RELATION_NOE 能<|>RELATION_NOE 不<|>RELATION_NOE 依赖<|>RELATION_NOE 细胞<|>RELATION_NOE 毒<|>RELATION_NOE 作用<|>RELATION_NOE 减少<|>RELATION_NOE 细胞培养<|>RELATION_NOE 液中<|>RELATION_NOE MMP-2<|>RELATION_NOE 和<|>RELATION_NOE MMP-9<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 抑制<|>RELATION_S 4T1<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 。<|>RELATION_NOE
二氢<|>RELATION_NOE 杨梅素<|>RELATION_NOE 给<|>RELATION_NOE 药<|>RELATION_NOE 能<|>RELATION_NOE 抑制<|>RELATION_S 4T1<|>RELATION_NOE 小鼠<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 远端肺<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 二<|>RELATION_NOE 氢<|>RELATION_NOE 杨梅素<|>RELATION_NOE 下调<|>RELATION_NOE 荷瘤<|>RELATION_NOE 小鼠<|>RELATION_NOE 血清<|>RELATION_NOE MMP-9<|>RELATION_NOE 和<|>RELATION_NOE MMP-2<|>RELATION_NOE 水平<|>RELATION_NOE 相关<|>RELATION_NOE 。<|>RELATION_NOE 二氢<|>RELATION_NOE 杨梅素<|>RELATION_NOE 给<|>RELATION_NOE 药能<|>RELATION_NOE 抑制<|>RELATION_NOE 4T1<|>RELATION_NOE 小鼠<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 远端肺<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 二<|>RELATION_NOE 氢<|>RELATION_NOE 杨梅素<|>RELATION_NOE 下调<|>RELATION_NOE 荷瘤<|>RELATION_NOE 小鼠<|>RELATION_NOE 血清<|>RELATION_NOE MMP-9<|>RELATION_NOE 和<|>RELATION_NOE MMP-2<|>RELATION_NOE 水平<|>RELATION_NOE 相关<|>RELATION_S 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE SIL-2R<|>RELATION_NOE 、<|>RELATION_NOE IL-6<|>RELATION_NOE 、<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 浓度<|>RELATION_NOE 变化<|>RELATION_B 及<|>RELATION_I 临床<|>RELATION_I 价值<|>RELATION_E
研究<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 可溶性<|>RELATION_NOE 白细胞介素<|>RELATION_NOE -2<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE SIL-2R<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 白细胞介素<|>RELATION_NOE -6<|>RELATION_NOE (<|>RELATION_NOE IL-6<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE -<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 浓度<|>RELATION_NOE 变化<|>RELATION_NOE 对于<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 和<|>RELATION_I 预后<|>RELATION_I 判断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 试验组<|>RELATION_NOE ,<|>RELATION_NOE 选择<|>RELATION_NOE 同期<|>RELATION_NOE 健康<|>RELATION_NOE 体检<|>RELATION_NOE 的<|>RELATION_NOE 人群<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_NOE 对照组<|>RELATION_NOE 及<|>RELATION_NOE 试验组<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE SIL-2R<|>RELATION_NOE 、<|>RELATION_NOE IL-6<|>RELATION_NOE 、<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 浓度<|>RELATION_NOE 。<|>RELATION_NOE
检测<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE SIL-2R<|>RELATION_NOE 、<|>RELATION_NOE IL-6<|>RELATION_NOE 和<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 浓度<|>RELATION_NOE 变化<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_B 肺癌<|>RELATION_I 的<|>RELATION_I 诊断<|>RELATION_I 以及<|>RELATION_I 治疗<|>RELATION_I 预后<|>RELATION_I 判断<|>RELATION_E 的<|>RELATION_NOE 参考<|>RELATION_NOE 。<|>RELATION_NOE
沉默<|>RELATION_NOE 调节<|>RELATION_NOE 蛋白1<|>RELATION_NOE 在<|>RELATION_NOE 香烟<|>RELATION_NOE 烟雾<|>RELATION_NOE 提取物<|>RELATION_NOE 诱导<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
用<|>RELATION_NOE 免疫<|>RELATION_NOE 印迹<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE SIRT1<|>RELATION_NOE 、<|>RELATION_NOE 抑制<|>RELATION_NOE 凋亡<|>RELATION_NOE 基因<|>RELATION_NOE Bcl-2<|>RELATION_NOE 及<|>RELATION_NOE 促<|>RELATION_NOE 凋亡<|>RELATION_NOE 因子<|>RELATION_NOE 基因<|>RELATION_NOE Bax<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
2.5%<|>RELATION_NOE 、<|>RELATION_NOE 5.0%<|>RELATION_NOE 、<|>RELATION_NOE 10.0%<|>RELATION_NOE 、<|>RELATION_NOE 20.0%<|>RELATION_NOE 、<|>RELATION_NOE 40.0%<|>RELATION_NOE CSE<|>RELATION_NOE 分别<|>RELATION_NOE 处理<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE CSE<|>RELATION_NOE 呈<|>RELATION_NOE 浓度<|>RELATION_NOE 依赖性<|>RELATION_NOE 降低<|>RELATION_NOE 细胞<|>RELATION_NOE 内<|>RELATION_NOE SIRT1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 减少<|>RELATION_NOE 25.6%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 35.2%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 38.7%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 57.9%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 64.0%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
SIRT1<|>RELATION_NOE 可能<|>RELATION_NOE 通过<|>RELATION_NOE 的<|>RELATION_NOE 上调<|>RELATION_NOE 抑制<|>RELATION_NOE 凋亡<|>RELATION_NOE 基因<|>RELATION_NOE Bcl2<|>RELATION_NOE ,<|>RELATION_NOE 下调<|>RELATION_NOE 促<|>RELATION_NOE 凋亡<|>RELATION_NOE 基因<|>RELATION_NOE Bax<|>RELATION_NOE 对<|>RELATION_NOE CSE<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 具有<|>RELATION_B 保护<|>RELATION_I 作用<|>RELATION_E .<|>RELATION_NOE
尼妥<|>RELATION_B 珠单<|>RELATION_I 抗<|>RELATION_I 联合<|>RELATION_I 同期<|>RELATION_I 放<|>RELATION_I 化疗<|>RELATION_E 局部<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 耐受性<|>RELATION_NOE 研究<|>RELATION_NOE
最<|>RELATION_NOE 常见<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 为<|>RELATION_NOE 血液<|>RELATION_NOE 系统<|>RELATION_NOE ,<|>RELATION_NOE 3级<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 血红<|>RELATION_NOE 蛋白<|>RELATION_NOE 降低<|>RELATION_NOE 及<|>RELATION_NOE 血小板减少<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 66%<|>RELATION_NOE 、<|>RELATION_NOE 66%<|>RELATION_NOE 、<|>RELATION_NOE 11%<|>RELATION_NOE 、<|>RELATION_NOE 22%<|>RELATION_NOE ;<|>RELATION_NOE
未<|>RELATION_NOE 发现<|>RELATION_NOE 皮疹<|>RELATION_NOE 或<|>RELATION_NOE 皮肤<|>RELATION_NOE 过敏反应<|>RELATION_NOE .<|>RELATION_NOE
转化<|>RELATION_NOE 生长因子<|>RELATION_NOE β<|>RELATION_NOE -1<|>RELATION_NOE 与<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
研究<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE β<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE TGF<|>RELATION_NOE β<|>RELATION_NOE -1<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 情况<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE 二者<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE 研究<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE β<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE TGF<|>RELATION_NOE β<|>RELATION_NOE -1<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 二者<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
选取<|>RELATION_NOE 114<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 常规<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 行<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_S TGF<|>RELATION_NOE β<|>RELATION_NOE -1<|>RELATION_NOE 与<|>RELATION_NOE EGFR<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
二<|>RELATION_NOE 维<|>RELATION_NOE 超声<|>RELATION_NOE 评分法<|>RELATION_NOE 与<|>RELATION_NOE 超声<|>RELATION_NOE 造影<|>RELATION_NOE 鉴别诊断<|>RELATION_S 微小<|>RELATION_NOE 甲状腺结节<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
对<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 10月<|>RELATION_NOE 在<|>RELATION_NOE 宁波市<|>RELATION_NOE 第一<|>RELATION_NOE 医院<|>RELATION_NOE 欲<|>RELATION_NOE 行<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 216<|>RELATION_NOE 例<|>RELATION_NOE 连续<|>RELATION_NOE 的<|>RELATION_NOE 微小<|>RELATION_NOE 甲状腺结节<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 共计<|>RELATION_NOE 258<|>RELATION_NOE 个<|>RELATION_NOE 结节<|>RELATION_NOE )<|>RELATION_NOE 行<|>RELATION_NOE 2DUS<|>RELATION_NOE 及<|>RELATION_NOE CEUS<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对<|>RELATION_NOE 每个<|>RELATION_NOE 结节<|>RELATION_NOE 2DUS<|>RELATION_NOE 参数<|>RELATION_NOE (<|>RELATION_NOE 内部<|>RELATION_NOE 回声<|>RELATION_NOE 、<|>RELATION_NOE 形态<|>RELATION_NOE 、<|>RELATION_NOE 边界<|>RELATION_NOE 、<|>RELATION_NOE 钙化<|>RELATION_NOE 、<|>RELATION_NOE 纵横比<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 赋值<|>RELATION_NOE 评分<|>RELATION_NOE ,<|>RELATION_NOE 评估<|>RELATION_NOE 2DUS<|>RELATION_NOE 评分法<|>RELATION_NOE 及<|>RELATION_NOE CEUS<|>RELATION_NOE 诊断<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 、<|>RELATION_NOE 特异度<|>RELATION_NOE 及<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE
258<|>RELATION_NOE 个<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小<|>RELATION_NOE 结节<|>RELATION_NOE 均<|>RELATION_NOE 获得<|>RELATION_NOE 病理<|>RELATION_NOE 诊断<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 微小癌<|>RELATION_NOE 125<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE 结节<|>RELATION_NOE 133<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 每个<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小<|>RELATION_NOE 结节<|>RELATION_NOE 2DUS<|>RELATION_NOE 评分<|>RELATION_NOE 分<|>RELATION_NOE 值<|>RELATION_NOE 为<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 6<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 2DUS<|>RELATION_NOE 诊断<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小<|>RELATION_NOE 癌受试者<|>RELATION_NOE 操作<|>RELATION_NOE 特性<|>RELATION_NOE (<|>RELATION_NOE ROC<|>RELATION_NOE )<|>RELATION_NOE 曲线下面积<|>RELATION_NOE 为<|>RELATION_NOE 0.81<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 评分<|>RELATION_NOE ≥<|>RELATION_NOE 3分<|>RELATION_NOE 诊断<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 为<|>RELATION_NOE 78.4%<|>RELATION_NOE (<|>RELATION_NOE 98<|>RELATION_NOE /<|>RELATION_NOE 125<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 特异度<|>RELATION_NOE 为<|>RELATION_NOE 72.9%<|>RELATION_NOE (<|>RELATION_NOE 97<|>RELATION_NOE /<|>RELATION_NOE 133<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 准确性<|>RELATION_NOE 为<|>RELATION_NOE 75.6%<|>RELATION_NOE (<|>RELATION_NOE 195<|>RELATION_NOE /<|>RELATION_NOE 258<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
以<|>RELATION_NOE 早期<|>RELATION_NOE 低<|>RELATION_NOE 增强<|>RELATION_NOE 及<|>RELATION_NOE 低<|>RELATION_NOE 增强<|>RELATION_NOE 诊断<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE ,<|>RELATION_NOE CEUS<|>RELATION_NOE 诊断<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小<|>RELATION_NOE 癌敏<|>RELATION_NOE 感度<|>RELATION_NOE 、<|>RELATION_NOE 特异度<|>RELATION_NOE 及<|>RELATION_NOE 准确性<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 87.2%<|>RELATION_NOE (<|>RELATION_NOE 109<|>RELATION_NOE /<|>RELATION_NOE 125<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 75.9%<|>RELATION_NOE (<|>RELATION_NOE 101<|>RELATION_NOE /<|>RELATION_NOE 133<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 81.4%<|>RELATION_NOE (<|>RELATION_NOE 210<|>RELATION_NOE /<|>RELATION_NOE 258<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
缺血性<|>RELATION_NOE 卒中<|>RELATION_NOE 相关性<|>RELATION_NOE 肺炎<|>RELATION_NOE 风险<|>RELATION_B 评估<|>RELATION_E
SAP<|>RELATION_NOE 诊断<|>RELATION_NOE 标准<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE 卒中<|>RELATION_NOE 发生<|>RELATION_NOE 后<|>RELATION_NOE 胸部<|>RELATION_NOE 影像学<|>RELATION_NOE 检测<|>RELATION_NOE 发现<|>RELATION_NOE 新<|>RELATION_NOE 出现<|>RELATION_NOE 或<|>RELATION_NOE 进展性<|>RELATION_NOE 肺部<|>RELATION_NOE 浸润<|>RELATION_NOE 性病<|>RELATION_NOE 变<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 合并<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 以上<|>RELATION_NOE 临床<|>RELATION_NOE 感染<|>RELATION_NOE 症状<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 发热<|>RELATION_NOE ≥<|>RELATION_NOE 38<|>RELATION_NOE ℃<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 新<|>RELATION_NOE 出现<|>RELATION_NOE 的<|>RELATION_NOE 咳嗽<|>RELATION_NOE ,<|>RELATION_NOE 咳痰<|>RELATION_NOE 或<|>RELATION_NOE 原有<|>RELATION_NOE 呼吸道疾病<|>RELATION_NOE 症状<|>RELATION_NOE 加重<|>RELATION_NOE ,<|>RELATION_NOE 伴<|>RELATION_NOE 或<|>RELATION_NOE 不<|>RELATION_NOE 伴<|>RELATION_NOE 胸痛<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 肺实<|>RELATION_NOE 变<|>RELATION_NOE 体征<|>RELATION_NOE ,<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE 湿<|>RELATION_NOE 啰音<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 4<|>RELATION_NOE )<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 白细胞<|>RELATION_NOE ≥<|>RELATION_NOE 10<|>RELATION_NOE ×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 9<|>RELATION_NOE L<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE 或<|>RELATION_NOE ≤<|>RELATION_NOE 4×<|>RELATION_NOE 10<|>RELATION_NOE ^<|>RELATION_NOE 9<|>RELATION_NOE L<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE ,<|>RELATION_NOE 伴<|>RELATION_NOE 或<|>RELATION_NOE 不<|>RELATION_NOE 伴<|>RELATION_NOE 核左移<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 排除<|>RELATION_NOE 某些<|>RELATION_NOE 与<|>RELATION_NOE 肺炎<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 相近<|>RELATION_NOE 的<|>RELATION_NOE 疾病<|>RELATION_NOE 如<|>RELATION_NOE :<|>RELATION_NOE 肺结核<|>RELATION_NOE 、<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 感染性<|>RELATION_NOE 肺间<|>RELATION_NOE 质病<|>RELATION_NOE 、<|>RELATION_NOE 肺水肿<|>RELATION_NOE 、<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 、<|>RELATION_NOE 肺不张<|>RELATION_NOE 等<|>RELATION_NOE 病<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 68Ga-DOTA-cNGR<|>RELATION_NOE 的<|>RELATION_NOE 制备<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 荷<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 的<|>RELATION_NOE 显像<|>RELATION_NOE 研究<|>RELATION_S
以<|>RELATION_NOE 羟乙<|>RELATION_NOE 基哌嗪<|>RELATION_NOE 乙<|>RELATION_NOE 硫磺酸<|>RELATION_NOE (<|>RELATION_NOE HEPES<|>RELATION_NOE )<|>RELATION_NOE 为<|>RELATION_NOE 缓冲<|>RELATION_NOE 体系<|>RELATION_NOE (<|>RELATION_NOE pH<|>RELATION_NOE 值<|>RELATION_NOE 5.0<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 水浴<|>RELATION_NOE 合成<|>RELATION_NOE ^<|>RELATION_NOE 68Ga-DOTA-cNGR<|>RELATION_NOE ,<|>RELATION_NOE HPLC<|>RELATION_NOE 测定<|>RELATION_NOE 标记率<|>RELATION_NOE 及<|>RELATION_NOE 放化纯<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 稳定性<|>RELATION_NOE 。<|>RELATION_NOE
进行<|>RELATION_NOE ^<|>RELATION_NOE 68Ga-DOTA-cNGR<|>RELATION_NOE 的<|>RELATION_NOE 正常<|>RELATION_NOE 小鼠<|>RELATION_NOE 体内<|>RELATION_NOE 生物<|>RELATION_NOE 分布<|>RELATION_NOE 和<|>RELATION_NOE 荷<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 活体<|>RELATION_NOE microPET<|>RELATION_NOE 显像<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 荷<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 的<|>RELATION_NOE 瘤组织<|>RELATION_NOE 进行<|>RELATION_NOE 病理<|>RELATION_NOE 及<|>RELATION_NOE 氨肽酶<|>RELATION_NOE N<|>RELATION_NOE (<|>RELATION_NOE APN<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
正常<|>RELATION_NOE 小鼠<|>RELATION_NOE 体内<|>RELATION_NOE 生物<|>RELATION_NOE 分布<|>RELATION_NOE 结果<|>RELATION_NOE 表明<|>RELATION_S ,<|>RELATION_NOE ^<|>RELATION_NOE 68Ga-DOTA-cNGR<|>RELATION_NOE 主要<|>RELATION_NOE 经<|>RELATION_NOE 肾排泄<|>RELATION_NOE ,<|>RELATION_NOE 血液<|>RELATION_NOE 清除<|>RELATION_NOE 迅速<|>RELATION_NOE ,<|>RELATION_NOE 肝<|>RELATION_NOE 、<|>RELATION_NOE 胃肠道<|>RELATION_NOE 摄取<|>RELATION_NOE 较<|>RELATION_NOE 少<|>RELATION_NOE ;<|>RELATION_NOE
1h<|>RELATION_NOE 肾<|>RELATION_NOE 、<|>RELATION_NOE 血液<|>RELATION_NOE 、<|>RELATION_NOE 肝<|>RELATION_NOE 、<|>RELATION_NOE 胃<|>RELATION_NOE 、<|>RELATION_NOE 肠<|>RELATION_NOE 的<|>RELATION_NOE 放射性<|>RELATION_NOE 摄取<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 1.61<|>RELATION_NOE ±<|>RELATION_NOE 0.22<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.19<|>RELATION_NOE ±<|>RELATION_NOE 0.07<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.25<|>RELATION_NOE ±<|>RELATION_NOE 0.24<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.16<|>RELATION_NOE ±<|>RELATION_NOE 0.04<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.12<|>RELATION_NOE ±<|>RELATION_NOE 0.05<|>RELATION_NOE )%<|>RELATION_NOE ID<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE 。<|>RELATION_NOE
荷<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE microPET<|>RELATION_NOE 显像<|>RELATION_NOE 可见<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 有<|>RELATION_NOE 放射性<|>RELATION_NOE 浓<|>RELATION_NOE 聚影<|>RELATION_NOE ,<|>RELATION_NOE 1h<|>RELATION_NOE 肿瘤<|>RELATION_NOE 与<|>RELATION_NOE 对<|>RELATION_NOE 侧<|>RELATION_NOE 正常<|>RELATION_NOE 肌肉<|>RELATION_NOE T<|>RELATION_NOE /<|>RELATION_NOE NT<|>RELATION_NOE 高<|>RELATION_NOE 达<|>RELATION_NOE 7.61<|>RELATION_NOE ±<|>RELATION_NOE 0.47<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE DOTA-cNGR<|>RELATION_NOE 特异性<|>RELATION_NOE 阻断<|>RELATION_NOE 后<|>RELATION_NOE 降<|>RELATION_NOE 至<|>RELATION_NOE 1.83<|>RELATION_NOE ±<|>RELATION_NOE 0.25<|>RELATION_NOE ,<|>RELATION_NOE 阻断<|>RELATION_NOE 前后<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 18.80<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 检查<|>RELATION_NOE 证实<|>RELATION_S APN<|>RELATION_NOE 特异性<|>RELATION_NOE 聚集<|>RELATION_NOE 于<|>RELATION_NOE 肿瘤<|>RELATION_NOE 新<|>RELATION_NOE 生<|>RELATION_NOE 血管<|>RELATION_NOE 表面<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-<|>RELATION_NOE 精氨酸<|>RELATION_NOE -<|>RELATION_NOE 谷氨酸<|>RELATION_NOE -<|>RELATION_NOE 苏氨酸<|>RELATION_NOE 在<|>RELATION_NOE 荷<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE H1299<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体内<|>RELATION_B 分布<|>RELATION_I 和<|>RELATION_I 显像<|>RELATION_E
通过<|>RELATION_NOE 研究<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-<|>RELATION_NOE 精氨酸<|>RELATION_NOE -<|>RELATION_NOE 谷氨酸<|>RELATION_NOE -<|>RELATION_NOE 苏氨酸<|>RELATION_NOE (<|>RELATION_NOE RET<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 荷<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE H1299<|>RELATION_NOE 裸鼠<|>RELATION_NOE 体内<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 及<|>RELATION_NOE 显像<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 用于<|>RELATION_B 肺癌<|>RELATION_I 显像<|>RELATION_E 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
荷<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE H1299<|>RELATION_NOE 裸鼠尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-RET<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 行不同<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE 15<|>RELATION_NOE 、<|>RELATION_NOE 30min<|>RELATION_NOE ,<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE 2.4<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 、<|>RELATION_NOE 48h<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 4只鼠<|>RELATION_NOE )<|>RELATION_NOE 体内<|>RELATION_NOE 分布<|>RELATION_NOE 实验<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 测定<|>RELATION_NOE 组织<|>RELATION_NOE 放射性<|>RELATION_NOE 摄取<|>RELATION_NOE (<|>RELATION_NOE %<|>RELATION_NOE ID<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
荷瘤<|>RELATION_NOE 裸鼠尾<|>RELATION_NOE 静脉<|>RELATION_NOE 注射<|>RELATION_NOE ^<|>RELATION_NOE 99Tc<|>RELATION_NOE ^<|>RELATION_NOE m-RET<|>RELATION_NOE 后<|>RELATION_NOE 4h<|>RELATION_NOE 肿瘤<|>RELATION_NOE 放射性<|>RELATION_NOE 摄取达<|>RELATION_NOE (<|>RELATION_NOE 4.96<|>RELATION_NOE ±<|>RELATION_NOE 1.05<|>RELATION_NOE )%<|>RELATION_NOE ID<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE ,<|>RELATION_NOE 肝脏<|>RELATION_NOE 、<|>RELATION_NOE 脾脏<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE 放射性<|>RELATION_NOE 摄取<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 15.89<|>RELATION_NOE ±<|>RELATION_NOE 1.84<|>RELATION_NOE )%<|>RELATION_NOE ID<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 10.83<|>RELATION_NOE ±<|>RELATION_NOE 1.66<|>RELATION_NOE )%<|>RELATION_NOE ID<|>RELATION_NOE /<|>RELATION_NOE g<|>RELATION_NOE ]<|>RELATION_NOE ;<|>RELATION_NOE
而<|>RELATION_NOE 心脏<|>RELATION_NOE 和<|>RELATION_NOE 血液<|>RELATION_NOE 的<|>RELATION_NOE 放射性<|>RELATION_NOE 摄取<|>RELATION_NOE 较<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE T<|>RELATION_NOE /<|>RELATION_NOE NT<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5.70<|>RELATION_NOE ±<|>RELATION_NOE 0.21<|>RELATION_NOE 和<|>RELATION_NOE 12.40<|>RELATION_NOE ±<|>RELATION_NOE 0.11<|>RELATION_NOE 。<|>RELATION_NOE
低频<|>RELATION_NOE 超声<|>RELATION_NOE 辐射<|>RELATION_NOE 对<|>RELATION_NOE 化学<|>RELATION_NOE 治疗<|>RELATION_NOE 药物<|>RELATION_NOE 致<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 作用<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 低频<|>RELATION_NOE 超声<|>RELATION_NOE 辐射<|>RELATION_NOE 是否<|>RELATION_B 增加<|>RELATION_E 化学<|>RELATION_NOE 治疗<|>RELATION_NOE (<|>RELATION_NOE 化疗<|>RELATION_NOE )<|>RELATION_NOE 药物<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 分成<|>RELATION_NOE 4<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 常规<|>RELATION_NOE 培养<|>RELATION_NOE ;<|>RELATION_NOE
单纯<|>RELATION_NOE 低频<|>RELATION_NOE 超声<|>RELATION_NOE 辐射<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 单纯<|>RELATION_NOE 超声组<|>RELATION_NOE ,<|>RELATION_NOE 频率<|>RELATION_NOE 30<|>RELATION_NOE kHz<|>RELATION_NOE ,<|>RELATION_NOE 发射<|>RELATION_NOE 强度<|>RELATION_NOE 2.8<|>RELATION_NOE W<|>RELATION_NOE /<|>RELATION_NOE cm2<|>RELATION_NOE ,<|>RELATION_NOE 作用<|>RELATION_NOE 时间<|>RELATION_NOE 5min<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE 低频<|>RELATION_NOE 超声<|>RELATION_NOE 辐射<|>RELATION_NOE 联合<|>RELATION_NOE 顺氯<|>RELATION_NOE 氨铂<|>RELATION_NOE 化疗组<|>RELATION_NOE (<|>RELATION_NOE 超声<|>RELATION_NOE 联合化疗组<|>RELATION_NOE ,<|>RELATION_NOE 超声<|>RELATION_NOE 治疗<|>RELATION_NOE 和<|>RELATION_NOE 化疗<|>RELATION_NOE 方法<|>RELATION_NOE 同<|>RELATION_NOE 单纯<|>RELATION_NOE 超声组<|>RELATION_NOE 和<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
超声<|>RELATION_NOE 联合化疗<|>RELATION_NOE 组<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 7.84<|>RELATION_NOE ±<|>RELATION_NOE 2.74<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 5.06<|>RELATION_NOE ±<|>RELATION_NOE 0.88<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE 超声组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 2.71<|>RELATION_NOE ±<|>RELATION_NOE 0.99<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 2.64<|>RELATION_NOE ±<|>RELATION_NOE 0.99<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 10<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 超声<|>RELATION_NOE 联合化疗<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE 超声<|>RELATION_NOE 联合化疗组<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 7.84<|>RELATION_NOE ±<|>RELATION_NOE 2.74<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 5.06<|>RELATION_NOE ±<|>RELATION_NOE 0.88<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE 超声组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 2.71<|>RELATION_NOE ±<|>RELATION_NOE 0.99<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 2.64<|>RELATION_NOE ±<|>RELATION_NOE 0.99<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 10<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 超声<|>RELATION_NOE 联合化疗<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE 超声<|>RELATION_NOE 联合化疗<|>RELATION_NOE 组<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 7.84<|>RELATION_NOE ±<|>RELATION_NOE 2.74<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 5.06<|>RELATION_NOE ±<|>RELATION_NOE 0.88<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE 超声组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 2.71<|>RELATION_NOE ±<|>RELATION_NOE 0.99<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 2.64<|>RELATION_NOE ±<|>RELATION_NOE 0.99<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 10<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 超声<|>RELATION_NOE 联合化疗<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 也<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 空白<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 单纯<|>RELATION_NOE 超声组<|>RELATION_NOE 与<|>RELATION_NOE 超声<|>RELATION_NOE 联合化疗<|>RELATION_NOE 组<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 7.84<|>RELATION_NOE ±<|>RELATION_NOE 2.74<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 5.06<|>RELATION_NOE ±<|>RELATION_NOE 0.88<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 、<|>RELATION_NOE 单纯<|>RELATION_NOE 超声组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 2.71<|>RELATION_NOE ±<|>RELATION_NOE 0.99<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 2.64<|>RELATION_NOE ±<|>RELATION_NOE 0.99<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 10<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 超声<|>RELATION_NOE 联合化疗<|>RELATION_NOE 组<|>RELATION_NOE 及<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗组<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 也<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 单纯<|>RELATION_NOE 超声组<|>RELATION_NOE 与<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 间<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 55<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
体外<|>RELATION_NOE 低频<|>RELATION_NOE 超声<|>RELATION_NOE 辐射<|>RELATION_NOE 可以<|>RELATION_NOE 增加<|>RELATION_S 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
金黄色<|>RELATION_NOE 葡萄球菌<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 及<|>RELATION_NOE 药物<|>RELATION_NOE 敏感性<|>RELATION_NOE 分析<|>RELATION_S
分析<|>RELATION_B 和<|>RELATION_I 总结<|>RELATION_E 金黄色<|>RELATION_NOE 葡萄球菌<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 和<|>RELATION_NOE 对抗<|>RELATION_NOE 菌<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 金黄色<|>RELATION_NOE 葡萄球菌<|>RELATION_NOE 肺炎<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
并<|>RELATION_NOE 对<|>RELATION_NOE 所有<|>RELATION_NOE 细菌<|>RELATION_NOE 均<|>RELATION_NOE 按<|>RELATION_NOE 《<|>RELATION_NOE 全国<|>RELATION_NOE 临床<|>RELATION_NOE 检验<|>RELATION_NOE 操作<|>RELATION_NOE 规程<|>RELATION_NOE 》<|>RELATION_NOE 以<|>RELATION_NOE 常规<|>RELATION_NOE 方法<|>RELATION_NOE 鉴定<|>RELATION_NOE ,<|>RELATION_NOE 合格<|>RELATION_NOE 痰标本<|>RELATION_NOE 接种<|>RELATION_NOE 血<|>RELATION_NOE 琼脂<|>RELATION_NOE 、<|>RELATION_NOE 巧克力<|>RELATION_NOE 和<|>RELATION_NOE 麦康凯<|>RELATION_NOE 培养基<|>RELATION_NOE ,<|>RELATION_NOE 可疑<|>RELATION_NOE 菌落<|>RELATION_NOE 进行<|>RELATION_NOE 革兰<|>RELATION_NOE 染色<|>RELATION_NOE 和<|>RELATION_NOE 生化<|>RELATION_NOE 反应<|>RELATION_NOE 鉴定<|>RELATION_NOE ,<|>RELATION_NOE 金黄色<|>RELATION_NOE 葡萄<|>RELATION_NOE 球菌<|>RELATION_NOE 为<|>RELATION_NOE 革兰<|>RELATION_NOE 阳性<|>RELATION_NOE 球菌<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 西门子<|>RELATION_NOE 公司<|>RELATION_NOE PC33<|>RELATION_NOE 板条<|>RELATION_NOE 进行<|>RELATION_NOE 可疑菌<|>RELATION_NOE 落<|>RELATION_NOE 鉴定<|>RELATION_NOE ,<|>RELATION_NOE 确定<|>RELATION_NOE 为<|>RELATION_NOE 金黄色<|>RELATION_NOE 葡萄球菌<|>RELATION_NOE 并<|>RELATION_NOE 做<|>RELATION_NOE 药敏<|>RELATION_NOE 试验<|>RELATION_NOE 。<|>RELATION_NOE
分离<|>RELATION_NOE 的<|>RELATION_NOE 金黄色<|>RELATION_NOE 葡萄<|>RELATION_NOE 球菌<|>RELATION_NOE 对<|>RELATION_NOE 万古霉素<|>RELATION_NOE 、<|>RELATION_NOE 利奈唑胺<|>RELATION_NOE 、<|>RELATION_NOE 利福平<|>RELATION_NOE 及<|>RELATION_NOE 氯霉素<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_B 较<|>RELATION_I 高<|>RELATION_E [<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 29<|>RELATION_NOE 株<|>RELATION_NOE (<|>RELATION_NOE 100.0%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 46<|>RELATION_NOE 株<|>RELATION_NOE (<|>RELATION_NOE 100.0%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 42<|>RELATION_NOE 株<|>RELATION_NOE (<|>RELATION_NOE 85.7%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 11<|>RELATION_NOE 株<|>RELATION_NOE (<|>RELATION_NOE 78.6%<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 其他<|>RELATION_NOE 抗菌<|>RELATION_NOE 药物<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 。<|>RELATION_NOE
50<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 痊愈<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 54.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 显效<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 32.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 总<|>RELATION_NOE 有效率<|>RELATION_NOE 为<|>RELATION_NOE 86.0%<|>RELATION_NOE ,<|>RELATION_NOE 7例<|>RELATION_NOE (<|>RELATION_NOE 14.0%<|>RELATION_NOE )<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 死亡原因<|>RELATION_NOE :<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 急性<|>RELATION_NOE 加重<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 型<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 败血症<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 重症<|>RELATION_NOE 肺炎<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 间质性<|>RELATION_NOE 肺病<|>RELATION_NOE 伴<|>RELATION_NOE 感染<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 非霍奇金<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 广泛<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 脑梗死<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
金黄色<|>RELATION_NOE 葡萄球菌<|>RELATION_NOE 肺炎<|>RELATION_NOE 好<|>RELATION_B 发<|>RELATION_I 于<|>RELATION_E 老年<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 基础<|>RELATION_NOE 疾病<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 低下<|>RELATION_NOE 者<|>RELATION_NOE ,<|>RELATION_NOE 及早<|>RELATION_NOE 选择<|>RELATION_NOE 可能<|>RELATION_NOE 敏感<|>RELATION_NOE 的<|>RELATION_NOE 抗菌<|>RELATION_NOE 药物<|>RELATION_NOE 及<|>RELATION_NOE 进行<|>RELATION_NOE 细菌<|>RELATION_NOE 药敏<|>RELATION_NOE 检测<|>RELATION_NOE 将<|>RELATION_NOE 改善<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE 金黄色<|>RELATION_NOE 葡萄球菌<|>RELATION_NOE 肺炎<|>RELATION_NOE 好<|>RELATION_NOE 发<|>RELATION_NOE 于<|>RELATION_NOE 老年<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 基础<|>RELATION_NOE 疾病<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 低下<|>RELATION_NOE 者<|>RELATION_NOE ,<|>RELATION_NOE 及早<|>RELATION_NOE 选择<|>RELATION_NOE 可能<|>RELATION_NOE 敏感<|>RELATION_NOE 的<|>RELATION_NOE 抗菌<|>RELATION_NOE 药物<|>RELATION_NOE 及<|>RELATION_NOE 进行<|>RELATION_NOE 细菌<|>RELATION_NOE 药敏<|>RELATION_NOE 检测<|>RELATION_NOE 将<|>RELATION_NOE 改善<|>RELATION_S 预后<|>RELATION_NOE 。<|>RELATION_NOE
右<|>RELATION_NOE 美托<|>RELATION_NOE 咪定<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 苏醒<|>RELATION_NOE 质量<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 认知<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
选择<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 美国<|>RELATION_NOE 麻醉<|>RELATION_NOE 医师<|>RELATION_NOE 协会<|>RELATION_NOE Ⅰ<|>RELATION_NOE －Ⅱ级<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 在<|>RELATION_NOE 复合<|>RELATION_NOE 麻醉<|>RELATION_NOE 下<|>RELATION_NOE 手术<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 研究组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 静脉<|>RELATION_NOE 泵注<|>RELATION_NOE 同等<|>RELATION_NOE 剂量<|>RELATION_NOE 的<|>RELATION_NOE 0.9%<|>RELATION_NOE 氯化钠<|>RELATION_NOE 注射液<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_NOE 2组<|>RELATION_NOE 患者<|>RELATION_NOE 麻醉<|>RELATION_NOE 苏醒<|>RELATION_NOE 质量<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 认知<|>RELATION_NOE 功能<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
研究<|>RELATION_NOE 组术<|>RELATION_NOE 后<|>RELATION_NOE 呛咳<|>RELATION_NOE 和<|>RELATION_NOE 躁动评分<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 2.4<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 2.8<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 1.6<|>RELATION_NOE ±<|>RELATION_NOE 0.5<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 2.0<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 呼吸<|>RELATION_NOE 恢复<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE 和<|>RELATION_NOE 苏醒<|>RELATION_NOE 时间<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E [<|>RELATION_NOE (<|>RELATION_NOE 11.2<|>RELATION_NOE ±<|>RELATION_NOE 1.6<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 10.4<|>RELATION_NOE ±<|>RELATION_NOE 1.5<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 14.7<|>RELATION_NOE ±<|>RELATION_NOE 2.8<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 13.3<|>RELATION_NOE ±<|>RELATION_NOE 3.4<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 14.9<|>RELATION_NOE ±<|>RELATION_NOE 2.9<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 14.1<|>RELATION_NOE ±<|>RELATION_NOE 2.9<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE ]<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 与<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 二<|>RELATION_B 线<|>RELATION_I 治疗<|>RELATION_I 复发性<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞组<|>RELATION_NOE 给予<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 500mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE 30min<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 顺铂<|>RELATION_NOE 75mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 第1<|>RELATION_NOE －3<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE 肺叶切<|>RELATION_NOE 除术<|>RELATION_NOE 治疗<|>RELATION_B 原发性<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE
观察<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 杜冷丁<|>RELATION_NOE 用量<|>RELATION_NOE 、<|>RELATION_NOE 胸腔<|>RELATION_NOE 引流<|>RELATION_NOE 超过<|>RELATION_NOE 100ml<|>RELATION_NOE 天数<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 数目<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 血糖<|>RELATION_NOE (<|>RELATION_NOE GLU<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血清<|>RELATION_NOE 前白蛋白<|>RELATION_NOE (<|>RELATION_NOE PA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 白细胞计数<|>RELATION_NOE (<|>RELATION_NOE WBC<|>RELATION_NOE )<|>RELATION_NOE 等<|>RELATION_NOE 指标<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 切口<|>RELATION_NOE 长度<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 杜冷丁<|>RELATION_NOE 用量<|>RELATION_NOE 、<|>RELATION_NOE 引流<|>RELATION_NOE 超过<|>RELATION_NOE 100ml<|>RELATION_NOE 天数<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 住院<|>RELATION_NOE 费用<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 观察组<|>RELATION_NOE 切口<|>RELATION_NOE 长度<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 杜冷丁<|>RELATION_NOE 用量<|>RELATION_NOE 、<|>RELATION_NOE 引流<|>RELATION_NOE 超过<|>RELATION_NOE 100ml<|>RELATION_NOE 天数<|>RELATION_NOE 、<|>RELATION_NOE 住院时间<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 住院<|>RELATION_NOE 费用<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
相比<|>RELATION_NOE 于<|>RELATION_NOE 传统<|>RELATION_NOE 开胸<|>RELATION_NOE 肺叶切<|>RELATION_NOE 除术<|>RELATION_NOE ,<|>RELATION_NOE 电视<|>RELATION_B 胸腔镜<|>RELATION_I 治疗<|>RELATION_I 原发性<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 具有<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE ,<|>RELATION_NOE 但是<|>RELATION_NOE 住院<|>RELATION_NOE 费用<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 具体<|>RELATION_NOE 的<|>RELATION_NOE 选择<|>RELATION_NOE 上<|>RELATION_NOE 要<|>RELATION_NOE 根据<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 经济<|>RELATION_NOE 承受<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 尊重<|>RELATION_NOE 患者<|>RELATION_NOE 自愿<|>RELATION_NOE 予以<|>RELATION_NOE 选择<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_B 老年<|>RELATION_I 原发性<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE
选<|>RELATION_NOE 取经<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE ><|>RELATION_NOE 65<|>RELATION_NOE 岁<|>RELATION_NOE 、<|>RELATION_NOE 因<|>RELATION_NOE 各种<|>RELATION_NOE 原因<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 手术<|>RELATION_NOE 或<|>RELATION_NOE 拒绝<|>RELATION_NOE 其他<|>RELATION_NOE 治疗<|>RELATION_NOE 、<|>RELATION_NOE 愿<|>RELATION_NOE 接受<|>RELATION_NOE “<|>RELATION_NOE '<|>RELATION_NOE I<|>RELATION_NOE 粒子<|>RELATION_NOE 永久<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 的<|>RELATION_NOE 原<|>RELATION_NOE 发非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 59<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 永久<|>RELATION_NOE 植入<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 进行<|>RELATION_NOE 组织<|>RELATION_NOE 多肽特<|>RELATION_NOE 异抗原<|>RELATION_NOE (<|>RELATION_NOE TPS<|>RELATION_NOE )<|>RELATION_NOE 验证<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 封<|>RELATION_NOE 堵<|>RELATION_NOE 导管<|>RELATION_NOE 与<|>RELATION_NOE 双腔<|>RELATION_NOE 支气管<|>RELATION_NOE 导管<|>RELATION_NOE 用于<|>RELATION_B 单肺通气<|>RELATION_E 的<|>RELATION_NOE 对比<|>RELATION_NOE
对比<|>RELATION_NOE 支气管<|>RELATION_NOE 封<|>RELATION_NOE 堵<|>RELATION_NOE 导管<|>RELATION_NOE 与<|>RELATION_NOE 双腔<|>RELATION_NOE 支气管<|>RELATION_NOE 导管<|>RELATION_NOE 用于<|>RELATION_B 单肺通气<|>RELATION_E 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 需<|>RELATION_NOE 在<|>RELATION_NOE 单肺通气<|>RELATION_NOE 下行<|>RELATION_NOE 电视<|>RELATION_NOE 辅助<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 行<|>RELATION_NOE 支气管<|>RELATION_NOE 封<|>RELATION_NOE 堵<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 插<|>RELATION_NOE 双腔管<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
观察<|>RELATION_NOE 并<|>RELATION_NOE 记录<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 插管<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 定位<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 单肺通气<|>RELATION_NOE 时气道压<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 肺萎陷<|>RELATION_NOE 的<|>RELATION_NOE 质量<|>RELATION_NOE 以及<|>RELATION_NOE 术后<|>RELATION_NOE 声带<|>RELATION_NOE 和<|>RELATION_NOE 气道<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
A<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 插管<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 定位<|>RELATION_NOE 时间<|>RELATION_NOE 明显<|>RELATION_NOE 短<|>RELATION_NOE 于<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 声带<|>RELATION_NOE 和<|>RELATION_NOE 气道<|>RELATION_NOE 损伤<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E B<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
支气管<|>RELATION_NOE 封<|>RELATION_NOE 堵<|>RELATION_NOE 导管<|>RELATION_NOE 与<|>RELATION_NOE 双腔<|>RELATION_NOE 支气管<|>RELATION_NOE 导管<|>RELATION_NOE 用于<|>RELATION_B 单肺通气<|>RELATION_E 均<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 支气管<|>RELATION_NOE 封<|>RELATION_NOE 堵<|>RELATION_NOE 导管<|>RELATION_NOE 行<|>RELATION_NOE 单肺通气<|>RELATION_NOE 操作<|>RELATION_NOE 更<|>RELATION_NOE 简单<|>RELATION_NOE 快捷<|>RELATION_NOE ,<|>RELATION_NOE 单肺通气<|>RELATION_NOE 期间<|>RELATION_NOE 气道<|>RELATION_NOE 压低<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 少<|>RELATION_NOE 。<|>RELATION_NOE 支气管<|>RELATION_NOE 封<|>RELATION_NOE 堵<|>RELATION_NOE 导管<|>RELATION_NOE 与<|>RELATION_NOE 双腔<|>RELATION_NOE 支气管<|>RELATION_NOE 导管<|>RELATION_NOE 用于<|>RELATION_NOE 单肺通气<|>RELATION_NOE 均<|>RELATION_NOE 安全<|>RELATION_NOE 有效<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 支气管<|>RELATION_NOE 封<|>RELATION_NOE 堵<|>RELATION_NOE 导管<|>RELATION_NOE 行<|>RELATION_B 单肺通气<|>RELATION_I 操作<|>RELATION_E 更<|>RELATION_NOE 简单<|>RELATION_NOE 快捷<|>RELATION_NOE ,<|>RELATION_NOE 单肺通气<|>RELATION_NOE 期间<|>RELATION_NOE 气道<|>RELATION_NOE 压低<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 少<|>RELATION_NOE 。<|>RELATION_NOE
羧胺<|>RELATION_NOE 三<|>RELATION_NOE 唑<|>RELATION_NOE 通过<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相关<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 间接<|>RELATION_B 抑制<|>RELATION_E 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 迁移<|>RELATION_NOE
通过<|>RELATION_NOE 体外<|>RELATION_NOE 诱导<|>RELATION_NOE 探索<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相关<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE (<|>RELATION_NOE TAM<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE -<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_B 细胞增殖<|>RELATION_I 和<|>RELATION_I 迁移<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
建立<|>RELATION_NOE 腹腔<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 或<|>RELATION_NOE RAW264.7<|>RELATION_NOE 细胞<|>RELATION_NOE 与<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE LLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 共<|>RELATION_NOE 培养<|>RELATION_NOE 体系<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 对<|>RELATION_NOE LLC<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 迁移<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
向<|>RELATION_NOE 共<|>RELATION_NOE 培养<|>RELATION_NOE 体系<|>RELATION_NOE 中<|>RELATION_NOE 加入<|>RELATION_NOE CAI<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE 地塞米松<|>RELATION_NOE (<|>RELATION_NOE DEX<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 药物<|>RELATION_NOE 对<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE LLC<|>RELATION_NOE 增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
用<|>RELATION_NOE CAI<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE DEX<|>RELATION_NOE 预先<|>RELATION_NOE 处理<|>RELATION_NOE RAW264.7<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 然后<|>RELATION_NOE 检测<|>RELATION_NOE 不<|>RELATION_NOE 同<|>RELATION_NOE 药物<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE RAW264.7<|>RELATION_NOE 细胞<|>RELATION_NOE 诱导<|>RELATION_NOE LLC<|>RELATION_NOE 细胞迁移<|>RELATION_NOE 和<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 腹腔<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 共<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE LLC<|>RELATION_NOE 细胞<|>RELATION_NOE 比<|>RELATION_NOE 单独<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE LLC<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 显著<|>RELATION_NOE 增加<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 最为<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 前者<|>RELATION_NOE 比<|>RELATION_NOE 后者<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 增加<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE 2.5<|>RELATION_NOE ±<|>RELATION_NOE 77.7<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ;<|>RELATION_NOE
与<|>RELATION_NOE RAW264.7<|>RELATION_NOE 细胞<|>RELATION_NOE 共<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE LLC<|>RELATION_NOE 细胞<|>RELATION_NOE 比<|>RELATION_NOE 单独<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE LLC<|>RELATION_NOE 细胞<|>RELATION_NOE 迁移<|>RELATION_B 增加<|>RELATION_E (<|>RELATION_NOE 98.8<|>RELATION_NOE ±<|>RELATION_NOE 6.2<|>RELATION_NOE )%<|>RELATION_NOE 。<|>RELATION_NOE
CAI<|>RELATION_NOE 预处理<|>RELATION_NOE 的<|>RELATION_NOE RAW264.7<|>RELATION_NOE 细胞<|>RELATION_NOE 促进<|>RELATION_NOE LLC<|>RELATION_NOE 细胞迁移<|>RELATION_NOE 的<|>RELATION_NOE 能力<|>RELATION_NOE 减弱<|>RELATION_S ,<|>RELATION_NOE 其中<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 表达<|>RELATION_NOE 相比<|>RELATION_NOE 仅<|>RELATION_NOE 用<|>RELATION_NOE LLC<|>RELATION_NOE 条件<|>RELATION_NOE 培养基<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 对照组<|>RELATION_NOE 显著<|>RELATION_NOE 降低<|>RELATION_NOE (<|>RELATION_NOE CAI<|>RELATION_NOE 预处理<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 的<|>RELATION_NOE 相对<|>RELATION_NOE 表达量<|>RELATION_NOE 为<|>RELATION_NOE 0.66<|>RELATION_NOE ±<|>RELATION_NOE 0.03<|>RELATION_NOE vs<|>RELATION_NOE .<|>RELATION_NOE CAI<|>RELATION_NOE 预处理<|>RELATION_NOE 的<|>RELATION_NOE RAW264.7<|>RELATION_NOE 细胞<|>RELATION_NOE 促进<|>RELATION_NOE LLC<|>RELATION_NOE 细胞迁移<|>RELATION_NOE 的<|>RELATION_NOE 能力<|>RELATION_NOE 减弱<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 表达<|>RELATION_NOE 相比<|>RELATION_NOE 仅<|>RELATION_NOE 用<|>RELATION_NOE LLC<|>RELATION_NOE 条件<|>RELATION_NOE 培养基<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 对照组<|>RELATION_NOE 显著<|>RELATION_B 降低<|>RELATION_E (<|>RELATION_NOE CAI<|>RELATION_NOE 预处理<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 的<|>RELATION_NOE 相对<|>RELATION_NOE 表达量<|>RELATION_NOE 为<|>RELATION_NOE 0.66<|>RELATION_NOE ±<|>RELATION_NOE 0.03<|>RELATION_NOE vs<|>RELATION_NOE .<|>RELATION_NOE
CAI<|>RELATION_NOE 可以<|>RELATION_NOE 通过<|>RELATION_B 下调<|>RELATION_I 肿瘤<|>RELATION_I 条件<|>RELATION_I 诱导<|>RELATION_I 的<|>RELATION_I 巨噬细胞<|>RELATION_I 中<|>RELATION_I 的<|>RELATION_I TNF-<|>RELATION_I α<|>RELATION_I 水平<|>RELATION_I 间接<|>RELATION_I 抑制<|>RELATION_E 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 迁移<|>RELATION_NOE 。<|>RELATION_NOE
迭代<|>RELATION_NOE 重建<|>RELATION_NOE 结合<|>RELATION_NOE 自动<|>RELATION_NOE 管<|>RELATION_NOE 电流<|>RELATION_NOE 调节<|>RELATION_NOE 低<|>RELATION_NOE 剂量<|>RELATION_NOE 扫描<|>RELATION_NOE 技术<|>RELATION_NOE 在<|>RELATION_NOE 肺结节<|>RELATION_B 检查<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
噪声<|>RELATION_NOE 指数<|>RELATION_NOE 根据<|>RELATION_NOE 体重<|>RELATION_NOE 指数<|>RELATION_NOE (<|>RELATION_NOE BMI<|>RELATION_NOE )<|>RELATION_NOE 确定<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 次<|>RELATION_NOE 扫描<|>RELATION_NOE (<|>RELATION_NOE 纯<|>RELATION_NOE ATCM<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE BMI<|>RELATION_NOE ≤<|>RELATION_NOE 22<|>RELATION_NOE kg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 、<|>RELATION_NOE 噪声<|>RELATION_NOE 指数<|>RELATION_NOE 为<|>RELATION_NOE 14<|>RELATION_NOE ,<|>RELATION_NOE BMI<|>RELATION_NOE ><|>RELATION_NOE 22<|>RELATION_NOE kg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 、<|>RELATION_NOE 噪声<|>RELATION_NOE 指数<|>RELATION_NOE 为<|>RELATION_NOE 20<|>RELATION_NOE ;<|>RELATION_NOE
胸部<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 可<|>RELATION_NOE 提升<|>RELATION_S 噪声<|>RELATION_NOE 指数<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 应用<|>RELATION_NOE ASIR<|>RELATION_NOE 技术<|>RELATION_NOE 获得<|>RELATION_NOE 的<|>RELATION_NOE 图像<|>RELATION_NOE 能够<|>RELATION_NOE 保证<|>RELATION_NOE 图像<|>RELATION_NOE 质量<|>RELATION_NOE 符合<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 要求<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进一步<|>RELATION_NOE 减少<|>RELATION_NOE 辐射剂量<|>RELATION_NOE ,<|>RELATION_NOE 更<|>RELATION_NOE 适合<|>RELATION_NOE 对<|>RELATION_NOE 肺结节<|>RELATION_NOE 进行<|>RELATION_NOE 筛查<|>RELATION_NOE 、<|>RELATION_NOE 初步<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 随访<|>RELATION_NOE 。<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 可<|>RELATION_NOE 提升<|>RELATION_NOE 噪声<|>RELATION_NOE 指数<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 应用<|>RELATION_NOE ASIR<|>RELATION_NOE 技术<|>RELATION_NOE 获得<|>RELATION_NOE 的<|>RELATION_NOE 图像<|>RELATION_NOE 能够<|>RELATION_S 保证<|>RELATION_NOE 图像<|>RELATION_NOE 质量<|>RELATION_NOE 符合<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 要求<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进一步<|>RELATION_NOE 减少<|>RELATION_NOE 辐射剂量<|>RELATION_NOE ,<|>RELATION_NOE 更<|>RELATION_NOE 适合<|>RELATION_NOE 对<|>RELATION_NOE 肺结节<|>RELATION_NOE 进行<|>RELATION_NOE 筛查<|>RELATION_NOE 、<|>RELATION_NOE 初步<|>RELATION_NOE 诊断<|>RELATION_NOE 和<|>RELATION_NOE 随访<|>RELATION_NOE 。<|>RELATION_NOE
红细胞<|>RELATION_NOE 分布<|>RELATION_NOE 宽度<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 转移<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 红细胞<|>RELATION_NOE 分布<|>RELATION_NOE 宽度<|>RELATION_NOE (<|>RELATION_NOE RDW<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 提示<|>RELATION_B 肺癌<|>RELATION_I 患者<|>RELATION_I 转移<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 全部<|>RELATION_NOE 525<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 根据<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 转移<|>RELATION_NOE 等<|>RELATION_NOE 分组<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进一步<|>RELATION_NOE 对<|>RELATION_NOE 其中<|>RELATION_NOE 405<|>RELATION_NOE 例<|>RELATION_NOE 有<|>RELATION_NOE 转移者<|>RELATION_NOE 根据<|>RELATION_NOE 转移<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 其中<|>RELATION_NOE 246<|>RELATION_NOE 例<|>RELATION_NOE 有<|>RELATION_NOE 远端<|>RELATION_NOE 转移者<|>RELATION_NOE 根据<|>RELATION_NOE 远端<|>RELATION_NOE 转移<|>RELATION_NOE 器官<|>RELATION_NOE 数<|>RELATION_NOE 分别<|>RELATION_NOE 分组<|>RELATION_NOE 。<|>RELATION_NOE
ROC<|>RELATION_NOE 曲线<|>RELATION_NOE 分析<|>RELATION_NOE 表明<|>RELATION_NOE ,<|>RELATION_NOE RDW<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 是否<|>RELATION_NOE 发生<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 远端<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 曲线下面积<|>RELATION_NOE (<|>RELATION_NOE AUC<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.8<|>RELATION_NOE 23<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 0.7<|>RELATION_NOE 87<|>RELATION_NOE －0.8<|>RELATION_NOE 59<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 0.7<|>RELATION_NOE 10<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 0.6<|>RELATION_NOE 55<|>RELATION_NOE －0.7<|>RELATION_NOE 65<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE Youden<|>RELATION_NOE 指数<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 时<|>RELATION_NOE 的<|>RELATION_NOE 切点<|>RELATION_NOE 作为<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE cut-off<|>RELATION_NOE 值<|>RELATION_NOE (<|>RELATION_NOE 14.2<|>RELATION_NOE 5%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 此时<|>RELATION_NOE 敏感度<|>RELATION_NOE 为<|>RELATION_NOE 56.8%<|>RELATION_NOE ,<|>RELATION_NOE 特<|>RELATION_NOE 异度<|>RELATION_NOE 为<|>RELATION_NOE 98.3%<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE
RDW<|>RELATION_NOE 值<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 对<|>RELATION_NOE 判断<|>RELATION_B 肺癌<|>RELATION_I 患者<|>RELATION_I 转移<|>RELATION_I 情况<|>RELATION_E 有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 三维<|>RELATION_NOE 重建<|>RELATION_NOE 对<|>RELATION_NOE 微小<|>RELATION_NOE 肺癌<|>RELATION_NOE 早期<|>RELATION_B 诊断<|>RELATION_E 的<|>RELATION_NOE 价值<|>RELATION_NOE
利用<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 图像<|>RELATION_NOE 的<|>RELATION_NOE 后<|>RELATION_NOE 处理<|>RELATION_NOE 技术<|>RELATION_NOE ——<|>RELATION_NOE 多<|>RELATION_NOE 平面<|>RELATION_NOE 重建<|>RELATION_NOE (<|>RELATION_NOE multi-plane<|>RELATION_NOE reconstruction<|>RELATION_NOE ,<|>RELATION_NOE MPR<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 容积<|>RELATION_NOE 再现<|>RELATION_NOE 重建<|>RELATION_NOE (<|>RELATION_NOE volume<|>RELATION_NOE rendering<|>RELATION_NOE ,<|>RELATION_NOE VR<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 1cm<|>RELATION_NOE 周围型<|>RELATION_NOE 微小<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 恶性<|>RELATION_NOE 征象<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 其<|>RELATION_NOE 相<|>RELATION_NOE 对应<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 薄<|>RELATION_NOE 层<|>RELATION_NOE 扫描<|>RELATION_NOE (<|>RELATION_NOE thin-section<|>RELATION_NOE computed<|>RELATION_NOE tomography<|>RELATION_NOE ,<|>RELATION_NOE TSCT<|>RELATION_NOE )<|>RELATION_NOE 表现<|>RELATION_NOE 进行<|>RELATION_NOE 对比<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 评估<|>RELATION_NOE MPR<|>RELATION_NOE 联合<|>RELATION_NOE VR<|>RELATION_NOE 重建<|>RELATION_NOE 对<|>RELATION_NOE 微小<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 12<|>RELATION_NOE 月经<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 1cm<|>RELATION_NOE 周围型<|>RELATION_NOE 微小<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 及<|>RELATION_NOE 术前<|>RELATION_NOE TSCT<|>RELATION_NOE 、<|>RELATION_NOE MPR<|>RELATION_NOE 、<|>RELATION_NOE VR<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 单纯<|>RELATION_NOE TSCT<|>RELATION_NOE 与<|>RELATION_NOE MPR<|>RELATION_NOE 联合<|>RELATION_NOE VR<|>RELATION_NOE 重建<|>RELATION_NOE 对<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 1cm<|>RELATION_NOE 周围型<|>RELATION_NOE 微小<|>RELATION_NOE 肺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 征象<|>RELATION_NOE 的<|>RELATION_NOE 呈现<|>RELATION_NOE 能力<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 单纯<|>RELATION_NOE TSCT<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 联合<|>RELATION_NOE 运用<|>RELATION_NOE 对<|>RELATION_NOE 微小<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 分叶征<|>RELATION_NOE 、<|>RELATION_NOE 毛刺征<|>RELATION_NOE 、<|>RELATION_NOE 棘突征<|>RELATION_NOE 及<|>RELATION_NOE 胸膜<|>RELATION_NOE 牵拉<|>RELATION_NOE 等<|>RELATION_NOE 征象<|>RELATION_NOE 的<|>RELATION_NOE 呈现<|>RELATION_B 能力<|>RELATION_I 更<|>RELATION_I 高<|>RELATION_E 。<|>RELATION_NOE
MPR<|>RELATION_NOE 联合<|>RELATION_NOE VR<|>RELATION_NOE 重建<|>RELATION_NOE 对<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 1cm<|>RELATION_NOE 周围型<|>RELATION_NOE 微小<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 具有<|>RELATION_B 重大<|>RELATION_I 的<|>RELATION_I 临床<|>RELATION_I 应用<|>RELATION_I 价值<|>RELATION_E ,<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 发现<|>RELATION_NOE 和<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 提供<|>RELATION_NOE 了<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 策略.<|>RELATION_NOE MPR<|>RELATION_NOE 联合<|>RELATION_NOE VR<|>RELATION_NOE 重建<|>RELATION_NOE 对<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 1cm<|>RELATION_NOE 周围型<|>RELATION_NOE 微小<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 具有<|>RELATION_NOE 重大<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_B 的<|>RELATION_I 早期<|>RELATION_I 发现<|>RELATION_I 和<|>RELATION_I 早期<|>RELATION_I 诊断<|>RELATION_E 提供<|>RELATION_NOE 了<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 新<|>RELATION_NOE 的<|>RELATION_NOE 策略<|>RELATION_NOE .<|>RELATION_NOE
LyGDI<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 辐射<|>RELATION_B 抗性<|>RELATION_I 机制<|>RELATION_E 研究<|>RELATION_NOE
A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 转染<|>RELATION_NOE 50<|>RELATION_NOE nmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 的<|>RELATION_NOE miR-34c<|>RELATION_NOE 成熟<|>RELATION_NOE 序列<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 辐射<|>RELATION_NOE 抗性<|>RELATION_NOE 以及<|>RELATION_NOE LyGDI<|>RELATION_NOE 和<|>RELATION_NOE COX-2<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
LyGDI<|>RELATION_NOE 和<|>RELATION_NOE COX-2<|>RELATION_NOE 在<|>RELATION_NOE 辐射<|>RELATION_NOE 抗性<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 高于<|>RELATION_S H460<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE miR-34a<|>RELATION_NOE 以及<|>RELATION_NOE miR-34b<|>RELATION_NOE /<|>RELATION_NOE c<|>RELATION_NOE 在<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中低<|>RELATION_NOE 表达.<|>RELATION_NOE
转染<|>RELATION_NOE miR-34c<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_S LyGDI<|>RELATION_NOE 、<|>RELATION_NOE COX-2<|>RELATION_NOE 和<|>RELATION_NOE Bcl-2<|>RELATION_NOE 以及<|>RELATION_NOE 激活<|>RELATION_NOE p21<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 增强<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 辐射敏感性<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.85<|>RELATION_NOE 、<|>RELATION_NOE 5.89<|>RELATION_NOE 、<|>RELATION_NOE 5.12<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 转染<|>RELATION_NOE miR-34c<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_NOE LyGDI<|>RELATION_NOE 、<|>RELATION_NOE COX-2<|>RELATION_NOE 和<|>RELATION_NOE Bcl-2<|>RELATION_NOE 以及<|>RELATION_NOE 激活<|>RELATION_NOE p21<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 增强<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 辐射敏感性<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.85<|>RELATION_NOE 、<|>RELATION_NOE 5.89<|>RELATION_NOE 、<|>RELATION_NOE 5.12<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 血清<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_S
观察<|>RELATION_NOE 在<|>RELATION_NOE 中国<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 棘皮<|>RELATION_NOE 动物<|>RELATION_NOE 微管<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白样<|>RELATION_NOE 4-<|>RELATION_NOE 间变性<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE )<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 表达率<|>RELATION_NOE ,<|>RELATION_NOE 及<|>RELATION_NOE 血清<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 一致性<|>RELATION_S ,<|>RELATION_NOE 探讨<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE (<|>RELATION_NOE FQ-PCR<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 进行<|>RELATION_NOE 实时<|>RELATION_NOE 、<|>RELATION_NOE 动态<|>RELATION_NOE 检测<|>RELATION_NOE EML4-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 指导<|>RELATION_NOE 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE 观察<|>RELATION_NOE 在<|>RELATION_NOE 中国<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 棘皮<|>RELATION_NOE 动物<|>RELATION_NOE 微管<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白样<|>RELATION_NOE 4-<|>RELATION_NOE 间变性<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE )<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 表达率<|>RELATION_NOE ,<|>RELATION_NOE 及<|>RELATION_NOE 血清<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 一致性<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE (<|>RELATION_NOE FQ-PCR<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 进行<|>RELATION_B 实时<|>RELATION_I 、<|>RELATION_I 动态<|>RELATION_I 检测<|>RELATION_I EML4-ALK<|>RELATION_I 融合<|>RELATION_I 基因<|>RELATION_I 指导<|>RELATION_I 临床<|>RELATION_I 治疗<|>RELATION_E 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE FQ-PCR<|>RELATION_NOE 检测<|>RELATION_S 123<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 血清<|>RELATION_NOE 和<|>RELATION_NOE 98<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE EML4-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 77<|>RELATION_NOE 例<|>RELATION_NOE 血清<|>RELATION_NOE 和<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 进行<|>RELATION_NOE 配对<|>RELATION_NOE
123<|>RELATION_NOE 例<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE EMIA-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 10.6%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 98<|>RELATION_NOE 例<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE EMIA<|>RELATION_NOE .<|>RELATION_NOE
以<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 为<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 血清<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 突变<|>RELATION_NOE 一致性<|>RELATION_NOE 达到<|>RELATION_NOE 66.7%<|>RELATION_NOE (<|>RELATION_NOE 6/9<|>RELATION_NOE ,<|>RELATION_NOE κ<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 79<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
EMIA-ALK<|>RELATION_NOE 融合<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_B 间变性<|>RELATION_I 淋巴瘤<|>RELATION_I 激酶<|>RELATION_I (<|>RELATION_I ALK<|>RELATION_I )<|>RELATION_I 抑制剂<|>RELATION_I (<|>RELATION_I 克唑替尼<|>RELATION_I )<|>RELATION_I 治疗<|>RELATION_E 取得<|>RELATION_NOE 显著<|>RELATION_NOE 获益<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 无法<|>RELATION_NOE 获取<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 时<|>RELATION_NOE 可以<|>RELATION_NOE 采用<|>RELATION_B FQ-PCR<|>RELATION_I 检测<|>RELATION_I 血清<|>RELATION_I EMIA-ALK<|>RELATION_I 融合<|>RELATION_I 基因<|>RELATION_I 突变<|>RELATION_I 代替<|>RELATION_I 组织<|>RELATION_I 基因检测<|>RELATION_E ,<|>RELATION_NOE 筛选<|>RELATION_NOE 出<|>RELATION_NOE 适合<|>RELATION_NOE 克唑<|>RELATION_NOE 替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
持续<|>RELATION_NOE 质量<|>RELATION_NOE 改进<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 癌因性<|>RELATION_NOE 疲乏<|>RELATION_NOE 的<|>RELATION_NOE 改善<|>RELATION_B 及<|>RELATION_I 生活<|>RELATION_I 质量<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_E
干预<|>RELATION_NOE 后<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE Piper<|>RELATION_NOE 疲乏<|>RELATION_NOE 修正量表<|>RELATION_NOE 行为<|>RELATION_NOE 、<|>RELATION_NOE 情感<|>RELATION_NOE 、<|>RELATION_NOE 躯体<|>RELATION_NOE 、<|>RELATION_NOE 认知<|>RELATION_NOE 及<|>RELATION_NOE 疲乏<|>RELATION_NOE 总分<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 明显<|>RELATION_B 下降<|>RELATION_E (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疲乏<|>RELATION_NOE 程度<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 显著<|>RELATION_NOE 改善<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE Piper<|>RELATION_NOE 疲乏<|>RELATION_NOE 修正量表<|>RELATION_NOE 行为<|>RELATION_NOE 、<|>RELATION_NOE 情感<|>RELATION_NOE 、<|>RELATION_NOE 躯体<|>RELATION_NOE 、<|>RELATION_NOE 认知<|>RELATION_NOE 及<|>RELATION_NOE 疲乏<|>RELATION_NOE 总分<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 明显<|>RELATION_NOE 下降<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 疲乏<|>RELATION_NOE 程度<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 显著<|>RELATION_B 改善<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
预见性<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 氩氦<|>RELATION_B 刀<|>RELATION_I 冷冻<|>RELATION_I 治疗<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_I 患者<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
选取<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 4月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 4月<|>RELATION_NOE 来<|>RELATION_NOE 我院<|>RELATION_NOE 行氩<|>RELATION_NOE 氦刀<|>RELATION_NOE 冷冻<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 186<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 前<|>RELATION_NOE 半<|>RELATION_NOE 年<|>RELATION_NOE 就诊<|>RELATION_NOE 患者<|>RELATION_NOE 93<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 行<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ;<|>RELATION_NOE
观察组<|>RELATION_NOE 发热<|>RELATION_NOE 、<|>RELATION_NOE 气胸<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
预见性<|>RELATION_NOE 护理<|>RELATION_NOE 可以<|>RELATION_NOE 减少<|>RELATION_S 氩氦<|>RELATION_NOE 刀<|>RELATION_NOE 冷冻<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 和<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 科学<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 方式<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 借鉴<|>RELATION_NOE 。<|>RELATION_NOE 预见性<|>RELATION_NOE 护理<|>RELATION_NOE 可以<|>RELATION_NOE 减少<|>RELATION_NOE 氩氦<|>RELATION_NOE 刀<|>RELATION_NOE 冷冻<|>RELATION_NOE 治疗<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 和<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 科学<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 方式<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 借鉴<|>RELATION_NOE 。<|>RELATION_NOE
围术期<|>RELATION_NOE 呼吸<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 呼吸功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 围术期<|>RELATION_NOE 呼吸<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 呼吸功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
选择<|>RELATION_NOE 我<|>RELATION_NOE 院<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 7月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 的<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 围术期<|>RELATION_NOE 呼吸<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 对照组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
护理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 各项<|>RELATION_NOE 呼吸功<|>RELATION_NOE 能<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_B 明显<|>RELATION_I 低于<|>RELATION_E 对照组<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 痰液<|>RELATION_NOE 黏稠度<|>RELATION_NOE 、<|>RELATION_NOE 排痰<|>RELATION_NOE 难度<|>RELATION_NOE 、<|>RELATION_NOE 肺部<|>RELATION_NOE 啰音<|>RELATION_NOE 等<|>RELATION_NOE 评分<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 6.6<|>RELATION_NOE 7%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 护理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 各项<|>RELATION_NOE 呼吸功<|>RELATION_NOE 能<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 痰液<|>RELATION_NOE 黏稠度<|>RELATION_NOE 、<|>RELATION_NOE 排痰<|>RELATION_NOE 难度<|>RELATION_NOE 、<|>RELATION_NOE 肺部<|>RELATION_NOE 啰音<|>RELATION_NOE 等<|>RELATION_NOE 评分<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 具有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 6.6<|>RELATION_NOE 7%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 组间<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 明显<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 护理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 各项<|>RELATION_NOE 呼吸功<|>RELATION_NOE 能<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 痰液<|>RELATION_NOE 黏稠度<|>RELATION_NOE 、<|>RELATION_NOE 排痰<|>RELATION_NOE 难度<|>RELATION_NOE 、<|>RELATION_NOE 肺部<|>RELATION_NOE 啰音<|>RELATION_NOE 等<|>RELATION_NOE 评分<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而且<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 6.6<|>RELATION_NOE 7%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 组间<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 明显<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺腺<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 对<|>RELATION_NOE 纵隔<|>RELATION_B 淋巴结<|>RELATION_I 转移<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 旨在<|>RELATION_NOE 研究<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 大小<|>RELATION_NOE 对<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_B 相关性<|>RELATION_E ,<|>RELATION_NOE 并且<|>RELATION_NOE 阐明<|>RELATION_NOE 与<|>RELATION_NOE 纵隔<|>RELATION_NOE 本<|>RELATION_NOE 研究<|>RELATION_NOE 旨在<|>RELATION_NOE 研究<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 大小<|>RELATION_NOE 对<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 阐明<|>RELATION_NOE 与<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 高发<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 的<|>RELATION_NOE 临界<|>RELATION_B 值<|>RELATION_E 。<|>RELATION_NOE
顾性<|>RELATION_NOE 分析<|>RELATION_NOE 上海市<|>RELATION_NOE 肺科<|>RELATION_NOE 医院<|>RELATION_NOE 2005<|>RELATION_NOE 至<|>RELATION_NOE 2006<|>RELATION_NOE 年<|>RELATION_NOE 间<|>RELATION_NOE 1346<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 外科手术<|>RELATION_NOE 切除<|>RELATION_NOE 及<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 的<|>RELATION_NOE 直径<|>RELATION_NOE <<|>RELATION_NOE 8cm<|>RELATION_NOE 的<|>RELATION_NOE 肺原发性<|>RELATION_NOE 鳞<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 大小<|>RELATION_NOE 与<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 以及腺<|>RELATION_NOE 、<|>RELATION_NOE 鳞癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 与<|>RELATION_NOE 淋巴<|>RELATION_NOE 解<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 直径<|>RELATION_NOE 在<|>RELATION_NOE 2.0<|>RELATION_NOE －<|>RELATION_NOE 2.4cm<|>RELATION_NOE 的<|>RELATION_NOE 腺癌<|>RELATION_NOE 是<|>RELATION_NOE 淋巴结<|>RELATION_B 转移<|>RELATION_E 的<|>RELATION_NOE 危险度<|>RELATION_NOE 增加<|>RELATION_NOE 的<|>RELATION_NOE 节点<|>RELATION_NOE ,<|>RELATION_NOE 直径<|>RELATION_NOE ><|>RELATION_NOE 2cm<|>RELATION_NOE 的<|>RELATION_NOE 腺癌<|>RELATION_NOE 中<|>RELATION_NOE 43%<|>RELATION_NOE －<|>RELATION_NOE 63%<|>RELATION_NOE ,<|>RELATION_NOE 发生<|>RELATION_NOE 纵隔<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 大小<|>RELATION_NOE 与<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 大小<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 大小<|>RELATION_NOE 与<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 大小<|>RELATION_NOE 与<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相关性<|>RELATION_B 不<|>RELATION_I 大<|>RELATION_E 。<|>RELATION_NOE
吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 洛铂<|>RELATION_NOE 治疗<|>RELATION_S 紫杉类<|>RELATION_NOE 耐药<|>RELATION_NOE 晚期<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
共<|>RELATION_NOE 入<|>RELATION_NOE 组<|>RELATION_NOE 经<|>RELATION_NOE 含<|>RELATION_NOE 紫杉类<|>RELATION_NOE 联合化疗<|>RELATION_NOE 一线<|>RELATION_NOE 方案<|>RELATION_NOE 治疗失败<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 患者<|>RELATION_NOE 71<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 要求<|>RELATION_NOE 接受<|>RELATION_NOE 不<|>RELATION_NOE 少于<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 的<|>RELATION_NOE 二<|>RELATION_NOE 线<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 吉西<|>RELATION_NOE 他滨<|>RELATION_NOE 1000mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE )<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ;<|>RELATION_NOE
中<|>RELATION_NOE 位<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE mOS<|>RELATION_NOE )<|>RELATION_NOE 至<|>RELATION_NOE 疾病<|>RELATION_NOE 进展<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TTP<|>RELATION_NOE )<|>RELATION_NOE 13.6<|>RELATION_NOE 周<|>RELATION_NOE ,<|>RELATION_NOE mOS<|>RELATION_NOE 为<|>RELATION_NOE 7.9<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ,<|>RELATION_NOE 1年<|>RELATION_NOE 生存率<|>RELATION_NOE 42.6%<|>RELATION_NOE (<|>RELATION_NOE 29<|>RELATION_NOE /<|>RELATION_NOE 68<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胃复春片<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
68<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 单纯<|>RELATION_NOE 化疗<|>RELATION_NOE (<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨+<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 采用<|>RELATION_NOE 胃复春片<|>RELATION_NOE (<|>RELATION_NOE 1.436g<|>RELATION_NOE /<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 2次/<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE 联合化疗<|>RELATION_NOE ,<|>RELATION_NOE 完成<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 进行<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 毒副反应<|>RELATION_NOE 评价<|>RELATION_NOE 。<|>RELATION_NOE
但<|>RELATION_NOE 观察组<|>RELATION_NOE 改善<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 效果<|>RELATION_NOE 明显<|>RELATION_B 优于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 4.12<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 发生<|>RELATION_NOE 血小板<|>RELATION_NOE 、<|>RELATION_NOE 白细胞<|>RELATION_NOE 、<|>RELATION_NOE 血红<|>RELATION_NOE 蛋白<|>RELATION_NOE 减少<|>RELATION_NOE 及<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 等<|>RELATION_NOE 毒副反应<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE
热疗<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌伴<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌化<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
小<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 时<|>RELATION_NOE 序<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 研究<|>RELATION_E
选取<|>RELATION_NOE 我院<|>RELATION_NOE 2009年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2009年<|>RELATION_NOE 12月<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 按照<|>RELATION_NOE 随机<|>RELATION_NOE 数字法<|>RELATION_NOE 分为<|>RELATION_NOE 研究组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 给予<|>RELATION_NOE 小<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 时<|>RELATION_NOE 序<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 给予<|>RELATION_NOE 小<|>RELATION_NOE 剂量<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 常规<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 直接<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 检测<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 建立<|>RELATION_S
建立<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 适用<|>RELATION_NOE 于<|>RELATION_NOE 临床<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 直接<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 突变<|>RELATION_B 检测<|>RELATION_E
方法<|>RELATION_NOE :<|>RELATION_NOE 以<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 热点<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 为<|>RELATION_NOE 突变<|>RELATION_NOE 检测<|>RELATION_NOE 靶位点<|>RELATION_NOE 设计<|>RELATION_NOE 特异性<|>RELATION_NOE 扩增<|>RELATION_NOE 、<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 引物<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 已<|>RELATION_NOE 知<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 野生型<|>RELATION_NOE 、<|>RELATION_NOE 突变型<|>RELATION_NOE 样品<|>RELATION_NOE 分别<|>RELATION_NOE 做<|>RELATION_NOE 为<|>RELATION_NOE 阴<|>RELATION_NOE 、<|>RELATION_NOE 阳性<|>RELATION_NOE 对照品<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 直接<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 检测<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 方法学<|>RELATION_NOE 评估<|>RELATION_NOE 。<|>RELATION_NOE
成功<|>RELATION_NOE 建立<|>RELATION_NOE 了<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 直接<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 检测<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 该<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 灵敏度<|>RELATION_NOE 为<|>RELATION_NOE 4.7<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE μ<|>RELATION_NOE l<|>RELATION_NOE ,<|>RELATION_NOE 重复性<|>RELATION_NOE 良好<|>RELATION_NOE .<|>RELATION_NOE
本<|>RELATION_NOE 研究<|>RELATION_NOE 建立<|>RELATION_NOE 了<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 临床<|>RELATION_NOE 样品<|>RELATION_NOE 检测<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 直接<|>RELATION_NOE 测<|>RELATION_NOE 序<|>RELATION_NOE 检测<|>RELATION_B 方法<|>RELATION_E .<|>RELATION_NOE
肺癌<|>RELATION_NOE 合并<|>RELATION_B 静脉<|>RELATION_I 血栓<|>RELATION_I 栓塞症<|>RELATION_E 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 分析<|>RELATION_NOE
分析<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_B 静脉<|>RELATION_I 血栓<|>RELATION_I 栓塞症<|>RELATION_E (<|>RELATION_NOE VTE<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 2003年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 4月<|>RELATION_NOE 北京<|>RELATION_NOE 医院<|>RELATION_NOE 住院<|>RELATION_NOE 的<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE VTE<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 体力<|>RELATION_NOE 状态<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 等<|>RELATION_NOE 临床<|>RELATION_NOE 信息<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 肺血栓栓塞症<|>RELATION_NOE (<|>RELATION_NOE PTE<|>RELATION_NOE )<|>RELATION_NOE 合并<|>RELATION_NOE 深静脉血栓<|>RELATION_NOE 形成<|>RELATION_NOE (<|>RELATION_NOE DVT<|>RELATION_NOE )<|>RELATION_NOE 者<|>RELATION_NOE 归<|>RELATION_NOE 入<|>RELATION_NOE PTE<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE VTE<|>RELATION_NOE 的<|>RELATION_NOE 发病<|>RELATION_NOE 情况<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 了解<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 、<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 组织<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 低<|>RELATION_NOE 、<|>RELATION_NOE 含铂<|>RELATION_NOE 类<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 发生<|>RELATION_B VTE<|>RELATION_E 的<|>RELATION_NOE 风险<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 多<|>RELATION_NOE 发生<|>RELATION_NOE 于<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 后<|>RELATION_NOE 3－<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE ;<|>RELATION_NOE
自我<|>RELATION_NOE 效能<|>RELATION_NOE 理论<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 患者<|>RELATION_I 护理<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
探讨<|>RELATION_NOE 自我<|>RELATION_NOE 效能<|>RELATION_NOE 理论<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 患者<|>RELATION_I 护理<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 接受<|>RELATION_NOE 常规<|>RELATION_NOE 治疗<|>RELATION_NOE 和<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 在<|>RELATION_NOE 此<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 增加<|>RELATION_NOE 自我<|>RELATION_NOE 效能<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 一般<|>RELATION_NOE 自我<|>RELATION_NOE 效能<|>RELATION_NOE 感表<|>RELATION_NOE (<|>RELATION_NOE GSES<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 测定表<|>RELATION_NOE (<|>RELATION_NOE WHOQOL-100<|>RELATION_NOE )<|>RELATION_NOE 评价<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 自我<|>RELATION_NOE 效能感<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
干预<|>RELATION_NOE 后<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 自我<|>RELATION_NOE 效能感<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_B 有<|>RELATION_I 提高<|>RELATION_E ,<|>RELATION_NOE 研究组<|>RELATION_NOE 自我<|>RELATION_NOE 效能感<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 37.05<|>RELATION_NOE ±<|>RELATION_NOE 4.23<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 77.14<|>RELATION_NOE ±<|>RELATION_NOE 4.25<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 31.12<|>RELATION_NOE ±<|>RELATION_NOE 5.21<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 62.03<|>RELATION_NOE ±<|>RELATION_NOE 4.52<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5.6<|>RELATION_NOE 07<|>RELATION_NOE ,<|>RELATION_NOE 15.403<|>RELATION_NOE ;<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 自我<|>RELATION_NOE 效能感<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 提高<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 自我<|>RELATION_NOE 效能感<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 37.05<|>RELATION_NOE ±<|>RELATION_NOE 4.23<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 77.14<|>RELATION_NOE ±<|>RELATION_NOE 4.25<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 31.12<|>RELATION_NOE ±<|>RELATION_NOE 5.21<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 62.03<|>RELATION_NOE ±<|>RELATION_NOE 4.52<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_B 组<|>RELATION_I 比较<|>RELATION_I 差异<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 5.6<|>RELATION_NOE 07<|>RELATION_NOE ,<|>RELATION_NOE 15.403<|>RELATION_NOE ;<|>RELATION_NOE
自我<|>RELATION_NOE 效能<|>RELATION_NOE 理论<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 患者<|>RELATION_I 护理<|>RELATION_E 具有<|>RELATION_NOE 指导<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE .<|>RELATION_NOE
健康<|>RELATION_NOE 教育<|>RELATION_NOE 路径<|>RELATION_NOE 在<|>RELATION_NOE 高龄<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 效果<|>RELATION_E
将<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE 路径<|>RELATION_NOE 进行<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 传统<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE 方法<|>RELATION_NOE 进行<|>RELATION_NOE 健康<|>RELATION_NOE 教育.<|>RELATION_NOE
比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疾病<|>RELATION_NOE 认知<|>RELATION_NOE 、<|>RELATION_NOE 住院<|>RELATION_NOE 满意度<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 等<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疾病<|>RELATION_NOE 认知<|>RELATION_NOE 状况<|>RELATION_NOE 掌握<|>RELATION_NOE 、<|>RELATION_NOE 了解<|>RELATION_NOE 、<|>RELATION_NOE 不<|>RELATION_NOE 知道<|>RELATION_NOE 例数<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 19<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 8<|>RELATION_NOE ,<|>RELATION_NOE 15<|>RELATION_NOE ,<|>RELATION_NOE 7例<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_B 组<|>RELATION_I 比较<|>RELATION_I 差异<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE U<|>RELATION_NOE =<|>RELATION_NOE 2.1<|>RELATION_NOE 69<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_B 评价<|>RELATION_I 价值<|>RELATION_E 的<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE
研究<|>RELATION_NOE 血清<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 预后<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_B NSCLC<|>RELATION_I 患者<|>RELATION_E 的<|>RELATION_NOE 预后<|>RELATION_NOE 评价<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 高<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 对<|>RELATION_NOE 评价<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 更<|>RELATION_NOE 有<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 将<|>RELATION_NOE 更<|>RELATION_NOE 可靠<|>RELATION_NOE 。<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 评价<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 高<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 对<|>RELATION_NOE 评价<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 更<|>RELATION_B 有<|>RELATION_I 价值<|>RELATION_E ,<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 将<|>RELATION_NOE 更<|>RELATION_NOE 可靠<|>RELATION_NOE 。<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE CEA<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 评价<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 高<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 对<|>RELATION_NOE 评价<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 更<|>RELATION_NOE 有<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 将<|>RELATION_NOE 更<|>RELATION_B 可靠<|>RELATION_E 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_B 周<|>RELATION_I 血<|>RELATION_I 中<|>RELATION_I 多<|>RELATION_I 参数<|>RELATION_I 检测<|>RELATION_E 对<|>RELATION_NOE 诊断<|>RELATION_NOE 微<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE
总<|>RELATION_NOE RNA<|>RELATION_NOE 通过<|>RELATION_NOE 紫外<|>RELATION_NOE 分<|>RELATION_NOE 光光<|>RELATION_NOE 度仪<|>RELATION_NOE 检测<|>RELATION_S RNA<|>RELATION_NOE 纯度<|>RELATION_NOE ,<|>RELATION_NOE OD268<|>RELATION_NOE /<|>RELATION_NOE 280值<|>RELATION_NOE 在<|>RELATION_NOE 1.6<|>RELATION_NOE 12－<|>RELATION_NOE 2.1<|>RELATION_NOE 之间<|>RELATION_NOE ,<|>RELATION_NOE RNA<|>RELATION_NOE 浓度<|>RELATION_NOE 在<|>RELATION_NOE 100<|>RELATION_NOE －<|>RELATION_NOE 14<|>RELATION_NOE 10<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 之间<|>RELATION_NOE .<|>RELATION_NOE
经过<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE ,<|>RELATION_NOE 52<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 发生<|>RELATION_NOE 转移<|>RELATION_NOE 或<|>RELATION_NOE 复发<|>RELATION_NOE 共<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 转移<|>RELATION_NOE 复发率<|>RELATION_NOE 34.6%<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE /<|>RELATION_NOE 52<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
CK19<|>RELATION_NOE 、<|>RELATION_NOE LunX<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_B 预测<|>RELATION_I NSCLC<|>RELATION_I 转移<|>RELATION_I 或<|>RELATION_I 复发<|>RELATION_I 的<|>RELATION_I 指标<|>RELATION_E ,<|>RELATION_NOE 辅助<|>RELATION_NOE 诊断<|>RELATION_NOE NSCLC<|>RELATION_NOE 微<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE LunX<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 略<|>RELATION_NOE 显<|>RELATION_NOE 优势<|>RELATION_NOE .<|>RELATION_NOE
影响<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌脑<|>RELATION_NOE 转移<|>RELATION_NOE 患者<|>RELATION_NOE 放射<|>RELATION_B 治疗<|>RELATION_I 后<|>RELATION_I 生存<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 脑转移<|>RELATION_NOE 患者<|>RELATION_NOE 放射<|>RELATION_B 治疗<|>RELATION_I 后<|>RELATION_E 的<|>RELATION_NOE 预后<|>RELATION_NOE 转归<|>RELATION_NOE 及<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE 生存期<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
ECOG<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE GPA<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_B NSCLC<|>RELATION_I 脑<|>RELATION_I 转移<|>RELATION_I 放疗<|>RELATION_I 后<|>RELATION_I 患者<|>RELATION_I 生存率<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 随机<|>RELATION_NOE 对照<|>RELATION_NOE 试验<|>RELATION_NOE 文献<|>RELATION_NOE 的<|>RELATION_NOE 质量<|>RELATION_B 评价<|>RELATION_E
基于<|>RELATION_NOE 三维<|>RELATION_NOE 影像<|>RELATION_NOE 解剖<|>RELATION_NOE 结构<|>RELATION_NOE 的<|>RELATION_NOE 调强<|>RELATION_NOE 剂量<|>RELATION_NOE 验证<|>RELATION_NOE 的<|>RELATION_NOE 初步<|>RELATION_B 研究<|>RELATION_E
分别<|>RELATION_NOE 用<|>RELATION_NOE 指形<|>RELATION_NOE 电离室<|>RELATION_NOE 、<|>RELATION_NOE Matrixx<|>RELATION_NOE 和<|>RELATION_NOE ArcCheck<|>RELATION_NOE 测量<|>RELATION_NOE 鼻咽癌<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 调强<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE 各<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 比较<|>RELATION_NOE IMRT<|>RELATION_NOE 和<|>RELATION_NOE VMAT<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE 中心点<|>RELATION_NOE 测量<|>RELATION_NOE 剂量<|>RELATION_NOE 偏差<|>RELATION_NOE ,<|>RELATION_NOE 并行<|>RELATION_NOE 成组<|>RELATION_NOE t<|>RELATION_NOE 检验.<|>RELATION_NOE
3DVH<|>RELATION_NOE 系统<|>RELATION_NOE 比较<|>RELATION_NOE 结果<|>RELATION_NOE 表明<|>RELATION_NOE γ<|>RELATION_NOE 通过率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 情况<|>RELATION_NOE 下<|>RELATION_NOE (<|>RELATION_NOE 3%<|>RELATION_NOE /<|>RELATION_NOE 3mm<|>RELATION_NOE 标准<|>RELATION_NOE ><|>RELATION_NOE 95%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 2例<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE (<|>RELATION_NOE 占<|>RELATION_NOE 总<|>RELATION_NOE 计划<|>RELATION_NOE 16.7%<|>RELATION_NOE )<|>RELATION_NOE 测量<|>RELATION_NOE 结果<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 靶区<|>RELATION_NOE 和<|>RELATION_NOE OAR<|>RELATION_NOE 的<|>RELATION_NOE DVH<|>RELATION_NOE 存在<|>RELATION_NOE 明显<|>RELATION_NOE 偏差<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE GTV<|>RELATION_NOE 、<|>RELATION_NOE 脊髓<|>RELATION_NOE 和<|>RELATION_NOE 脑干<|>RELATION_NOE 等<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 指标<|>RELATION_NOE 下<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
每次<|>RELATION_NOE 在线<|>RELATION_NOE 图像<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE SBRT<|>RELATION_NOE 临床<|>RELATION_B 疗效<|>RELATION_I 分析<|>RELATION_E
回顾<|>RELATION_NOE 2009-2013<|>RELATION_NOE 年间<|>RELATION_NOE 采用<|>RELATION_NOE SBRT<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 原发<|>RELATION_NOE 肺癌<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 转移性<|>RELATION_NOE 肺癌<|>RELATION_NOE 12<|>RELATION_NOE 例.<|>RELATION_NOE
放疗<|>RELATION_NOE 前<|>RELATION_NOE HRCT<|>RELATION_NOE 肺组织<|>RELATION_NOE 异常<|>RELATION_NOE 影像学<|>RELATION_NOE 征象<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 三维<|>RELATION_NOE 技术<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE RP<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_B 研究<|>RELATION_E
314<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 胸内<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 规律<|>RELATION_S 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
回顾<|>RELATION_NOE 分析<|>RELATION_NOE 314<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 重点<|>RELATION_NOE 探讨<|>RELATION_NOE 胸内<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 范围<|>RELATION_NOE ,<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 部位<|>RELATION_NOE 的<|>RELATION_NOE 关系.<|>RELATION_NOE
原<|>RELATION_NOE 发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 部位<|>RELATION_NOE 与<|>RELATION_NOE N2<|>RELATION_NOE 组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 相近<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.10<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
而<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE T3<|>RELATION_NOE 、<|>RELATION_NOE T4<|>RELATION_NOE 期<|>RELATION_NOE 出现<|>RELATION_NOE N2<|>RELATION_NOE 组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 概率<|>RELATION_NOE 较<|>RELATION_B T1<|>RELATION_I 、<|>RELATION_I T2<|>RELATION_I 期<|>RELATION_E 明显<|>RELATION_NOE 增高<|>RELATION_NOE (<|>RELATION_NOE 17.0%<|>RELATION_NOE :<|>RELATION_NOE 11.6%<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 较<|>RELATION_NOE 鳞癌<|>RELATION_NOE N2<|>RELATION_NOE 组<|>RELATION_NOE 更<|>RELATION_NOE 易<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE 34.5%<|>RELATION_NOE :<|>RELATION_NOE 23.2%<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.008<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 而<|>RELATION_NOE 原发灶<|>RELATION_NOE T3<|>RELATION_NOE 、<|>RELATION_NOE T4<|>RELATION_NOE 期<|>RELATION_NOE 出现<|>RELATION_NOE N2<|>RELATION_NOE 组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 概率<|>RELATION_NOE 较<|>RELATION_NOE T1<|>RELATION_NOE 、<|>RELATION_NOE T2<|>RELATION_NOE 期<|>RELATION_NOE 明显<|>RELATION_NOE 增高<|>RELATION_NOE (<|>RELATION_NOE 17.0%<|>RELATION_NOE :<|>RELATION_NOE 11.6%<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 较<|>RELATION_B 鳞癌<|>RELATION_I N2<|>RELATION_I 组<|>RELATION_E 更<|>RELATION_NOE 易<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE 34.5%<|>RELATION_NOE :<|>RELATION_NOE 23.2%<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.008<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺<|>RELATION_NOE 滑膜肉瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊治<|>RELATION_S 现状<|>RELATION_NOE
探讨<|>RELATION_NOE 提高<|>RELATION_NOE 肺<|>RELATION_NOE 滑膜肉瘤<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 治愈率<|>RELATION_NOE 的<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 选择<|>RELATION_NOE 1例肺<|>RELATION_NOE 滑膜肉瘤<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 结合<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 10月<|>RELATION_NOE 中国<|>RELATION_NOE 期刊<|>RELATION_NOE 全文<|>RELATION_NOE 数据库<|>RELATION_NOE 收录<|>RELATION_NOE 发表<|>RELATION_NOE 的<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 资料<|>RELATION_NOE 较为<|>RELATION_NOE 完整<|>RELATION_NOE 的<|>RELATION_NOE 肺原发性<|>RELATION_NOE 滑膜肉瘤<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性研究<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 主要<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 影像学<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 病理学<|>RELATION_NOE 、<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 特点<|>RELATION_NOE 及<|>RELATION_NOE 分子生物学<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 进行<|>RELATION_NOE 诊断<|>RELATION_NOE 及<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 减少<|>RELATION_NOE 误诊<|>RELATION_NOE 。<|>RELATION_NOE
主要<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 有<|>RELATION_NOE 胸痛<|>RELATION_NOE 、<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 、<|>RELATION_NOE 咯血<|>RELATION_NOE 及<|>RELATION_NOE 咳嗽<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿<|>RELATION_NOE 刺<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 应用<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 间<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE TPS<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 穿刺<|>RELATION_NOE 种植<|>RELATION_NOE 放射性<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 治疗<|>RELATION_S 非<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE .<|>RELATION_NOE
择<|>RELATION_NOE 2002年<|>RELATION_NOE 12月<|>RELATION_NOE 至<|>RELATION_NOE 2006年<|>RELATION_NOE 12月<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 为<|>RELATION_NOE 早期<|>RELATION_NOE NSCLC<|>RELATION_NOE (<|>RELATION_NOE Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 处方<|>RELATION_NOE 剂量<|>RELATION_NOE (<|>RELATION_NOE PD<|>RELATION_NOE )<|>RELATION_NOE 110<|>RELATION_NOE Gy<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 活度<|>RELATION_NOE 0.7mCi<|>RELATION_NOE ,<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下行<|>RELATION_NOE 经皮<|>RELATION_NOE 穿刺<|>RELATION_NOE 种植<|>RELATION_NOE 放射性<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 、<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 、<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 、<|>RELATION_NOE 1<|>RELATION_NOE 年<|>RELATION_NOE 复查<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 和<|>RELATION_NOE 疗效<|>RELATION_NOE 判定.<|>RELATION_NOE
分析<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE SPECT<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 同机<|>RELATION_NOE 融合<|>RELATION_NOE 显<|>RELATION_NOE 像<|>RELATION_NOE 肋骨<|>RELATION_NOE 单发病灶<|>RELATION_NOE 的<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 诊断<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 相互<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 评价<|>RELATION_NOE 定位<|>RELATION_NOE CT<|>RELATION_NOE 在<|>RELATION_NOE 诊断<|>RELATION_S 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE SPECT<|>RELATION_NOE 全身<|>RELATION_NOE 骨<|>RELATION_NOE 显像<|>RELATION_NOE 中<|>RELATION_NOE 发现<|>RELATION_NOE 肋骨<|>RELATION_NOE 单发病灶<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 加行<|>RELATION_NOE SPECT<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 同机<|>RELATION_NOE 融合<|>RELATION_NOE 显像<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 病变<|>RELATION_NOE 按<|>RELATION_NOE 位置<|>RELATION_NOE 分为<|>RELATION_NOE 前<|>RELATION_NOE 肋<|>RELATION_NOE 、<|>RELATION_NOE 侧肋<|>RELATION_NOE 、<|>RELATION_NOE 后肋<|>RELATION_NOE 、<|>RELATION_NOE 肋骨<|>RELATION_NOE 与<|>RELATION_NOE 肋软骨<|>RELATION_NOE 交界处<|>RELATION_NOE 四<|>RELATION_NOE 个<|>RELATION_NOE 部位<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 病灶<|>RELATION_NOE 形状<|>RELATION_NOE 分为<|>RELATION_NOE 点状<|>RELATION_NOE 和<|>RELATION_NOE 条形<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 分类<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 分析<|>RELATION_NOE SPECT<|>RELATION_NOE 全身<|>RELATION_NOE 骨显像<|>RELATION_NOE 和<|>RELATION_NOE SPECT<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 同机<|>RELATION_NOE 融合<|>RELATION_NOE 显像<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效能<|>RELATION_NOE 。<|>RELATION_NOE
SPECT<|>RELATION_NOE 全身<|>RELATION_NOE 骨显像<|>RELATION_NOE 和<|>RELATION_NOE SPECT<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 同机<|>RELATION_NOE 融合<|>RELATION_NOE 显像<|>RELATION_NOE 诊断<|>RELATION_NOE 单<|>RELATION_NOE 发<|>RELATION_NOE 浓<|>RELATION_NOE 聚<|>RELATION_NOE 灶骨<|>RELATION_NOE 转移<|>RELATION_NOE 敏感度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 69.2<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE /<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 92.3<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE /<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 特<|>RELATION_NOE 异度<|>RELATION_NOE 59.5<|>RELATION_NOE 2%<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE /<|>RELATION_NOE 42<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 85.7<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE 36<|>RELATION_NOE /<|>RELATION_NOE 42<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 准确度<|>RELATION_NOE 63.2<|>RELATION_NOE 4%<|>RELATION_NOE (<|>RELATION_NOE 43<|>RELATION_NOE /<|>RELATION_NOE 68<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 88.2<|>RELATION_NOE 4%<|>RELATION_NOE (<|>RELATION_NOE 60<|>RELATION_NOE /<|>RELATION_NOE 68<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 预测<|>RELATION_NOE 值<|>RELATION_NOE 51.4<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE /<|>RELATION_NOE 35<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 80.00%<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE /<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 75.7<|>RELATION_NOE 6%<|>RELATION_NOE (<|>RELATION_NOE 25<|>RELATION_NOE /<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 94.7<|>RELATION_NOE 4%<|>RELATION_NOE (<|>RELATION_NOE 36<|>RELATION_NOE /<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肋骨<|>RELATION_NOE 单发病<|>RELATION_NOE 灶良<|>RELATION_NOE 恶性<|>RELATION_NOE 病变<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 图像<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 对于<|>RELATION_B 鉴别诊断<|>RELATION_I 具有<|>RELATION_I 十分<|>RELATION_I 重要<|>RELATION_I 的<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E ,<|>RELATION_NOE SPECT<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 同机<|>RELATION_NOE 融合<|>RELATION_NOE 显像<|>RELATION_NOE 提高<|>RELATION_NOE 了<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE
参附<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_NOE 参附<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 仅仅<|>RELATION_NOE 给予<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨+<|>RELATION_NOE 卡铂<|>RELATION_NOE 方案<|>RELATION_NOE 进行<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 此<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 给予<|>RELATION_NOE 参附<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 60<|>RELATION_NOE mL<|>RELATION_NOE ,<|>RELATION_NOE 每天<|>RELATION_NOE 1<|>RELATION_NOE 次<|>RELATION_NOE ,<|>RELATION_NOE 连续<|>RELATION_NOE 使用<|>RELATION_NOE 10<|>RELATION_NOE d<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 、<|>RELATION_NOE 观察组<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 淋巴细胞<|>RELATION_B 亚群<|>RELATION_I 的<|>RELATION_I 变化<|>RELATION_I 比较<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t1<|>RELATION_NOE =<|>RELATION_NOE 5.36<|>RELATION_NOE 、<|>RELATION_NOE 5.12<|>RELATION_NOE 、<|>RELATION_NOE 4.68<|>RELATION_NOE 、<|>RELATION_NOE 5.68<|>RELATION_NOE 、<|>RELATION_NOE 4.78<|>RELATION_NOE ,<|>RELATION_NOE t2<|>RELATION_NOE =<|>RELATION_NOE 5.28<|>RELATION_NOE 、<|>RELATION_NOE 5.13<|>RELATION_NOE 、<|>RELATION_NOE 5.68<|>RELATION_NOE 、<|>RELATION_NOE 4.12<|>RELATION_NOE 、<|>RELATION_NOE 4.66<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 5.22<|>RELATION_NOE 、<|>RELATION_NOE 5.73<|>RELATION_NOE 、<|>RELATION_NOE 4.56<|>RELATION_NOE 、<|>RELATION_NOE 5.03<|>RELATION_NOE 、<|>RELATION_NOE 4.85<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 观察组<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 亚群<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t1<|>RELATION_NOE =<|>RELATION_NOE 5.36<|>RELATION_NOE 、<|>RELATION_NOE 5.12<|>RELATION_NOE 、<|>RELATION_NOE 4.68<|>RELATION_NOE 、<|>RELATION_NOE 5.68<|>RELATION_NOE 、<|>RELATION_NOE 4.78<|>RELATION_NOE ,<|>RELATION_NOE t2<|>RELATION_NOE =<|>RELATION_NOE 5.28<|>RELATION_NOE 、<|>RELATION_NOE 5.13<|>RELATION_NOE 、<|>RELATION_NOE 5.68<|>RELATION_NOE 、<|>RELATION_NOE 4.12<|>RELATION_NOE 、<|>RELATION_NOE 4.66<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 5.22<|>RELATION_NOE 、<|>RELATION_NOE 5.73<|>RELATION_NOE 、<|>RELATION_NOE 4.56<|>RELATION_NOE 、<|>RELATION_NOE 5.03<|>RELATION_NOE 、<|>RELATION_NOE 4.85<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
参附<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_B 小细胞肺癌<|>RELATION_E ,<|>RELATION_NOE 疗效<|>RELATION_NOE 显著<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 改善<|>RELATION_NOE 了<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 肺功能<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 加以<|>RELATION_NOE 推广<|>RELATION_NOE 并<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
成年人<|>RELATION_NOE 活动性<|>RELATION_NOE 肺结核<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 腺苷脱氨酶<|>RELATION_NOE 和<|>RELATION_NOE 降钙素<|>RELATION_NOE 原<|>RELATION_NOE 联合<|>RELATION_B 检测<|>RELATION_I 的<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
选择<|>RELATION_NOE 81<|>RELATION_NOE 例<|>RELATION_NOE 活动性<|>RELATION_NOE 肺结核<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 结核性<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 患者<|>RELATION_NOE 43<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE ADA<|>RELATION_NOE 可以<|>RELATION_B 作为<|>RELATION_E 活动性<|>RELATION_NOE 肺结核<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE ADA<|>RELATION_NOE 和<|>RELATION_NOE PCT<|>RELATION_NOE 联合<|>RELATION_NOE 测定<|>RELATION_NOE 可以<|>RELATION_NOE 判断<|>RELATION_NOE 活动性<|>RELATION_NOE 肺结核<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE 血清<|>RELATION_NOE ADA<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_NOE 活动性<|>RELATION_NOE 肺结核<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE ADA<|>RELATION_NOE 和<|>RELATION_NOE PCT<|>RELATION_NOE 联合<|>RELATION_NOE 测定<|>RELATION_NOE 可以<|>RELATION_B 判断<|>RELATION_E 活动性<|>RELATION_NOE 肺结核<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE miRNA<|>RELATION_NOE 的<|>RELATION_NOE 模拟物<|>RELATION_NOE /<|>RELATION_NOE 抑制剂<|>RELATION_NOE 转染<|>RELATION_NOE 至<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 细胞株<|>RELATION_NOE PC9<|>RELATION_NOE /<|>RELATION_NOE GR<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 使<|>RELATION_NOE miRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 恢复<|>RELATION_NOE 至<|>RELATION_NOE PC9<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 中医<|>RELATION_B 护理<|>RELATION_I 体验<|>RELATION_E 的<|>RELATION_NOE 质性<|>RELATION_NOE 研究<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 中医<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 体验<|>RELATION_NOE 提炼<|>RELATION_NOE 为<|>RELATION_NOE 3<|>RELATION_NOE 大<|>RELATION_NOE 主题<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 中医<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 信息<|>RELATION_NOE 需求<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 接受<|>RELATION_NOE 中医<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 存在<|>RELATION_S 影响<|>RELATION_NOE 治疗效果<|>RELATION_NOE 的<|>RELATION_NOE 问题<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 提升<|>RELATION_NOE 中医<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE 和<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 自我<|>RELATION_NOE 管理<|>RELATION_NOE 能力<|>RELATION_NOE 是<|>RELATION_NOE 当前<|>RELATION_NOE 亟须<|>RELATION_NOE 解决<|>RELATION_NOE 的<|>RELATION_NOE 课题<|>RELATION_NOE 。<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 接受<|>RELATION_NOE 中医<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 存在<|>RELATION_NOE 影响<|>RELATION_NOE 治疗效果<|>RELATION_NOE 的<|>RELATION_NOE 问题<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 提升<|>RELATION_NOE 中医<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE 和<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 自我<|>RELATION_NOE 管理<|>RELATION_NOE 能力<|>RELATION_NOE 是<|>RELATION_NOE 当前<|>RELATION_B 亟须<|>RELATION_I 解决<|>RELATION_E 的<|>RELATION_NOE 课题<|>RELATION_NOE 。<|>RELATION_NOE
结构式<|>RELATION_NOE 心理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 自我<|>RELATION_NOE 效能<|>RELATION_NOE 感<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
将<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 研究组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 给予<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 增加<|>RELATION_NOE 结构式<|>RELATION_NOE 心理<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 加强<|>RELATION_NOE 应<|>RELATION_NOE 激<|>RELATION_NOE 处理<|>RELATION_NOE 和<|>RELATION_NOE 应对<|>RELATION_NOE 技巧<|>RELATION_NOE 针对性<|>RELATION_NOE 护理<|>RELATION_NOE 研究<|>RELATION_NOE 。<|>RELATION_NOE
结构式<|>RELATION_NOE 心理<|>RELATION_NOE 干预<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_B 提高<|>RELATION_E 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 自我<|>RELATION_NOE 效能<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 4.98<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
结构式<|>RELATION_NOE 心理<|>RELATION_NOE 干预<|>RELATION_NOE 能<|>RELATION_NOE 增强<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 的<|>RELATION_NOE 自我<|>RELATION_NOE 效能<|>RELATION_NOE ,<|>RELATION_NOE 有效<|>RELATION_NOE 帮助<|>RELATION_NOE 患者<|>RELATION_NOE 积极<|>RELATION_NOE 应对<|>RELATION_NOE 疾病<|>RELATION_NOE 和<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE 结构式<|>RELATION_NOE 心理<|>RELATION_NOE 干预<|>RELATION_NOE 能<|>RELATION_NOE 增强<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 的<|>RELATION_NOE 自我<|>RELATION_NOE 效能<|>RELATION_NOE ,<|>RELATION_NOE 有效<|>RELATION_B 帮助<|>RELATION_E 患者<|>RELATION_NOE 积极<|>RELATION_NOE 应对<|>RELATION_NOE 疾病<|>RELATION_NOE 和<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE
全人<|>RELATION_NOE 照护<|>RELATION_NOE 模式<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_B 肺癌<|>RELATION_I 患者<|>RELATION_I 康复<|>RELATION_I 护理<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
探讨<|>RELATION_NOE 全人<|>RELATION_NOE 照护<|>RELATION_NOE 模式<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_B 肺癌<|>RELATION_I 患者<|>RELATION_I 康复<|>RELATION_I 护理<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 84<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 干预组<|>RELATION_NOE 各<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 的<|>RELATION_NOE 整体<|>RELATION_NOE 护理<|>RELATION_NOE 模式<|>RELATION_NOE 康复<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 干预组<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 此<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 实施<|>RELATION_NOE 全人<|>RELATION_NOE 照护<|>RELATION_NOE 模式<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 生命<|>RELATION_NOE 质量<|>RELATION_NOE 测评量表<|>RELATION_NOE (<|>RELATION_NOE FACT<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 自<|>RELATION_NOE 评量表<|>RELATION_NOE (<|>RELATION_NOE SDS<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 焦虑<|>RELATION_NOE 自<|>RELATION_NOE 评量表<|>RELATION_NOE (<|>RELATION_NOE SAS<|>RELATION_NOE )<|>RELATION_NOE 评价<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 脑转移瘤<|>RELATION_NOE 的<|>RELATION_NOE 立体<|>RELATION_B 定向<|>RELATION_I 放射<|>RELATION_I 治疗<|>RELATION_E
肺原发性<|>RELATION_NOE 肝样<|>RELATION_NOE 腺癌<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 观察<|>RELATION_S
探讨<|>RELATION_NOE 肺原发性<|>RELATION_NOE 肝样<|>RELATION_NOE 腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 病理<|>RELATION_I 特征<|>RELATION_I 、<|>RELATION_I 免疫<|>RELATION_I 表型<|>RELATION_I 、<|>RELATION_I 诊断<|>RELATION_I 和<|>RELATION_I 鉴别诊断<|>RELATION_E 。<|>RELATION_NOE
对<|>RELATION_NOE 20<|>RELATION_NOE 14年<|>RELATION_NOE 1月<|>RELATION_NOE 收集<|>RELATION_NOE 的<|>RELATION_NOE 1例<|>RELATION_NOE 肺原发性<|>RELATION_NOE 肝样<|>RELATION_NOE 腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 、<|>RELATION_NOE 大体<|>RELATION_NOE 及<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 形态<|>RELATION_NOE 、<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 等<|>RELATION_NOE 进行<|>RELATION_NOE 观察<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 复习<|>RELATION_NOE 相关<|>RELATION_NOE 文献<|>RELATION_NOE 。<|>RELATION_NOE
患者<|>RELATION_NOE 为<|>RELATION_NOE 64<|>RELATION_NOE 岁<|>RELATION_NOE 吸烟<|>RELATION_NOE 男性<|>RELATION_NOE ,<|>RELATION_NOE 因<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 咯血<|>RELATION_NOE 8d<|>RELATION_NOE 入院<|>RELATION_NOE 。<|>RELATION_NOE
肺肝<|>RELATION_NOE 样腺癌<|>RELATION_NOE 是<|>RELATION_NOE 原发<|>RELATION_NOE 于<|>RELATION_NOE 肺<|>RELATION_NOE 的<|>RELATION_NOE 上皮性<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 诊断<|>RELATION_B 的<|>RELATION_I 确立<|>RELATION_E 主要<|>RELATION_NOE 依赖<|>RELATION_NOE 发现<|>RELATION_NOE 相似<|>RELATION_NOE 于<|>RELATION_NOE 肝细胞癌<|>RELATION_NOE 的<|>RELATION_NOE 形态<|>RELATION_NOE (<|>RELATION_NOE 肝样<|>RELATION_NOE 结构<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 通过<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 与<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 检测<|>RELATION_NOE 除外<|>RELATION_NOE 肝细胞癌<|>RELATION_NOE 等<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 。<|>RELATION_NOE
盐酸埃克替尼<|>RELATION_NOE 治疗<|>RELATION_S 终末期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 多发脑<|>RELATION_NOE 转移<|>RELATION_NOE 放疗<|>RELATION_NOE 失败<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE
终末期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 多发脑<|>RELATION_NOE 转移<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 失败<|>RELATION_NOE 患者<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 盐酸埃克替尼<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 不<|>RELATION_NOE 接受<|>RELATION_NOE 盐酸埃克替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 和<|>RELATION_NOE 其他<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 。<|>RELATION_NOE
盐酸埃克替尼<|>RELATION_NOE 可<|>RELATION_NOE 延长<|>RELATION_S 终末期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 多发脑<|>RELATION_NOE 转移<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 失败<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存期<|>RELATION_NOE 。<|>RELATION_NOE
脑膜癌<|>RELATION_NOE 的<|>RELATION_NOE 脑脊液<|>RELATION_NOE 细胞学<|>RELATION_NOE 诊断<|>RELATION_B 相关<|>RELATION_I 因素<|>RELATION_I 分析<|>RELATION_E
1例<|>RELATION_NOE 左右<|>RELATION_NOE 顶叶<|>RELATION_NOE 双<|>RELATION_NOE 侧脑室<|>RELATION_NOE 旁<|>RELATION_NOE 、<|>RELATION_NOE 左<|>RELATION_NOE 枕叶<|>RELATION_NOE 及<|>RELATION_NOE 小脑<|>RELATION_NOE 半球<|>RELATION_NOE 见<|>RELATION_NOE 多<|>RELATION_NOE 个<|>RELATION_NOE 大小<|>RELATION_NOE 不等<|>RELATION_NOE 的<|>RELATION_NOE 圆形<|>RELATION_NOE 强化<|>RELATION_NOE 影<|>RELATION_NOE ;<|>RELATION_NOE
1例示<|>RELATION_NOE 侧脑室<|>RELATION_NOE 、<|>RELATION_NOE 三<|>RELATION_NOE 脑室<|>RELATION_NOE 、<|>RELATION_NOE 四<|>RELATION_NOE 脑室<|>RELATION_NOE 室管膜<|>RELATION_NOE 下<|>RELATION_NOE 广泛<|>RELATION_NOE 异常<|>RELATION_NOE 长<|>RELATION_NOE T1<|>RELATION_NOE 、<|>RELATION_NOE 长<|>RELATION_NOE T2<|>RELATION_NOE 信号<|>RELATION_NOE 且<|>RELATION_NOE 表面<|>RELATION_NOE 不<|>RELATION_NOE 光滑<|>RELATION_NOE 。<|>RELATION_NOE
(<|>RELATION_NOE 3<|>RELATION_NOE )<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 与<|>RELATION_NOE 脑脊液<|>RELATION_NOE 癌细胞<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 关系<|>RELATION_NOE :<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 发现<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 白血病<|>RELATION_NOE 5例<|>RELATION_NOE (<|>RELATION_NOE 急性<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 白血病<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 急性<|>RELATION_NOE 非<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 白血病<|>RELATION_NOE 2例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 脑<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 黑色素瘤<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 何杰<|>RELATION_NOE 金氏<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 鼻咽癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 阴道<|>RELATION_NOE 鳞状<|>RELATION_NOE 上皮<|>RELATION_NOE 癌1<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
E3<|>RELATION_NOE 泛素<|>RELATION_NOE 连接<|>RELATION_NOE 酶<|>RELATION_NOE Iduna<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE :<|>RELATION_NOE Iduna<|>RELATION_NOE 在<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_B 阴性<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 正常<|>RELATION_NOE 支气管<|>RELATION_NOE 黏膜<|>RELATION_NOE 上皮<|>RELATION_NOE 中<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE :<|>RELATION_NOE Iduna<|>RELATION_NOE 在<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_NOE 阴性<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 正常<|>RELATION_NOE 支气管<|>RELATION_NOE 黏膜<|>RELATION_NOE 上皮<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_B 阴性<|>RELATION_I 或<|>RELATION_I 弱阳性<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE .<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE :<|>RELATION_NOE Iduna<|>RELATION_NOE 在<|>RELATION_NOE 肺泡<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_NOE 阴性<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 正常<|>RELATION_NOE 支气管<|>RELATION_NOE 黏膜<|>RELATION_NOE 上皮<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_NOE 阴性<|>RELATION_NOE 或<|>RELATION_NOE 弱阳性<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 呈<|>RELATION_B 不同<|>RELATION_I 程度<|>RELATION_I 的<|>RELATION_I 阳性<|>RELATION_I 表达<|>RELATION_E .<|>RELATION_NOE
Iduna<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达率<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 呈<|>RELATION_B 负<|>RELATION_I 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.009<|>RELATION_NOE )<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 16<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE Iduna<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达率<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 呈<|>RELATION_NOE 负<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.009<|>RELATION_NOE )<|>RELATION_NOE 呈<|>RELATION_B 正<|>RELATION_I 相关<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 16<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE Iduna<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达率<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 呈<|>RELATION_NOE 负<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.009<|>RELATION_NOE )<|>RELATION_NOE 呈<|>RELATION_NOE 正<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 16<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Iduna<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 过程<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE 有<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 提示<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE .<|>RELATION_NOE Iduna<|>RELATION_NOE 的<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 过程<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 可能<|>RELATION_B 是<|>RELATION_I 提示<|>RELATION_E 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 不良<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE .<|>RELATION_NOE
血清<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE 检测<|>RELATION_NOE 用于<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_B 评价<|>RELATION_I 的<|>RELATION_I 价值<|>RELATION_E
用<|>RELATION_NOE ELISA<|>RELATION_NOE 法<|>RELATION_NOE 分析<|>RELATION_NOE 86<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 经<|>RELATION_NOE 一线<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE (<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨+<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 与<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 对照<|>RELATION_NOE 人群<|>RELATION_NOE 血清<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE 作<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE (<|>RELATION_NOE 1.98<|>RELATION_NOE ±<|>RELATION_NOE 1.17<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 17.36<|>RELATION_NOE ±<|>RELATION_NOE 13.28<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 12.56<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 25.47<|>RELATION_NOE ±<|>RELATION_NOE 15.31<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 17.36<|>RELATION_NOE ±<|>RELATION_NOE 13.28<|>RELATION_NOE )<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 5.84<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
此外<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 一线<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_I 化疗<|>RELATION_I 前<|>RELATION_E ,<|>RELATION_NOE 而<|>RELATION_NOE 对<|>RELATION_NOE 一线<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 无效<|>RELATION_NOE 或<|>RELATION_NOE 有<|>RELATION_NOE 抵抗<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 化疗<|>RELATION_NOE 前后<|>RELATION_NOE 变化<|>RELATION_NOE 并<|>RELATION_NOE 不<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 甚至<|>RELATION_NOE 有<|>RELATION_NOE 升高<|>RELATION_NOE 的<|>RELATION_NOE 趋势<|>RELATION_NOE 。<|>RELATION_NOE 此外<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 一线<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 对<|>RELATION_NOE 一线<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 无效<|>RELATION_NOE 或<|>RELATION_NOE 有<|>RELATION_NOE 抵抗<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_B 化疗<|>RELATION_I 前后<|>RELATION_I 变化<|>RELATION_E 并<|>RELATION_NOE 不<|>RELATION_NOE 明显<|>RELATION_NOE ,<|>RELATION_NOE 甚至<|>RELATION_NOE 有<|>RELATION_NOE 升高<|>RELATION_NOE 的<|>RELATION_NOE 趋势<|>RELATION_NOE 。<|>RELATION_NOE
异<|>RELATION_NOE 氟烷<|>RELATION_NOE 复合<|>RELATION_NOE 麻醉<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 异<|>RELATION_NOE 氟烷<|>RELATION_NOE 复合<|>RELATION_NOE 麻醉<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
观察组<|>RELATION_NOE 给予<|>RELATION_NOE 异<|>RELATION_NOE 氟烷<|>RELATION_NOE 复合<|>RELATION_NOE 芬太尼<|>RELATION_NOE 、<|>RELATION_NOE 咪达唑仑<|>RELATION_NOE 、<|>RELATION_NOE 维库溴铵<|>RELATION_NOE 麻醉<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 给予<|>RELATION_NOE 丙泊酚<|>RELATION_NOE 复合<|>RELATION_NOE 芬太尼<|>RELATION_NOE 、<|>RELATION_NOE 咪达唑仑<|>RELATION_NOE 、<|>RELATION_NOE 维库溴铵<|>RELATION_NOE 麻醉<|>RELATION_NOE .<|>RELATION_NOE
观察组<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 指标<|>RELATION_NOE 及<|>RELATION_NOE 炎性<|>RELATION_NOE 因子<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 小于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE T2<|>RELATION_NOE 、<|>RELATION_NOE T3<|>RELATION_NOE 、<|>RELATION_NOE T4<|>RELATION_NOE 时段<|>RELATION_NOE CD4<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 、<|>RELATION_NOE CD4<|>RELATION_NOE ^+/<|>RELATION_NOE CD8<|>RELATION_NOE ^<|>RELATION_NOE +<|>RELATION_NOE 、<|>RELATION_NOE TNF<|>RELATION_NOE 、<|>RELATION_NOE IL-6<|>RELATION_NOE 、<|>RELATION_NOE 皮质醇<|>RELATION_NOE 水平<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE T2<|>RELATION_NOE :<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.1<|>RELATION_NOE 43<|>RELATION_NOE 、<|>RELATION_NOE 2.1<|>RELATION_NOE 83<|>RELATION_NOE 、<|>RELATION_NOE 2.1<|>RELATION_NOE 44<|>RELATION_NOE 、<|>RELATION_NOE 2.0<|>RELATION_NOE 88<|>RELATION_NOE 、<|>RELATION_NOE 2.004<|>RELATION_NOE ,<|>RELATION_NOE T3<|>RELATION_NOE :<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.0<|>RELATION_NOE 77<|>RELATION_NOE 、<|>RELATION_NOE 2.1<|>RELATION_NOE 77<|>RELATION_NOE 、<|>RELATION_NOE 2.1<|>RELATION_NOE 62<|>RELATION_NOE 、<|>RELATION_NOE 2.1<|>RELATION_NOE 37<|>RELATION_NOE 、<|>RELATION_NOE 2.<|>RELATION_NOE 109<|>RELATION_NOE ,<|>RELATION_NOE T4<|>RELATION_NOE :<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 2.<|>RELATION_NOE 104<|>RELATION_NOE 、<|>RELATION_NOE 2.201<|>RELATION_NOE 、<|>RELATION_NOE 2.1<|>RELATION_NOE 43<|>RELATION_NOE 、<|>RELATION_NOE 2.8<|>RELATION_NOE 41<|>RELATION_NOE 、<|>RELATION_NOE 2.1<|>RELATION_NOE 34<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
丙泊酚<|>RELATION_NOE 和<|>RELATION_NOE 异<|>RELATION_NOE 氟烷<|>RELATION_NOE 均<|>RELATION_NOE 能<|>RELATION_NOE 促进<|>RELATION_B 肺癌<|>RELATION_I 根治术<|>RELATION_I 患者<|>RELATION_E 产生<|>RELATION_NOE 致炎性<|>RELATION_NOE 和<|>RELATION_NOE 抗<|>RELATION_NOE 炎性<|>RELATION_NOE 细胞<|>RELATION_NOE 因子<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 异<|>RELATION_NOE 氟烷<|>RELATION_NOE 较<|>RELATION_NOE 丙泊酚<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 炎症<|>RELATION_NOE 作用<|>RELATION_NOE .<|>RELATION_NOE
PTEN<|>RELATION_NOE 、<|>RELATION_NOE Survivin<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_B 小细胞肺癌<|>RELATION_I 组织<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE PTEN<|>RELATION_NOE 、<|>RELATION_NOE Survivin<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE PTEN<|>RELATION_NOE 、<|>RELATION_NOE Survivin<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
66<|>RELATION_NOE 份<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 作为<|>RELATION_NOE 观察组<|>RELATION_NOE ,<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 测定<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE PTEN<|>RELATION_NOE 、<|>RELATION_NOE Survivin<|>RELATION_NOE 和<|>RELATION_NOE 微血管<|>RELATION_NOE 密度<|>RELATION_NOE (<|>RELATION_NOE MVD<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
PTEN<|>RELATION_NOE 、<|>RELATION_NOE Survivin<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 关系<|>RELATION_E (<|>RELATION_NOE χ^2<|>RELATION_NOE =<|>RELATION_NOE 0.16<|>RELATION_NOE 、<|>RELATION_NOE 0.27<|>RELATION_NOE 、<|>RELATION_NOE 0.22<|>RELATION_NOE 、<|>RELATION_NOE 0.24<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 无远处<|>RELATION_NOE 转移<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_NOE 关系<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 4.<|>RELATION_NOE 39<|>RELATION_NOE 、<|>RELATION_NOE 4.92<|>RELATION_NOE 、<|>RELATION_NOE 5.76<|>RELATION_NOE 、<|>RELATION_NOE 5.29<|>RELATION_NOE 、<|>RELATION_NOE 6.26<|>RELATION_NOE 、<|>RELATION_NOE 4.25<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE PTEN<|>RELATION_NOE 、<|>RELATION_NOE Survivin<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 关系<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 0.16<|>RELATION_NOE 、<|>RELATION_NOE 0.27<|>RELATION_NOE 、<|>RELATION_NOE 0.22<|>RELATION_NOE 、<|>RELATION_NOE 0.24<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 有<|>RELATION_NOE 无远处<|>RELATION_NOE 转移<|>RELATION_NOE 有<|>RELATION_B 明显<|>RELATION_I 关系<|>RELATION_E (<|>RELATION_NOE χ^2<|>RELATION_NOE =<|>RELATION_NOE 4.<|>RELATION_NOE 39<|>RELATION_NOE 、<|>RELATION_NOE 4.92<|>RELATION_NOE 、<|>RELATION_NOE 5.76<|>RELATION_NOE 、<|>RELATION_NOE 5.29<|>RELATION_NOE 、<|>RELATION_NOE 6.26<|>RELATION_NOE 、<|>RELATION_NOE 4.25<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 抑郁<|>RELATION_NOE 情绪<|>RELATION_NOE 与<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 相关性<|>RELATION_S 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 焦虑<|>RELATION_NOE 抑郁<|>RELATION_NOE 情绪<|>RELATION_NOE 与<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S ,<|>RELATION_NOE 为<|>RELATION_NOE 临床<|>RELATION_NOE 有效<|>RELATION_NOE 干预<|>RELATION_NOE 提供<|>RELATION_NOE 理论<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 肺癌<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 专用<|>RELATION_NOE 量表<|>RELATION_NOE 即<|>RELATION_NOE 肺癌<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 评估量表<|>RELATION_NOE (<|>RELATION_NOE FACT-L<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 综合<|>RELATION_NOE 医院<|>RELATION_NOE 焦虑<|>RELATION_NOE 抑郁量表<|>RELATION_NOE (<|>RELATION_NOE HADS<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 170<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 调查<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 测量<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 48.2%<|>RELATION_NOE ,<|>RELATION_NOE 抑郁<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 54.7%<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 生理<|>RELATION_NOE 状态<|>RELATION_NOE 、<|>RELATION_NOE 情绪<|>RELATION_NOE 状态<|>RELATION_NOE 、<|>RELATION_NOE 功能<|>RELATION_NOE 状态<|>RELATION_NOE 、<|>RELATION_NOE 社会<|>RELATION_NOE 家庭<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 总体<|>RELATION_NOE 健康<|>RELATION_NOE 状况<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 焦虑<|>RELATION_NOE 抑郁<|>RELATION_NOE 状态<|>RELATION_NOE 均<|>RELATION_B 呈<|>RELATION_I 负<|>RELATION_I 相关<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 住院<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_B 抑郁<|>RELATION_I 状况<|>RELATION_E 程度<|>RELATION_NOE 重<|>RELATION_NOE ,<|>RELATION_NOE 发生率<|>RELATION_NOE 高<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 临床<|>RELATION_NOE 护理<|>RELATION_NOE 工作<|>RELATION_NOE 中<|>RELATION_NOE 应<|>RELATION_NOE 采取<|>RELATION_B 积极<|>RELATION_I 有效<|>RELATION_I 的<|>RELATION_I 干预<|>RELATION_I 措施<|>RELATION_E ,<|>RELATION_NOE 以<|>RELATION_NOE 预防<|>RELATION_NOE 和<|>RELATION_NOE 降低<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 和<|>RELATION_NOE 抑郁<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 进而<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE .<|>RELATION_NOE
白细胞介素<|>RELATION_NOE 21<|>RELATION_NOE 基因<|>RELATION_NOE 联合<|>RELATION_NOE 放射<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 协同<|>RELATION_B 抑制<|>RELATION_I 作用<|>RELATION_E
探讨<|>RELATION_NOE 白细胞介素<|>RELATION_NOE 21<|>RELATION_NOE (<|>RELATION_NOE IL-21<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 联合<|>RELATION_NOE 放射<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 协同<|>RELATION_B 抑制<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
将<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 分为<|>RELATION_NOE 4<|>RELATION_NOE 组<|>RELATION_NOE :<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE Ad-IL-21<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 用<|>RELATION_NOE Ad-IL-21<|>RELATION_NOE 腺病毒<|>RELATION_NOE 转染<|>RELATION_NOE 细胞<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 照射组<|>RELATION_NOE (<|>RELATION_NOE 行6<|>RELATION_NOE Gy<|>RELATION_NOE 137Cs<|>RELATION_NOE γ射线<|>RELATION_NOE 照射<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE Ad-IL-21<|>RELATION_NOE 联合<|>RELATION_NOE 照射组<|>RELATION_NOE (<|>RELATION_NOE 用<|>RELATION_NOE Ad-IL-21<|>RELATION_NOE 腺病毒<|>RELATION_NOE 转染<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE 再行6<|>RELATION_NOE Gy<|>RELATION_NOE 137Cs<|>RELATION_NOE γ射线<|>RELATION_NOE 照射<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE IL-21<|>RELATION_NOE 基因<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 效应<|>RELATION_NOE 。<|>RELATION_NOE
IL-21<|>RELATION_NOE 基因<|>RELATION_NOE 联合<|>RELATION_NOE 放射<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 细胞<|>RELATION_I 生长<|>RELATION_I 的<|>RELATION_I 抑制<|>RELATION_I 效应<|>RELATION_E 具有<|>RELATION_NOE 协同<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 显著<|>RELATION_NOE 地<|>RELATION_NOE 抑制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 。<|>RELATION_NOE
78<|>RELATION_NOE 例<|>RELATION_NOE 骨肉瘤<|>RELATION_NOE 患者<|>RELATION_NOE 使用<|>RELATION_NOE SPECT<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 行<|>RELATION_NOE 全身<|>RELATION_NOE 骨<|>RELATION_NOE 显像<|>RELATION_NOE 的<|>RELATION_NOE 同时<|>RELATION_NOE 获得<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 诊断<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE 肺转移<|>RELATION_NOE 发生<|>RELATION_NOE 。<|>RELATION_NOE
分析<|>RELATION_NOE 血清<|>RELATION_NOE 碱性磷酸酶<|>RELATION_NOE (<|>RELATION_NOE ALP<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 有<|>RELATION_NOE 肺转移<|>RELATION_NOE 与<|>RELATION_NOE 无<|>RELATION_NOE 肺转移者<|>RELATION_NOE 之间<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 有<|>RELATION_NOE 钙化<|>RELATION_NOE 与<|>RELATION_NOE 无<|>RELATION_NOE 钙化者<|>RELATION_NOE 之间<|>RELATION_NOE 以及<|>RELATION_NOE 转移<|>RELATION_NOE 灶骨<|>RELATION_NOE 显像<|>RELATION_NOE 阳性<|>RELATION_NOE 与<|>RELATION_NOE 阴<|>RELATION_NOE 性者<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
骨肉瘤<|>RELATION_NOE 患者<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 较<|>RELATION_B 高<|>RELATION_E ,<|>RELATION_NOE 使用<|>RELATION_NOE SPECT<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 同时<|>RELATION_NOE 行<|>RELATION_NOE 全身<|>RELATION_NOE 骨显像<|>RELATION_NOE 和<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 检<|>RELATION_NOE 出<|>RELATION_NOE 具有<|>RELATION_NOE
46<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 无<|>RELATION_NOE 症状<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 低<|>RELATION_NOE 剂量<|>RELATION_NOE CT<|>RELATION_NOE 早期<|>RELATION_B 肺癌<|>RELATION_I 筛查<|>RELATION_E 研究<|>RELATION_NOE
46<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 无<|>RELATION_NOE 症状者<|>RELATION_NOE (<|>RELATION_NOE ≥<|>RELATION_NOE 40<|>RELATION_NOE 岁<|>RELATION_NOE )<|>RELATION_NOE 接受肺<|>RELATION_NOE LDCT<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 受检<|>RELATION_NOE 人群<|>RELATION_NOE 分为<|>RELATION_NOE 高危组<|>RELATION_NOE 、<|>RELATION_NOE 中危组<|>RELATION_NOE 和<|>RELATION_NOE 低危组<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 根据<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 和<|>RELATION_NOE 被动吸烟<|>RELATION_NOE 史分<|>RELATION_NOE 为<|>RELATION_NOE 女性<|>RELATION_NOE 被动吸烟<|>RELATION_NOE 暴露组<|>RELATION_NOE (<|>RELATION_NOE FN<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 男性<|>RELATION_NOE 被动吸烟<|>RELATION_NOE 暴露组<|>RELATION_NOE (<|>RELATION_NOE MN<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
24<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 和<|>RELATION_NOE 1例<|>RELATION_NOE 类癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 24<|>RELATION_NOE 个<|>RELATION_NOE 病灶<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 为<|>RELATION_NOE 6.9<|>RELATION_NOE －<|>RELATION_NOE 29.5mm<|>RELATION_NOE ,<|>RELATION_NOE 中位值<|>RELATION_NOE 为<|>RELATION_NOE 16.3mm<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 筛查<|>RELATION_NOE 时<|>RELATION_NOE 应<|>RELATION_B 重视<|>RELATION_E 有<|>RELATION_NOE 被动吸烟<|>RELATION_NOE 暴露史<|>RELATION_NOE ≥<|>RELATION_NOE 40<|>RELATION_NOE 岁<|>RELATION_NOE 女性<|>RELATION_NOE 的<|>RELATION_NOE 筛查<|>RELATION_NOE .<|>RELATION_NOE
临床<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_B 规律<|>RELATION_I 和<|>RELATION_I 清扫<|>RELATION_I 方式<|>RELATION_E 的<|>RELATION_NOE 探讨<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 3月<|>RELATION_NOE 1日<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 8月<|>RELATION_NOE 31日<|>RELATION_NOE 间<|>RELATION_NOE 270<|>RELATION_NOE 例<|>RELATION_NOE 原发<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 270<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 3cm<|>RELATION_NOE ,<|>RELATION_NOE 术前<|>RELATION_NOE 分期<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE c<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
腺癌<|>RELATION_NOE 245<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 类癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 大细胞癌<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 肉瘤<|>RELATION_NOE 样癌<|>RELATION_NOE 1例.<|>RELATION_NOE
全<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 总<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移率<|>RELATION_NOE 为<|>RELATION_NOE 18.9%<|>RELATION_NOE (<|>RELATION_NOE 51<|>RELATION_NOE /<|>RELATION_NOE 270<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE p-GGO<|>RELATION_NOE 、<|>RELATION_NOE 混合型<|>RELATION_NOE 、<|>RELATION_NOE 实<|>RELATION_NOE 性结节型<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0<|>RELATION_NOE (<|>RELATION_NOE 0/34<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 2.1%<|>RELATION_NOE (<|>RELATION_NOE 1/47<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 26.5%<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE /<|>RELATION_NOE 189<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
右肺<|>RELATION_NOE 上<|>RELATION_NOE 叶癌<|>RELATION_NOE 、<|>RELATION_NOE 右<|>RELATION_NOE 肺下<|>RELATION_NOE 叶癌<|>RELATION_NOE 、<|>RELATION_NOE 左肺<|>RELATION_NOE 上<|>RELATION_NOE 叶癌<|>RELATION_NOE 和<|>RELATION_NOE 左肺<|>RELATION_NOE 下<|>RELATION_NOE 叶癌<|>RELATION_NOE 中<|>RELATION_NOE 特异性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 引流区<|>RELATION_NOE 阳性<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 特异性<|>RELATION_NOE 引流区<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 30.0%<|>RELATION_NOE 、<|>RELATION_NOE 20.0%<|>RELATION_NOE 、<|>RELATION_NOE 44.4%<|>RELATION_NOE 和<|>RELATION_NOE 50.0%<|>RELATION_NOE ,<|>RELATION_NOE 特异性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 引流区<|>RELATION_NOE 阴性<|>RELATION_NOE 组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0<|>RELATION_NOE 、<|>RELATION_NOE 0<|>RELATION_NOE 、<|>RELATION_NOE 0<|>RELATION_NOE 和<|>RELATION_NOE 2.9%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
影像学<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE p-GGO<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE NSCLC<|>RELATION_NOE 一般<|>RELATION_B 不<|>RELATION_I 发生<|>RELATION_I 淋巴结<|>RELATION_I 转移<|>RELATION_E ,<|>RELATION_NOE 术中<|>RELATION_NOE 可<|>RELATION_NOE 不行<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE .<|>RELATION_NOE
对于<|>RELATION_NOE 结节型<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移率<|>RELATION_NOE 随<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 实性<|>RELATION_NOE 结节<|>RELATION_NOE 成分<|>RELATION_NOE 的<|>RELATION_NOE 增大<|>RELATION_NOE 而<|>RELATION_NOE 增高<|>RELATION_S ,<|>RELATION_NOE 当<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 2cm<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 可<|>RELATION_NOE 先<|>RELATION_NOE 清扫<|>RELATION_NOE 特异性<|>RELATION_NOE 引流区<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 并行<|>RELATION_NOE 冰冻<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 若<|>RELATION_NOE 为<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 建议<|>RELATION_NOE 行<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE ;<|>RELATION_NOE 对于<|>RELATION_NOE 结节型<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移率<|>RELATION_NOE 随<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 实性<|>RELATION_NOE 结节<|>RELATION_NOE 成分<|>RELATION_NOE 的<|>RELATION_NOE 增大<|>RELATION_NOE 而<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 当<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE ≤<|>RELATION_NOE 2cm<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 可<|>RELATION_NOE 先<|>RELATION_NOE 清扫<|>RELATION_NOE 特异性<|>RELATION_NOE 引流区<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 并行<|>RELATION_NOE 冰冻<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 若<|>RELATION_B 为<|>RELATION_I 阳性<|>RELATION_E ,<|>RELATION_NOE 建议<|>RELATION_NOE 行<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE ;<|>RELATION_NOE
若<|>RELATION_NOE 为<|>RELATION_NOE 阴性<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 考虑<|>RELATION_NOE 不<|>RELATION_B 进一步<|>RELATION_I 行<|>RELATION_E 非<|>RELATION_NOE 特异性<|>RELATION_NOE 淋巴<|>RELATION_NOE 引流区<|>RELATION_NOE 的<|>RELATION_NOE 系统性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_S 标准<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 完全性<|>RELATION_NOE 切除<|>RELATION_NOE 手术<|>RELATION_NOE 标准<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 预后<|>RELATION_B 的<|>RELATION_I 影响<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 27<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 完全性<|>RELATION_NOE 切除<|>RELATION_NOE 手术<|>RELATION_NOE 标准<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 范围<|>RELATION_NOE 、<|>RELATION_NOE 手术<|>RELATION_NOE 切缘<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 组数<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 个数<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE T<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 放疗<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 完全<|>RELATION_NOE 性切除<|>RELATION_NOE 手术<|>RELATION_NOE 标准<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_B 小细胞肺癌<|>RELATION_I 患者<|>RELATION_I 预后<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 达到<|>RELATION_NOE 甚至<|>RELATION_NOE 超过<|>RELATION_NOE 完全性<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 能够<|>RELATION_NOE 明显<|>RELATION_NOE 改善<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 状况<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 推荐<|>RELATION_NOE 完全<|>RELATION_NOE 性切除<|>RELATION_NOE 手术<|>RELATION_NOE 标准<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE .<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 完全<|>RELATION_NOE 性切除<|>RELATION_NOE 手术<|>RELATION_NOE 标准<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 达到<|>RELATION_NOE 甚至<|>RELATION_NOE 超过<|>RELATION_NOE 完全性<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 能够<|>RELATION_NOE 明显<|>RELATION_B 改善<|>RELATION_E 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 状况<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 推荐<|>RELATION_NOE 完全<|>RELATION_NOE 性切除<|>RELATION_NOE 手术<|>RELATION_NOE 标准<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE .<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 完全<|>RELATION_NOE 性切除<|>RELATION_NOE 手术<|>RELATION_NOE 标准<|>RELATION_NOE 为<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 达到<|>RELATION_NOE 甚至<|>RELATION_NOE 超过<|>RELATION_NOE 完全性<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 能够<|>RELATION_NOE 明显<|>RELATION_NOE 改善<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 状况<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_NOE 推荐<|>RELATION_S 完全性<|>RELATION_NOE 切除<|>RELATION_NOE 手术<|>RELATION_NOE 标准<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE .<|>RELATION_NOE
经<|>RELATION_NOE 支气管镜<|>RELATION_NOE 确诊<|>RELATION_S CT<|>RELATION_NOE 隐性<|>RELATION_NOE 肺癌<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 胸部<|>RELATION_NOE 平扫<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 异常<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 经<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检查<|>RELATION_NOE 确诊<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 、<|>RELATION_NOE 病变<|>RELATION_NOE 部位<|>RELATION_NOE 和<|>RELATION_NOE 支气管镜<|>RELATION_NOE 检<|>RELATION_NOE 特征<|>RELATION_NOE 。<|>RELATION_NOE
病变<|>RELATION_NOE 部位<|>RELATION_NOE 涉及<|>RELATION_NOE 两<|>RELATION_NOE 肺<|>RELATION_NOE 各<|>RELATION_NOE 支气管<|>RELATION_NOE 分支<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 好<|>RELATION_NOE 发<|>RELATION_NOE 于<|>RELATION_NOE 双<|>RELATION_NOE 上<|>RELATION_NOE 肺<|>RELATION_NOE ;<|>RELATION_NOE
反复<|>RELATION_NOE 咯血<|>RELATION_NOE 或<|>RELATION_NOE 痰血<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 胸部<|>RELATION_NOE 平扫<|>RELATION_NOE CT<|>RELATION_NOE 未<|>RELATION_NOE 见<|>RELATION_NOE 异常<|>RELATION_NOE ,<|>RELATION_NOE 也<|>RELATION_NOE 应<|>RELATION_B 及时<|>RELATION_I 行<|>RELATION_I 支气管镜<|>RELATION_I 检<|>RELATION_E 以<|>RELATION_NOE 明确<|>RELATION_NOE 有<|>RELATION_NOE 无<|>RELATION_NOE CT<|>RELATION_NOE 隐性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 可能<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 相关<|>RELATION_NOE 呕吐<|>RELATION_NOE 前驱症状<|>RELATION_NOE 的<|>RELATION_NOE 筛选<|>RELATION_S 及其<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 相关<|>RELATION_NOE 呕吐<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 相关<|>RELATION_NOE 呕吐<|>RELATION_NOE 前驱症状<|>RELATION_NOE 的<|>RELATION_NOE 筛选<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 相关<|>RELATION_NOE 呕吐<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 相关性<|>RELATION_NOE 呕吐<|>RELATION_NOE (<|>RELATION_NOE CIV<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE CIV<|>RELATION_NOE 前驱症状<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
选择<|>RELATION_NOE 250<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 分析<|>RELATION_NOE CIV<|>RELATION_NOE 的<|>RELATION_NOE 前驱症状<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 定义<|>RELATION_NOE CIV<|>RELATION_NOE 最<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 前驱症状<|>RELATION_NOE ;<|>RELATION_NOE
选择<|>RELATION_NOE 157<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE CIV<|>RELATION_NOE 前驱症状<|>RELATION_NOE 进行<|>RELATION_NOE 药物<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 干预<|>RELATION_NOE 组<|>RELATION_NOE 与<|>RELATION_NOE 未<|>RELATION_NOE 干预<|>RELATION_NOE 组<|>RELATION_NOE 前驱症状<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE CIV<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
Logistic<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 便秘<|>RELATION_NOE 、<|>RELATION_NOE 失眠<|>RELATION_NOE 、<|>RELATION_NOE 呃逆<|>RELATION_NOE 和<|>RELATION_NOE 食欲<|>RELATION_NOE 减退<|>RELATION_NOE 与<|>RELATION_NOE CIV<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
在<|>RELATION_NOE 观察<|>RELATION_NOE 的<|>RELATION_NOE 20<|>RELATION_NOE 个<|>RELATION_NOE 前驱症状<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_NOE 常见<|>RELATION_NOE 的<|>RELATION_NOE 症状<|>RELATION_NOE 为<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 食欲<|>RELATION_NOE 减退<|>RELATION_NOE 、<|>RELATION_NOE 味觉<|>RELATION_NOE 改变<|>RELATION_NOE 、<|>RELATION_NOE 便秘<|>RELATION_NOE 、<|>RELATION_NOE 腹胀<|>RELATION_NOE 、<|>RELATION_NOE 胃胀<|>RELATION_NOE 和<|>RELATION_NOE 失眠<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 发生率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 72.0%<|>RELATION_NOE 、<|>RELATION_NOE 68.4%<|>RELATION_NOE 、<|>RELATION_NOE 48.8%<|>RELATION_NOE 、<|>RELATION_NOE 45.6%<|>RELATION_NOE 、<|>RELATION_NOE 45.6%<|>RELATION_NOE 、<|>RELATION_NOE 40.4%<|>RELATION_NOE 和<|>RELATION_NOE 40.0%<|>RELATION_NOE .<|>RELATION_NOE
核糖<|>RELATION_NOE 核苷酸<|>RELATION_NOE 还原<|>RELATION_NOE 酶<|>RELATION_NOE M1<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_S 根治<|>RELATION_NOE 术后<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE RRM1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 根治<|>RELATION_NOE 术后<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
检测<|>RELATION_S 肺腺癌<|>RELATION_NOE 活检<|>RELATION_NOE 标本<|>RELATION_NOE 间变性<|>RELATION_NOE 淋巴<|>RELATION_NOE 瘤激<|>RELATION_NOE 酶<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 基因<|>RELATION_NOE 融合<|>RELATION_NOE
探讨<|>RELATION_NOE 采用<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 支气管镜<|>RELATION_NOE 活检<|>RELATION_NOE 标本<|>RELATION_NOE 检测<|>RELATION_S 间变性<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE ALK<|>RELATION_NOE )<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 基因<|>RELATION_NOE 融合<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE ,<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
74<|>RELATION_NOE 例<|>RELATION_NOE 福尔<|>RELATION_NOE 马林<|>RELATION_NOE 固定<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 支气管镜<|>RELATION_NOE 活检<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Bench<|>RELATION_NOE Mark<|>RELATION_NOE 全自动<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 染<|>RELATION_NOE 色机<|>RELATION_NOE 和<|>RELATION_NOE D5F3<|>RELATION_NOE 抗体<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_S ALK<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Abbott<|>RELATION_NOE ALK<|>RELATION_NOE 分离<|>RELATION_NOE 探针<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 荧光<|>RELATION_NOE 原位杂交<|>RELATION_NOE (<|>RELATION_NOE FISH<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 74<|>RELATION_NOE 例<|>RELATION_NOE 福尔<|>RELATION_NOE 马林<|>RELATION_NOE 固定<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 支气管镜<|>RELATION_NOE 活检<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Bench<|>RELATION_NOE Mark<|>RELATION_NOE 全自动<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 染<|>RELATION_NOE 色机<|>RELATION_NOE 和<|>RELATION_NOE D5F3<|>RELATION_NOE 抗体<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 免疫<|>RELATION_NOE 组化法<|>RELATION_NOE 检测<|>RELATION_NOE ALK<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Abbott<|>RELATION_NOE ALK<|>RELATION_NOE 分离<|>RELATION_NOE 探针<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 荧光<|>RELATION_NOE 原位杂交<|>RELATION_NOE (<|>RELATION_NOE FISH<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S ALK<|>RELATION_NOE 基因融合<|>RELATION_NOE 。<|>RELATION_NOE
ALK<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 基因<|>RELATION_NOE 融合<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 均<|>RELATION_B 无关<|>RELATION_E 。<|>RELATION_NOE
肺腺癌<|>RELATION_NOE 支气管镜<|>RELATION_NOE 活检<|>RELATION_NOE 标本<|>RELATION_NOE 可<|>RELATION_B 用以<|>RELATION_I 检测<|>RELATION_E ALK<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 基因<|>RELATION_NOE 融合<|>RELATION_NOE .<|>RELATION_NOE
夏枯草<|>RELATION_NOE 提取物<|>RELATION_NOE 对<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE 蛋白质组<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
应用<|>RELATION_NOE 双向<|>RELATION_NOE 电泳<|>RELATION_NOE 和<|>RELATION_NOE 质谱<|>RELATION_NOE 技术<|>RELATION_NOE 研究<|>RELATION_NOE 夏枯草<|>RELATION_NOE 提取物<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE A549<|>RELATION_NOE 蛋白质组<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 从<|>RELATION_NOE 蛋白质组<|>RELATION_NOE 学<|>RELATION_NOE 水平<|>RELATION_NOE 探讨<|>RELATION_B 夏枯草<|>RELATION_I 抗<|>RELATION_I 肺腺癌<|>RELATION_E 的<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
提取<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 经过<|>RELATION_NOE 300<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 夏枯草<|>RELATION_NOE 提取物<|>RELATION_NOE 处理<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 总<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 双向<|>RELATION_NOE 电泳<|>RELATION_NOE 技术<|>RELATION_NOE 进行<|>RELATION_NOE 分离<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 银染<|>RELATION_NOE 后<|>RELATION_NOE 扫描<|>RELATION_NOE 得到<|>RELATION_NOE 蛋白质组<|>RELATION_NOE 图谱<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE Image<|>RELATION_NOE Master2D<|>RELATION_NOE 6.0<|>RELATION_NOE 软件<|>RELATION_NOE 进行<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白质组<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 筛选<|>RELATION_NOE 差异<|>RELATION_NOE 在<|>RELATION_NOE 2<|>RELATION_NOE 倍<|>RELATION_NOE 以上<|>RELATION_NOE 的<|>RELATION_NOE 蛋白质<|>RELATION_NOE 作为<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白<|>RELATION_NOE 进行<|>RELATION_NOE 质谱<|>RELATION_NOE 鉴定<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE Western<|>RELATION_NOE 印迹<|>RELATION_NOE 方法<|>RELATION_NOE 进行<|>RELATION_NOE 初步<|>RELATION_NOE 验证<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 夏枯草<|>RELATION_NOE 提取物<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 4<|>RELATION_NOE ,<|>RELATION_NOE 5-<|>RELATION_NOE 三<|>RELATION_NOE 磷酸<|>RELATION_NOE 肌醇<|>RELATION_NOE 受体<|>RELATION_NOE 相互作用<|>RELATION_NOE 样前体<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE 热休克<|>RELATION_NOE 同<|>RELATION_NOE 源<|>RELATION_NOE 蛋白<|>RELATION_NOE 70<|>RELATION_NOE 、<|>RELATION_NOE 丝氨酸<|>RELATION_NOE -<|>RELATION_NOE 苏氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 相关<|>RELATION_NOE 受体<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE 1型<|>RELATION_NOE 原肌球蛋白<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE β<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞周期<|>RELATION_NOE 蛋白<|>RELATION_NOE B3<|>RELATION_NOE 、<|>RELATION_NOE MED12L<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE 微丝<|>RELATION_NOE 交联<|>RELATION_NOE 蛋白<|>RELATION_NOE 亚型<|>RELATION_NOE 2<|>RELATION_NOE 表达量<|>RELATION_B 增加<|>RELATION_E (<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 蛋白<|>RELATION_NOE 比值<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE 2.05<|>RELATION_NOE 193<|>RELATION_NOE 、<|>RELATION_NOE 1000001<|>RELATION_NOE 、<|>RELATION_NOE 2.20<|>RELATION_NOE 308<|>RELATION_NOE 、<|>RELATION_NOE 5.04<|>RELATION_NOE 201<|>RELATION_NOE 、<|>RELATION_NOE 15.17<|>RELATION_NOE 800<|>RELATION_NOE 、<|>RELATION_NOE 1000001<|>RELATION_NOE 、<|>RELATION_NOE 1000001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 烯醇<|>RELATION_NOE 酶<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE M2<|>RELATION_NOE 型<|>RELATION_NOE 丙酮酸激酶<|>RELATION_NOE 、<|>RELATION_NOE 热休克<|>RELATION_NOE 蛋白<|>RELATION_NOE 27<|>RELATION_NOE 、<|>RELATION_NOE Rho<|>RELATION_NOE 家族<|>RELATION_NOE GDP<|>RELATION_NOE 分离<|>RELATION_NOE 抑制<|>RELATION_NOE 剂1<|>RELATION_NOE 、<|>RELATION_NOE 热休克<|>RELATION_NOE 蛋白<|>RELATION_NOE β1<|>RELATION_NOE 、<|>RELATION_NOE TapasinERP57<|>RELATION_NOE 异源<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE A<|>RELATION_NOE 链<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 机焦<|>RELATION_NOE 磷酸<|>RELATION_NOE 酶<|>RELATION_NOE 、<|>RELATION_NOE 线粒体<|>RELATION_NOE 半胱<|>RELATION_NOE 氨酰<|>RELATION_NOE -tRNA<|>RELATION_NOE 合成酶2<|>RELATION_NOE (<|>RELATION_NOE 假定<|>RELATION_NOE 的<|>RELATION_NOE )<|>RELATION_NOE 表达量<|>RELATION_NOE 降低<|>RELATION_NOE (<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 蛋白<|>RELATION_NOE 比值<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE 0.4<|>RELATION_NOE 85<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 0.49<|>RELATION_NOE 153<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 65<|>RELATION_NOE 43<|>RELATION_NOE 、<|>RELATION_NOE 0.45<|>RELATION_NOE 471<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 99<|>RELATION_NOE 34<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 5036<|>RELATION_NOE 、<|>RELATION_NOE 0.49<|>RELATION_NOE 462<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 37<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 经<|>RELATION_NOE 夏枯草<|>RELATION_NOE 提取物<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 1<|>RELATION_NOE ,<|>RELATION_NOE 4<|>RELATION_NOE ,<|>RELATION_NOE 5-<|>RELATION_NOE 三<|>RELATION_NOE 磷酸<|>RELATION_NOE 肌醇<|>RELATION_NOE 受体<|>RELATION_NOE 相互作用<|>RELATION_NOE 样前体<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE 热休克<|>RELATION_NOE 同<|>RELATION_NOE 源<|>RELATION_NOE 蛋白<|>RELATION_NOE 70<|>RELATION_NOE 、<|>RELATION_NOE 丝氨酸<|>RELATION_NOE -<|>RELATION_NOE 苏氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 相关<|>RELATION_NOE 受体<|>RELATION_NOE 蛋白<|>RELATION_NOE 、<|>RELATION_NOE 1型<|>RELATION_NOE 原肌球蛋白<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE β<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞周期<|>RELATION_NOE 蛋白<|>RELATION_NOE B3<|>RELATION_NOE 、<|>RELATION_NOE MED12L<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE 微丝<|>RELATION_NOE 交联<|>RELATION_NOE 蛋白<|>RELATION_NOE 亚型<|>RELATION_NOE 2表<|>RELATION_NOE 达量<|>RELATION_NOE 增加<|>RELATION_NOE (<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 蛋白<|>RELATION_NOE 比值<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE 2.05<|>RELATION_NOE 193<|>RELATION_NOE 、<|>RELATION_NOE 1000001<|>RELATION_NOE 、<|>RELATION_NOE 2.20<|>RELATION_NOE 308<|>RELATION_NOE 、<|>RELATION_NOE 5.04<|>RELATION_NOE 201<|>RELATION_NOE 、<|>RELATION_NOE 15.17<|>RELATION_NOE 800<|>RELATION_NOE 、<|>RELATION_NOE 1000001<|>RELATION_NOE 、<|>RELATION_NOE 1000001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 烯醇<|>RELATION_NOE 酶<|>RELATION_NOE 1<|>RELATION_NOE 、<|>RELATION_NOE M2<|>RELATION_NOE 型<|>RELATION_NOE 丙酮酸激酶<|>RELATION_NOE 、<|>RELATION_NOE 热休克<|>RELATION_NOE 蛋白<|>RELATION_NOE 27<|>RELATION_NOE 、<|>RELATION_NOE Rho<|>RELATION_NOE 家族<|>RELATION_NOE GDP<|>RELATION_NOE 分离<|>RELATION_NOE 抑制<|>RELATION_NOE 剂1<|>RELATION_NOE 、<|>RELATION_NOE 热休克<|>RELATION_NOE 蛋白<|>RELATION_NOE β1<|>RELATION_NOE 、<|>RELATION_NOE TapasinERP57<|>RELATION_NOE 异源<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE A<|>RELATION_NOE 链<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 机焦<|>RELATION_NOE 磷酸<|>RELATION_NOE 酶<|>RELATION_NOE 、<|>RELATION_NOE 线粒体<|>RELATION_NOE 半胱<|>RELATION_NOE 氨酰<|>RELATION_NOE -tRNA<|>RELATION_NOE 合成酶2<|>RELATION_NOE (<|>RELATION_NOE 假定<|>RELATION_NOE 的<|>RELATION_NOE )<|>RELATION_NOE 表达量<|>RELATION_B 降低<|>RELATION_E (<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 蛋白<|>RELATION_NOE 比值<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE 0.4<|>RELATION_NOE 85<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 0.49<|>RELATION_NOE 153<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 65<|>RELATION_NOE 43<|>RELATION_NOE 、<|>RELATION_NOE 0.45<|>RELATION_NOE 471<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 99<|>RELATION_NOE 34<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 5036<|>RELATION_NOE 、<|>RELATION_NOE 0.49<|>RELATION_NOE 462<|>RELATION_NOE 、<|>RELATION_NOE 0.4<|>RELATION_NOE 37<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
夏枯草<|>RELATION_NOE 提取物<|>RELATION_NOE 具有<|>RELATION_B 多<|>RELATION_I 靶点<|>RELATION_I 、<|>RELATION_I 多<|>RELATION_I 途径<|>RELATION_I 地<|>RELATION_E 发挥<|>RELATION_NOE 抗<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 调节<|>RELATION_NOE Ca2<|>RELATION_NOE +<|>RELATION_NOE 平衡<|>RELATION_NOE 、<|>RELATION_NOE 维护<|>RELATION_NOE 细胞周期<|>RELATION_NOE 、<|>RELATION_NOE 抑制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_NOE .<|>RELATION_NOE 夏枯草<|>RELATION_NOE 提取物<|>RELATION_NOE 具有<|>RELATION_NOE 多<|>RELATION_NOE 靶点<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 途径<|>RELATION_NOE 地<|>RELATION_NOE 发挥<|>RELATION_NOE 抗<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 调节<|>RELATION_NOE Ca2<|>RELATION_NOE +<|>RELATION_NOE 平衡<|>RELATION_NOE 、<|>RELATION_NOE 维护<|>RELATION_NOE 细胞周期<|>RELATION_NOE 、<|>RELATION_NOE 抑制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_S .<|>RELATION_NOE
通过<|>RELATION_NOE 脂质体<|>RELATION_NOE 介导<|>RELATION_NOE 将<|>RELATION_NOE Survivin<|>RELATION_NOE 基因<|>RELATION_NOE siRNA<|>RELATION_NOE 瞬时<|>RELATION_NOE 转染<|>RELATION_NOE H1299<|>RELATION_NOE 细胞<|>RELATION_NOE 。<|>RELATION_NOE
Survivin<|>RELATION_NOE 参与<|>RELATION_S NSCLC<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 、<|>RELATION_NOE 凋亡<|>RELATION_NOE 、<|>RELATION_NOE 周期<|>RELATION_NOE 这<|>RELATION_NOE 一<|>RELATION_NOE 生物学过程<|>RELATION_NOE 。<|>RELATION_NOE
原发性<|>RELATION_NOE 及<|>RELATION_NOE 继发性<|>RELATION_NOE 肺<|>RELATION_B 淋巴瘤<|>RELATION_E 40<|>RELATION_NOE 例<|>RELATION_NOE 临床<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 原发性<|>RELATION_NOE 及<|>RELATION_NOE 继发性<|>RELATION_NOE 肺<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 和<|>RELATION_NOE 预后<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 提高<|>RELATION_B 早期<|>RELATION_I 诊治<|>RELATION_I 水平<|>RELATION_E 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2003<|>RELATION_NOE 20<|>RELATION_NOE 13<|>RELATION_NOE 年<|>RELATION_NOE 解放军<|>RELATION_NOE 总医院<|>RELATION_NOE 经<|>RELATION_NOE 肺活检<|>RELATION_NOE 或<|>RELATION_NOE 手术肺<|>RELATION_NOE 组织<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 及<|>RELATION_NOE 继发性<|>RELATION_NOE 肺<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 。<|>RELATION_NOE
40<|>RELATION_NOE 例<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 原发性<|>RELATION_NOE 肺<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE (<|>RELATION_NOE PPL<|>RELATION_NOE )<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 继发性<|>RELATION_NOE 肺<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE (<|>RELATION_NOE SPL<|>RELATION_NOE )<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 男<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 15<|>RELATION_NOE －<|>RELATION_NOE 84<|>RELATION_NOE 岁<|>RELATION_NOE .<|>RELATION_NOE
SPL<|>RELATION_NOE 的<|>RELATION_NOE 特点<|>RELATION_NOE 以<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 浅表<|>RELATION_NOE 无<|>RELATION_NOE 压痛<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 及<|>RELATION_NOE 发热<|>RELATION_NOE 最<|>RELATION_B 多<|>RELATION_I 见<|>RELATION_E ,<|>RELATION_NOE 8例<|>RELATION_NOE 无<|>RELATION_NOE 症状<|>RELATION_NOE ;<|>RELATION_NOE
胸部<|>RELATION_NOE CT<|>RELATION_NOE 示<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 胸膜<|>RELATION_NOE 受累<|>RELATION_NOE ,<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE 纵隔<|>RELATION_NOE 及<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE ,<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 斑片<|>RELATION_NOE 实<|>RELATION_NOE 变影<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE 多<|>RELATION_NOE 发<|>RELATION_NOE 结节<|>RELATION_NOE ;<|>RELATION_NOE
全身<|>RELATION_NOE PET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 检查<|>RELATION_NOE 除<|>RELATION_NOE 肺部<|>RELATION_NOE 病变<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 还<|>RELATION_NOE 累及<|>RELATION_NOE 颈部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺<|>RELATION_NOE 、<|>RELATION_NOE 胃及<|>RELATION_NOE 胰腺<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 肺病灶<|>RELATION_NOE SUVmax<|>RELATION_NOE 为<|>RELATION_NOE 2.40<|>RELATION_NOE －<|>RELATION_NOE 19.60<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE SUVmax<|>RELATION_NOE 为<|>RELATION_NOE 5.70<|>RELATION_NOE ;<|>RELATION_NOE
SPL<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 示<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 非霍奇金<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE ,<|>RELATION_NOE 9例霍奇金<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE ;<|>RELATION_NOE
原发性<|>RELATION_NOE 与<|>RELATION_NOE 继发性<|>RELATION_NOE 肺<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 的<|>RELATION_NOE 影像学<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 治疗<|>RELATION_NOE 方法<|>RELATION_NOE 有所不同<|>RELATION_S .<|>RELATION_NOE
PPL<|>RELATION_NOE 以<|>RELATION_NOE 肿块<|>RELATION_NOE 影<|>RELATION_NOE 多<|>RELATION_NOE 见<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE SPL<|>RELATION_NOE 多<|>RELATION_NOE 有<|>RELATION_NOE 胸膜<|>RELATION_NOE 受累<|>RELATION_NOE 及<|>RELATION_NOE 纵隔<|>RELATION_NOE 和<|>RELATION_NOE 肺门<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大.<|>RELATION_NOE
PPL<|>RELATION_NOE 病理<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 非霍奇金<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE SPL<|>RELATION_NOE 除非<|>RELATION_NOE 霍奇金<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 部分<|>RELATION_NOE 为<|>RELATION_NOE 霍奇金<|>RELATION_NOE 淋巴<|>RELATION_NOE 瘤.<|>RELATION_NOE
肺<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 误诊率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_B 必须<|>RELATION_I 依靠<|>RELATION_E 肺组织<|>RELATION_NOE 病理<|>RELATION_NOE 活检<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE .<|>RELATION_NOE
辐射<|>RELATION_NOE 增强<|>RELATION_NOE 启动子<|>RELATION_NOE 调控<|>RELATION_NOE 的<|>RELATION_NOE p53<|>RELATION_NOE 基因<|>RELATION_NOE 联合<|>RELATION_NOE 照射<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S
研究<|>RELATION_NOE 辐射<|>RELATION_NOE 增强<|>RELATION_NOE 启动子<|>RELATION_NOE 调控<|>RELATION_NOE 的<|>RELATION_NOE 野生型<|>RELATION_NOE -p53<|>RELATION_NOE 抑癌<|>RELATION_NOE 基因<|>RELATION_NOE 系统<|>RELATION_NOE 联合<|>RELATION_NOE 照射<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肿瘤细胞系<|>RELATION_NOE HeLa<|>RELATION_NOE 和<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 特异性<|>RELATION_B 杀伤<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
构建<|>RELATION_NOE 辐射<|>RELATION_NOE 增强<|>RELATION_NOE 启动子<|>RELATION_NOE pE6<|>RELATION_NOE (<|>RELATION_NOE TATA<|>RELATION_NOE )<|>RELATION_NOE -p53<|>RELATION_NOE ,<|>RELATION_NOE Westernblot<|>RELATION_NOE 检测<|>RELATION_S 不同<|>RELATION_NOE 射线<|>RELATION_NOE 剂量<|>RELATION_NOE 诱导<|>RELATION_NOE 下<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞系<|>RELATION_NOE 和<|>RELATION_NOE 人<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE HeLa<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 筛选<|>RELATION_NOE 出<|>RELATION_NOE 最<|>RELATION_NOE 适<|>RELATION_NOE 的<|>RELATION_NOE 照射<|>RELATION_NOE 剂量<|>RELATION_NOE ;<|>RELATION_NOE
利用<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_NOE 此<|>RELATION_NOE 系统<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
实验组<|>RELATION_NOE 质粒<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 早期<|>RELATION_NOE 凋亡率<|>RELATION_NOE 与<|>RELATION_NOE 转染<|>RELATION_NOE 对照组<|>RELATION_NOE 质粒<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 早期<|>RELATION_NOE 凋亡率<|>RELATION_NOE 相比<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_B 提高<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 11.0<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 10.7<|>RELATION_NOE 36<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
辐射<|>RELATION_NOE 增强<|>RELATION_NOE 启动子<|>RELATION_NOE 调控<|>RELATION_NOE 的<|>RELATION_NOE p53<|>RELATION_NOE 基因<|>RELATION_NOE 系统<|>RELATION_NOE 具有<|>RELATION_B 显著<|>RELATION_I 的<|>RELATION_I 诱导<|>RELATION_I 肿瘤<|>RELATION_I 细胞凋亡<|>RELATION_I 的<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 辐射敏感性<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 提供<|>RELATION_NOE 了<|>RELATION_NOE 新<|>RELATION_NOE 思路<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE CEA<|>RELATION_B 、<|>RELATION_I CYFRA21-1<|>RELATION_I 、<|>RELATION_I NSE<|>RELATION_I 联检<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 探讨<|>RELATION_NOE
应用<|>RELATION_NOE 化学发光<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE 79<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 查体者<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 进行<|>RELATION_NOE 检测<|>RELATION_S 。<|>RELATION_NOE
79<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 三<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 16.2<|>RELATION_NOE ±<|>RELATION_NOE 8.1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 21.0<|>RELATION_NOE ±<|>RELATION_NOE 11.2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 20.6<|>RELATION_NOE ±<|>RELATION_NOE 9.0)<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 三<|>RELATION_NOE 项<|>RELATION_NOE 标志物<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 1.6<|>RELATION_NOE ±<|>RELATION_NOE 0.9<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.6<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 2.4<|>RELATION_NOE ±<|>RELATION_NOE 0.9<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_B 组<|>RELATION_I 比较<|>RELATION_I 差异<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 79<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 三<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 16.2<|>RELATION_NOE ±<|>RELATION_NOE 8.1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 21.0<|>RELATION_NOE ±<|>RELATION_NOE 11.2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 20.6<|>RELATION_NOE ±<|>RELATION_NOE 9.0)<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 三<|>RELATION_NOE 项<|>RELATION_NOE 标志物<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 1.6<|>RELATION_NOE ±<|>RELATION_NOE 0.9<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.6<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 2.4<|>RELATION_NOE ±<|>RELATION_NOE 0.9<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE ;<|>RELATION_NOE
三<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 类型<|>RELATION_NOE 肺癌<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 对<|>RELATION_NOE 鳞癌<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 指标<|>RELATION_NOE 升高<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 其他<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 的<|>RELATION_NOE CEA<|>RELATION_NOE 检测<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 其他<|>RELATION_NOE 类型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 三<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 类型<|>RELATION_NOE 肺癌<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 对<|>RELATION_NOE 鳞癌<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 指标<|>RELATION_NOE 升高<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 其他<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 的<|>RELATION_NOE CEA<|>RELATION_NOE 检测<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 其他<|>RELATION_NOE 类型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 水平<|>RELATION_NOE 三<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 类型<|>RELATION_NOE 肺癌<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 对<|>RELATION_NOE 鳞癌<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 指标<|>RELATION_NOE 升高<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 其他<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 的<|>RELATION_NOE CEA<|>RELATION_NOE 检测<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 其他<|>RELATION_NOE 类型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 三<|>RELATION_NOE 项<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 类型<|>RELATION_NOE 肺癌<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 对<|>RELATION_NOE 鳞癌<|>RELATION_NOE 的<|>RELATION_NOE 检测<|>RELATION_NOE 指标<|>RELATION_NOE 升高<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 其他<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 的<|>RELATION_NOE CEA<|>RELATION_NOE 检测<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 其他<|>RELATION_NOE 类型<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE NSE<|>RELATION_NOE 在<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 水平<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_B 高<|>RELATION_I 的<|>RELATION_I 诊断<|>RELATION_I 价值<|>RELATION_E ,<|>RELATION_NOE 尤其<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 有<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 了<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE NSE<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 三<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 有<|>RELATION_NOE 更<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_S 了<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 分别<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 或者<|>RELATION_NOE 顺铂<|>RELATION_NOE 在<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 观察<|>RELATION_E
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 我院<|>RELATION_NOE 2008年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 6月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 72<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 纳入<|>RELATION_NOE 标准<|>RELATION_NOE 及<|>RELATION_NOE 用药<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE 研究组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 给予<|>RELATION_NOE 培<|>RELATION_NOE 美曲<|>RELATION_NOE 塞<|>RELATION_NOE 500<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE d1<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 80<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE d2<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 予<|>RELATION_NOE 顺铂<|>RELATION_NOE 80<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE d2<|>RELATION_NOE ,<|>RELATION_NOE 至少<|>RELATION_NOE 化疗2<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 评价<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
不良<|>RELATION_NOE 反应<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 3－<|>RELATION_NOE 4<|>RELATION_NOE 级<|>RELATION_NOE 毒性<|>RELATION_NOE 研究组<|>RELATION_NOE 以<|>RELATION_NOE 中性<|>RELATION_NOE 粒细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 血小板<|>RELATION_NOE 下降<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 以<|>RELATION_NOE 恶心<|>RELATION_NOE 呕吐<|>RELATION_NOE 、<|>RELATION_NOE 肾功能<|>RELATION_NOE 异常<|>RELATION_NOE 为主<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
清<|>RELATION_NOE 金化<|>RELATION_NOE 痰汤<|>RELATION_NOE 联合<|>RELATION_NOE 吉非替尼<|>RELATION_NOE 治疗<|>RELATION_B 化疗<|>RELATION_I 失败<|>RELATION_I 晚期<|>RELATION_I 肺腺癌<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
选取<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 化疗<|>RELATION_NOE 失败<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 按照<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 连续<|>RELATION_NOE 服用<|>RELATION_NOE 吉非替尼<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 加<|>RELATION_NOE 用<|>RELATION_NOE 清<|>RELATION_NOE 金化<|>RELATION_NOE 痰汤<|>RELATION_NOE 进行<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 临床<|>RELATION_NOE 治疗效果<|>RELATION_NOE 、<|>RELATION_NOE 毒副作用<|>RELATION_NOE 等<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 临床<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 均<|>RELATION_NOE 为<|>RELATION_NOE 53.8<|>RELATION_NOE 5%<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 为<|>RELATION_NOE 84.6<|>RELATION_NOE 2%<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 为<|>RELATION_NOE 69.2<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 4.92<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
癌症<|>RELATION_NOE 晚期<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_E
研究<|>RELATION_NOE 癌症<|>RELATION_NOE 晚期<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 护理<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 选取<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 3月<|>RELATION_NOE 我院<|>RELATION_NOE 诊治<|>RELATION_NOE 的<|>RELATION_NOE 321<|>RELATION_NOE 例<|>RELATION_NOE 癌症<|>RELATION_NOE 晚期<|>RELATION_NOE 病人<|>RELATION_NOE 为<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 肺癌<|>RELATION_NOE 138<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 食道癌<|>RELATION_NOE 96<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 结肠癌<|>RELATION_NOE 87<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 321<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 癌症<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 评估<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
引起<|>RELATION_NOE 癌症<|>RELATION_NOE 晚期<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE 很<|>RELATION_NOE 多<|>RELATION_NOE ,<|>RELATION_NOE 护理<|>RELATION_NOE 主要<|>RELATION_NOE 措施<|>RELATION_NOE 是<|>RELATION_NOE 指导<|>RELATION_S 患者<|>RELATION_NOE 持续性<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 。<|>RELATION_NOE
癌症<|>RELATION_NOE 晚期<|>RELATION_NOE 患者<|>RELATION_NOE 大多<|>RELATION_NOE 可<|>RELATION_NOE 伴<|>RELATION_NOE 疼痛<|>RELATION_NOE ,<|>RELATION_NOE 护士<|>RELATION_S 应<|>RELATION_NOE 指导<|>RELATION_NOE 患者<|>RELATION_NOE 持续性<|>RELATION_NOE 用药<|>RELATION_NOE 止痛<|>RELATION_NOE ,<|>RELATION_NOE 鼓励<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 给予<|>RELATION_NOE 心理<|>RELATION_NOE 干预<|>RELATION_NOE 和<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 围术期<|>RELATION_NOE 并发症<|>RELATION_NOE 护理<|>RELATION_S
收集<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE 我院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 详细<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 上述<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 肺癌<|>RELATION_NOE 围术期<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 干预<|>RELATION_NOE 组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 全面<|>RELATION_NOE 的<|>RELATION_NOE 围术期<|>RELATION_NOE 护理<|>RELATION_NOE 。<|>RELATION_NOE
干预<|>RELATION_NOE 组<|>RELATION_NOE 并发症<|>RELATION_NOE 几率<|>RELATION_NOE (<|>RELATION_NOE 20.0%<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 46.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 干预组<|>RELATION_NOE 患者<|>RELATION_NOE 死亡率<|>RELATION_NOE (<|>RELATION_NOE 3.3%<|>RELATION_NOE )<|>RELATION_NOE 干预<|>RELATION_NOE 组<|>RELATION_NOE 并发症<|>RELATION_NOE 几<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 20.0%<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 46.7%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 干预组<|>RELATION_NOE 患者<|>RELATION_NOE 死亡率<|>RELATION_NOE (<|>RELATION_NOE 3.3%<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 10.0%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
Trop-2<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 临床<|>RELATION_I 病理<|>RELATION_I 分析<|>RELATION_E
RT-PCR<|>RELATION_NOE 检测<|>RELATION_S 9例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE Trop-2mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE RT-PCR<|>RELATION_NOE 检测<|>RELATION_NOE 9例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE Trop-2mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 检测<|>RELATION_S 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞系<|>RELATION_NOE 中<|>RELATION_NOE Trop-2<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
Trop-2<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE 高<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 检测<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 恶性<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 标记物<|>RELATION_NOE 。<|>RELATION_NOE Trop-2<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞系<|>RELATION_NOE 中高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 检测<|>RELATION_B 人<|>RELATION_I 肺腺癌<|>RELATION_I 恶性<|>RELATION_I 程度<|>RELATION_E 的<|>RELATION_NOE 标记物<|>RELATION_NOE 。<|>RELATION_NOE
CD146<|>RELATION_NOE 对<|>RELATION_NOE 获得性<|>RELATION_NOE Erlotinib<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间充质<|>RELATION_NOE 转化<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 干扰<|>RELATION_NOE H1650ER<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE CD146<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE Transwell<|>RELATION_NOE 侵袭<|>RELATION_NOE 小室<|>RELATION_NOE 及<|>RELATION_NOE 细胞计数<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE (<|>RELATION_NOE CCK-8<|>RELATION_NOE )<|>RELATION_NOE 实验<|>RELATION_NOE 分别<|>RELATION_NOE 评价<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 及<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 检测<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
CD146-siRNA<|>RELATION_NOE 干扰<|>RELATION_NOE H1650ER<|>RELATION_NOE 细胞<|>RELATION_NOE CD146<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 后<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_NOE 抑制<|>RELATION_NOE 其<|>RELATION_NOE 增殖<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
T1aN0M0<|>RELATION_NOE 期<|>RELATION_NOE 浸润性<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 术后<|>RELATION_B 复发<|>RELATION_E 的<|>RELATION_NOE 危险因素<|>RELATION_NOE 分析<|>RELATION_NOE
分析<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 淋巴<|>RELATION_NOE 血管<|>RELATION_NOE 浸润<|>RELATION_NOE (<|>RELATION_NOE LVI<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 新<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 与<|>RELATION_NOE 无<|>RELATION_NOE 复发<|>RELATION_NOE 生存<|>RELATION_NOE (<|>RELATION_NOE RFS<|>RELATION_NOE )<|>RELATION_NOE 率<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 统计学<|>RELATION_NOE 分析<|>RELATION_NOE 使用<|>RELATION_NOE Log-rank<|>RELATION_NOE 检验<|>RELATION_NOE 和<|>RELATION_NOE Cox<|>RELATION_NOE 回归<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 危组<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 乳头<|>RELATION_NOE 状<|>RELATION_NOE 、<|>RELATION_NOE 鳞屑样<|>RELATION_NOE 、<|>RELATION_NOE 腺<|>RELATION_NOE 泡样<|>RELATION_NOE 为<|>RELATION_NOE 主型<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 显著<|>RELATION_B 优于<|>RELATION_E 高危组<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 混合<|>RELATION_NOE 乳头状<|>RELATION_NOE 、<|>RELATION_NOE 实性<|>RELATION_NOE 和<|>RELATION_NOE 微<|>RELATION_NOE 乳头<|>RELATION_NOE 状<|>RELATION_NOE 为<|>RELATION_NOE 主型<|>RELATION_NOE .<|>RELATION_NOE
IASLC<|>RELATION_NOE /<|>RELATION_NOE ATS<|>RELATION_NOE /<|>RELATION_NOE ERS<|>RELATION_NOE 新<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 实性<|>RELATION_NOE 和<|>RELATION_NOE 微<|>RELATION_NOE 乳头<|>RELATION_NOE 状<|>RELATION_NOE 为<|>RELATION_NOE 主型<|>RELATION_NOE 是<|>RELATION_NOE T1aN0M0<|>RELATION_NOE 期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 唯一<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 提示<|>RELATION_S 这<|>RELATION_NOE 类<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 更<|>RELATION_NOE 具<|>RELATION_NOE 侵袭性<|>RELATION_NOE .<|>RELATION_NOE
微管<|>RELATION_NOE 不<|>RELATION_NOE 稳定<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE 肽基脯<|>RELATION_NOE 氨酰顺<|>RELATION_NOE 反<|>RELATION_NOE 异构酶<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 76<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE Stathmin<|>RELATION_NOE 和<|>RELATION_NOE Pin1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
Stathmin<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 65.7<|>RELATION_NOE 9%<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE /<|>RELATION_NOE 76<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 34.21%<|>RELATION_NOE (<|>RELATION_NOE 26<|>RELATION_NOE /<|>RELATION_NOE 76<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Stathmin<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
Pin1<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 84.21%<|>RELATION_NOE (<|>RELATION_NOE 64<|>RELATION_NOE /<|>RELATION_NOE 76<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达率<|>RELATION_NOE 为<|>RELATION_NOE 27.6<|>RELATION_NOE 3%<|>RELATION_NOE (<|>RELATION_NOE 21<|>RELATION_NOE /<|>RELATION_NOE 76<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Pin1<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
黑皮<|>RELATION_NOE 质素<|>RELATION_NOE 受体<|>RELATION_NOE 4基因<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
观察<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 黑皮素<|>RELATION_NOE 受体4<|>RELATION_NOE (<|>RELATION_NOE MC4R<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE MC4R<|>RELATION_NOE 表达<|>RELATION_NOE 处于<|>RELATION_NOE 上调<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 发挥<|>RELATION_B 重要<|>RELATION_I 作用<|>RELATION_E .<|>RELATION_NOE
磷酸<|>RELATION_NOE 果糖<|>RELATION_NOE 激酶<|>RELATION_NOE 4<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
探讨<|>RELATION_NOE 磷酸<|>RELATION_NOE 果糖<|>RELATION_NOE 激酶4<|>RELATION_NOE (<|>RELATION_NOE PFKFB4<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 男性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及<|>RELATION_I 预后<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 90<|>RELATION_NOE 例<|>RELATION_NOE 男性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE PFKFB4<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 参数<|>RELATION_NOE 及<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
PFKFB4<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE Cox<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_NOE PFKFB4<|>RELATION_NOE 表达<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_B 患者<|>RELATION_I 术后<|>RELATION_I 生存<|>RELATION_I 时间<|>RELATION_I 评估<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
PFKFB4<|>RELATION_NOE 在<|>RELATION_NOE 男性<|>RELATION_B 肺癌<|>RELATION_I 的<|>RELATION_I 发展<|>RELATION_E 中<|>RELATION_NOE 起<|>RELATION_NOE 重要<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 评估<|>RELATION_NOE .<|>RELATION_NOE
N2<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 早期<|>RELATION_NOE 复发<|>RELATION_NOE 与<|>RELATION_NOE CXC<|>RELATION_NOE 趋化<|>RELATION_NOE 因子<|>RELATION_NOE 受体4<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
探讨<|>RELATION_NOE CXC<|>RELATION_NOE 趋化<|>RELATION_NOE 因子<|>RELATION_NOE 受体4<|>RELATION_NOE (<|>RELATION_NOE CXCR4<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE N2<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 早期<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
采用<|>RELATION_NOE 逆转录<|>RELATION_NOE -<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 84<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE N2<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 癌组织<|>RELATION_NOE 中<|>RELATION_NOE CXCR4mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE x2<|>RELATION_NOE 检验<|>RELATION_NOE 比较<|>RELATION_NOE CXCR4<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE .<|>RELATION_NOE
应用<|>RELATION_NOE Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 判定<|>RELATION_NOE N2<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 早期<|>RELATION_NOE 复发<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
CXCR4mRNA<|>RELATION_NOE 在<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 71.4%<|>RELATION_NOE )<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE T<|>RELATION_NOE 分期<|>RELATION_NOE 均<|>RELATION_B 无<|>RELATION_I 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
术后<|>RELATION_NOE 1<|>RELATION_NOE 年<|>RELATION_NOE 内<|>RELATION_NOE 39<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 46.4%<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 转移性<|>RELATION_NOE 复发<|>RELATION_NOE 为主<|>RELATION_NOE (<|>RELATION_NOE 74.4%<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
Logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 癌组织<|>RELATION_NOE 中<|>RELATION_NOE CXCR4<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE 未<|>RELATION_NOE 行术<|>RELATION_NOE 后<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE 是<|>RELATION_NOE N2<|>RELATION_B 期<|>RELATION_I 肺癌<|>RELATION_I 术后<|>RELATION_I 早期<|>RELATION_I 复发<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
CXCR4<|>RELATION_NOE 在<|>RELATION_NOE N2<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 高<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 与<|>RELATION_NOE 术后<|>RELATION_NOE 早期<|>RELATION_NOE 复发<|>RELATION_NOE 密切<|>RELATION_NOE 相关<|>RELATION_NOE ;<|>RELATION_NOE CXCR4<|>RELATION_NOE 在<|>RELATION_NOE N2<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中高<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 术后<|>RELATION_NOE 早期<|>RELATION_NOE 复发<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ;<|>RELATION_NOE
N2<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 早期<|>RELATION_NOE 复发<|>RELATION_NOE 模式<|>RELATION_NOE 主要<|>RELATION_NOE 为<|>RELATION_NOE 转移性<|>RELATION_B 复发<|>RELATION_E .<|>RELATION_NOE
重组<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 介导<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 抑制<|>RELATION_NOE DNA<|>RELATION_NOE 依赖<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE 催化<|>RELATION_NOE 亚基<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE C225<|>RELATION_NOE 诱导<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE 核转位<|>RELATION_NOE 及<|>RELATION_NOE 敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
构建<|>RELATION_NOE 人<|>RELATION_NOE DNA<|>RELATION_NOE 依赖<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE 催化亚基<|>RELATION_NOE (<|>RELATION_NOE DNA-PKcs<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 株<|>RELATION_NOE 中<|>RELATION_NOE 沉默<|>RELATION_NOE DNA-PKcs<|>RELATION_NOE 对<|>RELATION_NOE C225<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 核转位<|>RELATION_NOE 及<|>RELATION_NOE C225<|>RELATION_NOE 抑制<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
细胞计数<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE (<|>RELATION_NOE CCK-8<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S C225<|>RELATION_NOE 对<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
LV-si-DNA-PKcs<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 见<|>RELATION_NOE 绿色<|>RELATION_NOE 荧光<|>RELATION_NOE ,<|>RELATION_NOE 感染率<|>RELATION_NOE 达<|>RELATION_NOE 95%<|>RELATION_NOE 以上<|>RELATION_NOE ;<|>RELATION_NOE
C225<|>RELATION_NOE 处理<|>RELATION_NOE 1h<|>RELATION_NOE ,<|>RELATION_NOE LV-si-DNA-PKcs<|>RELATION_NOE 细胞<|>RELATION_NOE 株见<|>RELATION_NOE 细胞核<|>RELATION_NOE EGFR<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 持续<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 24h<|>RELATION_NOE 细胞核<|>RELATION_NOE EGFR<|>RELATION_NOE 表达<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 增加<|>RELATION_E ;<|>RELATION_NOE
抑制<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE DNA-PKcs<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 一定<|>RELATION_NOE 程度<|>RELATION_NOE 上<|>RELATION_NOE 抑制<|>RELATION_S 了<|>RELATION_NOE C225<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 细胞核<|>RELATION_NOE 转位<|>RELATION_NOE ,<|>RELATION_NOE 增强<|>RELATION_NOE C225<|>RELATION_NOE 对<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE DNA-PKcs<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 一定<|>RELATION_NOE 程度<|>RELATION_NOE 上<|>RELATION_NOE 抑制<|>RELATION_NOE 了<|>RELATION_NOE C225<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE EGFR<|>RELATION_NOE 细胞核<|>RELATION_NOE 转位<|>RELATION_NOE ,<|>RELATION_NOE 增强<|>RELATION_S C225<|>RELATION_NOE 对<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE .<|>RELATION_NOE
侵犯<|>RELATION_NOE 喉<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 的<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 的<|>RELATION_NOE 外科<|>RELATION_B 治疗<|>RELATION_E
探讨<|>RELATION_NOE 累及<|>RELATION_NOE 喉<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 的<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 的<|>RELATION_NOE 外科<|>RELATION_NOE 处理<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 29<|>RELATION_NOE 例<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 喉<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 受累<|>RELATION_NOE 的<|>RELATION_NOE 分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 行<|>RELATION_NOE 一<|>RELATION_NOE 期<|>RELATION_NOE 肿瘤<|>RELATION_NOE 切除<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 单纯<|>RELATION_NOE 喉受<|>RELATION_NOE 侵6<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 喉<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 受<|>RELATION_NOE 侵3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 受侵<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 喉<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 受侵<|>RELATION_NOE 同时<|>RELATION_NOE 伴<|>RELATION_NOE 有<|>RELATION_NOE 带状<|>RELATION_NOE 肌及<|>RELATION_NOE 皮肤<|>RELATION_NOE 受侵<|>RELATION_NOE 4例<|>RELATION_NOE ;<|>RELATION_NOE
所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 行<|>RELATION_NOE 甲状腺<|>RELATION_NOE 全切<|>RELATION_NOE 除术<|>RELATION_NOE ,<|>RELATION_NOE 喉<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 受<|>RELATION_NOE 侵者<|>RELATION_NOE 9例行<|>RELATION_NOE 肿瘤<|>RELATION_NOE 气管<|>RELATION_NOE 壁削<|>RELATION_NOE 除术<|>RELATION_NOE (<|>RELATION_NOE I<|>RELATION_NOE 、<|>RELATION_NOE II<|>RELATION_NOE 型<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 分别<|>RELATION_NOE 行<|>RELATION_NOE 气管<|>RELATION_NOE 窗状<|>RELATION_NOE 切除<|>RELATION_NOE 胸锁<|>RELATION_NOE 乳突<|>RELATION_NOE 肌肌<|>RELATION_NOE 骨膜<|>RELATION_NOE 瓣<|>RELATION_NOE 修复<|>RELATION_NOE 术<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 袖状<|>RELATION_NOE 切除<|>RELATION_NOE 端端<|>RELATION_NOE 吻<|>RELATION_NOE 合术<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 窗状<|>RELATION_NOE 切除<|>RELATION_NOE 造<|>RELATION_NOE 瘘术<|>RELATION_NOE ,<|>RELATION_NOE 3例行<|>RELATION_NOE 全<|>RELATION_NOE 喉切除术<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 部分<|>RELATION_NOE 喉切除术<|>RELATION_NOE ;<|>RELATION_NOE
3例<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 气管<|>RELATION_NOE 壁<|>RELATION_NOE 复发<|>RELATION_NOE 再手术<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 颈部<|>RELATION_NOE 淋巴结<|>RELATION_NOE 复发<|>RELATION_NOE 放弃<|>RELATION_NOE 治疗<|>RELATION_NOE 术后<|>RELATION_NOE 40<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
分化型<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 侵犯<|>RELATION_NOE 喉<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 应<|>RELATION_B 争取<|>RELATION_I 手术<|>RELATION_I 切除<|>RELATION_E 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 切<|>RELATION_NOE 勿<|>RELATION_NOE 放弃<|>RELATION_NOE 手术<|>RELATION_NOE 。<|>RELATION_NOE
应<|>RELATION_NOE 尽可能<|>RELATION_NOE 切除<|>RELATION_NOE 受累<|>RELATION_NOE 器官<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 不仅<|>RELATION_NOE 可<|>RELATION_NOE 消除<|>RELATION_B 或<|>RELATION_I 缓解<|>RELATION_E 由<|>RELATION_NOE 出血<|>RELATION_NOE 及<|>RELATION_NOE 梗阻<|>RELATION_NOE 引起<|>RELATION_NOE 的<|>RELATION_NOE 窒息<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 使<|>RELATION_NOE 患者<|>RELATION_NOE 有<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 机会<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 通过<|>RELATION_NOE 皮瓣<|>RELATION_NOE 修复<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 端端<|>RELATION_NOE 吻合<|>RELATION_NOE 等<|>RELATION_NOE 技术<|>RELATION_NOE 重建<|>RELATION_NOE 喉<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 功能<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE 应<|>RELATION_NOE 尽可能<|>RELATION_NOE 切除<|>RELATION_NOE 受累<|>RELATION_NOE 器官<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 不仅<|>RELATION_NOE 可<|>RELATION_NOE 消除<|>RELATION_NOE 或<|>RELATION_NOE 缓解<|>RELATION_NOE 由<|>RELATION_NOE 出血<|>RELATION_NOE 及<|>RELATION_NOE 梗阻<|>RELATION_NOE 引起<|>RELATION_NOE 的<|>RELATION_NOE 窒息<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 使<|>RELATION_NOE 患者<|>RELATION_NOE 有<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 机会<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 通过<|>RELATION_NOE 皮瓣<|>RELATION_NOE 修复<|>RELATION_NOE 、<|>RELATION_NOE 气管<|>RELATION_NOE 端端<|>RELATION_NOE 吻合<|>RELATION_NOE 等<|>RELATION_NOE 技术<|>RELATION_NOE 重建<|>RELATION_B 喉<|>RELATION_I 、<|>RELATION_I 气管<|>RELATION_I 功能<|>RELATION_E ,<|>RELATION_NOE 以<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE ProGRP<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 血清<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 鳞状细胞癌<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE SCC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 胃泌素<|>RELATION_NOE 释放<|>RELATION_NOE 肽前体<|>RELATION_NOE (<|>RELATION_NOE ProGRP<|>RELATION_NOE )<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 8月<|>RELATION_NOE 我院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 已经<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 作为<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE (<|>RELATION_NOE 实验组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 选取<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 良性<|>RELATION_NOE 肺病<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 对照<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 分析法<|>RELATION_NOE 检测<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE ProGRP<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE ProGRP<|>RELATION_NOE 4<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 与<|>RELATION_NOE 水平<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE 选取<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 8月<|>RELATION_NOE 我院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 已经<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 作为<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE (<|>RELATION_NOE 实验组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 选取<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 良性<|>RELATION_NOE 肺病<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 对照<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 分析<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE ProGRP<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 用<|>RELATION_NOE 电<|>RELATION_NOE 化学发光<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE ProGRP<|>RELATION_NOE 4<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 与<|>RELATION_NOE 水平<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
实验组<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE ProGRP<|>RELATION_NOE 4<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 53.3%<|>RELATION_NOE 、<|>RELATION_NOE 21.7%<|>RELATION_NOE 、<|>RELATION_NOE 41.7%<|>RELATION_NOE 、<|>RELATION_NOE 10.0%<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE ProGRP<|>RELATION_NOE 4<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 10.0%<|>RELATION_NOE 、<|>RELATION_NOE 15.0%<|>RELATION_NOE 、<|>RELATION_NOE 8.3%<|>RELATION_NOE 、<|>RELATION_NOE 1.7%<|>RELATION_NOE 。<|>RELATION_NOE
实验组<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE ProGRP<|>RELATION_NOE 4<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 20.1<|>RELATION_NOE ±<|>RELATION_NOE 2.3<|>RELATION_NOE 、<|>RELATION_NOE 1.0<|>RELATION_NOE ±<|>RELATION_NOE 0.5<|>RELATION_NOE 、<|>RELATION_NOE 8.5<|>RELATION_NOE ±<|>RELATION_NOE 1.6<|>RELATION_NOE 、<|>RELATION_NOE 17<|>RELATION_NOE 9.5<|>RELATION_NOE ±<|>RELATION_NOE 37.8<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE ProGRP<|>RELATION_NOE 4<|>RELATION_NOE 种<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 的<|>RELATION_NOE 水平<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 3.5<|>RELATION_NOE ±<|>RELATION_NOE 2.1<|>RELATION_NOE 、<|>RELATION_NOE 0.8<|>RELATION_NOE ±<|>RELATION_NOE 0.4<|>RELATION_NOE 、<|>RELATION_NOE 1.1<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE 、<|>RELATION_NOE 4.5<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE ProGRP<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_S 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效率<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 有<|>RELATION_NOE 很<|>RELATION_NOE 大<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疾病<|>RELATION_NOE 治疗<|>RELATION_NOE 争取<|>RELATION_NOE 到<|>RELATION_NOE 了<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 大力<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE 采用<|>RELATION_NOE 血清<|>RELATION_NOE CEA<|>RELATION_NOE 、<|>RELATION_NOE SCC<|>RELATION_NOE 、<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE ProGRP<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 效率<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 诊断<|>RELATION_E 有<|>RELATION_NOE 很<|>RELATION_NOE 大<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疾病<|>RELATION_NOE 治疗<|>RELATION_NOE 争取<|>RELATION_NOE 到<|>RELATION_NOE 了<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 大力<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
经<|>RELATION_NOE 支气管镜<|>RELATION_NOE 针吸<|>RELATION_NOE 活<|>RELATION_NOE 检术<|>RELATION_NOE 在<|>RELATION_NOE 气管<|>RELATION_B 纵隔<|>RELATION_I 周围<|>RELATION_I 病变<|>RELATION_I 诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 应用<|>RELATION_NOE
TBNA<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 气管<|>RELATION_B 纵隔<|>RELATION_I 周围<|>RELATION_I 病变<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 第四<|>RELATION_NOE 军医<|>RELATION_NOE 大学<|>RELATION_NOE 唐都<|>RELATION_NOE 医院<|>RELATION_NOE 呼吸<|>RELATION_NOE 内科<|>RELATION_NOE 自<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 11月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 8月<|>RELATION_NOE 采用<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 诊断<|>RELATION_NOE 气管<|>RELATION_NOE 纵隔<|>RELATION_NOE 周围<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 74<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 结合<|>RELATION_NOE 组织<|>RELATION_NOE 病理学<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 作为<|>RELATION_NOE 诊断<|>RELATION_NOE 标准<|>RELATION_NOE ;<|>RELATION_NOE
74<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE 检查<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 确诊<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 6例鳞癌<|>RELATION_NOE ,<|>RELATION_NOE 3例腺癌<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE 神经<|>RELATION_NOE 内分泌癌<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE 为<|>RELATION_NOE 未<|>RELATION_NOE 分<|>RELATION_NOE 型癌<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 支气管<|>RELATION_NOE 源性<|>RELATION_NOE 囊肿<|>RELATION_NOE ;<|>RELATION_NOE
28<|>RELATION_NOE 例<|>RELATION_NOE 提示<|>RELATION_NOE 慢性<|>RELATION_NOE 肉芽肿<|>RELATION_NOE 性炎<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 最终<|>RELATION_NOE 确诊<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 结核<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 结节病<|>RELATION_NOE ,<|>RELATION_NOE 5例<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 区分<|>RELATION_NOE 结核<|>RELATION_NOE 或<|>RELATION_NOE 结节病<|>RELATION_NOE ,<|>RELATION_NOE 7例<|>RELATION_NOE 提示<|>RELATION_NOE 慢性<|>RELATION_NOE 非<|>RELATION_NOE 特异性炎<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 6月<|>RELATION_NOE 或<|>RELATION_NOE 经<|>RELATION_NOE 胸外科手术<|>RELATION_NOE ,<|>RELATION_NOE 最终<|>RELATION_NOE 诊断<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 结核<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 结节病<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 慢性<|>RELATION_NOE 炎性<|>RELATION_NOE 反应<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 恶性病<|>RELATION_NOE 变<|>RELATION_NOE 敏感性<|>RELATION_NOE 为<|>RELATION_NOE 97.4%<|>RELATION_NOE ,<|>RELATION_NOE 特异性<|>RELATION_NOE 88.6%<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 100%<|>RELATION_NOE ,<|>RELATION_NOE 阴性<|>RELATION_NOE 预测<|>RELATION_NOE 值<|>RELATION_NOE 97.1%<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE 病变<|>RELATION_NOE 诊断<|>RELATION_NOE 敏感性<|>RELATION_NOE 88.6%<|>RELATION_NOE ,<|>RELATION_NOE 特异性<|>RELATION_NOE 91.2%<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 预测<|>RELATION_NOE 值<|>RELATION_NOE 97.1%<|>RELATION_NOE ,<|>RELATION_NOE 阴性<|>RELATION_NOE 预测<|>RELATION_NOE 值<|>RELATION_NOE 97.1%<|>RELATION_NOE ,<|>RELATION_NOE 总体<|>RELATION_NOE 诊断<|>RELATION_NOE 准确率<|>RELATION_NOE 93.2%<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 发生<|>RELATION_NOE 严重<|>RELATION_NOE 并发症<|>RELATION_NOE 。<|>RELATION_NOE
EBUS-TBNA<|>RELATION_NOE 细胞学<|>RELATION_NOE 检查<|>RELATION_NOE 对<|>RELATION_NOE 气管<|>RELATION_B 纵隔<|>RELATION_I 周围<|>RELATION_I 病变<|>RELATION_I 诊断<|>RELATION_E 的<|>RELATION_NOE 敏感度<|>RELATION_NOE 及<|>RELATION_NOE 特异度<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 安全性<|>RELATION_NOE 高<|>RELATION_NOE .<|>RELATION_NOE
FBP<|>RELATION_NOE 和<|>RELATION_NOE ASiR<|>RELATION_NOE 重建<|>RELATION_NOE 算法<|>RELATION_NOE 对<|>RELATION_NOE 肺部<|>RELATION_NOE 小结节<|>RELATION_NOE 显示<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_S 研究<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 后<|>RELATION_NOE 发现<|>RELATION_NOE 57<|>RELATION_NOE 个<|>RELATION_NOE 肺结节<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 肺窗<|>RELATION_NOE 图像<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE FBP<|>RELATION_NOE ,<|>RELATION_NOE 20%<|>RELATION_NOE 、<|>RELATION_NOE 40%<|>RELATION_NOE 、<|>RELATION_NOE 60%<|>RELATION_NOE 、<|>RELATION_NOE 80%<|>RELATION_NOE ASiR-FBP<|>RELATION_NOE 混合<|>RELATION_NOE 和<|>RELATION_NOE 100%<|>RELATION_NOE ASiR<|>RELATION_NOE 重建<|>RELATION_NOE 算法<|>RELATION_NOE 进行<|>RELATION_NOE 重建<|>RELATION_NOE 获得<|>RELATION_NOE 6组<|>RELATION_NOE 图像<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 测量<|>RELATION_NOE 肺结节<|>RELATION_NOE 胸膜<|>RELATION_NOE 下<|>RELATION_NOE 肺组织<|>RELATION_NOE 及<|>RELATION_NOE 周围<|>RELATION_NOE 空气<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 值<|>RELATION_NOE 及<|>RELATION_NOE 噪声<|>RELATION_NOE 值<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 各<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_NOE 噪声<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE CNR<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
结节<|>RELATION_NOE 的<|>RELATION_NOE 噪声<|>RELATION_NOE 值<|>RELATION_NOE 在<|>RELATION_NOE 6组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ﹥0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE CNR<|>RELATION_NOE 、<|>RELATION_NOE 肺泡<|>RELATION_NOE 噪声值<|>RELATION_NOE 、<|>RELATION_NOE 结节<|>RELATION_NOE 评分<|>RELATION_NOE 和<|>RELATION_NOE 肺组织<|>RELATION_NOE 评分<|>RELATION_NOE 在<|>RELATION_NOE 各组<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 随着<|>RELATION_NOE ASiR<|>RELATION_NOE 百分比<|>RELATION_NOE 的<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 肺组织<|>RELATION_NOE 噪声<|>RELATION_NOE 逐渐<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 肺结节<|>RELATION_NOE 的<|>RELATION_NOE CNR<|>RELATION_NOE 及<|>RELATION_NOE 主观<|>RELATION_NOE 评分<|>RELATION_NOE 逐渐<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 100%<|>RELATION_NOE ASiR<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 结节<|>RELATION_NOE 评分<|>RELATION_NOE 优于<|>RELATION_NOE 其他<|>RELATION_NOE 组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 60%<|>RELATION_NOE ASiR-FBP<|>RELATION_NOE 混合<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 对<|>RELATION_NOE 肺部<|>RELATION_NOE 结构<|>RELATION_NOE 显示<|>RELATION_NOE 的<|>RELATION_NOE 评分<|>RELATION_NOE 优于<|>RELATION_NOE 其他<|>RELATION_NOE 组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 。<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 噪声<|>RELATION_NOE 值<|>RELATION_NOE 在<|>RELATION_NOE 6组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹥0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE CNR<|>RELATION_NOE 、<|>RELATION_NOE 肺泡<|>RELATION_NOE 噪声值<|>RELATION_NOE 、<|>RELATION_NOE 结节<|>RELATION_NOE 评分<|>RELATION_NOE 和<|>RELATION_NOE 肺组织<|>RELATION_NOE 评分<|>RELATION_NOE 在<|>RELATION_NOE 各组<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 随着<|>RELATION_NOE ASiR<|>RELATION_NOE 百分比<|>RELATION_NOE 的<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 肺组织<|>RELATION_NOE 噪声<|>RELATION_NOE 逐渐<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 肺结节<|>RELATION_NOE 的<|>RELATION_NOE CNR<|>RELATION_NOE 及<|>RELATION_NOE 主观<|>RELATION_NOE 评分<|>RELATION_NOE 逐渐<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 100%<|>RELATION_NOE ASiR<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 结节<|>RELATION_NOE 评分<|>RELATION_NOE 优于<|>RELATION_NOE 其他<|>RELATION_NOE 组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 60%<|>RELATION_NOE ASiR-FBP<|>RELATION_NOE 混合<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 对<|>RELATION_NOE 肺部<|>RELATION_NOE 结构<|>RELATION_NOE 显示<|>RELATION_NOE 的<|>RELATION_NOE 评分<|>RELATION_NOE 优于<|>RELATION_NOE 其他<|>RELATION_NOE 组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 。<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 噪声<|>RELATION_NOE 值<|>RELATION_NOE 在<|>RELATION_NOE 6组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹥0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE CNR<|>RELATION_NOE 、<|>RELATION_NOE 肺泡<|>RELATION_NOE 噪声值<|>RELATION_NOE 、<|>RELATION_NOE 结节<|>RELATION_NOE 评分<|>RELATION_NOE 和<|>RELATION_NOE 肺组织<|>RELATION_NOE 评分<|>RELATION_NOE 在<|>RELATION_NOE 各组<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 随着<|>RELATION_NOE ASiR<|>RELATION_NOE 百分比<|>RELATION_NOE 的<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 肺组织<|>RELATION_NOE 噪声<|>RELATION_NOE 逐渐<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 肺结节<|>RELATION_B 的<|>RELATION_I CNR<|>RELATION_I 及<|>RELATION_I 主观<|>RELATION_I 评分<|>RELATION_I 逐渐<|>RELATION_I 升高<|>RELATION_E ,<|>RELATION_NOE 100%<|>RELATION_NOE ASiR<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 结节<|>RELATION_NOE 评分<|>RELATION_NOE 优于<|>RELATION_NOE 其他<|>RELATION_NOE 组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 60%<|>RELATION_NOE ASiR-FBP<|>RELATION_NOE 混合<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 对<|>RELATION_NOE 肺部<|>RELATION_NOE 结构<|>RELATION_NOE 显示<|>RELATION_NOE 的<|>RELATION_NOE 评分<|>RELATION_NOE 优于<|>RELATION_NOE 其他<|>RELATION_NOE 组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 。<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 噪声<|>RELATION_NOE 值<|>RELATION_NOE 在<|>RELATION_NOE 6组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹥0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE CNR<|>RELATION_NOE 、<|>RELATION_NOE 肺泡<|>RELATION_NOE 噪声值<|>RELATION_NOE 、<|>RELATION_NOE 结节<|>RELATION_NOE 评分<|>RELATION_NOE 和<|>RELATION_NOE 肺组织<|>RELATION_NOE 评分<|>RELATION_NOE 在<|>RELATION_NOE 各组<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 随着<|>RELATION_NOE ASiR<|>RELATION_NOE 百分比<|>RELATION_NOE 的<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 肺组织<|>RELATION_NOE 噪声<|>RELATION_NOE 逐渐<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 肺结节<|>RELATION_NOE 的<|>RELATION_NOE CNR<|>RELATION_NOE 及<|>RELATION_NOE 主观<|>RELATION_NOE 评分<|>RELATION_NOE 逐渐<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 100%<|>RELATION_NOE ASiR<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 结节<|>RELATION_NOE 评分<|>RELATION_NOE 优于<|>RELATION_S 其他<|>RELATION_NOE 组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 60%<|>RELATION_NOE ASiR-FBP<|>RELATION_NOE 混合<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 对<|>RELATION_NOE 肺部<|>RELATION_NOE 结构<|>RELATION_NOE 显示<|>RELATION_NOE 的<|>RELATION_NOE 评分<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE 噪声<|>RELATION_NOE 值<|>RELATION_NOE 在<|>RELATION_NOE 6组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹥0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 结节<|>RELATION_NOE 的<|>RELATION_NOE CNR<|>RELATION_NOE 、<|>RELATION_NOE 肺泡<|>RELATION_NOE 噪声值<|>RELATION_NOE 、<|>RELATION_NOE 结节<|>RELATION_NOE 评分<|>RELATION_NOE 和<|>RELATION_NOE 肺组织<|>RELATION_NOE 评分<|>RELATION_NOE 在<|>RELATION_NOE 各组<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 随着<|>RELATION_NOE ASiR<|>RELATION_NOE 百分比<|>RELATION_NOE 的<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 肺组织<|>RELATION_NOE 噪声<|>RELATION_NOE 逐渐<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 肺结节<|>RELATION_NOE 的<|>RELATION_NOE CNR<|>RELATION_NOE 及<|>RELATION_NOE 主观<|>RELATION_NOE 评分<|>RELATION_NOE 逐渐<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 100%<|>RELATION_NOE ASiR<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 结节<|>RELATION_NOE 评分<|>RELATION_NOE 优于<|>RELATION_NOE 其他<|>RELATION_NOE 组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 60%<|>RELATION_NOE ASiR-FBP<|>RELATION_NOE 混合<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 对<|>RELATION_NOE 肺部<|>RELATION_NOE 结构<|>RELATION_NOE 显示<|>RELATION_NOE 的<|>RELATION_NOE 评分<|>RELATION_NOE 优于<|>RELATION_S 其他<|>RELATION_NOE 组<|>RELATION_NOE 重建<|>RELATION_NOE 图像<|>RELATION_NOE 。<|>RELATION_NOE
洛铂<|>RELATION_NOE 或<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
顺铂<|>RELATION_NOE 组<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 即<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 500<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE ;<|>RELATION_NOE
洛铂<|>RELATION_NOE 或<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 都<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 肺腺癌<|>RELATION_E 的<|>RELATION_NOE 有效<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 疗效<|>RELATION_NOE 相似<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 洛铂<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_NOE 顺铂<|>RELATION_NOE ,<|>RELATION_NOE 安全<|>RELATION_NOE 耐受性<|>RELATION_NOE 好<|>RELATION_NOE 。<|>RELATION_NOE 洛铂<|>RELATION_NOE 或<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 都<|>RELATION_NOE 是<|>RELATION_NOE 治疗<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 有效<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 两者<|>RELATION_NOE 疗效<|>RELATION_NOE 相似<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 洛铂<|>RELATION_NOE 胃肠道<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_S 顺铂<|>RELATION_NOE ,<|>RELATION_NOE 安全<|>RELATION_NOE 耐受性<|>RELATION_NOE 好<|>RELATION_NOE 。<|>RELATION_NOE
病友<|>RELATION_NOE 互助<|>RELATION_NOE 护理<|>RELATION_NOE 模式<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 社会<|>RELATION_NOE 支持<|>RELATION_NOE 及<|>RELATION_NOE 希望<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
将<|>RELATION_NOE 72<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 干预组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 各<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 干预<|>RELATION_NOE 组<|>RELATION_NOE 接受<|>RELATION_NOE 病友<|>RELATION_NOE 互助<|>RELATION_NOE 护理<|>RELATION_NOE 模式<|>RELATION_NOE ,<|>RELATION_NOE 即<|>RELATION_NOE 组织<|>RELATION_NOE 身心<|>RELATION_NOE 恢复<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE 康复期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 初次<|>RELATION_NOE 住院<|>RELATION_NOE 治疗<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 情感<|>RELATION_NOE 沟通<|>RELATION_NOE 和<|>RELATION_NOE 互动<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 接受<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE .<|>RELATION_NOE
病友<|>RELATION_NOE 互助<|>RELATION_NOE 护理<|>RELATION_NOE 模式<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_B 肺癌<|>RELATION_I 患者<|>RELATION_E 的<|>RELATION_NOE 社会<|>RELATION_NOE 支持<|>RELATION_NOE 和<|>RELATION_NOE 希望<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE .<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_B 早期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 效果<|>RELATION_NOE 探讨<|>RELATION_NOE
探讨<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_B 早期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按照<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 采用<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE (<|>RELATION_NOE VATS<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 为<|>RELATION_NOE VATS<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 传统<|>RELATION_NOE 开放<|>RELATION_NOE 手术<|>RELATION_NOE (<|>RELATION_NOE TOS<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 为<|>RELATION_NOE TOS<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 失血量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 引流量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 卧床<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院<|>RELATION_NOE 天数<|>RELATION_NOE ;<|>RELATION_NOE
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE VATS<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 卧床<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 住院时间<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 69.50<|>RELATION_NOE ±<|>RELATION_NOE 15.33<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 60.23<|>RELATION_NOE ±<|>RELATION_NOE 9.75<|>RELATION_NOE )<|>RELATION_NOE h<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 46.75<|>RELATION_NOE ±<|>RELATION_NOE 7.36<|>RELATION_NOE )<|>RELATION_NOE h<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 3.54<|>RELATION_NOE ±<|>RELATION_NOE 1.58<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 9.50<|>RELATION_NOE ±<|>RELATION_NOE 2.50<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE TOS<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 86.77<|>RELATION_NOE ±<|>RELATION_NOE 19.56<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 66.50<|>RELATION_NOE ±<|>RELATION_NOE 10.50<|>RELATION_NOE )<|>RELATION_NOE h<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 58.36<|>RELATION_NOE ±<|>RELATION_NOE 9.58<|>RELATION_NOE )<|>RELATION_NOE h<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 5.50<|>RELATION_NOE ±<|>RELATION_NOE 1.55<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 13.55<|>RELATION_NOE ±<|>RELATION_NOE 3.18<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 的<|>RELATION_NOE 短<|>RELATION_S ;<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_B 早期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 疗效<|>RELATION_NOE 显著<|>RELATION_NOE ,<|>RELATION_NOE 安全性<|>RELATION_NOE 高<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 体位<|>RELATION_NOE 固定<|>RELATION_NOE 方式<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 中<|>RELATION_NOE 摆位<|>RELATION_B 误差<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_E
小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 中<|>RELATION_NOE 髓样<|>RELATION_NOE 抑制<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 鉴定<|>RELATION_B 及<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
采用<|>RELATION_NOE 流式<|>RELATION_NOE 细胞<|>RELATION_NOE 技术<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 抗<|>RELATION_NOE CDllb<|>RELATION_NOE 、<|>RELATION_NOE CD33<|>RELATION_NOE 、<|>RELATION_NOE CDl4<|>RELATION_NOE 、<|>RELATION_NOE HLA-DR<|>RELATION_NOE 等<|>RELATION_NOE 不同<|>RELATION_NOE 荧光<|>RELATION_NOE 抗体<|>RELATION_NOE 组合<|>RELATION_NOE 鉴定<|>RELATION_NOE SCLC<|>RELATION_NOE 患者<|>RELATION_NOE 外<|>RELATION_NOE 周<|>RELATION_NOE 血<|>RELATION_NOE 中<|>RELATION_NOE MDSCs<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 表面<|>RELATION_NOE 标志<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE MDSCs<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE SCLC<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
MDSCs<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE SCLC<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤转移<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 情况<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 状况<|>RELATION_NOE 及<|>RELATION_NOE 体力<|>RELATION_NOE 状态<|>RELATION_NOE 无关<|>RELATION_NOE 。<|>RELATION_NOE MDSCs<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE SCLC<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤转移<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 情况<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 状况<|>RELATION_NOE 及<|>RELATION_NOE 体力<|>RELATION_NOE 状态<|>RELATION_NOE 无关<|>RELATION_S 。<|>RELATION_NOE
裸鼠<|>RELATION_NOE 皮<|>RELATION_NOE 下<|>RELATION_NOE 及<|>RELATION_NOE 肾<|>RELATION_NOE 被<|>RELATION_NOE 膜下<|>RELATION_NOE 建立<|>RELATION_S 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 模型<|>RELATION_NOE 的<|>RELATION_NOE 初步<|>RELATION_NOE 探索<|>RELATION_NOE
探讨<|>RELATION_NOE 裸鼠<|>RELATION_NOE 皮<|>RELATION_NOE 下<|>RELATION_NOE 及<|>RELATION_NOE 肾<|>RELATION_NOE 被<|>RELATION_NOE 膜下<|>RELATION_NOE 建立<|>RELATION_B 人<|>RELATION_I 肺癌<|>RELATION_I 移植<|>RELATION_I 瘤<|>RELATION_I 模型<|>RELATION_E 的<|>RELATION_NOE 可行性<|>RELATION_NOE 及<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 分别<|>RELATION_NOE 种植<|>RELATION_NOE 在<|>RELATION_NOE 裸鼠<|>RELATION_NOE 的<|>RELATION_NOE 皮<|>RELATION_NOE 下<|>RELATION_NOE 及<|>RELATION_NOE 肾<|>RELATION_NOE 被<|>RELATION_NOE 膜下<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 成瘤<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 切片<|>RELATION_NOE 观察<|>RELATION_NOE 移植瘤<|>RELATION_NOE 和<|>RELATION_NOE 原<|>RELATION_NOE 发瘤<|>RELATION_NOE 的<|>RELATION_NOE 一致性<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 抗人<|>RELATION_NOE CD31<|>RELATION_NOE 单克隆抗体<|>RELATION_NOE 进行<|>RELATION_NOE 移植<|>RELATION_NOE 瘤切<|>RELATION_NOE 片<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 染色<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 鉴定<|>RELATION_NOE 第1<|>RELATION_NOE 代<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 血<|>RELATION_NOE 供<|>RELATION_NOE 来源<|>RELATION_NOE 。<|>RELATION_NOE
人<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 均<|>RELATION_NOE 成功<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 裸鼠<|>RELATION_NOE 皮<|>RELATION_NOE 下<|>RELATION_NOE 及<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肾<|>RELATION_NOE 被<|>RELATION_NOE 膜下<|>RELATION_NOE ,<|>RELATION_NOE 裸鼠<|>RELATION_NOE 皮<|>RELATION_NOE 下<|>RELATION_NOE 接种<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 操作<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 13min<|>RELATION_NOE ,<|>RELATION_NOE 裸鼠<|>RELATION_NOE 肾<|>RELATION_NOE 被<|>RELATION_NOE 膜下<|>RELATION_NOE 接种<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 操作<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 45min<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 裸鼠<|>RELATION_NOE 皮<|>RELATION_NOE 下<|>RELATION_NOE 接种<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 和<|>RELATION_NOE 肾<|>RELATION_NOE 被<|>RELATION_NOE 膜下<|>RELATION_NOE 接种<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 均<|>RELATION_NOE 能<|>RELATION_B 建立<|>RELATION_E 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 模型<|>RELATION_NOE 。<|>RELATION_NOE
化疗<|>RELATION_NOE 序贯<|>RELATION_NOE EGFR-TKI<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_I EGFR-TKI<|>RELATION_I 获得<|>RELATION_I 性耐<|>RELATION_I 药<|>RELATION_E 患者<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE
观察<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE -<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE (<|>RELATION_NOE EGFR-TKI<|>RELATION_NOE )<|>RELATION_NOE 获得<|>RELATION_NOE 性耐<|>RELATION_NOE 药<|>RELATION_NOE 后<|>RELATION_NOE 应用<|>RELATION_B 化疗<|>RELATION_I 序贯<|>RELATION_I EGFR-TKI<|>RELATION_I 治疗<|>RELATION_E 的<|>RELATION_NOE 效果<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
回顾<|>RELATION_NOE 分析<|>RELATION_NOE 复旦<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 中山<|>RELATION_NOE 医院<|>RELATION_NOE 2006年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 14年<|>RELATION_NOE 4月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE EGFR-TKI<|>RELATION_NOE 获得<|>RELATION_NOE 性耐药<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 化疗<|>RELATION_NOE 序贯<|>RELATION_NOE EGFR-TKI<|>RELATION_NOE 组<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 单<|>RELATION_NOE 用<|>RELATION_NOE 化疗组<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 与<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 肺腺癌<|>RELATION_E 患者<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 分析<|>RELATION_NOE
纳入<|>RELATION_NOE 2006年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 2007年<|>RELATION_NOE 9月<|>RELATION_NOE ,<|>RELATION_NOE 广东省<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE ≥<|>RELATION_NOE 18<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 接受<|>RELATION_NOE 过<|>RELATION_NOE 化疗<|>RELATION_NOE 、<|>RELATION_NOE 生物学<|>RELATION_NOE 或<|>RELATION_NOE 免疫学<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 或<|>RELATION_NOE 少<|>RELATION_NOE 吸烟<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 体能<|>RELATION_NOE 状态<|>RELATION_NOE (<|>RELATION_NOE PS<|>RELATION_NOE )<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 状况<|>RELATION_NOE 和<|>RELATION_NOE 性别<|>RELATION_NOE 采用<|>RELATION_NOE 动态<|>RELATION_NOE 均衡<|>RELATION_NOE 随机化<|>RELATION_NOE 方法<|>RELATION_NOE 随机<|>RELATION_NOE 纳入<|>RELATION_NOE 吉<|>RELATION_NOE 非替尼组<|>RELATION_NOE 和<|>RELATION_NOE 联合化疗<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 吉非<|>RELATION_NOE 替尼组<|>RELATION_NOE 接受<|>RELATION_NOE 一线吉非替尼<|>RELATION_NOE 治疗<|>RELATION_NOE (<|>RELATION_NOE 250<|>RELATION_NOE mg<|>RELATION_NOE ,<|>RELATION_NOE 口服<|>RELATION_NOE ,<|>RELATION_NOE 1次/<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 联合化疗<|>RELATION_NOE 组<|>RELATION_NOE 接受<|>RELATION_NOE 化疗<|>RELATION_NOE [<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 200<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ;<|>RELATION_NOE
卡铂<|>RELATION_NOE 按<|>RELATION_NOE 剂量<|>RELATION_NOE 血药<|>RELATION_NOE 浓度<|>RELATION_NOE -<|>RELATION_NOE 时间<|>RELATION_NOE 曲线下面积<|>RELATION_NOE (<|>RELATION_NOE AUC<|>RELATION_NOE )<|>RELATION_NOE =<|>RELATION_NOE 5mg<|>RELATION_NOE .<|>RELATION_NOE
ml-1<|>RELATION_NOE ·<|>RELATION_NOE min-1<|>RELATION_NOE 计算<|>RELATION_NOE ,<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE ,<|>RELATION_NOE 21d<|>RELATION_NOE 为<|>RELATION_NOE 1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 药<|>RELATION_NOE 都<|>RELATION_NOE 在<|>RELATION_NOE 每<|>RELATION_NOE 周期<|>RELATION_NOE 的<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 使用<|>RELATION_NOE ]<|>RELATION_NOE .<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE Cox<|>RELATION_NOE 回归分析<|>RELATION_NOE 显示<|>RELATION_NOE :<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.004<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 后续<|>RELATION_NOE 治疗<|>RELATION_NOE [<|>RELATION_NOE 含<|>RELATION_NOE 铂化疗<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.001<|>RELATION_NOE ;<|>RELATION_NOE
对于<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 或<|>RELATION_NOE 少<|>RELATION_NOE 吸烟<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 一线吉非替尼<|>RELATION_NOE 治疗<|>RELATION_NOE 与<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 联合<|>RELATION_NOE 卡铂<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 客观<|>RELATION_B 疗效<|>RELATION_I 近似<|>RELATION_E .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 病理<|>RELATION_I 特征<|>RELATION_E
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 病理<|>RELATION_I 特征<|>RELATION_E 。<|>RELATION_NOE
通过<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 资料<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 状态<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
其中<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE Ⅰ<|>RELATION_NOE a<|>RELATION_NOE －<|>RELATION_NOE Ⅲ<|>RELATION_NOE a<|>RELATION_NOE 期<|>RELATION_NOE 、<|>RELATION_NOE 高<|>RELATION_NOE 分化<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 60.4%<|>RELATION_NOE 、<|>RELATION_NOE 54.8%<|>RELATION_NOE 、<|>RELATION_NOE 51.1%<|>RELATION_NOE 、<|>RELATION_NOE 81.1%<|>RELATION_NOE 、<|>RELATION_NOE 50.7%<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_B 分别<|>RELATION_I 显著<|>RELATION_I 高于<|>RELATION_E 男性<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE Ⅲ<|>RELATION_NOE b<|>RELATION_NOE －Ⅳ期<|>RELATION_NOE 、<|>RELATION_NOE 中低<|>RELATION_NOE 分化<|>RELATION_NOE 、<|>RELATION_NOE 非腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 33.3%<|>RELATION_NOE 、<|>RELATION_NOE 32.4%<|>RELATION_NOE 、<|>RELATION_NOE 38.6%<|>RELATION_NOE 、<|>RELATION_NOE 46.1%<|>RELATION_NOE 、<|>RELATION_NOE 15.3%<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变型<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 野生型<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE 4.5<|>RELATION_NOE 比<|>RELATION_NOE 41.8<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE ,<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 38<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 在<|>RELATION_NOE 女性<|>RELATION_NOE 、<|>RELATION_NOE 非<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE Ⅰ<|>RELATION_NOE a<|>RELATION_NOE －<|>RELATION_NOE Ⅲ<|>RELATION_NOE a<|>RELATION_NOE 期<|>RELATION_NOE 、<|>RELATION_NOE 高<|>RELATION_NOE 分化<|>RELATION_NOE 的<|>RELATION_NOE 腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 更<|>RELATION_B 常见<|>RELATION_E .<|>RELATION_NOE
病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 和<|>RELATION_NOE 血型<|>RELATION_NOE 为<|>RELATION_NOE 预计<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 因素<|>RELATION_E .<|>RELATION_NOE
外<|>RELATION_NOE 周血<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE EGFR-TKI<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
探讨<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 癌胚抗原<|>RELATION_NOE (<|>RELATION_NOE CEA<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE -<|>RELATION_NOE 酪氨酸<|>RELATION_NOE 激酶<|>RELATION_NOE 抑制剂<|>RELATION_NOE (<|>RELATION_NOE EGFR-TKI<|>RELATION_NOE )<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 在<|>RELATION_B 手术<|>RELATION_I 为主<|>RELATION_I 综合治疗<|>RELATION_I 局限性<|>RELATION_I 小细胞肺癌<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE 回归分析<|>RELATION_NOE 表明<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_B Ⅲ<|>RELATION_I 期<|>RELATION_I LD-SCLC<|>RELATION_I 患者<|>RELATION_I 预后<|>RELATION_E 的<|>RELATION_NOE 重要<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 与<|>RELATION_NOE 开<|>RELATION_NOE 胸肺<|>RELATION_NOE 叶切<|>RELATION_NOE 除术<|>RELATION_NOE 淋巴结<|>RELATION_B 清扫<|>RELATION_I 及<|>RELATION_I 生存<|>RELATION_E 的<|>RELATION_NOE meta<|>RELATION_NOE 分析<|>RELATION_NOE
全腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 用于<|>RELATION_NOE 治疗<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 时<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 、<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 术式<|>RELATION_NOE ,<|>RELATION_NOE 即便<|>RELATION_NOE 在<|>RELATION_NOE 进展期<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 也<|>RELATION_NOE 是<|>RELATION_NOE 如此<|>RELATION_NOE .<|>RELATION_NOE
协同<|>RELATION_NOE 护理<|>RELATION_NOE 模式<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 晚期<|>RELATION_NOE 疼痛<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
探讨<|>RELATION_NOE 协同<|>RELATION_NOE 模式<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 晚期<|>RELATION_NOE 疼痛<|>RELATION_NOE 患者<|>RELATION_NOE 护理<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_B 效果<|>RELATION_E 。<|>RELATION_NOE
选择<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 1-12<|>RELATION_NOE 月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 晚期<|>RELATION_NOE 疼痛<|>RELATION_NOE 患者<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 按照<|>RELATION_NOE 入院<|>RELATION_NOE 顺序<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE 各<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 应用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 应用<|>RELATION_NOE 协同<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 协同<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 2周<|>RELATION_NOE 后<|>RELATION_NOE 进行<|>RELATION_NOE 疼痛<|>RELATION_NOE 缓解<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 药物<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 及<|>RELATION_NOE 干预<|>RELATION_NOE 前后<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 干预<|>RELATION_NOE 前<|>RELATION_NOE 疼痛<|>RELATION_NOE 程度<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 协同<|>RELATION_NOE 护理<|>RELATION_NOE 2周<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 缓解率<|>RELATION_NOE 为<|>RELATION_NOE 95.0%<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 77.5%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE =<|>RELATION_NOE 6.64<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 干预<|>RELATION_NOE 前<|>RELATION_NOE 疼痛<|>RELATION_NOE 程度<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 协同<|>RELATION_NOE 护理<|>RELATION_NOE 2周<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 缓解率<|>RELATION_NOE 为<|>RELATION_NOE 95.0%<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S 对照组<|>RELATION_NOE 的<|>RELATION_NOE 77.5%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2<|>RELATION_NOE =<|>RELATION_NOE 6.64<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 干预<|>RELATION_NOE 前<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 各<|>RELATION_NOE 领域<|>RELATION_NOE 评分<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 生理<|>RELATION_NOE 领域<|>RELATION_NOE 、<|>RELATION_NOE 心理<|>RELATION_NOE 领域<|>RELATION_NOE 、<|>RELATION_NOE 社会关系<|>RELATION_NOE 领域<|>RELATION_NOE 、<|>RELATION_NOE 环境<|>RELATION_NOE 领域<|>RELATION_NOE 评分<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 13.4<|>RELATION_NOE ±<|>RELATION_NOE 1.8<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 12.1<|>RELATION_NOE ±<|>RELATION_NOE 1.9<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 12.6<|>RELATION_NOE ±<|>RELATION_NOE 1.7<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 12.5<|>RELATION_NOE ±<|>RELATION_NOE 1.8<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 优于<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 12.3<|>RELATION_NOE ±<|>RELATION_NOE 2.0<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 11.0<|>RELATION_NOE ±<|>RELATION_NOE 1.8<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 11.7<|>RELATION_NOE ±<|>RELATION_NOE 1.6<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 12.0<|>RELATION_NOE ±<|>RELATION_NOE 1.9<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.45<|>RELATION_NOE ,<|>RELATION_NOE 4.24<|>RELATION_NOE ,<|>RELATION_NOE 3.57<|>RELATION_NOE ,<|>RELATION_NOE 2.49<|>RELATION_NOE ;<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 干预<|>RELATION_NOE 前<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 各<|>RELATION_NOE 领域<|>RELATION_NOE 评分<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 生理<|>RELATION_NOE 领域<|>RELATION_NOE 、<|>RELATION_NOE 心理<|>RELATION_NOE 领域<|>RELATION_NOE 、<|>RELATION_NOE 社会关系<|>RELATION_NOE 领域<|>RELATION_NOE 、<|>RELATION_NOE 环境<|>RELATION_NOE 领域<|>RELATION_NOE 评分<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 13.4<|>RELATION_NOE ±<|>RELATION_NOE 1.8<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 12.1<|>RELATION_NOE ±<|>RELATION_NOE 1.9<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 12.6<|>RELATION_NOE ±<|>RELATION_NOE 1.7<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 12.5<|>RELATION_NOE ±<|>RELATION_NOE 1.8<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_B 优于<|>RELATION_E 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 12.3<|>RELATION_NOE ±<|>RELATION_NOE 2.0<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 11.0<|>RELATION_NOE ±<|>RELATION_NOE 1.8<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 11.7<|>RELATION_NOE ±<|>RELATION_NOE 1.6<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 12.0<|>RELATION_NOE ±<|>RELATION_NOE 1.9<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 4.45<|>RELATION_NOE ,<|>RELATION_NOE 4.24<|>RELATION_NOE ,<|>RELATION_NOE 3.57<|>RELATION_NOE ,<|>RELATION_NOE 2.49<|>RELATION_NOE ;<|>RELATION_NOE
协同<|>RELATION_NOE 护理<|>RELATION_NOE 能<|>RELATION_NOE 增强<|>RELATION_NOE 癌症<|>RELATION_NOE 晚期<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 的<|>RELATION_NOE 治疗效果<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 疼痛<|>RELATION_NOE 缓解率<|>RELATION_NOE ;<|>RELATION_NOE
降低<|>RELATION_NOE 阿片<|>RELATION_NOE 类<|>RELATION_NOE 药物<|>RELATION_NOE 引起<|>RELATION_NOE 的<|>RELATION_NOE 便秘<|>RELATION_NOE 以及<|>RELATION_NOE 恶心<|>RELATION_NOE /<|>RELATION_NOE 呕吐<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
腹壁<|>RELATION_NOE 隆突性<|>RELATION_NOE 皮肤<|>RELATION_NOE 纤维肉瘤<|>RELATION_NOE 诊治<|>RELATION_NOE 策略<|>RELATION_NOE 及<|>RELATION_NOE 复发<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_S
探讨<|>RELATION_NOE 腹壁<|>RELATION_NOE 隆突性<|>RELATION_NOE 纤维肉瘤<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 与<|>RELATION_NOE 治疗<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 对<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE 腹壁<|>RELATION_NOE 隆突性<|>RELATION_NOE 皮肤<|>RELATION_NOE 纤维肉瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 进行<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 是否<|>RELATION_NOE 放疗<|>RELATION_NOE 、<|>RELATION_NOE 切缘<|>RELATION_NOE 距离<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE 进行<|>RELATION_NOE 分组<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 组<|>RELATION_NOE 间术<|>RELATION_NOE 后<|>RELATION_NOE 复发率<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
右<|>RELATION_NOE 美托<|>RELATION_NOE 咪定<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 根治术<|>RELATION_I 患者<|>RELATION_I 单肺通气<|>RELATION_E 时<|>RELATION_NOE 的<|>RELATION_NOE 肺保护<|>RELATION_NOE 作用<|>RELATION_NOE
D<|>RELATION_NOE 组<|>RELATION_NOE 于<|>RELATION_NOE 麻醉<|>RELATION_NOE 诱导<|>RELATION_NOE 前经<|>RELATION_NOE 10min<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE 右<|>RELATION_NOE 美托<|>RELATION_NOE 咪定<|>RELATION_NOE 负荷量<|>RELATION_NOE 1.0μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE ,<|>RELATION_NOE 随后<|>RELATION_NOE 以<|>RELATION_NOE 0.6<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE ·<|>RELATION_NOE kg<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE ·<|>RELATION_NOE h<|>RELATION_NOE ^<|>RELATION_NOE -1<|>RELATION_NOE 速率<|>RELATION_NOE 静脉<|>RELATION_NOE 输注<|>RELATION_NOE 至<|>RELATION_NOE 关胸<|>RELATION_NOE 。<|>RELATION_NOE
于<|>RELATION_NOE 麻醉<|>RELATION_NOE 诱导<|>RELATION_NOE 后<|>RELATION_NOE 即刻<|>RELATION_NOE (<|>RELATION_NOE Tl<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 单肺通气<|>RELATION_NOE 30min<|>RELATION_NOE (<|>RELATION_NOE T2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 60min<|>RELATION_NOE (<|>RELATION_NOE T3<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 术毕<|>RELATION_NOE (<|>RELATION_NOE T4<|>RELATION_NOE )<|>RELATION_NOE 时<|>RELATION_NOE 分别<|>RELATION_NOE 采集<|>RELATION_NOE 动脉<|>RELATION_NOE 血<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE ELISA<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_NOE 血清<|>RELATION_NOE TNF-a<|>RELATION_NOE 、<|>RELATION_NOE IL-6<|>RELATION_NOE 及<|>RELATION_NOE IL-8<|>RELATION_NOE 的<|>RELATION_NOE 浓度<|>RELATION_NOE ,<|>RELATION_NOE 并行<|>RELATION_NOE 动脉<|>RELATION_NOE 血气分析<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 氧合<|>RELATION_NOE 指数<|>RELATION_NOE 。<|>RELATION_NOE
杂交式<|>RELATION_NOE 单操作孔<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_S 早期<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_NOE 杂交式<|>RELATION_NOE 单操作孔<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_B 早期<|>RELATION_I 肺癌<|>RELATION_E 疗效<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 本院<|>RELATION_NOE 于<|>RELATION_NOE 20<|>RELATION_NOE 14年<|>RELATION_NOE 1－<|>RELATION_NOE 6月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 患者<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 符合<|>RELATION_NOE 手术<|>RELATION_NOE 指征<|>RELATION_NOE ,<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 手术<|>RELATION_NOE 方法<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 采取<|>RELATION_NOE 杂交式<|>RELATION_NOE 单操作孔<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采取<|>RELATION_NOE 单纯<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 一般<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 情况<|>RELATION_NOE 及<|>RELATION_NOE 并发症<|>RELATION_NOE 发生<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
杂交式<|>RELATION_NOE 单操作孔<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_B 早期<|>RELATION_I 肺癌<|>RELATION_E 疗效<|>RELATION_NOE 较<|>RELATION_NOE 佳<|>RELATION_NOE ,<|>RELATION_NOE 创伤<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 出血量<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 恢复<|>RELATION_NOE 快<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 安全<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 重要<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
完全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺癌<|>RELATION_NOE 155<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 外科<|>RELATION_B 治疗<|>RELATION_E
我们<|>RELATION_NOE 于<|>RELATION_NOE 2009年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 采用<|>RELATION_NOE 完全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 治疗<|>RELATION_NOE 155<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 该<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 及<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
低<|>RELATION_NOE 分子量<|>RELATION_NOE 肝素<|>RELATION_NOE 联合<|>RELATION_NOE 华法林<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 急性<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_NOE 低<|>RELATION_NOE 分子量<|>RELATION_NOE 肝素<|>RELATION_NOE 联合<|>RELATION_NOE 华法林<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 肺癌<|>RELATION_I 合并<|>RELATION_I 急性<|>RELATION_I 非<|>RELATION_I 大面积<|>RELATION_I 肺栓塞<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 对<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 症状<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
2008年<|>RELATION_NOE 7月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 6月<|>RELATION_NOE 收治<|>RELATION_NOE Ⅲ<|>RELATION_NOE B-<|>RELATION_NOE Ⅳ<|>RELATION_NOE 期<|>RELATION_NOE 肺癌<|>RELATION_NOE 合并<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 患者<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 经<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 动脉<|>RELATION_NOE 造影<|>RELATION_NOE (<|>RELATION_NOE SCTPA<|>RELATION_NOE )<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 急性<|>RELATION_NOE 非<|>RELATION_NOE 大面积<|>RELATION_NOE 肺栓塞<|>RELATION_NOE 。<|>RELATION_NOE
给予<|>RELATION_NOE 依诺肝素<|>RELATION_NOE (<|>RELATION_NOE 1mg<|>RELATION_NOE /<|>RELATION_NOE kg<|>RELATION_NOE 体重<|>RELATION_NOE )<|>RELATION_NOE 每<|>RELATION_NOE 12h<|>RELATION_NOE 皮下注射<|>RELATION_NOE 1<|>RELATION_NOE 次<|>RELATION_NOE (<|>RELATION_NOE 7-14d<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 在<|>RELATION_NOE 应用<|>RELATION_NOE 依诺肝素<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE 加<|>RELATION_NOE 用<|>RELATION_NOE 华法林<|>RELATION_NOE ,<|>RELATION_NOE 调整<|>RELATION_NOE 华法林<|>RELATION_NOE 剂量<|>RELATION_NOE 使<|>RELATION_NOE 国际<|>RELATION_NOE 标准化<|>RELATION_NOE 比值<|>RELATION_NOE (<|>RELATION_NOE INR<|>RELATION_NOE )<|>RELATION_NOE 维持<|>RELATION_NOE 在<|>RELATION_NOE 2.0-3.0<|>RELATION_NOE 。<|>RELATION_NOE
监测<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 7<|>RELATION_NOE 、<|>RELATION_NOE 14d<|>RELATION_NOE 的<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 分级<|>RELATION_NOE (<|>RELATION_NOE MRC<|>RELATION_NOE 分级<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 动脉<|>RELATION_NOE 血气分析<|>RELATION_NOE 等<|>RELATION_NOE 指标<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
2例<|>RELATION_NOE 合并<|>RELATION_NOE 下肢<|>RELATION_NOE 深静脉血栓<|>RELATION_NOE 形成<|>RELATION_NOE (<|>RELATION_NOE DVT<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 因<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 多<|>RELATION_NOE 器官<|>RELATION_NOE 功能<|>RELATION_NOE 衰竭<|>RELATION_NOE 分别<|>RELATION_NOE 于<|>RELATION_NOE 治疗<|>RELATION_NOE 第6<|>RELATION_NOE 天<|>RELATION_NOE 和<|>RELATION_NOE 第11<|>RELATION_NOE 天<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 治愈<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 显效<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 好转<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 生存期<|>RELATION_NOE 9.2<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 。<|>RELATION_NOE
治疗<|>RELATION_NOE 后<|>RELATION_NOE 4<|>RELATION_NOE 、<|>RELATION_NOE 7<|>RELATION_NOE 、<|>RELATION_NOE 14d<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE MRC<|>RELATION_NOE 分级<|>RELATION_NOE 由<|>RELATION_NOE (<|>RELATION_NOE 3.1<|>RELATION_NOE ±<|>RELATION_NOE 0.5<|>RELATION_NOE )<|>RELATION_NOE 级<|>RELATION_NOE 降低<|>RELATION_NOE 至<|>RELATION_NOE (<|>RELATION_NOE 1.9<|>RELATION_NOE ±<|>RELATION_NOE 0.8<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.5<|>RELATION_NOE ±<|>RELATION_NOE 0.5<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.6<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE )<|>RELATION_NOE 级<|>RELATION_NOE ,<|>RELATION_NOE 动脉<|>RELATION_NOE 血氧<|>RELATION_NOE 分压<|>RELATION_NOE (<|>RELATION_NOE Pa02<|>RELATION_NOE )<|>RELATION_NOE 由<|>RELATION_NOE (<|>RELATION_NOE 60.5<|>RELATION_NOE ±<|>RELATION_NOE 7.2<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE (<|>RELATION_NOE 1mmHg<|>RELATION_NOE =<|>RELATION_NOE 0.133kPa<|>RELATION_NOE )<|>RELATION_NOE 升高<|>RELATION_NOE 至<|>RELATION_NOE (<|>RELATION_NOE 76.1<|>RELATION_NOE ±<|>RELATION_NOE 9.7<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 81.6<|>RELATION_NOE ±<|>RELATION_NOE 9.2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 86.2<|>RELATION_NOE ±<|>RELATION_NOE 7.5<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE ,<|>RELATION_NOE 血浆<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 由<|>RELATION_NOE (<|>RELATION_NOE 9.44<|>RELATION_NOE ±<|>RELATION_NOE 5.29<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 降低<|>RELATION_NOE 至<|>RELATION_NOE (<|>RELATION_NOE 4.33<|>RELATION_NOE ±<|>RELATION_NOE 3.34<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.88<|>RELATION_NOE ±<|>RELATION_NOE 0.32<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 0.41<|>RELATION_NOE ±<|>RELATION_NOE 0.17<|>RELATION_NOE )<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 肺泡<|>RELATION_NOE .<|>RELATION_NOE
动脉<|>RELATION_NOE 血氧<|>RELATION_NOE 分压<|>RELATION_NOE 差<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE (<|>RELATION_NOE A-n<|>RELATION_NOE )<|>RELATION_NOE O2<|>RELATION_NOE )<|>RELATION_NOE 由<|>RELATION_NOE (<|>RELATION_NOE 38.5<|>RELATION_NOE ±<|>RELATION_NOE 6.7<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE 降低<|>RELATION_NOE 至<|>RELATION_NOE (<|>RELATION_NOE 35.5<|>RELATION_NOE ±<|>RELATION_NOE 5.1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 29.3<|>RELATION_NOE ±<|>RELATION_NOE 3.2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 24.1<|>RELATION_NOE ±<|>RELATION_NOE 4.1<|>RELATION_NOE )<|>RELATION_NOE mmHg<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE Pa02<|>RELATION_NOE 、<|>RELATION_NOE MRC<|>RELATION_NOE 分级<|>RELATION_NOE 、<|>RELATION_NOE 血浆<|>RELATION_NOE D<|>RELATION_NOE .<|>RELATION_NOE
低<|>RELATION_NOE 分子量<|>RELATION_NOE 肝素<|>RELATION_NOE 联合<|>RELATION_NOE 华法林<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 肺癌<|>RELATION_I 合并<|>RELATION_I 急性<|>RELATION_I 非<|>RELATION_I 大面积<|>RELATION_I 肺栓塞<|>RELATION_E 可<|>RELATION_NOE 显著<|>RELATION_NOE 改善<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 呼吸困难<|>RELATION_NOE 症状<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 安全性<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 。<|>RELATION_NOE
腋下<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 后<|>RELATION_NOE 外侧<|>RELATION_NOE 切口<|>RELATION_NOE 肺癌<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 对比<|>RELATION_S 分析<|>RELATION_NOE
将<|>RELATION_NOE 87<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 腋下<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 45<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 传统<|>RELATION_NOE 后<|>RELATION_NOE 外侧<|>RELATION_NOE 切口<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 开胸<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 开<|>RELATION_NOE 胸出<|>RELATION_NOE 血量<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 引流量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 强度<|>RELATION_NOE 评分<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 在<|>RELATION_NOE 开胸<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 关胸<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 引流量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 疼痛<|>RELATION_NOE 强度<|>RELATION_NOE 评分<|>RELATION_NOE 各项<|>RELATION_NOE 指标<|>RELATION_NOE 方面<|>RELATION_NOE 比较<|>RELATION_B 差异<|>RELATION_I 均<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 观察组<|>RELATION_NOE 出现<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 、<|>RELATION_NOE 肺不张<|>RELATION_NOE 、<|>RELATION_NOE 切口<|>RELATION_NOE 感染<|>RELATION_NOE 、<|>RELATION_NOE 肩关节<|>RELATION_NOE 活动<|>RELATION_NOE 障碍<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
腋下<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 能<|>RELATION_NOE 作为<|>RELATION_B 肺癌<|>RELATION_I 手术<|>RELATION_I 治疗<|>RELATION_I 的<|>RELATION_I 常规<|>RELATION_I 切口<|>RELATION_E 疗效<|>RELATION_NOE 确切<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 后<|>RELATION_NOE 外侧<|>RELATION_NOE 切口<|>RELATION_NOE 相比<|>RELATION_NOE 具有<|>RELATION_NOE 术中<|>RELATION_NOE 效果<|>RELATION_NOE 好<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE 、<|>RELATION_NOE 对<|>RELATION_NOE 机体<|>RELATION_NOE 损伤<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 轻<|>RELATION_NOE 等<|>RELATION_NOE 优点<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE 腋下<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 能<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 常规<|>RELATION_NOE 切口<|>RELATION_NOE 疗效<|>RELATION_NOE 确切<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 传统<|>RELATION_NOE 后<|>RELATION_NOE 外侧<|>RELATION_NOE 切口<|>RELATION_NOE 相比<|>RELATION_NOE 具有<|>RELATION_NOE 术中<|>RELATION_NOE 效果<|>RELATION_NOE 好<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE 、<|>RELATION_NOE 对<|>RELATION_NOE 机体<|>RELATION_NOE 损伤<|>RELATION_NOE 小<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 轻<|>RELATION_NOE 等<|>RELATION_NOE 优点<|>RELATION_S ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE
陀螺<|>RELATION_NOE 旋转<|>RELATION_NOE 式<|>RELATION_NOE 伽玛刀<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 应用<|>RELATION_E
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 自<|>RELATION_NOE 2008年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 10<|>RELATION_NOE 月经<|>RELATION_NOE 陀螺<|>RELATION_NOE 旋转<|>RELATION_NOE 式伽玛刀<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 161<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 原发<|>RELATION_NOE 疾病<|>RELATION_NOE 中<|>RELATION_NOE 肺癌<|>RELATION_NOE 67<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 脑瘤<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 食管癌<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 包括<|>RELATION_NOE 直肠癌<|>RELATION_NOE 、<|>RELATION_NOE 胆管癌<|>RELATION_NOE 、<|>RELATION_NOE 肾癌<|>RELATION_NOE 、<|>RELATION_NOE 头颈部肿瘤<|>RELATION_NOE 共<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
18F-FDGPET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_NOE 正确<|>RELATION_NOE 25<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 假阴性<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 假阳性<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE SPN<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 灵敏度<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE 、<|>RELATION_NOE 阳性<|>RELATION_NOE 预测值<|>RELATION_NOE 和<|>RELATION_NOE 阴性<|>RELATION_NOE 预测值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 89.5%<|>RELATION_NOE 、<|>RELATION_NOE 88.9%<|>RELATION_NOE 、<|>RELATION_NOE 89.3%<|>RELATION_NOE 、<|>RELATION_NOE 94.4%<|>RELATION_NOE 和<|>RELATION_NOE 80.0%<|>RELATION_NOE 。<|>RELATION_NOE
综合<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 患者<|>RELATION_I 行伽玛刀<|>RELATION_I 治疗<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
探讨<|>RELATION_NOE 综合<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 行伽玛刀<|>RELATION_NOE 治疗<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE 、<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S ,<|>RELATION_NOE 以期<|>RELATION_NOE 为<|>RELATION_NOE 临床<|>RELATION_NOE 工作<|>RELATION_NOE 提供<|>RELATION_NOE 理论<|>RELATION_NOE 帮助<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 144<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 行伽玛刀<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE 74<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 进行<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ;<|>RELATION_NOE
观察组<|>RELATION_NOE 应用<|>RELATION_NOE 特定<|>RELATION_NOE 的<|>RELATION_NOE 综合<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 2组<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE 、<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 差别<|>RELATION_NOE 。<|>RELATION_NOE
护理<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 评分<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 评分<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 评分<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 睡眠<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE 。<|>RELATION_NOE
晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 累及<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 行<|>RELATION_B 根治<|>RELATION_I 切除<|>RELATION_I 的<|>RELATION_I 手术<|>RELATION_E 配合<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 收集<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 累及<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 行根<|>RELATION_NOE 治<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 需要<|>RELATION_NOE 根据<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 受累<|>RELATION_NOE 程度<|>RELATION_NOE 采用<|>RELATION_NOE 不同<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 采用<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 修补<|>RELATION_NOE 、<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 壁<|>RELATION_NOE 部分<|>RELATION_NOE 切除<|>RELATION_NOE 直接<|>RELATION_NOE 缝合<|>RELATION_NOE 、<|>RELATION_NOE 上腔静脉<|>RELATION_NOE 切除<|>RELATION_NOE 置换<|>RELATION_NOE 。<|>RELATION_NOE
2例<|>RELATION_NOE 患者<|>RELATION_NOE 因<|>RELATION_NOE 术<|>RELATION_NOE 中大<|>RELATION_NOE 血管<|>RELATION_NOE 损伤<|>RELATION_NOE 出血<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
综合<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
评价<|>RELATION_NOE 综合治疗<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_S 。<|>RELATION_NOE
对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 综合治疗<|>RELATION_NOE 较<|>RELATION_B 单纯<|>RELATION_I 放<|>RELATION_I 、<|>RELATION_I 化疗<|>RELATION_E 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 更为<|>RELATION_NOE 积极<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
吉非替尼<|>RELATION_NOE 与<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE meta<|>RELATION_NOE 分析<|>RELATION_NOE
尼美<|>RELATION_NOE 舒利<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 细胞增殖<|>RELATION_I 与<|>RELATION_I 凋亡<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE 及其<|>RELATION_NOE 机制<|>RELATION_NOE 探讨<|>RELATION_NOE
将<|>RELATION_NOE 裸鼠<|>RELATION_NOE 用<|>RELATION_NOE 统计学<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 依<|>RELATION_NOE 体重<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 4组<|>RELATION_NOE :<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 尼美<|>RELATION_NOE 舒利组<|>RELATION_NOE 、<|>RELATION_NOE 顺铂组<|>RELATION_NOE 和<|>RELATION_NOE 联合<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 尼美<|>RELATION_NOE 舒利<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 接种<|>RELATION_NOE 至<|>RELATION_NOE 裸鼠皮<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 给予<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 药物治疗<|>RELATION_NOE 21d<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
尼美<|>RELATION_NOE 舒利<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE 较<|>RELATION_NOE 单独<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 明显<|>RELATION_S ,<|>RELATION_NOE 抑瘤率<|>RELATION_NOE 尼美<|>RELATION_NOE 舒利组<|>RELATION_NOE 为<|>RELATION_NOE 44.3<|>RELATION_NOE 3%<|>RELATION_NOE ,<|>RELATION_NOE 顺铂组<|>RELATION_NOE 为<|>RELATION_NOE 53.6<|>RELATION_NOE 1%<|>RELATION_NOE ,<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE 为<|>RELATION_NOE 80.4<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
尼美<|>RELATION_NOE 舒利<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_S 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 可<|>RELATION_NOE 增强<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 尼美<|>RELATION_NOE 舒利<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 联合<|>RELATION_NOE 可<|>RELATION_NOE 增强<|>RELATION_NOE 顺铂<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 抑制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE Ki67<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 增强<|>RELATION_NOE Caspase-3<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 诱导<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
SurvivinsiRNA<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_B 肺腺<|>RELATION_I 癌细胞株<|>RELATION_I AGZY<|>RELATION_I 增殖<|>RELATION_I 及<|>RELATION_I 凋亡<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
采用<|>RELATION_NOE RNAi<|>RELATION_NOE 技术<|>RELATION_NOE 靶向<|>RELATION_NOE 干扰<|>RELATION_NOE AGZY<|>RELATION_NOE 细胞<|>RELATION_NOE survivin<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分<|>RELATION_NOE 空白<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 转染<|>RELATION_NOE 试剂<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 阴性<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 转染组<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE survivin<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 绘制<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE Hoechst<|>RELATION_NOE 染色<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE 印迹<|>RELATION_NOE 采用<|>RELATION_NOE RNAi<|>RELATION_NOE 技术<|>RELATION_NOE 靶向<|>RELATION_NOE 干扰<|>RELATION_NOE AGZY<|>RELATION_NOE 细胞<|>RELATION_NOE survivin<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分<|>RELATION_NOE 空白<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 转染<|>RELATION_NOE 试剂<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 阴性<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 转染组<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE RT-PCR<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE survivin<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 绘制<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 曲线<|>RELATION_NOE ,<|>RELATION_NOE Hoechst<|>RELATION_NOE 染色<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE 印迹<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 蛋白<|>RELATION_NOE survivin<|>RELATION_NOE 、<|>RELATION_NOE caspase-3<|>RELATION_NOE 、<|>RELATION_NOE caspase-8<|>RELATION_NOE 、<|>RELATION_NOE cyclinB1<|>RELATION_NOE 、<|>RELATION_NOE cyclinD1<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
Survivin<|>RELATION_NOE 特异性<|>RELATION_NOE siRNA<|>RELATION_NOE 可<|>RELATION_NOE 在<|>RELATION_NOE mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 有效<|>RELATION_B 下调<|>RELATION_I survivin<|>RELATION_I 的<|>RELATION_I 表达<|>RELATION_E ,<|>RELATION_NOE 转染组<|>RELATION_NOE 与<|>RELATION_NOE 其他<|>RELATION_NOE 3组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 17<|>RELATION_NOE 85.25<|>RELATION_NOE ,<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 38.67<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE Survivin<|>RELATION_NOE 特异性<|>RELATION_NOE siRNA<|>RELATION_NOE 可<|>RELATION_NOE 在<|>RELATION_NOE mRNA<|>RELATION_NOE 及<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 有效<|>RELATION_NOE 下调<|>RELATION_NOE survivin<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 转染组<|>RELATION_NOE 与<|>RELATION_NOE 其他<|>RELATION_NOE 3组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 17<|>RELATION_NOE 85.25<|>RELATION_NOE ,<|>RELATION_NOE F<|>RELATION_NOE =<|>RELATION_NOE 38.67<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
探讨<|>RELATION_NOE 干扰素γ<|>RELATION_NOE (<|>RELATION_NOE IFN-<|>RELATION_NOE γ<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE β1<|>RELATION_NOE (<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE )<|>RELATION_NOE 诱导<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间充质<|>RELATION_NOE 转化<|>RELATION_NOE (<|>RELATION_NOE EMT<|>RELATION_NOE )<|>RELATION_NOE 过程<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_S 及<|>RELATION_NOE 对<|>RELATION_NOE 胞外<|>RELATION_NOE 调节<|>RELATION_NOE 激酶<|>RELATION_NOE 1/2<|>RELATION_NOE (<|>RELATION_NOE ERK1<|>RELATION_NOE /<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 信号<|>RELATION_NOE 转导<|>RELATION_NOE 和<|>RELATION_NOE 转录激活<|>RELATION_NOE 因子<|>RELATION_NOE 3<|>RELATION_NOE (<|>RELATION_NOE STAT3<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE
带翼<|>RELATION_NOE 髋臼<|>RELATION_NOE 加强<|>RELATION_NOE 杯<|>RELATION_NOE 在<|>RELATION_NOE 髋臼<|>RELATION_B 周围<|>RELATION_I 肿瘤<|>RELATION_I 切除术<|>RELATION_I 后<|>RELATION_I 髋臼<|>RELATION_I 重建<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
探讨<|>RELATION_NOE 带翼<|>RELATION_NOE 髋臼<|>RELATION_NOE 加强<|>RELATION_NOE 杯<|>RELATION_NOE 在<|>RELATION_NOE 髋臼<|>RELATION_B 周围<|>RELATION_I 肿瘤<|>RELATION_I 切除术<|>RELATION_I 后<|>RELATION_I 髋臼<|>RELATION_I 重建<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
回顾<|>RELATION_NOE 分析<|>RELATION_NOE 2006年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 3月<|>RELATION_NOE 期间<|>RELATION_NOE 应用<|>RELATION_NOE 带翼<|>RELATION_NOE 髋臼<|>RELATION_NOE 加强<|>RELATION_NOE 杯<|>RELATION_NOE 联合<|>RELATION_NOE 人工<|>RELATION_NOE 全<|>RELATION_NOE 髋关节<|>RELATION_NOE 置换术<|>RELATION_NOE 对<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE Harrington<|>RELATION_NOE Ⅲ<|>RELATION_NOE 型<|>RELATION_NOE 髋臼<|>RELATION_NOE 周围<|>RELATION_NOE 肿瘤<|>RELATION_NOE 行<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 女6<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 26<|>RELATION_NOE －<|>RELATION_NOE 65<|>RELATION_NOE 岁<|>RELATION_NOE (<|>RELATION_NOE 平均<|>RELATION_NOE 45.3<|>RELATION_NOE 岁<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE I<|>RELATION_NOE 级<|>RELATION_NOE 软骨肉瘤<|>RELATION_NOE 6例<|>RELATION_NOE 、<|>RELATION_NOE 骨巨细胞瘤<|>RELATION_NOE 5例<|>RELATION_NOE 、<|>RELATION_NOE 软骨<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE 2例<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
本组<|>RELATION_NOE 病例术<|>RELATION_NOE 中<|>RELATION_NOE 出血量<|>RELATION_NOE 500<|>RELATION_NOE －2<|>RELATION_NOE 600<|>RELATION_NOE ml<|>RELATION_NOE (<|>RELATION_NOE 平均<|>RELATION_NOE 11<|>RELATION_NOE 30<|>RELATION_NOE ml<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 手术时间<|>RELATION_NOE 156<|>RELATION_NOE －<|>RELATION_NOE 262min<|>RELATION_NOE (<|>RELATION_NOE 平均<|>RELATION_NOE 185min<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 住院时间<|>RELATION_NOE 15－<|>RELATION_NOE 32d<|>RELATION_NOE (<|>RELATION_NOE 平均<|>RELATION_NOE 22.8d<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 时间<|>RELATION_NOE 12<|>RELATION_NOE －<|>RELATION_NOE 60<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 平均<|>RELATION_NOE 27.1<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
术后<|>RELATION_NOE 1例<|>RELATION_NOE 出现<|>RELATION_NOE 手术<|>RELATION_NOE 切口<|>RELATION_NOE 血肿<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 腘静脉血栓<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 坠积性<|>RELATION_NOE 肺炎<|>RELATION_NOE ,<|>RELATION_NOE 1例术后<|>RELATION_NOE 15d<|>RELATION_NOE 出现<|>RELATION_NOE 髋关节<|>RELATION_NOE 脱位<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 病例术<|>RELATION_NOE 后<|>RELATION_NOE 22<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 因<|>RELATION_NOE 骨巨细胞瘤<|>RELATION_NOE 复发<|>RELATION_NOE 导致<|>RELATION_NOE 假体<|>RELATION_NOE 松动<|>RELATION_NOE ;<|>RELATION_NOE
1例术<|>RELATION_NOE 后<|>RELATION_NOE 18<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 死<|>RELATION_NOE 于<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 进展期<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 骨巨细胞瘤<|>RELATION_NOE 术后<|>RELATION_NOE 20<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 发现<|>RELATION_NOE 复发<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE Ⅰ<|>RELATION_NOE 软骨肉瘤<|>RELATION_NOE 术<|>RELATION_NOE 后<|>RELATION_NOE 33<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 发现<|>RELATION_NOE 复发<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 带翼<|>RELATION_NOE 髋臼<|>RELATION_NOE 加强<|>RELATION_NOE 杯<|>RELATION_NOE 联合<|>RELATION_NOE 人工<|>RELATION_NOE 全<|>RELATION_NOE 髋关节<|>RELATION_NOE 置换术<|>RELATION_NOE 治疗<|>RELATION_B Harrington<|>RELATION_I Ⅲ<|>RELATION_I 型<|>RELATION_I 髋臼<|>RELATION_I 周围<|>RELATION_I 肿瘤<|>RELATION_E 安全<|>RELATION_NOE 、<|>RELATION_NOE 可靠<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 髋关节<|>RELATION_NOE 功能<|>RELATION_NOE 恢复<|>RELATION_NOE 良好<|>RELATION_NOE 。<|>RELATION_NOE
原<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE -20<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 机制<|>RELATION_E
探讨<|>RELATION_NOE 原<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE -20<|>RELATION_NOE (<|>RELATION_NOE PCDH20<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 其<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 以及<|>RELATION_NOE PCDH20<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_B 及<|>RELATION_I 相关<|>RELATION_I 的<|>RELATION_I 作用<|>RELATION_I 机制<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE 半定量<|>RELATION_NOE 逆转录<|>RELATION_NOE -<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE SqRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S PCDH20<|>RELATION_NOE 在<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 成人<|>RELATION_NOE 肺组织<|>RELATION_NOE 和<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
用<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE PCR<|>RELATION_NOE (<|>RELATION_NOE MSP<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 20<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE PCDH20<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
PCDH20<|>RELATION_NOE 在<|>RELATION_NOE 几乎<|>RELATION_NOE 所有<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_S ,<|>RELATION_NOE 在<|>RELATION_NOE 95%<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 不<|>RELATION_NOE PCDH20<|>RELATION_NOE 在<|>RELATION_NOE 几乎<|>RELATION_NOE 所有<|>RELATION_NOE 正常<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 95%<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 不<|>RELATION_B 表达<|>RELATION_E (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
80%<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 存在<|>RELATION_S PCDH20<|>RELATION_NOE 启动子<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 在<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 未<|>RELATION_NOE 检测<|>RELATION_NOE 到<|>RELATION_NOE 。<|>RELATION_NOE 80%<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 存在<|>RELATION_NOE PCDH20<|>RELATION_NOE 启动子<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 在<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE 未<|>RELATION_B 检测<|>RELATION_I 到<|>RELATION_E 。<|>RELATION_NOE
DNA<|>RELATION_NOE 甲基化<|>RELATION_NOE 是<|>RELATION_NOE PCDH20<|>RELATION_B 在<|>RELATION_I 肺癌<|>RELATION_I 中<|>RELATION_I 表达<|>RELATION_I 下调<|>RELATION_I 或<|>RELATION_I 缺失<|>RELATION_E 的<|>RELATION_NOE 原因<|>RELATION_NOE 之一<|>RELATION_NOE ,<|>RELATION_NOE PCDH20<|>RELATION_NOE 在<|>RELATION_NOE 大肠癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 起<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE .<|>RELATION_NOE DNA<|>RELATION_NOE 甲基化<|>RELATION_NOE 是<|>RELATION_NOE PCDH20<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 或<|>RELATION_NOE 缺失<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE 之一<|>RELATION_NOE ,<|>RELATION_NOE PCDH20<|>RELATION_NOE 在<|>RELATION_B 大肠癌<|>RELATION_I 的<|>RELATION_I 发生<|>RELATION_I 发展<|>RELATION_I 中<|>RELATION_E 起<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE .<|>RELATION_NOE
参<|>RELATION_NOE 一<|>RELATION_NOE 胶囊<|>RELATION_NOE 联合<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 同步<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_B 老年人<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
评价<|>RELATION_NOE 参<|>RELATION_NOE 一<|>RELATION_NOE 胶囊<|>RELATION_NOE 联合<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 同步<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_B 老年<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
按<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 将<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 2组<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 给予<|>RELATION_NOE 放疗<|>RELATION_NOE 同时<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 并<|>RELATION_NOE 口服<|>RELATION_NOE 参<|>RELATION_NOE 一<|>RELATION_NOE 胶囊<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE 给予<|>RELATION_NOE 放疗<|>RELATION_NOE 同时<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 观察<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 客观<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE (<|>RELATION_NOE ORR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE (<|>RELATION_NOE DCR<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 远期<|>RELATION_NOE 生存率<|>RELATION_NOE 及<|>RELATION_NOE 出现<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 常见<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 为<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 、<|>RELATION_NOE 消化道<|>RELATION_NOE 反应<|>RELATION_NOE 、<|>RELATION_NOE 脱发<|>RELATION_NOE 、<|>RELATION_NOE 乏力<|>RELATION_NOE 、<|>RELATION_NOE 关节<|>RELATION_NOE 酸<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 因<|>RELATION_NOE 严重<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 停<|>RELATION_NOE 药<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE 方面<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
一<|>RELATION_NOE 胶囊<|>RELATION_NOE 联合<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 同步<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_B 老年<|>RELATION_I NSCLC<|>RELATION_E ,<|>RELATION_NOE 能够<|>RELATION_NOE 延长<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_NOE 预后<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 增加<|>RELATION_NOE .<|>RELATION_NOE
超声<|>RELATION_NOE 支气管镜<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 的<|>RELATION_NOE 经<|>RELATION_NOE 支气管<|>RELATION_NOE 针吸<|>RELATION_NOE 活<|>RELATION_NOE 检<|>RELATION_NOE 对<|>RELATION_NOE 老年人<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
评价<|>RELATION_NOE 超声<|>RELATION_NOE 支气管镜<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 的<|>RELATION_NOE 经<|>RELATION_NOE 支气管<|>RELATION_NOE 针吸<|>RELATION_NOE 活<|>RELATION_NOE 检<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 老年人<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_I 和<|>RELATION_I 安全性<|>RELATION_E 。<|>RELATION_NOE
于<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 8月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 14年<|>RELATION_NOE 7月<|>RELATION_NOE 对<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 胸部<|>RELATION_NOE CT<|>RELATION_NOE 或<|>RELATION_NOE 正电子<|>RELATION_NOE 发射<|>RELATION_NOE 计算机<|>RELATION_NOE 断层<|>RELATION_NOE 显像<|>RELATION_NOE (<|>RELATION_NOE PET-CT<|>RELATION_NOE )<|>RELATION_NOE 检查<|>RELATION_NOE 显示<|>RELATION_NOE 肺内<|>RELATION_NOE 占位<|>RELATION_NOE 伴多<|>RELATION_NOE 发<|>RELATION_NOE 纵膈<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 的<|>RELATION_NOE ≥<|>RELATION_NOE 65<|>RELATION_NOE 岁<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE EBUS-TBNA<|>RELATION_NOE ,<|>RELATION_NOE 未<|>RELATION_NOE 采取<|>RELATION_NOE 现场<|>RELATION_NOE 细胞学<|>RELATION_NOE 。<|>RELATION_NOE
乳头<|>RELATION_NOE 状<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 颈部<|>RELATION_NOE 中央组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_B 规律<|>RELATION_I 及<|>RELATION_I 影响<|>RELATION_I 因素<|>RELATION_I 分析<|>RELATION_E
患者<|>RELATION_NOE 均<|>RELATION_NOE 接受<|>RELATION_NOE 了<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 甲状腺<|>RELATION_NOE 全<|>RELATION_NOE 切除<|>RELATION_NOE 加<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 颈部<|>RELATION_NOE 中央组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE 治疗<|>RELATION_NOE 。<|>RELATION_NOE
乳头<|>RELATION_NOE 状<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 可<|>RELATION_B 发生<|>RELATION_E 中央组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 当<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 年轻人<|>RELATION_NOE 或<|>RELATION_NOE 男性<|>RELATION_NOE ,<|>RELATION_NOE 病灶<|>RELATION_NOE 呈<|>RELATION_NOE 多灶性<|>RELATION_NOE 或<|>RELATION_NOE 总<|>RELATION_NOE 直径<|>RELATION_NOE ><|>RELATION_NOE 0.5cm<|>RELATION_NOE 时<|>RELATION_NOE 转移<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 增加<|>RELATION_NOE .<|>RELATION_NOE
中心<|>RELATION_NOE 静脉<|>RELATION_NOE 导管<|>RELATION_NOE 置管<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 应用<|>RELATION_B 不同<|>RELATION_I 含铂<|>RELATION_I 方案<|>RELATION_I 化疗<|>RELATION_E 时<|>RELATION_NOE 血栓<|>RELATION_NOE 发生<|>RELATION_NOE 风险<|>RELATION_NOE 分析<|>RELATION_NOE
选取<|>RELATION_NOE 112<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 行<|>RELATION_NOE PICC<|>RELATION_NOE 置管<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 按照<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 分为<|>RELATION_NOE 六<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 对照组<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 未<|>RELATION_NOE 行<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 五<|>RELATION_NOE 组<|>RELATION_NOE 为<|>RELATION_NOE 紫杉醇<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 组<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 组<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨+<|>RELATION_NOE 顺铂<|>RELATION_NOE 组<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨+<|>RELATION_NOE 卡铂组<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 依托<|>RELATION_NOE 泊苷<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE 组<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 比较<|>RELATION_NOE 六<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 及<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 不同<|>RELATION_NOE 时段<|>RELATION_NOE 部分<|>RELATION_NOE 纤维蛋白原<|>RELATION_NOE 含量<|>RELATION_NOE (<|>RELATION_NOE FIB<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 、<|>RELATION_NOE 血流<|>RELATION_NOE 流速<|>RELATION_NOE 、<|>RELATION_NOE 管径<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 不<|>RELATION_NOE 同<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 血栓<|>RELATION_NOE 形成<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
不同<|>RELATION_NOE 含<|>RELATION_NOE 铂化疗<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 血液<|>RELATION_NOE 动力学<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 管径<|>RELATION_NOE 变化<|>RELATION_NOE 影响<|>RELATION_B 不<|>RELATION_I 大<|>RELATION_E ,<|>RELATION_NOE 但<|>RELATION_NOE D-<|>RELATION_NOE 二<|>RELATION_NOE 聚体<|>RELATION_NOE 及<|>RELATION_NOE 纤维蛋白原<|>RELATION_NOE 含量<|>RELATION_NOE 对<|>RELATION_NOE 凝血<|>RELATION_NOE 功能<|>RELATION_NOE 改变<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 评估<|>RELATION_NOE 有<|>RELATION_NOE 重要<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE PICC<|>RELATION_NOE 置管<|>RELATION_NOE 患者<|>RELATION_NOE 日常<|>RELATION_NOE 维护<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 监测<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE 不同<|>RELATION_NOE 含<|>RELATION_NOE 铂化疗<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 患者<|>RELATION_NOE 血液<|>RELATION_NOE 动力学<|>RELATION_NOE 变化<|>RELATION_NOE 及<|>RELATION_NOE 管径<|>RELATION_NOE 变化<|>RELATION_NOE 影响<|>RELATION_NOE 不<|>RELATION_NOE 大<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE D-<|>RELATION_NOE 二聚体<|>RELATION_NOE 及<|>RELATION_NOE 纤维蛋白原<|>RELATION_NOE 含量<|>RELATION_NOE 对<|>RELATION_NOE 凝血<|>RELATION_NOE 功能<|>RELATION_NOE 改变<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 评估<|>RELATION_NOE 有<|>RELATION_NOE 重要<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_B 作为<|>RELATION_E PICC<|>RELATION_NOE 置管<|>RELATION_NOE 患者<|>RELATION_NOE 日常<|>RELATION_NOE 维护<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 监测<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
PRKACB<|>RELATION_NOE 表达<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 病理<|>RELATION_I 意义<|>RELATION_I 及<|>RELATION_I 预后<|>RELATION_I 分析<|>RELATION_E
测定<|>RELATION_NOE PRKACB<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_B 小细胞肺癌<|>RELATION_I 中<|>RELATION_I 的<|>RELATION_I 表达<|>RELATION_I 情况<|>RELATION_E ,<|>RELATION_NOE 研究<|>RELATION_NOE 其<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 测定<|>RELATION_S 10<|>RELATION_NOE 9例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 及其<|>RELATION_NOE 中<|>RELATION_NOE 对应<|>RELATION_NOE 的<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 内<|>RELATION_NOE PRKACB<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 情况<|>RELATION_NOE 进行<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE PRKACB<|>RELATION_NOE 在<|>RELATION_NOE 109<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 内<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 下调<|>RELATION_S ,<|>RELATION_NOE 低<|>RELATION_NOE 表达率<|>RELATION_NOE (<|>RELATION_NOE 69.7%<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 癌旁<|>RELATION_NOE 肺组织<|>RELATION_NOE (<|>RELATION_NOE 10.0%<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE χ2<|>RELATION_NOE =<|>RELATION_NOE 25.2<|>RELATION_NOE 17<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE 与<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE PRKACB<|>RELATION_NOE 在<|>RELATION_NOE 109<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 内<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 下调<|>RELATION_NOE ,<|>RELATION_NOE 低<|>RELATION_NOE 表达率<|>RELATION_NOE (<|>RELATION_NOE 69.7%<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 20<|>RELATION_NOE 例<|>RELATION_NOE 癌旁肺<|>RELATION_NOE 组织<|>RELATION_NOE (<|>RELATION_NOE 10.0%<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE χ2<|>RELATION_NOE =<|>RELATION_NOE 25.2<|>RELATION_NOE 17<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
PRKACB<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 内<|>RELATION_NOE 呈现<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_B 成为<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_I 临床<|>RELATION_I 诊断<|>RELATION_E 的<|>RELATION_NOE 一个<|>RELATION_NOE 重要<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
人文<|>RELATION_NOE 护理<|>RELATION_NOE 关怀<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 依从性<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
对照组<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 融入<|>RELATION_NOE 人文<|>RELATION_NOE 护理<|>RELATION_NOE 关怀<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 的<|>RELATION_NOE 疲乏<|>RELATION_NOE 程度<|>RELATION_NOE 轻于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 依从性<|>RELATION_NOE 、<|>RELATION_NOE 希望<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_NOE 高于<|>RELATION_NOE 观察组<|>RELATION_NOE 的<|>RELATION_NOE 疲乏<|>RELATION_NOE 程度<|>RELATION_NOE 轻<|>RELATION_NOE 于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 依从性<|>RELATION_NOE 、<|>RELATION_NOE 希望<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 毒副反应<|>RELATION_NOE 程度<|>RELATION_NOE 轻于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 高于<|>RELATION_NOE 观察组<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 毒副反应<|>RELATION_NOE 程度<|>RELATION_NOE 轻<|>RELATION_NOE 于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 高于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 患者<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 后<|>RELATION_NOE 心血管系统<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_B 分析<|>RELATION_I 及<|>RELATION_I 护理<|>RELATION_I 对策<|>RELATION_E
选取<|>RELATION_NOE 行<|>RELATION_NOE 肺癌<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 200<|>RELATION_NOE 例<|>RELATION_NOE 为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 统计术<|>RELATION_NOE 后<|>RELATION_NOE 心血管<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 种类<|>RELATION_NOE 及<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 提出<|>RELATION_NOE 相关<|>RELATION_NOE 护理<|>RELATION_NOE 对策<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 后<|>RELATION_NOE 主要<|>RELATION_B 心血管<|>RELATION_I 并发症<|>RELATION_I 包括<|>RELATION_E 左<|>RELATION_NOE 心衰<|>RELATION_NOE 、<|>RELATION_NOE 窦性<|>RELATION_NOE 心动过速<|>RELATION_NOE 、<|>RELATION_NOE 心房纤颤<|>RELATION_NOE 、<|>RELATION_NOE 频发房性<|>RELATION_NOE 早搏<|>RELATION_NOE 、<|>RELATION_NOE 频发室性<|>RELATION_NOE 早搏<|>RELATION_NOE 及<|>RELATION_NOE 阵发<|>RELATION_NOE 性室<|>RELATION_NOE 上速<|>RELATION_NOE 。<|>RELATION_NOE
老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 行全<|>RELATION_NOE 肺切除<|>RELATION_NOE 患者<|>RELATION_NOE 应<|>RELATION_B 于<|>RELATION_I 手术<|>RELATION_I 早期<|>RELATION_E 给予<|>RELATION_NOE 患者<|>RELATION_NOE 吸氧<|>RELATION_NOE ,<|>RELATION_NOE 指导<|>RELATION_NOE 并<|>RELATION_NOE 帮助<|>RELATION_NOE 患者<|>RELATION_NOE 咯痰<|>RELATION_NOE ,<|>RELATION_NOE 避免<|>RELATION_NOE 过度<|>RELATION_NOE 活动<|>RELATION_NOE ,<|>RELATION_NOE 严密<|>RELATION_NOE 监护<|>RELATION_NOE 患者<|>RELATION_NOE 生命体征<|>RELATION_NOE ,<|>RELATION_NOE 密切<|>RELATION_NOE 观察<|>RELATION_NOE 引<|>RELATION_NOE 流管<|>RELATION_NOE 状态<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 应<|>RELATION_NOE 适时<|>RELATION_NOE 监测<|>RELATION_NOE 患者<|>RELATION_NOE 血<|>RELATION_NOE 氧饱<|>RELATION_NOE 和<|>RELATION_NOE 度<|>RELATION_NOE ,<|>RELATION_NOE 如<|>RELATION_NOE 有<|>RELATION_NOE 异常<|>RELATION_NOE 立即<|>RELATION_NOE 处理<|>RELATION_NOE 。<|>RELATION_NOE
术<|>RELATION_NOE 前<|>RELATION_NOE 呼吸<|>RELATION_NOE 指导<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 耐受性<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 肺功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
选择<|>RELATION_NOE 本院<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 10月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 11月<|>RELATION_NOE 接诊<|>RELATION_NOE 的<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病例<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 观察组<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 了<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 呼吸<|>RELATION_NOE 指导<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 对照组<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 了<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 手术<|>RELATION_NOE 耐受性<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 肺功能<|>RELATION_NOE 变化<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
护理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 收缩<|>RELATION_NOE 压<|>RELATION_NOE 等<|>RELATION_NOE 指标<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 了<|>RELATION_NOE 明显<|>RELATION_B 改善<|>RELATION_E ,<|>RELATION_NOE 组间<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 术后<|>RELATION_NOE 肺功能<|>RELATION_NOE 指标<|>RELATION_NOE MVV<|>RELATION_NOE 、<|>RELATION_NOE FVC<|>RELATION_NOE 、<|>RELATION_NOE FEV1<|>RELATION_NOE 护理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 心率<|>RELATION_NOE 、<|>RELATION_NOE 收缩<|>RELATION_NOE 压<|>RELATION_NOE 等<|>RELATION_NOE 指标<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 了<|>RELATION_NOE 明显<|>RELATION_NOE 改善<|>RELATION_NOE ,<|>RELATION_NOE 组间<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 术后<|>RELATION_NOE 肺功能<|>RELATION_NOE 指标<|>RELATION_NOE MVV<|>RELATION_NOE 、<|>RELATION_NOE FVC<|>RELATION_NOE 、<|>RELATION_NOE FEV1<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 出现<|>RELATION_NOE 了<|>RELATION_NOE 明显<|>RELATION_B 提高<|>RELATION_E ,<|>RELATION_NOE 组间<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
基于<|>RELATION_NOE 广东省<|>RELATION_NOE 人群<|>RELATION_NOE 调查<|>RELATION_NOE 的<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 严重度<|>RELATION_B 分布<|>RELATION_I 构成<|>RELATION_I 及其<|>RELATION_I 生活<|>RELATION_I 质量<|>RELATION_I 状况<|>RELATION_E
入选<|>RELATION_NOE 的<|>RELATION_NOE 人群<|>RELATION_NOE 都<|>RELATION_NOE 进行<|>RELATION_NOE 问卷调查<|>RELATION_NOE 和<|>RELATION_NOE 肺功能<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张<|>RELATION_NOE 试验<|>RELATION_NOE 后<|>RELATION_NOE 1秒率<|>RELATION_NOE (<|>RELATION_NOE FEV1<|>RELATION_NOE /<|>RELATION_NOE FVC<|>RELATION_NOE )<|>RELATION_NOE <<|>RELATION_NOE 0.70<|>RELATION_NOE 者<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE COPD<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 药敏<|>RELATION_NOE 与<|>RELATION_NOE 耐药<|>RELATION_NOE 基因<|>RELATION_NOE MRP1<|>RELATION_NOE 、<|>RELATION_NOE P-gp<|>RELATION_NOE 、<|>RELATION_NOE GST-<|>RELATION_NOE π<|>RELATION_NOE 和<|>RELATION_NOE Topo<|>RELATION_NOE Ⅱ<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_B 研究<|>RELATION_E
药物<|>RELATION_NOE 敏感<|>RELATION_NOE 试验<|>RELATION_NOE 采用<|>RELATION_S MTT<|>RELATION_NOE 比色法<|>RELATION_NOE ,<|>RELATION_NOE MRP1<|>RELATION_NOE 、<|>RELATION_NOE P-gp<|>RELATION_NOE 、<|>RELATION_NOE GST-<|>RELATION_NOE π<|>RELATION_NOE 及<|>RELATION_NOE Topo<|>RELATION_NOE Ⅱ<|>RELATION_NOE 药物<|>RELATION_NOE 敏感<|>RELATION_NOE 试验<|>RELATION_NOE 采用<|>RELATION_NOE MTT<|>RELATION_NOE 比色法<|>RELATION_NOE ,<|>RELATION_NOE MRP1<|>RELATION_NOE 、<|>RELATION_NOE P-gp<|>RELATION_NOE 、<|>RELATION_NOE GST-<|>RELATION_NOE π<|>RELATION_NOE 及<|>RELATION_NOE Topo<|>RELATION_NOE Ⅱ<|>RELATION_NOE 采用<|>RELATION_S 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 检测<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 四<|>RELATION_NOE 种<|>RELATION_NOE 因子<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 无<|>RELATION_B 显著性<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE P-gp<|>RELATION_NOE 、<|>RELATION_NOE GST-<|>RELATION_NOE π<|>RELATION_NOE 在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 或<|>RELATION_NOE 腺癌<|>RELATION_NOE 中<|>RELATION_NOE 与<|>RELATION_NOE 在<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 有<|>RELATION_NOE 明显<|>RELATION_NOE 差异<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE 在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 和<|>RELATION_NOE 腺癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 四<|>RELATION_NOE 种<|>RELATION_NOE 因子<|>RELATION_NOE 其<|>RELATION_NOE 表达<|>RELATION_NOE 无<|>RELATION_NOE 显著性<|>RELATION_NOE 差异<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE P-gp<|>RELATION_NOE 、<|>RELATION_NOE GST-<|>RELATION_NOE π<|>RELATION_NOE 在<|>RELATION_NOE 鳞癌<|>RELATION_NOE 或<|>RELATION_NOE 腺癌<|>RELATION_NOE 中<|>RELATION_NOE 与<|>RELATION_NOE 在<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 有<|>RELATION_B 明显<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
UGT1A1<|>RELATION_NOE *<|>RELATION_NOE 28<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 在<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_S
收集<|>RELATION_NOE 中南<|>RELATION_NOE 大学<|>RELATION_NOE 湘雅<|>RELATION_NOE 医院<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 中国<|>RELATION_NOE 人<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 33<|>RELATION_NOE 名<|>RELATION_NOE 中国<|>RELATION_NOE 正常人<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 抽提<|>RELATION_NOE 基因组<|>RELATION_NOE DNA<|>RELATION_NOE ,<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 扩增<|>RELATION_NOE 目的<|>RELATION_NOE :<|>RELATION_NOE 基因<|>RELATION_NOE 片段<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 标记<|>RELATION_NOE 测序法<|>RELATION_NOE 测定<|>RELATION_S UGT1A1<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子区<|>RELATION_NOE TATA<|>RELATION_NOE 盒<|>RELATION_NOE 胸腺嘧啶<|>RELATION_NOE -<|>RELATION_NOE 腺嘌呤<|>RELATION_NOE (<|>RELATION_NOE TA<|>RELATION_NOE )<|>RELATION_NOE 序列<|>RELATION_NOE 重复<|>RELATION_NOE 次数<|>RELATION_NOE ,<|>RELATION_NOE 统计<|>RELATION_NOE 中国<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 和<|>RELATION_NOE 正常<|>RELATION_NOE 人中<|>RELATION_NOE UGT1A1<|>RELATION_NOE *<|>RELATION_NOE 28<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 分布<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE D-<|>RELATION_NOE 二聚体<|>RELATION_NOE 、<|>RELATION_NOE 纤维蛋白原<|>RELATION_NOE 水平<|>RELATION_NOE 分析<|>RELATION_S
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血浆<|>RELATION_NOE D-<|>RELATION_NOE 二聚体<|>RELATION_NOE (<|>RELATION_NOE D-dimer<|>RELATION_NOE ,<|>RELATION_NOE D-D<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 纤维蛋白原<|>RELATION_NOE (<|>RELATION_NOE fibrinogen<|>RELATION_NOE ,<|>RELATION_NOE FIB<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 高凝<|>RELATION_NOE 状态<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 特征<|>RELATION_E 。<|>RELATION_NOE
病理<|>RELATION_NOE 分型<|>RELATION_NOE 分组<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 组<|>RELATION_NOE D-D<|>RELATION_NOE 水平<|>RELATION_NOE 较<|>RELATION_NOE 鳞<|>RELATION_NOE 癌组<|>RELATION_NOE 、<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 组<|>RELATION_NOE 明显<|>RELATION_B 升高<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 鳞<|>RELATION_NOE 癌组<|>RELATION_NOE FIB<|>RELATION_NOE 水平<|>RELATION_NOE 较<|>RELATION_NOE 腺癌<|>RELATION_NOE 组高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE 病理<|>RELATION_NOE 分型<|>RELATION_NOE 分组<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 组<|>RELATION_NOE D-D<|>RELATION_NOE 水平<|>RELATION_NOE 较<|>RELATION_NOE 鳞<|>RELATION_NOE 癌组<|>RELATION_NOE 、<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 组<|>RELATION_NOE 明显<|>RELATION_NOE 升高<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 鳞<|>RELATION_NOE 癌组<|>RELATION_NOE FIB<|>RELATION_NOE 水平<|>RELATION_NOE 较腺<|>RELATION_NOE 癌组<|>RELATION_NOE 高<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
在<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE ^<|>RELATION_NOE 18F-FDG<|>RELATION_NOE PET<|>RELATION_NOE /<|>RELATION_NOE CT<|>RELATION_NOE 的<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 标准化<|>RELATION_NOE 摄取值<|>RELATION_NOE (<|>RELATION_NOE SUVmax<|>RELATION_NOE )<|>RELATION_NOE 已<|>RELATION_NOE 被<|>RELATION_NOE 证实<|>RELATION_NOE 是<|>RELATION_NOE 独立<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 因子<|>RELATION_NOE ,<|>RELATION_NOE 本<|>RELATION_NOE 研究<|>RELATION_NOE 旨在<|>RELATION_NOE 探讨<|>RELATION_NOE SUVmax<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_B 患者<|>RELATION_I 术后<|>RELATION_I 复发<|>RELATION_E 的<|>RELATION_NOE 预测<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
肺纤维化<|>RELATION_NOE 合并<|>RELATION_NOE 肺气肿<|>RELATION_NOE 综合征<|>RELATION_NOE 7例<|>RELATION_NOE 并<|>RELATION_NOE 文献<|>RELATION_B 复习<|>RELATION_E
分析<|>RELATION_NOE 、<|>RELATION_NOE 总结<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 合并<|>RELATION_NOE 肺气肿<|>RELATION_NOE (<|>RELATION_NOE CPFE<|>RELATION_NOE )<|>RELATION_NOE 综合征<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 一般<|>RELATION_NOE 资料<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 体征<|>RELATION_NOE 、<|>RELATION_NOE 肺功能<|>RELATION_NOE 、<|>RELATION_NOE 肺动脉<|>RELATION_NOE 压力<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 标志<|>RELATION_NOE 物<|>RELATION_NOE 、<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 等<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 我院<|>RELATION_NOE 2010-2012<|>RELATION_NOE 年<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 7例<|>RELATION_NOE CPFE<|>RELATION_NOE 综合征<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 一般<|>RELATION_NOE 资料<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 体征<|>RELATION_NOE 、<|>RELATION_NOE 肺功能<|>RELATION_NOE 、<|>RELATION_NOE 肺动脉<|>RELATION_NOE 压力<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 标志物<|>RELATION_NOE 及<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 文献<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 、<|>RELATION_NOE 归纳<|>RELATION_NOE 、<|>RELATION_NOE 总结<|>RELATION_NOE 。<|>RELATION_NOE
肺功能<|>RELATION_NOE 结果<|>RELATION_NOE [<|>RELATION_NOE 中<|>RELATION_NOE 位数<|>RELATION_NOE (<|>RELATION_NOE 范围<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE :<|>RELATION_NOE FEV1<|>RELATION_NOE %<|>RELATION_NOE pred<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE 73%<|>RELATION_NOE (<|>RELATION_NOE 39%<|>RELATION_NOE －9<|>RELATION_NOE 8%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE FVC<|>RELATION_NOE %<|>RELATION_NOE pred<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE 73%<|>RELATION_NOE (<|>RELATION_NOE 54%<|>RELATION_NOE －<|>RELATION_NOE 101%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE FEV1<|>RELATION_NOE /<|>RELATION_NOE FVC<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE 81%<|>RELATION_NOE (<|>RELATION_NOE 61%<|>RELATION_NOE －<|>RELATION_NOE 96%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺活量%<|>RELATION_NOE pred<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE 79%<|>RELATION_NOE (<|>RELATION_NOE 57%<|>RELATION_NOE －<|>RELATION_NOE 86%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 肺总量%<|>RELATION_NOE pred<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE 85%<|>RELATION_NOE (<|>RELATION_NOE 53%<|>RELATION_NOE －1<|>RELATION_NOE 10%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 残气量<|>RELATION_NOE /<|>RELATION_NOE 肺总量<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE 41%<|>RELATION_NOE (<|>RELATION_NOE 21%<|>RELATION_NOE －<|>RELATION_NOE 58%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE DLCO<|>RELATION_NOE %<|>RELATION_NOE pred<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE 46%<|>RELATION_NOE (<|>RELATION_NOE 20%<|>RELATION_NOE －<|>RELATION_NOE 58%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE DLCO<|>RELATION_NOE /<|>RELATION_NOE 肺泡<|>RELATION_NOE 气量<|>RELATION_NOE 平均<|>RELATION_NOE 为<|>RELATION_NOE 53%<|>RELATION_NOE (<|>RELATION_NOE 19%<|>RELATION_NOE －9<|>RELATION_NOE 8%<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
肺癌<|>RELATION_NOE 标志物<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_NOE 2例<|>RELATION_NOE 出现<|>RELATION_NOE 神经元<|>RELATION_NOE 特异性<|>RELATION_NOE 烯醇化酶<|>RELATION_NOE 升高.<|>RELATION_NOE
胸部<|>RELATION_NOE CT<|>RELATION_NOE 可见<|>RELATION_S 双<|>RELATION_NOE 上<|>RELATION_NOE 肺<|>RELATION_NOE 肺气肿<|>RELATION_NOE 及<|>RELATION_NOE 双<|>RELATION_NOE 下<|>RELATION_NOE 肺磨<|>RELATION_NOE 玻璃样<|>RELATION_NOE 、<|>RELATION_NOE 网格状<|>RELATION_NOE 、<|>RELATION_NOE 蜂窝样<|>RELATION_NOE 及<|>RELATION_NOE 牵拉性<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张<|>RELATION_NOE 的<|>RELATION_NOE 肺纤维化<|>RELATION_NOE 表现<|>RELATION_NOE 。<|>RELATION_NOE
临床<|>RELATION_NOE 特征<|>RELATION_NOE 包括<|>RELATION_S 呼吸困难<|>RELATION_NOE 、<|>RELATION_NOE 低氧血症<|>RELATION_NOE 、<|>RELATION_NOE 肺动脉高压<|>RELATION_NOE .<|>RELATION_NOE
中国<|>RELATION_NOE 城市<|>RELATION_NOE 地区<|>RELATION_NOE 成年人<|>RELATION_NOE 二手<|>RELATION_NOE 烟暴露<|>RELATION_NOE 水平<|>RELATION_NOE 及<|>RELATION_NOE 相关<|>RELATION_NOE 知识<|>RELATION_NOE 和<|>RELATION_NOE 态度<|>RELATION_NOE 调查<|>RELATION_S
利用<|>RELATION_NOE 全球<|>RELATION_NOE 成人<|>RELATION_NOE 烟草<|>RELATION_NOE 调查<|>RELATION_NOE 中国<|>RELATION_NOE 调查<|>RELATION_NOE (<|>RELATION_NOE GATS<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 国际<|>RELATION_NOE 烟草<|>RELATION_NOE 控制<|>RELATION_NOE 政策<|>RELATION_NOE 评估<|>RELATION_NOE 项目<|>RELATION_NOE 中国<|>RELATION_NOE 调查<|>RELATION_NOE (<|>RELATION_NOE ITC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 有关<|>RELATION_NOE 二手<|>RELATION_NOE 烟暴露<|>RELATION_NOE 、<|>RELATION_NOE 禁烟<|>RELATION_NOE 规定<|>RELATION_NOE 、<|>RELATION_NOE 二手<|>RELATION_NOE 烟相关<|>RELATION_NOE 知识<|>RELATION_NOE 态度<|>RELATION_NOE 的<|>RELATION_NOE 变量<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE SAS<|>RELATION_NOE 软件<|>RELATION_NOE 计算率<|>RELATION_NOE 及其<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 。<|>RELATION_NOE
2项<|>RELATION_NOE 调查<|>RELATION_NOE 中<|>RELATION_NOE 调查<|>RELATION_NOE 对象<|>RELATION_NOE 报告<|>RELATION_NOE 的<|>RELATION_NOE 工作<|>RELATION_NOE 场所<|>RELATION_NOE 室内<|>RELATION_NOE 全面<|>RELATION_NOE 禁<|>RELATION_NOE 烟<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 均<|>RELATION_B 低于<|>RELATION_E 40%<|>RELATION_NOE .<|>RELATION_NOE
GATS<|>RELATION_NOE 调查<|>RELATION_NOE 中<|>RELATION_NOE 60.6%<|>RELATION_NOE 的<|>RELATION_NOE 吸烟者<|>RELATION_NOE 和<|>RELATION_NOE 68.5%<|>RELATION_NOE 的<|>RELATION_NOE 非吸烟者<|>RELATION_NOE 知晓<|>RELATION_S 二<|>RELATION_NOE 手烟<|>RELATION_NOE 导致<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 只有<|>RELATION_NOE 三分之一<|>RELATION_NOE 的<|>RELATION_NOE 调查<|>RELATION_NOE 对象<|>RELATION_NOE GATS<|>RELATION_NOE 调查<|>RELATION_NOE 中<|>RELATION_NOE 60.6%<|>RELATION_NOE 的<|>RELATION_NOE 吸烟者<|>RELATION_NOE 和<|>RELATION_NOE 68.5%<|>RELATION_NOE 的<|>RELATION_NOE 非吸烟者<|>RELATION_NOE 知晓二<|>RELATION_NOE 手烟<|>RELATION_NOE 导致<|>RELATION_NOE 肺癌<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 只有<|>RELATION_NOE 三分之一<|>RELATION_NOE 的<|>RELATION_NOE 调查<|>RELATION_NOE 对象<|>RELATION_NOE 知晓<|>RELATION_S 二<|>RELATION_NOE 手烟<|>RELATION_NOE 导致<|>RELATION_NOE 成年人<|>RELATION_NOE 心脏病<|>RELATION_NOE .<|>RELATION_NOE
ITC<|>RELATION_NOE 调查<|>RELATION_NOE 对象<|>RELATION_NOE 对<|>RELATION_NOE 二手<|>RELATION_NOE 烟<|>RELATION_NOE 危害<|>RELATION_NOE 的<|>RELATION_NOE 知晓率<|>RELATION_NOE 高于<|>RELATION_S GATS<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 知晓二<|>RELATION_NOE 手烟<|>RELATION_NOE 导致<|>RELATION_NOE 成年人<|>RELATION_NOE 心脏病<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 仅<|>RELATION_NOE 有<|>RELATION_NOE 58.2%<|>RELATION_NOE .<|>RELATION_NOE
中国<|>RELATION_NOE 城市<|>RELATION_NOE 地区<|>RELATION_NOE 室内<|>RELATION_NOE 工作<|>RELATION_NOE 场所<|>RELATION_NOE 全面<|>RELATION_NOE 禁<|>RELATION_NOE 烟<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 较<|>RELATION_NOE 低<|>RELATION_NOE ,<|>RELATION_NOE 二手<|>RELATION_NOE 烟<|>RELATION_NOE 暴露<|>RELATION_NOE 情况<|>RELATION_NOE 严重<|>RELATION_NOE ,<|>RELATION_NOE 公众<|>RELATION_NOE 对<|>RELATION_NOE 二手<|>RELATION_NOE 烟<|>RELATION_NOE 危害<|>RELATION_NOE 的<|>RELATION_NOE 认识<|>RELATION_NOE 以及<|>RELATION_NOE 对<|>RELATION_NOE 工作<|>RELATION_NOE 场所<|>RELATION_NOE 全面<|>RELATION_NOE 禁烟<|>RELATION_NOE 的<|>RELATION_NOE 支持率<|>RELATION_NOE 有待<|>RELATION_NOE 提高<|>RELATION_NOE .<|>RELATION_NOE
白细胞介素<|>RELATION_NOE -27<|>RELATION_NOE 对<|>RELATION_NOE 结核性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
对<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 3月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 14年<|>RELATION_NOE 2月<|>RELATION_NOE 山东省<|>RELATION_NOE 立<|>RELATION_NOE 医院<|>RELATION_NOE 呼吸科<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 按照<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 性质<|>RELATION_NOE 分为<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE 结核组<|>RELATION_NOE :<|>RELATION_NOE 结核性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
包括<|>RELATION_NOE 肺癌<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 食管癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 原<|>RELATION_NOE 发<|>RELATION_NOE 部位<|>RELATION_NOE 不<|>RELATION_NOE 确定<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 4例.<|>RELATION_NOE
采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 检测<|>RELATION_S 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 和<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE IL-27<|>RELATION_NOE 浓度<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 统计学<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 受试者<|>RELATION_NOE 工作<|>RELATION_NOE 特征<|>RELATION_NOE (<|>RELATION_NOE ROC<|>RELATION_NOE )<|>RELATION_NOE 曲线<|>RELATION_NOE 判断<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 结核性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 左<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 第<|>RELATION_NOE 4L<|>RELATION_NOE 组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_S
收集<|>RELATION_NOE 我<|>RELATION_NOE 科<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 5月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 2月<|>RELATION_NOE 全腔镜<|>RELATION_NOE 下<|>RELATION_NOE 左侧<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 的<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 第<|>RELATION_NOE 4L<|>RELATION_NOE 组<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 及其<|>RELATION_NOE 转移<|>RELATION_NOE 规律<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 临床<|>RELATION_NOE 上<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 高选择性<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 寻找<|>RELATION_NOE 理论<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
资料<|>RELATION_NOE 和<|>RELATION_NOE 方法<|>RELATION_NOE :<|>RELATION_NOE 04<|>RELATION_NOE 例<|>RELATION_NOE 左侧<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 于<|>RELATION_NOE 我<|>RELATION_NOE 科行<|>RELATION_NOE 全腔镜<|>RELATION_NOE 下<|>RELATION_NOE 左侧<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
信号素<|>RELATION_NOE 3A<|>RELATION_NOE 和<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -14<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及<|>RELATION_NOE 意义<|>RELATION_NOE
检测<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 信号素<|>RELATION_NOE 3A<|>RELATION_NOE (<|>RELATION_NOE Semaphorin3A<|>RELATION_NOE 和<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -14<|>RELATION_NOE (<|>RELATION_NOE MMP-14<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 关系<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE Semaphorin3A<|>RELATION_NOE 及<|>RELATION_NOE MMP-14<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 判断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE 检测<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 信号素<|>RELATION_NOE 3A<|>RELATION_NOE (<|>RELATION_NOE Semaphorin3A<|>RELATION_NOE 和<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -14<|>RELATION_NOE (<|>RELATION_NOE MMP-14<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE Semaphorin3A<|>RELATION_NOE 及<|>RELATION_NOE MMP-14<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 判断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
94<|>RELATION_NOE 例非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 术后<|>RELATION_NOE 留取<|>RELATION_NOE 的<|>RELATION_NOE 蜡块<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE 作为<|>RELATION_NOE 观察组<|>RELATION_NOE ,<|>RELATION_NOE 选择<|>RELATION_NOE 80<|>RELATION_NOE 例<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S 二<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE Semaphorin3A<|>RELATION_NOE 和<|>RELATION_NOE MMP-14<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 肿瘤<|>RELATION_NOE 中<|>RELATION_NOE Semaphorin3A<|>RELATION_NOE 及<|>RELATION_NOE MMP-14<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 中<|>RELATION_NOE Semaphorin3A<|>RELATION_NOE 及<|>RELATION_NOE MMP-14<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 阳性率<|>RELATION_NOE 均<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 胸膜<|>RELATION_NOE 侵犯<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 个数<|>RELATION_NOE 、<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 脉管<|>RELATION_NOE 浸润<|>RELATION_NOE 及<|>RELATION_NOE PCNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 密切<|>RELATION_B 相关<|>RELATION_E ;<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE Semaphorin3A<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE MMP-14<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 时<|>RELATION_NOE 促进<|>RELATION_S 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 和<|>RELATION_NOE 进展<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 可能<|>RELATION_NOE 具有<|>RELATION_NOE 负<|>RELATION_NOE 向<|>RELATION_NOE 协同<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE Semaphorin3A<|>RELATION_NOE 及<|>RELATION_NOE MMP-14<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 判断<|>RELATION_NOE 预后<|>RELATION_NOE 有<|>RELATION_NOE 一定<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE Semaphorin3A<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 、<|>RELATION_NOE MMP-14<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 时<|>RELATION_NOE 促进<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 和<|>RELATION_NOE 进展<|>RELATION_NOE ,<|>RELATION_NOE 二者<|>RELATION_NOE 可能<|>RELATION_NOE 具有<|>RELATION_NOE 负<|>RELATION_NOE 向<|>RELATION_NOE 协同<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE Semaphorin3A<|>RELATION_NOE 及<|>RELATION_NOE MMP-14<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 判断<|>RELATION_B 预后<|>RELATION_E 有<|>RELATION_NOE 一定<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 在<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_B 趋势<|>RELATION_E
检测<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 突变<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 初步<|>RELATION_NOE 探讨<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_B 特征<|>RELATION_E 。<|>RELATION_NOE
收集<|>RELATION_NOE 272<|>RELATION_NOE 例<|>RELATION_NOE 术后<|>RELATION_NOE 病理<|>RELATION_NOE 为<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 提取<|>RELATION_NOE DNA<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE ARMS<|>RELATION_NOE 法<|>RELATION_NOE 对<|>RELATION_NOE EGFR<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 第18<|>RELATION_NOE 、<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 20<|>RELATION_NOE 及<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 片段<|>RELATION_NOE 进行<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 阳性<|>RELATION_NOE 质控<|>RELATION_NOE 、<|>RELATION_NOE 阴性<|>RELATION_NOE 质控<|>RELATION_NOE 和<|>RELATION_NOE DNA<|>RELATION_NOE 质控<|>RELATION_NOE 对<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 类型<|>RELATION_NOE 分析<|>RELATION_NOE 判断<|>RELATION_NOE 。<|>RELATION_NOE
27<|>RELATION_NOE 2例Ⅰ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 154<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 56.6<|>RELATION_NOE 2%<|>RELATION_NOE )<|>RELATION_NOE 存在<|>RELATION_B EGFR<|>RELATION_I 的<|>RELATION_I 体细胞<|>RELATION_I 突变<|>RELATION_E 。<|>RELATION_NOE
其中<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 1.3%<|>RELATION_NOE )<|>RELATION_NOE 18<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 上<|>RELATION_NOE 发生<|>RELATION_NOE 替代<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE G719S<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 34.4%<|>RELATION_NOE )<|>RELATION_NOE 19<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 上<|>RELATION_NOE 发生<|>RELATION_NOE 缺<|>RELATION_NOE 失<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 19-del<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 6例<|>RELATION_NOE (<|>RELATION_NOE 3.9%<|>RELATION_NOE )<|>RELATION_NOE 20<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 上<|>RELATION_NOE 发生<|>RELATION_NOE 插入突变<|>RELATION_NOE (<|>RELATION_NOE 20-ins<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 97<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 63.9%<|>RELATION_NOE )<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE 上<|>RELATION_NOE 发生<|>RELATION_NOE 替代<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE L858R<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
21<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 敏药<|>RELATION_NOE 突变<|>RELATION_NOE )<|>RELATION_NOE 合并<|>RELATION_NOE 20<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 突变<|>RELATION_NOE )<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 4/11<|>RELATION_NOE ,<|>RELATION_NOE 36.3%<|>RELATION_NOE )<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 19<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 敏药<|>RELATION_NOE 突变<|>RELATION_NOE )<|>RELATION_NOE 合并<|>RELATION_NOE 20<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 突变<|>RELATION_NOE )<|>RELATION_NOE 率<|>RELATION_NOE (<|>RELATION_NOE 1/11<|>RELATION_NOE ,<|>RELATION_NOE 9.1%<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE ;<|>RELATION_NOE
Ⅰ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 突变率<|>RELATION_NOE 56.6<|>RELATION_NOE 2%<|>RELATION_NOE ,<|>RELATION_NOE 肺腺<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 提示<|>RELATION_S 突变<|>RELATION_NOE 的<|>RELATION_NOE 高发性<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 多<|>RELATION_NOE 集中<|>RELATION_NOE 在<|>RELATION_NOE 19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE ,<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 比<|>RELATION_NOE 19<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 更<|>RELATION_NOE 易<|>RELATION_NOE 合并<|>RELATION_NOE 20<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 突变<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE Ⅰ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 突变率<|>RELATION_NOE 56.6<|>RELATION_NOE 2%<|>RELATION_NOE ,<|>RELATION_NOE 肺腺<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 提示<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 高发性<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 多<|>RELATION_B 集中<|>RELATION_E 在<|>RELATION_NOE 19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE ,<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 比<|>RELATION_NOE 19<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 更<|>RELATION_NOE 易<|>RELATION_NOE 合并<|>RELATION_NOE 20<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 突变<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE Ⅰ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE EGFR<|>RELATION_NOE 突变率<|>RELATION_NOE 56.6<|>RELATION_NOE 2%<|>RELATION_NOE ,<|>RELATION_NOE 肺腺<|>RELATION_NOE 鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 腺癌<|>RELATION_NOE 提示<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 高发性<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 多<|>RELATION_NOE 集中<|>RELATION_NOE 在<|>RELATION_NOE 19<|>RELATION_NOE 和<|>RELATION_NOE 21<|>RELATION_NOE 号<|>RELATION_NOE 外显子<|>RELATION_NOE ,<|>RELATION_NOE 21<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE 比<|>RELATION_B 19<|>RELATION_I 外显子<|>RELATION_I 突变<|>RELATION_E 更<|>RELATION_NOE 易<|>RELATION_NOE 合并<|>RELATION_NOE 20<|>RELATION_NOE 外显子<|>RELATION_NOE 突变<|>RELATION_NOE (<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 突变<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
局限<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 外科<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_S
对于<|>RELATION_NOE 局限<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 首选<|>RELATION_B 的<|>RELATION_I 初始<|>RELATION_I 治疗<|>RELATION_E 应<|>RELATION_NOE 推荐<|>RELATION_NOE 肺叶<|>RELATION_NOE 或<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 建议<|>RELATION_NOE 常规<|>RELATION_NOE 行<|>RELATION_NOE 辅助性<|>RELATION_NOE 化放疗<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术中<|>RELATION_NOE 肺动<|>RELATION_NOE 、<|>RELATION_NOE 静脉<|>RELATION_NOE 切断<|>RELATION_NOE 顺序<|>RELATION_NOE 对<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
根据<|>RELATION_NOE 血管<|>RELATION_NOE 处理<|>RELATION_NOE 顺序<|>RELATION_NOE 分为<|>RELATION_NOE 先<|>RELATION_NOE 断<|>RELATION_NOE 静脉组<|>RELATION_NOE (<|>RELATION_NOE Group<|>RELATION_NOE V<|>RELATION_NOE )<|>RELATION_NOE 152<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 先断<|>RELATION_NOE 动脉组<|>RELATION_NOE (<|>RELATION_NOE Group<|>RELATION_NOE A<|>RELATION_NOE )<|>RELATION_NOE 76<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 动脉<|>RELATION_NOE -<|>RELATION_NOE 静脉<|>RELATION_NOE -<|>RELATION_NOE 动脉<|>RELATION_NOE 混合<|>RELATION_NOE 离断组<|>RELATION_NOE (<|>RELATION_NOE Group<|>RELATION_NOE M<|>RELATION_NOE )<|>RELATION_NOE 49<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 方式<|>RELATION_NOE 相似<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 以<|>RELATION_B 远处<|>RELATION_I 转移<|>RELATION_I 为主<|>RELATION_E ;<|>RELATION_NOE
血管<|>RELATION_NOE 处理<|>RELATION_NOE 顺序<|>RELATION_NOE 不<|>RELATION_B 影响<|>RELATION_E 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 生存<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 根据<|>RELATION_NOE 术中<|>RELATION_NOE 需要<|>RELATION_NOE 合理<|>RELATION_NOE 选择<|>RELATION_NOE 。<|>RELATION_NOE
双源<|>RELATION_NOE CT<|>RELATION_NOE 定量<|>RELATION_NOE 容积<|>RELATION_NOE 成像<|>RELATION_NOE 技术<|>RELATION_NOE 预测<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 肺功能<|>RELATION_NOE 改变<|>RELATION_NOE 的<|>RELATION_NOE 前瞻性研究<|>RELATION_NOE
选择<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 6月<|>RELATION_NOE 住院<|>RELATION_NOE 行单<|>RELATION_NOE 操作孔<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺叶<|>RELATION_NOE 或<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 233<|>RELATION_NOE 例<|>RELATION_NOE 进行<|>RELATION_NOE 前瞻性研究<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男性<|>RELATION_NOE 121<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 112<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE 53<|>RELATION_NOE ±<|>RELATION_NOE 16<|>RELATION_NOE )<|>RELATION_NOE 岁.<|>RELATION_NOE
CT<|>RELATION_NOE 容积<|>RELATION_NOE 扫描<|>RELATION_NOE 所得<|>RELATION_NOE 数据<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 前<|>RELATION_NOE 常规<|>RELATION_NOE 肺功能<|>RELATION_NOE 指标<|>RELATION_NOE 肺总量<|>RELATION_NOE 、<|>RELATION_NOE 用力肺活量<|>RELATION_NOE (<|>RELATION_NOE FVC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 第一<|>RELATION_NOE 秒<|>RELATION_NOE 用力呼气量<|>RELATION_NOE (<|>RELATION_NOE FEV1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 残气量<|>RELATION_NOE 、<|>RELATION_NOE FEV1<|>RELATION_NOE /<|>RELATION_NOE FVC<|>RELATION_NOE 之间<|>RELATION_NOE 相关<|>RELATION_NOE 系数<|>RELATION_NOE 最高<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.92<|>RELATION_NOE 、<|>RELATION_NOE 0.76<|>RELATION_NOE 、<|>RELATION_NOE 0.70<|>RELATION_NOE 、<|>RELATION_NOE 0.85<|>RELATION_NOE 、<|>RELATION_NOE 0.53<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.14<|>RELATION_NOE 、<|>RELATION_NOE 3.05<|>RELATION_NOE 、<|>RELATION_NOE 2.86<|>RELATION_NOE 、<|>RELATION_NOE 3.09<|>RELATION_NOE 、<|>RELATION_NOE 2.68<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 术后<|>RELATION_NOE 实测<|>RELATION_NOE 指标<|>RELATION_NOE 最高<|>RELATION_NOE 相关<|>RELATION_NOE 系数<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.87<|>RELATION_NOE 、<|>RELATION_NOE 0.68<|>RELATION_NOE 、<|>RELATION_NOE 0.75<|>RELATION_NOE 、<|>RELATION_NOE 0.81<|>RELATION_NOE 、<|>RELATION_NOE -0.64<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 3.<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 2.85<|>RELATION_NOE 、<|>RELATION_NOE 3.05<|>RELATION_NOE 、<|>RELATION_NOE 3.02<|>RELATION_NOE 、<|>RELATION_NOE 2.79<|>RELATION_NOE ;<|>RELATION_NOE
盐酸<|>RELATION_NOE 氨溴索<|>RELATION_NOE 在<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 吸烟<|>RELATION_NOE 患者<|>RELATION_NOE 围术期<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
观察<|>RELATION_NOE 术前<|>RELATION_NOE 应用<|>RELATION_NOE 盐酸<|>RELATION_NOE 氨溴索<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_B 肺癌<|>RELATION_I 吸烟<|>RELATION_I 患者<|>RELATION_I 围术期<|>RELATION_I 肺保护<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 220<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 长期<|>RELATION_NOE 吸烟<|>RELATION_NOE 且<|>RELATION_NOE 需<|>RELATION_NOE 开<|>RELATION_NOE 胸行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 于<|>RELATION_NOE 术前<|>RELATION_NOE 5d<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 开始<|>RELATION_NOE 给予<|>RELATION_NOE 盐酸<|>RELATION_NOE 氨溴索<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 咳痰<|>RELATION_NOE 难<|>RELATION_NOE 易<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 痰液<|>RELATION_NOE 性质<|>RELATION_NOE 、<|>RELATION_NOE 抗生素<|>RELATION_NOE 应用<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 发生<|>RELATION_NOE 肺部<|>RELATION_NOE 并发症<|>RELATION_NOE 和<|>RELATION_NOE 药物<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
术后<|>RELATION_NOE 试验组<|>RELATION_NOE 患者<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 和<|>RELATION_NOE 肺不张<|>RELATION_NOE 发生率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 19.6%<|>RELATION_NOE (<|>RELATION_NOE 22<|>RELATION_NOE /<|>RELATION_NOE 112<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 6.3%<|>RELATION_NOE (<|>RELATION_NOE 7/1<|>RELATION_NOE 12<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE 33.3%<|>RELATION_NOE (<|>RELATION_NOE 36<|>RELATION_NOE /<|>RELATION_NOE 108<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 16.7%<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE /<|>RELATION_NOE 108<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 5.31<|>RELATION_NOE 、<|>RELATION_NOE 5.92<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 21<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 三维<|>RELATION_B 适形<|>RELATION_I 放疗<|>RELATION_I 所<|>RELATION_I 致<|>RELATION_I 放射性<|>RELATION_I 食管炎<|>RELATION_E 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE
观察<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 三维<|>RELATION_B 适形<|>RELATION_I 放疗<|>RELATION_I 所<|>RELATION_I 致<|>RELATION_I 放射性<|>RELATION_I 食管炎<|>RELATION_E 的<|>RELATION_NOE 相关<|>RELATION_NOE 影响<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2001年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2008年<|>RELATION_NOE 12月<|>RELATION_NOE 期间<|>RELATION_NOE 接受<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 203<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男性<|>RELATION_NOE 163<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 中<|>RELATION_NOE 位<|>RELATION_NOE 年龄<|>RELATION_NOE 63<|>RELATION_NOE 岁<|>RELATION_NOE ;<|>RELATION_NOE
急性<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 采用<|>RELATION_NOE 美国<|>RELATION_NOE 肿瘤<|>RELATION_NOE 放射<|>RELATION_NOE 治疗<|>RELATION_NOE 协作组<|>RELATION_NOE (<|>RELATION_NOE RTOG<|>RELATION_NOE )<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 剂量<|>RELATION_NOE 体积<|>RELATION_NOE 直方图<|>RELATION_NOE (<|>RELATION_NOE DVH<|>RELATION_NOE )<|>RELATION_NOE 评估<|>RELATION_NOE 物理<|>RELATION_NOE 参数<|>RELATION_NOE 。<|>RELATION_NOE
203<|>RELATION_NOE 例<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 发生<|>RELATION_NOE 1级<|>RELATION_NOE 急性<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎者<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 2级<|>RELATION_NOE 37<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 3级<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE ≥<|>RELATION_NOE 2级<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 20.2%<|>RELATION_NOE (<|>RELATION_NOE 41<|>RELATION_NOE /<|>RELATION_NOE 203<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 与否<|>RELATION_NOE 、<|>RELATION_NOE T<|>RELATION_NOE 、<|>RELATION_NOE N<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 放疗<|>RELATION_NOE 剂量<|>RELATION_NOE 、<|>RELATION_NOE 分割<|>RELATION_NOE 方式<|>RELATION_NOE 、<|>RELATION_NOE GTV<|>RELATION_NOE 平均<|>RELATION_NOE 剂量<|>RELATION_NOE 、<|>RELATION_NOE LETT55<|>RELATION_NOE 、<|>RELATION_NOE LETT60<|>RELATION_NOE 与<|>RELATION_NOE ≥<|>RELATION_NOE 2级<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 相关<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE -0.106<|>RELATION_NOE －0.1<|>RELATION_NOE 22<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 以上<|>RELATION_NOE 所有<|>RELATION_NOE 因素<|>RELATION_NOE 进行<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 结果<|>RELATION_NOE 仅<|>RELATION_NOE 化疗<|>RELATION_NOE 和<|>RELATION_NOE 食管<|>RELATION_NOE V45<|>RELATION_NOE 是<|>RELATION_NOE ≥<|>RELATION_B 2级<|>RELATION_I 放射性<|>RELATION_I 食管炎<|>RELATION_I 发生<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE (<|>RELATION_NOE Wald<|>RELATION_NOE =<|>RELATION_NOE 4.6<|>RELATION_NOE 26<|>RELATION_NOE 和<|>RELATION_NOE 9.8<|>RELATION_NOE 82<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 明显<|>RELATION_B 增加<|>RELATION_E 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE ;<|>RELATION_NOE
DVH<|>RELATION_NOE 中<|>RELATION_NOE 物理学<|>RELATION_NOE 参数<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 预测<|>RELATION_B 和<|>RELATION_I 评价<|>RELATION_E 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 食管<|>RELATION_NOE V45<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 最<|>RELATION_NOE 有<|>RELATION_NOE 价值<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE DVH<|>RELATION_NOE 中<|>RELATION_NOE 物理学<|>RELATION_NOE 参数<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_NOE 预测<|>RELATION_NOE 和<|>RELATION_NOE 评价<|>RELATION_NOE 放射性<|>RELATION_NOE 食管炎<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 食管<|>RELATION_NOE V45<|>RELATION_NOE 可能<|>RELATION_B 是<|>RELATION_E 最<|>RELATION_NOE 有<|>RELATION_NOE 价值<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_NOE 指标<|>RELATION_NOE 。<|>RELATION_NOE
隐匿型<|>RELATION_NOE 肺癌<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 胸片<|>RELATION_NOE 漏诊<|>RELATION_NOE 分析<|>RELATION_NOE 及<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
分析<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 胸片<|>RELATION_NOE 漏诊<|>RELATION_S 隐匿性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 评价<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 对<|>RELATION_NOE 隐匿性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE 分析<|>RELATION_NOE X<|>RELATION_NOE 线<|>RELATION_NOE 胸片<|>RELATION_NOE 漏诊<|>RELATION_NOE 隐匿性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 评价<|>RELATION_NOE CT<|>RELATION_NOE 扫描<|>RELATION_NOE 对<|>RELATION_NOE 隐匿性<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
CT<|>RELATION_NOE 扫描<|>RELATION_NOE 对<|>RELATION_NOE 支气管<|>RELATION_NOE 腔<|>RELATION_NOE 内<|>RELATION_NOE 、<|>RELATION_NOE 肺门区<|>RELATION_NOE 肿块<|>RELATION_NOE 及<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 肿大<|>RELATION_NOE 的<|>RELATION_NOE 显示<|>RELATION_NOE 情况<|>RELATION_NOE 优于<|>RELATION_S X<|>RELATION_NOE 线<|>RELATION_NOE 胸片<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
十<|>RELATION_NOE 全<|>RELATION_NOE 大<|>RELATION_NOE 补<|>RELATION_NOE 汤<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 应用<|>RELATION_B 于<|>RELATION_E 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 十<|>RELATION_NOE 全<|>RELATION_NOE 大<|>RELATION_NOE 补<|>RELATION_NOE 汤<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分成<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE (<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 1000<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 第1<|>RELATION_NOE 、<|>RELATION_NOE 8<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE ,<|>RELATION_NOE 顺铂<|>RELATION_NOE 60<|>RELATION_NOE mg<|>RELATION_NOE /<|>RELATION_NOE m3<|>RELATION_NOE 第1<|>RELATION_NOE 天<|>RELATION_NOE 静脉<|>RELATION_NOE 滴注<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 组予<|>RELATION_NOE 十<|>RELATION_NOE 全<|>RELATION_NOE 大<|>RELATION_NOE 补<|>RELATION_NOE 汤<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 至少<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
十<|>RELATION_NOE 全<|>RELATION_NOE 大<|>RELATION_NOE 补<|>RELATION_NOE 汤<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 可以<|>RELATION_NOE 增强<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 减<|>RELATION_NOE 毒<|>RELATION_NOE 增效<|>RELATION_NOE 及<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE 十<|>RELATION_NOE 全<|>RELATION_NOE 大<|>RELATION_NOE 补<|>RELATION_NOE 汤<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 可以<|>RELATION_NOE 增强<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 减<|>RELATION_NOE 毒<|>RELATION_NOE 增效<|>RELATION_NOE 及<|>RELATION_NOE 提高<|>RELATION_S 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 手术<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 效果<|>RELATION_NOE
将<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 依据<|>RELATION_NOE 抽签法<|>RELATION_NOE 分为<|>RELATION_NOE 实验组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 采用<|>RELATION_NOE 电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 传统<|>RELATION_NOE 肺癌<|>RELATION_NOE 根治术<|>RELATION_NOE 。<|>RELATION_NOE
实验组<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 引流量<|>RELATION_NOE 及<|>RELATION_NOE 引流<|>RELATION_NOE 时间<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2.7min<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 143<|>RELATION_NOE ±<|>RELATION_NOE 2.4<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 555<|>RELATION_NOE ±<|>RELATION_NOE 851<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 3.7<|>RELATION_NOE ±<|>RELATION_NOE 1.4<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 2.7<|>RELATION_NOE ±<|>RELATION_NOE 0.3<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 229<|>RELATION_NOE ±<|>RELATION_NOE 26<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 710<|>RELATION_NOE ±<|>RELATION_NOE 125<|>RELATION_NOE )<|>RELATION_NOE ml<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 4.6<|>RELATION_NOE ±<|>RELATION_NOE 1.1<|>RELATION_NOE )<|>RELATION_NOE min<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_B 组<|>RELATION_I 比较<|>RELATION_I 差异<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ﹤0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
实验组<|>RELATION_NOE 止痛药<|>RELATION_NOE 使用<|>RELATION_NOE 次数<|>RELATION_NOE 、<|>RELATION_NOE 胸腔<|>RELATION_NOE 引<|>RELATION_NOE 流量<|>RELATION_NOE 、<|>RELATION_NOE 引<|>RELATION_NOE 汉管<|>RELATION_NOE 拔<|>RELATION_NOE 出<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 住院时间<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 5.8<|>RELATION_NOE ±<|>RELATION_NOE 1.5<|>RELATION_NOE )<|>RELATION_NOE 次<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 4.4<|>RELATION_NOE ±<|>RELATION_NOE 1.5<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 83<|>RELATION_NOE ±<|>RELATION_NOE 1.4<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 9.4<|>RELATION_NOE ±<|>RELATION_NOE 1.6<|>RELATION_NOE )<|>RELATION_NOE 次<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 5.8<|>RELATION_NOE ±<|>RELATION_NOE 1.8<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 9.9<|>RELATION_NOE ±<|>RELATION_NOE 1.3<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 辅助<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 根治术<|>RELATION_E 中<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 疗效<|>RELATION_NOE 确切<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 出血<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 引流管<|>RELATION_NOE 保留<|>RELATION_NOE 时间<|>RELATION_NOE 短<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
健康<|>RELATION_NOE 教育<|>RELATION_NOE 对<|>RELATION_NOE 降低<|>RELATION_S PICC<|>RELATION_NOE 置管<|>RELATION_NOE 后<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
选取<|>RELATION_NOE 湖南省<|>RELATION_NOE 肿瘤<|>RELATION_NOE 医院<|>RELATION_NOE 胸部<|>RELATION_NOE 内<|>RELATION_NOE 二<|>RELATION_NOE 科<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 7月<|>RELATION_NOE 至<|>RELATION_NOE 12月<|>RELATION_NOE PICC<|>RELATION_NOE 置管<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 6月<|>RELATION_NOE PICC<|>RELATION_NOE 置管<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE 实验组<|>RELATION_NOE 。<|>RELATION_NOE
与<|>RELATION_NOE 对照组<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE PICC<|>RELATION_NOE 置管<|>RELATION_NOE 后<|>RELATION_NOE 感染<|>RELATION_NOE (<|>RELATION_NOE 1.9<|>RELATION_NOE 6%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 静脉炎<|>RELATION_NOE (<|>RELATION_NOE 1.9<|>RELATION_NOE 6%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血栓<|>RELATION_NOE (<|>RELATION_NOE 0%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 导管<|>RELATION_NOE 堵塞<|>RELATION_NOE (<|>RELATION_NOE 0%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 导管<|>RELATION_NOE 脱出<|>RELATION_NOE (<|>RELATION_NOE 1.9<|>RELATION_NOE 6%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 穿刺点<|>RELATION_NOE 出血<|>RELATION_NOE (<|>RELATION_NOE 血肿<|>RELATION_NOE )<|>RELATION_NOE (<|>RELATION_NOE 3.9<|>RELATION_NOE 2%<|>RELATION_NOE )<|>RELATION_NOE 等<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_B 降低<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
研究<|>RELATION_NOE 西妥昔<|>RELATION_NOE 单抗<|>RELATION_NOE 与<|>RELATION_NOE 盐酸埃克替尼<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 克服<|>RELATION_S 表皮<|>RELATION_NOE 生长因子<|>RELATION_NOE 受体<|>RELATION_NOE (<|>RELATION_NOE EGFR<|>RELATION_NOE )<|>RELATION_NOE T790M<|>RELATION_NOE 突变<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 继发性<|>RELATION_NOE 耐药<|>RELATION_NOE 的<|>RELATION_NOE 机制<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 临床<|>RELATION_NOE 合理<|>RELATION_NOE 应用<|>RELATION_NOE 提供<|>RELATION_NOE 依据<|>RELATION_NOE 。<|>RELATION_NOE
以<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 西妥昔<|>RELATION_NOE 单抗<|>RELATION_NOE 和<|>RELATION_NOE 盐酸埃克替尼<|>RELATION_NOE 单药<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 处理<|>RELATION_NOE EGFRT790M<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 细胞系<|>RELATION_NOE H1975<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 四<|>RELATION_NOE 甲<|>RELATION_NOE 基偶<|>RELATION_NOE 氮唑<|>RELATION_NOE 蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 和<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE .<|>RELATION_NOE
将<|>RELATION_NOE H1975<|>RELATION_NOE 细胞<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 裸鼠<|>RELATION_NOE ,<|>RELATION_NOE 建立<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 以西<|>RELATION_NOE 妥昔<|>RELATION_NOE 单抗<|>RELATION_NOE 和<|>RELATION_NOE 盐酸埃克替尼<|>RELATION_NOE 单药<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE 用<|>RELATION_NOE 药<|>RELATION_NOE 治疗<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_NOE 和<|>RELATION_NOE 组织<|>RELATION_NOE 形态<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE .<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 染色<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 小鼠<|>RELATION_NOE 抗人<|>RELATION_NOE 增殖<|>RELATION_NOE 细胞核<|>RELATION_NOE 抗原<|>RELATION_NOE (<|>RELATION_NOE PCNA<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE Ki-67<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE
裸鼠<|>RELATION_NOE 体内<|>RELATION_NOE 实验<|>RELATION_NOE 的<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 和<|>RELATION_NOE 盐酸埃克替尼组<|>RELATION_NOE 裸鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 体积<|>RELATION_NOE 均<|>RELATION_NOE 随<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 延长<|>RELATION_NOE 逐渐<|>RELATION_B 增大<|>RELATION_E ,<|>RELATION_NOE 至<|>RELATION_NOE 28d<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 移植<|>RELATION_NOE 瘤体积<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 61<|>RELATION_NOE 4.5<|>RELATION_NOE ±<|>RELATION_NOE 10.8<|>RELATION_NOE )<|>RELATION_NOE mm3<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 61<|>RELATION_NOE 1.2<|>RELATION_NOE ±<|>RELATION_NOE 8.7<|>RELATION_NOE )<|>RELATION_NOE mm3<|>RELATION_NOE ;<|>RELATION_NOE
而<|>RELATION_NOE 西妥昔<|>RELATION_NOE 单抗组<|>RELATION_NOE 和<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 体积<|>RELATION_NOE 随<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 延长<|>RELATION_NOE 逐渐<|>RELATION_B 缩小<|>RELATION_E ,<|>RELATION_NOE 至<|>RELATION_NOE 28d<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 移植<|>RELATION_NOE 瘤体积<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 30.8<|>RELATION_NOE ±<|>RELATION_NOE 2.0<|>RELATION_NOE )<|>RELATION_NOE mm3<|>RELATION_NOE 和<|>RELATION_NOE 0.<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE Ki-67<|>RELATION_NOE 和<|>RELATION_NOE PCNA<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE STAT3<|>RELATION_NOE 、<|>RELATION_NOE AKT<|>RELATION_NOE 和<|>RELATION_NOE MAPK<|>RELATION_NOE 的<|>RELATION_NOE 磷酸化<|>RELATION_NOE 水平<|>RELATION_NOE 下调<|>RELATION_NOE 。<|>RELATION_NOE 而<|>RELATION_NOE 西妥昔<|>RELATION_NOE 单抗组<|>RELATION_NOE 和<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 体积<|>RELATION_NOE 随<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 延长<|>RELATION_NOE 逐渐<|>RELATION_NOE 缩小<|>RELATION_NOE ,<|>RELATION_NOE 至<|>RELATION_NOE 28d<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 移植<|>RELATION_NOE 瘤体积<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 30.8<|>RELATION_NOE ±<|>RELATION_NOE 2.0<|>RELATION_NOE )<|>RELATION_NOE mm3<|>RELATION_NOE 和<|>RELATION_NOE 0.<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE 移植<|>RELATION_NOE 瘤组织<|>RELATION_NOE 中<|>RELATION_NOE Ki-67<|>RELATION_NOE 和<|>RELATION_NOE PCNA<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 下降<|>RELATION_E ,<|>RELATION_NOE EGFR<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE STAT3<|>RELATION_NOE 、<|>RELATION_NOE AKT<|>RELATION_NOE 和<|>RELATION_NOE MAPK<|>RELATION_NOE 的<|>RELATION_NOE 磷酸化<|>RELATION_NOE 水平<|>RELATION_NOE 下调<|>RELATION_NOE 。<|>RELATION_NOE 而<|>RELATION_NOE 西妥昔<|>RELATION_NOE 单抗组<|>RELATION_NOE 和<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 体积<|>RELATION_NOE 随<|>RELATION_NOE 时间<|>RELATION_NOE 的<|>RELATION_NOE 延长<|>RELATION_NOE 逐渐<|>RELATION_NOE 缩小<|>RELATION_NOE ,<|>RELATION_NOE 至<|>RELATION_NOE 28d<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 移植<|>RELATION_NOE 瘤体积<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 30.8<|>RELATION_NOE ±<|>RELATION_NOE 2.0<|>RELATION_NOE )<|>RELATION_NOE mm3<|>RELATION_NOE 和<|>RELATION_NOE 0.<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE Ki-67<|>RELATION_NOE 和<|>RELATION_NOE PCNA<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 下降<|>RELATION_NOE ,<|>RELATION_NOE EGFR<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE STAT3<|>RELATION_NOE 、<|>RELATION_NOE AKT<|>RELATION_NOE 和<|>RELATION_NOE MAPK<|>RELATION_NOE 的<|>RELATION_NOE 磷酸化<|>RELATION_NOE 水平<|>RELATION_NOE 下调<|>RELATION_S 。<|>RELATION_NOE
PI3K<|>RELATION_NOE 和<|>RELATION_NOE MEK<|>RELATION_NOE 联合<|>RELATION_NOE 抑制<|>RELATION_NOE 增强<|>RELATION_NOE 对<|>RELATION_NOE K-ras<|>RELATION_NOE 基因<|>RELATION_NOE 单<|>RELATION_NOE 突变<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 生长<|>RELATION_B 抑制<|>RELATION_I 作用<|>RELATION_E
观察<|>RELATION_NOE RAS<|>RELATION_NOE /<|>RELATION_NOE MEK<|>RELATION_NOE /<|>RELATION_NOE ERK<|>RELATION_NOE 通路<|>RELATION_NOE 单独<|>RELATION_NOE 抑制<|>RELATION_NOE 或<|>RELATION_NOE 联合<|>RELATION_NOE PI3K<|>RELATION_NOE /<|>RELATION_NOE AKT<|>RELATION_NOE /<|>RELATION_NOE mTOR<|>RELATION_NOE 通路<|>RELATION_NOE 抑制<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 相关<|>RELATION_NOE 分子<|>RELATION_NOE 机制<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 分为<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 0.5<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE GDC-0941<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 低<|>RELATION_NOE 浓度<|>RELATION_NOE 联合组<|>RELATION_NOE (<|>RELATION_NOE 0.5<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE AZD6244<|>RELATION_NOE +<|>RELATION_NOE 0.5<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE LGDC-0941<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 5.0μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE GDC-0941<|>RELATION_NOE 处理组<|>RELATION_NOE 和<|>RELATION_NOE 高浓度<|>RELATION_NOE 联合<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 5.0μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE AZD6244<|>RELATION_NOE +<|>RELATION_NOE 5.0μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE GDC-0941<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 细胞周期<|>RELATION_NOE 和<|>RELATION_NOE 凋亡<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE
对于<|>RELATION_NOE K-ras<|>RELATION_NOE 基因<|>RELATION_NOE 单<|>RELATION_NOE 突变<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 单独<|>RELATION_B 使用<|>RELATION_I 一<|>RELATION_I 条<|>RELATION_I 信号<|>RELATION_I 通路<|>RELATION_I 的<|>RELATION_I 抑制剂<|>RELATION_E 会<|>RELATION_NOE 反馈性<|>RELATION_NOE 激活<|>RELATION_NOE 另<|>RELATION_NOE 一<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE .<|>RELATION_NOE
孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 肺隐球菌病<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 鉴别诊断<|>RELATION_S
肺<|>RELATION_NOE 隐球菌病<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 复杂<|>RELATION_NOE 多样<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 难<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 鉴别<|>RELATION_NOE ,<|>RELATION_NOE 我们<|>RELATION_NOE 将<|>RELATION_NOE 被<|>RELATION_NOE 误诊<|>RELATION_NOE 为<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE 孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 肺隐球菌病<|>RELATION_NOE 挑选<|>RELATION_NOE 出来<|>RELATION_NOE 与<|>RELATION_NOE CT<|>RELATION_NOE 表现<|>RELATION_NOE 类似<|>RELATION_NOE 的<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 进行<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 影像<|>RELATION_NOE 特征<|>RELATION_NOE ,<|>RELATION_NOE 总结<|>RELATION_NOE 二者<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 鉴别诊断<|>RELATION_NOE 关键<|>RELATION_NOE 。<|>RELATION_NOE
33<|>RELATION_NOE 例<|>RELATION_NOE 肺<|>RELATION_NOE 隐球菌病<|>RELATION_NOE :<|>RELATION_NOE 左肺<|>RELATION_NOE 6例<|>RELATION_NOE 、<|>RELATION_NOE 右肺<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 上叶<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 下叶<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 胸膜<|>RELATION_NOE 下<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 分<|>RELATION_NOE 叶征<|>RELATION_NOE 4例<|>RELATION_NOE 、<|>RELATION_NOE 毛刺征<|>RELATION_NOE 7例<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 充气<|>RELATION_NOE 征<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 晕征<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 穿过<|>RELATION_NOE 征<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
31<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE :<|>RELATION_NOE 左肺<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 右肺<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 上叶<|>RELATION_NOE 21<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 中叶<|>RELATION_NOE 2例<|>RELATION_NOE 、<|>RELATION_NOE 下叶<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 胸膜<|>RELATION_NOE 下<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 分叶<|>RELATION_NOE 征<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 毛刺征<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 充气征<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 晕征3<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 穿过<|>RELATION_NOE 征<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
孤立<|>RELATION_NOE 结节型<|>RELATION_NOE 肺隐球菌病<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 难以<|>RELATION_NOE 鉴别<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 分叶<|>RELATION_NOE 、<|>RELATION_NOE 毛刺<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 充气<|>RELATION_NOE 征<|>RELATION_NOE 或<|>RELATION_NOE 穿过<|>RELATION_NOE 征<|>RELATION_NOE 、<|>RELATION_NOE 晕征<|>RELATION_NOE 对于<|>RELATION_NOE 其<|>RELATION_NOE 鉴别<|>RELATION_NOE 诊断<|>RELATION_NOE 可<|>RELATION_NOE 提供<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 参考<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 工作<|>RELATION_NOE 中<|>RELATION_NOE 应<|>RELATION_NOE 结合<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 及<|>RELATION_NOE 其他<|>RELATION_NOE 资料<|>RELATION_NOE 综合<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 配合<|>RELATION_NOE 支气管镜<|>RELATION_NOE 、<|>RELATION_NOE 穿刺活检<|>RELATION_NOE 等<|>RELATION_NOE 其他<|>RELATION_NOE 的<|>RELATION_NOE 检查<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 做出<|>RELATION_B 正确<|>RELATION_I 诊断<|>RELATION_E ,<|>RELATION_NOE 减少<|>RELATION_NOE 误诊<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 。<|>RELATION_NOE
色素<|>RELATION_NOE 上皮<|>RELATION_NOE 衍生<|>RELATION_NOE 因子<|>RELATION_NOE 通过<|>RELATION_NOE 诱导<|>RELATION_B 肺癌<|>RELATION_I 血管<|>RELATION_I 正常化<|>RELATION_E 增强<|>RELATION_NOE 照射<|>RELATION_NOE 作用<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_NOE 色素<|>RELATION_NOE 上皮<|>RELATION_NOE 衍生<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE PEDF<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 血管<|>RELATION_I 正常化<|>RELATION_E 的<|>RELATION_NOE 作用<|>RELATION_NOE 及<|>RELATION_NOE PEDF<|>RELATION_NOE 与<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 不同<|>RELATION_NOE 联合<|>RELATION_NOE 模式<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 观察<|>RELATION_NOE 色素<|>RELATION_NOE 上皮<|>RELATION_NOE 衍生<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE PEDF<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 血管<|>RELATION_NOE 正常化<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 及<|>RELATION_NOE PEDF<|>RELATION_NOE 与<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 不同<|>RELATION_NOE 联合<|>RELATION_NOE 模式<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 荧光<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 观测<|>RELATION_S PEDF<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 血管<|>RELATION_NOE 正常化<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 并<|>RELATION_NOE 确定<|>RELATION_NOE 其<|>RELATION_NOE 正常化<|>RELATION_NOE 时间<|>RELATION_NOE 窗<|>RELATION_NOE .<|>RELATION_NOE
建立<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE C57BL<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE 小鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 区<|>RELATION_NOE 组法<|>RELATION_NOE 随机<|>RELATION_NOE 分成<|>RELATION_NOE 4<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 给予<|>RELATION_NOE 对照<|>RELATION_NOE 、<|>RELATION_NOE PEDF<|>RELATION_NOE 、<|>RELATION_NOE 照射<|>RELATION_NOE 和<|>RELATION_NOE 照射<|>RELATION_NOE 联合<|>RELATION_NOE PEDF<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 不同<|>RELATION_NOE 处理<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
PEDF<|>RELATION_NOE 可<|>RELATION_NOE 降低<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 血管<|>RELATION_NOE 密度<|>RELATION_NOE 、<|>RELATION_NOE 降低<|>RELATION_NOE 血管<|>RELATION_NOE 的<|>RELATION_NOE 基底膜<|>RELATION_NOE 厚度<|>RELATION_NOE 、<|>RELATION_NOE 增加<|>RELATION_S 血管<|>RELATION_NOE 的<|>RELATION_NOE 周细胞<|>RELATION_NOE 覆盖率<|>RELATION_NOE 及<|>RELATION_NOE 降低<|>RELATION_NOE 移植瘤<|>RELATION_NOE 的<|>RELATION_NOE 乏氧<|>RELATION_NOE 比例<|>RELATION_NOE .<|>RELATION_NOE
PEDF<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 第3<|>RELATION_NOE －7<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 乏<|>RELATION_NOE 氧细胞<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 下降<|>RELATION_S ,<|>RELATION_NOE 其中<|>RELATION_NOE 以<|>RELATION_NOE 第3<|>RELATION_NOE 天<|>RELATION_NOE
PEDF<|>RELATION_NOE 诱导<|>RELATION_NOE 肺癌<|>RELATION_NOE 血管<|>RELATION_NOE 正常化<|>RELATION_NOE 的<|>RELATION_NOE 时间<|>RELATION_B 窗<|>RELATION_E 为<|>RELATION_NOE 第3<|>RELATION_NOE －<|>RELATION_NOE 7<|>RELATION_NOE 天<|>RELATION_NOE .<|>RELATION_NOE
PEDF<|>RELATION_NOE 可<|>RELATION_NOE 促进<|>RELATION_S 肺癌<|>RELATION_NOE 血管<|>RELATION_NOE 正常化<|>RELATION_NOE 并<|>RELATION_NOE 增强<|>RELATION_NOE 照射<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 肺癌<|>RELATION_NOE 生长<|>RELATION_NOE 作用<|>RELATION_NOE .<|>RELATION_NOE
模拟<|>RELATION_NOE 呼吸<|>RELATION_NOE 运动<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_B 三维<|>RELATION_I 技术<|>RELATION_I 放疗<|>RELATION_E 的<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE 影响<|>RELATION_NOE
对<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 三维<|>RELATION_NOE 技术<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 设计<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 二<|>RELATION_NOE 维<|>RELATION_NOE 半导体<|>RELATION_NOE 阵列<|>RELATION_NOE Mapcheck<|>RELATION_NOE 放在<|>RELATION_NOE 呼吸<|>RELATION_NOE 模拟<|>RELATION_NOE 运动<|>RELATION_NOE 平板<|>RELATION_NOE 3cm<|>RELATION_NOE 等<|>RELATION_NOE 效<|>RELATION_NOE 水模<|>RELATION_NOE 上<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE 近似<|>RELATION_NOE 呼吸<|>RELATION_NOE 运动<|>RELATION_NOE 周期<|>RELATION_NOE 为<|>RELATION_NOE 3.5s<|>RELATION_NOE ,<|>RELATION_NOE 运动<|>RELATION_NOE 幅度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE ±<|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE ±<|>RELATION_NOE 5<|>RELATION_NOE 、<|>RELATION_NOE ±<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE ±<|>RELATION_NOE 15mm<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 运动<|>RELATION_NOE 和<|>RELATION_NOE 静止<|>RELATION_NOE 状态<|>RELATION_NOE 下<|>RELATION_NOE Mapcheck<|>RELATION_NOE 实测<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE 和<|>RELATION_NOE 治疗<|>RELATION_NOE 计划<|>RELATION_NOE 系统<|>RELATION_NOE 输出<|>RELATION_NOE 的<|>RELATION_NOE 相应<|>RELATION_NOE 平面<|>RELATION_NOE 剂量<|>RELATION_NOE 分布.<|>RELATION_NOE
对<|>RELATION_NOE 呼吸<|>RELATION_NOE 运动<|>RELATION_NOE 幅度<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 建议<|>RELATION_NOE 采用<|>RELATION_B 3DCRT<|>RELATION_I 技术<|>RELATION_E ,<|>RELATION_NOE 更<|>RELATION_NOE 能<|>RELATION_NOE 确保<|>RELATION_NOE 运动<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 得到<|>RELATION_NOE 预期<|>RELATION_NOE 较<|>RELATION_NOE 准确<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE ,<|>RELATION_NOE 若<|>RELATION_NOE 采用<|>RELATION_NOE IMRT<|>RELATION_NOE 技术<|>RELATION_NOE 应<|>RELATION_NOE 根据<|>RELATION_NOE 情况<|>RELATION_NOE 对<|>RELATION_NOE 运动<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进行<|>RELATION_NOE 呼吸<|>RELATION_NOE 运动<|>RELATION_NOE 补偿<|>RELATION_NOE 等<|>RELATION_NOE 方法<|>RELATION_NOE 以<|>RELATION_NOE 确保<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相对<|>RELATION_NOE 静止.<|>RELATION_NOE 对<|>RELATION_NOE 呼吸<|>RELATION_NOE 运动<|>RELATION_NOE 幅度<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 建议<|>RELATION_NOE 采用<|>RELATION_NOE 3DCRT<|>RELATION_NOE 技术<|>RELATION_NOE ,<|>RELATION_NOE 更<|>RELATION_NOE 能<|>RELATION_NOE 确保<|>RELATION_NOE 运动<|>RELATION_NOE 的<|>RELATION_NOE 肿瘤<|>RELATION_NOE 得到<|>RELATION_NOE 预期<|>RELATION_NOE 较<|>RELATION_NOE 准确<|>RELATION_NOE 的<|>RELATION_NOE 剂量<|>RELATION_NOE 分布<|>RELATION_NOE ,<|>RELATION_NOE 若<|>RELATION_NOE 采用<|>RELATION_NOE IMRT<|>RELATION_NOE 技术<|>RELATION_NOE 应<|>RELATION_NOE 根据<|>RELATION_NOE 情况<|>RELATION_NOE 对<|>RELATION_NOE 运动<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进行<|>RELATION_NOE 呼吸<|>RELATION_NOE 运动<|>RELATION_NOE 补偿<|>RELATION_NOE 等<|>RELATION_NOE 方法<|>RELATION_NOE 以<|>RELATION_NOE 确保<|>RELATION_B 肿瘤<|>RELATION_I 相对<|>RELATION_I 静止<|>RELATION_E .<|>RELATION_NOE
胸部<|>RELATION_NOE 3DCRT<|>RELATION_NOE 在<|>RELATION_NOE 广泛期<|>RELATION_NOE SCLC<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S 研究<|>RELATION_NOE
胸部<|>RELATION_NOE 放疗<|>RELATION_NOE 和<|>RELATION_NOE 4周期<|>RELATION_NOE 以上<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE OS<|>RELATION_NOE 是<|>RELATION_NOE 独立<|>RELATION_B 的<|>RELATION_I 预后<|>RELATION_I 有利<|>RELATION_I 因素<|>RELATION_E .<|>RELATION_NOE
3DCRT<|>RELATION_NOE 计划<|>RELATION_NOE 中<|>RELATION_NOE 不同<|>RELATION_NOE 肺定义<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
结核<|>RELATION_NOE 分枝杆菌<|>RELATION_NOE Ag85B<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_B 特点<|>RELATION_I 及其<|>RELATION_I 病理学<|>RELATION_I 诊断<|>RELATION_I 价值<|>RELATION_E
测<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE 结核<|>RELATION_NOE 分枝杆菌<|>RELATION_NOE 分泌<|>RELATION_NOE 蛋白<|>RELATION_NOE Ag85B<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 在<|>RELATION_NOE 结核病<|>RELATION_B 病理学<|>RELATION_I 诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 收集<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 7月<|>RELATION_NOE 首都<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 附属<|>RELATION_NOE 北京<|>RELATION_NOE 胸科<|>RELATION_NOE 医院<|>RELATION_NOE 病理科<|>RELATION_NOE 结核病<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 105<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 肺结核<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 淋巴<|>RELATION_NOE 结核<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 其他<|>RELATION_NOE 疾病<|>RELATION_NOE 石蜡包埋<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 肺癌<|>RELATION_NOE 8例<|>RELATION_NOE 、<|>RELATION_NOE 肺脓肿<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 支气管<|>RELATION_NOE 扩张症<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 7例<|>RELATION_NOE 、<|>RELATION_NOE 坏死性<|>RELATION_NOE 淋巴结炎<|>RELATION_NOE 5例<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 反应性<|>RELATION_NOE 增生<|>RELATION_NOE 4例<|>RELATION_NOE 、<|>RELATION_NOE 结节病<|>RELATION_NOE 7例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 检测<|>RELATION_NOE 采用<|>RELATION_NOE 一<|>RELATION_NOE 步<|>RELATION_NOE 法<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE Ag85B<|>RELATION_NOE 抗体<|>RELATION_NOE 进行<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 与<|>RELATION_NOE 抗酸<|>RELATION_NOE 染色<|>RELATION_NOE 检测<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 中<|>RELATION_NOE Ag85B<|>RELATION_NOE 表达<|>RELATION_NOE 部位<|>RELATION_NOE 及<|>RELATION_NOE 强度<|>RELATION_NOE 与<|>RELATION_NOE 抗<|>RELATION_NOE 酸杆菌<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 部位<|>RELATION_NOE 及<|>RELATION_NOE 数量<|>RELATION_NOE 一致<|>RELATION_S 。<|>RELATION_NOE
此外<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 不<|>RELATION_NOE 使用<|>RELATION_NOE 油镜<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 大幅<|>RELATION_B 提高<|>RELATION_E 病理<|>RELATION_NOE 医师<|>RELATION_NOE 阅片<|>RELATION_NOE 诊断<|>RELATION_NOE 速度<|>RELATION_NOE 。<|>RELATION_NOE
利用<|>RELATION_NOE Ag85B<|>RELATION_NOE 抗体<|>RELATION_NOE 进行<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 方法<|>RELATION_NOE 简单<|>RELATION_NOE 易行<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 抗酸<|>RELATION_NOE 染色法<|>RELATION_NOE 相比<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_B 阳性<|>RELATION_I 检出率<|>RELATION_E ,<|>RELATION_NOE 在<|>RELATION_NOE 结核病<|>RELATION_NOE 的<|>RELATION_NOE 病理学<|>RELATION_NOE 诊断<|>RELATION_NOE 中<|>RELATION_NOE 具有<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE 利用<|>RELATION_NOE Ag85B<|>RELATION_NOE 抗体<|>RELATION_NOE 进行<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 方法<|>RELATION_NOE 简单易行<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 抗酸<|>RELATION_NOE 染色法<|>RELATION_NOE 相比<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_NOE 阳性<|>RELATION_NOE 检出率<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 结核病<|>RELATION_B 的<|>RELATION_I 病理学<|>RELATION_I 诊断<|>RELATION_E 中<|>RELATION_NOE 具有<|>RELATION_NOE 良好<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
甲状腺<|>RELATION_NOE 微小<|>RELATION_NOE 乳头状癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 与<|>RELATION_I 治疗<|>RELATION_E
探讨<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小<|>RELATION_NOE 乳头状癌<|>RELATION_NOE (<|>RELATION_NOE PTMC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 和<|>RELATION_I 外科<|>RELATION_I 治疗<|>RELATION_E
所有<|>RELATION_NOE 病例<|>RELATION_NOE 中<|>RELATION_NOE 单侧<|>RELATION_NOE 单<|>RELATION_NOE 发<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 96<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 单侧<|>RELATION_NOE 多<|>RELATION_NOE 发<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 双<|>RELATION_NOE 侧<|>RELATION_NOE 多<|>RELATION_NOE 发<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 22<|>RELATION_NOE 例.<|>RELATION_NOE
其中<|>RELATION_NOE 合并<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 112<|>RELATION_NOE 例.<|>RELATION_NOE
术后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 1－<|>RELATION_NOE 6<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 出现<|>RELATION_NOE 喉返神经<|>RELATION_NOE 损伤<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 喉上<|>RELATION_NOE 神经<|>RELATION_NOE 损伤<|>RELATION_NOE 2例<|>RELATION_NOE ,<|>RELATION_NOE 一过性<|>RELATION_NOE 甲状旁腺<|>RELATION_NOE 损伤<|>RELATION_NOE 2例.<|>RELATION_NOE
局部<|>RELATION_NOE 复发<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 无远处<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 死亡<|>RELATION_NOE 病例<|>RELATION_NOE 。<|>RELATION_NOE
新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 评价<|>RELATION_NOE
2006<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13<|>RELATION_NOE 年<|>RELATION_NOE ,<|>RELATION_NOE 太原市<|>RELATION_NOE 第七<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 胸外科<|>RELATION_NOE 对<|>RELATION_NOE 103<|>RELATION_NOE 例<|>RELATION_NOE Ⅲ<|>RELATION_NOE 期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 前瞻性<|>RELATION_NOE 随机<|>RELATION_NOE 对照<|>RELATION_NOE 试验<|>RELATION_NOE ,<|>RELATION_NOE 按<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分组<|>RELATION_NOE ,<|>RELATION_NOE 53<|>RELATION_NOE 例<|>RELATION_NOE 分<|>RELATION_NOE 入<|>RELATION_NOE 新<|>RELATION_NOE 辅助<|>RELATION_NOE 化疗组<|>RELATION_NOE ,<|>RELATION_NOE 行术<|>RELATION_NOE 前<|>RELATION_NOE 化疗2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE ,<|>RELATION_NOE 化疗<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE 4周<|>RELATION_NOE 手术.<|>RELATION_NOE
复方<|>RELATION_NOE 斑蝥<|>RELATION_NOE 胶囊<|>RELATION_NOE 在<|>RELATION_NOE 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 维持<|>RELATION_NOE 治疗<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
观察<|>RELATION_NOE 复方<|>RELATION_NOE 斑蝥<|>RELATION_NOE 胶囊<|>RELATION_NOE 对<|>RELATION_NOE 中晚期<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_I 维持<|>RELATION_I 治疗<|>RELATION_E 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 5月<|>RELATION_NOE 解放军<|>RELATION_NOE 第二<|>RELATION_NOE 七<|>RELATION_NOE 二<|>RELATION_NOE 医院<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 77<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 正规4<|>RELATION_NOE －6<|>RELATION_NOE 周期<|>RELATION_NOE 化疗<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 中晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE (<|>RELATION_NOE 54<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
复方<|>RELATION_NOE 斑蝥<|>RELATION_NOE 胶囊<|>RELATION_NOE 用于<|>RELATION_B 中晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_I 维持<|>RELATION_I 治疗<|>RELATION_E 可以<|>RELATION_NOE 改善<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 延长<|>RELATION_NOE PFS<|>RELATION_NOE 时间<|>RELATION_NOE .<|>RELATION_NOE
人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 转移<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白质<|>RELATION_NOE 生物<|>RELATION_NOE 信息学<|>RELATION_NOE 分析<|>RELATION_S
利用<|>RELATION_NOE Cytoscape<|>RELATION_NOE 软件<|>RELATION_NOE 对<|>RELATION_NOE 前期<|>RELATION_NOE 发现<|>RELATION_NOE 无<|>RELATION_NOE 转移<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 和<|>RELATION_NOE 有<|>RELATION_NOE 转移<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 表达<|>RELATION_NOE 差异<|>RELATION_NOE 的<|>RELATION_NOE 20<|>RELATION_NOE 个<|>RELATION_NOE 蛋白质<|>RELATION_NOE 进行<|>RELATION_NOE 基因<|>RELATION_NOE 本体论<|>RELATION_NOE (<|>RELATION_NOE GO<|>RELATION_NOE )<|>RELATION_NOE 功能<|>RELATION_NOE 富集<|>RELATION_NOE 分析<|>RELATION_NOE 和<|>RELATION_NOE 蛋白质<|>RELATION_NOE 相互作用<|>RELATION_NOE 网络<|>RELATION_NOE 构建<|>RELATION_NOE 。<|>RELATION_NOE
20<|>RELATION_NOE 种<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 转移<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 蛋白质<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 生物学过程<|>RELATION_NOE 为<|>RELATION_NOE 葡萄糖<|>RELATION_NOE 分解<|>RELATION_NOE 和<|>RELATION_NOE 酒精<|>RELATION_NOE 分解<|>RELATION_NOE 等<|>RELATION_NOE 过程<|>RELATION_NOE ,<|>RELATION_NOE 主要<|>RELATION_NOE 分子<|>RELATION_NOE 功能<|>RELATION_NOE 为<|>RELATION_NOE 磷脂<|>RELATION_NOE 酶<|>RELATION_NOE A2<|>RELATION_NOE 抑制剂<|>RELATION_NOE 活性<|>RELATION_NOE 和<|>RELATION_NOE 钙依赖<|>RELATION_NOE 的<|>RELATION_NOE 磷脂<|>RELATION_NOE 结合<|>RELATION_NOE ,<|>RELATION_NOE 蛋白质<|>RELATION_NOE 相互作用<|>RELATION_NOE 网络<|>RELATION_NOE 为<|>RELATION_NOE 包含<|>RELATION_NOE 245<|>RELATION_NOE 种<|>RELATION_NOE 不同<|>RELATION_NOE 蛋白质<|>RELATION_NOE 和<|>RELATION_NOE 230<|>RELATION_NOE 种<|>RELATION_NOE 不同<|>RELATION_NOE 蛋白质<|>RELATION_NOE 相互作用<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
葡萄糖<|>RELATION_NOE 分解<|>RELATION_NOE 过程<|>RELATION_NOE 、<|>RELATION_NOE 酒精<|>RELATION_NOE 分解<|>RELATION_NOE 过程<|>RELATION_NOE 、<|>RELATION_NOE 磷脂<|>RELATION_NOE 酶<|>RELATION_NOE A2<|>RELATION_NOE 抑制剂<|>RELATION_NOE 活性<|>RELATION_NOE 和<|>RELATION_NOE 钙依赖<|>RELATION_NOE 的<|>RELATION_NOE 磷脂<|>RELATION_NOE 结合<|>RELATION_NOE 及<|>RELATION_NOE ACTB<|>RELATION_NOE 、<|>RELATION_NOE ANXA1<|>RELATION_NOE 、<|>RELATION_NOE ANXA2<|>RELATION_NOE 、<|>RELATION_NOE ANXA3<|>RELATION_NOE 、<|>RELATION_NOE VCP<|>RELATION_NOE 、<|>RELATION_NOE NPM1<|>RELATION_NOE 、<|>RELATION_NOE KRT1<|>RELATION_NOE 、<|>RELATION_NOE SUMO4<|>RELATION_NOE 等<|>RELATION_NOE 关键<|>RELATION_NOE 蛋白质<|>RELATION_NOE 在<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 转移<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 发挥<|>RELATION_B 重要<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 为<|>RELATION_NOE 进一步<|>RELATION_NOE 研究<|>RELATION_NOE 提供<|>RELATION_NOE 线索<|>RELATION_NOE .<|>RELATION_NOE
超声<|>RELATION_NOE 评估<|>RELATION_NOE 甲状腺结节<|>RELATION_NOE 纵横<|>RELATION_NOE 比<|>RELATION_NOE ≥<|>RELATION_NOE 1时<|>RELATION_NOE 对<|>RELATION_NOE 甲状腺<|>RELATION_NOE 微小癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
选择<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 89<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 共<|>RELATION_NOE 124<|>RELATION_NOE 个<|>RELATION_NOE 结节<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 超声<|>RELATION_NOE 测量<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 横切面<|>RELATION_NOE 纵横径<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 根据<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径将<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 甲状腺<|>RELATION_NOE 癌组<|>RELATION_NOE (<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径><|>RELATION_NOE 1cm<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE TMC<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE 径≤<|>RELATION_NOE 1cm<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两组<|>RELATION_NOE A<|>RELATION_NOE /<|>RELATION_NOE T<|>RELATION_NOE ≥<|>RELATION_NOE 1<|>RELATION_NOE 的<|>RELATION_NOE 分布<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 临床<|>RELATION_NOE 研究<|>RELATION_NOE
将<|>RELATION_NOE 2009年<|>RELATION_NOE 7月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 7月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 治疗组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 。<|>RELATION_NOE
所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 经病<|>RELATION_NOE 理学<|>RELATION_NOE 或<|>RELATION_NOE 细胞学<|>RELATION_NOE 确诊<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 给予<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 奈达铂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 他<|>RELATION_NOE 赛<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 至少<|>RELATION_NOE 治疗<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 以上<|>RELATION_NOE 。<|>RELATION_NOE
晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE c-MET<|>RELATION_B 基因扩增<|>RELATION_E 的<|>RELATION_NOE 研究<|>RELATION_NOE
研究<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 和<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE c-MET<|>RELATION_NOE 扩增阳<|>RELATION_NOE 性率<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
收集<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 11月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 11月<|>RELATION_NOE 北京<|>RELATION_NOE 军区<|>RELATION_NOE 总医院<|>RELATION_NOE NSCLC<|>RELATION_NOE 原发灶<|>RELATION_NOE 147<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 配对<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 71<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 取<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE 标本<|>RELATION_NOE 47<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE 对照<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE 反转录<|>RELATION_NOE -<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链式<|>RELATION_NOE 反应<|>RELATION_NOE 检测<|>RELATION_NOE 其<|>RELATION_NOE c-MET<|>RELATION_NOE 拷贝数<|>RELATION_NOE ,<|>RELATION_NOE 统计<|>RELATION_NOE 得出<|>RELATION_NOE c-MET<|>RELATION_NOE 扩增阳<|>RELATION_NOE 性率<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 与<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE c-MET<|>RELATION_NOE 扩增<|>RELATION_NOE 的<|>RELATION_NOE 一致性<|>RELATION_NOE 、<|>RELATION_NOE c-MET<|>RELATION_NOE 扩增<|>RELATION_NOE 阳性<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 基线<|>RELATION_NOE 资料<|>RELATION_NOE 间<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
c-MET<|>RELATION_NOE 扩增阳<|>RELATION_NOE 性率<|>RELATION_NOE 配对<|>RELATION_NOE 原发灶<|>RELATION_NOE 为<|>RELATION_NOE 8.4<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 6/71<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 配对<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 为<|>RELATION_NOE 18.3<|>RELATION_NOE 1%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 71<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 扩增<|>RELATION_NOE 阳性<|>RELATION_NOE 而<|>RELATION_NOE 对应<|>RELATION_NOE 的<|>RELATION_NOE 原发灶<|>RELATION_NOE 扩增<|>RELATION_NOE 阴性<|>RELATION_NOE 8例<|>RELATION_NOE ,<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE 扩增<|>RELATION_NOE 阳性<|>RELATION_NOE 而<|>RELATION_NOE 对应<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 扩增<|>RELATION_NOE 阴性<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 间<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE McNemar<|>RELATION_NOE 检验<|>RELATION_NOE ,<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 4.2<|>RELATION_NOE 74<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 39<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 预测<|>RELATION_NOE 原<|>RELATION_NOE 发灶<|>RELATION_NOE c-MET<|>RELATION_NOE 扩增<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_B 一致<|>RELATION_I 性良好<|>RELATION_E (<|>RELATION_NOE Kappa<|>RELATION_NOE 值<|>RELATION_NOE =<|>RELATION_NOE 0.4<|>RELATION_NOE 64<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ﹤<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 敏感性<|>RELATION_NOE 为<|>RELATION_NOE 83.3%<|>RELATION_NOE ,<|>RELATION_NOE 特异性<|>RELATION_NOE 为<|>RELATION_NOE 87.7%<|>RELATION_NOE 。<|>RELATION_NOE
c-MET<|>RELATION_NOE 扩增<|>RELATION_NOE 阳性<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 特征<|>RELATION_E 为<|>RELATION_NOE N2<|>RELATION_NOE 以上<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 男性<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶阳<|>RELATION_NOE 性率<|>RELATION_NOE 高于<|>RELATION_S 原<|>RELATION_NOE 发灶<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 能<|>RELATION_NOE 筛<|>RELATION_NOE 出<|>RELATION_NOE 更<|>RELATION_NOE 多<|>RELATION_NOE 有<|>RELATION_NOE 适应证<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ;<|>RELATION_NOE NSCLC<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 灶阳<|>RELATION_NOE 性率<|>RELATION_NOE 高于<|>RELATION_NOE 原发灶<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 能<|>RELATION_NOE 筛<|>RELATION_B 出<|>RELATION_E 更<|>RELATION_NOE 多<|>RELATION_NOE 有<|>RELATION_NOE 适应证<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ;<|>RELATION_NOE
肺组织<|>RELATION_NOE 中<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 连环<|>RELATION_NOE 蛋白<|>RELATION_NOE 及其<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S
取<|>RELATION_NOE 胸外科手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 肺叶<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE COPD<|>RELATION_NOE 阶段<|>RELATION_NOE Ⅲ<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE COPD<|>RELATION_NOE 阶段<|>RELATION_NOE Ⅳ<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE qRT-PCR<|>RELATION_NOE 检测<|>RELATION_S 肺组织<|>RELATION_NOE 中<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 连环<|>RELATION_NOE 蛋白<|>RELATION_NOE mRNA<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 分析<|>RELATION_NOE 肺组织<|>RELATION_NOE 中<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 连环<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE 。<|>RELATION_NOE
COPD<|>RELATION_NOE 阶段<|>RELATION_NOE Ⅲ<|>RELATION_NOE 和<|>RELATION_NOE Ⅳ<|>RELATION_NOE 组<|>RELATION_NOE 中<|>RELATION_NOE β<|>RELATION_NOE -<|>RELATION_NOE 连环<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白水<|>RELATION_NOE 平均<|>RELATION_B 显著<|>RELATION_I 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 组β<|>RELATION_NOE -<|>RELATION_NOE 连环<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白水<|>RELATION_NOE 平均<|>RELATION_B 显著<|>RELATION_I 高于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
肺结核<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 特征<|>RELATION_I 及<|>RELATION_I 预后<|>RELATION_I 影响<|>RELATION_I 因素<|>RELATION_E
分析<|>RELATION_NOE 肺结核<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 特征<|>RELATION_I 及<|>RELATION_I 预后<|>RELATION_I 影响<|>RELATION_I 因素<|>RELATION_E 。<|>RELATION_NOE
对<|>RELATION_NOE 19<|>RELATION_NOE 98年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 2005年<|>RELATION_NOE 1月<|>RELATION_NOE 青岛市<|>RELATION_NOE 胸科<|>RELATION_NOE 医院<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 肺结核<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 58<|>RELATION_NOE 例<|>RELATION_NOE 住院<|>RELATION_NOE 及<|>RELATION_NOE 门诊<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 影像学<|>RELATION_NOE 特征<|>RELATION_NOE 进行<|>RELATION_NOE 综合<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
肺结核<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 临床<|>RELATION_B 首发<|>RELATION_I 症状<|>RELATION_E 依次<|>RELATION_NOE 为<|>RELATION_NOE 咳嗽<|>RELATION_NOE 、<|>RELATION_NOE 胸闷<|>RELATION_NOE 、<|>RELATION_NOE 发热<|>RELATION_NOE 及<|>RELATION_NOE 咯血<|>RELATION_NOE 。<|>RELATION_NOE
肺结核<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 影像学<|>RELATION_NOE 特征<|>RELATION_NOE 有助于<|>RELATION_S 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 早期<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 肺结核<|>RELATION_NOE 是否<|>RELATION_NOE 活动<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE 肺结核<|>RELATION_NOE 合并<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 影像学<|>RELATION_NOE 特征<|>RELATION_NOE 有助于<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 早期<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 肺癌<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 和<|>RELATION_NOE 肺结核<|>RELATION_NOE 是否<|>RELATION_NOE 活动<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_B 患者<|>RELATION_I 预后<|>RELATION_E 的<|>RELATION_NOE 主要<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
不同<|>RELATION_NOE 病理<|>RELATION_NOE 分级<|>RELATION_NOE 的<|>RELATION_NOE 直肠<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 特征<|>RELATION_I 与<|>RELATION_I 预后<|>RELATION_E 分析<|>RELATION_NOE
探讨<|>RELATION_NOE 不同<|>RELATION_NOE 病理<|>RELATION_NOE 分级<|>RELATION_NOE 的<|>RELATION_NOE 直肠<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 特征<|>RELATION_I 与<|>RELATION_I 预后<|>RELATION_E 情况<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 2001年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 4月<|>RELATION_NOE 解放军<|>RELATION_NOE 总医院<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE 183<|>RELATION_NOE 例<|>RELATION_NOE 直肠<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE .<|>RELATION_NOE
从<|>RELATION_NOE 医生<|>RELATION_NOE 工作站<|>RELATION_NOE 及<|>RELATION_NOE 内镜<|>RELATION_NOE 中心<|>RELATION_NOE 数据库<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 检索<|>RELATION_NOE 经<|>RELATION_NOE 内镜<|>RELATION_NOE 治疗<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 或<|>RELATION_NOE )<|>RELATION_NOE 外科手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 直肠<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 资料.<|>RELATION_NOE
按照<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE WHO<|>RELATION_NOE 消化系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分类<|>RELATION_NOE 标准<|>RELATION_NOE ,<|>RELATION_NOE 依<|>RELATION_NOE 核分裂<|>RELATION_NOE 象数<|>RELATION_NOE 对<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE
临床<|>RELATION_NOE 症状<|>RELATION_NOE :<|>RELATION_NOE 便血者<|>RELATION_NOE 74<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 健康<|>RELATION_NOE 体检<|>RELATION_NOE 无意<|>RELATION_NOE 发现者<|>RELATION_NOE 70<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 腹痛<|>RELATION_NOE 及<|>RELATION_NOE 大便<|>RELATION_NOE 习惯<|>RELATION_NOE 改变<|>RELATION_NOE 者<|>RELATION_NOE 各<|>RELATION_NOE 9例<|>RELATION_NOE ,<|>RELATION_NOE 其他<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE 有<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 升高<|>RELATION_NOE 、<|>RELATION_NOE 腹胀<|>RELATION_NOE 或<|>RELATION_NOE 合并<|>RELATION_NOE 多种<|>RELATION_NOE 症状<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 1例<|>RELATION_NOE 表现<|>RELATION_NOE 为<|>RELATION_NOE 类癌<|>RELATION_NOE 综合征<|>RELATION_NOE .<|>RELATION_NOE
183<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 伴发<|>RELATION_NOE 肠道<|>RELATION_NOE 息肉<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 合并<|>RELATION_NOE 管状<|>RELATION_NOE 腺瘤<|>RELATION_NOE 5<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 合并<|>RELATION_NOE 结<|>RELATION_NOE 直肠腺<|>RELATION_NOE 癌3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 合并<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 1例.<|>RELATION_NOE
183<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 6例<|>RELATION_NOE 发生<|>RELATION_NOE 肝转移<|>RELATION_NOE ,<|>RELATION_NOE 9例<|>RELATION_NOE 发生<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ,<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 死亡<|>RELATION_NOE (<|>RELATION_NOE G1<|>RELATION_NOE 级<|>RELATION_NOE 4例<|>RELATION_NOE 、<|>RELATION_NOE G2<|>RELATION_NOE 级<|>RELATION_NOE 6例<|>RELATION_NOE 、<|>RELATION_NOE G3<|>RELATION_NOE 级<|>RELATION_NOE 4例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存率<|>RELATION_NOE 为<|>RELATION_NOE 92.3<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 169<|>RELATION_NOE /<|>RELATION_NOE 183<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
不同<|>RELATION_NOE 分级<|>RELATION_NOE 直肠<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤分期<|>RELATION_NOE 、<|>RELATION_NOE 肝转移<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 5<|>RELATION_NOE 年<|>RELATION_NOE 生存<|>RELATION_NOE 情况<|>RELATION_NOE 等<|>RELATION_NOE 方面<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE x<|>RELATION_NOE ^2<|>RELATION_NOE =<|>RELATION_NOE 60.9<|>RELATION_NOE 49<|>RELATION_NOE ,<|>RELATION_NOE 71.5<|>RELATION_NOE 87<|>RELATION_NOE ,<|>RELATION_NOE 32.1<|>RELATION_NOE 35<|>RELATION_NOE ,<|>RELATION_NOE 55.4<|>RELATION_NOE 86<|>RELATION_NOE ,<|>RELATION_NOE 56.5<|>RELATION_NOE 12<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
直肠<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 缺乏<|>RELATION_NOE 特异性<|>RELATION_NOE 临床<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 好<|>RELATION_NOE 发<|>RELATION_NOE ,<|>RELATION_NOE 部位<|>RELATION_NOE 多<|>RELATION_NOE 位于<|>RELATION_NOE 直肠<|>RELATION_NOE 中<|>RELATION_NOE 下<|>RELATION_NOE 段<|>RELATION_NOE ,<|>RELATION_NOE 多数<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE <<|>RELATION_NOE 1cm<|>RELATION_NOE ,<|>RELATION_NOE 多数<|>RELATION_NOE 患者<|>RELATION_NOE 为<|>RELATION_NOE TNM<|>RELATION_NOE Ⅰ<|>RELATION_NOE 期<|>RELATION_NOE ,<|>RELATION_NOE G1<|>RELATION_NOE 级<|>RELATION_NOE .<|>RELATION_NOE
不同<|>RELATION_NOE 分级<|>RELATION_NOE 的<|>RELATION_NOE 直肠<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE 预后<|>RELATION_NOE 不同<|>RELATION_S ,<|>RELATION_NOE 按照<|>RELATION_NOE 20<|>RELATION_NOE 10<|>RELATION_NOE 年<|>RELATION_NOE WHO<|>RELATION_NOE 消化系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分类<|>RELATION_NOE 标准<|>RELATION_NOE 进行<|>RELATION_NOE 分级<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 有<|>RELATION_NOE 参考<|>RELATION_NOE 价值<|>RELATION_NOE ,<|>RELATION_NOE 制订<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 时<|>RELATION_NOE 应<|>RELATION_NOE 考虑<|>RELATION_NOE 分级<|>RELATION_NOE 的<|>RELATION_NOE 因素.<|>RELATION_NOE
容积<|>RELATION_NOE 弧形<|>RELATION_NOE 调强<|>RELATION_NOE 放疗<|>RELATION_NOE 与<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 计划<|>RELATION_NOE 在<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 剂量学<|>RELATION_B 对比<|>RELATION_I 研究<|>RELATION_E
能谱<|>RELATION_NOE CT<|>RELATION_NOE 成像<|>RELATION_NOE 在<|>RELATION_NOE 鉴别<|>RELATION_S 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE 肺炎<|>RELATION_NOE 性肿块<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 能谱<|>RELATION_NOE CT<|>RELATION_NOE 成<|>RELATION_NOE 像<|>RELATION_NOE 定量分析<|>RELATION_NOE 在<|>RELATION_NOE 鉴别诊断<|>RELATION_S 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 和<|>RELATION_NOE 肺炎<|>RELATION_NOE 性肿块<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
运用<|>RELATION_NOE 能谱<|>RELATION_NOE CT<|>RELATION_NOE 成像<|>RELATION_NOE 的<|>RELATION_NOE 参数<|>RELATION_NOE 进行<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 周围型<|>RELATION_B 肺癌<|>RELATION_I 和<|>RELATION_I 肺炎<|>RELATION_I 性肿块<|>RELATION_I 的<|>RELATION_I 鉴别诊断<|>RELATION_E 有<|>RELATION_NOE 较<|>RELATION_NOE 大<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
电脉<|>RELATION_NOE 冲转<|>RELATION_NOE 癌抑素<|>RELATION_NOE 基因<|>RELATION_NOE 对<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 体内<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E
构建<|>RELATION_NOE 人<|>RELATION_NOE canstatin<|>RELATION_NOE 克隆载体<|>RELATION_NOE 及<|>RELATION_NOE 重组<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 电脉<|>RELATION_NOE 冲<|>RELATION_NOE 介导<|>RELATION_NOE 骨骼肌<|>RELATION_NOE 内<|>RELATION_NOE canstatin<|>RELATION_NOE 基因<|>RELATION_NOE 导入<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 皮下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
将<|>RELATION_NOE 该<|>RELATION_NOE 重组<|>RELATION_NOE 质粒<|>RELATION_NOE 通过<|>RELATION_NOE 电脉冲<|>RELATION_NOE 转入<|>RELATION_NOE 荷瘤<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 小鼠<|>RELATION_NOE 肌肉<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 逆转录<|>RELATION_NOE PCR<|>RELATION_NOE 、<|>RELATION_NOE 荧光<|>RELATION_NOE 显微镜<|>RELATION_NOE 测量<|>RELATION_S 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 称<|>RELATION_NOE 重<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 测定<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE canstatin<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 体内<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE 将<|>RELATION_NOE 该<|>RELATION_NOE 重组<|>RELATION_NOE 质粒<|>RELATION_NOE 通过<|>RELATION_NOE 电脉冲<|>RELATION_NOE 转入<|>RELATION_NOE 荷瘤<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 小鼠<|>RELATION_NOE 肌肉<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE 逆转录<|>RELATION_NOE PCR<|>RELATION_NOE 、<|>RELATION_NOE 荧光<|>RELATION_NOE 显微镜<|>RELATION_NOE 测量<|>RELATION_NOE 荧光<|>RELATION_NOE 强度<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 称<|>RELATION_NOE 重<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 测定<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 组化<|>RELATION_NOE 的<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S canstatin<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 体内<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 和<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
电脉<|>RELATION_NOE 冲<|>RELATION_NOE 介导<|>RELATION_NOE 的<|>RELATION_NOE 质粒<|>RELATION_NOE 基因<|>RELATION_NOE 导入<|>RELATION_NOE 效率<|>RELATION_NOE 较<|>RELATION_B 单纯<|>RELATION_I 质粒<|>RELATION_I 注射<|>RELATION_E 高<|>RELATION_NOE 30<|>RELATION_NOE 倍<|>RELATION_NOE 以上<|>RELATION_NOE ;<|>RELATION_NOE
实验组<|>RELATION_NOE 肿瘤<|>RELATION_NOE 颜色<|>RELATION_NOE 苍白<|>RELATION_NOE ,<|>RELATION_NOE 毛细血管<|>RELATION_NOE 稀少<|>RELATION_NOE ,<|>RELATION_NOE 坏死<|>RELATION_NOE 多<|>RELATION_NOE ,<|>RELATION_NOE 体积<|>RELATION_NOE 小<|>RELATION_NOE ,<|>RELATION_NOE 瘤重<|>RELATION_NOE 抑制率<|>RELATION_NOE 57.7%<|>RELATION_NOE 。<|>RELATION_NOE
成功<|>RELATION_NOE 构建<|>RELATION_NOE 了<|>RELATION_NOE 重组<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE pEGFP-N1<|>RELATION_NOE /<|>RELATION_NOE canstatin<|>RELATION_NOE ,<|>RELATION_NOE 电脉<|>RELATION_NOE 冲<|>RELATION_NOE 介导<|>RELATION_NOE 的<|>RELATION_NOE 骨骼<|>RELATION_NOE 肌内<|>RELATION_NOE 基因<|>RELATION_NOE 导入法<|>RELATION_NOE 的<|>RELATION_NOE 转移<|>RELATION_NOE 效率<|>RELATION_NOE 较<|>RELATION_B 单纯<|>RELATION_I 质粒<|>RELATION_I 注射<|>RELATION_E 高且<|>RELATION_NOE 持续<|>RELATION_NOE 时间<|>RELATION_NOE 长<|>RELATION_NOE ;<|>RELATION_NOE
电脉<|>RELATION_NOE 冲<|>RELATION_NOE 介导<|>RELATION_NOE 骨骼肌<|>RELATION_NOE 内<|>RELATION_NOE canstatin<|>RELATION_NOE 基因<|>RELATION_NOE 导入<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 皮下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 生长<|>RELATION_NOE 具有<|>RELATION_B 显著<|>RELATION_I 的<|>RELATION_I 抑制<|>RELATION_I 作用<|>RELATION_E .<|>RELATION_NOE
腹型<|>RELATION_NOE 肥胖<|>RELATION_NOE 对<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 围手术期<|>RELATION_NOE 肺功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 腹型<|>RELATION_NOE 肥胖<|>RELATION_NOE 对<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 围手术期<|>RELATION_NOE 肺功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
按<|>RELATION_NOE 准入<|>RELATION_NOE 条件<|>RELATION_NOE 选取<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 且<|>RELATION_NOE 有<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 手术<|>RELATION_NOE 指征<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 体质量<|>RELATION_NOE 指数<|>RELATION_NOE (<|>RELATION_NOE BMI<|>RELATION_NOE )<|>RELATION_NOE ><|>RELATION_NOE 35<|>RELATION_NOE kg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 腰围<|>RELATION_NOE ><|>RELATION_NOE 95cm<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 腰围<|>RELATION_NOE ><|>RELATION_NOE 90cm<|>RELATION_NOE 的<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 设<|>RELATION_NOE 为<|>RELATION_NOE 腹型<|>RELATION_NOE 肥胖组<|>RELATION_NOE ,<|>RELATION_NOE BMI<|>RELATION_NOE <<|>RELATION_NOE 25<|>RELATION_NOE kg<|>RELATION_NOE /<|>RELATION_NOE m2<|>RELATION_NOE ,<|>RELATION_NOE 男性<|>RELATION_NOE 腰围<|>RELATION_NOE <<|>RELATION_NOE 85cm<|>RELATION_NOE ,<|>RELATION_NOE 女性<|>RELATION_NOE 腰围<|>RELATION_NOE <<|>RELATION_NOE 80<|>RELATION_NOE cm<|>RELATION_NOE 的<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE 设<|>RELATION_NOE 为<|>RELATION_NOE 正常<|>RELATION_NOE 体质<|>RELATION_NOE 量组<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE 采取<|>RELATION_NOE 4孔法<|>RELATION_NOE 完成<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 及<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE ,<|>RELATION_NOE 记录<|>RELATION_NOE 手术时间<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 前后<|>RELATION_NOE 查<|>RELATION_NOE 血气分析<|>RELATION_NOE 及<|>RELATION_NOE 肺功能<|>RELATION_NOE ,<|>RELATION_NOE 记录术<|>RELATION_NOE 后<|>RELATION_NOE 并发症<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 二<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 参数<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
二<|>RELATION_NOE 组<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 血气分析<|>RELATION_NOE 指标<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 12h<|>RELATION_NOE 腹型<|>RELATION_NOE 肥胖组<|>RELATION_NOE 自身<|>RELATION_NOE 比较<|>RELATION_NOE 动脉<|>RELATION_NOE 血氧<|>RELATION_NOE 分压<|>RELATION_NOE (<|>RELATION_NOE PaO2<|>RELATION_NOE )<|>RELATION_NOE 下降<|>RELATION_NOE 、<|>RELATION_NOE 肺泡<|>RELATION_NOE 动脉<|>RELATION_NOE 血氧<|>RELATION_NOE 分压<|>RELATION_NOE 差<|>RELATION_NOE (<|>RELATION_NOE PA-aO2<|>RELATION_NOE )<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_NOE 正常<|>RELATION_NOE 体质<|>RELATION_NOE 量组<|>RELATION_NOE PaO2<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 动脉<|>RELATION_NOE 血<|>RELATION_NOE 二氧化碳<|>RELATION_NOE 分压<|>RELATION_NOE (<|>RELATION_NOE PaCO2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE PA-aO2<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE 二<|>RELATION_NOE 组术<|>RELATION_NOE 前<|>RELATION_NOE 血气分析<|>RELATION_NOE 指标<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 12h<|>RELATION_NOE 腹型<|>RELATION_NOE 肥胖组<|>RELATION_NOE 自身<|>RELATION_B 比较<|>RELATION_E 动脉<|>RELATION_NOE 血氧<|>RELATION_NOE 分压<|>RELATION_NOE (<|>RELATION_NOE PaO2<|>RELATION_NOE )<|>RELATION_NOE 下降<|>RELATION_NOE 、<|>RELATION_NOE 肺泡<|>RELATION_NOE 动脉<|>RELATION_NOE 血氧<|>RELATION_NOE 分压<|>RELATION_NOE 差<|>RELATION_NOE (<|>RELATION_NOE PA-aO2<|>RELATION_NOE )<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_NOE 正常<|>RELATION_NOE 体质<|>RELATION_NOE 量组<|>RELATION_NOE PaO2<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 动脉<|>RELATION_NOE 血<|>RELATION_NOE 二氧化碳<|>RELATION_NOE 分压<|>RELATION_NOE (<|>RELATION_NOE PaCO2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE PA-aO2<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE 二<|>RELATION_NOE 组术<|>RELATION_NOE 前<|>RELATION_NOE 血气分析<|>RELATION_NOE 指标<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 12h<|>RELATION_NOE 腹型<|>RELATION_NOE 肥胖组<|>RELATION_NOE 自身<|>RELATION_NOE 比较<|>RELATION_NOE 动脉<|>RELATION_NOE 血氧<|>RELATION_NOE 分压<|>RELATION_NOE (<|>RELATION_NOE PaO2<|>RELATION_NOE )<|>RELATION_NOE 下降<|>RELATION_NOE 、<|>RELATION_NOE 肺泡<|>RELATION_NOE 动脉<|>RELATION_NOE 血氧<|>RELATION_NOE 分压<|>RELATION_NOE 差<|>RELATION_NOE (<|>RELATION_NOE PA-aO2<|>RELATION_NOE )<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_B 正常<|>RELATION_I 体质<|>RELATION_I 量组<|>RELATION_E PaO2<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 动脉<|>RELATION_NOE 血<|>RELATION_NOE 二氧化碳<|>RELATION_NOE 分压<|>RELATION_NOE (<|>RELATION_NOE PaCO2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE PA-aO2<|>RELATION_NOE 增高<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
二<|>RELATION_NOE 组<|>RELATION_NOE 术前<|>RELATION_NOE 用力肺活量<|>RELATION_NOE (<|>RELATION_NOE FVC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE FEV1<|>RELATION_NOE )<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 第3<|>RELATION_NOE 天<|>RELATION_NOE 腹型<|>RELATION_NOE 肥胖组<|>RELATION_NOE 自身<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 除<|>RELATION_NOE FEV<|>RELATION_NOE /<|>RELATION_NOE FVC<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE FVC<|>RELATION_NOE 、<|>RELATION_NOE FEV1<|>RELATION_NOE 、<|>RELATION_NOE 最大通气量<|>RELATION_NOE (<|>RELATION_NOE MVV<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 功能<|>RELATION_NOE 残气量<|>RELATION_NOE (<|>RELATION_NOE FRC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 一氧化碳<|>RELATION_NOE 弥散量<|>RELATION_NOE (<|>RELATION_NOE DLCO<|>RELATION_NOE )<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_NOE 正常<|>RELATION_NOE 体质<|>RELATION_NOE 量组<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE FVC<|>RELATION_NOE 、<|>RELATION_NOE FEV1<|>RELATION_NOE 、<|>RELATION_NOE FRC<|>RELATION_NOE 、<|>RELATION_NOE DLCO<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 二<|>RELATION_NOE 组术<|>RELATION_NOE 前<|>RELATION_NOE 用力肺活量<|>RELATION_NOE (<|>RELATION_NOE FVC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE FEV1<|>RELATION_NOE )<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 第3<|>RELATION_NOE 天<|>RELATION_NOE 腹型<|>RELATION_NOE 肥胖组<|>RELATION_NOE 自身<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 除<|>RELATION_NOE FEV<|>RELATION_NOE /<|>RELATION_NOE FVC<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE FVC<|>RELATION_NOE 、<|>RELATION_NOE FEV1<|>RELATION_NOE 、<|>RELATION_NOE 最大通气量<|>RELATION_NOE (<|>RELATION_NOE MVV<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 功能<|>RELATION_NOE 残气量<|>RELATION_NOE (<|>RELATION_NOE FRC<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 一氧化碳<|>RELATION_NOE 弥散量<|>RELATION_NOE (<|>RELATION_NOE DLCO<|>RELATION_NOE )<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 较<|>RELATION_B 正常<|>RELATION_I 体质<|>RELATION_I 量组<|>RELATION_I 比较<|>RELATION_E ,<|>RELATION_NOE FVC<|>RELATION_NOE 、<|>RELATION_NOE FEV1<|>RELATION_NOE 、<|>RELATION_NOE FRC<|>RELATION_NOE 、<|>RELATION_NOE DLCO<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
神经<|>RELATION_NOE 刺激仪<|>RELATION_NOE 引导<|>RELATION_NOE 胸椎<|>RELATION_NOE 旁<|>RELATION_NOE 神经<|>RELATION_NOE 阻滞<|>RELATION_NOE 复合<|>RELATION_NOE 全身麻醉<|>RELATION_NOE 在<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
选择<|>RELATION_NOE 拟<|>RELATION_NOE 行<|>RELATION_NOE 小<|>RELATION_NOE 切口<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE ASA<|>RELATION_NOE Ⅰ<|>RELATION_NOE －Ⅱ级<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 胸椎<|>RELATION_NOE 旁<|>RELATION_NOE 神经<|>RELATION_NOE 阻滞<|>RELATION_NOE 复合<|>RELATION_NOE 全麻<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 全身麻醉<|>RELATION_NOE (<|>RELATION_NOE G<|>RELATION_NOE )<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE .<|>RELATION_NOE
记录<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 麻醉<|>RELATION_NOE 诱导<|>RELATION_NOE 前<|>RELATION_NOE (<|>RELATION_NOE T0<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 气管<|>RELATION_NOE 插<|>RELATION_NOE 管<|>RELATION_NOE 后<|>RELATION_NOE (<|>RELATION_NOE T1<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 切皮<|>RELATION_NOE 即刻<|>RELATION_NOE (<|>RELATION_NOE T2<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 打开<|>RELATION_NOE 胸腔<|>RELATION_NOE 即刻<|>RELATION_NOE (<|>RELATION_NOE T3<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 单肺通气<|>RELATION_NOE 30<|>RELATION_NOE min<|>RELATION_NOE (<|>RELATION_NOE T4<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 关闭<|>RELATION_NOE 胸腔<|>RELATION_NOE 即刻<|>RELATION_NOE (<|>RELATION_NOE T5<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 手术<|>RELATION_NOE 结束<|>RELATION_NOE (<|>RELATION_NOE T6<|>RELATION_NOE )<|>RELATION_NOE 各<|>RELATION_NOE 时点<|>RELATION_NOE 平均<|>RELATION_NOE 动脉压<|>RELATION_NOE (<|>RELATION_NOE MAP<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 心率<|>RELATION_NOE (<|>RELATION_NOE HR<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
观察<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 术毕<|>RELATION_NOE 自主<|>RELATION_NOE 呼吸<|>RELATION_NOE 恢复<|>RELATION_NOE 、<|>RELATION_NOE 拔除<|>RELATION_NOE 气管<|>RELATION_NOE 导管<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 发生率<|>RELATION_NOE .<|>RELATION_NOE
P<|>RELATION_NOE 组<|>RELATION_NOE 自主<|>RELATION_NOE 呼吸<|>RELATION_NOE 恢复<|>RELATION_NOE 、<|>RELATION_NOE 拔除<|>RELATION_NOE 气管<|>RELATION_NOE 导管<|>RELATION_NOE 时间<|>RELATION_NOE 显著<|>RELATION_B 短于<|>RELATION_E G<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
神经<|>RELATION_NOE 刺激仪<|>RELATION_NOE 引导<|>RELATION_NOE 胸椎<|>RELATION_NOE 旁<|>RELATION_NOE 神经<|>RELATION_NOE 阻滞<|>RELATION_NOE 复合<|>RELATION_NOE 全身麻醉<|>RELATION_NOE 用于<|>RELATION_B 小<|>RELATION_I 切口<|>RELATION_I 肺癌<|>RELATION_I 手术<|>RELATION_E 全麻<|>RELATION_NOE 用药量<|>RELATION_NOE 少<|>RELATION_NOE 、<|>RELATION_NOE 苏醒<|>RELATION_NOE 快<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 镇痛<|>RELATION_NOE 时间<|>RELATION_NOE 长<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 值得<|>RELATION_NOE 推广<|>RELATION_NOE 的<|>RELATION_NOE 麻醉<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
微创<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_S 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE
评价<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 联合化疗<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 气胸<|>RELATION_NOE 、<|>RELATION_NOE 血气胸<|>RELATION_NOE 或<|>RELATION_NOE 咯血<|>RELATION_NOE 等<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 经<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 可以<|>RELATION_NOE 控制<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 血液<|>RELATION_NOE 学<|>RELATION_NOE 毒性<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
术后<|>RELATION_NOE 三<|>RELATION_NOE 维<|>RELATION_NOE 适行<|>RELATION_NOE 放疗<|>RELATION_NOE 治疗<|>RELATION_B 肺鳞癌<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE
围术期<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 并发症<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
方法<|>RELATION_NOE :<|>RELATION_NOE 90<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 按照<|>RELATION_NOE 随机<|>RELATION_NOE 、<|>RELATION_NOE 双盲<|>RELATION_NOE 对照<|>RELATION_NOE 的<|>RELATION_NOE 原则<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 围术期<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 采用<|>RELATION_NOE 人性化<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
人性化<|>RELATION_NOE 护理<|>RELATION_NOE 充分<|>RELATION_B 体现<|>RELATION_I 以<|>RELATION_I 人<|>RELATION_I 为<|>RELATION_I 本<|>RELATION_I 的<|>RELATION_I 护理<|>RELATION_I 理念<|>RELATION_E ,<|>RELATION_NOE 有效<|>RELATION_NOE 提高<|>RELATION_NOE 了<|>RELATION_NOE 护理<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 了<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE ,<|>RELATION_NOE 改善<|>RELATION_NOE 了<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质<|>RELATION_NOE 量<|>RELATION_NOE 。<|>RELATION_NOE
血浆<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CA199<|>RELATION_NOE 、<|>RELATION_NOE CA153<|>RELATION_NOE 联合<|>RELATION_NOE 检测<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_B 诊断<|>RELATION_I 价值<|>RELATION_E
探讨<|>RELATION_NOE 血浆<|>RELATION_NOE 细胞角蛋白<|>RELATION_NOE 19<|>RELATION_NOE 片<|>RELATION_NOE 段<|>RELATION_NOE (<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 糖链<|>RELATION_NOE 抗原<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE 水平<|>RELATION_NOE 测定<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 诊断<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 放射<|>RELATION_NOE 免疫<|>RELATION_NOE 分析法<|>RELATION_NOE 和<|>RELATION_NOE 化学发光<|>RELATION_NOE 免疫法<|>RELATION_NOE 检测<|>RELATION_S 了<|>RELATION_NOE 184<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE (<|>RELATION_NOE 包括<|>RELATION_NOE 81<|>RELATION_NOE 例<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 、<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 和<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 血浆<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 和<|>RELATION_NOE 糖链<|>RELATION_NOE 抗原<|>RELATION_NOE 125<|>RELATION_NOE 、<|>RELATION_NOE 199<|>RELATION_NOE 和<|>RELATION_NOE 153<|>RELATION_NOE (<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CA199<|>RELATION_NOE 和<|>RELATION_NOE CA153<|>RELATION_NOE )<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 与<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 60<|>RELATION_NOE 名<|>RELATION_NOE 正常<|>RELATION_NOE 对照者<|>RELATION_NOE 进行<|>RELATION_NOE 了<|>RELATION_NOE 比较性<|>RELATION_NOE 分析<|>RELATION_NOE ;<|>RELATION_NOE
与<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE 肺部<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 患者<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 184<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 血浆<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CA199<|>RELATION_NOE 和<|>RELATION_NOE CA153<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_B 升高<|>RELATION_E (<|>RELATION_NOE tCYFRA21-1<|>RELATION_NOE =<|>RELATION_NOE 5.6<|>RELATION_NOE 37<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 184<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 81<|>RELATION_NOE 例<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 血浆<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE 升高<|>RELATION_NOE 最为<|>RELATION_B 显著<|>RELATION_E ,<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 血浆<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CA199<|>RELATION_NOE 和<|>RELATION_NOE CA153<|>RELATION_NOE 水平<|>RELATION_NOE 升高<|>RELATION_NOE 最为<|>RELATION_NOE 明显<|>RELATION_NOE 。<|>RELATION_NOE 在<|>RELATION_NOE 184<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 81<|>RELATION_NOE 例<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 血浆<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 水平<|>RELATION_NOE 升高<|>RELATION_NOE 最为<|>RELATION_NOE 显著<|>RELATION_NOE ,<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 血浆<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CA199<|>RELATION_NOE 和<|>RELATION_NOE CA153<|>RELATION_NOE 水平<|>RELATION_NOE 升高<|>RELATION_NOE 最为<|>RELATION_B 明显<|>RELATION_E 。<|>RELATION_NOE
血浆<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CA199<|>RELATION_NOE 和<|>RELATION_NOE CA153<|>RELATION_NOE 水平<|>RELATION_NOE 测定<|>RELATION_NOE 是<|>RELATION_NOE 诊断<|>RELATION_B 肺癌<|>RELATION_E 的<|>RELATION_NOE 有<|>RELATION_NOE 价值<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE ,<|>RELATION_NOE 它们<|>RELATION_NOE 的<|>RELATION_NOE 联合<|>RELATION_NOE 测定<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_NOE 诊断<|>RELATION_NOE 灵敏度<|>RELATION_NOE 和<|>RELATION_NOE 准确率<|>RELATION_NOE 。<|>RELATION_NOE 血浆<|>RELATION_NOE CYFRA21-1<|>RELATION_NOE 、<|>RELATION_NOE CA125<|>RELATION_NOE 、<|>RELATION_NOE CA199<|>RELATION_NOE 和<|>RELATION_NOE CA153<|>RELATION_NOE 水平<|>RELATION_NOE 测定<|>RELATION_NOE 是<|>RELATION_NOE 诊断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 有<|>RELATION_NOE 价值<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标志物<|>RELATION_NOE ,<|>RELATION_NOE 它们<|>RELATION_NOE 的<|>RELATION_NOE 联合<|>RELATION_NOE 测定<|>RELATION_NOE 可以<|>RELATION_NOE 提高<|>RELATION_S 诊断<|>RELATION_NOE 灵敏度<|>RELATION_NOE 和<|>RELATION_NOE 准确率<|>RELATION_NOE 。<|>RELATION_NOE
电视<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 治疗<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 倾向性<|>RELATION_NOE 匹配<|>RELATION_NOE 研究<|>RELATION_NOE 的<|>RELATION_NOE 系统性<|>RELATION_NOE 评价<|>RELATION_NOE
按照<|>RELATION_NOE Cochrane<|>RELATION_NOE 系统<|>RELATION_NOE 评价<|>RELATION_NOE 制作<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 收集<|>RELATION_NOE 所有<|>RELATION_NOE 倾向<|>RELATION_NOE 值<|>RELATION_NOE 匹配<|>RELATION_NOE 研究<|>RELATION_NOE 的<|>RELATION_NOE 病例<|>RELATION_NOE 对照<|>RELATION_NOE 试验<|>RELATION_NOE ,<|>RELATION_NOE 研究<|>RELATION_NOE 内容<|>RELATION_NOE 包括<|>RELATION_NOE 围手术期<|>RELATION_NOE 死亡率<|>RELATION_NOE 、<|>RELATION_NOE 复发率<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE RevMan5.0<|>RELATION_NOE 软件<|>RELATION_NOE 进行<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
共<|>RELATION_NOE 纳入<|>RELATION_NOE 11<|>RELATION_NOE 篇<|>RELATION_NOE 病例<|>RELATION_NOE 对照<|>RELATION_NOE 试验<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 40<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE 表明<|>RELATION_NOE :<|>RELATION_NOE VATS<|>RELATION_NOE 能<|>RELATION_NOE 明显<|>RELATION_NOE 降低<|>RELATION_NOE 术后<|>RELATION_NOE 肺部<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.0001<|>RELATION_NOE ,<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.67<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 0.55<|>RELATION_NOE －0.81<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 全身<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.00001<|>RELATION_NOE ,<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.66<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 0.57<|>RELATION_NOE －0.76<|>RELATION_NOE )<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 、<|>RELATION_NOE 减少<|>RELATION_S 肿瘤<|>RELATION_NOE 复发率<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.00001<|>RELATION_NOE ,<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.62<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 0.53<|>RELATION_NOE －0.71<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 对<|>RELATION_NOE 总<|>RELATION_NOE 死亡率<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.32<|>RELATION_NOE ,<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.78<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 0.47<|>RELATION_NOE －1.27<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 开<|>RELATION_NOE 胸术<|>RELATION_NOE 相比<|>RELATION_NOE 没有<|>RELATION_NOE 优势<|>RELATION_NOE 。<|>RELATION_NOE
针对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE 综合<|>RELATION_NOE 分期Ⅰ<|>RELATION_NOE 、<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_B 传统<|>RELATION_I 开<|>RELATION_I 胸术<|>RELATION_I 相比<|>RELATION_E ,<|>RELATION_NOE VATS<|>RELATION_NOE 能<|>RELATION_NOE 明显<|>RELATION_NOE 减少<|>RELATION_NOE 肺部<|>RELATION_NOE 及<|>RELATION_NOE 全身<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生率<|>RELATION_NOE 、<|>RELATION_NOE 降低<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发率<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 总<|>RELATION_NOE 死亡率<|>RELATION_NOE 相比<|>RELATION_NOE 没有<|>RELATION_NOE 优势<|>RELATION_NOE 。<|>RELATION_NOE
异丙酚<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 及<|>RELATION_NOE 侵袭力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
用<|>RELATION_NOE RPMI-1640<|>RELATION_NOE 培养液<|>RELATION_NOE 将<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 株<|>RELATION_NOE 按<|>RELATION_NOE 2×<|>RELATION_NOE 105<|>RELATION_NOE 个<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE 细胞密度<|>RELATION_NOE 接种<|>RELATION_NOE 于<|>RELATION_NOE 96<|>RELATION_NOE 孔<|>RELATION_NOE 培养板<|>RELATION_NOE 和<|>RELATION_NOE 6孔<|>RELATION_NOE 培养<|>RELATION_NOE 板<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 每孔<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 100<|>RELATION_NOE μ<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE 2000<|>RELATION_NOE μ<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 于<|>RELATION_NOE 5%<|>RELATION_NOE CO2<|>RELATION_NOE 、<|>RELATION_NOE 饱和<|>RELATION_NOE 湿度<|>RELATION_NOE 37<|>RELATION_NOE ℃<|>RELATION_NOE 培养<|>RELATION_NOE 24h<|>RELATION_NOE .<|>RELATION_NOE
于<|>RELATION_NOE 药物<|>RELATION_NOE 孵育<|>RELATION_NOE 24h<|>RELATION_NOE 时<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE HCS<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S caspase-3<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE
异丙酚<|>RELATION_NOE 可<|>RELATION_NOE 促进<|>RELATION_S 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 力.<|>RELATION_NOE 异丙酚<|>RELATION_NOE 可<|>RELATION_NOE 促进<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭力<|>RELATION_NOE .<|>RELATION_NOE
风险<|>RELATION_NOE 预警<|>RELATION_NOE 管理<|>RELATION_NOE 在<|>RELATION_NOE 预防<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE 外周<|>RELATION_NOE 静脉<|>RELATION_NOE 置入<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 导管<|>RELATION_NOE 相关性<|>RELATION_NOE 血栓<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
探讨<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE 外周<|>RELATION_NOE 静脉<|>RELATION_NOE 置入<|>RELATION_NOE 中心<|>RELATION_NOE 静脉<|>RELATION_NOE 导管<|>RELATION_NOE (<|>RELATION_NOE PICC<|>RELATION_NOE )<|>RELATION_NOE 导管<|>RELATION_NOE 相关性<|>RELATION_NOE 血栓<|>RELATION_NOE 的<|>RELATION_NOE 风险<|>RELATION_NOE 预警<|>RELATION_NOE 管理<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 提高<|>RELATION_S 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE PICC<|>RELATION_NOE 置管<|>RELATION_NOE 的<|>RELATION_NOE 有效性<|>RELATION_NOE 和<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
将<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 12月<|>RELATION_NOE 在<|>RELATION_NOE 上海市<|>RELATION_NOE 胸科<|>RELATION_NOE 医院<|>RELATION_NOE 进行<|>RELATION_NOE PICC<|>RELATION_NOE 置管<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 761<|>RELATION_NOE 例<|>RELATION_NOE 作为<|>RELATION_NOE 观察组<|>RELATION_NOE ,<|>RELATION_NOE 运用<|>RELATION_NOE Autar<|>RELATION_NOE 量表<|>RELATION_NOE 对<|>RELATION_NOE 置管<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 血栓<|>RELATION_NOE 风险<|>RELATION_NOE 评估<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 风险<|>RELATION_NOE 评估<|>RELATION_NOE 将<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 低<|>RELATION_NOE 风险组<|>RELATION_NOE 332<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 中<|>RELATION_NOE 风险组<|>RELATION_NOE 36<|>RELATION_NOE 4例<|>RELATION_NOE 和<|>RELATION_NOE 高<|>RELATION_NOE 风险<|>RELATION_NOE 组<|>RELATION_NOE 65<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 3组<|>RELATION_NOE 患者<|>RELATION_NOE 给予<|>RELATION_NOE 分级<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE ,<|>RELATION_NOE 低<|>RELATION_NOE 风险组<|>RELATION_NOE 和<|>RELATION_NOE 中<|>RELATION_NOE 风险组<|>RELATION_NOE 给予<|>RELATION_NOE 物理<|>RELATION_NOE 干预<|>RELATION_NOE 、<|>RELATION_NOE 基本<|>RELATION_NOE 药物<|>RELATION_NOE 干预<|>RELATION_NOE ;<|>RELATION_NOE
对照组<|>RELATION_NOE 873<|>RELATION_NOE 例<|>RELATION_NOE 置管<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE PICC<|>RELATION_NOE 导管<|>RELATION_NOE 相关性<|>RELATION_NOE 血栓<|>RELATION_NOE ,<|>RELATION_NOE 血栓<|>RELATION_NOE 发生率<|>RELATION_NOE 为<|>RELATION_NOE 3.6<|>RELATION_NOE 6%<|>RELATION_NOE .<|>RELATION_NOE
运用<|>RELATION_NOE 风险<|>RELATION_NOE 预警<|>RELATION_NOE 管理<|>RELATION_NOE 可以<|>RELATION_NOE 降低<|>RELATION_S 高凝<|>RELATION_NOE 状态<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE PICC<|>RELATION_NOE 导管<|>RELATION_NOE 相关性<|>RELATION_NOE 血栓<|>RELATION_NOE 等<|>RELATION_NOE 并发症<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE .<|>RELATION_NOE
MRP1<|>RELATION_NOE 与<|>RELATION_NOE ToPo-<|>RELATION_NOE Ⅱ<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_B 及其<|>RELATION_I 临床<|>RELATION_I 意义<|>RELATION_E
(<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE MRP1<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 高于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE MRP1<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 分期<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
两<|>RELATION_NOE 种<|>RELATION_NOE 不同<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 及<|>RELATION_NOE 免疫力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 不同<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 及<|>RELATION_NOE 免疫力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
选择<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 46<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE NP<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE 和<|>RELATION_NOE DP<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 多<|>RELATION_NOE 西<|>RELATION_NOE 紫杉醇<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE )<|>RELATION_NOE 23<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 于<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 和<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 化疗<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE 监测<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 及<|>RELATION_NOE 免疫力<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
NP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 能够<|>RELATION_B 减轻<|>RELATION_E 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 因<|>RELATION_NOE 化疗<|>RELATION_NOE 造成<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 降低<|>RELATION_NOE 程度<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 造成<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 降低<|>RELATION_NOE 程度<|>RELATION_NOE 优于<|>RELATION_NOE DP<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE ;<|>RELATION_NOE NP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 能够<|>RELATION_NOE 减轻<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 因<|>RELATION_NOE 化疗<|>RELATION_NOE 造成<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 降低<|>RELATION_NOE 程度<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 化疗<|>RELATION_NOE 造成<|>RELATION_NOE 的<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 降低<|>RELATION_NOE 程度<|>RELATION_NOE 优于<|>RELATION_S DP<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE ;<|>RELATION_NOE
立体<|>RELATION_NOE 定向<|>RELATION_NOE 放疗<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 中心<|>RELATION_NOE 位置<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_S
尽管<|>RELATION_NOE 分<|>RELATION_NOE 次间<|>RELATION_NOE 肺部肿瘤<|>RELATION_NOE 平均<|>RELATION_NOE 中心<|>RELATION_NOE 位置<|>RELATION_NOE 移动<|>RELATION_NOE 在<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 方向上<|>RELATION_NOE 均<|>RELATION_B 较<|>RELATION_I 小<|>RELATION_E ,<|>RELATION_NOE 但<|>RELATION_NOE 超过<|>RELATION_NOE 5mm<|>RELATION_NOE 的<|>RELATION_NOE 次数<|>RELATION_NOE 约<|>RELATION_NOE 占<|>RELATION_NOE 1/3<|>RELATION_NOE ,<|>RELATION_NOE 这<|>RELATION_NOE 提示<|>RELATION_NOE PTV<|>RELATION_NOE 外<|>RELATION_NOE 扩<|>RELATION_NOE 的<|>RELATION_NOE 边界<|>RELATION_NOE 不够<|>RELATION_NOE ,<|>RELATION_NOE 尤其<|>RELATION_NOE 是<|>RELATION_NOE 在<|>RELATION_NOE 腹背<|>RELATION_NOE 方向<|>RELATION_NOE .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE DLC-1<|>RELATION_NOE 、<|>RELATION_NOE ROCKI<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
选取<|>RELATION_NOE 48<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 并<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 组织<|>RELATION_NOE 及<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S DLC-1<|>RELATION_NOE 、<|>RELATION_NOE ROCKI<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 二者<|>RELATION_NOE 之间<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 及其<|>RELATION_NOE 与<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE DLC-1<|>RELATION_NOE 基因<|>RELATION_NOE 对<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
NSCLC<|>RELATION_NOE 中<|>RELATION_NOE DLC-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 等<|>RELATION_NOE 无关<|>RELATION_S ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分<|>RELATION_NOE 期<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ;<|>RELATION_NOE NSCLC<|>RELATION_NOE 中<|>RELATION_NOE DLC-1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 等<|>RELATION_NOE 无关<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE TNM<|>RELATION_NOE 分期<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE 且<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ;<|>RELATION_NOE
DLC-1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 或<|>RELATION_NOE 表达<|>RELATION_NOE 缺失<|>RELATION_NOE 、<|>RELATION_NOE ROCKI<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_B 的<|>RELATION_I 发生<|>RELATION_I 、<|>RELATION_I 发展<|>RELATION_E 中<|>RELATION_NOE 可能<|>RELATION_NOE 扮演<|>RELATION_NOE 重要<|>RELATION_NOE 角色<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE DLC-1<|>RELATION_NOE 及<|>RELATION_NOE ROCKI<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_NOE 判断<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE DLC-1<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 低<|>RELATION_NOE 表达<|>RELATION_NOE 或<|>RELATION_NOE 表达<|>RELATION_NOE 缺失<|>RELATION_NOE 、<|>RELATION_NOE ROCKI<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 中<|>RELATION_NOE 可能<|>RELATION_NOE 扮演<|>RELATION_NOE 重要<|>RELATION_NOE 角色<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE DLC-1<|>RELATION_NOE 及<|>RELATION_NOE ROCKI<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_B 判断<|>RELATION_E NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
同期<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 2<|>RELATION_NOE 和<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE β1<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 及其<|>RELATION_NOE 意义<|>RELATION_NOE
比较<|>RELATION_NOE 同期<|>RELATION_NOE 放化疗<|>RELATION_NOE 和<|>RELATION_NOE 放化<|>RELATION_NOE 序贯<|>RELATION_NOE 治疗<|>RELATION_NOE 对<|>RELATION_NOE 局部<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE 2<|>RELATION_NOE (<|>RELATION_NOE MMP-2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 转化<|>RELATION_NOE 生长因子<|>RELATION_NOE β1<|>RELATION_NOE (<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
20<|>RELATION_NOE 10年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 12月<|>RELATION_NOE 64<|>RELATION_NOE 例经<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE Ⅱ<|>RELATION_NOE B<|>RELATION_NOE 至<|>RELATION_NOE Ⅲ<|>RELATION_NOE B<|>RELATION_NOE 期<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 通过<|>RELATION_NOE 抽签<|>RELATION_NOE 方法<|>RELATION_NOE 被<|>RELATION_NOE 随机<|>RELATION_NOE 分成<|>RELATION_NOE 放化<|>RELATION_NOE 同期<|>RELATION_NOE 治疗组<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 放化<|>RELATION_NOE 序贯<|>RELATION_NOE 治疗组<|>RELATION_NOE (<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE 采用<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 及<|>RELATION_NOE 同期<|>RELATION_NOE EP<|>RELATION_NOE 或<|>RELATION_NOE TC<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE 接受<|>RELATION_NOE 三维<|>RELATION_NOE 适形<|>RELATION_NOE 放疗<|>RELATION_NOE 后<|>RELATION_NOE 序贯<|>RELATION_NOE EP<|>RELATION_NOE 或<|>RELATION_NOE TC<|>RELATION_NOE 方案<|>RELATION_NOE 化疗.<|>RELATION_NOE
表面<|>RELATION_NOE 增强<|>RELATION_NOE 激光解<|>RELATION_NOE 吸<|>RELATION_NOE 电离<|>RELATION_NOE 飞行<|>RELATION_NOE 时间<|>RELATION_NOE 质谱<|>RELATION_NOE 蛋白质芯片<|>RELATION_NOE 筛查<|>RELATION_S 肺癌<|>RELATION_NOE 血清<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白质<|>RELATION_NOE 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
应用<|>RELATION_NOE CM-10<|>RELATION_NOE 蛋白质芯片<|>RELATION_NOE 对<|>RELATION_NOE 肺鳞状细胞癌<|>RELATION_NOE 38<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 健康<|>RELATION_NOE 对照组<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE 的<|>RELATION_NOE 血清<|>RELATION_NOE 样品<|>RELATION_NOE 进行<|>RELATION_NOE 蛋白质<|>RELATION_NOE 指纹<|>RELATION_NOE 图谱<|>RELATION_NOE 测定<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 34<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 术前<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 对比<|>RELATION_NOE 检测<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE BioMarker<|>RELATION_NOE Wizard<|>RELATION_NOE 及<|>RELATION_NOE BioMarker<|>RELATION_NOE pattern<|>RELATION_NOE system<|>RELATION_NOE 分析<|>RELATION_NOE 软件<|>RELATION_NOE 对<|>RELATION_NOE 所得<|>RELATION_NOE 的<|>RELATION_NOE 数据<|>RELATION_NOE 进行<|>RELATION_NOE 处理<|>RELATION_NOE 并<|>RELATION_NOE 建立<|>RELATION_NOE 诊断<|>RELATION_NOE 模型<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 术前<|>RELATION_NOE 和<|>RELATION_NOE 术后<|>RELATION_NOE 有<|>RELATION_NOE 9<|>RELATION_NOE 个<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白质<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 转移<|>RELATION_NOE 和<|>RELATION_NOE 无<|>RELATION_NOE 转移<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 有<|>RELATION_NOE 8<|>RELATION_NOE 个<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白质<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
SELDI<|>RELATION_NOE 技术<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 的<|>RELATION_I 诊断<|>RELATION_E 中<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 成为<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 有效<|>RELATION_NOE 的<|>RELATION_NOE 筛查<|>RELATION_NOE 手段<|>RELATION_NOE .<|>RELATION_NOE
TNF-<|>RELATION_NOE α<|>RELATION_NOE -308<|>RELATION_NOE 位点<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 关系<|>RELATION_S 的<|>RELATION_NOE Meta<|>RELATION_NOE 分析<|>RELATION_NOE
在<|>RELATION_NOE 亚洲<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE -308<|>RELATION_NOE 位点<|>RELATION_NOE 可能<|>RELATION_B 是<|>RELATION_I 增加<|>RELATION_E 肺癌<|>RELATION_NOE 患病<|>RELATION_NOE 风险<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 高加索<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE -308<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发病<|>RELATION_NOE 风险<|>RELATION_NOE 不<|>RELATION_NOE 存在<|>RELATION_NOE 相关<|>RELATION_NOE 性.<|>RELATION_NOE 在<|>RELATION_NOE 亚洲<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE -308<|>RELATION_NOE 位点<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 增加<|>RELATION_NOE 肺癌<|>RELATION_NOE 患病<|>RELATION_NOE 风险<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 高加索<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE -308<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发病<|>RELATION_NOE 风险<|>RELATION_NOE 不<|>RELATION_B 存在<|>RELATION_I 相关性<|>RELATION_E .<|>RELATION_NOE
二甲双胍<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 耐厄<|>RELATION_NOE 洛替尼<|>RELATION_NOE 细胞株<|>RELATION_NOE A549ER<|>RELATION_NOE 的<|>RELATION_NOE 耐药<|>RELATION_B 逆转<|>RELATION_I 作用<|>RELATION_E
将<|>RELATION_NOE 耐<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 细胞株<|>RELATION_NOE A549ER<|>RELATION_NOE 细胞<|>RELATION_NOE 分为<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 厄洛替尼组<|>RELATION_NOE 、<|>RELATION_NOE 二甲双胍<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE (<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE ±<|>RELATION_NOE 二甲双胍<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE CCK8<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 药物<|>RELATION_NOE 作用<|>RELATION_NOE 下<|>RELATION_NOE 各组<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 50%<|>RELATION_NOE 抑制<|>RELATION_NOE 浓度<|>RELATION_NOE (<|>RELATION_NOE IC50<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 耐药<|>RELATION_NOE 倍数<|>RELATION_NOE 和<|>RELATION_NOE 逆转<|>RELATION_NOE 倍数.<|>RELATION_NOE
采用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE A549ER<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 凋亡率<|>RELATION_NOE 和<|>RELATION_NOE 细胞周期<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 增殖<|>RELATION_NOE 指数<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 0<|>RELATION_NOE －<|>RELATION_NOE 20<|>RELATION_NOE mmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 浓度<|>RELATION_NOE 范围<|>RELATION_NOE 内<|>RELATION_NOE ,<|>RELATION_NOE 二甲双胍<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 及<|>RELATION_NOE A549ER<|>RELATION_NOE 细胞<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 生长<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 抑制率<|>RELATION_NOE 随<|>RELATION_NOE 二甲双胍<|>RELATION_NOE 浓度<|>RELATION_NOE 升高<|>RELATION_NOE 而<|>RELATION_NOE 增加<|>RELATION_S .<|>RELATION_NOE
厄洛替尼<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE A549ER<|>RELATION_NOE 的<|>RELATION_NOE IC50<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 15.15<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE 118.8<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE A549ER<|>RELATION_NOE 的<|>RELATION_NOE 耐药<|>RELATION_NOE 倍数<|>RELATION_NOE 为<|>RELATION_NOE 7.8<|>RELATION_NOE 4.<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE A549ER<|>RELATION_NOE 细胞<|>RELATION_NOE IC50<|>RELATION_NOE 为<|>RELATION_NOE 73.55<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ,<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE 倍数<|>RELATION_NOE 为<|>RELATION_NOE 4.8<|>RELATION_NOE 5.<|>RELATION_NOE 二甲双胍<|>RELATION_NOE 对<|>RELATION_NOE A549ER<|>RELATION_NOE 厄洛替尼<|>RELATION_NOE 耐药性<|>RELATION_NOE 的<|>RELATION_NOE 逆转<|>RELATION_NOE 倍数<|>RELATION_NOE 为<|>RELATION_NOE 1.6<|>RELATION_NOE 2.<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 厄洛替尼组<|>RELATION_NOE 、<|>RELATION_NOE 二甲双胍<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE 的<|>RELATION_NOE 凋亡率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 5.53<|>RELATION_NOE ±<|>RELATION_NOE 3.00<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 7.51<|>RELATION_NOE ±<|>RELATION_NOE 3.73<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 10.25<|>RELATION_NOE ±<|>RELATION_NOE 4.23<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE 和<|>RELATION_NOE (<|>RELATION_NOE 16.92<|>RELATION_NOE ±<|>RELATION_NOE 1.20<|>RELATION_NOE )<|>RELATION_NOE %.<|>RELATION_NOE
根据<|>RELATION_NOE 细胞周期<|>RELATION_NOE 结果<|>RELATION_NOE 计算<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 厄洛替尼组<|>RELATION_NOE 、<|>RELATION_NOE 二甲双胍<|>RELATION_NOE 组<|>RELATION_NOE 和<|>RELATION_NOE 联合<|>RELATION_NOE 用药组<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 指数<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.84<|>RELATION_NOE ±<|>RELATION_NOE 0.15<|>RELATION_NOE 、<|>RELATION_NOE 0.78<|>RELATION_NOE ±<|>RELATION_NOE 0.10<|>RELATION_NOE 、<|>RELATION_NOE 0.73<|>RELATION_NOE ±<|>RELATION_NOE 0.08<|>RELATION_NOE 和<|>RELATION_NOE 0.60<|>RELATION_NOE ±<|>RELATION_NOE 0.09<|>RELATION_NOE 。<|>RELATION_NOE
二甲双胍<|>RELATION_NOE 通过<|>RELATION_B 抑制<|>RELATION_I 细胞<|>RELATION_I 生长<|>RELATION_I 、<|>RELATION_I 促进<|>RELATION_I 细胞凋亡<|>RELATION_I 、<|>RELATION_I 减缓<|>RELATION_I 细胞周期<|>RELATION_I 进程<|>RELATION_I 等<|>RELATION_I 途径<|>RELATION_E 逆转<|>RELATION_NOE A549ER<|>RELATION_NOE 细胞<|>RELATION_NOE 耐<|>RELATION_NOE 药<|>RELATION_NOE .<|>RELATION_NOE
慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 甲状腺<|>RELATION_NOE 激素<|>RELATION_NOE 水平<|>RELATION_NOE 变化<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 意义<|>RELATION_E
将<|>RELATION_NOE 兰州<|>RELATION_NOE 军区<|>RELATION_NOE 兰州<|>RELATION_NOE 总医院<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 1月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 96<|>RELATION_NOE 例<|>RELATION_NOE COPD<|>RELATION_NOE 患者<|>RELATION_NOE 纳入<|>RELATION_NOE COPD<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 按<|>RELATION_NOE 病情<|>RELATION_NOE 分为<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 亚组<|>RELATION_NOE ,<|>RELATION_NOE COPD<|>RELATION_NOE 缓解<|>RELATION_NOE 期组<|>RELATION_NOE (<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE COPD<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 无<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE COPD<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 并<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
对照组<|>RELATION_NOE 血清<|>RELATION_NOE 总<|>RELATION_NOE 三<|>RELATION_NOE 碘<|>RELATION_NOE 甲状腺<|>RELATION_NOE 原<|>RELATION_NOE 氨酸<|>RELATION_NOE (<|>RELATION_NOE TT3<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 总<|>RELATION_NOE 四<|>RELATION_NOE 碘<|>RELATION_NOE 甲状腺<|>RELATION_NOE 原<|>RELATION_NOE 氨酸<|>RELATION_NOE (<|>RELATION_NOE TT4<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 促<|>RELATION_NOE 甲状腺<|>RELATION_NOE 激素<|>RELATION_NOE (<|>RELATION_NOE TSH<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 游离<|>RELATION_NOE 三<|>RELATION_NOE 碘<|>RELATION_NOE 甲状腺<|>RELATION_NOE 原<|>RELATION_NOE 氨酸<|>RELATION_NOE (<|>RELATION_NOE FT3<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 游离<|>RELATION_NOE 四<|>RELATION_NOE 碘<|>RELATION_NOE 甲状腺<|>RELATION_NOE 原<|>RELATION_NOE 氨酸<|>RELATION_NOE (<|>RELATION_NOE FT4<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 1.5<|>RELATION_NOE ±<|>RELATION_NOE 0.5<|>RELATION_NOE )<|>RELATION_NOE nmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 96<|>RELATION_NOE ±<|>RELATION_NOE 36<|>RELATION_NOE )<|>RELATION_NOE nmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 3.3<|>RELATION_NOE ±<|>RELATION_NOE 1.2<|>RELATION_NOE )<|>RELATION_NOE mU<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 4.4<|>RELATION_NOE ±<|>RELATION_NOE 1.2<|>RELATION_NOE )<|>RELATION_NOE pmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 16.6<|>RELATION_NOE ±<|>RELATION_NOE 9.6<|>RELATION_NOE )<|>RELATION_NOE pmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ;<|>RELATION_NOE
COPD<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 无<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 0.77<|>RELATION_NOE ±<|>RELATION_NOE 0.45<|>RELATION_NOE )<|>RELATION_NOE nmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 66<|>RELATION_NOE ±<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE nmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 2.6<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE )<|>RELATION_NOE mU<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.9<|>RELATION_NOE ±<|>RELATION_NOE 0.8<|>RELATION_NOE )<|>RELATION_NOE pmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 11.3<|>RELATION_NOE ±<|>RELATION_NOE 6.6<|>RELATION_NOE )<|>RELATION_NOE pmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ;<|>RELATION_NOE
COPD<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 并<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 组<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 0.45<|>RELATION_NOE ±<|>RELATION_NOE 0.24<|>RELATION_NOE )<|>RELATION_NOE nmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 44<|>RELATION_NOE ±<|>RELATION_NOE 25<|>RELATION_NOE )<|>RELATION_NOE nmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.2<|>RELATION_NOE ±<|>RELATION_NOE 0.6<|>RELATION_NOE )<|>RELATION_NOE mU<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 1.5<|>RELATION_NOE ±<|>RELATION_NOE 0.7<|>RELATION_NOE )<|>RELATION_NOE pmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 7.9<|>RELATION_NOE ±<|>RELATION_NOE 3.4<|>RELATION_NOE )<|>RELATION_NOE pmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ;<|>RELATION_NOE
COPD<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 无<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 组<|>RELATION_NOE TT3<|>RELATION_NOE 、<|>RELATION_NOE FT3<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E COPD<|>RELATION_NOE 缓解<|>RELATION_NOE 期组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE TT4<|>RELATION_NOE 、<|>RELATION_NOE FT4<|>RELATION_NOE 、<|>RELATION_NOE TSH<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE COPD<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 并<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 组<|>RELATION_NOE TT3<|>RELATION_NOE 、<|>RELATION_NOE FT3<|>RELATION_NOE 、<|>RELATION_NOE TT4<|>RELATION_NOE 、<|>RELATION_NOE FT4<|>RELATION_NOE 、<|>RELATION_NOE TSH<|>RELATION_NOE 均<|>RELATION_NOE COPD<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 无<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 组<|>RELATION_NOE TT3<|>RELATION_NOE 、<|>RELATION_NOE FT3<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE COPD<|>RELATION_NOE 缓解<|>RELATION_NOE 期组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE TT4<|>RELATION_NOE 、<|>RELATION_NOE FT4<|>RELATION_NOE 、<|>RELATION_NOE TSH<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE COPD<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 并<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 组<|>RELATION_NOE TT3<|>RELATION_NOE 、<|>RELATION_NOE FT3<|>RELATION_NOE 、<|>RELATION_NOE COPD<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 无<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 组<|>RELATION_NOE TT3<|>RELATION_NOE 、<|>RELATION_NOE FT3<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE COPD<|>RELATION_NOE 缓解<|>RELATION_NOE 期组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE TT4<|>RELATION_NOE 、<|>RELATION_NOE FT4<|>RELATION_NOE 、<|>RELATION_NOE TSH<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE COPD<|>RELATION_NOE 急性<|>RELATION_NOE 发作<|>RELATION_NOE 并<|>RELATION_NOE 呼吸衰竭<|>RELATION_NOE 组<|>RELATION_NOE TT3<|>RELATION_NOE 、<|>RELATION_NOE FT3<|>RELATION_NOE 、<|>RELATION_NOE TT4<|>RELATION_NOE 、<|>RELATION_NOE FT4<|>RELATION_NOE 、<|>RELATION_NOE TSH<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E COPD<|>RELATION_NOE 缓解组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
甲状腺<|>RELATION_NOE 激素<|>RELATION_NOE 水平<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE COPD<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病情<|>RELATION_NOE 有<|>RELATION_NOE 密切<|>RELATION_B 关系<|>RELATION_E ,<|>RELATION_NOE 测定<|>RELATION_NOE 甲状腺<|>RELATION_NOE 激素<|>RELATION_NOE 水平<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE COPD<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病情<|>RELATION_NOE 有<|>RELATION_NOE 密切<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 测定<|>RELATION_NOE 甲状腺<|>RELATION_NOE 激素<|>RELATION_NOE 水平<|>RELATION_NOE 可<|>RELATION_NOE 用于<|>RELATION_B 评估<|>RELATION_I COPD<|>RELATION_I 患者<|>RELATION_I 病情<|>RELATION_I 的<|>RELATION_I 严重<|>RELATION_I 程度<|>RELATION_E ,<|>RELATION_NOE 病情<|>RELATION_NOE 越<|>RELATION_NOE 重<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺<|>RELATION_NOE 激素<|>RELATION_NOE 水平<|>RELATION_NOE 下降<|>RELATION_NOE 幅度<|>RELATION_NOE 越<|>RELATION_NOE 大<|>RELATION_NOE .<|>RELATION_NOE
CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 的<|>RELATION_NOE 表面<|>RELATION_NOE 通透性<|>RELATION_NOE 参数<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_B 早期<|>RELATION_I 应用<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE (<|>RELATION_NOE CT-p<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表面<|>RELATION_NOE 通透性<|>RELATION_NOE 参数<|>RELATION_NOE (<|>RELATION_NOE PS<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 及<|>RELATION_NOE 化疗<|>RELATION_NOE 早期<|>RELATION_NOE (<|>RELATION_NOE 第1<|>RELATION_NOE 个<|>RELATION_NOE 化疗<|>RELATION_NOE 周期<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 及<|>RELATION_NOE 与<|>RELATION_B 化疗<|>RELATION_I 疗效<|>RELATION_I 的<|>RELATION_I 关系<|>RELATION_E 。<|>RELATION_NOE
将<|>RELATION_NOE 80<|>RELATION_NOE 例经<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE 的<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 一线<|>RELATION_NOE 药物<|>RELATION_NOE 进行<|>RELATION_NOE 标准化<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 于<|>RELATION_NOE 化疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 化疗1<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 对<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进行<|>RELATION_NOE CT-p<|>RELATION_NOE 检查.<|>RELATION_NOE
在<|>RELATION_NOE 化疗<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 后<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 进行<|>RELATION_NOE 实体瘤<|>RELATION_NOE 评价<|>RELATION_NOE 标准<|>RELATION_NOE (<|>RELATION_NOE RECIST<|>RELATION_NOE )<|>RELATION_NOE 评价<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 按<|>RELATION_NOE 评价<|>RELATION_NOE 的<|>RELATION_NOE
化疗<|>RELATION_NOE 早期<|>RELATION_NOE PS<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 反映<|>RELATION_E 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 血管<|>RELATION_NOE 灌注<|>RELATION_NOE 情况<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE .<|>RELATION_NOE
在<|>RELATION_NOE 化疗<|>RELATION_NOE 早期<|>RELATION_NOE 可<|>RELATION_NOE 根据<|>RELATION_NOE PS<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 来<|>RELATION_NOE 预判<|>RELATION_S 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 预测<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 疗效<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE 之一<|>RELATION_NOE .<|>RELATION_NOE 在<|>RELATION_NOE 化疗<|>RELATION_NOE 早期<|>RELATION_NOE 可<|>RELATION_NOE 根据<|>RELATION_NOE PS<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 来<|>RELATION_NOE 预判<|>RELATION_NOE 患者<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 预测<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_I 化疗<|>RELATION_I 疗效<|>RELATION_E 的<|>RELATION_NOE 指标<|>RELATION_NOE 之一<|>RELATION_NOE .<|>RELATION_NOE
放松<|>RELATION_NOE 训练<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 康复效果<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
对照组<|>RELATION_NOE 进行<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 干预组<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 采取<|>RELATION_NOE 音乐疗法<|>RELATION_NOE 、<|>RELATION_NOE 渐进性<|>RELATION_NOE 肌肉<|>RELATION_NOE 放松<|>RELATION_NOE 及<|>RELATION_NOE 引导性<|>RELATION_NOE 想象<|>RELATION_NOE 等<|>RELATION_NOE 放松<|>RELATION_NOE 训练<|>RELATION_NOE 方法<|>RELATION_NOE 。<|>RELATION_NOE
干预<|>RELATION_NOE 前<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 状态<|>RELATION_NOE 焦虑<|>RELATION_NOE 问卷<|>RELATION_NOE 得分<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE 干预组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 状态<|>RELATION_NOE 焦虑<|>RELATION_NOE 问卷<|>RELATION_NOE 得分<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 干预<|>RELATION_NOE 前<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 状态<|>RELATION_NOE 焦虑<|>RELATION_NOE 问卷<|>RELATION_NOE 得分<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE 干预组<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 状态<|>RELATION_NOE 焦虑<|>RELATION_NOE 问卷<|>RELATION_NOE 得分<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
放松<|>RELATION_NOE 训练<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_B 缓解<|>RELATION_E 患者<|>RELATION_NOE 的<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 身体<|>RELATION_NOE 的<|>RELATION_NOE 不适感<|>RELATION_NOE 及<|>RELATION_NOE 疼痛<|>RELATION_NOE 度<|>RELATION_NOE 。<|>RELATION_NOE 放松<|>RELATION_NOE 训练<|>RELATION_NOE 可<|>RELATION_NOE 有效<|>RELATION_NOE 缓解<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 焦虑<|>RELATION_NOE 情绪<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_S 身体<|>RELATION_NOE 的<|>RELATION_NOE 不适感<|>RELATION_NOE 及<|>RELATION_NOE 疼痛<|>RELATION_NOE 度<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 心理<|>RELATION_B 体验<|>RELATION_E 的<|>RELATION_NOE 质性<|>RELATION_NOE 研究<|>RELATION_NOE
出现<|>RELATION_NOE 焦虑<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 、<|>RELATION_NOE 愤怒<|>RELATION_NOE 等<|>RELATION_NOE 负性<|>RELATION_NOE 情绪<|>RELATION_NOE ;<|>RELATION_NOE
肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 因<|>RELATION_NOE 多种<|>RELATION_NOE 因素<|>RELATION_NOE 存在<|>RELATION_B 明显<|>RELATION_E 焦虑<|>RELATION_NOE 和<|>RELATION_NOE 抑郁<|>RELATION_NOE ,<|>RELATION_NOE 医务<|>RELATION_NOE 人员<|>RELATION_NOE 应<|>RELATION_NOE 根据<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 需求<|>RELATION_NOE ,<|>RELATION_NOE 制定<|>RELATION_NOE 相应<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 治疗效果<|>RELATION_NOE 。<|>RELATION_NOE
肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术围<|>RELATION_NOE 术期<|>RELATION_NOE 加强<|>RELATION_NOE 优质<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 皆<|>RELATION_NOE 采用<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 下<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 围术期<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 健康<|>RELATION_NOE 宣教<|>RELATION_NOE 、<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 、<|>RELATION_NOE 术前<|>RELATION_NOE 准备<|>RELATION_NOE 、<|>RELATION_NOE 术中<|>RELATION_NOE 配合<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 护理<|>RELATION_NOE 及<|>RELATION_NOE 呼吸道<|>RELATION_NOE 管理<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 围术期<|>RELATION_NOE 加用<|>RELATION_NOE 优质<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 处理<|>RELATION_NOE ,<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 停留<|>RELATION_NOE 胸管<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 护理<|>RELATION_NOE 满意<|>RELATION_NOE 评分<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
研究组<|>RELATION_NOE 患者<|>RELATION_NOE 经过<|>RELATION_NOE 治疗<|>RELATION_NOE 护理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 停留<|>RELATION_NOE 胸管<|>RELATION_NOE 时间<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 、<|>RELATION_NOE 护理<|>RELATION_NOE 满意<|>RELATION_NOE 评分<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 依次<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 2.25<|>RELATION_NOE ±<|>RELATION_NOE 1.43<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 6.29<|>RELATION_NOE ±<|>RELATION_NOE 1.93<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 98.16<|>RELATION_NOE ±<|>RELATION_NOE 0.98<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 、<|>RELATION_NOE 7.50%<|>RELATION_NOE (<|>RELATION_NOE 6/80<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 则<|>RELATION_NOE 依次<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 4.68<|>RELATION_NOE ±<|>RELATION_NOE 1.86<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 8.89<|>RELATION_NOE ±<|>RELATION_NOE 2.55<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 89.22<|>RELATION_NOE ±<|>RELATION_NOE 1.06<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 、<|>RELATION_NOE 23.7<|>RELATION_NOE 5%<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE /<|>RELATION_NOE 80<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 研究组<|>RELATION_NOE 各个<|>RELATION_NOE 指标<|>RELATION_NOE 明显<|>RELATION_B 优于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 组间<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
局部<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 与<|>RELATION_NOE 序贯<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_S
p16<|>RELATION_NOE 和<|>RELATION_NOE FHIT<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S
应用<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 甲基化<|>RELATION_NOE 特异性<|>RELATION_NOE PCR<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 180<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 180<|>RELATION_NOE 名<|>RELATION_NOE 健康<|>RELATION_NOE 对照者<|>RELATION_NOE 外<|>RELATION_NOE 周血<|>RELATION_NOE p16<|>RELATION_NOE 、<|>RELATION_NOE FHIT<|>RELATION_NOE 基因<|>RELATION_NOE 启动<|>RELATION_NOE 子序列<|>RELATION_NOE 的<|>RELATION_NOE 甲基化率<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE 两者<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 和<|>RELATION_NOE 健康<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE 存在<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE .<|>RELATION_NOE
探讨<|>RELATION_NOE 各个<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 是否<|>RELATION_NOE 对<|>RELATION_NOE 两者<|>RELATION_NOE 的<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 的<|>RELATION_NOE 甲基化率<|>RELATION_NOE 产生<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 两者<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 以及<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 和<|>RELATION_NOE 吸烟史<|>RELATION_NOE 等<|>RELATION_NOE 因素<|>RELATION_NOE 与<|>RELATION_NOE 发生<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 危险<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
肺癌组<|>RELATION_NOE p16<|>RELATION_NOE 和<|>RELATION_NOE FHIT<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 高于<|>RELATION_S 对照组<|>RELATION_NOE (<|>RELATION_NOE p16<|>RELATION_NOE :<|>RELATION_NOE Z<|>RELATION_NOE =<|>RELATION_NOE -2.560<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 10<|>RELATION_NOE ;<|>RELATION_NOE
p16<|>RELATION_NOE 和<|>RELATION_NOE FHIT<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 性别<|>RELATION_NOE 、<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟史<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 组织<|>RELATION_NOE 类型<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 分期<|>RELATION_NOE 均<|>RELATION_B 无<|>RELATION_I 明显<|>RELATION_I 关联<|>RELATION_E (<|>RELATION_NOE p16<|>RELATION_NOE :<|>RELATION_NOE Z<|>RELATION_NOE =<|>RELATION_NOE -1.121<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.2<|>RELATION_NOE 62<|>RELATION_NOE ,<|>RELATION_NOE Z<|>RELATION_NOE =<|>RELATION_NOE -0.304<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 61<|>RELATION_NOE ,<|>RELATION_NOE Z<|>RELATION_NOE =<|>RELATION_NOE -0.082<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.9<|>RELATION_NOE 35<|>RELATION_NOE ,<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 0.5<|>RELATION_NOE 82<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.7<|>RELATION_NOE 48<|>RELATION_NOE ,<|>RELATION_NOE Z<|>RELATION_NOE =<|>RELATION_NOE -1.605<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.<|>RELATION_NOE 108<|>RELATION_NOE ;<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE 性别<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 危险性<|>RELATION_NOE 无<|>RELATION_B 影响<|>RELATION_E (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.2<|>RELATION_NOE 74<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.2<|>RELATION_NOE 97<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE p16<|>RELATION_NOE 和<|>RELATION_NOE FHIT<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE 性别<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 危险性<|>RELATION_NOE 无<|>RELATION_NOE 影响<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.2<|>RELATION_NOE 74<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.2<|>RELATION_NOE 97<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE p16<|>RELATION_NOE 和<|>RELATION_NOE FHIT<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 危险性<|>RELATION_NOE 有<|>RELATION_B 影响<|>RELATION_E (<|>RELATION_NOE OR<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.9<|>RELATION_NOE 52<|>RELATION_NOE 、<|>RELATION_NOE 1.8<|>RELATION_NOE 88<|>RELATION_NOE 、<|>RELATION_NOE 1.5<|>RELATION_NOE 98<|>RELATION_NOE 、<|>RELATION_NOE 1.8<|>RELATION_NOE 30<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE 值<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 0.002<|>RELATION_NOE 、<|>RELATION_NOE 0.003<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 27<|>RELATION_NOE 、<|>RELATION_NOE 0.005<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
多<|>RELATION_NOE 因素<|>RELATION_NOE logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE FHIT<|>RELATION_NOE 随着<|>RELATION_NOE 其<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 升高<|>RELATION_NOE ,<|>RELATION_NOE 患<|>RELATION_B 肺癌<|>RELATION_I 的<|>RELATION_I 危险性<|>RELATION_I 明显<|>RELATION_I 增加<|>RELATION_E (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.8<|>RELATION_NOE 67<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.006<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
联合2<|>RELATION_NOE 个<|>RELATION_NOE 基因<|>RELATION_NOE 甲基化<|>RELATION_NOE 检测<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_S 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE (<|>RELATION_NOE AUC<|>RELATION_NOE =<|>RELATION_NOE 0.8<|>RELATION_NOE 32<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
外<|>RELATION_NOE 周血<|>RELATION_NOE p16<|>RELATION_NOE 和<|>RELATION_NOE FHIT<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE 和<|>RELATION_NOE 肺癌<|>RELATION_NOE 有关<|>RELATION_S ;<|>RELATION_NOE
联合2<|>RELATION_NOE 个<|>RELATION_NOE 基因检测<|>RELATION_NOE 比<|>RELATION_NOE 单个<|>RELATION_NOE 基因检测<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 诊断<|>RELATION_NOE 价值<|>RELATION_NOE 高<|>RELATION_S ;<|>RELATION_NOE
p16<|>RELATION_NOE 和<|>RELATION_NOE FHIT<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE 水平<|>RELATION_NOE 检测<|>RELATION_NOE 有望<|>RELATION_B 成为<|>RELATION_E 肺癌<|>RELATION_NOE 筛查<|>RELATION_NOE 、<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 指标<|>RELATION_NOE .<|>RELATION_NOE
含铂<|>RELATION_NOE 与<|>RELATION_NOE 不<|>RELATION_NOE 含铂<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_B 三阴性<|>RELATION_I 乳腺癌<|>RELATION_I 首发<|>RELATION_I 肺<|>RELATION_I 转移<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 比较<|>RELATION_NOE
符合<|>RELATION_NOE 入选<|>RELATION_NOE 标准<|>RELATION_NOE 的<|>RELATION_NOE 65<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 按照<|>RELATION_NOE 一线<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE 是否<|>RELATION_NOE 含<|>RELATION_NOE 铂类<|>RELATION_NOE 药物<|>RELATION_NOE (<|>RELATION_NOE 顺铂<|>RELATION_NOE 或<|>RELATION_NOE 卡铂<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 分为<|>RELATION_NOE 含<|>RELATION_NOE 铂组<|>RELATION_NOE 与<|>RELATION_NOE 不<|>RELATION_NOE 含<|>RELATION_NOE 铂组.<|>RELATION_NOE
疗效<|>RELATION_NOE 观察<|>RELATION_NOE 指标<|>RELATION_NOE 包括<|>RELATION_NOE 无<|>RELATION_NOE 进展<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE PFS<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 总<|>RELATION_NOE 生存<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE OS<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 客观<|>RELATION_NOE 缓解率<|>RELATION_NOE 。<|>RELATION_NOE
Cox<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 仅<|>RELATION_NOE 一线<|>RELATION_NOE 含铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 有关<|>RELATION_S (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 三阴性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 首发<|>RELATION_NOE 肺转移<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_NOE 预后<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE Cox<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 仅<|>RELATION_NOE 一线<|>RELATION_NOE 含铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 与<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 有关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 三阴性<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 首发<|>RELATION_NOE 肺<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 预后<|>RELATION_I 因素<|>RELATION_E 。<|>RELATION_NOE
临床<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 选择性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_S
分析<|>RELATION_NOE 选择性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 和<|>RELATION_NOE 系统性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 对<|>RELATION_NOE 临床<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 和<|>RELATION_NOE 围手术期<|>RELATION_NOE 指标<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S ,<|>RELATION_NOE 以<|>RELATION_NOE 探讨<|>RELATION_NOE 前者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 98<|>RELATION_NOE 4例<|>RELATION_NOE 临床<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 病例<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 接受<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术加<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男<|>RELATION_NOE 581<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女<|>RELATION_NOE 403<|>RELATION_NOE 例<|>RELATION_NOE ;<|>RELATION_NOE
其中<|>RELATION_NOE 786<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 系统性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE ,<|>RELATION_NOE 198<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 选择性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 生存率<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.8<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 选择性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫组<|>RELATION_NOE 总体<|>RELATION_NOE 复发率<|>RELATION_NOE 25.3%<|>RELATION_NOE ,<|>RELATION_NOE 系统性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫组<|>RELATION_NOE 总体<|>RELATION_NOE 复发率<|>RELATION_NOE 27.5%<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 生存率<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.8<|>RELATION_NOE 44<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 选择性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫组<|>RELATION_NOE 总体<|>RELATION_NOE 复发率<|>RELATION_NOE 25.3%<|>RELATION_NOE ,<|>RELATION_NOE 系统性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫组<|>RELATION_NOE 总体<|>RELATION_NOE 复发率<|>RELATION_NOE 27.5%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.5<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
对于<|>RELATION_NOE 临床<|>RELATION_NOE Ⅰ期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE ,<|>RELATION_NOE 选择性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE 的<|>RELATION_NOE 生存<|>RELATION_NOE 不<|>RELATION_B 劣<|>RELATION_I 于<|>RELATION_E 系统性<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 手术时间<|>RELATION_NOE 更<|>RELATION_NOE 短<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 更<|>RELATION_NOE 少<|>RELATION_NOE .<|>RELATION_NOE
糖皮质<|>RELATION_NOE 激素<|>RELATION_NOE 诱导<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE 1<|>RELATION_NOE 基因<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 临床<|>RELATION_NOE 意义<|>RELATION_NOE
观察<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 糖<|>RELATION_NOE 皮质<|>RELATION_NOE 激素<|>RELATION_NOE 诱导<|>RELATION_S 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE SGK1<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 逆转录<|>RELATION_NOE -<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 10<|>RELATION_NOE 例<|>RELATION_NOE 中晚期<|>RELATION_NOE 肺癌<|>RELATION_NOE 及其<|>RELATION_NOE 癌旁<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE SGK1mRNA<|>RELATION_NOE 的<|>RELATION_NOE 相对<|>RELATION_NOE 表达量<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 采用<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE
肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE SGK1<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 、<|>RELATION_NOE 发展<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 发挥<|>RELATION_B 重要<|>RELATION_I 作用<|>RELATION_E .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 表面<|>RELATION_NOE 活性<|>RELATION_NOE 蛋白<|>RELATION_NOE A<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE 以<|>RELATION_NOE 铂类<|>RELATION_NOE 为<|>RELATION_NOE 基础<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE 效果<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_B 价值<|>RELATION_E
探讨<|>RELATION_NOE 表面<|>RELATION_NOE 活性<|>RELATION_NOE 蛋白<|>RELATION_NOE A<|>RELATION_NOE (<|>RELATION_NOE SP-A<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_B 的<|>RELATION_I 影响<|>RELATION_I 及<|>RELATION_I 对<|>RELATION_I 化疗<|>RELATION_I 疗效<|>RELATION_I 的<|>RELATION_I 预测<|>RELATION_I 价值<|>RELATION_E 。<|>RELATION_NOE
130<|>RELATION_NOE 例<|>RELATION_NOE 接受<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 98<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 腺鳞癌<|>RELATION_NOE 4例<|>RELATION_NOE ,<|>RELATION_NOE 大细胞癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 未分化癌<|>RELATION_NOE 1例.<|>RELATION_NOE
柯里拉<|>RELATION_NOE 京<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 和<|>RELATION_NOE Notch<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
通过<|>RELATION_NOE 体外<|>RELATION_NOE 细胞培养<|>RELATION_NOE 、<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 、<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 、<|>RELATION_NOE 流式<|>RELATION_NOE 细胞仪<|>RELATION_NOE 观察<|>RELATION_NOE 35<|>RELATION_NOE μ<|>RELATION_NOE mol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 柯里拉<|>RELATION_NOE 京<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 细胞周期<|>RELATION_NOE 、<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 和<|>RELATION_NOE Notch<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 蛋白<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE 。<|>RELATION_NOE
短<|>RELATION_NOE 发夹<|>RELATION_NOE RNA<|>RELATION_NOE 稳定<|>RELATION_NOE 沉默<|>RELATION_NOE Y<|>RELATION_NOE 盒<|>RELATION_NOE 结合<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞株<|>RELATION_NOE 的<|>RELATION_NOE 建立<|>RELATION_B 及<|>RELATION_I 增殖<|>RELATION_I 能力<|>RELATION_E 研究<|>RELATION_NOE
构建<|>RELATION_NOE 稳定<|>RELATION_NOE 沉默<|>RELATION_NOE Y<|>RELATION_NOE 盒<|>RELATION_NOE 结合<|>RELATION_NOE 蛋白1<|>RELATION_NOE (<|>RELATION_NOE YB-1<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞株<|>RELATION_NOE 并<|>RELATION_NOE 观察<|>RELATION_B 其<|>RELATION_I 增殖<|>RELATION_I 能力<|>RELATION_E 。<|>RELATION_NOE
以<|>RELATION_NOE 脂质体<|>RELATION_NOE 将<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 沉默<|>RELATION_NOE YB-1<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE shRNA<|>RELATION_NOE 真<|>RELATION_NOE 核<|>RELATION_NOE 表达<|>RELATION_NOE 载体<|>RELATION_NOE 转染<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549<|>RELATION_NOE ,<|>RELATION_NOE G418<|>RELATION_NOE 筛选<|>RELATION_NOE 稳定<|>RELATION_NOE 转染<|>RELATION_NOE 细胞<|>RELATION_NOE 株.<|>RELATION_NOE
稳定<|>RELATION_NOE 转染<|>RELATION_NOE 细胞<|>RELATION_NOE 株<|>RELATION_NOE 稳定<|>RELATION_NOE 表达<|>RELATION_NOE 绿色<|>RELATION_NOE 荧光<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE GFP<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
成功<|>RELATION_NOE 建立<|>RELATION_NOE 稳定<|>RELATION_NOE 表达<|>RELATION_NOE GFP<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 稳定<|>RELATION_NOE 沉默<|>RELATION_NOE YB-1<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞株<|>RELATION_NOE A549-746<|>RELATION_NOE 和<|>RELATION_NOE A549-326<|>RELATION_NOE ,<|>RELATION_NOE 沉默<|>RELATION_NOE YB-1<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_S A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 能力<|>RELATION_NOE .<|>RELATION_NOE
靶<|>RELATION_NOE 向<|>RELATION_NOE 神经<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 转化<|>RELATION_NOE 因子<|>RELATION_NOE -1<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 内皮细胞<|>RELATION_NOE 生长因子<|>RELATION_NOE 基因<|>RELATION_NOE 的<|>RELATION_NOE 双靶<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE 干预<|>RELATION_S 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_NOE 同时<|>RELATION_NOE 下调<|>RELATION_NOE 神经<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 转化<|>RELATION_NOE 因子<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE NET-1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 血管<|>RELATION_NOE 内皮细胞<|>RELATION_NOE 生长因子<|>RELATION_NOE (<|>RELATION_NOE VEGF<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺<|>RELATION_NOE 癌细胞<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 及<|>RELATION_NOE 血管<|>RELATION_NOE 形成<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
分别<|>RELATION_NOE 设计<|>RELATION_NOE 与<|>RELATION_NOE 合成<|>RELATION_NOE 靶向<|>RELATION_NOE NET-1<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 单靶<|>RELATION_NOE 小<|>RELATION_NOE 干扰<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE NET-1<|>RELATION_NOE siRNA<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 双靶<|>RELATION_NOE siRNA<|>RELATION_NOE (<|>RELATION_NOE DGT<|>RELATION_NOE siRNA<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞.<|>RELATION_NOE
噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE Hoechst<|>RELATION_NOE 染色法<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE Hoechst<|>RELATION_NOE 染色法<|>RELATION_NOE 检测<|>RELATION_S 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE Transwell<|>RELATION_NOE 小室<|>RELATION_NOE 实验<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE Hoechst<|>RELATION_NOE 染色法<|>RELATION_NOE 检测<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE ,<|>RELATION_NOE Transwell<|>RELATION_NOE 小室<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 的<|>RELATION_NOE 迁移<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE .<|>RELATION_NOE
提取<|>RELATION_NOE 转染<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 上清液<|>RELATION_NOE ,<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附<|>RELATION_NOE 实验<|>RELATION_NOE (<|>RELATION_NOE ELISA<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE 上<|>RELATION_NOE 清液<|>RELATION_NOE 中<|>RELATION_NOE VEGF<|>RELATION_NOE 的<|>RELATION_NOE 含量<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 上<|>RELATION_NOE 清液<|>RELATION_NOE 孵<|>RELATION_NOE 育人<|>RELATION_NOE 血管<|>RELATION_NOE 内皮细胞<|>RELATION_NOE (<|>RELATION_NOE HUVECs<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 其<|>RELATION_NOE 管<|>RELATION_NOE 形成<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE siRNA<|>RELATION_NOE 干预<|>RELATION_NOE 癌细胞<|>RELATION_NOE 后<|>RELATION_NOE 对<|>RELATION_NOE 血管<|>RELATION_NOE 形成<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
MTT<|>RELATION_NOE 实验<|>RELATION_NOE 显示<|>RELATION_NOE 单<|>RELATION_NOE 、<|>RELATION_NOE 双靶<|>RELATION_NOE siRNA<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 点<|>RELATION_NOE 均<|>RELATION_B 能<|>RELATION_I 明显<|>RELATION_I 抑制<|>RELATION_E 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE DGTsiRNA<|>RELATION_NOE 组<|>RELATION_NOE 效应<|>RELATION_NOE 明显<|>RELATION_NOE 优于<|>RELATION_NOE 单靶组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE MTT<|>RELATION_NOE 实验<|>RELATION_NOE 显示<|>RELATION_NOE 单<|>RELATION_NOE 、<|>RELATION_NOE 双靶<|>RELATION_NOE siRNA<|>RELATION_NOE 在<|>RELATION_NOE 不同<|>RELATION_NOE 时间<|>RELATION_NOE 点<|>RELATION_NOE 均<|>RELATION_NOE 能<|>RELATION_NOE 明显<|>RELATION_NOE 抑制<|>RELATION_NOE 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE DGTsiRNA<|>RELATION_NOE 组<|>RELATION_NOE 效应<|>RELATION_NOE 明显<|>RELATION_B 优于<|>RELATION_E 单靶组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
Transwell<|>RELATION_NOE 实验<|>RELATION_NOE 中<|>RELATION_NOE DGTsiRNA<|>RELATION_NOE 组<|>RELATION_NOE 穿膜<|>RELATION_NOE 细胞数<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 25.63<|>RELATION_NOE ±<|>RELATION_NOE 7.27<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE /<|>RELATION_NOE 视野<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 少于<|>RELATION_E NET-1<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 35.70<|>RELATION_NOE ±<|>RELATION_NOE 7.15<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE /<|>RELATION_NOE 视野<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 28.00<|>RELATION_NOE ±<|>RELATION_NOE 4.90<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE /<|>RELATION_NOE 视野<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 个<|>RELATION_NOE 单靶组<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
DGT<|>RELATION_NOE siRNA<|>RELATION_NOE 组<|>RELATION_NOE 细胞培养<|>RELATION_NOE 上<|>RELATION_NOE 清中<|>RELATION_NOE VEGF<|>RELATION_NOE 浓度<|>RELATION_NOE [<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 22.12<|>RELATION_NOE ±<|>RELATION_NOE 4.23<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE NET-1<|>RELATION_NOE 单靶组<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE 8.00<|>RELATION_NOE ±<|>RELATION_NOE 12.10<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 、<|>RELATION_NOE VEGF<|>RELATION_NOE 单靶组<|>RELATION_NOE (<|>RELATION_NOE 35.56<|>RELATION_NOE ±<|>RELATION_NOE 7.40<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 2.00<|>RELATION_NOE ±<|>RELATION_NOE 10.31<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE HUVEC<|>RELATION_NOE 成<|>RELATION_NOE 管数<|>RELATION_NOE 在<|>RELATION_NOE DGT<|>RELATION_NOE siRNA<|>RELATION_NOE 组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 32.67<|>RELATION_NOE ±<|>RELATION_NOE 4.50<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE ]<|>RELATION_NOE 、<|>RELATION_NOE NET-1<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 48.33<|>RELATION_NOE ±<|>RELATION_NOE 3.50<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 33<|>RELATION_NOE .<|>RELATION_NOE 20<|>RELATION_NOE ±<|>RELATION_NOE 2.65<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE ]<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 个<|>RELATION_NOE 单靶组<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 未<|>RELATION_NOE 处理<|>RELATION_NOE 组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 73.43<|>RELATION_NOE ±<|>RELATION_NOE 4.58<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE DGTsiRNA<|>RELATION_NOE 组<|>RELATION_NOE 优于<|>RELATION_S 单靶组<|>RELATION_NOE 。<|>RELATION_NOE
同时<|>RELATION_NOE 下调<|>RELATION_NOE NET-1<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 基因<|>RELATION_NOE 可<|>RELATION_B 明显<|>RELATION_I 抑制<|>RELATION_E 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 及<|>RELATION_NOE 血管<|>RELATION_NOE 形成<|>RELATION_NOE ,<|>RELATION_NOE 效果<|>RELATION_NOE 显著<|>RELATION_NOE 优于<|>RELATION_NOE 单基因<|>RELATION_NOE 调控<|>RELATION_NOE .<|>RELATION_NOE 同时<|>RELATION_NOE 下调<|>RELATION_NOE NET-1<|>RELATION_NOE 和<|>RELATION_NOE VEGF<|>RELATION_NOE 基因<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_NOE 抑制<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 及<|>RELATION_NOE 血管<|>RELATION_NOE 形成<|>RELATION_NOE ,<|>RELATION_NOE 效果<|>RELATION_NOE 显著<|>RELATION_B 优于<|>RELATION_E 单基因<|>RELATION_NOE 调控<|>RELATION_NOE .<|>RELATION_NOE
抑癌<|>RELATION_NOE 基因<|>RELATION_NOE SARI<|>RELATION_NOE 抑制<|>RELATION_NOE 雌激素<|>RELATION_NOE 诱导<|>RELATION_S 的<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
Western<|>RELATION_NOE blot<|>RELATION_NOE 实验<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE SARI<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 雌激素<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 磷酸化<|>RELATION_NOE 肉瘤<|>RELATION_NOE 病毒基因<|>RELATION_NOE (<|>RELATION_NOE pSrcy416<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 磷酸化<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE B<|>RELATION_NOE (<|>RELATION_NOE pAkts473<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 磷酸化<|>RELATION_NOE 细胞<|>RELATION_NOE 外<|>RELATION_NOE 调节<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE pErk<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_B 下调<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE Src<|>RELATION_NOE 、<|>RELATION_NOE Akt<|>RELATION_NOE 及<|>RELATION_NOE Erk<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 不<|>RELATION_NOE 变<|>RELATION_NOE 。<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 实验<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 过<|>RELATION_NOE 表达<|>RELATION_NOE SARI<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 在<|>RELATION_NOE 雌激素<|>RELATION_NOE 处理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 磷酸化<|>RELATION_NOE 肉瘤<|>RELATION_NOE 病毒基因<|>RELATION_NOE (<|>RELATION_NOE pSrcy416<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 磷酸化<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE B<|>RELATION_NOE (<|>RELATION_NOE pAkts473<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 磷酸化<|>RELATION_NOE 细胞<|>RELATION_NOE 外<|>RELATION_NOE 调节<|>RELATION_NOE 蛋白<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE pErk<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 显著<|>RELATION_NOE 下调<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE Src<|>RELATION_NOE 、<|>RELATION_NOE Akt<|>RELATION_NOE 及<|>RELATION_NOE Erk<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 不<|>RELATION_B 变<|>RELATION_E 。<|>RELATION_NOE
莪术<|>RELATION_NOE 提取<|>RELATION_NOE 物榄<|>RELATION_NOE 香烯<|>RELATION_NOE 对<|>RELATION_NOE 多种<|>RELATION_NOE 癌细胞增殖<|>RELATION_NOE 、<|>RELATION_NOE 侵袭<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相关<|>RELATION_NOE 钙信号传导<|>RELATION_NOE 蛋白<|>RELATION_NOE -2<|>RELATION_NOE 基因表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
采用<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 榄香烯<|>RELATION_NOE 处理<|>RELATION_NOE 人<|>RELATION_NOE 食管癌<|>RELATION_NOE TE-1<|>RELATION_NOE 和<|>RELATION_NOE Ca-ES-17<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 喉鳞癌<|>RELATION_NOE Hep-2<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE NCI-H1975<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 大肠癌<|>RELATION_NOE SW-480<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 前列腺癌<|>RELATION_NOE PC-3<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 癌细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE Boyden<|>RELATION_NOE 小室<|>RELATION_NOE 方法<|>RELATION_NOE 采用<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 榄香烯<|>RELATION_NOE 处理<|>RELATION_NOE 人<|>RELATION_NOE 食管癌<|>RELATION_NOE TE-1<|>RELATION_NOE 和<|>RELATION_NOE Ca-ES-17<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 喉鳞癌<|>RELATION_NOE Hep-2<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE NCI-H1975<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 大肠癌<|>RELATION_NOE SW-480<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 前列腺癌<|>RELATION_NOE PC-3<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 噻唑<|>RELATION_NOE 蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 癌细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE Boyden<|>RELATION_NOE 小室<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 癌细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE FQ-PCR<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 采用<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 榄香烯<|>RELATION_NOE 处理<|>RELATION_NOE 人<|>RELATION_NOE 食管癌<|>RELATION_NOE TE-1<|>RELATION_NOE 和<|>RELATION_NOE Ca-ES-17<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 喉鳞癌<|>RELATION_NOE Hep-2<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE NCI-H1975<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 大肠癌<|>RELATION_NOE SW-480<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 前列腺癌<|>RELATION_NOE PC-3<|>RELATION_NOE 细胞<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 噻唑<|>RELATION_NOE 蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 癌细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE Boyden<|>RELATION_NOE 小室<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 癌细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE FQ-PCR<|>RELATION_NOE )<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 癌细胞<|>RELATION_NOE 肿瘤<|>RELATION_NOE 相关<|>RELATION_NOE 钙信号传导<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE TROP<|>RELATION_NOE )<|>RELATION_NOE -2<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
72h<|>RELATION_NOE 后<|>RELATION_NOE 食管癌<|>RELATION_NOE TE-1<|>RELATION_NOE 和<|>RELATION_NOE Ca-ES-17<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 喉鳞癌<|>RELATION_NOE Hep-2<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE NCI-H1975<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 大肠癌<|>RELATION_NOE SW-480<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 前列腺癌<|>RELATION_NOE PC-3<|>RELATION_NOE 细胞<|>RELATION_NOE 半数<|>RELATION_NOE 抑制<|>RELATION_NOE 剂量<|>RELATION_NOE (<|>RELATION_NOE IC5o<|>RELATION_NOE )<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 43.9<|>RELATION_NOE 19<|>RELATION_NOE 、<|>RELATION_NOE 18<|>RELATION_NOE 9.0<|>RELATION_NOE 36<|>RELATION_NOE 、<|>RELATION_NOE 48.6<|>RELATION_NOE 90<|>RELATION_NOE 、<|>RELATION_NOE 75.5<|>RELATION_NOE 38<|>RELATION_NOE 、<|>RELATION_NOE 35.1<|>RELATION_NOE 45<|>RELATION_NOE 、<|>RELATION_NOE 31.063mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE .<|>RELATION_NOE
Boyden<|>RELATION_NOE 小室<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 榄香烯<|>RELATION_NOE 对<|>RELATION_NOE 以上<|>RELATION_NOE 各组<|>RELATION_NOE 癌细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 均<|>RELATION_B 有<|>RELATION_I 明显<|>RELATION_I 的<|>RELATION_I 抑制<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 食管癌<|>RELATION_NOE TE-1<|>RELATION_NOE 和<|>RELATION_NOE Ca-ES-17<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 喉鳞癌<|>RELATION_NOE Hep-2<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE NCI-H1975<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 大肠癌<|>RELATION_NOE SW-480<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 前列腺癌<|>RELATION_NOE PC-3<|>RELATION_NOE 细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 抑制率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 25.6%<|>RELATION_NOE 、<|>RELATION_NOE 18.9%<|>RELATION_NOE 、<|>RELATION_NOE 23.8%<|>RELATION_NOE 、<|>RELATION_NOE 22.2%<|>RELATION_NOE 、<|>RELATION_NOE 26.5%<|>RELATION_NOE 、<|>RELATION_NOE 27.8%<|>RELATION_NOE .<|>RELATION_NOE
FQ-PCR<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 各组<|>RELATION_NOE 癌细胞<|>RELATION_NOE 均<|>RELATION_NOE 呈<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE TROP-2mRNA<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_B 榄香烯<|>RELATION_I 处理<|>RELATION_E 后<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 癌细胞<|>RELATION_NOE TROP-2mRNA<|>RELATION_NOE 水平<|>RELATION_NOE 均<|>RELATION_NOE 被<|>RELATION_NOE 明显<|>RELATION_NOE 抑制<|>RELATION_NOE ,<|>RELATION_NOE 食管癌<|>RELATION_NOE TE-1<|>RELATION_NOE 和<|>RELATION_NOE Ca-ES-17<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 喉鳞癌<|>RELATION_NOE Hep-2<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE NCI-H1975<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 大肠癌<|>RELATION_NOE SW-480<|>RELATION_NOE 细胞<|>RELATION_NOE 、<|>RELATION_NOE 前列腺癌<|>RELATION_NOE PC-3<|>RELATION_NOE 细胞<|>RELATION_NOE TROP-2<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 抑制率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 35.8%<|>RELATION_NOE 、<|>RELATION_NOE 25.6%<|>RELATION_NOE 、<|>RELATION_NOE 32.5%<|>RELATION_NOE 、<|>RELATION_NOE 25.6%<|>RELATION_NOE 、<|>RELATION_NOE 29.8%<|>RELATION_NOE 、<|>RELATION_NOE 33.6%<|>RELATION_NOE 。<|>RELATION_NOE
Ⅳ期<|>RELATION_NOE NSCLC<|>RELATION_NOE 化疗<|>RELATION_NOE 同期<|>RELATION_NOE 三维<|>RELATION_NOE 放疗<|>RELATION_NOE 的<|>RELATION_NOE 预后<|>RELATION_NOE 再<|>RELATION_NOE 分析<|>RELATION_S
神经<|>RELATION_NOE 纤毛<|>RELATION_NOE 蛋白1<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
通过<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_NOE 不<|>RELATION_NOE 同<|>RELATION_NOE 来源<|>RELATION_NOE 的<|>RELATION_NOE 5<|>RELATION_NOE 种<|>RELATION_NOE 人<|>RELATION_NOE NSCLC<|>RELATION_NOE 细胞系<|>RELATION_NOE (<|>RELATION_NOE H358<|>RELATION_NOE 、<|>RELATION_NOE H460<|>RELATION_NOE 、<|>RELATION_NOE H1299<|>RELATION_NOE 、<|>RELATION_NOE A549<|>RELATION_NOE 、<|>RELATION_NOE SK-MES-1<|>RELATION_NOE )<|>RELATION_NOE NRP1<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE MTT<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 经<|>RELATION_NOE 不同<|>RELATION_NOE 剂量<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 照射<|>RELATION_NOE 后<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 存活<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 初步<|>RELATION_NOE 筛选<|>RELATION_NOE 5<|>RELATION_NOE 种<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 辐射<|>RELATION_NOE 敏感<|>RELATION_NOE 和<|>RELATION_NOE 辐射<|>RELATION_NOE 抵抗<|>RELATION_NOE 的<|>RELATION_NOE 2种<|>RELATION_NOE 细胞<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 及<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 分别<|>RELATION_B 检测<|>RELATION_E 细胞存活<|>RELATION_NOE 分数<|>RELATION_NOE 及<|>RELATION_NOE 凋亡率<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 2<|>RELATION_NOE 种<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射敏感性<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 检测<|>RELATION_NOE 2<|>RELATION_NOE 种<|>RELATION_NOE 细胞<|>RELATION_NOE 受<|>RELATION_NOE X<|>RELATION_NOE 射线<|>RELATION_NOE 作用<|>RELATION_NOE 后<|>RELATION_NOE NRP1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 克隆<|>RELATION_NOE 形成<|>RELATION_NOE 实验<|>RELATION_NOE 检测<|>RELATION_NOE 靶向<|>RELATION_NOE 抑制<|>RELATION_NOE NRP1<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE
X<|>RELATION_NOE 射线<|>RELATION_NOE 对<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 能力<|>RELATION_NOE 呈<|>RELATION_B 剂量<|>RELATION_I 依赖性<|>RELATION_I 增强<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 抑制率<|>RELATION_NOE 由<|>RELATION_NOE 高<|>RELATION_NOE 到<|>RELATION_NOE 低<|>RELATION_NOE 依次<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE H460<|>RELATION_NOE ><|>RELATION_NOE H1299<|>RELATION_NOE ><|>RELATION_NOE H358<|>RELATION_NOE ><|>RELATION_NOE SK-MES-1<|>RELATION_NOE ><|>RELATION_NOE A549<|>RELATION_NOE ,<|>RELATION_NOE 因此<|>RELATION_NOE 选取<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE 做<|>RELATION_NOE 后续<|>RELATION_NOE 研究<|>RELATION_NOE .<|>RELATION_NOE
A549<|>RELATION_NOE 细胞<|>RELATION_NOE 受照<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 凋亡率<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 12<|>RELATION_NOE 2.5<|>RELATION_NOE 4%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E H460<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 23<|>RELATION_NOE 8.8<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 辐射<|>RELATION_NOE 可以<|>RELATION_NOE 诱导<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE NRP1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 上调<|>RELATION_NOE 达<|>RELATION_NOE 40%<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 靶向<|>RELATION_NOE 抑制<|>RELATION_NOE NRP1<|>RELATION_NOE 则<|>RELATION_NOE 可以<|>RELATION_NOE 增强<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 。<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 受照<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 凋亡率<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 12<|>RELATION_NOE 2.5<|>RELATION_NOE 4%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 23<|>RELATION_NOE 8.8<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 辐射<|>RELATION_NOE 可以<|>RELATION_NOE 诱导<|>RELATION_B A549<|>RELATION_I 细胞<|>RELATION_I NRP1<|>RELATION_I 的<|>RELATION_I 表达<|>RELATION_E 上调<|>RELATION_NOE 达<|>RELATION_NOE 40%<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 靶向<|>RELATION_NOE 抑制<|>RELATION_NOE NRP1<|>RELATION_NOE 则<|>RELATION_NOE 可以<|>RELATION_NOE 增强<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 。<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 受照<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 凋亡率<|>RELATION_NOE 为<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE 12<|>RELATION_NOE 2.5<|>RELATION_NOE 4%<|>RELATION_NOE ,<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE H460<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 23<|>RELATION_NOE 8.8<|>RELATION_NOE 8%<|>RELATION_NOE ,<|>RELATION_NOE 辐射<|>RELATION_NOE 可以<|>RELATION_NOE 诱导<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE NRP1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 上调<|>RELATION_NOE 达<|>RELATION_NOE 40%<|>RELATION_NOE ,<|>RELATION_NOE 同时<|>RELATION_NOE 靶向<|>RELATION_NOE 抑制<|>RELATION_NOE NRP1<|>RELATION_NOE 则<|>RELATION_NOE 可以<|>RELATION_NOE 增强<|>RELATION_B A549<|>RELATION_I 细胞<|>RELATION_E 的<|>RELATION_NOE 放射敏感性<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE NSCLC<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 具有<|>RELATION_B 较<|>RELATION_I 强<|>RELATION_I 的<|>RELATION_I 辐射<|>RELATION_I 抗性<|>RELATION_E ,<|>RELATION_NOE 且<|>RELATION_NOE 辐射<|>RELATION_NOE 抗性<|>RELATION_NOE 的<|>RELATION_NOE 形成<|>RELATION_NOE 与<|>RELATION_NOE 其<|>RELATION_NOE NRP1<|>RELATION_NOE 表达<|>RELATION_NOE 上调<|>RELATION_NOE 有关<|>RELATION_NOE 。<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 具有<|>RELATION_NOE 较<|>RELATION_NOE 强<|>RELATION_NOE 的<|>RELATION_NOE 辐射<|>RELATION_NOE 抗性<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 辐射<|>RELATION_NOE 抗性<|>RELATION_NOE 的<|>RELATION_NOE 形成<|>RELATION_NOE 与其<|>RELATION_NOE NRP1<|>RELATION_NOE 表达<|>RELATION_NOE 上调<|>RELATION_NOE 有关<|>RELATION_S 。<|>RELATION_NOE
福清市<|>RELATION_NOE 2007<|>RELATION_NOE －<|>RELATION_NOE 2009年<|>RELATION_NOE 居民<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 与<|>RELATION_NOE 死亡<|>RELATION_NOE 特征<|>RELATION_NOE 调查<|>RELATION_S
回顾性<|>RELATION_NOE 调查<|>RELATION_NOE 福清市<|>RELATION_NOE 2007-2009<|>RELATION_NOE 年<|>RELATION_NOE 居民<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 与<|>RELATION_NOE 死亡<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 以及<|>RELATION_NOE 与<|>RELATION_NOE 核辐射<|>RELATION_NOE 相关<|>RELATION_NOE 的<|>RELATION_NOE 主要<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 发病<|>RELATION_NOE 与<|>RELATION_NOE 死亡<|>RELATION_NOE 分布<|>RELATION_NOE 特征<|>RELATION_NOE 。<|>RELATION_NOE
肝癌<|>RELATION_NOE 、<|>RELATION_NOE 胃癌<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 、<|>RELATION_NOE 食管癌<|>RELATION_NOE 和<|>RELATION_NOE 结直肠癌<|>RELATION_NOE 是<|>RELATION_NOE 前<|>RELATION_B 5<|>RELATION_I 位<|>RELATION_E 恶性肿瘤<|>RELATION_NOE ;<|>RELATION_NOE
白血病<|>RELATION_NOE 发病率<|>RELATION_NOE 3.77<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 死亡率<|>RELATION_NOE 2.61<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 发病率<|>RELATION_NOE 6.95<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE ,<|>RELATION_NOE 死亡率<|>RELATION_NOE 0.46<|>RELATION_NOE /<|>RELATION_NOE 10万<|>RELATION_NOE 。<|>RELATION_NOE
核电站<|>RELATION_NOE 运行<|>RELATION_NOE 之前<|>RELATION_NOE ,<|>RELATION_NOE 福清市<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 以<|>RELATION_B 消化<|>RELATION_I 系<|>RELATION_I 肿瘤<|>RELATION_I 和<|>RELATION_I 肺癌<|>RELATION_I 为主<|>RELATION_E ;<|>RELATION_NOE
白血病<|>RELATION_NOE 发病率<|>RELATION_NOE 与<|>RELATION_NOE 死亡率<|>RELATION_NOE 低于<|>RELATION_S 全国<|>RELATION_NOE 平均<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 发病率<|>RELATION_NOE 与<|>RELATION_NOE 死亡率<|>RELATION_NOE 高于<|>RELATION_NOE 白血病<|>RELATION_NOE 发病率<|>RELATION_NOE 与<|>RELATION_NOE 死亡率<|>RELATION_NOE 低于<|>RELATION_NOE 全国<|>RELATION_NOE 平均<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 发病率<|>RELATION_NOE 与<|>RELATION_NOE 死亡率<|>RELATION_NOE 高于<|>RELATION_S 全国<|>RELATION_NOE 平均<|>RELATION_NOE 水平<|>RELATION_NOE .<|>RELATION_NOE
4D-CT<|>RELATION_NOE 与<|>RELATION_NOE PET-CT<|>RELATION_NOE 勾画<|>RELATION_S 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE IGTV<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_NOE 研究<|>RELATION_NOE
在<|>RELATION_NOE 4D-CT<|>RELATION_NOE 10<|>RELATION_NOE 个<|>RELATION_NOE 呼吸<|>RELATION_NOE 时<|>RELATION_NOE 相<|>RELATION_NOE 图像<|>RELATION_NOE 上<|>RELATION_NOE 勾画<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大体<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE (<|>RELATION_NOE GTV<|>RELATION_NOE )<|>RELATION_NOE 并<|>RELATION_NOE 融合<|>RELATION_NOE 获得<|>RELATION_NOE IGTV10<|>RELATION_NOE .<|>RELATION_NOE 基于<|>RELATION_NOE PET<|>RELATION_NOE 图像<|>RELATION_NOE 不同<|>RELATION_NOE SUV<|>RELATION_NOE 值<|>RELATION_NOE (<|>RELATION_NOE ≥<|>RELATION_NOE 1.5<|>RELATION_NOE 、<|>RELATION_NOE ≥<|>RELATION_NOE 2.0<|>RELATION_NOE 、<|>RELATION_NOE ≥<|>RELATION_NOE 2.5<|>RELATION_NOE 、<|>RELATION_NOE ≥<|>RELATION_NOE 3.0<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE SUV<|>RELATION_NOE 值<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 百分比<|>RELATION_NOE (<|>RELATION_NOE ≥<|>RELATION_NOE 20%<|>RELATION_NOE 、<|>RELATION_NOE ≥<|>RELATION_NOE 25%<|>RELATION_NOE 、<|>RELATION_NOE ≥<|>RELATION_NOE 30%<|>RELATION_NOE 、<|>RELATION_NOE ≥<|>RELATION_NOE 35%<|>RELATION_NOE 、<|>RELATION_NOE ≥<|>RELATION_NOE 40%<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 目测法<|>RELATION_NOE 勾画<|>RELATION_NOE 原发<|>RELATION_NOE 肿瘤<|>RELATION_NOE 靶区<|>RELATION_NOE (<|>RELATION_NOE IGTVPET<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE IGTVPET<|>RELATION_NOE 与<|>RELATION_NOE IGTV10<|>RELATION_NOE 靶<|>RELATION_NOE 区间<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE 体积<|>RELATION_NOE 大小<|>RELATION_NOE 、<|>RELATION_NOE 包含<|>RELATION_NOE 度<|>RELATION_NOE (<|>RELATION_NOE DI<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 适形<|>RELATION_NOE 指数<|>RELATION_NOE (<|>RELATION_NOE CI<|>RELATION_NOE )<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
儿童<|>RELATION_NOE 胸膜<|>RELATION_NOE 肺<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE 临床<|>RELATION_NOE 病理学<|>RELATION_NOE 观察<|>RELATION_S
探讨<|>RELATION_NOE 胸膜<|>RELATION_NOE 肺<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 组织<|>RELATION_NOE 起源<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 胸膜<|>RELATION_NOE 肺<|>RELATION_NOE 母细胞<|>RELATION_NOE 瘤患儿<|>RELATION_NOE (<|>RELATION_NOE 年龄<|>RELATION_NOE 1.7<|>RELATION_NOE －5.3<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE 3<|>RELATION_NOE 岁<|>RELATION_NOE )<|>RELATION_NOE 肿瘤<|>RELATION_NOE 标本<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE HE<|>RELATION_NOE 、<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE (<|>RELATION_NOE EnVision<|>RELATION_NOE 法<|>RELATION_NOE )<|>RELATION_NOE 染色<|>RELATION_NOE 及<|>RELATION_NOE 电镜<|>RELATION_NOE 技术<|>RELATION_NOE 进行<|>RELATION_NOE 观察<|>RELATION_NOE 。<|>RELATION_NOE
Ⅱ型实<|>RELATION_NOE 性区<|>RELATION_NOE 和<|>RELATION_NOE Ⅲ型实<|>RELATION_NOE 性型<|>RELATION_NOE 肿瘤<|>RELATION_NOE 成分镜<|>RELATION_B 下<|>RELATION_E 呈<|>RELATION_NOE 原始<|>RELATION_NOE 胚芽<|>RELATION_NOE 、<|>RELATION_NOE 梭形<|>RELATION_NOE 原始<|>RELATION_NOE 间叶<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 不同<|>RELATION_NOE 肉瘤<|>RELATION_NOE 成分<|>RELATION_NOE 的<|>RELATION_NOE 混合<|>RELATION_NOE ;<|>RELATION_NOE
Ⅱ型<|>RELATION_NOE 及<|>RELATION_NOE Ⅲ<|>RELATION_NOE 型<|>RELATION_NOE 肿瘤<|>RELATION_NOE 内<|>RELATION_NOE 常见<|>RELATION_S 间变<|>RELATION_NOE 瘤细胞<|>RELATION_NOE 及<|>RELATION_NOE 细胞<|>RELATION_NOE 内外<|>RELATION_NOE 嗜酸性<|>RELATION_NOE 小体<|>RELATION_NOE 。<|>RELATION_NOE
3型<|>RELATION_NOE 胸膜<|>RELATION_NOE 肺<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 上皮<|>RELATION_NOE 成分<|>RELATION_NOE 均<|>RELATION_B 为<|>RELATION_I 良性<|>RELATION_E 。<|>RELATION_NOE
16<|>RELATION_NOE 例<|>RELATION_NOE 均<|>RELATION_B 表达<|>RELATION_E 波形蛋白<|>RELATION_NOE ,<|>RELATION_NOE 骨骼肌<|>RELATION_NOE 分化<|>RELATION_NOE 呈<|>RELATION_NOE 结蛋白<|>RELATION_NOE 、<|>RELATION_NOE Myogenin<|>RELATION_NOE 、<|>RELATION_NOE 平滑肌<|>RELATION_NOE 肌动<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 软骨<|>RELATION_NOE 分化<|>RELATION_NOE 呈<|>RELATION_NOE S-100<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 纤维<|>RELATION_NOE 组织细胞<|>RELATION_NOE 分化<|>RELATION_NOE 呈<|>RELATION_NOE CD68<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 余<|>RELATION_NOE 突触素<|>RELATION_NOE 、<|>RELATION_NOE CD99<|>RELATION_NOE 、<|>RELATION_NOE CD117<|>RELATION_NOE 均<|>RELATION_NOE 阴性<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE 上皮<|>RELATION_NOE 成分呈<|>RELATION_NOE AE1<|>RELATION_NOE /<|>RELATION_NOE AE3<|>RELATION_NOE 及<|>RELATION_NOE 上皮细胞膜<|>RELATION_NOE 抗原<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 均<|>RELATION_NOE 表达<|>RELATION_NOE 波形蛋白<|>RELATION_NOE ,<|>RELATION_NOE 骨骼肌<|>RELATION_NOE 分化<|>RELATION_NOE 呈<|>RELATION_NOE 结蛋白<|>RELATION_NOE 、<|>RELATION_NOE Myogenin<|>RELATION_NOE 、<|>RELATION_NOE 平滑肌<|>RELATION_NOE 肌动<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 软骨<|>RELATION_NOE 分化<|>RELATION_NOE 呈<|>RELATION_NOE S-100<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 均<|>RELATION_NOE 表达<|>RELATION_NOE 波形蛋白<|>RELATION_NOE ,<|>RELATION_NOE 骨骼肌<|>RELATION_NOE 分化<|>RELATION_NOE 呈<|>RELATION_NOE 结蛋白<|>RELATION_NOE 、<|>RELATION_NOE Myogenin<|>RELATION_NOE 、<|>RELATION_NOE 平滑肌<|>RELATION_NOE 肌动<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 软骨<|>RELATION_NOE 分化<|>RELATION_NOE 呈<|>RELATION_NOE S-100<|>RELATION_NOE 阳性<|>RELATION_B 表达<|>RELATION_E ,<|>RELATION_NOE 纤维<|>RELATION_NOE 组织细胞<|>RELATION_NOE 分化<|>RELATION_NOE 呈<|>RELATION_NOE CD68<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 余<|>RELATION_NOE 突触素<|>RELATION_NOE 、<|>RELATION_NOE CD99<|>RELATION_NOE 、<|>RELATION_NOE CD117<|>RELATION_NOE 均<|>RELATION_NOE 阴性<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE 上皮<|>RELATION_NOE 成分呈<|>RELATION_NOE AE1<|>RELATION_NOE /<|>RELATION_NOE AE3<|>RELATION_NOE 及<|>RELATION_NOE 上皮细胞膜<|>RELATION_NOE 抗原<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE 均<|>RELATION_NOE 表达<|>RELATION_NOE 波形蛋白<|>RELATION_NOE ,<|>RELATION_NOE 骨骼肌<|>RELATION_NOE 分化<|>RELATION_NOE 呈<|>RELATION_NOE 结蛋白<|>RELATION_NOE 、<|>RELATION_NOE Myogenin<|>RELATION_NOE 、<|>RELATION_NOE 平滑肌<|>RELATION_NOE 肌动<|>RELATION_NOE 蛋白<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 软骨<|>RELATION_NOE 分化<|>RELATION_NOE 呈<|>RELATION_NOE S-100<|>RELATION_NOE 阳性<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 纤维<|>RELATION_NOE 组织细胞<|>RELATION_NOE 分化<|>RELATION_NOE 呈<|>RELATION_NOE CD68<|>RELATION_NOE 表达<|>RELATION_S ,<|>RELATION_NOE 余<|>RELATION_NOE 突触素<|>RELATION_NOE 、<|>RELATION_NOE CD99<|>RELATION_NOE 、<|>RELATION_NOE CD117<|>RELATION_NOE 均<|>RELATION_NOE 阴性<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE 上皮<|>RELATION_NOE 成分呈<|>RELATION_NOE AE1<|>RELATION_NOE /<|>RELATION_NOE AE3<|>RELATION_NOE 及<|>RELATION_NOE 上皮细胞膜<|>RELATION_NOE 抗原<|>RELATION_NOE 阳性<|>RELATION_NOE
电镜<|>RELATION_NOE 下<|>RELATION_NOE 12<|>RELATION_B 例<|>RELATION_I 均<|>RELATION_I 可见<|>RELATION_E 细胞器<|>RELATION_NOE 稀少<|>RELATION_NOE 的<|>RELATION_NOE 原始<|>RELATION_NOE 间<|>RELATION_NOE 叶细胞<|>RELATION_NOE 及<|>RELATION_NOE 核<|>RELATION_NOE 异染色质<|>RELATION_NOE 丰富<|>RELATION_NOE 的<|>RELATION_NOE 间叶<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 后者<|>RELATION_NOE 部分<|>RELATION_NOE 胞质<|>RELATION_NOE 内<|>RELATION_NOE 见<|>RELATION_NOE 发育<|>RELATION_NOE 不良<|>RELATION_NOE 的<|>RELATION_NOE 肌丝<|>RELATION_NOE 。<|>RELATION_NOE
胸膜<|>RELATION_NOE 肺<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE 好<|>RELATION_B 发<|>RELATION_I 于<|>RELATION_E 6<|>RELATION_NOE 岁<|>RELATION_NOE 以下<|>RELATION_NOE 的<|>RELATION_NOE 儿童<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 特殊<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 形态<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 起源<|>RELATION_NOE 于<|>RELATION_NOE 胸腔<|>RELATION_NOE 脏层<|>RELATION_NOE 胸膜<|>RELATION_NOE 或<|>RELATION_NOE 胚体<|>RELATION_NOE 中胚层<|>RELATION_NOE 的<|>RELATION_NOE 多潜能<|>RELATION_NOE 干细胞<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 预后<|>RELATION_NOE 差<|>RELATION_NOE 的<|>RELATION_NOE 儿童<|>RELATION_NOE 罕见<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 。<|>RELATION_NOE 胸膜<|>RELATION_NOE 肺<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE 好<|>RELATION_NOE 发<|>RELATION_NOE 于<|>RELATION_NOE 6<|>RELATION_NOE 岁<|>RELATION_NOE 以下<|>RELATION_NOE 的<|>RELATION_NOE 儿童<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_S 特殊<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 形态<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 起源<|>RELATION_NOE 于<|>RELATION_NOE 胸腔<|>RELATION_NOE 脏层<|>RELATION_NOE 胸膜<|>RELATION_NOE 或<|>RELATION_NOE 胚体<|>RELATION_NOE 中胚层<|>RELATION_NOE 的<|>RELATION_NOE 多潜能<|>RELATION_NOE 干细胞<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 预后<|>RELATION_NOE 差<|>RELATION_NOE 的<|>RELATION_NOE 儿童<|>RELATION_NOE 罕见<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 。<|>RELATION_NOE 胸膜<|>RELATION_NOE 肺<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE 好<|>RELATION_NOE 发<|>RELATION_NOE 于<|>RELATION_NOE 6<|>RELATION_NOE 岁<|>RELATION_NOE 以下<|>RELATION_NOE 的<|>RELATION_NOE 儿童<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 特殊<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 形态<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_B 起源于<|>RELATION_E 胸腔<|>RELATION_NOE 脏层<|>RELATION_NOE 胸膜<|>RELATION_NOE 或<|>RELATION_NOE 胚体<|>RELATION_NOE 中胚层<|>RELATION_NOE 的<|>RELATION_NOE 多潜能<|>RELATION_NOE 干细胞<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 预后<|>RELATION_NOE 差<|>RELATION_NOE 的<|>RELATION_NOE 儿童<|>RELATION_NOE 罕见<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 。<|>RELATION_NOE 胸膜<|>RELATION_NOE 肺<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE 好<|>RELATION_NOE 发<|>RELATION_NOE 于<|>RELATION_NOE 6<|>RELATION_NOE 岁<|>RELATION_NOE 以下<|>RELATION_NOE 的<|>RELATION_NOE 儿童<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 特殊<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 形态<|>RELATION_NOE ,<|>RELATION_NOE 可能<|>RELATION_NOE 起源<|>RELATION_NOE 于<|>RELATION_NOE 胸腔<|>RELATION_NOE 脏层<|>RELATION_NOE 胸膜<|>RELATION_NOE 或<|>RELATION_NOE 胚体<|>RELATION_NOE 中胚层<|>RELATION_NOE 的<|>RELATION_NOE 多潜能<|>RELATION_NOE 干细胞<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_B 预后<|>RELATION_I 差<|>RELATION_E 的<|>RELATION_NOE 儿童<|>RELATION_NOE 罕见<|>RELATION_NOE 肺肿瘤<|>RELATION_NOE 。<|>RELATION_NOE
间变性<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 激酶<|>RELATION_NOE 阳性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 筛查<|>RELATION_B 及其<|>RELATION_I 临床<|>RELATION_I 病理<|>RELATION_I 特征<|>RELATION_E
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 中<|>RELATION_NOE 不同<|>RELATION_NOE 间变性<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE 激酶<|>RELATION_NOE (<|>RELATION_NOE ALK<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_NOE
100<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ALK<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 强度<|>RELATION_NOE 为<|>RELATION_NOE 3+<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 0<|>RELATION_NOE (<|>RELATION_NOE 78<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 与<|>RELATION_NOE FISH<|>RELATION_NOE 检查<|>RELATION_NOE 结果<|>RELATION_NOE 一致<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学2<|>RELATION_NOE +<|>RELATION_NOE 和<|>RELATION_NOE 1<|>RELATION_NOE +<|>RELATION_NOE 患者<|>RELATION_NOE FISH<|>RELATION_NOE 检测<|>RELATION_NOE 阳性<|>RELATION_NOE 比例<|>RELATION_NOE 为<|>RELATION_NOE 6/7<|>RELATION_NOE 和<|>RELATION_NOE 2/3<|>RELATION_NOE 。<|>RELATION_NOE
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 染色<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 和<|>RELATION_NOE 特异性<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 100%<|>RELATION_NOE 和<|>RELATION_NOE 98%<|>RELATION_NOE 。<|>RELATION_NOE
ALK<|>RELATION_NOE 阳性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 具有<|>RELATION_S 一定<|>RELATION_NOE 的<|>RELATION_NOE 组织学<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 标记<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 筛选<|>RELATION_NOE ALK<|>RELATION_NOE 阳性<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 常规<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 阳性<|>RELATION_NOE 患者<|>RELATION_NOE 进一步<|>RELATION_NOE 行<|>RELATION_NOE FISH<|>RELATION_NOE 法<|>RELATION_NOE 确诊<|>RELATION_NOE ,<|>RELATION_NOE 正确<|>RELATION_NOE 指导<|>RELATION_NOE 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 选择<|>RELATION_NOE 。<|>RELATION_NOE ALK<|>RELATION_NOE 阳性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 组织学<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 标记<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 筛选<|>RELATION_B ALK<|>RELATION_I 阳性<|>RELATION_I 患者<|>RELATION_E 的<|>RELATION_NOE 常规<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 阳性<|>RELATION_NOE 患者<|>RELATION_NOE 进一步<|>RELATION_NOE 行<|>RELATION_NOE FISH<|>RELATION_NOE 法<|>RELATION_NOE 确诊<|>RELATION_NOE ,<|>RELATION_NOE 正确<|>RELATION_NOE 指导<|>RELATION_NOE 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 选择<|>RELATION_NOE 。<|>RELATION_NOE ALK<|>RELATION_NOE 阳性<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 组织学<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 标记<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_NOE 筛选<|>RELATION_NOE ALK<|>RELATION_NOE 阳性<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 常规<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 阳性<|>RELATION_NOE 患者<|>RELATION_NOE 进一步<|>RELATION_NOE 行<|>RELATION_NOE FISH<|>RELATION_NOE 法<|>RELATION_NOE 确诊<|>RELATION_NOE ,<|>RELATION_NOE 正确<|>RELATION_B 指导<|>RELATION_E 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 的<|>RELATION_NOE 选择<|>RELATION_NOE 。<|>RELATION_NOE
内镜<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 细针<|>RELATION_NOE 穿刺术<|>RELATION_NOE 对<|>RELATION_NOE 纵隔<|>RELATION_NOE 良<|>RELATION_NOE 恶性<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E
探讨<|>RELATION_NOE 内镜<|>RELATION_NOE 超声<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 的<|>RELATION_NOE 细针<|>RELATION_NOE 穿刺术<|>RELATION_NOE (<|>RELATION_NOE EUS-FNA<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE 纵隔<|>RELATION_NOE 良<|>RELATION_NOE 恶性<|>RELATION_NOE 病变<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
EUS-FNA<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 恶性肿瘤者<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE 病变者<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 患者<|>RELATION_NOE 因<|>RELATION_NOE 未<|>RELATION_NOE 取得<|>RELATION_NOE 足够<|>RELATION_NOE 组织<|>RELATION_NOE 标本<|>RELATION_NOE 、<|>RELATION_NOE 后<|>RELATION_NOE 经<|>RELATION_NOE 手术<|>RELATION_NOE 确诊<|>RELATION_NOE 为<|>RELATION_NOE 小细胞癌<|>RELATION_NOE .<|>RELATION_NOE
使用<|>RELATION_NOE TGF-<|>RELATION_NOE β1<|>RELATION_NOE 诱导<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE EMT<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 在<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE 使用<|>RELATION_NOE p38<|>RELATION_NOE MAPK<|>RELATION_NOE 抑制剂<|>RELATION_NOE SB203580<|>RELATION_NOE 和<|>RELATION_NOE JNK<|>RELATION_NOE 抑制剂<|>RELATION_NOE SP600125<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE RNA<|>RELATION_NOE 水平<|>RELATION_NOE (<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE )<|>RELATION_NOE 抑制<|>RELATION_NOE p38<|>RELATION_NOE MAPK<|>RELATION_NOE 和<|>RELATION_NOE JNK<|>RELATION_NOE 信号通道<|>RELATION_NOE ,<|>RELATION_NOE 检测<|>RELATION_NOE 抑制<|>RELATION_NOE 后<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE p38<|>RELATION_NOE MAPK<|>RELATION_NOE 和<|>RELATION_NOE JNK<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE mRNA<|>RELATION_NOE ,<|>RELATION_NOE 以及<|>RELATION_NOE 间质细胞<|>RELATION_NOE 表型<|>RELATION_NOE 蛋白<|>RELATION_NOE 包括<|>RELATION_NOE 结蛋白<|>RELATION_NOE 、<|>RELATION_NOE 波形蛋白<|>RELATION_NOE 、<|>RELATION_NOE α<|>RELATION_NOE -<|>RELATION_NOE 平滑肌<|>RELATION_NOE 肌动<|>RELATION_NOE 蛋白<|>RELATION_NOE 和<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 表型<|>RELATION_NOE 蛋白<|>RELATION_NOE 包括<|>RELATION_NOE E-<|>RELATION_NOE 钙黏素<|>RELATION_NOE 、<|>RELATION_NOE 紧密<|>RELATION_NOE 连接<|>RELATION_NOE 蛋白<|>RELATION_NOE -1<|>RELATION_NOE 、<|>RELATION_NOE 水通道<|>RELATION_NOE 蛋白<|>RELATION_NOE -5<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞系<|>RELATION_NOE A549<|>RELATION_NOE 线粒体<|>RELATION_NOE 差异<|>RELATION_NOE 蛋白质组<|>RELATION_NOE 学<|>RELATION_NOE 研究<|>RELATION_S
研究<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞系<|>RELATION_NOE A549<|>RELATION_NOE 与<|>RELATION_NOE 人<|>RELATION_NOE 正常<|>RELATION_NOE 支气管<|>RELATION_NOE 上皮细胞系<|>RELATION_NOE 16HBE<|>RELATION_NOE 线粒体<|>RELATION_NOE 蛋白质组<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_B 表达<|>RELATION_E 。<|>RELATION_NOE
传代<|>RELATION_NOE 培养<|>RELATION_NOE 细胞系<|>RELATION_NOE A549<|>RELATION_NOE 及<|>RELATION_NOE 16HBE<|>RELATION_NOE ,<|>RELATION_NOE 用<|>RELATION_NOE 线粒体<|>RELATION_NOE 提取<|>RELATION_NOE 试剂<|>RELATION_NOE 盒<|>RELATION_NOE 获取<|>RELATION_NOE 细胞<|>RELATION_NOE 线粒体<|>RELATION_NOE 蛋白质<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 双向<|>RELATION_NOE 凝胶<|>RELATION_NOE 电泳<|>RELATION_NOE ,<|>RELATION_NOE 运用<|>RELATION_NOE 液相<|>RELATION_NOE 色谱<|>RELATION_NOE 串联<|>RELATION_NOE 质谱<|>RELATION_NOE 分析<|>RELATION_NOE 技术<|>RELATION_NOE 筛选<|>RELATION_NOE 出<|>RELATION_NOE A549<|>RELATION_NOE 和<|>RELATION_NOE 16HBE<|>RELATION_NOE 细胞系<|>RELATION_NOE 线粒体<|>RELATION_NOE 间<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_NOE 差异<|>RELATION_NOE 的<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 所得<|>RELATION_NOE
结果<|>RELATION_NOE :<|>RELATION_NOE 双向<|>RELATION_NOE 电泳<|>RELATION_NOE 结果<|>RELATION_NOE 显示<|>RELATION_S A549<|>RELATION_NOE 、<|>RELATION_NOE 16HBE<|>RELATION_NOE 细胞系<|>RELATION_NOE 线粒体<|>RELATION_NOE 存在<|>RELATION_NOE 差异<|>RELATION_NOE 的<|>RELATION_NOE 蛋白质<|>RELATION_NOE 点<|>RELATION_NOE 共<|>RELATION_NOE 41<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 3<|>RELATION_NOE 倍<|>RELATION_NOE 以上<|>RELATION_NOE 差异<|>RELATION_NOE 的<|>RELATION_NOE 16<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞系<|>RELATION_NOE 中<|>RELATION_NOE 表达<|>RELATION_NOE 上调<|>RELATION_NOE 的<|>RELATION_NOE 15<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 的<|>RELATION_NOE 26<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 3<|>RELATION_NOE 倍<|>RELATION_NOE 以上<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 上调<|>RELATION_NOE 的<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE ,<|>RELATION_NOE 表达<|>RELATION_NOE 下调<|>RELATION_NOE 的<|>RELATION_NOE 9<|>RELATION_NOE 个<|>RELATION_NOE .<|>RELATION_NOE
应用<|>RELATION_NOE 亚细胞<|>RELATION_NOE 蛋白质组<|>RELATION_NOE 学<|>RELATION_NOE 方法<|>RELATION_NOE ,<|>RELATION_NOE 鉴定<|>RELATION_NOE 出<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞系<|>RELATION_NOE 线粒体<|>RELATION_NOE 差异<|>RELATION_NOE 表达<|>RELATION_NOE 蛋白<|>RELATION_NOE ,<|>RELATION_NOE 为<|>RELATION_NOE 阐明<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 分子<|>RELATION_NOE 机制<|>RELATION_NOE 、<|>RELATION_NOE 筛选<|>RELATION_NOE 早期<|>RELATION_NOE 诊断<|>RELATION_NOE 标志物<|>RELATION_NOE 提供<|>RELATION_B 了<|>RELATION_I 有益<|>RELATION_I 的<|>RELATION_I 线索<|>RELATION_E .<|>RELATION_NOE
人<|>RELATION_NOE 端粒<|>RELATION_NOE 酶<|>RELATION_NOE 逆转录酶<|>RELATION_NOE 基因<|>RELATION_NOE 5'<|>RELATION_NOE 调控<|>RELATION_NOE 区单<|>RELATION_NOE 核苷酸多态性<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 人<|>RELATION_NOE 端粒<|>RELATION_NOE 酶<|>RELATION_NOE 逆转录酶<|>RELATION_NOE (<|>RELATION_NOE hTERT<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 5'<|>RELATION_NOE 调控<|>RELATION_NOE 区单<|>RELATION_NOE 核苷酸多态性<|>RELATION_NOE (<|>RELATION_NOE SNP<|>RELATION_NOE )<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 发生<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_S 。<|>RELATION_NOE
其中<|>RELATION_NOE rs2735846<|>RELATION_NOE 位点<|>RELATION_NOE CG<|>RELATION_NOE +<|>RELATION_NOE CC<|>RELATION_NOE 基因型<|>RELATION_NOE 与<|>RELATION_NOE GG<|>RELATION_NOE 基因型<|>RELATION_NOE (<|>RELATION_NOE 即<|>RELATION_NOE 显性<|>RELATION_NOE 遗传<|>RELATION_NOE 模式<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 病例组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 中<|>RELATION_NOE 具有<|>RELATION_B 显著<|>RELATION_I 的<|>RELATION_I 统计学<|>RELATION_I 差异<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
hTERT<|>RELATION_NOE 基因<|>RELATION_NOE rs2735846<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 有<|>RELATION_B 显著<|>RELATION_I 相关性<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 等位基因<|>RELATION_NOE C<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 易感<|>RELATION_NOE 基因<|>RELATION_NOE .<|>RELATION_NOE hTERT<|>RELATION_NOE 基因<|>RELATION_NOE rs2735846<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 有<|>RELATION_NOE 显著<|>RELATION_NOE 相关性<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 等位基因<|>RELATION_NOE C<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 易感<|>RELATION_B 基因<|>RELATION_E .<|>RELATION_NOE
CCL18<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 和<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S 及其<|>RELATION_NOE 对外<|>RELATION_NOE 周血<|>RELATION_NOE 单核细胞<|>RELATION_NOE 向<|>RELATION_NOE 树突<|>RELATION_NOE 状<|>RELATION_NOE 细胞<|>RELATION_NOE 分化<|>RELATION_NOE 的<|>RELATION_NOE 调控<|>RELATION_NOE 作用<|>RELATION_NOE CCL18<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 和<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 及其<|>RELATION_NOE 对<|>RELATION_NOE 外<|>RELATION_B 周血<|>RELATION_I 单核细胞<|>RELATION_I 向<|>RELATION_I 树突<|>RELATION_I 状<|>RELATION_I 细胞<|>RELATION_I 分化<|>RELATION_E 的<|>RELATION_NOE 调控<|>RELATION_NOE 作用<|>RELATION_NOE
以<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 对照者<|>RELATION_NOE 血清<|>RELATION_NOE 、<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 肺<|>RELATION_NOE 感染性疾病<|>RELATION_NOE 渗出性<|>RELATION_NOE 良性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 及<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 炎症性<|>RELATION_NOE 疾病<|>RELATION_NOE 漏出性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 作为<|>RELATION_NOE 对照<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 比较<|>RELATION_NOE 62<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 和<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE CCL18<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平.<|>RELATION_NOE
在<|>RELATION_NOE 重组<|>RELATION_NOE 人<|>RELATION_NOE 源<|>RELATION_NOE 粒细胞<|>RELATION_NOE 巨噬细胞<|>RELATION_NOE 集落<|>RELATION_NOE 刺激<|>RELATION_NOE 因子<|>RELATION_NOE (<|>RELATION_NOE GM-CSF<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 白细胞介素<|>RELATION_NOE 4<|>RELATION_NOE (<|>RELATION_NOE IL-4<|>RELATION_NOE )<|>RELATION_NOE 体外<|>RELATION_NOE 诱导<|>RELATION_NOE 培养<|>RELATION_NOE 单核<|>RELATION_NOE 来源<|>RELATION_NOE 树突<|>RELATION_NOE 状<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE Mo-DC<|>RELATION_NOE )<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 加入<|>RELATION_NOE 外源性<|>RELATION_NOE CCL18<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 流式细胞术<|>RELATION_NOE (<|>RELATION_NOE FCM<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S CD14<|>RELATION_NOE 、<|>RELATION_NOE CD80<|>RELATION_NOE 、<|>RELATION_NOE CD83<|>RELATION_NOE 、<|>RELATION_NOE CD86<|>RELATION_NOE 和<|>RELATION_NOE 人类<|>RELATION_NOE 白细胞抗原<|>RELATION_NOE (<|>RELATION_NOE HLA<|>RELATION_NOE )<|>RELATION_NOE -DR<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE CCL18<|>RELATION_NOE 水平<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 15<|>RELATION_NOE 5.6<|>RELATION_NOE ±<|>RELATION_NOE 13.58<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 非<|>RELATION_NOE 炎症<|>RELATION_NOE 性漏<|>RELATION_NOE 出<|>RELATION_NOE 液中<|>RELATION_NOE CCL18<|>RELATION_NOE 水平<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 20.89<|>RELATION_NOE ±<|>RELATION_NOE 3.03<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE ,<|>RELATION_NOE 肺<|>RELATION_NOE 感染性疾病<|>RELATION_NOE 渗出性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE CCL18<|>RELATION_NOE 水平<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 190.4<|>RELATION_NOE ±<|>RELATION_NOE 22.33<|>RELATION_NOE )<|>RELATION_NOE ng<|>RELATION_NOE /<|>RELATION_NOE ml<|>RELATION_NOE .<|>RELATION_NOE
恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE CCL18<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_B 高于<|>RELATION_E 漏出液<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 良性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE CCL18<|>RELATION_NOE 水平<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.1<|>RELATION_NOE 72<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE CCL18<|>RELATION_NOE 水平<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 漏出液<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 但<|>RELATION_NOE 与<|>RELATION_NOE 良性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 中<|>RELATION_NOE CCL18<|>RELATION_NOE 水平<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.1<|>RELATION_NOE 72<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
相关性<|>RELATION_NOE 分析<|>RELATION_NOE 表明<|>RELATION_NOE ,<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 恶性<|>RELATION_NOE 胸腔积液<|>RELATION_NOE 和<|>RELATION_NOE 血清<|>RELATION_NOE 间<|>RELATION_NOE CCL18<|>RELATION_NOE 水平<|>RELATION_NOE 呈<|>RELATION_B 中度<|>RELATION_I 正<|>RELATION_I 相关<|>RELATION_E (<|>RELATION_NOE r<|>RELATION_NOE =<|>RELATION_NOE 0.4<|>RELATION_NOE 21<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
Ⅲ<|>RELATION_NOE A-N2<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 完全<|>RELATION_B 切除<|>RELATION_I 术后<|>RELATION_I 复发<|>RELATION_E 危险因素<|>RELATION_NOE 分析<|>RELATION_NOE
探讨<|>RELATION_NOE Ⅲ<|>RELATION_NOE A-N2<|>RELATION_NOE 期非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 特征<|>RELATION_NOE 和<|>RELATION_NOE 完全<|>RELATION_B 切除<|>RELATION_I 术后<|>RELATION_I 复发<|>RELATION_E 的<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 提示<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 总数<|>RELATION_NOE 、<|>RELATION_NOE 淋巴结<|>RELATION_NOE 总阳<|>RELATION_NOE 性率<|>RELATION_NOE 、<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 数<|>RELATION_NOE 、<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 阳<|>RELATION_NOE 性率<|>RELATION_NOE 、<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 数量<|>RELATION_NOE ><|>RELATION_NOE 3<|>RELATION_NOE 、<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 多<|>RELATION_NOE 站<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 跨<|>RELATION_NOE 区域<|>RELATION_NOE 转移<|>RELATION_NOE 、<|>RELATION_NOE 多<|>RELATION_NOE 区域<|>RELATION_NOE 转移<|>RELATION_NOE 是<|>RELATION_NOE 影响<|>RELATION_B 预后<|>RELATION_E 的<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE Cox<|>RELATION_NOE 多<|>RELATION_NOE
跨<|>RELATION_NOE 区域<|>RELATION_NOE 转移者<|>RELATION_NOE 复发<|>RELATION_NOE 风险<|>RELATION_NOE 是<|>RELATION_NOE 区域<|>RELATION_NOE 内<|>RELATION_NOE 转移<|>RELATION_NOE 者<|>RELATION_NOE 的<|>RELATION_NOE 2.0<|>RELATION_B 倍<|>RELATION_E ,<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 数量<|>RELATION_NOE ><|>RELATION_NOE 3者<|>RELATION_NOE 的<|>RELATION_NOE 复发<|>RELATION_NOE 风险<|>RELATION_NOE 是<|>RELATION_NOE 1－3<|>RELATION_NOE 者<|>RELATION_NOE 的<|>RELATION_NOE 2.2<|>RELATION_NOE 倍<|>RELATION_NOE 。<|>RELATION_NOE 跨<|>RELATION_NOE 区域<|>RELATION_NOE 转移者<|>RELATION_NOE 复发<|>RELATION_NOE 风险<|>RELATION_NOE 是<|>RELATION_NOE 区域<|>RELATION_NOE 内<|>RELATION_NOE 转移者<|>RELATION_NOE 的<|>RELATION_NOE 2.0<|>RELATION_NOE 倍<|>RELATION_NOE ,<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 数量<|>RELATION_NOE ><|>RELATION_NOE 3者<|>RELATION_NOE 的<|>RELATION_NOE 复发<|>RELATION_NOE 风险<|>RELATION_NOE 是<|>RELATION_NOE 1－3<|>RELATION_NOE 者<|>RELATION_NOE 的<|>RELATION_NOE 2.2<|>RELATION_B 倍<|>RELATION_E 。<|>RELATION_NOE
结合<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 位置<|>RELATION_NOE 和<|>RELATION_NOE 数量<|>RELATION_NOE 可<|>RELATION_NOE 判断<|>RELATION_S Ⅲ<|>RELATION_NOE A-N2<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 风险<|>RELATION_NOE ,<|>RELATION_NOE 跨<|>RELATION_NOE 区域<|>RELATION_NOE 转移<|>RELATION_NOE 并且<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 数量<|>RELATION_NOE ><|>RELATION_NOE 3者<|>RELATION_NOE 是<|>RELATION_NOE 复发<|>RELATION_NOE 风险<|>RELATION_NOE 最高<|>RELATION_NOE 的<|>RELATION_NOE 亚组.<|>RELATION_NOE 结合<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 的<|>RELATION_NOE 位置<|>RELATION_NOE 和<|>RELATION_NOE 数量<|>RELATION_NOE 可<|>RELATION_NOE 判断<|>RELATION_NOE Ⅲ<|>RELATION_NOE A-N2<|>RELATION_NOE 期<|>RELATION_NOE NSCLC<|>RELATION_NOE 术后<|>RELATION_NOE 复发<|>RELATION_NOE 风险<|>RELATION_NOE ,<|>RELATION_NOE 跨<|>RELATION_NOE 区域<|>RELATION_NOE 转移<|>RELATION_NOE 并且<|>RELATION_NOE 纵隔<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE 数量<|>RELATION_NOE ><|>RELATION_NOE 3者<|>RELATION_NOE 是<|>RELATION_NOE 复发<|>RELATION_B 风险<|>RELATION_I 最高<|>RELATION_E 的<|>RELATION_NOE 亚组<|>RELATION_NOE .<|>RELATION_NOE
59<|>RELATION_NOE 例<|>RELATION_NOE 肺腺<|>RELATION_NOE 鳞癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 病理<|>RELATION_NOE 特征<|>RELATION_NOE 对<|>RELATION_NOE 其<|>RELATION_NOE 外科手术<|>RELATION_B 后<|>RELATION_I 生存<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
选择<|>RELATION_NOE 肿瘤<|>RELATION_NOE 亚型<|>RELATION_NOE 、<|>RELATION_NOE 生物学<|>RELATION_NOE 行为<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 等<|>RELATION_NOE 因素<|>RELATION_NOE ,<|>RELATION_NOE 应用<|>RELATION_NOE SPSS17.0<|>RELATION_NOE 分析<|>RELATION_NOE 影响<|>RELATION_NOE 患者<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
59<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 52<|>RELATION_NOE 例<|>RELATION_NOE 病理<|>RELATION_NOE 标本行<|>RELATION_NOE 基因检测<|>RELATION_NOE ,<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE EGFR<|>RELATION_NOE 突变<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 为<|>RELATION_NOE 21.2%<|>RELATION_NOE (<|>RELATION_NOE 11<|>RELATION_NOE /<|>RELATION_NOE 52<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 2例<|>RELATION_NOE 患者<|>RELATION_NOE KRAS<|>RELATION_NOE 突变<|>RELATION_NOE 阳性<|>RELATION_NOE ,<|>RELATION_NOE 阳性率<|>RELATION_NOE 3.8%<|>RELATION_NOE (<|>RELATION_NOE 2/<|>RELATION_NOE 52<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
三维<|>RELATION_NOE 影像<|>RELATION_NOE 技术<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE 模式<|>RELATION_NOE 对<|>RELATION_NOE 住院<|>RELATION_NOE 肺癌<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 希望<|>RELATION_NOE 水平<|>RELATION_NOE 与<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 住院<|>RELATION_NOE 化疗<|>RELATION_NOE 期间<|>RELATION_NOE 的<|>RELATION_NOE 希望<|>RELATION_NOE 水平<|>RELATION_NOE 和<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两者<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 三维<|>RELATION_NOE 影像<|>RELATION_NOE 技术<|>RELATION_NOE 对<|>RELATION_NOE 住院<|>RELATION_NOE 化疗<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 健康<|>RELATION_NOE 教育<|>RELATION_NOE ,<|>RELATION_NOE 能够<|>RELATION_NOE 明显<|>RELATION_B 提高<|>RELATION_E 患者<|>RELATION_NOE 希望<|>RELATION_NOE 水平<|>RELATION_NOE 和<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 推广<|>RELATION_NOE 。<|>RELATION_NOE
p16<|>RELATION_NOE 和<|>RELATION_NOE Smad4<|>RELATION_NOE 表达<|>RELATION_NOE 缺失<|>RELATION_NOE 在<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 意义<|>RELATION_S
免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S p16<|>RELATION_NOE 、<|>RELATION_NOE Smad4<|>RELATION_NOE 蛋白<|>RELATION_NOE 在<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 缺失<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_NOE p16<|>RELATION_NOE 和<|>RELATION_NOE Smad4<|>RELATION_NOE 缺失<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 因素<|>RELATION_NOE 及<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
p16<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 缺失<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Smad4<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 缺失<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE p16<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 缺失<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 分期<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE Smad4<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 缺失<|>RELATION_NOE 与<|>RELATION_NOE 肿瘤<|>RELATION_NOE 大小<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 分化<|>RELATION_NOE 程度<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E .<|>RELATION_NOE
非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 胰岛素<|>RELATION_NOE 样<|>RELATION_NOE 生长因子<|>RELATION_NOE -1<|>RELATION_NOE 水平<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_S
探讨<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 血清<|>RELATION_NOE 中<|>RELATION_NOE 胰岛素<|>RELATION_NOE 样<|>RELATION_NOE 生长因子<|>RELATION_NOE -1<|>RELATION_NOE (<|>RELATION_NOE IGF-1<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 及其<|>RELATION_NOE 在<|>RELATION_NOE NSCLC<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_B 价值<|>RELATION_E 。<|>RELATION_NOE
采用<|>RELATION_NOE 放射<|>RELATION_NOE 免疫<|>RELATION_NOE 分析法<|>RELATION_NOE (<|>RELATION_NOE RIA<|>RELATION_NOE 法<|>RELATION_NOE )<|>RELATION_NOE 检测<|>RELATION_S 63<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 健康<|>RELATION_NOE 体检者<|>RELATION_NOE 血清<|>RELATION_NOE IGF-1<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 比较<|>RELATION_NOE 44<|>RELATION_NOE 例<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 手术<|>RELATION_NOE 前后<|>RELATION_NOE 血清<|>RELATION_NOE IGF-1<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
肺癌<|>RELATION_NOE 组<|>RELATION_NOE 血浆<|>RELATION_NOE 和<|>RELATION_NOE BALF<|>RELATION_NOE 中<|>RELATION_NOE TMS1<|>RELATION_NOE /<|>RELATION_NOE ASC<|>RELATION_NOE 基因<|>RELATION_NOE 启动子<|>RELATION_NOE 甲基化<|>RELATION_NOE 阳性<|>RELATION_NOE 率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 27.2%<|>RELATION_NOE 和<|>RELATION_NOE 32.6%<|>RELATION_NOE .<|>RELATION_NOE
Toll<|>RELATION_NOE 样受体<|>RELATION_NOE 3-<|>RELATION_NOE 小<|>RELATION_NOE 分子<|>RELATION_NOE RNA<|>RELATION_NOE 干扰<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE A549<|>RELATION_NOE 增殖<|>RELATION_NOE 分化<|>RELATION_NOE 及<|>RELATION_NOE 免疫<|>RELATION_NOE 逃逸<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
给予<|>RELATION_NOE TLR3-RNA<|>RELATION_NOE 干扰<|>RELATION_NOE (<|>RELATION_NOE RNAi<|>RELATION_NOE )<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 转染<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 未<|>RELATION_NOE 转染组<|>RELATION_NOE 和<|>RELATION_NOE 空载<|>RELATION_NOE 对照组<|>RELATION_NOE TLR3<|>RELATION_NOE 的<|>RELATION_NOE 配体<|>RELATION_NOE Poly<|>RELATION_NOE (<|>RELATION_NOE I<|>RELATION_NOE :<|>RELATION_NOE C<|>RELATION_NOE )<|>RELATION_NOE 刺激<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 通过<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S B7-H1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 实时<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE Real-time<|>RELATION_NOE PCR<|>RELATION_NOE )<|>RELATION_NOE
在<|>RELATION_NOE Poly<|>RELATION_NOE (<|>RELATION_NOE I<|>RELATION_NOE :<|>RELATION_NOE C<|>RELATION_NOE )<|>RELATION_NOE 刺激<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 浓度<|>RELATION_NOE 相同<|>RELATION_NOE 的<|>RELATION_NOE 情况<|>RELATION_NOE 下<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_NOE TLR3-RNAi<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 载体<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞组<|>RELATION_NOE 中<|>RELATION_NOE B7-H1<|>RELATION_NOE 阳性<|>RELATION_NOE 细胞<|>RELATION_NOE 百分比<|>RELATION_NOE 、<|>RELATION_NOE PGE-2<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 以及<|>RELATION_NOE 磷酸化<|>RELATION_NOE p38<|>RELATION_NOE 的<|>RELATION_NOE 百分比<|>RELATION_NOE 相对值<|>RELATION_NOE 均<|>RELATION_B 低于<|>RELATION_E 未<|>RELATION_NOE 转染组<|>RELATION_NOE 和<|>RELATION_NOE 空载<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
凋亡<|>RELATION_NOE 实验<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE 转染<|>RELATION_NOE TLR3-RNAi<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 载体<|>RELATION_NOE 的<|>RELATION_NOE A549<|>RELATION_NOE 细胞组<|>RELATION_NOE 细胞凋亡率<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 44.40<|>RELATION_NOE ±<|>RELATION_NOE 1.41<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 未<|>RELATION_NOE 转染<|>RELATION_NOE 慢<|>RELATION_NOE 病毒<|>RELATION_NOE 载体组<|>RELATION_NOE (<|>RELATION_NOE 34.70<|>RELATION_NOE ±<|>RELATION_NOE 0.89<|>RELATION_NOE )%<|>RELATION_NOE ]<|>RELATION_NOE 和<|>RELATION_NOE 空载<|>RELATION_NOE 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 36.50<|>RELATION_NOE ±<|>RELATION_NOE 1.12<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE 。<|>RELATION_NOE
TLR3<|>RELATION_NOE 基因沉默<|>RELATION_NOE 抑制<|>RELATION_S 了<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE p38<|>RELATION_NOE 、<|>RELATION_NOE PGE-2<|>RELATION_NOE 、<|>RELATION_NOE B7-H1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 降低<|>RELATION_NOE 了<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 凋亡<|>RELATION_NOE 能力<|>RELATION_NOE .<|>RELATION_NOE TLR3<|>RELATION_NOE 基因沉默<|>RELATION_NOE 抑制<|>RELATION_NOE 了<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE p38<|>RELATION_NOE 、<|>RELATION_NOE PGE-2<|>RELATION_NOE 、<|>RELATION_NOE B7-H1<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 降低<|>RELATION_S 了<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 凋亡<|>RELATION_NOE 能力<|>RELATION_NOE .<|>RELATION_NOE
下调<|>RELATION_NOE Kru<|>RELATION_NOE ;<|>RELATION_NOE ppel<|>RELATION_NOE 样因子8<|>RELATION_NOE 表达<|>RELATION_NOE 抑制<|>RELATION_S 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE A549<|>RELATION_NOE 侵袭<|>RELATION_NOE
应用<|>RELATION_NOE 短发卡<|>RELATION_NOE RNA<|>RELATION_NOE (<|>RELATION_NOE shRNA<|>RELATION_NOE )<|>RELATION_NOE 瞬时<|>RELATION_NOE 转染<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE A549<|>RELATION_NOE 干扰<|>RELATION_NOE KLF8<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 形成<|>RELATION_NOE A549<|>RELATION_NOE 、<|>RELATION_NOE Mock<|>RELATION_NOE 及<|>RELATION_NOE sh-KLF8<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 亚组<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 检测<|>RELATION_NOE KLF8<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Transwell<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 癌细胞<|>RELATION_NOE 侵袭<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE blot<|>RELATION_NOE 法<|>RELATION_NOE
上皮<|>RELATION_NOE -<|>RELATION_NOE 间充质<|>RELATION_NOE 转化<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE E-<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 上调<|>RELATION_S 4.9<|>RELATION_NOE 倍<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N-<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE N-cadherin<|>RELATION_NOE )<|>RELATION_NOE 下调<|>RELATION_NOE 44.5%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 下调<|>RELATION_NOE 62.1%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间充质<|>RELATION_NOE 转化<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE E-<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 上调<|>RELATION_NOE 4.9<|>RELATION_NOE 倍<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N-<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE N-cadherin<|>RELATION_NOE )<|>RELATION_NOE 下调<|>RELATION_S 44.5%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间充质<|>RELATION_NOE 转化<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE E-<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE E-cadherin<|>RELATION_NOE )<|>RELATION_NOE 上调<|>RELATION_NOE 4.9<|>RELATION_NOE 倍<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE N-<|>RELATION_NOE 钙黏<|>RELATION_NOE 蛋白<|>RELATION_NOE (<|>RELATION_NOE N-cadherin<|>RELATION_NOE )<|>RELATION_NOE 下调<|>RELATION_NOE 44.5%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 波形蛋白<|>RELATION_NOE (<|>RELATION_NOE Vimentin<|>RELATION_NOE )<|>RELATION_NOE 下调<|>RELATION_S 62.1%<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.01<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
干扰<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE A549<|>RELATION_NOE 的<|>RELATION_NOE KLF8<|>RELATION_NOE 后<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_S 癌细胞<|>RELATION_NOE 的<|>RELATION_NOE 迁移<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 作用<|>RELATION_NOE 机制<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 通过<|>RELATION_NOE 上皮<|>RELATION_NOE -<|>RELATION_NOE 间充质<|>RELATION_NOE 转化<|>RELATION_NOE 通路<|>RELATION_NOE 实现<|>RELATION_NOE 的<|>RELATION_NOE .<|>RELATION_NOE
金属硫蛋白<|>RELATION_NOE -3<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 株生物学<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 金属硫蛋白<|>RELATION_NOE -3<|>RELATION_NOE (<|>RELATION_NOE MT-3<|>RELATION_NOE )<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE 、<|>RELATION_NOE 凋亡<|>RELATION_NOE 和<|>RELATION_NOE 生物学<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S 。<|>RELATION_NOE
应用<|>RELATION_NOE 基因<|>RELATION_NOE 转录<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S MT-3<|>RELATION_NOE 表达<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞株<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 增殖<|>RELATION_NOE 作用<|>RELATION_NOE 和<|>RELATION_NOE 生物学<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
通过<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 和<|>RELATION_NOE 逆转录<|>RELATION_NOE -<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE RT-PCR<|>RELATION_NOE )<|>RELATION_NOE 技术<|>RELATION_NOE 检测<|>RELATION_S MT-3mRNA<|>RELATION_NOE 在<|>RELATION_NOE A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 株中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 半定量<|>RELATION_NOE RT-PCR<|>RELATION_NOE (<|>RELATION_NOE SqRT-PCR<|>RELATION_NOE )<|>RELATION_NOE 测定<|>RELATION_NOE 转染<|>RELATION_NOE 后<|>RELATION_NOE A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE c-fos<|>RELATION_NOE 、<|>RELATION_NOE c-jun<|>RELATION_NOE mRNA<|>RELATION_NOE 水平<|>RELATION_NOE 表达<|>RELATION_NOE 变化<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 通过<|>RELATION_NOE 显微镜<|>RELATION_NOE 、<|>RELATION_NOE 苏木素<|>RELATION_NOE -<|>RELATION_NOE 伊红<|>RELATION_NOE (<|>RELATION_NOE HE<|>RELATION_NOE )<|>RELATION_NOE 染色<|>RELATION_NOE 、<|>RELATION_NOE 透射<|>RELATION_NOE 电镜<|>RELATION_NOE 等<|>RELATION_NOE 观察<|>RELATION_NOE 凋亡<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 形态学<|>RELATION_NOE 改变<|>RELATION_NOE 。<|>RELATION_NOE
RT-PCR<|>RELATION_NOE 和<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞化学<|>RELATION_NOE 证实<|>RELATION_S 转染<|>RELATION_NOE 后<|>RELATION_NOE A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE 有<|>RELATION_NOE MT-3<|>RELATION_NOE 稳定<|>RELATION_NOE 表达<|>RELATION_NOE ;<|>RELATION_NOE
噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 比色法<|>RELATION_NOE 表明<|>RELATION_NOE 随着<|>RELATION_NOE MT-3<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 效靶<|>RELATION_NOE 比<|>RELATION_NOE 增加<|>RELATION_NOE 及<|>RELATION_NOE 作用<|>RELATION_NOE 时间<|>RELATION_NOE 延长<|>RELATION_NOE ,<|>RELATION_NOE 抑制率<|>RELATION_NOE 明显<|>RELATION_B 增强<|>RELATION_E (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 2.7<|>RELATION_NOE 95<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
MT-3<|>RELATION_NOE 作用<|>RELATION_NOE 于<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 24h<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 形态学<|>RELATION_B 观察<|>RELATION_E 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 发生<|>RELATION_NOE 凋亡<|>RELATION_NOE 或<|>RELATION_NOE 坏死<|>RELATION_NOE 。<|>RELATION_NOE
体外<|>RELATION_NOE 制备<|>RELATION_NOE 的<|>RELATION_NOE MT-3<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 具有<|>RELATION_B 抑制<|>RELATION_I 增殖<|>RELATION_I 和<|>RELATION_I 促进<|>RELATION_I 凋亡<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 其<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 通过<|>RELATION_NOE 负性<|>RELATION_NOE 调控<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 降低<|>RELATION_NOE A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 株中<|>RELATION_NOE c-fos<|>RELATION_NOE 、<|>RELATION_NOE c-jun<|>RELATION_NOE 的<|>RELATION_NOE 表达.<|>RELATION_NOE 体外<|>RELATION_NOE 制备<|>RELATION_NOE 的<|>RELATION_NOE MT-3<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 具有<|>RELATION_NOE 抑制<|>RELATION_NOE 增殖<|>RELATION_NOE 和<|>RELATION_NOE 促进<|>RELATION_NOE 凋亡<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 可能<|>RELATION_NOE 是<|>RELATION_NOE 通过<|>RELATION_NOE 负性<|>RELATION_NOE 调控<|>RELATION_NOE 信号<|>RELATION_NOE 通路<|>RELATION_NOE 降低<|>RELATION_S A549<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 株中<|>RELATION_NOE c-fos<|>RELATION_NOE 、<|>RELATION_NOE c-jun<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE .<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 及<|>RELATION_NOE 医院感染<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
探讨<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_B 及其<|>RELATION_I 医院<|>RELATION_I 感染<|>RELATION_I 情况<|>RELATION_E 。<|>RELATION_NOE
本院<|>RELATION_NOE 2008年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 6月<|>RELATION_NOE 收治<|>RELATION_NOE 的<|>RELATION_NOE 110<|>RELATION_NOE 例<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 晚期<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 长春<|>RELATION_NOE 瑞滨<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗组<|>RELATION_NOE (<|>RELATION_NOE 常规组<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗组<|>RELATION_NOE (<|>RELATION_NOE 试验组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 及<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 、<|>RELATION_NOE 血液<|>RELATION_NOE 毒性<|>RELATION_NOE 及<|>RELATION_NOE 医院感染<|>RELATION_NOE 发生率<|>RELATION_NOE 情况<|>RELATION_NOE 进行<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
化疗<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 试验组<|>RELATION_NOE 感染<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_S 常规组<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 其<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE 病原<|>RELATION_NOE 菌<|>RELATION_NOE 种类<|>RELATION_NOE 组成<|>RELATION_NOE 与<|>RELATION_NOE 化疗<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 试验组<|>RELATION_NOE 感染<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_NOE 常规组<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 其<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE 病原<|>RELATION_NOE 菌<|>RELATION_NOE 种类<|>RELATION_NOE 组成<|>RELATION_NOE 与<|>RELATION_NOE 常规组<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 所有<|>RELATION_NOE 的<|>RELATION_NOE 细菌<|>RELATION_NOE 感染<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 试验组<|>RELATION_NOE 患者<|>RELATION_NOE 产<|>RELATION_NOE ESBLs<|>RELATION_NOE 大肠<|>RELATION_NOE 埃希菌<|>RELATION_NOE 的<|>RELATION_NOE 感染率<|>RELATION_NOE 低于<|>RELATION_S 常规组<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 铜绿<|>RELATION_NOE 假<|>RELATION_NOE 单胞菌<|>RELATION_NOE 的<|>RELATION_NOE 感染率<|>RELATION_NOE 高于<|>RELATION_NOE 化疗<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 试验组<|>RELATION_NOE 感染<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_NOE 常规组<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 其<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE 病原<|>RELATION_NOE 菌<|>RELATION_NOE 种类<|>RELATION_NOE 组成<|>RELATION_NOE 与<|>RELATION_NOE 常规组<|>RELATION_NOE 差异<|>RELATION_NOE 具有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 所有<|>RELATION_NOE 的<|>RELATION_NOE 细菌<|>RELATION_NOE 感染<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 试验组<|>RELATION_NOE 患者<|>RELATION_NOE 产<|>RELATION_NOE ESBLs<|>RELATION_NOE 大肠<|>RELATION_NOE 埃希菌<|>RELATION_NOE 的<|>RELATION_NOE 感染率<|>RELATION_NOE 低于<|>RELATION_NOE 常规组<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE 铜绿<|>RELATION_NOE 假<|>RELATION_NOE 单胞菌<|>RELATION_NOE 的<|>RELATION_NOE 感染率<|>RELATION_NOE 高于<|>RELATION_S 常规组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE ^<|>RELATION_NOE 2=<|>RELATION_NOE 3.8<|>RELATION_NOE 91<|>RELATION_NOE 、<|>RELATION_NOE 4.8<|>RELATION_NOE 57<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.0<|>RELATION_NOE 48<|>RELATION_NOE 、<|>RELATION_NOE 0.0<|>RELATION_NOE 27<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
培美<|>RELATION_NOE 曲塞<|>RELATION_NOE 联合<|>RELATION_NOE 顺铂<|>RELATION_NOE 化疗<|>RELATION_NOE 有助于<|>RELATION_S 减轻<|>RELATION_NOE 化疗<|>RELATION_NOE 导致<|>RELATION_NOE 的<|>RELATION_NOE 骨髓<|>RELATION_NOE 抑制<|>RELATION_NOE 与<|>RELATION_NOE 血液<|>RELATION_NOE 毒性<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 免疫力<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 住院<|>RELATION_NOE 期间<|>RELATION_NOE 院感<|>RELATION_NOE 发生率<|>RELATION_NOE 。<|>RELATION_NOE
121<|>RELATION_NOE 例<|>RELATION_NOE 脊柱<|>RELATION_NOE 转移瘤<|>RELATION_NOE 手术<|>RELATION_B 治疗<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
肺癌<|>RELATION_NOE 35<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 28.9%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 26<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 21.4%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肾癌<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 14.O<|>RELATION_NOE %<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 前列腺癌<|>RELATION_NOE 20<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 16.5%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 甲状腺癌<|>RELATION_NOE 14<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 11.6%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肝癌<|>RELATION_NOE 2例<|>RELATION_NOE (<|>RELATION_NOE 1.7%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 结肠癌<|>RELATION_NOE 1例<|>RELATION_NOE (<|>RELATION_NOE 0.8%<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 其他<|>RELATION_NOE 肿瘤<|>RELATION_NOE 6<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 5.0%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
应用<|>RELATION_NOE 疼痛<|>RELATION_NOE 视觉<|>RELATION_NOE 模拟<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE visualanaloguescale<|>RELATION_NOE ,<|>RELATION_NOE VAS<|>RELATION_NOE )<|>RELATION_NOE 于<|>RELATION_NOE 术前<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 进行<|>RELATION_NOE 评估<|>RELATION_NOE 、<|>RELATION_NOE Frankel<|>RELATION_NOE 分级<|>RELATION_NOE 评估<|>RELATION_S 脊髓<|>RELATION_NOE 损害<|>RELATION_NOE 恢复<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE Karnofsky<|>RELATION_NOE 体能<|>RELATION_NOE 状况<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE Karnofskyperformancescore<|>RELATION_NOE ,<|>RELATION_NOE KPS<|>RELATION_NOE 评分<|>RELATION_NOE )<|>RELATION_NOE 应用<|>RELATION_NOE 疼痛<|>RELATION_NOE 视觉<|>RELATION_NOE 模拟<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE visualanaloguescale<|>RELATION_NOE ,<|>RELATION_NOE VAS<|>RELATION_NOE )<|>RELATION_NOE 于<|>RELATION_NOE 术前<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 进行<|>RELATION_NOE 评估<|>RELATION_NOE 、<|>RELATION_NOE Frankel<|>RELATION_NOE 分级<|>RELATION_NOE 评估<|>RELATION_NOE 脊髓<|>RELATION_NOE 损害<|>RELATION_NOE 恢复<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE Karnofsky<|>RELATION_NOE 体能<|>RELATION_NOE 状况<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE Karnofskyperformancescore<|>RELATION_NOE ,<|>RELATION_NOE KPS<|>RELATION_NOE 评分<|>RELATION_NOE )<|>RELATION_NOE 评估<|>RELATION_S 患者<|>RELATION_NOE 身体<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 观察<|>RELATION_NOE 二<|>RELATION_NOE 便<|>RELATION_NOE 恢复<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE EORTC<|>RELATION_NOE QLQ-C30<|>RELATION_NOE 评分<|>RELATION_NOE 应用<|>RELATION_NOE 疼痛<|>RELATION_NOE 视觉<|>RELATION_NOE 模拟<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE visualanaloguescale<|>RELATION_NOE ,<|>RELATION_NOE VAS<|>RELATION_NOE )<|>RELATION_NOE 于<|>RELATION_NOE 术前<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 3<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE 进行<|>RELATION_NOE 评估<|>RELATION_NOE 、<|>RELATION_NOE Frankel<|>RELATION_NOE 分级<|>RELATION_NOE 评估<|>RELATION_NOE 脊髓<|>RELATION_NOE 损害<|>RELATION_NOE 恢复<|>RELATION_NOE 情况<|>RELATION_NOE 、<|>RELATION_NOE Karnofsky<|>RELATION_NOE 体能<|>RELATION_NOE 状况<|>RELATION_NOE 评分<|>RELATION_NOE (<|>RELATION_NOE Karnofskyperformancescore<|>RELATION_NOE ,<|>RELATION_NOE KPS<|>RELATION_NOE 评分<|>RELATION_NOE )<|>RELATION_NOE 评估<|>RELATION_NOE 患者<|>RELATION_NOE 身体<|>RELATION_NOE 状况<|>RELATION_NOE 、<|>RELATION_NOE 观察<|>RELATION_NOE 二<|>RELATION_NOE 便<|>RELATION_NOE 恢复<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE EORTC<|>RELATION_NOE QLQ-C30<|>RELATION_NOE 评分<|>RELATION_NOE 评估<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE Kaplan-meier<|>RELATION_NOE 法<|>RELATION_NOE 进行<|>RELATION_S 生存<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
外科手术<|>RELATION_NOE 治疗<|>RELATION_B 脊柱<|>RELATION_I 转移瘤<|>RELATION_E 能<|>RELATION_NOE 有效<|>RELATION_NOE 地<|>RELATION_NOE 缓解<|>RELATION_NOE 患者<|>RELATION_NOE 疼痛<|>RELATION_NOE 、<|>RELATION_NOE 改善<|>RELATION_NOE 脊髓<|>RELATION_NOE 功能<|>RELATION_NOE ,<|>RELATION_NOE 使<|>RELATION_NOE 部分<|>RELATION_NOE 患者<|>RELATION_NOE 二<|>RELATION_NOE 便<|>RELATION_NOE 功能<|>RELATION_NOE 得以<|>RELATION_NOE 恢复<|>RELATION_NOE ,<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 得到<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_NOE 。<|>RELATION_NOE
乳腺癌<|>RELATION_NOE 及<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 脊柱<|>RELATION_NOE 转移<|>RELATION_NOE 采用<|>RELATION_NOE 外科手术<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 较<|>RELATION_B 其他<|>RELATION_I 恶性肿瘤<|>RELATION_E 高<|>RELATION_NOE ;<|>RELATION_NOE
相对<|>RELATION_NOE 于<|>RELATION_NOE 乳腺癌<|>RELATION_NOE ,<|>RELATION_NOE 恶性<|>RELATION_NOE 程度<|>RELATION_NOE 更<|>RELATION_NOE 高<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 脊柱<|>RELATION_NOE 转移<|>RELATION_NOE 后<|>RELATION_NOE 采用<|>RELATION_NOE 外科手术<|>RELATION_NOE 干预<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_B 更<|>RELATION_I 高<|>RELATION_E 。<|>RELATION_NOE
165<|>RELATION_NOE 例<|>RELATION_NOE 骨盆<|>RELATION_NOE 软骨肉瘤<|>RELATION_NOE 外科<|>RELATION_B 治疗<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 分析<|>RELATION_NOE
总结<|>RELATION_NOE 骨盆<|>RELATION_NOE 软骨肉瘤<|>RELATION_NOE 外科<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 长期<|>RELATION_NOE 结果<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 肿瘤<|>RELATION_NOE 学<|>RELATION_NOE 预后<|>RELATION_NOE 和<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 功能<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 探讨<|>RELATION_B 骨盆<|>RELATION_I 软骨肉瘤<|>RELATION_I 合理<|>RELATION_I 的<|>RELATION_I 切除<|>RELATION_I 及<|>RELATION_I 重建<|>RELATION_I 方式<|>RELATION_E 。<|>RELATION_NOE
复发<|>RELATION_NOE 病例<|>RELATION_NOE 、<|>RELATION_NOE 累及<|>RELATION_NOE Ⅳ<|>RELATION_NOE 区<|>RELATION_NOE 、<|>RELATION_NOE 分<|>RELATION_NOE 块<|>RELATION_NOE 切除<|>RELATION_NOE 肿瘤<|>RELATION_NOE 为<|>RELATION_NOE 导致<|>RELATION_B 术后<|>RELATION_I 复发<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE 。<|>RELATION_NOE
胰腺<|>RELATION_NOE 转移<|>RELATION_NOE 癌<|>RELATION_NOE 超声<|>RELATION_NOE 造影<|>RELATION_NOE 表现<|>RELATION_S 探讨<|>RELATION_NOE
回顾性<|>RELATION_NOE 分析<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 病理<|>RELATION_NOE 或<|>RELATION_NOE CT<|>RELATION_NOE 、<|>RELATION_NOE MRI<|>RELATION_NOE 等<|>RELATION_NOE 增强<|>RELATION_NOE 影像学<|>RELATION_NOE 检查<|>RELATION_NOE 及<|>RELATION_NOE 临床<|>RELATION_NOE 综合<|>RELATION_NOE 诊断<|>RELATION_NOE 的<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移癌<|>RELATION_NOE 病例<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 病变<|>RELATION_NOE 常规<|>RELATION_NOE 超声<|>RELATION_NOE 表现<|>RELATION_NOE ,<|>RELATION_NOE 超声<|>RELATION_NOE 造影<|>RELATION_NOE 增强<|>RELATION_NOE 与<|>RELATION_NOE 消退<|>RELATION_NOE 速度<|>RELATION_NOE 、<|>RELATION_NOE 强化<|>RELATION_NOE 程度<|>RELATION_NOE 及<|>RELATION_NOE 强化<|>RELATION_NOE 特点<|>RELATION_NOE 。<|>RELATION_NOE
11<|>RELATION_NOE 例<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移<|>RELATION_NOE 癌原<|>RELATION_NOE 发<|>RELATION_NOE 于<|>RELATION_NOE 肺癌<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 乳腺癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 肾透明<|>RELATION_NOE 细胞癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 胃癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 直肠癌<|>RELATION_NOE 1例<|>RELATION_NOE ,<|>RELATION_NOE 子宫<|>RELATION_NOE 平滑肌肉瘤<|>RELATION_NOE 1例<|>RELATION_NOE 。<|>RELATION_NOE
超声<|>RELATION_NOE 造影<|>RELATION_NOE 6例<|>RELATION_NOE 诊断<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移癌<|>RELATION_NOE ,<|>RELATION_NOE 3例<|>RELATION_NOE 诊断<|>RELATION_NOE 为<|>RELATION_NOE 恶性<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 诊断<|>RELATION_NOE 神经<|>RELATION_NOE 内<|>RELATION_NOE 分泌<|>RELATION_NOE 肿瘤<|>RELATION_NOE ,<|>RELATION_NOE 1例<|>RELATION_NOE 性质<|>RELATION_NOE 待定<|>RELATION_NOE 。<|>RELATION_NOE
胰腺<|>RELATION_NOE 转移癌<|>RELATION_NOE 的<|>RELATION_NOE 超声<|>RELATION_NOE 造影<|>RELATION_NOE 表现<|>RELATION_NOE 有别于<|>RELATION_S 胰腺<|>RELATION_NOE 原<|>RELATION_NOE 发癌<|>RELATION_NOE ,<|>RELATION_NOE 重视<|>RELATION_NOE 原<|>RELATION_NOE 发癌<|>RELATION_NOE 的<|>RELATION_NOE 病史<|>RELATION_NOE 、<|>RELATION_NOE 超声<|>RELATION_NOE 造影<|>RELATION_NOE 增强<|>RELATION_NOE 早期<|>RELATION_NOE 表现<|>RELATION_NOE 特点<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE 胰腺<|>RELATION_NOE 转移癌<|>RELATION_NOE 的<|>RELATION_NOE 超声<|>RELATION_NOE 造影<|>RELATION_NOE 表现<|>RELATION_NOE 有别于<|>RELATION_NOE 胰腺<|>RELATION_NOE 原<|>RELATION_NOE 发癌<|>RELATION_NOE ,<|>RELATION_NOE 重视<|>RELATION_NOE 原<|>RELATION_NOE 发癌<|>RELATION_NOE 的<|>RELATION_NOE 病史<|>RELATION_NOE 、<|>RELATION_NOE 超声<|>RELATION_NOE 造影<|>RELATION_NOE 增强<|>RELATION_NOE 早期<|>RELATION_NOE 表现<|>RELATION_NOE 特点<|>RELATION_NOE 等<|>RELATION_NOE ,<|>RELATION_NOE 有助于<|>RELATION_S 胰腺<|>RELATION_NOE 转移癌<|>RELATION_NOE 的<|>RELATION_NOE 诊断<|>RELATION_NOE 。<|>RELATION_NOE
医用<|>RELATION_NOE 三<|>RELATION_NOE 氧<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他滨<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 医用<|>RELATION_NOE 三<|>RELATION_NOE 氧<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他滨<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE GP<|>RELATION_NOE )<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
共<|>RELATION_NOE 55<|>RELATION_NOE 例<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 采用<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 对照组<|>RELATION_NOE 27<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 加用<|>RELATION_NOE 三氧<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 、<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 、<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 及<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 功能<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
治疗<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 观察组<|>RELATION_NOE 优于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 肝功能<|>RELATION_NOE 损伤<|>RELATION_NOE 低于<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 观察组<|>RELATION_NOE 优于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 肝功能<|>RELATION_NOE 损伤<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 功能<|>RELATION_NOE 较<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE 观察组<|>RELATION_NOE 优于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 肝功能<|>RELATION_NOE 损伤<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 细胞免疫<|>RELATION_NOE 功能<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 明显<|>RELATION_B 增强<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
螺旋<|>RELATION_NOE CT<|>RELATION_NOE 动态<|>RELATION_NOE 增强<|>RELATION_NOE 扫描<|>RELATION_NOE 在<|>RELATION_NOE 孤立性<|>RELATION_B 肺结节<|>RELATION_I 鉴别诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
回顾<|>RELATION_NOE 分析<|>RELATION_NOE 65<|>RELATION_NOE 例<|>RELATION_NOE 孤立性<|>RELATION_NOE 肺结节<|>RELATION_NOE (<|>RELATION_NOE SPN<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病例<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 经<|>RELATION_NOE 手术<|>RELATION_NOE 病理<|>RELATION_NOE 证实<|>RELATION_NOE ,<|>RELATION_NOE 良性<|>RELATION_NOE SPN<|>RELATION_NOE 17<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 炎性<|>RELATION_NOE SPN<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 恶性<|>RELATION_NOE SPN<|>RELATION_NOE 36<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 多<|>RELATION_NOE 层<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 扫描机<|>RELATION_NOE 对<|>RELATION_NOE SPN<|>RELATION_NOE 行<|>RELATION_NOE 平扫<|>RELATION_NOE 和<|>RELATION_NOE 增强<|>RELATION_NOE 后<|>RELATION_NOE 15s<|>RELATION_NOE 、<|>RELATION_NOE 30s<|>RELATION_NOE 、<|>RELATION_NOE 60s<|>RELATION_NOE 、<|>RELATION_NOE 120s<|>RELATION_NOE 、<|>RELATION_NOE 180s<|>RELATION_NOE 、<|>RELATION_NOE 240s<|>RELATION_NOE 、<|>RELATION_NOE 300s<|>RELATION_NOE 等<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE 序列<|>RELATION_NOE 扫描<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 结节<|>RELATION_NOE 增强<|>RELATION_NOE 参数<|>RELATION_NOE ,<|>RELATION_NOE 统计<|>RELATION_NOE 各个<|>RELATION_NOE 期相<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 净增值<|>RELATION_NOE 与<|>RELATION_NOE 最<|>RELATION_NOE 大<|>RELATION_NOE CT<|>RELATION_NOE 净增值<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 结节<|>RELATION_NOE 形态学<|>RELATION_NOE 征象<|>RELATION_NOE ,<|>RELATION_NOE 计算<|>RELATION_NOE 多<|>RELATION_NOE 期<|>RELATION_NOE 动态<|>RELATION_NOE 扫描<|>RELATION_NOE 的<|>RELATION_NOE △<|>RELATION_NOE CT<|>RELATION_NOE 值<|>RELATION_NOE 对<|>RELATION_NOE 诊断<|>RELATION_NOE 恶性<|>RELATION_NOE 与<|>RELATION_NOE 非恶性<|>RELATION_NOE SPN<|>RELATION_NOE 的<|>RELATION_NOE 敏感性<|>RELATION_NOE 、<|>RELATION_NOE 特异性<|>RELATION_NOE 、<|>RELATION_NOE 准确性<|>RELATION_NOE 。<|>RELATION_NOE
袖状<|>RELATION_NOE 与<|>RELATION_NOE 楔形<|>RELATION_NOE 支气管<|>RELATION_NOE 切除术<|>RELATION_NOE 在<|>RELATION_NOE 支气管<|>RELATION_B 肺癌<|>RELATION_I 治疗<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 对照<|>RELATION_NOE 研究<|>RELATION_NOE
观察<|>RELATION_NOE 对比<|>RELATION_NOE 分析<|>RELATION_NOE 袖状<|>RELATION_NOE 切除术<|>RELATION_NOE 与<|>RELATION_NOE 楔形<|>RELATION_NOE 切除术<|>RELATION_NOE 在<|>RELATION_NOE 支气管<|>RELATION_B 肺癌<|>RELATION_I 治疗<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 100<|>RELATION_NOE 例<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 作为<|>RELATION_NOE 研究<|>RELATION_NOE 对象<|>RELATION_NOE ,<|>RELATION_NOE 选用<|>RELATION_NOE 随机<|>RELATION_NOE 表格法<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 所有<|>RELATION_NOE 患者<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 袖状<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 50<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 给予<|>RELATION_NOE 楔形<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 在<|>RELATION_NOE 术后<|>RELATION_NOE 进行<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 辅助<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 结束<|>RELATION_NOE 后<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 3<|>RELATION_NOE 年<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 在<|>RELATION_NOE 随访期<|>RELATION_NOE 内<|>RELATION_NOE 的<|>RELATION_NOE 吻合口<|>RELATION_NOE 瘢痕<|>RELATION_NOE 组织<|>RELATION_NOE 增生率<|>RELATION_NOE 与<|>RELATION_NOE 复发率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 2%<|>RELATION_NOE 、<|>RELATION_NOE 2%<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE 的<|>RELATION_NOE 16%<|>RELATION_NOE 、<|>RELATION_NOE 18%<|>RELATION_NOE (<|>RELATION_NOE χ^2<|>RELATION_NOE =<|>RELATION_NOE 4.40<|>RELATION_NOE 、<|>RELATION_NOE 7.11<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
采取<|>RELATION_NOE 袖状切<|>RELATION_NOE 除术<|>RELATION_NOE 治疗<|>RELATION_B 支气管<|>RELATION_I 肺癌<|>RELATION_E ,<|>RELATION_NOE 能够<|>RELATION_NOE 有效<|>RELATION_NOE 控制<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 支气管<|>RELATION_NOE 残端<|>RELATION_NOE 癌细胞阳<|>RELATION_NOE 性率<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_NOE 吻合口<|>RELATION_NOE 瘢痕<|>RELATION_NOE 组织<|>RELATION_NOE 增生<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 复发率<|>RELATION_NOE ,<|>RELATION_NOE 并且<|>RELATION_NOE 远期<|>RELATION_NOE 疗效<|>RELATION_NOE 非常<|>RELATION_NOE 理想<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 中<|>RELATION_NOE 推广<|>RELATION_NOE 应用<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 肺动脉<|>RELATION_NOE 成形术<|>RELATION_NOE 在<|>RELATION_NOE 老年人<|>RELATION_B 中央型<|>RELATION_I 肺癌<|>RELATION_I 治疗<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
探讨<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_B 支气管<|>RELATION_I 肺动脉<|>RELATION_I 成形术<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 。<|>RELATION_NOE
78<|>RELATION_NOE 例<|>RELATION_NOE 老年<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按照<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 各<|>RELATION_NOE 39<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 采用<|>RELATION_NOE 支气管<|>RELATION_NOE 肺动脉<|>RELATION_NOE 成形术<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 采用<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 。<|>RELATION_NOE
支气管<|>RELATION_NOE 肺动脉<|>RELATION_NOE 成形术<|>RELATION_NOE 治疗<|>RELATION_B 老年<|>RELATION_I 中央型<|>RELATION_I 肺癌<|>RELATION_E 疗效<|>RELATION_NOE 显著<|>RELATION_NOE ,<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 可以<|>RELATION_NOE 进一步<|>RELATION_NOE 改善<|>RELATION_NOE 肺功能<|>RELATION_NOE 。<|>RELATION_NOE
人类<|>RELATION_NOE 白细胞抗原<|>RELATION_NOE HLA-DQA1<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 在<|>RELATION_NOE 尘肺<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_S
用<|>RELATION_NOE 多<|>RELATION_NOE 重<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE -<|>RELATION_NOE 连接<|>RELATION_NOE 酶<|>RELATION_NOE 检测<|>RELATION_NOE 反应<|>RELATION_NOE 分型法<|>RELATION_NOE (<|>RELATION_NOE PCR-LDR<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 检测<|>RELATION_S 21<|>RELATION_NOE 例<|>RELATION_NOE 尘肺<|>RELATION_NOE 并<|>RELATION_NOE 发<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 及<|>RELATION_NOE 40<|>RELATION_NOE 例<|>RELATION_NOE 非职业性<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE HLA-DQA1<|>RELATION_NOE 共<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 位点<|>RELATION_NOE 的<|>RELATION_NOE 等位基因<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 和<|>RELATION_NOE 尘肺<|>RELATION_NOE 肺癌<|>RELATION_NOE 发病<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
尘肺<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE HLA-DQA1<|>RELATION_NOE 0<|>RELATION_NOE 301<|>RELATION_NOE 基因频率<|>RELATION_NOE 19%<|>RELATION_NOE ,<|>RELATION_NOE 非职业性<|>RELATION_NOE 肺癌<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE HLA-DQA1<|>RELATION_NOE 0<|>RELATION_NOE 301<|>RELATION_NOE 基因频率<|>RELATION_NOE 2.5%<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE χ<|>RELATION_NOE 2=<|>RELATION_NOE 10.0<|>RELATION_NOE 22<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE =<|>RELATION_NOE 0.002<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 其余<|>RELATION_NOE 等位基因<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
HLA-DQA1<|>RELATION_NOE 的<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 可能<|>RELATION_NOE 与<|>RELATION_NOE 尘肺<|>RELATION_NOE 肺癌<|>RELATION_NOE 易<|>RELATION_NOE 感性<|>RELATION_NOE 相关<|>RELATION_S .<|>RELATION_NOE
经<|>RELATION_NOE 导管<|>RELATION_NOE 动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 栓塞术<|>RELATION_NOE 在<|>RELATION_NOE 婴幼儿<|>RELATION_NOE 肝<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 前<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_S
探讨<|>RELATION_NOE 经<|>RELATION_NOE 导管<|>RELATION_NOE 动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 栓塞术<|>RELATION_NOE 在<|>RELATION_NOE 婴幼儿<|>RELATION_NOE 肝<|>RELATION_NOE 母细胞瘤<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 前<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_S 。<|>RELATION_NOE
首诊<|>RELATION_NOE 后<|>RELATION_NOE 难以<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE ,<|>RELATION_NOE 先<|>RELATION_NOE 予<|>RELATION_NOE 经<|>RELATION_NOE 导管<|>RELATION_NOE 动脉<|>RELATION_NOE 化疗<|>RELATION_NOE 栓塞术<|>RELATION_NOE (<|>RELATION_NOE TACE<|>RELATION_NOE )<|>RELATION_NOE 11<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 手术组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 即将<|>RELATION_NOE 导管<|>RELATION_NOE 插入<|>RELATION_NOE 肿瘤<|>RELATION_NOE 供<|>RELATION_NOE 血<|>RELATION_NOE 动脉<|>RELATION_NOE ,<|>RELATION_NOE 注入<|>RELATION_NOE 吡柔<|>RELATION_NOE 比星<|>RELATION_NOE (<|>RELATION_NOE 30mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE +<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE 60mg<|>RELATION_NOE /<|>RELATION_NOE m<|>RELATION_NOE ^<|>RELATION_NOE 2<|>RELATION_NOE )<|>RELATION_NOE +<|>RELATION_NOE 超<|>RELATION_NOE 液化<|>RELATION_NOE 碘油<|>RELATION_NOE 形成<|>RELATION_NOE 的<|>RELATION_NOE 乳剂<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 用<|>RELATION_NOE 聚乙烯<|>RELATION_NOE 醇颗粒<|>RELATION_NOE (<|>RELATION_NOE PVA<|>RELATION_NOE )<|>RELATION_NOE 栓塞<|>RELATION_NOE 肿瘤<|>RELATION_NOE 供<|>RELATION_NOE 血<|>RELATION_NOE 动脉<|>RELATION_NOE 。<|>RELATION_NOE
若术<|>RELATION_NOE 前<|>RELATION_NOE 出现<|>RELATION_NOE 肺部<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 则<|>RELATION_NOE 予<|>RELATION_NOE 全身<|>RELATION_NOE 化疗<|>RELATION_NOE 直至<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 消失<|>RELATION_NOE ,<|>RELATION_NOE 而后<|>RELATION_NOE 再行<|>RELATION_NOE TACE<|>RELATION_NOE 治疗<|>RELATION_NOE 直至<|>RELATION_NOE 肿瘤<|>RELATION_NOE 切除<|>RELATION_NOE 。<|>RELATION_NOE
工期<|>RELATION_NOE 手术<|>RELATION_NOE 组<|>RELATION_NOE 术后<|>RELATION_NOE 因<|>RELATION_NOE 肺转移<|>RELATION_NOE 或<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 死亡<|>RELATION_NOE 2例<|>RELATION_NOE ;<|>RELATION_NOE
Ⅱ<|>RELATION_NOE 期<|>RELATION_NOE 手术<|>RELATION_NOE 组<|>RELATION_NOE 1例<|>RELATION_NOE 因<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 肺转移<|>RELATION_NOE 放弃<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 另<|>RELATION_NOE 1例<|>RELATION_NOE 因<|>RELATION_NOE 术后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 复发<|>RELATION_NOE 死亡<|>RELATION_NOE 。<|>RELATION_NOE
早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 立体<|>RELATION_B 定向<|>RELATION_I 放射<|>RELATION_I 治疗<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE
58<|>RELATION_NOE 例<|>RELATION_NOE I<|>RELATION_NOE 期<|>RELATION_NOE 和<|>RELATION_NOE II<|>RELATION_NOE 期<|>RELATION_NOE (<|>RELATION_NOE T1<|>RELATION_NOE ,<|>RELATION_NOE 2<|>RELATION_NOE ,<|>RELATION_NOE 3N0M0<|>RELATION_NOE )<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 接受<|>RELATION_NOE 国产<|>RELATION_NOE 旋转<|>RELATION_NOE 式体部<|>RELATION_NOE 伽玛刀<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 治疗<|>RELATION_NOE 时<|>RELATION_NOE 用<|>RELATION_NOE 真空<|>RELATION_NOE 负<|>RELATION_NOE 压袋<|>RELATION_NOE 固定<|>RELATION_NOE 体位<|>RELATION_NOE ,<|>RELATION_NOE CT<|>RELATION_NOE 定位<|>RELATION_NOE 扫描<|>RELATION_NOE 扣<|>RELATION_NOE 三维<|>RELATION_NOE 计划<|>RELATION_NOE 。<|>RELATION_NOE
体部<|>RELATION_NOE 伽玛刀<|>RELATION_NOE 治疗<|>RELATION_B 早期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 近期<|>RELATION_NOE 疗效<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 放射<|>RELATION_NOE 反应<|>RELATION_NOE 轻<|>RELATION_NOE ,<|>RELATION_NOE 能<|>RELATION_NOE 为<|>RELATION_NOE 患者<|>RELATION_NOE 耐受<|>RELATION_NOE ,<|>RELATION_NOE 是<|>RELATION_NOE 不<|>RELATION_NOE 能<|>RELATION_NOE 接受<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 早期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 安全<|>RELATION_NOE 的<|>RELATION_NOE 局部<|>RELATION_NOE 治疗<|>RELATION_NOE 手段<|>RELATION_NOE 。<|>RELATION_NOE
艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_B 分析<|>RELATION_E
研究<|>RELATION_NOE 艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 对<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_S 。<|>RELATION_NOE
艾迪<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE GP<|>RELATION_NOE 方案<|>RELATION_NOE 治疗<|>RELATION_B NSCLC<|>RELATION_E ,<|>RELATION_NOE 可<|>RELATION_NOE 提升<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 评分<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE 一定<|>RELATION_NOE 程度<|>RELATION_NOE 上<|>RELATION_NOE 降低<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 的<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE ,<|>RELATION_NOE 效果<|>RELATION_NOE 较<|>RELATION_NOE 好<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 临床<|>RELATION_NOE 关注<|>RELATION_NOE 。<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 微波<|>RELATION_NOE 消融<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE 治疗<|>RELATION_S 中晚期<|>RELATION_NOE 肺鳞癌<|>RELATION_NOE 临床<|>RELATION_NOE 观察<|>RELATION_NOE
观察组<|>RELATION_NOE 采用<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 经皮<|>RELATION_NOE 冷循环<|>RELATION_NOE 微波<|>RELATION_NOE 消融<|>RELATION_NOE 联合<|>RELATION_NOE 4周期<|>RELATION_NOE 吉西<|>RELATION_NOE 他滨<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ;<|>RELATION_NOE
对照组<|>RELATION_NOE 单纯<|>RELATION_NOE 采用<|>RELATION_NOE 吉西<|>RELATION_NOE 他滨<|>RELATION_NOE 、<|>RELATION_NOE 顺铂<|>RELATION_NOE 方案<|>RELATION_NOE 化疗<|>RELATION_NOE ,<|>RELATION_NOE 共<|>RELATION_NOE 4<|>RELATION_NOE 个<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
窄谱<|>RELATION_NOE 成<|>RELATION_NOE 像<|>RELATION_NOE 支气管镜<|>RELATION_NOE 对<|>RELATION_NOE 评估<|>RELATION_B 中央型<|>RELATION_I 肺癌<|>RELATION_I 浸润<|>RELATION_I 范围<|>RELATION_I 及<|>RELATION_I 制定<|>RELATION_I 治疗<|>RELATION_I 方案<|>RELATION_E 的<|>RELATION_NOE 价值<|>RELATION_NOE
使用<|>RELATION_NOE 日本<|>RELATION_NOE 奥林巴斯<|>RELATION_NOE 公司<|>RELATION_NOE 的<|>RELATION_NOE EVIS<|>RELATION_NOE LUCERA<|>RELATION_NOE 光谱<|>RELATION_NOE 支气管镜<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 6月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 14年<|>RELATION_NOE 6月<|>RELATION_NOE 上海市<|>RELATION_NOE 第十<|>RELATION_NOE 人民<|>RELATION_NOE 医院<|>RELATION_NOE 符合<|>RELATION_NOE 入选<|>RELATION_NOE 标准<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 进行<|>RELATION_NOE 白光<|>RELATION_NOE 支气管镜<|>RELATION_NOE (<|>RELATION_NOE WLB<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE NBI<|>RELATION_NOE 检查<|>RELATION_NOE ,<|>RELATION_NOE 统计<|>RELATION_NOE 并<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 种<|>RELATION_NOE 方法镜<|>RELATION_NOE 下<|>RELATION_NOE 肿瘤<|>RELATION_NOE 浸润<|>RELATION_NOE 范围<|>RELATION_NOE 、<|>RELATION_NOE 阳性<|>RELATION_NOE 表现<|>RELATION_NOE 和<|>RELATION_NOE 病理学<|>RELATION_NOE
分析<|>RELATION_NOE 确诊<|>RELATION_NOE 中央型<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 168<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE NBI<|>RELATION_NOE 发现<|>RELATION_NOE 22<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 13.1%<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 浸润<|>RELATION_NOE 范围<|>RELATION_NOE 比<|>RELATION_NOE WLB<|>RELATION_NOE 更<|>RELATION_B 广<|>RELATION_E (<|>RELATION_NOE NBI<|>RELATION_NOE 下<|>RELATION_NOE 浸润<|>RELATION_NOE
临床<|>RELATION_NOE 上<|>RELATION_NOE 使用<|>RELATION_NOE NBI<|>RELATION_NOE 利于<|>RELATION_B 早期<|>RELATION_I 中央型<|>RELATION_I 肺癌<|>RELATION_I 的<|>RELATION_I 诊断<|>RELATION_E ,<|>RELATION_NOE 便于<|>RELATION_NOE 更<|>RELATION_NOE 准确<|>RELATION_NOE 的<|>RELATION_NOE 判断<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 浸润<|>RELATION_NOE 范围<|>RELATION_NOE ,<|>RELATION_NOE 帮助<|>RELATION_NOE 临床<|>RELATION_NOE 医师<|>RELATION_NOE 制定<|>RELATION_NOE 最佳<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 方案<|>RELATION_NOE 。<|>RELATION_NOE
中性<|>RELATION_NOE 粒细胞<|>RELATION_NOE 与<|>RELATION_NOE 淋巴细胞<|>RELATION_NOE 比值<|>RELATION_NOE 变化<|>RELATION_NOE 对<|>RELATION_NOE 肺大<|>RELATION_B 细胞<|>RELATION_I 神经<|>RELATION_I 内分泌癌<|>RELATION_I 患者<|>RELATION_I 预后<|>RELATION_E 的<|>RELATION_NOE 影响<|>RELATION_NOE
分析<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE 肺大<|>RELATION_NOE 细胞<|>RELATION_NOE 神经<|>RELATION_NOE 内分泌癌<|>RELATION_NOE 患者<|>RELATION_NOE 临床<|>RELATION_NOE 资料<|>RELATION_NOE ,<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 吸烟<|>RELATION_NOE 指数<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 、<|>RELATION_NOE 肿瘤分期<|>RELATION_NOE 、<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 术后<|>RELATION_NOE NLR<|>RELATION_NOE 、<|>RELATION_NOE 和<|>RELATION_NOE 术前<|>RELATION_NOE NLR<|>RELATION_NOE /<|>RELATION_NOE 术后<|>RELATION_NOE NLR<|>RELATION_NOE 比值<|>RELATION_NOE 等<|>RELATION_NOE 对<|>RELATION_NOE 预后<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 的<|>RELATION_NOE 单<|>RELATION_NOE 因素<|>RELATION_NOE 进入<|>RELATION_NOE Cox<|>RELATION_NOE 回归<|>RELATION_NOE 模型<|>RELATION_NOE 进行<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE 。<|>RELATION_NOE
对于<|>RELATION_NOE 接受<|>RELATION_NOE 手术<|>RELATION_NOE 的<|>RELATION_NOE 肺大<|>RELATION_NOE 细胞<|>RELATION_NOE 神经<|>RELATION_NOE 内分泌癌<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 术后<|>RELATION_NOE NLR<|>RELATION_NOE 升高<|>RELATION_NOE 可能<|>RELATION_B 提示<|>RELATION_I 其<|>RELATION_I 预后<|>RELATION_I 不良<|>RELATION_E .<|>RELATION_NOE
唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 与<|>RELATION_NOE 顺铂<|>RELATION_NOE 异序<|>RELATION_NOE 联合<|>RELATION_NOE 应用<|>RELATION_NOE 对<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE 的<|>RELATION_NOE 比较<|>RELATION_S
按照<|>RELATION_NOE 唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 药物<|>RELATION_NOE 处理<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 顺序<|>RELATION_NOE 将<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 分为<|>RELATION_NOE 4组<|>RELATION_NOE (<|>RELATION_NOE 唑<|>RELATION_NOE 来<|>RELATION_NOE 膦酸<|>RELATION_NOE 和<|>RELATION_NOE 顺铂<|>RELATION_NOE 的<|>RELATION_NOE 药物<|>RELATION_NOE 浓度<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 1.5<|>RELATION_NOE 60<|>RELATION_NOE 0mmol<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE 和<|>RELATION_NOE 0.3<|>RELATION_NOE 12<|>RELATION_NOE 5mg<|>RELATION_NOE /<|>RELATION_NOE L<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE (<|>RELATION_NOE 1<|>RELATION_NOE )<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 对照组<|>RELATION_NOE )<|>RELATION_NOE :<|>RELATION_NOE 肺腺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 常规<|>RELATION_NOE 培养<|>RELATION_NOE ,<|>RELATION_NOE 不<|>RELATION_NOE 作<|>RELATION_NOE 药物<|>RELATION_NOE 处理<|>RELATION_NOE ;<|>RELATION_NOE
实时<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE 聚合<|>RELATION_NOE 酶链<|>RELATION_NOE 反应<|>RELATION_NOE (<|>RELATION_NOE FQ-PCR<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 细胞<|>RELATION_NOE DNA<|>RELATION_NOE 损伤<|>RELATION_NOE 检查点<|>RELATION_NOE 蛋白<|>RELATION_NOE 调节<|>RELATION_NOE 因子1<|>RELATION_NOE (<|>RELATION_NOE MDC1<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE DNA<|>RELATION_NOE 切除<|>RELATION_NOE 修复<|>RELATION_NOE 交叉<|>RELATION_NOE 互补<|>RELATION_NOE 基因<|>RELATION_NOE 1<|>RELATION_NOE (<|>RELATION_NOE ERCC1<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 受体<|>RELATION_NOE 相关<|>RELATION_NOE 蛋白<|>RELATION_NOE 80<|>RELATION_NOE (<|>RELATION_NOE RAP80<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
B<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 、<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE MDC1<|>RELATION_NOE 和<|>RELATION_NOE RAP80<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 0.3<|>RELATION_NOE 74<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 22<|>RELATION_NOE 和<|>RELATION_NOE 1.1<|>RELATION_NOE 27<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 0.3<|>RELATION_NOE 20<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 23<|>RELATION_NOE 和<|>RELATION_NOE 1.0<|>RELATION_NOE 36<|>RELATION_NOE ±<|>RELATION_NOE 0.02<|>RELATION_NOE 79.4<|>RELATION_NOE 16<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 16<|>RELATION_NOE 和<|>RELATION_NOE 1.18<|>RELATION_NOE 1<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 41<|>RELATION_NOE )<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_B 低于<|>RELATION_E A<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 0.6<|>RELATION_NOE 77<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 28<|>RELATION_NOE 和<|>RELATION_NOE 1.5<|>RELATION_NOE 48<|>RELATION_NOE ±<|>RELATION_NOE 0.038-P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE B<|>RELATION_NOE 、<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE B<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 、<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE 细胞<|>RELATION_NOE 中<|>RELATION_NOE MDC1<|>RELATION_NOE 和<|>RELATION_NOE RAP80<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE (<|>RELATION_NOE 0.3<|>RELATION_NOE 74<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 22<|>RELATION_NOE 和<|>RELATION_NOE 1.1<|>RELATION_NOE 27<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 18<|>RELATION_NOE 、<|>RELATION_NOE 0.3<|>RELATION_NOE 20<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 23<|>RELATION_NOE 和<|>RELATION_NOE 1.0<|>RELATION_NOE 36<|>RELATION_NOE ±<|>RELATION_NOE 0.02<|>RELATION_NOE 79.4<|>RELATION_NOE 16<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 16<|>RELATION_NOE 和<|>RELATION_NOE 1.18<|>RELATION_NOE 1<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 41<|>RELATION_NOE )<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_NOE 低于<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 0.6<|>RELATION_NOE 77<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 28<|>RELATION_NOE 和<|>RELATION_NOE 1.5<|>RELATION_NOE 48<|>RELATION_NOE ±<|>RELATION_NOE 0.038-P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE B<|>RELATION_NOE 、<|>RELATION_NOE D<|>RELATION_NOE 组<|>RELATION_NOE 均<|>RELATION_B 显著<|>RELATION_I 高于<|>RELATION_E C<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
各组<|>RELATION_NOE 细胞<|>RELATION_NOE ERCCl<|>RELATION_NOE 基因<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
半胱<|>RELATION_NOE 氨酰<|>RELATION_NOE 天冬氨酸<|>RELATION_NOE 特异性<|>RELATION_NOE 蛋白酶<|>RELATION_NOE -8<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_B 小细胞肺<|>RELATION_I 癌脑<|>RELATION_I 转移<|>RELATION_E 的<|>RELATION_NOE 预测<|>RELATION_NOE 价值<|>RELATION_NOE
探讨<|>RELATION_NOE 半胱<|>RELATION_NOE 氨酰<|>RELATION_NOE 天冬氨酸<|>RELATION_NOE 特异性<|>RELATION_NOE 蛋白酶<|>RELATION_NOE (<|>RELATION_NOE Caspase<|>RELATION_NOE )<|>RELATION_NOE -8<|>RELATION_NOE 在<|>RELATION_NOE 非<|>RELATION_B 小细胞肺<|>RELATION_I 癌脑<|>RELATION_I 转移<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 预测<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 研究<|>RELATION_S 28<|>RELATION_NOE 4例<|>RELATION_NOE 手术<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE Caspase-8<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 利用<|>RELATION_NOE Kaplan-Meier<|>RELATION_NOE 法<|>RELATION_NOE 评价<|>RELATION_NOE 脑转移<|>RELATION_NOE 发生<|>RELATION_NOE 时间<|>RELATION_NOE 与<|>RELATION_NOE Caspase-8<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 。<|>RELATION_NOE
中<|>RELATION_NOE 位<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 时间<|>RELATION_NOE 29.5<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE －<|>RELATION_NOE 108<|>RELATION_NOE 个<|>RELATION_NOE 月<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 随<|>RELATION_NOE 访<|>RELATION_NOE 期间<|>RELATION_NOE 共有<|>RELATION_NOE 8.1%<|>RELATION_NOE (<|>RELATION_NOE 23<|>RELATION_NOE /<|>RELATION_NOE 284<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 发生<|>RELATION_NOE 了<|>RELATION_NOE 脑<|>RELATION_NOE 转移<|>RELATION_NOE .<|>RELATION_NOE
单<|>RELATION_NOE 因素<|>RELATION_NOE 和<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE Cox<|>RELATION_NOE 回归<|>RELATION_NOE 模型<|>RELATION_NOE 提示<|>RELATION_NOE ,<|>RELATION_NOE Caspase-8<|>RELATION_NOE 是<|>RELATION_NOE 肺癌<|>RELATION_B 脑转移<|>RELATION_E 的<|>RELATION_NOE 独立<|>RELATION_NOE 危险因素<|>RELATION_NOE .<|>RELATION_NOE
Caspase-8<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 后脑<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_B 相关<|>RELATION_E ,<|>RELATION_NOE Caspase-8<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_NOE 脑转移<|>RELATION_NOE 高危<|>RELATION_NOE 患者<|>RELATION_NOE 筛选<|>RELATION_NOE 的<|>RELATION_NOE 标志.<|>RELATION_NOE Caspase-8<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 后脑<|>RELATION_NOE 转移<|>RELATION_NOE 明显<|>RELATION_NOE 相关<|>RELATION_NOE ,<|>RELATION_NOE Caspase-8<|>RELATION_NOE 可以<|>RELATION_NOE 作为<|>RELATION_NOE 肺癌<|>RELATION_B 脑转移<|>RELATION_I 高危<|>RELATION_I 患者<|>RELATION_I 筛选<|>RELATION_E 的<|>RELATION_NOE 标志<|>RELATION_NOE .<|>RELATION_NOE
血管<|>RELATION_NOE 抑素<|>RELATION_NOE 基因<|>RELATION_NOE 治疗<|>RELATION_B Lewis<|>RELATION_I 肺癌<|>RELATION_I 移植<|>RELATION_I 瘤<|>RELATION_I 小鼠<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 研究<|>RELATION_NOE
探讨<|>RELATION_NOE 血管<|>RELATION_NOE 抑素<|>RELATION_NOE 基因<|>RELATION_NOE (<|>RELATION_NOE PAng<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_B Lewis<|>RELATION_I 肺癌<|>RELATION_I 移植<|>RELATION_I 瘤<|>RELATION_I 小鼠<|>RELATION_E 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
45<|>RELATION_NOE 只<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤模型<|>RELATION_NOE 的<|>RELATION_NOE 小鼠<|>RELATION_NOE ,<|>RELATION_NOE 根据<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 小鼠<|>RELATION_NOE 治疗<|>RELATION_NOE 方式<|>RELATION_NOE 的<|>RELATION_NOE 不同<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 3<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 小鼠<|>RELATION_NOE 15<|>RELATION_NOE 只<|>RELATION_NOE ,<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 空白组<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 空白<|>RELATION_NOE 脂质体组<|>RELATION_NOE )<|>RELATION_NOE 以及<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE PAng<|>RELATION_NOE 组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 治疗<|>RELATION_NOE 前后<|>RELATION_NOE 肿瘤<|>RELATION_NOE 体积<|>RELATION_NOE 、<|>RELATION_NOE 重量<|>RELATION_NOE 的<|>RELATION_NOE 变化<|>RELATION_NOE 以及<|>RELATION_NOE 比较<|>RELATION_NOE 肺<|>RELATION_NOE 表面<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 数目<|>RELATION_NOE 和<|>RELATION_NOE 小鼠<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 生存<|>RELATION_NOE 周期<|>RELATION_NOE 。<|>RELATION_NOE
PAng<|>RELATION_NOE 组<|>RELATION_NOE 小鼠<|>RELATION_NOE 治疗<|>RELATION_NOE 21d<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 移植<|>RELATION_NOE 肿瘤<|>RELATION_NOE 重量<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 3.54<|>RELATION_NOE ±<|>RELATION_NOE 0.48<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 4.21<|>RELATION_NOE ±<|>RELATION_NOE 0.58<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 4.26<|>RELATION_NOE ±<|>RELATION_NOE 0.59<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE 比较<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
PAng<|>RELATION_NOE 组<|>RELATION_NOE 小鼠<|>RELATION_NOE 治疗<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 肺表面<|>RELATION_NOE 转移<|>RELATION_NOE 灶<|>RELATION_NOE 数目<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 4.30<|>RELATION_NOE ±<|>RELATION_NOE 0.42<|>RELATION_NOE )<|>RELATION_NOE 个<|>RELATION_NOE 、<|>RELATION_NOE 平均<|>RELATION_NOE 生存<|>RELATION_NOE 周期<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 54.6<|>RELATION_NOE ±<|>RELATION_NOE 6.52<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
PPAR<|>RELATION_NOE γ<|>RELATION_NOE 激动剂<|>RELATION_NOE 对<|>RELATION_NOE RSV<|>RELATION_B 感染<|>RELATION_I 的<|>RELATION_I A549<|>RELATION_I 细胞<|>RELATION_I TLR3<|>RELATION_I 、<|>RELATION_I TNF-<|>RELATION_I α<|>RELATION_I 表达<|>RELATION_E 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE
探讨<|>RELATION_NOE A549<|>RELATION_NOE 细胞呼吸道<|>RELATION_NOE 合胞<|>RELATION_NOE 病毒<|>RELATION_NOE (<|>RELATION_NOE RSV<|>RELATION_NOE )<|>RELATION_NOE 感染<|>RELATION_NOE 后<|>RELATION_NOE Toll<|>RELATION_NOE 样<|>RELATION_NOE 受体<|>RELATION_NOE 3<|>RELATION_NOE (<|>RELATION_NOE TLR3<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 坏死<|>RELATION_NOE 因子<|>RELATION_NOE -<|>RELATION_NOE α<|>RELATION_NOE (<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE )<|>RELATION_NOE mRNA<|>RELATION_NOE 和<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 及<|>RELATION_NOE PPAR<|>RELATION_NOE γ<|>RELATION_NOE 激动剂<|>RELATION_NOE 15-<|>RELATION_NOE 脱氧<|>RELATION_NOE 前列腺素<|>RELATION_NOE J2<|>RELATION_NOE (<|>RELATION_NOE 15d-PGJ2<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 罗格列酮<|>RELATION_NOE 的<|>RELATION_NOE 干预<|>RELATION_B 作用<|>RELATION_E 。<|>RELATION_NOE
建立<|>RELATION_NOE RSV<|>RELATION_NOE 感染<|>RELATION_NOE 的<|>RELATION_NOE 细胞<|>RELATION_NOE 模型<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 传代<|>RELATION_NOE 培养的细胞<|>RELATION_NOE 随机<|>RELATION_NOE 分成<|>RELATION_NOE 6组<|>RELATION_NOE :<|>RELATION_NOE 15d-PGJ2<|>RELATION_NOE 干预组<|>RELATION_NOE (<|>RELATION_NOE A<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 罗格列酮<|>RELATION_NOE 干预组<|>RELATION_NOE (<|>RELATION_NOE B<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE RSV<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE C<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE PDTC<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE D<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE GW9662<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE E<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE F<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
各组<|>RELATION_NOE 在<|>RELATION_NOE 培养<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 和<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE 收获<|>RELATION_NOE 上<|>RELATION_NOE 清液<|>RELATION_NOE 和<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE RT-PCR<|>RELATION_NOE 检测<|>RELATION_S TLR3<|>RELATION_NOE 和<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE Blot<|>RELATION_NOE 各组<|>RELATION_NOE 在<|>RELATION_NOE 培养<|>RELATION_NOE 12<|>RELATION_NOE 、<|>RELATION_NOE 24<|>RELATION_NOE 和<|>RELATION_NOE 48h<|>RELATION_NOE 后<|>RELATION_NOE 收获<|>RELATION_NOE 上<|>RELATION_NOE 清液<|>RELATION_NOE 和<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 实时<|>RELATION_NOE 荧光<|>RELATION_NOE RT-PCR<|>RELATION_NOE 检测<|>RELATION_NOE TLR3<|>RELATION_NOE 和<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE mRNA<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE Blot<|>RELATION_NOE 检测<|>RELATION_NOE TLR3<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE ELISA<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 上清<|>RELATION_NOE 中<|>RELATION_NOE TNF-<|>RELATION_NOE α<|>RELATION_NOE 蛋白<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
云南<|>RELATION_NOE 汉族<|>RELATION_NOE 人群<|>RELATION_NOE 内质网<|>RELATION_NOE 氨肽<|>RELATION_NOE 酶<|>RELATION_NOE 2基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 遗传易感性<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S
采用<|>RELATION_NOE Taq<|>RELATION_NOE Man<|>RELATION_NOE 探针<|>RELATION_NOE 基因<|>RELATION_NOE 分型<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE ERAP2<|>RELATION_NOE 基因<|>RELATION_NOE 单<|>RELATION_NOE 核苷酸多态性<|>RELATION_NOE (<|>RELATION_NOE SNP<|>RELATION_NOE )<|>RELATION_NOE rs2248374<|>RELATION_NOE 和<|>RELATION_NOE rs2549782<|>RELATION_NOE 位点<|>RELATION_NOE 进行<|>RELATION_NOE 基因<|>RELATION_NOE 分型<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 构建<|>RELATION_NOE 单倍型<|>RELATION_NOE ,<|>RELATION_NOE 评估<|>RELATION_NOE 上述<|>RELATION_NOE 2<|>RELATION_NOE 个<|>RELATION_NOE SNP<|>RELATION_NOE 位点<|>RELATION_NOE 及<|>RELATION_NOE 单倍型<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
ERAP2<|>RELATION_NOE 基因<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 有关<|>RELATION_S ,<|>RELATION_NOE rs2248374<|>RELATION_NOE 和<|>RELATION_NOE rs2549782<|>RELATION_NOE 位点<|>RELATION_NOE AG<|>RELATION_NOE 单倍型<|>RELATION_NOE 可能<|>RELATION_NOE 增加<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 患病<|>RELATION_NOE 风险<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.4<|>RELATION_NOE 35<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 1.0<|>RELATION_NOE 88<|>RELATION_NOE －1.8<|>RELATION_NOE 93<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE rs2248374<|>RELATION_NOE 和<|>RELATION_NOE rs2549782<|>RELATION_NOE 位点<|>RELATION_NOE GT<|>RELATION_NOE 单倍型<|>RELATION_NOE 可能<|>RELATION_NOE 降低<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 患病<|>RELATION_NOE 风险<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.6<|>RELATION_NOE 97<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 0.5<|>RELATION_NOE 28<|>RELATION_NOE －0.9<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE ERAP2<|>RELATION_NOE 基因<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE rs2248374<|>RELATION_NOE 和<|>RELATION_NOE rs2549782<|>RELATION_NOE 位点<|>RELATION_NOE AG<|>RELATION_NOE 单倍型<|>RELATION_NOE 可能<|>RELATION_B 增加<|>RELATION_E NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 患病<|>RELATION_NOE 风险<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.4<|>RELATION_NOE 35<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 1.0<|>RELATION_NOE 88<|>RELATION_NOE －1.8<|>RELATION_NOE 93<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE rs2248374<|>RELATION_NOE 和<|>RELATION_NOE rs2549782<|>RELATION_NOE 位点<|>RELATION_NOE GT<|>RELATION_NOE 单倍型<|>RELATION_NOE 可能<|>RELATION_NOE 降低<|>RELATION_NOE ERAP2<|>RELATION_NOE 基因<|>RELATION_NOE 与<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 及<|>RELATION_NOE 病理<|>RELATION_NOE 类型<|>RELATION_NOE 有关<|>RELATION_NOE ,<|>RELATION_NOE rs2248374<|>RELATION_NOE 和<|>RELATION_NOE rs2549782<|>RELATION_NOE 位点<|>RELATION_NOE AG<|>RELATION_NOE 单倍型<|>RELATION_NOE 可能<|>RELATION_NOE 增加<|>RELATION_NOE NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 患病<|>RELATION_NOE 风险<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.4<|>RELATION_NOE 35<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 1.0<|>RELATION_NOE 88<|>RELATION_NOE －1.8<|>RELATION_NOE 93<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 而<|>RELATION_NOE rs2248374<|>RELATION_NOE 和<|>RELATION_NOE rs2549782<|>RELATION_NOE 位点<|>RELATION_NOE GT<|>RELATION_NOE 单倍型<|>RELATION_NOE 可能<|>RELATION_B 降低<|>RELATION_E NSCLC<|>RELATION_NOE 的<|>RELATION_NOE 患病<|>RELATION_NOE 风险<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.6<|>RELATION_NOE 97<|>RELATION_NOE ,<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE 为<|>RELATION_NOE 0.5<|>RELATION_NOE 28<|>RELATION_NOE －0.9<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
肺功能<|>RELATION_NOE 正常<|>RELATION_NOE 吸烟者<|>RELATION_NOE 和<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE 患者<|>RELATION_NOE 肺动脉<|>RELATION_NOE 炎症<|>RELATION_NOE 和<|>RELATION_NOE 小气道<|>RELATION_NOE 炎症<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 研究<|>RELATION_NOE
研究<|>RELATION_NOE 肺功能<|>RELATION_NOE 正常<|>RELATION_NOE 吸烟者<|>RELATION_NOE 和<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE (<|>RELATION_NOE 慢阻肺<|>RELATION_NOE )<|>RELATION_NOE 患者<|>RELATION_NOE 肺腺泡<|>RELATION_NOE 动脉<|>RELATION_NOE 炎症<|>RELATION_NOE 与<|>RELATION_NOE 小气道<|>RELATION_NOE 炎症<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_S 。<|>RELATION_NOE
选取<|>RELATION_NOE 广西<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 第一<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 心胸<|>RELATION_NOE 外科<|>RELATION_NOE 因<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE 61<|>RELATION_NOE ±<|>RELATION_NOE 9<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 肺功能<|>RELATION_NOE 正常<|>RELATION_NOE 不<|>RELATION_NOE 吸烟组<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 肺功能<|>RELATION_NOE 正常<|>RELATION_NOE 吸烟组<|>RELATION_NOE ,<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 吸烟<|>RELATION_NOE 慢<|>RELATION_NOE 阻肺<|>RELATION_NOE 稳定<|>RELATION_NOE 期组<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 取<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 远离<|>RELATION_NOE 肺癌<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE ,<|>RELATION_NOE HE<|>RELATION_NOE 和<|>RELATION_NOE 维多利亚蓝<|>RELATION_NOE +<|>RELATION_NOE 范吉逊<|>RELATION_NOE 染色<|>RELATION_NOE 检测<|>RELATION_S 各组<|>RELATION_NOE 肺腺泡<|>RELATION_NOE 肌型<|>RELATION_NOE 动脉<|>RELATION_NOE (<|>RELATION_NOE MA<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 小气道<|>RELATION_NOE 病理<|>RELATION_NOE 形态<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 测量<|>RELATION_NOE MA<|>RELATION_NOE 管壁<|>RELATION_NOE 厚度<|>RELATION_NOE 并<|>RELATION_NOE 计算<|>RELATION_NOE 小气道<|>RELATION_NOE 病理<|>RELATION_NOE 积分<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 选取<|>RELATION_NOE 广西<|>RELATION_NOE 医科<|>RELATION_NOE 大学<|>RELATION_NOE 第一<|>RELATION_NOE 附属<|>RELATION_NOE 医院<|>RELATION_NOE 心胸<|>RELATION_NOE 外科<|>RELATION_NOE 因<|>RELATION_NOE 周围型<|>RELATION_NOE 肺癌<|>RELATION_NOE 行<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除术<|>RELATION_NOE 的<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 男<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 女3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE 61<|>RELATION_NOE ±<|>RELATION_NOE 9<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 分为<|>RELATION_NOE A<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 肺功能<|>RELATION_NOE 正常<|>RELATION_NOE 不<|>RELATION_NOE 吸烟组<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE B<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 肺功能<|>RELATION_NOE 正常<|>RELATION_NOE 吸烟组<|>RELATION_NOE ,<|>RELATION_NOE 13<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE C<|>RELATION_NOE 组<|>RELATION_NOE (<|>RELATION_NOE 吸烟<|>RELATION_NOE 慢<|>RELATION_NOE 阻肺<|>RELATION_NOE 稳定<|>RELATION_NOE 期组<|>RELATION_NOE ,<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 取<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 的<|>RELATION_NOE 远离<|>RELATION_NOE 肺癌<|>RELATION_NOE 病灶<|>RELATION_NOE 的<|>RELATION_NOE 正常<|>RELATION_NOE 肺组织<|>RELATION_NOE ,<|>RELATION_NOE HE<|>RELATION_NOE 和<|>RELATION_NOE 维多利亚蓝<|>RELATION_NOE +<|>RELATION_NOE 范吉逊<|>RELATION_NOE 染色<|>RELATION_NOE 检测<|>RELATION_NOE 各组<|>RELATION_NOE 肺腺泡<|>RELATION_NOE 肌型<|>RELATION_NOE 动脉<|>RELATION_NOE (<|>RELATION_NOE MA<|>RELATION_NOE )<|>RELATION_NOE 及<|>RELATION_NOE 小气道<|>RELATION_NOE 病理<|>RELATION_NOE 形态<|>RELATION_NOE 改变<|>RELATION_NOE ,<|>RELATION_NOE 测量<|>RELATION_NOE MA<|>RELATION_NOE 管壁<|>RELATION_NOE 厚度<|>RELATION_NOE 并<|>RELATION_NOE 计算<|>RELATION_NOE 小气道<|>RELATION_NOE 病理<|>RELATION_NOE 积分<|>RELATION_NOE ,<|>RELATION_NOE 使用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE 方法<|>RELATION_NOE 检测<|>RELATION_S 淋巴细胞<|>RELATION_NOE 在<|>RELATION_NOE MA<|>RELATION_NOE 和<|>RELATION_NOE 小气道<|>RELATION_NOE 的<|>RELATION_NOE 浸润<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 分析<|>RELATION_NOE MA<|>RELATION_NOE 炎症<|>RELATION_NOE 和<|>RELATION_NOE 小气道<|>RELATION_NOE 炎症<|>RELATION_NOE 的<|>RELATION_NOE 相关性<|>RELATION_NOE 。<|>RELATION_NOE
膜式<|>RELATION_NOE 液基<|>RELATION_NOE 细胞学<|>RELATION_NOE 检测<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
探讨<|>RELATION_NOE 纤维<|>RELATION_NOE 支气管镜<|>RELATION_NOE 刷片<|>RELATION_NOE (<|>RELATION_NOE BWC<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 支气管<|>RELATION_NOE 肺泡灌洗液<|>RELATION_NOE (<|>RELATION_NOE BALF<|>RELATION_NOE )<|>RELATION_NOE 膜式<|>RELATION_NOE 液基<|>RELATION_NOE 细胞学<|>RELATION_NOE 检测<|>RELATION_NOE (<|>RELATION_NOE TCT<|>RELATION_NOE )<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 诊断<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 价值<|>RELATION_NOE 。<|>RELATION_NOE
TCT<|>RELATION_NOE 与<|>RELATION_NOE 组织<|>RELATION_NOE 学<|>RELATION_NOE 的<|>RELATION_NOE 符合率<|>RELATION_NOE ,<|>RELATION_NOE 在<|>RELATION_NOE BWC<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 鳞癌<|>RELATION_NOE 为<|>RELATION_NOE 92.7%<|>RELATION_NOE (<|>RELATION_NOE 127<|>RELATION_NOE /<|>RELATION_NOE 137<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 腺癌<|>RELATION_NOE 为<|>RELATION_NOE 92.6%<|>RELATION_NOE (<|>RELATION_NOE 151<|>RELATION_NOE /<|>RELATION_NOE 163<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 小细胞癌<|>RELATION_NOE 为<|>RELATION_NOE 96.8%<|>RELATION_NOE (<|>RELATION_NOE 61<|>RELATION_NOE /<|>RELATION_NOE 63<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 总<|>RELATION_NOE 符合率<|>RELATION_NOE 为<|>RELATION_NOE 91.9%<|>RELATION_NOE (<|>RELATION_NOE 354<|>RELATION_NOE /<|>RELATION_NOE 385<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
临床<|>RELATION_NOE 拟诊<|>RELATION_NOE 机化性<|>RELATION_NOE 肺炎<|>RELATION_NOE 31<|>RELATION_NOE 例<|>RELATION_NOE 诊疗<|>RELATION_S 的<|>RELATION_NOE 回顾性<|>RELATION_NOE 分析<|>RELATION_NOE
31<|>RELATION_NOE 例<|>RELATION_NOE 经<|>RELATION_NOE 抗生素<|>RELATION_NOE 治疗无效<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 支气管镜<|>RELATION_NOE 肺活检<|>RELATION_NOE 病理<|>RELATION_NOE 或<|>RELATION_NOE 经皮肺<|>RELATION_NOE 穿刺<|>RELATION_NOE 病理<|>RELATION_NOE 除外<|>RELATION_NOE 结核<|>RELATION_NOE 、<|>RELATION_NOE 真菌<|>RELATION_NOE 、<|>RELATION_NOE 化脓<|>RELATION_NOE 性炎<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE 而<|>RELATION_NOE 拟诊<|>RELATION_NOE 机化性<|>RELATION_NOE 肺炎<|>RELATION_NOE 24<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 无<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 结果<|>RELATION_NOE 而<|>RELATION_NOE 经激素<|>RELATION_NOE 治疗<|>RELATION_NOE 有效<|>RELATION_NOE 拟诊<|>RELATION_NOE 7例.<|>RELATION_NOE
临床<|>RELATION_NOE 上<|>RELATION_NOE 经<|>RELATION_NOE 抗生素<|>RELATION_NOE 治疗无效<|>RELATION_NOE 、<|>RELATION_NOE 结合<|>RELATION_NOE 临床<|>RELATION_NOE 影像学<|>RELATION_NOE 特点<|>RELATION_NOE 、<|>RELATION_NOE 病理<|>RELATION_NOE 检查<|>RELATION_NOE 除外<|>RELATION_NOE 其他<|>RELATION_NOE 疾病<|>RELATION_NOE 是<|>RELATION_NOE 拟诊<|>RELATION_NOE 机化性<|>RELATION_NOE 肺炎<|>RELATION_NOE 的<|>RELATION_NOE 重要<|>RELATION_B 指标<|>RELATION_E ;<|>RELATION_NOE
健康<|>RELATION_NOE 教育<|>RELATION_NOE 对<|>RELATION_NOE 老年<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 及<|>RELATION_NOE 情绪<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
采用<|>RELATION_NOE 癌症<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 测定量表<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 焦虑<|>RELATION_NOE 自<|>RELATION_NOE 评量表<|>RELATION_NOE (<|>RELATION_NOE SAS<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 抑郁<|>RELATION_NOE 自<|>RELATION_NOE 评量表<|>RELATION_NOE (<|>RELATION_NOE SDS<|>RELATION_NOE )<|>RELATION_NOE 评价<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 焦虑<|>RELATION_NOE 、<|>RELATION_NOE 抑郁<|>RELATION_NOE 情绪<|>RELATION_NOE 。<|>RELATION_NOE
观察组<|>RELATION_NOE 躯体<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 角色<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 情绪<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 认知<|>RELATION_NOE 功能<|>RELATION_NOE 和<|>RELATION_NOE 社会<|>RELATION_NOE 功能<|>RELATION_NOE 评分<|>RELATION_NOE 及<|>RELATION_NOE 总体<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_NOE 较<|>RELATION_NOE 教育<|>RELATION_NOE 前<|>RELATION_NOE 显著<|>RELATION_B 提高<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 11.34<|>RELATION_NOE 、<|>RELATION_NOE 8.78<|>RELATION_NOE 、<|>RELATION_NOE 10.56<|>RELATION_NOE 、<|>RELATION_NOE 7.92<|>RELATION_NOE 、<|>RELATION_NOE 9.31<|>RELATION_NOE 、<|>RELATION_NOE 12.92<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 均<|>RELATION_NOE 显著<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE 5.12<|>RELATION_NOE 、<|>RELATION_NOE 5.28<|>RELATION_NOE 、<|>RELATION_NOE 6.20<|>RELATION_NOE 、<|>RELATION_NOE 5.12<|>RELATION_NOE 、<|>RELATION_NOE 5.28<|>RELATION_NOE 、<|>RELATION_NOE 4.98<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
华蟾素<|>RELATION_NOE 治疗<|>RELATION_B 中晚期<|>RELATION_I 肺癌<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 观察<|>RELATION_NOE
将<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE 原发性<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 按<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 治疗组<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 在<|>RELATION_NOE 一般<|>RELATION_NOE 治疗<|>RELATION_NOE 的<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 对<|>RELATION_NOE 症<|>RELATION_NOE 治疗<|>RELATION_NOE 和<|>RELATION_NOE 辩证<|>RELATION_NOE 施<|>RELATION_NOE 治<|>RELATION_NOE 口服<|>RELATION_NOE 中药<|>RELATION_NOE 汤剂<|>RELATION_NOE ;<|>RELATION_NOE
傣药<|>RELATION_NOE 牙帕汤<|>RELATION_NOE 抑制<|>RELATION_S 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 生长<|>RELATION_NOE 转移<|>RELATION_NOE 及<|>RELATION_NOE 小鼠<|>RELATION_NOE 免疫<|>RELATION_NOE 功能<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE
C57BL<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE 小鼠<|>RELATION_NOE 右腋<|>RELATION_NOE 皮下注射<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE (<|>RELATION_NOE lewislungcarcinoma<|>RELATION_NOE ,<|>RELATION_NOE LLC<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 随机<|>RELATION_NOE 双盲法<|>RELATION_NOE (<|>RELATION_NOE 随机<|>RELATION_NOE 抽取<|>RELATION_NOE 仅<|>RELATION_NOE 留<|>RELATION_NOE 有<|>RELATION_NOE 一侧<|>RELATION_NOE 开口<|>RELATION_NOE 的<|>RELATION_NOE 密闭<|>RELATION_NOE 黑<|>RELATION_NOE 盒子<|>RELATION_NOE 中<|>RELATION_NOE 的<|>RELATION_NOE 30<|>RELATION_NOE 只<|>RELATION_NOE 雄性<|>RELATION_NOE 小鼠<|>RELATION_NOE ,<|>RELATION_NOE 放<|>RELATION_NOE 入<|>RELATION_NOE 事先<|>RELATION_NOE 备<|>RELATION_NOE 好<|>RELATION_NOE 的<|>RELATION_NOE 6<|>RELATION_NOE 个<|>RELATION_NOE 鼠笼<|>RELATION_NOE 中<|>RELATION_NOE ,<|>RELATION_NOE 雌性<|>RELATION_NOE 小鼠<|>RELATION_NOE 依<|>RELATION_NOE 此<|>RELATION_NOE 法<|>RELATION_NOE 进行<|>RELATION_NOE 分组<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 接种<|>RELATION_NOE 的<|>RELATION_NOE 60<|>RELATION_NOE 只<|>RELATION_NOE 小鼠<|>RELATION_NOE 分为<|>RELATION_NOE 空白<|>RELATION_NOE 对照组<|>RELATION_NOE 、<|>RELATION_NOE 牙帕汤<|>RELATION_NOE 高<|>RELATION_NOE 、<|>RELATION_NOE 中<|>RELATION_NOE 、<|>RELATION_NOE 低<|>RELATION_NOE 剂量组<|>RELATION_NOE 、<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 牙帕汤<|>RELATION_NOE 与<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 联合组<|>RELATION_NOE 各<|>RELATION_NOE 10<|>RELATION_NOE 只<|>RELATION_NOE 。<|>RELATION_NOE
环磷酰胺<|>RELATION_NOE 组<|>RELATION_NOE 每<|>RELATION_NOE 隔<|>RELATION_NOE 2d<|>RELATION_NOE 腹腔<|>RELATION_NOE 注射<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 0.2ml<|>RELATION_NOE /<|>RELATION_NOE 只<|>RELATION_NOE ;<|>RELATION_NOE
牙帕汤<|>RELATION_NOE 与<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 联合<|>RELATION_NOE 组按<|>RELATION_NOE 0.4ml<|>RELATION_NOE /<|>RELATION_NOE (<|>RELATION_NOE 只<|>RELATION_NOE ·<|>RELATION_NOE d<|>RELATION_NOE )<|>RELATION_NOE 灌胃<|>RELATION_NOE 给予<|>RELATION_NOE 中<|>RELATION_NOE 剂量<|>RELATION_NOE 牙帕汤<|>RELATION_NOE 、<|>RELATION_NOE 每<|>RELATION_NOE 隔<|>RELATION_NOE 2d<|>RELATION_NOE 按<|>RELATION_NOE 0.2ml<|>RELATION_NOE /<|>RELATION_NOE 只<|>RELATION_NOE 腹腔<|>RELATION_NOE 注射<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 。<|>RELATION_NOE
第21<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 摘<|>RELATION_NOE 眼球<|>RELATION_NOE 取<|>RELATION_NOE 血<|>RELATION_NOE ,<|>RELATION_NOE 取<|>RELATION_NOE 肿瘤<|>RELATION_NOE 组织<|>RELATION_NOE 、<|>RELATION_NOE 脾<|>RELATION_NOE 、<|>RELATION_NOE 胸腺<|>RELATION_NOE 并<|>RELATION_NOE 称<|>RELATION_NOE 重<|>RELATION_NOE ,<|>RELATION_NOE 计算抑<|>RELATION_NOE 瘤率<|>RELATION_NOE 、<|>RELATION_NOE 脾指数<|>RELATION_NOE 和<|>RELATION_NOE 胸腺<|>RELATION_NOE 指数<|>RELATION_NOE ;<|>RELATION_NOE
采用<|>RELATION_NOE 酶<|>RELATION_NOE 联<|>RELATION_NOE 免疫<|>RELATION_NOE 吸附法<|>RELATION_NOE 检测<|>RELATION_S 血清<|>RELATION_NOE 中<|>RELATION_NOE 白细胞介素<|>RELATION_NOE -2<|>RELATION_NOE (<|>RELATION_NOE IL-2<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 白细胞介素<|>RELATION_NOE -10<|>RELATION_NOE (<|>RELATION_NOE IL-10<|>RELATION_NOE )<|>RELATION_NOE 含量<|>RELATION_NOE 。<|>RELATION_NOE
牙帕汤<|>RELATION_NOE 高<|>RELATION_NOE 剂量<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 牙帕汤<|>RELATION_NOE 与<|>RELATION_NOE 环磷酰胺<|>RELATION_NOE 联合组<|>RELATION_NOE 的<|>RELATION_NOE 瘤重<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 3.46<|>RELATION_NOE ±<|>RELATION_NOE 0.39<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 2.39<|>RELATION_NOE ±<|>RELATION_NOE 1.04<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 2.30<|>RELATION_NOE ±<|>RELATION_NOE 0.76<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_B 低于<|>RELATION_E 空白<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 5.21<|>RELATION_NOE ±<|>RELATION_NOE 0.50<|>RELATION_NOE )<|>RELATION_NOE g<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 抑瘤率<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 33.6<|>RELATION_NOE 9%<|>RELATION_NOE 、<|>RELATION_NOE 54.12%<|>RELATION_NOE 、<|>RELATION_NOE 56.00%<|>RELATION_NOE ;<|>RELATION_NOE
牙帕汤<|>RELATION_NOE 可以<|>RELATION_NOE 抑制<|>RELATION_S Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 数目<|>RELATION_NOE ,<|>RELATION_NOE 调节<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞<|>RELATION_NOE 因子<|>RELATION_NOE IL-2<|>RELATION_NOE 、<|>RELATION_NOE IL-10<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE 牙帕汤<|>RELATION_NOE 可以<|>RELATION_NOE 抑制<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_S 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 数目<|>RELATION_NOE ,<|>RELATION_NOE 调节<|>RELATION_NOE 免疫<|>RELATION_NOE 细胞<|>RELATION_NOE 因子<|>RELATION_NOE IL-2<|>RELATION_NOE 、<|>RELATION_NOE IL-10<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE 牙帕汤<|>RELATION_NOE 可以<|>RELATION_NOE 抑制<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 肺转移<|>RELATION_NOE 灶<|>RELATION_NOE 数目<|>RELATION_NOE ,<|>RELATION_NOE 调节<|>RELATION_S 免疫<|>RELATION_NOE 细胞<|>RELATION_NOE 因子<|>RELATION_NOE IL-2<|>RELATION_NOE 、<|>RELATION_NOE IL-10<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 。<|>RELATION_NOE
季铵盐<|>RELATION_NOE 壳聚糖<|>RELATION_NOE 影响<|>RELATION_S A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 及<|>RELATION_NOE 基质<|>RELATION_NOE 金属蛋白酶<|>RELATION_NOE -9<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 研究<|>RELATION_NOE
研究<|>RELATION_NOE 季铵盐<|>RELATION_NOE 壳聚糖<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞增殖<|>RELATION_NOE 能力<|>RELATION_NOE 、<|>RELATION_NOE 侵袭力<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_B 及<|>RELATION_I 机制<|>RELATION_E 。<|>RELATION_NOE
使用<|>RELATION_NOE 含有<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 季铵<|>RELATION_NOE 盐<|>RELATION_NOE 壳聚糖<|>RELATION_NOE 的<|>RELATION_NOE RPMI1640<|>RELATION_NOE 培养基<|>RELATION_NOE 培养<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 台<|>RELATION_NOE 盼<|>RELATION_NOE 蓝<|>RELATION_NOE 拒染法<|>RELATION_NOE 检测<|>RELATION_S A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 存活率<|>RELATION_NOE ,<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 使用<|>RELATION_NOE 含有<|>RELATION_NOE 不同<|>RELATION_NOE 浓度<|>RELATION_NOE 季铵<|>RELATION_NOE 盐<|>RELATION_NOE 壳聚糖<|>RELATION_NOE 的<|>RELATION_NOE RPMI1640<|>RELATION_NOE 培养基<|>RELATION_NOE 培养<|>RELATION_NOE 肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 台<|>RELATION_NOE 盼<|>RELATION_NOE 蓝<|>RELATION_NOE 拒<|>RELATION_NOE 染<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 存活率<|>RELATION_NOE ,<|>RELATION_NOE MTT<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 季铵盐<|>RELATION_NOE 壳聚糖<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 抑制率<|>RELATION_NOE ,<|>RELATION_NOE Western<|>RELATION_NOE Blot<|>RELATION_NOE
台<|>RELATION_NOE 盼<|>RELATION_NOE 蓝<|>RELATION_NOE 拒染<|>RELATION_NOE 实验<|>RELATION_NOE 显微镜<|>RELATION_NOE 下<|>RELATION_NOE 细胞计数<|>RELATION_NOE 显示<|>RELATION_NOE ,<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 存活率<|>RELATION_NOE 大于<|>RELATION_S 95%<|>RELATION_NOE ,<|>RELATION_NOE 满足<|>RELATION_NOE 实验<|>RELATION_NOE 要求<|>RELATION_NOE .<|>RELATION_NOE
MTT<|>RELATION_NOE 实验<|>RELATION_NOE 中<|>RELATION_NOE 随着<|>RELATION_NOE 季铵盐<|>RELATION_NOE 壳聚糖<|>RELATION_NOE 浓度<|>RELATION_NOE 的<|>RELATION_NOE 增高<|>RELATION_NOE (<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 50<|>RELATION_NOE ,<|>RELATION_NOE 100<|>RELATION_NOE ,<|>RELATION_NOE 200<|>RELATION_NOE μ<|>RELATION_NOE g<|>RELATION_NOE /<|>RELATION_NOE mL<|>RELATION_NOE )<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 生长<|>RELATION_NOE 的<|>RELATION_NOE 抑制率<|>RELATION_NOE 的<|>RELATION_NOE 逐渐<|>RELATION_NOE 增强<|>RELATION_NOE [<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 27.57<|>RELATION_NOE ±<|>RELATION_NOE 0.03<|>RELATION_NOE 7)%<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 66.69<|>RELATION_NOE ±<|>RELATION_NOE 0.40<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 81.55<|>RELATION_NOE ±<|>RELATION_NOE 0.72<|>RELATION_NOE )<|>RELATION_NOE %<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE MMP-9<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE 也<|>RELATION_NOE 随之<|>RELATION_NOE 降低<|>RELATION_NOE ,<|>RELATION_NOE 呈<|>RELATION_NOE 剂量<|>RELATION_NOE 依赖性<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 有<|>RELATION_NOE 差异<|>RELATION_B 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
季铵盐<|>RELATION_NOE 壳聚糖<|>RELATION_NOE 能够<|>RELATION_NOE 抑制<|>RELATION_NOE 人非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE A549<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 增殖<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE MMP-9<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 进而<|>RELATION_NOE 降低<|>RELATION_NOE 肿瘤<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 侵袭<|>RELATION_NOE 、<|>RELATION_NOE 转移<|>RELATION_NOE 能力<|>RELATION_NOE ,<|>RELATION_NOE 其<|>RELATION_NOE 作用<|>RELATION_B 效应<|>RELATION_I 呈<|>RELATION_I 剂量<|>RELATION_I 依赖性<|>RELATION_E .<|>RELATION_NOE
化疗<|>RELATION_NOE 联合<|>RELATION_NOE DC-CIK<|>RELATION_NOE 生物<|>RELATION_NOE 治疗<|>RELATION_B 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 价值<|>RELATION_NOE 及<|>RELATION_NOE CT<|>RELATION_NOE 灌注成像<|>RELATION_NOE 的<|>RELATION_NOE 疗效<|>RELATION_NOE 评价<|>RELATION_NOE
方法<|>RELATION_NOE :<|>RELATION_NOE 选取<|>RELATION_NOE 经<|>RELATION_NOE 确诊<|>RELATION_NOE 的<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE (<|>RELATION_NOE 男性<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE 、<|>RELATION_NOE 女性<|>RELATION_NOE 15<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 年龄<|>RELATION_NOE (<|>RELATION_NOE 70.5<|>RELATION_NOE ±<|>RELATION_NOE 2.1<|>RELATION_NOE )<|>RELATION_NOE 岁<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 患者<|>RELATION_NOE 按照<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表<|>RELATION_NOE 分成<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 治疗组<|>RELATION_NOE (<|>RELATION_NOE n<|>RELATION_NOE =<|>RELATION_NOE 15<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
对照组<|>RELATION_NOE 选用<|>RELATION_NOE 奥沙利<|>RELATION_NOE 铂+多烯<|>RELATION_NOE 紫杉醇<|>RELATION_NOE 的<|>RELATION_NOE 化疗<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 治疗组<|>RELATION_NOE 在<|>RELATION_NOE 此<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 增加<|>RELATION_NOE DC-CIK<|>RELATION_NOE 生物<|>RELATION_NOE 治疗<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 后<|>RELATION_NOE 均<|>RELATION_NOE 进行<|>RELATION_NOE 多<|>RELATION_NOE 层<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 肺<|>RELATION_NOE 灌注成像<|>RELATION_NOE .<|>RELATION_NOE
比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 治疗<|>RELATION_NOE 有效率<|>RELATION_NOE (<|>RELATION_NOE RR<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 临床<|>RELATION_NOE 获益率<|>RELATION_NOE (<|>RELATION_NOE CBR<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 治疗<|>RELATION_NOE 前<|>RELATION_NOE 、<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE CT<|>RELATION_NOE 灌注<|>RELATION_NOE 指标<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_NOE 血流量<|>RELATION_NOE (<|>RELATION_NOE BF<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血容量<|>RELATION_NOE (<|>RELATION_NOE BV<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 表面<|>RELATION_NOE 通透性<|>RELATION_NOE (<|>RELATION_NOE PS<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 达峰<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE TP<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 平均<|>RELATION_NOE 通过<|>RELATION_NOE 时间<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
人类<|>RELATION_NOE 平衡型<|>RELATION_NOE 核苷<|>RELATION_NOE 转运<|>RELATION_NOE 蛋白<|>RELATION_NOE 1高<|>RELATION_NOE 表达<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 应用<|>RELATION_B 不同<|>RELATION_I 剂量<|>RELATION_I 吉西<|>RELATION_I 他<|>RELATION_I 滨<|>RELATION_I 治疗<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 观察<|>RELATION_NOE
观察<|>RELATION_NOE 晚期<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 中<|>RELATION_NOE 人类<|>RELATION_NOE 平衡型<|>RELATION_NOE 核苷<|>RELATION_NOE 转运<|>RELATION_NOE 蛋白1<|>RELATION_NOE (<|>RELATION_NOE hENT1<|>RELATION_NOE )<|>RELATION_NOE 高<|>RELATION_NOE 表达<|>RELATION_NOE 患者<|>RELATION_NOE 应用<|>RELATION_B 不同<|>RELATION_I 剂量<|>RELATION_I 吉西<|>RELATION_I 他<|>RELATION_I 滨<|>RELATION_I 治疗<|>RELATION_E 的<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
选取<|>RELATION_NOE 2008年<|>RELATION_NOE 7月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 12月<|>RELATION_NOE 于<|>RELATION_NOE 浙江<|>RELATION_NOE 金华<|>RELATION_NOE 广福<|>RELATION_NOE 医院<|>RELATION_NOE 行晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 确诊<|>RELATION_NOE 晚期<|>RELATION_NOE NSCLC<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 采用<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学<|>RELATION_NOE SP<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 肺癌<|>RELATION_NOE 组织<|>RELATION_NOE 中<|>RELATION_NOE hENT1<|>RELATION_NOE 抗体<|>RELATION_NOE 的<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE .<|>RELATION_NOE
对照组<|>RELATION_NOE 和<|>RELATION_NOE 观察组<|>RELATION_NOE 近期<|>RELATION_NOE 有<|>RELATION_NOE 效率<|>RELATION_NOE 和<|>RELATION_NOE 疾病<|>RELATION_NOE 控制率<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E [<|>RELATION_NOE 43.3%<|>RELATION_NOE (<|>RELATION_NOE 13<|>RELATION_NOE /<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 46.9%<|>RELATION_NOE (<|>RELATION_NOE 15<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 76.9%<|>RELATION_NOE (<|>RELATION_NOE 23<|>RELATION_NOE /<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE 81.2%<|>RELATION_NOE (<|>RELATION_NOE 26<|>RELATION_NOE /<|>RELATION_NOE 32<|>RELATION_NOE )<|>RELATION_NOE ]<|>RELATION_NOE (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 0.08<|>RELATION_NOE ,<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 0.20<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE ><|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
观察组<|>RELATION_NOE Ⅲ<|>RELATION_NOE 、<|>RELATION_NOE Ⅳ<|>RELATION_NOE 度<|>RELATION_NOE 白细胞减少<|>RELATION_NOE 、<|>RELATION_NOE 血小板减少<|>RELATION_NOE 及<|>RELATION_NOE 恶心<|>RELATION_NOE 、<|>RELATION_NOE 呕吐<|>RELATION_NOE 发生率<|>RELATION_NOE 低于<|>RELATION_S 对照组<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
除<|>RELATION_NOE 角色<|>RELATION_NOE 功能<|>RELATION_NOE 外<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 化疗<|>RELATION_NOE 后<|>RELATION_NOE 总体<|>RELATION_NOE 生活<|>RELATION_NOE 评分<|>RELATION_NOE 及<|>RELATION_NOE 躯体<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 情绪<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 认知<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 社会<|>RELATION_NOE 功能<|>RELATION_NOE 、<|>RELATION_NOE 经济<|>RELATION_NOE 状况<|>RELATION_NOE 各项<|>RELATION_NOE 评分<|>RELATION_NOE 均<|>RELATION_B 优于<|>RELATION_E 对照组<|>RELATION_NOE [<|>RELATION_NOE (<|>RELATION_NOE 54<|>RELATION_NOE ±<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 54<|>RELATION_NOE ±<|>RELATION_NOE 16<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ,<|>RELATION_NOE (<|>RELATION_NOE 72<|>RELATION_NOE ±<|>RELATION_NOE 25<|>RELATION_NOE )<|>RELATION_NOE 分比<|>RELATION_NOE (<|>RELATION_NOE 62<|>RELATION_NOE ±<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 85<|>RELATION_NOE ±<|>RELATION_NOE 20<|>RELATION_NOE )<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 72<|>RELATION_NOE ±<|>RELATION_NOE 19<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 76<|>RELATION_NOE ±<|>RELATION_NOE 28<|>RELATION_NOE )<|>RELATION_NOE 分比<|>RELATION_NOE (<|>RELATION_NOE 62<|>RELATION_NOE ±<|>RELATION_NOE 25<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 61<|>RELATION_NOE ±<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 49<|>RELATION_NOE ±<|>RELATION_NOE 30<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 、<|>RELATION_NOE (<|>RELATION_NOE 36<|>RELATION_NOE ±<|>RELATION_NOE 24<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE 比<|>RELATION_NOE (<|>RELATION_NOE 56<|>RELATION_NOE ±<|>RELATION_NOE 21<|>RELATION_NOE )<|>RELATION_NOE 分<|>RELATION_NOE ]<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 均<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 同步<|>RELATION_NOE 放<|>RELATION_NOE 化疗<|>RELATION_NOE 患者<|>RELATION_NOE 生存<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
对照组<|>RELATION_NOE 患者<|>RELATION_NOE 实施<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 实施<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 。<|>RELATION_NOE
护理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 总体<|>RELATION_NOE 健康<|>RELATION_NOE 状况<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 躯体<|>RELATION_NOE 功能<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 角色<|>RELATION_NOE 功能<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 认知<|>RELATION_NOE 功能<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 均<|>RELATION_B 明显<|>RELATION_I 高于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 疲倦<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 食欲<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 护理<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 患者<|>RELATION_NOE 总体<|>RELATION_NOE 健康<|>RELATION_NOE 状况<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 躯体<|>RELATION_NOE 功能<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 角色<|>RELATION_NOE 功能<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 认知<|>RELATION_NOE 功能<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 护理<|>RELATION_NOE 满意度<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 疲倦<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 食欲<|>RELATION_NOE 评分<|>RELATION_NOE 、<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 均<|>RELATION_B 明显<|>RELATION_I 低于<|>RELATION_E 对照组<|>RELATION_NOE (<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
如实<|>RELATION_NOE 告知<|>RELATION_NOE 癌症<|>RELATION_NOE 患者<|>RELATION_NOE 病情<|>RELATION_NOE 对<|>RELATION_NOE 治疗<|>RELATION_NOE 依从性<|>RELATION_NOE 及<|>RELATION_NOE 心理<|>RELATION_NOE 状态<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
将<|>RELATION_NOE 我<|>RELATION_NOE 院<|>RELATION_NOE 20<|>RELATION_NOE 11年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 1月<|>RELATION_NOE 肿瘤科<|>RELATION_NOE 住院<|>RELATION_NOE 的<|>RELATION_NOE 非<|>RELATION_NOE 小细胞肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE 各<|>RELATION_NOE 16<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 征求<|>RELATION_NOE 患者<|>RELATION_NOE 家属<|>RELATION_NOE 同意<|>RELATION_NOE 的<|>RELATION_NOE 情况<|>RELATION_NOE 下<|>RELATION_NOE 如实<|>RELATION_NOE 告知<|>RELATION_NOE 患者<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 治疗方案<|>RELATION_NOE 、<|>RELATION_NOE 治疗<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 可能<|>RELATION_NOE 出现<|>RELATION_NOE 的<|>RELATION_NOE 毒副作用<|>RELATION_NOE ,<|>RELATION_NOE 预后<|>RELATION_NOE 及<|>RELATION_NOE 注意<|>RELATION_NOE 事项<|>RELATION_NOE ;<|>RELATION_NOE
对照组<|>RELATION_NOE 只是<|>RELATION_NOE 把<|>RELATION_NOE 诊断<|>RELATION_NOE 、<|>RELATION_NOE 治疗方案<|>RELATION_NOE 等<|>RELATION_NOE 告知<|>RELATION_NOE 给<|>RELATION_NOE 患者<|>RELATION_NOE 家属<|>RELATION_NOE ,<|>RELATION_NOE 2周<|>RELATION_NOE 后<|>RELATION_NOE 根据<|>RELATION_NOE 我院<|>RELATION_NOE 制定<|>RELATION_NOE 的<|>RELATION_NOE 癌症<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 治疗<|>RELATION_NOE 依从性<|>RELATION_NOE 及<|>RELATION_NOE 心理<|>RELATION_NOE 适应性<|>RELATION_NOE 调查<|>RELATION_NOE 分析<|>RELATION_NOE 评定表<|>RELATION_NOE ,<|>RELATION_NOE 评定<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 对<|>RELATION_NOE 治疗<|>RELATION_NOE 依从性<|>RELATION_NOE 及<|>RELATION_NOE 心理<|>RELATION_NOE 状态<|>RELATION_NOE 的<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
综合<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 改善<|>RELATION_B 肺癌<|>RELATION_I 患者<|>RELATION_I 术后<|>RELATION_I 呼吸功能<|>RELATION_I 及<|>RELATION_I 生活<|>RELATION_I 质量<|>RELATION_E 的<|>RELATION_NOE 效果<|>RELATION_NOE
观察<|>RELATION_NOE 分析<|>RELATION_NOE 综合<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 改善<|>RELATION_B 肺癌<|>RELATION_I 患者<|>RELATION_I 术后<|>RELATION_I 呼吸功能<|>RELATION_I 及<|>RELATION_I 生活<|>RELATION_I 质量<|>RELATION_E 的<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
随机<|>RELATION_NOE 将<|>RELATION_NOE 我院<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 平均<|>RELATION_NOE 分为<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE ,<|>RELATION_NOE 进行<|>RELATION_NOE 手术<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE 采用<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 采用<|>RELATION_NOE 综合<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 进行<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 观察<|>RELATION_NOE 并<|>RELATION_NOE 比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 经过<|>RELATION_NOE 护理<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 呼吸功能<|>RELATION_NOE 及<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 的<|>RELATION_NOE 改善<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 经过<|>RELATION_NOE 不同<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 患者<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 、<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 最大通气量<|>RELATION_NOE 、<|>RELATION_NOE 时间<|>RELATION_NOE 通气量<|>RELATION_NOE 和<|>RELATION_NOE 第一<|>RELATION_NOE 秒<|>RELATION_NOE 用力<|>RELATION_NOE 呼吸<|>RELATION_NOE 容量<|>RELATION_NOE 均<|>RELATION_B 明显<|>RELATION_I 优于<|>RELATION_E 对照组<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 患者<|>RELATION_NOE 肺不张<|>RELATION_NOE 和<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 等<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 总评分<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 经过<|>RELATION_NOE 不同<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 患者<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 、<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 最大通气量<|>RELATION_NOE 、<|>RELATION_NOE 时间<|>RELATION_NOE 通气量<|>RELATION_NOE 和<|>RELATION_NOE 第一<|>RELATION_NOE 秒<|>RELATION_NOE 用力<|>RELATION_NOE 呼吸<|>RELATION_NOE 容量<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 优于<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 患者<|>RELATION_NOE 肺不张<|>RELATION_NOE 和<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 等<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 对照组<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 总评分<|>RELATION_NOE 明显<|>RELATION_NOE 高于<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 经过<|>RELATION_NOE 不同<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 患者<|>RELATION_NOE 呼吸频率<|>RELATION_NOE 、<|>RELATION_NOE 血氧<|>RELATION_NOE 饱和度<|>RELATION_NOE 、<|>RELATION_NOE 最大通气量<|>RELATION_NOE 、<|>RELATION_NOE 时间<|>RELATION_NOE 通气量<|>RELATION_NOE 和<|>RELATION_NOE 第一<|>RELATION_NOE 秒<|>RELATION_NOE 用力<|>RELATION_NOE 呼吸<|>RELATION_NOE 容量<|>RELATION_NOE 均<|>RELATION_NOE 明显<|>RELATION_NOE 优于<|>RELATION_NOE 对照组<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 患者<|>RELATION_NOE 肺不张<|>RELATION_NOE 和<|>RELATION_NOE 肺部<|>RELATION_NOE 感染<|>RELATION_NOE 等<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 明显<|>RELATION_NOE 低于<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 实验组<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE 总评<|>RELATION_NOE 分<|>RELATION_NOE 明显<|>RELATION_B 高于<|>RELATION_E 对照组<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
胸腔镜<|>RELATION_NOE 肺叶<|>RELATION_NOE 切除<|>RELATION_NOE 术时<|>RELATION_NOE 中转<|>RELATION_NOE 开胸<|>RELATION_NOE 对<|>RELATION_B 患者<|>RELATION_I 的<|>RELATION_I 影响<|>RELATION_I 及其<|>RELATION_I 原因<|>RELATION_E 分析<|>RELATION_NOE
中转<|>RELATION_NOE 开<|>RELATION_NOE 胸组<|>RELATION_NOE 和<|>RELATION_NOE 胸腔镜组<|>RELATION_NOE 中<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 及<|>RELATION_NOE 手术<|>RELATION_NOE 类型<|>RELATION_NOE 无<|>RELATION_B 明显<|>RELATION_I 差别<|>RELATION_E ,<|>RELATION_NOE 中转<|>RELATION_NOE 开<|>RELATION_NOE 胸组<|>RELATION_NOE 的<|>RELATION_NOE 手术时间<|>RELATION_NOE 较<|>RELATION_NOE 长<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 中<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 、<|>RELATION_NOE 术后病死率<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 差异<|>RELATION_NOE 无<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE 。<|>RELATION_NOE 中转<|>RELATION_NOE 开<|>RELATION_NOE 胸组<|>RELATION_NOE 和<|>RELATION_NOE 胸腔镜组<|>RELATION_NOE 中<|>RELATION_NOE 患者<|>RELATION_NOE 的<|>RELATION_NOE 年龄<|>RELATION_NOE 、<|>RELATION_NOE 性别<|>RELATION_NOE 及<|>RELATION_NOE 手术<|>RELATION_NOE 类型<|>RELATION_NOE 无<|>RELATION_NOE 明显<|>RELATION_NOE 差别<|>RELATION_NOE ,<|>RELATION_NOE 中转<|>RELATION_NOE 开<|>RELATION_NOE 胸组<|>RELATION_NOE 的<|>RELATION_NOE 手术时间<|>RELATION_NOE 较<|>RELATION_NOE 长<|>RELATION_NOE ,<|>RELATION_NOE 术中<|>RELATION_NOE 出血量<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE ,<|>RELATION_NOE 病理<|>RELATION_NOE 中<|>RELATION_NOE 良性<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 比例<|>RELATION_NOE 较<|>RELATION_NOE 高<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 的<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE 、<|>RELATION_NOE 术后病死率<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE 及<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 差异<|>RELATION_B 无<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E 。<|>RELATION_NOE
中转<|>RELATION_NOE 开胸<|>RELATION_NOE 的<|>RELATION_NOE 原因<|>RELATION_NOE 分类<|>RELATION_NOE 为<|>RELATION_NOE :<|>RELATION_NOE 血管<|>RELATION_NOE 损伤<|>RELATION_NOE 出血<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 致密<|>RELATION_NOE 粘连<|>RELATION_NOE 6例<|>RELATION_NOE ,<|>RELATION_NOE 器械<|>RELATION_NOE 相关<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 肺裂<|>RELATION_NOE 不<|>RELATION_NOE 全<|>RELATION_NOE 5例<|>RELATION_NOE ,<|>RELATION_NOE 解剖<|>RELATION_NOE 间隙<|>RELATION_NOE 不<|>RELATION_NOE 清3<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 血管<|>RELATION_NOE 变异<|>RELATION_NOE 3例<|>RELATION_NOE ,<|>RELATION_NOE 切缘<|>RELATION_NOE 不足<|>RELATION_NOE 2例<|>RELATION_NOE 。<|>RELATION_NOE
吸烟<|>RELATION_NOE 及<|>RELATION_NOE 烟碱型<|>RELATION_NOE 乙酰胆碱受体<|>RELATION_NOE 亚<|>RELATION_NOE 单位<|>RELATION_NOE α<|>RELATION_NOE 5基因<|>RELATION_NOE rs17486278<|>RELATION_NOE 位点<|>RELATION_NOE 多态性<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 交互<|>RELATION_B 作用<|>RELATION_E
探讨<|>RELATION_NOE 在<|>RELATION_NOE 中国<|>RELATION_NOE 男性<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE 烟碱型<|>RELATION_NOE 乙酰胆碱受体<|>RELATION_NOE 亚<|>RELATION_NOE 单位<|>RELATION_NOE α<|>RELATION_NOE 5<|>RELATION_NOE (<|>RELATION_NOE CHRNA5<|>RELATION_NOE )<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 关联<|>RELATION_B 及其<|>RELATION_I 交互<|>RELATION_I 作用<|>RELATION_E 。<|>RELATION_NOE
应用<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE logistic<|>RELATION_NOE 回归<|>RELATION_NOE 模型<|>RELATION_NOE 分析<|>RELATION_NOE 吸烟<|>RELATION_NOE 、<|>RELATION_NOE CHRNA5<|>RELATION_NOE 的<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 关系<|>RELATION_NOE 及其<|>RELATION_NOE 交互<|>RELATION_NOE 作用<|>RELATION_NOE 。<|>RELATION_NOE
根据<|>RELATION_NOE rs17486278<|>RELATION_NOE 多态性<|>RELATION_NOE 和<|>RELATION_NOE 吸烟<|>RELATION_NOE 行为<|>RELATION_NOE 进行<|>RELATION_NOE 分层<|>RELATION_NOE 分析<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 不<|>RELATION_NOE 吸烟<|>RELATION_NOE 并<|>RELATION_NOE 携带<|>RELATION_NOE rs17486278<|>RELATION_NOE 野生<|>RELATION_NOE 基因型<|>RELATION_NOE (<|>RELATION_NOE AA<|>RELATION_NOE )<|>RELATION_NOE 者<|>RELATION_NOE 相比<|>RELATION_NOE ,<|>RELATION_NOE 每天<|>RELATION_NOE 吸烟量<|>RELATION_NOE 1－<|>RELATION_NOE 15<|>RELATION_NOE 支<|>RELATION_NOE 并<|>RELATION_NOE 携带<|>RELATION_NOE 纯合<|>RELATION_NOE 变异<|>RELATION_NOE 基因型<|>RELATION_NOE (<|>RELATION_NOE CC<|>RELATION_NOE )<|>RELATION_NOE 者<|>RELATION_NOE 、<|>RELATION_NOE 每天<|>RELATION_NOE 吸烟量<|>RELATION_NOE ><|>RELATION_NOE 15<|>RELATION_NOE 支<|>RELATION_NOE 并<|>RELATION_NOE 携带<|>RELATION_NOE 野生<|>RELATION_NOE 基因型<|>RELATION_NOE (<|>RELATION_NOE AA<|>RELATION_NOE )<|>RELATION_NOE 者<|>RELATION_NOE 和<|>RELATION_NOE 每天<|>RELATION_NOE 吸烟量<|>RELATION_NOE ><|>RELATION_NOE 15<|>RELATION_NOE 支<|>RELATION_NOE 并<|>RELATION_NOE 携带<|>RELATION_NOE 杂合<|>RELATION_NOE 变异<|>RELATION_NOE 基因型<|>RELATION_NOE (<|>RELATION_NOE AC<|>RELATION_NOE )<|>RELATION_NOE 者<|>RELATION_NOE 发生<|>RELATION_B 肺癌<|>RELATION_I 风险<|>RELATION_I 增高<|>RELATION_E ,<|>RELATION_NOE OR<|>RELATION_NOE 直<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 8.14<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 1.17<|>RELATION_NOE －5<|>RELATION_NOE 6.56<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 3.84<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 1.30<|>RELATION_NOE －1<|>RELATION_NOE 1.40<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 5.32<|>RELATION_NOE (<|>RELATION_NOE 95%<|>RELATION_NOE CI<|>RELATION_NOE :<|>RELATION_NOE 1.78<|>RELATION_NOE －1<|>RELATION_NOE 5.93<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
在<|>RELATION_NOE 中国<|>RELATION_NOE 男性<|>RELATION_NOE 人群<|>RELATION_NOE 中<|>RELATION_NOE CHRNA5<|>RELATION_NOE 的<|>RELATION_NOE 基因<|>RELATION_NOE 多态性<|>RELATION_NOE 与<|>RELATION_NOE 吸烟<|>RELATION_NOE 行为<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE 存在<|>RELATION_B 正<|>RELATION_I 交互<|>RELATION_I 作用<|>RELATION_E .<|>RELATION_NOE
CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植入<|>RELATION_NOE 治疗<|>RELATION_B 肺癌<|>RELATION_I 术后<|>RELATION_I 气胸<|>RELATION_I 发生率<|>RELATION_E 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 分析<|>RELATION_NOE
观察<|>RELATION_NOE 821<|>RELATION_NOE 例<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 肺穿<|>RELATION_NOE 刺<|>RELATION_NOE 肺癌<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 术后<|>RELATION_NOE 患者<|>RELATION_NOE 198<|>RELATION_NOE 例<|>RELATION_NOE 发生<|>RELATION_NOE 气胸<|>RELATION_NOE 的<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 分析<|>RELATION_NOE 其<|>RELATION_NOE 出现<|>RELATION_NOE 的<|>RELATION_NOE 相关<|>RELATION_NOE 因素<|>RELATION_NOE 。<|>RELATION_NOE
发现<|>RELATION_NOE 植入<|>RELATION_NOE 针进针<|>RELATION_NOE 平均<|>RELATION_NOE 深度<|>RELATION_NOE 、<|>RELATION_NOE 患者<|>RELATION_NOE 是否<|>RELATION_NOE 合并<|>RELATION_NOE 慢性<|>RELATION_NOE 阻塞性<|>RELATION_NOE 肺疾病<|>RELATION_NOE (<|>RELATION_NOE COPD<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 是否<|>RELATION_NOE 合并<|>RELATION_NOE 肺不张<|>RELATION_NOE 、<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 针道<|>RELATION_NOE 数目<|>RELATION_NOE 、<|>RELATION_NOE 手术时间<|>RELATION_NOE 、<|>RELATION_NOE 进<|>RELATION_NOE 针角度<|>RELATION_NOE 及<|>RELATION_NOE 肿瘤<|>RELATION_NOE 直径<|>RELATION_NOE 7<|>RELATION_NOE 个<|>RELATION_NOE 因素<|>RELATION_NOE 与<|>RELATION_NOE 术后<|>RELATION_NOE 气胸<|>RELATION_NOE 发生率<|>RELATION_NOE 相关<|>RELATION_S (<|>RELATION_NOE x2<|>RELATION_NOE =<|>RELATION_NOE 10.2<|>RELATION_NOE 93<|>RELATION_NOE 、<|>RELATION_NOE 11.4<|>RELATION_NOE 63<|>RELATION_NOE 、<|>RELATION_NOE 5.3<|>RELATION_NOE 10<|>RELATION_NOE 、<|>RELATION_NOE 8.8<|>RELATION_NOE 68<|>RELATION_NOE 、<|>RELATION_NOE 13.3<|>RELATION_NOE 48<|>RELATION_NOE 、<|>RELATION_NOE 9.3<|>RELATION_NOE 26<|>RELATION_NOE 、<|>RELATION_NOE 16.504<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE .<|>RELATION_NOE
其中<|>RELATION_NOE 前<|>RELATION_NOE 4<|>RELATION_NOE 项<|>RELATION_NOE 经<|>RELATION_NOE 多<|>RELATION_NOE 因素<|>RELATION_NOE logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 是<|>RELATION_NOE 气胸<|>RELATION_B 发生<|>RELATION_E 的<|>RELATION_NOE 危险因素<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.6<|>RELATION_NOE 76<|>RELATION_NOE 、<|>RELATION_NOE 2.1<|>RELATION_NOE 47<|>RELATION_NOE 、<|>RELATION_NOE 1.8<|>RELATION_NOE 27<|>RELATION_NOE 、<|>RELATION_NOE 2.3<|>RELATION_NOE 68<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 1项<|>RELATION_NOE 是<|>RELATION_NOE 气胸<|>RELATION_NOE 的<|>RELATION_NOE 保护因素<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 67<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE 其中<|>RELATION_NOE 前<|>RELATION_NOE 4<|>RELATION_NOE 项<|>RELATION_NOE 经多<|>RELATION_NOE 因素<|>RELATION_NOE logistic<|>RELATION_NOE 回归分析<|>RELATION_NOE 是<|>RELATION_NOE 气胸<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 危险因素<|>RELATION_NOE (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 1.6<|>RELATION_NOE 76<|>RELATION_NOE 、<|>RELATION_NOE 2.1<|>RELATION_NOE 47<|>RELATION_NOE 、<|>RELATION_NOE 1.8<|>RELATION_NOE 27<|>RELATION_NOE 、<|>RELATION_NOE 2.3<|>RELATION_NOE 68<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 最后<|>RELATION_NOE 1<|>RELATION_NOE 项<|>RELATION_NOE 是<|>RELATION_NOE 气胸<|>RELATION_NOE 的<|>RELATION_NOE 保护因素<|>RELATION_S (<|>RELATION_NOE OR<|>RELATION_NOE =<|>RELATION_NOE 0.3<|>RELATION_NOE 67<|>RELATION_NOE ,<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
当<|>RELATION_NOE 病灶<|>RELATION_NOE 离<|>RELATION_NOE 胸壁<|>RELATION_NOE 远<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 合并<|>RELATION_NOE 有<|>RELATION_NOE COPD<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 植入<|>RELATION_NOE 针道<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 粒子<|>RELATION_B 植<|>RELATION_I 入<|>RELATION_I 前<|>RELATION_I 要<|>RELATION_I 充分<|>RELATION_I 考虑<|>RELATION_E 到<|>RELATION_NOE 气胸<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 可能<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 穿<|>RELATION_NOE 刺针<|>RELATION_NOE 数目<|>RELATION_NOE 及<|>RELATION_NOE 加快<|>RELATION_NOE 手术时间<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 使<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 肺癌<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 术后<|>RELATION_NOE 气胸<|>RELATION_NOE 发生率<|>RELATION_NOE 大为<|>RELATION_NOE 降低<|>RELATION_NOE .<|>RELATION_NOE 当<|>RELATION_NOE 病灶<|>RELATION_NOE 离<|>RELATION_NOE 胸壁<|>RELATION_NOE 远<|>RELATION_NOE ,<|>RELATION_NOE 患者<|>RELATION_NOE 合并<|>RELATION_NOE 有<|>RELATION_NOE COPD<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 植入<|>RELATION_NOE 针道<|>RELATION_NOE 较<|>RELATION_NOE 多<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE ,<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 前<|>RELATION_NOE 要<|>RELATION_NOE 充分<|>RELATION_NOE 考虑<|>RELATION_NOE 到<|>RELATION_NOE 气胸<|>RELATION_NOE 发生<|>RELATION_NOE 的<|>RELATION_NOE 可能<|>RELATION_NOE ,<|>RELATION_NOE 减少<|>RELATION_NOE 穿<|>RELATION_NOE 刺针<|>RELATION_NOE 数目<|>RELATION_NOE 及<|>RELATION_NOE 加快<|>RELATION_NOE 手术时间<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 使<|>RELATION_NOE CT<|>RELATION_NOE 引导<|>RELATION_NOE 下<|>RELATION_NOE 经皮<|>RELATION_NOE 肺癌<|>RELATION_NOE 125I<|>RELATION_NOE 粒子<|>RELATION_NOE 植<|>RELATION_NOE 入<|>RELATION_NOE 术后<|>RELATION_NOE 气胸<|>RELATION_NOE 发生率<|>RELATION_NOE 大为<|>RELATION_B 降低<|>RELATION_E .<|>RELATION_NOE
γ射线<|>RELATION_NOE 诱导<|>RELATION_S 人<|>RELATION_NOE 肺腺癌<|>RELATION_NOE H322<|>RELATION_NOE 细胞<|>RELATION_NOE STAT3<|>RELATION_NOE 激活<|>RELATION_NOE 的<|>RELATION_NOE 实验<|>RELATION_NOE 研究<|>RELATION_NOE
18F-FDG<|>RELATION_NOE 对<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植瘤<|>RELATION_NOE P53<|>RELATION_NOE 、<|>RELATION_NOE XIAP<|>RELATION_NOE 与<|>RELATION_NOE GADD45<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
观察<|>RELATION_NOE 18F-<|>RELATION_NOE 氟代<|>RELATION_NOE 脱氧葡萄糖<|>RELATION_NOE (<|>RELATION_NOE 18F-FDG<|>RELATION_NOE )<|>RELATION_NOE 内<|>RELATION_NOE 照射<|>RELATION_NOE 对<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植瘤<|>RELATION_NOE P53<|>RELATION_NOE 、<|>RELATION_NOE XIAP<|>RELATION_NOE 与<|>RELATION_NOE GADD45<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 作为<|>RELATION_NOE 内<|>RELATION_NOE 照射<|>RELATION_NOE 治疗<|>RELATION_NOE 药<|>RELATION_NOE 的<|>RELATION_NOE 可行性<|>RELATION_NOE 。<|>RELATION_NOE
建立<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE C57BL<|>RELATION_NOE /<|>RELATION_NOE 6<|>RELATION_NOE 小鼠<|>RELATION_NOE 皮下<|>RELATION_NOE 移植瘤<|>RELATION_NOE 模型<|>RELATION_NOE 48<|>RELATION_NOE 只<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 分为<|>RELATION_NOE 高<|>RELATION_NOE 剂量<|>RELATION_NOE 组<|>RELATION_NOE 、<|>RELATION_NOE 低<|>RELATION_NOE 剂量组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 16<|>RELATION_NOE 只<|>RELATION_NOE .<|>RELATION_NOE
接种<|>RELATION_NOE 后<|>RELATION_NOE 第7<|>RELATION_NOE 天<|>RELATION_NOE ,<|>RELATION_NOE 3组<|>RELATION_NOE 小鼠<|>RELATION_NOE 分别<|>RELATION_NOE 腹腔<|>RELATION_NOE 注射<|>RELATION_NOE 0.2ml<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 及<|>RELATION_NOE 等<|>RELATION_NOE 体积<|>RELATION_NOE 生理<|>RELATION_NOE 盐水<|>RELATION_NOE ,<|>RELATION_NOE 使<|>RELATION_NOE 高<|>RELATION_NOE 、<|>RELATION_NOE 低<|>RELATION_NOE 剂量组<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 注射量<|>RELATION_NOE 分别<|>RELATION_NOE 为<|>RELATION_NOE 18.5<|>RELATION_NOE ×<|>RELATION_NOE 107<|>RELATION_NOE 和<|>RELATION_NOE 9.25<|>RELATION_NOE ×<|>RELATION_NOE 107<|>RELATION_NOE Bq<|>RELATION_NOE .<|>RELATION_NOE
第<|>RELATION_NOE 22<|>RELATION_NOE 天<|>RELATION_NOE 处死<|>RELATION_NOE 小鼠<|>RELATION_NOE ,<|>RELATION_NOE SP<|>RELATION_NOE 免疫<|>RELATION_NOE 组织<|>RELATION_NOE 化学法<|>RELATION_NOE 检测<|>RELATION_S 移植瘤<|>RELATION_NOE 组织<|>RELATION_NOE P53<|>RELATION_NOE 、<|>RELATION_NOE XIAP<|>RELATION_NOE 与<|>RELATION_NOE GADD45<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 。<|>RELATION_NOE
3组<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE P53<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE 的<|>RELATION_NOE 平均<|>RELATION_NOE 积分<|>RELATION_NOE 光密度<|>RELATION_NOE 分别<|>RELATION_NOE 从<|>RELATION_NOE 对照组<|>RELATION_NOE 的<|>RELATION_NOE (<|>RELATION_NOE 0.0<|>RELATION_NOE 89<|>RELATION_NOE ±<|>RELATION_NOE 0.0<|>RELATION_NOE 33<|>RELATION_NOE )<|>RELATION_NOE 随<|>RELATION_B 照射<|>RELATION_I 剂量<|>RELATION_I 增大<|>RELATION_I 为<|>RELATION_I 高剂<|>RELATION_I 量组<|>RELATION_I 的<|>RELATION_I (<|>RELATION_I 0.3<|>RELATION_I 15<|>RELATION_I ±<|>RELATION_I 0.0<|>RELATION_I 28<|>RELATION_I )<|>RELATION_E ;<|>RELATION_NOE
18F-FDG<|>RELATION_NOE 能够<|>RELATION_NOE 上调<|>RELATION_S P53<|>RELATION_NOE 和<|>RELATION_NOE GADD45<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 下调<|>RELATION_NOE XIAP<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 促使<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织细胞<|>RELATION_NOE 以<|>RELATION_NOE P53<|>RELATION_NOE 依赖<|>RELATION_NOE 的<|>RELATION_NOE 方式<|>RELATION_NOE 凋亡<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 生长.<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 能够<|>RELATION_NOE 上调<|>RELATION_NOE P53<|>RELATION_NOE 和<|>RELATION_NOE GADD45<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 下调<|>RELATION_S XIAP<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 促使<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织细胞<|>RELATION_NOE 以<|>RELATION_NOE P53<|>RELATION_NOE 依赖<|>RELATION_NOE 的<|>RELATION_NOE 方式<|>RELATION_NOE 凋亡<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 生长.<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 能够<|>RELATION_NOE 上调<|>RELATION_NOE P53<|>RELATION_NOE 和<|>RELATION_NOE GADD45<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 下调<|>RELATION_NOE XIAP<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 促使<|>RELATION_S 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织细胞<|>RELATION_NOE 以<|>RELATION_NOE P53<|>RELATION_NOE 依赖<|>RELATION_NOE 的<|>RELATION_NOE 方式<|>RELATION_NOE 凋亡<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 生长.<|>RELATION_NOE 18F-FDG<|>RELATION_NOE 能够<|>RELATION_NOE 上调<|>RELATION_NOE P53<|>RELATION_NOE 和<|>RELATION_NOE GADD45<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 下调<|>RELATION_NOE XIAP<|>RELATION_NOE 蛋白<|>RELATION_NOE 表达<|>RELATION_NOE ,<|>RELATION_NOE 促使<|>RELATION_NOE 小鼠<|>RELATION_NOE Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 组织细胞<|>RELATION_NOE 以<|>RELATION_NOE P53<|>RELATION_NOE 依赖<|>RELATION_NOE 的<|>RELATION_NOE 方式<|>RELATION_NOE 凋亡<|>RELATION_NOE ,<|>RELATION_NOE 抑制<|>RELATION_S Lewis<|>RELATION_NOE 肺癌<|>RELATION_NOE 移植<|>RELATION_NOE 瘤<|>RELATION_NOE 生长<|>RELATION_NOE .<|>RELATION_NOE
周围型<|>RELATION_NOE 小<|>RELATION_NOE 肺癌<|>RELATION_NOE 16<|>RELATION_NOE 排<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_S 分析<|>RELATION_NOE
16<|>RELATION_NOE 排<|>RELATION_NOE 螺旋<|>RELATION_NOE CT<|>RELATION_NOE 诊断<|>RELATION_B 周围型<|>RELATION_I 小<|>RELATION_I 肺癌<|>RELATION_E 可<|>RELATION_NOE 显示<|>RELATION_NOE 肿块<|>RELATION_NOE 形态<|>RELATION_NOE 、<|>RELATION_NOE 位置<|>RELATION_NOE 、<|>RELATION_NOE 内部<|>RELATION_NOE 结构<|>RELATION_NOE 、<|>RELATION_NOE 血管<|>RELATION_NOE 走行<|>RELATION_NOE 及<|>RELATION_NOE 隐蔽<|>RELATION_NOE 部位<|>RELATION_NOE 病灶<|>RELATION_NOE ,<|>RELATION_NOE 结合<|>RELATION_NOE 薄<|>RELATION_NOE 层<|>RELATION_NOE 扫描<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 明显<|>RELATION_NOE 提高<|>RELATION_NOE 早期<|>RELATION_NOE 诊断率<|>RELATION_NOE .<|>RELATION_NOE
^<|>RELATION_NOE 89Sr<|>RELATION_NOE 联合<|>RELATION_NOE 伊班<|>RELATION_NOE 膦酸钠<|>RELATION_NOE 治疗<|>RELATION_B 肺癌<|>RELATION_I 骨<|>RELATION_I 转移<|>RELATION_I 疼痛<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE
探讨<|>RELATION_NOE ^<|>RELATION_NOE 89Sr<|>RELATION_NOE 联合<|>RELATION_NOE 伊班<|>RELATION_NOE 膦酸钠<|>RELATION_NOE 治疗<|>RELATION_B 肺癌<|>RELATION_I 骨<|>RELATION_I 转移<|>RELATION_I 疼痛<|>RELATION_E 的<|>RELATION_NOE 疗效<|>RELATION_NOE 及<|>RELATION_NOE 安全性<|>RELATION_NOE 。<|>RELATION_NOE
收集<|>RELATION_NOE 肺癌<|>RELATION_NOE 骨<|>RELATION_NOE 转移<|>RELATION_NOE 疼痛<|>RELATION_NOE 患者<|>RELATION_NOE 216<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 将<|>RELATION_NOE 其<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 和<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 各<|>RELATION_NOE 108<|>RELATION_NOE 例<|>RELATION_NOE 。<|>RELATION_NOE
^<|>RELATION_NOE 89Sr<|>RELATION_NOE 联合<|>RELATION_NOE 伊班<|>RELATION_NOE 膦酸钠<|>RELATION_NOE 能<|>RELATION_NOE 起<|>RELATION_NOE 到<|>RELATION_NOE 协同<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 方法<|>RELATION_NOE 简单<|>RELATION_NOE ,<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 作为<|>RELATION_B 肺癌<|>RELATION_I 骨<|>RELATION_I 转移<|>RELATION_I 疼痛<|>RELATION_I 的<|>RELATION_I 一个<|>RELATION_I 有效<|>RELATION_I 方法<|>RELATION_E 。<|>RELATION_NOE
microRNA-429<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE SPC-A1<|>RELATION_NOE 增殖<|>RELATION_NOE 抑制<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
合成<|>RELATION_NOE miR-429<|>RELATION_NOE 前体<|>RELATION_NOE (<|>RELATION_NOE Pre-miRTM<|>RELATION_NOE miR-429<|>RELATION_NOE precursor<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 至<|>RELATION_NOE SPC-A1<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S miR-429<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE CCK-8<|>RELATION_NOE 法<|>RELATION_NOE 合成<|>RELATION_NOE miR-429<|>RELATION_NOE 前体<|>RELATION_NOE (<|>RELATION_NOE Pre-miRTM<|>RELATION_NOE miR-429<|>RELATION_NOE precursor<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 至<|>RELATION_NOE SPC-A1<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE miR-429<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE CCK-8<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_S 细胞<|>RELATION_NOE 活性<|>RELATION_NOE ,<|>RELATION_NOE Annexin<|>RELATION_NOE V<|>RELATION_NOE Assay<|>RELATION_NOE 合成<|>RELATION_NOE miR-429<|>RELATION_NOE 前体<|>RELATION_NOE (<|>RELATION_NOE Pre-miRTM<|>RELATION_NOE miR-429<|>RELATION_NOE precursor<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 至<|>RELATION_NOE SPC-A1<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE miR-429<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE CCK-8<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE 活性<|>RELATION_NOE ,<|>RELATION_NOE Annexin<|>RELATION_NOE V<|>RELATION_NOE Assay<|>RELATION_NOE 检测<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_S 细胞周期<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE Western-blot<|>RELATION_NOE 合成<|>RELATION_NOE miR-429<|>RELATION_NOE 前体<|>RELATION_NOE (<|>RELATION_NOE Pre-miRTM<|>RELATION_NOE miR-429<|>RELATION_NOE precursor<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 通过<|>RELATION_NOE 脂质体<|>RELATION_NOE 转染<|>RELATION_NOE 至<|>RELATION_NOE SPC-A1<|>RELATION_NOE 细胞<|>RELATION_NOE ,<|>RELATION_NOE 荧光<|>RELATION_NOE 定量<|>RELATION_NOE PCR<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE miR-429<|>RELATION_NOE 表达<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE CCK-8<|>RELATION_NOE 法<|>RELATION_NOE 检测<|>RELATION_NOE 细胞<|>RELATION_NOE 活性<|>RELATION_NOE ,<|>RELATION_NOE Annexin<|>RELATION_NOE V<|>RELATION_NOE Assay<|>RELATION_NOE 检测<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE 流式细胞术<|>RELATION_NOE 检测<|>RELATION_NOE 细胞周期<|>RELATION_NOE 情况<|>RELATION_NOE ,<|>RELATION_NOE Western-blot<|>RELATION_NOE 检测<|>RELATION_S 细胞周期<|>RELATION_NOE 蛋白<|>RELATION_NOE 情况<|>RELATION_NOE 。<|>RELATION_NOE
pre-miR-429<|>RELATION_NOE 转染<|>RELATION_NOE 后<|>RELATION_NOE ,<|>RELATION_NOE SPC-A1<|>RELATION_NOE 细胞<|>RELATION_NOE miR-429<|>RELATION_NOE 表达<|>RELATION_NOE 较<|>RELATION_NOE 对照组<|>RELATION_NOE 明显<|>RELATION_B 增高<|>RELATION_E ,<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.001<|>RELATION_NOE )<|>RELATION_NOE ;<|>RELATION_NOE
在<|>RELATION_NOE 肺腺<|>RELATION_NOE 癌细胞<|>RELATION_NOE SPC-A1<|>RELATION_NOE 中<|>RELATION_NOE 增加<|>RELATION_B miR-429<|>RELATION_I 表达量<|>RELATION_E ,<|>RELATION_NOE 可<|>RELATION_NOE 抑制<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞增殖<|>RELATION_NOE ,<|>RELATION_NOE 促进<|>RELATION_NOE 细胞周期<|>RELATION_NOE 阻滞<|>RELATION_NOE .<|>RELATION_NOE
20<|>RELATION_NOE 56<|>RELATION_NOE 例<|>RELATION_NOE 手术<|>RELATION_NOE 切除<|>RELATION_NOE 肺腺癌<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 病理<|>RELATION_NOE 分析<|>RELATION_S
组织<|>RELATION_NOE 学<|>RELATION_NOE 亚型<|>RELATION_NOE 以<|>RELATION_NOE 腺泡<|>RELATION_NOE 为<|>RELATION_NOE 主型<|>RELATION_NOE 和<|>RELATION_NOE 乳头<|>RELATION_NOE 为<|>RELATION_NOE 主型<|>RELATION_NOE 浸润性<|>RELATION_NOE 腺癌<|>RELATION_NOE 多<|>RELATION_B 见<|>RELATION_E ;<|>RELATION_NOE
微<|>RELATION_NOE 乳头<|>RELATION_NOE 为<|>RELATION_NOE 主型<|>RELATION_NOE 和<|>RELATION_NOE 实性<|>RELATION_NOE 为<|>RELATION_NOE 主型<|>RELATION_NOE 浸润性<|>RELATION_NOE 腺癌<|>RELATION_NOE 更<|>RELATION_B 易<|>RELATION_I 发生<|>RELATION_E 胸膜<|>RELATION_NOE 侵犯<|>RELATION_NOE 和<|>RELATION_NOE 淋巴结<|>RELATION_NOE 转移<|>RELATION_NOE ;<|>RELATION_NOE
我国<|>RELATION_NOE 肾移植术<|>RELATION_NOE 后<|>RELATION_NOE 新<|>RELATION_NOE 发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 总结<|>RELATION_B 分析<|>RELATION_E
探讨<|>RELATION_NOE 我国<|>RELATION_NOE 公开<|>RELATION_NOE 报道<|>RELATION_NOE 的<|>RELATION_NOE 肾移植术<|>RELATION_NOE 后<|>RELATION_NOE 新<|>RELATION_NOE 发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 流行病学<|>RELATION_B 特征<|>RELATION_I 、<|>RELATION_I 临床<|>RELATION_I 特点<|>RELATION_I 及<|>RELATION_I 危险因素<|>RELATION_E 。<|>RELATION_NOE
本组<|>RELATION_NOE 数据<|>RELATION_NOE 共<|>RELATION_NOE 入<|>RELATION_NOE 组<|>RELATION_NOE 19<|>RELATION_NOE 74<|>RELATION_NOE －<|>RELATION_NOE 20<|>RELATION_NOE 14<|>RELATION_NOE 年<|>RELATION_NOE 间<|>RELATION_NOE 肾移植<|>RELATION_NOE 受者<|>RELATION_NOE 306<|>RELATION_NOE 32<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 新<|>RELATION_NOE 发<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 患者<|>RELATION_NOE 671<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 肿瘤<|>RELATION_NOE 发病率<|>RELATION_NOE 约<|>RELATION_NOE 为<|>RELATION_NOE 2.19<|>RELATION_NOE %<|>RELATION_NOE (<|>RELATION_NOE 0.60%<|>RELATION_NOE －<|>RELATION_NOE 5.1<|>RELATION_NOE 7%<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
前<|>RELATION_NOE 5<|>RELATION_NOE 位<|>RELATION_NOE 最<|>RELATION_B 常见<|>RELATION_I 的<|>RELATION_I 肿瘤<|>RELATION_I 部位<|>RELATION_E 是<|>RELATION_NOE 泌尿<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE 339<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 消化系统<|>RELATION_NOE (<|>RELATION_NOE 143<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 血液<|>RELATION_NOE 系统<|>RELATION_NOE (<|>RELATION_NOE 51<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 呼吸系统<|>RELATION_NOE (<|>RELATION_NOE 33<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 皮肤<|>RELATION_NOE (<|>RELATION_NOE 30<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
前<|>RELATION_NOE 10<|>RELATION_NOE 位<|>RELATION_NOE 最<|>RELATION_B 常见<|>RELATION_I 的<|>RELATION_I 肿瘤<|>RELATION_I 类型<|>RELATION_E 是<|>RELATION_NOE 尿路<|>RELATION_NOE 上皮细胞癌<|>RELATION_NOE (<|>RELATION_NOE 283<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肝细胞癌<|>RELATION_NOE (<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 胃肠道<|>RELATION_NOE 肿瘤<|>RELATION_NOE (<|>RELATION_NOE 63<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肾细胞癌<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 淋巴瘤<|>RELATION_NOE (<|>RELATION_NOE 42<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 肺癌<|>RELATION_NOE (<|>RELATION_NOE 28<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 乳腺癌<|>RELATION_NOE (<|>RELATION_NOE 19<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE 皮肤癌<|>RELATION_NOE (<|>RELATION_NOE 18<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 、<|>RELATION_NOE Kaposi<|>RELATION_NOE 肉瘤<|>RELATION_NOE (<|>RELATION_NOE 12<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 宫<|>RELATION_NOE 颈癌<|>RELATION_NOE (<|>RELATION_NOE 10<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
而<|>RELATION_NOE 消化系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发病率<|>RELATION_NOE 南方<|>RELATION_NOE 为<|>RELATION_NOE 0.2<|>RELATION_NOE 4%<|>RELATION_NOE ,<|>RELATION_NOE 高于<|>RELATION_S 北方<|>RELATION_NOE 的<|>RELATION_NOE 0.1<|>RELATION_NOE 7%<|>RELATION_NOE 。<|>RELATION_NOE
我国<|>RELATION_NOE 肾移植<|>RELATION_NOE 受者<|>RELATION_NOE 恶性肿瘤<|>RELATION_NOE 的<|>RELATION_NOE 发病率<|>RELATION_NOE 明显<|>RELATION_B 低于<|>RELATION_E 国外<|>RELATION_NOE 水平<|>RELATION_NOE ,<|>RELATION_NOE 泌尿<|>RELATION_NOE 系统<|>RELATION_NOE 及<|>RELATION_NOE 消化系统<|>RELATION_NOE 肿瘤<|>RELATION_NOE 高<|>RELATION_NOE 发<|>RELATION_NOE ,<|>RELATION_NOE 其中<|>RELATION_NOE 以<|>RELATION_NOE 尿路<|>RELATION_NOE 上皮细胞<|>RELATION_NOE 癌最为<|>RELATION_NOE 常见<|>RELATION_NOE ,<|>RELATION_NOE 南<|>RELATION_NOE 、<|>RELATION_NOE 北方<|>RELATION_NOE 不同<|>RELATION_NOE 类型<|>RELATION_NOE 肿瘤<|>RELATION_NOE 发病率<|>RELATION_NOE 有<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
预见性<|>RELATION_NOE 护理<|>RELATION_NOE 在<|>RELATION_NOE 肺癌<|>RELATION_B 全<|>RELATION_I 肺切除术<|>RELATION_I 后<|>RELATION_I 并发症<|>RELATION_I 管理<|>RELATION_E 中<|>RELATION_NOE 的<|>RELATION_NOE 应用<|>RELATION_NOE
观察<|>RELATION_NOE 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 后<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE 有<|>RELATION_NOE 预见性<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 后<|>RELATION_NOE 的<|>RELATION_NOE 并发症<|>RELATION_B 发生<|>RELATION_I 情况<|>RELATION_E ,<|>RELATION_NOE 探讨<|>RELATION_NOE 其<|>RELATION_NOE 护理<|>RELATION_NOE 效果<|>RELATION_NOE 。<|>RELATION_NOE
选择<|>RELATION_NOE 20<|>RELATION_NOE 12年<|>RELATION_NOE 1月<|>RELATION_NOE 至<|>RELATION_NOE 20<|>RELATION_NOE 13年<|>RELATION_NOE 12月<|>RELATION_NOE 肺癌<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 加<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清扫术<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 68<|>RELATION_NOE 例<|>RELATION_NOE ,<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 观察组<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE ,<|>RELATION_NOE 每<|>RELATION_NOE 组<|>RELATION_NOE 34<|>RELATION_NOE 例.<|>RELATION_NOE
对照组<|>RELATION_NOE 采用<|>RELATION_NOE 胸外科<|>RELATION_NOE 护理<|>RELATION_NOE 常规<|>RELATION_NOE 方案<|>RELATION_NOE ,<|>RELATION_NOE 观察组<|>RELATION_NOE 在<|>RELATION_NOE 常规<|>RELATION_NOE 护理<|>RELATION_NOE 基础<|>RELATION_NOE 上<|>RELATION_NOE 采取<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 有<|>RELATION_NOE 预见性<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 即<|>RELATION_NOE 由<|>RELATION_NOE 责任<|>RELATION_NOE 护士<|>RELATION_NOE 对<|>RELATION_NOE 一侧<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 的<|>RELATION_NOE 患者<|>RELATION_NOE 加强<|>RELATION_NOE 治疗<|>RELATION_NOE 过程<|>RELATION_NOE 中<|>RELATION_NOE 护理<|>RELATION_NOE 问题<|>RELATION_NOE 的<|>RELATION_NOE 前瞻性<|>RELATION_NOE 全面<|>RELATION_NOE 评估<|>RELATION_NOE ,<|>RELATION_NOE 找<|>RELATION_NOE 出<|>RELATION_NOE 患者<|>RELATION_NOE 现存<|>RELATION_NOE 的<|>RELATION_NOE 和<|>RELATION_NOE 潜在<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 问题<|>RELATION_NOE ,<|>RELATION_NOE 有<|>RELATION_NOE 针对性<|>RELATION_NOE 制定<|>RELATION_NOE 相应<|>RELATION_NOE 的<|>RELATION_NOE 护理<|>RELATION_NOE 干预<|>RELATION_NOE 措施<|>RELATION_NOE ,<|>RELATION_NOE 对<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 患者<|>RELATION_NOE 围术期<|>RELATION_NOE 进行<|>RELATION_NOE 管理<|>RELATION_NOE 。<|>RELATION_NOE
预见性<|>RELATION_NOE 护理<|>RELATION_NOE 能<|>RELATION_NOE 有效<|>RELATION_B 减少<|>RELATION_E 全<|>RELATION_NOE 肺切除术<|>RELATION_NOE 后<|>RELATION_NOE 肺部<|>RELATION_NOE 并发症<|>RELATION_NOE 和<|>RELATION_NOE 心律失常<|>RELATION_NOE 发生率<|>RELATION_NOE ,<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_NOE 有<|>RELATION_NOE 统计学<|>RELATION_NOE 意义<|>RELATION_NOE (<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
对<|>RELATION_NOE 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 经<|>RELATION_NOE 预见性<|>RELATION_NOE 护理<|>RELATION_NOE ,<|>RELATION_NOE 包括<|>RELATION_S 对<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 全面<|>RELATION_NOE 检查<|>RELATION_NOE 评估<|>RELATION_NOE ,<|>RELATION_NOE 加强<|>RELATION_NOE 基础<|>RELATION_NOE 疾病<|>RELATION_NOE 的<|>RELATION_NOE 治疗<|>RELATION_NOE 和<|>RELATION_NOE 控制<|>RELATION_NOE 、<|>RELATION_NOE 呼吸功<|>RELATION_NOE 能<|>RELATION_NOE 锻炼<|>RELATION_NOE ;<|>RELATION_NOE
加强<|>RELATION_NOE 术后<|>RELATION_NOE 监测<|>RELATION_NOE 和<|>RELATION_NOE 气道<|>RELATION_NOE 、<|>RELATION_NOE 氧疗<|>RELATION_NOE 、<|>RELATION_NOE 液体<|>RELATION_NOE 、<|>RELATION_NOE 体位<|>RELATION_NOE 、<|>RELATION_NOE 胸管<|>RELATION_NOE 、<|>RELATION_NOE 疼痛<|>RELATION_NOE 等<|>RELATION_NOE 的<|>RELATION_NOE 管理<|>RELATION_NOE 可以<|>RELATION_NOE 有效<|>RELATION_B 地<|>RELATION_I 降低<|>RELATION_E 全<|>RELATION_NOE 肺切除<|>RELATION_NOE 患者<|>RELATION_NOE 术后<|>RELATION_NOE 并发症<|>RELATION_NOE 发生率<|>RELATION_NOE .<|>RELATION_NOE
康莱特<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨和<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 的<|>RELATION_NOE 效果<|>RELATION_NOE 评价<|>RELATION_NOE
评价<|>RELATION_NOE 康莱特<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨和<|>RELATION_NOE 顺铂<|>RELATION_NOE (<|>RELATION_NOE GP<|>RELATION_NOE )<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E (<|>RELATION_NOE NSCLC<|>RELATION_NOE )<|>RELATION_NOE 的<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 及其<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 。<|>RELATION_NOE
康莱特<|>RELATION_NOE 注射<|>RELATION_NOE 液<|>RELATION_NOE 联合<|>RELATION_NOE 吉西<|>RELATION_NOE 他<|>RELATION_NOE 滨和<|>RELATION_NOE 顺铂<|>RELATION_NOE 治疗<|>RELATION_B 晚期<|>RELATION_I 非<|>RELATION_I 小细胞肺癌<|>RELATION_E 疗效<|>RELATION_NOE 显著<|>RELATION_NOE ,<|>RELATION_NOE 可<|>RELATION_NOE 提高<|>RELATION_NOE 患者<|>RELATION_NOE 生活<|>RELATION_NOE 质量<|>RELATION_NOE ,<|>RELATION_NOE 降低<|>RELATION_NOE 化疗<|>RELATION_NOE 药物<|>RELATION_NOE 不良<|>RELATION_NOE 反应<|>RELATION_NOE 的<|>RELATION_NOE 发生<|>RELATION_NOE .<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 解剖性<|>RELATION_NOE 肺段<|>RELATION_NOE 切除<|>RELATION_NOE 治疗<|>RELATION_B 肺部疾病<|>RELATION_E 效果<|>RELATION_NOE 探讨<|>RELATION_NOE
所有<|>RELATION_NOE 患者<|>RELATION_NOE 均<|>RELATION_NOE 成功<|>RELATION_NOE 实施<|>RELATION_NOE 全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 解剖<|>RELATION_NOE 肺段<|>RELATION_NOE 切除术<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 手术时间<|>RELATION_NOE 为<|>RELATION_NOE 134.1min<|>RELATION_NOE ,<|>RELATION_NOE 平均<|>RELATION_NOE 出血量<|>RELATION_NOE 为<|>RELATION_NOE 86.7ml<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 平均<|>RELATION_NOE 住院时间<|>RELATION_NOE 为<|>RELATION_NOE 6.8d<|>RELATION_NOE ,<|>RELATION_NOE 胸腔<|>RELATION_NOE 导流<|>RELATION_NOE 管<|>RELATION_NOE 平均<|>RELATION_NOE 留置<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE 3.4d<|>RELATION_NOE .<|>RELATION_NOE
5例<|>RELATION_NOE 原发性<|>RELATION_NOE 支气管<|>RELATION_NOE 肺癌<|>RELATION_NOE 除行<|>RELATION_NOE 肺段<|>RELATION_NOE 切除术<|>RELATION_NOE 再行<|>RELATION_NOE 纵隔<|>RELATION_NOE 系统<|>RELATION_NOE 的<|>RELATION_NOE 淋巴结<|>RELATION_NOE 清除术<|>RELATION_NOE ,<|>RELATION_NOE 淋巴结<|>RELATION_NOE 平均<|>RELATION_NOE 清除<|>RELATION_NOE 12.4<|>RELATION_NOE 枚<|>RELATION_NOE 。<|>RELATION_NOE
全<|>RELATION_NOE 胸腔镜<|>RELATION_NOE 解剖性<|>RELATION_NOE 肺段<|>RELATION_NOE 切除术<|>RELATION_NOE 治疗<|>RELATION_B 肺部疾病<|>RELATION_E 安全<|>RELATION_NOE 可行<|>RELATION_NOE ,<|>RELATION_NOE 术<|>RELATION_NOE 中<|>RELATION_NOE 失血<|>RELATION_NOE 较<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 并发症<|>RELATION_NOE 少<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 住院时间<|>RELATION_NOE 较<|>RELATION_NOE 短<|>RELATION_NOE ,<|>RELATION_NOE 临床<|>RELATION_NOE 效果<|>RELATION_NOE 显著<|>RELATION_NOE ,<|>RELATION_NOE 值得<|>RELATION_NOE 在<|>RELATION_NOE 临床<|>RELATION_NOE 推广<|>RELATION_NOE 使用<|>RELATION_NOE .<|>RELATION_NOE
个体化<|>RELATION_NOE 心理<|>RELATION_NOE 干预<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 焦虑<|>RELATION_NOE 与<|>RELATION_NOE 术后<|>RELATION_NOE 恢复<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_S
将<|>RELATION_NOE 接受<|>RELATION_NOE 肺癌<|>RELATION_NOE 手术<|>RELATION_NOE 患者<|>RELATION_NOE 120<|>RELATION_NOE 例<|>RELATION_NOE 按<|>RELATION_NOE 数字<|>RELATION_NOE 表法<|>RELATION_NOE 随机<|>RELATION_NOE 分为<|>RELATION_NOE 对照组<|>RELATION_NOE (<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE 和<|>RELATION_NOE 实验组<|>RELATION_NOE (<|>RELATION_NOE 60<|>RELATION_NOE 例<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 对照组<|>RELATION_NOE 接受<|>RELATION_NOE 常规<|>RELATION_NOE 的<|>RELATION_NOE 心理<|>RELATION_NOE 护理<|>RELATION_NOE 措施<|>RELATION_NOE 。<|>RELATION_NOE
比较<|>RELATION_NOE 两<|>RELATION_NOE 组<|>RELATION_NOE 患者<|>RELATION_NOE 术<|>RELATION_NOE 前<|>RELATION_NOE 焦虑<|>RELATION_NOE 、<|>RELATION_NOE 术后<|>RELATION_NOE 自主<|>RELATION_NOE 运动<|>RELATION_NOE 、<|>RELATION_NOE 肺复张<|>RELATION_NOE 情况<|>RELATION_NOE 以及<|>RELATION_NOE 胸管<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE 等<|>RELATION_NOE 各项<|>RELATION_NOE 指标<|>RELATION_NOE 的<|>RELATION_NOE 差异<|>RELATION_NOE 。<|>RELATION_NOE
实验<|>RELATION_NOE 组术<|>RELATION_NOE 前<|>RELATION_NOE 焦虑值<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 46.85<|>RELATION_NOE ±<|>RELATION_NOE 5.20<|>RELATION_NOE )<|>RELATION_NOE ,<|>RELATION_NOE 术后<|>RELATION_NOE 自主<|>RELATION_NOE 运动<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 92.57<|>RELATION_NOE ±<|>RELATION_NOE 17.92<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 胸管<|>RELATION_NOE 拔管<|>RELATION_NOE 时间<|>RELATION_NOE 为<|>RELATION_NOE (<|>RELATION_NOE 9.<|>RELATION_NOE 52<|>RELATION_NOE ±<|>RELATION_NOE 1.27<|>RELATION_NOE )<|>RELATION_NOE d<|>RELATION_NOE ,<|>RELATION_NOE 与<|>RELATION_NOE 对照组<|>RELATION_NOE 比较<|>RELATION_NOE 差异<|>RELATION_B 均<|>RELATION_I 有<|>RELATION_I 统计学<|>RELATION_I 意义<|>RELATION_E (<|>RELATION_NOE t<|>RELATION_NOE =<|>RELATION_NOE －<|>RELATION_NOE 9.8<|>RELATION_NOE 57<|>RELATION_NOE 、<|>RELATION_NOE 7.72<|>RELATION_NOE 、<|>RELATION_NOE 11.84<|>RELATION_NOE ,<|>RELATION_NOE 均<|>RELATION_NOE P<|>RELATION_NOE <<|>RELATION_NOE 0.05<|>RELATION_NOE )<|>RELATION_NOE 。<|>RELATION_NOE
苦<|>RELATION_NOE 豆子<|>RELATION_NOE 生物碱<|>RELATION_NOE 对<|>RELATION_NOE 体外<|>RELATION_NOE 培养<|>RELATION_NOE 的<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_B 作用<|>RELATION_E
对<|>RELATION_NOE 4<|>RELATION_NOE 种<|>RELATION_NOE 苦<|>RELATION_NOE 豆子<|>RELATION_NOE 生物碱<|>RELATION_NOE 的<|>RELATION_NOE 体外<|>RELATION_NOE 抗<|>RELATION_NOE 肺癌<|>RELATION_NOE 活性<|>RELATION_NOE 及<|>RELATION_NOE 机制<|>RELATION_NOE 进行<|>RELATION_NOE 研究<|>RELATION_NOE ,<|>RELATION_NOE 并<|>RELATION_NOE 评价<|>RELATION_NOE 其<|>RELATION_NOE 对<|>RELATION_NOE 正常<|>RELATION_NOE 细胞<|>RELATION_NOE 的<|>RELATION_NOE 毒性<|>RELATION_NOE ,<|>RELATION_NOE 以期<|>RELATION_NOE 筛选<|>RELATION_B 出<|>RELATION_E 具有<|>RELATION_NOE 高效<|>RELATION_NOE 低毒<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 作用<|>RELATION_NOE 的<|>RELATION_NOE 药物<|>RELATION_NOE 。<|>RELATION_NOE
用<|>RELATION_NOE 噻唑蓝<|>RELATION_NOE (<|>RELATION_NOE MTT<|>RELATION_NOE )<|>RELATION_NOE 法<|>RELATION_NOE 测定<|>RELATION_S 4种<|>RELATION_NOE 苦<|>RELATION_NOE 豆子<|>RELATION_NOE 生物碱<|>RELATION_NOE 对<|>RELATION_NOE 人<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞<|>RELATION_NOE 和<|>RELATION_NOE 仓鼠<|>RELATION_NOE 肺细胞增殖<|>RELATION_NOE 活性<|>RELATION_NOE 的<|>RELATION_NOE 影响<|>RELATION_NOE ;<|>RELATION_NOE
用<|>RELATION_NOE 激光<|>RELATION_NOE 共<|>RELATION_NOE 聚焦<|>RELATION_NOE 显微镜<|>RELATION_NOE 观察<|>RELATION_NOE Hochest33342<|>RELATION_NOE 染色<|>RELATION_NOE 后<|>RELATION_NOE 肺癌<|>RELATION_NOE 细胞凋亡<|>RELATION_NOE 的<|>RELATION_NOE 形态学<|>RELATION_NOE 变化<|>RELATION_NOE ;<|>RELATION_NOE
4<|>RELATION_NOE 种<|>RELATION_NOE 苦<|>RELATION_NOE 豆子<|>RELATION_NOE 生物碱<|>RELATION_NOE 对<|>RELATION_NOE 肺癌<|>RELATION_B 细胞<|>RELATION_I 的<|>RELATION_I 生长<|>RELATION_E 具有<|>RELATION_NOE 不同<|>RELATION_NOE 程度<|>RELATION_NOE 的<|>RELATION_NOE 抑制<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 呈<|>RELATION_NOE 剂量<|>RELATION_NOE 依赖<|>RELATION_NOE 关系<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 氧化槐<|>RELATION_NOE 定碱<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 肺癌<|>RELATION_NOE 活性<|>RELATION_NOE 最<|>RELATION_NOE 强<|>RELATION_NOE ,<|>RELATION_NOE 且<|>RELATION_NOE 对<|>RELATION_NOE 正常<|>RELATION_NOE 肺细胞<|>RELATION_NOE 的<|>RELATION_NOE 毒性<|>RELATION_NOE 较<|>RELATION_NOE 小<|>RELATION_NOE ;<|>RELATION_NOE
4<|>RELATION_NOE 种<|>RELATION_NOE 苦<|>RELATION_NOE 豆子<|>RELATION_NOE 生物碱<|>RELATION_NOE 均<|>RELATION_B 具有<|>RELATION_E 一定<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 肺癌<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 氧化槐<|>RELATION_NOE 定碱<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 最<|>RELATION_NOE 强<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 高效<|>RELATION_NOE 低毒<|>RELATION_NOE 的<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 适合<|>RELATION_NOE 作为<|>RELATION_NOE 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 候选<|>RELATION_NOE 药物<|>RELATION_NOE 进一步<|>RELATION_NOE 开发<|>RELATION_NOE .<|>RELATION_NOE 4<|>RELATION_NOE 种<|>RELATION_NOE 苦<|>RELATION_NOE 豆子<|>RELATION_NOE 生物<|>RELATION_NOE 碱均<|>RELATION_NOE 具有<|>RELATION_NOE 一定<|>RELATION_NOE 的<|>RELATION_NOE 抗<|>RELATION_NOE 肺癌<|>RELATION_NOE 作用<|>RELATION_NOE ,<|>RELATION_NOE 以<|>RELATION_NOE 氧化槐<|>RELATION_NOE 定碱<|>RELATION_NOE 的<|>RELATION_NOE 活性<|>RELATION_NOE 最<|>RELATION_NOE 强<|>RELATION_NOE ,<|>RELATION_NOE 具有<|>RELATION_NOE 高效<|>RELATION_NOE 低毒<|>RELATION_NOE 的<|>RELATION_NOE 特点<|>RELATION_NOE ,<|>RELATION_NOE 适合<|>RELATION_B 作为<|>RELATION_E 抗<|>RELATION_NOE 肿瘤<|>RELATION_NOE 候选<|>RELATION_NOE 药物<|>RELATION_NOE 进一步<|>RELATION_NOE 开发<|>RELATION_NOE .<|>RELATION_NOE
Cdc42<|>RELATION_NOE 独立<|>RELATION_B 调节<|>RELATION_I A549<|>RELATION_I 细胞迁移<|>RELATION_I 能力<|>RELATION_E 的<|>RELATION_NOE 自动<|>RELATION_NOE 测量<|>RELATION_NOE
定量分析<|>RELATION_NOE Cdc42<|>RELATION_NOE 对<|>RELATION_NOE A549<|>RELATION_NOE 细胞迁移<|>RELATION_NOE 能力<|>RELATION_NOE 的<|>RELATION_NOE 独立<|>RELATION_B 调节<|>RELATION_I 作用<|>RELATION_E ,<|>RELATION_NOE 并<|>RELATION_NOE 验证<|>RELATION_NOE 一<|>RELATION_NOE 种<|>RELATION_NOE 自动<|>RELATION_NOE 测量<|>RELATION_NOE 和<|>RELATION_NOE 计算<|>RELATION_NOE 体外<|>RELATION_NOE 细胞迁移<|>RELATION_NOE 距离<|>RELATION_NOE 的<|>RELATION_NOE 新<|>RELATION_NOE
应用<|>RELATION_NOE 多种<|>RELATION_NOE 测量<|>RELATION_NOE 方法<|>RELATION_NOE 对<|>RELATION_NOE 图像<|>RELATION_NOE 进行<|>RELATION_NOE 定量分析<|>RELATION_NOE ,<|>RELATION_NOE 统计<|>RELATION_NOE 分析<|>RELATION_NOE 各<|>RELATION_NOE 方法<|>RELATION_NOE 针对<|>RELATION_NOE 细胞迁移<|>RELATION_NOE 距离<|>RELATION_NOE 测量<|>RELATION_NOE 的<|>RELATION_NOE 精确度<|>RELATION_NOE 和<|>RELATION_NOE 可<|>RELATION_NOE 重复性<|>RELATION_NOE 。<|>RELATION_NOE
